PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ElAntak, L; Tzakos, AG; Locker, N; Lukavsky, PJ				ElAntak, Latifa; Tzakos, Andreas G.; Locker, Nicolas; Lukavsky, Peter J.			Structure of eIF3b RNA recognition motif and its interaction with eIF3j - Structural insights into the recruitment of eIF3b to the 40 S ribosomal subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 3; TRANSLATION INITIATION; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; PROTEIN STRUCTURES; BINDING PROTEIN; PRT1 PROTEIN; COMPLEX; SUBUNITS; NMR	Mammalian eIF3 is a 700-kDa multiprotein complex essential for initiation of protein synthesis in eukaryotic cells. It consists of 13 subunits (eIF3a to -m), among which eIF3b serves as a major scaffolding protein. Here we report the solution structure of the N-terminal RNA recognition motif of human eIF3b (eIF3b-RRM) determined by NMR spectroscopy. The structure reveals a noncanonical RRM with a negatively charged surface in the beta-sheet area contradictory with potential RNA binding activity. Instead, eIF3j, which is required for stable 40 S ribosome binding of the eIF3 complex, specifically binds to the rear a-helices of the eIF3b-RRM, opposite to its beta-sheet surface. Moreover, we identify that an N-terminal 69-amino acid peptide of eIF3j is sufficient for binding to eIF3b-RRM and that this interaction is essential for eIF3b-RRM recruitment to the 40 S ribosomal subunit. Our results provide the first structure of an important subdomain of a core eIF3 subunit and detailed insights into protein-protein interactions between two eIF3 subunits required for stable eIF3 recruitment to the 40 S subunit.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology		pjl@mrc-lmb.cam.ac.uk	ELANTAK, Latifa/S-7004-2019; tzakos, Andreas/V-9624-2019; Tzakos, Andreas G./B-2875-2017	Tzakos, Andreas G./0000-0001-6391-0288; Locker, Nicolas/0000-0002-0053-2897	MRC [MC_U105170649] Funding Source: UKRI; Medical Research Council [MC_U105170649] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Auweter SD, 2006, EMBO J, V25, P163, DOI 10.1038/sj.emboj.7600918; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; Calero G, 2002, NAT STRUCT BIOL, V9, P912, DOI 10.1038/nsb874; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Fraser CS, 2004, J BIOL CHEM, V279, P8946, DOI 10.1074/jbc.M312745200; Goddard TD, 2004, SPARKY; Guntert P, 1997, Methods Mol Biol, V60, P157; Hinnebusch AG, 2006, TRENDS BIOCHEM SCI, V31, P553, DOI 10.1016/j.tibs.2006.08.005; Kadlec J, 2004, NAT STRUCT MOL BIOL, V11, P330, DOI 10.1038/nsmb741; Kielkopf CL, 2004, GENE DEV, V18, P1513, DOI 10.1101/gad.1206204; Kielkopf CL, 2001, CELL, V106, P595, DOI 10.1016/S0092-8674(01)00480-9; KLOTZ IM, 1973, ANN NY ACAD SCI, V226, P18, DOI 10.1111/j.1749-6632.1973.tb20465.x; Kolupaeva VG, 2005, RNA, V11, P470, DOI 10.1261/rna.7215305; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Maris C, 2005, FEBS J, V272, P2118, DOI 10.1111/j.1742-4658.2005.04653.x; Mayeur GL, 2003, EUR J BIOCHEM, V270, P4133, DOI 10.1046/j.1432-1033.2003.03807.x; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; Miyamoto S, 2005, J BIOL CHEM, V280, P28251, DOI 10.1074/jbc.M414129200; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Nederveen AJ, 2005, PROTEINS, V59, P662, DOI 10.1002/prot.20408; Nielsen KH, 2006, MOL CELL BIOL, V26, P2984, DOI 10.1128/MCB.26.8.2984-2998.2006; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Schellenberg MJ, 2006, P NATL ACAD SCI USA, V103, P1266, DOI 10.1073/pnas.0508048103; Selenko P, 2003, MOL CELL, V11, P965, DOI 10.1016/S1097-2765(03)00115-1; Shalev A, 2001, J BIOL CHEM, V276, P34948, DOI 10.1074/jbc.M102161200; Shi H, 2003, GENE DEV, V17, P971, DOI 10.1101/gad.260403; Siridechadilok B, 2005, SCIENCE, V310, P1513, DOI 10.1126/science.1118977; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; Unbehaun A, 2004, GENE DEV, V18, P3078, DOI 10.1101/gad.1255704; Valasek L, 2001, EMBO J, V20, P891, DOI 10.1093/emboj/20.4.891; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Volpon L, 2005, BIOCHEMISTRY-US, V44, P3708, DOI 10.1021/bi047450e; Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449	40	52	55	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8165	8174		10.1074/jbc.M610860200	http://dx.doi.org/10.1074/jbc.M610860200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17190833	Green Published, hybrid			2022-12-25	WOS:000245081000049
J	Jung, WS; Hong, CK; Lee, S; Kin, CS; Kim, SJ; Kim, SI; Rhee, S				Jung, Woo-Suk; Hong, Chang-Ki; Lee, Sujin; Kin, Chung-Sei; Kim, Soon-Jong; Kim, Su-Il; Rhee, Sangkee			Structural and functional insights into intramolecular fructosyl transfer by inulin fructotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BETA-HELIX; PROTEIN; PURIFICATION; EXPRESSION; FOLD; FRUCTAN; CLONING; DOMAIN; GLYCOSYLTRANSFERASE	Inulin fructotransferase (IFTase), a member of glycoside hydrolase family 91, catalyzes depolymerization of beta-2,1-fructans inulin by successively removing the terminal difructosaccharide units as cyclic anhydrides via intramolecular fructosyl transfer. The crystal structures of IFTase and its substrate-bound complex reveal that IFTase is a trimeric enzyme, and each monomer folds into a right-handed parallel beta-helix. Despite variation in the number and conformation of its beta-strands, the IFTase beta-helix has a structure that is largely reminiscent of other beta-helix structures but is unprecedented in that trimerization is a prerequisite for catalytic activity, and the active site is located at the monomer-monomer interface. Results from crystallographic studies and site-directed mutagenesis provide a structural basis for the exolytic-type activity of IFTase and a functional resemblance to inverting-type glycosyltransferases.	Seoul Natl Univ, Coll Agr & Life Sci, Dept Agr Biotecnol, Seoul 151921, South Korea; Seoul Natl Univ, Coll Agr & Life Sci, Ctr Agr Biomat, Seoul 151921, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Rhee, S (corresponding author), Seoul Natl Univ, Coll Agr & Life Sci, Dept Agr Biotecnol, Rm 7117,Bldg 200, Seoul 151921, South Korea.	srheesnu@snu.ac.kr						Alberto F, 2006, BIOCHEM J, V395, P457, DOI [10.1042/BJ20051936, 10.1042/Bj20051936]; Alberto F, 2004, J BIOL CHEM, V279, P18903, DOI 10.1074/jbc.M313911200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Cowen L, 2002, J COMPUT BIOL, V9, P261, DOI 10.1089/10665270252935458; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Di Matteo A, 2005, PLANT CELL, V17, P849, DOI 10.1105/tpc.104.028886; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Haraguchi K, 2003, BIOTECHNOL LETT, V25, P1049, DOI 10.1023/A:1024138428965; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Herron SR, 2000, P NATL ACAD SCI USA, V97, P8762, DOI 10.1073/pnas.97.16.8762; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Jenkins J, 2001, PROG BIOPHYS MOL BIO, V77, P111, DOI 10.1016/S0079-6107(01)00013-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JURNAK F, 1994, CURR OPIN STRUC BIOL, V4, P802, DOI 10.1016/0959-440X(94)90259-3; JURNAK F, 1995, FASEB J, V9, P335; Kang SI, 1998, BIOSCI BIOTECH BIOCH, V62, P628, DOI 10.1271/bbb.62.628; Kim CH, 2005, LETT APPL MICROBIOL, V40, P228, DOI 10.1111/j.1472-765X.2005.01658.x; Kim CS, 2007, J MICROBIOL BIOTECHN, V17, P37; Kim KY, 2005, J BIOCHEM, V138, P27, DOI 10.1093/jb/mvi093; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; Kreisberg JF, 2002, PROTEIN SCI, V11, P820, DOI 10.1110/ps.3440102; Larsson AM, 2003, STRUCTURE, V11, P1111, DOI 10.1016/S0969-2126(03)00147-3; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Martinez-Fleites C, 2005, BIOCHEM J, V390, P19, DOI 10.1042/BJ20050324; Meng GY, 2003, NAT STRUCT BIOL, V10, P935, DOI 10.1038/nsb974; Michel G, 2003, J MOL BIOL, V334, P421, DOI 10.1016/j.jmb.2003.09.056; Momma M, 2003, ACTA CRYSTALLOGR D, V59, P2286, DOI 10.1107/S0907444903019140; Nagem RAP, 2004, J MOL BIOL, V344, P471, DOI 10.1016/j.jmb.2004.09.024; Offen W, 2006, EMBO J, V25, P1396, DOI 10.1038/sj.emboj.7600970; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ritsema T, 2003, CURR OPIN PLANT BIOL, V6, P223, DOI 10.1016/S1369-5266(03)00034-7; Schubot FD, 2004, BIOCHEMISTRY-US, V43, P1163, DOI 10.1021/bi030202i; Shao H, 2005, PLANT CELL, V17, P3141, DOI 10.1105/tpc.105.035055; Simkovsky R, 2006, P NATL ACAD SCI USA, V103, P3575, DOI 10.1073/pnas.0509087103; Steinbacher S, 1996, P NATL ACAD SCI USA, V93, P10584, DOI 10.1073/pnas.93.20.10584; TANIGUCHI T, 1982, CARBOHYD RES, V107, P255, DOI 10.1016/S0008-6215(00)80543-1; Tarbouriech N, 2001, J MOL BIOL, V314, P655, DOI 10.1006/jmbi.2001.5159; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Van den Ende W, 2004, TRENDS PLANT SCI, V9, P523, DOI 10.1016/j.tplants.2004.09.008; van Hijum SAFT, 2003, FEBS LETT, V534, P207, DOI 10.1016/S0014-5793(02)03841-3; Van Riet L, 2006, J EXP BOT, V57, P213, DOI 10.1093/jxb/erj031; van Santen Y, 1999, J BIOL CHEM, V274, P30474, DOI 10.1074/jbc.274.43.30474; Verhaest M, 2005, PLANT J, V41, P400, DOI 10.1111/j.1365-313X.2004.02304.x; Vijn I, 1999, PLANT PHYSIOL, V120, P351, DOI 10.1104/pp.120.2.351; Yang SJ, 2002, BIOTECHNOL APPL BIOC, V35, P199, DOI 10.1042/BA20020008; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	50	38	40	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8414	8423		10.1074/jbc.M607143200	http://dx.doi.org/10.1074/jbc.M607143200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17192265	hybrid			2022-12-25	WOS:000245081000074
J	Goetzl, EJ				Goetzl, Edward J.			Diverse pathways for nuclear signaling by G protein-coupled receptors and their ligands	FASEB JOURNAL			English	Article						signal transduction; lipid mediators; receptor downregulation; MAP kinases; peroxisome proliferator-activated receptor; transcription	TRANSLOCATION; ACID; ENDOCYTOSIS; LOCALIZATION; ACTIVATION; WINGLESS; PEA-15	Recent realization that plasma membrane G protein-coupled receptors (GPCRs) may translocate and establish ligand-responsive signaling complexes in other cellular structures has motivated studies of site-specific differences in transductional pathways. GPCRs and their ligands may signal transcription and other nuclear events by two basic mechanisms. The first consists of GPCR-complex activation of messengers that enter the nucleus and there initiate cell-modifying processes without the GPCR leaving the plasma membrane. The second encompasses entry into the nuclear membranes or matrix of either GPCR ligands, which bind to non-GPCR nuclear signaling proteins, proteolytic fragments of GPCRs capable of ligand-independent signaling, or intact GPCRs with transduction-competent factors that directly initiate or regulate transcriptional events. With the second mechanism, often concurrent down-regulation of plasma membrane GPCRs terminates signaling from the cell-surface and moves it into the nuclear domain. Site-dependent differences in signals from the same GPCR provide potentials for unique cellular abnormalities attributable to defective intracellular movement and distribution of a GPCR, site-specific alterations in ligand concentration, and limited intracellular bioavailability of pharmacological agents that can interact specifically with both nuclear and plasma membrane forms of a GPCR. Goetzl, E. J. Diverse pathways for nuclear signaling by G Protein-coupled receptors and their ligands.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Immunol Microbiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), UC Box 0711,533 Parnassus Ave & 4th Ave, San Francisco, CA 94143 USA.	edward.goetzl@ucsf.edu						Ajenjo N, 2004, J BIOL CHEM, V279, P32813, DOI 10.1074/jbc.M313656200; Bkaily G, 2003, CAN J PHYSIOL PHARM, V81, P274, DOI 10.1139/Y03-007; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gaumont-Leclerc MF, 2004, J BIOL CHEM, V279, P46802, DOI 10.1074/jbc.M403893200; Gayral S, 2006, CIRC RES, V99, P132, DOI 10.1161/01.RES.0000232323.86227.8b; Gobeil F, 2003, J BIOL CHEM, V278, P38875, DOI 10.1074/jbc.M212481200; Gobeil F, 2006, J BIOL CHEM, V281, P16058, DOI 10.1074/jbc.M602219200; GOGOLAK P, 2006, IN PRESS BLOOD; Gripentrog JM, 2005, CELL SIGNAL, V17, P1300, DOI 10.1016/j.cellsig.2005.01.006; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; Jafri F, 2006, J BIOL CHEM, V281, P19346, DOI 10.1074/jbc.M512643200; Kobayashi H, 2005, CELL SIGNAL, V17, P1248, DOI 10.1016/j.cellsig.2004.12.014; Ledeen RW, 2006, BBA-MOL CELL BIOL L, V1761, P588, DOI 10.1016/j.bbalip.2006.04.010; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIAO JJ, IN PRESS J BIOL CHEM; Mathew D, 2005, SCIENCE, V310, P1344, DOI 10.1126/science.1117051; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Packard M, 2002, CELL, V111, P319, DOI 10.1016/S0092-8674(02)01047-4; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Rosenfeldt HM, 2003, FASEB J, V17, P1789, DOI 10.1096/fj.02-0836com; Tsukahara T, 2006, J BIOL CHEM, V281, P3398, DOI 10.1074/jbc.M510843200; Waters CM, 2006, BIOCHEM J, V398, P55, DOI 10.1042/BJ20060155; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619; Zhao M, 2006, MOL PHARMACOL, V69, P66, DOI 10.1124/mol.105.016923	30	31	34	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					638	642		10.1096/fj.06-6624hyp	http://dx.doi.org/10.1096/fj.06-6624hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17194692				2022-12-25	WOS:000244686400002
J	Ptasinska, A; Wang, SB; Zhang, JH; Wesley, RA; Danner, RL				Ptasinska, Anetta; Wang, Shuibang; Zhang, Jianhua; Wesley, Robert A.; Danner, Robert L.			Nitric oxide activation of peroxisome proliferator-activated receptor gamma through a p38 MAPK signaling pathway	FASEB JOURNAL			English	Article						endothelial cells; gene expression; inflammation; peroxisome proliferator response element; vascular homeostasis	VASCULAR ENDOTHELIAL-CELLS; PPAR-GAMMA; HUMAN NEUTROPHILS; EXPRESSION; INHIBITION; KINASE; TRANSDUCTION; SUPEROXIDE; MECHANISMS; SYNTHASE	Both nitric oxide (NO center dot) and peroxisome proliferator-activated receptors (PPARs) protect the endothelium and regulate its function. Here, we tested for crosstalk between these signaling pathways. Human umbilical vein and hybrid EA.hy926 endothelial cells were exposed to S-nitrosoglutathione (GSNO) or diethylenetriamine NONOate (DETA NONOate). Electrophoretic mobility shift assays using PPAR-response element (PPRE) probe showed that NO center dot caused a rapid dose-dependent increase in PPAR gamma binding, an effect that was confirmed in vivo by chromatin inummoprecipitation. Conversely, N-G-monomethyl-L-arginine, a NOS inhibitor, decreased PPAR gamma binding. NO center dot-mediated PPAR gamma binding and NO center dot induction of cyclooxygenase-2 (COX-2), diacylglycerol (DAG) kinase alpha (DGK alpha), and heme oxygenase-1 (HO-1), genes with well-characterized PPRE motifs, were cGMP independent. NO center dot dose dependently activated p38 MAPK, and p38 MAPK inhibition with SB202190 or knockdown with siRNA was shown to block NO center dot activation of PPAR gamma. Likewise, p38 MAPK and PPAR gamma inhibitors or knockdown of either transcript all significantly blocked NO center dot induction of PPRE-regulated genes. PPAR gamma activation by p38 MAPK may contribute to the anti-inflammatory and cytoprotective effects of NO center dot in the vasculature. This crosstalk mechanism suggests new strategies for preventing and treating vascular dysfunction.	Ctr Clin, Crit Care Med Dept, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Danner, RL (corresponding author), Ctr Clin, Crit Care Med Dept, NIH, Bethesda, MD 20892 USA.	rdanner@cc.nih.gov			Intramural NIH HHS Funding Source: Medline; CLINICAL CENTER [ZIACL001164, Z01CL001158, Z01CL000188, ZIACL001158, ZIACL000188, Z01CL001164] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CLINICAL CENTER		AZUMA H, 1986, BRIT J PHARMACOL, V88, P411, DOI 10.1111/j.1476-5381.1986.tb10218.x; Beckman JS, 1999, CIRC RES, V85, P870, DOI 10.1161/01.RES.85.9.870; Bolego C, 2006, BIOCHEM BIOPH RES CO, V339, P188, DOI 10.1016/j.bbrc.2005.11.017; Caballero AE, 2003, METABOLISM, V52, P173, DOI 10.1053/meta.2003.50023; Chen YQE, 2003, VITAM HORM, V66, P157, DOI 10.1016/S0083-6729(03)01005-7; Cines DB, 1998, BLOOD, V91, P3527; Cobb JP, 1996, JAMA-J AM MED ASSOC, V275, P1192, DOI 10.1001/jama.275.15.1192; Corriveau CC, 1998, J INFECT DIS, V177, P116, DOI 10.1086/513829; Cui XL, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-151; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; Estevez AG, 1998, J NEUROSCI, V18, P923; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Hata K, 2003, MOL BIOL CELL, V14, P545, DOI 10.1091/mbc.E02-06-0356; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Inoue I, 2001, METABOLISM, V50, P3, DOI 10.1053/meta.2001.19415; Jackson SM, 1999, ARTERIOSCL THROM VAS, V19, P2094, DOI 10.1161/01.ATV.19.9.2094; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; Kota BP, 2005, PHARMACOL RES, V51, P85, DOI 10.1016/j.phrs.2004.07.012; KUBES P, 1993, FASEB J, V7, P1293, DOI 10.1096/fasebj.7.13.8405815; Ma PL, 2004, J LEUKOCYTE BIOL, V76, P278, DOI 10.1189/jlb.1203653; Marx N, 2004, CIRC RES, V94, P1168, DOI 10.1161/01.RES.0000127122.22685.0A; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546, DOI 10.1161/01.ATV.19.3.546; Marx N, 2000, J IMMUNOL, V164, P6503, DOI 10.4049/jimmunol.164.12.6503; MONCADA S, 1991, PHARMACOL REV, V43, P109; Pang LH, 2003, J IMMUNOL, V170, P1043, DOI 10.4049/jimmunol.170.2.1043; Patel RP, 2000, CARDIOVASC RES, V47, P465, DOI 10.1016/S0008-6363(00)00086-9; Pawliczak R, 2002, J BIOL CHEM, V277, P33153, DOI 10.1074/jbc.M200246200; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Polikandriotis JA, 2005, ARTERIOSCL THROM VAS, V25, P1810, DOI 10.1161/01.ATV.0000177805.65864.d4; Pontsler AV, 2002, J BIOL CHEM, V277, P13029, DOI 10.1074/jbc.M109546200; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Schopfer FJ, 2005, P NATL ACAD SCI USA, V102, P2340, DOI 10.1073/pnas.0408384102; Semple RK, 2006, J CLIN INVEST, V116, P581, DOI 10.1172/JCI28003; Takata Y, 2002, CIRC RES, V91, P427, DOI 10.1161/01.RES.0000031271.20771.4F; VANDERVORT AL, 1994, J IMMUNOL, V152, P4102; Verrier E, 2004, CIRC RES, V94, P1515, DOI 10.1161/01.RES.0000130527.92537.06; von Knethen A, 2002, J IMMUNOL, V169, P2619, DOI 10.4049/jimmunol.169.5.2619; Wang NP, 2002, J BIOL CHEM, V277, P34176, DOI 10.1074/jbc.M203436200; Wang SB, 1997, J BIOL CHEM, V272, P5959, DOI 10.1074/jbc.272.9.5959; Wang SB, 2006, NUCLEIC ACIDS RES, V34, P3044, DOI 10.1093/nar/gkl386; Wang WH, 2001, AM J PHYSIOL-CELL PH, V281, pC544, DOI 10.1152/ajpcell.2001.281.2.C544; Wever RMF, 1998, CIRCULATION, V97, P108, DOI 10.1161/01.CIR.97.1.108; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Zhang JH, 2003, J BIOL CHEM, V278, P29192, DOI 10.1074/jbc.M213043200; Zingarelli B, 2003, J IMMUNOL, V171, P6827, DOI 10.4049/jimmunol.171.12.6827	48	66	67	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					950	961		10.1096/fj.06-6822com	http://dx.doi.org/10.1096/fj.06-6822com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197391				2022-12-25	WOS:000244686400031
J	Su, Y; Zhang, L; Gao, X; Meng, FW; Wen, J; Zhou, H; Meng, AM; Chen, YG				Su, Ying; Zhang, Long; Gao, Xia; Meng, Fanwei; Wen, Jun; Zhou, Hu; Meng, Anming; Chen, Ye-Guang			The evolutionally conserved activity of Dapper2 in antagonizing TGF-beta signaling	FASEB JOURNAL			English	Article						receptor degradation; embryonic expression	ONE-EYED PINHEAD; MESODERM; ZEBRAFISH; IDENTIFICATION; SMAD7; INHIBITOR; REGULATOR; INTERACTS; RECEPTOR; PROTEIN	Dapper1 and Dapper2, two divergent members of the Dapper family, have been suggested to modulate Wnt and TGF-beta/Nodal signaling in Xenopus and zebrafish. To get a better understanding of Dapper function in mammals, we have cloned the mouse ortholog of zebrafish Dapper2, mDpr2 and investigated its function in regulating TGF-beta signaling activity. Here, we showed that, like zebrafish Dapper2, overexpression of mDpr2 inhibited the TGF-beta-induced expression of the Smad-responsive reporters and targeted TGF-beta type I receptor ALK5 for degradation in mammalian cells. Overexpression of mBpr2 in the zebrafish embryos led to a decrease in expression of the mesoderm marker no tail and goosecoid at the shield stage and eye fusion later, implying that mDpr2 may have an intrinsic in vivo activity similar to fish Dapper2 activity. The expression of mDpr2 was detected throughout the epiblast around the onset of gastrulation and in somites, the neural tube and gut at later stages in mouse embryos, implying a role in early embryonic development. Our data indicate that the function of Dpr2 as a negative regulator of the TGF-beta/Nodal signal pathway is evolutionally conserved, at least in part, in fish and mammals.	Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China	Tsinghua University	Meng, AM (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China.	mengam@mail.tsinghua.edu.cn; ygchen@tsinghua.edu.cn	Chen, Ye-Guang/L-6998-2019; Zhang, Long/AAT-6571-2021; Meng, Anming/A-4785-2012; Su, Ying/ABA-8545-2021; Su, Ying/M-5825-2013	Zhang, Long/0000-0001-8139-0474; Su, Ying/0000-0002-8466-0043; Su, Ying/0000-0002-8466-0043; Meng, Anming/0000-0001-7228-3431				Brott BK, 2005, DEV CELL, V8, P703, DOI 10.1016/j.devcel.2005.02.012; Chen YG, 2004, CELL RES, V14, P441, DOI 10.1038/sj.cr.7290246; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Correia KM, 2001, METHODS, V23, P335, DOI 10.1006/meth.2000.1145; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Gillhouse M, 2004, DEV DYNAM, V230, P403, DOI 10.1002/dvdy.20060; Gloy J, 2002, NAT CELL BIOL, V4, P351, DOI 10.1038/ncb784; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hikasa H, 2004, DEVELOPMENT, V131, P4725, DOI 10.1242/dev.01369; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Katoh M, 2005, INT J MOL MED, V15, P1045; Katoh M, 2003, INT J ONCOL, V22, P907; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Schier AF, 1997, DEVELOPMENT, V124, P327; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Thisse C, 1999, DEVELOPMENT, V126, P229; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Waxman JS, 2004, DEVELOPMENT, V131, P5909, DOI 10.1242/dev.01520; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Zhang L, 2006, J BIOL CHEM, V281, P8607, DOI 10.1074/jbc.M600274200; Zhang LX, 2004, SCIENCE, V306, P114, DOI 10.1126/science.1100569; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	34	52	59	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					682	690		10.1096/fj.06-6246com	http://dx.doi.org/10.1096/fj.06-6246com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197390				2022-12-25	WOS:000244686400007
J	Lawrence, CL; Maekarwa, H; Worthington, JL; Reiter, W; Wilkinson, CRM; Jones, N				Lawrence, Clare L.; Maekarwa, Hiromi; Worthington, Jessica L.; Reiter, Wolfgang; Wilkinson, Caroline R. M.; Jones, Nic			Regulation of Schizosaccharomyces pombe Atf 1 protein levels by Sty1-mediated phosphorylation and heterodimerization with Pcr1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN ACTIVATION DOMAIN; FISSION YEAST; TRANSCRIPTION FACTOR; MAP KINASE; SEXUAL DEVELOPMENT; INFLAMMATORY CYTOKINES; ENVIRONMENTAL-STRESS; OXIDATIVE STRESS; GENE-EXPRESSION; OSMOTIC-STRESS	The Atf1 transcription factor plays a vital role in the ability of Schizosaccharomyces pombe cells to respond to various stress conditions. It regulates the expression of many genes in a stress-dependent manner, and its function is dependent upon the stress-activated MAPK, Sty1/Spc1. Moreover, Atf1 is directly phosphorylated by Sty1. Here we have investigated the role of such phosphorylation. Atf1 protein accumulates following stress, and this accumulation is lost in a strain defective in the Sty1 signaling pathway. In addition, accumulation of a mutant Atf1 I protein that can no longer be phosphorylated is lost. Measurement of the half-life of Atf1 demonstrates that changes in Atf1 stability are responsible for this accumulation. Atf1 stability is also regulated by its heterodimeric partner, Pcr1. Similarly, Pcr1 levels are regulated by Atf1. Thus multiple pathways exist that ensure that Atf1 levels are appropriately regulated. Phosphorylation of Atf1 is important for cells to mount a robust response to H2O2 stress, because the Atf1 phospho-mutant displays sensitivity to this stress, and induction of gene expression is lower than that observed in wild-type cells. Surprisingly, however, loss of Atf1 I phosphorylation does not lead to the complete loss of stress-activated expression of Atf1 target genes. Accordingly, the Atf1 phospho-mutant does not display the same overall stress sensitivities as the atf1 deletion mutant. Taken together, these data suggest that Sty1 phosphorylation of Atf1 is not required for activation of Atf1 per se but rather for modulating its stability.	Univ Manchester, Paterson Inst Canc Res, Canc Res UK Cell Regulat Lab, Manchester M20 4BX, Lancs, England	Paterson Institute for Cancer Research; University of Manchester	Wilkinson, CRM (corresponding author), Heidelberg Univ, ZMBH, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	cwilkinson@picr.man.ac.uk; Njones@picr.man.ac.uk		Lawrence, Clare/0000-0003-0170-0079; Reiter, Wolfgang/0000-0003-1266-8975	Cancer Research UK [12485] Funding Source: researchfish	Cancer Research UK(Cancer Research UK)		Alepuz PM, 2003, EMBO J, V22, P2433, DOI 10.1093/emboj/cdg243; Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; de Nadal E, 2004, NATURE, V427, P370, DOI 10.1038/nature02258; de Nadal E, 2003, MOL CELL BIOL, V23, P229, DOI 10.1128/MCB.23.1.229-237.2003; Degols G, 1996, MOL CELL BIOL, V16, P2870; Degols G, 1997, MOL CELL BIOL, V17, P3356, DOI 10.1128/MCB.17.6.3356; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hecht A, 1999, METH MOL B, V119, P469; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; Kanoh J, 1996, GENES CELLS, V1, P391, DOI 10.1046/j.1365-2443.1996.d01-247.x; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; Kon N, 1997, P NATL ACAD SCI USA, V94, P13765, DOI 10.1073/pnas.94.25.13765; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lyne R, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-27; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nguyen AN, 2000, MOL BIOL CELL, V11, P1169, DOI 10.1091/mbc.11.4.1169; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Quinn J, 2002, MOL BIOL CELL, V13, P805, DOI 10.1091/mbc.01-06-0288; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rodriguez-Gabriel MA, 2003, EMBO J, V22, P6256, DOI 10.1093/emboj/cdg597; Seeger M, 1996, J MOL BIOL, V263, P423, DOI 10.1006/jmbi.1996.0586; Shiozaki K, 1998, MOL BIOL CELL, V9, P1339, DOI 10.1091/mbc.9.6.1339; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Watanabe Y, 1996, MOL CELL BIOL, V16, P704; Wilkinson CRM, 1997, J BIOL CHEM, V272, P25768, DOI 10.1074/jbc.272.41.25768; Yamada K, 1999, YEAST, V15, P1125, DOI 10.1002/(SICI)1097-0061(199908)15:11<1125::AID-YEA442>3.0.CO;2-Z	48	74	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5160	5170		10.1074/jbc.M608526200	http://dx.doi.org/10.1074/jbc.M608526200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17182615	hybrid			2022-12-25	WOS:000244482300010
J	Lesnyak, DV; Osipiuk, J; Skarina, T; Sergiev, PV; Bogdanov, AA; Edwards, A; Savchenko, A; Joachimiak, A; Dontsova, OA				Lesnyak, Dmitry V.; Osipiuk, Jerzy; Skarina, Tatiana; Sergiev, Petr V.; Bogdanov, Alexey A.; Edwards, Aled; Savchenko, Alexei; Joachimiak, Andrzej; Dontsova, Olga A.			Methyltransferase that modifies guanine 966 of the 16 S rRNA - Functional identification and tertiary structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN-STRUCTURE; M(5)C967 METHYLTRANSFERASE; SECONDARY-STRUCTURE; MODEL; PURIFICATION; DIFFRACTION; SUBUNIT; BINDING; NUCLEOTIDES	N-2-Methylguanine 966 is located in the loop of Escherichia coli 16 S rRNA helix 31, forming a part of the P-site tRNA-binding pocket. We found yhhF to be a gene encoding for m(2)G966 specific 16 S rRNA methyltransferase. Disruption of the yhhF gene by kanamycin resistance marker leads to a loss of modification at G966. The modification could be rescued by expression of recombinant protein from the plasmid carrying the yhhF gene. Moreover, purified m(2)G966 methyltransferase, in the presence of S-adenosylomethionine (AdoMet), is able to methylate 30 S ribosomal subunits that were purified from yhhF knock-out strain in vitro. The methylation is specific for G966 base of the 16 S rRNA. The m(2)G966 methyltransferase was crystallized, and its structure has been determined and refined to 2.05 angstrom. The structure closely resembles RsmC rRNA methyltransferase, specific for m(2)G1207 of the 16 S rRNA. Structural comparisons and analysis of the enzyme active site suggest modes for binding AdoMet and rRNA to m(2)G966 methyltransferase. Based on the experimental data and current nomenclature the protein expressed from the yhhF gene was renamed to RsmD. A model for interaction of RsmD with ribosome has been proposed.	Argonne Natl Lab, Midwest Ctr Struct Genom, Biosci Div, Argonne, IL 60439 USA; Argonne Natl Lab, Struct Biol Ctr, Biosci Div, Argonne, IL 60439 USA; Moscow MV Lomonosov State Univ, Dept Bioinformat & Bioengn, Moscow 119992, Russia; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119992, Russia; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119992, Russia	United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; Lomonosov Moscow State University; University of Toronto; Lomonosov Moscow State University; Lomonosov Moscow State University	Joachimiak, A (corresponding author), Argonne Natl Lab, Midwest Ctr Struct Genom, Biosci Div, 9700 S Cass Ave,Bldg 202, Argonne, IL 60439 USA.	andrzejj@anl.gov; dontsova@genebee.msu.su	Bogdanov, Alexey A/L-1407-2013; Sergiev, Petr V/D-7493-2012; Dontsova, Olga/T-6072-2019	Sergiev, Petr V/0000-0001-8866-1863; Edwards, Aled/0000-0002-4782-6016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM074942, P50GM062414] Funding Source: NIH RePORTER; NIGMS NIH HHS [U54 GM074942, P50 GM062414-01, GM074942, P50 GM062414, GM62414, U54 GM074942-04S2] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersen NM, 2006, J MOL BIOL, V359, P777, DOI 10.1016/j.jmb.2006.04.007; Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bujnicki JM, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-10; Cannone JJ, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-15; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; CUNNINGHAM PR, 1991, BIOCHIMIE, V73, P789, DOI 10.1016/0300-9084(91)90058-9; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Foster PG, 2003, STRUCTURE, V11, P1609, DOI 10.1016/j.str.2003.10.014; Gabashvili IS, 1999, J MOL BIOL, V286, P1285, DOI 10.1006/jmbi.1999.2538; Gu XR, 1999, BIOCHEMISTRY-US, V38, P4053, DOI 10.1021/bi982364y; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Huang Lan, 2002, Journal of Structural and Functional Genomics, V2, P121, DOI 10.1023/A:1021279113558; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; JEMIOLO DK, 1991, NUCLEIC ACIDS RES, V19, P4259, DOI 10.1093/nar/19.15.4259; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kitagawa M, 2005, DNA RES, V12, P291, DOI 10.1093/dnares/dsi012; Klimasauskas S, 1998, EMBO J, V17, P317, DOI 10.1093/emboj/17.1.317; Kowalak JA, 2000, J BIOL CHEM, V275, P24484, DOI 10.1074/jbc.M002153200; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laskowski Roman A., 2003, Journal of Structural and Functional Genomics, V4, P167, DOI 10.1023/A:1026127927612; Lesnyak DV, 2006, J MOL BIOL, V364, P20, DOI 10.1016/j.jmb.2006.09.009; Levy M, 1999, J MOL EVOL, V48, P631, DOI 10.1007/PL00006506; McCloskey JA, 2005, NUCLEIC ACIDS RES, V33, pD135, DOI 10.1093/nar/gki015; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; OGara M, 1997, EUR J BIOCHEM, V247, P1009, DOI 10.1111/j.1432-1033.1997.01009.x; Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Petry S, 2005, CELL, V123, P1255, DOI 10.1016/j.cell.2005.09.039; POWERS T, 1988, J MOL BIOL, V200, P309, DOI 10.1016/0022-2836(88)90243-4; QORONFLEH MW, 1995, J BIOTECHNOL, V39, P119, DOI 10.1016/0168-1656(94)00149-7; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schuwirth BS, 2005, SCIENCE, V310, P827, DOI 10.1126/science.1117230; Sergiev PV, 2000, J MOL BIOL, V299, P379, DOI 10.1006/jmbi.2000.3739; SERGIEV PV, 2006, J MOL BIOL, V364, P25; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Tscherne JS, 1999, J BIOL CHEM, V274, P924, DOI 10.1074/jbc.274.2.924; Tscherne JS, 1999, BIOCHEMISTRY-US, V38, P1884, DOI 10.1021/bi981880l; Walsh MA, 1999, ACTA CRYSTALLOGR D, V55, P1168, DOI 10.1107/S0907444999003698; WEITZMANN C, 1991, NUCLEIC ACIDS RES, V19, P7089, DOI 10.1093/nar/19.25.7089; YOUVAN DC, 1981, NUCLEIC ACIDS RES, V9, P1723, DOI 10.1093/nar/9.7.1723; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	50	67	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5880	5887		10.1074/jbc.M608214200	http://dx.doi.org/10.1074/jbc.M608214200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189261	Green Accepted, hybrid			2022-12-25	WOS:000244482300084
J	Tang, WF; Yang, SY; Wu, BW; Jheng, JR; Chen, YL; Shih, CH; Lin, KH; Lai, HC; Tang, P; Horng, JT				Tang, Wen-Fang; Yang, Shing-Ying; Wu, Bin-Wen; Jheng, Jia-Rong; Chen, Yin-Li; Shih, Chung-Hsuan; Lin, Kwang-Huei; Lai, Hsin-Chi; Tang, Petrus; Horng, Jim-Tong			Reticulon 3 binds the 2C protein of enterovirus 71 and is required for viral replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; POLIOVIRUS REPLICATION; RNA; VIRUS; COMPLEX; INDUCTION; MEMBRANES; GOLGI; PICORNAVIRUSES; ORGANIZATION	Enterovirus 71 is an enterovirus of the family Picornaviridae. The 2C protein of poliovirus, a relative of enterovirus 71, is essential for viral replication. The poliovirus 2C protein is associated with host membrane vesicles, which form viral replication complexes where viral RNA synthesis takes place. We have now identified a host-encoded 2C binding protein called reticulon 3, which we found to be associated with the replication complex through direct interaction with the enterovirus 71-encoded 2C protein. We observed that the N terminus of the 2C protein, which has both RNA- and membrane-binding activity, interacted with reticulon 3. This region of interaction was mapped to its reticulon homology domain, whereas that of 2C was encoded by the 25th amino acid, isoleucine. Reticulon 3 could also interact with the 2C proteins encoded by other enteroviruses, such as poliovirus and coxsackievirus A16, implying that it is a common factor for such viral replication. Reduced production of reticulon 3 by RNA interference markedly reduced the synthesis of enterovirus 71-encoded viral proteins and replicative double-stranded RNA, reducing plaque formation and apoptosis. Furthermore, reintroduction of nondegradable reticulon 3 into these knockdown cells rescued enterovirus 71 infectivity, and viral protein and double-stranded RNA synthesis. Thus, reticulon 3 is an important component of enterovirus 71 replication, through its potential role in modulation of the sequential interactions between enterovirus 71 viral RNA and the replication complex.	Chang Gung Univ, Dept Biochem, Tao Yuan 333, Taiwan; Chang Gung Univ, Chang Gung Bioinformat Ctr, Tao Yuan 333, Taiwan; Natl Taiwan Univ, Dept Clin Lab Sci & Med Biotechnol, Taipei 106, Taiwan	Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; National Taiwan University	Horng, JT (corresponding author), Chang Gung Univ, Dept Biochem, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.	jimtong@mail.cgu.edu.tw		Horng, Jim-Tong/0000-0001-6294-9981; Tang, Petrus/0000-0002-2779-0116				Agol VI, 1999, VIRUS RES, V62, P129, DOI 10.1016/S0168-1702(99)00037-4; ALDABE R, 1995, BIOCHEM BIOPH RES CO, V206, P64, DOI 10.1006/bbrc.1995.1010; *APPL BIOS, 2001, US B APPL BIOS, V2; ARGOS P, 1984, NUCLEIC ACIDS RES, V12, P7251, DOI 10.1093/nar/12.18.7251; Banerjee R, 2001, J GEN VIROL, V82, P2621, DOI 10.1099/0022-1317-82-11-2621; BIENZ K, 1983, VIROLOGY, V131, P39, DOI 10.1016/0042-6822(83)90531-7; BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8; BIENZ K, 1990, J VIROL, V64, P1156, DOI 10.1128/JVI.64.3.1156-1163.1990; Bolten R, 1998, J VIROL, V72, P8578, DOI 10.1128/JVI.72.11.8578-8585.1998; CHO MW, 1994, VIROLOGY, V202, P129, DOI 10.1006/viro.1994.1329; DALES S, 1965, VIROLOGY, V26, P379, DOI 10.1016/0042-6822(65)90001-2; Di Scala F, 2005, BIOCHEM J, V385, P125, DOI 10.1042/BJ20040458; ECHEVERRI AC, 1995, VIROLOGY, V208, P540, DOI 10.1006/viro.1995.1185; Egger D, 1996, J VIROL, V70, P8675, DOI 10.1128/JVI.70.12.8675-8683.1996; Franklin NM, 2000, AQUAT TOXICOL, V48, P275, DOI 10.1016/S0166-445X(99)00042-9; FRANSSEN H, 1984, EMBO J, V3, P855, DOI 10.1002/j.1460-2075.1984.tb01896.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; HANECAK R, 1982, P NATL ACAD SCI-BIOL, V79, P3973, DOI 10.1073/pnas.79.13.3973; Iwahashi J, 2002, BIOCHEM BIOPH RES CO, V293, P698, DOI 10.1016/S0006-291X(02)00282-6; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Lai MMC, 1998, VIROLOGY, V244, P1, DOI 10.1006/viro.1998.9098; Lin XY, 2005, NUCLEIC ACIDS RES, V33, P4527, DOI 10.1093/nar/gki762; Oertle T, 2003, TRENDS CELL BIOL, V13, P187, DOI 10.1016/S0962-8924(03)00035-7; PAUL AV, 1994, VIROLOGY, V199, P188, DOI 10.1006/viro.1994.1111; Pfister T, 1999, J BIOL CHEM, V274, P6992, DOI 10.1074/jbc.274.11.6992; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Racaniello V.R., 2001, FIELDS VIROLOGY, P455; RODRIGUEZ PL, 1995, J BIOL CHEM, V270, P10105, DOI 10.1074/jbc.270.17.10105; Rust RC, 2001, J VIROL, V75, P9808, DOI 10.1128/JVI.75.20.9808-9818.2001; Salem N, 1998, NAT NEUROSCI, V1, P551, DOI 10.1038/2787; Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996; SCHONBORN J, 1991, NUCLEIC ACIDS RES, V19, P2993, DOI 10.1093/nar/19.11.2993; Senden N, 1997, HISTOCHEM CELL BIOL, V108, P155, DOI 10.1007/s004180050157; Snove O, 2004, BIOCHEM BIOPH RES CO, V319, P256, DOI 10.1016/j.bbrc.2004.04.175; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Steiner P, 2004, J NEUROCHEM, V89, P569, DOI 10.1111/j.1471-4159.2004.02345.x; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; TERSHAK DR, 1984, J VIROL, V52, P777, DOI 10.1128/JVI.52.3.777-783.1984; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Wakana Y, 2005, BIOCHEM BIOPH RES CO, V334, P1198, DOI 10.1016/j.bbrc.2005.07.012; Wong WR, 2005, LIFE SCI, V78, P82, DOI 10.1016/j.lfs.2005.04.076; Woolf CJ, 2003, NEURON, V38, P153, DOI 10.1016/S0896-6273(03)00233-2	44	111	126	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5888	5898		10.1074/jbc.M611145200	http://dx.doi.org/10.1074/jbc.M611145200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17182608	hybrid			2022-12-25	WOS:000244482300085
J	Hagerty, L; Weitzel, DH; Chambers, J; Fortner, CN; Brush, MH; Loiselle, D; Hosoya, H; Haystead, TAJ				Hagerty, Laura; Weitzel, Douglas H.; Chambers, Jenica; Fortner, Christopher N.; Brush, Matthew H.; Loiselle, David; Hosoya, Hiroshi; Haystead, Timothy A. J.			ROCK1 phosphorylates and activates zipper-interacting protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT-CHAIN; RHO-ASSOCIATED KINASE; SMOOTH-MUSCLE CONTRACTION; PHOSPHATASE-ASSOCIATED KINASE; GTP-BINDING PROTEIN; CA2+ SENSITIZATION; IN-VIVO; REGULATORY SUBUNIT; GAMMA-S; CELLS	Zipper-interacting protein kinase (ZIPK) regulates Ca2+-independent phosphorylation of both smooth muscle (to regulate contraction) and non-muscle myosin (to regulate non-apoptotic cell death) through either phosphorylation and inhibition of myosin phosphatase, the myosin phosphatase inhibitor CPI17, or direct phosphorylation of myosin light chain. ZIPK is regulated by multisite phosphorylation. Phosphorylation at least three sites Thr-180, Thr-225, and Thr-265 has been shown to be essential for full activity, whereas phosphorylation at Thr-299 regulates its intracellular localization. Herein we utilized an unbiased proteomics screen of smooth muscle extracts with synthetic peptides derived from the sequence of the regulatory phosphorylation sites of the enzyme to identify the protein kinases that might regulate ZIPK activity in vivo. Discrete kinase activities toward Thr-265 and Thr-299 were defined and identified by mass spectrometry as Rho kinase 1 (ROCK1). In vitro, ROCK1 showed a high degree of substrate specificity toward native ZIPK, both stoichiometrically phosphorylating the enzyme at Thr-265 and Thr-299 as well as bringing about activation. In HeLa cells, coexpression of ZIPK with ROCK1 altered the ROCK-induced phenotype of focused stress fiber pattern to a Rho-like phenotype of parallel stress fiber pattern. This effect was also dependent upon phosphorylation at Thr-265. Our findings provide a new regulatory pathway in smooth muscle and non-muscle cells whereby ROCK1 phosphorylates and regulates ZIP kinase.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Hiroshima Univ, Grad Sch Sci, Dept Biol Sci, Hiroshima 7398526, Japan	Duke University; Hiroshima University	Haystead, TAJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	hayst001@mc.duke.edu			NHLBI NIH HHS [R01 HL07895] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Borman MA, 2002, J BIOL CHEM, V277, P23441, DOI 10.1074/jbc.M201597200; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Croft DR, 2005, J CELL BIOL, V168, P245, DOI 10.1083/jcb.200409049; Endo A, 2004, J BIOL CHEM, V279, P42055, DOI 10.1074/jbc.M403676200; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Fu XH, 1998, FEBS LETT, V440, P183, DOI 10.1016/S0014-5793(98)01455-0; FUJITA A, 1995, J PHARMACOL EXP THER, V274, P555; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Gong MC, 1997, J BIOL CHEM, V272, P10704; Graves PR, 2005, J BIOL CHEM, V280, P9363, DOI 10.1074/jbc.M412538200; Graves PR, 2002, MOL PHARMACOL, V62, P1364, DOI 10.1124/mol.62.6.1364; Hartshorne DJ, 2004, J BIOL CHEM, V279, P37211, DOI 10.1074/jbc.R400018200; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; Haystead TAJ, 2005, CELL SIGNAL, V17, P1313, DOI 10.1016/j.cellsig.2005.05.008; Hickson GRX, 2006, CURR BIOL, V16, P359, DOI 10.1016/j.cub.2005.12.043; Hirano M, 1999, BIOCHEM BIOPH RES CO, V254, P490, DOI 10.1006/bbrc.1998.9973; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ito M, 2004, MOL CELL BIOCHEM, V259, P197, DOI 10.1023/B:MCBI.0000021373.14288.00; KAWAHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P673, DOI 10.1016/0006-291X(90)92144-O; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Leung T, 1996, MOL CELL BIOL, V16, P5313; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lontay B, 2005, CELL SIGNAL, V17, P1265, DOI 10.1016/j.cellsig.2005.01.008; Lubomirov LT, 2006, CIRC RES, V98, P1159, DOI 10.1161/01.RES.0000219904.43852.3e; Miyazaki K, 2002, J BIOL CHEM, V277, P725, DOI 10.1074/jbc.M108568200; Muranyi A, 2005, FEBS LETT, V579, P6611, DOI 10.1016/j.febslet.2005.10.055; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Murata-Hori M, 2001, ONCOGENE, V20, P8175, DOI 10.1038/sj.onc.1205055; Murthy KS, 2006, ANNU REV PHYSIOL, V68, P345, DOI 10.1146/annurev.physiol.68.040504.094707; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Niiro N, 2003, BIOCHEM J, V369, P117, DOI 10.1042/BJ20021040; Niiro N, 2001, J BIOL CHEM, V276, P29567, DOI 10.1074/jbc.M102753200; NODA M, 1995, FEBS LETT, V367, P246, DOI 10.1016/0014-5793(95)00573-R; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sato N, 2006, IMMUNOL LETT, V103, P127, DOI 10.1016/j.imlet.2005.10.015; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Sebbagh M, 2005, J EXP MED, V201, P465, DOI 10.1084/jem.20031877; Shani G, 2004, MOL CELL BIOL, V24, P8611, DOI 10.1128/MCB.24.19.8611-8626.2004; Shimizu Y, 2005, J CELL BIOL, V168, P941, DOI 10.1083/jcb.200411179; Shin HM, 2002, CIRC RES, V90, P546, DOI 10.1161/01.RES.0000012822.23273.EC; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Takizawa N, 2002, BIOCHEM BIOPH RES CO, V297, P773, DOI 10.1016/S0006-291X(02)02302-1; Thumkeo D, 2003, MOL CELL BIOL, V23, P5043, DOI 10.1128/MCB.23.14.5043-5055.2003; TRINKLEMULCAHY L, 1995, J BIOL CHEM, V270, P18191, DOI 10.1074/jbc.270.31.18191; Ueda K, 2002, ONCOGENE, V21, P5852, DOI 10.1038/sj.onc.1205747; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Velasco G, 2002, FEBS LETT, V527, P101, DOI 10.1016/S0014-5793(02)03175-7; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wooldridge AA, 2004, J BIOL CHEM, V279, P34496, DOI 10.1074/jbc.M405957200; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056	57	67	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4884	4893		10.1074/jbc.M609990200	http://dx.doi.org/10.1074/jbc.M609990200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158456	hybrid			2022-12-25	WOS:000244482000071
J	Kaileh, M; Vanden Berghe, W; Heyerick, A; Horion, J; Piette, J; Libert, C; De Keukeleire, D; Essawi, T; Haegeman, G				Kaileh, Mary; Vanden Berghe, Wim; Heyerick, Arne; Horion, Julie; Piette, Jacques; Libert, Claude; De Keukeleire, Denis; Essawi, Tamer; Haegeman, Guy			Withaferin A strongly elicits I kappa B kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; WITHANIA-SOMNIFERA; TRANSCRIPTION FACTOR; GENE-EXPRESSION; IKK-BETA; POSITIVE REGULATION; MAPK PHOSPHATASE; ACTIVATION; APOPTOSIS; ALPHA	The transcription factor NF kappa B plays a critical role in normal and pathophysiological immune responses. Therefore, NF kappa B and the signaling pathways that regulate its activation have become a major focus of drug development programs. Withania somnifera (WS) is a medicinal plant that is widely used in Palestine for the treatment of various inflammatory disorders. In this study we show that the leave extract of WS, as well as its major constituent withaferin A (WA), potently inhibits NF kappa B activation by preventing the tumor necrosis factor-induced activation of I kappa B kinase beta via a thicialkylation-sensitive redox mechanism, whereas other WS-derived steroidal lactones, such as withanolide A and 12-deoxywithastramonolide, are far less effective. To our knowledge, this is the first communication of I kappa B kinase beta inhibition by a plant-derived inhibitor, coinciding with MEK1/ERK-dependent Ser-181 hyperphosphorylation. This prevents I kappa B phosphorylation and degradation, which subsequently blocks NF kappa B translocation, NF kappa B/DNA binding, and gene transcription. Taken together, our results indicate that pure WA or WA-enriched WS extracts can be considered as a novel class of NF kappa B inhibitors, which hold promise as novel anti-inflammatory agents for treatment of various inflammatory disorders and/or cancer.	Univ Ghent, Dept Mol Biol, LEGEST, B-9000 Ghent, Belgium; Birzeit Univ, Master Program Clin Lab Sci, Birzeit, Israel; CBIG, Virol & Immunol Unit, Inst Pathol, B-4000 Liege, Belgium; Inst Pathol, Virol & Immunol Unit, CBIG, B-4000 Liege, Belgium; Flanders Interuniv Biotechnol, Dept Mol Biomed Res, B-9052 Zwijnaarde, Belgium; Univ Ghent, Lab Pharmacognosy & Phytochem, B-9000 Ghent, Belgium	Ghent University; Birzeit University; Ghent University	Haegeman, G (corresponding author), Univ Ghent, Dept Mol Biol, LEGEST, B-9000 Ghent, Belgium.	Guy.Haegeman@UGent.be	Berghe, Wim Vanden/S-6425-2018; Libert, Claude/A-6504-2010; Heyerick, Arne/A-9633-2008; Vanden Berghe, Wim/HGE-4696-2022	Berghe, Wim Vanden/0000-0003-0161-7355; Heyerick, Arne/0000-0001-6159-8040				Adams DG, 2005, J BIOL CHEM, V280, P42644, DOI 10.1074/jbc.M502464200; Aggarwal BB, 2006, EXPERT OPIN THER TAR, V10, P87, DOI 10.1517/14728222.10.1.87; Ali-Shtayeh MS, 1998, J ETHNOPHARMACOL, V60, P265, DOI 10.1016/S0378-8741(97)00153-0; Ali-Shtayeh MS, 1999, MYCOSES, V42, P665, DOI 10.1046/j.1439-0507.1999.00499.x; Amit S, 2003, SEMIN CANCER BIOL, V13, P15, DOI 10.1016/S1044-579X(02)00096-2; [Anonymous], 2004, Altern Med Rev, V9, P211; Archana R, 1999, J ETHNOPHARMACOL, V64, P91, DOI 10.1016/S0378-8741(98)00107-X; ASCHER KRS, 1984, PHYTOPARASITICA, V12, P147, DOI 10.1007/BF02981166; Azaizeh H, 2003, FITOTERAPIA, V74, P98, DOI 10.1016/S0367-326X(02)00285-X; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; Bernier M, 2006, J BIOL CHEM, V281, P2551, DOI 10.1074/jbc.M511878200; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen F, 1999, CLIN CHEM, V45, P7; Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103; Codreanu SG, 2006, BIOCHEMISTRY-US, V45, P10020, DOI 10.1021/bi060551n; Davis L, 2001, J ETHNOPHARMACOL, V75, P165, DOI 10.1016/S0378-8741(00)00404-9; De Bosscher K, 2005, P NATL ACAD SCI USA, V102, P15827, DOI 10.1073/pnas.0505554102; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Essawi T, 2000, J ETHNOPHARMACOL, V70, P343, DOI 10.1016/S0378-8741(99)00187-7; Foley TD, 2004, BIOCHEM BIOPH RES CO, V315, P568, DOI 10.1016/j.bbrc.2004.01.096; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; FUSKA J, 1984, NEOPLASMA, V31, P31; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GLOTTER E, 1973, TETRAHEDRON, V29, P1353, DOI 10.1016/S0040-4020(01)83156-2; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hertlein E, 2005, MOL CELL BIOL, V25, P4956, DOI 10.1128/MCB.25.12.4956-4968.2005; Heyninck K, 2005, TRENDS BIOCHEM SCI, V30, P1, DOI 10.1016/j.tibs.2004.11.001; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Humphries KM, 2005, J BIOL CHEM, V280, P2750, DOI 10.1074/jbc.M410242200; Jayaprakasam B, 2003, LIFE SCI, V74, P125, DOI 10.1016/j.lfs.2003.07.007; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; KIRSON I, 1977, ISRAEL J CHEM, V16, P20; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kray AE, 2005, J BIOL CHEM, V280, P35974, DOI 10.1074/jbc.M506093200; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Liang MC, 2006, BIOCHEM PHARMACOL, V71, P634, DOI 10.1016/j.bcp.2005.11.013; Liang MC, 2003, MOL PHARMACOL, V64, P123, DOI 10.1124/mol.64.1.123; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Maeng YS, 2006, CELL SIGNAL, V18, P994, DOI 10.1016/j.cellsig.2005.08.007; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Mishra L C, 2000, Altern Med Rev, V5, P334; Mohan Royce, 2004, Angiogenesis, V7, P115, DOI 10.1007/s10456-004-1026-3; Na HK, 2006, MOL CARCINOGEN, V45, P368, DOI 10.1002/mc.20225; NICHOLAS AW, 1976, BIOORG CHEM, V5, P367, DOI 10.1016/0045-2068(76)90021-3; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Pasparakis M, 2006, CELL DEATH DIFFER, V13, P861, DOI 10.1038/sj.cdd.4401870; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Peyregne VP, 2005, MOL CANCER THER, V4, P595, DOI 10.1158/1535-7163.MCT-04-0274; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Prajapati S, 2004, J BIOL CHEM, V279, P1739, DOI 10.1074/jbc.M306273200; Rahmouni S, 2006, NAT CELL BIOL, V8, P524, DOI 10.1038/ncb1398; Ran RQ, 2004, GENE DEV, V18, P1466, DOI 10.1101/gad.1188204; Reynaert NL, 2006, P NATL ACAD SCI USA, V103, P13086, DOI 10.1073/pnas.0603290103; Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899; Sandur SK, 2006, J BIOL CHEM, V281, P17023, DOI 10.1074/jbc.M601595200; Schirmer A, 2006, P NATL ACAD SCI USA, V103, P4234, DOI 10.1073/pnas.0600445103; Seth D, 2006, BIOCHEMISTRY-US, V45, P8476, DOI 10.1021/bi060157p; Shin HM, 2006, INT IMMUNOPHARMACOL, V6, P916, DOI 10.1016/j.intimp.2006.01.006; Takada Y, 2005, J BIOL CHEM, V280, P17203, DOI 10.1074/jbc.M500077200; Takada Y, 2005, BLOOD, V106, P641, DOI 10.1182/blood-2004-12-4589; Takada Y, 2006, J BIOL CHEM, V281, P5612, DOI 10.1074/jbc.M507213200; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Ueda K, 2002, FEBS LETT, V525, P48, DOI 10.1016/S0014-5793(02)03065-X; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vanden Berghe W, 1999, MOL PHARMACOL, V56, P797; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Vanden Berghe W, 2006, CANCER RES, V66, P4852, DOI 10.1158/0008-5472.CAN-05-2957; Vasudevan SA, 2005, BIOCHEM BIOPH RES CO, V330, P511, DOI 10.1016/j.bbrc.2005.03.028; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004; Wei HC, 2003, J NUTR, V133, p3811S, DOI 10.1093/jn/133.11.3811S; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yokota Y, 2006, BIOORG MED CHEM LETT, V16, P2603, DOI 10.1016/j.bmcl.2006.02.039; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	81	230	237	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4253	4264		10.1074/jbc.M606728200	http://dx.doi.org/10.1074/jbc.M606728200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17150968	hybrid			2022-12-25	WOS:000244482000005
J	Koivunen, P; Hirsila, M; Remes, AM; Hassinen, IE; Kivirikko, KI; Myllyharju, J				Koivunen, Peppi; Hirsila, Maija; Remes, Anne M.; Hassinen, Ilmo E.; Kivirikko, Kari I.; Myllyharju, Johanna			Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates - Possible links between cell metabolism and stabilization of HIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROLYL 4-HYDROXYLASE; OXYGEN SENSING PATHWAY; HEREDITARY PARAGANGLIOMA; PROLINE HYDROXYLATION; EXPRESSION; MUTATIONS; CANCER; ENZYMES; FAMILY; ALPHA	The stability and transcriptional activity of the hypoxia-inducible factors (HIFs) are regulated by two oxygen-dependent events that are catalyzed by three HIF prolyl 4-hydroxylases (HIF-P4Hs) and one HIF asparaginyl hydroxylase (FIH). We have studied possible links between metabolic pathways and HIF hydroxylases by analyzing the abilities of citric acid cycle intermediates to inhibit purified human HIF-P4Hs and FIH. Fumarate and succinate were identified as in vitro inhibitors of all three HIF-P4Hs, fumarate having K-i values of 50-80 mu M and succinate 350-460 mu M, whereas neither inhibited FIH. Oxaloacetate was an additional inhibitor of all three HIF-P4Hs with K-i values of 400-1000 mu M and citrate of HIF-P4H-3, citrate being the most effective inhibitor of FIH with a K-i of 110 mu M. Culturing of cells with fumarate diethyl or dimethyl ester, or a high concentration of monoethyl ester, stabilized HIF-1 alpha and increased production of vascular endothelial growth factor and erythropoietin. Similar, although much smaller, changes were found in cultured fibroblasts from a patient with fumarate hydratase (FH) deficiency and upon silencing FH using small interfering RNA. No such effects were seen upon culturing of cells with succinate diethyl or dimethyl ester. As FIH was not inhibited by fumarate, our data indicate that the transcriptional activity of HIF is quite high even when binding of the coactivator p300 is prevented. Our data also support recent suggestions that the increased fumarate and succinate levels present in the FH and succinate dehydrogenase-deficient tumors, respectively, can inhibit the HIF-P4Hs with consequent stabilization of HIF-alpha s and effects on tumor pathology.	Univ Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Oulu, Dept Neurol, FIN-90014 Oulu, Finland	University of Oulu; University of Oulu; University of Oulu; University of Oulu	Myllyharju, J (corresponding author), Univ Oulu, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi						Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Baysal BE, 2003, TRENDS ENDOCRIN MET, V14, P453, DOI 10.1016/j.tem.2003.08.004; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Dalgard CL, 2004, BIOCHEM J, V380, P419, DOI 10.1042/BJ20031647; Devlin AM, 2003, AM J PHYSIOL-RENAL, V284, pF753, DOI 10.1152/ajprenal.00252.2002; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gimenez-Roqueplo AP, 2001, AM J HUM GENET, V69, P1186, DOI 10.1086/324413; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; HIRSCHKAUFFMANN M, 1985, HUM GENET, V69, P332, DOI 10.1007/BF00291651; Hirsila M, 2005, FASEB J, V19, P1308, DOI 10.1096/fj.04-3399fje; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lu HS, 2005, J BIOL CHEM, V280, P41928, DOI 10.1074/jbc.M508718200; MAJAMAA K, 1984, EUR J BIOCHEM, V138, P239, DOI 10.1111/j.1432-1033.1984.tb07907.x; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Pavlicek V, 2000, EUR J APPL PHYSIOL, V81, P497, DOI 10.1007/s004210050074; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Remes AM, 2004, J MOL MED, V82, P550, DOI 10.1007/s00109-004-0563-y; SASAKI T, 1987, J BIOL CHEM, V262, P9397; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; TSCHANK G, 1991, BIOCHEM J, V275, P469, DOI 10.1042/bj2750469; Tuckerman JR, 2004, FEBS LETT, V576, P145, DOI 10.1016/j.febslet.2004.09.005; TUDERMAN L, 1977, EUR J BIOCHEM, V80, P341, DOI 10.1111/j.1432-1033.1977.tb11888.x; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	43	380	403	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4524	4532		10.1074/jbc.M610415200	http://dx.doi.org/10.1074/jbc.M610415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17182618	hybrid			2022-12-25	WOS:000244482000034
J	Mohammad, S; Baldini, G; Granell, S; Narducci, P; Martelli, AM; Baldini, G				Mohammad, Sameer; Baldini, Giovanna; Granell, Susana; Narducci, Paola; Martelli, Alberto M.; Baldini, Giulia			Constitutive traffic of melanocortin-4 receptor in neuro2A cells and immortalized hypothalamic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BETA-ARRESTINS; INTRACELLULAR-LOCALIZATION; MEDIATED ENDOCYTOSIS; ACTIVATED RECEPTOR-1; THROMBIN RECEPTORS; MORBID-OBESITY; INTERNALIZATION; AGONIST; SNAP-25	Melanocortin-4 receptor (MC4R) is a G protein-coupled receptor (GPCR) that binds a-melanocyte-stimulating hormone (alpha-MSH) and has a central role in the regulation of appetite and energy expenditure. Most GPCRs are endocytosed following binding to the agonist and receptor desensitization. Other GPCRs are internalized and recycled back to the plasma membrane constitutively, in the absence of the agonist. In unstimulated neuroblastoma cells and immortalized hypothalamic neurons, epitopetagged MC4R was localized both at the plasma membrane and in an intracellular compartment. These two pools of receptors were in dynamic equilibrium, with MC4R being rapidly internalized and exocytosed. In the absence of a-MSH, a fraction of cell surface MC4R localized together with transferrin receptor and to clathrin-coated pits. Constitutive MC4R internalization was impaired by expression of a dominant negative dynamin mutant. Thus, MC4R is internalized together with transferrin receptor by clathrin-dependent endocytosis. Cell exposure to a-MSH reduced the amount of MC4R at the plasma membrane by blocking recycling of a fraction of internalized receptor, rather than by increasing its rate of endocytosis. The data indicate that, in neuronal cells, MC4R recycles constitutively and that a-MSH modulates MC4R residency at the plasma membrane by acting at an intracellular sorting step.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; Univ Trieste, Dipartimento Morfol Umana Normale, I-34138 Trieste, Italy; Univ Bologna, Sez Anat, Cell Signalling Lab, Dipartimento Sci Anat Umane & Fisiopatol Apparato, I-40126 Bologna, Italy	University of Arkansas System; University of Arkansas Medical Sciences; University of Trieste; University of Bologna	Baldini, G (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA.	gbaldini@uams.edu	Mohammad, Sameer/GWV-2875-2022; granell, susana/H-2734-2012	Mohammad, Sameer/0000-0002-1129-7685	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053293] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53293] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adan RAH, 1996, MOL BRAIN RES, V36, P37, DOI 10.1016/0169-328X(95)00236-L; Baldini G, 1998, J CELL BIOL, V140, P305, DOI 10.1083/jcb.140.2.305; Baratti-Elbaz C, 1999, MOL ENDOCRINOL, V13, P1751, DOI 10.1210/me.13.10.1751; Chen D, 1999, BIOCHEM BIOPH RES CO, V255, P340, DOI 10.1006/bbrc.1999.0173; Chen LY, 2000, J CELL BIOL, V151, P731, DOI 10.1083/jcb.151.3.731; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Clement Karine, 2002, Am J Pharmacogenomics, V2, P177, DOI 10.2165/00129785-200202030-00003; Cone RD, 2005, NAT NEUROSCI, V8, P571, DOI 10.1038/nn1455; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; Farooqi IS, 2003, NEW ENGL J MED, V348, P1085, DOI 10.1056/NEJMoa022050; Fraile-Ramos A, 2003, TRAFFIC, V4, P243, DOI 10.1034/j.1600-0854.2003.00079.x; Gao ZH, 2003, J PHARMACOL EXP THER, V307, P870, DOI 10.1124/jpet.103.055525; Hadley ME, 1999, ANN NY ACAD SCI, V885, P1; HEIN L, 1994, J BIOL CHEM, V269, P27719; Hong Wanjin, 2005, Biochim Biophys Acta, V1744, P493; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Khong K, 2001, NEUROENDOCRINOLOGY, V74, P193, DOI 10.1159/000054686; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Koticha DK, 2002, J CELL SCI, V115, P3341; Leterrier C, 2004, J BIOL CHEM, V279, P36013, DOI 10.1074/jbc.M403990200; Leung SM, 1998, J BIOL CHEM, V273, P17732, DOI 10.1074/jbc.273.28.17732; Lubrano-Berthelier C, 2003, ANN NY ACAD SCI, V994, P49, DOI 10.1111/j.1749-6632.2003.tb03161.x; MARTYS JL, 1995, J BIOL CHEM, V270, P25976, DOI 10.1074/jbc.270.43.25976; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Mitchell H, 2004, MOL BIOL CELL, V15, P4166, DOI 10.1091/mbc.E04-03-0245; Morris DP, 2004, MOL PHARMACOL, V66, P843, DOI 10.1124/mol.104.000430; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; Murphy B, 2000, J APPL PHYSIOL, V89, P273, DOI 10.1152/jappl.2000.89.1.273; Nijenhuis WAJ, 2001, MOL ENDOCRINOL, V15, P164, DOI 10.1210/me.15.1.164; Paing MM, 2006, MOL CELL BIOL, V26, P3231, DOI 10.1128/MCB.26.8.3231-3242.2006; Paing MM, 2004, J BIOL CHEM, V279, P21938, DOI 10.1074/jbc.M401672200; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Pediani JD, 2005, MOL PHARMACOL, V67, P992, DOI 10.1124/mol.104.008417; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Pooley RD, 2006, MOL BIOL CELL, V17, P3176, DOI 10.1091/mbc.E05-12-1127; ROSS J, 1975, TISSUE CELL, V7, P107, DOI 10.1016/S0040-8166(75)80010-3; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Shinyama H, 2003, ENDOCRINOLOGY, V144, P1301, DOI 10.1210/en.2002-220931; Srinivasan S, 2004, J CLIN INVEST, V114, P1158, DOI 10.1172/JCI200421927; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; von Zastrow M, 2003, LIFE SCI, V74, P217, DOI 10.1016/j.lfs.2003.09.008; Wang GY, 1997, J CELL SCI, V110, P505; Washbourne P, 1999, J NEUROCHEM, V73, P2424, DOI 10.1046/j.1471-4159.1999.0732424.x; WEINER RI, 1992, FRONT NEUROENDOCRIN, V13, P95	48	45	46	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4963	4974		10.1074/jbc.m608283200	http://dx.doi.org/10.1074/jbc.m608283200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17166828	hybrid			2022-12-25	WOS:000244482000079
J	Yamamoto, N; Sawada, H; Izumi, Y; Kume, T; Katsuki, H; Shimohama, S; Akaike, A				Yamamoto, Noriyuki; Sawada, Hideyuki; Izumi, Yasuhiko; Kume, Toshiaki; Katsuki, Hiroshi; Shimohama, Shun; Akaike, Akinori			Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress - Relevance to Parkinson disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; ANTIOXIDANT RESPONSE ELEMENT; NERVE GROWTH-FACTOR; NF-KAPPA-B; GENE-EXPRESSION; SUBSTANTIA-NIGRA; DOPAMINERGIC-NEURONS; NF-E2-RELATED FACTOR-2; HEME OXYGENASE-1; SUBUNIT GENE	The cause of selective dopaminergic neuronal degeneration in Parkinson disease has still not been resolved, but it has been hypothesized that oxidative stress and the ubiquitin-proteasome system are important in the pathogenesis. In this report, we investigated the effect of proteasome inhibition on oxidative stress-induced cytotoxicity in PC12 cells, an in vitro model of Parkinson disease. Treatment with proteasome inhibitors provided significant protection against toxicity by 6-hydroxydopamine and H2O2 in a concentration-dependent manner. The measurement of intracellular reactive oxygen species using 2',7'-dichlorofluorescein diacetate demonstrated that lactacystin, a proteasome inhibitor, significantly reduced 6-hydroxydopamine- and H2O2-induced reactive oxygen species production. Proteasome inhibitors elevated the amount of glutathione and phosphorylated p38 mitogen-activated protein kinase (MAPK) prior to glutathione elevation. The treatment with lactacystin induced the nuclear translocation of NF-E2-related factor 2 (Nrf2) and increased the level of mRNA for gamma-glutamylcysteine synthetase, a rate-limiting enzyme in glutathione synthesis. Furthermore, SB203580, an inhibitor of p38 MAPK, abolished glutathione elevation and cytoprotection by lacta-cystin. These data suggest that proteasome inhibition afforded cyto-protection against oxidative stress by the elevation of glutathione content, and its elevation was mediated by p38 MAPK phosphorylation.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sakyo, Kyoto 6068501, Japan; Utano Natl Hosp, Ctr Neurol Dis, Dept Neurol & Clin Res Ctr, Ukyo Ku, Kyoto 6165152, Japan; Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Akaike, A (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sakyo, 46-29 Shimoadachi Cho, Kyoto 6068501, Japan.	aakaike@pharm.kyoto-u.ac.jp		Sawada, Hideyuki/0000-0002-5909-3366; Katsuki, Hiroshi/0000-0001-7595-3154				Alam ZI, 1997, J NEUROCHEM, V69, P1326; Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; AMBANI LM, 1975, ARCH NEUROL-CHICAGO, V32, P114, DOI 10.1001/archneur.1975.00490440064010; Bush KT, 1997, J BIOL CHEM, V272, P9086; Cao C, 2003, BIOCHEMISTRY-US, V42, P10348, DOI 10.1021/bi035023f; Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Dick LR, 1997, J BIOL CHEM, V272, P182; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Ding QX, 2001, FREE RADICAL BIO MED, V31, P574, DOI 10.1016/S0891-5849(01)00635-9; Dorion S, 1999, J BIOL CHEM, V274, P37591, DOI 10.1074/jbc.274.53.37591; Floor E, 1998, J NEUROCHEM, V70, P268; Galindo MF, 2003, J NEUROCHEM, V84, P1066, DOI 10.1046/j.1471-4159.2003.01592.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Huang HC, 2001, P NATL ACAD SCI USA, V98, P379; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Ibi M, 1999, J NEUROCHEM, V73, P1696, DOI 10.1046/j.1471-4159.1999.731696.x; Inden M, 2005, J PHARMACOL SCI, V97, P203, DOI 10.1254/jphs.FP0040525; Izumi Y, 2005, J NEUROSCI RES, V79, P849, DOI 10.1002/jnr.20382; Izumi Y, 2005, J NEUROSCI RES, V82, P126, DOI 10.1002/jnr.20595; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jenner P, 1998, MOVEMENT DISORD, V13, P24; JENNER P, 1993, ACTA NEUROL SCAND, V87, P6; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kitazawa M, 2001, FREE RADICAL BIO MED, V31, P1473, DOI 10.1016/S0891-5849(01)00726-2; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; LIANG YO, 1977, J MED CHEM, V20, P581, DOI 10.1021/jm00214a026; McNaught KS, 2003, ANN NEUROL, V53, pS73, DOI 10.1002/ana.10512; McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; NAPPI AJ, 1994, BBA-GEN SUBJECTS, V1201, P498, DOI 10.1016/0304-4165(94)90082-5; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Numazawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC334, DOI 10.1152/ajpcell.00043.2003; Orimo S, 1999, J NEUROL NEUROSUR PS, V67, P189, DOI 10.1136/jnnp.67.2.189; Pearce RKB, 1997, J NEURAL TRANSM, V104, P661, DOI 10.1007/BF01291884; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Phillips JB, 2000, STROKE, V31, P1686, DOI 10.1161/01.STR.31.7.1686; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Salinas M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/jbc.M209164200; Sawada H, 2005, JAMA-J AM MED ASSOC, V293, P932, DOI 10.1001/jama.293.8.932-c; Sawada H, 2004, J BIOL CHEM, V279, P10710, DOI 10.1074/jbc.M308434200; SEEGAL RF, 1989, NEUROTOXICOLOGY, V10, P757; Sekhar KR, 2000, BIOCHEM BIOPH RES CO, V270, P311, DOI 10.1006/bbrc.2000.2419; Sekhar KR, 2002, ONCOGENE, V21, P6829, DOI 10.1038/sj.onc.1205905; SHAFER TJ, 1991, NEUROTOXICOLOGY, V12, P473; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimizu E, 2002, NEUROPHARMACOLOGY, V43, P434, DOI 10.1016/S0028-3908(02)00108-9; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; van Leyen K, 2005, J NEUROCHEM, V92, P824, DOI 10.1111/j.1471-4159.2004.02915.x; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wojcik C, 2004, STROKE, V35, P1506, DOI 10.1161/01.STR.0000126891.93919.4e; Wu WT, 2004, BIOCHEM J, V379, P587, DOI 10.1042/BJ20031579; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zipper LM, 2000, BIOCHEM BIOPH RES CO, V278, P484, DOI 10.1006/bbrc.2000.3830; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	62	121	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4364	4372		10.1074/jbc.M603712200	http://dx.doi.org/10.1074/jbc.M603712200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158454	hybrid			2022-12-25	WOS:000244482000016
J	Oguariri, RM; Brann, TW; Imamichi, T				Oguariri, Raphael M.; Brann, Terrence W.; Imamichi, Tomozumi			Hydroxyurea and interleukin-6 synergistically reactivate HIV-1 replication in a latently infected promonocytic cell line via SP1/SP3 transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; NF-KAPPA-B; TUMOR NECROSIS FACTOR; LONG TERMINAL REPEAT; CD4(+) T-CELLS; IN-VIVO; HIV-1-INFECTED PATIENTS; PROMOTER ACTIVITY; ACTINOMYCIN-D	The existence of viral latency limits the success of highly active antiretroviral therapy. With the therapeutic intention of reactivating latent virus to induce a cure, in this study we assessed the impact of cell synchronizers on HIV gene activation in latently infected U1 cells and investigated the molecular mechanisms responsible for such effect. Latently infected U1 cells were treated with 10 drugs including hydroxyurea (HU) and HIV-1 replication monitored using a p24 antigen capture assay. We found that HU was able to induce HIV-1 replication by 5-fold. HU has been used in the clinical treatment of HIV-1-infected patients in combination with didanosine; therefore, we investigated the impact of HU on HIV-1 activation in the presence of the proinflammatory cytokines, interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha). IL-6 or TNF-alpha alone induced HIV replication by 18- and similar to 500-fold, respectively. Of interest, in the presence of HU, IL-6-mediated HIV-1 activation was enhanced by > 90-fold, whereas TNF-alpha-mediated activation was inhibited by > 30%. A reporter gene assay showed that HU and IL-6 synergized to activate HIV promoter activity via the Sp1 binding site. Electrophoretic mobility shift and supershift assays revealed increased binding of the Sp1 and Sp3 transcription factors to this region. Western blot analysis showed that HU and IL-6 co-stimulation resulted in increased levels of Sp1 and Sp3 proteins. In contrast, treatment with HU plus TNF-alpha down-regulated the expression of NF-kappa B. These findings suggest that Sp1/Sp3 is involved in controlling the HU/IL-6-induced reactivation of HIV-1 in latently infected cells.	SAIC Frederick Inc, Clin Serv Program, Lab Human Retrovirol, NCI Frederick,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Imamichi, T (corresponding author), SAIC Frederick Inc, Clin Serv Program, Lab Human Retrovirol, NCI Frederick,NIH, POB B,Bldg 550,Rm 126, Frederick, MD 21702 USA.	timamichi@mail.nih.gov		Imamichi, Tomozumi/0000-0002-1474-1796	NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; ANTONI BA, 1994, VIROLOGY, V202, P684, DOI 10.1006/viro.1994.1390; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; Barreiro P, 2003, HIV CLIN TRIALS, V4, P361, DOI 10.1310/4GMU-AG3T-Q3CC-GE5D; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; CANNON P, 1994, J VIROL, V68, P1993, DOI 10.1128/JVI.68.3.1993-1997.1994; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cohen J, 1998, SCIENCE, V279, P1854, DOI 10.1126/science.279.5358.1854; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Emiliani S, 1996, P NATL ACAD SCI USA, V93, P6377, DOI 10.1073/pnas.93.13.6377; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Foli A, 1997, Antivir Ther, V2, P31; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOLKS TM, 1988, J IMMUNOL, V140, P1117; Frank I, 1999, J BIOL REG HOMEOS AG, V13, P186; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; GAO WY, 1994, MOL PHARMACOL, V46, P767; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAREL J, 1981, VIROLOGY, V110, P202, DOI 10.1016/0042-6822(81)90022-2; Havlir DV, 2001, AIDS, V15, P1379, DOI 10.1097/00002030-200107270-00007; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; Imamichi T, 2005, JAIDS-J ACQ IMM DEF, V40, P388, DOI 10.1097/01.qai.0000179466.25700.2f; Imamichi T, 2003, J VIROL, V77, P1011, DOI 10.1128/JVI.77.2.1011-1020.2003; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; Johns DG, 1998, BIOCHEM PHARMACOL, V55, P1551, DOI 10.1016/S0006-2952(97)00664-3; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Loeffler S, 2005, INT J CANCER, V115, P202, DOI 10.1002/ijc.20871; Lori F, 2000, J BIOL REG HOMEOS AG, V14, P45; Lori F, 1998, ANTIVIR THER, V3, P81; Lori F, 1997, AIDS RES HUM RETROV, V13, P1403, DOI 10.1089/aid.1997.13.1403; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; Lori Franco, 2004, Expert Opin Drug Saf, V3, P279, DOI 10.1517/14740338.3.4.279; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALLEY SD, 1994, LANCET, V343, P1292, DOI 10.1016/S0140-6736(94)92182-2; Marcello A, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-7; MCCUNE JM, 1995, CELL, V82, P183, DOI 10.1016/0092-8674(95)90305-4; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; Quivy V, 2002, J VIROL, V76, P11091, DOI 10.1128/JVI.76.21.11091-11103.2002; Romanelli F, 2006, CURR PHARM DESIGN, V12, P1121, DOI 10.2174/138161206776055868; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; Rutschmann OT, 1998, ANTIVIR THER, V3, P65; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; Siliciano Robert F, 2005, Top HIV Med, V13, P96; Yedavalli VSRK, 2003, J BIOL CHEM, V278, P6404, DOI 10.1074/jbc.M209162200	62	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3594	3604		10.1074/jbc.M608150200	http://dx.doi.org/10.1074/jbc.M608150200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17150965	hybrid			2022-12-25	WOS:000244481900021
J	Kondoh, K; Sunadome, K; Nishida, E				Kondoh, Kunio; Sunadome, Kazunori; Nishida, Eisuke			Notch signaling suppresses p38 MAPK activity via induction of MKP-1 in myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION; SATELLITE CELL; RBP-J; PATHWAY; PHOSPHATASES; MYOD; TRANSCRIPTION; PHOSPHORYLATION	Cross-talks among intracellular signaling pathways are important for the regulation of cell fate decisions and cellular responses to extracellular signals. Both the Notch pathway and the MAPK pathways play important roles in many biological processes, and the Notch pathway has been shown to interact with the ERK-type MAPK pathway. However, its interaction with the other MAPK pathways is unknown. Here we show that Notch signaling activation in C2C12 cells suppresses the activity of p38 MAPK to inhibit myogenesis. Our results show that Notch specifically induces expression of MKP-1, a member of the dual-specificity MAPK phosphatase, which directly inactivates p38 to negatively regulate C2C12 myogenesis. The Notch-induced expression of MKP-1 is shown to depend on RBP-J. Moreover, inhibition of MKP-1 expression by short interfering RNA suppresses p38 inactivation and partially rescues the negative regulation of myogenesis. These results reveal a novel cross-talk between the Notch pathway and the p38 MAPK pathway that is mediated by Notch induction of MKP-1.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.	L50174@sakura.kudpc.kyoto-u.ac.jp		Kondoh, Kunio/0000-0002-1139-328X				Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bergstrom DA, 2002, MOL CELL, V9, P587, DOI 10.1016/S1097-2765(02)00481-1; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHARLES CH, 1992, ONCOGENE, V7, P187; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dinev D, 2001, EMBO REP, V2, P829, DOI 10.1093/embo-reports/kve177; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jones NC, 2005, J CELL BIOL, V169, P105, DOI 10.1083/jcb.200408066; Kato H, 1997, DEVELOPMENT, V124, P4133; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; Nakagawa S, 1998, DEVELOPMENT, V125, P2963; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Penn BH, 2004, GENE DEV, V18, P2348, DOI 10.1101/gad.1234304; Shawber C, 1996, DEVELOPMENT, V122, P3765; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	37	66	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3058	3065		10.1074/jbc.M607630200	http://dx.doi.org/10.1074/jbc.M607630200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17158101	hybrid			2022-12-25	WOS:000243793900032
J	Luthra, R; Kerr, SC; Harreman, MT; Apponi, LH; Fasken, MB; Ramineni, S; Chaurasia, S; Valentini, SR; Corbett, AH				Luthra, Roopa; Kerr, Shana C.; Harreman, Michelle T.; Apponi, Luciano H.; Fasken, Milo B.; Ramineni, Suneela; Chaurasia, Shyam; Valentini, Sandro R.; Corbett, Anita H.			Actively transcribed GAL genes can be physically linked to the nuclear pore by the SAGA chromatin modifying complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; IN-VIVO; CHROMOSOME TERRITORIES; NUCLEOSOME ACETYLATION; YEAST; RECRUITMENT; ORGANIZATION; COACTIVATOR; COMPONENTS; EXPRESSION	Recent work has demonstrated that some actively transcribed genes closely associate with nuclear pore complexes (NPC) at the nuclear periphery. The Saccharomyces cerevisiae Mlp1 and Mlp2 proteins are components of the inner nuclear basket of the nuclear pore that mediate interactions with these active genes. To investigate the physical link between the NPC and active loci, we identified proteins that interact with the carboxyl-terminal globular domain of Mlp1 by tandem affinity purification coupled with mass spectrometry. This analysis led to the identification of several components of the Spt-Ada-Gcn5-acetyltransferase ( SAGA) histone acetyltransferase complex, Gcn5, Ada2, and Spt7. We utilized co-immunoprecipitation and in vitro binding assays to confirm the interaction between the Mlp proteins and SAGA components. Chromatin immunoprecipitation experiments revealed that Mlp1 and SAGA components associate with the same region of the GAL promoters. Critically, this Mlp-promoter interaction depends on the integrity of the SAGA complex. These results identify a physical association between SAGA and the NPC, and support previous results that relied upon visualization of GAL loci at the nuclear periphery by microscopy ( Cabal, G. G. Genovesio, A., Rodriguez-Navarro, S., Zimmer, C., Gadal, O., Lesne, A., Buc, H., Feuerbach- Fournier, F., Olivo-Marin, J.-C., Hurt, E. C., and Nehrbass, U. ( 2006) Nature 441, 770-773). We propose that a physical interaction between nuclear pore components and the SAGA complex can link the actively transcribed GAL genes to the nuclear pore.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA; Univ Estadual Paulista, Sao Paulo State Univ, Sch Pharmaceut Sci, Dept Biol Sci, BR-14801902 Sao Paulo, Brazil	Emory University; Emory University; Emory University; Universidade Estadual Paulista	Corbett, AH (corresponding author), 1510 Clifton Rd NE, Atlanta, GA 30322 USA.	acorbe2@emory.edu	Corbett, Anita/AAH-6106-2021; Chaurasia, Shyam/AAB-4709-2019; Fasken, Milo/K-2177-2019; Valentini, Sandro R/C-4353-2012; Apponi, Luciano H/A-4081-2013	Corbett, Anita/0000-0002-0461-6895; Chaurasia, Shyam/0000-0001-8725-676X; Fasken, Milo/0000-0003-4317-7909; Valentini, Sandro Roberto/0000-0003-4453-5413	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058728] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058728] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; Balasubramanian R, 2002, J BIOL CHEM, V277, P7989, DOI 10.1074/jbc.M110849200; Baxter J, 2002, CURR OPIN CELL BIOL, V14, P372, DOI 10.1016/S0955-0674(02)00339-3; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brickner JH, 2004, PLOS BIOL, V2, P1843, DOI 10.1371/journal.pbio.0020342; Bryant GO, 2003, MOL CELL, V11, P1301, DOI 10.1016/S1097-2765(03)00144-8; Cabal GG, 2006, NATURE, V441, P770, DOI 10.1038/nature04752; Casolari JM, 2005, GENE DEV, V19, P1188, DOI 10.1101/gad.1307205; Casolari JM, 2004, CELL, V117, P427, DOI 10.1016/S0092-8674(04)00448-9; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Cremer T, 2006, CURR OPIN CELL BIOL, V18, P307, DOI 10.1016/j.ceb.2006.04.007; Dieppois G, 2006, MOL CELL BIOL, V26, P7858, DOI 10.1128/MCB.00870-06; Drubin DA, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-19; Galy V, 2004, CELL, V116, P63, DOI 10.1016/S0092-8674(03)01026-2; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Green DM, 2003, P NATL ACAD SCI USA, V100, P1010, DOI 10.1073/pnas.0336594100; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Larschan E, 2005, MOL CELL BIOL, V25, P114, DOI 10.1128/MCB.25.1.114-123.2005; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lei EP, 2003, MOL BIOL CELL, V14, P836, DOI 10.1091/mbc.E02-08-0520; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007; Menon BB, 2005, P NATL ACAD SCI USA, V102, P5749, DOI 10.1073/pnas.0501768102; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmid M, 2006, MOL CELL, V21, P379, DOI 10.1016/j.molcel.2005.12.012; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; Sterner DE, 2002, J BIOL CHEM, V277, P8178, DOI 10.1074/jbc.M108601200; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Strambio-de-Castillia C, 1999, J CELL BIOL, V144, P839, DOI 10.1083/jcb.144.5.839; Taddei A, 2006, NATURE, V441, P774, DOI 10.1038/nature04845; Vinciguerra P, 2005, EMBO J, V24, P813, DOI 10.1038/sj.emboj.7600527; Williams RRE, 2003, TRENDS GENET, V19, P298, DOI 10.1016/S0168-9525(03)00109-4; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wu PYJ, 2004, MOL CELL, V15, P199, DOI 10.1016/j.molcel.2004.06.005; Wu PYJ, 2002, MOL CELL BIOL, V22, P5367, DOI 10.1128/MCB.22.15.5367-5379.2002	49	102	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3042	3049		10.1074/jbc.M608741200	http://dx.doi.org/10.1074/jbc.M608741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17158105	hybrid			2022-12-25	WOS:000243793900030
J	Orth, JHC; Aktories, K; Kubatzky, KF				Orth, Joachim H. C.; Aktories, Klaus; Kubatzky, Katharina F.			Modulation of host cell gene expression through activation of STAT transcription factors by Pasteurella multocida toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICOBACTER-PYLORI; ALPHA-INTERFERON; CYCLE PROGRESSION; BACTERIAL TOXINS; GAMMA-INTERFERON; JAK/STAT PATHWAY; TYROSINE KINASE; GROWTH; RECEPTOR; G-ALPHA(Q)	The Pasteurella multocida toxin (PMT) is highly mitogenic and has potential carcinogenic properties. PMT causes porcine atrophic rhinitis that is characterized by bone resorption and loss of nasal turbinates, but experimental nasal infection also leads to excess proliferation of bladder epithelial cells. PMT acts intracellularly and activates phospholipase C-linked signals and MAPK pathways via the heterotrimeric G alpha(q) and G alpha(12/13) proteins. We found that PMT induces activation of STAT proteins, and we identified STAT1, STAT3, and STAT5 as new targets of PMT-induced G alpha q signaling. Inhibition of Janus kinases completely abolished STAT activation. PMT-dependent STAT phosphorylation remained constitutive for at least 18 h. PMT caused down-regulation of the expression of the suppressor of cytokine signaling-3, indicating a novel mechanism to maintain activation of STATs. Moreover, stimulation of Swiss 3T3 cells with PMT increased transcription of the cancer-associated STAT-dependent gene cyclooxygenase-2. Because constitutive activation of STATs has been found in a number of cancers, our findings offer a new mechanism for a carcinogenic role of PMT.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Kubatzky, KF (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Albertstr 25, D-79104 Freiburg, Germany.	kubatzky@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436; Kubatzky, Katharina F./0000-0003-3739-9329				Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Busch C, 2001, INFECT IMMUN, V69, P3628, DOI 10.1128/IAI.69.6.3628-3634.2001; Court M, 2002, J INFECT DIS, V186, P1348, DOI 10.1086/344321; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dudet LI, 1996, J CELL PHYSIOL, V168, P173; Dumoutier L, 2004, J BIOL CHEM, V279, P32269, DOI 10.1074/jbc.M404789200; FERRAND A, 1995, J BIOL CHEM, V280, P10710; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Gilsbach R, 2006, BIOTECHNIQUES, V40, P173, DOI 10.2144/000112052; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; Juttner S, 2003, CELL MICROBIOL, V5, P821, DOI 10.1046/j.1462-5822.2003.00324.x; KIMMAN TG, 1987, INFECT IMMUN, V55, P2110, DOI 10.1128/IAI.55.9.2110-2116.1987; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; Lax AJ, 2005, NAT REV MICROBIOL, V3, P343, DOI 10.1038/nrmicro1130; Lax AJ, 2004, INT J MED MICROBIOL, V293, P505, DOI 10.1078/1438-4221-00287; Lax AJ, 2002, TRENDS MICROBIOL, V10, P293, DOI 10.1016/S0966-842X(02)02360-0; Lax AJ, 2001, INT J MED MICROBIOL, V291, P261, DOI 10.1078/1438-4221-00129; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Nardone G, 2004, ALIMENT PHARM THER, V20, P261, DOI 10.1111/j.1365-2036.2004.02075.x; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Offermanns S, 1998, ONCOGENE, V17, P1375, DOI 10.1038/sj.onc.1202173; Orth JHC, 2005, J BIOL CHEM, V280, P36701, DOI 10.1074/jbc.M507203200; Orth JHC, 2004, J BIOL CHEM, V279, P34150, DOI 10.1074/jbc.M405353200; Oswald E, 2005, CURR OPIN MICROBIOL, V8, P83, DOI 10.1016/j.mib.2004.12.011; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; Sabri A, 2002, CIRC RES, V90, P850, DOI 10.1161/01.RES.0000016165.23795.1F; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Stross C, 2006, J BIOL CHEM, V281, P8458, DOI 10.1074/jbc.M511212200; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Thompson JE, 2002, BIOORG MED CHEM LETT, V12, P1219, DOI 10.1016/S0960-894X(02)00106-3; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Ward PN, 1998, INFECT IMMUN, V66, P5636, DOI 10.1128/IAI.66.12.5636-5642.1998; Wilson BA, 2000, INFECT IMMUN, V68, P4531, DOI 10.1128/IAI.68.8.4531-4538.2000; Wilson BA, 1999, INFECT IMMUN, V67, P80, DOI 10.1128/IAI.67.1.80-87.1999; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zywietz A, 2001, J BIOL CHEM, V276, P3840, DOI 10.1074/jbc.M007819200	49	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3050	3057		10.1074/jbc.M609018200	http://dx.doi.org/10.1074/jbc.M609018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17150962	hybrid			2022-12-25	WOS:000243793900031
J	Ferrand, N; Demange, C; Prunier, C; Seo, SR; Atfi, A				Ferrand, Nathalie; Demange, Christine; Prunier, Celine; Seo, Su Ryeon; Atfi, Azeddine			A mechanism for mutational inactivation of the homeodomain protein TGIF in holoprosencephaly	FASEB JOURNAL			English	Article						nuclear aggregates; severe forebrain and craniofacial malformations; transcriptional repression; ubiquitin-dependent degradation	SMAD2 TRANSCRIPTIONAL ACTIVITY; TGF-BETA RECEPTOR; DEGRADATION; COREPRESSOR; COMPLEX; GENE; MICE	The homeodomain protein TGIF functions as a negative modulator for multiple classes of transcription factors. Loss of function mutations in a single copy of TGIF result in holoprosencephaly, a developmental anomaly leading to severe forebrain and craniofacial malformations. However, the mechanisms by which these mutations disrupt the functions of TGIF remain to be elucidated. Here we show that a holoprosencephaly mutation (P63R) interferes with the ability of TGIF to act as a corepressor for c-Jun and Smad2, suggesting that this holoprosencephaly mutation may lead to a general defect in the TGIF protein. In fact, we observed that the P63R mutation affects folding of the TGIF protein, resulting in the disruption of the diffuse nuclear staining pattern characteristic of wild-type (WT) TGIF and the accumulation of TGIF in nuclear aggregates. We also show that the mutant TGIF.P63R is degraded more rapidly when compared with WT TGIF and that this degradation occurs through the ubiquitin-proteasome pathway. Furthermore, we observed that TGIF.P63R homodimerizes with WT TGIF to sequester it into nuclear aggregates and to enhance its ubiquitin-dependent degradation. These results reveal an important mechanism for the degradation of TGIF through the ubiquitin-proteasome pathway, whose deregulation might contribute to the development of human holoprosencephaly.	Hop St Antoine, INSERM, U 673, F-75571 Paris 12, France; Lerner Res Inst, Dept Cell Biol, Cleveland, OH USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Cleveland Clinic Foundation	Atfi, A (corresponding author), Hop St Antoine, INSERM, U 673, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	atfi@st-antoine.inserm.fr	Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273				Bartholin L, 2006, MOL CELL BIOL, V26, P990, DOI 10.1128/MCB.26.3.990-1001.2006; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 2000, J CELL BIOCHEM, P40; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823; Gripp KW, 2000, NAT GENET, V25, P205, DOI 10.1038/76074; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Mar L, 2006, MOL CELL BIOL, V26, P4302, DOI 10.1128/MCB.02156-05; Massague J, 2000, GENE DEV, V14, P627; Pessah M, 2002, J BIOL CHEM, V277, P29094, DOI 10.1074/jbc.M202831200; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; Shen J, 2005, MOL CELL BIOL, V25, P3639, DOI 10.1128/MCB.25.9.3639-3647.2005; Wallis D, 2000, HUM MUTAT, V16, P99, DOI 10.1002/1098-1004(200008)16:2<99::AID-HUMU2>3.0.CO;2-0; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1	27	10	11	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					488	496		10.1096/fj.06-6423com	http://dx.doi.org/10.1096/fj.06-6423com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158784				2022-12-25	WOS:000244686300022
J	Lee, SY; Patton, SM; Henderson, RJ; Connor, JR				Lee, Sang Y.; Patton, Stephanie M.; Henderson, Rebecca J.; Connor, James R.			Consequences of expressing mutants of the hemochromatosis gene (HFE) into a human neuronal cell line lacking endogenous HFE	FASEB JOURNAL			English	Article						gene expression; iron-responsive elements; iron regulatory proteins; quantitative real-time polymerase chain reaction; oxidative stress	AMYOTROPHIC-LATERAL-SCLEROSIS; REGULATORY PROTEIN-ACTIVITY; LABILE IRON POOL; TRANSFERRIN RECEPTOR; ALZHEIMERS-DISEASE; INTRACELLULAR IRON; MUTATIONS; ASSOCIATION; C282Y; SYSTEM	HFE mutations have traditionally been associated with the iron overload disorder known as hemochromatosis. Recently, it has become clear that the two most common mutations in the HFE gene, H63D and C282Y, may be genetic modifiers for risk of neurodegenerative disorders and cancer, respectively. We developed human neuroblastoma stable cell lines that express either wild-type (WT) or mutant HFE to determine the cellular consequences of the mutant forms of HFE. The presence of the C282Y mutation was associated with relatively higher labile iron pool and iron regulatory protein activity than WT or H63D HFE. Targeted gene arrays revealed that the signal transduction pathway was up-regulated in the C282Y cells. H63D cells had higher levels of lipid peroxidation, protein oxidation, and lower mitochondrial membrane potential, suggesting higher baseline stress. This cell fine was also more vulnerable to exposure to oxidative stress agents and more responsive to iron chelation than the C282Y cells. These data demonstrate that the different mutations in the HFE gene have unique effects on the cells and provide insights into how the different mutations may have different clinical consequences. The results also raise multiple novel questions for future study about the function of the HFE protein.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Neurosurg,GM Leader Family Lab Alzheimers Di, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Connor, JR (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Neurosurg,GM Leader Family Lab Alzheimers Di, H110,500 Univ Dr,H110, Hershey, PA 17033 USA.	jconnor@psu.edu		Lee, Sang/0000-0003-3911-8316				Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1; Berlin D, 2004, NEUROBIOL AGING, V25, P465, DOI 10.1016/j.neurobiolaging.2003.06.008; Best LG, 2001, CLIN GENET, V60, P68, DOI 10.1034/j.1399-0004.2001.600111.x; Byrnes V, 2001, GENET TEST, V5, P127, DOI 10.1089/109065701753145583; Cabantchik ZI, 1996, ANAL BIOCHEM, V233, P221, DOI 10.1006/abio.1996.0032; Candore G, 2003, MECH AGEING DEV, V124, P525, DOI 10.1016/S0047-6374(03)00031-9; Cauza E, 2003, AM J GASTROENTEROL, V98, P442, DOI 10.1016/S0002-9270(02)05890-2; Combarros O, 2003, DEMENT GERIATR COGN, V15, P151, DOI 10.1159/000068480; CONNNOR JR, 2006, IN PRESS J ALZHEIMER; Connor JR, 2001, J ALZHEIMERS DIS, V3, P471, DOI 10.3233/JAD-2001-3506; CONNOR JR, 1994, J NEUROSCI RES, V37, P461, DOI 10.1002/jnr.490370405; Corsi B, 1999, FEBS LETT, V460, P149, DOI 10.1016/S0014-5793(99)01330-7; Drakesmith H, 2002, P NATL ACAD SCI USA, V99, P15602, DOI 10.1073/pnas.242614699; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; Esteller M, 2002, CANCER RES, V62, P5902; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feeney GP, 2001, BBA-MOL CELL RES, V1538, P242, DOI 10.1016/S0167-4889(01)00075-1; Floor E, 2000, CELL MOL BIOL, V46, P709; Goodall EF, 2005, NEUROLOGY, V65, P934, DOI 10.1212/01.wnl.0000176032.94434.d4; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Hellerbrand C, 2003, CLIN GASTROENTEROL H, V1, P279, DOI 10.1016/S1542-3565(03)00132-0; Henderson RJ, 2005, BBA-MOL CELL RES, V1743, P162, DOI 10.1016/j.bbamcr.2004.09.032; Jason J, 2001, CLIN EXP IMMUNOL, V126, P466, DOI 10.1046/j.1365-2249.2001.01707.x; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; Kallianpur AR, 2004, CANCER EPIDEM BIOMAR, V13, P205, DOI 10.1158/1055-9965.EPI-03-0188; Lee SY, 2005, NEUROBIOL AGING, V26, P803, DOI 10.1016/j.neurobiolaging.2004.08.006; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Li PA, 2004, MOL BRAIN RES, V120, P115, DOI 10.1016/j.molbrainres.2003.10.013; Lucotte G, 2001, BLOOD CELL MOL DIS, V27, P892, DOI 10.1006/bcmd.2001.0451; Malaspina A, 2001, J NEUROCHEM, V77, P132, DOI 10.1046/j.1471-4159.2001.t01-1-00231.x; Merryweather-Clarke AT, 2000, GENET TEST, V4, P183, DOI 10.1089/10906570050114902; Moalem S, 2000, AM J MED GENET, V95, P189, DOI 10.1002/1096-8628(20001113)95:2<189::AID-AJMG21>3.0.CO;2-7; Murphy S, 1998, TISSUE ANTIGENS, V52, P484, DOI 10.1111/j.1399-0039.1998.tb03076.x; Niederau Claus, 1999, Journal of Hepatology, V30, P6; Nonn L, 2003, MOL CANCER RES, V1, P682; Pantopoulos K, 2004, ANN NY ACAD SCI, V1012, P1, DOI 10.1196/annals.1306.001; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; Powell LW, 2000, J HEPATOL, V32, P48, DOI 10.1016/S0168-8278(00)80415-8; Pulliam JF, 2003, AM J MED GENET B, V119B, P48, DOI 10.1002/ajmg.b.10069; Riedel HD, 1999, BLOOD, V94, P3915, DOI 10.1182/blood.V94.11.3915.423k27_3915_3921; Robb SJ, 1999, J NEUROSCI RES, V56, P166, DOI 10.1002/(SICI)1097-4547(19990415)56:2<166::AID-JNR6>3.0.CO;2-S; Robb SJ, 1998, BRAIN RES, V788, P125, DOI 10.1016/S0006-8993(97)01543-6; Robb SJ, 1999, J NEUROSCI RES, V55, P674, DOI 10.1002/(SICI)1097-4547(19990315)55:6<674::AID-JNR3>3.0.CO;2-J; Robson KJH, 2004, J MED GENET, V41, P261, DOI 10.1136/jmg.2003.015552; Roy CN, 2000, FEBS LETT, V484, P271, DOI 10.1016/S0014-5793(00)02173-6; Roy CN, 2002, J CELL PHYSIOL, V190, P218, DOI 10.1002/JCP.10056; Ryan E, 1998, BLOOD CELL MOL DIS, V24, P428, DOI 10.1006/bcmd.1998.0211; Ryan F, 2000, BRIT J BIOMED SCI, V57, P315; Sampietro M, 2001, NEUROBIOL AGING, V22, P563, DOI 10.1016/S0197-4580(01)00219-6; Shaheen NJ, 2003, JNCI-J NATL CANCER I, V95, P154, DOI 10.1093/jnci/95.2.154; Syrjakoski K, 2006, INT J CANCER, V118, P518, DOI 10.1002/ijc.21331; Wang J, 2003, BIOCHEM J, V370, P891, DOI 10.1042/BJ20021607; Wang XS, 2004, J NEUROL SCI, V227, P27, DOI 10.1016/j.jns.2004.08.003; Ye Z, 1999, BIOCHEM BIOPH RES CO, V264, P709, DOI 10.1006/bbrc.1999.1554; Yen AA, 2004, NEUROLOGY, V62, P1611, DOI 10.1212/01.WNL.0000123114.04644.CC; Zhang XS, 2005, GLIA, V52, P199, DOI 10.1002/glia.20235	58	52	53	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					564	576		10.1096/fj.06-6397com	http://dx.doi.org/10.1096/fj.06-6397com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17194693				2022-12-25	WOS:000244686300029
J	Milton, CC; Ulane, CM; Rutherford, S				Milton, Claire C.; Ulane, Christina M.; Rutherford, Suzannah			Control of Canalization and Evolvability by Hsp90	PLOS ONE			English	Article								Partial reduction of Hsp90 increases expression of morphological novelty in qualitative traits of Drosophila and Arabidopsis, but the extent to which the Hsp90 chaperone also controls smaller and more likely adaptive changes in natural quantitative traits has been unclear. To determine the effect of Hsp90 on quantitative trait variability we deconstructed genetic, stochastic and environmental components of variation in Drosophila wing and bristle traits of genetically matched flies, differing only by Hsp90 loss-of-function or wild-type alleles. Unexpectedly, Hsp90 buffering was remarkably specific to certain normally invariant and highly discrete quantitative traits. Like the qualitative trait phenotypes controlled by Hsp90, highly discrete quantitative traits such as scutellor and thoracic bristle number are threshold traits. When tested across genotypes sampled from a wild population or in laboratory strains, the sensitivity of these traits to many types of variation was coordinately controlled, while continuously variable bristle types and wing size, and critically invariant left-right wing asymmetry, remained relatively unaffected. Although increased environmental variation and developmental noise would impede many types of selection response, in replicate populations in which Hsp90 was specifically impaired, heritability and 'extrinsic evolvability', the expected response to selection, were also markedly increased. However, despite the overall buffering effect of Hsp90 on variation in populations, for any particular individual or genotype in which Hsp90 was impaired, the size and direction of its effects were unpredictable. The trait and genetic-background dependence of Hsp90 effects and its remarkable bias toward invariant or canalized traits support the idea that traits evolve independent and trait-specific mechanisms of canalization and evolvability through their evolution of non-linearity and thresholds. Highly non-linear responses would buffer variation in Hsp90-dependent signaling over a wide range, while over a narrow range of signaling near trait thresholds become more variable with increasing probability of triggering all-or-none developmental responses.	[Rutherford, Suzannah] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; [Milton, Claire C.] Univ Melbourne, Ctr Environm Stress & Adaptat Res, Melbourne, Vic, Australia	Fred Hutchinson Cancer Center; University of Melbourne	Rutherford, S (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1124 Columbia St, Seattle, WA 98104 USA.	srutherf@fhcrc.org	Rutherford, Suzannah/L-7355-2019	Rutherford, Suzannah/0000-0002-7809-3337	Damon Runyon-Walter Winchel Foundation; NIH [R01 GM068873]; Australian Research Council; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068873] Funding Source: NIH RePORTER	Damon Runyon-Walter Winchel Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Australian Research Council(Australian Research Council); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a Scholar Award of the Damon Runyon-Walter Winchel Foundation and by NIH R01 GM068873 ( S. R.) and by the Australian Research Council ( C. C. M.).	Ancel LW, 2000, J EXP ZOOL, V288, P242, DOI 10.1002/1097-010X(20001015)288:3<242::AID-JEZ5>3.0.CO;2-O; Bergman A, 2003, NATURE, V424, P549, DOI 10.1038/nature01765; Bishop CD, 2002, DEV GENES EVOL, V212, P70, DOI 10.1007/s00427-002-0212-9; Calleja M, 2002, GENE, V292, P1, DOI 10.1016/S0378-1119(02)00628-5; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DEBAT V, 2006, EVOLUTION IN PRESS; Dickinson WJ, 1999, NATURE, V399, P30, DOI 10.1038/19894; DING D, 1993, MOL CELL BIOL, V13, P3773, DOI 10.1128/MCB.13.6.3773; Eshel I, 1998, GENETICS, V149, P2119; FALCONER DS, 1996, INTRO QUANTITATIVE G, pR13; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Frankel J, 2001, J EUKARYOT MICROBIOL, V48, P147, DOI 10.1111/j.1550-7408.2001.tb00297.x; Frankel J, 2001, J EUKARYOT MICROBIOL, V48, P135, DOI 10.1111/j.1550-7408.2001.tb00296.x; Fry JD, 1998, GENETICS, V148, P1171; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Gibson G, 2000, BIOESSAYS, V22, P372, DOI 10.1002/(SICI)1521-1878(200004)22:4<372::AID-BIES7>3.0.CO;2-J; Gilchrist GW, 2001, GENETICA, V112, P273, DOI 10.1023/A:1013358931816; GOLDBETER A, 1984, J BIOL CHEM, V259, P14441; Hermisson J, 2004, GENETICS, V168, P2271, DOI 10.1534/genetics.104.029173; HOULE D, 1992, GENETICS, V130, P195; Huey RB, 2000, SCIENCE, V287, P308, DOI 10.1126/science.287.5451.308; Judd EM, 2000, BIOESSAYS, V22, P507, DOI 10.1002/(SICI)1521-1878(200006)22:6<507::AID-BIES3>3.0.CO;2-0; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; Loubradou G, 1997, GENETICS, V147, P581; Loubradou G, 1999, GENETICS, V152, P519; Lynch Michael, 1998; MARKOW T.A., 1994, DEV INSTABILITY ITS; Meiklejohn CD, 2002, TRENDS ECOL EVOL, V17, P468, DOI 10.1016/S0169-5347(02)02596-X; Milton CC, 2003, P NATL ACAD SCI USA, V100, P13396, DOI 10.1073/pnas.1835613100; MOHLER JD, 1965, GENETICS, V51, P329; Nijhout HF, 2003, EVOL DEV, V5, P281, DOI 10.1046/j.1525-142X.2003.03035.x; Nollen EAA, 2002, J CELL SCI, V115, P2809; PALMER RA, 1994, FLUCTUATING ASYMMETR; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PINEIRO R, 1992, J HERED, V83, P445, DOI 10.1093/oxfordjournals.jhered.a111249; Powell J. R., 1997, PROGR PROSPECTS EVOL; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Rendel J. M., 1967, CANALISATION GENE CO; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Roberts SP, 1999, OECOLOGIA, V121, P323, DOI 10.1007/s004420050935; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Rutherford SL, 2000, BIOESSAYS, V22, P1095, DOI 10.1002/1521-1878(200012)22:12&lt;1095::AID-BIES7&gt;3.0.CO;2-A; Rutherford SL, 2003, NAT REV GENET, V4, P263, DOI 10.1038/nrg1041; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SCHARLOO W, 1991, ANNU REV ECOL SYST, V22, P65, DOI 10.1146/annurev.es.22.110191.000433; SCHMALHAUSEN, 1986, FACTORS EVOLUTION TH; Simpson P, 1999, DEVELOPMENT, V126, P1349; STEARNS SC, 1995, J EVOLUTION BIOL, V8, P539, DOI 10.1046/j.1420-9101.1995.8050539.x; vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961; WADDINGTON C. H., 1957, The strategy of the genes. A discussion of some aspects of theoretical biology. With an appendix by H. Kacser.; Wagner GP, 1997, EVOLUTION, V51, P329, DOI [10.2307/2411105, 10.1111/j.1558-5646.1997.tb02420.x]; Wagner GP, 1996, EVOLUTION, V50, P967, DOI 10.1111/j.1558-5646.1996.tb02339.x; Wagner GP, 1999, J EXP ZOOL, V285, P116, DOI 10.1002/(SICI)1097-010X(19990815)285:2<116::AID-JEZ3>3.0.CO;2-P; Wiesgigl M, 2001, MOL BIOL CELL, V12, P3307, DOI 10.1091/mbc.12.11.3307; Wright S, 1934, GENETICS, V19, P0506	55	47	47	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e75	10.1371/journal.pone.0000075	http://dx.doi.org/10.1371/journal.pone.0000075			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183707	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600075
J	Leotlela, PD; Wade, MS; Duray, PH; Rhode, MJ; Brown, HF; Rosenthal, DT; Dissanayake, SK; Earley, R; Indig, FE; Nickoloff, BJ; Taub, DD; Kallioniemi, OP; Meltzer, P; Morin, PJ; Weeraratna, AT				Leotlela, P. D.; Wade, M. S.; Duray, P. H.; Rhode, M. J.; Brown, H. F.; Rosenthal, D. T.; Dissanayake, S. K.; Earley, R.; Indig, F. E.; Nickoloff, B. J.; Taub, D. D.; Kallioniemi, O. P.; Meltzer, P.; Morin, P. J.; Weeraratna, A. T.			Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility	ONCOGENE			English	Article						claudin; melanoma; PKC; motility; tissue array	PROTEIN-KINASE-C; TIGHT JUNCTION PROTEINS; OVARIAN-CANCER; INVASION; ACTIVATION; EXPRESSION; ADHESION; BARRIER; MICE	Serial analysis of gene expression followed by pathway analysis implicated the tight junction protein claudin-1 (CLDN1) in melanoma progression. Tight junction proteins regulate the paracellular transport of molecules, but staining of a tissue microarray revealed that claudin-1 was overexpressed in melanoma, and aberrantly expressed in the cytoplasm of malignant cells, suggesting a role other than transport. Indeed, melanoma cells in culture demonstrate no tight junction function. It has been shown that protein kinase C (PKC) can affect expression of claudin-1 in rat choroid plexus cells, and we observed a correlation between levels of activated PKC and claudin expression in our melanoma cells. To determine if PKC could affect the expression of CLDN1 in human melanoma, cells lacking endogenous claudin-1 were treated with 200 nM phorbol myristic acid (PMA). PKC activation by PMA caused an increase in CLDN1 transcription in 30 min, and an increase in claudin-1 protein by 12 h. Inhibition of PKC signaling in cells with high claudin-1 expression resulted in decreased claudin-1 expression. CLDN1 appears to contribute to melanoma cell invasion, as transient transfection of melanoma cells with CLDN1 increased metalloproteinase 2 (MMP-2) secretion and activation, and subsequently, motility of melanoma cells as demonstrated by wound-healing assays. Conversely, knockdown of CLDN1 by siRNA resulted in the inhibition of motility, as well as decreases in MMP-2 secretion and activation. These data implicate claudin-1 in melanoma progression.	NIA, Immunol Lab, NIH, Gerontol Res Ctr, Baltimore, MD 21224 USA; VA Healthcare Syst, Boston, MA USA; Univ Maryland Eastern Shore, MARC Scholar, Princess Anne, MD USA; Univ N Carolina, Dept Biol & Marine Biol, Wilmington, NC 28401 USA; NIA, Res Resources Branch, Gerontol Res Ctr, Baltimore, MD 21224 USA; Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Univ Turku, VTT Tech Res Ctr Finland, Med Biotechnol Dept, SF-20500 Turku, Finland; Natl Human Genome Res Inst, Canc Genet Branch, Bethesda, MD USA; NIA, Lab Cellular & Mol Biol, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Maryland; University of Maryland Eastern Shore; University of North Carolina; University of North Carolina Wilmington; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Loyola University Chicago; University of Turku; VTT Technical Research Center Finland; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Weeraratna, AT (corresponding author), NIA, Immunol Lab, NIH, Gerontol Res Ctr, 5600 Nathan Shock Dr,Box 21, Baltimore, MD 21224 USA.	weerarat@grc.nia.nih.gov	Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332	NATIONAL CANCER INSTITUTE [Z01BC010759, ZIABC010759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000395, Z01AG000615, ZICAG000615, Z01AG000395, ZIAAG000442, Z01AG000442, Z01AG000512] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Betanzos A, 2004, EXP CELL RES, V292, P51, DOI 10.1016/j.yexcr.2003.08.007; Cohn ML, 2005, J CUTAN PATHOL, V32, P533, DOI 10.1111/j.0303-6987.2005.00324.x; D'Souza T, 2005, J BIOL CHEM, V280, P26233, DOI 10.1074/jbc.M502003200; da Rocha AB, 2000, PATHOBIOLOGY, V68, P113, DOI 10.1159/000055911; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; DUMONT JA, 1992, CANCER RES, V52, P1195; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Heiskala M, 2001, TRAFFIC, V2, P92, DOI 10.1034/j.1600-0854.2001.020203.x; Lippoldt A, 2000, NEUROREPORT, V11, P1427, DOI 10.1097/00001756-200005150-00015; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Nakamura K, 2003, ANTICANCER RES, V23, P1395; Oku N, 2006, CANCER RES, V66, P5251, DOI 10.1158/0008-5472.CAN-05-4478; Park MJ, 2003, INT J ONCOL, V22, P137; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rangel LBA, 2003, CLIN CANCER RES, V9, P2567; Sawada Norimasa, 2003, Medical Electron Microscopy, V36, P147, DOI 10.1007/s00795-003-0219-y; Smalley KSM, 2005, AM J PATHOL, V166, P1541, DOI 10.1016/S0002-9440(10)62370-X; Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4	23	128	135	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3846	3856		10.1038/sj.onc.1210155	http://dx.doi.org/10.1038/sj.onc.1210155			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17160014				2022-12-25	WOS:000247026400008
J	Hamdane, D; Vasseur-Godbillion, C; Baudin-Creuza, V; Hoa, GHB; Marden, MC				Hamdane, Djemel; Vasseur-Godbillion, Corinne; Baudin-Creuza, Veronique; Hoa, Gaston Hui Bon; Marden, Michael C.			Reversible hexacoordination of alpha-hemoglobin-stabilizing protein (AHSP)/alpha-hemoglobin versus pressure - Evidence for protection of the alpha-chains by their chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-WHALE MYOGLOBIN; LIGAND-BINDING; BETA-CHAINS; HYDROSTATIC-PRESSURE; GLOBIN; NEUROGLOBIN; CYTOGLOBIN; MECHANISM; AHSP; METHEMOGLOBIN	Using high hydrostatic pressure or hydrogen peroxide as perturbing agents, we demonstrate a protective effect of the chaperone AHSP for the a-chains of Hb. High pressure induces an irreversible aggregation of the ferrous deoxy alpha-chains, whereas the AHSP/alpha-Hb complex shows reversible hexacoordination of the alpha-Hb without protein aggregation. Upon pressure release, the relaxation kinetics of the transition from the hexacoordinated to pentacoordinated form of alpha-Hb in the presence of AHSP exhibit a biphasic shape. High pressure did not induce dissociation of alpha-Hb from its chaperone, as evidenced by the ligand binding kinetics that show a unique rate for the AHSP/alpha-Hb complex. For both free alpha-Hb and the AHSP/alpha-Hb complex, the bimolecular rate constant of CO binding (k(on)(CO)) versus pressure exhibits a on bell shape, attributed to the transition of the rate-determining step from the chemical barrier to the migration of CO within the protein matrix. These results reveal a plasticity of the alpha-Hb active site in the presence of the chaperone and indicate that the AHSP was still active at 300 MPa. The ferric state of the AHSP/ alpha-Hb complex shows hexacoordination even at atmospheric pressures, indicating a His-Fe-His binding scheme as previously observed in neuroglobin and cytoglobin. The reaction with hydrogen peroxide of ferric alpha-Hb within the complex also demonstrates a protection against aggregation.	Univ Paris 11, INSERM, U779, F-94275 Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Marden, MC (corresponding author), Univ Paris 11, INSERM, U779, Rue 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	marden@kb.inserm.fr	BAUDIN-CREUZA, Véronique/K-7309-2017; Marden, Michael/AAA-5923-2020; Marden, Michael C/G-3139-2012; Vasseur, Corinne/AAV-1384-2021	BAUDIN-CREUZA, Véronique/0000-0003-1032-3236; Marden, Michael C/0000-0002-5254-6385; Vasseur, Corinne/0000-0002-4422-7069				ALDEN RG, 1989, J BIOL CHEM, V264, P1923; Baudin-Creuza V, 2004, J BIOL CHEM, V279, P36530, DOI 10.1074/jbc.M405389200; BISPO JA, 2006, IN PRESS BIOPHYS CHE; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Feng L, 2005, NATURE, V435, P697, DOI 10.1038/nature03609; Feng L, 2004, CELL, V119, P629, DOI 10.1016/j.cell.2004.11.025; FISHER MT, 1985, ARCH BIOCHEM BIOPHYS, V240, P456, DOI 10.1016/0003-9861(85)90050-5; Gell D, 2002, J BIOL CHEM, V277, P40602, DOI 10.1074/jbc.M206084200; GERACI G, 1969, J BIOL CHEM, V244, P4664; Hamdane D, 2003, J BIOL CHEM, V278, P51713, DOI 10.1074/jbc.M309396200; Hamdane D, 2005, FEBS J, V272, P2076, DOI 10.1111/j.1742-4658.2005.04635.x; Hamdane D, 2005, J BIOL CHEM, V280, P36809, DOI 10.1074/jbc.M506253200; JUNG C, 1995, EUR J BIOCHEM, V233, P600, DOI 10.1111/j.1432-1033.1995.600_2.x; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; KORNBLATT JA, 1995, BIOCHEMISTRY-US, V34, P1218, DOI 10.1021/bi00004a015; KORNBLATT MJ, 1987, ARCH BIOCHEM BIOPHYS, V257, P277; Lardinois OM, 2004, BIOCHEMISTRY-US, V43, P4601, DOI 10.1021/bi036241b; Lardinois OM, 2003, J BIOL CHEM, V278, P36214, DOI 10.1074/jbc.M304726200; MESSANA C, 1978, BIOCHEMISTRY-US, V17, P3652, DOI 10.1021/bi00610a035; MORISHIMA I, 1983, J BIOL CHEM, V258, P4428; NEWMANN RC, 1973, J PHYS CHEM-US, V77, P2687; OGUNMOLA GB, 1976, P NATL ACAD SCI USA, V73, P4271, DOI 10.1073/pnas.73.12.4271; PARKHURST KM, 1992, INT J BIOCHEM, V24, P993, DOI 10.1016/0020-711X(92)90109-E; PIN S, 1990, BIOCHEMISTRY-US, V29, P9194, DOI 10.1021/bi00491a013; Santiveri CM, 2004, J BIOL CHEM, V279, P34963, DOI 10.1074/jbc.M405016200; Silva JL, 2001, TRENDS BIOCHEM SCI, V26, P612, DOI 10.1016/S0968-0004(01)01949-1; TAUBE DJ, 1990, J AM CHEM SOC, V112, P6880, DOI 10.1021/ja00175a023; TEW D, 1988, J BIOL CHEM, V263, P17880; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Uchida T, 2000, J BIOL CHEM, V275, P30309, DOI 10.1074/jbc.M910287199; UNNO M, 1991, BIOCHEMISTRY-US, V30, P10679, DOI 10.1021/bi00108a011; Vasseur-Godbillon C, 2006, PROTEIN ENG DES SEL, V19, P91, DOI 10.1093/protein/gzj006; Weatherall DJ., 2001, THALASSAEMIA SYNDROM, V4th ed; WILKS A, 1992, J BIOL CHEM, V267, P8827; Zhou SP, 2006, J BIOL CHEM, V281, P32611, DOI 10.1074/jbc.M607311200	37	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6398	6404		10.1074/jbc.M610543200	http://dx.doi.org/10.1074/jbc.M610543200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17194704	hybrid			2022-12-25	WOS:000244867200047
J	Rosenberger, S; Thorey, IS; Werner, S; Boukamp, P				Rosenberger, Sabine; Thorey, Irmgard S.; Werner, Sabine; Boukamp, Petra			A novel regulator of telomerase - S100A8 mediates differentiation-dependent and calcium-induced inhibition of telomerase activity in the human epidermal keratinocyte line HaCaT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT GENE; ION-BINDING PROPERTIES; ULTRASTRUCTURAL-LOCALIZATION; INTERMEDIATE-FILAMENTS; EXTRACELLULAR CALCIUM; SKIN KERATINOCYTES; CELL-LINES; PROTEINS; EXPRESSION; COMPLEX	Recently we reported a differentiation-dependent inhibition of telomerase activity in human epidermis. Consistent with this observation we found that in keratinocyte cultures calcium-induced differentiation correlates with a decline in telomerase activity. To get further support for a role of calcium in the regulation of telomerase and to elucidate the underlying molecular mechanisms we investigated the effect of calcium on telomerase in the human epidermal keratinocyte line HaCaT. Treatment with thapsigargin, which increases intracellular calcium concentrations, inhibited telomerase activity without down-regulating the expression of hTERT (human telomerase reverse transcriptase). This observation together with the fact that increasing calcium reduced telomerase activity in cell-free extracts suggests that calcium directly interacts with the telomerase complex. This interaction could be mediated by the calcium-binding protein S100A8 as indicated by its ability to mimic the inhibitory effect of calcium. S100A8-induced reduction in telomerase activity was abrogated by S100A9. The ratio of both proteins remained constant in cells treated with thapsigargin, but their interactions were altered similarly in intact cells after thapsigargin treatment and in cell-free extracts in response to calcium. We hypothesize that calcium binds to S100A8/S100A9 complexes and alters their composition, thus enabling S100A8 to interact with the telomerase complex and inhibit its activity.	German Canc Res Ctr, D-69120 Heidelberg, Germany; THP GmbH, D-82347 Bernried, Germany; ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland	Helmholtz Association; German Cancer Research Center (DKFZ); Swiss Federal Institutes of Technology Domain; ETH Zurich	Rosenberger, S (corresponding author), German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	s.rosenberger@dkfz.de		Werner, Sabine/0000-0001-7397-8710				Avilion AA, 1996, CANCER RES, V56, P645; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; Bickenbach JR, 1998, J INVEST DERMATOL, V111, P1045, DOI 10.1046/j.1523-1747.1998.00420.x; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broome AM, 2003, J HISTOCHEM CYTOCHEM, V51, P675, DOI 10.1177/002215540305100513; Cerezo A, 2003, J INVEST DERMATOL, V121, P110, DOI 10.1046/j.1523-1747.2003.12304.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; Elias PM, 2002, J INVEST DERMATOL, V119, P1128, DOI 10.1046/j.1523-1747.2002.19512.x; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Forslind B, 1987, Acta Derm Venereol Suppl (Stockh), V134, P1; GOEBELER M, 1995, BIOCHEM J, V309, P419, DOI 10.1042/bj3090419; GOEBELER M, 1993, J LEUKOCYTE BIOL, V53, P11, DOI 10.1002/jlb.53.1.11; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Gribenko AV, 1998, J MOL BIOL, V283, P679, DOI 10.1006/jmbi.1998.2116; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Harrington L, 2003, CANCER LETT, V194, P139, DOI 10.1016/S0304-3835(02)00701-2; Hennings H, 1980, Curr Probl Dermatol, V10, P3; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hunter MJ, 1998, J BIOL CHEM, V273, P12427, DOI 10.1074/jbc.273.20.12427; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Lansdown ABG, 2002, WOUND REPAIR REGEN, V10, P271, DOI 10.1046/j.1524-475X.2002.10502.x; LEE SH, 1992, J CLIN INVEST, V89, P530, DOI 10.1172/JCI115617; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MANI RS, 1983, BIOCHEMISTRY-US, V22, P3902, DOI 10.1021/bi00285a027; Marionnet C, 2003, J INVEST DERMATOL, V121, P1447, DOI 10.1111/j.1523-1747.2003.12629.x; MELY Y, 1990, ARCH BIOCHEM BIOPHYS, V279, P174, DOI 10.1016/0003-9861(90)90478-H; MENON GK, 1991, ARCH DERMATOL, V127, P57, DOI 10.1001/archderm.127.1.57; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; PILLAI S, 1993, J CELL PHYSIOL, V154, P101, DOI 10.1002/jcp.1041540113; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; ROTH J, 1993, BLOOD, V82, P1875; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rustandi RR, 1998, BIOCHEMISTRY-US, V37, P1951, DOI 10.1021/bi972701n; SAINTIGNY G, 1992, J INVEST DERMATOL, V99, P639, DOI 10.1111/1523-1747.ep12668098; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Smith SP, 1998, BIOCHEM CELL BIOL, V76, P324, DOI 10.1139/bcb-76-2-3-324; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; Vogl T, 1999, J AM SOC MASS SPECTR, V10, P1124; VOLZ A, 1993, GENOMICS, V18, P92, DOI 10.1006/geno.1993.1430; YUSPA SH, 1988, ANN NY ACAD SCI, V548, P191, DOI 10.1111/j.1749-6632.1988.tb18806.x; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963; Zhao XP, 1997, GENOMICS, V45, P250, DOI 10.1006/geno.1997.4952; Zimmer DB, 2003, MICROSC RES TECHNIQ, V60, P552, DOI 10.1002/jemt.10297	52	40	41	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6126	6135		10.1074/jbc.M610529200	http://dx.doi.org/10.1074/jbc.M610529200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17197440	hybrid			2022-12-25	WOS:000244867200018
J	Wei, YA; Zavilowitz, B; Satlin, LM; Wang, WH				Wei, Yuan; Zavilowitz, Beth; Satlin, Lisa M.; Wang, Wen-Hui			Angiotensin II inhibits the ROMK-like small conductance K channel in renal cortical collecting duct during dietary potassium restriction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE KINASE; APICAL MEMBRANE; NADPH OXIDASE; SKELETAL-MUSCLE; EXPRESSION; RAT; SECRETION; TRANSPORT; ACTIVATION	Base-line urinary potassium secretion in the distal nephron is mediated by small conductance rat outer medullary K (ROMK)like channels. We used the patch clamp technique applied to split-open cortical collecting ducts (CCDs) isolated from rats fed a normal potassium (NK) or low potassium (LK) diet to test the hypothesis that AngII directly inhibits ROMK channel activity. We found that AngII inhibited ROMK channel activity in LK but not NK rats in a dose-dependent manner. The AngII-induced reduction in channel activity was mediated by AT 1 receptor (AT1R) binding, because pretreatment of CCDs with losartan but not PD123319 AT1. and AT2 receptor antagonists, respectively, blocked the response. Pretreatment of CCDs with U73122 and calphostin C, inhibitors of phospholipase C (PLC) and protein kinase C (PKC), respectively, abolished the AngII-induced decrease in ROMK channel activity, confirming a role of the PLC-PKC pathway in this response. Studies by others suggest that AngII stimulates an Src family protein-tyrosine kinase (PTK) via PKC-NADPH oxidase. PTK has been shown to regulate the ROMK channel. Inhibition of NADPH oxidase with diphenyliodonium abolished the inhibitory effect of AngII or the PKC activator phorbol 12-myristate 13-acetate on ROMK channels. Suppression of PTK by herbimycin A significantly attenuated the inhibitory effect of AngII on ROMK channel activity. We conclude that AngII inhibits ROMK channel activity through PKC-, NADPH oxidase-, and PTK-dependent pathways under conditions of dietary potassium restriction.	Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	Icahn School of Medicine at Mount Sinai; New York Medical College	Wei, YA (corresponding author), Mt Sinai Sch Med, Dept Pediat, Box 1664,1 Gustave L Levy Pl, New York, NY 10029 USA.	yuan.wei@mssm.edu			NATIONAL CANCER INSTITUTE [R24CA095823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK051391, R01DK047402, R29DK047402, R01DK038470, R29DK038470, R01DK051391] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA095823, 5R24 CA095823-04] Funding Source: Medline; NIDDK NIH HHS [DK47402, DK51391, R01 DK047402-13, R01 DK047402, DK38470] Funding Source: Medline; PHS HHS [1 S10 RRO 9145-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Babilonia E, 2005, J BIOL CHEM, V280, P10790, DOI 10.1074/jbc.M414610200; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bailey MA, 2006, KIDNEY INT, V70, P51, DOI 10.1038/sj.ki.5000388; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; BRAAM B, 1993, AM J PHYSIOL, V264, pF891, DOI 10.1152/ajprenal.1993.264.5.F891; Braiman L, 1999, DIABETES, V48, P1922, DOI 10.2337/diabetes.48.10.1922; Burns KD, 1998, NEPHRON, V78, P73, DOI 10.1159/000044885; Carey RM, 2005, CURR OPIN NEPHROL HY, V14, P67, DOI 10.1097/00041552-200501000-00011; Chabrashvili T, 2003, AM J PHYSIOL-REG I, V285, pR117, DOI 10.1152/ajpregu.00476.2002; Chabrashvili T, 2002, HYPERTENSION, V39, P269, DOI 10.1161/hy0202.103264; COX JA, 1985, J CLIN INVEST, V76, P1932, DOI 10.1172/JCI112190; ENGELS F, 1992, FEBS LETT, V305, P254, DOI 10.1016/0014-5793(92)80680-F; Frank GD, 2000, ENDOCRINOLOGY, V141, P3120, DOI 10.1210/en.141.9.3120; FRINDT G, 1989, AM J PHYSIOL, V256, pF143, DOI 10.1152/ajprenal.1989.256.1.F143; FRINDT G, 1987, AM J PHYSIOL, V252, pF458, DOI 10.1152/ajprenal.1987.252.3.F458; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; HarrisonBernard LM, 1997, AM J PHYSIOL-RENAL, V273, pF170, DOI 10.1152/ajprenal.1997.273.1.F170; Imanishi K, 2003, HYPERTENS RES, V26, P405, DOI 10.1291/hypres.26.405; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Komlosi P, 2003, HYPERTENSION, V42, P195, DOI 10.1161/01.HYP.0000081221.36703.01; Lin DH, 2002, J BIOL CHEM, V277, P44278, DOI 10.1074/jbc.M203702200; LINAS SL, 1979, KIDNEY INT, V15, P601, DOI 10.1038/ki.1979.79; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Moral Z, 2001, J BIOL CHEM, V276, P7156, DOI 10.1074/jbc.M008671200; Najjar F, 2005, AM J PHYSIOL-RENAL, V289, pF922, DOI 10.1152/ajprenal.00057.2005; Navar LG, 2004, CURR OPIN NEPHROL HY, V13, P107, DOI 10.1097/00041552-200401000-00015; OKUSA MD, 1992, AM J PHYSIOL, V262, pF488, DOI 10.1152/ajprenal.1992.262.3.F488; PACHA J, 1991, AM J PHYSIOL, V261, pF696, DOI 10.1152/ajprenal.1991.261.4.F696; Ray PE, 2001, KIDNEY INT, V59, P1850, DOI 10.1046/j.1523-1755.2001.0590051850.x; Rohrwasser A, 1999, HYPERTENSION, V34, P1265, DOI 10.1161/01.HYP.34.6.1265; Rosenzweig T, 2004, CELL SIGNAL, V16, P1299, DOI 10.1016/j.cellsig.2004.03.015; Sampson SR, 2006, MOL GENET METAB, V89, P32, DOI 10.1016/j.ymgme.2006.04.017; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Schmidt A, 2001, NEPHROL DIAL TRANSPL, V16, P1034, DOI 10.1093/ndt/16.5.1034; SEIKALY MG, 1990, J CLIN INVEST, V86, P1352, DOI 10.1172/JCI114846; STERLING H, 2004, AM J PHYSIOL, V26, pF1072; Toyz RM, 2002, BRAZ J MED BIOL RES, V35, P1001, DOI 10.1590/S0100-879X2002000900001; Wang CT, 2003, J HYPERTENS, V21, P353, DOI 10.1097/00004872-200302000-00027; Wang T, 1996, AM J PHYSIOL-RENAL, V271, pF143, DOI 10.1152/ajprenal.1996.271.1.F143; Wang WH, 2004, ANNU REV PHYSIOL, V66, P547, DOI 10.1146/annurev.physiol.66.032102.112025; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; Wang WH, 2000, AM J PHYSIOL-RENAL, V278, pF165, DOI 10.1152/ajprenal.2000.278.1.F165; Wei Y, 2005, AM J PHYSIOL-RENAL, V289, pF1065, DOI 10.1152/ajprenal.00063.2005; Wei Y, 2002, AM J PHYSIOL-RENAL, V282, pF680, DOI 10.1152/ajprenal.00229.2001; Wei Y, 2001, AM J PHYSIOL-RENAL, V281, pF206, DOI 10.1152/ajprenal.2001.281.2.F206; Woda CB, 2003, AM J PHYSIOL-RENAL, V285, pF629, DOI 10.1152/ajprenal.00191.2003; Woda CB, 2001, AM J PHYSIOL-RENAL, V280, pF786, DOI 10.1152/ajprenal.2001.280.5.F786; Zeng WZ, 2003, J BIOL CHEM, V278, P16852, DOI 10.1074/jbc.M300619200	50	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6455	6462		10.1074/jbc.M607477200	http://dx.doi.org/10.1074/jbc.M607477200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17194699	hybrid, Green Accepted			2022-12-25	WOS:000244867200053
J	Zheng, ZD; Chen, GZ; Joshi, S; Brutinel, ED; Yahr, TL; Chen, LL				Zheng, Zhida; Chen, Guozhou; Joshi, Shreyas; Brutinel, Evan D.; Yahr, Timothy L.; Chen, Lingling			Biochemical characterization of a regulatory cascade controlling transcription of the Pseudomonas aeruginosa type III secretion system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTENSIVE-CARE UNITS; NOSOCOMIAL INFECTIONS; ANTI-ACTIVATOR; CHAPERONE; REGULON; STATES; EXSD	Many Gram-negative pathogens utilize type III secretion systems (T3SS) to translocate effector proteins into eukaryotic host cells. Expression of T3SS genes is highly regulated and is often coupled to type III secretory activity. Transcription of the Pseudomonas aeruginosa T3SS genes is coupled to secretion by a cascade of interacting regulatory proteins (ExsA, ExsD, ExsC, and ExsE). ExsA is an activator of type III gene transcription, ExsD binds ExsA to inhibit: transcription, ExsC inhibits ExsD activity, and ExsE inhibits ExsC activity. The entire process is coupled to secretion by virtue of the fact that ExsE is a secreted substrate of the T3SS. Changes in the intracellular concentration of ExsE are thought to govern formation of the ExsC-ExsE, ExsC-ExsD, and ExsD-ExsA complexes. Whereas formation of the ExsC-ExsE complex allows ExsD to bind ExsA and transcription of the T3SS is repressed, formation of the ExsC-ExsD complex sequesters ExsD from ExsA and transcription of the T3SS is induced. In this study, we characterized the self-association states of ExsC, ExsD, and ExsE and the binding interactions of ExsC with ExsE and ExsD. ExsC exists as a homodimer and binds one molecule of ExsE substrate. Dimeric ExsC also interacts directly with ExsD to form a heterotetrameric complex. The difference in binding affinities between the ExsC-ExsE (K-d 1nm) and ExsC-ExsD (K-d 18 nm) complexes supports a model in which ExsC preferentially binds cytoplasmic ExsE, resulting in the inhibition of T3SS gene transcription.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Indiana Univ, Interdisciplinary Biochem Program, Bloomington, IN 47405 USA; Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; University of Iowa	Chen, LL (corresponding author), Indiana Univ, Dept Biol, 915 E 3rd St, Bloomington, IN 47405 USA.	linchen@indiana.edu	Joshi, Shreyas/M-6411-2019; Chen, Ling-Ling/AAY-3547-2021	Yahr, Timothy/0000-0001-9054-8704	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065260] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI055042, R01 AI055042] Funding Source: Medline; NIGMS NIH HHS [R01-GM065260-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbieri JT, 2005, REV PHYSIOL BIOCH P, V152, P79, DOI 10.1007/s10254-004-0031-7; Birtalan S, 2001, NAT STRUCT BIOL, V8, P974, DOI 10.1038/nsb1101-974; Birtalan SC, 2002, MOL CELL, V9, P971, DOI 10.1016/S1097-2765(02)00529-4; Dasgupta N, 2004, MOL MICROBIOL, V53, P297, DOI 10.1111/j.1365-2958.2004.04128.x; Feldman MF, 2003, FEMS MICROBIOL LETT, V219, P151, DOI 10.1016/S0378-1097(03)00042-9; Frank DW, 1997, MOL MICROBIOL, V26, P621, DOI 10.1046/j.1365-2958.1997.6251991.x; FRANK DW, 1991, J BACTERIOL, V173, P6460, DOI 10.1128/jb.173.20.6460-6468.1991; Fu YX, 1998, J BACTERIOL, V180, P3393, DOI 10.1128/JB.180.13.3393-3399.1998; Ghosh P, 2004, MICROBIOL MOL BIOL R, V68, P771, DOI 10.1128/MMBR.68.4.771-795.2004; LEMAIRE M, 1989, ANAL BIOCHEM, V177, P50, DOI 10.1016/0003-2697(89)90012-2; Luo Y, 2001, NAT STRUCT BIOL, V8, P1031, DOI 10.1038/nsb717; Lykken GL, 2006, J BACTERIOL, V188, P6832, DOI 10.1128/JB.00884-06; McCaw ML, 2002, MOL MICROBIOL, V46, P1123, DOI 10.1046/j.1365-2958.2002.03228.x; Page AL, 2002, MOL MICROBIOL, V46, P1, DOI 10.1046/j.1365-2958.2002.03138.x; Parsot C, 2005, MOL MICROBIOL, V56, P1627, DOI 10.1111/j.1365-2958.2005.04645.x; Richards MJ, 2000, INFECT CONT HOSP EP, V21, P510, DOI 10.1086/501795; Richards MJ, 1999, CRIT CARE MED, V27, P887, DOI 10.1097/00003246-199905000-00020; Rietsch A, 2005, P NATL ACAD SCI USA, V102, P8006, DOI 10.1073/pnas.0503005102; Sato H, 2004, MOL MICROBIOL, V53, P1279, DOI 10.1111/j.1365-2958.2004.04194.x; Urbanowski ML, 2005, P NATL ACAD SCI USA, V102, P9930, DOI 10.1073/pnas.0504405102; Vallis AJ, 1999, INFECT IMMUN, V67, P914, DOI 10.1128/IAI.67.2.914-920.1999; Van Holde K. E., 1998, PRINCIPLES PHYS BIOC, P194; Walker KA, 2004, J BACTERIOL, V186, P4056, DOI 10.1128/JB.186.13.4056-4066.2004; Wei CF, 2005, MOL MICROBIOL, V57, P520, DOI 10.1111/j.1365-2958.2005.04704.x	24	26	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6136	6142		10.1074/jbc.M611664200	http://dx.doi.org/10.1074/jbc.M611664200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17197437	hybrid			2022-12-25	WOS:000244867200019
J	Huang, YC; Laval, SH; van Remoortere, A; Baudier, J; Benaud, C; Anderson, LVB; Straub, V; Deelder, A; Frants, RR; den Dunnen, JT; Bushby, K; van der Maarel, SM				Huang, Yanchao; Laval, Steven H.; van Remoortere, Alexandra; Baudier, Jacques; Benaud, Chriselle; Anderson, Louise V. B.; Straub, Volker; Deelder, Andre; Frants, Rune R.; den Dunnen, Johan T.; Bushby, Kate; van der Maarel, Silvere M.			AHNAR, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration	FASEB JOURNAL			English	Article						protein interaction; dysferlinopathies; membrane repair; LGMD2B; MM	GIRDLE MUSCULAR-DYSTROPHY; CALCIUM-CHANNEL; GENE; MYOPATHY; CELLS; CAVEOLIN-3; EXPRESSION; DESMOYOKIN; INTERACTS; MUTATION	Mutations in dysferlin cause limb girdle muscular dystrophy 2B, Miyoshi myopathy and distal anterior compartment myopathy. Dysferlin is proposed to play a role in muscle membrane repair. To gain functional insight into the molecular mechanisms of dysferlin, we have searched for dysferlin-interacting proteins in skeletal muscle. By coimmunoprecipitation coupled with mass spectrometry, we demonstrate that AHNAK interacts with dysferlin. We defined the binding sites in dysferlin and AHNAK as the C2A domain in dysferlin and the carboxyterminal domain of AHNAK by glutathione S-transferase (GST)-pull down assays. As expected, the N-terminal domain of myoferlin also interacts with the carboxyterminal domain of AHNAK In normal skeletal muscle, dysferlin and AHNAK colocalize at the sarcolemmal membrane and T-tubules. In dysferlinopathies, reduction or absence of dysferlin correlates with a secondary muscle-specific loss of AHNAK. Moreover, in regenerating rat muscle, dysferlin and AHNAK showed a marked increase and cytoplasmic localization, consistent with the direct interaction between them. Our data suggest that dysferlin participates in the recruitment and stabilization of AHNAK to the sarcolemma and that AHNAK plays a role in dysferlin membrane repair process. It may also have significant implications for understanding the biology of AHNAK-containing exocytotic vesicles, "enlargosomes," in plasma membrane remodeling and repair.	Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Dept Human Genet, NL-2333 ZA Leiden, Netherlands; Int Ctr Life, Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England; Leiden Univ, Med Ctr, Dept Parasitol, NL-2300 RA Leiden, Netherlands; CEA, INSERM, DRDC, EMI104, Grenoble, France	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Newcastle University - UK; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	van der Maarel, SM (corresponding author), Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Dept Human Genet, Hlbinusdreef 2, NL-2333 ZA Leiden, Netherlands.	maarel@lumc.nl	dunnen, johan den/ABH-4228-2020; van der Maarel, Silvere/X-3631-2018; Baudier, Jacques/O-2183-2016; Benaud, Christelle/M-1178-2018; jacques, baudier/T-3300-2019	dunnen, johan den/0000-0002-6304-1710; van der Maarel, Silvere/0000-0001-8103-711X; jacques, baudier/0000-0001-8427-4444; Straub, Volker/0000-0001-9046-3540	NIAMS NIH HHS [R21-AR48327-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR048327] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Achanzar WE, 1997, J CELL SCI, V110, P1073; Ampong Beryl N, 2005, Acta Myol, V24, P134; Anderson LVB, 1999, HUM MOL GENET, V8, P855, DOI 10.1093/hmg/8.5.855; Anderson LVB, 1999, AM J PATHOL, V154, P1017, DOI 10.1016/S0002-9440(10)65354-0; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; Benaud C, 2004, J CELL BIOL, V164, P133, DOI 10.1083/jcb.200307098; Borgonovo B, 2002, NAT CELL BIOL, V4, P955, DOI 10.1038/ncb888; Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200; Gentil BJ, 2003, J HISTOCHEM CYTOCHEM, V51, P339, DOI 10.1177/002215540305100309; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; HASHIMOTO T, 1993, J CELL SCI, V105, P275; Hernandez-Deviez DJ, 2006, HUM MOL GENET, V15, P129, DOI 10.1093/hmg/ddi434; Hohaus A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0855com; Huang YC, 2005, EUR J HUM GENET, V13, P721, DOI 10.1038/sj.ejhg.5201414; Illa I, 2001, ANN NEUROL, V49, P130, DOI 10.1002/1531-8249(200101)49:1<130::AID-ANA22>3.0.CO;2-0; Illarioshkin SN, 2000, NEUROLOGY, V55, P1931, DOI 10.1212/WNL.55.12.1931; Komuro A, 2004, P NATL ACAD SCI USA, V101, P4053, DOI 10.1073/pnas.0308619101; Lennon NJ, 2003, J BIOL CHEM, V278, P50466, DOI 10.1074/jbc.M307247200; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; MASUNAGA T, 1995, J INVEST DERMATOL, V104, P941, DOI 10.1111/1523-1747.ep12606213; Matsuda C, 2005, J NEUROPATH EXP NEUR, V64, P334, DOI 10.1093/jnen/64.4.334; Matsuda C, 2001, HUM MOL GENET, V10, P1761, DOI 10.1093/hmg/10.17.1761; Piccolo F, 2000, ANN NEUROL, V48, P902, DOI 10.1002/1531-8249(200012)48:6<902::AID-ANA11>3.3.CO;2-Q; Salani S, 2004, MUSCLE NERVE, V30, P366, DOI 10.1002/mus.20106; Schneider MF, 2004, J MUSCLE RES CELL M, V25, P587; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; Shevchenko A, 1996, BIOCHEM SOC T, V24, P893, DOI 10.1042/bst0240893	29	108	115	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					732	742		10.1096/fj.06-6628com	http://dx.doi.org/10.1096/fj.06-6628com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17185750				2022-12-25	WOS:000244686400012
J	Martini, L; Waldhoer, M; Pusch, M; Kharazia, V; Fong, J; Lee, JH; Freissmuth, C; Whistler, JL				Martini, Lene; Waldhoer, Maria; Pusch, Margareta; Kharazia, Viktor; Fong, Jamie; Lee, Josephine H.; Freissmuth, Clarissa; Whistler, Jennifer L.			Ligand-induced down-regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptor-associated sorting protein GASP1	FASEB JOURNAL			English	Article						degradation; GPCR; postendocytic sorting; tolerance	MESSENGER-RNA LEVELS; RAT-BRAIN; CB1 RECEPTORS; BASAL GANGLIA; MOUSE-BRAIN; DELTA(9)-TETRAHYDROCANNABINOL; BINDING; MICE; INTERNALIZATION; LOCALIZATION	The cannabinoid 1 receptor (CB1R) is one of the most abundant seven transmembrane (7TM) spanning/G-protein-coupled receptors in the central nervous system and plays an important role in pain transmission, feeding, and the rewarding effects of cannabis. Tolerance to cannabinoids has been widely observed after long-term use, with concomitant receptor desensitization and/or down-regulation depending on the brain region studied. Several CB1R agonists promote receptor internalization after activation, but the postendocytic sorting of the receptor has not been studied in detail. Utilizing human embryonic kidney (HEK293) cells stably expressing the CB1R and primary cultured neurons expressing endogenous CB1R, we show that treatment with cannabinoid agonists results in CBIR degradation after endocytosis and that the G-protein-coupled receptor-associated sorting protein GASP1 plays a major role in the postendocytic sorting process. Thus, these results may identify a molecular mechanism underlying tolerance and receptor down-regulation after long-term use of cannabinoids.	Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Oakland, CA 94608 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Whistler, JL (corresponding author), Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, 5858 Horton St,Ste 200, Oakland, CA 94608 USA.	jennifer.whistler@ucsf.edu	Waldhoer, Maria/HDO-0619-2022	Waldhoer, Maria/0000-0003-3534-1959; Kharazia, Viktor/0000-0003-0642-6080	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015232] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA15232] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Baker D, 2006, TRENDS PHARMACOL SCI, V27, P1, DOI 10.1016/j.tips.2005.11.003; Bartlett SE, 2005, P NATL ACAD SCI USA, V102, P11521, DOI 10.1073/pnas.0502418102; Beardsley PM, 2005, BEHAV PHARMACOL, V16, P275, DOI 10.1097/00008877-200509000-00003; Breivogel CS, 2001, MOL PHARMACOL, V60, P155, DOI 10.1124/mol.60.1.155; Breivogel CS, 1999, J NEUROCHEM, V73, P2447, DOI 10.1046/j.1471-4159.1999.0732447.x; Corchero J, 2002, J PSYCHOPHARMACOL, V16, P283, DOI 10.1177/026988110201600401; Coutts AA, 2001, J NEUROSCI, V21, P2425; De Vry J, 2004, BEHAV PHARMACOL, V15, P1, DOI 10.1097/00008877-200402000-00001; DEFONSECA FR, 1994, PHARMACOL BIOCHEM BE, V47, P33, DOI 10.1016/0091-3057(94)90108-2; Di Marzo V, 2000, J NEUROCHEM, V74, P1627, DOI 10.1046/j.1471-4159.2000.0741627.x; Di Marzo V, 2005, NAT NEUROSCI, V8, P585, DOI 10.1038/nn1457; Fan F, 1996, BRAIN RES, V706, P13, DOI 10.1016/0006-8993(95)01113-7; Gear RW, 1999, PAIN, V83, P339, DOI 10.1016/S0304-3959(99)00119-0; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; Heydorn A, 2004, J BIOL CHEM, V279, P54291, DOI 10.1074/jbc.M406169200; Howard AD, 2001, TRENDS PHARMACOL SCI, V22, P132, DOI 10.1016/S0165-6147(00)01636-9; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Hsieh C, 1999, J NEUROCHEM, V73, P493, DOI 10.1046/j.1471-4159.1999.0730493.x; HUNTER SA, 1986, NEUROCHEM RES, V11, P1273, DOI 10.1007/BF00966122; Leterrier C, 2006, J NEUROSCI, V26, P3141, DOI 10.1523/JNEUROSCI.5437-05.2006; Leterrier C, 2004, J BIOL CHEM, V279, P36013, DOI 10.1074/jbc.M403990200; Martin BR, 2004, TRENDS PHARMACOL SCI, V25, P325, DOI 10.1016/j.tips.2004.04.005; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Matyas F, 2006, NEUROSCIENCE, V137, P337, DOI 10.1016/j.neuroscience.2005.09.005; OVIEDO A, 1993, BRAIN RES, V616, P293, DOI 10.1016/0006-8993(93)90220-H; Romero J, 1998, J MOL NEUROSCI, V11, P109, DOI 10.1385/JMN:11:2:109; Romero J, 1999, NEUROCHEM INT, V34, P473, DOI 10.1016/S0197-0186(99)00020-0; Romero J, 1998, SYNAPSE, V30, P298, DOI 10.1002/(SICI)1098-2396(199811)30:3<298::AID-SYN7>3.0.CO;2-6; Romero J, 1997, MOL BRAIN RES, V46, P100, DOI 10.1016/S0169-328X(96)00277-X; RUBINO T, 1994, NEUROREPORT, V5, P2493, DOI 10.1097/00001756-199412000-00022; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Sim LJ, 1996, J NEUROSCI, V16, P8057; Sim-Selley LJ, 2006, MOL PHARMACOL, V70, P986, DOI 10.1124/mol.105.019612; Sim-Selley LJ, 2002, J PHARMACOL EXP THER, V303, P36, DOI 10.1124/jpet.102.035618; Simonin F, 2004, J NEUROCHEM, V89, P766, DOI 10.1111/j.1471-4159.2004.02411.x; Song ZH, 1996, MOL PHARMACOL, V49, P891; Suyama M, 1999, NUCLEIC ACIDS RES, V27, P338, DOI 10.1093/nar/27.1.338; Tang Stephanie L, 2005, J Am Osteopath Assoc, V105, P26; Thanos PK, 2005, BEHAV BRAIN RES, V164, P206, DOI 10.1016/j.bbr.2005.06.021; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; Walker JM, 2005, HANDB EXP PHARMACOL, V168, P509; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Willoughby KA, 1997, J PHARMACOL EXP THER, V282, P243	43	111	114	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					802	811		10.1096/fj.06-7132com	http://dx.doi.org/10.1096/fj.06-7132com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197383				2022-12-25	WOS:000244686400018
J	Beyea, MM; Heslop, CL; Sawyez, CG; Edwards, JY; Markle, JG; Hegele, RA; Huff, MW				Beyea, Michael M.; Heslop, Claire L.; Sawyez, Cynthia G.; Edwards, Jane Y.; Markle, Janet G.; Hegele, Robert A.; Huff, Murray W.			Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RETINOID-X-RECEPTOR; ATP-BINDING CASSETTE; LANOSTEROL CYCLASE; PHARMACOLOGICAL ACTIVATION; HYPERTRIGLYCERIDEMIC VLDL; CHOLESTEROL EFFLUX; ELEMENT; EXPRESSION; PROMOTER	Liver X receptor (LXR) activation represents a mechanism to prevent macrophage foam cell formation. Previously, we demonstrated that partial inhibition of oxidosqualene:lanosterol cyclase (OSC) stimulated synthesis of the LXR agonist 24(S),25-epoxycholesterol (24(S),25-epoxy) and enhanced ABCA1-mediated cholesterol efflux. In contrast to a synthetic, nonsteroidal LXR activator, TO-901317, triglyceride accumulation was not observed. In the present study, we determined whether endogenous 24(S),25-epoxy synthesis selectively enhanced expression of macrophage LXR-regulated cholesterol efflux genes but not genes that regulate fatty acid metabolism. THP-1 human macrophages incubated with the OSC inhibitor (OSCi) RO0714565 (15 mm) significantly reduced cholesterol synthesis and maximized synthesis of 24(S),25-epoxy. Endogenous 24(S),25-epoxy increased ABCA1, ABCG1, and APOE mRNA abundance and consequently increased cholesterol efflux to apoAI. In contrast, OSCi had no effect on LXR-regulated genes LPL (lipoprotein lipase) and FAS (fatty acid synthase). TO-901317 (>= 10 nm) significantly enhanced expression of all genes examined. OSCi and TO-901317 increased the mRNA and precursor form of SREBP-1c, a major regulator of fatty acid and triglyceride synthesis. However, conversion of the precursor to the active form (nSREBP-1c) was blocked by OSCi-induced 24(S),25-epoxy but not by TO-901317 (>= 10 nm), which instead markedly increased nSREBP-1c. Disruption of nSREBP-1c formation by 24(S),25-epoxy accounted for diminished FAS and LPL expression. In summary, endogenous synthesis of 24(S),25-epoxy selectively up-regulates expression of macrophage LXR-regulated cholesterol efflux genes without stimulating genes linked to fatty acid and triglyceride synthesis.	Univ Western Ontario, Robarts Res Inst, Vasc Biol Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5K8, Canada; Univ Western Ontario, Schulich Sch Med & Dent, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Huff, MW (corresponding author), Rm 4-16,100 Perth Dr, London, ON N6A 5K8, Canada.	mhuff@uwo.ca	Markle, Janet/X-1975-2019; Hegele, Robert/G-3301-2011; Hegele, Robert/AAF-6482-2020; Huff, Murray/G-3307-2011	Hegele, Robert/0000-0003-2861-5325; Markle, Janet/0000-0003-2189-4368				Adams CM, 2004, J BIOL CHEM, V279, P52772, DOI 10.1074/jbc.M410302200; Argmann CA, 2005, J BIOL CHEM, V280, P22212, DOI 10.1074/jbc.M502761200; Argmann CA, 2003, ARTERIOSCL THROM VAS, V23, P475, DOI 10.1161/01.ATV.0000058860.62870.6E; Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; Borradaile NM, 2003, DIABETES, V52, P2554, DOI 10.2337/diabetes.52.10.2554; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Cagen LM, 2005, BIOCHEM J, V385, P207, DOI 10.1042/BJ20040162; Chisholm JW, 2003, J LIPID RES, V44, P2039, DOI 10.1194/jlr.M300135-JLR200; EVANS AJ, 1993, J LIPID RES, V34, P703; Field FJ, 2001, J LIPID RES, V42, P1687; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Huff MW, 2005, TRENDS PHARMACOL SCI, V26, P335, DOI 10.1016/j.tips.2005.05.004; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Langmann T, 2000, BBA-GENE STRUCT EXPR, V1494, P175, DOI 10.1016/S0167-4781(00)00215-3; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lehrke M, 2005, CELL METAB, V1, P297, DOI 10.1016/j.cmet.2005.04.005; Linton MF, 2003, INT J OBESITY, V27, pS35, DOI 10.1038/sj.ijo.0802498; Morand OH, 1997, J LIPID RES, V38, P373; Naik SU, 2006, CIRCULATION, V113, P90, DOI 10.1161/CIRCULATIONAHA.105.560177; Quinet EM, 2004, J LIPID RES, V45, P1929, DOI 10.1194/jlr.M400257-JLR200; Rowe AH, 2003, CIRC RES, V93, P717, DOI 10.1161/01.RES.0000097606.43659.F4; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; Schoonjans K, 2000, J MOL BIOL, V304, P323, DOI 10.1006/jmbi.2000.4218; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shulman AI, 2005, NEW ENGL J MED, V353, P604, DOI 10.1056/NEJMra043590; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; Takahashi Kiyoshi, 2002, Medical Electron Microscopy, V35, P179, DOI 10.1007/s007950200023; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; TAYLOR FR, 1986, J BIOL CHEM, V261, P5039; Telford DE, 2005, ARTERIOSCL THROM VAS, V25, P2608, DOI 10.1161/01.ATV.0000189158.28455.94; Terasaka N, 2003, FEBS LETT, V536, P6, DOI 10.1016/S0014-5793(02)03578-0; Thoma R, 2004, NATURE, V432, P118, DOI 10.1038/nature02993; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Whitman SC, 1997, ARTERIOSCL THROM VAS, V17, P1707, DOI 10.1161/01.ATV.17.9.1707; Whitman SC, 1999, J LIPID RES, V40, P1017; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200	44	85	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5207	5216		10.1074/jbc.M611063200	http://dx.doi.org/10.1074/jbc.M611063200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17186944	hybrid			2022-12-25	WOS:000244482300015
J	Granneman, JG; Moore, HPH; Granneman, RL; Greenberg, AS; Obin, MS; Zhu, ZX				Granneman, James G.; Moore, Hsiao-Ping H.; Granneman, Rachel L.; Greenberg, Andrew S.; Obin, Martin S.; Zhu, Zhengxian			Analysis of lipolytic protein trafficking and interactions in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; ADIPOSE TRIGLYCERIDE LIPASE; CHANARIN-DORFMAN-SYNDROME; LIPID STORAGE DROPLETS; PERILIPIN-A; 3T3-L1 ADIPOCYTES; RAT ADIPOCYTES; FLUORESCENCE COMPLEMENTATION; MEDIATED LIPOLYSIS; KINASE	This work examined the colocalization, trafficking, and interactions of key proteins involved in lipolysis during brief cAMP-dependent protein kinase A (PKA) activation. Double label immunofluorescence analysis of 3T3-L1 adipocytes indicated that PKA activation increases the translocation of hormone-sensitive lipase (HSL) to perilipin A (Plin)-containing droplets and increases the colocalization of adipose tissue triglyceride lipase (Atgl) with its coactivator, Abhd5. Imaging of live 3T3-L1 preadipocytes transfected with Aquorea victoria-based fluorescent reporters demonstrated that HSL rapidly and specifically translocates to lipid droplets (LDs) containing Plin, and that this translocation is partially dependent on Plin phosphorylation. HSL closely, if not directly, interacts with Plin, as indicated by fluorescence resonance energy transfer (FRET) and bimolecular fluorescence complementation (BiFC) experiments. In contrast, tagged Atg1 did not support FRET or BiFC with Plin, although it did modestly translocate to LDs upon stimulation. Abhd5 strongly interacted with Plin in the basal state, as indicated by FRET and BiFC. PKA activation rapidly (within minutes) decreased FRET between Abhd5 and Plin, and this decrease depended upon Plin phosphorylation. Together, these results indicate that Plin mediates hormone-stimulated lipolysis via direct and indirect mechanisms. Plin indirectly controls Atg1 activity by regulating accessibility to its coactivator, Abhd5. In contrast, Plin directly regulates the access of HSL to substrate via close, if not direct, interactions. The differential interactions of HSL and Atg1 with Plin and Abhd5 also explain the findings that following stimulation, HSL and Atg1 are differentially enriched at specific LDs.	Wayne State Univ, Sch Med, Dept Psychiat, Ctr Integrat Metab & Endocrine Res, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Behav Neurosci, Ctr Integrat Metab & Endocrine Res, Detroit, MI 48201 USA; Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA	Wayne State University; Wayne State University; Tufts University; United States Department of Agriculture (USDA)	Granneman, JG (corresponding author), Wayne State Univ, Sch Med, Dept Psychiat, Ctr Integrat Metab & Endocrine Res, 550 E Canfield, Detroit, MI 48201 USA.	jgranne@med.wayne.edu			NIDDK NIH HHS [DK 62292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062292, R01DK062292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; Hu CD, 2003, NAT BIOTECHNOL, V21, P539, DOI 10.1038/nbt816; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Langin D, 2006, TRENDS ENDOCRIN MET, V17, P314, DOI 10.1016/j.tem.2006.08.003; Lass A, 2006, CELL METAB, V3, P309, DOI 10.1016/j.cmet.2006.03.005; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912; Martin S, 2005, J BIOL CHEM, V280, P42325, DOI 10.1074/jbc.M506651200; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Miyoshi H, 2007, J BIOL CHEM, V282, P996, DOI 10.1074/jbc.M605770200; Miyoshi H, 2006, J BIOL CHEM, V281, P15837, DOI 10.1074/jbc.M601097200; Moore HPH, 2005, J BIOL CHEM, V280, P43109, DOI 10.1074/jbc.M506336200; NEGOESCU A, 1994, J HISTOCHEM CYTOCHEM, V42, P433, DOI 10.1177/42.3.7508473; Smith AJ, 2004, J BIOL CHEM, V279, P52399, DOI 10.1074/jbc.M410301200; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Subramanian V, 2004, J BIOL CHEM, V279, P42062, DOI 10.1074/jbc.M407462200; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tsien RY, 2005, FEBS LETT, V579, P927, DOI 10.1016/j.febslet.2004.11.025; Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200; Wolins NE, 2006, FEBS LETT, V580, P5484, DOI 10.1016/j.febslet.2006.08.040; Yamaguchi T, 2004, J BIOL CHEM, V279, P30490, DOI 10.1074/jbc.M403920200; Zechner R, 2005, CURR OPIN LIPIDOL, V16, P333, DOI 10.1097/01.mol.0000169354.20395.1c; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	33	232	241	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5726	5735		10.1074/jbc.M610580200	http://dx.doi.org/10.1074/jbc.M610580200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189257	hybrid			2022-12-25	WOS:000244482300069
J	Rah, SY; Park, KH; Nam, TS; Kim, SJ; Kim, H; Im, MJ; Kim, UH				Rah, So-Young; Park, Kwang-Hyun; Nam, Tae-Sik; Kim, Sang-Jin; Kim, Hyuntae; Im, Mie-Jae; Kim, Uh-Hyun			Association of CD38 with nonmuscle myosin heavy chain IIA and Lck is essential for the internalization and activation of CD38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-ADP-RIBOSE; INTRACELLULAR CA2+; TYROSINE KINASE; CALCIUM-RELEASE; CYCLASE; CELLS; PROTEIN; MESSENGERS; TRANSPORT; MOVEMENT	Activation of CD38 in lymphokine-activated killer (LAK) cells involves interleukin-8 (IL8)-mediated protein kinase G (PKG) activation and results in an increase in the sustained intracellular Ca2+ concentration ([Ca2+](i)), cADP-ribose, and LAK cell migration. However, direct phosphorylation or activation of CD38 by PKG has not been observed in vitro. In this study, we examined the molecular mechanism of PKG-mediated activation of CD38. Nonmuscle myosin heavy chain IIA (MHCIIA) was identified as a CD38-associated protein upon IL8 stimulation. The IL8-induced association of MHCIIA with CD38 was dependent on PKG-mediated phosphorylation of MHCIIA. Supporting these observations, IL8- or cell-permeable cGMP analog-induced formation of cADP-ribose, increase in [Ca2+](i), and migration of LAK cells were inhibited by treatment with the MHCIIA inhibitor blebbistatin. Binding studies using purified proteins revealed that the association of MHCIIA with CD38 occurred through Lck, a tyrosine kinase. Moreover, these three molecules co-immunoprecipitated upon IL8 stimulation of LAK cells. IL8 treatment of LAK cells resulted in internalization of CD38, which co-localized with MHCIIA and Lck, and blebbistatin blocked internalization of CD38. These findings demonstrate that the association of phospho-MHCIIA with Lck and CD38 is a critical step in the internalization and activation of CD38.	Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju 561182, South Korea; Chonbuk Natl Univ, Sch Med, Cardiovasc Res Inst, Jeonju 561182, South Korea	Jeonbuk National University; Jeonbuk National University	Kim, UH (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju 561182, South Korea.	uhkim@chonbuk.ac.kr		Kim, Uh-Hyun/0000-0003-3304-7190; Rah, So-Young/0000-0002-0255-1960				Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Boittin FX, 2003, J BIOL CHEM, V278, P9602, DOI 10.1074/jbc.M204891200; Cho YS, 2000, J BIOL CHEM, V275, P1685, DOI 10.1074/jbc.275.3.1685; De Flora A, 2004, ANN NY ACAD SCI, V1028, P176, DOI 10.1196/annals.1322.021; De Flora Antonio, 1998, Cell Biochemistry and Biophysics, V28, P45; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Gorska MM, 2004, J EXP MED, V199, P369, DOI 10.1084/jem.20030589; Graeff R, 2002, BIOCHEM J, V361, P379, DOI 10.1042/bj3610379; Graeff RM, 1998, J BIOL CHEM, V273, P118, DOI 10.1074/jbc.273.1.118; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Han MK, 2002, J BIOL CHEM, V277, P5315, DOI 10.1074/jbc.M106439200; Higashida H, 1997, J BIOL CHEM, V272, P31272, DOI 10.1074/jbc.272.50.31272; Higashida H, 1999, J BIOL CHEM, V274, P33348, DOI 10.1074/jbc.274.47.33348; Higashida H, 2000, BIOCHEM J, V352, P197, DOI 10.1042/0264-6021:3520197; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Jacobelli J, 2004, NAT IMMUNOL, V5, P531, DOI 10.1038/ni1065; JOUNG I, 1995, P NATL ACAD SCI USA, V92, P5778, DOI 10.1073/pnas.92.13.5778; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; Lee HC, 2004, CURR MOL MED, V4, P227, DOI 10.2174/1566524043360753; LEE HC, 1995, J BIOL CHEM, V270, P9060, DOI 10.1074/jbc.270.16.9060; Linz-McGillem LA, 2003, EXP EYE RES, V76, P543, DOI 10.1016/S0014-4835(03)00031-9; LUND F, 1995, IMMUNOL TODAY, V16, P469, DOI 10.1016/0167-5699(95)80029-8; MAUPIN P, 1994, J CELL SCI, V107, P3077; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; MELDER RJ, 1988, CANCER RES, V48, P3461; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Munoz P, 2003, J BIOL CHEM, V278, P50791, DOI 10.1074/jbc.M308034200; Musch A, 1997, J CELL BIOL, V138, P291, DOI 10.1083/jcb.138.2.291; Neel NF, 2005, CYTOKINE GROWTH F R, V16, P637, DOI 10.1016/j.cytogfr.2005.05.008; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Rah SY, 2005, J BIOL CHEM, V280, P2888, DOI 10.1074/jbc.M409592200; SEBOK K, 1993, J IMMUNOL, V150, P1524; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Xie GH, 2005, BIOCHEM BIOPH RES CO, V330, P1290, DOI 10.1016/j.bbrc.2005.03.114; Xie GH, 2003, BIOCHEM BIOPH RES CO, V307, P713, DOI 10.1016/S0006-291X(03)01240-3; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416	41	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5653	5660		10.1074/jbc.M609478200	http://dx.doi.org/10.1074/jbc.M609478200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17182620	hybrid			2022-12-25	WOS:000244482300062
J	Gupta, M; Trott, D; Porter, ACG				Gupta, Mita; Trott, Deborah; Porter, Andrew C. G.			Rescue of a human cell line from endogenous Cdk1 depletion by Cdk1 lacking inhibitory phosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; FISSION YEAST; S-PHASE; TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; MITOSIS; DNA; REPLICATION; ACTIVATION; EVENTS	Cells that transiently overexpress cyclin-dependent kinase 1 lacking inhibitory phosphorylation sites (Cdk1-AF) undergo premature and catastrophic mitosis, reflecting the key role for Cdk1 in promoting a timely transit from G, into mitosis. Conversely, cells depleted of Cdk1 undergo repeated S phases Without intervening mitoses (endoreduplication), reflecting a role for Cdk1 in preventing premature S phases. It is not known how Cdk1 prevents entry into S phase at times in G, when it does not promote mitosis. Also uncertain is the extent of redundancy between inhibitory phosphorylation and other mechanisms for controlling Cdk1 activity. We describe here human cells that not only tolerate stable Cdk1-AF expression but also rely on it for survival when endogenous Cdk1 is depleted. When residual endogenous Cdk1 expression is further depleted, however, proliferation of Cdk1-AF-rescued cells is inhibited. Interestingly, this inhibition is not accompanied by endoreduplication. These results are consistent with a two-threshold model for Cdk1 kinase activity, one for suppressing endoreduplication and one for promoting mitosis. They also indicate that inhibitory phosphorylation is indispensable for only a fraction of the total cellular complement of Cdk1.	Hammersmith Hosp, Imperial Coll Fac Med, Dept Haematol, Gene Targeting Grp, London W12 0NN, England; Univ London Imperial Coll Sci & Technol, Fac Med, Med Res Council Clin Sci Ctr, London W12 0NN, England	Imperial College London; Imperial College London; UK Research & Innovation (UKRI); Medical Research Council UK (MRC)	Porter, ACG (corresponding author), Hammersmith Hosp, Imperial Coll Fac Med, Dept Haematol, Gene Targeting Grp, Du Cane Rd, London W12 0NN, England.	andy.porter@imperial.ac.uk						Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Carpenter AJ, 2004, MOL BIOL CELL, V15, P5700, DOI 10.1091/mbc.E04-08-0732; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; Fletcher L, 2002, CANCER RES, V62, P241; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; ITALIEN L, 2006, CELL CYCLE, V5, P984; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1992, J CELL SCI, V102, P43; Laronne A, 2003, MOL BIOL CELL, V14, P3730, DOI 10.1091/mbc.E02-12-0850; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Nurse P, 2002, CHEMBIOCHEM, V3, P596, DOI 10.1002/1439-7633(20020703)3:7<596::AID-CBIC596>3.0.CO;2-U; O'Farrell PH, 2001, TRENDS CELL BIOL, V11, P512, DOI 10.1016/S0962-8924(01)02142-0; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; PARIS J, 1994, J CELL SCI, V107, P615; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; Stern B, 1996, TRENDS GENET, V12, P345; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Wuarin J, 2002, CELL, V111, P419, DOI 10.1016/S0092-8674(02)01042-5	35	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4301	4309		10.1074/jbc.M607910200	http://dx.doi.org/10.1074/jbc.M607910200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17164242	hybrid			2022-12-25	WOS:000244482000009
J	Tudor, C; Feige, JN; Pingali, H; Lohray, VB; Wahli, W; Desvergne, B; Engelborghs, Y; Gelman, L				Tudor, Cicerone; Feige, Jerome N.; Pingali, Harikishore; Lohray, Vidya Bhushan; Wahli, Walter; Desvergne, Beatrice; Engelborghs, Yves; Gelman, Laurent			Association with coregulators is the major determinant governing peroxisome proliferator-activated receptor mobility in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; RETINOID-X-RECEPTOR; ANDROGEN RECEPTOR; NUCLEAR RECEPTORS; GLUCOCORTICOID-RECEPTOR; CHROMATIN PROTEINS; HORMONE-RECEPTORS; BINDING-PROTEIN; DNA-BINDING; PPAR-GAMMA	The nucleus is an extxemely dynamic compartment, and protein mobility represents a key factor in transcriptional regulation. We showed in a previous study that the diffusion of peroxisome proliferator-activated receptors (PPARs), a family of nuclear receptors regulating major cellular and metabolic functions, is modulated by ligand binding. In this study, we combine fluorescence correlation spectroscopy, dual color fluorescence cross-correlation microscopy, and fluorescence resonance energy transfer to dissect the molecular mechanisms controlling PPAR mobility and transcriptional activity in living cells. First, we bring new evidence that in vivo a high percentage of PPARs and retinoid X receptors is associated even in the absence of ligand. Second, we demonstrate that coregulator recruitment (and not DNA binding) plays a crucial role in receptor mobility, suggesting that transcriptional complexes are formed prior to promoter binding. In addition, association with coactivators in the absence of a ligand in living cells, both through the N-terminal AB domain and the AF-2 function of the ligand binding domain, provides a molecular basis to explain PPAR constitutive activity.	Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Louvain, Belgium; Univ Lausanne, Natl Res Ctr Frontiers Genet, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland; Zydus Res Ctr, Ahmadabad 382210, Gujarat, India	KU Leuven; University of Lausanne	Engelborghs, Y (corresponding author), Katholieke Univ Leuven, Lab Biomol Dynam, Celestjnenlaan 200G, B-3001 Louvain, Belgium.	yves.engelborghs@fys.kuleuven.be; laurent.gelman@fmi.ch	Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009; Desvergne, Beatrice/C-8892-2016	Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X; Gelman, Laurent/0000-0003-3277-3115				Agresti A, 2005, MOL CELL, V18, P109, DOI 10.1016/j.molcel.2005.03.005; Auwerx J, 1999, CELL, V97, P161; Bacia K, 2006, NAT METHODS, V3, P83, DOI 10.1038/NMETH822; Berger JP, 2005, TRENDS PHARMACOL SCI, V26, P244, DOI 10.1016/j.tips.2005.03.003; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Chui PC, 2005, J CLIN INVEST, V115, P2244, DOI 10.1172/JCI24130; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; Dittrich P, 2001, BIOL CHEM, V382, P491, DOI 10.1515/BC.2001.061; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Elbi C, 2004, P NATL ACAD SCI USA, V101, P2876, DOI 10.1073/pnas.0400116101; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Farla P, 2005, J CELL SCI, V118, P4187, DOI 10.1242/jcs.02546; Farla P, 2004, J STRUCT BIOL, V147, P50, DOI 10.1016/j.jsb.2004.01.002; Feige JN, 2006, PROG LIPID RES, V45, P120, DOI 10.1016/j.plipres.2005.12.002; Feige JN, 2005, MICROSC RES TECHNIQ, V68, P51, DOI 10.1002/jemt.20215; Feige JN, 2005, J BIOL CHEM, V280, P17880, DOI 10.1074/jbc.M500786200; Gelman L, 2005, CURR OPIN CELL BIOL, V17, P216, DOI 10.1016/j.ceb.2005.02.002; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Gorisch SM, 2005, J CELL SCI, V118, P5825, DOI 10.1242/jcs.02689; Gorski SA, 2006, CURR OPIN CELL BIOL, V18, P284, DOI 10.1016/j.ceb.2006.03.002; Guan HP, 2005, GENE DEV, V19, P453, DOI 10.1101/gad.1263305; HUANG Q, 1994, J BIOL CHEM, V269, P8493; Hummasti S, 2006, MOL ENDOCRINOL, V20, P1261, DOI 10.1210/me.2006-0025; IJpenberg A, 2004, EMBO J, V23, P2083, DOI 10.1038/sj.emboj.7600209; Jankevics H, 2005, BIOCHEMISTRY-US, V44, P11676, DOI 10.1021/bi050744v; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; Karpova TS, 2004, EMBO REP, V5, P1064, DOI 10.1038/sj.embor.7400281; Keller H, 1997, BIOL CHEM, V378, P651, DOI 10.1515/bchm.1997.378.7.651; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Lonard DM, 2006, CELL, V125, P411, DOI 10.1016/j.cell.2006.04.021; Marcelli M, 2006, J CELL BIOCHEM, V98, P770, DOI 10.1002/jcb.20593; Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200; Matsuda KI, 2002, MOL ENDOCRINOL, V16, P2215, DOI 10.1210/me.2002-0110; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Meshorer E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Michalik L, 2006, J CLIN INVEST, V116, P598, DOI 10.1172/JCI27958; Michalik L, 2005, MOL ENDOCRINOL, V19, P2335, DOI 10.1210/me.2005-0068; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; Molnar F, 2005, J BIOL CHEM, V280, P26543, DOI 10.1074/jbc.M502463200; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; Schaaf MJM, 2005, MOL ENDOCRINOL, V19, P1501, DOI 10.1210/me.2005-0050; Schaaf MJM, 2003, MOL CELL BIOL, V23, P1922, DOI 10.1128/MCB.23.6.1922-1934.2003; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sohn YC, 2003, MOL ENDOCRINOL, V17, P366, DOI 10.1210/me.2002-0150; Sprague BL, 2004, BIOPHYS J, V86, P3473, DOI 10.1529/biophysj.103.026765; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Sumanasekera WK, 2003, J BIOL CHEM, V278, P4467, DOI 10.1074/jbc.M211261200; Wachsmuth M, 2000, J MOL BIOL, V298, P677, DOI 10.1006/jmbi.2000.3692; Weidemann T, 2003, J MOL BIOL, V334, P229, DOI 10.1016/j.jmb.2003.08.063; Zhao Y, 2002, J BIOL CHEM, V277, P30031, DOI 10.1074/jbc.M203811200	55	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4417	4426		10.1074/jbc.M608172200	http://dx.doi.org/10.1074/jbc.M608172200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17164241	hybrid			2022-12-25	WOS:000244482000022
J	Wang, W; Bernard, K; Li, G; Kirk, KL				Wang, Wei; Bernard, Karen; Li, Ge; Kirk, Kevin L.			Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; ABC TRANSPORTER; R-DOMAIN; PHOSPHORYLATION; SITES; GENISTEIN; 2ND	Cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels are essential mediators of salt transport across epithelia. Channel opening normally requires ATP binding to both nucleotide-binding domains (NBDs), probable dimerization of the two NBDs, and phosphorylation of the R domain. How phosphorylation controls channel gating is unknown. Loss-of-function mutations in the CFTR gene cause cystic fibrosis; thus, there is considerable interest in compounds that improve mutant CFTR function. Here we investigated the mechanism by which CFTR is activated by curcumin, a natural compound found in turmeric. Curcumin opened CFTR channels by a novel mechanism that required neither ATP nor the second nucleotide-binding domain (NBD2). Consequently, this compound potently activated CF mutant channels that are defective for the normal ATP-dependent mode of gating (e.g. G551D and W1282X), including channels that lack NBD2. The stimulation of NBD2 deletion mutants by curcumin was strongly inhibited by ATP binding to NBD1, which implicates NBD1 as a plausible activation site. Curcumin activation became irreversible during prolonged exposure to this compound following which persistently activated channels gated dynamically in the absence of any agonist. Although CFTR activation by curcumin required neither ATP binding nor heterodimerization of the two NBDs, it was strongly dependent on prior channel phosphorylation by protein kinase A. Curcumin is a useful functional probe of CFTR gating that opens mutant channels by circumventing the normal requirements for ATP binding and NBD heterodimerization. The phosphorylation dependence of curcumin activation indicates that the R domain can modulate channel opening without affecting ATP binding to the NBDs or their heterodimerization.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Wang, W (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, 717 MCLM, Birmingham, AL 35294 USA.	weiwang@uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056796] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK56796] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Basso C, 2003, J GEN PHYSIOL, V122, P333, DOI 10.1085/jgp.200308798; Berger AL, 2005, J BIOL CHEM, V280, P5221, DOI 10.1074/jbc.M412972200; Berger AL, 2005, P NATL ACAD SCI USA, V102, P455, DOI 10.1073/pnas.0408575102; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Cui LY, 2007, J MOL BIOL, V365, P981, DOI 10.1016/j.jmb.2006.10.086; Dragomir A, 2004, BIOCHEM BIOPH RES CO, V322, P447, DOI 10.1016/j.bbrc.2004.07.146; Egan ME, 2004, SCIENCE, V304, P600, DOI 10.1126/science.1093941; Fang JG, 2005, J BIOL CHEM, V280, P25284, DOI 10.1074/jbc.M414645200; FRIZZELL RA, 1995, AM J RESP CRIT CARE, V151, pS54, DOI 10.1164/ajrccm/151.3_Pt_2.S54; Fu J, 2001, J PHYSIOL-LONDON, V536, P459, DOI 10.1111/j.1469-7793.2001.0459c.xd; GADSBY DC, 1999, PHYSIOL REV, V79, P577; Goforth RL, 2003, J GEN PHYSIOL, V121, P477, DOI 10.1085/jgp.200308797; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; Gross CH, 2006, J BIOL CHEM, V281, P4058, DOI 10.1074/jbc.M511113200; Hwang TC, 2003, BIOCHEMISTRY-US, V42, P13646, DOI 10.1021/bi034887y; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Kidd JF, 2004, J BIOL CHEM, V279, P41664, DOI 10.1074/jbc.M407666200; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; Linsdell P, 2005, J BIOL CHEM, V280, P8945, DOI 10.1074/jbc.M414354200; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Lundbaek JA, 2004, J GEN PHYSIOL, V123, P599, DOI 10.1085/jgp.200308996; Mathews CJ, 1998, J MEMBRANE BIOL, V163, P55, DOI 10.1007/s002329900370; Mathews CJ, 1998, J PHYSIOL-LONDON, V508, P365, DOI 10.1111/j.1469-7793.1998.365bq.x; Mense M, 2006, EMBO J, V25, P4728, DOI 10.1038/sj.emboj.7601373; Quint A, 2005, AM J MED GENET A, V136A, P246, DOI 10.1002/ajmg.a.30823; Reiter TA, 2002, BIOCHEMISTRY-US, V41, P15404, DOI 10.1021/bi026317o; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Shim JS, 2003, CHEM BIOL, V10, P695, DOI 10.1016/S1074-5521(03)00169-8; Shiraki T, 2005, J BIOL CHEM, V280, P14145, DOI 10.1074/jbc.M500901200; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Song YL, 2004, J BIOL CHEM, V279, P40629, DOI 10.1074/jbc.M407308200; Vais H, 2004, AM J PHYSIOL-CELL PH, V287, pC737, DOI 10.1152/ajpcell.00504.2003; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; Wang F, 1998, J GEN PHYSIOL, V111, P477, DOI 10.1085/jgp.111.3.477; Wang W, 2005, J BIOL CHEM, V280, P23622, DOI 10.1074/jbc.M503118200; Wang W, 2005, J GEN PHYSIOL, V125, P127, DOI 10.1085/jgp.200409115; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R	40	81	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4533	4544		10.1074/jbc.M609942200	http://dx.doi.org/10.1074/jbc.M609942200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17178710	hybrid			2022-12-25	WOS:000244482000035
J	Wei, Y; Tang, CH; Kim, Y; Robillard, L; Zhang, F; Kugler, MC; Chapman, HA				Wei, Ying; Tang, Chi-Hui; Kim, Young; Robillard, Liliane; Zhang, Feng; Kugler, Matthias C.; Chapman, Harold A.			Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; SMOOTH-MUSCLE-CELLS; PLASMINOGEN-ACTIVATOR; GENE-EXPRESSION; FIBROSARCOMA CELLS; ANTISENSE UPAR; OVARIAN-CANCER; GELATINASE B; IN-VIVO; FIBRONECTIN	Up-regulation of urokinase receptors is common during tumor progression and thought to promote invasion and metastasis. Urokinase receptors bind urokinase and a set of beta 1 integrins, but it remains unclear to what degree urokinase receptor/integrin binding is important to beta 1 integrin signaling. Using site-directed mutagenesis, single amino acid mutants of the urokinase receptor were identified that fail to associate with either alpha 3 beta 1 (D262A) or alpha 5 beta 1 (H249A) but associate normally with urokinase. To study the effects of these mutations on beta 1 integrin function, endogenous urokinase receptors were first stably silenced in tumor cell lines HT1080 and H1299, and then wild type or mutant receptors were expressed. Knockdown of urokinase receptors resulted in markedly reduced fibronectin and alpha 5 beta 1-dependent ERK activation and metalloproteinase MMP-9 expression. Re-expression of wild type or D262A mutant receptors but not the alpha 5 beta 1 binding-deficient H249A mutant reconstituted fibronectin responses. Because urokinase receptor-alpha 5 beta 1 complexes bind in the fibronectin heparin-binding domain (Type III 12-14) whereas alpha 5 beta 1 primarily binds in the RGD-containing domain (Type III 7-10), signaling pathways leading to ERK and MMP-9 responses were dissected. Binding to III 7-10 led to Src/focal adhesion kinase activation, whereas binding to III 7-14 caused Rac 1 activation. Tumor cells engaging fibronectin required both Type III 7-10- and 12-14-initiated signals to activate ERK and up-regulate MMP-9. Thus urokinase receptor binding to alpha 5 beta 1 is required for maximal responses to fibronectin and tumor cell invasion, and this operates through an enhanced Src/Rac/ERK signaling pathway.	Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Wei, Y (corresponding author), Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, 513 Parnassus Ave,HSE201, San Francisco, CA 94143 USA.	ying.wei@ucsf.edu; hal.chapman@ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044712] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL044712, HL44712] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Ahmed N, 2003, BRIT J CANCER, V89, P374, DOI 10.1038/sj.bjc.6601098; Ahmed N, 2002, J CELL BIOCHEM, V84, P675, DOI 10.1002/jcb.10080; Alberts AS, 2005, J BIOL CHEM, V280, P12152, DOI 10.1074/jbc.M405073200; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; Carriero MV, 1999, CANCER RES, V59, P5307; Chaurasia P, 2006, J BIOL CHEM, V281, P14852, DOI 10.1074/jbc.M512311200; Costa G L, 1996, Methods Mol Biol, V57, P239; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; de Bock CE, 2004, MED RES REV, V24, P13, DOI 10.1002/med.10054; Degryse B, 2005, J BIOL CHEM, V280, P24792, DOI 10.1074/jbc.M413954200; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Gardsvoll H, 2006, J BIOL CHEM, V281, P19260, DOI 10.1074/jbc.M513583200; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342; Ghosh S, 2006, J BIOL CHEM, V281, P13021, DOI 10.1074/jbc.M508526200; Ginestra A, 1997, J BIOL CHEM, V272, P17216, DOI 10.1074/jbc.272.27.17216; Gondi CS, 2003, ONCOGENE, V22, P5967, DOI 10.1038/sj.onc.1206535; Hahn-Dantona E, 1999, ANN NY ACAD SCI, V878, P372, DOI 10.1111/j.1749-6632.1999.tb07696.x; Hamelers IHL, 2005, J CELL BIOL, V171, P871, DOI 10.1083/jcb.200509172; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Inuzuka K, 2000, J SURG RES, V93, P211, DOI 10.1006/jsre.2000.5952; Jeong J, 2001, BIOCHEM J, V356, P531, DOI 10.1042/0264-6021:3560531; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Kim J, 2001, BIOCHEM J, V360, P239, DOI 10.1042/0264-6021:3600239; Kiyan J, 2005, EMBO J, V24, P1787, DOI 10.1038/sj.emboj.7600669; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Kugler MC, 2003, CURR PHARM DESIGN, V9, P1565, DOI 10.2174/1381612033454658; Lakka SS, 2001, CLIN CANCER RES, V7, P1087; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; Loeser RF, 2003, J BIOL CHEM, V278, P24577, DOI 10.1074/jbc.M304530200; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; Mao Y, 2005, MATRIX BIOL, V24, P389, DOI 10.1016/j.matbio.2005.06.008; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Mazzieri R, 2006, MOL BIOL CELL, V17, P367, DOI 10.1091/mbc.E05-07-0635; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Rao JS, 2005, MOL CANCER THER, V4, P1399, DOI 10.1158/1535-7163.MCT-05-0082; Schedin P, 2000, J CELL SCI, V113, P795; Schmitz U, 2001, J BIOL CHEM, V276, P22003, DOI 10.1074/jbc.M102450200; Segarra M, 2005, FASEB J, V19, P1875, DOI 10.1096/fj.04-3574fje; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Shibata K, 1997, CANCER RES, V57, P5416; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; Stanton H, 2002, BIOCHEM J, V364, P181, DOI 10.1042/bj3640181; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; Wang XF, 2001, CHINESE J ASTRON AST, V1, P257, DOI 10.1088/1009-9271/1/3/257; Wang Y, 2001, MED RES REV, V21, P146, DOI 10.1002/1098-1128(200103)21:2<146::AID-MED1004>3.0.CO;2-B; Wei Y, 2005, J CELL BIOL, V168, P501, DOI 10.1083/jcb.200404112; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576; Xue W, 1997, CANCER RES, V57, P1682; Yasuda T, 2003, ARTHRITIS RHEUM, V48, P1271, DOI 10.1002/art.10951; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Zhang F, 2003, J CELL BIOL, V163, P177, DOI 10.1083/jcb.200304065; Zhou H, 2005, J BIOL CHEM, V280, P10624, DOI 10.1074/jbc.M411900200	78	88	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3929	3939		10.1074/jbc.M607989200	http://dx.doi.org/10.1074/jbc.M607989200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17145753	hybrid			2022-12-25	WOS:000244481900057
J	Lokmic, Z; Stillaert, F; Morrison, WA; Thompson, EW; Mitchell, GM				Lokmic, Zerina; Stillaert, Filip; Morrison, Wayne A.; Thompson, Erik W.; Mitchell, Geraldine M.			An arteriovenous loop in a protected space generates a permanent, highly vascular, tissue-engineered construct	FASEB JOURNAL			English	Article						chamber space; macrovascular loop; angiogenesis; growth and remodeling; in vivo tissue engineering	ENDOTHELIAL GROWTH-FACTOR; EXTRACELLULAR-MATRIX; IN-VIVO; GRANULATION-TISSUE; CELL-PROLIFERATION; CONTROLLED-RELEASE; ANGIOGENESIS; HYPOXIA; MODEL; APOPTOSIS	A major obstacle to 3-dimensional tissue engineering is incorporation of a functional vascular supply to support the expanding new tissue. This is overcome in an in vivo intrinsic vascularization model where an arteriovenous loop (AVL) is placed in a noncollapsible space protected by a polycarbonate chamber. Vascular development and hypoxia were examined from 3 days to 112 days by vascular casting, morphometric, and morphological techniques to understand the model's vascular growth and remodeling parameters for tissue engineering purposes. At 3 days a fibrin exudate surrounded the AVL, providing a scaffold to migrating inflammatory, endothelial, and mesenchymal cells. Capillaries formed between 3 and 7 days. Hypoxia and cell proliferation were maximal at 7 days, followed by a peak in percent vascular volume at 10 days (23.20 +/- 3.14% compared with 3.59 +/- 2.68% at 3 days, P < 0.001). Maximal apoptosis was observed at 112 days. The protected space and spontaneous microcirculatory development in this model suggest it would be applicable for in vivo tissue engineering. A temporal window in a period of intense angiogenesis at 7 to 10 days is optimal for exogenous cell seeding and survival in the chamber, potentially enabling specific tissue outcomes to be achieved.	Bernard OBrien Inst Microsurg, Melbourne, Vic 3065, Australia; Univ Melbourne, St Vincent Hosp, Dept Surg, Melbourne, Vic, Australia; Univ Hosp Gent, UZ Gent, Dept Plast, Ghent, Belgium; Univ Hosp Gent, UZ Gent, Reconstruct Surg Unit, Ghent, Belgium	St Vincent's Hospital Melbourne; University of Melbourne; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Mitchell, GM (corresponding author), Bernard OBrien Inst Microsurg, 42 Fitzroy St, Melbourne, Vic 3065, Australia.	mitcg@unimelb.edu.au	Thompson, Erik/GPK-2067-2022; Thompson, Erik W/A-1425-2009; Lokmic-Tomkins, Zerina/AAC-6962-2022	Thompson, Erik/0000-0002-9723-4924; Thompson, Erik W/0000-0002-9723-4924; Lokmic-Tomkins, Zerina/0000-0003-0266-9536				Alenghat Francis J, 2002, Sci STKE, V2002, ppe6, DOI 10.1126/stke.2002.119.pe6; Auger FA, 2004, BIOTECHNOL APPL BIOC, V39, P263; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; Darby IA, 2002, J PATHOL, V197, P117, DOI 10.1002/path.1074; Egginton S, 2003, MICROCIRCULATION, V10, P45, DOI 10.1038/sj.mn.7800174; Elcin YM, 2001, ARTIF ORGANS, V25, P558, DOI 10.1046/j.1525-1594.2001.025007558.x; EXCELL L, 2004, AUSTR NZ ORG DON REG; Frerich B, 2001, INT J ORAL MAX SURG, V30, P414, DOI 10.1054/ijom.2001.0130; Hewitson TD, 2000, METH MOL B, V123, P157; Hossler FE, 2001, MICROSC MICROANAL, V7, P253, DOI 10.1017/S1431927601010261; Howard C, 1998, UNBIASED STEREOLOGY; Ichioka S, 1997, J SURG RES, V72, P29, DOI 10.1006/jsre.1997.5170; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Lee KY, 2003, J CONTROL RELEASE, V87, P49, DOI 10.1016/S0168-3659(02)00349-8; Levenberg S, 2005, NAT BIOTECHNOL, V23, P879, DOI 10.1038/nbt1109; LOKMIC Z, 2004, ENCY BIOMATERIALS BI, P1750; Lokmic Z, 2006, WOUND REPAIR REGEN, V14, P277, DOI 10.1111/j.1743-6109.2006.00122.x; Lu YX, 2001, CIRCULATION, V104, P594, DOI 10.1161/hc3101.092215; McIntire LV, 2002, ANN NY ACAD SCI, V961, P246, DOI 10.1111/j.1749-6632.2002.tb03092.x; Mian RW, 2000, TISSUE ENG, V6, P595, DOI 10.1089/10763270050199541; Muskhelishvili L, 2003, J HISTOCHEM CYTOCHEM, V51, P1681, DOI 10.1177/002215540305101212; OEHMICHEN M, 1982, Z RECHTSMED, V88, P285; Paige K T, 1995, Tissue Eng, V1, P97, DOI 10.1089/ten.1995.1.97; Park KD, 2000, YONSEI MED J, V41, P780, DOI 10.3349/ymj.2000.41.6.780; Ratcliffe A, 2000, MATRIX BIOL, V19, P353, DOI 10.1016/S0945-053X(00)00080-9; Rinsch C, 2001, GENE THER, V8, P523, DOI 10.1038/sj.gt.3301436; SCHERLE W, 1970, Mikroskopie, V26, P57; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stupack DG, 2003, ONCOGENE, V22, P9022, DOI 10.1038/sj.onc.1207110; Tabata Y, 2000, TISSUE ENG, V6, P279, DOI 10.1089/10763270050044452; Tanaka Y, 2003, PLAST RECONSTR SURG, V112, P1636, DOI 10.1097/01.PRS.0000086140.49022.AB; van Hinsbergh VWM, 2001, ANN NY ACAD SCI, V936, P426	38	139	143	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					511	522		10.1096/fj.06-6614com	http://dx.doi.org/10.1096/fj.06-6614com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17172640	Green Published			2022-12-25	WOS:000244686300024
J	Pourmand, N; Diamond, L; Garten, R; Erickson, JP; Kumm, J; Donis, RO; Davis, RW				Pourmand, Nader; Diamond, Lisa; Garten, Rebecca; Erickson, Julianna P.; Kumm, Jochen; Donis, Ruben O.; Davis, Ronald W.			Rapid and Highly Informative Diagnostic Assay for H5N1 Influenza Viruses	PLOS ONE			English	Article								A highly discriminative and information-rich diagnostic assay for H5N1 avian influenza would meet immediate patient care needs and provide valuable information for public health interventions, e. g., tracking of new and more dangerous variants by geographic area as well as avian-to-human or human-to-human transmission. In the present study, we have designed a rapid assay based on multilocus nucleic acid sequencing that focuses on the biologically significant regions of the H5N1 hemagglutinin gene. This allows the prediction of viral strain, clade, receptor binding properties, low-or high-pathogenicity cleavage site and glycosylation status. H5 HA genes were selected from nine known high-pathogenicity avian influenza subtype H5N1 viruses, based on their diversity in biologically significant regions of hemagglutinin and/or their ability to cause infection in humans. We devised a consensus pre-programmed pyrosequencing strategy, which may be used as a faster, more accurate alternative to de novo sequencing. The available data suggest that the assay described here is a reliable, rapid, information-rich and cost-effective approach for definitive diagnosis of H5N1 avian influenza. Knowledge of the predicted functional sequences of the HA will enhance H5N1 avian influenza surveillance efforts.	[Pourmand, Nader; Diamond, Lisa; Erickson, Julianna P.; Kumm, Jochen; Davis, Ronald W.] Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA; [Garten, Rebecca; Donis, Ruben O.] Ctr Dis Control & Prevent, Mol Virol & Vaccines Branch, Influenza Div, Atlanta, GA USA	Stanford University; Centers for Disease Control & Prevention - USA	Pourmand, N (corresponding author), Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA.	pourmand@stanford.edu		Pourmand, Nader/0000-0003-0251-9060	National Institutes of Health [1R21 A1059499- 01, PO1-HG000205]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000205] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	National Institutes of Health, 1R21 A1059499- 01 and PO1-HG000205	Banks J, 2003, AVIAN DIS, V47, P942, DOI 10.1637/0005-2086-47.s3.942; BOSCH FX, 1981, VIROLOGY, V113, P725, DOI 10.1016/0042-6822(81)90201-4; Bright RA, 2005, LANCET, V366, P1175, DOI 10.1016/S0140-6736(05)67338-2; *CDC, 2006, MMWR-MORBID MORTAL W, V10, P127; CONNOR RJ, 1994, VIROLOGY, V205, P17, DOI 10.1006/viro.1994.1615; Cover TM, 1991, ELEMENTS INFORM THEO, Vxxii; Cristianini N, 2000, INTRO SUPPORT VECTOR, pxiii; DUDA RO, 2001, PATTERN CLASSIFICATI, pR25; Effler PV, 2002, EMERG INFECT DIS, V8, P23, DOI 10.3201/eid0801.010067; Fan J, 1998, CLIN INFECT DIS, V26, P1397, DOI 10.1086/516357; Gharizadeh B, 2005, INT J ANTIMICROB AG, V26, P486, DOI 10.1016/j.ijantimicag.2005.08.017; Gharizadeh B, 2006, MOL CELL PROBE, V20, P230, DOI 10.1016/j.mcp.2006.01.002; Ha Y, 2002, EMBO J, V21, P865, DOI 10.1093/emboj/21.5.865; Habib-Bein NF, 2003, J CLIN MICROBIOL, V41, P3597, DOI 10.1128/JCM.41.8.3597-3601.2003; Hatta M, 2000, ARCH VIROL, V145, P1947, DOI 10.1007/s007050070068; KENDAL AP, 1982, CONCEPTS PROCEDURES, pB17; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Matrosovich M, 2000, J VIROL, V74, P8502, DOI 10.1128/JVI.74.18.8502-8512.2000; MEYER D, 2006, SUPPORT VECTOR MACHI, pE1071; Obenauer JC, 2006, SCIENCE, V311, P1576, DOI 10.1126/science.1121586; OHUCHI M, 1989, VIROLOGY, V168, P274, DOI 10.1016/0042-6822(89)90267-5; PAULSON JC, 1985, RECEPTORS; Reid AH, 1999, P NATL ACAD SCI USA, V96, P1651, DOI 10.1073/pnas.96.4.1651; Ronaghi M, 1998, SCIENCE, V281, P363, DOI 10.1126/science.281.5375.363; Scheffner M, 1998, PHARMACOL THERAPEUT, V78, P129, DOI 10.1016/S0163-7258(98)00003-5; SCHMIDT NJ, 1989, DIAGNOSTIC PROCEDURE, pR15; Shinya K, 2005, J VIROL, V79, P9926, DOI 10.1128/JVI.79.15.9926-9932.2005; Smith GJD, 2006, P NATL ACAD SCI USA, V103, P16936, DOI 10.1073/pnas.0608157103; Stevens J, 2006, SCIENCE, V312, P404, DOI 10.1126/science.1124513; Stevens J, 2006, J MOL BIOL, V355, P1143, DOI 10.1016/j.jmb.2005.11.002; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; Templeton KE, 2004, J CLIN MICROBIOL, V42, P1564, DOI 10.1128/JCM.42.4.1564-1569.2004; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vines A, 1998, J VIROL, V72, P7626, DOI 10.1128/JVI.72.9.7626-7631.1998; WHILEY DM, 2005, DIAGN MICROBIOL INFE; *WHO, 2005, EMERG INFECT DIS, V11; Xu XY, 1999, VIROLOGY, V261, P15, DOI 10.1006/viro.1999.9820; R STAT PACKAGE	38	29	31	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e95	10.1371/journal.pone.0000095	http://dx.doi.org/10.1371/journal.pone.0000095			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183727	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600094
J	Yu, LL; Tucci, V; Kishi, S; Zhdanova, IV				Yu, Lili; Tucci, Valter; Kishi, Shuji; Zhdanova, Irina V.			Cognitive Aging in Zebrafish	PLOS ONE			English	Article								Background. Age-related impairments in cognitive functions represent a growing clinical and social issue. Genetic and behavioral characterization of animal models can provide critical information on the intrinsic and environmental factors that determine the deterioration or preservation of cognitive abilities throughout life. Methodology/Principal Findings. Behavior of wild-type, mutant and gamma-irradiated zebrafish (Danio rerio) was documented using image-analysis technique. Conditioned responses to spatial, visual and temporal cues were investigated in young, middle-aged and old animals. The results demonstrate that zebrafish aging is associated with changes in cognitive responses to emotionally positive and negative experiences, reduced generalization of adaptive associations, increased stereotypic and reduced exploratory behavior and altered temporal entrainment. Genetic upregulation of cholinergic transmission attenuates cognitive decline in middle-aged achesb55/+ mutants, compared to wild-type siblings. In contrast, the genotoxic stress of gamma-irradiation accelerates the onset of cognitive impairment in young zebrafish. Conclusions/Significance. These findings would allow the use of powerful molecular biological resources accumulated in the zebrafish field to address the mechanisms of cognitive senescence, and promote the search for therapeutic strategies which may attenuate age-related cognitive decline.	[Yu, Lili; Tucci, Valter; Zhdanova, Irina V.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Kishi, Shuji] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA	Boston University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Zhdanova, IV (corresponding author), Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA.	zhdanova@bu.edu		Tucci, Valter/0000-0002-3796-3826; Zhdanova, Irina/0000-0002-8401-9571	NIH [MH065528, AG02264]; Chaikin-Wile foundation; Ellison Medical Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH065528] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chaikin-Wile foundation; Ellison Medical Foundation(Lawrence Ellison Foundation); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by the grants awarded by NIH (MH065528; to IZ), (AG02264, to SK), Chaikin-Wile foundation (IZ), and Ellison Medical Foundation (SK).	Bartus RT, 2000, EXP NEUROL, V163, P495, DOI 10.1006/exnr.2000.7397; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; Behra M, 2002, NAT NEUROSCI, V5, P111, DOI 10.1038/nn788; BOLLES RC, 1965, J COMP PHYSIOL PSYCH, V60, P290, DOI 10.1037/h0022308; Cahill GM, 2002, CELL TISSUE RES, V309, P27, DOI 10.1007/s00441-002-0570-7; Craik FIM, 2006, TRENDS COGN SCI, V10, P131, DOI 10.1016/j.tics.2006.01.007; Delaney M, 2002, BIOL BULL, V203, P240, DOI 10.2307/1543418; Engeszer RE, 2004, CURR BIOL, V14, P881, DOI 10.1016/j.cub.2004.04.042; Gerhard GS, 2003, EXP GERONTOL, V38, P1333, DOI 10.1016/j.exger.2003.10.022; Gerhard GS, 2002, AGING CELL, V1, P104, DOI 10.1046/j.1474-9728.2002.00012.x; Gooley JJ, 2006, NAT NEUROSCI, V9, P398, DOI 10.1038/nn1651; GREENWOOD B, 1995, AM J PHYSIOL-GASTR L, V268, pG514, DOI 10.1152/ajpgi.1995.268.3.G514; INGLIS FM, 1994, NEUROSCIENCE, V62, P1049, DOI 10.1016/0306-4522(94)90342-5; Keller ET, 2004, COMP BIOCHEM PHYS C, V138, P335, DOI 10.1016/j.cca.2004.04.001; Kishi S, 2004, ANN NY ACAD SCI, V1019, P521, DOI 10.1196/annals.1297.097; Lalonde R, 2002, NEUROSCI BIOBEHAV R, V26, P91, DOI 10.1016/S0149-7634(01)00041-0; Larson ET, 2006, BEHAV BRAIN RES, V167, P94, DOI 10.1016/j.bbr.2005.08.020; MISTLBERGER RE, 1990, NEUROBIOL AGING, V11, P619, DOI 10.1016/0197-4580(90)90027-W; MISTLBERGER RE, 1994, NEUROSCI BIOBEHAV R, V18, P171, DOI 10.1016/0149-7634(94)90023-X; Mueller T, 2004, BRAIN RES, V1011, P156, DOI 10.1016/j.brainres.2004.02.073; Myers KM, 2002, NEURON, V36, P567, DOI 10.1016/S0896-6273(02)01064-4; Ninkovic J, 2006, J NEUROBIOL, V66, P463, DOI 10.1002/neu.20231; ONO M, 1995, PHYSIOL BEHAV, V57, P189, DOI 10.1016/0031-9384(94)00248-4; Peters A, 2002, J NEUROCYTOL, V31, P581, DOI 10.1023/A:1025731309829; RAZA A, 1994, HEARING RES, V77, P221, DOI 10.1016/0378-5955(94)90270-4; ROBINSON J, 1993, P NATL ACAD SCI USA, V90, P6009, DOI 10.1073/pnas.90.13.6009; Sarter M, 2004, NEUROBIOL AGING, V25, P1127, DOI 10.1016/j.neurobiolaging.2003.11.011; Schaffitzel E, 2006, EXP GERONTOL, V41, P557, DOI 10.1016/j.exger.2006.02.008; Schibler U, 2003, J BIOL RHYTHM, V18, P250, DOI 10.1177/0748730403018003007; Tanaka Y, 2000, PHARMACOL BIOCHEM BE, V66, P827, DOI 10.1016/S0091-3057(00)00288-4; TSAI SB, 2006, AGING CELL IN PRESS; Walcott EC, 1996, PHYSIOL BEHAV, V60, P1205, DOI 10.1016/S0031-9384(96)00215-6; Zhdanova IV, 2001, BRAIN RES, V903, P263, DOI 10.1016/S0006-8993(01)02444-1	33	107	108	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e14	10.1371/journal.pone.0000014	http://dx.doi.org/10.1371/journal.pone.0000014			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183640	gold, Green Published			2022-12-25	WOS:000207443600014
J	Nekhai, S; Bhat, UG; Ammosova, T; Radhakrishnan, SK; Jerebtsova, M; Niu, X; Foster, A; Layden, TJ; Gartel, AL				Nekhai, S.; Bhat, U. G.; Ammosova, T.; Radhakrishnan, S. K.; Jerebtsova, M.; Niu, X.; Foster, A.; Layden, T. J.; Gartel, A. L.			A novel anticancer agent ARC antagonizes HIV-1 and HCV	ONCOGENE			English	Article						HIV; HCV; anticancer drug; nucleoside analog	RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; CYCLIN T1; P-TEFB; LARGE SUBUNIT; TAT; TRANSCRIPTION; PROTEIN; HEPATITIS; INTERACTS	Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) pose major public health concerns worldwide. HCV is clearly associated with the occurrence of hepatocellular carcinoma, and recently HIV infection has also been linked to the development of a multitude of cancers. Previously, we identified a novel nucleoside analog transcriptional inhibitor ARC (4-amino-6-hydrazino-7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carboxamide) that exhibited proapoptotic and antiangiogenic properties in vitro. Here, we evaluated the effect of ARC on HIV-1 transcription and HCV replication. Using reporter assays, we found that ARC inhibited HIV-1 Tat-based transactivation in different cell systems. Also, using hepatoma cells that harbor subgenomic and full-length replicons of HCV, we found that ARC inhibited HCV replication. Together, our data indicate that ARC could be a promising candidate for the development of antiviral therapeutics against HIV and HCV.	Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Howard Univ, Coll Med, Ctr Sickle Cell Dis, Washington, DC 20059 USA; Howard Univ, Coll Med, Dept Biochem & Mol Biol, Washington, DC 20059 USA; CRI Ctr, Childrens Natl Med Ctr, Washington, DC 20059 USA; Howard Univ, Coll Med, Dept Microbiol, Washington, DC 20059 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Howard University; Howard University; Children's National Health System; Howard University	Nekhai, S (corresponding author), Univ Illinois, Coll Med, Dept Med, 840 S Wood,Room 1041, Chicago, IL 60612 USA.	snekhai@howard.edu; agartel@uic.edu	, nekhai/AFO-2652-2022; Ammosova, Tatiana/HIA-0704-2022; , nekhai/AAW-3105-2021; Ammosova, Tatiana/J-7564-2018	Ammosova, Tatiana/0000-0001-8777-1032; Radhakrishnan, Senthil/0000-0002-5211-9498	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [UH1HL003679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI056973] Funding Source: NIH RePORTER; NHLBI NIH HHS [UH1HL 03679] Funding Source: Medline; NIAID NIH HHS [R21 AI156973-01, R21 AI056973-02, R21 AI056973] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ammosova T, 2005, J BIOL CHEM, V280, P36364, DOI 10.1074/jbc.M503673200; Ammosova T, 2003, J BIOL CHEM, V278, P32189, DOI 10.1074/jbc.M300521200; Bark-Jones SJ, 2006, ONCOGENE, V25, P1775, DOI 10.1038/sj.onc.1209205; Berretta M, 2003, ONCOGENE, V22, P6646, DOI 10.1038/sj.onc.1206771; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Brady J, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-69; Brigati C, 2003, FEMS MICROBIOL LETT, V220, P57, DOI 10.1016/S0378-1097(03)00067-3; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Deng LW, 2002, J BIOL CHEM, V277, P33922, DOI 10.1074/jbc.M111349200; Garber ME, 1998, COLD SPRING HARB SYM, V63, P371, DOI 10.1101/sqb.1998.63.371; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Giacca Mauro, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P277, DOI 10.2174/1568008043339767; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Lau JYN, 2002, HEPATOLOGY, V35, P1002, DOI 10.1053/jhep.2002.32672; Levrero M, 2006, ONCOGENE, V25, P3834, DOI 10.1038/sj.onc.1209562; Liang Chen, 2002, AIDS Reviews, V4, P41; Liang TJ, 2004, GASTROENTEROLOGY, V127, pS62, DOI 10.1053/j.gastro.2004.09.017; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233; Marcello A, 2001, IUBMB LIFE, V51, P175, DOI 10.1080/152165401753544241; Nekhai S, 2000, PEPTIDES, V21, P1449, DOI 10.1016/S0196-9781(00)00297-7; PETRYSHYN R, 1984, BIOCHEM BIOPH RES CO, V119, P891, DOI 10.1016/0006-291X(84)90857-X; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Radhakrishnan SK, 2006, CANCER RES, V66, P3264, DOI 10.1158/0008-5472.CAN-05-3940; Radhakrishnan SK, 2004, VIROLOGY, V323, P173, DOI 10.1016/j.virol.2004.02.021; Roden R, 2006, NAT REV CANCER, V6, P753, DOI 10.1038/nrc1973; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Tamrakar S, 2005, J VIROL, V79, P15477, DOI 10.1128/JVI.79.24.15477-15493.2005; Wang D, 2001, J VIROL, V75, P7266, DOI 10.1128/JVI.75.16.7266-7279.2001; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Zhou MS, 2006, J VIROL, V80, P4781, DOI 10.1128/JVI.80.10.4781-4791.2006	34	18	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3899	3903		10.1038/sj.onc.1210158	http://dx.doi.org/10.1038/sj.onc.1210158			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173067				2022-12-25	WOS:000247026400013
J	Poppe, M; Feller, SM; Romer, G; Wessler, S				Poppe, M.; Feller, S. M.; Romer, G.; Wessler, S.			Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility	ONCOGENE			English	Article						c-Abl; CagA; helicobacter pylori; Src	GASTRIC EPITHELIAL-CELLS; IV SECRETION SYSTEM; TYROSINE KINASES; PATHOGENICITY ISLAND; FAMILY KINASES; GROWTH-FACTOR; PROTEIN; CRK; TRANSLOCATION; SRC	Helicobacter pylori induces a strong motogenic response in infected gastric epithelial host cells, which is enhanced by translocation of the pathogenic factor cytotoxinassociated gene A (CagA) into host cells via a specialized type IV secretion system. Once injected into the cytosol CagA is rapidly tyrosine phosphorylated by Src family kinases followed by Src inactivation. Hence, it remained unknown why CagA is constantly phosphorylated in sustained H. pylori infections to induce cell migration, whereas other substrates of Src kinases are dephosphorylated. Here, we identify the non- receptor tyrosine kinase c-Abl as a crucial mediator of H. pylori-induced migration and novel CagA kinase in epithelial cells. Upon H. pylori infection c-Abl directly interacts with CagA and localizes in focal adhesion complexes and membrane ruf. es, which are highly dynamic cytoskeletal structures necessary for cell motility. Selective inhibition of c-Abl kinase activity by STI571 or shRNA abrogates sustained CagA phosphorylation and epithelial cell migration, indicating a pivotal role of c-Abl in H. pylori infection and pathogenicity. These results implicate c-Abl as a novel molecular target for therapeutic intervention in H. pylor-related gastric diseases.	Paul Ehrlich Inst, Jr Res Grp, D-63225 Langen, Hessen, Germany; Weatherall Inst Mol Med, Canc Res UK, Oxford, England	Paul Ehrlich Institute; Cancer Research UK; University of Oxford	Wessler, S (corresponding author), Paul Ehrlich Inst, Jr Res Grp, Paul Ehrlich Str 51-59, D-63225 Langen, Hessen, Germany.	wessi@pei.de	Wessler, Silja/C-6309-2015	Wessler, Silja/0000-0001-7011-6162				Al-Ghoul L, 2004, BIOCHEM BIOPH RES CO, V322, P860, DOI 10.1016/j.bbrc.2004.07.199; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Argent RH, 2005, J CLIN MICROBIOL, V43, P791, DOI 10.1128/JCM.43.2.791-795.2005; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Backert S, 2001, MOL MICROBIOL, V42, P631, DOI 10.1046/j.1365-2958.2001.02649.x; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; Bagnoli F, 2005, P NATL ACAD SCI USA, V102, P16339, DOI 10.1073/pnas.0502598102; Barila D, 2003, MOL CELL BIOL, V23, P2790, DOI 10.1128/MCB.23.8.2790-2799.2003; Bauer B, 2005, INFECT IMMUN, V73, P4643, DOI 10.1128/IAI.73.8.4643-4652.2005; Churin Y, 2003, J CELL BIOL, V161, P249, DOI 10.1083/jcb.200208039; CorthesyTheulaz I, 1996, INFECT IMMUN, V64, P3827; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Frasca F, 2001, ONCOGENE, V20, P3845, DOI 10.1038/sj.onc.1204531; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Machuy N, 2004, CELL DEATH DIFFER, V11, P290, DOI 10.1038/sj.cdd.4401336; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0; Moese S, 2004, INFECT IMMUN, V72, P3646, DOI 10.1128/IAI.72.6.3646-3649.2004; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Selbach M, 2004, PROTEOMICS, V4, P2961, DOI 10.1002/pmic.200400915; Selbach M, 2003, EMBO J, V22, P515, DOI 10.1093/emboj/cdg050; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; Suzuki M, 2005, J EXP MED, V202, P1235, DOI 10.1084/jem.20051027; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Van Etten RA, 2003, CURR BIOL, V13, pR608, DOI 10.1016/S0960-9822(03)00528-1; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; *WHO, 1994, IARC MON EV CARC RIS, V61, P1; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	46	131	138	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3462	3472		10.1038/sj.onc.1210139	http://dx.doi.org/10.1038/sj.onc.1210139			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160020				2022-12-25	WOS:000246799200002
J	Lauren, J; Hu, FH; Chin, J; Liao, J; Airaksinen, MS; Strittmatter, SM				Lauren, Juha; Hu, Fenghua; Chin, Joanna; Liao, Ji; Airaksinen, Matti S.; Strittmatter, Stephen M.			Characterization of myelin ligand complexes with neuronal Nogo-66 receptor family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXON REGENERATION; GLYCOPROTEIN; RECOVERY; INHIBITION; GROWTH; OUTGROWTH; IDENTIFICATION; INTERACTS; PROTEINS; ANTIBODY	Nogo, MAG, and OMgp are myelin-associated proteins that bind to a neuronal Nogo-66 receptor (NgR/NgR1) to limit axonal regeneration after central nervous system injury. Within Nogo-A, two separate domains are known interact with NgR1. NgR1 is the founding member of the three-member NgR family, whereas Nogo-A (RTN4A) belongs to a four-member reticulon family. Here, we systematically mapped the interactions between these superfamilies, demonstrating novel nanomolar interactions of RTN2 and RTN3 with NgR1. Because RTN3 is expressed in spinal cord white matter, it may have a role in myelin inhibition of axonal growth. Further analysis of the Nogo-A and NgR1 interactions revealed a novel third interaction site between the proteins, suggesting a trivalent Nogo-A interaction with NgR1. We also confirmed here that MAG binds to NgR2, but not to NgR3. Unexpectedly, we found that OMgp interacts with MAG with a higher affinity compared with NgR1. To better define how these multiple structurally distinct ligands bind to NgR1, we examined a series of Ala-substituted NgR1 mutants for ligand binding activity. We found that the core of the binding domain is centered in the middle of the concave surface of the NgR1 leucine-rich repeat domain and surrounded by differentially utilized residues. This detailed knowledge of the molecular interactions between NgR1 and its ligands is imperative when assessing options for development of NgR1-based therapeutics for central nervous system injuries.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA; Univ Helsinki, Ctr Neurosci, FIN-00014 Helsinki, Finland	Yale University; Yale University; University of Helsinki	Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Dept Neurol, 333 Cedar St, New Haven, CT 06520 USA.	stephen.strittmatter@yale.edu	Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092; Airaksinen, Matti/0000-0002-7199-4984	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS056485, R01NS039962, R37NS033020, R01NS042304] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS042304-09, R37 NS033020, R01 NS056485, R01 NS039962-10, R01 NS042304, R37 NS033020-17, NS42304, NS39962, R01 NS056485-05, R01 NS039962] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barton WA, 2003, EMBO J, V22, P3291, DOI 10.1093/emboj/cdg325; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Dodd DA, 2005, J BIOL CHEM, V280, P12494, DOI 10.1074/jbc.M411827200; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Flanagan JG, 2000, METHOD ENZYMOL, V327, P19, DOI 10.1016/S0076-6879(00)27264-9; Fournier AE, 2002, J NEUROSCI, V22, P8876; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Habib AA, 1998, J NEUROCHEM, V70, P1704; He XLL, 2003, NEURON, V38, P177, DOI 10.1016/S0896-6273(03)00232-0; Hu FH, 2005, J NEUROSCI, V25, P5298, DOI 10.1523/JNEUROSCI.5235-04.2005; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; Lauren J, 2003, MOL CELL NEUROSCI, V24, P581, DOI 10.1016/S1044-7431(03)00199-4; Lee DHS, 2003, NAT REV DRUG DISCOV, V2, P872, DOI 10.1038/nrd1228; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Levy D, 1996, Essays Biochem, V31, P49; Li SX, 2003, J NEUROSCI, V23, P4219; Li SX, 2004, J NEUROSCI, V24, P10511, DOI 10.1523/JNEUROSCI.2828-04.2004; Liu BP, 2006, PHILOS T R SOC B, V361, P1593, DOI 10.1098/rstb.2006.1891; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Niederost B, 2002, J NEUROSCI, V22, P10368; Oertle T, 2003, FASEB J, V17, P1238, DOI 10.1096/fj.02-1166hyp; Oertle T, 2003, J NEUROSCI, V23, P5393; Pignot V, 2003, J NEUROCHEM, V85, P717, DOI 10.1046/j.1471-4159.2003.01710.x; Qi B, 2003, J CELL PHYSIOL, V196, P312, DOI 10.1002/jcp.10297; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Schubert WD, 2002, CELL, V111, P825, DOI 10.1016/S0092-8674(02)01136-4; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; Venkatesh K, 2005, J NEUROSCI, V25, P808, DOI 10.1523/JNEUROSCI.4464-04.2005; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Wang XX, 2006, ANN NEUROL, V60, P540, DOI 10.1002/ana.20953; Wiessner C, 2003, J CEREBR BLOOD F MET, V23, P154, DOI 10.1097/01.WCB.0000040400.30600.AF; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zheng BH, 2005, P NATL ACAD SCI USA, V102, P1205, DOI 10.1073/pnas.0409026102; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3; Zhou D, 2006, CELL MOL LIFE SCI, V63, P2260, DOI 10.1007/s00018-006-6184-6	41	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5715	5725		10.1074/jbc.M609797200	http://dx.doi.org/10.1074/jbc.M609797200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189258	Green Accepted, hybrid			2022-12-25	WOS:000244482300068
J	Oestreich, EA; Wang, HA; Malik, S; Kaproth-Joslin, KA; Blaxall, BC; Kelley, GG; Dirksen, RT; Smrcka, AV				Oestreich, Emily A.; Wang, Huan; Malik, Sundeep; Kaproth-Joslin, Katherine A.; Blaxall, Burns C.; Kelley, Grant G.; Dirksen, Robert T.; Smrcka, Alan V.			Epac-mediated activation of phospholipase C epsilon plays a critical role in 6-adrenergic receptor-dependent enhancement of Ca2+ mobilization in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE; CYCLIC-AMP; PROTEIN; RAP1; KINASE; HYPERTROPHY; EFFECTOR; RAS; IDENTIFICATION; CONTRACTION	Recently we demonstrated that PLC is an element of plays an important role in beta-adrenergic receptor (PAR) stimulation of Ca2+-induced Ca2+ release (CICR) in cardiac myocytes. Here we have reported for the first time that a pathway downstream of PAR involving the cAMP-dependent Rap GTP exchange factor, Epac, and PLGE regulates CICR in cardiac myocytes. To demonstrate a role for Epac in the stimulation of CICR, cardiac myocytes were treated with an Epac-selective cAMP analog, 8-4-(chlorophenylthio)-2'-O-methyladenosine-3',5'-monophosphate (cpTOME). cpTOME treatment increased the amplitude of electrically evoked Ca2+ transients, implicating Epac for the first time in cardiac CICR. This response is abolished in PLC is an element of(-/-) cardiac myocytes but rescued by transduction with PLC is an element of, indicating that Epac is upstream of PLC is an element of. Furthermore, transduction of PLC is an element of(+/+) cardiac myocytes with a Rap inhibitor, RapGAP1, significantly inhibited isoproterenol-dependent CICR. Using a combination of cpTOME and PKA-selective activators and inhibitors, we have shown that PAR-dependent increases in CICR consist of two independent components mediated by PKA and the novel Epac/PLC is an element of pathway. We also show that Epac/PLC is an element of-dependent effects on CICR are independent of sarcoplasmic reticulum loading and Ca2+ clearance mechanisms. These data define a novel endogenous PKA-independent PAR-signaling pathway through cAMP-dependent Epac activation, Rap, and PLCE that enhances intracellular Ca2+ release in cardiac myocytes.	Univ Rochester, Sch Med, Dept Pharmacol, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Physiol, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Cardiovasc Res Inst, Rochester, NY 14642 USA; Wistar Inst Anat & Biol, Syst Biol Div, Philadelphia, PA 19104 USA; SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA	University of Rochester; University of Rochester; University of Rochester; The Wistar Institute; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Smrcka, AV (corresponding author), Univ Rochester, Sch Med, Dept Pharmacol, 601 Elmwood Ave,Box 711, Rochester, NY 14642 USA.	alan_smrcka@urmc.rochester.edu	Blaxall, Burns/ABD-8289-2021		NIAMS NIH HHS [R01 AR044657, AR44657, R01 AR044657-10] Funding Source: Medline; NIDCR NIH HHS [T32 DE07202-15] Funding Source: Medline; NIDDK NIH HHS [DK56294] Funding Source: Medline; NIGMS NIH HHS [GM053536, R01 GM053536] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044657, R01AR044657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053536] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Brodde OE, 1999, PHARMACOL REV, V51, P651; Chang YJ, 2004, MOL PHARMACOL, V65, P589, DOI 10.1124/mol.65.3.589; Chen FL, 1997, P NATL ACAD SCI USA, V94, P12485, DOI 10.1073/pnas.94.23.12485; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dodge-Kafka KL, 2005, NATURE, V437, P574, DOI 10.1038/nature03966; Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178; Hwang JI, 2005, BIOCHEM J, V389, P181, DOI 10.1042/BJ20041677; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Kelley GG, 2004, BIOCHEM J, V378, P129, DOI 10.1042/BJ20031370; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Li XD, 2005, CIRC RES, V96, P1274, DOI 10.1161/01.RES.0000172556.05576.4c; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Morel E, 2005, CIRC RES, V97, P1296, DOI 10.1161/01.RES.0000194325.31359.86; Olson EN, 2004, NAT MED, V10, P467, DOI 10.1038/nm0504-467; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Seifert JP, 2004, J BIOL CHEM, V279, P47992, DOI 10.1074/jbc.M407111200; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; Wang H, 2005, CIRC RES, V97, P1305, DOI 10.1161/01.RES.0000196578.15385.bb; Wing MR, 2003, J BIOL CHEM, V278, P41253, DOI 10.1074/jbc.M306904200; Wittchen ES, 2005, J BIOL CHEM, V280, P11675, DOI 10.1074/jbc.M412595200; Wu X, 2006, J CLIN INVEST, V116, P675, DOI 10.1172/JCI27374; YULE DI, 1992, J BIOL CHEM, V267, P13830	30	136	141	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5488	5495		10.1074/jbc.M608495200	http://dx.doi.org/10.1074/jbc.M608495200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17178726	hybrid			2022-12-25	WOS:000244482300043
J	Orlandi, A; Francesconi, A; Marcellini, M; Di Lascio, A; Spagnoli, LG				Orlandi, Augusto; Francesconi, Arianna; Marcellini, Marcella; Di Lascio, Antonio; Spagnoli, Luigi Giusto			Propionyl-L-carnitine reduces proliferation and potentiates Bax-related apoptosis of aortic intimal smooth muscle cells by modulating nuclear factor-kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; CORONARY ANGIOPLASTY; SIGNALING PATHWAY; ARTERIAL INJURY; RETINOIC ACID; HUMAN ATHEROSCLEROSIS; GROWTH-FACTOR; ACTIVATION; EXPRESSION; RESTENOSIS	Propionyl-L-carnitine (PLC) has been introduced among the therapeutic approaches of peripheral arterial disease, and more recently, an increase of intimal cell apoptosis has been demonstrated to contribute to its effectiveness in rabbit carotid postinjury myointimal hyperplasia prevention. How PLC mediates these effects on vascular smooth muscle cells (SMCs) remains poorly understood. We investigated the role of NF-kappa B in PLC-induced arterial remodeling. In vivo, daily PLC treatment 15 days after injury resulted in a reduction of relative rat aortic intimal volume, an increase of apoptosis, Bax up-regulation without changing the Bcl-2 level, and a reduction of NF-kappa B, vascular cell adhesion molecule-1, monocyte chemotactic protein-1, and survivin in myointimal thickening compared with controls. In the presence of 10% serum, a reduced G(1) -> S phase progression preceded PLC-induced intimal cell apoptosis; in 0.1% serum cultures, in a dose-dependent manner, PLC rapidly induced intimal cell apoptosis and reduced p65, p50, IAP-1, and IAP-2 expression. Inhibiting NF-kappa B activation through SN50 increased apoptotic rate and Bax expression in intimal but not in medial SMCs, and successive PLC treatment failed to induce a further increase in apoptotic rate. Bax antisense oligodeoxynucleotide reduced PLC-induced intimal cell apoptosis and cytochrome c release. The PLC-induced attenuation of NF-kappa B activity in intimal cells was also due to the increase of I kappa B-alpha bioavailability, as the result of a parallel induction of I kappa B-alpha synthesis and reduction of phosphorylation and degradation. Collectively, these findings document that NF-kappa B activity inhibition contributes to PLC-induced proliferative arrest and Bax-related apoptosis of intimal SMCs.	Univ Roma Tor Vergata, Dept Biopathol & Image Diagnost, Inst Pathol Anat, I-00133 Rome, Italy; Sigma Tau Res Labs, I-00040 Rome, Italy	University of Rome Tor Vergata	Orlandi, A (corresponding author), Univ Roma Tor Vergata, Dept Biopathol & Image Diagnost, Inst Pathol Anat, Via Montpellier 1, I-00133 Rome, Italy.	orlandi@uniroma2.it	Orlandi, Augusto/AHE-8753-2022	orlandi, augusto/0000-0001-7202-5854; Spagnoli, Luigi Giusto/0000-0002-0684-5501				ADAMS SS, 1992, J CLIN PHARMACOL, V32, P317, DOI 10.1002/j.1552-4604.1992.tb03842.x; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Aoki M, 2003, CURR DRUG TARGETS, V4, P613, DOI 10.2174/1389450033490830; Arsenian MA, 1997, PROG CARDIOVASC DIS, V40, P265, DOI 10.1016/S0033-0620(97)80037-0; Bellas RE, 1997, AM J PATHOL, V151, P891; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; Bhargava B, 2003, BMJ-BRIT MED J, V327, P274, DOI 10.1136/bmj.327.7409.274; Billiet L, 2005, J BIOL CHEM, V280, P40310, DOI 10.1074/jbc.M503644200; Blanc-Brude OP, 2002, NAT MED, V8, P987, DOI 10.1038/nm750; BOCHATONPIALLAT ML, 1995, AM J PATHOL, V146, P1059; Bourcier T, 1997, J BIOL CHEM, V272, P15817, DOI 10.1074/jbc.272.25.15817; Breuss JM, 2002, CIRCULATION, V105, P633, DOI 10.1161/hc0502.102966; Brevetti G, 1999, J AM COLL CARDIOL, V34, P1618, DOI 10.1016/S0735-1097(99)00373-3; Cipolla MJ, 1999, J VASC SURG, V29, P1097, DOI 10.1016/S0741-5214(99)70251-X; CLOWES AW, 1988, J CELL BIOL, V107, P1939, DOI 10.1083/jcb.107.5.1939; CLOWES AW, 1983, LAB INVEST, V49, P208; CORSICO N, 1993, CARDIOVASC DRUG THER, V7, P241, DOI 10.1007/BF00878514; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Erl W, 1999, CIRC RES, V84, P668, DOI 10.1161/01.RES.84.6.668; Erl Wolfgang, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P135, DOI 10.2174/1568006043586134; FERRARI R, 1992, J MOL CELL CARDIOL, V24, P219, DOI 10.1016/0022-2828(92)93160-L; Fisher SA, 2000, CIRC RES, V87, P856, DOI 10.1161/01.RES.87.10.856; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; Geng YH, 2002, ARTERIOSCL THROM VAS, V22, P1370, DOI 10.1161/01.ATV.0000031341.84618.A4; Hao HY, 2003, ARTERIOSCL THROM VAS, V23, P1510, DOI 10.1161/01.ATV.0000090130.85752.ED; Hayakawa Y, 1999, ARTERIOSCL THROM VAS, V19, P2066, DOI 10.1161/01.ATV.19.9.2066; Hiatt WR, 2001, NEW ENGL J MED, V344, P1608, DOI 10.1056/NEJM200105243442108; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; Kimmel SE, 1997, J AM COLL CARDIOL, V30, P193, DOI 10.1016/S0735-1097(97)00149-6; KOCHER O, 1984, LAB INVEST, V50, P645; Kopp CW, 2004, CURR VASC PHARMACOL, V2, P183, DOI 10.2174/1570161043476438; Landry DB, 1997, AM J PATHOL, V151, P1085; Lango R, 2001, CARDIOVASC RES, V51, P21, DOI 10.1016/S0008-6363(01)00313-3; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; LIN YC, 1995, EXP CELL RES, V221, P73, DOI 10.1006/excr.1995.1354; Lindner V, 1998, PATHOBIOLOGY, V66, P311, DOI 10.1159/000028039; Maier W, 1999, EUR HEART J, V20, P325; Matsumoto Y, 2004, ARTERIOSCL THROM VAS, V24, P181, DOI 10.1161/01.ATV.0000105053.46994.5B; Mintz GS, 1996, CIRCULATION, V94, P35, DOI 10.1161/01.CIR.94.1.35; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Neuville P, 1999, ARTERIOSCL THROM VAS, V19, P1430, DOI 10.1161/01.ATV.19.6.1430; Orlandi A, 2005, ARTERIOSCL THROM VAS, V25, P348, DOI 10.1161/01.ATV.0000152609.28569.e1; Orlandi A, 2002, ATHEROSCLEROSIS, V160, P81, DOI 10.1016/S0021-9150(01)00568-8; Orlandi A, 2001, ARTERIOSCL THROM VAS, V21, P1118, DOI 10.1161/hq0701.092144; ORLANDI A, 1994, ARTERIOSCLER THROMB, V14, P982, DOI 10.1161/01.ATV.14.6.982; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SACHS L, 1978, STAT METHODEN IHRE A; Sethi G, 2006, J BIOL CHEM, V281, P23425, DOI 10.1074/jbc.M602627200; Shishodia S, 2002, J BIOCHEM MOL BIOL, V35, P28; Shou Y, 2002, J NEUROCHEM, V81, P842, DOI 10.1046/j.1471-4159.2002.00880.x; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; SPAGNOLI LG, 1995, ATHEROSCLEROSIS, V114, P29, DOI 10.1016/0021-9150(94)05460-Z; Stroh R, 1998, SHOCK, V9, P216, DOI 10.1097/00024382-199803000-00010; Takada Y, 2005, J BIOL CHEM, V280, P17203, DOI 10.1074/jbc.M500077200; TASSANI V, 1994, BIOCHEM BIOPH RES CO, V199, P949, DOI 10.1006/bbrc.1994.1321; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Uberti D, 1998, EUR J NEUROSCI, V10, P246, DOI 10.1046/j.1460-9568.1998.00042.x; Walker A, 1997, CANCER RES, V57, P1939; WALKER LN, 1986, P NATL ACAD SCI USA, V83, P7311, DOI 10.1073/pnas.83.19.7311; Walsh K, 2000, CIRC RES, V87, P184, DOI 10.1161/01.RES.87.3.184; Weber C, 2000, CURR TOP CELL REGUL, V36, P217; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x	67	32	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4932	4942		10.1074/jbc.M606148200	http://dx.doi.org/10.1074/jbc.M606148200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17178728	hybrid			2022-12-25	WOS:000244482000076
J	Osterloh, A; Kalinke, U; Weiss, S; Fleischer, B; Breloer, M				Osterloh, Anke; Kalinke, Ulrich; Weiss, Siegfried; Fleischer, Bernhard; Breloer, Minka			Synergistic and differential modulation of immune responses by Hsp60 and lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TUMOR-NECROSIS-FACTOR; IFN-GAMMA PRODUCTION; T-CELLS; IN-VIVO; HUMAN HEAT-SHOCK-PROTEIN-60; MEMBRANE EXPRESSION; ALPHA PRODUCTION; DANGER SIGNALS; RECEPTOR	Activation of professional antigen-presenting cells (APC) is a crucial step in the initiation of an efficient immune response. In this study we show that Hsp60 mediates immune stimulation by different mechanisms, dependent and independent of lipopolysaccharide (LPS). We have demonstrated earlier that both, Hsp60 and LPS, increase antigen-specific interferon (IFN) gamma release in T cells. Here we show that in contrast to LPS Hsp60 induces IFN alpha production in professional APC. Neutralization of IFNa as well as the absence of functional IFN alpha beta receptor on APC and T cells interfered with Hsp60-mediated IFN gamma secretion in antigen-dependent T cell activation, strongly suggesting that IFNa represents one factor contributing to Hsp60-specific immune stimulation. On the other hand, we show that Hsp60 bound to the cell surface of APC colocalizes with the LPS co-receptor CD14 and LPS binding sites. Hsp60 specifically binds bacterial LPS and both molecules synergistically enhanced IL-12p40 production in APC and IFN gamma release in antigen-dependent T cell activation. This effect was Hsp60-specific and dependent on LPS-binding by Hsp60. Furthermore, we show that Hsp60 exclusively binds to macrophages and DC but not to T or B lymphocytes and that both, T cell stimulation by Hsp60 as well as Hsp60/LPS complexes, strictly depends on the presence of professional APC and is not mediated by B cells. Taken together, our data support an extension of the concept of Hsp60 as an endogenous danger signal: besides its function as a classical danger signal indicating unplanned tissue destruction to the innate immune system, in the incident of bacterial infection extracellular Hsp60 may bind LPS and facilitate microbe recognition by lowering the threshold of pathogen-associated molecular pattern (PAMP) detection and enhancing Toll-like receptor (TLR) signaling.	Bernhard Nocht Inst Trop Med, Dept Immunol, D-20359 Hamburg, Germany; Paul Ehrlich Inst, Dept Immunol, D-63225 Langen, Germany; Helmholtz Ctr Infect Res, Dept Mol Immunol, HZI, D-38124 Braunschweig, Germany	Bernhard Nocht Institut fur Tropenmedizin; Paul Ehrlich Institute; Helmholtz Association; Helmholtz-Center for Infection Research	Osterloh, A (corresponding author), Bernhard Nocht Inst Trop Med, Dept Immunol, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	osterloh@bni.uni-hamburg.de	Osterloh, Anke/ABA-8626-2021; Breloer, Minka/F-3999-2018	Breloer, Minka/0000-0001-6199-4908; Kalinke, Ulrich/0000-0003-0503-9564				Akira S, 2003, J INFECT DIS, V187, pS356, DOI 10.1086/374749; Barreto A, 2003, CELL IMMUNOL, V222, P97, DOI 10.1016/S0008-8749(03)00115-1; Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C; Belles C, 1999, INFECT IMMUN, V67, P4191, DOI 10.1128/IAI.67.8.4191-4200.1999; Breloer M, 1999, J IMMUNOL, V162, P3141; Breloer M, 2002, INT IMMUNOL, V14, P1247, DOI 10.1093/intimm/dxf090; Breloer M, 2001, EUR J IMMUNOL, V31, P2051, DOI 10.1002/1521-4141(200107)31:7<2051::AID-IMMU2051>3.0.CO;2-H; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; Chen W, 1999, J IMMUNOL, V162, P3212; Cohen-Sfady M, 2005, J IMMUNOL, V175, P3594, DOI 10.4049/jimmunol.175.6.3594; Dai JH, 2004, J IMMUNOL, V173, P1535, DOI 10.4049/jimmunol.173.3.1535; Erlandsson L, 1998, CURR BIOL, V8, P223, DOI 10.1016/S0960-9822(98)70086-7; Flohe SB, 2003, J IMMUNOL, V170, P2340, DOI 10.4049/jimmunol.170.5.2340; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; Gao BC, 2004, BIOCHEM BIOPH RES CO, V317, P1149, DOI 10.1016/j.bbrc.2004.03.160; Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; Gelman AE, 2004, J IMMUNOL, V172, P6065, DOI 10.4049/jimmunol.172.10.6065; Gerlach N, 2006, J VIROL, V80, P3438, DOI 10.1128/JVI.80.7.3438-3444.2006; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Habich C, 2005, J IMMUNOL, V174, P1298, DOI 10.4049/jimmunol.174.3.1298; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Honda K, 2005, INT IMMUNOL, V17, P1367, DOI 10.1093/intimm/dxh318; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Hoshino K, 2002, INT IMMUNOL, V14, P1225, DOI 10.1093/intimm/dxf089; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Janeway CA, 1999, CURR BIOL, V9, pR879, DOI 10.1016/S0960-9822(00)80073-1; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kirschning CJ, 2002, CURR TOP MICROBIOL, V270, P121; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Komai-Koma M, 2004, P NATL ACAD SCI USA, V101, P3029, DOI 10.1073/pnas.0400171101; Lang A, 2005, J AM SOC NEPHROL, V16, P383, DOI 10.1681/ASN.2004040276; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; More SH, 2001, INT IMMUNOL, V13, P1121, DOI 10.1093/intimm/13.9.1121; Moseley P, 2000, IMMUNOPHARMACOLOGY, V48, P299, DOI 10.1016/S0162-3109(00)00227-7; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Osterloh A, 2004, J BIOL CHEM, V279, P47906, DOI 10.1074/jbc.M408440200; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Pfister G, 2005, J CELL SCI, V118, P1587, DOI 10.1242/jcs.02292; Sapozhnikov AM, 1999, CELL PROLIFERAT, V32, P363, DOI 10.1111/j.1365-2184.1999.tb01354.x; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Vendetti S, 2000, J EXP CLIN CANC RES, V19, P329; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; Warger T, 2006, J BIOL CHEM, V281, P22545, DOI 10.1074/jbc.M502900200; Xu DM, 2004, CELL MOL IMMUNOL, V1, P239; Zanin-Zhorov A, 2003, FASEB J, V17, P1567, DOI 10.1096/fj.02-1139fje	55	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4669	4680		10.1074/jbc.M608666200	http://dx.doi.org/10.1074/jbc.M608666200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17164250	hybrid, Green Submitted			2022-12-25	WOS:000244482000048
J	Hopkins, EJ; Layfield, S; Ferraro, T; Bathgate, RAD; Gooley, PR				Hopkins, Emma J.; Layfield, Sharon; Ferraro, Tania; Bathgate, Ross A. D.; Gooley, Paul R.			The NMR solution structure of the relaxin (RXFP1) receptor lipoprotein receptor class A module and identification of key residues in the N-terminal region of the module that mediate receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH REPEAT; TORSION ANGLE DYNAMICS; LIGAND-BINDING MODULES; LDL RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; 3-DIMENSIONAL STRUCTURE; PROTEIN STRUCTURES; CALCIUM-BINDING; DOMAIN; LGR7	The receptors for the peptide hormones relaxin and insulin-like peptide 3 (INSL3) are the leucine-rich repeat-containing G-protein-coupled receptors LGR7 and LGR8 recently renamed as the relaxin family peptide (RXFP) receptors, RXFP1 and RXFP2, respectively. These receptors differ from other LGRs by the addition of an N-terminal low density lipoprotein receptor class A (LDLa) module and are the only human G-protein-coupled receptors to contain such a domain. Recently it was shown that the LDLa module of the RXFP1 and RXFP2 receptors is essential for ligand-stimulated cAMP signaling. The mechanism by which the LDLa module modulates receptor signaling is unknown; however, it represents a unique paradigm in understanding G-protein-coupled receptor signaling. Here we present the structure of the RXFP1 receptor LDLa module determined by solution NMR spectroscopy. The structure is similar to other LDLa modules but shows small differences in side chain orientations and inter-residue packing. Interchange of the module with the second ligand binding domain of the LDL receptor, LB2, results in a receptor that binds relaxin with full affinity but is unable to signal. Furthermore, we demonstrate via structural studies on mutated LDLa modules and functional studies on mutated full-length receptors that a hydrophobic surface within the N-terminal region of the module is essential for activation of RXFP1 receptor signal in response to relaxin stimulation. This study has highlighted the necessity to understand the structural effects of single amino acid mutations on the LDLa module to fully interpret the effects of these mutations on receptor activity.	Univ Melbourne, Dept Biochem & Mol Biol, Bio21 Mol Sci & Biotechnol Inst, Parkville, Vic 3010, Australia; Univ Melbourne, Howard Florey Inst, Melbourne, Vic 3010, Australia	University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Gooley, PR (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Bio21 Mol Sci & Biotechnol Inst, 30 Flemington Rd, Parkville, Vic 3010, Australia.	prg@unimelb.edu.au	Bathgate, Ross/ABE-6471-2020	Bathgate, Ross/0000-0001-6301-861X; Petrie, Emma/0000-0002-9827-3378; Gooley, Paul/0000-0002-0323-449X				Abdul-Aziz D, 2005, BIOCHEMISTRY-US, V44, P5075, DOI 10.1021/bi047575j; ADHAM IM, 1993, J BIOL CHEM, V268, P26668; Andersen Olav M, 2003, BMC Biochem, V4, P7, DOI 10.1186/1471-2091-4-7; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; Bani D, 1997, B CANCER, V84, P179; Bathgate RA, 2006, PHARMACOL REV, V58, P7, DOI 10.1124/pr.58.1.9; Bieri S, 1998, BIOCHEMISTRY-US, V37, P10994, DOI 10.1021/bi980452c; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; Bogatcheva NV, 2003, MOL ENDOCRINOL, V17, P2639, DOI 10.1210/me.2003-0096; BURKHARDT E, 1994, HUM GENET, V94, P91, DOI 10.1007/BF02272850; Cai ML, 1998, J BIOMOL NMR, V11, P97, DOI 10.1023/A:1008222131470; CASTEN GG, 1958, JAMA-J AM MED ASSOC, V166, P319, DOI 10.1001/jama.1958.02990040005002; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dolmer K, 1998, BIOCHEMISTRY-US, V37, P17016, DOI 10.1021/bi982022s; Dolmer K, 2000, J BIOL CHEM, V275, P3264, DOI 10.1074/jbc.275.5.3264; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; GIDDARD TD, 2004, SPARKY 3; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hisaw FL, 1926, P SOC EXP BIOL MED, V23, P661; Hopkins EJ, 2005, ANN NY ACAD SCI, V1041, P27, DOI 10.1196/annals.1282.006; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z; Huang W, 1999, J BIOL CHEM, V274, P14130, DOI 10.1074/jbc.274.20.14130; JOHNSON B, 1994, J BIOMOL NMR, V5, P603; Kawamura K, 2004, P NATL ACAD SCI USA, V101, P7323, DOI 10.1073/pnas.0307061101; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Mertens HDT, 2005, FEBS LETT, V579, P5542, DOI 10.1016/j.febslet.2005.09.017; Nef S, 1999, NAT GENET, V22, P295, DOI 10.1038/10364; North CL, 1999, BIOCHEMISTRY-US, V38, P3926, DOI 10.1021/bi9821622; North CL, 2000, BIOCHEMISTRY-US, V39, P2564, DOI 10.1021/bi992087a; Pusch W, 1996, ENDOCRINOLOGY, V137, P3009, DOI 10.1210/en.137.7.3009; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Scott DJ, 2006, J BIOL CHEM, V281, P34942, DOI 10.1074/jbc.M602728200; Scott DJ, 2004, CLIN EXP PHARMACOL P, V31, P828, DOI 10.1111/j.1440-1681.2004.04075.x; Simonovic M, 2001, BIOCHEMISTRY-US, V40, P15127, DOI 10.1021/bi015688m; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; Tonelli M, 2001, FEBS LETT, V509, P161, DOI 10.1016/S0014-5793(01)03086-1; UNEMORI EN, 1990, J BIOL CHEM, V265, P10681; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; Wang QY, 2002, J VIROL, V76, P2848, DOI 10.1128/JVI.76.6.2848-2856.2002; Wang QY, 2001, J VIROL, V75, P2051, DOI 10.1128/JVI.75.5.2051-2058.2001; Wilkinson TN, 2005, ANN NY ACAD SCI, V1041, P534, DOI 10.1196/annals.1282.080; Zimmermann S, 1999, MOL ENDOCRINOL, V13, P681, DOI 10.1210/me.13.5.681	52	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4172	4184		10.1074/jbc.M609526200	http://dx.doi.org/10.1074/jbc.M609526200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148455	hybrid			2022-12-25	WOS:000244481900080
J	Iwashita, S; Kobayashi, M; Kubo, Y; Hinohara, Y; Sezaki, M; Nakamura, K; Suzuki-Migishima, R; Yokoyama, M; Sato, S; Fukuda, M; Ohba, M; Kato, C; Adachi, E; Song, SY				Iwashita, Shintaro; Kobayashi, Mariko; Kubo, Yuya; Hinohara, Yoshimi; Sezaki, Mariko; Nakamura, Kenji; Suzuki-Migishima, Rika; Yokoyama, Minesuke; Sato, Showbu; Fukuda, Mitsunori; Ohba, Masayuki; Kato, Chieko; Adachi, Eijiro; Song, Si-Young			Versatile roles of R-Ras GAP in neurite formation of PC12 cells and embryonic vascular development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; INTEGRIN ACTIVATION; MUTATION; P120GAP; SYSTEM	Ras GTPase-activating proteins (GAP) are negative regulators of Ras that convert active Ras-GTP to inactive Ras-GDP. R-Ras GAP is a membrane-associated molecule with stronger GAP activity for R-Ras, an activator of integrin, than H-Ras. We found that R-Ras GAP is down-regulated during neurite formation in rat pheochromocytoma PC12 cells by nerve growth factor (NGF), which is blocked by the transient expression of R-Ras gap or dominant negative R-ras cDNA. By establishing a PC12 subclone that stably expresses exogenous R-Ras GAP, it was found that NGF reduced endogenous R-Ras GAP but not exogenous R-Ras GAP, suggesting that down-regulation of R-Ras GAP occurs at the transcription level. To clarify the physiological role of R-Ras GAP, we generated mice that express mutant Ras GAP with knocked down activity. While heterozygotes are normal, homozygous mice die at E12.5-13.5 of massive subcutaneous and intraparenchymal bleeding, probably due to underdeveloped adherens junctions between capillary endothelial cells. These results show essential roles of R-Ras GAP in development and differentiation: its expression is needed for embryonic development of blood vessel barriers, whereas its down-regulation facilitates NGF-induced neurite formation of PC12 cells via maintaining activated R-Ras.	Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1948511, Japan; Yokohama Natl Univ, Yokohama, Kanagawa 2408501, Japan; RIKEN, Brain Sci Inst, Wako, Saitama 3510198, Japan; Kitasato Univ, Sch Med, Sagamihara, Kanagawa 2288555, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS); Yokohama National University; RIKEN; Kitasato University	Song, SY (corresponding author), Iwaki Meisei Univ, 5-5-1 Chuodai Lino, Iwaki, Fukushima 9708551, Japan.	sysong@kph.bunri-u.ac.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853; Iwashita, Shintaro/0000-0001-8086-9192				Ahmadian MR, 2003, J MOL BIOL, V329, P699, DOI 10.1016/S0022-2836(03)00514-X; Biesebeke RT, 2001, BIOCHEMISTRY-US, V40, P7474, DOI 10.1021/bi010027a; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Cole AL, 2003, ARTERIOSCL THROM VAS, V23, P1384, DOI 10.1161/01.ATV.0000081215.45714.71; Cozier GE, 2000, J BIOL CHEM, V275, P28261; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Ishiwata T, 2003, CIRC RES, V93, P857, DOI 10.1161/01.RES.0000100389.57520.1A; Ito Y, 2006, EMBO REP, V7, P704, DOI 10.1038/sj.embor.7400737; Ivins JK, 2000, J NEUROSCI, V20, P6551, DOI 10.1523/JNEUROSCI.20-17-06551.2000; IWASHITA S, 1992, CELL SIGNAL, V4, P123, DOI 10.1016/0898-6568(92)90076-K; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Kim JH, 2003, J NEUROSCI, V23, P1119; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Komatsu M, 2005, NAT MED, V11, P1346, DOI 10.1038/nm1324; Kupzig S, 2006, J BIOL CHEM, V281, P9891, DOI 10.1074/jbc.M512802200; Li SW, 1997, J BIOL CHEM, V272, P19328, DOI 10.1074/jbc.272.31.19328; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; Perez de Castro I, 2003, CANCER RES, V63, P1615; Ridley AJ, 2001, FEBS LETT, V498, P168, DOI 10.1016/S0014-5793(01)02481-4; Self AJ, 2001, J CELL SCI, V114, P1357; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	26	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3413	3417		10.1074/jbc.C600293200	http://dx.doi.org/10.1074/jbc.C600293200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17179160	hybrid			2022-12-25	WOS:000244481900001
J	Reinhold, MI; Naski, MC				Reinhold, Martina I.; Naski, Michael C.			Direct interactions of Runx2 and canonical Wnt signaling induce FGF18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TCF TRANSCRIPTION FACTORS; FACTOR RECEPTOR-3 GENE; BETA-CATENIN; CHONDROCYTE PROLIFERATION; NEGATIVE REGULATOR; ENDOCHONDRAL BONE; OSTEOBLAST; DIFFERENTIATION; EXPRESSION; OSTEOGENESIS	Canonical Wnt signaling is clearly required for skeletal development and bone formation. However, the targets of Wnt signaling that convert this signal into bone are unclear. Identification of these targets will yield insight into normal bone physiology and suggest new therapeutics for treatment of bone disease. Here we show that an essential regulator of bone development, FGF18, is a direct target of canonical Writ signaling. A single DNA binding site for the Wnt-dependent transcription factors TCF/Lef accounted for the stimulation of fgf18 promoter in response to Wnt signaling. Additionally, targeted disruption of beta cat blocked fgf18 expression in vivo. Partially overlapping the TCF/Lef binding site is a Runx2 binding site and experiments showed that Runx2 and TCF/Lef work cooperatively to induced fgf18 expression. RNA interference knockdown of Runx2 inhibited and Runx2 forced expression augmented the induction of fgf18 by canonical Writ signaling. Significantly, Runx2 formed a complex with Lef1 or TCF4 and this complex bound the composite binding site in the fgf18 promoter. These results demonstrate that two transcription pathways that are essential for bone, physically and functionally converge at the fgf18 promoter.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Naski, MC (corresponding author), 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	naski@uthscsa.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050024] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR050024] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brault V, 2001, DEVELOPMENT, V128, P1253; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Hinoi E, 2006, GENE DEV, V20, P2937, DOI 10.1101/gad.1482906; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; James MJ, 2006, J BONE MINER RES, V21, P1034, DOI 10.1359/JBMR.060413; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kahler RA, 2003, J BIOL CHEM, V278, P11937, DOI 10.1074/jbc.M211443200; Kapadia RA, 2005, DEV BIOL, V285, P496, DOI 10.1016/j.ydbio.2005.07.029; Kim S, 2006, J BIOL CHEM, V281, P14066, DOI 10.1074/jbc.M602696200; Mak KK, 2006, DEVELOPMENT, V133, P3695, DOI 10.1242/dev.02546; Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; McEwen DG, 1999, J BIOL CHEM, V274, P30934, DOI 10.1074/jbc.274.43.30934; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Naski MC, 1998, DEVELOPMENT, V125, P4977; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; Reinhold MI, 2004, MOL ENDOCRINOL, V18, P241, DOI 10.1210/me.2003-0312; Reinhold MI, 2004, J BIOL CHEM, V279, P38209, DOI 10.1074/jbc.M404855200; Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Shimokawa T, 2003, CANCER RES, V63, P6116; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324; Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491	47	84	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3653	3663		10.1074/jbc.M608995200	http://dx.doi.org/10.1074/jbc.M608995200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158875	hybrid			2022-12-25	WOS:000244481900027
J	Schneider, HP; Broeer, S; Broeer, A; Deitmer, JW				Schneider, Hans-Peter; Broeer, Stefan; Broeer, Angelika; Deitmer, Joachim W.			Heterologous expression of the glutamine transporter SNAT3 in Xenopus oocytes is associated with four modes of uncoupled transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; MAMMALIAN SEROTONIN TRANSPORTER; CHLORIDE CHANNEL ACTIVITY; PERFUSED-RAT-LIVER; LAEVIS OOCYTES; NEUROTRANSMITTER TRANSPORTERS; GLIAL-CELLS; SYSTEM; PH; PROTEOLYSIS	The glutamine transporter SNAT3 (SLC38A3, former SN1) plays a major role in glutamine release from brain astrocytes and in glutamine uptake into hepatocytes and kidney epithelial cells. Here we expressed rat SNAT3 in oocytes of Xenopus laevis and reinvestigated its transport modes using two-electrode voltage clamp and pH-sensitive microelectrodes. In addition to the established coupled Na+-glutamine-cotransport/H+ antiport, we found that there are three conductances associated with SNAT3, two dependent and one independent of the amino acid substrate. The glutamine-dependent conductance is carried by cations at pH 7.4, whereas at pH 8.4 the inward currents are still dependent on the presence of external Na+ but are carried by H+. Mutation of threonine 380 to alanine abolishes the cation conductance but leaves the proton conductance intact. Under Na+-free conditions, where the substrate - dependent conductance is suppressed, a substrate-independent, outwardly rectifying current becomes apparent at pH 8.4 that is carried by K+ and H+. In addition, we identified a glutamine-dependent uncoupled Na+/H+ exchange activity that becomes apparent upon removal of Na+ in the presence of glutamine. In conclusion, our results suggest that, in addition to coupled transport, SNAT3 mediates four modes of uncoupled ion movement across the membrane.	Australian Natl Univ, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia; TU Kaiserslautern, Fachbereich Biol, Abt Allgemeine Zool, D-67653 Kaiserslautern, Germany	Australian National University; University of Kaiserslautern	Broeer, S (corresponding author), Australian Natl Univ, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia.	stefan.broeer@anu.edu.au; deitmer@biologie.uni-ki.de	Broer, Stefan/A-1286-2008	Broer, Stefan/0000-0002-8040-1634				Becker HM, 2004, BIOPHYS J, V86, P235, DOI 10.1016/S0006-3495(04)74099-0; Blakely RD, 2005, PHYSIOLOGY, V20, P225, DOI 10.1152/physiol.00013.2005; Boll M, 2004, PFLUG ARCH EUR J PHY, V447, P776, DOI 10.1007/s00424-003-1073-4; Broer A, 2000, BIOCHEM J, V346, P705, DOI 10.1042/0264-6021:3460705; Broer A, 2002, J PHYSIOL-LONDON, V539, P3, DOI 10.1013/jphysiol.2001.013303; Broer S, 2002, PFLUG ARCH EUR J PHY, V444, P457, DOI 10.1007/s00424-002-0840-y; Broer S, 1998, BIOCHEM J, V333, P167, DOI 10.1042/bj3330167; Broer Stefan, 2003, Methods Mol Biol, V227, P245, DOI 10.1385/1-59259-387-9:245; Cao YW, 1997, J NEUROSCI, V17, P2257; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Fei YJ, 2000, J BIOL CHEM, V275, P23707, DOI 10.1074/jbc.M002282200; Galli A, 1996, P NATL ACAD SCI USA, V93, P8671, DOI 10.1073/pnas.93.16.8671; Gasnier B, 2004, PFLUG ARCH EUR J PHY, V447, P756, DOI 10.1007/s00424-003-1091-2; Gouaux E, 2005, SCIENCE, V310, P1461, DOI 10.1126/science.1113666; Gu SM, 2000, P NATL ACAD SCI USA, V97, P3230, DOI 10.1073/pnas.050318197; HAUSSINGER D, 1990, EUR J BIOCHEM, V188, P689, DOI 10.1111/j.1432-1033.1990.tb15451.x; HAUSSINGER D, 1990, BIOCHEM J, V272, P239, DOI 10.1042/bj2700039; Hill, 2001, ION CHANNELS EXCITAB, P441; Ingram SL, 2002, NAT NEUROSCI, V5, P971, DOI 10.1038/nn920; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P784, DOI 10.1007/s00424-003-1117-9; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MATHISEN J, 2001, EMBO J, V20, P7041; MUNSCH T, 1994, J PHYSIOL-LONDON, V474, P43, DOI 10.1113/jphysiol.1994.sp020001; Nelson N, 2002, NAT REV MOL CELL BIO, V3, P876, DOI 10.1038/nrm955; Ryan RM, 2005, CLIN EXP PHARMACOL P, V32, P1, DOI 10.1111/j.1440-1681.2005.04164.x; Ryan RM, 2002, J BIOL CHEM, V277, P13494, DOI 10.1074/jbc.M109970200; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Stegen C, 2000, BBA-BIOMEMBRANES, V1467, P91, DOI 10.1016/S0005-2736(00)00209-1; Sulzer D, 2003, TRENDS NEUROSCI, V26, P173, DOI 10.1016/S0166-2236(03)00063-8; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991	36	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3788	3798		10.1074/jbc.M609452200	http://dx.doi.org/10.1074/jbc.M609452200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148440	hybrid			2022-12-25	WOS:000244481900042
J	Tresini, M; Lorenzini, A; Torres, C; Cristofalo, VJ				Tresini, Maria; Lorenzini, Antonello; Torres, Claudio; Cristofalo, Vincent J.			Modulation of replicative senescence of diploid human cells by nuclear ERK signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TERNARY COMPLEX-FORMATION; OF-FUNCTION MUTATION; SINGLE-STEP METHOD; MAP-KINASE; IN-VITRO; REGULATED KINASE; RNA ISOLATION; CYCLE ARREST; PHOSPHORYLATION	Normal somatic cells have a limited replicative lifespan, and serial subcultivation ultimately results in senescence. Senescent cells are irreversibly growth-arrested and show impaired responses to mitogens. Activation of the ERK signaling pathway, an absolute requirement for cell proliferation, results in nuclear relocalization of active ERKs, an event impaired in senescent fibroblasts. This impairment coincides with increased activity of the nuclear ERK phosphatase MKP2. Here we show that replicative lifespan can be altered by changes in nuclear ERK activity. Ectopic expression of MKP2 results in premature senescence. In contrast, knock-down of MKP2 expression, through transduction of MKP2 sequence-specific short hairpin RNA, or expression of the phosphatase resistant ERK2(D319N) mutant, abrogates the effects of increased endogenous MKP2 levels and senescence is postponed. Nuclear targeting of ERK2(D319N) significantly augments its effects and the transduced cultures show higher than 60% increase in replicative lifespan compared with cultures transduced with wt ERK2. Long-lived cultures senesce with altered molecular characteristics and retain the ability to express c-fos, and Rb is maintained in its inactive form. Our results support that MKP2-mediated inactivation of nuclear ERK2 represents a key event in the establishment of replicative senescence. Although it is evident that senescence can be imposed through multiple mechanisms, restoration of nuclear ERK activity can bypass a critical senescence checkpoint and, thus, extend replicative lifespan.	Lankenau Inst Med Res, Wynnewood, PA 19106 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19101 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; Jefferson University	Tresini, M (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19106 USA.	tresini@netscape.net	LORENZINI, ANTONELLO/E-6582-2016; Lorenzini, Antonello/G-4463-2012	LORENZINI, ANTONELLO/0000-0001-9615-9697; Tresini, Maria/0000-0001-7711-3204	NIA NIH HHS [AG20955] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG020955] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHYFLICK L, 1977, HDB BIOL AGING, P159; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; Bose C, 2004, J GERONTOL A-BIOL, V59, P126; Bost F, 2005, DIABETES, V54, P402, DOI 10.2337/diabetes.54.2.402; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Burack WR, 2005, J BIOL CHEM, V280, P3832, DOI 10.1074/jbc.M410031200; Cadalbert L, 2005, CELL SIGNAL, V17, P1254, DOI 10.1016/j.cellsig.2005.01.003; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Cristofalo VJ, 2004, MECH AGEING DEV, V125, P827, DOI 10.1016/j.mad.2004.07.010; CRISTOFALO VJ, 1976, GERONTOLOGY, V22, P9, DOI 10.1159/000212122; CRISTOFALO VJ, 1998, METHODS AGING, P77; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Echeverria V, 2004, NEUROSCIENCE, V129, P583, DOI 10.1016/j.neuroscience.2004.07.036; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Gaumont-Leclerc MF, 2004, J BIOL CHEM, V279, P46802, DOI 10.1074/jbc.M403893200; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; Hatano N, 2003, GENES CELLS, V8, P847, DOI 10.1046/j.1365-2443.2003.00680.x; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Katagiri C, 2005, J BIOL CHEM, V280, P14716, DOI 10.1074/jbc.M500200200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim-Kaneyama JR, 2000, J BIOL CHEM, V275, P20685, DOI 10.1074/jbc.M908723199; Kohno Michiaki, 2003, Prog Cell Cycle Res, V5, P219; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lim IK, 2000, MECH AGEING DEV, V119, P113, DOI 10.1016/S0047-6374(00)00167-6; Lim IK, 2001, ANN NY ACAD SCI, V928, P176; Lips DJ, 2004, CIRCULATION, V109, P1938, DOI 10.1161/01.CIR.0000127126.73759.23; Marais R, 1996, CANCER SURV, V27, P101; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Mazzucchelli C, 2002, NEURON, V34, P807, DOI 10.1016/S0896-6273(02)00716-X; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; O'Neill E, 2004, BRIT J CANCER, V90, P283, DOI 10.1038/sj.bjc.6601488; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Pages G, 2000, ANN NY ACAD SCI, V902, P187; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Saba-El-Leil MK, 2003, EMBO REP, V4, P964, DOI 10.1038/sj.embor.embor939; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Severino J, 2000, EXP CELL RES, V257, P162, DOI 10.1006/excr.2000.4875; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Stewart SA, 2002, ONCOGENE, V21, P627, DOI 10.1038/sj.onc.1205062; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Tarrega C, 2005, J BIOL CHEM, V280, P37885, DOI 10.1074/jbc.M504366200; Thomas DM, 2003, CANCER BIOL THER, V2, P124, DOI 10.4161/cbt.2.2.235; Tombes RM, 1998, BIOCHEM J, V330, P1451; Torres C, 2003, EXP CELL RES, V290, P195, DOI 10.1016/S0014-4827(03)00309-4; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tresini M, 2001, EXP CELL RES, V269, P287, DOI 10.1006/excr.2001.5334; Venter DJ, 2005, CANCER GENET CYTOGEN, V160, P134, DOI 10.1016/j.cancergencyto.2004.12.007; Vial E, 2004, ANN NY ACAD SCI, V1030, P208, DOI 10.1196/annals.1329.027; Volmat V, 2001, J CELL SCI, V114, P3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Yao Y, 2003, P NATL ACAD SCI USA, V100, P12759, DOI 10.1073/pnas.2134254100; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	95	49	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4136	4151		10.1074/jbc.M604955200	http://dx.doi.org/10.1074/jbc.M604955200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17145763	hybrid			2022-12-25	WOS:000244481900077
J	Wu, CY; Huang, JT				Wu, Chengyu; Huang, Jiaoti			Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RECEPTOR; LNCAP CELLS; PROTEIN-KINASE; IN-VIVO; AKT; PROGRESSION; TRANSDIFFERENTIATION; GROWTH; SUPPRESSOR; EXPRESSION	Hormonal therapy of prostate cancer, by inhibiting androgen production and/or androgen function, is the treatment of choice for advanced prostate cancer. Although most patients respond initially, the effect is only temporary, and the tumor cells win resume proliferation in an androgen-deprived environment. The mechanism for androgen-independent proliferation of cancer cells is unclear. Hormonal therapy induces neuroendocrine differentiation of prostate cancer cells, which is hypothesized to contribute to tumor recurrence by a paracrine mechanism. We studied signal transduction pathways of neuroendocrine differentiation in LNCaP cells after androgen withdrawal, and we showed that both the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway and ERK are activated, but only the former is required for neuroendocrine differentiation. A constitutively active AKT promotes neuroendocrine differentiation and a dominant negative AKT inhibits it. Activation of AKT by IGF-1 leads to neuroendocrine differentiation, and neuroendocrine differentiation induced by epinephrine requires AKT activation. We also show that the AKT pathway is likely responsible for neuroendocrine differentiation in DU145, an androgen-independent prostate cancer cell line. Therefore, our study demonstrated a novel function of the AKT pathway in prostate cancer progression and identified potential targets that may be explored for the treatment of androgen-independent cancer.	Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA	University of Rochester	Huang, JT (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, Box 626,601 Elmwood Ave, Rochester, NY 14642 USA.	Jiaoti_Huang@urmc.rochester.edu		Huang, Jiaoti/0000-0003-1195-1998				Adam RM, 2002, ENDOCRINOLOGY, V143, P4599, DOI 10.1210/en.2002-220561; Ayala G, 2004, CLIN CANCER RES, V10, P6572, DOI 10.1158/1078-0432.CCR-04-0477; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Burchardt T, 1999, J UROLOGY, V162, P1800, DOI 10.1016/S0022-5347(05)68241-9; Chan JM, 2002, J NATL CANCER I, V94, P1099; Cinar B, 2005, CANCER RES, V65, P2547, DOI 10.1158/0008-5472.CAN-04-3411; Cox ME, 1999, CANCER RES, V59, P3821; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Culig Z, 2005, ENDOCR-RELAT CANCER, V12, P229, DOI 10.1677/erc.1.00775a; DISANTAGNESE PA, 1985, ARCH PATHOL LAB MED, V109, P607; Evangelou AI, 2004, J CELL BIOCHEM, V91, P671, DOI 10.1002/jcb.10771; Gregory CW, 2001, CANCER RES, V61, P2892; HUANG J, 2002, ADV ONCOLOGY EXPANDI, P243; Huang JT, 2006, PROSTATE, V66, P1399, DOI 10.1002/pros.20434; Huang JT, 2005, AM J PATHOL, V166, P1807, DOI 10.1016/S0002-9440(10)62490-X; Huss WJ, 2004, PROSTATE, V60, P91, DOI 10.1002/pros.20032; Jin RJ, 2004, CANCER RES, V64, P5489, DOI 10.1158/0008-5472.CAN-03-3117; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kim J, 2002, CANCER RES, V62, P1549; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; Lei QY, 2006, CANCER CELL, V9, P367, DOI 10.1016/j.ccr.2006.03.031; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li L, 2005, PROSTATE CANCER P D, V8, P108, DOI 10.1038/sj.pcan.4500776; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Quinn M, 2002, BJU INT, V90, P162, DOI 10.1046/j.1464-410X.2002.2822.x; Sharifi N, 2005, JAMA-J AM MED ASSOC, V294, P238, DOI 10.1001/jama.294.2.238; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stern DF, 2004, CLIN CANCER RES, V10, P6407, DOI 10.1158/1078-0432.CCR-04-1783; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; Thomas GV, 2004, CLIN CANCER RES, V10, P8351, DOI 10.1158/1078-0432.CCR-04-0130; Uchida K, 2005, PROSTATE, V62, P40, DOI 10.1002/pros.20111; Vashchenko N, 2005, EUR UROL, V47, P147, DOI 10.1016/j.eururo.2004.09.007; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Webber MM, 1997, PROSTATE, V30, P136, DOI 10.1002/(SICI)1097-0045(19970201)30:2<136::AID-PROS9>3.0.CO;2-M; Wright ME, 2003, MOL ENDOCRINOL, V17, P1726, DOI 10.1210/me.2003-0031; Wu CY, 2006, PROSTATE, V66, P1125, DOI 10.1002/pros.20412; Wyszomierski SL, 2005, CANCER CELL, V8, P437, DOI 10.1016/j.ccr.2005.11.006; Xin L, 2006, P NATL ACAD SCI USA, V103, P7789, DOI 10.1073/pnas.0602567103; Yang X, 2006, ONCOGENE, V25, P3436, DOI 10.1038/sj.onc.1209366; Yang XZ, 2005, CANCER RES, V65, P5263, DOI 10.1158/0008-5472.CAN-05-0162; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986; Zelivianski S, 2001, BBA-MOL CELL RES, V1539, P28, DOI 10.1016/S0167-4889(01)00087-8; Zhang XQ, 2003, ONCOGENE, V22, P6704, DOI 10.1038/sj.onc.1206764; ZHUANG S, 2006, IN PRESS AM J PHYSL	51	66	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3571	3583		10.1074/jbc.M608487200	http://dx.doi.org/10.1074/jbc.M608487200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148458	hybrid			2022-12-25	WOS:000244481900019
J	Baens, M; Noels, H; Broeckx, V; Hagens, S; Fevery, S; Billiau, AD; Vankelecom, H; Marynen, P				Baens, Mathijs; Noels, Heidi; Broeckx, Vicky; Hagens, Sofie; Fevery, Sabine; Billiau, An D.; Vankelecom, Hugo; Marynen, Peter			The Dark Side of EGFP: Defective Polyubiquitination	PLOS ONE			English	Article							KAPPA-B ACTIVATION; EXPRESSION; PROTEIN; TRAF6; MICE; CELL; APOPTOSIS; PROMOTES; MYOSIN; GAMMA	Enhanced Green Fluorescent Protein (EGFP) is the most commonly used live cell reporter despite a number of conflicting reports that it can affect cell physiology. Thus far, the precise mechanism of GFP-associated defects remained unclear. Here we demonstrate that EGFP and EGFP fusion proteins inhibit polyubiquitination, a posttranslational modification that controls a wide variety of cellular processes, like activation of kinase signalling or protein degradation by the proteasome. As a consequence, the NF-kappa B and JNK signalling pathways are less responsive to activation, and the stability of the p53 tumour suppressor is enhanced in cell lines and in vivo. In view of the emerging role of polyubiquitination in the regulation of numerous cellular processes, the use of EGFP as a live cell reporter should be carefully considered.	[Baens, Mathijs; Noels, Heidi; Broeckx, Vicky; Hagens, Sofie; Marynen, Peter] Univ Leuven VIB, Ctr Human Genet, Mol Genet, Louvain, Belgium; [Fevery, Sabine; Billiau, An D.] Univ Leuven, Lab Expt Transplantat, Leuven, Belgium; [Vankelecom, Hugo] Univ Leuven, Lab Cell Pharmacol, Leuven, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; KU Leuven	Baens, M (corresponding author), Univ Leuven VIB, Ctr Human Genet, Mol Genet, Louvain, Belgium.	Mathijs.Baens@Med.KULeuven.be	Noels, Heidi/AAQ-2622-2020	Vankelecom, Hugo/0000-0002-2251-7284	Belgische Federatie tegen Kanker [SCIE2003-09]; Association for International Cancer Research [04-149]; Fonds voor Wetenschappelijk Onderzoek (FWO) - Vlaanderen [1.5.145.04]	Belgische Federatie tegen Kanker; Association for International Cancer Research; Fonds voor Wetenschappelijk Onderzoek (FWO) - Vlaanderen(FWO)	This work was supported by grant SCIE2003-09 of the "Belgische Federatie tegen Kanker" to PM, by grant 04-149 of the "Association for International Cancer Research" to PM and a "Krediet aan Navorsers" (1.5.145.04) from the "Fonds voor Wetenschappelijk Onderzoek (FWO) - Vlaanderen" to MB. HN is an "aspirant" from the "FWO - Vlaanderen".	Agbulut O, 2006, NAT METHODS, V3, P331, DOI 10.1038/nmeth0506-331; Baens M, 2006, CANCER RES, V66, P5270, DOI 10.1158/0008-5472.CAN-05-4590; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen HQ, 2006, FEBS LETT, V580, P3145, DOI 10.1016/j.febslet.2006.04.066; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dixit R, 2003, PLANT J, V36, P280, DOI 10.1046/j.1365-313X.2003.01868.x; Fei PW, 2002, CANCER RES, V62, P7316; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Krestel HE, 2004, NEUROBIOL DIS, V17, P310, DOI 10.1016/j.nbd.2004.05.012; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kudryashova E, 2005, J MOL BIOL, V354, P413, DOI 10.1016/j.jmb.2005.09.068; LEUNG TKC, 1990, BIOCHEM J, V267, P125, DOI 10.1042/bj2670125; Liu HS, 1999, BIOCHEM BIOPH RES CO, V260, P712, DOI 10.1006/bbrc.1999.0954; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Ran RQ, 2004, GENE DEV, V18, P1466, DOI 10.1101/gad.1188204; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; [孙雪涛 Sun Xuetao], 2004, [中国工程科学, Engineering science], V6, P1; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Zhang F, 2003, BLOOD, V102, P2115, DOI 10.1182/blood-2003-01-0049; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012	28	119	120	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e54	10.1371/journal.pone.0000054	http://dx.doi.org/10.1371/journal.pone.0000054			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183684	Green Submitted, gold, Green Published			2022-12-25	WOS:000207443600054
J	Nagaev, I; Bokarewa, M; Tarkowski, A; Smith, U				Nagaev, Ivan; Bokarewa, Maria; Tarkowski, Andrej; Smith, Ulf			Human Resistin Is a Systemic Immune-Derived Proinflammatory Cytokine Targeting both Leukocytes and Adipocytes	PLOS ONE			English	Article							EPICARDIAL ADIPOSE-TISSUE; BINDING-PROTEIN-EPSILON; C/EBP-EPSILON; FUNCTIONAL-CHARACTERIZATION; MESSENGER-RNA; EXPRESSION; GENE; OBESITY; CELLS; DIFFERENTIATION	The characteristics of human resistin (RETN) are unclear and controversial despite intensive adipose-focused research. Its transcriptional and functional similarity with the murine myeloid-specific and CCAAT/enhancer binding protein epsilon (Cebpe)-dependent gene, resistin-like gamma (Retnlg), is unexplored. We examined the human CEBPE-regulatory pathway by unbiased reference and custom gene expression assays. Real-time RT-PCR analysis demonstrated lack of both the transcriptional factor CEBPE and RETN expression in adipose and muscle cells. In contrast, primary myelocytic samples revealed a concerted CEBPE-RETN transcription that was significantly elevated in inflammatory synoviocytes relative to intact peripheral blood mononuclear cells (PBMC). Mouse Cebpe and Retnlg were predictably expressed in macrophages, whereas Retn was abundant in adipocytes. Quite the opposite, a low and inconsistent RETN transcription was seen in some human white adipose tissue (WAT) biopsies without any relationship to body mass index, insulin sensitivity, or fat depot. However, in these cases, RETN was co-detected with CEBPE and the leukocyte-specific marker, EMR1, indicating the presence of inflammatory cells and their possible resistin-mediated effect on adipocytes. Indeed, addition of human resistin to WAT in culture induced, like in PBMC, the inflammatory cytokines IL6, IL8 and TNF. Importantly, the expression of the adipose-specific markers CEBPA, FABP4 and SLC2A4 was unchanged, while the expected inhibitory effect was seen with TNF. Both cytokines increased the mRNA level of CCL2 and MMP3, which may further promote inflammation in WAT. Thus, the myeloid-restricted nature of CEBPE precludes the expression of RETN in human adipocytes which, however, are targeted by this innate immune-derived proinflammatory cytokine.	[Nagaev, Ivan; Smith, Ulf] Gothenburg Univ, Sahlgrenska Acad, Dept Internal Med, Lundberg Lab Diabet Res, Gothenburg, Sweden; [Bokarewa, Maria; Tarkowski, Andrej] Gothenburg Univ, Sahlgrenska Acad, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden	University of Gothenburg; University of Gothenburg	Nagaev, I (corresponding author), Gothenburg Univ, Sahlgrenska Acad, Dept Internal Med, Lundberg Lab Diabet Res, Gothenburg, Sweden.	ivan.nagaev@.gu.se	Bokarewa, Maria I/A-8114-2019	Bokarewa, Maria I/0000-0001-9424-5145	Swedish Research Council [K 2004-72x-03506-33A, K2004-74P-15176-01A, K2004-06X-08674-16A]; European Community [LSHM-CT-2004-512013]; Swedish Diabetes Association; Novo Nordisk Foundation; Torsten and Ragnar Soderberg's Foundation; National Inflammation Network; Swedish Association against Rheumatism; King Gustaf V's Foundation; Nanna Svartz's Foundation; Goteborg Medical Society; Borje Dahlin's Foundation; Goteborg University	Swedish Research Council(Swedish Research CouncilEuropean Commission); European Community(European Commission); Swedish Diabetes Association; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Torsten and Ragnar Soderberg's Foundation; National Inflammation Network; Swedish Association against Rheumatism; King Gustaf V's Foundation; Nanna Svartz's Foundation; Goteborg Medical Society; Borje Dahlin's Foundation; Goteborg University	Funding: The Swedish Research Council (K 2004-72x-03506-33A, K2004-74P-15176-01A, K2004-06X-08674-16A), the European Community's FP6 EUGENE2 (LSHM-CT-2004-512013), the Swedish Diabetes Association, the Novo Nordisk Foundation, the Torsten and Ragnar Soderberg's Foundation, National Inflammation Network, Swedish Association against Rheumatism, King Gustaf V's Foundation, Nanna Svartz's Foundation, Goteborg Medical Society, Borje Dahlin's Foundation, and the Goteborg University.	Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; Baker AR, 2006, CARDIOVASC DIABETOL, V5, DOI 10.1186/1475-2840-5-1; Bokarewa M, 2005, J IMMUNOL, V174, P5789, DOI 10.4049/jimmunol.174.9.5789; Burnett MS, 2005, ATHEROSCLEROSIS, V182, P241, DOI 10.1016/j.atherosclerosis.2005.02.014; Chen XD, 2004, DIABETES OBES METAB, V6, P271, DOI 10.1111/j.1462-8902.2004.0346.x; Chih DY, 2004, EXP HEMATOL, V32, P1173, DOI 10.1016/j.exphem.2004.08.014; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Chumakov AM, 2004, ONCOGENE, V23, P3414, DOI 10.1038/sj.onc.1207126; Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200; Curat CA, 2006, DIABETOLOGIA, V49, P744, DOI 10.1007/s00125-006-0173-z; Dai MH, 2006, DOMEST ANIM ENDOCRIN, V30, P88, DOI 10.1016/j.domaniend.2005.06.003; Degawa-Yamauchi M, 2003, J CLIN ENDOCR METAB, V88, P5452, DOI 10.1210/jc.2002-021808; Fain JN, 2003, BIOCHEM BIOPH RES CO, V300, P674, DOI 10.1016/S0006-291X(02)02864-4; Gerstmayer B, 2003, GENOMICS, V81, P588, DOI 10.1016/S0888-7543(03)00070-3; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Jonke J, 2002, OBES RES, V10, P1; Jung HS, 2006, CARDIOVASC RES, V69, P76, DOI 10.1016/j.cardiores.2005.09.015; Kaser S, 2003, BIOCHEM BIOPH RES CO, V309, P286, DOI 10.1016/j.bbrc.2003.07.003; Kawanami D, 2004, BIOCHEM BIOPH RES CO, V314, P415, DOI 10.1016/j.bbrc.2003.12.104; Khazen W, 2005, FEBS LETT, V579, P5631, DOI 10.1016/j.febslet.2005.09.032; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Korner A, 2005, BIOCHEM BIOPH RES CO, V337, P540, DOI 10.1016/j.bbrc.2005.09.064; Kubota T, 2000, BLOOD, V96, P3953, DOI 10.1182/blood.V96.12.3953.h8003953_3953_3957; Lehrke M, 2004, PLOS MED, V1, P161, DOI 10.1371/journal.pmed.0010045; Lu SC, 2002, FEBS LETT, V530, P158, DOI 10.1016/S0014-5793(02)03450-6; Mazurek T, 2003, CIRCULATION, V108, P2460, DOI 10.1161/01.CIR.0000099542.57313.C5; McTernan CL, 2002, LANCET, V359, P46, DOI 10.1016/S0140-6736(02)07281-1; McTernan PG, 2003, J CLIN ENDOCR METAB, V88, P6098, DOI 10.1210/jc.2003-030898; McTernan PG, 2002, J CLIN ENDOCR METAB, V87, P2407, DOI 10.1210/jc.87.5.2407; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; Nagaev I, 2001, BIOCHEM BIOPH RES CO, V285, P561, DOI 10.1006/bbrc.2001.5173; Nohira T, 2004, EUR J ENDOCRINOL, V151, P151, DOI 10.1530/eje.0.1510151; Ort T, 2005, ENDOCRINOLOGY, V146, P2200, DOI 10.1210/en.2004-1421; Osawa H, 2004, AM J HUM GENET, V75, P678, DOI 10.1086/424761; Patel L, 2003, BIOCHEM BIOPH RES CO, V300, P472, DOI 10.1016/S0006-291X(02)02841-3; Savage DB, 2001, DIABETES, V50, P2199, DOI 10.2337/diabetes.50.10.2199; Schinke T, 2004, BIOCHEM BIOPH RES CO, V314, P356, DOI 10.1016/j.bbrc.2003.12.100; Seo JB, 2003, MOL ENDOCRINOL, V17, P1522, DOI 10.1210/me.2003-0028; Shojima N, 2005, DIABETOLOGIA, V48, P984, DOI 10.1007/s00125-005-1735-1; Sopasakis VR, 2005, INT J OBESITY, V29, P1144, DOI 10.1038/sj.ijo.0803002; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Williamson EA, 2005, BLOOD, V105, P3841, DOI 10.1182/blood-2004-09-3708; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Yang RZ, 2003, BIOCHEM BIOPH RES CO, V310, P927, DOI 10.1016/j.bbrc.2003.09.093	45	115	117	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e31	10.1371/journal.pone.0000031	http://dx.doi.org/10.1371/journal.pone.0000031			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183659	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600031
J	Zhou, Y; Wu, H; Li, SA; Chen, Q; Cheng, XW; Zheng, J; Takemori, H; Xiong, ZQ				Zhou, Yang; Wu, Hao; Li, Shuai; Chen, Qian; Cheng, Xue-Wen; Zheng, Jing; Takemori, Hiroshi; Xiong, Zhi-Qi			Requirement of TORC1 for Late-Phase Long-Term Potentiation in the Hippocampus	PLOS ONE			English	Article								Late-phase long-term potentiation (L-LTP) and long-term memory depend on the transcription of mRNA of CRE-driven genes and synthesis of proteins. However, how synaptic signals propagate to the nucleus is unclear. Here we report that the CREB coactivator TORC1 (transducer of regulated CREB activity 1) undergoes neuronal activity-induced translocation from the cytoplasm to the nucleus, a process required for CRE-dependent gene expression and L-LTP. Overexpressing a dominant-negative form of TORC1 or down-regulating TORC1 expression prevented activity-dependent transcription of CREB target genes in cultured hippocampal neurons, while overexpressing a wild-type form of TORC1 facilitated basal and activity-induced transcription of CREB target genes. Furthermore, overexpressing the dominant-negative form of TORC1 suppressed the maintenance of L-LTP without affecting early-phase LTP, while overexpressing the wild-type form of TORC1 facilitated the induction of L-LTP in hippocampal slices. Our results indicate that TORC1 is essential for CRE-driven gene expression and maintenance of long-term synaptic potentiation.	[Zhou, Yang; Wu, Hao; Li, Shuai; Chen, Qian; Cheng, Xue-Wen; Zheng, Jing; Xiong, Zhi-Qi] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai, Peoples R China; [Zhou, Yang; Wu, Hao; Li, Shuai; Chen, Qian; Cheng, Xue-Wen; Zheng, Jing; Xiong, Zhi-Qi] Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Neurobiol, Shanghai, Peoples R China; [Zhou, Yang; Wu, Hao; Li, Shuai; Chen, Qian; Cheng, Xue-Wen; Zheng, Jing; Xiong, Zhi-Qi] Chinese Acad Sci, Grad Sch, Shanghai, Peoples R China; [Takemori, Hiroshi] Natl Inst Biomed Innovat, Lab Cell Signal & Metab, Osaka, Japan	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; National Institute of Health Sciences - Japan	Xiong, ZQ (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai, Peoples R China.	xiongzhiqi@ion.ac.cn	Li, Shuai/ABD-5132-2021; Cheng, Xuewen/L-7124-2019	Li, Shuai/0000-0002-9574-9609; cheng, xue wen/0000-0001-9898-4404	Major State Basic Research Program of China [2006CB806600]; Chinese Academy of Sciences; Shanghai Pujiang Program	Major State Basic Research Program of China(National Basic Research Program of China); Chinese Academy of Sciences(Chinese Academy of Sciences); Shanghai Pujiang Program(Shanghai Pujiang Program)	This work was supported by grants from Major State Basic Research Program of China (2006CB806600) and "Hundreds Talents Plan'' of the Chinese Academy of Sciences and Shanghai Pujiang Program to Z.Q.X.	Alarcon JM, 2004, NEURON, V42, P947, DOI 10.1016/j.neuron.2004.05.021; Balschun D, 2003, J NEUROSCI, V23, P6304; Barco A, 2005, NEURON, V48, P123, DOI 10.1016/j.neuron.2005.09.005; Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; Blendy JA, 1996, EMBO J, V15, P1098, DOI 10.1002/j.1460-2075.1996.tb00447.x; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Deisseroth K, 2003, CURR OPIN NEUROBIOL, V13, P354, DOI 10.1016/S0959-4388(03)00076-X; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Ding YQ, 2003, NAT NEUROSCI, V6, P933, DOI 10.1038/nn1104; Dzeja PP, 2002, P NATL ACAD SCI USA, V99, P10156, DOI 10.1073/pnas.152259999; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; Gass P, 1998, LEARN MEMORY, V5, P274; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Josselyn Sheena A., 2005, Current Drug Targets - CNS and Neurological Disorders, V4, P481, DOI 10.2174/156800705774322058; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Liu FC, 1996, NEURON, V17, P1133, DOI 10.1016/S0896-6273(00)80245-7; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Lu YF, 1999, J NEUROSCI, V19, P10250; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Marie H, 2005, NEURON, V45, P741, DOI 10.1016/j.neuron.2005.01.039; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Park M, 2004, SCIENCE, V305, P1972, DOI 10.1126/science.1102026; Patterson SL, 2001, NEURON, V32, P123, DOI 10.1016/S0896-6273(01)00443-3; Pittenger C, 2002, NEURON, V34, P447, DOI 10.1016/S0896-6273(02)00684-0; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Rammes G, 2000, EUR J NEUROSCI, V12, P2534, DOI 10.1046/j.1460-9568.2000.00108.x; Sala C, 2000, J NEUROSCI, V20, P3529, DOI 10.1523/JNEUROSCI.20-10-03529.2000; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Wu LZ, 2005, EMBO J, V24, P2391, DOI 10.1038/sj.emboj.7600719; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; Zhu DY, 2003, J NEUROSCI, V23, P223	54	88	94	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e16	10.1371/journal.pone.0000016	http://dx.doi.org/10.1371/journal.pone.0000016			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183642	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600016
J	Wang, L; Kurosaki, T; Corey, SJ				Wang, L.; Kurosaki, T.; Corey, S. J.			Engagement of the B-cell antigen receptor activates STAT through Lyn in a Jak-independent pathway	ONCOGENE			English	Article						Lyn; STAT; Jak; B-cell antigen receptor	STIMULATING FACTOR-RECEPTOR; TYROSINE KINASE; BCR-ABL; NUCLEAR EXPRESSION; PROTEIN; SRC; PHOSPHORYLATION; REGIONS; SITE; SYK	Engagement of the B-cell antigen receptor (BCR) initiated by the Src kinase Lyn triggers rapid signaling cascades, leading to proliferation, differentiation or growth arrest of B cells. The Janus kinase (JAK)-STAT (signal transducer and activator of transcription) pathway, activated through cytokine receptors, mediates similar responses. Hypothesizing that Src and JAK pathways engage in crosstalk in B-cell signaling, we studied wild-type and Lyn-null B-cell lines, which express BCR. We found that activated BCR results in tyrosine phosphorylation of JAK-STAT, which required Lyn. To confirm that STAT activation is not due to JAK, we cloned the chicken homologs of JAK1 and JAK2 and made their antisense constructs. In cells expressing antisense JAK1 and JAK2, tyrosine phosphorylation of STAT was not inhibited following BCR stimulation. Using activation loop-specific phosphotyrosine antibodies, we did not detect phospho-JAK1 and phospho-JAK2 after BCR stimulation. The JAK inhibitor AG490 did not inhibit the tyrosine phosphorylation of Lyn or STAT after BCR simulation. An in vitro phosphorylation assay showed that Lyn directly phosphorylates STAT3. In an electrophoretic mobility shift assay, BCR stimulation led to enhanced DNA binding of the STAT3 in DT40, but not in the Lyn-null cells. We conclude that BCR engagement activates the STAT pathway via Lyn, independent of JAK.	Univ Texas, MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA; RIKEN, Lymphocyte Differentiat Res Ctr Allergy & Immunol, Yokohama, Kanagawa, Japan	University of Texas System; UTMD Anderson Cancer Center; RIKEN	Corey, SJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Pediat, 1515 Holcombe Blvd,Unit 853, Houston, TX 77030 USA.	sjcorey@mdanderson.org	Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X				Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chin H, 1998, BLOOD, V91, P3734; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Coppo P, 2003, ONCOGENE, V22, P4102, DOI 10.1038/sj.onc.1206607; Corey SJ, 1998, J BIOL CHEM, V273, P3230, DOI 10.1074/jbc.273.6.3230; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; DeFranco AL, 1995, ANN NY ACAD SCI, V766, P195, DOI 10.1111/j.1749-6632.1995.tb26662.x; Dorsey JF, 2002, LEUKEMIA, V16, P1589, DOI 10.1038/sj.leu.2402678; Fan H, 2001, EUR J IMMUNOL, V31, P665, DOI 10.1002/1521-4141(200102)31:2<665::AID-IMMU665>3.0.CO;2-1; FINBLOOM DS, 1995, CELL SIGNAL, V7, P739, DOI 10.1016/0898-6568(95)02004-7; Hibbs ML, 2002, J EXP MED, V196, P1593, DOI 10.1084/jem.20020515; Ihle J N, 1995, Semin Immunol, V7, P247, DOI 10.1006/smim.1995.0029; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Ishikawa H, 2002, BLOOD, V99, P2172, DOI 10.1182/blood.V99.6.2172; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Karras JG, 1996, J IMMUNOL, V157, P2299; Karras JG, 1996, J IMMUNOL, V157, P39; Keshvara LM, 1998, J IMMUNOL, V161, P5276; Koay DC, 2002, CELL SIGNAL, V14, P239, DOI 10.1016/S0898-6568(01)00237-6; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lund TC, 1999, CELL SIGNAL, V11, P789, DOI 10.1016/S0898-6568(99)00045-5; Mirnics ZK, 2004, J IMMUNOL, V172, P4133, DOI 10.4049/jimmunol.172.7.4133; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; Pereira S, 2003, J IMMUNOL, V171, P1319, DOI 10.4049/jimmunol.171.3.1319; Saharinen P, 2003, MOL BIOL CELL, V14, P1448, DOI 10.1091/mbc.E02-06-0342; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Sarmay G, 1997, IMMUNOL LETT, V57, P159, DOI 10.1016/S0165-2478(97)00055-2; Scheeren FA, 2005, NAT IMMUNOL, V6, P303, DOI 10.1038/ni1172; Sternberg DW, 2004, J CLIN ONCOL, V22, P361, DOI 10.1200/JCO.2004.10.124; Su L, 1999, J BIOL CHEM, V274, P31770, DOI 10.1074/jbc.274.45.31770; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Winding P, 2001, J IMMUNOL METHODS, V249, P1, DOI 10.1016/S0022-1759(00)00333-1; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 1997, J IMMUNOL, V159, P5206; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	43	42	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2851	2859		10.1038/sj.onc.1210092	http://dx.doi.org/10.1038/sj.onc.1210092			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17146444				2022-12-25	WOS:000246210800005
J	Bloch, M; Ousingsawat, J; Simon, R; Schraml, P; Gasser, TC; Mihatsch, MJ; Kunzelmann, K; Bubendorf, L				Bloch, M.; Ousingsawat, J.; Simon, R.; Schraml, P.; Gasser, T. C.; Mihatsch, M. J.; Kunzelmann, K.; Bubendorf, L.			KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer	ONCOGENE			English	Article						prostate cancer; progression; amplification; BK channel; KCNMA1	COMPARATIVE GENOMIC HYBRIDIZATION; ACTIVATED POTASSIUM CHANNELS; MAXI-K CHANNELS; LARGE-CONDUCTANCE; EPITHELIAL-CELLS; UROKINASE GENE; BREAST-CANCER; BK CHANNELS; RECEPTOR; KINASE	Molecular mechanisms of prostate cancer progression are poorly understood. Here, we studied gene amplification of the large conductance calcium-activated potassium channel alpha subunit (KCNMA1), which is located at the chromosomal region 10q22. Fluorescence in situ hybridization ( FISH) revealed KCNMA1 amplification in 16% of 119 late-stage human prostate cancers and in the hormone-insensitive prostate cancer cell line PC-3. In contrast, KCNMA1 amplification was absent in 33 benign controls, 32 precursor lesions and in 105 clinically organ-confined prostate cancers. Amplification was associated with mRNA and protein overexpression as well as increased density of BK channel protein and beta-estradiol-insensitive BK currents in PC-3 cells as compared to non-amplified control cell lines. Specific blockade of BK channels by iberiotoxin or RNA(i) significantly inhibited K+ currents and growth of PC-3 cells. The data demonstrate that 10q22 amplification drives KCNMA1 expression and cell proliferation. Thus, KCNMA1 qualifies as a promising diagnostic and therapeutic target in patients with prostate cancer.	Univ Basel Hosp, Inst Pathol, CH-4003 Basel, Switzerland; Univ Regensburg, Dept Physiol, D-8400 Regensburg, Germany; Univ Basel, Dept Urol, Liestal, Switzerland	University of Basel; University of Regensburg; University of Basel	Bubendorf, L (corresponding author), Univ Basel Hosp, Inst Pathol, Schonbeinstr 40, CH-4003 Basel, Switzerland.	lbubendorf@uhbs.ch	Bubendorfl, Lukas/H-5880-2011; Bubendorf, Lukas/G-5299-2015	Bubendorf, Lukas/0000-0001-5970-1803; Kunzelmann, Karl/0000-0002-4583-7037				Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Amberg GC, 2003, J CLIN INVEST, V112, P717, DOI 10.1172/JC1200318684; Amberg GC, 2003, CIRC RES, V93, P965, DOI 10.1161/01.RES.0000100068.43006.36; Basrai D, 2002, NEUROREPORT, V13, P403, DOI 10.1097/00001756-200203250-00008; Bernardino J, 1997, CANCER GENET CYTOGEN, V96, P123, DOI 10.1016/S0165-4608(96)00258-0; Calderone V, 2002, CURR MED CHEM, V9, P1385, DOI 10.2174/0929867023369871; Christow SP, 1999, EUR J BIOCHEM, V265, P264, DOI 10.1046/j.1432-1327.1999.00729.x; Coiret G, 2005, FEBS LETT, V579, P2995, DOI 10.1016/j.febslet.2005.02.085; Conti DJ, 2004, AM J TRANSPLANT, V4, P166; Davies AG, 2003, CELL, V115, P655, DOI 10.1016/S0092-8674(03)00979-6; El Gedaily A, 2001, PROSTATE, V46, P184; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; HAYWARD SW, 1995, IN VITRO CELL DEV-AN, V31, P14; Helenius MA, 2006, BJU INT, V97, P404, DOI 10.1111/j.1464-410X.2005.05912.x; Helenius MA, 2001, CANCER RES, V61, P5340; Henke G, 2004, J CELL PHYSIOL, V199, P194, DOI 10.1002/jcp.10430; Ho SM, 2004, J CELL BIOCHEM, V91, P491, DOI 10.1002/jcb.10759; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;60::AID-IJC11&gt;3.0.CO;2-B; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Koochekpour S, 2005, GENE CHROMOSOME CANC, V44, P351, DOI 10.1002/gcc.20249; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; Lau KM, 2000, CANCER RES, V60, P3175; MCCOBB DP, 1995, AM J PHYSIOL, V269, P767; O'Grady SM, 2005, INT J BIOCHEM CELL B, V37, P1578, DOI 10.1016/j.biocel.2005.04.002; O'Malley D, 2004, MOL PHARMACOL, V65, P1352, DOI 10.1124/mol.65.6.1352; Olsen ML, 2005, J NEUROSCI RES, V81, P179, DOI 10.1002/jnr.20543; Orio P, 2002, NEWS PHYSIOL SCI, V17, P156, DOI 10.1152/nips.01387.2002; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pardo LA, 2004, PHYSIOLOGY, V19, P285, DOI 10.1152/physiol.00011.2004; Parihar AS, 2003, EUR J PHARMACOL, V471, P157, DOI 10.1016/S0014-2999(03)01825-9; Pei L, 2003, P NATL ACAD SCI USA, V100, P7803, DOI 10.1073/pnas.1232448100; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Quirk JC, 2001, NEURON, V32, P13, DOI 10.1016/S0896-6273(01)00444-5; Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168-9525(97)01103-7; Reiter RE, 2000, GENE CHROMOSOME CANC, V27, P95, DOI 10.1002/(SICI)1098-2264(200001)27:1<95::AID-GCC12>3.0.CO;2-3; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; Sausbier M, 2006, J AM SOC NEPHROL, V17, P1275, DOI 10.1681/ASN.2005101111; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Van Coppenolle F, 2004, BIOCHEM J, V377, P569, DOI 10.1042/BJ20030859; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; Wang ZG, 2004, PFLUG ARCH EUR J PHY, V448, P274, DOI 10.1007/s00424-004-1258-5; Weaver AK, 2004, J NEUROSCI RES, V78, P224, DOI 10.1002/jnr.20240; Zhou XB, 2000, AM J PHYSIOL-CELL PH, V279, pC1751, DOI 10.1152/ajpcell.2000.279.6.C1751	48	101	108	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2007	26	17					2525	2534		10.1038/sj.onc.1210036	http://dx.doi.org/10.1038/sj.onc.1210036			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17146446				2022-12-25	WOS:000245831000014
J	Escamilia-Powers, JR; Sears, RC				Escamilia-Powers, Julienne R.; Sears, Rosalie C.			A conserved pathway that controls c-Myc protein stability through opposing phosphorylation events occurs in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; SACCHAROMYCES-CEREVISIAE GENE; F-BOX; UBIQUITIN LIGASE; CELL-CYCLE; S-PHASE; MULTISITE PHOSPHORYLATION; DEPENDENT DEGRADATION; SIGNALING PATHWAY; PROLYL ISOMERASE	The c-Myc transcription factor is a key regulator of cell proliferation and cell fate decisions. c-Myc overexpression is observed in a variety of human tumors, revealing the importance of maintaining normal levels of c-Myc protein. c-Myc protein stability in mammalian cells is controlled by interdependent and sequential phosphorylation and dephosphorylation events on two highly conserved residues, serine 62 and threonine 58. Here we show that these sequential phosphorylation and dephosphorylation events and their effect on c-Myc stability also occurs in the model system Saccharomyces cerevisiae. These results suggest the presence of a conserved pathway in yeast that controls protein turnover in response to a specific phospho-degron sequence. These findings have implications regarding conserved pathways for regulated protein degradation, and they validate the use of genetically tractable yeast for the study of the turnover of proteins such as c-Myc that contain this motif.	Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA	Oregon Health & Science University	Sears, RC (corresponding author), Oregon Hlth Sci Univ, Dept Mol & Med Genet, 3181 SW Sam Jackson Pk Rd,L103A, Portland, OR 97239 USA.	searsr@ohsu.edu			NCI NIH HHS [K01 CA086957, K01 CA086957-06, R01 CA100855, R01 CA100855-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA086957, R01CA100855] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Arvanitis C, 2005, CANCER LETT, V226, P95, DOI 10.1016/j.canlet.2004.10.043; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BIANCHI MW, 1993, GENE, V134, P51, DOI 10.1016/0378-1119(93)90173-Z; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Casamayor A, 1996, YEAST, V12, P1013, DOI 10.1002/(SICI)1097-0061(199609)12:10B<1013::AID-YEA980>3.3.CO;2-X; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Drury LS, 2000, CURR BIOL, V10, P231, DOI 10.1016/S0960-9822(00)00355-9; ELION EA, 1991, COLD SPRING HARB SYM, V56, P41; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Goh PY, 1999, MOL CELL BIOL, V19, P5512; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARDY TA, 1995, BIOCHEM BIOPH RES CO, V208, P728, DOI 10.1006/bbrc.1995.1398; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; Herbst A, 2005, EMBO REP, V6, P177, DOI 10.1038/sj.embor.7400333; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Lu KP, 1996, NATURE, V380, P544; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Perkins G, 2001, EMBO J, V20, P4836, DOI 10.1093/emboj/20.17.4836; Popescu NC, 2002, J CELL MOL MED, V6, P151, DOI 10.1111/j.1582-4934.2002.tb00183.x; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sherman F, 1986, LAB COURSE MANUAL ME; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Weiwad M, 2000, FEBS LETT, V478, P39, DOI 10.1016/S0014-5793(00)01794-4; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Wu XY, 2000, EMBO J, V19, P3727, DOI 10.1093/emboj/19.14.3727; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yeh ES, 2006, J BIOL CHEM, V281, P241, DOI 10.1074/jbc.M505770200; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	53	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5432	5442		10.1074/jbc.M611437200	http://dx.doi.org/10.1074/jbc.M611437200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17192266	Green Accepted, hybrid			2022-12-25	WOS:000244482300038
J	Horenstein, NA; McCormack, TJ; Stokes, C; Ren, K; Papke, RL				Horenstein, Nicole A.; McCormack, Thomas J.; Stokes, Clare; Ren, Ke; Papke, Roger L.			Reversal of agonist selectivity by mutations of conserved amino acids in the binding site of nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT; ACTIVATION; SUBUNIT; MUSCLE	Homomeric alpha 7 and heteromeric alpha 4 beta 2 nicotinic acetylcholine receptors (nAChR) can be distinguished by their pharmacological properties, including agonist specificity. We introduced point mutations of conserved amino acids within the C loop, a region of the receptor critical for agonist binding, and we examined the expression of the mutant receptors in Xenopus oocytes. Mutation of either a conserved C loop tyrosine (188) to phenylalanine or a nearby conserved aspartate (197) to alanine resulted in alpha 7 receptors for which the alpha 7-selective agonist 3-(4-hydroxy,2-methoxybenzylidene)anabaseine (4OH-GTS-21) had roughly the same potency as for wild-type receptors, whereas the physiologic agonist acetylcholine (ACh) showed drastically reduced potency for these mutant receptors. Corresponding mutations in alpha 4 receptors co-expressed with 62 resulted in alpha 4 beta 2 receptors for which ACh potency was relatively unchanged, although the efficacy of the alpha 7-selective agonist 4OH-GTS-21 was increased greatly relative to that of ACh. We also investigated the significance of a conserved lysine (145 in alpha 7), proposed to form a stable salt bridge with Asp-197 in the resting state of the receptor. Mutations of this residue in both alpha 7 and alpha 4 resulted in receptors that were largely unresponsive to both ACh and 4OH-GTS-21. Our results suggest that initiation of gating depends both on specific interactions between residues in the C loop domain and, depending on receptor subtype, the physiochemical properties of the agonist, so that in the altered environment of the alpha 4Y190F-binding site, large hydrophobic benzylidene anabaseines may close the C loop and initiate channel gating more effectively than the polar agonist ACh.	Univ Florida, Dept Pharmacol & Therapeut, Coll Med, Gainesville, FL 32610 USA; Univ Florida, Dept Chem, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Papke, RL (corresponding author), Univ Florida, Dept Pharmacol & Therapeut, Coll Med, POB 100267, Gainesville, FL 32610 USA.	rlpapke@ufl.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000196, P01AG010485] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG10485, T32 AG00196] Funding Source: Medline; NIGMS NIH HHS [R01 GM57481] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; Halevi S, 2003, J BIOL CHEM, V278, P34411, DOI 10.1074/jbc.M300170200; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Kem WR, 1997, J PHARMACOL EXP THER, V283, P979; Kem WR, 2000, BEHAV BRAIN RES, V113, P169, DOI 10.1016/S0166-4328(00)00211-4; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; Martin LF, 2004, PSYCHOPHARMACOLOGY, V174, P54, DOI 10.1007/s00213-003-1750-1; Meyer EM, 1998, J PHARMACOL EXP THER, V287, P918; Mukhtasimova N, 2005, J GEN PHYSIOL, V126, P23, DOI 10.1085/jgp.200509283; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; Palma E, 1996, J PHYSIOL-LONDON, V491, P151, DOI 10.1113/jphysiol.1996.sp021203; Papke RL, 1996, NEUROSCI LETT, V213, P201; Papke RL, 2002, BRIT J PHARMACOL, V137, P49, DOI 10.1038/sj.bjp.0704833; Papke RL, 2005, BIOORG MED CHEM LETT, V15, P3874, DOI 10.1016/j.bmcl.2005.05.118; Philipson KD, 2001, AM J PHYSIOL-CELL PH, V281, pC195, DOI 10.1152/ajpcell.2001.281.1.C195; Placzek AN, 2005, MOL PHARMACOL, V68, P1863, DOI 10.1124/mol.105.016402; SINE SM, 1994, J BIOL CHEM, V269, P8808; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Stokes C, 2004, MOL PHARMACOL, V66, P14, DOI 10.1124/mol.66.1.14; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339	21	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5899	5909		10.1074/jbc.M609202200	http://dx.doi.org/10.1074/jbc.M609202200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189260	hybrid			2022-12-25	WOS:000244482300086
J	Jia, YP; Buehler, PW; Boykins, RA; Venable, RM; Alayash, AI				Jia, Yiping; Buehler, Paul W.; Boykins, Robert A.; Venable, Richard M.; Alayash, Abdu I.			Structural basis of peroxide-mediated changes in human hemoglobin - A novel oxidative pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME PROSTHETIC GROUP; HYDROGEN-PEROXIDE; CROSS-LINKING; METHIONINE OXIDATION; FREE-RADICALS; IN-VITRO; MYOGLOBIN; ACID; METMYOGLOBIN; DEGRADATION	Hydrogen peroxide (H2O2) triggers a redox cycle between ferric and ferryl hemoglobin (Hb) leading to the formation of a transient protein radical and a covalent hemeprotein cross-link. Addition of H2O2 to highly purified human hemoglobin (HbA(0)) induced structural changes that primarily resided within beta subunits followed by the internalization of the heme moiety within a subunits. These modifications were observed when an equal molar concentration of H2O2 was added to HbA(0) yet became more abundant with greater concentrations of H2O2. Mass spectrometric and amino acid analysis revealed for the first time that beta Cys-93 and beta Cys-112 were oxidized extensively and irreversibly to cysteic acid when HbA(0) was treated with H2O2. Oxidation of further amino acids in HbA(0) exclusive to the beta-globin chain included modification of beta Trp-15 to oxyindolyl and kynureninyl products as well as beta Met-55 to methionine sulfoxide. These findings may therefore explain the premature collapse of the beta subunits as a result of the H2O2 attack. Analysis of a tryptic digest of the main reversed phase-high pressure liquid chromatography fraction revealed two a-peptide fragments (alpha 128 - alpha 139) and a heme moiety with the loss of iron, cross-linked between alpha Ser-138 and the porphyrin ring. The novel oxidative pathway of HbA(0) modification detailed here may explain the diverse oxidative, toxic, and potentially immunogenic effects associated with the release of hemoglobin from red blood cells during hemolytic diseases and/or when cell-free Hb is used as a blood substitute.	Food & Drug Adm, Ctr Biol Evaluat & Res, Lab Biochem & Vasc Biol, Div Hematol, Bethesda, MD 20892 USA; Food & Drug Adm, Ctr Biol Evaluat & Res, Biophys Lab, Div Bacterial Parasit & Allergen Prod, Bethesda, MD 20892 USA; NHLBI, Membrane Biophys Sect, Lab Computat Biol, NIH, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Alayash, AI (corresponding author), Food & Drug Adm, Ctr Biol Evaluat & Res, Lab Biochem & Vasc Biol, Div Hematol, Bethesda, MD 20892 USA.	abdu.alayash@fda.hhs.gov						Adamson JG, 1998, TISS ENG, P62; Alayash AI, 2004, NAT REV DRUG DISCOV, V3, P152, DOI 10.1038/nrd1307; Alayash AI, 2001, ARTIF CELL BLOOD SUB, V29, P415, DOI 10.1081/BIO-100108547; AMICONI G, 1991, ADV EXP MED BIOL, V307, P185; AMICONI G, 1989, J BIOL CHEM, V264, P17745; Atassi MZ, 2005, PROTEIN J, V24, P51, DOI 10.1007/s10930-004-0605-x; BARKER PD, 1993, P NATL ACAD SCI USA, V90, P6542, DOI 10.1073/pnas.90.14.6542; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Boykins RA, 2005, PROTEINS, V59, P840, DOI 10.1002/prot.20453; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Buehler PW, 2004, TRANSFUSION, V44, P1516, DOI 10.1111/j.1537-2995.2004.04081.x; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; Deterding LJ, 2004, J BIOL CHEM, V279, P11600, DOI 10.1074/jbc.M310704200; Feng L, 2005, NATURE, V435, P697, DOI 10.1038/nature03609; Fontana M, 2005, BIOCHEM J, V389, P233, DOI 10.1042/BJ20041696; FREI B, 1988, ANAL BIOCHEM, V175, P120, DOI 10.1016/0003-2697(88)90369-7; Griffiths SW, 2002, J BIOL CHEM, V277, P25486, DOI 10.1074/jbc.M203089200; Griffiths SW, 2002, J CHROMATOGR A, V942, P133, DOI 10.1016/S0021-9673(01)01350-4; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Gunther MR, 2000, FREE RADICAL BIO MED, V28, P709, DOI 10.1016/S0891-5849(00)00164-7; He YY, 2003, PHOTOCHEM PHOTOBIOL, V77, P585, DOI 10.1562/0031-8655(2003)077<0585:UHRDBI>2.0.CO;2; Huang LS, 2006, J BIOL CHEM, V281, P18983, DOI 10.1074/jbc.M602307200; Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005; Khor HK, 2004, J BIOL CHEM, V279, P19486, DOI 10.1074/jbc.M310045200; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; MARKS DH, 1987, MIL MED, V152, P473; MARTIN WJ, 1984, AM REV RESPIR DIS, V130, P209; Mason RP, 2004, FREE RADICAL BIO MED, V36, P1214, DOI 10.1016/j.freeradbiomed.2004.02.077; Mekecha TT, 2006, J AM SOC MASS SPECTR, V17, P923, DOI 10.1016/j.jasms.2006.01.004; Nagababu E, 2000, BIOCHEMISTRY-US, V39, P12503, DOI 10.1021/bi992170y; Nagababu E, 2004, ANTIOXID REDOX SIGN, V6, P967, DOI 10.1089/1523086042259823; Nagababu E, 2002, BIOCHEMISTRY-US, V41, P7407, DOI 10.1021/bi0121048; OSAWA Y, 1991, P NATL ACAD SCI USA, V88, P7081, DOI 10.1073/pnas.88.16.7081; OSAWA Y, 1993, BIOCHEM PHARMACOL, V46, P2299, DOI 10.1016/0006-2952(93)90621-3; Osawa Y, 1996, FREE RADICAL BIO MED, V21, P35, DOI 10.1016/0891-5849(95)02215-5; Patel MJ, 1998, BLOOD, V91, P710, DOI 10.1182/blood.V91.2.710.710_710_716; Ramirez DC, 2003, FREE RADICAL BIO MED, V34, P830, DOI 10.1016/S0891-5849(02)01437-5; Reeder BJ, 2004, ANTIOXID REDOX SIGN, V6, P954, DOI 10.1089/ars.2004.6.954; Reeder BJ, 2002, BIOCHEMISTRY-US, V41, P367, DOI 10.1021/bi011335b; Riess JG, 2001, CHEM REV, V101, P2797, DOI 10.1021/cr970143c; Schaer DJ, 2006, BLOOD, V107, P373, DOI 10.1182/blood-2005-03-1014; Shacter E, 2000, DRUG METAB REV, V32, P307, DOI 10.1081/DMR-100102336; Stadtman ER, 2005, BBA-PROTEINS PROTEOM, V1703, P135, DOI 10.1016/j.bbapap.2004.08.010; STEFFEK RP, 1991, FREE RADICAL RES COM, V12-3, P489; Stone JR, 2006, ANTIOXID REDOX SIGN, V8, P243, DOI 10.1089/ars.2006.8.243; Sugiyama K, 1997, P NATL ACAD SCI USA, V94, P796, DOI 10.1073/pnas.94.3.796; Svistunenko DA, 2002, BIOPHYS J, V83, P2845, DOI 10.1016/S0006-3495(02)75293-4	47	116	119	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4894	4907		10.1074/jbc.M609955200	http://dx.doi.org/10.1074/jbc.M609955200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17178725	hybrid			2022-12-25	WOS:000244482000072
J	Donkor, J; Sariahmetoglu, M; Dewald, J; Brindley, DN; Reue, K				Donkor, Jimmy; Sariahmetoglu, Meltem; Dewald, Jay; Brindley, David N.; Reue, Karen			Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-GAMMA; RAT-LIVER; SUBCELLULAR-LOCALIZATION; INSULIN-RESISTANCE; ADIPOSE-TISSUE; FATTY-ACIDS; PHOSPHOHYDROLASE; PHOSPHORYLATION; LIPODYSTROPHY; GENE	We previously identified mutations in the Lpin1 gene, encoding lipin-1, as the underlying cause of lipodystrophy in the fatty liver dystrophy (fld) mutant mouse. Lipin-1 is normally expressed at high levels in adipose tissue and skeletal muscle, and deficiency in the fld mouse causes impaired adipose tissue development, insulin resistance, and altered energy expenditure. We also identified two additional lipin protein family members of unknown function, lipin-2 and lipin-3. Han et al. (Han, G. S., Wu, W. I., and Carman, G. M. (2006) J. Biol. Chem. 281,9210-9218) recently demonstrated that the single lipin homolog in yeast, Smp2, exhibits phosphatidate phosphatase type-1 (PAP1) activity, which has a key role in glycerolipid synthesis. Here we demonstrate that lipin-1 accounts for all of the PAPI activity in white and brown adipose tissue and skeletal muscle. However, livers of lipin-1-deficient mice exhibited normal PAP1 activity, indicating that other members of the lipin protein family could have PAPI activity. Consistent with this possibility, recombinant lipin-2 and lipin-3 possess PAPI activity. Each of the three lipin family members showed Mg2+-dependent activity that was specific for phosphatidate under the conditions employed. The different lipins showed distinct tissue expression patterns. Our results establish the three mammalian lipin proteins as PAP I enzymes and explain the biochemical basis for lipodystrophy in the lipin-1-deficient fld mouse.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Alberta, Dept Biochem, Signal Transduct Res Grp, Edmonton, AB T6G 2S2, Canada	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Alberta	Reue, K (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Gonda 6506A,695 Charles E Young Dr S, Los Angeles, CA 90095 USA.	reuek@ucla.edu			NHGRI NIH HHS [S-T32-HG002536, T32 HG002536] Funding Source: Medline; NHLBI NIH HHS [HL-28481] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG002536] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Brindley D N, 1974, Biomembranes, V4B, P621; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Brindley DN, 2004, J CELL BIOCHEM, V92, P900, DOI 10.1002/jcb.20126; BRINDLEY DN, 1988, PHOSPHATIDATE PHOSPH, P21; BUTTERWITH SC, 1984, BIOCHEM J, V220, P825, DOI 10.1042/bj2200825; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Finck BN, 2006, CELL METAB, V4, P199, DOI 10.1016/j.cmet.2006.08.005; GOMEZMUNOZ A, 1992, BIOCHIM BIOPHYS ACTA, V1127, P49, DOI 10.1016/0005-2760(92)90200-F; Han GS, 2006, J BIOL CHEM, V281, P9210, DOI 10.1074/jbc.M600425200; Harris TE, 2007, J BIOL CHEM, V282, P277, DOI 10.1074/jbc.M609537200; Hegele RA, 2005, AM J PHYSIOL-REG I, V289, pR663, DOI 10.1152/ajpregu.00275.2005; Huffman TA, 2002, P NATL ACAD SCI USA, V99, P1047, DOI 10.1073/pnas.022634399; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; LINDEGAARD B, 2007, IN PRESS INT J OBES; MARTIN A, 1991, METHOD ENZYMOL, V197, P553; MARTINSANZ P, 1984, FEBS LETT, V175, P284, DOI 10.1016/0014-5793(84)80752-8; O'Hara L, 2006, J BIOL CHEM, V281, P34537, DOI 10.1074/jbc.M606654200; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; Peterfy M, 2005, J BIOL CHEM, V280, P32883, DOI 10.1074/jbc.M503885200; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Petersen KF, 2006, AM J MED, V119, p10S, DOI 10.1016/j.amjmed.2006.01.009; Phan J, 2005, CELL METAB, V1, P73, DOI 10.1016/j.cmet.2004.12.002; Phan J, 2004, J BIOL CHEM, V279, P29558, DOI 10.1074/jbc.M403506200; Reue K, 2000, J LIPID RES, V41, P1067; Reue K, 2006, CURR OPIN CLIN NUTR, V9, P436, DOI 10.1097/01.mco.0000232904.82038.db; Reue K, 2006, FUTURE LIPIDOL, V1, P91, DOI 10.2217/17460875.1.1.91; SAGGERSON ED, 1988, PHOSPHATIDATE PHOSPH, P79; Suviolahti E, 2006, HUM MOL GENET, V15, P377, DOI 10.1093/hmg/ddi448; van Harmelen V, 2007, J LIPID RES, V48, P201, DOI 10.1194/jlr.M600272-JLR200; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; Yao-Borengasser A, 2006, DIABETES, V55, P2811, DOI 10.2337/db05-1688	34	276	299	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3450	3457		10.1074/jbc.M610745200	http://dx.doi.org/10.1074/jbc.M610745200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158099	hybrid			2022-12-25	WOS:000244481900007
J	Fazal, F; Minhajuddin, M; Bijli, KM; McGrath, JL; Rahman, A				Fazal, Fabeha; Minhajuddin, Mohd; Bijli, Kaiser M.; McGrath, James L.; Rahman, Arshad			Evidence for actin cytoskeleton-dependent and -independent pathways for RelA/p65 nuclear translocation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERCELLULAR-ADHESION MOLECULE-1; GENE-EXPRESSION; ACTIVATION; THROMBIN; PROTEIN; PHOSPHORYLATION; KINASE; ALPHA; TRANSCRIPTION	Activation of the transcription factor NF-kappa B involves its release from the inhibitory protein I kappa B alpha in the cytoplasm and subsequently, its translocation to the nucleus. Whereas the events responsible for its release have been elucidated, mechanisms regulating the nuclear transport of NF-kappa B remain elusive. We now provide evidence for actin cytoskeleton-dependent and-independent mechanisms of RelA/p65 nuclear transport using the proinflammatory mediators, thrombin and tumor necrosis factor a, respectively. We demonstrate that thrombin alters the actin cytoskeleton in endothelial cells and interfering with these alterations, whether by stabilizing or destabilizing the actin filaments, prevents thrombin-induced NF-kappa B activation and consequently, expression of its target gene, ICAM-1. The blockade of NF-kappa B activation occurs downstream of I kappa B alpha degradation and is associated with impaired RelA/p65 nuclear translocation. Importantly, thrombin induces association of RelA/p65 with actin and this interaction is sensitive to stabilization/destabilization of the actin filaments. In parallel studies, stabilizing or destabilizing the actin filaments fails to inhibit RelA/p65 nuclear accumulation and ICAM-1 expression by tumor necrosis factor a, consistent with its inability to induce actin filament formation comparable with thrombin. Thus, these studies reveal the existence of actin cytoskeleton-dependent and-independent pathways that may be engaged in a stimulus-specific manner to facilitate RelA/p65 nuclear import and thereby ICAM-1 expression in endothelial cells.	Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biomed Engn, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Rahman, A (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pediat, Box 850,601 Elmwood Ave, Rochester, NY 14642 USA.	Arshad_Rahman@urmc.rochester.edu		McGrath, James/0000-0003-2017-8335	NHLBI NIH HHS [HL67424, R01 HL067424] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067424] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887; Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Anwar KN, 2004, J IMMUNOL, V173, P6965, DOI 10.4049/jimmunol.173.11.6965; Are AF, 2000, EXP CELL RES, V256, P533, DOI 10.1006/excr.2000.4830; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Bourgarel-Rey V, 2000, EUR J CANCER, V36, P1043, DOI 10.1016/S0959-8049(00)00042-3; Bourgarel-Rey V, 2001, MOL PHARMACOL, V59, P1165, DOI 10.1124/mol.59.5.1165; BUBB MR, 1994, J BIOL CHEM, V269, P14869; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Doerschuk CM, 2000, AM J RESP CELL MOL, V23, P133, DOI 10.1165/ajrcmb.23.2.f193; Fazal F, 2005, MOL CELL BIOL, V25, P6259, DOI 10.1128/MCB.25.14.6259-6266.2005; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; Geiger RC, 2006, GENE THER, V13, P725, DOI 10.1038/sj.gt.3302693; Ghisletti S, 2005, MOL CELL BIOL, V25, P2957, DOI 10.1128/MCB.25.8.2957-2968.2005; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hofmann WA, 2004, NAT CELL BIOL, V6, P1094, DOI 10.1038/ncb1182; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawkitinarong K, 2004, AM J RESP CELL MOL, V31, P517, DOI 10.1165/rcmb.2003-0432OC; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Mackenzie GG, 2002, J BIOL CHEM, V277, P34610, DOI 10.1074/jbc.M203616200; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Minhajuddin M, 2005, J IMMUNOL, V174, P5823, DOI 10.4049/jimmunol.174.9.5823; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Posern G, 2002, MOL BIOL CELL, V13, P4167, DOI 10.1091/mbc.02-05-0068; Qiao J, 2003, AM J PHYSIOL-LUNG C, V284, pL972, DOI 10.1152/ajplung.00429.2002; Rahman A, 1999, J IMMUNOL, V162, P5466; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Rivas FV, 2004, MOL CELL BIOL, V24, P1628, DOI 10.1128/MCB.24.4.1628-1639.2004; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Spencer W, 1999, ONCOGENE, V18, P495, DOI 10.1038/sj.onc.1202335; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VALLEE R, 1993, P NATL ACAD SCI USA, V90, P8769, DOI 10.1073/pnas.90.19.8769; VandenBerg E, 2004, J CELL BIOCHEM, V91, P926, DOI 10.1002/jcb.20011; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003	58	53	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3940	3950		10.1074/jbc.M608074200	http://dx.doi.org/10.1074/jbc.M608074200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158457	hybrid			2022-12-25	WOS:000244481900058
J	Hofacker, M; Gompf, S; Zutz, A; Presenti, C; Haase, W; van der Does, C; Model, K; Tampe, R				Hofacker, Matthias; Gompf, Simone; Zutz, Ariane; Presenti, Chiara; Haase, Winfried; van der Does, Chris; Model, Kirstin; Tampe, Robert			Structural and functional fingerprint of the mitochondrial ATP-binding cassette transporter Mdl1 from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINATORIAL PEPTIDE LIBRARIES; ABC TRANSPORTER; ESCHERICHIA-COLI; LACTOCOCCUS-LACTIS; NUCLEOTIDE-BINDING; MEMBRANE-PROTEIN; ELECTRON-MICROSCOPY; BACILLUS-SUBTILIS; 3-DIMENSIONAL RECONSTRUCTION; HYDROLYSIS CYCLE	The ATP-binding cassette half-transporter Mdl1 from Saccharomyces cerevisiae has been proposed to be involved in the quality control of misassembled respiratory chain complexes by exporting degradation products generated by the m-AAA proteases from the matrix. Direct functional or structural data of the transport complex are, however, not known so far. After screening expression in various hosts, Mdl1 was overexpressed 100-fold to 1% of total mitochondrial membrane protein in S. cerevisiae. Based on detergent screens, Mdl1 was solubilized and purified to homogeneity. Mdl1 showed a high binding affinity for MgATP (K-d = 0.26 mu M) and an ATPase activity with a K. of 0.86 mM (Hill coefficient of 0.98) and a turnover rate of 2.6 ATP/s. Mutagenesis of the conserved glutamate downstream of the Walker B motif (E599Q) or the conserved histidine of the H-loop (H631A) abolished ATP hydrolysis, whereas ATP binding was not affected. Mdl1 reconstituted into liposomes showed an ATPase activity similar to the solubilized complex. By single particle electron microscopy, a first three-dimensional structure of the mitochondrial ATP-binding cassette transporter was derived at 2.3-nm resolution, revealing a homodimeric complex in an open conformation.	Goethe Univ Frankfurt, Inst Biochem, Bioctr, D-60438 Frankfurt, Germany; Max Planck Inst Biophys, D-60438 Frankfurt, Germany; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Goethe University Frankfurt; Max Planck Society; MRC Laboratory Molecular Biology	Tampe, R (corresponding author), Goethe Univ Frankfurt, Inst Biochem, Bioctr, Max Von Laue Str 9, D-60438 Frankfurt, Germany.	tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; Awayn NH, 2005, BIOCHEM SOC T, V33, P996, DOI 10.1042/BST0330996; BANEYX F, 1990, J BACTERIOL, V172, P491, DOI 10.1128/JB.172.1.491-494.1990; Brachmann CB, 1998, YEAST, V14, P115; Chami M, 2002, J MOL BIOL, V315, P1075, DOI 10.1006/jmbi.2001.5309; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chloupkova M, 2003, J MOL BIOL, V331, P155, DOI 10.1016/S0022-2836(03)00666-1; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; DEAN M, 1994, YEAST, V10, P377, DOI 10.1002/yea.320100310; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Detmers FJM, 2000, P NATL ACAD SCI USA, V97, P12487, DOI 10.1073/pnas.220308797; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Doeven MK, 2004, J BIOL CHEM, V279, P32301, DOI 10.1074/jbc.M404343200; Ferreira-Pereira A, 2003, J BIOL CHEM, V278, P11995, DOI 10.1074/jbc.M212198200; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hogue DL, 1999, J MOL BIOL, V285, P379, DOI 10.1006/jmbi.1998.2259; Horn C, 2003, J MOL BIOL, V334, P403, DOI 10.1016/j.jmb.2003.09.079; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; JOBLING MG, 1990, NUCLEIC ACIDS RES, V18, P5315, DOI 10.1093/nar/18.17.5315; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Kuhnke G, 2006, MOL MEMBR BIOL, V23, P173, DOI 10.1080/09687860500473630; Kunji ERS, 2003, BBA-BIOMEMBRANES, V1610, P97, DOI 10.1016/S0005-2736(02)00712-5; Lapinski PE, 2003, J BIOL CHEM, V278, P8229, DOI 10.1074/jbc.M208930200; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Meisinger C, 2000, ANAL BIOCHEM, V287, P339, DOI 10.1006/abio.2000.4868; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1170, DOI 10.1021/bi026555j; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; Ravaud S, 2006, BIOCHEM J, V395, P345, DOI 10.1042/BJ20051719; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shirihai OS, 2000, EMBO J, V19, P2492, DOI 10.1093/emboj/19.11.2492; Sorzano COS, 2004, J STRUCT BIOL, V148, P194, DOI 10.1016/j.jsb.2004.06.006; Uebel S, 1997, P NATL ACAD SCI USA, V94, P8976, DOI 10.1073/pnas.94.17.8976; UEBEL S, 1995, J BIOL CHEM, V270, P18512, DOI 10.1074/jbc.270.31.18512; van der Does C, 2006, J BIOL CHEM, V281, P5694, DOI 10.1074/jbc.M511730200; van der Does C, 2004, BIOL CHEM, V385, P927, DOI 10.1515/BC.2004.121; van der Does C, 2003, METHOD ENZYMOL, V372, P86; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van der Laan M, 2001, EMBO REP, V2, P519, DOI 10.1093/embo-reports/kve106; van der Sluis EO, 2002, FEBS LETT, V527, P159, DOI 10.1016/S0014-5793(02)03202-7; Velarde G, 2001, J BIOL CHEM, V276, P46054, DOI 10.1074/jbc.M108435200; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wada S, 2002, J BIOL CHEM, V277, P46809, DOI 10.1074/jbc.M207817200; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3; Wolters JC, 2005, J BIOL CHEM, V280, P23631, DOI 10.1074/jbc.M503231200; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957; Zhang F, 2000, FEBS LETT, V478, P89, DOI 10.1016/S0014-5793(00)01823-8	64	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3951	3961		10.1074/jbc.M609899200	http://dx.doi.org/10.1074/jbc.M609899200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17150958	Green Published, hybrid			2022-12-25	WOS:000244481900059
J	Chau, BN; Pan, CW; Wang, JYJ				Chau, B. Nelson; Pan, Chris W.; Wang, Jean Y. J.			Separation of Anti-Proliferation and Anti-Apoptotic Functions of Retinoblastoma Protein through Targeted Mutations of Its A/B Domain	PLOS ONE			English	Article							TUMOR-SUPPRESSOR PROTEIN; BINDING DOMAIN; CELL-DEATH; RB; E2F; INHIBITION; PRB; PHOSPHORYLATION; ARREST; GENE	Background. The human retinoblastoma susceptibility gene encodes a nuclear phosphoprotein RB, which is a negative regulator of cell proliferation. The growth suppression function of RB requires an evolutionarily conserved A/B domain that contains two distinct peptide-binding pockets. At the A/B interface is a binding site for the C-terminal trans-activation domain of E2F. Within the B-domain is a binding site for proteins containing the LxCxE peptide motif. Methodology/Principle Findings. Based on the crystal structure of the A/B domain, we have constructed an RB-K530A/N757F (KN) mutant to disrupt the E2F- and LxCxE-binding pockets. The RB-K530A (K) mutant is sufficient to inactivate the E2F-binding pocket, whereas the RB-N757F (N) mutant is sufficient to inactivate the LxCxE-binding pocket. Each single mutant inhibits cell proliferation, but the RB-KN double mutant is defective in growth suppression. Nevertheless, the RB-KN mutant is capable of reducing etoposide-induced apoptosis. Conclusion/Significance. Previous studies have established that RB-dependent G1-arrest can confer resistance to DNA damage-induced apoptosis. Results from this study demonstrate that RB can also inhibit apoptosis independent of growth suppression.	[Chau, B. Nelson; Pan, Chris W.; Wang, Jean Y. J.] Univ Calif San Diego, Dept Med, Div Hematol Oncol, Moores UCSD Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Wang, JYJ (corresponding author), Univ Calif San Diego, Dept Med, Div Hematol Oncol, Moores UCSD Canc Ctr, La Jolla, CA 92093 USA.	jywang@ucsd.edu			NIH-NCI (USA) [CA58320]; Damon Runyon Medical Research Foundation Postdoctoral Fellowship; NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER	NIH-NCI (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Damon Runyon Medical Research Foundation Postdoctoral Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	NIH-NCI (USA) CA58320 to JYJW; Damon Runyon Medical Research Foundation Postdoctoral Fellowship (BNC)	Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; CAVENEE W, 1984, AM J HUM GENET, V36, P10; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Goodrich DW, 2006, ONCOGENE, V25, P5233, DOI 10.1038/sj.onc.1209616; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Masselli A, 2006, ONCOGENE, V25, P1290, DOI 10.1038/sj.onc.1209161; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Ross JF, 2001, GENE DEV, V15, P392, DOI 10.1101/gad.858501; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Wang JYJ, 2005, CELL RES, V15, P43, DOI 10.1038/sj.cr.7290263; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; Xiao H, 2005, ONCOGENE, V24, P8105, DOI 10.1038/sj.onc.1208958	34	21	21	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e82	10.1371/journal.pone.0000082	http://dx.doi.org/10.1371/journal.pone.0000082			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183714	Green Published, gold			2022-12-25	WOS:000207443600082
J	Drake, JM; Chew, SK; Ma, S				Drake, John M.; Chew, Suok Kai; Ma, Stefan			Societal Learning in Epidemics: Intervention Effectiveness during the 2003 SARS Outbreak in Singapore	PLOS ONE			English	Article							ACUTE RESPIRATORY SYNDROME; TRANSMISSION DYNAMICS; SPREAD; MODELS; AGENT	Background. Rapid response to outbreaks of emerging infectious diseases is impeded by uncertain diagnoses and delayed communication. Understanding the effect of inefficient response is a potentially important contribution of epidemic theory. To develop this understanding we studied societal learning during emerging outbreaks wherein patient removal accelerates as information is gathered and disseminated. Methods and Findings. We developed an extension of a standard outbreak model, the simple stochastic epidemic, which accounts for societal learning. We obtained expressions for the expected outbreak size and the distribution of epidemic duration. We found that rapid learning noticeably affects the final outbreak size even when learning exhibits diminishing returns (relaxation). As an example, we estimated the learning rate for the 2003 outbreak of severe acute respiratory syndrome (SARS) in Singapore. Evidence for relaxation during the first eight weeks of the outbreak was inconclusive. We estimated that if societal learning had occurred at half the actual rate, the expected final size of the outbreak would have reached nearly 800 cases, more than three times the observed number of infections. By contrast, the expected outbreak size for societal learning twice as effective was 116 cases. Conclusion. These results show that the rate of societal learning can greatly affect the final size of disease outbreaks, justifying investment in early warning systems and attentiveness to disease outbreak by both government authorities and the public. We submit that the burden of emerging infections, including the risk of a global pandemic, could be efficiently reduced by improving procedures for rapid detection of outbreaks, alerting public health officials, and aggressively educating the public at the start of an outbreak.	[Drake, John M.] Natl Ctr Ecol Anal & Synth, Santa Barbara, CA USA; [Chew, Suok Kai; Ma, Stefan] Minist Hlth, Singapore, Singapore	National Center for Ecological Analysis & Synthesis; Ministry of Health-Singapore	Drake, JM (corresponding author), Univ Georgia, Inst Ecol, Athens, GA 30602 USA.	jdrake@uga.edu	Drake, John/D-6622-2012	Drake, John/0000-0003-4646-1235	NSF [DEB0072909]; University of California; Santa Barbara campus	NSF(National Science Foundation (NSF)); University of California(University of California System); Santa Barbara campus	This work was conducted while J. M. D was a Postdoctoral Associate at the National Center for Ecological Analysis and Synthesis, a Center funded by NSF (Grant#DEB0072909), the University of California, and the Santa Barbara campus.	ANDERSON R M, 1991; Anderson RM, 2004, PHILOS T R SOC B, V359, P1091, DOI 10.1098/rstb.2004.1490; [Anonymous], 1999, EPIDEMIC MODELLING I; [Anonymous], 2013, WHOCDSCSRGAR2003; Bailey N. T. J., 1964, ELEMENTS STOCHASTIC; Barnett DJ, 2005, PLOS MED, V2, P1235, DOI 10.1371/journal.pmed.0020359; Dodd SC, 1952, AM SOCIOL REV, V17, P167, DOI 10.2307/2087656; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Drake JM, 2006, PLOS MED, V3, P57, DOI 10.1371/journal.pmed.0030003; Ferrari MJ, 2005, MATH BIOSCI, V198, P14, DOI 10.1016/j.mbs.2005.08.002; GILLESPIE DT, 1976, J COMPUT PHYS, V22, P403, DOI 10.1016/0021-9991(76)90041-3; Hartley DM, 2003, LANCET, V362, P170, DOI 10.1016/S0140-6736(03)13875-5; Holmes EC, 2005, SCIENCE, V309, P989, DOI 10.1126/science.1117128; Hsieh YH, 2004, EMERG INFECT DIS, V10, P1165, DOI 10.3201/eid1006.031023; James L, 2006, PUBLIC HEALTH, V120, P20, DOI 10.1016/j.puhe.2005.10.005; KENDALL DG, 1949, J R STAT SOC B, V11, P230; KENDALL DG, 1948, ANN MATH STAT, V19, P1, DOI 10.1214/aoms/1177730285; Kuk AYC, 2005, STAT MED, V24, P2525, DOI 10.1002/sim.2123; Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616; Lloyd AL, 2001, THEOR POPUL BIOL, V60, P59, DOI 10.1006/tpbi.2001.1525; Lloyd-Smith JO, 2005, NATURE, V438, P355, DOI 10.1038/nature04153; MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102; O'Toole Tara, 2003, Biosecur Bioterror, V1, P1, DOI 10.1089/15387130360514760; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Razum O, 2003, LANCET, V361, P1739, DOI 10.1016/S0140-6736(03)13335-1; Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478; Trapman P, 2004, J MATH BIOL, V49, P553, DOI 10.1007/s00285-004-0267-5; Wallinga J, 2004, AM J EPIDEMIOL, V160, P509, DOI 10.1093/aje/kwh255; Wearing HJ, 2005, PLOS MED, V2, P621, DOI 10.1371/journal.pmed.0020174; WHO, 2005, SUMM PROB SARS CAS O; Zhou GF, 2004, EMERG INFECT DIS, V10, P1167; Zhou GF, 2003, EMERG INFECT DIS, V9, P1608	32	21	21	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e20	10.1371/journal.pone.0000020	http://dx.doi.org/10.1371/journal.pone.0000020			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183647	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600020
J	Kosmider, O; Denis, N; Dubreuil, P; Moreau-Gachelin, F				Kosmider, O.; Denis, N.; Dubreuil, P.; Moreau-Gachelin, F.			Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate	ONCOGENE			English	Article						erythroleukemia; Kit; SU5416; semaxinib; imatinib mesylate	ACUTE MYELOID-LEUKEMIA; RECEPTOR TYROSINE KINASE; GASTROINTESTINAL STROMAL TUMORS; C-KIT; WILD-TYPE; INHIBITOR; MUTATIONS; MASTOCYTOSIS; ACTIVATION; GROWTH	Activating mutations in the Kit receptor are frequently observed in various malignancies, pointing Kit as a molecule of interest for drug inhibit ion. When mutated on Asp 816 (corresponding to Asp 814 in the mouse), as preferentially found in human mastocytosis and acute myeloid leukemia, Kit became non-sensitive to imatinib mesylate (Gleevec). Erythroleukemic cells isolated from Spi-1/PU.1 transgenic mice express Kit mutated at codon 814 (Kit(D814Y) or Kit(D814V)) or codon 818 (Kit(D818Y)). Using these cells in vitro, we demonstrate that the tyrosine kinase inhibitor SU5416 (Semaxinib) induces growth arrest and apoptosis independent of the mutation type by inhibiting the functions of Kit, including Kit autophosphorylation and activation of Akt, Erk1/Erk2 and Stat3 downstream signaling pathways. These findings indicate that SU5416 may be a promising tool to kill cancer cells driven by Kit oncogenic mutations that are resistant to treatment with imatinib mesylate.	Inst Curie, INSERM, U528, F-75248 Paris 05, France; Inst J Paoli I Calmettes, INSERM, UMR 599, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Moreau-Gachelin, F (corresponding author), Inst Curie, INSERM, U528, 26 Rue Ulm, F-75248 Paris 05, France.	framoreau@curie.fr	dubreuil, patrice/F-5346-2011; Dubreuil, Patrice/V-4816-2019	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; KOSMIDER, olivier/0000-0002-6021-4057				Akin C, 2004, BLOOD, V103, P3222, DOI 10.1182/blood-2003-11-3816; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Chen H, 2003, INT J CANCER, V105, P130, DOI 10.1002/ijc.11025; Fiedler W, 2003, BLOOD, V102, P2763, DOI 10.1182/blood-2002-10-2998; Fong TAT, 1999, CANCER RES, V59, P99; Giles FJ, 2003, BLOOD, V102, P795, DOI 10.1182/blood-2002-10-3023; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Heymach JV, 2004, CLIN CANCER RES, V10, P5732, DOI 10.1158/1078-0432.CCR-04-0157; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Itokawa T, 2002, MOL CANCER THER, V1, P295; Kosmider O, 2005, CANCER CELL, V8, P467, DOI 10.1016/j.ccr.2005.11.009; Krystal GW, 2001, CANCER RES, V61, P3660; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Mesters RM, 2001, BLOOD, V98, P241, DOI 10.1182/blood.V98.1.241; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; O'Farrell AM, 2004, LEUKEMIA RES, V28, P679, DOI 10.1016/j.leukres.2003.11.004; Pignon JM, 1997, BRIT J HAEMATOL, V96, P374, DOI 10.1046/j.1365-2141.1997.d01-2042.x; Smolich BD, 2001, BLOOD, V97, P1413, DOI 10.1182/blood.V97.5.1413; Wang YY, 2005, P NATL ACAD SCI USA, V102, P1104, DOI 10.1073/pnas.0408831102; Yee KWH, 2002, BLOOD, V100, P2941, DOI 10.1182/blood-2002-02-0531; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120	24	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3904	3908		10.1038/sj.onc.1210159	http://dx.doi.org/10.1038/sj.onc.1210159			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173066				2022-12-25	WOS:000247026400014
J	Tong, WM; Yang, YG; Cao, WH; Galendo, D; Frappart, L; Shen, Y; Wang, ZQ				Tong, W. M.; Yang, Y. G.; Cao, W. H.; Galendo, D.; Frappart, L.; Shen, Y.; Wang, Z. Q.			Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice	ONCOGENE			English	Article						breast cancer; DNA damage response; PARP-1; p53; BRCA1	DNA-DAMAGE RESPONSE; HUMAN BREAST-CANCER; TUMOR-FORMATION; HISTONE H2AX; P53; BRCA1; PARP-1; PHOSPHORYLATION; SUSCEPTIBILITY; DEFICIENT	The DNA strand break-binding molecule, poly(ADPribose) polymerase-1 (PARP-1), plays a role in DNA repair, chromosomal stability, transcription and cell death. Accumulating evidence suggests that dysfunction of PARP-1 contributes to tumorigenesis. Here, we report that PARP-1 deficiency causes mammary carcinoma formation in female mice, and that the introduction of Trp53 mutations accelerates the onset and shortens the latency of mammary tumorigenesis. We show that PARP1 deficiency results in chromosomal aneuploidy and centrosome amplification, which are substantiated by the inactivation of Trp53 in primary mammary epithelial (PME) cells. In addition, PARP-1 deficiency compromises p53 activation and impairs BRCA1 recruitment to the sites of DNA damage in PME cells. PARP-1 complementation partly rescues the defective DNA damage response mediated by p53 and BRCA1. The present study thus identifies a role of PARP-1 in suppressing mammary tumorigenesis in vivo and suggests that dysfunction of PARP-1 may be a risk factor for breast cancer in humans.	IARC, Pathol Grp, F-69008 Lyon, France; Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100037, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China; Hosp Edouard Herriot, Dept Pathol, Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC); Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; bioMerieux; CHU Lyon	Tong, WM (corresponding author), IARC, Pathol Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	tong@iarc.fr						Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Beneke R, 2001, ONCOGENE, V20, P8136, DOI 10.1038/sj.onc.1205056; Bieche I, 1996, CLIN CANCER RES, V2, P1163; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; De Soto Joseph A, 2006, Int J Med Sci, V3, P117; De Soto JA, 2006, INT J BIOL SCI, V2, P179; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Edwards PAW, 1996, J MAMMARY GLAND BIOL, V1, P75, DOI 10.1007/BF02096304; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao BT, 2004, CANCER RES, V64, P4378, DOI 10.1158/0008-5472.CAN-04-0372; Helleday T, 2005, CELL CYCLE, V4, P1176, DOI 10.4161/cc.4.9.2031; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Hu JJ, 1997, PHARMACOGENETICS, V7, P309, DOI 10.1097/00008571-199708000-00006; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kanai M, 2003, MOL CELL BIOL, V23, P2451, DOI 10.1128/MCB.23.7.2451-2462.2003; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Lebel M, 2003, AM J PATHOL, V162, P1559, DOI 10.1016/S0002-9440(10)64290-3; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lockett KL, 2004, CANCER RES, V64, P6344, DOI 10.1158/0008-5472.CAN-04-0338; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; MALKIN D, 1998, LI FRAUMENI SYNDROME, P393; Masutani M, 2003, GENE CHROMOSOME CANC, V38, P339, DOI 10.1002/gcc.10250; McCabe N, 2005, CANCER BIOL THER, V4, P934, DOI 10.4161/cbt.4.9.2141; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Nozaki T, 2003, CANCER SCI, V94, P497, DOI 10.1111/j.1349-7006.2003.tb01472.x; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rajaee-Behbahani N, 2002, INT J CANCER, V98, P780, DOI 10.1002/ijc.10234; Shibata A, 2005, ONCOGENE, V24, P1328, DOI 10.1038/sj.onc.1208289; Shiokawa M, 2005, JPN J CLIN ONCOL, V35, P97, DOI 10.1093/jjco/hyi028; STEWART BW, 2003, BREAST CANC WORLD CA; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; Tong WM, 2002, CANCER RES, V62, P6990; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; Turner JMA, 2004, CURR BIOL, V14, P2135, DOI 10.1016/j.cub.2004.11.032; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhang XM, 2005, CANCER RES, V65, P722	48	65	70	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3857	3867		10.1038/sj.onc.1210156	http://dx.doi.org/10.1038/sj.onc.1210156			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17160013				2022-12-25	WOS:000247026400009
J	Iotti, G; Ferrari-Amorotti, G; Rosafio, C; Corradini, F; Lidonnici, MR; Ronchetti, M; Bardini, M; Zhang, Y; Martinez, R; Blasi, F; Calabretta, B				Iotti, G.; Ferrari-Amorotti, G.; Rosafio, C.; Corradini, F.; Lidonnici, M. R.; Ronchetti, M.; Bardini, M.; Zhang, Y.; Martinez, R.; Blasi, F.; Calabretta, B.			Expression of CCL9/MIP-1 gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells	ONCOGENE			English	Article						CML; STI571; CCL9; transcription regulation; chemokine production; in vivo leukemogenesis	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; MULTIPOTENT HEMATOPOIETIC-CELLS; C/EBP-ALPHA EXPRESSION; PROTEIN-KINASE PATHWAY; BCR-ABL; CHEMOTACTIC RESPONSE; TRANSCRIPTION-FACTOR; IMATINIB MESYLATE; MOLECULAR-CLONING	Transformation of hematopoietic cells by the BCR/ABL oncogene is caused by perturbation of signal transduction pathways leading to altered patterns of gene expression and activity. By oligonucleotide microarray hybridization of polysomal RNA of untreated and STI571-treated 32DBCR/ABL cells, we identified the beta-chemokine CCL9 as a gene regulated by BCR/ABL in a tyrosine kinasedependent manner. BCR/ABL repressed CCL9 expression at the transcriptional level by mechanisms involving suppression of p38 MAP kinase, and modulation of the activity of CDP/cut and C/EBP alpha, two transcription regulators of myeloid differentiation. However, repression of C/EBP-dependent transcription did not prevent the induction of CCL9 expression by STI571, suggesting that C/EBP alpha is involved in maintaining rather than in inducing CCL9 expression. Restoration of CCL9 expression in 32D-BCR/ABL cells had no effect on the in vitro proliferation of these cells, but reduced their leukemogenic potential in vivo, possibly by recruitment of CD3-positive immune cells. Together, these findings suggest that downregulation of chemokine expression may be involved in BCR/ABL-dependent leukemogenesis by altering the relationship between transformed cells and the microenvironment.	Thomas Jefferson Med Coll, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Univ Modena, Dept Biomed Sci, I-41100 Modena, Italy; FIRC Inst Mol Oncol, IFOM, Milan, Italy; Wyeth Genet Inst, Cambridge, MA USA	Jefferson University; Universita di Modena e Reggio Emilia; IFOM - FIRC Institute of Molecular Oncology; Pfizer	Calabretta, B (corresponding author), Thomas Jefferson Med Coll, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.	B_Calabretta@mail.jci.tju.edu	Lidonnici, Maria Rosa/AAN-2208-2020	Lidonnici, Maria Rosa/0000-0003-3413-8414; Blasi, Francesco/0000-0001-9406-1784; BARDINI, MICHELA/0000-0002-6942-2274	PHS HHS [P01 78890] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Berahovich RD, 2005, J IMMUNOL, V174, P7341, DOI 10.4049/jimmunol.174.11.7341; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; EAVES CJ, 1993, P NATL ACAD SCI USA, V90, P12015, DOI 10.1073/pnas.90.24.12015; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Ferrari-Amorotti G, 2006, BLOOD, V108, P1353, DOI 10.1182/blood-2006-01-011833; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Geay JF, 2005, CANCER RES, V65, P2676, DOI 10.1158/0008-5472.CAN-04-2152; Guerzoni C, 2006, BLOOD, V107, P4080, DOI 10.1182/blood-2005-08-3181; HARA T, 1995, J IMMUNOL, V155, P5352; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; Jongen-Lavrencic M, 2005, LEUKEMIA, V19, P373, DOI 10.1038/sj.leu.2403626; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; KANTARJIAN HM, 1993, BLOOD, V82, P691; Khanna-Gupta A, 2003, BLOOD, V101, P3460, DOI 10.1182/blood-2002-09-2767; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Lane CM, 1999, MOL MED, V5, P55, DOI 10.1007/BF03402139; Lawson ND, 1998, BLOOD, V91, P2517, DOI 10.1182/blood.V91.7.2517.2517_2517_2524; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Mohamadzadeh M, 1996, J IMMUNOL, V156, P3102; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Okuda K, 1996, ONCOGENE, V13, P1147; Parmar S, 2004, J BIOL CHEM, V279, P25345, DOI 10.1074/jbc.M400590200; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Pierce A, 2002, ONCOGENE, V21, P3068, DOI 10.1038/sj.onc.1205424; POLTORAK AN, 1995, J INFLAMM, V45, P207; Ptasznik A, 2002, J EXP MED, V196, P667, DOI 10.1084/jem.20020519; Salgia R, 1999, BLOOD, V94, P4233; Sattler M, 2003, SEMIN HEMATOL, V40, P4, DOI 10.1053/shem.2003.50034; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schuster C, 2003, BLOOD, V101, P655, DOI 10.1182/blood-2002-01-0043; Tavor S, 2003, J BIOL CHEM, V278, P52651, DOI 10.1074/jbc.M307077200; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Wark G, 1998, ONCOGENE, V16, P1319, DOI 10.1038/sj.onc.1201914; Wong S, 2003, BLOOD, V101, P4088, DOI 10.1182/blood-2002-11-3376; YOUN BS, 1995, J IMMUNOL, V155, P2661	42	10	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3482	3491		10.1038/sj.onc.1210146	http://dx.doi.org/10.1038/sj.onc.1210146			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160016				2022-12-25	WOS:000246799200004
J	Kweon, MH; Afaq, F; Bhat, KMR; Setaluri, V; Mukhtar, H				Kweon, M-H; Afaq, F.; Bhat, K. M. R.; Setaluri, V.; Mukhtar, H.			A novel antioxidant 3-O-Caffeoyl-1-methylquinic acid enhances ultraviolet A-mediated apoptosis in immortalized HaCaT keratinocytes via Sp1-dependent transcriptional activation of p21(WAF1/Cip1)	ONCOGENE			English	Article						MCGA3; UVA; p21; Sp1; iron chelation	SIGNAL-REGULATED KINASE; CELL-CYCLE ARREST; IRON CHELATION; GROWTH ARREST; HYPOXIA; UVA; EXPRESSION; INDUCTION; P53; PROLIFERATION	It has become clearthat ultraviolet A (UVA) radiation from the solar spectrum is a major environmental challenge to the skin. This necessitates developing novel mechanism- based agents capable of ameliorating UVAinduced effects in the skin. We recently described a novel antioxidant, 3-O-Caffeoyl-1-methylquinic acid (MCGA3) from leaves of bamboo. Here, we investigated the photochemopreventive effects of MCGA3 against UVA mediated apoptosis in immortalized HaCaT keratinocytes. Pretreatment of MCGA3 rendered cells more sensitive to subsequent UVA irradiation-induced apoptosis as well as completely reversed UVA-induced sustained phosphorylation of extracellular signal-regulated kinase 1/2 and protein kinase C alpha, downregulation of p21, and reactive oxygen species generation. Interestingly, MCGA3 itself effectively induced p21 protein and mRNA levels. Silencing of p21 by RNA interference revealed a pivotal role of p21 in generating G(1)-S arrest and in enhancing UVA-mediated apoptosis. Transcriptional activation of p21 by MCGA3 was mediated through the proximal region of multiple Sp1 sites regardless of p53-binding site in p21 promoter, and this effect was augmented by desferroioxamine, an iron chelating agent. Additional studies suggested that iron chelation-driven hypoxia by MCGA3 may function in activation of p21. MCGA3 could be a useful agent to prevent photocarcinogenesis via apoptotic elimination of p53 mutant and DNA- repair defective cells caused by UVA radiation.	Univ Wisconsin, Dept Dermatol, Med Sci Ctr, Madison, WI 53706 USA; Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea	University of Wisconsin System; University of Wisconsin Madison; Korea University	Mukhtar, H (corresponding author), Univ Wisconsin, Dept Dermatol, Med Sci Ctr, 1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Bhat, Kumar/AAD-8831-2019	Bhat, Kumar/0000-0003-1805-3453; Bhat, Kumar MR/0000-0002-2346-6634	NCI NIH HHS [R01 CA78809, R01 CA101039] Funding Source: Medline; NIDDK NIH HHS [P50 DK065303] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078809, R01CA101039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abeysinghe RD, 2001, CARCINOGENESIS, V22, P1607, DOI 10.1093/carcin/22.10.1607; Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Baby SM, 2003, HISTOCHEM CELL BIOL, V120, P343, DOI 10.1007/s00418-003-0588-2; Bachelor MA, 2004, SEMIN CANCER BIOL, V14, P131, DOI 10.1016/j.semcancer.2003.09.017; Bianchi L, 1999, NUCLEIC ACIDS RES, V27, P4223, DOI 10.1093/nar/27.21.4223; Bossenmeyer-Pourie C, 2002, NEUROSCIENCE, V114, P869, DOI 10.1016/S0306-4522(02)00324-X; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Catalano A, 2005, EMBO J, V24, P170, DOI 10.1038/sj.emboj.7600502; Chung JH, 2003, FASEB J, V17, P1913, DOI 10.1096/fj.02-0914fje; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; Fan LJ, 2001, CANCER RES, V61, P1073; FUKUCHI K, 1995, BIOL CHEM H-S, V376, P627; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154; He YY, 2006, ONCOGENE, V25, P3680, DOI 10.1038/sj.onc.1209384; He YY, 2004, J BIOL CHEM, V279, P53867, DOI 10.1074/jbc.M405781200; Jiao Y, 2006, FREE RADICAL BIO MED, V40, P1152, DOI 10.1016/j.freeradbiomed.2005.11.003; Kallassy M, 1998, MOL CARCINOGEN, V21, P26, DOI 10.1002/(SICI)1098-2744(199801)21:1<26::AID-MC5>3.0.CO;2-N; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; Kweon MH, 2006, FREE RADICAL BIO MED, V40, P1349, DOI 10.1016/j.freeradbiomed.2005.12.002; Kweon MH, 2004, FREE RADICAL BIO MED, V36, P40, DOI 10.1016/j.freeradbiomed.2003.09.023; Kweon MH, 2001, J AGR FOOD CHEM, V49, P4646, DOI 10.1021/jf010514x; Martin BD, 1998, CHEM RES TOXICOL, V11, P1402, DOI 10.1021/tx9801559; Mukherjee S, 2005, J BIOL CHEM, V280, P17617, DOI 10.1074/jbc.M502278200; Patel V, 2002, CANCER RES, V62, P1401; Reagan-Shaw S, 2006, MOL CANCER THER, V5, P418, DOI 10.1158/1535-7163.MCT-05-0250; Song HJ, 2005, J PHARMACOL EXP THER, V312, P391, DOI 10.1124/jpet.104.074401; Valencia A, 2006, FREE RADICAL BIO MED, V40, P641, DOI 10.1016/j.freeradbiomed.2005.09.036; Wang SW, 2000, AM J PHYSIOL-CELL PH, V279, pC868, DOI 10.1152/ajpcell.2000.279.3.C868; Wanner R, 2002, J MOL MED, V80, P61, DOI 10.1007/s00109-001-0288-0	34	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3559	3571		10.1038/sj.onc.1210135	http://dx.doi.org/10.1038/sj.onc.1210135			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17146435				2022-12-25	WOS:000246799200012
J	Jang, H; Choi, DE; Kim, H; Cho, EJ; Youn, HD				Jang, Hyonchol; Choi, Doo-Eun; Kim, Hyungsoo; Cho, Eun-Jung; Youn, Hong-Duk			Cabin1 represses MEF2 transcriptional activity by association with a methyltransferase, SUV39H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCYTE ENHANCER FACTOR-2; HISTONE H3; LYSINE-9 METHYLATION; DEACETYLASE; HP1; DIFFERENTIATION; DEMETHYLATION; CALCINEURIN; EXPRESSION; REGULATOR	Myocyte enhancer factor 2 ( MEF2) plays pivotal roles in various biological processes, and its transcriptional activity is regulated by histone acetylation/deacetylation enzymes in a calcium-dependent fashion. A calcineurin-binding protein 1 ( Cabin1) has been shown to participate in repression of MEF2 by recruiting mSin3 and its associated histone deacetylases. Here, we report that histone methylation also takes a part in Cabin1-mediated repression of MEF2. Immunoprecipitate of Cabin1 complex can methylate histone H3 by association with SUV39H1. SUV39H1 increased Cabin1-mediated repression of MEF2 transcriptional activity in MEF2-targeting promoters. The SUV39H1 was revealed to bind to the 501-900-amino acid region of Cabin1, which was distinct from its histone deacetylase-recruiting domain. In addition, the Gal4-Cabin1-( 501-900) alone repressed a constitutively active Gal4-tk-promoter, indicating that Cabin1 recruits SUV39H1 and represses transcriptional activity. Finally, both SUV39H1 and Cabin1 were shown to bind on the MEF2 target promoter in a calcium-dependent manner. Thus, Cabin1 recruits chromatin-modifying enzymes, both histone deacetylases and a histone methyltransferase, to repress MEF2 transcriptional activity.	Seoul Natl Univ, Coll Med, Dept Biochem & Mol Bil, Canc Res Inst,Interdisciplinary Program Genet Eng, Seoul 110799, South Korea; Sungkyunkwan Univ, Coll Pharm, Suwon 440746, South Korea	Seoul National University (SNU); Sungkyunkwan University (SKKU)	Youn, HD (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Bil, Canc Res Inst,Interdisciplinary Program Genet Eng, 28 Yongon Dong, Seoul 110799, South Korea.	hdyoun@snu.ac.kr	Jang, Hyonchol/F-6217-2012; Youn, Hong-Duk/J-2774-2012; Cho, Eun-Jung/AAR-1785-2020	Cho, Eun-Jung/0000-0002-6610-5329; Kim, Hyungsoo/0000-0002-8189-5939; Jang, Hyonchol/0000-0003-1436-457X				Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Brand NJ, 1997, INT J BIOCHEM CELL B, V29, P1467, DOI 10.1016/S1357-2725(97)00084-8; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chan JKL, 2003, J BIOL CHEM, V278, P23515, DOI 10.1074/jbc.M301922200; Chikashige Y, 2006, CELL, V125, P59, DOI 10.1016/j.cell.2006.01.048; Featherstone M, 2002, CURR OPIN GENET DEV, V12, P149, DOI 10.1016/S0959-437X(02)00280-0; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Flavell SW, 2006, SCIENCE, V311, P1008, DOI 10.1126/science.1122511; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; Heidenreich KA, 2004, MOL NEUROBIOL, V29, P155, DOI 10.1385/MN:29:2:155; Kim H, 2003, CANCER RES, V63, P6135; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Roopra A, 2004, MOL CELL, V14, P727, DOI 10.1016/j.molcel.2004.05.026; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Shalizi A, 2006, SCIENCE, V311, P1012, DOI 10.1126/science.1122513; Shalizi AK, 2005, CURR TOP DEV BIOL, V69, P239, DOI 10.1016/S0070-2153(05)69009-6; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Wang HB, 2003, MOL CELL, V12, P475, DOI 10.1016/j.molcel.2003.08.007; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wu R, 2005, MOL BIOL CELL, V16, P2872, DOI 10.1091/mbc.e04-11-0997; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Zhang CL, 2002, MOL CELL BIOL, V22, P7302, DOI 10.1128/MCB.22.20.7302-7312.2002; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	45	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11172	11179		10.1074/jbc.M611199200	http://dx.doi.org/10.1074/jbc.M611199200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17172641	hybrid			2022-12-25	WOS:000245941500038
J	Collins, CR; Withers-Martinez, C; Bentley, GA; Batchelor, AH; Thomas, AW; Blackman, MJ				Collins, Christine R.; Withers-Martinez, Chrislaine; Bentley, Graham A.; Batchelor, Adrian H.; Thomas, Alan W.; Blackman, Michael J.			Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-YOELII-YOELII; BLOOD-STAGE VACCINE; ERYTHROCYTE INVASION; SEQUENCE-ANALYSIS; PASSIVE-IMMUNIZATION; IMMUNE-RESPONSES; SURFACE-ANTIGEN; CLINICAL-TRIAL; PROTECTS MICE; I AMA-1	Antibodies that inhibit red blood cell invasion by the Plasmodium merozoite block the erythrocytic cycle responsible for clinical malaria. The invasion-inhibitory monoclonal antibody (mAb) 4G2 recognizes a conserved epitope in the ectodomain of the essential Plasmodium falciparum microneme protein and vaccine candidate, apical membrane antigen 1 (PfAMA1). Here we demonstrate that purified Fab fragments of 4G2 inhibit invasion markedly more efficiently than the intact mAb, suggesting that the invasion-inhibitory activity of this mAb is not due solely to steric effects and that the epitope lies within a functionally critical region of the molecule. We have taken advantage of a synthetic gene encoding a modified form of PfAMA1, and existing x-ray crystal structure data, to fully characterize this epitope. We first validate the gene by demonstrating that it fully complements the function of the authentic gene in P. falciparum. We then use it to identify a group of residues within the previously described domain 11 loop of PfAMA1 that are critical for recognition by mAb 4G2 and demonstrate that the epitope lies exclusively within this loop with no contributions from residues in other domains of the molecule. This is the first complete characterization of a conserved invasion-inhibitory epitope on PfAMA1. Our results will aid in the design of subunit vaccines designed to generate a broadly effective, focused anti-PfAMA1 protective immune response and may help elucidate the function of PfAMA1.	Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; Inst Pasteur, Unite Immunol Struct, CNRS, URA 2185,Dept Biol Struct & Chim, F-75724 Paris 15, France; Biomed Primate Res Ctr, NL-2280 GH Rijswijk, Netherlands	MRC National Institute for Medical Research; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Blackman, MJ (corresponding author), Natl Inst Med Res, Div Parasitol, Mill Hill, London NW7 1AA, England.	mblackm@nimr.mrc.ac.uk	Bentley, Graham/B-3623-2011		Medical Research Council [MC_U117532063] Funding Source: Medline; MRC [MC_U117532063] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alexander DL, 2006, EUKARYOT CELL, V5, P1169, DOI 10.1128/EC.00040-06; Alexander DL, 2005, PLOS PATHOG, V1, P137, DOI 10.1371/journal.ppat.0010017; Anders RF, 1998, VACCINE, V16, P240, DOI 10.1016/S0264-410X(97)88331-4; Bai T, 2005, P NATL ACAD SCI USA, V102, P12736, DOI 10.1073/pnas.0501808102; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bannister LH, 2003, J CELL SCI, V116, P3825, DOI 10.1242/jcs.00665; BLACKMAN MJ, 1994, METHOD CELL BIOL, V45, P213; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURGHAUS PA, 1994, MOL BIOCHEM PARASIT, V64, P165, DOI 10.1016/0166-6851(94)90144-9; CHENG Q, 1994, MOL BIOCHEM PARASIT, V65, P183, DOI 10.1016/0166-6851(94)90127-9; Chesne-Seck ML, 2005, MOL BIOCHEM PARASIT, V144, P55, DOI 10.1016/j.molbiopara.2005.07.007; Coley AM, 2006, INFECT IMMUN, V74, P2628, DOI 10.1128/IAI.74.5.2628-2636.2006; COLLINS WE, 1994, AM J TROP MED HYG, V51, P711, DOI 10.4269/ajtmh.1994.51.711; Cortes A, 2003, INFECT IMMUN, V71, P1416, DOI 10.1128/IAI.71.3.1416-1426.2003; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; Crewther PE, 1996, INFECT IMMUN, V64, P3310, DOI 10.1128/IAI.64.8.3310-3317.1996; DEANS JA, 1982, CLIN EXP IMMUNOL, V49, P297; DEANS JA, 1988, PARASITE IMMUNOL, V10, P535, DOI 10.1111/j.1365-3024.1988.tb00241.x; Donahue CG, 2000, MOL BIOCHEM PARASIT, V111, P15, DOI 10.1016/S0166-6851(00)00289-9; Dutta S, 2005, INFECT IMMUN, V73, P2116, DOI 10.1128/IAI.73.4.2116-2122.2005; DUTTA S, 1995, MOL BIOCHEM PARASIT, V73, P267, DOI 10.1016/0166-6851(95)00112-E; Dutta S, 2003, P NATL ACAD SCI USA, V100, P12295, DOI 10.1073/pnas.2032858100; EPSTEIN N, 1981, J IMMUNOL, V127, P212; Fraser TS, 2001, MOL BIOCHEM PARASIT, V117, P49, DOI 10.1016/S0166-6851(01)00326-7; Gaffar FR, 2004, INFECT IMMUN, V72, P2947, DOI 10.1128/IAI.72.5.2947-2955.2004; Harris PK, 2005, PLOS PATHOG, V1, P241, DOI 10.1371/journal.ppat.0010029; Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; Healer J, 2002, INFECT IMMUN, V70, P5751, DOI 10.1128/IAI.70.10.5751-5758.2002; Healer J, 2004, MOL MICROBIOL, V52, P159, DOI 10.1111/j.1365-2958.2003.03974.x; Hehl AB, 2000, INFECT IMMUN, V68, P7078, DOI 10.1128/IAI.68.12.7078-7086.2000; HEIDRICH HG, 1982, J PARASITOL, V68, P443, DOI 10.2307/3280956; Hodder AN, 1996, J BIOL CHEM, V271, P29446, DOI 10.1074/jbc.271.46.29446; Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001; Howell SA, 2005, MOL MICROBIOL, V57, P1342, DOI 10.1111/j.1365-2958.2005.04772.x; Howell SA, 2003, J BIOL CHEM, V278, P23890, DOI 10.1074/jbc.M302160200; Howell SA, 2001, J BIOL CHEM, V276, P31311, DOI 10.1074/jbc.M103076200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kappe SHI, 1996, MOL BIOCHEM PARASIT, V78, P279, DOI 10.1016/S0166-6851(96)02619-9; Kato K, 2005, P NATL ACAD SCI USA, V102, P5552, DOI 10.1073/pnas.0501594102; Kocken CHM, 1998, J BIOL CHEM, V273, P15119, DOI 10.1074/jbc.273.24.15119; Kocken CHM, 2002, INFECT IMMUN, V70, P4471, DOI 10.1128/IAI.70.8.4471-4476.2002; Langermans JAM, 2006, HUM VACCINES, V2, P222, DOI 10.4161/hv.2.5.3276; Malkin EM, 2005, INFECT IMMUN, V73, P3677, DOI 10.1128/IAI.73.6.3677-3685.2005; MARSHALL VM, 1989, MOL BIOCHEM PARASIT, V37, P281, DOI 10.1016/0166-6851(89)90160-6; Miao J, 2006, VACCINE, V24, P6187, DOI 10.1016/j.vaccine.2006.05.099; Mital J, 2005, MOL BIOL CELL, V16, P4341, DOI 10.1091/mbc.E05-04-0281; Mitchell GH, 2004, INFECT IMMUN, V72, P154, DOI 10.1128/IAI.72.1.154-158.2004; Narum DL, 2006, INFECT IMMUN, V74, P5529, DOI 10.1128/IAI.00573-06; NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5; Narum DL, 2000, INFECT IMMUN, V68, P2899, DOI 10.1128/IAI.68.5.2899-2906.2000; O'Donnell RA, 2006, J CELL BIOL, V174, P1023, DOI 10.1083/jcb.200604136; PETERSON MG, 1989, MOL CELL BIOL, V9, P3151, DOI 10.1128/MCB.9.7.3151; PETERSON MG, 1990, MOL BIOCHEM PARASIT, V39, P279, DOI 10.1016/0166-6851(90)90067-V; Pizarro JC, 2005, SCIENCE, V308, P408, DOI 10.1126/science.1107449; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Saul A, 2005, VACCINE, V23, P3076, DOI 10.1016/j.vaccine.2004.09.040; Silvie O, 2004, J BIOL CHEM, V279, P9490, DOI 10.1074/jbc.M311331200; THOMAS AW, 1984, MOL BIOCHEM PARASIT, V13, P187, DOI 10.1016/0166-6851(84)90112-9; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x; WATERS AP, 1991, MOL BIOCHEM PARASIT, V44, P141, DOI 10.1016/0166-6851(91)90230-4; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; Withers-Martinez C, 1999, PROTEIN ENG, V12, P1113, DOI 10.1093/protein/12.12.1113; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973; Zhou JL, 2006, EXP PARASITOL, V114, P329, DOI 10.1016/j.exppara.2006.04.012	65	79	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7431	7441		10.1074/jbc.M610562200	http://dx.doi.org/10.1074/jbc.M610562200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17192270	hybrid			2022-12-25	WOS:000245080900055
J	Kreimeyer, A; Perret, A; Lechaplais, C; Vallenet, D; Medigue, C; Salanoubat, M; Weissenbach, J				Kreimeyer, Annett; Perret, Alain; Lechaplais, Christophe; Vallenet, David; Medigue, Claudine; Salanoubat, Marcel; Weissenbach, Jean			Identification of the last unknown genes in the fermentation pathway of lysine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERMENTING CLOSTRIDIUM; FUSOBACTERIUM-NUCLEATUM; PURIFICATION; BREVIBACTERIUM; DEHYDROGENASE; DEGRADATION; CLONING; ACID; 3-KETO-5-AMINOHEXANOATE; 3,5-DIAMINOHEXANOATE	Although the proteins of the lysine fermentation pathway were biochemically characterized more than thirty years ago, the genes encoding the proteins that catalyze three steps of this pathway are still unknown. We combined gene context, similarity of enzymatic mechanisms, and molecular weight comparisons with known proteins to select candidate genes for these three orphan proteins. We used a wastewater metagenomic collection of sequences to find and characterize the missing genes of the lysine fermentation pathway. After recombinant protein production and purification following cloning in Escherichia coli, we demonstrated that these genes (named kdd, kce, and kal) encode a L-erythro-3,5-diaminohexanoate dehydrogenase, a 3-keto-5-aminohexanoate cleavage enzyme, and a 3-aminobutyryl-CoA ammonia lyase, respectively. Because all of the genes of the pathway are now identified, we used this breakthrough to detect lysine-fermenting bacteria in sequenced genomes. We identified twelve bacteria that possess these genes and thus are expected to ferment lysine, and their gene organization is discussed.	CNRS, UMR 8030, F-91057 Evry, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA	Kreimeyer, A (corresponding author), CNRS, UMR 8030, 2 Rue Gaston Cremieux, F-91057 Evry, France.	akreimey@genoscope.cns.fr; aperret@genoscope.cns.fr		Vallenet, David/0000-0001-6648-0332; PERRET, Alain/0000-0002-8896-1978				BAILEY J, 1982, J BIOL CHEM, V257, P5579; BAKER J J, 1974, Biochemistry, V13, P292, DOI 10.1021/bi00699a010; BAKER JJ, 1972, J BIOL CHEM, V247, P7724; BARKER HA, 1980, J BACTERIOL, V143, P1165, DOI 10.1128/JB.143.3.1165-1170.1980; BARKER HA, 1982, J BACTERIOL, V152, P201; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; Chang CH, 2000, J BIOL CHEM, V275, P106, DOI 10.1074/jbc.275.1.106; Chouari R, 2005, APPL ENVIRON MICROB, V71, P2145, DOI 10.1128/AEM.71.4.2145-2153.2005; CorthesyTheulaz IE, 1997, J BIOL CHEM, V272, P25659, DOI 10.1074/jbc.272.41.25659; DOHNER PM, 1954, J BACTERIOL, V67, P608, DOI 10.1128/JB.67.5.608-611.1954; Herrmann G, 2005, FEBS J, V272, P813, DOI 10.1111/j.1742-4658.2004.04518.x; HONG SCL, 1972, J BACTERIOL, V112, P231, DOI 10.1128/JB.112.1.231-234.1972; HONG SL, 1973, J BIOL CHEM, V248, P41; JENG I, 1974, J BIOL CHEM, V249, P6578; LOESCHE WJ, 1968, ARCH ORAL BIOL, V13, P191, DOI 10.1016/0003-9969(68)90051-4; MORIYAMA T, 1971, J BIOL CHEM, V246, P3217; RIMERMAN EA, 1968, J BIOL CHEM, V243, P6151; Ruzicka FJ, 2000, J BACTERIOL, V182, P469, DOI 10.1128/JB.182.2.469-476.2000; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STADTMAN TC, 1973, ADV ENZYMOL RAMB, V38, P413; STADTMAN TC, 1954, J BACTERIOL, V67, P651, DOI 10.1128/JB.67.6.651-657.1954; Vallenet D, 2006, NUCLEIC ACIDS RES, V34, P53, DOI 10.1093/nar/gkj406; WILLIAMSON DH, 1962, BIOCHEM J, V82, P90, DOI 10.1042/bj0820090; YORIFUJI T, 1977, J BIOL CHEM, V252, P20	24	51	91	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7191	7197		10.1074/jbc.M609829200	http://dx.doi.org/10.1074/jbc.M609829200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17166837	hybrid			2022-12-25	WOS:000245080900031
J	Gao, XP; Zhu, XD; Fu, J; Liu, QH; Frey, RS; Malik, AB				Gao, Xiao-Pei; Zhu, Xiangdong; Fu, Jian; Liu, Qinghui; Frey, Randall S.; Malik, Asrar B.			Blockade of class IA phosphoinositide 3-kinase in neutrophils prevents NADPH oxidase activation- and adhesion-dependent inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ADHERENT HUMAN NEUTROPHILS; FACTOR-ALPHA; RESPIRATORY BURST; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOTHELIAL-CELLS; HUMAN EOSINOPHILS; REACTIVE OXYGEN; TNF RECEPTOR; LUNG INJURY	We examined the role of class IA phosphoinositide 3-kinase (PI3K) in the regulation of activation of NADPH oxidase in PMNs and the mechanism of PMN-dependent lung inflammation and microvessel injury induced by the pro-inflammatory cytokine TNF-alpha. TNF-alpha stimulation of PMNs resulted in superoxide production that was dependent on CD11b/CD18-mediated PMN adhesion. Additionally, TNF-a induced the association of CD11b/CD18 with the NADPH oxidase subunit Nox2 (gp91(phox)) and phosphorylation of p47(phox), indicating the CD11b/CD18 dependence of NADPH oxidase activation. Transduction of wild-type PMNs with Delta p85 protein, a dominant-negative form of the class IA PI3K regulatory subunit, p85 alpha, fused to HIV-TAT (TAT-Delta p85) prevented (i) CD11b/CD18-dependent PMN adhesion, (ii) interaction of CD11b/CD18 with Nox2 and phosphorylation of p47(phox), and (iii) PMN oxidant production. Furthermore, studies in mice showed that i.v. infusion of TAT Delta p85 significantly reduced the recruitment of pMNs in lungs and increase in lung microvascular permeability induced by TNF-a. We conclude that class IA PI3K serves as a nodal point regulating CD11b/CD18-integrin-dependent PMN adhesion and activation of NADPH oxidase, and leads to oxidant production at sites of PMN adhesion, and the resultant lung microvascular injury in mice.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60612 USA; Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Malik, AB (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	abmalik@uic.edu		zhu, xiangdong/0000-0002-5627-8082; Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [HL77806, HL45638, HL46350, HL64573] Funding Source: Medline; NIAID NIH HHS [AI52109] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064573, R01HL046350, P01HL077806, R01HL045638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI052109] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Balazovich KJ, 1996, BLOOD, V88, P690, DOI 10.1182/blood.V88.2.690.bloodjournal882690; BARNARD JW, 1995, J IMMUNOL, V155, P4876; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Boulven I, 2006, J IMMUNOL, V176, P7621, DOI 10.4049/jimmunol.176.12.7621; Chen QD, 2003, J IMMUNOL, V170, P5302, DOI 10.4049/jimmunol.170.10.5302; Dang PMC, 1999, J BIOL CHEM, V274, P20704, DOI 10.1074/jbc.274.29.20704; DAPINO P, 1993, CLIN EXP IMMUNOL, V94, P533; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Ding ZM, 1999, J IMMUNOL, V163, P5029; Frey RS, 2006, J BIOL CHEM, V281, P16128, DOI 10.1074/jbc.M508810200; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Gao XP, 2005, PHYSIOL GENOMICS, V21, P230, DOI 10.1152/physiolgenomics.00291.2004; Gao XP, 2002, J IMMUNOL, V168, P3974, DOI 10.4049/jimmunol.168.8.3974; Gao XP, 2001, J IMMUNOL, V167, P2895, DOI 10.4049/jimmunol.167.5.2895; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Kitagawa Y, 1997, J APPL PHYSIOL, V82, P1397, DOI 10.1152/jappl.1997.82.5.1397; Korchak HM, 2001, BIOCHEM BIOPH RES CO, V281, P651, DOI 10.1006/bbrc.2001.4406; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; LAUDANNA C, 1993, BIOCHEM BIOPH RES CO, V190, P935, DOI 10.1006/bbrc.1993.1139; Lin P, 2005, J IMMUNOL, V174, P2981, DOI 10.4049/jimmunol.174.5.2981; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Mukherjee G, 1998, ARCH BIOCHEM BIOPHYS, V357, P164, DOI 10.1006/abbi.1998.0807; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Myou S, 2003, J EXP MED, V198, P1573, DOI 10.1084/jem.20030298; Myou S, 2003, J IMMUNOL, V171, P4399, DOI 10.4049/jimmunol.171.8.4399; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; RICHTER J, 1995, J IMMUNOL, V154, P4142; Sano M, 2005, AM J RESP CELL MOL, V33, P65, DOI 10.1165/rcmb.2005-0076OC; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Serrander L, 1999, BBA-MOL CELL RES, V1452, P133, DOI 10.1016/S0167-4889(99)00123-8; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672, DOI 10.1002/jlb.56.6.672; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Ushio-Fukai M, 2006, SCI STKE, V2006, pre8, DOI DOI 10.1126/STKE.3492006RE8; Vaporciyan Ara A., 1993, Biological Signals, V2, P126; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; WINDSOR ACJ, 1993, J CLIN INVEST, V91, P1459, DOI 10.1172/JCI116351; Wymann MP, 2000, IMMUNOL TODAY, V21, P260, DOI 10.1016/S0167-5699(00)01649-2; Yamamori T, 2004, BIOCHEM BIOPH RES CO, V316, P720, DOI 10.1016/j.bbrc.2004.02.108; Zhao TM, 2003, J CLIN INVEST, V112, P1732, DOI 10.1172/JCI200319108	49	41	42	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6116	6125		10.1074/jbc.M610248200	http://dx.doi.org/10.1074/jbc.M610248200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17197441	hybrid			2022-12-25	WOS:000244867200017
J	Louis, E; Boschi, CDE; Ortega, GJ; Fernandez, E				Louis, E.; Boschi, C. Degli Esposti; Ortega, G. J.; Fernandez, E.			Role of transport performance for neuron cell morphology	FASEB JOURNAL			English	Article						compartmental model; passive properties	JUNCTION-CONNECTED CELLS; ELECTRICAL-PROPERTIES; RETINA; NETWORKS; MODELS	The compartmental model is a basic tool for studying signal propagation in neurons; if the model parameters are adequately redefined, it can also be helpful in the study of electrical or fluid transport in other biological systems. Here we show that the input resistance in different networks that simulate the morphology of neurons is the result of the interplay between the relevant conductances, neuron morphology, and neuron size. The results suggest that neurons may grow in such a way that facilitates the current How to the synapses, concurrently minimizing power consumption.	Univ Miguel Hernandez, Fac Med, Dept Histol, Alicante 03550, Spain; Univ Miguel Hernandez, Fac Med, Inst Bioengn, Alicante 03550, Spain; Univ Alicante, Inst Univ Mat, IUMA, Dept Fis Aplicada, E-03080 Alicante, Spain; Univ Alicante, CSIC, Unidad Asociada, E-03080 Alicante, Spain; CNR, INFM, Unita Ric, CNISM Bologna, I-40126 Bologna, Italy; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fis, FCEN, RA-1428 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina	Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche; Universitat d'Alacant; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat d'Alacant; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Fernandez, E (corresponding author), Univ Miguel Hernandez, Fac Med, Dept Histol, Alicante 03550, Spain.	e.fernandez@umh.es	Fernandez, Eduardo/S-8206-2016; Degli Esposti Boschi, Cristian/AAF-8855-2020; Degli Esposti Boschi, Cristian/P-1559-2014	Fernandez, Eduardo/0000-0002-7052-6011; Degli Esposti Boschi, Cristian/0000-0002-3190-2985; Degli Esposti Boschi, Cristian/0000-0002-3190-2985; louis, enrique/0000-0001-8631-0189				Andreu E, 1997, J PHYSIOL-LONDON, V498, P753, DOI 10.1113/jphysiol.1997.sp021899; Andreu E, 2000, PFLUG ARCH EUR J PHY, V439, P789, DOI 10.1007/s004249900190; Bejan A, 1997, FRACTALS, V5, P685, DOI 10.1142/S0218348X97000553; Bejan A., 2000, SHAPE STRUCTURE ENG; CHERNIAK C, 1994, J NEUROSCI, V14, P2418; Chklovskii DB, 2000, J NEUROPHYSIOL, V83, P2113, DOI 10.1152/jn.2000.83.4.2113; Duijnhouwer J, 2001, NEUROCOMPUTING, V38, P183, DOI 10.1016/S0925-2312(01)00502-1; Fernandez E, 2001, METHODS, V24, P309, DOI 10.1006/meth.2001.1201; Fernandez-Ballesteros R, 1999, EUR J PSYCHOL ASSESS, V15, P1, DOI 10.1027//1015-5759.15.1.1; GARCIARUIZ JM, 1993, NATO ASI SERIES; Hageman L.A., 1981, APPL ITERATIVE METHO; Haldane JB., 1985, BEING RIGHT SIZE OTH; Hille B., 1991, IONIC CHANNELS EXCIT; JAMES T, 1963, MATH THEORY ELECT MA; Jelinek HF, 1998, J NEUROSCI METH, V81, P9, DOI 10.1016/S0165-0270(98)00021-1; KOCH C, 1999, BIOPHYS COMPUTATION; LAMB TD, 1976, J PHYSIOL-LONDON, V263, P257, DOI 10.1113/jphysiol.1976.sp011631; Laughlin SB, 2003, SCIENCE, V301, P1870, DOI 10.1126/science.1089662; Louis E, 2002, NEUROSCI LETT, V323, P21, DOI 10.1016/S0304-3940(02)00115-5; PANICO J, 1995, J COMP NEUROL, V361, P479, DOI 10.1002/cne.903610311; Poznanski RR, 1997, PROG NEUROBIOL, V53, P273, DOI 10.1016/S0301-0082(97)00037-3; QIAN HH, 1993, VISUAL NEUROSCI, V10, P287, DOI 10.1017/S0952523800003680; RALL W, 1959, EXP NEUROL, V1, P491, DOI 10.1016/0014-4886(59)90046-9; Rall W, 1998, METHODS NEURONAL MOD, P27; Ramon y Cajal S, 1995, HISTOLOGY NERVOUS SY; RAPP M, 1994, J PHYSIOL-LONDON, V474, P101, DOI 10.1113/jphysiol.1994.sp020006; RUSHTON WAH, 1951, J PHYSIOL-LONDON, V115, P101, DOI 10.1113/jphysiol.1951.sp004655; SEGEV I, 1992, TRENDS NEUROSCI, V15, P414, DOI 10.1016/0166-2236(92)90003-Q; Surkis A, 1996, NEUROSCIENCE, V74, P375, DOI 10.1016/0306-4522(96)00139-X; THOMPSON WD, 2000, GROWTH FORM ABRIGED; UMINO O, 1994, VISUAL NEUROSCI, V11, P533, DOI 10.1017/S0952523800002443; Valiunas V, 1997, CIRC RES, V80, P708, DOI 10.1161/01.RES.80.5.708; Vicsek T, 1992, FRACTAL GROWTH PHENO; West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122	34	1	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					866	871		10.1096/fj.06-5977com	http://dx.doi.org/10.1096/fj.06-5977com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17194694	Green Submitted			2022-12-25	WOS:000244686400023
J	Robinson, P; Lipscomb, S; Preston, LC; Altin, E; Watkins, H; Ashley, CC; Redwood, CS				Robinson, Paul; Lipscomb, Simon; Preston, Laura C.; Altin, Elissa; Watkins, Hugh; Ashley, Christopher C.; Redwood, Charles S.			Mutations in fast skeletal troponin I, troponin T, and beta-tropomyosin that cause distal arthrogryposis all increase contractile function	FASEB JOURNAL			English	Article						contractility; muscle disease	THIN FILAMENT REGULATION; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; MYOSIN-ACTIN INTERACTIONS; ALPHA-TROPOMYOSIN; COILED-COIL; DILATED CARDIOMYOPATHY; COOPERATIVE REGULATION; REGULATORY PROPERTIES; MULTIPLEX CONGENITA; CLINICAL ANALYSIS	Distal arthrogryposes (DAs) are a group of disorders characterized by congenital contractures of distal limbs without overt neurological or muscle disease. Unexpectedly, mutations in genes encoding the fast skeletal muscle regulatory proteins troponin T (TnT), troponin I (TnI), and beta-tropomyosin (beta-TM) have been shown to cause autosomal dominant DA. We tested how these mutations affect contractile function by comparing wild-type (WT) and mutant proteins in actomyosin ATPase assays and in troponin-replaced rabbit psoas fibers. We have analyzed all four reported mutants: Arg63His TnT, Arg91Gly beta-TM, Arg174GIn TnI, and a TnI truncation mutant (Arg156ter). Thin filaments, reconstituted using actin and WT troponin and beta-TM, activated myosin subfragment-1 ATPase in a calcium-dependent, cooperative manner. Thin filaments containing either a troponin or beta-TM DA mutant produced significantly enhanced ATPase rates at all calcium concentrations without alternating calcium-sensitivity or cooperativity. In troponin-exchanged skinned fibers, each mutant caused a significant increase in Ca2+ sensitivity, and Arg156ter TnI generated significantly higher maximum force. Arg91Gly beta-TM was found to have a lower actin affinity than WT and forma less stable coiled coil. We propose the mutations cause increased contractility of developing fast-twitch skeletal muscles, thus causing muscle contractures and the development of the observed limb deformities.	Univ Oxford, Dept Cardiovasc Med, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, Dept Physiol, Oxford, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Redwood, CS (corresponding author), Univ Oxford, Dept Cardiovasc Med, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.	credwood@well.ox.ac.uk		Watkins, Hugh/0000-0002-5287-9016				ASHLEY CC, 1993, ADV EXP MED BIOL, V332, P97; ASHLEY CC, 1993, ADV EXP MED BIOL, V332, P114; BAMSHAD M, 1994, AM J HUM GENET, V55, P1153; Bamshad M, 1996, AM J MED GENET, V65, P277, DOI 10.1002/(SICI)1096-8628(19961111)65:4<277::AID-AJMG6>3.0.CO;2-M; Bamshad M, 1996, AM J MED GENET, V65, P282, DOI 10.1002/(SICI)1096-8628(19961111)65:4<282::AID-AJMG7>3.0.CO;2-R; Beals RK, 2005, CLIN ORTHOP RELAT R, P203; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Bing W, 1997, BIOCHEM BIOPH RES CO, V236, P760, DOI 10.1006/bbrc.1997.7045; Bottinelli R, 1998, CIRC RES, V82, P106; Brenner B, 1999, BIOPHYS J, V77, P2677, DOI 10.1016/S0006-3495(99)77102-X; BRONSON DD, 1982, J BIOL CHEM, V257, P3937; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; Craig R, 2001, J MOL BIOL, V311, P1027, DOI 10.1006/jmbi.2001.4897; Elliott K, 2000, J BIOL CHEM, V275, P22069, DOI 10.1074/jbc.M002502200; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Gordon N, 1998, BRAIN DEV-JPN, V20, P507, DOI 10.1016/S0387-7604(98)00037-0; Greenfield NJ, 1995, BIOCHEMISTRY-US, V34, P16797, DOI 10.1021/bi00051a030; GRIFFITHS PJ, 1994, J PHYSL, V438, pB146; Hall JG, 1997, J PEDIATR ORTHOP B, V6, P159, DOI 10.1097/01202412-199707000-00002; HALL JG, 1982, AM J MED GENET, V11, P185, DOI 10.1002/ajmg.1320110208; Heller MJ, 2003, J BIOL CHEM, V278, P41742, DOI 10.1074/jbc.M303408200; Hernandez OM, 2001, J APPL PHYSIOL, V90, P1125, DOI 10.1152/jappl.2001.90.3.1125; Hitchcock-DeGregori SE, 2002, BIOCHEMISTRY-US, V41, P15036, DOI 10.1021/bi026519k; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; Krakowiak PA, 1998, AM J MED GENET, V76, P93, DOI 10.1002/(SICI)1096-8628(19980226)76:1<93::AID-AJMG17>3.0.CO;2-K; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; LEHRER SS, 1991, BIOCHEMISTRY-US, V30, P5682, DOI 10.1021/bi00237a007; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; Lipscomb S, 2005, BIOCHEM J, V388, P905, DOI 10.1042/BJ20041841; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; Mirza M, 2005, J BIOL CHEM, V280, P28498, DOI 10.1074/jbc.M412281200; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Palm T, 2001, BIOPHYS J, V81, P2827, DOI 10.1016/S0006-3495(01)75924-3; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PERRY SV, 1985, J EXP BIOL, V115, P31; Ramos CHI, 1999, J BIOL CHEM, V274, P18189, DOI 10.1074/jbc.274.26.18189; Rarick HM, 1997, J BIOL CHEM, V272, P26887, DOI 10.1074/jbc.272.43.26887; Redwood C, 2000, CIRC RES, V86, P1146; Robinson P, 2002, J BIOL CHEM, V277, P40710, DOI 10.1074/jbc.M203446200; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; She MD, 2000, J MUSCLE RES CELL M, V21, P737, DOI 10.1023/A:1010300802980; Singh A, 2006, STRUCTURE, V14, P43, DOI 10.1016/j.str.2005.09.016; Singh A, 2003, BIOCHEMISTRY-US, V42, P14114, DOI 10.1021/bi0348462; SMITH DA, 1995, BIOPHYS J, V69, P524, DOI 10.1016/S0006-3495(95)79926-X; Smith DA, 2003, BIOPHYS J, V84, P3155, DOI 10.1016/S0006-3495(03)70040-X; Smith DA, 2003, BIOPHYS J, V84, P3168, DOI 10.1016/S0006-3495(03)70041-1; Smith R. M., 1974, CRITICAL STABILITY C, P1; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sung SS, 2003, AM J HUM GENET, V73, P212, DOI 10.1086/376418; Sung SS, 2003, AM J HUM GENET, V72, P681, DOI 10.1086/368294; Varnava A, 1999, HEART, V82, P621, DOI 10.1136/hrt.82.5.621; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x	58	74	83	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					896	905		10.1096/fj.06-6899com	http://dx.doi.org/10.1096/fj.06-6899com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17194691				2022-12-25	WOS:000244686400026
J	Silvertown, JD; Symes, JC; Neschadim, A; Nonaka, T; Kao, JCH; Summerlee, AJS; Medin, JA				Silvertown, Josh D.; Symes, Juliane C.; Neschadim, Anton; Nonaka, Takahiro; Kao, Jessica C. H.; Summerlee, Alastair J. S.; Medin, Jeffrey A.			Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth	FASEB JOURNAL			English	Article						lentivirus; LGR7; blood vessel; MMP-9	RECEPTOR-BINDING SITE; EXPRESSION; PEPTIDES; ACTIVATION; BENIGN; INSL3; MICE	Hormone antagonists can be effective tools to delineate receptor signaling pathways and their resulting downstream physiological actions. Mutation of the receptor binding domain (RBD) of human H2 relaxin (Delta H2) impaired its biological function as measured by cAMP signaling. In a competition assay, Delta H2 exhibited antagonistic activity by blocking recombinant H2 relaxin from binding to receptors on THP-1 cells. In a flow cytometry-based binding assay, Delta H2 demonstrated weak binding to 293T cells expressing the LGR7 receptor in the presence of biotinylated H2 relaxin. When human prostate cancer cell lines (PC-3 and LNCaP) were engineered to overexpress eGFP, wildtype (WT) H2, or Delta H2, and subsequently implanted into NOD/SCID mice, tumor xenografts overexpressing Delta H2 displayed smaller volumes compared to H2 and eGFP controls. Plasma osmolality readings and microvessel density and area assessment suggest that Delta H2 modulates physiological parameters in vivo. In a second murine model, intratumoral injections of lentivectors engineered to express Delta H2/eGFP led to suppressed tumor growth compared to controls. This study provides further evidence supporting a role for H2 relaxin in prostate tumor growth. More importantly, we report how mutation of the H2 relaxin RBD confers the hormone derivative with antagonistic properties, offering a novel reagent for relaxin research.	Univ Toronto, Hlth Network, Ontario Canc Inst, Div Stem Cell & Dev Biol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Guelph; University of Toronto	Medin, JA (corresponding author), Univ Toronto, Hlth Network, Ontario Canc Inst, Div Stem Cell & Dev Biol, Canadian Blood Serv Bldg,67 Coll St,Rm 406, Toronto, ON M5G 2M1, Canada.	jmedin@uhnres.utoronto.ca	Neschadim, Anton/G-3041-2011	Neschadim, Anton/0000-0003-1750-9703				Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; Bathgate RA, 2006, PHARMACOL REV, V58, P7, DOI 10.1124/pr.58.1.9; Bathgate RA, 2005, ANN NY ACAD SCI, V1041, P61, DOI 10.1196/annals.1282.010; Bathgate RAD, 2003, TRENDS ENDOCRIN MET, V14, P207, DOI 10.1016/S1043-2760(03)00081-X; BULLESBACH EE, 1992, J BIOL CHEM, V267, P22957; Bullesbach EE, 2000, J BIOL CHEM, V275, P35276, DOI 10.1074/jbc.M005728200; Bullesbach EE, 2005, J BIOL CHEM, V280, P14586, DOI 10.1074/jbc.M414443200; Danielson LA, 1999, J CLIN INVEST, V103, P525, DOI 10.1172/JCI5630; Del Borgo MP, 2006, J BIOL CHEM, V281, P13068, DOI 10.1074/jbc.M600472200; Halls ML, 2005, J PHARMACOL EXP THER, V313, P677, DOI 10.1124/jpet.104.080655; Hombach-Klonisch S, 2006, AM J PATHOL, V169, P617, DOI 10.2353/ajpath.2006.050876; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Kamat AA, 2006, CANCER BIOL THER, V5, P71, DOI 10.4161/cbt.5.1.2289; Klonisch T, 2005, INT J ONCOL, V27, P307; Lee HY, 2005, ENDOCRINOLOGY, V146, P511, DOI 10.1210/en.2004-0796; McGuane Jonathan T., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009944; Parsell DA, 1996, J BIOL CHEM, V271, P27936, DOI 10.1074/jbc.271.44.27936; Samuel CS, 2003, LAB INVEST, V83, P1055, DOI 10.1097/01.LAB.0000079784.81186.B9; Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013; Silvertown JD, 2005, ANN NY ACAD SCI, V1041, P216, DOI 10.1196/annals.1282.033; Silvertown JD, 2006, INT J CANCER, V118, P62, DOI 10.1002/ijc.21288; Silvertown JD, 2003, INT J CANCER, V107, P513, DOI 10.1002/ijc.11424; Silvertown JD, 2003, ENDOCRINOLOGY, V144, P3683, DOI 10.1210/en.2003-0248; Silvertown JD, 2006, ENDOCRINOLOGY, V147, P3797, DOI 10.1210/en.2006-0028; TASHIMA LS, 1994, J MOL ENDOCRINOL, V12, P351, DOI 10.1677/jme.0.0120351; Thompson HJ, 2002, CARCINOGENESIS, V23, P847, DOI 10.1093/carcin/23.5.847; Thompson VC, 2006, PROSTATE, V66, P1698, DOI 10.1002/pros.20423; WEISINGER RS, 1993, J ENDOCRINOL, V137, P505, DOI 10.1677/joe.0.1370505; Yoshimitsu M, 2004, P NATL ACAD SCI USA, V101, P16909, DOI 10.1073/pnas.0407572101; Zhao L, 1999, ENDOCRINOLOGY, V140, P445, DOI 10.1210/en.140.1.445	30	49	53	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					754	765		10.1096/fj.06-6847com	http://dx.doi.org/10.1096/fj.06-6847com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197386				2022-12-25	WOS:000244686400014
J	Yung, HW; Korolchuk, S; Tolkovsky, AM; Charnock-Jones, DS; Burton, GJ				Yung, Hong-Wa; Korolchuk, Svitlana; Tolkovsky, Aviva M.; Charnock-Jones, D. Stephen; Burton, Graham J.			Endoplasmic reticulum stress exacerbates ischemia-reperfusion-induced apoptosis through attenuation of Akt protein synthesis in human choriocarcinoma cells	FASEB JOURNAL			English	Article						unfolded protein response; placenta; oxidative stress; trophoblast; CHOP	P70 S6 KINASE; OXIDATIVE STRESS; GENE-EXPRESSION; TRANSLATION INITIATION; CEREBRAL-ISCHEMIA; ALPHA-TOCOPHEROL; BRAIN ISCHEMIA; ER STRESS; PHOSPHORYLATION; ACTIVATION	Oxidative stress is central to ischemia-reperfusion injury. The role of the endoplasmic reticulum (ER) in this process is uncertain. In ER signaling, PERK-Nrf2 and Ire-CHOP are two pathways that determine cell fate under stress. PERK-Nrf2 up-regulates antioxidant enzyme expression whereas Ire-CHOP promotes apoptosis. We have identified a novel pathway in ER stress-induced apoptosis after ischemia-reperfusion in vitro involving translational suppression of the survival kinase PKB/Akt (Akt), and elucidated an alternative protective role of antioxidants in the regulation of Akt activity. Using human choriocarcinoma JEG-3 cells, we found that sustained activation of ER stress by tunicamycin or thapsigargin exacerbated apoptosis in oxygen-glucose-deprived cells during reoxygenation. This was mediated via a reduction in phosphorylated Akt secondary to down-regulation of protein translation rather than suppression of phosphorylation. Transient overexpression of wild-type Akt, but not kinase-dead Akt, in JEG-3 cells diminished tunicamycin-OGD reoxygenation-induced apoptosis. The antioxidants Trolox and Edaravone reduced apoptosis, but the protective effect of Trolox was abrogated by the PI3K inhibitor, LY294002. We speculate that sustained ER stress may contribute to the placental dysfunction seen in human pregnancy complications.	Univ Cambridge, Dept Physiol Dev & Neurosci, Physiol Lab, Cambridge CB2 3EG, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Cambridge, Dept Obstet & Gynaecol, Cambridge CB2 1QW, England	University of Cambridge; University of Cambridge; University of Cambridge	Burton, GJ (corresponding author), Univ Cambridge, Dept Physiol Dev & Neurosci, Physiol Lab, Downing St, Cambridge CB2 3EG, England.	gjb2@cam.ac.uk	Charnock-Jones, D. Stephen/B-3743-2009; Charnock-Jones, D. Stephen/AAE-3391-2020	Charnock-Jones, D. Stephen/0000-0002-2936-4890; Charnock-Jones, D. Stephen/0000-0002-2936-4890	Wellcome Trust [069027/Z/02/Z, 069027] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Althausen S, 2001, J NEUROCHEM, V78, P779, DOI 10.1046/j.1471-4159.2001.00462.x; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Benavides A, 2005, GLIA, V52, P261, DOI 10.1002/glia.20242; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Brosens JJ, 2002, AM J OBSTET GYNECOL, V187, P1416, DOI 10.1067/mob.2002.127305; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Burns DM, 1998, SENSOR ACTUAT A-PHYS, V70, P6, DOI 10.1016/S0924-4247(98)00106-X; Burton GJ, 2004, J SOC GYNECOL INVEST, V11, P342, DOI 10.1016/j.jsgi.2004.03.003; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Clement S, 1997, EUR J BIOCHEM, V246, P745, DOI 10.1111/j.1432-1033.1997.t01-2-00745.x; Cullinan SB, 2006, INT J BIOCHEM CELL B, V38, P317, DOI 10.1016/j.biocel.2005.09.018; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de la Vega CM, 2001, BIOCHEM J, V357, P819; DeGracia DJ, 2004, J NEUROCHEM, V91, P1, DOI 10.1111/j.1471-4159.2004.02703.x; DeGracia DJ, 2004, J NEUROSCI RES, V77, P771, DOI 10.1002/jnr.20225; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; DEL PL, 1997, SCIENCE, V278, P687; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hayashi T, 2005, J CEREBR BLOOD F MET, V25, P41, DOI 10.1038/sj.jcbfm.9600005; Hayashi T, 2004, NEUROBIOL DIS, V15, P229, DOI 10.1016/j.nbd.2003.10.005; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; HOSSMANN KA, 1993, PROG BRAIN RES, V96, P161; Hung TH, 2002, CIRC RES, V90, P1274, DOI 10.1161/01.RES.0000024411.22110.AA; Hyoda K, 2006, BIOCHEM BIOPH RES CO, V340, P286, DOI 10.1016/j.bbrc.2005.12.007; Ishihara N, 2002, AM J OBSTET GYNECOL, V186, P158, DOI 10.1067/mob.2002.119176; Jan E, 2001, COLD SPRING HARB SYM, V66, P285, DOI 10.1101/sqb.2001.66.285; KIMBALL SR, 1992, AM J PHYSIOL, V263, pE958, DOI 10.1152/ajpendo.1992.263.5.E958; Kumar R, 2003, J CEREBR BLOOD F MET, V23, P462, DOI 10.1097/01.WCB.0000056064.25434.CA; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; MARTIN CB, 1964, AM J OBSTET GYNECOL, V90, P819, DOI 10.1016/0002-9378(64)90948-2; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Qi X, 2004, J PHARMACOL EXP THER, V311, P388, DOI 10.1124/jpet.104.069088; Rajesh KG, 2003, AM J PHYSIOL-HEART C, V285, pH2171, DOI 10.1152/ajpheart.00143.2003; Ricciarelli R, 1998, BIOCHEM J, V334, P243, DOI 10.1042/bj3340243; Rimbach G, 2002, P NUTR SOC, V61, P415, DOI 10.1079/PNS2002183; Roberts JM, 1999, LANCET, V354, P788, DOI 10.1016/S0140-6736(99)80002-6; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shang J, 2004, BIOCHEM BIOPH RES CO, V317, P390, DOI 10.1016/j.bbrc.2004.03.058; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Srinivasan S, 2005, DIABETES, V54, P968, DOI 10.2337/diabetes.54.4.968; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Ubeda M, 2000, NUCLEIC ACIDS RES, V28, P4987, DOI 10.1093/nar/28.24.4987; Virdee K, 1999, BRAIN RES, V837, P127, DOI 10.1016/S0006-8993(99)01643-1; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Yoneda Y, 2003, STROKE, V34, P718, DOI 10.1161/01.STR.0000056171.55342.FF; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2001, J INVEST DERM SYMP P, V6, P1, DOI 10.1046/j.0022-202x.2001.00006.x; Yung HW, 2003, J NEUROCHEM, V86, P1281, DOI 10.1046/j.1471-4159.2003.01946.x	56	97	101	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					872	884		10.1096/fj.06-6054com	http://dx.doi.org/10.1096/fj.06-6054com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17167073	Green Accepted			2022-12-25	WOS:000244686400024
J	Freshour, J; Yokoyama, R; Mitchell, DR				Freshour, Judy; Yokoyama, Ruth; Mitchell, David R.			Chlamydomonas flagellar outer row dynein assembly protein Oda7 interacts with both outer row and I1 inner row dyneins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; HEAVY-CHAIN; LIGHT-CHAIN; NUCLEAR TRANSFORMATION; MOTOR DOMAIN; ARM DYNEIN; MUTANT; REINHARDTII; MOVEMENT; MOTILITY	We previously found that a mutation at the ODA7 locus in Chlamydomonas prevents axonemal outer row dynein assembly by blocking association of heavy chains and intermediate chains in the cytoplasm. We have now cloned the ODA 7 locus by walking in the Chlamydomonas genome from nearby molecular markers, confirmed the identity of the gene by rescuing the mutant phenotype with genomic clones, and identified the ODA7 gene product as a 58-kDa leucine-rich repeat protein unrelated to outer row dynein LC1. Oda7p is missing from oda7 mutant flagella but is present in flagella of other outer row or inner row dynein assembly mutants. However, Oda7 levels are greatly reduced in flagella that lack both outer row dynein and inner row 11 dynein. Biochemical fractionation and rebinding studies support a model in which Oda7 participates in a previously uncharacterized structural link between inner and outer row dyneins.	SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Mitchell, DR (corresponding author), SUNY Upstate Med Univ, Dept Cell & Dev Biol, 1133 WH,750 E Adams St, Syracuse, NY 13210 USA.	mitcheld@upstate.edu		Mitchell, David/0000-0003-2821-7511	NIGMS NIH HHS [GM44228, R01 GM044228-15, R01 GM044228] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed NT, 2005, MOL BIOL CELL, V16, P5004, DOI 10.1091/mbc.E05-07-0627; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asai DJ, 2004, J EUKARYOT MICROBIOL, V51, P23, DOI 10.1111/j.1550-7408.2004.tb00157.x; Asai DJ, 2001, TRENDS CELL BIOL, V11, P196, DOI 10.1016/S0962-8924(01)01970-5; Benashski SE, 1999, BIOCHEMISTRY-US, V38, P7253, DOI 10.1021/bi990466y; BLOODGOOD RA, 1994, J CELL BIOL, V127, P803, DOI 10.1083/jcb.127.3.803; Bowman AB, 1999, J CELL BIOL, V146, P165; BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; DiBella LM, 2004, MOL BIOL CELL, V15, P4633, DOI 10.1091/mbc.E04-06-0461; DiBella LM, 2004, J BIOL CHEM, V279, P21666, DOI 10.1074/jbc.M313540200; Fowkes ME, 1998, MOL BIOL CELL, V9, P2337, DOI 10.1091/mbc.9.9.2337; GIBBONS BH, 1973, J CELL SCI, V13, P337; GIBBONS I. R., 1965, ARCH BIOL, V76, P317; Kajava AV, 2002, PROTEIN SCI, V11, P1082, DOI 10.1110/ps.4010102; KAMIYA R, 1988, J CELL BIOL, V107, P2253, DOI 10.1083/jcb.107.6.2253; Kamiya R, 2002, INT REV CYTOL, V219, P115; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; King SJ, 1997, J CELL BIOL, V136, P177, DOI 10.1083/jcb.136.1.177; KING SM, 1994, J BIOL CHEM, V269, P5452; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kohl L, 2005, INT REV CYTOL, V244, P227, DOI 10.1016/S0074-7696(05)44006-1; LEDIZET M, 1995, MOL BIOL CELL, V6, P697, DOI 10.1091/mbc.6.6.697; Liu SM, 2004, CELL MOTIL CYTOSKEL, V59, P201, DOI 10.1002/cm.20034; Marchler-Bauer A, 2004, NUCLEIC ACIDS RES, V32, pW327, DOI 10.1093/nar/gkh454; Mitchell BF, 2005, MOL BIOL CELL, V16, P4509, DOI 10.1091/mbc.E05-04-0347; MITCHELL DR, 1986, CELL MOTIL CYTOSKEL, V6, P510, DOI 10.1002/cm.970060510; MITCHELL DR, 1985, J CELL BIOL, V100, P1228, DOI 10.1083/jcb.100.4.1228; Mitchell DR, 1999, J CELL BIOL, V144, P293, DOI 10.1083/jcb.144.2.293; MITCHELL DR, 1991, J CELL BIOL, V113, P835, DOI 10.1083/jcb.113.4.835; Nicastro D, 2006, SCIENCE, V313, P944, DOI 10.1126/science.1128618; Perrone CA, 1998, MOL BIOL CELL, V9, P3351, DOI 10.1091/mbc.9.12.3351; PFISTER KK, 1982, CELL MOTIL CYTOSKEL, V2, P525, DOI 10.1002/cm.970020604; PORTONI L, 2000, P SOC PHOTO-OPT INS, V1, P37; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SAGER R, 1953, ANN NY ACAD SCI, V466, P18; SAKAKIBARA H, 1991, J CELL BIOL, V113, P615, DOI 10.1083/jcb.113.3.615; SAKAKIBARA H, 1989, J CELL SCI, V92, P77; SILFLOW CD, 1995, METHOD CELL BIOL, V47, P525, DOI 10.1016/S0091-679X(08)60856-0; Takada S, 2002, MOL BIOL CELL, V13, P1015, DOI 10.1091/mbc.01-04-0201; TAKADA S, 1992, J BIOCHEM, V111, P758, DOI 10.1093/oxfordjournals.jbchem.a123832; Wirschell M, 2004, MOL BIOL CELL, V15, P2729, DOI 10.1091/mbc.E03-11-0820; Wu HW, 2003, BIOCHEMISTRY-US, V42, P57, DOI 10.1021/bi026762j; Yagi T, 2005, J BIOL CHEM, V280, P41412, DOI 10.1074/jbc.M509072200	44	43	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5404	5412		10.1074/jbc.M607509200	http://dx.doi.org/10.1074/jbc.M607509200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17194703	Green Accepted, hybrid			2022-12-25	WOS:000244482300035
J	Leveille, C; Bouillon, M; Guo, W; Bolduc, J; Sharif-Askari, E; El-Fakhry, Y; Reyes-Moreno, C; Lapointe, R; Merhi, Y; Wilkins, JA; Mourad, W				Leveille, Claire; Bouillon, Marlene; Guo, Wen; Bolduc, Julie; Sharif-Askari, Ehssan; El-Fakhry, Youssef; Reyes-Moreno, Carlos; Lapointe, Rejean; Merhi, Yahye; Wilkins, John A.; Mourad, Walid			CD40 ligand binds to alpha 5 beta 1 integrin and triggers cell signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; HUMAN ARTICULAR CHONDROCYTES; INFLAMMATORY-BOWEL-DISEASE; HUMAN B-LYMPHOCYTES; HUMAN MONOCYTES; MAST-CELLS; CARDIOVASCULAR-DISEASE; COSTIMULATORY PATHWAY; FIBRONECTIN FRAGMENTS	It was originally thought that the critical role of the CD40 ligand (CD40L) in normal and inflammatory immune responses was mainly mediated through its interaction with the classic receptor, CD40. However, data from CD40L(-/-) and CD40(-/-) mice suggest that the CD40L-induced inflammatory immune response involves at least one other receptor. This hypothesis is supported by the fact that CD40L stabilizes arterial thrombi through an alpha IIb beta 3-dependent mechanism. Here we provide evidence that soluble CD40L (sCD40L) binds to cells of the undifferentiated human monocytic U937 cell line in a CD40- and alpha IIb beta 3-independent manner. Binding of sCD40L to U937 cells was inhibited by anti-CD40L monoclonal antibody 5C8, anti-alpha 5 beta 1 monoclonal antibody P1D6, and soluble alpha 5 beta 1. The direct binding of sCD40L to purified alpha 5 beta 1 was confirmed in a solid phase binding assay. Binding of sCD40L to alpha 5 beta 1 was modulated by the form of alpha 5 beta 1 expressed on the cell surface as the activation of alpha 5 beta 1 by Mn2+ or dithiothreitol resulted in the loss of sCD40L binding. Moreover, sCD40L induced the translocation of alpha 5 beta 1 to the Triton X-100-insoluble fraction of U937 cells, the rapid activation of the MAPK pathways ERK1/2, and interleukin-8 gene expression. The binding of sCD40L to CD40 on BJAB cells, an alpha 5 beta 1-negative B cell line, and the resulting activation of ERK1/2 was not inhibited by soluble alpha 5 beta 1, suggesting that sCD40L can bind concomitantly to both receptors. These results document the existence of novel CD40L-dependent pathways of physiological relevance for cells expressing multiple receptors (CD40, alpha 5 beta 1, and alpha IIb beta 3) for CD40L.	Ctr Hosp Univ Montreal, Hop St Luc, Lab Immunol Cellulaire & Mol, Montreal, PQ H2X 1P1, Canada; CHU Laval, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1V 4G2, Canada; Ctr Hosp Univ Montreal, Hop Notre Dame, Montreal, PQ H2W 1T8, Canada; Univ Montreal, Inst Rech Cardiol, Montreal, PQ H1T 1C8, Canada; Univ Manitoba, Dept Med, Manitoba Ctr Proteom & Rheumat Dis Res Lab, Winnipeg, MB R3E 3P4, Canada; Univ Montreal, Dept Med, Montreal, PQ H3T 3J7, Canada	Universite de Montreal; Laval University; Universite de Montreal; Universite de Montreal; University of Manitoba; Universite de Montreal	Mourad, W (corresponding author), Ctr Hosp Univ Montreal, Hop St Luc, Lab Immunol Cellulaire & Mol, Campus St Luc,Pavillon Edouard Asselin,264 Blvd R, Montreal, PQ H2X 1P1, Canada.	MW.Mourad@umontreal.ca		Mourad, Walid/0000-0002-1859-9387				Andre P, 2002, CIRCULATION, V106, P896, DOI 10.1161/01.CIR.0000028962.04520.01; Andre P, 2002, NAT MED, V8, P247, DOI 10.1038/nm0302-247; Aukrust P, 2004, J AM COLL CARDIOL, V43, P2326, DOI 10.1016/j.jacc.2004.03.023; Bajorath J, 1998, J BIOL CHEM, V273, P24603, DOI 10.1074/jbc.273.38.24603; Berner B, 2000, ANN RHEUM DIS, V59, P190, DOI 10.1136/ard.59.3.190; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; CASAMAYORPALLEJA M, 1995, J EXP MED, V181, P1293, DOI 10.1084/jem.181.4.1293; Crow AR, 2003, J THROMB HAEMOST, V1, P850, DOI 10.1046/j.1538-7836.2003.t01-1-00115.x; Danese S, 2004, GUT, V53, P1035, DOI 10.1136/gut.2003.026278; Danese S, 2003, GUT, V52, P1435, DOI 10.1136/gut.52.10.1435; de Fougerolles AR, 2002, IMMUNOL REV, V186, P208, DOI 10.1034/j.1600-065X.2002.18617.x; Delmas Y, 2005, M S-MED SCI, V21, P825, DOI 10.1051/medsci/20052110825; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; DING L, 1995, J IMMUNOL, V155, P5124; Elzey BD, 2003, IMMUNITY, V19, P9, DOI 10.1016/S1074-7613(03)00177-8; Emambokus NR, 2003, IMMUNITY, V19, P33, DOI 10.1016/S1074-7613(03)00173-0; Forsyth CB, 2002, ARTHRITIS RHEUM, V46, P2368, DOI 10.1002/art.10502; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Goules A, 2006, J AUTOIMMUN, V26, P165, DOI 10.1016/j.jaut.2006.02.002; Grammer A C, 2000, Adv Immunol, V76, P61; Grammer AC, 2004, ARTHRITIS RES THER, V6, P28, DOI 10.1186/ar1155; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; Houtman R, 2001, CLIN EXP ALLERGY, V31, P817, DOI 10.1046/j.1365-2222.2001.01104.x; Howard LM, 2004, AUTOIMMUNITY, V37, P411, DOI 10.1080/08916930410001716095; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Inoue Y, 2004, J IMMUNOL, V172, P2147, DOI 10.4049/jimmunol.172.4.2147; Jin Yinzhu, 2001, Journal of Medical and Dental Sciences, V48, P23; Juliano RL, 2004, BIOCHEM SOC T, V32, P443, DOI 10.1042/BST0320443; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; Katsiari CG, 2002, LUPUS, V11, P370, DOI 10.1191/0961203302lu211oa; Kaufman J, 2004, J IMMUNOL, V172, P1862, DOI 10.4049/jimmunol.172.3.1862; KIENER PA, 1995, J IMMUNOL, V155, P4917; Krokhin OV, 2003, BIOCHEMISTRY-US, V42, P12950, DOI 10.1021/bi034726u; Leveille C, 1999, EUR J IMMUNOL, V29, P3516, DOI 10.1002/(SICI)1521-4141(199911)29:11<3516::AID-IMMU3516>3.3.CO;2-4; Lindmark E, 2000, ARTERIOSCL THROM VAS, V20, P2322, DOI 10.1161/01.ATV.20.10.2322; Lishko VK, 2003, EXP CELL RES, V283, P116, DOI 10.1016/S0014-4827(02)00024-1; Liu MF, 2001, AUTOIMMUNITY, V34, P107, DOI 10.3109/08916930109001958; Mehlhop PD, 2000, AM J RESP CELL MOL, V23, P646, DOI 10.1165/ajrcmb.23.5.3954; Morris AE, 1999, J BIOL CHEM, V274, P418, DOI 10.1074/jbc.274.1.418; Neff L, 2003, J BIOL CHEM, V278, P27721, DOI 10.1074/jbc.M212065200; Ni HY, 1998, J BIOL CHEM, V273, P7981, DOI 10.1074/jbc.273.14.7981; Ody C, 2001, MOL IMMUNOL, V38, P45, DOI 10.1016/S0161-5890(01)00030-X; Oki T, 2006, J IMMUNOL, V176, P52, DOI 10.4049/jimmunol.176.1.52; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Pearson LL, 2001, INT IMMUNOL, V13, P273, DOI 10.1093/intimm/13.3.273; Pietravalle F, 1996, J BIOL CHEM, V271, P5965, DOI 10.1074/jbc.271.11.5965; Prasad KSS, 2003, P NATL ACAD SCI USA, V100, P12367, DOI 10.1073/pnas.2032886100; Pulai JI, 2005, J IMMUNOL, V174, P5781, DOI 10.4049/jimmunol.174.9.5781; Qiang YW, 2000, EXP HEMATOL, V28, P1147, DOI 10.1016/S0301-472X(00)00521-X; Reyes-Moreno C, 2004, J BIOL CHEM, V279, P7799, DOI 10.1074/jbc.M313168200; Roman J, 2000, CYTOKINE, V12, P1581, DOI 10.1006/cyto.2000.0759; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; Shattil SJ, 2004, BLOOD, V104, P1606, DOI 10.1182/blood-2004-04-1257; Sidiropoulos PI, 2004, LUPUS, V13, P391, DOI 10.1191/0961203304lu1032oa; Stout RD, 1996, J IMMUNOL, V156, P8; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Suttles J, 1999, J BIOL CHEM, V274, P5835, DOI 10.1074/jbc.274.9.5835; TAKIZAWA T, 1995, CLIN EXP IMMUNOL, V101, P376; Toubi E, 2004, AUTOIMMUNITY, V37, P457, DOI 10.1080/08916930400002386; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Vishnevetsky D, 2004, ANN PHARMACOTHER, V38, P1500, DOI 10.1345/aph.1D611; Wagner AH, 2004, ARTERIOSCL THROM VAS, V24, P715, DOI 10.1161/01.ATV.0000122853.99978.b1; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wilkins JA, 1996, J BIOL CHEM, V271, P3046, DOI 10.1074/jbc.271.6.3046	67	79	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5143	5151		10.1074/jbc.M608342200	http://dx.doi.org/10.1074/jbc.M608342200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17182621	hybrid			2022-12-25	WOS:000244482300008
J	Werner, ME; Chen, F; Moyano, JV; Yehiely, F; Jones, JCR; Cryns, VL				Werner, Michael E.; Chen, Feng; Moyano, Jose V.; Yehiely, Fruma; Jones, Jonathan C. R.; Cryns, Vincent L.			Caspase proteolysis of the integrin beta 4 subunit disrupts hemidesmosome assembly, promotes apoptosis, and inhibits cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; N-END RULE; JUNCTIONAL EPIDERMOLYSIS-BULLOSA; TRAIL-INDUCED APOPTOSIS; FACTOR-KAPPA-B; INTERMEDIATE-FILAMENTS; CYTOPLASMIC DOMAIN; ALPHA-6-BETA-4 INTEGRIN; MEDIATED DEGRADATION; PEMPHIGOID ANTIGEN	Caspases are a conserved family of cell death proteases that cleave intracellular substrates at Asp residues to modify their function and promote apoptosis. In this report we identify the integrin 134 subunit as a novel caspase substrate using an expression cloning strategy. Together with its alpha 6 partner, alpha 6 beta 4 integrin anchors epithelial cells to the basement membrane at specialized adhesive structures known as hemidesmosomes and plays a critical role in diverse epithelial cell functions including cell survival and migration. We show that integrin 134 is cleaved by caspase-3 and -7 at a conserved Asp residue (Asp(1109)) in vitro and in epithelial cells undergoing apoptosis, resulting in the removal of most of its cytoplasmic tail. Caspase cleavage of integrin 64 produces two products, 1) a carboxyl-terminal product that is unstable and rapidly degraded by the proteasome and 2) an amino-terminal cleavage product (amino acids 1-1109) that is unable to assemble into mature hemidesmosomes. We also demonstrate that caspase cleavage of integrin beta 4 sensitizes epithelial cells to apoptosis and inhibits cell migration. Taken together, we have identified a previously unrecognized proteolytic truncation of integrin beta 4 generated by caspases that disrupts key structural and functional properties of epithelial cells and promotes apoptosis.	Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Mol & Cell Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Cell Death Regulat Lab, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Cryns, VL (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Lurie 4-113,303 E Super St, Chicago, IL 60611 USA.	v-cryns@northwestern.edu	Jones, Jonathan C R/T-9467-2017	Jones, Jonathan C R/0000-0002-1496-4922	NATIONAL CANCER INSTITUTE [P50CA089018, R01CA097198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA097198, P50 CA089018, P50CA89018, R01CA097198] Funding Source: Medline; NIAMS NIH HHS [R01 AR054184-17, R01 AR054184-18, R01 AR054184, R01AR054184] Funding Source: Medline; NIDDK NIH HHS [T32 DK007169, T32DK07169] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Benoit V, 2004, CANCER RES, V64, P2684, DOI 10.1158/0008-5472.CAN-03-2914; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; Chen F, 2004, J BIOL CHEM, V279, P27542, DOI 10.1074/jbc.M400971200; Chen F, 2003, J BIOL CHEM, V278, P6848, DOI 10.1074/jbc.M212021200; Chen F, 2002, J BIOL CHEM, V277, P16775, DOI 10.1074/jbc.M201322200; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Demontis S, 2006, CELL DEATH DIFFER, V13, P335, DOI 10.1038/sj.cdd.4401744; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Dusek RL, 2006, J BIOL CHEM, V281, P3614, DOI 10.1074/jbc.M508258200; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Geuijen CAW, 2002, MOL BIOL CELL, V13, P3845, DOI 10.1091/mbc.02-01-0601; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gonzalez AM, 2001, J CELL SCI, V114, P4197; He YY, 2006, ONCOGENE, V25, P1521, DOI 10.1038/sj.onc.1209184; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; Hopkinson SB, 1998, J INVEST DERMATOL, V111, P1015, DOI 10.1046/j.1523-1747.1998.00452.x; HOPKINSON SB, 1992, J INVEST DERMATOL, V99, P264, DOI 10.1111/1523-1747.ep12616615; HOPKINSON SB, 1995, J CELL BIOL, V130, P117, DOI 10.1083/jcb.130.1.117; Hopkinson SB, 2000, MOL BIOL CELL, V11, P277, DOI 10.1091/mbc.11.1.277; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; Kamradt MC, 2005, J BIOL CHEM, V280, P11059, DOI 10.1074/jbc.M413382200; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lu ML, 2005, J BIOL CHEM, V280, P6742, DOI 10.1074/jbc.M411519200; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Morishima N, 1999, GENES CELLS, V4, P401, DOI 10.1046/j.1365-2443.1999.00270.x; Moyano JV, 2006, J CLIN INVEST, V116, P261, DOI 10.1172/JCI25888; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Niessen CM, 1997, J CELL SCI, V110, P1705; Nievers MG, 1999, MATRIX BIOL, V18, P5, DOI 10.1016/S0945-053X(98)00003-1; Nikolopoulos SN, 2005, MOL CELL BIOL, V25, P6090, DOI 10.1128/MCB.25.14.6090-6102.2005; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rathore N, 2004, J BIOL CHEM, V279, P39358, DOI 10.1074/jbc.M406712200; Russell AJ, 2003, J CELL SCI, V116, P3543, DOI 10.1242/jcs.00663; Ruzzi L, 1997, J CLIN INVEST, V99, P2826, DOI 10.1172/JCI119474; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schaapveld RQJ, 1998, J CELL BIOL, V142, P271, DOI 10.1083/jcb.142.1.271; SKALLI O, 1994, J CELL BIOL, V125, P159, DOI 10.1083/jcb.125.1.159; SOULE HD, 1990, CANCER RES, V50, P6075; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; Stahl S, 1997, J CELL SCI, V110, P55; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Tasanen K, 2004, AM J PATHOL, V164, P2027, DOI 10.1016/S0002-9440(10)63762-5; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tikhomirov O, 2001, J BIOL CHEM, V276, P33675, DOI 10.1074/jbc.M101394200; Tsuruta D, 2003, J BIOL CHEM, V278, P38707, DOI 10.1074/jbc.M301637200; Tsuruta D, 2003, CELL MOTIL CYTOSKEL, V54, P122, DOI 10.1002/cm.10089; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; Varshavsky A, 2003, NAT CELL BIOL, V5, P373, DOI 10.1038/ncb0503-373; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Weiske J, 2001, J BIOL CHEM, V276, P41175, DOI 10.1074/jbc.M105769200; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023; Zhao XX, 2006, J BIOL CHEM, V281, P29357, DOI 10.1074/jbc.M513105200	66	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5560	5569		10.1074/jbc.M603669200	http://dx.doi.org/10.1074/jbc.M603669200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17178732	hybrid, Green Accepted			2022-12-25	WOS:000244482300052
J	Liebscher, M; Jahreis, G; Lucke, C; Grabley, S; Raina, S; Schiene-Fischer, C				Liebscher, Markus; Jahreis, Guenther; Luecke, Christian; Grabley, Susanne; Raina, Satish; Schiene-Fischer, Cordelia			Fatty acyl benzamido antibacterials based on inhibition of DnaK-catalyzed protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAK; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE SYSTEM; TRIGGER FACTOR; SUBSTRATE-BINDING; BACTERIAL HSP70; GRPE; MACHINERY; SUSCEPTIBILITY; REPLICATION	We have reported that the hsp70 chaperone DnaK from Escherichia coli might assist protein folding by catalyzing the cis/trans isomerization of secondary amide peptide bonds in unfolded or partially folded proteins. In this study a series of fatty acylated benzamido inhibitors of the cis/trans isomerase activity of DnaK was developed and tested for antibacterial effects in E coli MC4100 cells. N-alpha-[Tetradecanoyl-(4-aminomethylbenzoyl)]-L-asparagine is the most effective antibacterial with a minimal inhibitory concentration of 100 +/- 20 mu g/ml. The compounds were shown to compete with fluorophore-labeled sigma(32)-derived peptide for the peptide binding site of DnaK and to increase the fraction of aggregated proteins in heat-shocked bacteria. Despite its inability to serve as a folding helper in vivo a DnaK-inhibitor complex was still able to sequester an unfolded protein in vitro. Structure activity relationships revealed a distinct dependence of DnaK-assisted refolding of luciferase on the fatty acyl chain length, whereas the minimal inhibitory concentration was most sensitive to the structural nature of the benzamido core. We conclude that the isomerase activity of DnaK is a major survival factor in the heat shock response of bacteria and that small molecule inhibitors can lead to functional inactivation of DnaK and thus will display antibacterial activity.	Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle, Germany; Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, D-07745 Jena, Germany; Univ Geneva, Ctr Med, Dept Biochim Med, CH-1211 Geneva 4, Switzerland	Max Planck Society; Hans Knoll Institute (HKI); University of Geneva	Schiene-Fischer, C (corresponding author), Max Planck Res Unit Enzymol Prot Folding, Weinbergweg 22, D-06120 Halle, Germany.	schiene@enzyme-halle.mpg.de	Raina, Satish/AAU-9550-2021	Raina, Satish/0000-0003-3175-4932				Amsterdam D, 1996, ANTIBIOTICS LAB MED, V4, P52; Apfel CM, 2001, ANTIMICROB AGENTS CH, V45, P1058, DOI 10.1128/AAC.45.4.1058-1064.2001; Blagg BSJ, 2006, MED RES REV, V26, P310, DOI 10.1002/med.20052; BUKAU B, 1993, MOL MICROBIOL, V9, P671, DOI 10.1111/j.1365-2958.1993.tb01727.x; CRAIG DA, 1993, TRENDS PHARMACOL SCI, V14, P89, DOI 10.1016/0165-6147(93)90070-Z; Cudic M, 2002, PEPTIDES, V23, P2071, DOI 10.1016/S0196-9781(02)00244-9; Dathe M, 1996, BIOCHEMISTRY-US, V35, P12612, DOI 10.1021/bi960835f; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Fischer G, 2006, MOL MICROBIOL, V61, P1388, DOI 10.1111/j.1365-2958.2006.05349.x; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; GARBE TR, 1992, EXPERIENTIA, V48, P635, DOI 10.1007/BF02118308; Hanawa T, 1999, CELL STRESS CHAPERON, V4, P118, DOI 10.1379/1466-1268(1999)004<0118:TLMDCI>2.3.CO;2; HANCOCK REW, 1988, EUR J CLIN MICROBIOL, V7, P713, DOI 10.1007/BF01975036; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Kluck CJ, 2002, J BIOL CHEM, V277, P41060, DOI 10.1074/jbc.M206520200; Kohler S, 1996, MOL MICROBIOL, V20, P701, DOI 10.1111/j.1365-2958.1996.tb02510.x; Kragol G, 2001, BIOCHEMISTRY-US, V40, P3016, DOI 10.1021/bi002656a; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEHRER RI, 1988, J IMMUNOL METHODS, V108, P153, DOI 10.1016/0022-1759(88)90414-0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Montgomery DL, 1999, J MOL BIOL, V286, P915, DOI 10.1006/jmbi.1998.2514; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; ROCKABRAND D, 1995, J BACTERIOL, V177, P3695, DOI 10.1128/jb.177.13.3695-3703.1995; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Schiene-Fischer C, 2002, BIOL CHEM, V383, P1865, DOI 10.1515/BC.2002.210; Schiene-Fischer C, 2002, NAT STRUCT BIOL, V9, P419, DOI 10.1038/nsb804; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Soti C, 2005, BRIT J PHARMACOL, V146, P769, DOI 10.1038/sj.bjp.0706396; SPENCE J, 1990, J BACTERIOL, V172, P7157, DOI 10.1128/jb.172.12.7157-7166.1990; Stevens SY, 2003, PROTEIN SCI, V12, P2588, DOI 10.1110/ps.03269103; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Takaya A, 2004, INFECT IMMUN, V72, P1364, DOI 10.1128/IAI.72.3.1364-1373.2004; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; THONUS IP, 1982, ANTIMICROB AGENTS CH, V22, P386, DOI 10.1128/AAC.22.3.386; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; Wolska KI, 2000, MICROB DRUG RESIST, V6, P119, DOI 10.1089/107662900419429; Yoshimune K, 2002, BIOCHEM BIOPH RES CO, V293, P1389, DOI 10.1016/S0006-291X(02)00403-5; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	46	26	26	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4437	4446		10.1074/jbc.M607667200	http://dx.doi.org/10.1074/jbc.M607667200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17170117	hybrid			2022-12-25	WOS:000244482000024
J	Nightingale, KP; Gendreizig, S; White, DA; Bradbury, C; Hollfelder, F; Turner, BM				Nightingale, Karl P.; Gendreizig, Susanne; White, Darren A.; Bradbury, Charlotte; Hollfelder, Florian; Turner, Bryan M.			Cross-talk between histone modifications in response to histone deacetylase inhibitors - MLL4 links histone H3 acetylation and histone H3K4 methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE GENES; DEMETHYLATION; CHROMATIN; LYSINE-4; PATTERN; K4	Histones are subject to a wide variety of post-translational modifications that play a central role in gene activation and silencing. We have used histone modification-specific antibodies to demonstrate that two histone modifications involved in gene activation, histone H3 acetylation and H3 lysine 4 methylation, are functionally linked. This interaction, in which the extent of histone H3 acetylation determines both the abundance and the "degree" of H3K4 methylation, plays a major role in the epigenetic response to histone deacetylase inhibitors. A combination of in vivo knockdown experiments and in vitro methyltransferase assays shows that the abundance of H3K4 methylation is regulated by the activities of two opposing enzyme activities, the methyltransferase MLL4, which is stimulated by acetylated substrates, and a novel and as yet unidentified H3K4me3 demethylase.	Univ Birmingham, Inst Biomed Res, Med Sch, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Birmingham; University of Cambridge	Turner, BM (corresponding author), Univ Birmingham, Inst Biomed Res, Med Sch, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England.	b.m.turner@bham.ac.uk		Hollfelder, Florian/0000-0002-1367-6312	Biotechnology and Biological Sciences Research Council [G20017] Funding Source: Medline; Medical Research Council [G0300332] Funding Source: Medline; MRC [G0300332] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; COVAULT J, 1980, J BIOL CHEM, V255, P9110; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Hazzalin CA, 2005, PLOS BIOL, V3, P2111, DOI 10.1371/journal.pbio.0030393; HENDZEL MJ, 1991, BIOCHEM J, V273, P753, DOI 10.1042/bj2730753; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004; Mateescu B, 2004, EMBO REP, V5, P490, DOI 10.1038/sj.embor.7400139; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Mito Y, 2005, NAT GENET, V37, P1090, DOI 10.1038/ng1637; Morillon A, 2005, MOL CELL, V18, P723, DOI 10.1016/j.molcel.2005.05.009; Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015; O'Neill LP, 2003, HUM MOL GENET, V12, P1783, DOI 10.1093/hmg/ddg193; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider J, 2005, MOL CELL, V19, P849, DOI 10.1016/j.molcel.2005.07.024; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Shahbazian MD, 2005, MOL CELL, V19, P271, DOI 10.1016/j.molcel.2005.06.010; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sims RJ, 2005, J BIOL CHEM, V280, P41789, DOI 10.1074/jbc.C500395200; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Xiao B, 2003, NATURE, V421, P652, DOI 10.1038/nature01378; Zhang KL, 2004, PROTEOMICS, V4, P3765, DOI 10.1002/pmic.200400819	32	154	156	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4408	4416		10.1074/jbc.M606773200	http://dx.doi.org/10.1074/jbc.M606773200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17166833	hybrid			2022-12-25	WOS:000244482000021
J	Pan, ZQ; Rimando, AM; Baerson, SR; Fishbein, M; Duke, SO				Pan, Zhiqiang; Rimando, Agnes M.; Baerson, Scott R.; Fishbein, Mark; Duke, Stephen O.			Functional characterization of desaturases involved in the formation of the terminal double bond of an unusual 16 : 3 Delta(9,12,15) fatty acid isolated from Sorghum bicolor root hairs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORGOLEONE; GENE; EXPRESSION; EXUDATE; STRATEGIES; INHIBITOR; DELTA-12; LOCATION; ENZYME	Sorgoleone, produced in root hair cells of sorghum (Sorghum bicolor), is likely responsible for much of the allelopathic properties of sorghum root exudates against broadleaf and grass weeds. Previous studies suggest that the biosynthetic pathway of this compound initiates with the synthesis of an unusual 16:3 fatty acid possessing a terminal double bond. The corresponding fatty acyl-CoA serves as a starter unit for polyketide synthases, resulting in the formation of 5-pentadecatrienyl resorcinol. This resorcinolic intermediate is then methylated by an S-adenosylmethionine-dependent O-methyltransferase and subsequently dihydroxylated, yielding the reduced (hydroquinone) form of sorgoleone. To characterize the corresponding enzymes responsible for the biosynthesis of the 16:3 fatty acyl-CoA precursor, we identified and cloned three putative fatty acid desaturases, designated SbDES1, SbDES2, and SbDES3, from an expressed sequence tag (EST) data base prepared from isolated root hairs. Quantitative real-time RT-PCR analyses revealed that these three genes were preferentially expressed in sorghum root hairs where the 16:2 and 16:3 fatty acids were exclusively localized. Heterologous expression of the cDNAs in Saccharomyces cerevisiae revealed that recombinant SbDES2 converted palmitoleic acid (16:1 Delta(9)) to hexadecadienoic acid (16:2 Delta(9,12)), and that recombinant SbDES3 was capable of converting hexadecadienoic acid into hexadecatrienoic acid (16:3 Delta(9,12,15)). Unlike other desaturases reported to date, the double bond introduced by SbDES3 occurred between carbons 15 and 16 resulting in a terminal double bond aliphatic chain. Collectively, the present results strongly suggest that these fatty acid desaturases represent key enzymes involved in the biosynthesis of the allelochemical sorgoleone.	USDA ARS, Nat Prod Utilizat Res Unit, University, MS 38677 USA; Portland State Univ, Dept Biol, Portland, OR 97207 USA	United States Department of Agriculture (USDA); Portland State University	Pan, ZQ (corresponding author), USDA ARS, Nat Prod Utilizat Res Unit, POB 8048, University, MS 38677 USA.	zpan@msa-oxford.ars.usda.gov		Fishbein, Mark/0000-0003-3099-4387				Baerson SR, 2005, J BIOL CHEM, V280, P21867, DOI 10.1074/jbc.M500694200; Bais HP, 2004, TRENDS PLANT SCI, V9, P26, DOI 10.1016/j.tplants.2003.11.008; Behrouzian B, 2002, CURR OPIN CHEM BIOL, V6, P577, DOI 10.1016/S1367-5931(02)00365-4; BROWSE J, 1993, J BIOL CHEM, V268, P16345; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; Bucher M, 1997, PLANT MOL BIOL, V35, P497, DOI 10.1023/A:1005869717158; Burke D, 2000, METHODS YEAST GENETI, P103; CHANG M, 1986, J AM CHEM SOC, V108, P7858, DOI 10.1021/ja00284a074; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cordonnier-Pratt MM, 2004, COMP FUNCT GENOM, V5, P268, DOI 10.1002/cfg.399; Czarnota MA, 2003, INT J PLANT SCI, V164, P861, DOI 10.1086/378661; Czarnota MA, 2003, J CHEM ECOL, V29, P2073, DOI 10.1023/A:1025634402071; Czarnota MA, 2001, WEED TECHNOL, V15, P813, DOI 10.1614/0890-037X(2001)015[0813:MOALOP]2.0.CO;2; Dayan FE, 2003, J BIOL CHEM, V278, P28607, DOI 10.1074/jbc.M304185200; Domergue F, 2005, BIOCHEM J, V389, P483, DOI 10.1042/BJ20050111; Duke SO, 2002, J PESTIC SCI, V27, P298; Duke SO, 2003, TRENDS BIOTECHNOL, V21, P192, DOI 10.1016/S0167-7799(03)00056-8; Dyer JM, 2002, PLANT PHYSIOL, V130, P2027, DOI 10.1104/pp.102.010835; EINHELLIG FA, 1993, J CHEM ECOL, V19, P369, DOI 10.1007/BF00993702; EINHELLIG FA, 1992, J CHEM ECOL, V18, P1, DOI 10.1007/BF00997160; Einhellig FA, 1996, AGRON J, V88, P886, DOI 10.2134/agronj1996.00021962003600060007x; Fate GD, 1996, J AM CHEM SOC, V118, P11369, DOI 10.1021/ja961395i; FAY L, 1991, J CHROMATOGR, V541, P89, DOI 10.1016/S0021-9673(01)95986-2; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Gonzalez VM, 1997, J AGR FOOD CHEM, V45, P1415, DOI 10.1021/jf960733w; Heilmann I, 2004, P NATL ACAD SCI USA, V101, P10266, DOI 10.1073/pnas.0402200101; Horiguchi G, 2000, PLANT J, V24, P805, DOI 10.1046/j.1365-313x.2000.00925.x; Inderjit, 2003, PLANTA, V217, P529, DOI 10.1007/s00425-003-1054-z; Kodama H, 1997, PLANT MOL BIOL, V33, P493, DOI 10.1023/A:1005726210977; Los DA, 1998, BBA-LIPID LIPID MET, V1394, P3, DOI 10.1016/S0005-2760(98)00091-5; Martin CE, 2002, BIOCHEM SOC T, V30, P1080, DOI 10.1042/bst0301080; MIQUEL M, 1993, P NATL ACAD SCI USA, V90, P6208, DOI 10.1073/pnas.90.13.6208; Mongrand S, 1998, PHYTOCHEMISTRY, V49, P1049, DOI 10.1016/S0031-9422(98)00243-X; NETZLY DH, 1986, CROP SCI, V26, P775, DOI 10.2135/cropsci1986.0011183X002600040031x; NETZLY DH, 1988, WEED SCI, V36, P441, DOI 10.1017/S0043174500075172; Peyou-Ndi MM, 2000, ARCH BIOCHEM BIOPHYS, V376, P399, DOI 10.1006/abbi.2000.1733; RASMUSSEN JA, 1992, J CHEM ECOL, V18, P197, DOI 10.1007/BF00993753; Rimando AM, 1998, J NAT PROD, V61, P927, DOI 10.1021/np9800708; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sayanova O, 2006, J BIOL CHEM, V281, P36533, DOI 10.1074/jbc.M605158200; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; Suga K, 2002, BIOSCI BIOTECH BIOCH, V66, P1314, DOI 10.1271/bbb.66.1314; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wallis JG, 2002, TRENDS BIOCHEM SCI, V27, P467, DOI 10.1016/S0968-0004(02)02168-0; Yang XH, 2004, J EXP BOT, V55, P2251, DOI 10.1093/jxb/erh252	47	30	35	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4326	4335		10.1074/jbc.M606343200	http://dx.doi.org/10.1074/jbc.M606343200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17178719	hybrid			2022-12-25	WOS:000244482000012
J	Schleicher, E; Hitomi, K; Kay, CWM; Getzoff, ED; Todo, T; Weber, S				Schleicher, Erik; Hitomi, Kenichi; Kay, Christopher W. M.; Getzoff, Elizabeth D.; Todo, Takeshi; Weber, Stefan			Electron nuclear double resonance differentiates complementary roles for active site histidines in (6-4) photolyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA PHOTOLYASE; ESCHERICHIA-COLI; PARAMAGNETIC-RESONANCE; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; SOLVENT POLARITY; FLAVIN COFACTOR; SPIN RESONANCE; X-BAND; SPECTROSCOPY	(6-4) photolyase catalyzes the light-dependent repair of UV-damaged DNA containing (6-4) photoproducts. Blue light excitation of the enzyme generates the neutral FAD radical, FADH(center dot), which is believed to be transiently formed during the enzymatic DNA repair. Here (6-4) photolyase has been examined by optical spectroscopy, electron paramagnetic resonance, and pulsed electron nuclear double resonance spectroscopy. Characterization of selected proton hyperfine couplings of FADH(center dot), namely those of H-8 alpha and H-1', yields information on the micropolarity at the site where the DNA substrate is expected to bind. Shifts in the hyperfine couplings as a function of structural modifications induced by point mutations and pH changes distinguish the protonation states of two highly conserved histidines, His(354) and His(358), in Xenopus laevis (6-4) photolyase. These are proposed to catalyze formation of the oxetane intermediate that precedes light-initiated DNA repair. The results show that at pH 9.5, where the enzymatic repair activity is highest, His 358 is deprotonated, whereas His(354) is protonated. Hence, the latter is likely the proton donor that initiates oxetane formation from the (6-4) photoproduct.	Free Univ Berlin, Fachbereich Phys, D-14195 Berlin, Germany; Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; UCL, Dept Biol, London WC1E 6BT, England; Kyoto Univ, Radiat Biol Ctr, Kyoto 6068501, Japan	Free University of Berlin; Scripps Research Institute; Scripps Research Institute; University of London; University College London; Kyoto University	Weber, S (corresponding author), Free Univ Berlin, Fachbereich Phys, Arnimallee 14, D-14195 Berlin, Germany.	Stefan.Weber@physik.fu-berlin.de	Kay, Christopher William Michael/C-2467-2008; Schleicher, Erik/C-9951-2010; Weber, Stefan/G-6164-2010	Kay, Christopher William Michael/0000-0002-5200-6004; Schleicher, Erik/0000-0003-2953-050X				Barquera B, 2003, J AM CHEM SOC, V125, P265, DOI 10.1021/ja0207201; Byrdin M, 2004, BBA-BIOENERGETICS, V1655, P64, DOI 10.1016/j.bbabio.2003.07.001; CARRINGTON A, 1967, INTRO MAGNETIC RESON, P83; DAVIES ER, 1974, PHYS LETT A, VA 47, P1, DOI 10.1016/0375-9601(74)90078-4; Deisenhofer J, 2000, MUTAT RES-DNA REPAIR, V460, P143, DOI 10.1016/S0921-8777(00)00023-9; EDMONDSON DE, 1983, TOP CURR CHEM, V108, P109; EKER APM, 1990, J BIOL CHEM, V265, P8009; Essen LO, 2006, CURR OPIN STRUC BIOL, V16, P51, DOI 10.1016/j.sbi.2006.01.004; FASANELL.EL, 1969, P NATL ACAD SCI USA, V62, P299, DOI 10.1073/pnas.62.2.299; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Garcia JI, 2002, J PHYS CHEM A, V106, P4729, DOI 10.1021/jp014696; HEELIS PF, 1990, BIOCHEMISTRY-US, V29, P5694, DOI 10.1021/bi00476a008; HELLER C, 1960, J CHEM PHYS, V32, P1535, DOI 10.1063/1.1730955; Hitomi K, 2001, J BIOL CHEM, V276, P10103, DOI 10.1074/jbc.M008828200; Hitomi K, 1997, J BIOL CHEM, V272, P32591, DOI 10.1074/jbc.272.51.32591; JORDAN SP, 1988, BIOCHEMISTRY-US, V27, P8915, DOI 10.1021/bi00425a007; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; Kato R, 1997, J BACTERIOL, V179, P6499, DOI 10.1128/jb.179.20.6499-6503.1997; Kay C.W.M., 2002, ELECT PARAMAGNETIC R, V18, P222; Kay CWM, 2005, MAGN RESON CHEM, V43, pS96, DOI 10.1002/mrc.1667; Kay CWM, 2003, J BIOL CHEM, V278, P10973, DOI 10.1074/jbc.M205509200; Kay CWM, 1999, BIOCHEMISTRY-US, V38, P16740, DOI 10.1021/bi991442u; KHRAMTSOV VV, 1982, CHEM PHYS LETT, V91, P69, DOI 10.1016/0009-2614(82)87035-8; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; KIM JK, 1995, EUR J BIOCHEM, V228, P849, DOI 10.1111/j.1432-1033.1995.0849m.x; KIM ST, 1994, J BIOL CHEM, V269, P8535; KNAUER BR, 1976, J AM CHEM SOC, V98, P4395, DOI 10.1021/ja00431a010; KURRECK H, 1984, J AM CHEM SOC, V106, P737, DOI 10.1021/ja00315a048; Li J, 2006, J PHYS CHEM B, V110, P16724, DOI 10.1021/jp062998b; LI YF, 1991, BIOCHEMISTRY-US, V30, P6322, DOI 10.1021/bi00239a034; Medina M, 1999, BIOPHYS J, V77, P1712, DOI 10.1016/S0006-3495(99)77017-7; Mees A, 2004, SCIENCE, V306, P1789, DOI 10.1126/science.1101598; Nakajima S, 1998, NUCLEIC ACIDS RES, V26, P638, DOI 10.1093/nar/26.2.638; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; SANCAR A, 1984, J MOL BIOL, V172, P223, DOI 10.1016/S0022-2836(84)80040-6; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; SANCAR GB, 1987, J BIOL CHEM, V262, P15457; Saracino GAA, 2002, J PHYS CHEM A, V106, P10700, DOI 10.1021/jp026492e; Schelvis JPM, 2003, J PHYS CHEM B, V107, P12352, DOI 10.1021/jp034209l; Schwartz RN, 1997, J PHYS CHEM B, V101, P8735, DOI 10.1021/jp970555p; Stoll S, 2006, J MAGN RESON, V178, P42, DOI 10.1016/j.jmr.2005.08.013; STONE EW, 1962, J CHEM PHYS, V37, P1326, DOI 10.1063/1.1733281; Todo T, 1999, MUTAT RES-DNA REPAIR, V434, P89, DOI 10.1016/S0921-8777(99)00013-0; Todo T, 1997, NUCLEIC ACIDS RES, V25, P764, DOI 10.1093/nar/25.4.764; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; Weber S, 2005, BBA-BIOENERGETICS, V1707, P1, DOI 10.1016/j.bbabio.2004.02.010; Weber S, 2005, CHEMPHYSCHEM, V6, P292, DOI 10.1002/cphc.200400377; Weber S, 2002, P NATL ACAD SCI USA, V99, P1319, DOI 10.1073/pnas.032469399; Weber S, 2001, BIOPHYS J, V81, P1195, DOI 10.1016/S0006-3495(01)75777-3; Weber S, 2001, J AM CHEM SOC, V123, P3790, DOI 10.1021/ja003426m; WILLIAMSSMITH DL, 1977, BIOCHEM J, V167, P593, DOI 10.1042/bj1670593; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580	54	69	70	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4738	4747		10.1074/jbc.M604734200	http://dx.doi.org/10.1074/jbc.M604734200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17164245	hybrid			2022-12-25	WOS:000244482000055
J	Stephens, JL; Lee, SH; Paul, KS; Englund, PT				Stephens, Jennifer L.; Lee, Soo Hee; Paul, Kimberly S.; Englund, Paul T.			Mitochondrial fatty acid synthesis in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-CARRIER PROTEIN; VARIANT SURFACE GLYCOPROTEIN; NEUROSPORA-CRASSA MITOCHONDRIA; NADH-UBIQUINONE OXIDOREDUCTASE; 2-ENOYL THIOESTER REDUCTASES; LIPOATE BIOSYNTHETIC LOCUS; BLOOD-STREAM FORMS; SACCHAROMYCES-CEREVISIAE; LIPOIC ACID; ESCHERICHIA-COLI	Whereas other organisms utilize type I or type II synthases to make fatty acids, trypanosomatid parasites such as Trypanosoma brucei are unique in their use of a microsomal elongase pathway (ELO) for de novo fatty acid synthesis (FAS). Because of the unusual lipid metabolism of the trypanosome, it was important to study a second FAS pathway predicted by the genome to be a type II synthase. We localized this pathway to the mitochondrion, and RNA interference (RNAi) or genomic deletion of acyl carrier protein (ACP) and beta-ketoacyl-ACP synthase indicated that this pathway is likely essential for bloodstream and procyclic life cycle stages of the parasite. In vitro assays show that the largest major fatty acid product of the pathway is C16, whereas the ELO pathway, utilizing ELOs 1, 2, and 3, synthesizes up to C18. To demonstrate mitochondrial FAS in vivo, we radiolabeled fatty acids in cultured procyclic parasites with [C-14]pyruvate or [C-14]threonine, either of which is catabolized to [C-14]acetyl-CoA in the mitochondrion. Although some of the [C-14]acetyl-CoA may be utilized by the ELO pathway, a striking reduction in radiolabeled fatty acids following ACP RNAi confirmed that it is also consumed by mitochondrial FAS. ACP depletion by RNAi or gene knockout also reduces lipoic acid levels and drastically decreases protein lipoylation. Thus, octanoate (C8), the precursor for lipoic acid synthesis, must also be a product of mitochondrial FAS. Trypanosomes employ two FAS systems: the unconventional ELO pathway that synthesizes bulk fatty acids and a mitochondrial pathway that synthesizes specialized fatty acids that are likely utilized intramitochondrially.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Englund, PT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	penglund@jhmi.edu	Paul, Kimberly/AAO-4275-2020; Lee, Soo Hee/E-9494-2012	Guler, Jennifer/0000-0001-6301-4563	NIAID NIH HHS [AI21334] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021334] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; Boesen CC, 2000, PROTEIN EXPRES PURIF, V20, P98, DOI 10.1006/prep.2000.1306; Bowman I.B.R., 1976, P435; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; Bringaud F, 2006, MOL BIOCHEM PARASIT, V149, P1, DOI 10.1016/j.molbiopara.2006.03.017; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; Brown SV, 2006, EUKARYOT CELL, V5, P45, DOI 10.1128/EC.5.1.45-53.2006; BRUN R, 1979, ACTA TROP, V36, P289; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Cronan JE, 2006, CELL, V126, P641, DOI 10.1016/j.cell.2006.08.001; CROSS GAM, 1975, PARASITOLOGY, V71, P311, DOI 10.1017/S0031182000046758; DIXON H, 1971, COMP BIOCHEM PHYSIOL, V39, P247, DOI 10.1016/0305-0491(71)90168-4; DOERING TL, 1993, J BIOL CHEM, V268, P9215; DURIEUX PO, 1991, MOL BIOCHEM PARASIT, V45, P19, DOI 10.1016/0166-6851(91)90023-Y; EFFRON PN, 1993, MOL BIOCHEM PARASIT, V59, P191, DOI 10.1016/0166-6851(93)90217-L; FAIRLAMB AH, 1992, MOL BIOCHEM PARASIT, V53, P223, DOI 10.1016/0166-6851(92)90024-E; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; GILBERT RJ, 1983, COMP BIOCHEM PHYS B, V74, P277, DOI 10.1016/0305-0491(83)90012-3; GILBERT RJ, 1984, COMP BIOCHEM PHYS B, V78, P595, DOI 10.1016/0305-0491(84)90104-4; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; HARINGTON A, 1993, MOL MICROBIOL, V9, P545, DOI 10.1111/j.1365-2958.1993.tb01715.x; HAYDEN MA, 1992, J BIOL CHEM, V267, P9512; HERELD D, 1986, J BIOL CHEM, V261, P3813; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; INUI H, 1984, EUR J BIOCHEM, V142, P121, DOI 10.1111/j.1432-1033.1984.tb08258.x; JACKMAN SA, 1990, EUR J BIOCHEM, V193, P91, DOI 10.1111/j.1432-1033.1990.tb19308.x; Jensen BC, 2003, J BIOL CHEM, V278, P32204, DOI 10.1074/jbc.M304198200; Jones SM, 2005, J MED CHEM, V48, P5932, DOI 10.1021/jm049067d; KLEIN RA, 1976, BIOCHEM SOC T, V4, P48, DOI 10.1042/bst0040048; KLEIN RA, 1982, MOL BIOCHEM PARASIT, V6, P93, DOI 10.1016/0166-6851(82)90068-8; Klingbeil MM, 2002, MOL CELL, V10, P175, DOI 10.1016/S1097-2765(02)00571-3; Lamb JR, 2001, J BIOL CHEM, V276, P21512, DOI 10.1074/jbc.M100235200; Lamour N, 2005, J BIOL CHEM, V280, P11902, DOI 10.1074/jbc.M414274200; Lee SH, 2006, CELL, V126, P691, DOI 10.1016/j.cell.2006.06.045; LINSTEAD DJ, 1977, J GEN MICROBIOL, V101, P243, DOI 10.1099/00221287-101-2-243; MIKOLAJCZYK S, 1990, EUR J BIOCHEM, V187, P431, DOI 10.1111/j.1432-1033.1990.tb15322.x; Moon YA, 2001, J BIOL CHEM, V276, P45358, DOI 10.1074/jbc.M108413200; Morita YS, 2000, SCIENCE, V288, P140, DOI 10.1126/science.288.5463.140; Motyka SA, 2006, J BIOL CHEM, V281, P18499, DOI 10.1074/jbc.M602880200; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Panigrahi AK, 2003, J AM SOC MASS SPECTR, V14, P728, DOI 10.1016/S1044-0305(03)00126-0; Panigrahi AK, 2003, RNA, V9, P484, DOI 10.1261/rna.2194603; Paul KS, 2004, EUKARYOT CELL, V3, P855, DOI 10.1128/EC.3.4.855-861.2004; Ragone G, 1999, MOL GEN GENET, V261, P690, DOI 10.1007/s004380050012; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; SACKMANN U, 1991, EUR J BIOCHEM, V200, P463, DOI 10.1111/j.1432-1033.1991.tb16205.x; Schnaufer A, 2005, EMBO J, V24, P4029, DOI 10.1038/sj.emboj.7600862; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; Schneider R, 1997, CURR GENET, V32, P384, DOI 10.1007/s002940050292; SHIMAKATA T, 1982, ARCH BIOCHEM BIOPHYS, V217, P144, DOI 10.1016/0003-9861(82)90488-X; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SULO P, 1993, J BIOL CHEM, V268, P17634; Torkko JM, 2003, J BIOL CHEM, V278, P41213, DOI 10.1074/jbc.M307664200; Torkko JM, 2001, MOL CELL BIOL, V21, P6243, DOI 10.1128/MCB.21.18.6243-6253.2001; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; van Weelden SWH, 2005, J BIOL CHEM, V280, P12451, DOI 10.1074/jbc.M412447200; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591; Wang J, 2006, NATURE, V441, P358, DOI 10.1038/nature04784; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WEEKS G, 1968, J BIOL CHEM, V243, P1180; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WIRTZ E, 1995, SCIENCE, V268, P1179, DOI 10.1126/science.7761835; Yasuno R, 2004, J BIOL CHEM, V279, P8242, DOI 10.1074/jbc.M308894200; Young K, 2006, ANTIMICROB AGENTS CH, V50, P519, DOI 10.1128/AAC.50.2.519-526.2006; ZENSEN R, 1992, FEBS LETT, V310, P179, DOI 10.1016/0014-5793(92)81324-F; Zhang L, 2005, J BIOL CHEM, V280, P12422, DOI 10.1074/jbc.M413686200; Zhang YM, 2004, LIPIDS, V39, P1055, DOI 10.1007/s11745-004-1330-3; Zhang YM, 2006, J BIOL CHEM, V281, P17541, DOI 10.1074/jbc.R600004200; ZIMMERMAN SB, 1987, P NATL ACAD SCI USA, V84, P1871, DOI 10.1073/pnas.84.7.1871	71	86	91	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4427	4436		10.1074/jbc.M609037200	http://dx.doi.org/10.1074/jbc.M609037200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17166831	hybrid			2022-12-25	WOS:000244482000023
J	Bist, P; Madhusoodanan, UK; Rao, DN				Bist, Pradeep; Madhusoodanan, Urulangodi Kunhiraman; Rao, Desirazu N.			A mutation in the mod subunit of EcoP151 restriction enzyme converts the DNA methyltransferase to a site-specific endonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION SITES; ESCHERICHIA-COLI; ATP HYDROLYSIS; CLEAVAGE; TRANSLOCATION	A closer inspection of the amino acid sequence of EcoP15I DNA methyltransferase revealed a region of similarity to the PDXn(D/E)XK catalytic site of type II restriction endonucleases, except for methionine in EcoP15I DNA methyltransferase instead of proline. Substitution of methionine at position 357 by proline converts EcoP15I DNA methyltransferase to a site-specific endonuclease. EcoP15I-M357P DNA methyltransferase specifically binds to the recognition sequence 5'-CAGCAG-3' and cleaves DNA asymmetrically EcoP151-M357P(.)DNA methyltransferase specifically binds to the recognition sequence 5'-CAGCAG-3' and cleaves DNA asymmetrically, 5'-CAGCAG(N)(10)-3', as indicated by the arrows, in presence of magnesium ions.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rao, DN (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	dnrao@biochem.iisc.ernet.in	BIST, PRADEEP/AAG-7986-2019					AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; AHAMD I, 1994, J MOL BIOL, V242, P378, DOI 10.1006/jmbi.1994.1588; Bath AJ, 2002, J BIOL CHEM, V277, P4024, DOI 10.1074/jbc.M108441200; Bist P, 2003, J BIOL CHEM, V278, P41837, DOI 10.1074/jbc.M307053200; Bitinaite J, 1998, P NATL ACAD SCI USA, V95, P10570, DOI 10.1073/pnas.95.18.10570; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bujnicki JM, 2000, J MOL EVOL, V50, P39, DOI 10.1007/s002399910005; Dryden DTF, 2001, NUCLEIC ACIDS RES, V29, P3728, DOI 10.1093/nar/29.18.3728; Dupureur CM, 2001, BIOCHEMISTRY-US, V40, P387, DOI 10.1021/bi001680l; ENDLICH B, 1985, J BIOL CHEM, V260, P5729; Fuxreiter M, 2002, PROTEIN SCI, V11, P1978, DOI 10.1110/ps.4980102; JO K, 1995, SCIENCE, V267, P1817, DOI 10.1126/science.7892605; Kingston IJ, 2003, NUCLEIC ACIDS RES, V31, P5221, DOI 10.1093/nar/gkg743; Kosinski J, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-172; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lagunavicius A, 2003, J MOL BIOL, V326, P1051, DOI 10.1016/S0022-2836(03)00020-2; MEISEL A, 1995, EMBO J, V14, P2958, DOI 10.1002/j.1460-2075.1995.tb07296.x; MEISEL A, 1992, NATURE, V355, P467, DOI 10.1038/355467a0; MEISEL A, 1991, NUCLEIC ACIDS RES, V19, P3997, DOI 10.1093/nar/19.14.3997; Peakman LJ, 2004, NUCLEIC ACIDS RES, V32, P4166, DOI 10.1093/nar/gkh762; Pingoud A, 2005, CELL MOL LIFE SCI, V62, P685, DOI 10.1007/s00018-004-4513-1; Raghavendra NK, 2004, NUCLEIC ACIDS RES, V32, P5703, DOI 10.1093/nar/gkh899; RAO DN, 1989, J MOL BIOL, V209, P599, DOI 10.1016/0022-2836(89)90597-4; Reddy YVR, 1998, J BIOL CHEM, V273, P23866, DOI 10.1074/jbc.273.37.23866; Roberts RJ, 2005, NUCLEIC ACIDS RES, V33, pD230; Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P1805, DOI 10.1093/nar/gkg274; SAHA S, 1995, J MOL BIOL, V247, P559, DOI 10.1016/S0022-2836(05)80137-8; Sambrook J, 2001, MOL CLONING LAB MANU; SEGEL IH, 1975, BIOCH CALCULATIONS, P208; Vipond IB, 1995, MOL BIOTECHNOL, V4, P259, DOI 10.1007/BF02779019; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101	31	3	3	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3520	3530		10.1074/jbc.M603250200	http://dx.doi.org/10.1074/jbc.M603250200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148461	hybrid			2022-12-25	WOS:000244481900014
J	Kuniyeda, K; Okuno, T; Terawaki, K; Miyano, M; Yokomizo, T; Shimizu, T				Kuniyeda, Kanako; Okuno, Toshiaki; Terawaki, Kan; Miyano, Masashi; Yokomizo, Takehiko; Shimizu, Takao			Identification of the intracellular region of the leukotriene B-4 receptor type 1 that is specifically involved in G(i) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; B-4 RECEPTOR; STRUCTURAL DETERMINANTS; BINDING-SITE; IN-VITRO; RHODOPSIN; CLONING; MUTANT; CRYSTALLOGRAPHY; RECONSTITUTION	Many G-protein-coupled receptors can activate more than one G-protein subfamily member. Leukotriene B-4 receptor type 1 (BLT1) is a high affinity G-protein-coupled receptors for leukotriene B-4 functioning in host defense, inflammation, and immunity. Previous studies have shown that BLT1 utilizes different G-proteins (the G(i) family and G(16) G-proteins) in mediating diverse cellular events and that truncation of the cytoplasmic tail of BLT1 does not impair activation of Gi and G16 proteins. To determine responsive regions of BLT1 for G-protein coupling, we performed an extensive mutagenesis study of its intracellular loops. Three intracellular loops (i1, i2, and i3) of BLT1 were found to be important for both Gi and G16 coupling, as judged by G(i)-dependent guanosine 5'-(gamma-thio)triphosphate (GTP gamma S) binding and G(16)-dependent inositol phosphate accumulation assays. The i3-1 mutant, with a mutation at the i3 amino terminus, exhibited greatly reduced GTP gamma S binding but intact inositol phosphate accumulation triggered by leukotriene B, stimulation. These results suggest that the i3-1 region is required only for Gi activation. Moreover, in the i3-1 mutant, the deficiency in Gi activation was accompanied by a loss of the high affinity leukotriene B4 binding state seen with the wild type receptor. A three-dimensional model of BLT1 constructed based on the structure of bovine rhodopsin suggests that the i3-1 region may consist of the cytoplasmic end of the transmembrane helix V, which protrudes the helix into the cytoplasm. From mutational studies and three-dimensional modeling, we propose that the extended cytoplasmic helix connected to the transmembrane helix V of BLT1 might be a key region for selective activation of Gi proteins.	Univ Tokyo, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Metabolome, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Japan Sci & Technol Agcy, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Harima Inst, Struct Biophys Lab, Sayo, Hyogo 6795148, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; RIKEN	Yokomizo, T (corresponding author), Kyushu Univ, Dept Med Biochem, Fac Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yokomizo-tky@umin.ac.jp	Yokomizo, Takehiko/P-5673-2016; Shimizu, Takao/AAV-7052-2021; Miyano, Masashi/R-2785-2016	Yokomizo, Takehiko/0000-0002-5219-1553; Miyano, Masashi/0000-0003-2253-6175; Kuniyeda, Kanako/0000-0002-4466-0145				Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; Fukunaga K, 2001, J BIOL CHEM, V276, P43025, DOI 10.1074/jbc.M108288200; Gaudreau R, 2004, J BIOL CHEM, V279, P10338, DOI 10.1074/jbc.M309207200; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; GOLDMAN DW, 1984, J ALLERGY CLIN IMMUN, V74, P373, DOI 10.1016/0091-6749(84)90133-7; Haeggstrom JZ, 2004, J BIOL CHEM, V279, P50639, DOI 10.1074/jbc.R400027200; Hermans E, 2003, PHARMACOL THERAPEUT, V99, P25, DOI 10.1016/S0163-7258(03)00051-2; Horn F, 2001, NUCLEIC ACIDS RES, V29, P346, DOI 10.1093/nar/29.1.346; Igarashi T, 1999, EUR J BIOCHEM, V259, P419, DOI 10.1046/j.1432-1327.1999.00054.x; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Jala VR, 2004, TRENDS IMMUNOL, V25, P315, DOI 10.1016/j.it.2004.04.003; Janz JM, 2004, J BIOL CHEM, V279, P29767, DOI 10.1074/jbc.M402567200; Johnston CA, 2005, STRUCTURE, V13, P1069, DOI 10.1016/j.str.2005.04.007; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; Kamohara M, 2000, J BIOL CHEM, V275, P27000; Katada S, 2005, J NEUROSCI, V25, P1806, DOI 10.1523/jneurosci.4723-04.2005; Kusunoki H, 1998, BIOCHEMISTRY-US, V37, P4782, DOI 10.1021/bi972756p; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Luster AD, 2004, NAT REV IMMUNOL, V4, P711, DOI 10.1038/nri1438; Masuda K, 2003, J BIOL CHEM, V278, P24552, DOI 10.1074/jbc.M302801200; MIKI I, 1990, BIOCHEM BIOPH RES CO, V166, P342, DOI 10.1016/0006-291X(90)91951-N; Miyano M, 2005, STRUCTURE, V13, P946, DOI 10.1016/j.str.2005.06.002; Natochin M, 2003, J BIOL CHEM, V278, P37574, DOI 10.1074/jbc.M305136200; NEGISHI M, 1993, J BIOL CHEM, V268, P26067; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Shi LC, 1996, J NEUROCHEM, V67, P1478; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; Showell HJ, 1996, BRIT J PHARMACOL, V117, P1127, DOI 10.1111/j.1476-5381.1996.tb16706.x; SHOWELL HJ, 1995, J PHARMACOL EXP THER, V273, P176; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Tryselius Y, 2000, BIOCHEM BIOPH RES CO, V274, P377, DOI 10.1006/bbrc.2000.3152; Ulfers AL, 2002, PROTEIN SCI, V11, P2526, DOI 10.1110/ps.0218402; Wang SK, 2000, J BIOL CHEM, V275, P40686, DOI 10.1074/jbc.M004512200; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zeldin DC, 2001, J BIOL CHEM, V276, P36059, DOI 10.1074/jbc.R100030200	44	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3998	4006		10.1074/jbc.M610540200	http://dx.doi.org/10.1074/jbc.M610540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158791	hybrid			2022-12-25	WOS:000244481900064
J	Martinez-Caballero, S; Grigoriev, SM; Herrmann, JM; Campo, ML; Kinnally, KW				Martinez-Caballero, Sonia; Grigoriev, Sell M.; Herrmann, Johannes M.; Campo, Maria Luisa; Kinnally, Kathleen W.			Tim17p regulates the twin pore structure and voltage gating of the mitochondrial protein import complex TIM23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE CONDUCTANCE CHANNEL; INNER MEMBRANE; PREPROTEIN TRANSLOCASE; PRESEQUENCE TRANSLOCASE; OUTER-MEMBRANE; MOTOR; MACHINERY; COMPONENT; TIM50; PERMEABILITY	The TIM23 complex mediates import of preproteins into mitochondria, but little is known of the mechanistic properties of this translocase. Here patch clamping reconstituted inner membranes allowed for first time insights into the structure and function of the preprotein translocase. Our findings indicate that the TIM23 channel has "twin pores" (two equal sized pores that cooperatively gate) thereby strikingly resembling TOM, the translocase of the outer membrane. Tim17p and Tim23p are homologues, but their functions differ. Tim23p acts as receptor for preproteins and may largely constitute the preprotein- conducting passageway. Conversely depletion of Tim17p induces a collapse of the twin pores into a single pore, whereas N terminus deletion or C terminus truncation results in variable sized pores that cooperatively gate. Further analysis of Tim17p mutants indicates that the N terminus is vital for both voltage sensing and protein sorting. These results suggest that although Tim23p is the main structural unit of the pore Tim17p is required for twin pore structure and provides the voltage gate for the TIM23 channel.	NYU, Coll Dent, Dept Basic Sci, New York, NY 10010 USA; Univ Extremadura, Dept Bioquim & Biol Mol & Genet, Caceres 10071, Spain; Univ Kaiserslautern, Inst Cell Biol, D-67663 Kaiserslautern, Germany	New York University; Universidad de Extremadura; University of Kaiserslautern	Kinnally, KW (corresponding author), NYU, Coll Dent, Dept Basic Sci, 345 E 24th St, New York, NY 10010 USA.	kck1@nyu.edu	Martínez-Caballero, Sonia/AAB-8481-2022; Caballero, Sonia Martinez/B-7583-2013; Campo, Maria Luisa/L-5211-2014	Martínez-Caballero, Sonia/0000-0002-4401-6165; 	NIGMS NIH HHS [GM57249] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057249] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bezrukov SM, 1997, EUR BIOPHYS J BIOPHY, V26, P471, DOI 10.1007/s002490050101; Chacinska A, 2005, CELL, V120, P817, DOI 10.1016/j.cell.2005.01.011; Colombini M, 1996, Ion Channels, V4, P169; D'Silva PD, 2003, P NATL ACAD SCI USA, V100, P13839, DOI 10.1073/pnas.1936150100; DECKER GL, 1977, J ULTRA MOL STRUCT R, V59, P44, DOI 10.1016/S0022-5320(77)80027-0; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; Frazier AE, 2004, NAT STRUCT MOL BIOL, V11, P226, DOI 10.1038/nsmb735; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; Grigoriev SM, 2004, INT REV CYTOL, V238, P227, DOI 10.1016/S0074-7696(04)38005-8; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 2001, IONIC CHANNELS EXCIT, P351; Kozany C, 2004, NAT STRUCT MOL BIOL, V11, P234, DOI 10.1038/nsmb734; KRASILNIKOV OV, 1992, FEMS MICROBIOL IMMUN, V105, P93; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Kushnareva YE, 1999, ARCH BIOCHEM BIOPHYS, V366, P107, DOI 10.1006/abbi.1999.1190; Kushnareva YE, 2001, ARCH BIOCHEM BIOPHYS, V386, P251, DOI 10.1006/abbi.2000.2201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YF, 2004, J BIOL CHEM, V279, P38047, DOI 10.1074/jbc.M404319200; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; LOHRET TA, 1995, J BIOL CHEM, V270, P15950, DOI 10.1074/jbc.270.27.15950; Lohret TA, 1996, J BIOL CHEM, V271, P4846; LOHRET TA, 1995, BIOPHYS J, V68, P2299, DOI 10.1016/S0006-3495(95)80412-1; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; MARTINEZCABALLE.S, 2007, IN PRESS ANAL BIOCH; Meier S, 2005, J BIOL CHEM, V280, P7777, DOI 10.1074/jbc.M412158200; Meinecke M, 2006, SCIENCE, V312, P1523, DOI 10.1126/science.1127628; Milisav I, 2001, J BIOL CHEM, V276, P25856, DOI 10.1074/jbc.M102132200; Moczydlowski E., 1986, ION CHANNEL RECONSTI, P75; Mokranjac D, 2003, EMBO J, V22, P4945, DOI 10.1093/emboj/cdg485; Mokranjac D, 2003, EMBO J, V22, P816, DOI 10.1093/emboj/cdg090; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Muro C, 2003, BIOPHYS J, V84, P2981, DOI 10.1016/S0006-3495(03)70024-1; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Peixoto PM, 2004, RECENT RES DEV BIOPH, V3, P413; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pfanner N, 2002, BBA-MOL CELL RES, V1592, P15, DOI 10.1016/S0167-4889(02)00260-4; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Reichert AS, 2004, TRENDS GENET, V20, P555, DOI 10.1016/j.tig.2004.08.012; Ryan KR, 1998, MOL CELL BIOL, V18, P178, DOI 10.1128/MCB.18.1.178; SABIROV RZ, 1993, GEN PHYSIOL BIOPHYS, V12, P95; Sobko AA, 2006, J BIOL CHEM, V281, P14408, DOI 10.1074/jbc.M513634200; SZABO I, 1992, J BIOL CHEM, V267, P2940; Taylor RD, 2004, BBA-BIOENERGETICS, V1658, P37, DOI 10.1016/j.bbabio.2004.04.017; Truscott KN, 2003, J CELL BIOL, V163, P707, DOI 10.1083/jcb.200308004; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	52	88	88	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3584	3593		10.1074/jbc.M607551200	http://dx.doi.org/10.1074/jbc.M607551200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148445	hybrid			2022-12-25	WOS:000244481900020
J	Ottolia, M; John, S; Ren, XY; Philipson, KD				Ottolia, Michela; John, Scott; Ren, Xiaoyan; Philipson, Kenneth D.			Fluorescent Na+-Ca+ exchangers - Electrophysiological and optical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGE; NA+/CA2+ EXCHANGER; CA2+-BINDING DOMAIN; DYNAMIC PROPERTIES; MEMBRANE PATCHES; STEADY-STATE; XIP REGION; PROTEIN; CA2+	The cardiac sarcolemmal Na+-Ca2+ exchanger (NCX1) influences cardiac contractility by extruding Ca2+ from myocytes. As a Ca2+ efflux mechanism, the exchanger plays a prominent role in Ca2+ homeostasis. To track NCX1 and study changes in conformation, NCX1 was tagged with derivatives of green fluorescent protein. Cyan (CFP) and yellow (YFP) fluorescent proteins were used for both visualization of the protein in HEK cells and fluorescent resonance energy transfer (FRET). CFP or YFP was inserted at position 266, 371, 467, or 548 of the large intracellular loop of NCX1 located between transmembrane segments 5 and 6. These constructs were tested for functional activity and visualized for cell surface expression. All constructs were targeted to the plasma membrane. Transport properties were assessed by both Ca-45(2+) uptake and electrophysiological measurements. The fluorescent-tagged exchangers had similar biophysical proper-ties to the wild type NCX1. Unexpectedly, all constructs retain their sensitivity to regulation by cytoplasmic Na+ and Ca2+ ions. FRET analysis indicates the proximity of NCX1 to plasma membrane phosphatidylinositol 4,5-bisphosphate. These results indicate that insertion of CFP or YFP into the large intracellular loop of NCX1 protein does not impair exchanger proper-ties. These constructs will be useful to further characterize the biological properties of the exchanger in intact cells.	Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Philipson, KD (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Lab, MRL 3-645, Los Angeles, CA 90095 USA.	kphilipson@mednet.ucla.edu		John, Scott/0000-0002-1232-9140	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49101] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; Fujioka Y, 2000, J PHYSIOL-LONDON, V529, P611, DOI 10.1111/j.1469-7793.2000.00611.x; He ZP, 2000, AM J PHYSIOL-CELL PH, V278, pC661, DOI 10.1152/ajpcell.2000.278.4.C661; Hilge M, 2006, MOL CELL, V22, P15, DOI 10.1016/j.molcel.2006.03.008; Hilgemann DW, 1998, METHOD ENZYMOL, V293, P267; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; Kasir J, 1999, J BIOL CHEM, V274, P24873, DOI 10.1074/jbc.274.35.24873; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; Llopis J, 2000, P NATL ACAD SCI USA, V97, P4363, DOI 10.1073/pnas.97.8.4363; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Nicoll DA, 2006, J BIOL CHEM, V281, P21577, DOI 10.1074/jbc.C600117200; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Philipson KD, 2002, ANN NY ACAD SCI, V976, P1; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509	23	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3695	3701		10.1074/jbc.M610425200	http://dx.doi.org/10.1074/jbc.M610425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158867	hybrid			2022-12-25	WOS:000244481900032
J	Sakai, K; Kimata, K; Sato, T; Gotoh, M; Narimatsu, H; Shinomiya, K; Watanabe, H				Sakai, Kenichiro; Kimata, Koji; Sato, Takashi; Gotoh, Masanori; Narimatsu, Hisashi; Shinomiya, Kenichi; Watanabe, Hideto			Chondroitin sulfate N-acetylgalactosaminyltransferase-1 plays a critical role in chondroitin sulfate synthesis in cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; LOW-BACK-PAIN; MOLECULAR-CLONING; N-ACETYLGALACTOSAMINYLTRANSFERASE; DISC DEGENERATION; INTERVERTEBRAL DISC; RAT CHONDROSARCOMA; AGGRECAN TURNOVER; GLUCURONIC-ACID; ASPARTIC-ACID	Cartilage destruction leads to severe joint diseases, such as osteoarthritis and spinal disorders with back pain, and cartilage regeneration is very inefficient. A major component of the cartilage extracellular matrix is the proteoglycan aggrecan that contains approximately 100 chondroitin sulfate (CS) chains, which impart water absorption and resistance to compression. Here, we demonstrate that chondroitin sulfate N-acetylgalactosaminyltransferase-1 (CSGaINAcT-1) plays a critical role in CS biosynthesis in cartilage. By in situ hybridization and real time reverse transcription-PCR of developing cartilage, CSGal-NAcT-1 exhibited the highest level of expression. Its expression in chondrogenic ATDC5 cells correlated well with that of aggrecan core protein. In heterozygote and homozygote aggrecan-null cartilage where aggrecan transcription is decreased, CSGal-NAcT-1 transcription diminished accordingly. Overexpression of the enzyme in chondrocytic cells further enhanced CS biosynthesis but not that of the aggrecan core protein, indicating that the enzyme activity is not saturated in the cells and that aggrecan synthesized in the overexpressing cells is heavier than the native molecule. Analysis of the CS chains synthesized in the overexpressing cells by gel chromatography and that of disaccharide composition revealed that the CS chains had similar length and sulfation patterns. Furthermore, adenoviral gene delivery of the enzyme into intervertebral discs displayed a substantial increase in the level of CS biosynthesis. These observations indicate that CSGaINAcT-1 overexpression increases the number of CS chains attached to aggrecan core protein. Our studies may lead to a new therapeutic intervention, ameliorating the outcome of cartilage degenerative diseases.	Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan; Tokyo Med & Dent Univ, Dept Orthoped Surg, Bunkyo Ku, Tokyo 1138519, Japan; Natl Inst Adv Ind Sci & Technol, Ctr Glycosci, Tsukuba, Ibaraki 3058568, Japan	Aichi Medical University; Tokyo Medical & Dental University (TMDU); National Institute of Advanced Industrial Science & Technology (AIST)	Watanabe, H (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan.	wannabee@aichi-med-u.ac.jp	Narimatsu, Hisashi/M-4757-2018; Sato, Takashi/M-2577-2018	Narimatsu, Hisashi/0000-0002-8402-133X; Sato, Takashi/0000-0002-9973-8923; Watanabe, Hideto/0000-0001-5291-0696				Anderson DG, 2005, SPINE, V30, pS14, DOI 10.1097/01.brs.0000175174.50235.ba; Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; BAYLISS MT, 1990, BIOCHEM SOC T, V18, P799, DOI 10.1042/bst0180799; CHOI HU, 1971, P NATL ACAD SCI USA, V68, P877, DOI 10.1073/pnas.68.5.877; Creamer P, 1997, LANCET, V350, P503, DOI 10.1016/S0140-6736(97)07226-7; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Dieppe PA, 2005, LANCET, V365, P965, DOI 10.1016/S0140-6736(05)71086-2; DOEGE KJ, 1994, J BIOL CHEM, V269, P29232; Gotoh M, 2002, J BIOL CHEM, V277, P38189, DOI 10.1074/jbc.M203619200; Gotoh M, 2002, J BIOL CHEM, V277, P38179, DOI 10.1074/jbc.M202601200; Kamiya N, 2002, J BONE MINER RES, V17, P1832, DOI 10.1359/jbmr.2002.17.10.1832; Kitagawa H, 2003, J BIOL CHEM, V278, P23666, DOI 10.1074/jbc.M302493200; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Kuo CK, 2006, CURR OPIN RHEUMATOL, V18, P64, DOI 10.1097/01.bor.0000198005.88568.df; Luoma K, 2000, SPINE, V25, P487, DOI 10.1097/00007632-200002150-00016; Maroudas A, 1998, ARCH BIOCHEM BIOPHYS, V350, P61, DOI 10.1006/abbi.1997.0492; MAROUDAS A, 1975, PHILOS T ROY SOC B, V271, P293, DOI 10.1098/rstb.1975.0054; Martinek V, 2003, J BONE JOINT SURG BR, V85B, P782, DOI 10.1302/0301-620X.85B6.14351; Masuda K, 2004, SPINE, V29, P2757, DOI 10.1097/01.brs.0000146048.14946.af; Matsumoto K, 2006, J BIOL CHEM, V281, P18257, DOI 10.1074/jbc.M510330200; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; Nogami K, 2004, J BIOL CHEM, V279, P8219, DOI 10.1074/jbc.M307304200; OEGEMA TR, 1975, J BIOL CHEM, V250, P6151; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; Roughley P, 2006, EUR CELLS MATER, V11, P1; Sato T, 2003, J BIOL CHEM, V278, P3063, DOI 10.1074/jbc.M208886200; Shibata S, 2003, J ANAT, V203, P425, DOI 10.1046/j.1469-7580.2003.00226.x; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Silbert JE, 1996, GLYCOCONJUGATE J, V13, P907, DOI 10.1007/BF01053185; SILBERT JE, 1980, BIOCHEM J, V190, P307, DOI 10.1042/bj1900307; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Sivan SS, 2006, J BIOL CHEM, V281, P13009, DOI 10.1074/jbc.M600296200; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Uyama T, 2003, J BIOL CHEM, V278, P3072, DOI 10.1074/jbc.M209446200; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; Venkatesan N, 2004, P NATL ACAD SCI USA, V101, P18087, DOI 10.1073/pnas.0404504102; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P6943, DOI 10.1073/pnas.94.13.6943; Watanabe H, 1998, J BIOCHEM, V124, P687, DOI 10.1093/oxfordjournals.jbchem.a022166; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016; Yada T, 2003, J BIOL CHEM, V278, P39711, DOI 10.1074/jbc.M304421200; Yada T, 2003, J BIOL CHEM, V278, P30235, DOI 10.1074/jbc.M303657200	45	34	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4152	4161		10.1074/jbc.M606870200	http://dx.doi.org/10.1074/jbc.M606870200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17145758	hybrid			2022-12-25	WOS:000244481900078
J	Vingadassalom, D; Kolb, A; Mayer, C; Collatz, E; Podglajen, I				Vingadassalom, Didier; Kolb, Annie; Mayer, Claudine; Collatz, Ekkehard; Podglajen, Isabelle			Probing the importance of selected phylum-specific amino acids in sigma(A) of Bacteroides fragilis, a primary or factor naturally devoid of an N-terminal acidic region 1.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL RNA-POLYMERASE; ESCHERICHIA-COLI SIGMA(70); TRANSCRIPTION INITIATION; CONSERVED REGION-3; DNA-BINDING; RECOGNITION; HOLOENZYME; SUBUNIT; GENE; RESISTANCE	The sigma(A) factor of Bacteroides fragilis is the prototype of a novel subgroup of primary or factors that are essential for growth and ensure the initiation of transcription of the housekeeping genes. This subgroup is confined to the phyla Bacteroidetes and Chlorobi. Its members carry a specific amino acid signature and are notably characterized by a short, basic N-terminal segment instead of the typical acidic region 1.1. Using in vitro mutagenesis, we investigated the importance of this basic segment and of several residues of the signature for the function of sigma(A). We have shown that the conserved residues Phe-61 and Lys-265, located in the core binding and DNA binding subregions 2.1 and 4.2, respectively, are critical for full function of the B.fragilis holoenzyme. With respect to the unusual subregion composition of sigma(A), we have shown that truncation of the basic N-terminal segment, or reversion of its charge, strongly affects the overall transcriptional activity of B.fragilis RNA polymerase in vitro. Our results indicate that the presence of the intact basic segment is required for the formation of RNA polymerase (RNAP)promoter open complexes, the correct architecture of the transcription bubble, and efficient promoter clearance.	Univ Paris 06, Fac Med, F-75006 Paris, France; INSERM, Lab Rech Mol Antibiot, U655, F-75006 Paris, France; Inst Pasteur, CNRS, Unite Regulat Transcriptionnelles, URA 2172, F-75724 Paris, France; Hop Europeen Georges Pompidou, AP HP, F-75015 Paris, France	UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Kolb, A (corresponding author), 25 Rue Dr Roux, F-75724 Paris 15, France.	akolb@pasteur.fr						Andre E, 2004, ASSAY DRUG DEV TECHN, V2, P629, DOI 10.1089/adt.2004.2.629; Baldwin NE, 2001, MOL MICROBIOL, V42, P427, DOI 10.1046/j.1365-2958.2001.02642.x; Barne KA, 1997, EMBO J, V16, P4034, DOI 10.1093/emboj/16.13.4034; Bayley DP, 2000, FEMS MICROBIOL LETT, V193, P149, DOI 10.1111/j.1574-6968.2000.tb09417.x; Borukhov S, 2003, CURR OPIN MICROBIOL, V6, P93, DOI 10.1016/S1369-5274(03)00036-5; BREUIL J, 1989, PLASMID, V21, P151, DOI 10.1016/0147-619X(89)90060-7; Camarero JA, 2002, P NATL ACAD SCI USA, V99, P8536, DOI 10.1073/pnas.132033899; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Cashel M, 2003, J BIOL CHEM, V278, P5539, DOI 10.1074/jbc.M211430200; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; Dupuy B, 2006, RES MICROBIOL, V157, P201, DOI 10.1016/j.resmic.2005.11.004; Feklistov A, 2006, MOL CELL, V23, P97, DOI 10.1016/j.molcel.2006.06.010; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Gopal V, 1997, EUR J BIOCHEM, V244, P613, DOI 10.1111/j.1432-1033.1997.00613.x; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; Gruber TM, 2003, ANNU REV MICROBIOL, V57, P441, DOI 10.1146/annurev.micro.57.030502.090913; Gruber TM, 1997, J BACTERIOL, V179, P1734, DOI 10.1128/jb.179.5.1734-1747.1997; Haugen SP, 2006, CELL, V125, P1069, DOI 10.1016/j.cell.2006.04.034; Helmann JD, 2002, ADV MICROB PHYSIOL, V46, P47; HERNANDEZ VJ, 1995, J MOL BIOL, V252, P536; Hernandez VJ, 1996, J BIOL CHEM, V271, P18775, DOI 10.1074/jbc.271.31.18775; Hinton DM, 2006, J BACTERIOL, V188, P1279, DOI 10.1128/JB.188.4.1279-1285.2006; Hsu HH, 2004, J BACTERIOL, V186, P2366, DOI 10.1128/JB.186.8.2366-2375.2004; Imashimizu M, 2006, FEBS LETT, V580, P3439, DOI 10.1016/j.febslet.2006.05.017; Iyer LM, 2004, GENE, V335, P73, DOI 10.1016/j.gene.2004.03.017; Kuwahara T, 2004, P NATL ACAD SCI USA, V101, P14919, DOI 10.1073/pnas.0404172101; LISSER S, 1993, NUCLEIC ACIDS RES, V21, P1507, DOI 10.1093/nar/21.7.1507; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Marschall C, 1998, J MOL BIOL, V276, P339, DOI 10.1006/jmbi.1997.1533; Martinez-Argudo I, 2004, P NATL ACAD SCI USA, V101, P16316, DOI 10.1073/pnas.0405312101; Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0; Paget MSB, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-203; Podglajen I, 2001, J BACTERIOL, V183, P3531, DOI 10.1128/JB.183.11.3531-3535.2001; Susa M, 2006, MOL MICROBIOL, V59, P1807, DOI 10.1111/j.1365-2958.2006.05058.x; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Vingadassalom D, 2005, MOL MICROBIOL, V56, P888, DOI 10.1111/j.1365-2958.2005.04590.x; Vuthoori S, 2001, J MOL BIOL, V309, P561, DOI 10.1006/jmbi.2001.4690; Wilson C, 1997, J MOL BIOL, V267, P60, DOI 10.1006/jmbi.1997.0875; Wosten MMSM, 1998, FEMS MICROBIOL REV, V22, P127, DOI 10.1016/S0168-6445(98)00011-4; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029	41	1	1	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3442	3449		10.1074/jbc.M608855200	http://dx.doi.org/10.1074/jbc.M608855200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17150963	hybrid			2022-12-25	WOS:000244481900006
J	Xie, J; Burz, DS; He, W; Bronstein, IB; Lednev, I; Shekhtman, A				Xie, Jingjing; Burz, David S.; He, Wei; Bronstein, Igor B.; Lednev, Igor; Shekhtman, Alexander			Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; CELL-SURFACE RECEPTOR; SOLUBLE RECEPTOR; CALCIUM; PROTEINS; ACTIVATION; DOMAIN; MECHANISM; COMPLEX; STATES	Calgranulin C (S100A12) is a member of the S100 family of proteins that undergoes a conformational change upon calcium binding allowing them to interact with target molecules and initiate biological responses; one such target is the receptor for advanced glycation products (RAGE). The RAGE-calgranulin C interaction mediates a pro-inflammatory response to cellular stress and can contribute to the pathogenesis of inflammatory lesions. The soluble extracellular part of RAGE (sRAGE) was shown to decrease the inflammation response possibly by scavenging RAGE-activating ligands. Here, by using high resolution NMR spectroscopy, we identified the sRAGE-calgranulin C interaction surface. Ca2+ binding creates two symmetric hydrophobic surfaces on Ca2+-calgranulin C that allow calgranulin C to bind to the C-type immunoglobulin domain of RAGE. Apo-calgranulin C also binds to sRAGE using a completely different surface and with substantially lower affinity, thus underscoring the role of Ca2+ binding to S100 proteins as a molecular switch. By using native gel electrophoresis, chromatography, and fluorescence spectroscopy, we established that sRAGE forms tetramers that bind to hexamers of Ca2+-calgranulin C. This arrangement creates a large platform for effectively transmitting RAGE-dependent signals from extracellular S100 proteins to the cytoplasmic signaling complexes.	SUNY Albany, Dept Chem, Albany, NY 12222 USA; Natl Inst Med Res, London NW7 1AA, England	State University of New York (SUNY) System; State University of New York (SUNY) Albany; MRC National Institute for Medical Research	Shekhtman, A (corresponding author), SUNY Albany, Dept Chem, Albany, NY 12222 USA.	ashekhta@albany.edu	Lednev, Igor K/J-8387-2017	Lednev, Igor K/0000-0002-6504-531X; Shekhtman, Alexander/0000-0003-2649-2675				ABRAGAM A, 1961, PRINCIPLES NUCLEAR M, P427; BAUDIER J, 1983, BIOCHEMISTRY-US, V22, P3360, DOI 10.1021/bi00283a009; Bhattacharya S, 2004, BBA-MOL CELL RES, V1742, P69, DOI 10.1016/j.bbamcr.2004.09.002; Bhattacharya S, 2003, BIOCHEMISTRY-US, V42, P14416, DOI 10.1021/bi035089a; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; BOLLAG DM, 1996, PROTEIN METHODS, P155; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CAVANAGH J, 1996, PROTEIN NMR SPECTROS, P478; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; DELATORRE JG, 1994, BIOPHYS J, V67, P530, DOI 10.1016/S0006-3495(94)80512-0; Dempsey AC, 2003, STRUCTURE, V11, P887, DOI 10.1016/S0969-2126(03)00126-6; Ding QX, 2005, BBA-MOL CELL RES, V1746, P18, DOI 10.1016/j.bbamcr.2005.08.006; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Drohat AC, 1996, BIOCHEMISTRY-US, V35, P11577, DOI 10.1021/bi9612226; Dutta K, 2002, BIOCHEMISTRY-US, V41, P4239, DOI 10.1021/bi012061v; Eghbalnia HR, 2005, J BIOMOL NMR, V32, P71, DOI 10.1007/s10858-005-5705-1; Eisner DA, 2005, EXP PHYSIOL, V90, P3, DOI 10.1113/expphysiol.2004.029231; Ferrage F, 2003, J AM CHEM SOC, V125, P2541, DOI 10.1021/ja0211407; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hadding A, 2004, BBA-MOL CELL RES, V1691, P67, DOI 10.1016/j.bbamcr.2004.01.003; Hanford LE, 2004, J BIOL CHEM, V279, P50019, DOI 10.1074/jbc.M409782200; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hsieh HL, 2004, BIOCHEM BIOPH RES CO, V316, P949, DOI 10.1016/j.bbrc.2004.02.135; Inman KG, 2002, J MOL BIOL, V324, P1003, DOI 10.1016/S0022-2836(02)01152-X; Ishihara K, 2003, FEBS LETT, V550, P107, DOI 10.1016/S0014-5793(03)00846-9; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; LANE AN, 1994, METHOD ENZYMOL, V239, P596; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; Masse JE, 2005, J MAGN RESON, V174, P133, DOI 10.1016/j.jmr.2005.01.017; Matsuo H, 1999, J AM CHEM SOC, V121, P9903, DOI 10.1021/ja991881g; MCCLURE WO, 1966, BIOCHEMISTRY-US, V5, P1908, DOI 10.1021/bi00870a018; Moroz OV, 2002, ACTA CRYSTALLOGR D, V58, P407, DOI 10.1107/S0907444901021278; Moroz OV, 2003, MICROSC RES TECHNIQ, V60, P581, DOI 10.1002/jemt.10300; Moroz OV, 2001, ACTA CRYSTALLOGR D, V57, P20, DOI 10.1107/S090744490001458X; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Otterbein LR, 2002, STRUCTURE, V10, P557, DOI 10.1016/S0969-2126(02)00740-2; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rety S, 2000, STRUCTURE, V8, P175, DOI 10.1016/S0969-2126(00)00093-9; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Rintala AC, 2002, J BIOMOL NMR, V22, P191, DOI 10.1023/A:1014256512514; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Rustandi RR, 2002, BIOCHEMISTRY-US, V41, P788, DOI 10.1021/bi0118308; SCHIMMEL PR, 1980, BIOPHYS CHEM TECHNIQ, P549; Schmidt AM, 1996, DIABETES, V45, pS77, DOI 10.2337/diab.45.3.S77; SCHMIDT AM, 1997, CIRCULATION S, V1, P37; Shekhtman A, 2001, J MOL BIOL, V314, P129, DOI 10.1006/jmbi.2001.5126; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; Sousa MM, 2000, LAB INVEST, V80, P1101, DOI 10.1038/labinvest.3780116; Srikrishna G, 2002, J NEUROCHEM, V80, P998, DOI 10.1046/j.0022-3042.2002.00796.x; Strupat K, 2000, J AM SOC MASS SPECTR, V11, P780, DOI 10.1016/S1044-0305(00)00150-1; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; Vallely KM, 2002, BIOCHEMISTRY-US, V41, P12670, DOI 10.1021/bi020365r; Walters KJ, 1999, P NATL ACAD SCI USA, V96, P7877, DOI 10.1073/pnas.96.14.7877; Walters KJ, 2001, METHOD ENZYMOL, V339, P238, DOI 10.1016/S0076-6879(01)39316-3; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; Williams RJP, 1996, CELL CALCIUM, V20, P87, DOI 10.1016/S0143-4160(96)90054-8; Wright NT, 2005, J MOL BIOL, V353, P410, DOI 10.1016/j.jmb.2005.08.027; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	67	136	143	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4218	4231		10.1074/jbc.M608888200	http://dx.doi.org/10.1074/jbc.M608888200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158877	hybrid			2022-12-25	WOS:000244481900085
J	Chew, AGM; Bryant, DA				Chew, Aline Gomez Maqueo; Bryant, Donald A.			Characterization of a plant-like protochlorophyllide a divinyl reductase in green sulfur bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROBIUM-TEPIDUM; BACTERIOCHLOROPHYLL-C; RHODOBACTER-CAPSULATUS; ARABIDOPSIS-THALIANA; REACTION CENTERS; CHLOROPHYLL; MUTANT; GENE; PROCHLOROCOCCUS; IDENTIFICATION	The green sulfur bacterium Chlorobium tepidum synthesizes three types of (bacterio) chlorophyll ((B) Chl): BChl a(p), Chl a(PD), and BChl c(F). During the synthesis of all three molecules, a C-8 vinyl substituent is reduced to an ethyl group, and in the case of BChl c(F), the C-82 carbon of this ethyl group is subsequently methylated once or twice by the radical S-adenosylmethionine enzyme BchQ. The C. tepidum genome contains homologs of two genes, bchJ (CT2014) and CT1063, that are highly homologous to genes, bchJ and AT5G18660, and that have been reported to encode C-8 vinyl reductases in Rhodobacter capsulatus and Arabidopsis thaliana, respectively. To determine which gene product actually encodes a C-8 vinyl reductase activity, the bchJ and CT1063 genes were insertionally inactivated in C. tepidum. All three Ch1s synthesized by the CT1063 mutant of C. tepidum have a C-8 vinyl group. Using NADPH but not NADH as reductant, recombinant BciA reduces the C-8 vinyl group of 3,8-divinyl-protochlorophyllide in vitro. These data demonstrate that CT1063, renamed bciA, encodes a C-8 divinyl reductase in C. tepidum. The bchJ mutant produces detectable amounts of Chl a(PD), BChl a(P), and BChl c(F), all of which have reduced C-8 substituents, but the mutant cells secrete large amounts of 3,8-divinyl-protochlorophyllide a into the growth medium and have a greatly reduced BChl c(F) content. The results suggest that BchJ may play an important role in substrate channeling and/ or regulation of Chl biosynthesis but show that it is not a vinyl reductase. Because only some Ch1-synthesizing organisms possess homologs of bciA, at least two types of C-8 vinyl reductases must occur.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Bryant, DA (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	dab14@psu.edu	Gomez Maqueo Chew, Aline/D-8631-2016	Gomez Maqueo Chew, Aline/0000-0001-6075-2907				Allen JP, 1998, FEBS LETT, V438, P5, DOI 10.1016/S0014-5793(98)01245-9; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BACHMANN BJ, 1980, MICROBIOL REV, V44, P1; BAZZAZ MB, 1981, PHOTOBIOCH PHOTOBIOP, V2, P199; BOBE FW, 1990, BIOCHEMISTRY-US, V29, P4340, DOI 10.1021/bi00470a012; BOLLIVAR DW, 1994, J MOL BIOL, V237, P622, DOI 10.1006/jmbi.1994.1260; BROCKMANN H, 1976, PHILOS T ROY SOC B, V273, P277, DOI 10.1098/rstb.1976.0013; DEMEREC M, 1966, GENETICS, V54, P61; Eckhardt U, 2004, PLANT MOL BIOL, V56, P1, DOI 10.1007/s11103-004-2331-3; Eisen JA, 2002, P NATL ACAD SCI USA, V99, P9509, DOI 10.1073/pnas.132181499; Frigaard Niels-Ulrik, 2006, V25, P201; Frigaard NU, 1997, ARCH MICROBIOL, V167, P343, DOI 10.1007/s002030050453; Frigaard NU, 2002, J BACTERIOL, V184, P3368, DOI 10.1128/JB.184.12.3368-3376.2002; Frigaard NU, 2001, APPL ENVIRON MICROB, V67, P2538, DOI 10.1128/AEM.67.6.2538-2544.2001; GOLBECK JH, 1993, P NATL ACAD SCI USA, V90, P1642, DOI 10.1073/pnas.90.5.1642; GREEN BR, 2004, ADV PHOTOSYNTHESIS R, V13; Helfrich M, 1999, BBA-BIOENERGETICS, V1410, P262, DOI 10.1016/S0005-2728(99)00004-3; Kim JS, 1996, J BIOCHEM MOL BIOL, V29, P327; Kolossov VL, 2006, ANAL BIOCHEM, V348, P192, DOI 10.1016/j.ab.2005.07.031; Kolossov VL, 2001, ANAL BIOCHEM, V295, P214, DOI 10.1006/abio.2001.5195; Mizoguchi T, 2000, PHOTOCHEM PHOTOBIOL, V71, P596, DOI 10.1562/0031-8655(2000)071<0596:STATAF>2.0.CO;2; Nagata N, 2005, PLANT CELL, V17, P233, DOI 10.1105/tpc.104.027276; Nakanishi H, 2005, PLANT CELL PHYSIOL, V46, P467, DOI 10.1093/pcp/pci053; Partensky F, 1999, MICROBIOL MOL BIOL R, V63, P106, DOI 10.1128/MMBR.63.1.106-127.1999; Permentier HP, 2000, PHOTOSYNTH RES, V64, P27, DOI 10.1023/A:1026515027824; STANIER RY, 1960, BIOCHIM BIOPHYS ACTA, V41, P478, DOI 10.1016/0006-3002(60)90045-7; SUZUKI JY, 1995, J BIOL CHEM, V270, P3732, DOI 10.1074/jbc.270.8.3732; WAHLUND TM, 1995, J BACTERIOL, V177, P2583, DOI 10.1128/jb.177.9.2583-2588.1995; WAHLUND TM, 1991, ARCH MICROBIOL, V156, P81, DOI 10.1007/BF00290978	30	53	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2967	2975		10.1074/jbc.M609730200	http://dx.doi.org/10.1074/jbc.M609730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148453	hybrid			2022-12-25	WOS:000243793900023
J	Janovick, JA; Brothers, SP; Knollman, PE; Conn, PM				Janovick, Jo Ann; Brothers, Shaun P.; Knollman, Paul E.; Conn, P. Michael			Specializations of a G-protein-coupled receptor that appear to aid with detection of frequency-modulated signals from its ligand	FASEB JOURNAL			English	Article						quality control system; pharmacoperone; pharmacological chaperone; protein routing; receptor evolution	PLASMA-MEMBRANE EXPRESSION; HORMONE GNRH RECEPTOR; HYPOGONADOTROPIC HYPOGONADISM; PHARMACOLOGICAL CHAPERONES; GONADOTROPIN-SECRETION; DISEASE ETIOLOGY; MOLECULAR-BASIS; MUTANTS; RESCUE; IDENTIFICATION	The primate GnRH receptor (GnRHR) is a GPCR (G-protein-coupled receptor) that transduces both amplitude- and frequency-modulated signals; each modality conveys information that regulates primate reproduction. Slower GnRH pulses favor release (and higher circulating levels) of pituitary FSH, while faster pulses favor LH release. We used radioligand binding and inositol phosphate production (a measure of G-protein coupling) in association with mutational analysis to identify the impact of evolved sequence specializations that regulate receptor concentration at the plasma membrane and K-d in primate GnRHRs. Our results show that mutations appear to provide a mechanism that allows independent adjustment of response sensitivity and squelching (suppression) of low-level signals (noise), both desirable features for recognition of frequency-modulated signals. We identify specific amino acid residues that appear to be involved in these processes. This investigation occurred in light of recent observations that restriction of GnRHR plasma membrane expression developed under strong convergent pressure and concurrently with the complex pattern of cyclicity associated with primate reproduction. The findings present an evolved means for increased effectiveness of detection of a frequency-m modulated signal and provide a strategy to identify similar mechanisms in other receptors.	Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Reprod Sci, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Beaverton, OR 97006 USA	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University	Conn, PM (corresponding author), Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	connm@ohsu.edu	Brothers, Shaun/G-8690-2012	Brothers, Shaun/0000-0003-2184-4037	NCRR NIH HHS [RR-00163] Funding Source: Medline; NICHD NIH HHS [TW/HD-00668, HD-18185, HD-19899] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019899, R37HD019899] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Brothers SP, 2004, MOL ENDOCRINOL, V18, P1787, DOI 10.1210/me.2004-0091; Castro-Fernandez C, 2005, ENDOCR REV, V26, P479, DOI 10.1210/er.2004-0010; Conn P Michael, 2002, Mol Interv, V2, P308, DOI 10.1124/mi.2.5.308; CONN PM, 2006, IN PRESS MOL ENDOCRI; CONN PM, IN PRESS J ENDOCRINO; Corrada Y, 2006, THERIOGENOLOGY, V66, P1599, DOI 10.1016/j.theriogenology.2006.01.003; Crofford LJ, 2004, BRAIN BEHAV IMMUN, V18, P314, DOI 10.1016/j.bbi.2003.12.011; Cui JS, 2000, MOL ENDOCRINOL, V14, P671, DOI 10.1210/me.14.5.671; Darzy KH, 2006, J CLIN ENDOCR METAB, V91, P987, DOI 10.1210/jc.2005-2145; Gavrila A, 2003, J CLIN ENDOCR METAB, V88, P2838, DOI 10.1210/jc.2002-021721; Ikemoto T, 2004, MOL CELL ENDOCRINOL, V214, P137, DOI 10.1016/j.mce.2003.10.062; Janovick JA, 2006, J BIOL CHEM, V281, P8417, DOI 10.1074/jbc.M510601200; Janovick JA, 2003, J PHARMACOL EXP THER, V305, P608, DOI 10.1124/jpet.102.048454; Janovick JA, 2002, J CLIN ENDOCR METAB, V87, P3255, DOI 10.1210/jc.87.7.3255; Knollman PE, 2005, J BIOL CHEM, V280, P24506, DOI 10.1074/jbc.M501978200; Koutkia P, 2004, AM J PHYSIOL-ENDOC M, V287, pE506, DOI 10.1152/ajpendo.00548.2003; Leanos-Miranda A, 2003, J CLIN ENDOCR METAB, V88, P3360, DOI 10.1210/jc.2003-030084; Leanos-Miranda A, 2002, J CLIN ENDOCR METAB, V87, P4825, DOI 10.1210/jc.2002-020961; Lin XW, 1998, MOL ENDOCRINOL, V12, P161, DOI 10.1210/me.12.2.161; Maya-Nunez G, 2000, ENDOCRINE, V13, P401, DOI 10.1385/ENDO:13:3:401; McCartney CR, 2002, J CLIN ENDOCR METAB, V87, P2194, DOI 10.1210/jc.87.5.2194; MCNATTY KP, 1991, J REPROD FERTIL, V91, P583, DOI 10.1530/jrf.0.0910583; Misra M, 2005, AM J PHYSIOL-ENDOC M, V289, pE373, DOI 10.1152/ajpendo.00041.2005; Mogi K, 2004, J VET MED SCI, V66, P1071, DOI 10.1292/jvms.66.1071; Natalucci G, 2005, EUR J ENDOCRINOL, V152, P845, DOI 10.1530/eje.1.01919; Pawson AJ, 1998, J ENDOCRINOL, V156, pR9, DOI 10.1677/joe.0.156R009; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Petrovska R, 2005, BRIT J PHARMACOL, V144, P651, DOI 10.1038/sj.bjp.0706087; SCHEEN A, 2005, DIABETES METAB SPEC, V2, P27; Uberti MA, 2005, J PHARMACOL EXP THER, V313, P16, DOI 10.1124/jpet.104.079541; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; Ulloa-Aguirre A, 2003, EXPERT OPIN THER TAR, V7, P175, DOI 10.1517/eott.7.2.175.23780; Vandenberghe W, 2005, J NEUROSCI, V25, P1095, DOI 10.1523/JNEUROSCI.3568-04.2005; WILDT L, 1981, ENDOCRINOLOGY, V109, P376, DOI 10.1210/endo-109-2-376; Winters SJ, 2004, REPRODUCTION, V128, P13, DOI 10.1530/rep.1.00195	35	10	10	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					384	392		10.1096/fj.06-6901com	http://dx.doi.org/10.1096/fj.06-6901com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17172315				2022-12-25	WOS:000244686300012
J	Kerry, S; TeKippe, M; Gaddis, NC; Aballay, A				Kerry, Samantha; TeKippe, Michael; Gaddis, Nathan C.; Aballay, Alejandro			GATA Transcription Factor Required for Immunity to Bacterial and Fungal Pathogens	PLOS ONE			English	Article								In the past decade, Caenorhabditis elegans has been used to dissect several genetic pathways involved in immunity; however, little is known about transcription factors that regulate the expression of immune effectors. C. elegans does not appear to have a functional homolog of the key immune transcription factor NF-kappa B. Here we show that that the intestinal GATA transcription factor ELT-2 is required for both immunity to Salmonella enterica and expression of a C-type lectin gene, clec-67, which is expressed in the intestinal cells and is a good marker of S. enterica infection. We also found that ELT-2 is required for immunity to Pseudomonas aeruginosa, Enterococcus faecalis, and Cryptococcus neoformans. Lack of immune inhibition by DAF-2, which negatively regulates the FOXO transcription factor DAF-16, rescues the hypersusceptibility to pathogens phenotype of elt-2(RNAi) animals. Our results indicate that ELT-2 is part of a multi-pathogen defense pathway that regulates innate immunity independently of the DAF-2/DAF-16 signaling pathway.	[Kerry, Samantha; TeKippe, Michael; Gaddis, Nathan C.; Aballay, Alejandro] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	Duke University	Aballay, A (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.	a.aballay@duke.edu	Gaddis, Nathan/GXG-6395-2022; Gaddis, Nathan/GXG-6447-2022	Gaddis, Nathan/0000-0001-5205-7138; Elliott, Samantha/0000-0001-6146-5395	NIH [GM074461, GM070977, AI065641]; Whitehead Scholars Program; DCTR; NIH SERCEB; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI065641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM074461, R37GM070977, R01GM070977] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Whitehead Scholars Program; DCTR; NIH SERCEB(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	S. E. K is funded by the NIH Ruth-Kirschstein postdoctoral fellowship GM074461. A. A. is funded by The Whitehead Scholars Program, DCTR, NIH SERCEB, and NIH grants GM070977 and AI065641.	Aballay A, 2000, CURR BIOL, V10, P1539, DOI 10.1016/S0960-9822(00)00830-7; Aballay A, 2001, P NATL ACAD SCI USA, V98, P2735, DOI 10.1073/pnas.041613098; Aballay A, 2003, CURR BIOL, V13, P47, DOI 10.1016/S0960-9822(02)01396-9; Anyanful A, 2005, MOL MICROBIOL, V57, P988, DOI 10.1111/j.1365-2958.2005.04739.x; Aries A, 2004, P NATL ACAD SCI USA, V101, P6975, DOI 10.1073/pnas.0401833101; Bernal A, 2000, P NATL ACAD SCI USA, V97, P6019, DOI 10.1073/pnas.100391597; BRENNER S, 1974, GENETICS, V77, P71; Cash HL, 2006, SCIENCE, V313, P1126, DOI 10.1126/science.1127119; Cheng TC, 2006, GENOMICS, V87, P356, DOI 10.1016/j.ygeno.2005.11.018; Cheon HM, 2006, J BIOL CHEM, V281, P8426, DOI 10.1074/jbc.M510957200; Franzot SP, 1999, J CLIN MICROBIOL, V37, P838, DOI 10.1128/JCM.37.3.838-840.1999; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Fukushige T, 1998, DEV BIOL, V198, P286, DOI 10.1016/S0012-1606(98)80006-7; Fukushige T, 1999, P NATL ACAD SCI USA, V96, P11883, DOI 10.1073/pnas.96.21.11883; Fukushige T, 2003, GENETICS, V165, P575; Fukushige T, 2005, DEV BIOL, V279, P446, DOI 10.1016/j.ydbio.2004.12.012; GANDHI S, 1980, MECH AGEING DEV, V12, P137, DOI 10.1016/0047-6374(80)90090-1; Garigan D, 2002, GENETICS, V161, P1101; Garsin DA, 2001, P NATL ACAD SCI USA, V98, P10892, DOI 10.1073/pnas.191378698; Garsin DA, 2003, SCIENCE, V300, P1921, DOI 10.1126/science.1080147; Gravato-Nobre MJ, 2005, CELL MICROBIOL, V7, P741, DOI 10.1111/j.1462-5822.2005.00523.x; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Huffman DL, 2004, P NATL ACAD SCI USA, V101, P10995, DOI 10.1073/pnas.0404073101; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kim DH, 2005, CURR OPIN IMMUNOL, V17, P4, DOI 10.1016/j.coi.2004.11.007; Kim DH, 2004, P NATL ACAD SCI USA, V101, P10990, DOI 10.1073/pnas.0403546101; Kim DH, 2002, SCIENCE, V297, P623, DOI 10.1126/science.1073759; Kim T, 2005, J BIOCHEM MOL BIOL, V38, P121; Kurz CL, 2003, NAT REV GENET, V4, P380, DOI 10.1038/nrg1067; Kurz CL, 2004, AGING CELL, V3, P185, DOI 10.1111/j.1474-9728.2004.00108.x; Labrousse A, 2000, CURR BIOL, V10, P1543, DOI 10.1016/S0960-9822(00)00833-2; Lee RYN, 2001, CURR BIOL, V11, P1950, DOI 10.1016/S0960-9822(01)00595-4; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Mallo GV, 2002, CURR BIOL, V12, P1209, DOI 10.1016/S0960-9822(02)00928-4; Moilanen LH, 1999, J BIOL CHEM, V274, P29655, DOI 10.1074/jbc.274.42.29655; Moynagh PN, 2005, TRENDS IMMUNOL, V26, P469, DOI 10.1016/j.it.2005.06.009; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; MURRAY BE, 1993, J BACTERIOL, V175, P5216, DOI 10.1128/JB.175.16.5216-5223.1993; Mylonakis E, 2005, INFECT IMMUN, V73, P3833, DOI 10.1128/IAI.73.7.3833-3841.2005; Mylonakis E, 2002, P NATL ACAD SCI USA, V99, P15675, DOI 10.1073/pnas.232568599; Nicholas HR, 2004, MOL IMMUNOL, V41, P479, DOI 10.1016/j.molimm.2004.03.037; O'Rourke D, 2006, GENOME RES, V16, P1005, DOI 10.1101/gr.50823006; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Petersen UM, 1999, EMBO J, V18, P4013, DOI 10.1093/emboj/18.14.4013; Pujol N, 2001, CURR BIOL, V11, P809, DOI 10.1016/S0960-9822(01)00241-X; Reece-Hoyes JS, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-13-r110; Shapira M, 2006, P NATL ACAD SCI USA, V103, P14086, DOI 10.1073/pnas.0603424103; Sifri CD, 2005, TRENDS MICROBIOL, V13, P119, DOI 10.1016/j.tim.2005.01.003; Singh V, 2006, P NATL ACAD SCI USA, V103, P13092, DOI 10.1073/pnas.0604050103; Suzuki YJ, 2003, FREE RADICAL BIO MED, V34, P1589, DOI 10.1016/S0891-5849(03)00208-9; Tan MW, 1999, P NATL ACAD SCI USA, V96, P715, DOI 10.1073/pnas.96.2.715; Tenhunen O, 2004, J BIOL CHEM, V279, P24852, DOI 10.1074/jbc.M314317200; Tenor JL, 2004, CURR BIOL, V14, P1018, DOI 10.1016/j.cub.2004.05.050; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Wertheim B, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-11-r94; WRAY C, 1978, RES VET SCI, V25, P139, DOI 10.1016/S0034-5288(18)32968-0; Zhang Y, 2005, NATURE, V438, P179, DOI 10.1038/nature04216; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	58	68	80	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e77	10.1371/journal.pone.0000077	http://dx.doi.org/10.1371/journal.pone.0000077			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183709	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600077
J	Borges, HL; Hunton, IC; Wang, JYJ				Borges, H. L.; Hunton, I. C.; Wang, J. Y. J.			Reduction of apoptosis in Rb-deficient embryos via Abl knockout	ONCOGENE			English	Article						central nervous system; fetal live; haploid insufficiency; knockout mice; tumor suppressor	RETINOBLASTOMA TUMOR-SUPPRESSOR; KINASE C-ABL; TYROSINE KINASE; NERVOUS-SYSTEM; DNA-DAMAGE; NUCLEAR ENTRAPMENT; MICE DEFICIENT; MOUSE EMBRYOS; CELL-DEATH; PROTEIN	The retinoblastoma protein RB regulates cell proliferation, differentiation and apoptosis. Homozygous knockout of Rb in mice causes embryonic lethality owing to placental defects that result in excessive apoptosis. RB binds to a number of cellular proteins including the nuclear Abl protein and inhibits its tyrosine kinase activity. Ex vivo experiments have shown that genotoxic or inflammatory stress can activate Abl kinase to stimulate apoptosis. Employing the Rb-null embryos as an in vivo model of apoptosis, we have shown that the genetic ablation of Abl can reduce apoptosis in the developing central nervous system and the embryonic liver. These results are consistent with the inhibitory interaction between RB and Abl, and provide in vivo evidence for the proapoptotic function of Abl.	Univ Calif San Diego, Sch Med, Moores Canc Ctr, Div Hematol Oncol,Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Wang, JYJ (corresponding author), Univ Calif San Diego, Sch Med, Moores Canc Ctr, Div Hematol Oncol,Dept Med, 4328,3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	jywang@ucsd.edu	Borges, Helena/W-7533-2019; Borges, Helena/AAG-3701-2020; Borges, Helena L/E-5044-2013	Borges, Helena/0000-0003-2866-4223; Borges, Helena L/0000-0003-2866-4223	NATIONAL CANCER INSTITUTE [R37CA043054, R01CA058320, R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA043054, R01 CA043054, R01 CA058320, CA58320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1999, MOL CELL BIOL, V19, P1068; Agami R, 1999, NATURE, V399, P809; Aloisi A, 2006, BLOOD, V107, P1591, DOI 10.1182/blood-2005-05-2123; Alvarez AR, 2004, NEUROBIOL DIS, V17, P326, DOI 10.1016/j.nbd.2004.06.007; Borges HL, 2004, CELL DEATH DIFFER, V11, P494, DOI 10.1038/sj.cdd.4401366; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; GOGA A, 1995, ONCOGENE, V11, P791; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gong JG, 1999, NATURE, V399, P806; Guo Z, 2001, CANCER RES, V61, P8395; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kaufman M.H., 1992, ATLAS MOUSE DEV; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Levinson NM, 2006, PLOS BIOL, V4, P753, DOI 10.1371/journal.pbio.0040144; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Liu X, 2006, J BIOL CHEM, V281, P578, DOI 10.1074/jbc.M508455200; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Nguyen DX, 2005, J CELL BIOCHEM, V94, P870, DOI 10.1002/jcb.20375; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Simpson MTW, 2001, J NEUROSCI, V21, P7089, DOI 10.1523/JNEUROSCI.21-18-07089.2001; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Takao N, 2000, J BIOL CHEM, V275, P725, DOI 10.1074/jbc.275.2.725; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vella V, 2003, J BIOL CHEM, V278, P25151, DOI 10.1074/jbc.M301962200; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	50	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3868	3877		10.1038/sj.onc.1210157	http://dx.doi.org/10.1038/sj.onc.1210157			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173068				2022-12-25	WOS:000247026400010
J	Jell, J; Merali, S; Hensen, ML; Mazurchuk, R; Spernyak, JA; Diegelman, P; Kisiel, ND; Barrero, C; Deeb, KK; Alhonen, L; Patel, MS; Porter, CW				Jell, Jason; Merali, Salim; Hensen, Mary L.; Mazurchuk, Richard; Spernyak, Joseph A.; Diegelman, Paula; Kisiel, Nicholas D.; Barrero, Carlos; Deeb, Kristin K.; Alhonen, Leena; Patel, Mulchand S.; Porter, Carl W.			Genetically altered expression of spermidine/spermine N-1-acetyltransferase affects fat metabolism in mice via acetyl-CoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POLYAMINE CATABOLISM; SPERMINE N1-ACETYLTRANSFERASE; ORNITHINE-DECARBOXYLASE; TARGETED DISRUPTION; RECEPTOR-GAMMA; GENE; GROWTH; SENSITIVITY; TISSUE; HOMEOSTASIS	The acetylating enzyme, spermidine/spermine N-1-acetyltransferase, participates in polyamine homeostasis by regulating polyamine export and catabolism. Previously, we reported that overexpression of the enzyme in cultured tumor cells and mice activates metabolic flux through the polyamine pathway and depletes the N-1-acetyltransferase coenzyme and fatty acid precursor, acetyl-CoA. Here, we investigate this possibility in spermidine/spermine N-1-acetyltransferase transgenic mice in which the enzyme is systemically overexpressed and in spermidine/spermine N(-)(1)acetyltransferase knock-out mice. Tissues of the former were characterized by increased N-1-acetyltransferase activity, a marked elevation in tissue and urinary acetylated polyamines, a compensatory increase in polyamine biosynthetic enzyme activity, and an increase in metabolic flux through the polyamine pathway. These polyamine effects were accompanied by a decrease in white adipose acetyl- and malonyl-CoA pools, a major (20-fold) increase in glucose and palmitate oxidation, and a distinctly lean phenotype. In SSAT-ko mice, the opposite relationship between polyamine and fat metabolism was observed. In the absence of N-1-acetylation of polyamines, there was a shift in urinary and tissue polyamines indicative of a decline in metabolic flux. This was accompanied by an increase in white adipose acetyl- and malonyl-CoA pools, a decrease in adipose palmitate and glucose oxidation, and an accumulation of body fat. The latter was further exaggerated under a high fat diet, where knock-out mice gained twice as much weight as wild-type mice. A model is proposed whereby the expression status of spermidine/spermine N-1-acetyltransferase alters body fat accumulation by metabolically modulating tissue acetyl- and malonyl-CoA levels, thereby influencing fatty acid biosynthesis and oxidation.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Canc Biol, Buffalo, NY 14263 USA; Temple Univ, Sch Med, Fels Inst, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Univ Kuopio, AI Virtanen Inst Mol Sci, FI-70211 Kuopio, Finland; SUNY Buffalo, Sch Med, Dept Biochem, Buffalo, NY 14214 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Eastern Finland; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Porter, CW (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA.	carl.porter@roswellpark.org	Deeb, Kristin K/H-5619-2016	Barrero, Carlos/0000-0001-5779-6642	NATIONAL CANCER INSTITUTE [R01CA022153, R01CA076428, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA-076428, CA-CA09072, CA016056, CA-022153] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; AGIUS L, 1985, EUR J BIOCHEM, V152, P699, DOI 10.1111/j.1432-1033.1985.tb09250.x; ATTWOOD PV, 1995, INT J BIOCHEM CELL B, V27, P231, DOI 10.1016/1357-2725(94)00087-R; Babbar N, 2003, J BIOL CHEM, V278, P47762, DOI 10.1074/jbc.M307265200; CADHILL GF, 1958, AM J PHYSIOL, V192, P491; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; FogelPetrovic M, 1996, FEBS LETT, V391, P89, DOI 10.1016/0014-5793(96)00710-7; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; HENKELMAN RM, 1992, JMRI-J MAGN RESON IM, V2, P533; Janne J, 2006, J BIOCHEM, V139, P155, DOI 10.1093/jb/mvj035; Janne J, 2004, EUR J BIOCHEM, V271, P877, DOI 10.1111/j.1432-1033.2004.04009.x; Johnson KR, 2003, GENOMICS, V81, P6, DOI 10.1016/S0888-7543(02)00013-7; Kee K, 2004, J BIOL CHEM, V279, P40076, DOI 10.1074/jbc.M406002200; Kee K, 2004, J BIOL CHEM, V279, P27050, DOI 10.1074/jbc.M403323200; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; Linsalata M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-191; Liu GS, 2003, ANAL CHEM, V75, P78, DOI 10.1021/ac0261505; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Niiranen K, 2002, J BIOL CHEM, V277, P25323, DOI 10.1074/jbc.M203599200; Niiranen K, 2006, J CELL MOL MED, V10, P933, DOI 10.2755/jcmm010.004.02; Oh WK, 2005, P NATL ACAD SCI USA, V102, P1384, DOI 10.1073/pnas.0409451102; PAJUNEN AEI, 1982, J BIOL CHEM, V257, P8190; Pietila M, 1997, J BIOL CHEM, V272, P18746, DOI 10.1074/jbc.272.30.18746; PORTER CW, 1991, CANCER RES, V51, P3715; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Qi L, 2006, SCIENCE, V312, P1763, DOI 10.1126/science.1123374; Reitman ML, 2002, ANNU REV NUTR, V22, P459, DOI 10.1146/annurev.nutr.22.010402.102849; Rodriguez-Caso C, 2006, J BIOL CHEM, V281, P21799, DOI 10.1074/jbc.M602756200; Roduit R, 2004, DIABETES, V53, P1007, DOI 10.2337/diabetes.53.4.1007; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; SEILER N, 1985, ANTICANCER RES, V5, P371; Stein CJ, 2004, J CLIN ENDOCR METAB, V89, P2522, DOI 10.1210/jc.2004-0288; Sturm R, 2002, HEALTH AFFAIR, V21, P245, DOI 10.1377/hlthaff.21.2.245; Tucker JM, 2005, CANCER RES, V65, P5390, DOI 10.1158/0008-5472.CAN-05-0229; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; Vujcic S, 2000, J BIOL CHEM, V275, P38319, DOI 10.1074/jbc.M003270200; Wang AYH, 2005, AM J GASTROENTEROL, V100, P2717, DOI 10.1111/j.1572-0241.2005.00311.x; Yu XX, 2000, AM J PHYSIOL-ENDOC M, V279, pE433, DOI 10.1152/ajpendo.2000.279.2.E433	39	100	102	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8404	8413		10.1074/jbc.M610265200	http://dx.doi.org/10.1074/jbc.M610265200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17189273	hybrid			2022-12-25	WOS:000245081000073
J	Doukov, TI; Hemmi, H; Drennan, CL; Ragsdale, SW				Doukov, Tzanko I.; Hemmi, Hisashi; Drennan, Catherine L.; Ragsdale, Stephen W.			Structural and kinetic evidence for an extended hydrogen-bonding network in catalysis of methyl group transfer - Role of an active site asparagine residue inactivation of methyl transfer by methyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOSIDE PHOSPHORYLASE; COENZYME-M METHYLTRANSFERASE; IRON-SULFUR PROTEIN; DIHYDROFOLATE-REDUCTASE; CLOSTRIDIUM-THERMOACETICUM; METHIONINE SYNTHASE; CRYSTAL-STRUCTURE; MECHANISM; METHYLTETRAHYDROFOLATE; PROTONATION	The methyltetrahydrofolate (CH3-H(4)folate) corrinoid-iron-sulfur protein (CFeSP) methyltransferase (MeTr) catalyzes transfer of the methyl group of CH3-H(4)folate to cob(I)amide. This key step in anaerobic CO and CO, fixation is similar to the first half-reaction in the mechanisms of other cobalamin-dependent methyltransferases. Methyl transfer requires electrophilic activation of the methyl group of CH3-H(4)folate, which includes proton transfer to the N5 group of the pterin ring and poises the methyl group for reaction with the Co(I) nucleophile. The structure of the binary CH3-H(4)folate/MeTr complex (revealed here) lacks any obvious proton donor near the N5 group. Instead, an Asn residue and water molecules are found within H-bonding distance of N5. Structural and kinetic experiments described here are consistent with the involvement of an extended H-bonding network in proton transfer to N5 of the folate that includes an Asn (Asn-199 in MeTr), a conserved Asp (Asp-160), and a water molecule. This situation is reminiscent of purine nucleoside phosphorylase, which involves protonation of the purine N7 in the transition state and is accomplished by an extended H-bond network that includes water molecules, a Glu residue, and an Asn residue (Kicska, G. A., Tyler, P. C., Evans, G. B., Furneaux, R. H., Shi, W., Fedorov, A., Lewandowicz, A., Cahill, S. M., Almo, S. C., and Schramm, V. L. (2002) Biochemistry 41, 14489-14498). In MeTr, the Asn residue swings from a distant position to within H-bonding distance of the N5 atom upon CH3-H(4)folate binding. An N199A variant exhibits only similar to 20-fold weakened affinity for CH3-H(4)folate but a much more marked 20,000 - 40,000-fold effect on catalysis, suggesting that Asn-199 plays an important role in stabilizing a transition state or high energy intermediate for methyl transfer.	Univ Nebraska, Dept Biochem, Beadle Ctr, Lincoln, NE 68588 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	University of Nebraska System; University of Nebraska Lincoln; Massachusetts Institute of Technology (MIT)	Ragsdale, SW (corresponding author), Univ Nebraska, Dept Biochem, Beadle Ctr, 1901 Vine St, Lincoln, NE 68588 USA.	sragsdale1@unl.edu	Hemmi, Hisashi/I-6868-2014	Hemmi, Hisashi/0000-0002-9538-809X	NCRR NIH HHS [P20 RR017675, 1P20RR17675] Funding Source: Medline; NIGMS NIH HHS [GM69857, R01 GM039451, GM39451, R01 GM069857, R37 GM039451] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM039451, R01GM069857, R29GM039451, R01GM039451] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achari A, 1997, NAT STRUCT BIOL, V4, P490, DOI 10.1038/nsb0697-490; Babaoglu K, 2004, STRUCTURE, V12, P1705, DOI 10.1016/j.str.2004.07.011; Banerjee R, 2003, ANNU REV BIOCHEM, V72, P209, DOI 10.1146/annurev.biochem.72.121801.161828; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; Cannon WR, 1997, J MOL BIOL, V271, P656, DOI 10.1006/jmbi.1997.1173; Casarotto MG, 1999, BIOCHEMISTRY-US, V38, P8038, DOI 10.1021/bi990301p; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Cummins PL, 2001, J AM CHEM SOC, V123, P3418, DOI 10.1021/ja0038474; Doukov T, 2000, STRUCTURE, V8, P817, DOI 10.1016/S0969-2126(00)00172-6; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans JC, 2004, P NATL ACAD SCI USA, V101, P3729, DOI 10.1073/pnas.0308082100; Evans W, 1997, CHEM BRIT, V33, P22; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; Ferrer S, 2003, J PHYS CHEM B, V107, P14036, DOI 10.1021/jp0354898; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; Hippler B, 1999, FEBS LETT, V449, P165, DOI 10.1016/S0014-5793(99)00429-9; HOWELL EE, 1986, SCIENCE, V231, P1123, DOI 10.1126/science.3511529; KICSKA GA, 2005, BIOCHEMISTRY-US, V41, P14489; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Leslie AGW, 2006, ACTA CRYSTALLOGR D, V62, P48, DOI 10.1107/S0907444905039107; Lewandowicz A, 2005, J BIOL CHEM, V280, P30320, DOI 10.1074/jbc.M505033200; Matthews RG, 2001, ACCOUNTS CHEM RES, V34, P681, DOI 10.1021/ar0000051; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ragsdale SW, 2004, CRIT REV BIOCHEM MOL, V39, P165, DOI 10.1080/10409230490496577; RAGSDALE SW, 2003, ENCY CATALYSIS, P452; Rod TH, 2003, J AM CHEM SOC, V125, P8718, DOI 10.1021/ja035272r; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sauer K, 1997, EUR J BIOCHEM, V249, P280, DOI 10.1111/j.1432-1033.1997.t01-1-00280.x; Seravalli J, 1999, BIOCHEMISTRY-US, V38, P5736, DOI 10.1021/bi9824745; Seravalli J, 1999, BIOCHEMISTRY-US, V38, P5728, DOI 10.1021/bi982473c; Smith AE, 2000, BIOCHEMISTRY-US, V39, P13880, DOI 10.1021/bi001431x; SMITH AE, 2002, THESIS U MICHIGAN AN; Stoeckler JD, 1997, BIOCHEMISTRY-US, V36, P11749, DOI 10.1021/bi961971n; Taurog RE, 2006, BIOCHEMISTRY-US, V45, P5092, DOI 10.1021/bi060052m; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; ZHAO SY, 1995, BIOCHEMISTRY-US, V34, P15075, DOI 10.1021/bi00046a013; Zhao SY, 1996, BIOCHEMISTRY-US, V35, P2476, DOI 10.1021/bi952310d	39	34	35	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6609	6618		10.1074/jbc.M609828200	http://dx.doi.org/10.1074/jbc.M609828200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17172470	hybrid, Green Accepted			2022-12-25	WOS:000244867200070
J	Kunkel, MT; Toker, A; Tsien, RY; Newton, AC				Kunkel, Maya T.; Toker, Alex; Tsien, Roger Y.; Newton, Alexandra C.			Calcium-dependent regulation of protein kinase D revealed by a genetically encoded kinase activity reporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; FLUORESCENT REPORTER; LIVING CELLS; D ACTIVATION; PHOSPHORYLATION; SUBSTRATE; DOMAIN; CA2+; SPECIFICITY; RECEPTORS	Protein kinase D (PKD) regulates many diverse cellular functions in response to diacylglycerol. To monitor PKD signaling in live cells, we generated a genetically encoded fluorescent reporter for PKD activity, DKAR (D kinase activity reporter). DKAR expressed in mammalian cells undergoes reversible fluorescence resonance energy transfer changes upon activation and inhibition of endogenous PKD. Surprisingly, we find that agonist-evoked activation of PKD is driven not only by diacylglycerol production, but by Ca2+. Furthermore, elevation of intracellular Ca2+, in the absence of any other stimulus, is sufficient to activate PKD. Concurrent imaging of Ca2+, diacylglycerol, and PKD activity reveals that thapsigargin-mediated elevation of intracellular Ca2+ is closely followed by a robust increase in diacylglycerol production, in turn followed by PKD activation. The Ca2+-induced production of diacylglycerol and accompanying PKD activation is dependent on phospholipase C activity. These data reveal that Ca2+ is a major contributor to the initiation of PKD signaling through positive feedback regulation of diacylglycerol production, unveiling a new mechanism in PKD activation.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Newton, AC (corresponding author), Univ Calif San Diego, Dept Pharmacol, Leichtag 282,9500 Gilman Dr, La Jolla, CA 92093 USA.	anewton@ucsd.edu			NCI NIH HHS [R01 CA075134-03, CA075134, R01 CA075134] Funding Source: Medline; NIDDK NIH HHS [P01 DK54441, T32 DK007233, DK07233, P01 DK054441, P01 DK054441-020003] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441, T32DK007233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; Brunschweiger A, 2006, CURR MED CHEM, V13, P289, DOI 10.2174/092986706775476052; Carnegie GK, 2004, MOL CELL, V15, P889, DOI 10.1016/j.molcel.2004.09.015; Doppler H, 2005, J BIOL CHEM, V280, P15013, DOI 10.1074/jbc.C400575200; Dries DR, 2007, J BIOL CHEM, V282, P826, DOI 10.1074/jbc.C600268200; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; EBERHARD DA, 1988, TRENDS NEUROSCI, V11, P517, DOI 10.1016/0166-2236(88)90174-9; Gallegos LL, 2006, J BIOL CHEM, V281, P30947, DOI 10.1074/jbc.M603741200; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; Horowitz LF, 2005, J GEN PHYSIOL, V126, P243, DOI 10.1085/jgp.200509309; Hutti JE, 2004, NAT METHODS, V1, P27, DOI 10.1038/NMETH708; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Kunkel MT, 2005, J BIOL CHEM, V280, P5581, DOI 10.1074/jbc.M411534200; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Sato M, 2004, METHODS, V32, P451, DOI 10.1016/j.ymeth.2003.10.013; Thore S, 2005, J CELL SCI, V118, P4463, DOI 10.1242/jcs.02577; Toker A, 2005, EMBO REP, V6, P310, DOI 10.1038/sj.embor.7400378; Violin JD, 2003, IUBMB LIFE, V55, P653, DOI 10.1080/152165401310001642216; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; von Kugelgen I, 2000, N-S ARCH PHARMACOL, V362, P310, DOI 10.1007/s002100000310; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798	29	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6733	6742		10.1074/jbc.M608086200	http://dx.doi.org/10.1074/jbc.M608086200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17189263	Green Accepted, hybrid			2022-12-25	WOS:000244867200083
J	Oberholzer, M; Marti, G; Baresic, M; Kunz, S; Hemphill, A; Seebeck, T				Oberholzer, Michael; Marti, Gabriela; Baresic, Mario; Kunz, Stefan; Hemphill, Andrew; Seebeck, Thomas			The Trypanosoma brucei cAMP phosphodiesterases TbrPDEB1 and TbrPDEB2: flagellar enzymes that are essential for parasite virulence	FASEB JOURNAL			English	Article						African sleeping sickness; PDE inhibitor; cytokinesis; life cycle stages; paraflagellar rod structure	PROTEIN-KINASE-A; PARAFLAGELLAR ROD; SCHIZOSACCHAROMYCES-POMBE; ADENYLYL-CYCLASE; PATHWAY; CRUZI; ISOFORMS; CLONING; BINDING; SIGNAL	Cyclic nucleotide specific phosphodiesterases (PDEs) are pivotal regulators of cellular signaling. They are also important drug targets. Besides catalytic activity and substrate specificity, their subcellular localization and interaction with other cell components are also functionally important. In contrast to the mammalian PDEs, the significance of PDEs in protozoal pathogens remains mostly unknown. The genome of Trypanosoma brucei, the causative agent of human sleeping sickness, codes for five different PDEs. Two of these, TbrPDEB1 and TbrPDEB2, are closely similar, cAMP-specific. PDEs containing two GAF-domains in their N-terminal regions. Despite their similarity, these two PDEs exhibit different subcellular localizations. TbrPDEB1 is located in the flagellum, whereas TbrPDEB2 is distributed between flagellum and cytoplasm. RNAi against the two mRNAs revealed that the two enzymes can complement each other but that a simultaneous ablation of both leads to cell death in bloodstream form trypanosomes. RNAi against TbrPDEB1 and TbrPDEB2 also functions in vivo where it completely prevents infection and eliminates ongoing infections. Our data demonstrate that TbrPDEB2 and TbrPDEB2 are essential for virulence, making them valuable potential targets for new PDE-inhibitor based trypanocidal drugs. Furthermore, they are compatible with the notion that the flagellum of T. brucei is an important site of cAMP signaling.	Univ Bern, Inst Cell Biol, CH-3012 Bern, Switzerland; Univ Bern, Inst Parasitol, CH-3012 Bern, Switzerland	University of Bern; University of Bern	Seebeck, T (corresponding author), Univ Bern, Inst Cell Biol, Baltzerstr 4, CH-3012 Bern, Switzerland.	thomas.seebeck@izb.unibe.ch		Hemphill, Andrew/0000-0002-0622-2128				Bastin P, 1999, J CELL SCI, V112, P3769; Bastin P, 2000, J CELL SCI, V113, P3321; Beavo J.A., 2006, CYCLIC NUCLEOTIDE PH; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; Bradley J, 2005, CURR OPIN NEUROBIOL, V15, P343, DOI 10.1016/j.conb.2005.05.014; Broadhead R, 2006, NATURE, V440, P224, DOI 10.1038/nature04541; Bruder S, 2005, P NATL ACAD SCI USA, V102, P3088, DOI 10.1073/pnas.0409917102; BRUN R, 1979, ACTA TROP, V36, P289; Cann MJ, 2004, IUBMB LIFE, V56, P529, DOI 10.1080/15216540400013861; D'Angelo M, 2002, J BIOL CHEM, V277, P35025, DOI 10.1074/jbc.M204696200; D'Angelo MA, 2004, BIOCHEM J, V378, P63, DOI 10.1042/BJ20031147; Diaz-Benjumea R, 2006, BIOCHEM J, V399, P305, DOI 10.1042/BJ20060757; Eisenbach M, 2006, NAT REV MOL CELL BIO, V7, P276, DOI 10.1038/nrm1893; Fevre EM, 2006, ADV PARASIT, V61, P167, DOI 10.1016/S0065-308X(05)61005-6; Friebe A, 2003, CIRC RES, V93, P96, DOI 10.1161/01.RES.0000082524.34487.31; Gull K, 1999, ANNU REV MICROBIOL, V53, P629, DOI 10.1146/annurev.micro.53.1.629; Hatanaka M, 2001, YEAST, V18, P207, DOI 10.1002/1097-0061(200102)18:3<207::AID-YEA661>3.0.CO;2-I; HESSE F, 1995, MOL BIOCHEM PARASIT, V70, P157, DOI 10.1016/0166-6851(95)00027-X; Hoffman CS, 2005, BIOCHEM SOC T, V33, P257, DOI 10.1042/BST0330257; Houslay MD, 2003, BIOCHEM SOC T, V31, P1186; Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998; Johner A, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-25; Kimmel AR, 2003, SCIENCE, V300, P1525, DOI 10.1126/science.1085439; Kunz S, 2006, MOL BIOCHEM PARASIT, V145, P133, DOI 10.1016/j.molbiopara.2005.09.018; Laxman S, 2005, J BIOL CHEM, V280, P3771, DOI 10.1074/jbc.M408111200; Lerner A, 2000, LEUKEMIA LYMPHOMA, V37, P39, DOI 10.3109/10428190009057627; Maga JA, 1999, TRENDS CELL BIOL, V9, P409, DOI 10.1016/S0962-8924(99)01635-9; Manallack DT, 2005, J MED CHEM, V48, P3449, DOI 10.1021/jm040217u; Masciarelli S, 2004, J CLIN INVEST, V114, P196, DOI 10.1172/JCI2004210804; Millar JK, 2005, SCIENCE, V310, P1187, DOI 10.1126/science.1112915; Mongillo M, 2006, CIRC RES, V98, P226, DOI 10.1161/01.RES.0000200178.34179.93; O'Beirne C, 1998, MOL BIOCHEM PARASIT, V91, P165, DOI 10.1016/S0166-6851(97)00191-6; Oberholzer M, 2006, MOL BIOCHEM PARASIT, V145, P117, DOI 10.1016/j.molbiopara.2005.09.002; Ott A, 2000, EMBO J, V19, P5782, DOI 10.1093/emboj/19.21.5782; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; Park JI, 2005, BIOCHEM BIOPH RES CO, V327, P311, DOI 10.1016/j.bbrc.2004.12.019; Parsons M, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-127; Pays E, 2001, MOL BIOCHEM PARASIT, V114, P1, DOI 10.1016/S0166-6851(01)00242-0; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Rascon A, 2002, P NATL ACAD SCI USA, V99, P4714, DOI 10.1073/pnas.002031599; Rehmann H, 2006, NATURE, V439, P625, DOI 10.1038/nature04468; Rochais F, 2006, CIRC RES, V98, P1081, DOI 10.1161/01.RES.0000218493.09370.8e; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SCHLAEPPI K, 1989, J CELL BIOL, V109, P1695, DOI 10.1083/jcb.109.4.1695; SCHNEIDER A, 1987, J CELL BIOL, V104, P431, DOI 10.1083/jcb.104.3.431; Seebeck T, 2004, CURR MOL MED, V4, P585, DOI 10.2174/1566524043360113; Shalaby T, 2001, EUR J BIOCHEM, V268, P6197, DOI 10.1046/j.0014-2956.2001.02564.x; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Vassella E, 1997, J CELL SCI, V110, P2661; WENTZINGER L, 2006, CYCLIC NUCLEOTIDE PH; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Zoraghi R, 2005, J BIOL CHEM, V280, P12051, DOI 10.1074/jbc.M413611200; Zoraghi R, 2002, P NATL ACAD SCI USA, V99, P4343, DOI 10.1073/pnas.062716599	54	104	104	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					720	731		10.1096/fj.06-6818com	http://dx.doi.org/10.1096/fj.06-6818com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17167070				2022-12-25	WOS:000244686400011
J	Silva, AP; Lourenco, J; Xapelli, S; Ferreira, R; Kristiansen, H; Woldbye, DPD; Oliveira, CR; Malva, JO				Silva, Ana P.; Lourenco, Joana; Xapelli, Sara; Ferreira, Raquel; Kristiansen, Heidi; Woldbye, David P. D.; Oliveira, Catarina R.; Malva, Joao O.			Protein kinase C activity blocks neuropeptide Y-mediated inhibition of glutamate release and contributes to excitability of the hippocampus in status epilepticus	FASEB JOURNAL			English	Article						Y-2 receptor; nerve terminal; seizures; phosphorylation	ACID-INDUCED SEIZURES; PRESYNAPTIC INHIBITION; RAT HIPPOCAMPUS; IN-VITRO; SYNAPTIC-TRANSMISSION; PHORBOL ESTERS; MESSENGER-RNAS; GRANULE CELLS; UP-REGULATION; PEPTIDE YY	The unbalanced excitatory/inhibitory neurotransmitter function in the neuronal network afflicted by seizures is the main biochemical and biophysical hallmark of epilepsy. The aim of this work was to identify changes in the signaling mechanisms associated with neuropeptide Y (NPY)-mediated inhibition of glutamate release that may contribute to hyperexcitability. Using isolated rat hippocampal nerve terminals, we showed that the KCl-evoked glutamate release is inhibited by NPY Y-2 receptor activation and is potentiated by the stimulation of protein kinase C (PKC). Moreover, we observed that immediately after status epilepticus (6 h postinjection with kainate, 10 mg/kg), the functional inhibition of glutamate release by NPY Y-2 receptors was transiently blocked concomitantly with PKC hyperactivation. The pharmacological blockade of seizure-activated PKC revealed again the Y-2 receptor-mediated inhibition of glutamate release. The functional activity of PKC immediately after status epilepticus was assessed by evaluating phosphorylation of the AMPA receptor subunit GluR1 (Ser-831), a substrate for PKC. Moreover, NPY-stimulated [S-35]GTP gamma S autoradiographic binding studies indicated that the common target for Y-2 receptor and PKC on the inhibition/potentiation of glutamate release was located downstream of the Y-2 receptor, or its interacting G-protein, and involves voltage-gated calcium channels.	Univ Coimbra, Fac Med, Inst Biochem, Ctr Neurosci & Cell Biol, P-3004504 Coimbra, Portugal; Univ Coimbra, Fac Med, Inst Pharmacol & Therapeut, P-3004504 Coimbra, Portugal; Univ Coimbra, Ctr Neurosci & Cell Biol, P-3000 Coimbra, Portugal; Univ Copenhagen, Rigshosp, Univ Hosp, Lab Neuropsychiat, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Dept Pharmacol, DK-2100 Copenhagen, Denmark	Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Rigshospitalet; University of Copenhagen; University of Copenhagen	Malva, JO (corresponding author), Univ Coimbra, Fac Med, Inst Biochem, Ctr Neurosci & Cell Biol, P-3004504 Coimbra, Portugal.	jomalva@fmed.uc.pt	Silva, Ana Paula/L-4184-2014; Ferreira, Raquel/AAA-7401-2021; Oliveira, Catarina R./F-3685-2010; Malva, Joao/L-3557-2014	Silva, Ana Paula/0000-0002-7802-8690; Ferreira, Raquel/0000-0003-1014-0499; Xapelli, Sara/0000-0001-6854-2509; Oliveira, Catarina/0000-0001-6942-4328; Malva, Joao/0000-0002-5438-4447; Woldbye, David/0000-0002-6321-3850				Baraban SC, 1997, J NEUROSCI, V17, P8927, DOI 10.1523/jneurosci.17-23-08927.1997; Berglund MM, 2003, EXP BIOL MED, V228, P217, DOI 10.1177/153537020322800301; Bijak M, 1999, NEUROSCI LETT, V268, P115, DOI 10.1016/S0304-3940(99)00381-X; BLACKSTONE C, 1994, J NEUROSCI, V14, P7585; BLEAKMAN D, 1992, BRIT J PHARMACOL, V107, P334, DOI 10.1111/j.1476-5381.1992.tb12747.x; CAMBRAYDEAKIN MA, 1990, DEV BRAIN RES, V53, P40, DOI 10.1016/0165-3806(90)90122-F; CAMPENOT RB, 1994, J NEUROCHEM, V63, P868; Chow KBS, 2003, EUR J PHARMACOL, V474, P7, DOI 10.1016/S0014-2999(03)02006-5; COFFEY ET, 1993, J BIOL CHEM, V268, P21060; COLMERS WF, 1991, BRIT J PHARMACOL, V102, P41, DOI 10.1111/j.1476-5381.1991.tb12129.x; Colmers William F., 2003, Epilepsy Curr, V3, P53, DOI 10.1046/j.1535-7597.2003.03208.x; Dumont Y, 2000, BRIT J PHARMACOL, V129, P1075, DOI 10.1038/sj.bjp.0703162; El Bahh B, 2005, EUR J NEUROSCI, V22, P1417, DOI 10.1111/j.1460-9568.2005.04338.x; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; FELIPO V, 1993, BRAIN RES, V604, P192, DOI 10.1016/0006-8993(93)90368-W; GANDHI VC, 1992, NEUROPHARMACOLOGY, V31, P1101, DOI 10.1016/0028-3908(92)90005-A; Garcia-Sainz JA, 2001, BIOCHEM J, V353, P603, DOI 10.1042/0264-6021:3530603; Gobbi M, 1998, J NEUROCHEM, V70, P1615; GREBER S, 1994, BRIT J PHARMACOL, V113, P737, DOI 10.1111/j.1476-5381.1994.tb17055.x; Guglielmetti F, 1997, MOL BRAIN RES, V49, P188, DOI 10.1016/S0169-328X(97)00142-3; HERRERO I, 1992, J NEUROCHEM, V59, P1574, DOI 10.1111/j.1471-4159.1992.tb08478.x; Hoffman DA, 1998, J NEUROSCI, V18, P3521; Hori T, 1999, J NEUROSCI, V19, P7262, DOI 10.1523/JNEUROSCI.19-17-07262.1999; Hussain RJ, 2003, BRAIN RES, V990, P28, DOI 10.1016/S0006-8993(03)03381-X; KLAPSTEIN GJ, 1992, BRIT J PHARMACOL, V105, P470, DOI 10.1111/j.1476-5381.1992.tb14277.x; Klapstein GJ, 1997, J NEUROPHYSIOL, V78, P1651, DOI 10.1152/jn.1997.78.3.1651; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; Malva JO, 1996, NEUROREPORT, V7, P1330, DOI 10.1097/00001756-199605170-00023; Marsh DJ, 1999, P NATL ACAD SCI USA, V96, P13518, DOI 10.1073/pnas.96.23.13518; MCMAHON HT, 1992, J BIOL CHEM, V267, P21338; McNamara RK, 2000, J NEUROSCI RES, V62, P416, DOI 10.1002/1097-4547(20001101)62:3<416::AID-JNR12>3.0.CO;2-V; Michel MC, 1998, PHARMACOL REV, V50, P143; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; PARFITT KD, 1993, J PHYSIOL-LONDON, V471, P245, DOI 10.1113/jphysiol.1993.sp019900; Parker RMC, 1999, EUR J NEUROSCI, V11, P1431, DOI 10.1046/j.1460-9568.1999.00553.x; PARROW V, 1995, J NEUROSCI RES, V41, P782, DOI 10.1002/jnr.490410609; Pinheiro PS, 2005, NEUROCHEM INT, V47, P309, DOI 10.1016/j.neuint.2005.05.007; REDMAN RS, 1997, J PHYSL, V15, P41; Rhim H, 1997, J NEUROSCI, V17, P2980; Richichi C, 2004, J NEUROSCI, V24, P3051, DOI 10.1523/JNEUROSCI.4056-03.2004; ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; SanchezPrieto J, 1996, TRENDS NEUROSCI, V19, P235, DOI 10.1016/0166-2236(96)10031-X; Silva AP, 2005, CNS NEUROL DISORD-DR, V4, P331, DOI 10.2174/1568007054546153; Silva AP, 2005, J NEUROCHEM, V93, P163, DOI 10.1111/j.1471-4159.2004.03005.x; Silva AP, 2001, J NEUROCHEM, V79, P286, DOI 10.1046/j.1471-4159.2001.00560.x; Silva AP, 2003, NEUROPHARMACOLOGY, V44, P282, DOI 10.1016/S0028-3908(02)00382-9; SIM LJ, 1995, P NATL ACAD SCI USA, V92, P7242, DOI 10.1073/pnas.92.16.7242; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPERK G, 1985, BRAIN RES, V338, P289, DOI 10.1016/0006-8993(85)90159-3; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; Tang FR, 2004, HIPPOCAMPUS, V14, P87, DOI 10.1002/hipo.10156; TOTH PT, 1993, NATURE, V364, P635, DOI 10.1038/364635a0; Vezzani A, 2002, NEUROSCIENCE, V110, P237, DOI 10.1016/S0306-4522(01)00581-4; Vezzani A, 1999, TRENDS NEUROSCI, V22, P25, DOI 10.1016/S0166-2236(98)01284-3; WAHLESTEDT C, 1993, ANNU REV PHARMACOL, V33, P309, DOI 10.1146/annurev.pa.33.040193.001521; Wang SJ, 2006, NEUROCHEM INT, V48, P181, DOI 10.1016/j.neuint.2005.10.006; WETTSTEIN JG, 1995, PHARMACOL THERAPEUT, V65, P397, DOI 10.1016/0163-7258(95)98598-K; Whittaker E, 1999, BRAIN RES, V827, P229, DOI 10.1016/S0006-8993(99)01302-5; Whittaker V.P., 1984, HDB NEUROCHEMISTRY, V7, P1; Woldbye DPD, 2005, NEUROBIOL DIS, V20, P760, DOI 10.1016/j.nbd.2005.05.010; Woldbye DPD, 1997, NAT MED, V3, P761, DOI 10.1038/nm0797-761; Woldbye DPD, 2004, NEUROPEPTIDES, V38, P253, DOI 10.1016/j.npep.2004.07.001; Wu YF, 2005, ACTA PHARMACOL SIN, V26, P63, DOI 10.1111/j.1745-7254.2005.00011.x	66	32	32	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					671	681		10.1096/fj.06-6163com	http://dx.doi.org/10.1096/fj.06-6163com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17167071	Green Submitted			2022-12-25	WOS:000244686400006
J	Chen, CJ; Kirshner, J; Sherman, MA; Hu, WD; Nguyen, T; Shively, JE				Chen, Charng-Jui; Kirshner, Julia; Sherman, Mark A.; Hu, Weidong; Nguyen, Tung; Shively, John E.			Mutation analysis of the short cytoplasmic domain of the cell-cell adhesion molecule CEACAM1 identifies residues that orchestrate actin binding and lumen formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIARY GLYCOPROTEIN CD66A; C-CAM; CARCINOEMBRYONIC ANTIGENS; STRUCTURAL BASIS; EXPRESSION; PROTEINS; RECEPTOR; MODEL; MORPHOGENESIS; SYSTEM	CEACAM1-4S (carcinoembryonic antigen cell adhesion molecule 1, with 4 ectodomains and a short, 12-14 amino acid cytoplasmic domain) mediates lumen formation via an apoptotic and cytoskeletal reorganization mechanism when mammary epithelial cells are grown in a three-dimensional model of mammary morphogenesis. We show by quantitative yeast two-hybrid, BIAcore, NMR HSQC and STD, and confocal analyses that amino acids phenylalanine (Phe(454)) and lysine (Lys(456)) are key residues that interact with actin orchestrating the cytoskeletal reorganization. A CEACAM1 membrane model based on vitamin D-binding protein that predicts an interaction of Phe 454 at subdomain 3 of actin was supported by inhibition of binding of actin to vitamin D-binding protein by the cytoplasmic domain peptide. We also show that residues Thr(457) and/or Ser(419) are phosphorylated in CEACAM1-transfected cells grown in three-dimensional culture and that mutation analysis of these residues (T457A/S459A) or F454A blocks lumen formation. These studies demonstrate that a short cytoplasmic domain membrane receptor can directly mediate substantial intracellular signaling.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Dvi Informat Sci, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Shively, JE (corresponding author), 1450 E Duarte Rd, Duarte, CA 91010 USA.	jshively@coh.org			NCI NIH HHS [CA84202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blau DM, 2001, J VIROL, V75, P8173, DOI 10.1128/JVI.75.17.8173-8186.2001; Boulton IC, 2002, NAT IMMUNOL, V3, P229, DOI 10.1038/ni769; Chen CJ, 2004, J IMMUNOL, V172, P3544, DOI 10.4049/jimmunol.172.6.3544; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; Dominguez R, 2004, TRENDS BIOCHEM SCI, V29, P572, DOI 10.1016/j.tibs.2004.09.004; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; GrayOwen SD, 1997, EMBO J, V16, P3435, DOI 10.1093/emboj/16.12.3435; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HELLER H, 1993, J PHYS CHEM-US, V97, P8343, DOI 10.1021/j100133a034; Holmes KC, 2004, PHILOS T ROY SOC B, V359, P1819, DOI 10.1098/rstb.2004.1566; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; Huang J, 1998, ANTICANCER RES, V18, P3203; Huang J, 1999, J CELL SCI, V112, P4193; Iijima H, 2004, J EXP MED, V199, P471, DOI 10.1084/jem.20030437; Kammerer R, 2001, J IMMUNOL, V166, P6537, DOI 10.4049/jimmunol.166.11.6537; KANO K, 1978, BIOCHIM BIOPHYS ACTA, V509, P289, DOI 10.1016/0005-2736(78)90048-2; Kirshner J, 2004, J MOL HISTOL, V35, P287, DOI 10.1023/B:HIJO.0000032360.01976.81; Kirshner J, 2003, J BIOL CHEM, V278, P50338, DOI 10.1074/jbc.M309115200; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Kleinerman DI, 1996, CANCER RES, V56, P3431; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; Luo WP, 1999, CANCER GENE THER, V6, P313, DOI 10.1038/sj.cgt.7700055; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Markel G, 2002, J CLIN INVEST, V110, P943, DOI 10.1172/JCI200215643; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; Najjar SM, 2002, TRENDS ENDOCRIN MET, V13, P240, DOI 10.1016/S1043-2760(02)00608-2; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Nollau P, 1997, CANCER RES, V57, P2354; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; Otterbein LR, 2002, P NATL ACAD SCI USA, V99, P8003, DOI 10.1073/pnas.122126299; Schumann D, 2001, J BIOL CHEM, V276, P47421, DOI 10.1074/jbc.M109110200; Spaar A, 2003, BIOPHYS J, V85, P1576, DOI 10.1016/S0006-3495(03)74589-5; Virji M, 2000, MOL MICROBIOL, V36, P784, DOI 10.1046/j.1365-2958.2000.01885.x; WALLACH DFH, 1976, J CELL PHYSIOL, V89, P769, DOI 10.1002/jcp.1040890440; Watt SM, 2001, BLOOD, V98, P1469, DOI 10.1182/blood.V98.5.1469; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551	40	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5749	5760		10.1074/jbc.M610903200	http://dx.doi.org/10.1074/jbc.M610903200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17192268	hybrid			2022-12-25	WOS:000244482300071
J	Dial, JM; Petrotchenko, EV; Borchers, CH				Dial, J. Michael; Petrotchenko, Evgeniy V.; Borchers, Christoph H.			Inhibition of APC(Cdh1) activity by Cdh1/Acm1/Bmh1 ternary complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE CONTROL; S-PHASE; SUBCELLULAR-LOCALIZATION; SACCHAROMYCES-CEREVISIAE; 14-3-3 PROTEINS; MITOTIC CYCLIN; PERSISTS UNTIL; DIRECT BINDING; CDC20	The anaphase-promoting complex (APC) is an essential E3 ubiquitin ligase responsible for catalyzing proteolysis of key regulatory proteins in the cell cycle. Cdh1 is a co-activator of the APC aiding in the onset and maintenance of G, phase, whereas phosphorylation of Cdh1 at the end of G, phase by cyclin-dependent kinases assists in the inactivation of APC (Cdh)1. Here, we suggest additional components are involved in the inactivation of APC(Cdh1) independent of Cdh1 phosphorylation. We have identified proteins known as Acm1 and Bmh1, which bind and form a ternary complex with Cdh1. The presence of phosphorylated Acm1 is critical for the ternary complex formation, and Acm1 is predominantly expressed in S phase when APC(Cdh1) is inactive. The assembly of the ternary complex inhibits ubiquitination of Clb2 in vitro by blocking the interaction of Cdh1 with Clb2. In vivo, lethality caused by overexpression of constitutively active Cdh1 is rescued by overexpression of Acm1. Partially phosphorylated Cdh1 in the absence of ACM1 still binds to and activates the APC. However, the addition of Acm1 decreases Clb2 ubiquitination when using either phosphorylated or nonphosphorylated Cdh1. Taken together, our results suggest an additional inactivation mechanism exists for APC(Cdh1) that is independent of Cdh1 phosphorylation.	Univ Victoria, Proteom Ctr, Vancouver Isl Technol Pk, Dept Biochem & Microbiol, Victoria, BC V8Z 7X8, Canada; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of Victoria; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Borchers, CH (corresponding author), Univ Victoria, Proteom Ctr, Vancouver Isl Technol Pk, Dept Biochem & Microbiol, 3101-4464 Markham St, Victoria, BC V8Z 7X8, Canada.	christoph@proteincentre.com	BORCHERS, Christoph/U-5964-2019					AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Burton JL, 2005, MOL CELL, V18, P533, DOI 10.1016/j.molcel.2005.04.022; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Chen J, 2001, GENE DEV, V15, P1765, DOI 10.1101/gad.898701; Donaldson AD, 1998, MOL CELL, V2, P173, DOI 10.1016/S1097-2765(00)80127-6; Eytan E, 2006, P NATL ACAD SCI USA, V103, P2081, DOI 10.1073/pnas.0510695103; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Hall MC, 2004, CELL CYCLE, V3, P1278, DOI 10.4161/cc.3.10.1153; HARPER JW, 2003, J BIOL CHEM, V278, P16698; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Huang JN, 2001, J CELL BIOL, V154, P85, DOI 10.1083/jcb.200102007; Jaquenoud M, 2002, EMBO J, V21, P6515, DOI 10.1093/emboj/cdf634; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; Loog M, 2005, NATURE, V434, P104, DOI 10.1038/nature03329; McDonald ER, 2001, ANN MED, V33, P113, DOI 10.3109/07853890109002066; Michalides RJAM, 2002, HEAD NECK-J SCI SPEC, V24, P694, DOI 10.1002/hed.10109; Miller JJ, 2006, GENE DEV, V20, P2410, DOI 10.1101/gad.1454006; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Parker Carol E., 2005, V301, P117; Passmore LA, 2005, EMBO REP, V6, P873, DOI 10.1038/sj.embor.7400482; Passmore LA, 2003, EMBO J, V22, P786, DOI 10.1093/emboj/cdg084; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Pray TR, 2002, DRUG RESIST UPDATE, V5, P249, DOI 10.1016/S1368-7646(02)00121-8; Prinz S, 1998, CURR BIOL, V8, P750, DOI 10.1016/S0960-9822(98)70298-2; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Schwab M, 2001, EMBO J, V20, P5165, DOI 10.1093/emboj/20.18.5165; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Uchida S, 2004, J CELL SCI, V117, P3011, DOI 10.1242/jcs.01086; van Hemert MJ, 2001, YEAST, V18, P889, DOI 10.1002/yea.739; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yeong FM, 2001, MOL CELL BIOL, V21, P5071, DOI 10.1128/MCB.21.15.5071-5081.2001; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	47	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5237	5248		10.1074/jbc.M606589200	http://dx.doi.org/10.1074/jbc.M606589200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17178718	Green Published, hybrid			2022-12-25	WOS:000244482300018
J	Gerard, F; Cline, K				Gerard, Fabien; Cline, Kenneth			The thylakoid proton gradient promotes an advanced stage of signal peptide binding deep within the Tat pathway receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-TRANSPORT; DELTA-PH PATHWAY; TRANSLOCATION SYSTEM; PHOTOSYSTEM-II; SEC; CHLOROPLASTS; MEMBRANE; INTEGRATION; MACHINERY; EFFICIENT	Tat (twin arginine translocation) systems transport folded proteins across the thylakoid membrane of chloroplasts and the plasma membrane of most bacteria. Tat precursors are targeted by hydrophobic cleavable signal peptides with twin arginine (RR) motifs. Bacterial precursors possess an extended consensus, (S/T)RRXFLK, of which the two arginines and the phenylalanine are essential for efficient transport. Thylakoid Tat precursors possess twin arginines but lack the consensus phenylalanine. Here, we have characterized two stages of precursor binding to the thylakoid Tat signal peptide receptor, the 700-kDa cpTatC-Hcf106 complex. The OE17 precursor tOE17 binds to the receptor by RR-dependant electrostatic interactions and partially dissociates during blue native gel electrophoresis. In addition, the signal peptide of thylakoid-bound tOE17 is highly exposed to the membrane surface, as judged by accessibility to factor Xa of cleavage sites engineered into signal peptide flanking regions. By contrast, tOE17 containing a consensus phenylalanine in place of Val(-20) (V - 20F) binds the receptor more strongly and is completely stable during blue native gel electrophoresis. Thylakoid bound V - 20F is also completely protected from factor Xa at the identical sites. This suggests that the signal peptide is buried deeply in the cpTatC-Hcf106 binding site. We further provide evidence that the proton gradient, which is required for translocation, induces a tighter interaction between tOE17 and the cpTat machinery, similar to that exhibited by V - 20F. This implies that translocation involves a very intimate association of the signal peptide with the receptor complex binding site.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Univ Florida, Plant Mol & Cellular Biol Program, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Cline, K (corresponding author), Univ Florida, Dept Hort Sci, 1109 Fifield Hall,Box 110690, Gainesville, FL 32611 USA.	kcline@ufl.edu	Cline, Kenneth/J-6238-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048179] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM48179] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Berks BC, 2005, CURR OPIN MICROBIOL, V8, P174, DOI 10.1016/j.mib.2005.02.010; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bruser T, 2003, EUR J BIOCHEM, V270, P1211, DOI 10.1046/j.1432-1033.2003.03481.x; Bruser T, 2003, MICROBIOL RES, V158, P7, DOI 10.1078/0944-5013-00176; Calderone V, 2003, EMBO REP, V4, P900, DOI 10.1038/sj.embor.embor923; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1986, J BIOL CHEM, V261, P4804; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Dabney-Smith C, 2006, J BIOL CHEM, V281, P5476, DOI 10.1074/jbc.M512453200; Dabney-Smith C, 2003, J BIOL CHEM, V278, P43027, DOI 10.1074/jbc.M307923200; Gerard F, 2006, J BIOL CHEM, V281, P6130, DOI 10.1074/jbc.M512733200; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; Hou B, 2006, J MOL BIOL, V355, P957, DOI 10.1016/j.jmb.2005.11.029; Li HM, 2006, FEMS MICROBIOL LETT, V255, P268, DOI 10.1111/j.1574-6968.2005.00081.x; MA X, 1999, THESIS U FLORIDA GAI; Ma XY, 2000, J BIOL CHEM, V275, P10016, DOI 10.1074/jbc.275.14.10016; Marques JP, 2004, J EXP BOT, V55, P1697, DOI 10.1093/jxb/erh191; Mori H, 1998, J BIOL CHEM, V273, P11405, DOI 10.1074/jbc.273.19.11405; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Mori H, 2001, BBA-MOL CELL RES, V1541, P80, DOI 10.1016/S0167-4889(01)00150-1; Mori H, 2001, FEBS LETT, V501, P65, DOI 10.1016/S0014-5793(01)02626-6; Muller M, 2005, MOL MEMBR BIOL, V22, P113, DOI 10.1080/09687860500041809; Musser SM, 2000, EUR J BIOCHEM, V267, P2588, DOI 10.1046/j.1432-1327.2000.01269.x; Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304; Ristvejova J, 2006, BIOCHEM BIOPH RES CO, V345, P287, DOI 10.1016/j.bbrc.2006.04.087; Robinson C, 2004, BBA-MOL CELL RES, V1694, P135, DOI 10.1016/j.bbamcr.2004.03.010; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Summer EJ, 2000, J BIOL CHEM, V275, P23483, DOI 10.1074/jbc.M004137200; Wexler M, 1998, FEBS LETT, V431, P339, DOI 10.1016/S0014-5793(98)00790-X	30	55	56	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5263	5272		10.1074/jbc.M610337200	http://dx.doi.org/10.1074/jbc.M610337200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17172598	hybrid			2022-12-25	WOS:000244482300021
J	Hirst-Jensen, BJ; Sahoo, P; Kieken, F; Delmar, M; Sorgen, PL				Hirst-Jensen, Bethany J.; Sahoo, Prangya; Kieken, Fabien; Delmar, Mario; Sorgen, Paul L.			Characterization of the pH-dependent interaction between the gap junction protein connexin43 carboxyl terminus and cytoplasmic loop domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAMERIZATION DOMAIN; POTASSIUM CHANNELS; BINDING DOMAINS; COMMUNICATION; PEPTIDE; NMR; PHOSPHORYLATION; ACIDIFICATION; SPECTROSCOPY; DIMERIZATION	A prevailing view regarding the regulation of connexin43 (Cx43) gap junction channels is that, upon intracellular acidification, the carboxyl-terminal domain (Cx43CT) moves toward the channel opening to interact with specific residues acting as a receptor site. Previous studies have demonstrated a direct, pH-dependent interaction between the Cx43CT and a Cx43 cytoplasmic loop (Cx43CL) peptide. This interaction was dependent on alpha-helical formation for the peptide in response to acidification; more recent studies have shown that acidification also induces Cx43CT dimerization. Whether Cx43CT dimerization is an important structural component in Cx43 regulation remains to be determined. Here we used an assortment of complimentary biophysical techniques to characterize the binding of Cx43CT or its mutants to itself and/or to a more native-like Cx43CL construct (Cx43CL(100-155) residues 100-155). Our studies expand the observation that specific Cx43CT domains are important for dimerization. We further show that properties of the Cx43CL(100-155) are different from those of the Cx43CL peptide; solvent acidification leads to Cx43CL(100-155) oligomerization and a change in the stoichiometry and binding affinity for the Cx43CT. Homo-Cx43CT and Cx43CL(100-155) oligomerization as well as the Cx43CT/Cx43CL(100-155) interaction can occur under in vivo conditions; moreover, we show that Cx43CL(100-155) strongly affects resonance peaks corresponding to Cx43CT residues Arg-376-Asp-379 and Asn-343-Lys-346. Overall, our data indicate that many of the sites involved in Cx43CT dimerization are also involved in the Cx43CT/Cx43CL interaction; we further propose that chemically induced Cx43CT and Cx43CL oligomerization is important for the interaction between these cytoplasmic domains, which leads to chemically induced gating of Cx43 channels.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	University of Nebraska System; University of Nebraska Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sorgen, PL (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.	psorgen@unmc.edu		Delmar, Mario/0000-0002-2085-5589	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057691, R01GM072631] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL080602] Funding Source: Medline; NIGMS NIH HHS [GM072631, R01 GM072631, GM57691] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bentrop D, 2001, J BIOL CHEM, V276, P42116, DOI 10.1074/jbc.M107118200; Bukauskas FF, 2001, BIOPHYS J, V81, P137, DOI 10.1016/S0006-3495(01)75687-1; Calero G, 1998, CIRC RES, V82, P929, DOI 10.1161/01.RES.82.9.929; Cameron SJ, 2003, J BIOL CHEM, V278, P18682, DOI 10.1074/jbc.M213283200; CASCIO WE, 1995, J CARDIOVASC ELECTR, V6, P1039, DOI 10.1111/j.1540-8167.1995.tb00381.x; Dedmon MM, 2005, J AM CHEM SOC, V127, P476, DOI 10.1021/ja044834j; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; Duffy HS, 2004, CIRC RES, V94, P215, DOI 10.1161/01.RES.0000113924.06926.11; Duffy HS, 2002, J BIOL CHEM, V277, P36706, DOI 10.1074/jbc.M207016200; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; Francis D, 1999, DEV GENET, V24, P123, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<123::AID-DVG12>3.0.CO;2-H; Giepmans BNG, 2004, CARDIOVASC RES, V62, P233, DOI 10.1016/j.cardiores.2003.12.009; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Gutstein DE, 2001, CIRCULATION, V104, P1194, DOI 10.1161/hc3601.093990; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KLEBER AG, 1987, CIRC RES, V61, P271, DOI 10.1161/01.RES.61.2.271; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; Kobertz WR, 1999, NAT STRUCT BIOL, V6, P1122; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; Li WEI, 2002, DEVELOPMENT, V129, P2031; Miura T, 1999, J MOL BIOL, V290, P213, DOI 10.1006/jmbi.1999.2859; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; Peters NS, 1997, CIRCULATION, V95, P988; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Rousset B, 1996, ANN ENDOCRINOL-PARIS, V57, P476; Saffitz JE, 2000, CARDIOVASC RES, V45, P807, DOI 10.1016/S0008-6363(99)00421-6; Seki A, 2004, CIRC RES, V95, P22, DOI 10.1161/01.RES.0000140737.62245.c5; Shibayama J, 2006, CIRC RES, V98, P1365, DOI 10.1161/01.RES.0000225911.24228.9c; Sorgen PL, 2004, J BIOL CHEM, V279, P54695, DOI 10.1074/jbc.M409552200; Sorgen PL, 2004, BIOPHYS J, V87, P574, DOI 10.1529/biophysj.103.039230; Sorgen PL, 2002, J BIOMOL NMR, V23, P245, DOI 10.1023/A:1019892719979; SPRAY DC, 1985, ANNU REV PHYSIOL, V47, P281, DOI 10.1146/annurev.ph.47.030185.001433; SPRAY DC, 1990, AM J PHYSIOL, V258, P195; Stergiopoulos K, 1999, CIRC RES, V84, P1144, DOI 10.1161/01.RES.84.10.1144; TAI MH, 2003, PANCREAS, V26, P18; Torok K, 1997, BIOCHEM J, V326, P479; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; van Drogen-Petit A, 2004, J MOL BIOL, V336, P1195, DOI 10.1016/j.jmb.2003.12.062; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	44	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5801	5813		10.1074/jbc.M605233200	http://dx.doi.org/10.1074/jbc.M605233200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17178730	hybrid			2022-12-25	WOS:000244482300076
J	Liu, Q; Kriksunov, IA; Graeff, R; Lee, HC; Hao, Q				Liu, Qun; Kriksunov, Irina A.; Graeff, Richard; Lee, Hon Cheung; Hao, Quan			Structural basis for formation and hydrolysis of the calcium messenger cyclic ADP-ribose by human CD38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ACTIVE-SITE; CYCLASE; NAADP	Human CD38 is a multifunctional ectoenzyme responsible for catalyzing the conversions from nicotinamide adenine dinucleotide (NAD) to cyclic ADP-ribose (cADPR) and from cADPR to ADP-ribose (ADPR). Both cADPR and ADPR are calcium messengers that can mobilize intracellular stores and activate influx as well. In this study, we determined three crystal structures of the human CD38 enzymatic domain complexed with cADPR at 1.5-angstrom resolution, with its analog, cyclic GDP-ribose (cGDPR) (1.68 angstrom) and with NGD (2.1 angstrom), a substrate analog of NAD. The results indicate that the binding of cADPR or cGDPR to the active site induces structural rearrangements in the dipeptide Glu(116)-Asp(147) by as much as 2.7 angstrom, providing the first direct evidence of a conformational change at the active site during catalysis. In addition, Glu(226) is shown to be critical not only in catalysis but also in positioning of cADPR at the catalytic site through strong hydrogen bonding interactions. Structural details obtained from these complexes provide a step-by-step description of the catalytic processes in the synthesis and hydrolysis of cADPR.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Cornell Univ, MacCHESS, Cornell High Energy Synchrotron Source, Ithaca, NY 14853 USA; Univ Hong Kong, Dept Physiol, Hong Kong, Hong Kong, Peoples R China	University of Minnesota System; University of Minnesota Twin Cities; Cornell University; University of Hong Kong	Lee, HC (corresponding author), Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA.	leehc@hku.hk; qh22@cornell.edu	Liu, Qun/A-8757-2011; Graeff, Richard Milton/B-3425-2011; Hao, Quan/C-4304-2009; Lee, Hon Cheung/C-4329-2009	Liu, Qun/0000-0002-1179-290X; Hao, Quan/0000-0002-9642-0514	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061568] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01646] Funding Source: Medline; NIGMS NIH HHS [GM061568] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 2005, ANNU REV PHYSIOL, V67, P1, DOI 10.1146/annurev.physiol.67.040103.152647; Graeff R, 2001, J BIOL CHEM, V276, P12169, DOI 10.1074/jbc.M011299200; Graeff R, 2006, J BIOL CHEM, V281, P28951, DOI 10.1074/jbc.M604370200; Graeff RM, 1996, BIOCHEMISTRY-US, V35, P379, DOI 10.1021/bi952083f; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Lee HC, 2005, J BIOL CHEM, V280, P33693, DOI 10.1074/jbc.R500012200; Liu Q, 2005, STRUCTURE, V13, P1331, DOI 10.1016/j.str.2005.05.012; Liu Q, 2006, J BIOL CHEM, V281, P32861, DOI 10.1074/jbc.M606365200; Munshi C, 2000, J BIOL CHEM, V275, P21566, DOI 10.1074/jbc.M909365199; Munshi CB, 1997, METHOD ENZYMOL, V280, P318; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Zwart PH, 2004, ACTA CRYSTALLOGR D, V60, P2230, DOI 10.1107/S0907444904012995	24	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5853	5861		10.1074/jbc.M609093200	http://dx.doi.org/10.1074/jbc.M609093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17182614	hybrid			2022-12-25	WOS:000244482300081
J	Cunha, SR; Bhasin, N; Mohler, PJ				Cunha, Shane R.; Bhasin, Naina; Mohler, Peter J.			Targeting and stability of Na/Ca exchanger 1 in cardiomyocytes requires direct interaction with the membrane adaptor ankyrin-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGER; NA+/CA2+ EXCHANGER; NEONATAL CARDIOMYOCYTES; VENTRICULAR MYOCYTES; HEART-FAILURE; INOSITOL 1,4,5-TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; CYTOPLASMIC PROTONS; DYNAMIC PROPERTIES	Na/Ca exchanger activity is important for calcium extrusion from the cardiomyocyte cytosol during repolarization. Animal models exhibiting altered Na/Ca exchanger expression display abnormal cardiac phenotypes. In humans, elevated Na/Ca exchanger expression/activity is linked with pathophysiological conditions including arrhythmia and heart failure. Whereas the molecular mechanisms underlying Na/Ca exchanger biophysical properties are widely studied and generally well characterized, the cellular pathways and molecular partners underlying the specialized membrane localization of Na/Ca exchanger in cardiac tissue are essentially unknown. In this report, we present the first direct evidence for a protein pathway required for Na/Ca exchanger localization and stability in primary cardiomyocytes. We define the minimal structural requirements on ankyrin-B for direct Na/Ca exchanger interactions. Moreover, using ankyrin-B mutants that lack Na/Ca exchanger binding activity, and primary cardiomyocytes with reduced ankyrin-B expression, we demonstrate that direct interaction with the membrane adaptor ankyrin-B is required for the localization and post-translational stability of Na/Ca exchanger 1 in neonatal mouse cardiomyocytes. These results raise exciting new questions regarding potentially dynamic roles for ankyrin proteins in the biogenesis and maintenance of specialized membrane domains in excitable cells.	Univ Iowa, Carver Coll Med, Dept Internal Med, Div Cardiol, Iowa City, IA 52242 USA; Univ Iowa, Carver Coll Med, Dept Physiol & Mol Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Mohler, PJ (corresponding author), Univ Iowa, Carver Coll Med, Dept Internal Med, Div Cardiol, Iowa City, IA 52242 USA.	peter-mohler@uiowa.edu			NHLBI NIH HHS [R01HL083422, R01HL084583] Funding Source: Medline; NIMH NIH HHS [T32MH065215] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084583, R01HL083422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH065215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AdachiAkahane S, 1997, J GEN PHYSIOL, V109, P717, DOI 10.1085/jgp.109.6.717; BEAUGE L, 1991, ANN NY ACAD SCI, V639, P147, DOI 10.1111/j.1749-6632.1991.tb17298.x; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; BENNETT V, 1979, J BIOL CHEM, V254, P2533; BENNETT V, 1979, NATURE, V281, P597, DOI 10.1038/281597a0; Birkeland JA, 2005, SCAND CARDIOVASC J, V39, P13, DOI 10.1080/14017430410004632; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Bossuyt J, 2002, ANN NY ACAD SCI, V976, P197; Camors E, 2006, J MOL CELL CARDIOL, V40, P47, DOI 10.1016/j.yjmcc.2005.08.009; CARONI P, 1983, EUR J BIOCHEM, V132, P451, DOI 10.1111/j.1432-1033.1983.tb07383.x; Chen FH, 1997, J MOL CELL CARDIOL, V29, P2621, DOI 10.1006/jmcc.1997.0475; CHEN FH, 1995, AM J PHYSIOL-CELL PH, V268, pC1126, DOI 10.1152/ajpcell.1995.268.5.C1126; Cho CH, 2000, MOL CELLS, V10, P712; Condrescu M, 2006, AM J PHYSIOL-CELL PH, V290, pC691, DOI 10.1152/ajpcell.00232.2005; Dipla K, 1999, CIRC RES, V84, P435, DOI 10.1161/01.RES.84.4.435; DIPOLO R, 1987, BIOCHIM BIOPHYS ACTA, V897, P347, DOI 10.1016/0005-2736(87)90432-9; DIPOLO R, 1994, AM J PHYSIOL, V267, pC307, DOI 10.1152/ajpcell.1994.267.1.C307; DOERING AE, 1993, J PHYSIOL-LONDON, V466, P481; DOERING AE, 1994, J PHYSIOL-LONDON, V480, P9, DOI 10.1113/jphysiol.1994.sp020336; Dyck C, 1998, J BIOL CHEM, V273, P12981, DOI 10.1074/jbc.273.21.12981; Ebert AM, 2005, P NATL ACAD SCI USA, V102, P17705, DOI 10.1073/pnas.0502683102; FRANK JS, 1992, J CELL BIOL, V117, P337, DOI 10.1083/jcb.117.2.337; Henderson SA, 2004, CIRC RES, V95, P604, DOI 10.1161/01.RES.0000142316.08250.68; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; Hobai IA, 2000, CIRC RES, V87, P690, DOI 10.1161/01.RES.87.8.690; Kang TM, 2004, NATURE, V427, P544, DOI 10.1038/nature02271; Katanosaka Y, 2005, J BIOL CHEM, V280, P5764, DOI 10.1074/jbc.M410240200; KIEVAL RS, 1992, AM J PHYSIOL, V263, pC545, DOI 10.1152/ajpcell.1992.263.2.C545; Koushik SV, 2001, FASEB J, V15, P1209, DOI 10.1096/fj.00-0696fje; Langenbacher AD, 2005, P NATL ACAD SCI USA, V102, P17699, DOI 10.1073/pnas.0502679102; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1993, J BIOL CHEM, V268, P11489; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651; Mohler PJ, 2005, PLOS BIOL, V3, P2158, DOI 10.1371/journal.pbio.0030423; Mohler PJ, 2004, P NATL ACAD SCI USA, V101, P17533, DOI 10.1073/pnas.0403711101; Mohler PJ, 2004, J BIOL CHEM, V279, P40185, DOI 10.1074/jbc.M406018200; Mohler PJ, 2004, P NATL ACAD SCI USA, V101, P9137, DOI 10.1073/pnas.0402546101; Mohler PJ, 2004, J BIOL CHEM, V279, P25798, DOI 10.1074/jbc.M401296200; Mohler PJ, 2004, J BIOL CHEM, V279, P12980, DOI 10.1074/jbc.M313979200; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Mohler PJ, 2002, J BIOL CHEM, V277, P10599, DOI 10.1074/jbc.M110958200; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Pogwizd SM, 1999, CIRC RES, V85, P1009; Pulina MV, 2006, J BIOL CHEM, V281, P19645, DOI 10.1074/jbc.M602033200; Reuter H, 2005, CARDIOVASC RES, V67, P198, DOI 10.1016/j.cardiores.2005.04.031; Reuter H, 2004, J PHYSIOL-LONDON, V554, P779, DOI 10.1113/jphysiol.2003.055046; Reuter H, 2002, CIRC RES, V91, P90, DOI 10.1161/01.RES.0000027529.37429.38; Reuter H, 2002, CIRC RES, V90, P305, DOI 10.1161/hh0302.104562; SCHOTT JJ, 1995, AM J HUM GENET, V57, P1114; Schulze DH, 2003, J BIOL CHEM, V278, P28849, DOI 10.1074/jbc.M300754200; Scriven DRL, 2000, BIOPHYS J, V79, P2682, DOI 10.1016/S0006-3495(00)76506-4; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Shannon TR, 2004, ANN NY ACAD SCI, V1015, P28, DOI 10.1196/annals.1302.003; Shigekawa M, 2001, CIRC RES, V88, P864, DOI 10.1161/hh0901.090298; SHIRAHATA E, 2006, J NEUROPHYSIOL; Sipido KR, 2000, CIRCULATION, V102, P2137, DOI 10.1161/01.CIR.102.17.2137; Slodzinski MK, 1998, AM J PHYSIOL-CELL PH, V275, pC459, DOI 10.1152/ajpcell.1998.275.2.C459; STUDER R, 1994, CIRC RES, V75, P443, DOI 10.1161/01.RES.75.3.443; Wakimoto K, 2000, J BIOL CHEM, V275, P36991, DOI 10.1074/jbc.M004035200; Wang ZY, 2001, J BIOL CHEM, V276, P17706, DOI 10.1074/jbc.M100544200	65	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4875	4883		10.1074/jbc.M607096200	http://dx.doi.org/10.1074/jbc.M607096200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17178715	hybrid			2022-12-25	WOS:000244482000070
J	Estey, T; Cantore, M; Weston, PA; Carpenter, JF; Petrash, JM; Vasiliou, V				Estey, Tia; Cantore, Miriam; Weston, Philip A.; Carpenter, John F.; Petrash, J. Mark; Vasiliou, Vasilis			Mechanisms involved in the protection of UV-induced protein inactivation by the corneal crystallin ALDH3A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCULAR ALDEHYDE DEHYDROGENASE; HEAT-SHOCK PROTEINS; ULTRAVIOLET-LIGHT; ALPHA-CRYSTALLIN; CHAPERONE FUNCTION; EXPRESSION; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; LENS; SENSITIVITY; IRRADIATION	Various lines of evidence have shown that ALDH3A1 (aldehyde dehydrogenase 3A1) plays a critical and multifaceted role in protecting the cornea from UV-induced oxidative stress. ALDH3A1 is a corneal crystallin, which is defined as a protein recruited into the cornea for structural purposes without losing its primary function (i.e. metabolism). Although the primary role of ALDH3A1 in the metabolism of toxic aldehydes has been clearly demonstrated, including the detoxification of aldehydes produced during UV-induced lipid peroxidation, the structural role of ALDH3A1 in the cornea remains elusive. We therefore examined the potential contribution of ALDH3A1 in maintaining the optical integrity of the cornea by suppressing the aggregation and/or inactivation of other proteins through chaperone-like activity and other protective mechanisms. We found that ALDH3A1 underwent a structural transition near physiological temperatures to form a partially unfolded conformation that is suggestive of chaperone activity. Although this structural transition alone did not correlate with any protection, ALDH3A1 substantially reduced the inactivation of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal and malondialdehyde when co-incubated with NADP(+), reinforcing the importance of the metabolic function of this corneal enzyme in the detoxification of toxic aldehydes. A large excess of ALDH3A1 also protected glucose-6-phosphate dehydrogenase from inactivation because of direct exposure to UVB light, which suggests that ALDH3A1 may shield other proteins from damaging UV rays. Collectively, these data demonstrate that ALDH3A1 can reduce protein inactivation and/or aggregation not only by detoxification of reactive aldehydes but also by directly absorbing UV energy. This study provides for the first time mechanistic evidence supporting the structural role of the corneal crystallin ALDH3A1 as a UV-absorbing constituent of the cornea.	Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Ctr Pharmaceut Biotechnol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Mol Toxicol & Environm Hlth Sci Program, Denver, CO 80262 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63119 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Washington University (WUSTL)	Vasiliou, V (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Ctr Pharmaceut Biotechnol, Denver, CO 80262 USA.	vasilis.vasiliou@uchsc.edu		vasiliou, vasilis/0000-0003-2552-3118	NATIONAL EYE INSTITUTE [R01EY011490, R29EY011490] Funding Source: NIH RePORTER; NEI NIH HHS [EY11490, EY13987] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; Bulteau AL, 2002, FREE RADICAL BIO MED, V32, P1157, DOI 10.1016/S0891-5849(02)00816-X; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; Davies MJ, 2004, PHOTOCH PHOTOBIO SCI, V3, P17, DOI 10.1039/b307576c; Davies MJ, 2001, J PHOTOCH PHOTOBIO B, V63, P114, DOI 10.1016/S1011-1344(01)00208-1; DOWNES JE, 1994, CORNEA, V13, P67, DOI 10.1097/00003226-199401000-00011; DOWNES JE, 1993, CORNEA, V12, P241, DOI 10.1097/00003226-199305000-00010; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Estey T, 2007, EXP EYE RES, V84, P3, DOI 10.1016/j.exer.2006.04.010; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; Ganea E, 2006, CURR EYE RES, V31, P1, DOI 10.1080/02713680500477347; Ganea E, 2000, BBA-MOL BASIS DIS, V1500, P49, DOI 10.1016/S0925-4439(99)00087-3; Ganea E, 1996, BIOCHEM BIOPH RES CO, V222, P626, DOI 10.1006/bbrc.1996.0794; HAHN DW, 2005, ROLE KERATOCYTES COR; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Jester JV, 2005, INVEST OPHTH VIS SCI, V46, P2369, DOI 10.1167/iovs.04-1225; Jester JV, 1999, J CELL SCI, V112, P613; King G, 1998, J EXP ZOOL, V282, P12; Kolozsvari L, 2002, INVEST OPHTH VIS SCI, V43, P2165; Koteiche HA, 2003, J BIOL CHEM, V278, P10361, DOI 10.1074/jbc.M211851200; Kueltzo LA, 2003, J PHARM SCI-US, V92, P1805, DOI 10.1002/jps.10439; Kumar MS, 2005, BIOCHEM J, V391, P335, DOI 10.1042/BJ20050506; LINDAHL R, 1991, BIOCHEM PHARMACOL, V41, P1583, DOI 10.1016/0006-2952(91)90157-Z; MACH H, 1994, ANAL BIOCHEM, V222, P323, DOI 10.1006/abio.1994.1499; Manzer R, 2003, DNA CELL BIOL, V22, P329, DOI 10.1089/104454903322216671; Manzer R, 2003, CHEM-BIOL INTERACT, V143, P45, DOI 10.1016/S0009-2797(02)00171-0; MITCHELL J, 1995, CORNEA, V14, P266, DOI 10.1097/00003226-199505000-00007; MUROV SL, 1992, HDB PHOTOCHEMISTRY, P298; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; Pappa A, 2003, BIOCHEM J, V376, P615, DOI 10.1042/BJ20030810; Pappa A, 2003, FREE RADICAL BIO MED, V34, P1178, DOI 10.1016/S0891-5849(03)00070-4; Pappa A, 2001, CHEM-BIOL INTERACT, V130, P181, DOI 10.1016/S0009-2797(00)00233-7; Piatigorsky J, 2000, J OCUL PHARMACOL TH, V16, P173, DOI 10.1089/jop.2000.16.173; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; Piatigorsky J, 1998, ANN NY ACAD SCI, V842, P7, DOI 10.1111/j.1749-6632.1998.tb09626.x; Piatigorsky J, 2001, CORNEA, V20, P853, DOI 10.1097/00003226-200111000-00015; PITTS DG, 1993, ENV VISION, P2; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; Reddy GB, 2001, BIOCHEM BIOPH RES CO, V282, P712, DOI 10.1006/bbrc.2001.4642; Ringvold A, 1998, ACTA OPHTHALMOL SCAN, V76, P149, DOI 10.1034/j.1600-0420.1998.760205.x; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Shashidharamurthy R, 2005, J BIOL CHEM, V280, P5281, DOI 10.1074/jbc.M407236200; Shiao T, 1999, PHARMACOGENETICS, V9, P145; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; Uma L, 1996, EXP EYE RES, V63, P117, DOI 10.1006/exer.1996.0098; Uma L, 1996, CURR EYE RES, V15, P685, DOI 10.3109/02713689609008910; VANKUIJK FJGM, 1991, ENVIRON HEALTH PERSP, V96, P177, DOI 10.2307/3431229; Vasiliou V, 2004, DRUG METAB REV, V36, P279, DOI 10.1081/DMR-120034001; ZIGMAN S, 1993, PHOTOCHEM PHOTOBIOL, V57, P1060, DOI 10.1111/j.1751-1097.1993.tb02972.x	50	44	47	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4382	4392		10.1074/jbc.M607546200	http://dx.doi.org/10.1074/jbc.M607546200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158879	hybrid			2022-12-25	WOS:000244482000018
J	Praetorius-Ibba, M; Hausmann, CD; Paras, M; Rogers, TE; Ibba, M				Praetorius-Ibba, Mette; Hausmann, Corinne D.; Paras, Molly; Rogers, Theresa E.; Ibba, Michael			Functional association between three archaeal aminoacyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIENZYME COMPLEX; PROTEIN; DOMAIN; SEQUENCE; ARC1P	Aminoacyl-tRNA synthetases (aaRSs) are responsible for attaching amino acids to their cognate tRNAs during protein synthesis. In eukaryotes aaRSs are commonly found in multienzyme complexes, although the role of these complexes is still not completely clear. Associations between aaRSs have also been reported in archaea, including a complex between prolyl-(ProRS) and leucyl-tRNA synthetases (LeuRS) in Methanothermobacter thermautotrophicus that enhances tRNA(Pro) aminoacylation. Yeast two-hybrid screens suggested that lysyl-tRNA synthetase (LysRS) also associates with LeuRS in M. thermautotrophicus. Co-purification experiments confirmed that LeuRS, LysRS, and ProRS associate in cell-free extracts. LeuRS bound LysRS and ProRS with a comparable K-D of about 0.3-0.9 mu m, further supporting the formation of a stable multi-synthetase complex. The steady-state kinetics of aminoacylation by LysRS indicated that LeuRS specifically reduced the K-m for tRNA(Lys) over 3-fold, with no additional change seen upon the addition of ProRS. No significant changes in aminoacylation by LeuRS or ProRS were observed upon the addition of LysRS. These findings, together with earlier data, indicate the existence of a functional complex of three aminoacyl-tRNA synthetases in archaea in which LeuRS improves the catalytic efficiency of tRNA aminoacylation by both LysRS and ProRS.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Ibba, M (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.	ibba.1@osu.edu		Paras, Molly/0000-0001-6658-8634; Rogers, Theresa/0000-0002-9741-5768	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065183] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 65183] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An S, 2005, J BIOL CHEM, V280, P34465, DOI 10.1074/jbc.M507550200; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; Dagkessamanskaia A, 2001, FEMS MICROBIOL LETT, V200, P53, DOI 10.1016/S0378-1097(01)00203-8; de Pouplana LR, 2001, CELL, V104, P191, DOI 10.1016/S0092-8674(01)00204-5; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Fukunaga R, 2005, NAT STRUCT MOL BIOL, V12, P915, DOI 10.1038/nsmb985; Galani K, 2005, FEBS LETT, V579, P969, DOI 10.1016/j.febslet.2004.11.112; Galani K, 2001, EMBO J, V20, P6889, DOI 10.1093/emboj/20.23.6889; GOLDGUR Y, 1994, BIOCHEM MOL BIOL INT, V32, P1075; Hsu JL, 2006, J BIOL CHEM, V281, P23075, DOI 10.1074/jbc.M601606200; Ibba M., 2005, AMINOACYL TRNA SYNTH; JAKUBOWSKI H, 1984, J BACTERIOL, V158, P769, DOI 10.1128/JB.158.3.769-776.1984; Kovaleski BJ, 2006, J BIOL CHEM, V281, P19449, DOI 10.1074/jbc.M601189200; Lee SW, 2004, J CELL SCI, V117, P3725, DOI 10.1242/jcs.01342; Ling C, 2005, J BIOL CHEM, V280, P34755, DOI 10.1074/jbc.M413511200; Lipman RSA, 2003, BIOCHEMISTRY-US, V42, P7487, DOI 10.1021/bi0344533; MIRANDE M, 2005, AMINOACYL TRNA SYNTH, P298; Negrutskii BS, 1999, J BIOL CHEM, V274, P4545, DOI 10.1074/jbc.274.8.4545; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; Park SG, 2005, TRENDS BIOCHEM SCI, V30, P569, DOI 10.1016/j.tibs.2005.08.004; Polycarpo C, 2003, MOL CELL, V12, P287, DOI 10.1016/S1097-2765(03)00280-6; Praetorius-Ibba M, 2005, J BIOL CHEM, V280, P26099, DOI 10.1074/jbc.M503539200; Robinson JC, 2000, J MOL BIOL, V304, P983, DOI 10.1006/jmbi.2000.4242; Rocak S, 2002, FEMS MICROBIOL LETT, V214, P101, DOI 10.1111/j.1574-6968.2002.tb11331.x; Sampath P, 2004, CELL, V119, P195, DOI 10.1016/j.cell.2004.09.030; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Wang LN, 2005, RNA, V11, P1291, DOI 10.1261/rna.2060405; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Wolfe CL, 2005, J BIOL CHEM, V280, P38870, DOI 10.1074/jbc.M502759200; Wolfson A, 2005, FEBS LETT, V579, P3467, DOI 10.1016/j.febslet.2005.05.038; Xia QW, 2006, MOL CELL PROTEOMICS, V5, P868, DOI 10.1074/mcp.M500369-MCP200; Zhang CM, 2006, J MOL BIOL, V361, P300, DOI 10.1016/j.jmb.2006.06.015	36	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3680	3687		10.1074/jbc.M609988200	http://dx.doi.org/10.1074/jbc.M609988200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158871	Green Published, hybrid			2022-12-25	WOS:000244481900030
J	Scola, AM; Higginbottom, A; Partridge, LJ; Reid, RC; Woodruff, T; Taylor, SM; Fairlie, DP; Monk, PN				Scola, Anne-Marie; Higginbottom, Adrian; Partridge, Lynda J.; Reid, Robert C.; Woodruff, Trent; Taylor, Stephen M.; Fairlie, David P.; Monk, Peter N.			The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C5A RECEPTOR; HUMAN C3A RECEPTOR; AMINO-TERMINUS; PROTEIN; ANAPHYLATOXIN; IDENTIFICATION; SITE; ANTAGONISTS; ACTIVATION; ANTIBODIES	C5L2 is a new cellular receptor found to interact with the human anaphylatoxins complement factor C5a and its C-terminal cleavage product C5a des Arg. The classical human C5a receptor (CSaR) preferentially binds C5a, with a 10-100-fold lower affinity for C5a des Arg. In contrast, C5L2 binds both ligands with nearly equal affinity. C5aR presents acidic and tyrosine residues in its N terminus that interact with the core of C5a while a hydrophobic pocket formed by the transmembrane helices interacts with residues in the C terminus of C5a. Here, we have investigated the molecular basis for the increased affinity of C5L2 for C5a des Arg. Rat and mouse C5L2 preferentially bound C5a des Arg, whereas rodent C5aR showed much higher affinity for intact C5a. Effective peptidic and non-peptidic ligands for the transmembrane hydrophobic pocket of C5aR were poor inhibitors of ligand binding to C5L2. An antibody raised against the N terminus of human C5L2 did not affect the binding of C5a to C5L2 but did inhibit C5a des Arg binding. A chimeric C5L2, containing the N terminus of C5aR, had little effect on the affinity for C5a des Arg. Mutation of acidic and tyrosine residues in the N terminus of human C5L2 revealed that 3 residues were critical for C5a des Arg binding but had little involvement in C5a binding. C5L2 thus appears to bind C5a and C5a des Arg by different mechanisms, and, unlike C5aR, C5L2 uses critical residues in its N-terminal domain for binding only to C5a des Arg.	Univ Sheffield, Sch Med, Acad Neurol Unit, Sheffield S10 2RX, S Yorkshire, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2RX, S Yorkshire, England; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Biomed Sci, Brisbane, Qld 4072, Australia	University of Sheffield; University of Sheffield; University of Queensland; University of Queensland	Monk, PN (corresponding author), Univ Sheffield, Sch Med, Acad Neurol Unit, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	p.monk@shef.ac.uk	Woodruff, Trent M/B-4861-2009; Woodruff, Trent/AAS-4629-2020; Reid, Robert/D-8041-2012; Monk, Peter/C-6155-2008; Fairlie, David P/F-8865-2014	Woodruff, Trent M/0000-0003-1382-911X; Woodruff, Trent/0000-0003-1382-911X; Reid, Robert/0000-0002-0829-239X; Monk, Peter/0000-0003-4637-3059; Fairlie, David P/0000-0002-7856-8566	Wellcome Trust [072231] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; Cain SA, 2001, BIOCHEMISTRY-US, V40, P14047, DOI 10.1021/bi011055w; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; Chen ZG, 1998, J BIOL CHEM, V273, P10411, DOI 10.1074/jbc.273.17.10411; Crass T, 1999, J BIOL CHEM, V274, P8367, DOI 10.1074/jbc.274.13.8367; deLaszlo SE, 1997, BIOORG MED CHEM LETT, V7, P213, DOI 10.1016/S0960-894X(96)00606-3; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; Eglite S, 2000, J IMMUNOL, V165, P2183, DOI 10.4049/jimmunol.165.4.2183; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; Gao HW, 2005, FASEB J, V19, P1003, DOI 10.1096/fj.04-3424fje; Gavrilyuk V, 2005, J NEUROCHEM, V92, P1140, DOI 10.1111/j.1471-4159.2004.02942.x; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gerard NP, 2005, J BIOL CHEM, V280, P39677, DOI 10.1074/jbc.C500287200; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; HIGGINBOTTOM A, 2005, J BIOL CHEM; Kalant D, 2003, J BIOL CHEM, V278, P11123, DOI 10.1074/jbc.M206169200; LANZA TJ, 1992, J MED CHEM, V35, P252, DOI 10.1021/jm00080a008; MERY L, 1994, J BIOL CHEM, V269, P3457; MERY L, 1993, EUR J HAEMATOL, V51, P282; Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200; MORGAN EL, 1993, J IMMUNOL, V151, P377; Okinaga S, 2003, BIOCHEMISTRY-US, V42, P9406, DOI 10.1021/bi034489v; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; Otto M, 2004, J BIOL CHEM, V279, P142, DOI 10.1074/jbc.M310078200; Paczkowski NJ, 1999, BRIT J PHARMACOL, V128, P1461, DOI 10.1038/sj.bjp.0702938; PEASE JE, 1993, BIOCHEM MOL BIOL INT, V31, P719; Postma B, 2005, J BIOL CHEM, V280, P2020, DOI 10.1074/jbc.M412230200; Sun JZ, 1999, PROTEIN SCI, V8, P2304; Wilken HC, 1999, IMMUNOL LETT, V67, P141, DOI 10.1016/S0165-2478(99)00002-4; Wilken HC, 1999, J IMMUNOL METHODS, V226, P139, DOI 10.1016/S0022-1759(99)00064-2	32	43	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3664	3671		10.1074/jbc.M609178200	http://dx.doi.org/10.1074/jbc.M609178200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158873	Green Accepted, hybrid			2022-12-25	WOS:000244481900028
J	Kinukawa, M; Nomura, M; Vacquier, VD				Kinukawa, Masashi; Nomura, Mamoru; Vacquier, Victor D.			A sea urchin sperm flagellar adenylate kinase with triplicated catalytic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CREATINE-KINASE; PHOSPHOCREATINE SHUTTLE; PROTEOMIC ANALYSIS; ENERGY-TRANSPORT; OUTER ARM; MOTILITY; SPERMATOZOA; MOVEMENT; DYNEIN	The mitochondrion of sea urchin sperm is located at the base of the sperm head, and the flagellum extends from the mitochondrion for similar to 40 mu m. These sperm have two known flagellar, non-mitochondrial, enzymatic systems to rephosphorylate ADP. The first involves the phosphocreatine shuttle, where flagellar creatine kinase (Sp-CK) uses phosphocreatine to rephosphorylate ADP. The second system, studied in this report, is adenylate kinase (Sp-AK), which uses 2 ADP to make ATP + AMP. Cloning of Sp-AK shows that, like Sp-CK, Sp-AK has three catalytic domains. Sp-AK localizes along the entire flagellum, and most of it is tightly bound to the axoneme. Sp-AK activity and flagellar motility were studied using demembranated sperm. The specific Sp-AK inhibitor Ap5A blocks enzyme activity with an IC50 of 0.41 mu M. In 1 mM ADP, flagella reactivate motility in 5 min; 1 mu M Ap5A completely inhibits this reactivation. No inhibition of motility occurs in Ap5A when 1 mM ATP is added to the reactivation buffer. The pH optimum for Sp-AK is 7.7, an internal pH at which sperm are fully motile. The pH optimum for Sp-CK is 6.7, an internal pH at which sperm are immotile. In isolated, detergent-permeabilized flagella, assayed at pH 7.6, the K-m for Sp-AK is 0.32 mM and the V-max is 2.80 mu M ATP formed/min/mg of protein. When assayed at pH 7.6, the Sp-CK K-m is 0.25 mM and the V-max 5.25. At the measured in vivo concentrations of ADP of 114 mu M, at pH 7.6, the axonemal Sp-AK could contribute similar to 31%, and Sp-CK 69%, of the total non-mitochondrial ATP synthesis associated with the demembranated axoneme. Thus, Sp-AK could contribute substantially to ATP synthesis utilized for motility. Alternatively, Sp-AK could function in the removal of ADP, which is a potent inhibitor of dynein ATPase.	Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA; Univ Tsukuba, Shimoda Marine Res Ctr, Shizuoka 4150025, Japan	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Tsukuba	Kinukawa, M (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA.	makinukawa@ucsd.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012986, R01HD012986] Funding Source: NIH RePORTER; NICHD NIH HHS [HD12986] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BROKAW CJ, 1961, EXP CELL RES, V22, P151, DOI 10.1016/0014-4827(61)90094-5; BROKAW CJ, 1973, J CELL SCI, V13, P1; CHRISTEN R, 1983, J BIOL CHEM, V258, P5392; GIBBONS BH, 1972, J CELL BIOL, V54, P75, DOI 10.1083/jcb.54.1.75; GIBBONS IR, 1965, J CELL BIOL, V25, P400, DOI 10.1083/jcb.25.2.400; Gibbons IR, 1996, CELL STRUCT FUNCT, V21, P331, DOI 10.1247/csf.21.331; Ginger ML, 2005, J BIOL CHEM, V280, P11781, DOI 10.1074/jbc.M413821200; Inaba K, 2003, ZOOL SCI, V20, P1043, DOI 10.2108/zsj.20.1043; KAMIMURA S, 1981, NATURE, V293, P566, DOI 10.1038/293566a0; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; Miki K, 2004, P NATL ACAD SCI USA, V101, P16501, DOI 10.1073/pnas.0407708101; Mitchell BF, 2005, MOL BIOL CELL, V16, P4509, DOI 10.1091/mbc.E05-04-0347; Nakamura K, 1999, COMP BIOCHEM PHYS B, V124, P195, DOI 10.1016/S0305-0491(99)00114-5; Nakano I, 2003, J CELL SCI, V116, P1627, DOI 10.1242/jcs.00336; Newlon MG, 1997, J BIOL CHEM, V272, P23637, DOI 10.1074/jbc.272.38.23637; Ogawa K, 1996, MOL BIOL CELL, V7, P1895, DOI 10.1091/mbc.7.12.1895; OKUNO M, 1979, J CELL SCI, V38, P105; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Ostrowski LE, 2002, MOL CELL PROTEOMICS, V1, P451, DOI 10.1074/mcp.M200037-MCP200; Patel-King RS, 2002, J BIOL CHEM, V277, P34271, DOI 10.1074/jbc.M204137200; Pazour GJ, 2005, J CELL BIOL, V170, P103, DOI 10.1083/jcb.200504008; Pullen TJ, 2004, MOL BIOL CELL, V15, P3257, DOI 10.1091/mbc.E04-03-0217; Quest AFG, 1997, BIOCHEMISTRY-US, V36, P6993, DOI 10.1021/bi9629337; QUEST AFG, 1992, J BIOL CHEM, V267, P15080; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Saudrais C, 1998, CELL MOTIL CYTOSKEL, V41, P91; SCHOFF PK, 1989, J BIOL CHEM, V264, P6086; Su YH, 2005, DEV BIOL, V285, P116, DOI 10.1016/j.ydbio.2005.06.007; TANG WJY, 1982, J BIOL CHEM, V257, P508; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TOMBES RM, 1987, BIOPHYS J, V52, P75, DOI 10.1016/S0006-3495(87)83190-9; TOMBES RM, 1989, J EXP ZOOL, V251, P82, DOI 10.1002/jez.1402510110; TOMBES RM, 1987, J BIOL CHEM, V262, P16011; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; TOMBES RM, 1988, EXP CELL RES, V178, P307, DOI 10.1016/0014-4827(88)90401-6; Vacquier VD, 2004, METHOD CELL BIOL, V74, P523; vanDorsten FA, 1997, BIOCHEM J, V325, P411, DOI 10.1042/bj3250411; WATANABE T, 1976, J BIOL CHEM, V251, P182; Wirschell M, 2004, MOL BIOL CELL, V15, P2729, DOI 10.1091/mbc.E03-11-0820; WOTHE DD, 1990, P NATL ACAD SCI USA, V87, P5203, DOI 10.1073/pnas.87.13.5203; Zhang H, 2004, J CELL SCI, V117, P4179, DOI 10.1242/jcs.01297	43	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2947	2955		10.1074/jbc.M607972200	http://dx.doi.org/10.1074/jbc.M607972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145754	hybrid			2022-12-25	WOS:000243793900021
J	Malpica, JM; Sacristan, S; Fraile, A; Garcia-Arenal, F				Malpica, Jose M.; Sacristan, Soledad; Fraile, Aurora; Garcia-Arenal, Fernando			Association and Host Selectivity in Multi-Host Pathogens	PLOS ONE			English	Article							POPULATION-DYNAMICS; MOSAIC-VIRUS; EVOLUTION; RECOMBINATION; INFLUENZA; INFECTION; VIRULENCE; PATTERNS; COMPLEMENTATION; SPECIALIZATION	The distribution of multi-host pathogens over their host range conditions their population dynamics and structure. Also, host co-infection by different pathogens may have important consequences for the evolution of hosts and pathogens, and host-pathogen co-evolution. Hence it is of interest to know if the distribution of pathogens over their host range is random, or if there are associations between hosts and pathogens, or between pathogens sharing a host. To analyse these issues we propose indices for the observed patterns of host infection by pathogens, and for the observed patterns of co-infection, and tests to analyse if these patterns conform to randomness or reflect associations. Applying these tests to the prevalence of five plant viruses on 21 wild plant species evidenced host-virus associations: most hosts and viruses were selective for viruses and hosts, respectively. Interestingly, the more host-selective viruses were the more prevalent ones, suggesting that host specialisation is a successful strategy for multi-host pathogens. Analyses also showed that viruses tended to associate positively in co-infected hosts. The developed indices and tests provide the tools to analyse how strong and common are these associations among different groups of pathogens, which will help to understand and model the population biology of multi-host pathogens.	[Sacristan, Soledad; Fraile, Aurora; Garcia-Arenal, Fernando] Univ Politecn Madrid, Dept Biotecnol, Madrid, Spain; [Sacristan, Soledad; Fraile, Aurora; Garcia-Arenal, Fernando] Univ Politecn Madrid, Ctr Biotecnol & Genom Plantas, Madrid, Spain; [Malpica, Jose M.] Inst Nacl Invest Agr & Alimentaria, Dept Biotecnol, Madrid, Spain	Universidad Politecnica de Madrid; Universidad Politecnica de Madrid; Instituto Nacional Investigacion Tecnologia Agraria Alimentaria (INIA)	Garcia-Arenal, F (corresponding author), Univ Politecn Madrid, Dept Biotecnol, Madrid, Spain.	fernando.garcia-arenal@upm.es	Garcia-Arenal, Fernando/H-1603-2015; Fraile, Aurora/H-1532-2015; SACRISTAN, SOLEDAD/H-1062-2015	GARCIA-ARENAL RODRIGUEZ, FERNANDO/0000-0002-5327-3200; FRAILE PEREZ, AURORA/0000-0002-2785-7931; SACRISTAN, SOLEDAD/0000-0002-5753-2644	Ministerio de Educacion y Ciencia, Spain [AGL2004-03496]; FPU	Ministerio de Educacion y Ciencia, Spain(Spanish Government); FPU(Spanish Government)	Funding: This work was in part supported by grant AGL2004-03496, Ministerio de Educacion y Ciencia, Spain, to AF. SS was in receipt of a FPU fellowship, Ministerio de Educacion y Ciencia, Spain.	Briddon RW, 2003, MOL PLANT PATHOL, V4, P427, DOI [10.1046/j.1364-3703.2003.00188.x, 10.1046/J.1364-3703.2003.00188.X]; Brockhurst MA, 2006, J EVOLUTION BIOL, V19, P374, DOI 10.1111/j.1420-9101.2005.01026.x; Brown SP, 2002, TRENDS MICROBIOL, V10, P401, DOI 10.1016/S0966-842X(02)02413-7; Cicin-Sain L, 2005, J VIROL, V79, P9492, DOI 10.1128/JVI.79.15.9492-9502.2005; Cleaveland S, 1995, PARASITOLOGY, V111, pS33, DOI 10.1017/S0031182000075806; Cleaveland S, 2001, PHILOS T R SOC B, V356, P991, DOI 10.1098/rstb.2001.0889; Dunoyer P, 2005, CURR OPIN PLANT BIOL, V8, P415, DOI 10.1016/j.pbi.2005.05.012; Escriu F, 2003, EVOLUTION, V57, P755, DOI 10.1111/j.0014-3820.2003.tb00287.x; Fauquet C. M., 2000, VIRUS TAXONOMY; Foster KR, 2005, SCIENCE, V308, P1269, DOI 10.1126/science.1108158; Fry JD, 1996, AM NAT, V148, pS84, DOI 10.1086/285904; Gandon S, 2001, EVOLUTION, V55, P1056, DOI 10.1554/0014-3820(2001)055[1056:HLHATE]2.0.CO;2; Ganusov VV, 2002, EVOLUTION, V56, P213, DOI 10.1111/j.0014-3820.2002.tb01332.x; Garcia-Arenal F, 2003, PHYTOPATHOLOGY, V93, P941, DOI 10.1094/PHYTO.2003.93.8.941; Gibbs MJ, 1999, P NATL ACAD SCI USA, V96, P8022, DOI 10.1073/pnas.96.14.8022; Gibbs MJ, 2001, SCIENCE, V293, P1842, DOI 10.1126/science.1061662; Griffin AS, 2004, NATURE, V430, P1024, DOI 10.1038/nature02744; Griffiths PD, 2000, REV MED VIROL, V10, P351, DOI 10.1002/1099-1654(200011/12)10:6<351::AID-RMV302>3.0.CO;2-Y; Guan Y, 2004, P NATL ACAD SCI USA, V101, P8156, DOI 10.1073/pnas.0402443101; Haydon DT, 2002, EMERG INFECT DIS, V8, P1468; Hu WS, 2003, FRONT BIOSCI, V8, pD143, DOI 10.2741/940; Hudson PJ, 2006, TRENDS ECOL EVOL, V21, P381, DOI 10.1016/j.tree.2006.04.007; JAVIER RT, 1986, SCIENCE, V234, P746, DOI 10.1126/science.3022376; Karayiannis P, 1998, REV MED VIROL, V8, P13, DOI 10.1002/(SICI)1099-1654(199801/03)8:1&lt;13::AID-RMV208&gt;3.0.CO;2-L; Kawecki TJ, 1998, AM NAT, V152, P635, DOI 10.1086/286195; KENDALL M, ADV THEORY STAT, V2; Kilpatrick AM, 2005, EMERG INFECT DIS, V11, P425, DOI 10.3201/eid1103.040364; Kirchner JW, 2002, EVOL ECOL RES, V4, P27; KONDO A, 1991, J VIROL, V65, P3625, DOI 10.1128/JVI.65.7.3625-3632.1991; Legg JP, 2000, VIRUS RES, V71, P135, DOI 10.1016/S0168-1702(00)00194-5; Lloyd-Smith JO, 2005, TRENDS ECOL EVOL, V20, P511, DOI 10.1016/j.tree.2005.07.004; Lopez-Ferber M, 2003, P ROY SOC B-BIOL SCI, V270, P2249, DOI 10.1098/rspb.2003.2498; Luis-Arteaga M, 1998, PLANT DIS, V82, P979, DOI 10.1094/PDIS.1998.82.9.979; MANSKY LM, 1995, J PHYTOPATHOL, V143, P247, DOI 10.1111/j.1439-0434.1995.tb00607.x; May Robert M., 1995, Proceedings of the Royal Society of London Series B Biological Sciences, V261, P209, DOI 10.1098/rspb.1995.0138; McClelland EE, 2003, INFECT IMMUN, V71, P2079, DOI 10.1128/IAI.71.4.2079-2086.2003; McDonald BA, 2002, ANNU REV PHYTOPATHOL, V40, P349, DOI 10.1146/annurev.phyto.40.120501.101443; Mills JN, 1997, AM J TROP MED HYG, V56, P273; Monci F, 2002, VIROLOGY, V303, P317, DOI 10.1006/viro.2002.1633; Moreno IM, 1997, J VIROL, V71, P9157, DOI 10.1128/JVI.71.12.9157-9162.1997; Morgan AD, 2005, NATURE, V437, P253, DOI 10.1038/nature03913; MORIONES E, 1991, PLANT DIS, V75, P930, DOI 10.1094/PD-75-0930; Packer C, 1999, J ANIM ECOL, V68, P1161, DOI 10.1046/j.1365-2656.1999.00360.x; Raybould AF, 1999, NEW PHYTOL, V141, P265, DOI 10.1046/j.1469-8137.1999.00339.x; Read AF, 2001, SCIENCE, V292, P1099, DOI 10.1126/science.1059410; Regoes RR, 2000, EVOLUTION, V54, P64, DOI 10.1111/j.0014-3820.2000.tb00008.x; Reid AH, 2003, J GEN VIROL, V84, P2285, DOI 10.1099/vir.0.19302-0; Rest JS, 2003, INFECT GENET EVOL, V3, P219, DOI 10.1016/j.meegid.2003.08.001; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; Riley SPD, 2004, J WILDLIFE DIS, V40, P11, DOI 10.7589/0090-3558-40.1.11; Roy BA, 2001, EVOLUTION, V55, P41, DOI 10.1111/j.0014-3820.2001.tb01271.x; Russell CJ, 2005, CELL, V123, P368, DOI 10.1016/j.cell.2005.10.019; Sacristan S, 2004, PHYTOPATHOLOGY, V94, P992, DOI 10.1094/PHYTO.2004.94.9.992; SCHOENEWEISS DF, 1975, ANNU REV PHYTOPATHOL, V13, P193, DOI 10.1146/annurev.py.13.090175.001205; Simon AE, 2004, ANNU REV PHYTOPATHOL, V42, P415, DOI 10.1146/annurev.phyto.42.040803.140402; Soosaar JLM, 2005, NAT REV MICROBIOL, V3, P789, DOI 10.1038/nrmicro1239; Woolhouse MEJ, 2005, TRENDS ECOL EVOL, V20, P238, DOI 10.1016/j.tree.2005.02.009; Woolhouse MEJ, 2001, SCIENCE, V292, P1109, DOI 10.1126/science.1059026; Woolhouse MEJ, 2002, NAT GENET, V32, P569, DOI 10.1038/ng1202-569; [No title captured]	60	63	65	2	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e41	10.1371/journal.pone.0000041	http://dx.doi.org/10.1371/journal.pone.0000041			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183670	gold, Green Published, Green Submitted			2022-12-25	WOS:000207443600041
J	Shulman, LM; Manor, Y; Sofer, D; Handsher, R; Swartz, T; Delpeyroux, F; Mendelson, E				Shulman, Lester M.; Manor, Yossi; Sofer, Danit; Handsher, Rachel; Swartz, Tiberio; Delpeyroux, Francis; Mendelson, Ella			Neurovirulent Vaccine-Derived Polioviruses in Sewage from Highly Immune Populations	PLOS ONE			English	Article							ORAL POLIOVACCINE; RIVER WATER; POLIO; EVOLUTION; INFECTION; STRAINS; ISRAEL; POLIOMYELITIS; RECOMBINATION; SURVEILLANCE	Background. Vaccine-derived polioviruses (VDPVs) have caused poliomyelitis outbreaks in communities with sub-optimal vaccination. Israeli environmental surveillance of sewage from populations with high (> 95%) documented vaccine coverage of confirmed efficacy identified two separate evolutionary clusters of VDPVs: Group 1 (1998-2005, one system, population 1.6x10(6)) and Group 2 (2006, 2 systems, populations 0.7x10(6) and 5x10(4)). Principal Findings. Molecular analyses support evolution of nine Group 1 VDPVs along five different lineages, starting from a common ancestral type 2 vaccine-derived Sabin-2/Sabin-1 recombinant strain, and independent evolution of three Group 2 VDPVs along one lineage starting from a different recombinant strain. The primary evidence for two independent origins was based on comparison of unique recombination fingerprints, the number and distribution of identical substitutions, and evolutionary rates. Geometric mean titers of neutralizing antibodies against Group 1 VDPVs were significantly lower than against vaccine strains in all age-group cohorts tested. All individuals had neutralizing titers > 1:8 against these VDPVs except 7% of the 20-50 year cohort. Group 1 VDPVs were highly neurovirulent in a transgenic mouse model. Intermediate levels of protective immunity against Group 2 VDPVs correlated with fewer (5.0+1.0) amino acid substitutions in neutralizing antigenic sites than in Group 1 VDPV's (12.1 +/- 1.5). Significance. VDPVs that revert from live oral attenuated vaccines and reacquire characteristics of wild-type polioviruses not only threaten populations with poor immune coverage, but are also a potential source for re-introduction of poliomyelitis into highly immune populations through older individuals with waning immunity. The presence of two independently evolved groups of VDPVs in Israel and the growing number of reports of environmental VDPV elsewhere make it imperative to determine the global frequency of environmental VDPV. Our study underscores the importance of the environmental surveillance and the need to reconsider the global strategies for polio eradication and the proposed cessation of vaccination.	[Shulman, Lester M.; Manor, Yossi; Sofer, Danit; Handsher, Rachel; Mendelson, Ella] Chaim Sheba Med Ctr, Minist Hlth, Cent Virol Lab, Publ Hlth Serv, IL-52621 Tel Hashomer, Israel; [Swartz, Tiberio] Chaim Sheba Med Ctr, Israel Ctr Dis Control, Minist Hlth, IL-52621 Tel Hashomer, Israel; [Delpeyroux, Francis] Inst Pasteur, CNRS, FRE 2849, Unit Mol Prevent & Therapy Human Dis, Paris, France; [Mendelson, Ella] Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Bar Ilan University	Shulman, LM (corresponding author), Chaim Sheba Med Ctr, Minist Hlth, Cent Virol Lab, Publ Hlth Serv, IL-52621 Tel Hashomer, Israel.	cvlsheba@netvision.net.il	Shulman, Lester M./AAU-4372-2021; DELPEYROUX, Francis/ABA-5429-2021; Delpeyroux, Francis/H-8838-2016	Shulman, Lester M./0000-0002-6385-894X; DELPEYROUX, Francis/0000-0002-4895-823X; Delpeyroux, Francis/0000-0002-4895-823X	Israel Ministry of Health	Israel Ministry of Health	We thank the Israel Ministry of Health for supporting this study.	Agol VI, 1997, SEMIN VIROL, V8, P77, DOI 10.1006/smvy.1997.0112; Blomqvist S, 2004, J VIROL, V78, P4876, DOI 10.1128/JVI.78.9.4876-4883.2004; Buttinelli G, 2003, J GEN VIROL, V84, P1215, DOI 10.1099/vir.0.18974-0; Calderon-Margalit R, 2005, PREV MED, V40, P685, DOI 10.1016/j.ypmed.2004.09.008; *CDC, 2002, MMWR-MORBID MORTAL W, V51, P369; Cherkasova E, 2003, P NATL ACAD SCI USA, V100, P9398, DOI 10.1073/pnas.1633511100; Cuervo NS, 2001, J VIROL, V75, P5740, DOI 10.1128/JVI.75.13.5740-5751.2001; DE L, 1995, J CLIN MICROBIOL, V33, P562, DOI 10.1128/JCM.33.3.562-571.1995; DOMINGO E, 1985, GENE, V40, P1, DOI 10.1016/0378-1119(85)90017-4; FINE PEM, 1993, EPIDEMIOL REV, V15, P265, DOI 10.1093/oxfordjournals.epirev.a036121; GEORGESCU MM, 1994, J VIROL, V68, P8089, DOI 10.1128/JVI.68.12.8089-8101.1994; Grotto I, 2001, VACCINE, V19, P4162, DOI 10.1016/S0264-410X(01)00165-7; Guillot S, 2000, J VIROL, V74, P8434, DOI 10.1128/JVI.74.18.8434-8443.2000; Halsey NA, 2004, B WORLD HEALTH ORGAN, V82, P3; Kew OM, 2004, B WORLD HEALTH ORGAN, V82, P16; Kew OM, 2005, ANNU REV MICROBIOL, V59, P587, DOI 10.1146/annurev.micro.58.030603.123625; Kew OM, 1995, SEMIN VIROL, V6, P401, DOI 10.1016/S1044-5773(05)80017-4; KINNUNEN L, 1990, J GEN VIROL, V71, P317, DOI 10.1099/0022-1317-71-2-317; Korotkova EA, 2003, J VIROL, V77, P12460, DOI 10.1128/JVI.77.23.12460-12465.2003; Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999; MacLennan C, 2004, LANCET, V363, P1509, DOI 10.1016/S0140-6736(04)16150-3; Manor Y, 1999, J CLIN MICROBIOL, V37, P1670, DOI 10.1128/JCM.37.6.1670-1675.1999; MCGOLDRICK A, 1995, J VIROL, V69, P7601, DOI 10.1128/JVI.69.12.7601-7605.1995; MENDELSON E, 2002, GLASGOW SCOTLAND J C, V282; Pavlov DN, 2005, WATER RES, V39, P3309, DOI 10.1016/j.watres.2005.05.027; Pertinacova J., 2004, Epidemiologie Mikrobiologie Imunologie, V53, P22; Ranta J, 2001, RISK ANAL, V21, P1087, DOI 10.1111/0272-4332.t01-1-216174; Shulman LM, 2006, ISR MED ASSOC J, V8, P312; Shulman LM, 2000, J CLIN MICROBIOL, V38, P945, DOI 10.1128/JCM.38.3.945-952.2000; Shulman LM, 2000, J CLIN MICROBIOL, V38, P3729, DOI 10.1128/JCM.38.10.3729-3734.2000; SHULMAN LM, 1996, 10 INT C VIR JER ISR; SHULMAN LM, 2004, ANN M ISR SOC MICR H; SLATER PE, 1990, LANCET, V335, P1192, DOI 10.1016/0140-6736(90)92705-M; SLATER PE, 1988, LANCET, V335, P1196; Swartz TA, 1998, VACCINE, V16, P2090, DOI 10.1016/S0264-410X(98)00071-1; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TOYODA H, 1984, J MOL BIOL, V174, P561, DOI 10.1016/0022-2836(84)90084-6; Vidor E, 1997, PEDIATR INFECT DIS J, V16, P312, DOI 10.1097/00006454-199703000-00011; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; Yakovenko ML, 2006, J VIROL, V80, P2641, DOI 10.1128/JVI.80.6.2641-2653.2006; Yang CF, 2005, J VIROL, V79, P12623, DOI 10.1128/JVI.79.20.12623-12634.2005; Yoshida H, 2000, LANCET, V356, P1461, DOI 10.1016/S0140-6736(00)02868-3; 2005, MMWR, V54, P1053	43	51	54	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e69	10.1371/journal.pone.0000069	http://dx.doi.org/10.1371/journal.pone.0000069			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183700	Green Published, gold			2022-12-25	WOS:000207443600069
J	Feng, FY; Varambally, S; Tomlins, SA; Chun, PY; Lopez, CA; Li, X; Davis, MA; Chinnaiyan, AM; Lawrence, TS; Nyati, MK				Feng, F. Y.; Varambally, S.; Tomlins, S. A.; Chun, P. Y.; Lopez, C. A.; Li, X.; Davis, M. A.; Chinnaiyan, A. M.; Lawrence, T. S.; Nyati, M. K.			Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity	ONCOGENE			English	Article						gemcitabine; EGFR; head and neck neoplasm	SQUAMOUS-CELL CARCINOMA; NECK-CANCER; PHASE-II; EGF RECEPTOR; RADIATION CONCURRENT; SIGNALING NETWORK; DOWN-REGULATION; KINASE-ACTIVITY; ADVANCED HEAD; TGF-ALPHA	We have recently reported that treatment with gemcitabine, a potent chemotherapeutic agent and radiation sensitizer, stimulates phosphorylation of the epidermal growth factor receptor (EGFR). Because phosphorylation of EGFR is known to precede receptor degradation, we hypothesized that gemcitabine treatment may also result in EGFR degradation. In two human head and neck cancer cell lines, UMSCC-1 and UMSCC-6, we demonstrated an approximately 80% decrease in total EGFR levels at 72 h after a 2-h treatment with 1 mu m gemcitabine. Neither cisplatin nor 5-fluorouracil, which are used to treat head and neck cancer, caused EGFR degradation. EGFR downregulation did not occur at the level of transcription, as assessed by reverse transcription-polymerase chain reaction (RT-PCR), but instead occurred via phosphorylation and ubiquitination of the receptor along a proteosome/lysosome-mediated pathway. Inhibition of EGFR degradation, by either pretreatment with the EGFR tyrosine kinase inhibitor gefitinib or by exposure to the proteosome/lysosome inhibitor MG132, significantly reduced gemcitabine-induced cell death. These results suggest that EGFR degradation may be a novel mechanism for gemcitabine-mediated cell death. These findings also indicate that caution should be exercised when combining gemcitabine with agents that may prevent EGFR degradation, such as EGFR tyrosine kinase inhibitors administered in a suboptimal sequence or proteosome inhibitors.	Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nyati, MK (corresponding author), Univ Michigan, Dept Radiat Oncol, Room 3011,1331 E Ann St, Ann Arbor, MI 48109 USA.	nyati@umich.edu		Varambally, Sooryanarayana/0000-0002-2277-1127	NCI NIH HHS [5 P30 CA46592, P50 CA097248, 1 P50 CA97248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592, P50CA097248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491; Ang KK, 2002, CANCER RES, V62, P7350; Baselga J, 2005, J CLIN ONCOL, V23, P5568, DOI 10.1200/JCO.2005.07.119; Benhar M, 2002, ONCOGENE, V21, P8723, DOI 10.1038/sj.onc.1205980; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Chinnaiyan P, 2005, INT J RADIAT ONCOL, V62, P223, DOI 10.1016/j.ijrobp.2004.12.088; Chun PY, 2006, CANCER RES, V66, P981, DOI 10.1158/0008-5472.CAN-05-2665; Cohen EEW, 2003, J CLIN ONCOL, V21, P1980, DOI 10.1200/JCO.2003.10.051; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Eisbruch A, 2001, J CLIN ONCOL, V19, P792, DOI 10.1200/JCO.2001.19.3.792; Eisbruch A, 2002, INT J RADIAT ONCOL, V53, P23, DOI 10.1016/S0360-3016(02)02712-8; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; LAWRENCE TS, 1992, CANCER RES, V52, P3698; Lawrence TS, 2001, CLIN CANCER RES, V7, P314; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Macabeo-Ong M, 2002, MODERN PATHOL, V15, P979, DOI 10.1097/01.MP.0000026054.62220.FC; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; MIZUNO H, 2005, MOL CARCINOG; Nelson JM, 2001, J BIOL CHEM, V276, P14842, DOI 10.1074/jbc.M008786200; Nyati MK, 2004, CLIN CANCER RES, V10, P691, DOI 10.1158/1078-0432.CCR-1041-03; Oksvold MP, 2003, ONCOGENE, V22, P8509, DOI 10.1038/sj.onc.1207117; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Pomerantz RG, 2004, SEMIN ONCOL, V31, P734, DOI 10.1053/j.seminoncol.2004.09.015; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; Shewach DS, 1996, INVEST NEW DRUG, V14, P257, DOI 10.1007/BF00194528; Soulieres D, 2004, J CLIN ONCOL, V22, P77, DOI 10.1200/JCO.2004.06.075; Supino-Rosin L, 2000, J BIOL CHEM, V275, P21850, DOI 10.1074/jbc.M001834200; Tempero M, 2003, J CLIN ONCOL, V21, P3402, DOI 10.1200/JCO.2003.09.140; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhuang SG, 2003, ONCOGENE, V22, P4413, DOI 10.1038/sj.onc.1206604	40	61	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2007	26	23					3431	3439		10.1038/sj.onc.1210129	http://dx.doi.org/10.1038/sj.onc.1210129			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17146438				2022-12-25	WOS:000246579600013
J	Ma, Y; Cress, WD				Ma, Y.; Cress, W. D.			Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity	ONCOGENE			English	Article						CDK; CDKN1C; E2F; BMS-387032; SNS-032; apoptosis	FLAVOPIRIDOL-INDUCED APOPTOSIS; S-PHASE; POTENTIAL MEDIATOR; GENE-EXPRESSION; P57(KIP2); ACTIVATION; PROMOTER; PROTEIN; CELLS; P21(WAF1/CIP1)	In spite of the fact that cyclin-dependent kinase (cdk) inhibiting drugs are potent transcriptional repressors, we discover that p57 (Kip2, CDKN1C) transcription is significantly upregulated by three small molecule cdk inhibitors, including BMS-387032. Treatment of MDAMB231 breast cancer cells with BMS-387032 led to a stabilization of the E2F1 protein that was accompanied by significant increases in the p57 mRNA and protein. This increase did not occur in an E2F1-deficient cell line. An E2F1-estrogen receptor fusion protein activated the endogenous p57 promoter in response to hydroxytamoxifen treatment in the presence of cycloheximide. Luciferase constructs driven by the p57 promoter verified that upregulation of p57 mRNA byBMS-38 7032 is transcriptional and dependent on E2F-binding sites in the promoter. Expression of exogenous p57 significantly decreased the fraction of cells in S phase. Furthermore, p57-deficient MDA-MB-231 cell lines were significantly more sensitive to BMS-387032-induced apoptosis than controls. The results presented in this manuscript demonstrate that small molecule cdk inhibitors transcriptionally activate p57 dependent upon E2F1 and that this activation in turn serves to limit E2F1's death-inducing activity.	Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Cress, WD (corresponding author), Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	cressd@moffitt.usf.edu			NCI NIH HHS [R01 CA090489-05, CA90489-01, R01 CA090489-04, R01 CA090489] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afshari CA, 1996, CELL GROWTH DIFFER, V7, P979; Alheim K, 2003, J MOL ENDOCRINOL, V30, P359, DOI 10.1677/jme.0.0300359; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Brideau AD, 1998, J VIROL, V72, P4560, DOI 10.1128/JVI.72.6.4560-4570.1998; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; Devgan V, 2005, GENE DEV, V19, P1485, DOI 10.1101/gad.341405; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Gartel AL, 2000, ONCOGENE, V19, P961, DOI 10.1038/sj.onc.1203411; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Gonzalez S, 2005, CANCER RES, V65, P2186, DOI 10.1158/0008-5472.CAN-04-3047; HARPER JW, 1993, CELL, V75, P805; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jackson JF, 2002, MOLEC METH PLAN ANAL, V21, P1; Jackson RJ, 2003, CANCER RES, V63, P3021; Jiang J, 2003, CANCER RES, V63, P7410; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Lam LT, 2001, GENOME BIOL, V2; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lu X, 2004, MOL CANCER THER, V3, P861; Ma YH, 2004, CANCER BIOL THER, V3, P1262, DOI 10.4161/cbt.3.12.1239; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; Ma YH, 2003, MOL CANCER THER, V2, P73; Matranga CB, 2002, CANCER RES, V62, P1707; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Merlo P, 2005, J BIOL CHEM, V280, P30354, DOI 10.1074/jbc.M500635200; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Samuelsson MKR, 2002, BIOCHEM BIOPH RES CO, V296, P702, DOI 10.1016/S0006-291X(02)00912-9; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stewart MC, 2004, J BONE MINER RES, V19, P123, DOI 10.1359/JBMR.0301209; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	50	25	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3532	3540		10.1038/sj.onc.1210143	http://dx.doi.org/10.1038/sj.onc.1210143			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17173074	Green Accepted			2022-12-25	WOS:000246799200009
J	Shiroishi, M; Tsumoto, K; Tanaka, Y; Yokota, A; Nakanishi, T; Kondo, H; Kumagai, I				Shiroishi, Mitsunori; Tsumoto, Kouhei; Tanaka, Yoshikazu; Yokota, Akiko; Nakanishi, Takeshi; Kondo, Hidemasa; Kumagai, Izumi			Structural consequences of mutations in interfacial Tyr residues of a protein antigen-anti body complex - The case of HyHEL-10-HEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTILYSOZYME MONOCLONAL-ANTIBODY; SALT BRIDGE FORMATION; EGG-WHITE LYSOZYME; ENTROPIC CONTRIBUTION; CRYSTAL-STRUCTURE; CHICKEN LYSOZYME; HOT-SPOT; FV; EPITOPE; FAB	Tyrosine is an important amino acid in protein-protein interaction hot spots. In particular, many Tyr residues are located in the antigen-binding sites of antibodies and endow high affinity and high specificity to these antibodies. To investigate the role of interfacial Tyr residues in protein-protein interactions, we performed crystallographic studies and thermodynamic analyses of the interaction between hen egg lysozyme (HEL) and the anti-HEL antibody HyHEL-10 Fv fragment. HyHEL-10 has six Tyr residues in its antigen-binding site, which were systematically mutated to Phe and Ala using site-directed mutagenesis. The crystal structures revealed several critical roles for these Tyr residues in the interaction between HEL and HyHEL-10 as follows: 1) the aromatic ring of Tyr-50 in the light chain (LTyr-50) was important for the correct ternary structure of variable regions of the immunoglobulin light chain and heavy chain and of HEL; 2) deletion of the hydroxyl group of Tyr-50 in the heavy chain (HTyr-50) resulted in structural changes in the antigen-antibody interface; and 3) the side chains of HTyr-33 and HTyr-53 may help induce fitting of the antibody to the antigen. Hot spot Tyr residues may contribute to the high affinity and high specificity of the antigen-antibody interaction through a diverse set of structural and thermodynamic interactions.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Kashiwa, Chiba 2778562, Japan; Natl Inst Adv Ind Sci & Technol, Hokkaido Ctr, Sapporo, Hokkaido 0628517, Japan	Tohoku University; University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)	Tsumoto, K (corresponding author), Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Yama 6-6-11, Sendai, Miyagi 9808579, Japan.	tsumoto@k.u-tokyo.ac.jp; kmiz@mail.tains.tohoku.ac.jp	Kondo, Hidemasa/M-7465-2018; Yokota, Akiko/M-1807-2018	Kondo, Hidemasa/0000-0003-2799-1775; Yokota, Akiko/0000-0002-5896-9899; Shiroishi, Mitsunori/0000-0002-3133-157X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Braden BC, 1998, IMMUNOL REV, V163, P45, DOI 10.1111/j.1600-065X.1998.tb01187.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chakrabarti P, 2002, PROTEINS, V47, P334, DOI 10.1002/prot.10085; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Fellouse FA, 2006, J MOL BIOL, V357, P100, DOI 10.1016/j.jmb.2005.11.092; Fellouse FA, 2004, P NATL ACAD SCI USA, V101, P12467, DOI 10.1073/pnas.0401786101; Fields BA, 1996, BIOCHEMISTRY-US, V35, P15494, DOI 10.1021/bi961709e; Fleury D, 1998, NAT STRUCT BIOL, V5, P119, DOI 10.1038/nsb0298-119; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; Hubbard SJ, 1993, NACCESS COMPUTER PRO; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KAMMORGAN LNW, 1993, P NATL ACAD SCI USA, V90, P3958, DOI 10.1073/pnas.90.9.3958; Kondo H, 1999, J BIOL CHEM, V274, P27623, DOI 10.1074/jbc.274.39.27623; Kumagai I, 2003, J BIOL CHEM, V278, P24929, DOI 10.1074/jbc.M301149200; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB, P26; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; Li YL, 2005, STRUCTURE, V13, P297, DOI 10.1016/j.str.2004.12.012; Li YL, 2003, BIOCHEMISTRY-US, V42, P11, DOI 10.1021/bi020589+; Li YL, 2000, BIOCHEMISTRY-US, V39, P6296, DOI 10.1021/bi000054l; Li YL, 2001, BIOCHEMISTRY-US, V40, P2011, DOI 10.1021/bi0014148; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; Nishimiya Y, 2000, J BIOL CHEM, V275, P12813, DOI 10.1074/jbc.275.17.12813; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; Pons J, 1999, PROTEIN SCI, V8, P958, DOI 10.1110/ps.8.5.958; Rajpal A, 1998, PROTEIN SCI, V7, P1868, DOI 10.1002/pro.5560070903; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; Shiroishi M, 2001, J BIOL CHEM, V276, P23042, DOI 10.1074/jbc.M100480200; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; TRONRUD DE, 1987, SCIENCE, V235, P571, DOI 10.1126/science.3810156; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551; TSUMOTO K, 1994, J BIOL CHEM, V269, P28777; Tsumoto K, 1996, J BIOL CHEM, V271, P32612, DOI 10.1074/jbc.271.51.32612; UEDA Y, 1993, GENE, V129, P129; Yokota A, 2003, J BIOL CHEM, V278, P5410, DOI 10.1074/jbc.M210182200; YSERN X, 1994, J MOL BIOL, V238, P496	46	33	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6783	6791		10.1074/jbc.M605197200	http://dx.doi.org/10.1074/jbc.M605197200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17166830	hybrid			2022-12-25	WOS:000244867200088
J	Cuellar, K; Chuong, H; Hubbell, SM; Hinsdale, ME				Cuellar, Karen; Chuong, Hoa; Hubbell, Sherry M.; Hinsdale, Myron E.			Biosynthesis of chondroitin and heparan sulfate in Chinese hamster ovary cells depends on xylosyltransferase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; XT-II; PROTEOGLYCANS; EXPRESSION; MUTANTS; GALACTOSYLTRANSFERASE; PURIFICATION; RECEPTORS; BINDING; CLONING	Xylosyltransferase (XylT) catalyzes the initial enzymatic reaction in the glycosaminoglycan assembly pathway for proteoglycan biosynthesis. Its activity is thought to be rate-limiting. Two xylosyltransferases have been found using genomic analyses, and one of these, XylT1, has been shown to have xylosyltransferase activity. On the other hand, the less studied XylT2 in recombinant form lacks xylosyltransferase activity and has no known function. Wild-type Chinese hamster ovary cells express abundant Xylt2 mRNA levels and lack detectable Xylt1 mRNA levels. Analysis of a previously described Chinese hamster ovary cell xylosyltransferase mutant (psgA-745) shows that it harbors an Xylt2 nonsense mutation and fails to assemble glycosaminoglycans onto recombinant biglycan. Transfection of this cell line with a murine Xylt2 minigene results in the production of recombinant chondroitin sulfate-modified biglycan core protein and restoration of fibroblast growth factor binding to cell surface-associated heparan sulfate. Expression analyses on 10 different human transformed cell lines detect exclusive XYLT2 expression in two and co-expression of XYLT1 and XYLT2 in the others but at disparate ratios where XYLT2 expression is greater than XYLT1 in most cell lines. These results indicate that XylT2 has a significant role in proteoglycan biosynthesis and that cell type may control which family member is utilized.	Univ Oklahoma, Hlth Sci Ctr, Cardiovasc Biol Res Program, Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Hinsdale, ME (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Cardiovasc Biol Res Program, Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.	Myron-Hinsdale@omrf.ouhsc.edu			NCRR NIH HHS [P20 RR018758] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018758] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brunner A, 2006, GLYCOCONJUGATE J, V23, P543, DOI 10.1007/s10719-006-7633-z; Charnaux N, 2005, FEBS J, V272, P1937, DOI 10.1111/j.1742-4658.2005.04624.x; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; GRASSEL S, 1995, MOL CELL BIOCHEM, V145, P61, DOI 10.1007/BF00925714; Gustafsson M, 2004, CURR OPIN LIPIDOL, V15, P505, DOI 10.1097/00041433-200410000-00003; Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681; HINSDALE ME, 1993, GENOMICS, V16, P605, DOI 10.1006/geno.1993.1237; Hwang HY, 2003, J BIOL CHEM, V278, P11735, DOI 10.1074/jbc.C200518200; Iozzo RV, 2005, NAT REV MOL CELL BIO, V6, P646, DOI 10.1038/nrm1702; ISAACS RD, 1994, J CLIN INVEST, V93, P809, DOI 10.1172/JCI117035; KEARNS AE, 1993, J BIOL CHEM, V268, P11097; Kuhn J, 2003, BIOCHEM BIOPH RES CO, V312, P537, DOI 10.1016/j.bbrc.2003.10.157; Liuzzo JP, 1996, BLOOD, V87, P245; Mahley RW, 1999, J LIPID RES, V40, P1; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Schon S, 2006, J BIOL CHEM, V281, P14224, DOI 10.1074/jbc.M510690200; SCHWARTZ NB, 1974, BIOCHEM BIOPH RES CO, V56, P717, DOI 10.1016/0006-291X(74)90664-0; Shafti-Keramat S, 2003, J VIROL, V77, P13125, DOI 10.1128/JVI.77.24.13125-13135.2003; STOOLMILLER AC, 1972, J BIOL CHEM, V247, P3525; Wilson IBH, 2004, CELL MOL LIFE SCI, V61, P794, DOI 10.1007/s00018-003-3278-2	29	55	55	4	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5195	5200		10.1074/jbc.M611048200	http://dx.doi.org/10.1074/jbc.M611048200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189266	hybrid			2022-12-25	WOS:000244482300013
J	Saiyed, T; Paarmann, I; Schmitt, B; Haeger, S; Sola, M; Schmalzing, G; Weissenhorn, W; Betz, H				Saiyed, Taslimarif; Paarmann, Ingo; Schmitt, Bertram; Haeger, Svenja; Sola, Maria; Schmalzing, Guenther; Weissenhorn, Winfried; Betz, Heinrich			Molecular basis of gephyrin clustering at inhibitory synapses - Role of G- and E-domain interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR BIOSYNTHESIS; BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; GABA(A) RECEPTOR SUBTYPES; GLYCINE RECEPTOR; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; POSTSYNAPTIC DENSITY; SPLICE VARIANTS; DEFICIENT MICE	Gephyrin is a bifunctional modular protein that, in neurons, clusters glycine receptors and gamma-aminobutyric acid, type A receptors in the postsynaptic membrane of inhibitory synapses. By x-ray crystallography and cross-linking, the N-terminal G-domain of gephyrin has been shown to form trimers and the C-terminal E-domain dimers, respectively. Gephyrin therefore has been proposed to form a hexagonal submembranous lattice onto which inhibitory receptors are anchored. Here, crystal structure-based substitutions at oligomerization interfaces revealed that both G-domain trimerization and E-domain dimerization are essential for the formation of higher order gephyrin oligomers and postsynaptic gephyrin clusters. Insertion of the alternatively spliced C5' cassette into the G-domain inhibited clustering by interfering with trimerization, and mutation of the glycine receptor beta-subunit binding region prevented the localization of the clusters at synaptic sites. Together our findings show that domain interactions mediate gephyrin scaffold formation.	Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany; Rhein Westfal TH Aachen, Dept Mol Pharmacol, D-52074 Aachen, Germany; European Mol Biol Lab, F-38042 Grenoble 9, France	Max Planck Society; RWTH Aachen University; European Molecular Biology Laboratory (EMBL)	Betz, H (corresponding author), Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany.	neurochemie@mpih-frankfurt.mpg.de		Sola, Maria/0000-0002-0838-9706				Baron MK, 2006, SCIENCE, V311, P531, DOI 10.1126/science.1118995; Bedet C, 2006, J BIOL CHEM, V281, P30046, DOI 10.1074/jbc.M602155200; Christopherson KS, 2003, J CELL SCI, V116, P3213, DOI 10.1242/jcs.00617; Craig AM, 1996, J NEUROSCI, V16, P3166; Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525; Eckler SA, 2005, NEUROSCIENCE, V131, P661, DOI 10.1016/j.neuroscience.2004.11.035; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Fuhrmann JC, 2002, J NEUROSCI, V22, P5393; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Gendreau S, 2004, J BIOL CHEM, V279, P39505, DOI 10.1074/jbc.M408038200; GLOOR S, 1995, GENE, V160, P213, DOI 10.1016/0378-1119(95)00226-V; Hanus C, 2004, J NEUROSCI, V24, P1119, DOI 10.1523/JNEUROSCI.4380-03.2004; Heck S, 1997, DEV BRAIN RES, V98, P211, DOI 10.1016/S0165-3806(96)00181-2; Jacob TC, 2005, J NEUROSCI, V25, P10469, DOI 10.1523/JNEUROSCI.2267-05.2005; Kim EY, 2006, EMBO J, V25, P1385, DOI 10.1038/sj.emboj.7601029; Kins S, 2000, NAT NEUROSCI, V3, P22, DOI 10.1038/71096; KIRSCH J, 1995, MOL CELL NEUROSCI, V6, P450, DOI 10.1006/mcne.1995.1033; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; Kneussel M, 2000, TRENDS NEUROSCI, V23, P429, DOI 10.1016/S0166-2236(00)01627-1; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; Kneussel M, 2001, MOL CELL NEUROSCI, V17, P973, DOI 10.1006/mcne.2001.0983; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Liu MTW, 2000, J BIOL CHEM, V275, P1814, DOI 10.1074/jbc.275.3.1814; Maas C, 2006, J CELL BIOL, V172, P441, DOI 10.1083/jcb.200506066; Meier J, 2000, MOL CELL NEUROSCI, V16, P566, DOI 10.1006/mcne.2000.0899; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Paarmann I, 2006, BIOCHEM SOC T, V34, P45, DOI 10.1042/BST0340045; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; Ramming M, 2000, P NATL ACAD SCI USA, V97, P10266, DOI 10.1073/pnas.97.18.10266; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schrader N, 2004, J BIOL CHEM, V279, P18733, DOI 10.1074/jbc.M311245200; Schwarz G, 2001, J MOL BIOL, V312, P405, DOI 10.1006/jmbi.2001.4952; Sola M, 2004, EMBO J, V23, P2510, DOI 10.1038/sj.emboj.7600256; Sola M, 2001, J BIOL CHEM, V276, P25294, DOI 10.1074/jbc.M101923200; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; Xiang S, 2001, STRUCTURE, V9, P299, DOI 10.1016/S0969-2126(01)00588-3; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	43	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5625	5632		10.1074/jbc.M610290200	http://dx.doi.org/10.1074/jbc.M610290200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17182610	hybrid			2022-12-25	WOS:000244482300059
J	Tal, R; Winter, G; Ecker, N; Klionsky, DJ; Abeliovich, H				Tal, Ruth; Winter, Gal; Ecker, Nitai; Klionsky, Daniel J.; Abeliovich, Hagai			Aup1p, a yeast mitochondrial protein phosphatase homolog, is required for efficient stationary phase mitophagy and cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; AMINOPEPTIDASE-I; GENE DELETION; AUTOPHAGY; DEATH; DEGRADATION; BIOGENESIS; PATHWAY; LOCALIZATION; CYTOPLASM	Autophagy is a catabolic membrane-trafficking process that occurs in all eukaryotic cells and leads to the hydrolytic degradation of cytosolic material in the vacuolar or lysosomal lumen. Mitophagy, a selective form of autophagy targeting mitochondria, is poorly understood at present. Several recent reports suggest that mitophagy is a selective process that targets damaged mitochondria, whereas other studies imply a role for mitophagy in cell death processes. In a screen for protein phosphatase homologs that functionally interact with the autophagy-dedicated protein kinase Atg1p in yeast, we have identified Aup1p, encoded by Saccharomyces cerevisiae reading frame YCR079w. Aup1p is highly similar to a family of protein phosphatase homologs in animal cells that are predicted to localize to mitochondria based on sequence analysis. Interestingly, we found that Aulp1p localizes to the mitochondrial intermembrane space and is required for efficient mitophagy in stationary phase cells. Viability studies demonstrate that Aup1p is required for efficient survival of cells in prolonged stationary phase cultures, implying a pro-survival role for mitophagy under our working conditions. Our data suggest that Aup1p may be part of a signal transduction mechanism that marks mitochondria for sequestration into autophagosomes.	Hebrew Univ Jerusalem, Dept Biochem & Food Sci, Fac Agr Food & Environm Qual Sci, IL-76100 Rehovot, Israel; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	Hebrew University of Jerusalem; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Abeliovich, H (corresponding author), Hebrew Univ Jerusalem, Dept Biochem & Food Sci, Fac Agr Food & Environm Qual Sci, IL-76100 Rehovot, Israel.	ahagai@agri.huji.ac.il	Winter, Gal/B-9188-2012	Winter, Gal/0000-0003-3789-395X	NIGMS NIH HHS [GM53396] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 1999, EMBO J, V18, P6005, DOI 10.1093/emboj/18.21.6005; Abeliovich H, 2003, MOL BIOL CELL, V14, P477, DOI 10.1091/mbc.E02-07-0413; Abeliovich H, 2001, MICROBIOL MOL BIOL R, V65, P463, DOI 10.1128/MMBR.65.3.463-479.2001; Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Budovskaya YV, 2004, J BIOL CHEM, V279, P20663, DOI 10.1074/jbc.M400272200; Camougrand N, 2004, FEMS YEAST RES, V5, P133, DOI 10.1016/j.femsyr.2004.05.001; Campbell CL, 1998, J CELL SCI, V111, P2455; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CLAROS MG, 1995, COMPUT APPL BIOSCI, V11, P441; DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gerhardt B, 1998, J BIOL CHEM, V273, P15818, DOI 10.1074/jbc.273.25.15818; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Hutchins MU, 2001, J BIOL CHEM, V276, P20491, DOI 10.1074/jbc.M101150200; Kamada Y, 2003, CURR TOP MICROBIOL, V279, P73; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; Kissova I, 2004, J BIOL CHEM, V279, P39068, DOI 10.1074/jbc.M406960200; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Kowald A, 2000, J THEOR BIOL, V202, P145, DOI 10.1006/jtbi.1999.1046; Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011; Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; LVINE B, 2003, HARVEY LECT, V99, P47; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Onodera J, 2004, J BIOL CHEM, V279, P16071, DOI 10.1074/jbc.M312706200; Priault M, 2005, CELL DEATH DIFFER, V12, P1613, DOI 10.1038/sj.cdd.4401697; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Reggiori F, 2004, DEV CELL, V6, P79, DOI 10.1016/S1534-5807(03)00402-7; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Reggiori F, 2005, AUTOPHAGY, V1, P101, DOI 10.4161/auto.1.2.1840; RUAN H, 2006, IN PRESS FEMS YEAST; Sakumoto NM, 1999, YEAST, V15, P1669, DOI 10.1002/(SICI)1097-0061(199911)15:15<1669::AID-YEA480>3.0.CO;2-6; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; TUTTLE DL, 1993, EUR J CELL BIOL, V60, P283; Velours G, 2002, FEMS MICROBIOL LETT, V207, P165, DOI 10.1111/j.1574-6968.2002.tb11046.x; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Westermann B, 2000, YEAST, V16, P1421, DOI 10.1002/1097-0061(200011)16:15<1421::AID-YEA624>3.3.CO;2-L; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xie MW, 2005, P NATL ACAD SCI USA, V102, P7215, DOI 10.1073/pnas.0500297102; Yin VP, 2005, SEMIN CELL DEV BIOL, V16, P237, DOI 10.1016/j.semcdb.2004.12.007; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200	52	211	219	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5617	5624		10.1074/jbc.M605940200	http://dx.doi.org/10.1074/jbc.M605940200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17166847	hybrid			2022-12-25	WOS:000244482300058
J	de Eugenio, LI; Garcia, P; Luengo, JM; Sanz, JM; San Roman, J; Garcia, JL; Prieto, MA				de Eugenio, Laura I.; Garcia, Pedro; Luengo, Jose M.; Sanz, Jesus M.; San Roman, Julio; Garcia, Jose Luis; Prieto, Maria A.			Biochemical evidence that phaZ gene encodes a specific intracellular medium chain length polyhydroxyalkanoate depolymerase in Pseudomonas putida KT2442 - Characterization of a paradigmatic enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RALSTONIA-EUTROPHA H16; POLY(3-HYDROXYOCTANOIC ACID) P(3HO); 3-HYDROXYBUTYRATE-OLIGOMER HYDROLASE; OLEOVORANS INCLUSIONS; MICROBIAL SYNTHESIS; LONG ALKYL; DEGRADATION; POLY(3-HYDROXYBUTYRATE); PURIFICATION; IDENTIFICATION	Polyhydroxyalkanoates (PHAs) can be catabolized by many microorganisms using intra- or extracellular PHA depolymerases. Most of our current knowledge of these intracellular enzyme-coding genes comes from the analysis of short chain length PHA depolymerases, whereas medium chain length PHA (mcl-PHA) intracellular depolymerization systems still remained to be characterized. The phaZ gene of some Pseudomonas putida strains has been identified only by mutagenesis and complementation techniques as putative intracellular mcl-PHA depolymerase. However, none of their corresponding encoded PhaZ enzymes have been characterized in depth. In this study the PhaZ depolymerase from P. putida KT2442 has been purified and biochemically characterized after its overexpression in Escherichia coli. To facilitate these studies we have developed a new and very sensitive radioactive method for detecting PHA hydrolysis in vitro. We have demonstrated that PhaZ is an intracellular depolymerase that is located in PHA granules and that hydrolyzes specifically mcl-PHAs containing aliphatic and aromatic monomers. The enzyme behaves as a serine hydrolase that is inhibited by phenylmethylsulfonyl fluoride. We have modeled the three-dimensional structure of PhaZ complexed with a 3-hydroxyoctanoate dimer. Using this model, we found that the enzyme appears to be built up from a core alpha/beta hydrolase-type domain capped with a lid structure with an active site containing a catalytic triad buried near the connection between domains. All these data constitute the first biochemical characterization of PhaZ and allow us to propose this enzyme as the paradigmatic representative of intracellular endo/exo-mcl-PHA depolymerases.	CSIC, Ctr Invest Biol, Dept Mol Microbiol, E-28040 Madrid, Spain; Univ Leon, Dept Bioquim & Biol Mol, E-24007 Leon, Spain; Univ Miguel Hernandez, Inst Biol Mol & Celular, Alicante 03202, Spain; CSIC, Inst Ciencia & Tecnol Polimeros, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Universidad de Leon; Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencia & Tecnologia de Polimeros (ICTP)	Prieto, MA (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Microbiol, C Ramiro Maeztu 9, E-28040 Madrid, Spain.	auxi@cib.csic.es	Sanz, Jesus M/B-2244-2008; Prieto, María Auxiliadora/I-8092-2015; García, Pedro/L-2808-2017; Luengo, Jose M./E-1935-2016; Garcia Lopez, Jose Luis/G-9139-2015	Sanz, Jesus M/0000-0002-4421-9376; García, Pedro/0000-0001-6717-8717; Luengo, Jose M./0000-0002-4984-6256; Prieto Jimenez, M. Auxiliadora/0000-0002-8038-1223; Garcia Lopez, Jose Luis/0000-0002-9238-2485				Abe H, 1999, INT J BIOL MACROMOL, V25, P185, DOI 10.1016/S0141-8130(99)00033-1; Abe T, 2005, J BACTERIOL, V187, P6982, DOI 10.1128/JB.187.20.6982-6990.2005; Abraham GA, 2001, BIOMACROMOLECULES, V2, P562, DOI 10.1021/bm010018h; ANDERSON AJ, 1990, MICROBIOL REV, V54, P450, DOI 10.1128/MMBR.54.4.450-472.1990; Arpigny JL, 1999, BIOCHEM J, V343, P177, DOI 10.1042/0264-6021:3430177; Behrends A, 1996, FEMS MICROBIOL LETT, V143, P191, DOI 10.1016/0378-1097(96)00305-9; Bernstein HJ, 2000, TRENDS BIOCHEM SCI, V25, P453, DOI 10.1016/S0968-0004(00)01606-6; Braaz R, 2003, FEMS MICROBIOL LETT, V224, P107, DOI 10.1016/S0378-1097(03)00425-7; Cheeseman JD, 2004, ACTA CRYSTALLOGR D, V60, P1237, DOI 10.1107/S0907444904010522; Chung DM, 2001, INT J BIOL MACROMOL, V29, P243, DOI 10.1016/S0141-8130(01)00172-6; de Roo G, 2002, BIOTECHNOL BIOENG, V77, P717, DOI 10.1002/bit.10139; DESNUELLE P, 1960, BIOCHIM BIOPHYS ACTA, V37, P570, DOI 10.1016/0006-3002(60)90532-1; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; Dunn G, 2005, J MOL BIOL, V346, P253, DOI 10.1016/j.jmb.2004.11.033; Foster LJR, 1999, INT J BIOL MACROMOL, V26, P187, DOI 10.1016/S0141-8130(99)00081-1; Foster LJR, 1996, INT J BIOL MACROMOL, V19, P177, DOI 10.1016/0141-8130(96)01125-7; FOSTER LJR, 1994, FEMS MICROBIOL LETT, V118, P279, DOI 10.1111/j.1574-6968.1994.tb06841.x; FRITZSCHE K, 1990, INT J BIOL MACROMOL, V12, P85, DOI 10.1016/0141-8130(90)90058-I; FULLER RC, 1992, FEMS MICROBIOL LETT, V103, P279, DOI 10.1111/j.1574-6968.1992.tb05849.x; Fushinobu S, 2002, PROTEIN SCI, V11, P2184, DOI 10.1110/ps.0209602; Garcia B, 1999, J BIOL CHEM, V274, P29228, DOI 10.1074/jbc.274.41.29228; Gavrilescu M, 2005, BIOTECHNOL ADV, V23, P471, DOI 10.1016/j.biotechadv.2005.03.004; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Handrick R, 2000, J BACTERIOL, V182, P5916, DOI 10.1128/JB.182.20.5916-5918.2000; Handrick R, 2001, J BIOL CHEM, V276, P36215, DOI 10.1074/jbc.M101106200; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; HOROWITZ DM, 1994, J AM CHEM SOC, V116, P2695, DOI 10.1021/ja00086a001; HUISMAN GW, 1991, J BIOL CHEM, V266, P2191; HUISMAN GW, 1989, APPL ENVIRON MICROB, V55, P1949, DOI 10.1128/AEM.55.8.1949-1954.1989; Jendrossek D, 2002, ANNU REV MICROBIOL, V56, P403, DOI 10.1146/annurev.micro.56.012302.160838; Jimenez JI, 2002, ENVIRON MICROBIOL, V4, P824, DOI 10.1046/j.1462-2920.2002.00370.x; Kessler B, 2001, J BIOTECHNOL, V86, P97, DOI 10.1016/S0168-1656(00)00404-1; Kim DY, 2002, BIOMACROMOLECULES, V3, P291, DOI 10.1021/bm010113q; Kim HM, 2000, J BIOSCI BIOENG, V89, P196, DOI 10.1016/S1389-1723(00)88737-X; Kobayashi T, 2005, J BACTERIOL, V187, P5129, DOI 10.1128/JB.187.15.5129-5135.2005; Kobayashi T, 2003, J BACTERIOL, V185, P3485, DOI 10.1128/JB.185.12.3485-3490.2003; KOUKER G, 1987, APPL ENVIRON MICROB, V53, P211, DOI 10.1128/AEM.53.1.211-213.1987; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; LAGEVEEN RG, 1988, APPL ENVIRON MICROB, V54, P2924, DOI 10.1128/AEM.54.12.2924-2932.1988; Luengo JM, 2003, CURR OPIN MICROBIOL, V6, P251, DOI 10.1016/S1369-5274(03)00040-7; Madison LL, 1999, MICROBIOL MOL BIOL R, V63, P21, DOI 10.1128/MMBR.63.1.21-53.1999; MARTINEZBLANCO H, 1990, J BIOL CHEM, V265, P7084; Miller J. H., 1972, EXPT MOL GENETICS, P431; Moldes C, 2004, APPL ENVIRON MICROB, V70, P3205, DOI 10.1128/AEM.70.6.3205-3212.2004; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; Numata K, 2006, MACROMOL BIOSCI, V6, P41, DOI 10.1002/mabi.200500160; O'Leary ND, 2005, APPL ENVIRON MICROB, V71, P4380, DOI 10.1128/AEM.71.8.4380-4387.2005; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; Potter M, 2004, MICROBIOL-SGM, V150, P2301, DOI 10.1099/mic.0.26970-0; Prieto MA, 1999, APPL ENVIRON MICROB, V65, P3265; Prieto MA, 1999, J BACTERIOL, V181, P858, DOI 10.1128/JB.181.3.858-868.1999; Ren Q, 2005, BIOMACROMOLECULES, V6, P2290, DOI 10.1021/bm050187s; Saegusa H, 2001, J BACTERIOL, V183, P94, DOI 10.1128/JB.183.1.94-100.2001; Sambrook J, 2001, MOL CLONING LAB MANU; Sandoval A, 2005, APPL MICROBIOL BIOT, V67, P97, DOI 10.1007/s00253-004-1752-x; SCHIRMER A, 1993, APPL ENVIRON MICROB, V59, P1220, DOI 10.1128/AEM.59.4.1220-1227.1993; SCHIRMER A, 1994, J BACTERIOL, V176, P7065, DOI 10.1128/JB.176.22.7065-7073.1994; Steinbuchel A, 2001, ADV BIOCHEM ENG BIOT, V71, P81; Stuart ES, 1996, INT J BIOL MACROMOL, V19, P171, DOI 10.1016/0141-8130(96)01124-5; van Pouderoyen G, 2001, J MOL BIOL, V309, P215, DOI 10.1006/jmbi.2001.4659; WILLIAMSON DH, 1962, BIOCHEM J, V82, P90, DOI 10.1042/bj0820090; WITHOLT B, 1994, Patent No. 5344769; York GM, 2003, J BACTERIOL, V185, P3788, DOI 10.1128/JB.185.13.3788-3794.2003; Zinn M, 2001, ADV DRUG DELIVER REV, V53, P5, DOI 10.1016/S0169-409X(01)00218-6	64	67	71	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4951	4962		10.1074/jbc.M608119200	http://dx.doi.org/10.1074/jbc.M608119200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17170116	hybrid, Green Published			2022-12-25	WOS:000244482000078
J	Huang, YC; Lin, YM; Chang, TW; Wu, SJ; Lee, YS; Chang, MDT; Chen, C; Wu, SH; Liao, YD				Huang, Yu-Chie; Lin, Yu-Min; Chang, Ting-Wei; Wu, Shih-Jung; Lee, Yan-Shin; Chang, Margaret Dah-Tsyr; Chen, Chinpan; Wu, Shih-Hsiung; Liao, You-Di			The flexible and clustered lysine residues of human ribonuclease 7 are critical for membrane permeability and antimicrobial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL-DERIVED NEUROTOXIN; BULLFROG RANA-CATESBEIANA; CATIONIC PROTEIN; PEPTIDE; PURIFICATION; INDOLICIDIN; ANGIOGENIN; EVOLUTION; RNASE-7; CLONING	The ubiquitous ribonucleases (RNases) play important roles in RNA metabolism, angiogenesis, neurotoxicity, and antitumor or antimicrobial activity. Only the antimicrobial RNases possess high positively charged residues, although their mechanisms of action remain unclear. Here, we report on the role of cationic residues of human RNase7 (hRNase7) in its antimicrobial activity. It exerted antimicrobial activity against bacteria and yeast, even at 4 degrees C. The bacterial membrane became permeable to the DNA-binding dye SYTOX Green in only a few minutes after bactericidal RNase treatment. NMR studies showed that the 22 positively charged residues (Lys(18) and Arg(4)) are distributed into three clusters on the surface of hRNase7. The first cluster, K-1,K-3,K-111,K-112, was located at the flexible coil near the N terminus, whereas the other two, K-32,K-35 and K-96,R-97,K-100, were located on rigid secondary structures. Mutagenesis studies showed that the flexible cluster K-1,K-3,K-111,K-112, rather than the catalytic residues His(15), Lys(38), and His(123) or other clusters such as K-32,K-35 and K-96,R-97,K-100, is critical for the bactericidal activity. We suggest that the hRNase7 binds to bacterial membrane and renders the membrane permeable through the flexible and clustered Lys residues K-1,K-3,K-111,K-112. The conformation of hRNase7 can be adapted for pore formation or disruption of bacterial membrane even at 4 degrees C.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan; Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan; Natl Yang Ming Univ, Inst Pharmacol, Taipei 112, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Tsing Hua University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Wu, SH (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	shwu@gate.sinica.edu.tw; ydliao@ibms.sinica.edu.tw	Chang, Tse Wen/H-5955-2011; Liao, You-Di/S-7018-2018; Chen, Chinpan/O-4202-2018	Liao, You-Di/0000-0001-5527-4736; 				ALASKOWSKI RA, 1996, J BIOMOL NMR, V8, P477; Carreras E, 2003, BIOCHEMISTRY-US, V42, P6636, DOI 10.1021/bi0273011; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Harder J, 2002, J BIOL CHEM, V277, P46779, DOI 10.1074/jbc.M207587200; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Holloway DE, 2001, PROTEIN EXPRES PURIF, V22, P307, DOI 10.1006/prep.2001.1434; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Hsu CH, 2005, NUCLEIC ACIDS RES, V33, P4053, DOI 10.1093/nar/gki725; Hsu CH, 2003, J MOL BIOL, V326, P1189, DOI 10.1016/S0022-2836(02)01472-9; Huang HC, 1998, J BIOL CHEM, V273, P6395, DOI 10.1074/jbc.273.11.6395; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Liao YD, 2000, NUCLEIC ACIDS RES, V28, P4097, DOI 10.1093/nar/28.21.4097; LIAO YD, 1994, EUR J BIOCHEM, V222, P215, DOI 10.1111/j.1432-1033.1994.tb18859.x; MCLAREN DJ, 1981, PARASITE IMMUNOL, V3, P359, DOI 10.1111/j.1365-3024.1981.tb00414.x; Nekhotiaeva N, 2003, FASEB J, V17, P394, DOI 10.1096/fj.03-0449fje; Nitto T, 2006, J BIOL CHEM, V281, P25622, DOI 10.1074/jbc.M604313200; Powers JPS, 2003, PEPTIDES, V24, P1681, DOI 10.1016/j.peptides.2003.08.023; Robinson WE, 1998, J LEUKOCYTE BIOL, V63, P94, DOI 10.1002/jlb.63.1.94; ROSENBERG HF, 1995, J BIOL CHEM, V270, P21539, DOI 10.1074/jbc.270.37.21539; Zhang JZ, 2003, NUCLEIC ACIDS RES, V31, P602, DOI 10.1093/nar/gkg157	29	94	100	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4626	4633		10.1074/jbc.M607321200	http://dx.doi.org/10.1074/jbc.M607321200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17150966	hybrid, Green Published			2022-12-25	WOS:000244482000043
J	Pollok-Kopp, B; Huttenrauch, F; Rethorn, S; Oppermann, M				Pollok-Kopp, Beatrix; Huettenrauch, Friederike; Rethorn, Stephanie; Oppermann, Martin			Dynamics of protein kinase C-mediated phosphorylation of the complement C5a receptor on serine 334	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II RECEPTOR; 5 CCR5 PHOSPHORYLATION; COUPLED RECEPTOR; BETA-ARRESTIN; ANAPHYLATOXIN RECEPTOR; CHEMOATTRACTANT RECEPTORS; TERMINAL DOMAIN; HL-60 CELLS; INTERNALIZATION; BINDING	Upon agonist binding, the C5a anaphylatoxin receptor (C5aR) is rapidly phosphorylated on phosphorylation sites that are located within the C-terminal domain of the receptor. Previous studies suggested that C5aR phosphorylation proceeds in a hierarchical manner with serine 334 presenting a highly accessible priming site that controls subsequent phosphorylation at other positions. To better understand the dynamics of Ser-334 phosphorylation, we generated site-specific monoclonal antibodies that specifically react with phosphoserine 334. In differentiated U937 cells, which endogenously express C5aR, stimulation with low C5a concentrations resulted in a very rapid (t2/1 similar to 20 s), albeit transient, receptor phosphorylation. Whole cell phosphorylation assays with specific inhibitors as well as in vitro phosphorylation assays with recombinant enzymes and peptide substrates revealed that phosphorylation of Ser-334 is regulated by protein kinase C-beta and a calyculin A-sensitive protein phosphatase. Surprisingly, at high concentrations (> 10 nM) of C5a, the protein kinase C-mediated phosphorylation of Ser-334 was essentially blocked. This could be attributed to the even faster (t2/1 < 5 s) binding of beta-arrestin to the receptor. Analysis of C5aR Ser/Ala mutants that possess a single intact serine residue either at position 334 or at neighboring positions 327, 332, or 338 revealed functional redundancy of C-terminal phosphorylation sites since all 4 serine residues could individually support C5aR internalization and desensitization. This study is among the first to analyze in a detailed manner, using a non-mutational approach, modifications of a defined phosphorylation site in a G protein-coupled receptor and to correlate these findings with functional parameters of receptor deactivation.	Univ Gottingen, Dept Cellular & Mol Immunol, D-37073 Gottingen, Germany	University of Gottingen	Oppermann, M (corresponding author), Univ Gottingen, Dept Cellular & Mol Immunol, Humboldtallee 34, D-37073 Gottingen, Germany.	mopperm@gwdg.de						ALI H, 1993, J BIOL CHEM, V268, P24247; Balasubramanian N, 2002, LEUKEMIA RES, V26, P67, DOI 10.1016/S0145-2126(01)00098-4; BARKER MD, 1986, BIOCHEM J, V236, P621, DOI 10.1042/bj2360621; Bennett TA, 2001, J BIOL CHEM, V276, P49195, DOI 10.1074/jbc.M106414200; Braun L, 2003, J BIOL CHEM, V278, P4277, DOI 10.1074/jbc.M210120200; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Christophe T, 2000, J BIOL CHEM, V275, P1656, DOI 10.1074/jbc.275.3.1656; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; Gurevich VV, 2006, PHARMACOL THERAPEUT, V110, P465, DOI 10.1016/j.pharmthera.2005.09.008; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Jala VR, 2005, J BIOL CHEM, V280, P4880, DOI 10.1074/jbc.M409821200; Kim J, 2005, P NATL ACAD SCI USA, V102, P1442, DOI 10.1073/pnas.0409532102; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Langkabel P, 1999, EUR J IMMUNOL, V29, P3035, DOI 10.1002/(SICI)1521-4141(199909)29:09<3035::AID-IMMU3035>3.0.CO;2-Z; MONTZ H, 1990, CELL IMMUNOL, V127, P337, DOI 10.1016/0008-8749(90)90137-G; Naik N, 1997, J CELL SCI, V110, P2381; OGITA K, 1991, METHOD ENZYMOL, V200, P228; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Pollok-Kopp B, 2003, J BIOL CHEM, V278, P2190, DOI 10.1074/jbc.M209844200; Potter RM, 2006, J IMMUNOL, V176, P5418, DOI 10.4049/jimmunol.176.9.5418; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; Rothermel E, 1997, BBA-GENE STRUCT EXPR, V1351, P9, DOI 10.1016/S0167-4781(97)00006-7; TARDIF M, 1993, J IMMUNOL, V150, P3534; WERFEL T, 1992, BLOOD, V79, P152, DOI 10.1182/blood.V79.1.152.bloodjournal791152; Zwirner J, 1999, MOL IMMUNOL, V36, P877, DOI 10.1016/S0161-5890(99)00109-1	32	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4345	4353		10.1074/jbc.M601317200	http://dx.doi.org/10.1074/jbc.M601317200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17145764	hybrid			2022-12-25	WOS:000244482000014
J	Rong, JA; Li, SH; Sheng, GQ; Wu, M; Coblitz, B; Li, M; Fu, HA; Li, XJ				Rong, Juan; Li, Shihua; Sheng, Guoqing; Wu, Meng; Coblitz, Brian; Li, Min; Fu, Haian; Li, Xiao-Jiang			14-3-3 protein interacts with Huntingtin-associated protein 1 and regulates its trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINESIN LIGHT-CHAIN; INTRACELLULAR TRAFFICKING; AXONAL-TRANSPORT; ENDOPLASMIC-RETICULUM; SURFACE EXPRESSION; FEEDING-BEHAVIOR; HAP1 INTERACTS; IN-VITRO; BINDING; 14-3-3-PROTEINS	HAP1 (Huntingtin-associated protein 1) consists of two alternately spliced isoforms (HAP1A and HAP1B, which have unique C-terminal sequences) and participates in intracellular trafficking. The C terminus of HAP1A is phosphorylated, and this phosphorylation was found to decrease the association of HAP1A with kinesin light chain, a protein involved in anterograde transport in cells. It remains unclear how this phosphorylation functions to regulate the association of HAP1 with trafficking proteins. Using the yeast two-hybrid system, we found that HAP1 also interacts with 14-3-3 proteins, which are involved in the assembly of protein complexes and the regulation of protein trafficking. The interaction of HAP1 with 14-3-3 is confirmed by their immunoprecipitation and colocalization in mouse brain. Moreover, this interaction is specific to HAP1A and is increased by the phosphorylation of the C terminus of HAP1A. We also found that expression of 14-3-3 decreases the association of HAP1A with kinesin light chain. As a result, there is less HAP1A distributed in neurite tips of PC12 cells that overexpress 14-3-3. Also, overexpression of 14-3-3 reduces the effect of HAP1A in promoting neurite outgrowth of PC12 cells. We propose that the phosphorylation-dependent interaction of HAP1A with 14-3-3 regulates HAP1 function by influencing its association with kinesin light chain and trafficking in neuronal processes.	Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Emory University; Emory University; Johns Hopkins University	Li, XJ (corresponding author), Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA.	xiaoli@genetics.emory.edu	Wu, Meng/F-3958-2010	Wu, Meng/0000-0003-2222-0736	NIA NIH HHS [AG19206, R01 AG019206] Funding Source: Medline; NINDS NIH HHS [NS045016, R01 NS045016, NS36323, R01 NS036232] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036232, R01NS045016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019206] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Birkenfeld J, 2003, BIOCHEM BIOPH RES CO, V302, P526, DOI 10.1016/S0006-291X(03)00182-7; BlockGalarza J, 1997, NEUROREPORT, V8, P2247, DOI 10.1097/00001756-199707070-00031; BRIDGES D, 2005, SCI STKE, pRE10, DOI DOI 10.1126/STKE.2962005RE10; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; Chan EYW, 2002, HUM MOL GENET, V11, P945, DOI 10.1093/hmg/11.8.945; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; Coblitz B, 2005, J BIOL CHEM, V280, P36263, DOI 10.1074/jbc.M507559200; Dai JG, 2003, J NEUROCHEM, V84, P23, DOI 10.1046/j.1471-4159.2003.01254.x; Darling DL, 2005, CURR TOP DEV BIOL, V68, P281, DOI 10.1016/S0070-2153(05)68010-6; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Foucault I, 2003, J BIOL CHEM, V278, P7146, DOI 10.1074/jbc.M209509200; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Ganguly S, 2005, P NATL ACAD SCI USA, V102, P1222, DOI 10.1073/pnas.0406871102; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Gindhart JG, 1998, J CELL BIOL, V141, P443, DOI 10.1083/jcb.141.2.443; Gunawardena S, 2005, ARCH NEUROL-CHICAGO, V62, P46, DOI 10.1001/archneur.62.1.46; Gunawardena S, 2003, NEURON, V40, P25, DOI 10.1016/S0896-6273(03)00594-4; Gutekunst CA, 1998, J NEUROSCI, V18, P7674, DOI 10.1523/jneurosci.18-19-07674.1998; Ichimura T, 2002, BIOCHEMISTRY-US, V41, P5566, DOI 10.1021/bi015946f; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Kagan A, 2002, EMBO J, V21, P1889, DOI 10.1093/emboj/21.8.1889; Kamm C, 2004, J BIOL CHEM, V279, P19882, DOI 10.1074/jbc.M401332200; Kittler JT, 2004, P NATL ACAD SCI USA, V101, P12736, DOI 10.1073/pnas.0401860101; Li SH, 2003, J NEUROSCI, V23, P6956; Li SH, 1998, J NEUROCHEM, V71, P2178; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; Li SH, 2000, MOL CELL NEUROSCI, V16, P168, DOI 10.1006/mcne.2000.0858; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Li XJ, 2005, TRENDS PHARMACOL SCI, V26, P1, DOI 10.1016/j.tips.2004.11.001; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Martin EJ, 1999, J COMP NEUROL, V403, P421; McGuire JR, 2005, CURR GENOMICS, V6, P189, DOI 10.2174/1389202053971938; McGuire JR, 2006, J BIOL CHEM, V281, P3552, DOI 10.1074/jbc.M509806200; Morfini G, 2005, TRENDS MOL MED, V11, P64, DOI 10.1016/j.molmed.2004.12.002; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Obsil T, 2003, BIOCHEMISTRY-US, V42, P15264, DOI 10.1021/bi0352724; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; Porter GW, 2006, SEMIN CANCER BIOL, V16, P193, DOI 10.1016/j.semcancer.2006.03.003; Rahman A, 1998, J BIOL CHEM, V273, P15395, DOI 10.1074/jbc.273.25.15395; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rong J, 2006, J NEUROSCI, V26, P6019, DOI 10.1523/JNEUROSCI.1251-06.2006; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Sheng GQ, 2006, NAT MED, V12, P526, DOI 10.1038/nm1382; Shikano S, 2006, TRENDS CELL BIOL, V16, P370, DOI 10.1016/j.tcb.2006.05.006; Szebenyi G, 2003, NEURON, V40, P41, DOI 10.1016/S0896-6273(03)00569-5; Takeshita Y, 2006, HUM MOL GENET, V15, P2298, DOI 10.1093/hmg/ddl156; Tang SJ, 1998, J BIOL CHEM, V273, P25356, DOI 10.1074/jbc.273.39.25356; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Trushina E, 2004, MOL CELL BIOL, V24, P8195, DOI 10.1128/MCB.24.18.8195-8209.2004; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; van der Brug MP, 2002, BRAIN RES, V956, P110, DOI 10.1016/S0006-8993(02)03487-X; Vivithanaporn P, 2006, J BIOL CHEM, V281, P15475, DOI 10.1074/jbc.M512098200; Wu M, 2006, ANAL BIOCHEM, V349, P186, DOI 10.1016/j.ab.2005.11.030; Yaffe MB, 2004, ANNU REV BIOPH BIOM, V33, P225, DOI 10.1146/annurev.biophys.33.110502.133346; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4	59	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4748	4756		10.1074/jbc.M609057200	http://dx.doi.org/10.1074/jbc.M609057200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17166838	hybrid			2022-12-25	WOS:000244482000056
J	Sarto-Jackson, I; Furtmueller, R; Ernst, M; Huck, S; Sieghart, W				Sarto-Jackson, Isabella; Furtmueller, Roman; Ernst, Margot; Huck, Sigismund; Sieghart, Werner			Spontaneous cross-link of mutated alpha 1 subunits during GABA(A) receptor assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; BETA-SUBUNITS; QUANTITATIVE IMPORTANCE; INTERSUBUNIT CONTACTS; A RECEPTORS; IDENTIFICATION; STOICHIOMETRY; EXPRESSION; SIGNALS; PROTEIN	gamma-Aminobutyric acid, type A (GABA(A)) receptor alpha 1 subunits containing a cysteine mutation at a position in the channel mouth (H109C) surprisingly formed a spontaneous cross-link with each other in receptors composed of alpha 1H109C, beta 3, and gamma 2 subunits. Cross-linking of two alpha 1H109C subunits did not significantly change the affinity of [H-3]muscimol or [H-3]Ro15-1788 binding in alpha 1H109C beta 3 gamma 2 receptors, but GABA displayed a reduced potency for activating chloride currents. On reduction of the disulfide bond, however, GABA activation as well as diazepam modulation was similar in mutated and wild-type receptors, suggesting that these receptors exhibited the same subunit stoichiometry and arrangement. Disulfide bonds could not be reoxidized by copper phenanthroline after having been reduced in completely assembled receptors, suggesting that cross-linking can only occur at an early stage of assembly. The cross-link of alpha 1H109C subunits and the subsequent transport of the resulting homodimers to the cell surface caused a reduction of the intracellular pool of alpha 1H109C subunits and a reduced formation of completely assembled receptors. The formation of alpha 1H109C homodimers as well as of correctly assembled GABAA receptors containing cross-linked alpha 1H109C subunits could indicate that homodimerization of alpha 1 subunits via contacts located in the channel mouth might be one starting point of GABA, receptor assembly. Alternatively the assembly mechanism might have started with the formation of heterodimers followed by a cross-link of mutated alpha 1 subunits at the hetero trimeric stage. The formation of cross-linked alpha 1H109C homodimers would then have occurred independently in a separate pathway.	Med Univ Vienna, Ctr Brain Res, Div Biochem & Mol Biol, A-1090 Vienna, Austria; Univ Clin Psychiat, Sect Biochem Psychiat, A-1090 Vienna, Austria	Medical University of Vienna	Sieghart, W (corresponding author), Med Univ Vienna, Ctr Brain Res, Div Biochem & Mol Biol, Spitalgasse 4, A-1090 Vienna, Austria.	werner.sieghart@meduniwien.ac.at	Sieghart, Werner/A-4877-2013	Sieghart, Werner/0000-0002-0443-0302; Huck, Sigismund/0000-0003-2022-5680; Ernst, Margot/0000-0002-9809-2649				Amato A, 1999, J PHYSIOL-LONDON, V517, P35, DOI 10.1111/j.1469-7793.1999.0035z.x; Baumann SW, 2002, J BIOL CHEM, V277, P46020, DOI 10.1074/jbc.M207663200; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; Bollan K, 2003, BIOCHEM SOC T, V31, P875, DOI 10.1042/bst0310875; Bollan K, 2003, J BIOL CHEM, V278, P4747, DOI 10.1074/jbc.M210229200; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Chang YC, 1996, J NEUROSCI, V16, P5415; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Connolly CN, 1996, P NATL ACAD SCI USA, V93, P9899, DOI 10.1073/pnas.93.18.9899; Ehya N, 2003, J NEUROCHEM, V84, P127, DOI 10.1046/j.1471-4159.2003.01509.x; Ernst M, 2005, MOL PHARMACOL, V68, P1291, DOI 10.1124/mol.105.015982; Ernst M, 2003, NEUROSCIENCE, V119, P933, DOI 10.1016/S0306-4522(03)00288-4; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Klausberger T, 2000, J BIOL CHEM, V275, P8921, DOI 10.1074/jbc.275.12.8921; Klausberger T, 2001, J NEUROSCI, V21, P9124, DOI 10.1523/JNEUROSCI.21-23-09124.2001; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; NAYEEM N, 1994, J NEUROCHEM, V62, P815; Neville D M Jr, 1974, Methods Enzymol, V32, P92; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; PAULSON HL, 1990, J CELL BIOL, V110, P1705, DOI 10.1083/jcb.110.5.1705; Poltl A, 2003, J NEUROCHEM, V87, P1444, DOI 10.1046/j.1471-4159.2003.02135.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sarto I, 2002, J BIOL CHEM, V277, P30656, DOI 10.1074/jbc.M203597200; Sarto I, 2002, NEUROPHARMACOLOGY, V43, P482, DOI 10.1016/S0028-3908(02)00160-0; Sarto-Jackson I, 2006, J NEUROCHEM, V96, P983, DOI 10.1111/j.1471-4159.2005.03626.x; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Taylor PM, 2000, J NEUROSCI, V20, P1297; Taylor PM, 1999, J NEUROSCI, V19, P6360; Tretter V, 1997, J NEUROSCI, V17, P2728; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	36	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4354	4363		10.1074/jbc.M609676200	http://dx.doi.org/10.1074/jbc.M609676200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17148454	hybrid			2022-12-25	WOS:000244482000015
J	Jin, XH; Okamoto, Y; Morishita, J; Tsuboi, K; Tonai, T; Ueda, N				Jin, Xing-Hua; Okamoto, Yasuo; Morishita, Jun; Tsuboi, Kazuhito; Tonai, Takeharu; Ueda, Natsuo			Discovery and characterization of Ca2+-independent phosphatidylethanolarnine N-acyltransferase generating the anandarnide precursor and its congeners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-RETINOL ACYLTRANSFERASE; ACID AMIDE HYDROLASE; CANNABINOID-RECEPTOR-LIGAND; HYDROLYZING PHOSPHOLIPASE-D; ISCHEMIC RAT-BRAIN; ETHANOLAMINE PHOSPHOLIPIDS; ACYLETHANOLAMINE PHOSPHOLIPIDS; INFARCTED MYOCARDIUM; DOWN-REGULATION; ANANDAMIDE	N-Acylphosphatidylethanolamines (NAPEs) are precursors of bioactive N-acylethanolamines, including the endocannabinoid anandamide. In animal tissues, NAPE is formed by transfer of a fatty acyl chain at the sn-1 position of glycerophospholipids to the amino group of phosphatidylethanolamine (PE), and this reaction is believed to be the principal rate-limiting step in N-acylethanolamine synthesis. However, the Ca2+-dependent, membrane-associated N-acyltransferase (NAT) responsible for this reaction has not yet been cloned. In this study, on the basis of the functional similarity of NAT to lecithin-retinol acyltransferase (LRAT), we examined a possible PE N-acylation activity in two rat LRAT homologous proteins. Upon overexpression in COS-7 cells, one protein, named rat LRAT-like protein (RLP)-1, catalyzed transfer of a radioactive acyl group from phosphatidylicholine (PC) to PE, resulting in the formation of radioactive NAPE. However, the RLP-1 activity was detected mainly in the cytosolic rather than membrane fraction and was little stimulated by Ca2+. Moreover, RLP-1 did not show selectivity with respect to the sn-1 and sn-2 positions of PC as an acyl donor and therefore could generate N-arachidonoyl-PE (anandamide precursor) from 2-arachidonoyl-PC and PE. In contrast, under the same assay conditions, partially purified NAT from rat brain was highly Ca2+-dependent, membrane-associated, and specific for the sn-1-acyl group of PC. RLP-1 mRNA was expressed predominantly in testis among various rat tissues, and the testis cytosol exhibited an RLP-1-like activity. These results reveal that RLP-1 can function as a PE N-acyltransferase, catalytically distinguishable from the known Ca2+-dependent NAT.	Kagawa Univ, Sch Med, Dept Biochem, Miki, Kagawa 7610793, Japan; Natl Zentsuji Hosp, Dept Orthoped Surg, Kagawa 7650001, Japan; Natl Zentsuji Hosp, Clin Res Inst, Kagawa 7650001, Japan	Kagawa University	Ueda, N (corresponding author), Kagawa Univ, Sch Med, Dept Biochem, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	nueda@med.kagawa-u.ac.jp	Jin, Xinghua/K-1142-2015; OKAMOTO, Yasuo/J-8438-2015	Jin, Xinghua/0000-0002-8883-5234; 				Akiyama H, 1999, J BIOL CHEM, V274, P32192, DOI 10.1074/jbc.274.45.32192; Anantharaman V, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r11; ARAI H, 1985, J BIOCHEM-TOKYO, V97, P1525, DOI 10.1093/oxfordjournals.jbchem.a135209; Berdyshev EV, 2000, BIOCHEM J, V346, P369, DOI 10.1042/0264-6021:3460369; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadas H, 1997, J NEUROSCI, V17, P1226; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; EPPS DE, 1979, BIOCHEM BIOPH RES CO, V90, P628, DOI 10.1016/0006-291X(79)91281-6; EPPS DE, 1980, BIOCHIM BIOPHYS ACTA, V618, P420, DOI 10.1016/0005-2760(80)90260-X; Golczak M, 2005, J BIOL CHEM, V280, P42263, DOI 10.1074/jbc.M509351200; Guo Y, 2005, J BIOL CHEM, V280, P23429, DOI 10.1074/jbc.C500168200; HANJNAL A, 1994, ONCOGENE, V9, P479; HANSEN HS, 1995, BBA-LIPID LIPID MET, V1258, P303, DOI 10.1016/0005-2760(95)00134-X; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Jahng WJ, 2003, BIOCHEMISTRY-US, V42, P12805, DOI 10.1021/bi035370p; KERWIN JL, 1994, J LIPID RES, V35, P1102; Kondo S, 1998, ARCH BIOCHEM BIOPHYS, V354, P303, DOI 10.1006/abbi.1998.0688; Kurahashi Y, 1997, BIOCHEM BIOPH RES CO, V237, P512, DOI 10.1006/bbrc.1997.7180; Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; Maccarrone M, 2005, J CELL SCI, V118, P4393, DOI 10.1242/jcs.02536; McKinney MK, 2005, ANNU REV BIOCHEM, V74, P411, DOI 10.1146/annurev.biochem.74.082803.133450; Moesgaard B, 2000, J LIPID RES, V41, P985; NATARAJAN V, 1986, BIOCHIM BIOPHYS ACTA, V878, P32, DOI 10.1016/0005-2760(86)90341-3; NATARAJAN V, 1983, J NEUROCHEM, V41, P1303, DOI 10.1111/j.1471-4159.1983.tb00825.x; NATARAJAN V, 1982, BIOCHIM BIOPHYS ACTA, V712, P342, DOI 10.1016/0005-2760(82)90352-6; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Rando RR, 2002, BIOCHEM BIOPH RES CO, V292, P1243, DOI 10.1006/bbrc.2001.2021; REDDY PV, 1983, BIOCHIM BIOPHYS ACTA, V751, P241, DOI 10.1016/0005-2760(83)90178-9; REDDY PV, 1983, BIOCHIM BIOPHYS ACTA, V750, P472, DOI 10.1016/0005-2760(83)90187-X; REDDY PV, 1984, BIOCHIM BIOPHYS ACTA, V795, P130, DOI 10.1016/0005-2760(84)90113-9; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; Schmid HHO, 2002, PROSTAG LEUKOTR ESS, V66, P363, DOI 10.1054/plef.2001.0348; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, P71, DOI 10.1016/S0009-3084(00)00188-2; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V218, P113, DOI 10.1006/bbrc.1996.0020; Sun YX, 2004, BIOCHEM J, V380, P749, DOI 10.1042/BJ20040031; Terrazzino S, 2004, FASEB J, V18, P1580, DOI 10.1096/fj.03-1080fje; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UEDA N, 1995, BBA-LIPID LIPID MET, V1254, P127, DOI 10.1016/0005-2760(94)00170-4; Ueda N, 2000, CHEM PHYS LIPIDS, V108, P107, DOI 10.1016/S0009-3084(00)00190-0; Ueda N, 2005, CURR MED CHEM, V12, P1413, DOI 10.2174/0929867054020918; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Wang J, 2006, J BIOL CHEM, V281, P12325, DOI 10.1074/jbc.M512359200; Zolfaghari R, 2000, J LIPID RES, V41, P2024	53	117	125	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3614	3623		10.1074/jbc.M606369200	http://dx.doi.org/10.1074/jbc.M606369200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158102	hybrid			2022-12-25	WOS:000244481900023
J	Tanio, M; Kondo, S; Sugio, S; Kohno, T				Tanio, Michikazu; Kondo, Shin; Sugio, Shigetoshi; Kohno, Toshiyuki			Trivalent recognition unit of innate immunity system - Crystal structure of trimeric human M-ficolin fibrinogen-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECTIN-COMPLEMENT PATHWAY; MANNOSE-BINDING LECTIN; CARBOHYDRATE-RECOGNITION; LIGAND-BINDING; GAMMA-CHAIN; PROTEIN; PATTERN; CLONING; PURIFICATION; COLLECTINS	Ficohins are a kind of pathogen-recognition molecule in the innate immune systems. To investigate the discrimination mechanism between self and non-self by ficolins, we determined the crystal structure of the human M-ficolin fibrinogen-like domain (FD1), which is the ligand-binding domain, at 1.9 angstrom resolution. Although the FD1 monomer shares a common fold with the fibrinogen gamma fragment and tachylectin-SA, the Asp-282-Cys-283 peptide bond, which is the predicted ligand-binding site on the C-terminal P domain, is a normal trans bond, unlike the cases of the other two proteins. The trimeric formation of FD1 results in the separation of the three P domains, and the spatial arrangement of the three predicted ligand-binding sites on the trimer is very similar to that of the trimeric collectin, indicating that such an arrangement is generally required for pathogen-recognition. The ligand binding study of FD1 in solution indicated that the recombinant protein binds to N-acetyl-D-glucosamine and the peptide Gly-Pro-Arg-Pro and suggested that the ligand-binding region exhibits a conformational equilibrium involving cis-trans isomerization of the Asp-282-Cys-283 peptide bond. The crystal structure and the ligand binding study of FD1 provide an insight of the self- and non-self discrimination mechanism by ficolins.	ZOEGENE Corp, Aoba Ku, Yokohama, Kanagawa 2278502, Japan; Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1948511, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS)	Sugio, S (corresponding author), ZOEGENE Corp, Aoba Ku, 1000 Kamoshida, Yokohama, Kanagawa 2278502, Japan.	ssugio@rc.m-kagaku.co.jp	Tanio, Michikazu/F-2857-2013	Tanio, Michikazu/0000-0001-5652-4952				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barton WA, 2005, STRUCTURE, V13, P825, DOI 10.1016/j.str.2005.03.009; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Endo Y, 1996, GENOMICS, V36, P515, DOI 10.1006/geno.1996.0497; Frederiksen PD, 2005, SCAND J IMMUNOL, V62, P462, DOI 10.1111/j.1365-3083.2005.01685.x; Fujita T, 2004, MOL IMMUNOL, V41, P103, DOI 10.1016/j.molimm.2004.03.026; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; Fujita T, 2004, IMMUNOL REV, V198, P185, DOI 10.1111/j.0105-2896.2004.0123.x; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Head JF, 2003, J BIOL CHEM, V278, P43254, DOI 10.1074/jbc.M305628200; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; ICHIJO H, 1991, J BIOL CHEM, V266, P22459; IOBST ST, 1994, J BIOL CHEM, V269, P15505; Jabs A, 1999, J MOL BIOL, V286, P291, DOI 10.1006/jmbi.1998.2459; Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x; Kairies N, 2001, P NATL ACAD SCI USA, V98, P13519, DOI 10.1073/pnas.201523798; Kawabata S, 2002, BBA-GEN SUBJECTS, V1572, P414, DOI 10.1016/S0304-4165(02)00322-7; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Krarup A, 2005, INFECT IMMUN, V73, P1052, DOI 10.1128/IAI.73.2.1052-1060.2005; Krarup A, 2004, J BIOL CHEM, V279, P47513, DOI 10.1074/jbc.M407161200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Le Y, 1998, FEBS LETT, V425, P367, DOI 10.1016/S0014-5793(98)00267-1; Le Y, 1997, J IMMUNOL METHODS, V204, P43, DOI 10.1016/S0022-1759(97)00029-X; LEE RT, 1991, J BIOL CHEM, V266, P4810; Liu Y, 2005, J IMMUNOL, V175, P3150, DOI 10.4049/jimmunol.175.5.3150; Lu J, 1996, IMMUNOLOGY, V89, P289, DOI 10.1046/j.1365-2567.1996.d01-732.x; Lu JH, 1996, BIOCHEM J, V313, P473, DOI 10.1042/bj3130473; Lu JH, 2002, BBA-GEN SUBJECTS, V1572, P387, DOI 10.1016/S0304-4165(02)00320-3; Lynch NJ, 2004, J IMMUNOL, V172, P1198, DOI 10.4049/jimmunol.172.2.1198; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; Matsushita M, 2001, INT IMMUNOPHARMACOL, V1, P359, DOI 10.1016/S1567-5769(00)00045-X; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; Matsushita M, 2002, IMMUNOBIOLOGY, V205, P490, DOI 10.1078/0171-2985-00149; Matsushita M, 2002, J IMMUNOL, V168, P3502, DOI 10.4049/jimmunol.168.7.3502; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Ng KKS, 2002, J BIOL CHEM, V277, P16088, DOI 10.1074/jbc.M200493200; Ohashi T, 1997, J BIOL CHEM, V272, P14220, DOI 10.1074/jbc.272.22.14220; Ohashi T, 2004, J BIOL CHEM, V279, P6534, DOI 10.1074/jbc.M310555200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pratt KP, 1997, P NATL ACAD SCI USA, V94, P7176, DOI 10.1073/pnas.94.14.7176; Sano H, 2005, MOL IMMUNOL, V42, P279, DOI 10.1016/j.molimm.2004.07.014; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; Shrive AK, 2003, J MOL BIOL, V331, P509, DOI 10.1016/S0022-2836(03)00761-7; Sugimoto R, 1998, J BIOL CHEM, V273, P20721, DOI 10.1074/jbc.273.33.20721; Tanio M, 2006, ACTA CRYSTALLOGR F, V62, P652, DOI 10.1107/S1744309106019786; Teh C, 2000, IMMUNOLOGY, V101, P225, DOI 10.1046/j.1365-2567.2000.00099.x; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Yang IA, 2004, GENES IMMUN, V5, P41, DOI 10.1038/sj.gene.6364037; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8	53	52	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3889	3895		10.1074/jbc.M608627200	http://dx.doi.org/10.1074/jbc.M608627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148457	hybrid			2022-12-25	WOS:000244481900053
J	Diaz-Martinez, LA; Gimenez-Abian, JF; Azuma, Y; Guacci, V; Gimenez-Martin, G; Lanier, LM; Clarke, DJ				Diaz-Martinez, Laura A.; Gimenez-Abian, Juan F.; Azuma, Yoshiaki; Guacci, Vincent; Gimenez-Martin, Gonzalo; Lanier, Lorene M.; Clarke, Duncan J.			PIAS gamma Is Required for Faithful Chromosome Segregation in Human Cells	PLOS ONE			English	Article							ANAPHASE-PROMOTING COMPLEX; SISTER-CHROMATID COHESION; TOPOISOMERASE-II-ALPHA; MITOTIC CHROMOSOME; DNA-DAMAGE; CENP-E; CHECKPOINT; SUMOYLATION; SEPARATION; CENTROMERE	Background. The precision of the metaphase-anaphase transition ensures stable genetic inheritance. The spindle checkpoint blocks anaphase onset until the last chromosome biorients at metaphase plate, then the bonds between sister chromatids are removed and disjoined chromatids segregate to the spindle poles. But, how sister separation is triggered is not fully understood. Principal Findings. We identify PIAS gamma as a human E3 sumo ligase required for timely and efficient sister chromatid separation. In cells lacking PIAS gamma, normal metaphase plates form, but the spindle checkpoint is activated, leading to a prolonged metaphase block. Sister chromatids remain cohered even if cohesin is removed by depletion of hSgo1, because DNA catenations persist at centromeres. PIAS gamma-depleted cells cannot properly localize Topoisomerase II at centromeres or in the cores of mitotic chromosomes, providing a functional link between PIAS gamma and Topoisomerase II. Conclusions. PIAS gamma directs Topoisomerase II to specific chromosome regions that require efficient removal of DNA catenations prior to anaphase. The lack of this activity activates the spindle checkpoint, protecting cells from non-disjunction. Because DNA catenations persist without PIAS gamma in the absence of cohesin, removal of catenations and cohesin rings must be regulated in parallel.	[Diaz-Martinez, Laura A.; Gimenez-Abian, Juan F.; Clarke, Duncan J.] Univ Minnesota, Sch Med, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; [Gimenez-Abian, Juan F.; Gimenez-Martin, Gonzalo] CSIC, Ctr Invest Biol, Madrid, Spain; [Azuma, Yoshiaki] Univ Kansas, Dept Mol Biosci, Lawrence, KS USA; [Guacci, Vincent] Carnegie Inst, Dept Embryol, Baltimore, MD USA; [Lanier, Lorene M.] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Kansas; Carnegie Institution for Science; University of Minnesota System; University of Minnesota Twin Cities	Clarke, DJ (corresponding author), Univ Minnesota, Sch Med, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.	Duncan.J.Clarke-2@umn.edu	Díaz-Martínez, Laura/A-5357-2010; Abián, Juan F Giménez/E-6372-2015	Abián, Juan F Giménez/0000-0002-9220-286X; Clarke, Duncan/0000-0002-7795-3294; Diaz-Martinez, Laura/0000-0002-7226-7068	NIH [CA099033]; MEC-Spain DGI; CONACyT; NATIONAL CANCER INSTITUTE [R01CA099033] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MEC-Spain DGI; CONACyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by NIH grant CA099033 ( DJC). JFGA was partly supported by MEC-Spain DGI and LADM by CONACyT.	Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Azuma Y, 2005, EMBO J, V24, P2172, DOI 10.1038/sj.emboj.7600700; Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; CLARKE DJ, 1993, J CELL SCI, V105, P563; Clarke DJ, 2000, BIOESSAYS, V22, P351, DOI 10.1002/(SICI)1521-1878(200004)22:4<351::AID-BIES5>3.0.CO;2-W; Clarke DJ, 2006, CELL CYCLE, V5, P1925, DOI 10.4161/cc.5.17.3200; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Gimenez-Abian JF, 2005, CELL CYCLE, V4, P1561, DOI 10.4161/cc.4.11.2146; GIMENEZABIAN JF, 1995, J CELL BIOL, V131, P7, DOI 10.1083/jcb.131.1.7; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kitajima TS, 2005, CURR BIOL, V15, P353, DOI 10.1016/j.cub.2004.12.044; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; Lee KM, 2006, DNA REPAIR, V5, P138, DOI 10.1016/j.dnarep.2005.08.003; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; McGuinness BE, 2005, PLOS BIOL, V3, P433, DOI 10.1371/journal.pbio.0030086; Mikhailov A, 2004, J CELL BIOL, V166, P517, DOI 10.1083/jcb.200405167; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; Rankin S, 2005, CELL CYCLE, V4, P1039, DOI 10.4161/cc.4.8.1926; Rattner JB, 1996, J CELL BIOL, V134, P1097, DOI 10.1083/jcb.134.5.1097; Salic A, 2004, CELL, V118, P567, DOI 10.1016/j.cell.2004.08.016; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; Skoufias DA, 2004, MOL CELL, V15, P977, DOI 10.1016/j.molcel.2004.08.018; Stead K, 2003, J CELL BIOL, V163, P729, DOI 10.1083/jcb.200305080; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Sumner AT, 1996, CHROMOSOME RES, V4, P5, DOI 10.1007/BF02254938; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; Takahashi Y, 2006, GENETICS, V172, P783, DOI 10.1534/genetics.105.047167; Tang ZY, 2004, P NATL ACAD SCI USA, V101, P18012, DOI 10.1073/pnas.0408600102; Tavormina PA, 2002, J CELL BIOL, V158, P23, DOI 10.1083/jcb.200202053; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; Wirth KG, 2004, GENE DEV, V18, P88, DOI 10.1101/gad.285404; Wohlschlegel JA, 2004, J BIOL CHEM, V279, P45662, DOI 10.1074/jbc.M409203200; Wong KA, 2004, MOL CELL BIOL, V24, P5577, DOI 10.1128/MCB.24.12.5577-5586.2004; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; Yu HT, 2005, CELL CYCLE, V4, P262; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	49	59	59	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e53	10.1371/journal.pone.0000053	http://dx.doi.org/10.1371/journal.pone.0000053			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183683	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600053
J	Li, TS; Xie, J; He, YX; Fan, HW; Baril, L; Qiu, ZF; Han, Y; Xu, WB; Zhang, WH; You, H; Zuo, YL; Fang, Q; Yu, J; Chen, ZW; Zhang, LQ				Li, Taisheng; Xie, Jing; He, Yuxian; Fan, Hongwei; Baril, Laurence; Qiu, Zhifeng; Han, Yang; Xu, Wenbing; Zhang, Weihong; You, Hui; Zuo, Yanling; Fang, Qing; Yu, Jian; Chen, Zhiwei; Zhang, Linqi			Long-Term Persistence of Robust Antibody and Cytotoxic T Cell Responses in Recovered Patients Infected with SARS Coronavirus	PLOS ONE			English	Article								Most of the individuals infected with SARS coronavirus (SARS-CoV) spontaneously recovered without clinical intervention. However, the immunological correlates associated with patients' recovery are currently unknown. In this report, we have sequentially monitored 30 recovered patients over a two-year period to characterize temporal changes in SARS-CoV-specific antibody responses as well as cytotoxic T cell (CTL) responses. We have found persistence of robust antibody and CTL responses in all of the study subjects throughout the study period, with a moderate decline one year after the onset of symptoms. We have also identified two potential major CTL epitopes in N proteins based on ELISPOT analysis of pooled peptides. However, despite the potent immune responses and clinical recovery, peripheral lymphocyte counts in the recovered patients have not yet been restored to normal levels. In summary, our study has, for the first time, characterized the temporal and dynamic changes of humoral and CTL responses in the natural history of SARS-recovered individuals, and strongly supports the notion that high and sustainable levels of immune responses correlate strongly with the disease outcome. Our findings have direct implications for future design and development of effective therapeutic agents and vaccines against SARS-CoV infection.	[Li, Taisheng; Xie, Jing; He, Yuxian; Fan, Hongwei; Qiu, Zhifeng; Han, Yang; Xu, Wenbing; Zhang, Weihong; You, Hui; Zuo, Yanling; Zhang, Linqi] Peking Union Med Coll, Beijing 100021, Peoples R China; [Li, Taisheng; Xie, Jing; He, Yuxian; Fan, Hongwei; Qiu, Zhifeng; Han, Yang; Xu, Wenbing; Zhang, Weihong; You, Hui; Zuo, Yanling; Zhang, Linqi] Chinese Acad Med Sci, AIDS Res Ctr, Beijing 100037, Peoples R China; [Li, Taisheng; Xie, Jing; He, Yuxian; Fan, Hongwei; Qiu, Zhifeng; Han, Yang; Xu, Wenbing; Zhang, Weihong; You, Hui; Zuo, Yanling; Zhang, Linqi] Beijing Union Med Coll Hosp, Dept Infect Dis, Beijing, Peoples R China; [Li, Taisheng; Xie, Jing; He, Yuxian; Fan, Hongwei; Qiu, Zhifeng; Han, Yang; Xu, Wenbing; Zhang, Weihong; You, Hui; Zuo, Yanling; Zhang, Linqi] Chinese Acad Med Sci, Inst Pathogen Biol, Beijing 100037, Peoples R China; [He, Yuxian] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA; [Baril, Laurence] Inst Pasteur, Emerging Dis Epidemiol Unit, Paris, France; [Fang, Qing; Yu, Jian; Chen, Zhiwei; Zhang, Linqi] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10021 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Pathogen Biology - CAMS; New York Blood Center; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Rockefeller University	Li, TS (corresponding author), Beijing Union Med Coll Hosp, Dept Infect Dis, Beijing, Peoples R China.	litsh@263.net; lzhang07@hotmail.com	Chen, Zhiwei/B-7793-2019; ZHANG, LIN/GYD-9123-2022; han, yang/GRS-2388-2022	Chen, Zhiwei/0000-0002-4511-2888; Baril, Laurence/0000-0003-2346-883X	Chinese Ministry of Science and Technology; National Institute of Health (NIH) [U19 AI51915-02]; European Commission [SP22-CT2004-511063]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI051915] Funding Source: NIH RePORTER	Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Commission(European CommissionEuropean Commission Joint Research Centre); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the Chinese Ministry of Science and Technology, and partly by National Institute of Health (NIH) CIPRA-SARS Project (NIH U19 AI51915-02) and the European Commission grant EPISARS (SP22-CT2004-511063). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.	Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; Leung DTM, 2004, J INFECT DIS, V190, P379, DOI 10.1086/422040; Li TS, 2004, J INFECT DIS, V189, P648, DOI 10.1086/381535; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Nie YC, 2004, J INFECT DIS, V190, P1119, DOI 10.1086/423286; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Shi YL, 2004, J CLIN VIROL, V31, P66, DOI 10.1016/j.jcv.2004.05.006; Temperton NJ, 2005, EMERG INFECT DIS, V11, P411, DOI 10.3201/eid1103.040906; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; Woo PCY, 2004, CLIN DIAGN LAB IMMUN, V11, P665, DOI 10.1128/CDLI.11.4.665-668.2004; Woo PCY, 2004, J CLIN MICROBIOL, V42, P2306, DOI 10.1128/JCM.42.5.2306-2309.2004; Zhang LQ, 2006, J MED VIROL, V78, P1, DOI 10.1002/jmv.20499	17	51	55	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e24	10.1371/journal.pone.0000024	http://dx.doi.org/10.1371/journal.pone.0000024			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183651	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443600024
J	Seitz, AR; Nanez, JE; Holloway, SR; Watanabe, T				Seitz, Aaron R.; Nanez, Jose E., Sr.; Holloway, Steve R.; Watanabe, Takeo			Perceptual Learning of Motion Leads to Faster Flicker Perception	PLOS ONE			English	Article								Critical flicker fusion thresholds (CFFT) describe when quick amplitude modulations of a light source become undetectable as the frequency of the modulation increases. The threshold at which CFF occurs has been shown to remain constant under repeated testing. Additionally, CFF thresholds are correlated with various measures of intelligence, and have been regarded by clinicians as a general measure of cortical processing capacity. For these reasons, CFF is used as a cognitive indicator in drug studies, as a measure of fatigue, and has been suggested as a diagnostic measure for various brain diseases. Here we report that CFFT increases dramatically in subjects who are trained with a motion-direction learning procedure. Control tasks demonstrate that CFFT changes are tightly coupled with improvements in discriminating the direction of motion stimuli, and are likely related to plasticity in low-level visual areas that are specialized to process motion signals. This plasticity is long-lasting and is retained for at least one year after training. Combined, these results show that CFFT relates to a specialized sensory process and bring into question that CFFT is a measure of high-level, or general, processes.	[Seitz, Aaron R.; Watanabe, Takeo] Boston Univ, Dept Psychol, Boston, MA 02215 USA; [Nanez, Jose E., Sr.; Holloway, Steve R.] Arizona State Univ, Dept Social & Behav Sci, Phoenix, AZ USA	Boston University; Arizona State University; Arizona State University-Downtown Phoenix	Seitz, AR (corresponding author), Boston Univ, Dept Psychol, 64 Cummington St, Boston, MA 02215 USA.	aseitz@bu.edu	Holloway, Steven R/O-3032-2013	Holloway, Steven R/0000-0001-8900-5315	NSF [BCS-9905914]; NIH [R01EY015980-01]; Human Frontier [RGP18/2004]; NATIONAL EYE INSTITUTE [R01EY015980] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Human Frontier; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	Funding: This research was supported by NSF grant (BCS-9905914), NIH grant (R01EY015980-01), and Human Frontier Research grant (RGP18/2004) and NSF (CELEST).	Anderson AJ, 2002, VISION RES, V42, P1149, DOI 10.1016/S0042-6989(02)00033-0; Arnsten AFT, 1997, J PSYCHOPHARMACOL, V11, P151, DOI 10.1177/026988119701100208; Bao SW, 2001, NATURE, V412, P79, DOI 10.1038/35083586; Battelli L, 2003, NEUROPSYCHOLOGIA, V41, P1808, DOI 10.1016/S0028-3932(03)00182-9; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; CAVANAGH P, 1987, J OPT SOC AM A, V4, P1428, DOI 10.1364/JOSAA.4.001428; COLBY CL, 1993, J NEUROPHYSIOL, V69, P902, DOI 10.1152/jn.1993.69.3.902; Curran S, 2000, HUM PSYCHOPHARM CLIN, V15, P103, DOI 10.1002/(SICI)1099-1077(200003)15:2<103::AID-HUP149>3.0.CO;2-7; Dalley JW, 2001, J NEUROSCI, V21, P4908, DOI 10.1523/JNEUROSCI.21-13-04908.2001; del Romo GB, 2005, INVEST OPHTH VIS SCI, V46, P1107, DOI 10.1167/iovs.04-1138; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P219, DOI 10.1113/jphysiol.1984.sp015498; ERNST W, 1968, VISION RES, V8, P889, DOI 10.1016/0042-6989(68)90138-7; Green CS, 2003, NATURE, V423, P534, DOI 10.1038/nature01647; HALSTEAD WC, 1947, BRAIN INTELLIGENCE Q, V13; HARVEY LO, 1970, VISION RES, V10, P55, DOI 10.1016/0042-6989(70)90062-3; HINDMARCH I, 1982, PHARMACOPSYCHIATRIA, V15, P44, DOI 10.1055/s-2007-1019549; Hindmarch I, 1988, Psychopharmacol Ser, V6, P79; Hosokawa T, 1997, ERGONOMICS, V40, P887, DOI 10.1080/001401397187720; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; LEE BB, 1990, J OPT SOC AM A, V7, P2223, DOI 10.1364/JOSAA.7.002223; LEE BB, 1988, J PHYSIOL-LONDON, V404, P323, DOI 10.1113/jphysiol.1988.sp017292; Lisberger SG, 1999, J NEUROSCI, V19, P2224; LIVINGSTONE MS, 1991, P NATL ACAD SCI USA, V88, P7943, DOI 10.1073/pnas.88.18.7943; Martinez-Trujillo JC, 2002, NEURON, V35, P365, DOI 10.1016/S0896-6273(02)00778-X; MCCLELLAND GR, 1987, HUM PSYCHOPHARM CLIN, V2, P109; MERIGAN WH, 1991, J NEUROSCI, V11, P3422; Merzenich MM, 1996, SCIENCE, V271, P77, DOI 10.1126/science.271.5245.77; MISHKIN M, 1959, J COMP PHYSIOL PSYCH, V52, P660, DOI 10.1037/h0038577; Misiak H, 1948, J GEN PSYCHOL, V38, P251, DOI 10.1080/00221309.1948.9711786; MOULDEN B, 1990, PERCEPTION, V19, P79, DOI 10.1068/p190079; Parkin C, 1997, HUM PSYCHOPHARM CLIN, V12, P65, DOI 10.1002/(SICI)1099-1077(199701/02)12:1<65::AID-HUP838>3.0.CO;2-W; PLATEAU J, 1829, CERTAIN PROPERTIES I; Priebe NJ, 2003, J NEUROSCI, V23, P5650; Rota-Bartelink A, 1999, Curr Opin Ophthalmol, V10, P135, DOI 10.1097/00055735-199904000-00010; ROVAMO J, 1984, VISION RES, V24, P1127, DOI 10.1016/0042-6989(84)90166-4; SANDRY M, 1963, PERCEPT MOTOR SKILL, V16, P103, DOI 10.2466/pms.1963.16.1.103; SAUCER RT, 1958, SCIENCE, V127, P698, DOI 10.1126/science.127.3300.698; SCHILLER PH, 1991, NEUROPSYCHOLOGIA, V29, P433, DOI 10.1016/0028-3932(91)90003-Q; Schultz W, 2000, NAT REV NEUROSCI, V1, P199, DOI 10.1038/35044563; SCLAR G, 1990, VISION RES, V30, P1, DOI 10.1016/0042-6989(90)90123-3; Seitz A, 2005, TRENDS COGN SCI, V9, P329, DOI 10.1016/j.tics.2005.05.010; Seitz AR, 2005, P NATL ACAD SCI USA, V102, P9080, DOI 10.1073/pnas.0501026102; Seitz AR, 2005, HUM PSYCHOPHARM CLIN, V20, P55, DOI 10.1002/hup.661; Seitz AR, 2003, NATURE, V422, P36, DOI 10.1038/422036a; Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81; TANNER WP, 1950, SCIENCE, V112, P201, DOI 10.1126/science.112.2903.201; TURNER P, 1968, BRIT J OPHTHALMOL, V52, P245, DOI 10.1136/bjo.52.3.245; Vaina LM, 1998, VISUAL NEUROSCI, V15, P333, DOI 10.1017/S0952523898152082; Watanabe T, 2002, NAT NEUROSCI, V5, P1003, DOI 10.1038/nn915; Williams PE, 2004, J NEUROSCI, V24, P8278, DOI 10.1523/JNEUROSCI.2716-04.2004; Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481; Yoshiyama KK, 1997, INVEST OPHTH VIS SCI, V38, P2270; ZLODY RL, 1965, AM J PSYCHOL, V78, P596, DOI 10.2307/1420921; ZOHARY E, 1994, SCIENCE, V263, P1289, DOI 10.1126/science.8122114; ZUBEK JP, 1973, NATURE, V241, P288, DOI 10.1038/241288a0; ZUBEK JP, 1972, SCIENCE, V176, P1045, DOI 10.1126/science.176.4038.1045	56	46	46	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e28	10.1371/journal.pone.0000028	http://dx.doi.org/10.1371/journal.pone.0000028			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183655	Green Published, gold			2022-12-25	WOS:000207443600028
J	Lin, X; Morgan-Lappe, S; Huang, X; Li, L; Zakula, DM; Vernetti, LA; Fesik, SW; Shen, Y				Lin, X.; Morgan-Lappe, S.; Huang, X.; Li, L.; Zakula, D. M.; Vernetti, L. A.; Fesik, S. W.; Shen, Y.			'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X-L inhibitor ABT-737	ONCOGENE			English	Article						siRNA; off-target; seed; Mcl-1; ABT-737; Bcl-X-L	RNA; EXPRESSION; PROTEINS; CELLS	ABT-737 is a subnanomolar inhibitor of the antiapoptotic proteins Bcl-2, Bcl-XL and Bcl-w. Although ABT-737 triggers extensive cell death in many small-cell lung carcinoma ( SCLC) cell lines, some of the SCLC cell lines and the majority of the cancer cell lines derived from other solid tumors were found to be resistant to ABT-737. To better understand the mechanism of resistance to ABT-737, we screened a short interfering RNA library consisting of short interfering RNA against 4000 'druggable' targets in an SCLC-derived cell line, NCI-H196. By comparing the knockdowns with phenotypes, all of the three top 'hits' from the screen were found to result from off-target gene silencing. Interestingly, the three off-target siRNAs were found to knock down an antiapoptotic Bcl-2 family protein Mcl-1 owing to the complementation between their seed regions with the 30 untranslated region ( 30 UTR) of Mcl-1. Furthermore, reducing the level of Mcl-1 using siRNAs or the small-molecule compounds Bay43-9006 and Seliciclib was sufficient to overcome the resistance to ABT-737 in the resistant SCLC cell line and cancer cell lines derived from other solid tumors. These results provide further evidence that Mcl-1 is the major factor that causes resistance to ABT-737 in cancer cells derived from diverse solid tumors, and the combination of Mcl-1 downregulating agents with ABT-737 could be potent therapeutic regimens for patient with ABT-737 resistant SCLC and many other types of solid tumors.	Abbott Labs, Global Pharmaceut Res & Dev, Canc Res, Abbott Pk, IL 60064 USA	Abbott Laboratories	Shen, Y (corresponding author), Abbott Labs, Global Pharmaceut Res & Dev, Canc Res, AP10,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	yu.shen@abbott.com		Vernetti, Lawrence/0000-0003-4861-3167				Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kirkin V, 2004, BBA-MOL CELL RES, V1644, P229, DOI 10.1016/j.bbamcr.2003.08.009; Kitada S, 2000, BLOOD, V96, P393; Lin XY, 2005, NUCLEIC ACIDS RES, V33, P4527, DOI 10.1093/nar/gki762; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Saxena S, 2003, J BIOL CHEM, V278, P44312, DOI 10.1074/jbc.M307089200; Tijsterman M, 2002, ANNU REV GENET, V36, P489, DOI 10.1146/annurev.genet.36.043002.091619; van de Donk NWCJ, 2003, BLOOD, V102, P3354, DOI 10.1182/blood-2003-03-0970; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100	14	216	229	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3972	3979		10.1038/sj.onc.1210166	http://dx.doi.org/10.1038/sj.onc.1210166			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17173063				2022-12-25	WOS:000247144500007
J	Abdallah, BM; Boissy, P; Tan, QH; Dahlgaard, J; Traustadottir, GA; Kupisiewicz, K; Laborda, J; Delaisse, JM; Kassem, M				Abdallah, Basern M.; Boissy, Patrice; Tan, Qihua; Dahlgaard, Jesper; Traustadottir, Gunnhildur A.; Kupisiewicz, Katarzyna; Laborda, Jorge; Delaisse, Jean-Marie; Kassem, Moustapha			dlk1/FA1 regulates the function of human bone marrow mesenchymal stem cells by modulating gene expression of pro-inflammatory cytokines and immune response-related factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HOMEOTIC PROTEIN DLK; FETAL ANTIGEN-1; GROWTH; DIFFERENTIATION; INHIBITION; RECEPTORS; BIOLOGY; DISEASE; ALPHA	dlk1/FA1 (delta-like 1/fetal antigen-1) is a member of the epidermal growth factor-like homeotic protein family whose expression is known to modulate the differentiation signals of mesenchymal and hematopoietic stem cells in bone marrow. We have demonstrated previously that Dlk1 can maintain the human bone marrow mesenchymal stem cells (hMSC) in an undifferentiated state. To identify the molecular mechanisms underlying these effects, we compared the basal gene expression pattern in Dlk1-overexpressing hMSC cells (hMSC-dlk1) versus control hMSC (negative for Dlk1 expression) by using Affymetrix HG-U133A microarrays. In response to Dlk1 expression, 128 genes were significantly up-regulated (with > 2-fold; p < 0.001), and 24% of these genes were annotated as immune response-related factors, including pro-inflammatory cytokines, in addition to factors involved in the complement system, apoptosis, and cell adhesion. Also, addition of purified FA1 to hMSC up-regulated the same factors in a dose-dependent manner. As biological consequences of up-regulating these immune response-related factors, we showed that the inhibitory effects of dlk1 on osteoblast and adipocyte differentiation of hMSC are associated with Dlk1-induced cytokine expression. Furthermore, Dlk1 promoted B cell proliferation, synergized the immune response effects of the bacterial endotoxin lipopolysaccharide on hMSC, and led to marked transactivation of the NF-kappa B. Our data suggest a new role for Dlk1 in regulating the multiple biological functions of hMSC by influencing the composition of their microenvironment "niche." Our findings also demonstrate a role for Dlk1 in mediating the immune response.	Univ So Denmark, Dept Endocrinol & Metab, Ctr Med Biotechnol, Odense Univ Hosp,KMEB Lab, DK-5000 Odense C, Denmark; So Denmark Univ, Vejle Hosp, DK-7100 Vejle, Denmark; Odense Univ Hosp, Dept Clin Biochem & Genet, DK-5000 Odense, Denmark; Univ Castilla La Mancha, Sch Med, Dept Inorgan & Organ Chem & Biochem, Mol Biol Branch, Albacete 02006, Spain	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Lillebaelt Hospital; University of Southern Denmark; Odense University Hospital; Universidad de Castilla-La Mancha	Abdallah, BM (corresponding author), Univ So Denmark, Dept Endocrinol & Metab, Ctr Med Biotechnol, Odense Univ Hosp,KMEB Lab, DK-5000 Odense C, Denmark.	babdallah@health.sdu.dk	Abdallah, Basem/G-5667-2017; Kassem, Moustapha/J-7688-2013; Tan, Qihua/F-1349-2015; Tan, Qihua/AAG-2582-2019; Kassem, Moustapha/O-3819-2019; Laborda, Jorge/L-5726-2014	Abdallah, Basem/0000-0003-0324-8055; Kassem, Moustapha/0000-0003-1557-0869; Tan, Qihua/0000-0003-3194-0030; Tan, Qihua/0000-0003-3194-0030; Kassem, Moustapha/0000-0003-1557-0869; Laborda, Jorge/0000-0002-9210-838X; Boissy, Patrice/0000-0002-4025-1141; Traustadottir, Gunnhildur Asta/0000-0001-6044-0989; Delaisse, Jean-Marie/0000-0001-7370-1500; Dahlgaard, Jesper/0000-0002-1798-6799				Abdallah BM, 2004, J BONE MINER RES, V19, P841, DOI 10.1359/JBMR.040118; Ahdjoudj S, 2004, HISTOL HISTOPATHOL, V19, P151, DOI 10.14670/HH-19.151; Andela VB, 2002, BIOCHEM BIOPH RES CO, V297, P237, DOI 10.1016/S0006-291X(02)02141-1; Andersen M, 2001, J CLIN ENDOCR METAB, V86, P5465, DOI 10.1210/jc.86.11.5465; Atkins GJ, 2000, BONE, V26, P653, DOI 10.1016/S8756-3282(00)00280-5; Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073; Baladron V, 2005, EXP CELL RES, V303, P343, DOI 10.1016/j.yexcr.2004.10.001; Bauer SR, 1998, MOL CELL BIOL, V18, P5247, DOI 10.1128/MCB.18.9.5247; Berends MJW, 1999, AM J MED GENET, V84, P76, DOI 10.1002/(SICI)1096-8628(19990507)84:1<76::AID-AJMG16>3.0.CO;2-F; Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008-5472.CAN-05-0651; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Campbell DJ, 2003, IMMUNOL REV, V195, P58, DOI 10.1034/j.1600-065X.2003.00067.x; Carlsson C, 1997, ENDOCRINOLOGY, V138, P3940, DOI 10.1210/en.138.9.3940; Carter RA, 2001, ARTHRITIS RHEUM-US, V44, P985, DOI 10.1002/1529-0131(200105)44:5<985::AID-ANR176>3.3.CO;2-G; Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105-2896.2005.00334.x; Costaglioli P, 2001, FEBS LETT, V509, P413, DOI 10.1016/S0014-5793(01)03205-7; Crameri RM, 2004, J PHYSIOL-LONDON, V558, P333, DOI 10.1113/jphysiol.2004.061846; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Deyama Y, 2001, BIOCHEM BIOPH RES CO, V282, P1080, DOI 10.1006/bbrc.2001.4693; dos Santos CC, 2004, PHYSIOL GENOMICS, V19, P331, DOI 10.1152/physiolgenomics.00153.2004; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; Elenkov IJ, 2005, NEUROIMMUNOMODULAT, V12, P255, DOI 10.1159/000087104; Espinosa L, 2003, MOL BIOL CELL, V14, P491, DOI 10.1091/mbc.E02-07-0404; FAY TN, 1988, EUR J OBSTET GYN R B, V29, P73, DOI 10.1016/0028-2243(88)90167-0; Fleming RJ, 1998, SEMIN CELL DEV BIOL, V9, P599, DOI 10.1006/scdb.1998.0260; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GIMBLE JM, 1994, J CELL BIOCHEM, V54, P122, DOI 10.1002/jcb.240540113; Graves DT, 1999, FRONT BIOSCI, V4, P571; Hackney JA, 2002, P NATL ACAD SCI USA, V99, P13061, DOI 10.1073/pnas.192124499; Harp JB, 2004, CURR OPIN LIPIDOL, V15, P303, DOI 10.1097/00041433-200406000-00010; Henderson B, 2003, TRENDS MICROBIOL, V11, P570, DOI 10.1016/j.tim.2003.10.005; Heyninck Karen, 2001, Molecular Cell Biology Research Communications, V4, P259, DOI 10.1006/mcbr.2001.0295; Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553; Honczarenko M, 2006, STEM CELLS, V24, P1030, DOI 10.1634/stemcells.2005-0319; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Huang CC, 2004, J PATHOL, V202, P172, DOI 10.1002/path.1505; Jensen CH, 2004, AM J PATHOL, V164, P1347, DOI 10.1016/S0002-9440(10)63221-X; JENSEN CH, 1994, EUR J BIOCHEM, V225, P83, DOI 10.1111/j.1432-1033.1994.00083.x; JENSEN CH, 1993, HUM REPROD, V8, P635, DOI 10.1093/oxfordjournals.humrep.a138110; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KASSEM M, 1993, J BONE MINER RES, V8, P1453; Kassem M, 2004, BASIC CLIN PHARMACOL, V95, P209, DOI 10.1111/j.1742-7843.2004.pto950502.x; Kawakami T, 2006, HUM MOL GENET, V15, P821, DOI 10.1093/hmg/ddl001; Komor M, 2005, STEM CELLS, V23, P1154, DOI 10.1634/stemcells.2004-0171; Laborda J, 2000, HISTOL HISTOPATHOL, V15, P119, DOI 10.14670/HH-15.119; LABORDA J, 1993, J BIOL CHEM, V268, P3817; Lamkanfi M, 2004, J BIOL CHEM, V279, P24785, DOI 10.1074/jbc.M400985200; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MacKenzie S, 2006, MOL IMMUNOL, V43, P1340, DOI 10.1016/j.molimm.2005.09.005; Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Marriott I, 2004, IMMUNOL RES, V30, P291, DOI 10.1385/IR:30:3:291; Mastellos D, 2002, TRENDS IMMUNOL, V23, P485, DOI 10.1016/S1471-4906(02)02287-1; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; Moore KA, 1997, P NATL ACAD SCI USA, V94, P4011, DOI 10.1073/pnas.94.8.4011; Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371-2380.1996; Oakley F, 2003, J BIOL CHEM, V278, P24359, DOI 10.1074/jbc.M211051200; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pan GH, 1998, FEBS LETT, V431, P351, DOI 10.1016/S0014-5793(98)00791-1; Rankin James A, 2004, AACN Clin Issues, V15, P3, DOI 10.1097/00044067-200401000-00002; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Rougier F, 1998, CYTOKINE, V10, P93, DOI 10.1006/cyto.1997.0262; Ruiz-Hidalgo MJ, 2002, EXP CELL RES, V274, P178, DOI 10.1006/excr.2001.5464; Sakajiri S, 2005, LEUKEMIA, V19, P1404, DOI 10.1038/sj.leu.2403832; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Samulewicz SJ, 2002, WOUND REPAIR REGEN, V10, P215, DOI 10.1046/j.1524-475X.2002.10404.x; Schwarz H, 1996, BLOOD, V87, P2839, DOI 10.1182/blood.V87.7.2839.bloodjournal8772839; Shiffman D, 2000, J BIOL CHEM, V275, P37324, DOI 10.1074/jbc.M004732200; Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Stains Joseph P, 2005, Birth Defects Res C Embryo Today, V75, P72, DOI 10.1002/bdrc.20034; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; Taichman RS, 2005, BLOOD, V105, P2631, DOI 10.1182/blood-2004-06-2480; Tanaka Yoshiya, 2005, Current Drug Targets - Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015; Tanimizu N, 2004, GENE EXPR PATTERNS, V5, P209, DOI 10.1016/j.modgep.2004.08.003; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105-2896.2005.00338.x; Wang YH, 2006, MOL CELL BIOL, V26, P5421, DOI 10.1128/MCB.02437-05; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zhang HB, 2003, J BIOL CHEM, V278, P20906, DOI 10.1074/jbc.M300022200; Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211	88	70	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7339	7351		10.1074/jbc.M607530200	http://dx.doi.org/10.1074/jbc.M607530200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17182623	hybrid			2022-12-25	WOS:000245080900045
J	Gabrielli, B; Chau, YQ; Giles, N; Harding, A; Stevens, F; Beamish, H				Gabrielli, Brian; Chau, Yu Qian; Giles, Nichole; Harding, Angus; Stevens, Frankie; Beamish, Heather			Caffeine promotes apoptosis in mitotic spindle checkpoint-arrested cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DNA-DAMAGE; RADIOSENSITIZING AGENT; MICROTUBULE ATTACHMENT; AURORA-B; CENP-E; MITOSIS; CATASTROPHE; SURVIVAL; MAD2	The spindle assembly checkpoint arrests cells in mitosis when defects in mitotic spindle assembly or partitioning of the replicated genome are detected. This checkpoint blocks exit from mitosis until the defect is rectified or the cell initiates apoptosis. In this study we have used caffeine to identify components of the mechanism that signals apoptosis in mitotic checkpoint-arrested cells. Addition of caffeine to spindle checkpoint-arrested cells induced > 40% apoptosis within 5 h. It also caused proteasome-mediated destruction of cyclin B1, a corresponding reduction in cyclin B1/cdk1 activity, and reduction in NIPM-2 reactivity. However, cells retained MAD2 staining at the kinetochores, an indication of continued spindle checkpoint function. Blocking proteasome activity did not block apoptosis, but continued spindle checkpoint function was essential for apoptosis. After systematically eliminating all known targets, we have identified p21-activated kinase PAK1, which has an anti-apoptotic function in spindle checkpoint-arrested cells, as a target for caffeine inhibition. Knockdown of PAKI. also increased apoptosis in spindle checkpoint-arrested cells. This study demonstrates that the spindle checkpoint not only regulates mitotic exit but apoptosis in mitosis through the activity of PAKI.	Univ Queensland, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia	University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia.	bgabrielli@cicr.uq.edu.au	Gabrielli, Brian G/B-3655-2011	Gabrielli, Brian G/0000-0003-3933-1651; Stevens, Frankie/0000-0002-2556-473X				Anderson Hilary J, 2003, Prog Cell Cycle Res, V5, P423; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Bozko P, 2005, MOL CANCER THER, V4, P2016, DOI 10.1158/1535-7163.MCT-05-0138; Burgess A, 2004, ONCOGENE, V23, P6693, DOI 10.1038/sj.onc.1207893; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Deacon K, 2003, MOL BIOL CELL, V14, P2071, DOI 10.1091/mbc.e02-10-0653; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Eastman A, 2004, J CELL BIOCHEM, V91, P223, DOI 10.1002/jcb.10699; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Harding A, 2003, J BIOL CHEM, V278, P16747, DOI 10.1074/jbc.M301015200; Hardwick KG, 2005, CURR BIOL, V15, pR122, DOI 10.1016/j.cub.2005.02.008; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kohn EA, 2003, CANCER RES, V63, P31; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; Stewart ZA, 2003, TRENDS PHARMACOL SCI, V24, P139, DOI 10.1016/S0165-6147(03)00026-9; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 1999, CURR BIOL, V9, pR562, DOI 10.1016/S0960-9822(99)80355-8; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Vogel C, 2005, J BIOL CHEM, V280, P4025, DOI 10.1074/jbc.C400545200; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Warrener R, 2003, FASEB J, V17, P1550, DOI 10.1096/fj.02-1003fje; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; WELLS JN, 1988, METHOD ENZYMOL, V159, P489; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	47	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					6954	6964		10.1074/jbc.M610104200	http://dx.doi.org/10.1074/jbc.M610104200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17182611	hybrid			2022-12-25	WOS:000245080900007
J	Raschle, T; Arigoni, D; Brunisholz, R; Rechsteiner, H; Amrhein, N; Fitzpatrick, TB				Raschle, Thomas; Arigoni, Duilio; Brunisholz, Rene; Rechsteiner, Helene; Amrhein, Nikolaus; Fitzpatrick, Teresa B.			Reaction mechanism of pyridoxal 5 '-phosphate synthase - Detection of an enzyme-bound chromophoric intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; VITAMIN-B6 BIOSYNTHESIS; BIOCHEMICAL-CHARACTERIZATION; COENZYME BIOSYNTHESIS; INCORPORATION PATTERN; GENE; 1-DEOXY-D-XYLULOSE-5-PHOSPHATE; 4-(PHOSPHOHYDROXY)-L-THREONINE; PATHWAY; YEAST	Vitamin B6 is an essential metabolite in all. organisms. De novo synthesis of the vitamin can occur through either of two mutually exclusive pathways referred to as deoxyxylulose 5phosphate-dependent and deoxyxylulose 5-phosphate-independent. The latter pathway has only recently been discovered and is distinguished by the presence of two genes, Pdx1 and Pdx2, encoding the synthase and glutaminase subunit of PLP synthase, respectively. In the presence of ammonia, the synthase alone displays an exceptional polymorphic synthetic ability in carrying out a complex set of reactions, including pentose and triose isomerization, imine formation, ammonia addition, aldol-type condensation, cyclization, and aromatization, that convert C3 and C5 precursors into the cofactor B6 vitamer, pyridoxal 5'-phosphate. Here, employing the Bacillus subtilis proteins, we demonstrate key features along the catalytic path. We show that ribose 5-phosphate is the preferred C5 substrate and provide unequivocal evidence that the pent(ul)ose phosphate imine occurs at lysine 81 rather than lysine 149 as previously postulated. While this study was under review, corroborative crystallographic evidence has been provided for imine formation with the corresponding lysine group in the enzyme from Thermotoga maritima (Zein, F., Zhang, Y., Kang, Y.-N., Burns, K., Begley, T. P., and Ealick, S. E. (2006) Biochemistry 45,14609 14620). We have detected an unanticipated covalent reaction intermediate that occurs subsequent to imine formation and is dependent on the presence of Pdx2 and glutamine. This step most likely primes the enzyme for acceptance of the triose sugar, ultimately leading to formation of the pyridine ring. Two alternative structures are proposed for the chromophoric intermediate, both of which require substantial modifications of the proposed mechanism.	ETH, Inst Plant Sci, CH-8092 Zurich, Switzerland; ETH, Organ Chem Lab, CH-8092 Zurich, Switzerland; Funct Genom Ctr Zurich, CH-8057 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Fitzpatrick, TB (corresponding author), ETH, Inst Plant Sci, CH-8092 Zurich, Switzerland.	tfitzpatrick@ethz.ch						Agrawal GK, 2005, PROTEOMICS, V5, P4684, DOI 10.1002/pmic.200500021; Ames BN, 2004, ANN NY ACAD SCI, V1019, P406, DOI 10.1196/annals.1297.073; Begley TP, 2006, NAT PROD REP, V23, P15, DOI 10.1039/b207131m; Belitsky BR, 2004, J BACTERIOL, V186, P1191, DOI 10.1128/JB.186.4.1191-1196.2004; Bilski P, 2000, PHOTOCHEM PHOTOBIOL, V71, P129, DOI 10.1562/0031-8655(2000)071&lt;0129:SIPVBP&gt;2.0.CO;2; Burns KE, 2005, J AM CHEM SOC, V127, P3682, DOI 10.1021/ja042792t; Cane DE, 1998, J AM CHEM SOC, V120, P1936, DOI 10.1021/ja9742085; Cane DE, 1999, J AM CHEM SOC, V121, P7722, DOI 10.1021/ja9914947; Chaudhuri BN, 2003, BIOCHEMISTRY-US, V42, P7003, DOI 10.1021/bi034320h; Chen H, 2005, PLANT J, V44, P396, DOI 10.1111/j.1365-313X.2005.02538.x; Dong YX, 2004, EUR J BIOCHEM, V271, P745, DOI 10.1111/j.1432-1033.2003.03973.x; Dorrestein PC, 2004, J AM CHEM SOC, V126, P3091, DOI 10.1021/ja039616p; Ehrenshaft M, 1999, P NATL ACAD SCI USA, V96, P9374, DOI 10.1073/pnas.96.16.9374; Ehrenshaft M, 2001, J BACTERIOL, V183, P3383, DOI 10.1128/JB.183.11.3383-3390.2001; Gengenbacher M, 2006, J BIOL CHEM, V281, P3633, DOI 10.1074/jbc.M508696200; Gupta RN, 2001, J AM CHEM SOC, V123, P11353, DOI 10.1021/ja0113201; Jain SK, 2001, FREE RADICAL BIO MED, V30, P232, DOI 10.1016/S0891-5849(00)00462-7; Laber B, 1999, FEBS LETT, V449, P45, DOI 10.1016/S0014-5793(99)00393-2; LAM HM, 1990, J BACTERIOL, V172, P6518, DOI 10.1128/jb.172.11.6518-6528.1990; LAM HM, 1992, J BACTERIOL, V174, P1554, DOI 10.1128/jb.174.5.1554-1567.1992; Osmani AH, 1999, J BIOL CHEM, V274, P23565, DOI 10.1074/jbc.274.33.23565; PIERCE J, 1985, J AM CHEM SOC, V107, P2448, DOI 10.1021/ja00294a041; Raschle T, 2005, J BIOL CHEM, V280, P32291, DOI 10.1074/jbc.M501356200; Strohmeier M, 2006, P NATL ACAD SCI USA, V103, P19284, DOI 10.1073/pnas.0604950103; Tambasco-Studart M, 2005, P NATL ACAD SCI USA, V102, P13687, DOI 10.1073/pnas.0506228102; Voziyan PA, 2005, ANN NY ACAD SCI, V1043, P807, DOI 10.1196/annals.1333.093; Wrenger C, 2005, J BIOL CHEM, V280, P5242, DOI 10.1074/jbc.M412475200; Yang Y, 1998, J BACTERIOL, V180, P4294, DOI 10.1128/JB.180.16.4294-4299.1998; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87; Zeidler J, 2003, J ORG CHEM, V68, P3486, DOI 10.1021/jo020730k; Zeidler J, 2002, J AM CHEM SOC, V124, P4542, DOI 10.1021/ja012708z; Zein F, 2006, BIOCHEMISTRY-US, V45, P14609, DOI 10.1021/bi061464y; Zhang RG, 2003, J MOL BIOL, V332, P1083, DOI 10.1016/j.jmb.2003.08.009; ZHAO GS, 1994, J BACTERIOL, V176, P6134, DOI 10.1128/jb.176.19.6134-6138.1994; ZHAO GS, 1995, J BACTERIOL, V177, P2804, DOI 10.1128/jb.177.10.2804-2812.1995; Zhao GS, 1996, FEMS MICROBIOL LETT, V135, P275, DOI 10.1016/0378-1097(95)00466-1; Zhu JH, 2005, J BIOL CHEM, V280, P27914, DOI 10.1074/jbc.M503642200	37	43	45	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6098	6105		10.1074/jbc.M610614200	http://dx.doi.org/10.1074/jbc.M610614200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17189272	hybrid, Green Published, Green Accepted			2022-12-25	WOS:000244867200015
J	Voglmeir, J; Voglauer, R; Wilson, IBH				Voglmeir, Josef; Voglauer, Regina; Wilson, Iain B. H.			XT-II, the second isoform of human peptide-O-xylosyltransferase, displays enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-D-XYLOSE; BETA-D-XYLOSYLTRANSFERASE; RAY CRYSTAL-STRUCTURE; HEPARAN-SULFATE; CHONDROITIN SULFATE; CAENORHABDITIS-ELEGANS; LINKAGE REGION; BIOSYNTHESIS; PROTEOGLYCAN; PURIFICATION	Peptide O-xylosyltransferase (EC 2.4.2.26) is the first enzyme required for the generation of chondroitin and heparan sulfate glycosaminoglycan chains of proteoglycans. Cloning of cDNAs has previously shown that, whereas invertebrates, generally have a single xylosyltransferase gene, vertebrate genornes encode two similar proteins, xylosyltransferase I and II (XT-I and XT-II). To date enzymatic activity has only been demonstrated for the human XT-I, Caenorhabditis SQV-6, and Drosojghila OXT isoforms. In the present study, we demonstrate that a soluble form of human XT-II expressed in the xylosyltransferase-deficient pgsA-745 (S745) Chinese hamster ovary cell line is indeed capable of catalyzing the transfer of xylose to a variety of peptide substrates; its enzyme activity was also proven using a Pichia-expressed form of XT-II. Its pH, temperature, and cation dependences are similar to those of XT-I expressed in either mammalian cells or yeast. Our data suggest that XT-I and XT-II are, at least in vitro, functionally identical.	Univ Nat Resources & Appl Life Sci, Dept Chem, BOKU, A-1190 Vienna, Austria; Univ Nat Resources & Appl Life Sci, Inst Angew Mikrobiol, A-1190 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna	Wilson, IBH (corresponding author), Univ Nat Resources & Appl Life Sci, Dept Chem, BOKU, A-1190 Vienna, Austria.	iain.wilson@boku.ac.at	Wilson, Iain/B-3326-2009; Voglmeir, Josef/F-5722-2014	Wilson, Iain/0000-0001-8996-1518; Voglmeir, Josef/0000-0002-4096-4926; Grillari, Regina/0000-0002-5487-2838	Austrian Science Fund FWF [P 18447] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Akama TO, 2006, P NATL ACAD SCI USA, V103, P8983, DOI 10.1073/pnas.0603248103; Berninsone PM, 2002, GLYCOCONJUGATE J, V19, P325, DOI 10.1023/A:1025364820713; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; Brunner A, 2006, GLYCOCONJUGATE J, V23, P543, DOI 10.1007/s10719-006-7633-z; CAMPBELL P, 1984, ANAL BIOCHEM, V137, P505, DOI 10.1016/0003-2697(84)90119-2; Cuellar K, 2007, J BIOL CHEM, V282, P5195, DOI 10.1074/jbc.M611048200; Duncan G, 2001, J CLIN INVEST, V108, P511, DOI 10.1172/JCI200113737; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Gotting C, 2004, J BIOL CHEM, V279, P42566, DOI 10.1074/jbc.M401340200; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; GREBNER EE, 1966, BIOCHEM BIOPH RES CO, V22, P672, DOI 10.1016/0006-291X(66)90199-9; GREBNER EE, 1966, ARCH BIOCHEM BIOPHYS, V116, P391, DOI 10.1016/0003-9861(66)90045-2; GUILLAUMOND M, 1975, INT J BIOCHEM, V6, P491, DOI 10.1016/0020-711X(75)90029-4; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Hwang HY, 2003, J BIOL CHEM, V278, P11735, DOI 10.1074/jbc.C200518200; Inatani M, 2003, SCIENCE, V302, P1044, DOI 10.1126/science.1090497; KEARNS AE, 1991, BIOCHEMISTRY-US, V30, P7477, DOI 10.1021/bi00244a016; Kuhn J, 2003, BIOCHEM BIOPH RES CO, V312, P537, DOI 10.1016/j.bbrc.2003.10.157; Kuhn J, 2001, J BIOL CHEM, V276, P4940, DOI 10.1074/jbc.M005111200; Lin XH, 2002, GLYCOCONJUGATE J, V19, P363, DOI 10.1023/A:1025329323438; Mulloy B, 2005, AN ACAD BRAS CIENC, V77, P651, DOI 10.1590/S0001-37652005000400007; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; Pak JE, 2006, METHOD ENZYMOL, V416, P30, DOI 10.1016/S0076-6879(06)16003-6; Pak JE, 2006, J BIOL CHEM, V281, P26693, DOI 10.1074/jbc.M603534200; Petitou M, 2003, BIOCHIMIE, V85, P83, DOI 10.1016/S0300-9084(03)00078-6; Pfeil U, 2000, GLYCOBIOLOGY, V10, P803, DOI 10.1093/glycob/10.8.803; Ponighaus C, 2007, J BIOL CHEM, V282, P5201, DOI 10.1074/jbc.M611665200; ROBINSON HC, 1966, P NATL ACAD SCI USA, V56, P1859, DOI 10.1073/pnas.56.6.1859; Schon S, 2006, J MED GENET, V43, P745, DOI 10.1136/jmg.2006.040972; Schon S, 2006, OSTEOARTHR CARTILAGE, V14, P442, DOI 10.1016/j.joca.2005.11.004; Schon S, 2006, J BIOL CHEM, V281, P14224, DOI 10.1074/jbc.M510690200; Schon S, 2005, KIDNEY INT, V68, P1483, DOI 10.1111/j.1523-1755.2005.00561.x; SCHWARTZ NB, 1975, ARCH BIOCHEM BIOPHYS, V171, P136, DOI 10.1016/0003-9861(75)90016-8; Seidler DG, 2006, J MOL MED, V84, P583, DOI 10.1007/s00109-006-0046-4; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; SELLECK SB, 2006, SCI STKE, pPE17; Stickens D, 2005, DEVELOPMENT, V132, P5055, DOI 10.1242/dev.02088; STOOLMILLER AC, 1972, J BIOL CHEM, V247, P3525; Wilson IBH, 2002, J BIOL CHEM, V277, P21207, DOI 10.1074/jbc.M201634200; Wilson IBH, 2004, CELL MOL LIFE SCI, V61, P794, DOI 10.1007/s00018-003-3278-2; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200	42	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					5984	5990		10.1074/jbc.M608087200	http://dx.doi.org/10.1074/jbc.M608087200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17194707	Green Accepted, hybrid			2022-12-25	WOS:000244867200003
J	Choi, MG; Carman, GM				Choi, Mal-Gi; Carman, George M.			Phosphorylation of human CTP synthetase 1 by protein kinase A - Identification of Thr(455) as a major site of phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE-TRIPHOSPHATE-SYNTHETASE; HUMAN CTP SYNTHETASE; YEAST SACCHAROMYCES-CEREVISIAE; CYCLOPENTENYL CYTOSINE; 5'-TRIPHOSPHATE SYNTHETASE; PHOSPHOLIPID BIOSYNTHESIS; PYROPHOSPHATE PHOSPHATASE; LYMPHOBLASTIC-LEUKEMIA; MUTATOR GENE; URA7 GENE	CTP synthetase is an essential enzyme that generates the CTP required for the synthesis of nucleic acids and membrane phospholipids. In this study, we examined the phosphorylation of the human CTPS1-encoded CTP synthetase 1 by protein kinase A. CTP synthetase 1 was expressed and purified from a Saccharomyces cerevisiae ura7 Delta ura8 Delta double mutant that lacks CTP synthetase activity. Using purified CTP synthetase I as a substrate, protein kinase A activity was time- and dose-dependent. The phosphorylation, which primarily occurred on a threonine residue, was accompanied by a 50% decrease in CTP synthetase 1 activity. The synthetic peptide LGKRRTLFQT that contains the protein kinase A motif for Thr(455) was a substrate for protein kinase A. A Thr(455) to Ala (T455A) mutation in CTP synthetase 1 was constructed by site-directed mutagenesis and was expressed and purified from the S. cerevisiae ura7 Delta ura8 Delta mutant. The T455A mutation caused a 78% decrease in protein kinase A phosphorylation and the loss of the phosphothreonine residue and a major phosphopeptide that were present in the purified wild type enzyme phosphorylated by protein kinase A. The CTP synthetase 1 activity of the T455A mutant enzyme was 2-fold higher than the wild type enzyme. In addition, the T455A mutation caused a 44% decrease in the amount of human CTP synthetase 1 that was phosphorylated in S. cerevisiae cells, and this was accompanied by a 2.5-fold increase in the cellular concentration of CTP and a 1.5-fold increase in the choline-dependent synthesis of phosphatidylcholine.	Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050679, R01 GM050679-14, GM-50679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONOW B, 1984, J BIOL CHEM, V259, P9035; ARONOW B, 1987, J BIOL CHEM, V262, P5106; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; Choi MG, 2003, J BIOL CHEM, V278, P23610, DOI 10.1074/jbc.M303337200; CHU EHY, 1984, BIOCHEM GENET, V22, P701, DOI 10.1007/BF00485854; Dereuddre-Bosquet N, 2004, ANTIVIR RES, V61, P67, DOI 10.1016/j.antiviral.2003.08.002; Endrizzi JA, 2004, BIOCHEMISTRY-US, V43, P6447, DOI 10.1021/bi0496945; Fernandez F, 2001, J BIOL CHEM, V276, P41455, DOI 10.1074/jbc.M105544200; FRAENKEL DG, 1982, MOL BIOL YEAST SACCH, P1; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Goto M, 2004, STRUCTURE, V12, P1413, DOI 10.1016/j.str.2004.05.013; HAID A, 1983, METHOD ENZYMOL, V96, P192; Han GS, 2005, J BIOL CHEM, V280, P38328, DOI 10.1074/jbc.M509622200; Han GS, 2004, J BIOL CHEM, V279, P5338, DOI 10.1074/jbc.M311779200; Hatch GM, 1996, J BIOL CHEM, V271, P25810, DOI 10.1074/jbc.271.42.25810; HINDENBURG AA, 1985, CANCER RES, V45, P3048; Hofer A, 2001, P NATL ACAD SCI USA, V98, P6412, DOI 10.1073/pnas.111139498; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANG GJ, 1989, J BIOL CHEM, V264, P713; KAUFMAN ER, 1986, MUTAT RES, V161, P19, DOI 10.1016/0027-5107(86)90096-5; KIZAKI H, 1980, CANCER RES, V40, P3921; Krauss G., 2003, BIOCH SIGNAL TRANSDU; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; Kursula P, 2006, ACTA CRYSTALLOGR F, V62, P613, DOI 10.1107/S1744309106018136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3365, DOI 10.1021/bi00794a008; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LEWIS DA, 1989, BIOCHEMISTRY-US, V28, P8454, DOI 10.1021/bi00447a027; LIEBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; MEUTH M, 1982, SOMAT CELL GENET, V8, P423, DOI 10.1007/BF01538705; Mole ML, 1998, ANAL BIOCHEM, V259, P245, DOI 10.1006/abio.1998.2647; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; Pappas A, 1998, J BIOL CHEM, V273, P15954, DOI 10.1074/jbc.273.26.15954; Pappas A, 1999, BIOCHEMISTRY-US, V38, P16671, DOI 10.1021/bi9920127; Park TS, 1999, BIOCHEMISTRY-US, V38, P8839, DOI 10.1021/bi990784x; POLITI PM, 1995, CANCER CHEMOTH PHARM, V36, P513, DOI 10.1007/BF00685802; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; THEVELEIN JM, 1985, J GEN MICROBIOL, V131, P3199; THOMAS PE, 1988, BIOCHIM BIOPHYS ACTA, V953, P334, DOI 10.1016/0167-4838(88)90042-8; TRUDEL M, 1984, J BIOL CHEM, V259, P2355; Van Kuilenburg ABP, 2000, ADV EXP MED BIOL, V486, P257; VANDENBERG AA, 1995, EUR J CANCER, V31A, P108, DOI 10.1016/0959-8049(94)00442-8; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; Verschuur AC, 1998, ADV EXP MED BIOL, V431, P667; Verschuur AC, 2000, EUR J CANCER, V36, P627, DOI 10.1016/S0959-8049(00)00021-6; Verschuur AC, 2000, BRIT J HAEMATOL, V110, P161, DOI 10.1046/j.1365-2141.2000.02136.x; VINCENT BRD, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; VONDERSAAL W, 1985, J BIOL CHEM, V260, P4993; Wadskov-Hansen SLL, 2001, J BIOL CHEM, V276, P38002; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; Weber G, 1978, Adv Enzyme Regul, V17, P1; YAMAUCHI M, 1990, EMBO J, V9, P2095, DOI 10.1002/j.1460-2075.1990.tb07377.x; Yang WL, 1996, J BIOL CHEM, V271, P28777, DOI 10.1074/jbc.271.46.28777; Yang WL, 1996, J BIOL CHEM, V271, P11113, DOI 10.1074/jbc.271.19.11113; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; YANG WL, 1995, J BIOL CHEM, V270, P14983, DOI 10.1074/jbc.270.25.14983; ZHANG H, 1993, CANCER RES, V53, P5714	80	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5367	5377		10.1074/jbc.M610993200	http://dx.doi.org/10.1074/jbc.M610993200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189248	Green Accepted, hybrid			2022-12-25	WOS:000244482300032
J	Saparov, SM; Liu, K; Agre, P; Pohl, P				Saparov, Sapar M.; Liu, Kun; Agre, Peter; Pohl, Peter			Fast and selective ammonia transport by aquaporin-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR LIPID BILAYERS; ION-CHANNEL FUNCTION; WATER CHANNEL; MEMBRANE-PROTEINS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; RH GLYCOPROTEINS; XENOPUS OOCYTES; RAT HEPATOCYTES; VOLTAGE-CLAMP	The transport of ammonia/ammonium is fundamental to nitrogen metabolism in all forms of life. So far, no clear picture has emerged as to whether a protein channel is capable of transporting exclusively neutral NH3, while excluding H+ and NH4+. Our research is the first stoichiometric study to show the selective transport of NH3, by a membrane channel. The purified water channel protein aquaporin-8 was reconstituted into planar bilayers, and the exclusion of NH4+ or H+ was established by 4 ensuring a lack of current under voltage clamp conditions. The single channel water permeability coefficient of 1.2 X 10(-14) cm(3)/subunit/s was established by imposing an osmotic gradient across reconstituted planar bilayers, and resulting minute changes in ionic concentration close to the membrane surface were detected. It is more than 2-fold smaller than the single channel ammonia permeability (2.7 X 10(-14) cm(3)/subunit/s) that was derived by establishing a transmembrane ammonium concentration gradient and measuring the resulting concentration increases adjacent to the membrane. This permeability ratio suggests that electrically silent ammonia transport may be the main function of AQP8.	Johannes Kepler Univ, Inst Biophys, A-4040 Linz, Austria; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Johannes Kepler University Linz; Duke University	Pohl, P (corresponding author), Johannes Kepler Univ, Inst Biophys, Altenbergerstr 69, A-4040 Linz, Austria.	peter.pohl@jku.at	Pohl, Peter/A-5361-2008	Pohl, Peter/0000-0002-1792-2314	Austrian Science Fund FWF [W 1201] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Agre P, 1997, SCIENCE, V275, P1490, DOI 10.1126/science.275.5305.1490; Andrade SLA, 2005, P NATL ACAD SCI USA, V102, P14994, DOI 10.1073/pnas.0506254102; Antonenko YN, 1997, BIOPHYS J, V72, P2187, DOI 10.1016/S0006-3495(97)78862-3; ANTONENKO YN, 1993, BIOPHYS J, V64, P1701, DOI 10.1016/S0006-3495(93)81542-X; Beckstein O, 2003, P NATL ACAD SCI USA, V100, P7063, DOI 10.1073/pnas.1136844100; Boassa D, 2006, J NEUROSCI, V26, P7811, DOI 10.1523/JNEUROSCI.0525-06.2006; Calamita G, 2005, J BIOL CHEM, V280, P17149, DOI 10.1074/jbc.C400595200; Chambrey R, 2006, TRANSFUS CLIN BIOL, V13, P154, DOI 10.1016/j.tracli.2006.02.005; FINKELSTEIN A, 1987, WATER MOVEMENT LIPID, P10; Garcia F, 2001, J BIOL CHEM, V276, P12147, DOI 10.1074/jbc.M009403200; Holm LM, 2005, PFLUG ARCH EUR J PHY, V450, P415, DOI 10.1007/s00424-005-1399-1; Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535; Jahn TP, 2004, FEBS LETT, V574, P31, DOI 10.1016/j.febslet.2004.08.004; Khademi S, 2004, SCIENCE, V305, P1587, DOI 10.1126/science.1101952; King LS, 2004, NAT REV MOL CELL BIO, V5, P687, DOI 10.1038/nrm1469; Krylov AV, 2001, J GEN PHYSIOL, V118, P333, DOI 10.1085/jgp.118.4.333; Lin YC, 2006, J AM CHEM SOC, V128, P10876, DOI 10.1021/ja0631549; Liu K, 2006, BIOL CELL, V98, P153, DOI 10.1042/BC20050026; Ludewig U, 2002, J BIOL CHEM, V277, P13548, DOI 10.1074/jbc.M200739200; Ma TH, 1997, BIOCHEM BIOPH RES CO, V240, P324, DOI 10.1006/bbrc.1997.7664; Mak DOD, 2006, AM J PHYSIOL-RENAL, V290, pF297, DOI 10.1152/ajprenal.00147.2005; Mayer M, 2006, J GEN PHYSIOL, V127, P133, DOI 10.1085/jgp.200509369; Mayer M, 2006, BIOCHEM J, V396, P431, DOI 10.1042/BJ20060051; Mazzone A, 2006, HEPATOLOGY, V43, P287, DOI 10.1002/hep.21039; MONTAL M, 1981, Q REV BIOPHYS, V14, P1, DOI 10.1017/S0033583500002079; Nakhoul NL, 2005, AM J PHYSIOL-RENAL, V288, pF170, DOI 10.1152/ajprenal.00419.2003; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; Pohl P, 1997, BIOPHYS J, V72, P1711, DOI 10.1016/S0006-3495(97)78817-9; Pohl P, 2004, BIOL CHEM, V385, P921, DOI 10.1515/BC.2004.120; Pohl P, 2001, P NATL ACAD SCI USA, V98, P9624, DOI 10.1073/pnas.161299398; Ripoche P, 2004, P NATL ACAD SCI USA, V101, P17222, DOI 10.1073/pnas.0403704101; Saparov SM, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.148101; Saparov SM, 2005, BIOL CELL, V97, P545; Saparov SM, 2004, P NATL ACAD SCI USA, V101, P4805, DOI 10.1073/pnas.0308309101; Saparov SM, 2001, J BIOL CHEM, V276, P31515, DOI 10.1074/jbc.M104267200; Shimbo K, 1995, BIOPHYS J, V69, P1819, DOI 10.1016/S0006-3495(95)80052-4; Tsunoda SP, 2004, J BIOL CHEM, V279, P11364, DOI 10.1074/jbc.M310881200; Winkler F, 2006, PFLUG ARCH EUR J PHY, V451, P701, DOI 10.1007/s00424-005-1511-6; Yang BX, 2006, AM J PHYSIOL-CELL PH, V291, pC417, DOI 10.1152/ajpcell.00057.2006; Yang BX, 2006, J BIOL CHEM, V281, P16202, DOI 10.1074/jbc.M601864200; Yang BX, 2005, AM J PHYSIOL-CELL PH, V288, pC1161, DOI 10.1152/ajpcell.00564.2004; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045; Yool AJ, 2002, NEWS PHYSIOL SCI, V17, P68, DOI 10.1152/nips.01372.2001; ZAMPIGHI GA, 1985, P NATL ACAD SCI USA, V82, P8468, DOI 10.1073/pnas.82.24.8468; Zheng L, 2004, P NATL ACAD SCI USA, V101, P17090, DOI 10.1073/pnas.0406475101	45	150	155	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5296	5301		10.1074/jbc.M609343200	http://dx.doi.org/10.1074/jbc.M609343200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189259	Green Accepted, hybrid			2022-12-25	WOS:000244482300024
J	Bruzzone, S; Dodoni, G; Kaludercic, N; Basile, G; Millo, E; De Flora, A; Di Lisa, F; Zocchi, E				Bruzzone, Santina; Dodoni, Giuliano; Kaludercic, Nina; Basile, Giovanna; Millo, Enrico; De Flora, Antonio; Di Lisa, Fabio; Zocchi, Elena			Mitochondrial dysfunction induced by a cytotoxic adenine dinucleotide produced by ADP-ribosyl cyclases from cADPR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; CALCIUM; IDENTIFICATION; REPERFUSION; ACTIVATION; APOPTOSIS; GRANULES; CHANNELS; RELEASE; CA2+	ADP-ribosyl cyclases were previously shown to produce three new adenine dinucleotides, P1,P2 diadenosine 5'-diphosphate (Ap2A) and two isomers thereof (P18 and P24), from cyclic ADP-ribose (cADPR) and adenine (Basile, G., TaglialatelaScafati, O., Damonte, G., Armirotti, A., Bruzzone, S., Guida, L., Franco, L., Usai, C., Fattorusso, E., De Flora, A., and Zocchi, E. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 14509-14514). The Ap2A isomer P24, containing an unusual C1'-N3 N-glycosidic bond, is shown here to affect mitochondrial function through (i) opening of the permeability transition pore complex (and consequent proton gradient dissipation) and (ii) inhibition of Complex I of the respiratory chain. Whereas proton gradient dissipation is dependent upon the extracellular Ca2+ influx triggered by P24, the effect on oxygen consumption is Ca2+ independent. The proton gradient dissipation induces apoptosis in HeLa cells and thus appears to be responsible for the already described potent cytotoxic effect of P24 on several human cell types. The other products of ADP-ribosyl cyclase activity, Ap2A and cADPR, antagonize P24-induced proton gradient dissipation and cytotoxicity, suggesting that the relative concentration of P24, cADPR, and Ap2A in cyclase-positive cells may affect the balance between cell life and death.	Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy; Univ Padua, Dept Biochem, I-35121 Padua, Italy	University of Genoa; University of Genoa; University of Padua	Zocchi, E (corresponding author), Univ Genoa, Dept Expt Med, Biochem Sect, Via Benedetto XV1, I-16132 Genoa, Italy.	ezocchi@unige.it	Millo, Enrico/K-3218-2018	Millo, Enrico/0000-0002-4019-0051; Di Lisa, Fabio/0000-0001-9757-8818				Almofti MR, 2003, J BIOCHEM, V134, P43, DOI 10.1093/jb/mvg111; Basile G, 2005, P NATL ACAD SCI USA, V102, P14509, DOI 10.1073/pnas.0503691102; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Carafoli E, 2005, FEBS J, V272, P1073, DOI 10.1111/j.1742-4658.2005.04546.x; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; DeFlora A, 1997, J BIOL CHEM, V272, P12945, DOI 10.1074/jbc.272.20.12945; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Di Lisa F, 2006, CARDIOVASC RES, V70, P191, DOI 10.1016/j.cardiores.2006.01.016; Gasser A, 2006, J BIOL CHEM, V281, P2489, DOI 10.1074/jbc.M506525200; Guse AH, 2005, FEBS J, V272, P4590, DOI 10.1111/j.1742-4658.2005.04863.x; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Heiner I, 2006, BIOCHEM J, V398, P225, DOI 10.1042/BJ20060183; Jankowski J, 2001, J BIOL CHEM, V276, P8904, DOI 10.1074/jbc.M009527200; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 2005, J BIOL CHEM, V280, P33693, DOI 10.1074/jbc.R500012200; LEE HC, 2002, CYCLIC ADP RIBOSE NA; Luo J, 1999, FASEB J, V13, P695, DOI 10.1096/fasebj.13.6.695; Malkevitch NV, 1997, FEBS LETT, V412, P173, DOI 10.1016/S0014-5793(97)00666-2; Masuda W, 1997, FEBS LETT, V405, P104, DOI 10.1016/S0014-5793(97)00168-3; ORMEROD MG, 1993, ACTA ONCOL, V32, P417, DOI 10.3109/02841869309093620; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Podesta M, 2005, J BIOL CHEM, V280, P5343, DOI 10.1074/jbc.M408085200; Rossi L, 1998, AIDS RES HUM RETROV, V14, P435, DOI 10.1089/aid.1998.14.435; RYFFEL B, 1991, J RECEPTOR RES, V11, P675, DOI 10.3109/10799899109066435; Schuber F, 2004, CURR MOL MED, V4, P249, DOI 10.2174/1566524043360708; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Szabadkai G, 2003, J BIOL CHEM, V278, P15153, DOI 10.1074/jbc.M300180200; Walseth TF, 2005, P NATL ACAD SCI USA, V102, P14941, DOI 10.1073/pnas.0507258102; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126	35	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					5045	5052		10.1074/jbc.M609802200	http://dx.doi.org/10.1074/jbc.M609802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158448	hybrid			2022-12-25	WOS:000244482000087
J	Smallwood, PM; Williams, J; Xu, Q; Leahy, DJ; Nathans, J				Smallwood, Philip M.; Williams, John; Xu, Qiang; Leahy, Daniel J.; Nathans, Jeremy			Mutational analysis of Norrin-Frizzled4 recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL EXUDATIVE VITREORETINOPATHY; FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; HUMAN CHORIONIC-GONADOTROPIN; LIGAND-RECEPTOR INTERACTIONS; WNT SIGNALING PATHWAY; CRYSTAL-STRUCTURE; NORRIE-DISEASE; CELL-SURFACE; CYSTINE KNOT	Norrin and Frizzled4 (Fz4) function as a ligand-receptor pair to control vascular development in the retina and inner ear. In mice and humans, mutations in either of the corresponding genes lead to defects in vascular development. The present work is aimed at defining the sequence determinants of binding specificity between Norrin and the Fz4 amino-terminal ligand-binding domain (the "cysteine-rich domain" (CRD)). The principal conclusions are as follows: 1) Norrin binds to the Fz4 CRD and does not detectably bind to the 14 other mammalian Frizzled and secreted Frizzled-related protein CRDs; 2) Norrin and Xenopus Wnt8 recognize largely overlapping regions of the Fz4 CRD; 3) surface determinants on the Fz4 and Fz8 CRDs that allow Norrin to distinguish between these two CRDs reside within several small regions on one face of the CRD; 4) Norrin function depends critically on three pairs of cysteines that form the highly conserved trio of disulfide bonds shared among all cystine knot proteins, but the remaining two putative disulfide bonds are less important; 5) Norrin-CRD binding depends on a largely contiguous group of amino acids in the extended beta-sheet domain of Norrin that are predicted to face away from the interface between the two monomers in the Norrin homodimer; 6) Norrin-CRD binding is strongly modulated by interactions involving charged amino acid side chains; and 7) Norrin-CRD binding is enhanced similar to 10-fold by the addition of heparin. These observations are discussed in the context of Frizzled signaling and the structure and function of other cystine knot proteins.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Nathans, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 805 PCTB,725 N Wolfe St, Baltimore, MD 21205 USA.	jnathans@jhmi.edu		Nathans, Jeremy/0000-0001-8106-5460				Allendorph GP, 2006, P NATL ACAD SCI USA, V103, P7643, DOI 10.1073/pnas.0602558103; Belenkaya TY, 2004, CELL, V119, P231, DOI 10.1016/j.cell.2004.09.031; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BERGER W, 1992, NAT GENET, V1, P199, DOI 10.1038/ng0692-199; BERGER W, 2001, METABOLIC MOL BASES, P5977; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhanot P, 1999, DEVELOPMENT, V126, P4175; Binari RC, 1997, DEVELOPMENT, V124, P2623; Chang JHT, 1999, HUM MOL GENET, V8, P575, DOI 10.1093/hmg/8.4.575; Chen CM, 1999, DEVELOPMENT, V126, P5441; CHEN ZY, 1992, NAT GENET, V1, P204, DOI 10.1038/ng0692-204; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; FURUHASHI M, 1994, J BIOL CHEM, V269, P25543; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; Guo N, 2004, P NATL ACAD SCI USA, V101, P9277, DOI 10.1073/pnas.0402802101; Han C, 2005, DEVELOPMENT, V132, P667, DOI 10.1242/dev.01636; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Luhmann UFO, 2005, INVEST OPHTH VIS SCI, V46, P3372, DOI 10.1167/iovs.05-0174; Lyuksyutova AI, 2003, SCIENCE, V302, P1984, DOI 10.1126/science.1089610; McLellan JS, 2006, P NATL ACAD SCI USA, V103, P17208, DOI 10.1073/pnas.0606738103; MEINDL A, 1992, NAT GENET, V2, P139, DOI 10.1038/ng1092-139; MEITINGER T, 1993, NAT GENET, V5, P376, DOI 10.1038/ng1293-376; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; Mohammadi M, 2005, CURR OPIN STRUC BIOL, V15, P506, DOI 10.1016/j.sbi.2005.09.002; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Perez-Vilar J, 1997, J BIOL CHEM, V272, P33410, DOI 10.1074/jbc.272.52.33410; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; Potterton E, 2002, ACTA CRYSTALLOGR D, V58, P1955, DOI 10.1107/S0907444902015391; Povelones M, 2005, EMBO J, V24, P3493, DOI 10.1038/sj.emboj.7600817; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Rehm HL, 2002, J NEUROSCI, V22, P4286, DOI 10.1523/JNEUROSCI.22-11-04286.2002; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Richter M, 1998, INVEST OPHTH VIS SCI, V39, P2450; Rider CC, 2006, BIOCHEM SOC T, V34, P458, DOI 10.1042/BST0340458; Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957; Sato A, 1997, J BIOL CHEM, V272, P18098, DOI 10.1074/jbc.272.29.18098; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; Toomes C, 2004, AM J HUM GENET, V74, P721, DOI 10.1086/383202; Toomes C, 2004, INVEST OPHTH VIS SCI, V45, P2083, DOI 10.1167/iovs.03-1044; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Wang YS, 2002, J NEUROSCI, V22, P8563; Wu CH, 2002, J BIOL CHEM, V277, P41762, DOI 10.1074/jbc.M207850200; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	60	83	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4057	4068		10.1074/jbc.M609618200	http://dx.doi.org/10.1074/jbc.M609618200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158104	hybrid			2022-12-25	WOS:000244481900069
J	Ahmad, ST; Natochin, M; Artemyev, NO; O'Tousa, JE				Ahmad, Syed Tariq; Natochin, Michael; Artemyev, Nikolai O.; O'Tousa, Joseph E.			The Drosophila rhodopsin cytoplasmic tail domain is required for maintenance of rhabdomere structure	FASEB JOURNAL			English	Article						bovine rhodopsin; microvillus; retinal degeneration	RETINAL DEGENERATION; PHOTORECEPTOR CELLS; TERMINAL DOMAIN; PROTEIN; MEMBRANES; MUTANTS; GENE; MELANOGASTER; MATURATION; TRANSPORT	The ninaE-encoded Rh1 rhodopsin is the major light-sensitive pigment expressed in Drosophila R1-6 photoreceptor cells. Rh1 rhodopsin localizes to and is essential for the development and maintenance of the rhabdomere, the specialized membrane-rich organelle that serves as the site of phototransduction. We showed previously that the vertebrate bovine rhodopsin (Rho) is expressed and properly localized in Drosophila photoreceptor cells. Drosophila photoreceptors expressing only Rho have normal rhabdomere structure at young ages, but the rhabdomeres are not maintained and show extensive disorganization by 7-10 days of age. A series of Rho-Rh1 opsin chimeric rhodopsins were used to identify Rh1 domains required for maintenance of rhabdomeric structure. The results show that the Rh1 rhodopsin cytoplasmic tail domain, positioned to interact with cytoplasmic structural components, plays a major role in promoting rhabdomeric organization.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Notre Dame; University of Iowa	O'Tousa, JE (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.	jotousa@nd.edu		O'Tousa, Joseph/0000-0001-9754-6816; Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY12682, R01 EY010843, EY06808, R01 EY012682] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012682] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahmad ST, 2006, INVEST OPHTH VIS SCI, V47, P3722, DOI 10.1167/iovs.06-0281; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; Concepcion F, 2002, VISION RES, V42, P417, DOI 10.1016/S0042-6989(01)00195-X; Davies A, 2001, J MOL BIOL, V314, P455, DOI 10.1006/jmbi.2001.5167; FUKUDA MN, 1979, J BIOL CHEM, V254, P8201; Green ES, 2000, INVEST OPHTH VIS SCI, V41, P1546; Iakhine R, 2004, J NEUROSCI, V24, P2516, DOI 10.1523/JNEUROSCI.5426-03.2004; Katanosaka K, 1998, FEBS LETT, V424, P149, DOI 10.1016/S0014-5793(98)00160-4; Kumar JP, 1995, DEVELOPMENT, V121, P4359; Kurada P, 1998, VISUAL NEUROSCI, V15, P693, DOI 10.1017/S0952523898154093; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; MATSUMOTO H, 1987, P NATL ACAD SCI USA, V84, P985, DOI 10.1073/pnas.84.4.985; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; Nakagawa M, 1999, P NATL ACAD SCI USA, V96, P6189, DOI 10.1073/pnas.96.11.6189; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PAULSEN R, 1979, BIOCHIM BIOPHYS ACTA, V557, P385, DOI 10.1016/0005-2736(79)90336-5; PORTER JA, 1992, J CELL BIOL, V116, P683, DOI 10.1083/jcb.116.3.683; Seki T, 1998, EUR J BIOCHEM, V257, P522, DOI 10.1046/j.1432-1327.1998.2570522.x; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Sung CH, 2000, INT REV CYTOL, V195, P215; Tam BM, 2000, J CELL BIOL, V151, P1369, DOI 10.1083/jcb.151.7.1369; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; VENIENBRYAN C, 1995, FEBS LETT, V359, P45, DOI 10.1016/0014-5793(94)01449-B; WASHBURN T, 1989, J BIOL CHEM, V264, P15464; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	27	8	40	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					449	455		10.1096/fj.06-6530com	http://dx.doi.org/10.1096/fj.06-6530com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158966				2022-12-25	WOS:000244686300018
J	Donn, R; Berry, A; Stevens, A; Farrow, S; Betts, J; Stevens, R; Clayton, C; Wang, JX; Warnock, L; Worthington, J; Scott, L; Graham, S; Ray, D				Donn, Rachelle; Berry, Andy; Stevens, Adam; Farrow, Stuart; Betts, Joanna; Stevens, Richard; Clayton, Chris; Wang, Jixian; Warnock, Linda; Worthington, Jane; Scott, Laurie; Graham, Simon; Ray, David			Use of gene expression profiling to identify a novel glucocorticoid sensitivity determining gene, BMPRII	FASEB JOURNAL			English	Article						network; signaling; microarray; dexamethasone	NF-KAPPA-B; RECEPTOR GENE; RESISTANT ASTHMA; DOCKING PROTEIN; IN-VIVO; CELLS; MECHANISMS; DIFFERENTIATION; RECRUITMENT; MUTATIONS	Wide variation in glucocorticoid (Gc) sensitivity exists between individuals which may influence susceptibility to, and treatment response of, inflammatory diseases. To determine a genetic fingerprint of Gc sensitivity 100 healthy human volunteers were polarized into the 10% most Gc-sensitive and 10% most Gc-resistant following a low dose dexamethasone (0.25mg) suppression test. Gene expression profiling of primary lymphocytes identified the 98 most significantly Gc regulated genes. These genes were used to build a subnetwork of Gc signaling, with 54 genes mapping as nodes, and 6 non-Gc regulated genes inferred as signaling nodes. Twenty four of the 98 genes showed a difference in Gc response in vitro dependent on the Gc sensitivity of their donor individuals in vivo. A predictive model was built using both partial least squares discriminate analysis and support vector machines that predicted donor glucocorticoid sensitivity with 87% accuracy. Discriminating genes included bone morphogenetic protein receptor, type II (BMPRII). Transfection studies showed that BMPRII modulated Gc action. These studies reveal a broad base of gene expression that predicts Gc sensitivity and determine a Gc signaling network in human primary T lymphocytes. Furthermore, this combined gene profiling, and functional analysis approach has identified BMPRII as a modulator of Gc signaling.	Univ Manchester, Ctr Mol Med, Fac Med, Manchester M13 9PT, Lancs, England; Univ Manchester, Arthrit Res Campaign Epidemiol Unit, Manchester M13 9PT, Lancs, England; GlaxoSmithKline Res & Dev Ltd, Stevenage, Herts, England	University of Manchester; University of Manchester; GlaxoSmithKline	Ray, D (corresponding author), Univ Manchester, Ctr Mol Med, Fac Med, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	david.w.ray@manchester.ac.uk	Stevens, Adam/AAB-6301-2020; Worthington, Jane/M-9770-2014; Stevens, Adam/D-6476-2012	Stevens, Adam/0000-0002-1950-7325; Worthington, Jane/0000-0003-0544-042X; Stevens, Adam/0000-0002-1950-7325; Donn, Rachelle/0000-0001-6976-9828; Ray, David/0000-0002-4739-6773				ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; Aligianis IA, 2005, NAT GENET, V37, P221, DOI 10.1038/ng1517; Ambroise C, 2002, P NATL ACAD SCI USA, V99, P6562, DOI 10.1073/pnas.102102699; Boden SD, 1996, ENDOCRINOLOGY, V137, P3401, DOI 10.1210/en.137.8.3401; Boden SD, 1997, ENDOCRINOLOGY, V138, P2820, DOI 10.1210/en.138.7.2820; Breiman L, 1996, MACH LEARN, V24, P123, DOI 10.1007/bf00058655; Crown A, 2005, CLIN ENDOCRINOL, V63, P483, DOI 10.1111/j.1365-2265.2005.02320.x; Falkenauer E., 1997, GENETIC ALGORITHMS G; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; Garside H, 2004, J BIOL CHEM, V279, P50050, DOI 10.1074/jbc.M407309200; Guyon I, 2002, MACH LEARN, V46, P389, DOI 10.1023/A:1012487302797; Hakonarson H, 2005, P NATL ACAD SCI USA, V102, P14789, DOI 10.1073/pnas.0409904102; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; Huizenga NATM, 2000, J CLIN ENDOCR METAB, V85, P2076, DOI 10.1210/jc.85.5.2076; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kano Y, 2005, ENDOCRINOLOGY, V146, P5332, DOI 10.1210/en.2005-0474; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Kino T, 2001, J ENDOCRINOL, V169, P437, DOI 10.1677/joe.0.1690437; Kolchanov NA, 2002, NUCLEIC ACIDS RES, V30, P312, DOI 10.1093/nar/30.1.312; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Lane SJ, 1998, J CLIN INVEST, V102, P2156, DOI 10.1172/JCI2680; Law SF, 1996, MOL CELL BIOL, V16, P3327; Leung DYM, 1998, ANN NY ACAD SCI, V840, P735, DOI 10.1111/j.1749-6632.1998.tb09612.x; Lu NZ, 2004, ANN NY ACAD SCI, V1024, P102, DOI 10.1196/annals.1321.008; Luecke HF, 2005, GENE DEV, V19, P1116, DOI 10.1101/gad.1297105; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Matthews JG, 2004, J ALLERGY CLIN IMMUN, V113, P1100, DOI 10.1016/j.jaci.2004.03.018; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Rajagopalan D, 2005, BIOINFORMATICS, V21, P788, DOI 10.1093/bioinformatics/bti069; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Rogatsky I, 2003, P NATL ACAD SCI USA, V100, P13845, DOI 10.1073/pnas.2336092100; Schaaf MJM, 2002, J STEROID BIOCHEM, V83, P37, DOI 10.1016/S0960-0760(02)00263-7; Seckl JR, 2004, ANN NY ACAD SCI, V1032, P63, DOI 10.1196/annals.1314.006; Sierra DA, 2002, GENOMICS, V79, P177, DOI 10.1006/geno.2002.6693; Smoak KA, 2004, MECH AGEING DEV, V125, P697, DOI 10.1016/j.mad.2004.06.010; Stevens A, 2004, CLIN ENDOCRINOL, V61, P327, DOI 10.1111/j.1365-2265.2004.02097.x; Stevens A, 2004, J CLIN ENDOCR METAB, V89, P892, DOI 10.1210/jc.2003-031235; Stevens A, 2003, MOL ENDOCRINOL, V17, P845, DOI 10.1210/me.2002-0320; van Rossum EFC, 2002, DIABETES, V51, P3128, DOI 10.2337/diabetes.51.10.3128; van Rossum EFC, 2005, TRENDS ENDOCRIN MET, V16, P445, DOI 10.1016/j.tem.2005.10.009; van Rossum EFC, 2003, CLIN ENDOCRINOL, V59, P585, DOI 10.1046/j.1365-2265.2003.01888.x; Vapnik V., 1998, STAT LEARNING THEORY; Wang JC, 2006, GENE DEV, V20, P689, DOI 10.1101/gad.1400506; Wang JC, 2004, P NATL ACAD SCI USA, V101, P15603, DOI 10.1073/pnas.0407008101; Waters CE, 2004, J ENDOCRINOL, V183, P375, DOI 10.1677/joe.1.05804; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759	47	59	60	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					402	414		10.1096/fj.06-7236com	http://dx.doi.org/10.1096/fj.06-7236com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17185747				2022-12-25	WOS:000244686300014
J	Taniguchi, F; Couse, JF; Rodriguez, KF; Emmen, JMA; Poirier, D; Korach, KS				Taniguchi, Fuminori; Couse, John F.; Rodriguez, Karina F.; Emmen, Judith M. A.; Poirier, Donald; Korach, Kenneth S.			Estrogen receptor-alpha mediates an intraovarian negative feedback loop on thecal cell steroidogenesis via modulation of Cyp17a1 (cytochrome P450, steroid 17 alpha-hydroxylase/17,20 lyase) expression	FASEB JOURNAL			English	Article						hydroxysteroid (17 beta) dehydrogenase; hyperandrogenemia; folliculogenesis; aromatase	POLYCYSTIC-OVARY-SYNDROME; ANDROGEN PRODUCTION; 17-BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE-1; TESTOSTERONE PRODUCTION; AUTOREGULATORY PROCESS; LUTEINIZING-HORMONE; SEX REVERSAL; MOUSE; FOLLICLES; ENZYMES	Excess androgen synthesis by thecal cells is invariably detrimental to preovulatory follicles in the ovary and is considered a fundamental characteristic of polycystic ovary syndrome in women. Investigators have long postulated that granulosa cell-derived estrogens modulate thecal cell steroidogenesis via a short negative-feedback loop within the follicle. To test this hypothesis, we assessed the steroidogenic capacity of individual wild-type (WT) and estrogen receptor-alpha (ER alpha-)-null follicles when cultured in vitro under comparable conditions. Late-stage ER alpha-null follicles exhibited markedly increased expression of the thecal cell enzyme CYP17A1 and secreted much greater amounts of its end product, androstenedione. This phenotype was reproduced in WT follicles when exposed to an aromatase inhibitor or ER-antagonist, and prevented when the former treatment was supplemented with an ER alpha-specific agonist. ER alpha-null follicles also exhibited increased testosterone synthesis due to ectopic expression of hydroxysteroid (17 beta) dehydrogenase type 3 (HSD17B3), a testis-specific androgenic enzyme. These data indicate that ER alpha functions within thecal cells to negatively modulate the capacity for androgen synthesis by repressing Cyp17a1 expression, and the biological activity of androgens produced by inhibiting Hsd17b3 expression. Hence, these findings provide novel evidence of an intraovarian ER alpha function that may be critical to the latter stages of folliculogenesis and overall ovarian function.	NIEHS, Reprod & Dev Toxicol Lab, Receptor Biol Sect, NIH, Res Triangle Pk, NC 27709 USA; Tottori Univ Hosp, Dept Obstet & Gynecol, Yonago, Tottori, Japan; CHUQ, Oncol & Mol Endocrinol Res Ctr, Div Med Chem, Quebec City, PQ, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Tottori University; Laval University	Korach, KS (corresponding author), NIEHS, Reprod & Dev Toxicol Lab, Receptor Biol Sect, NIH, MD B3-02,POB 12233, Res Triangle Pk, NC 27709 USA.	korach@nichs.nih.gov		Korach, Kenneth/0000-0002-7765-418X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES070065, ZIAES070065] Funding Source: NIH RePORTER; Intramural NIH HHS [NIH0010047172] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Akingbemi BT, 2003, ENDOCRINOLOGY, V144, P84, DOI 10.1210/en.2002-220292; Azziz R, 2003, FERTIL STERIL, V80, P252, DOI 10.1016/S0015-0282(03)00735-0; BANKS PK, 1991, ENDOCRINOLOGY, V129, P1295, DOI 10.1210/endo-129-3-1295; Chaturvedi G, 2004, ENDOCRINE, V25, P147, DOI 10.1385/ENDO:25:2:147; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; Couse JF, 2003, MOL ENDOCRINOL, V17, P1039, DOI 10.1210/me.2002-0398; Couse JF, 2004, ENDOCRINOLOGY, V145, P4693, DOI 10.1210/en.2004-0548; Couse JF, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P593; Couse JF, 2006, ENDOCRINOLOGY, V147, P3666, DOI 10.1210/en.2006-0276; EHRMANN DA, 1995, ENDOCR REV, V16, P322, DOI 10.1210/er.16.3.322; Emmen JMA, 2005, ENDOCRINOLOGY, V146, P2817, DOI 10.1210/en.2004-1108; ERICKSON GF, 1985, ENDOCR REV, V6, P371, DOI 10.1210/edrv-6-3-371; EVANS G, 1981, BIOL REPROD, V25, P290, DOI 10.1095/biolreprod25.2.290; Gore-Langton Robert E., 1994, P571; Govoroun M, 2001, ENDOCRINOLOGY, V142, P1841, DOI 10.1210/en.142.5.1841; Greenwald Gilbert S., 1994, P629; Heikkila M, 2005, ENDOCRINOLOGY, V146, P4016, DOI 10.1210/en.2005-0463; HERNANDEZ ER, 1990, ENDOCRINOLOGY, V127, P2804, DOI 10.1210/endo-127-6-2804; Jakimiuk AJ, 2002, J CLIN ENDOCR METAB, V87, P5532, DOI 10.1210/jc.2002-020323; JOHNSON DC, 1984, MOL CELL ENDOCRINOL, V35, P199, DOI 10.1016/0303-7207(84)90017-0; Kobayashi S, 2004, J MOL ENDOCRINOL, V32, P69, DOI 10.1677/jme.0.0320069; LEUNG PCK, 1980, ANNU REV PHYSIOL, V42, P71, DOI 10.1146/annurev.ph.42.030180.000443; Liakos P, 2003, J ENDOCRINOL, V176, P69, DOI 10.1677/joe.0.1760069; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MAGOFFIN DA, 1982, MOL CELL ENDOCRINOL, V28, P81, DOI 10.1016/0303-7207(82)90042-9; MAGOFFIN DA, 1991, SEMIN REPROD ENDOCR, V9, P321, DOI 10.1055/s-2007-1019424; MAGOFFIN DA, 1981, ENDOCRINOLOGY, V108, P962, DOI 10.1210/endo-108-3-962; MAGOFFIN DA, 1995, BIOL REPROD, V53, P627, DOI 10.1095/biolreprod53.3.627; Mellgren G, 2003, MOL CELL ENDOCRINOL, V203, P91, DOI 10.1016/S0303-7207(03)00097-2; NAYUDU PL, 1992, J REPROD FERTIL, V95, P349, DOI 10.1530/jrf.0.0950349; Nelson VL, 1999, MOL ENDOCRINOL, V13, P946, DOI 10.1210/me.13.6.946; Nelson-Degrave VL, 2005, MOL ENDOCRINOL, V19, P379, DOI 10.1210/me.2004-0178; Ngatcha BT, 2005, J MED CHEM, V48, P5257, DOI 10.1021/jm058179h; Nokelainen P, 1996, EUR J BIOCHEM, V236, P482, DOI 10.1111/j.1432-1033.1996.00482.x; PAYNE AH, 1995, BIOL REPROD, V52, P217, DOI 10.1095/biolreprod52.2.217; Payne AH, 2004, ENDOCR REV, V25, P947, DOI 10.1210/er.2003-0030; Pencharz RI, 1940, SCIENCE, V91, P554, DOI 10.1126/science.91.2371.554; Penning TM, 1997, ENDOCR REV, V18, P281, DOI 10.1210/er.18.3.281; PERRIN A, 1991, ENDOCRINOLOGY, V128, P357, DOI 10.1210/endo-128-1-357; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Puranen T, 1997, ENDOCRINOLOGY, V138, P3532, DOI 10.1210/en.138.8.3532; Recanatini M, 2001, J MED CHEM, V44, P672, DOI 10.1021/jm000955s; Sakaue M, 2002, J VET MED SCI, V64, P107, DOI 10.1292/jvms.64.107; SIMONE DA, 1993, BIOL REPROD, V48, P46, DOI 10.1095/biolreprod48.1.46; SIMONE DA, 1993, BIOL REPROD, V49, P1190, DOI 10.1095/biolreprod49.6.1190; WELSH TH, 1984, CANCER RES, V44, P885; Wickenheisser JK, 2005, J CLIN ENDOCR METAB, V90, P1720, DOI 10.1210/jc.2004-1860; Wickenheisser JK, 2004, MOL ENDOCRINOL, V18, P588, DOI 10.1210/me.2003-0090; Wickenheisser JK, 2000, J CLIN ENDOCR METAB, V85, P2304, DOI 10.1210/jc.85.6.2304; Williams PC, 1940, NATURE, V145, P388, DOI 10.1038/145388c0; Zofkova I, 2002, STEROIDS, V67, P815, DOI 10.1016/S0039-128X(02)00034-X	51	52	57	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					586	595		10.1096/fj.06-6681com	http://dx.doi.org/10.1096/fj.06-6681com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158782	Green Accepted			2022-12-25	WOS:000244686300031
J	Al-Ani, B; Hewett, PW; Ahmed, S; Cudmore, M; Fujisawa, T; Ahmad, S; Ahmed, A				Al-Ani, Bahjat; Hewett, Peter W.; Ahmed, Suborna; Cudmore, Melissa; Fujisawa, Takeshi; Ahmad, Shakil; Ahmed, Asif			The Release of Nitric Oxide from S-Nitrosothiols Promotes Angiogenesis	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VITAMIN-C; ASCORBIC-ACID; RELAXING FACTOR; CELL APOPTOSIS; NITROSYLATION; SYNTHASE; VASCULATURE; DYSFUNCTION; ACTIVATION	Background. Free nitric oxide (NO) reacts with sulphydryl residues to form S-nitrosothiols, which act as NO reservoirs. We sought to determine whether thiol-preserving agents and antioxidants, such as dithiothreitol (DTT) and vitamin C, induce NO release from S-nitrosylated proteins in endothelial cell cultures to promote angiogenesis. Methodology/Principal Findings. NO release was measured directly in cell supernatants using a Sievers NO Analyser, and in vitro angiogenesis was assessed by quantifying capillary-like tube network formation of porcine aortic endothelial cells (PAEC) on growth factor-reduced Matrigel. Incubation of PAEC with DTT or vitamin C significantly increased NO release in a concentration-dependent manner. However, the nitric oxide synthase (NOS) inhibitors, L-NNA and L-NIO, had no effect on DTT- or vitamin C-induced NO release, and there was no concomitant increase in the phosphorylation of endothelial NOS at serine-1177 following DTT or vitamin C treatment. DTT and vitamin C increased capillary-like tube network formation by nine-and two-fold, respectively, and the addition of copper ions doubled the effect of vitamin C. Surprisingly, DTT maintained endothelial tube networks for up to one month under serum-free conditions, and selective inhibitors of guanylyl cyclase (ODQ) and PKG (KT-5823) blocked this, demonstrating the requirement of cyclic GMP and PKG in this process. Conclusions/Significance. Both DTT and vitamin C are capable of releasing sufficient NO from S-nitrosothiols to induce capillary morphogenesis. This study provides the first evidence that increased denitrosylation leads to increased bioavailability of NO, independent of NOS activity, to promote sustained angiogenesis.	[Al-Ani, Bahjat; Hewett, Peter W.; Ahmed, Suborna; Cudmore, Melissa; Fujisawa, Takeshi; Ahmad, Shakil; Ahmed, Asif] Univ Birmingham, Sch Med, Inst Biomed Res, Dept Reprod & Vasc Biol,Ctr Cardiovasc Sci, Birmingham, W Midlands, England; [Ahmed, Asif] Birmingham Womens Hosp NHS Trust, Birmingham, W Midlands, England	University of Birmingham; Birmingham Women's Hospital	Ahmed, A (corresponding author), Univ Birmingham, Sch Med, Inst Biomed Res, Dept Reprod & Vasc Biol,Ctr Cardiovasc Sci, Birmingham, W Midlands, England.	a.s.ahmed@bham.ac.uk	Fujisawa, Takeshi/F-9451-2010; Ahmed, Asif/ABE-9544-2020; Ahmed, Asif/A-7268-2010; Ahmad, Shakil/A-9421-2008; Cudmore, Melissa/B-5714-2008	Ahmed, Asif/0000-0002-8755-8546; Ahmad, Shakil/0000-0002-9294-0475; Goswami, Kaushal/0000-0002-7052-4358	British Heart Foundation; European Vascular Genomics Network; European Community [LSHM-CT-2003-503254]; MRC [G0600270] Funding Source: UKRI; Medical Research Council [G0600270] Funding Source: researchfish	British Heart Foundation(British Heart Foundation); European Vascular Genomics Network; European Community(European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by grants from the British Heart Foundation and the European Vascular Genomics Network, a network of excellence supported by the European Community's Sixth Framework Programme for Research Priority 1 "Life Sciences, Genomics and Biotechnology for Health'' (contractLSHM-CT-2003-503254).	Ahmed A, 1997, LAB INVEST, V76, P779; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; Ashino Hiromi, 2003, Angiogenesis, V6, P259, DOI 10.1023/B:AGEN.0000029390.09354.f8; Babaei S, 2003, AM J PATHOL, V162, P1927, DOI 10.1016/S0002-9440(10)64326-X; Bates CJ, 1998, J HYPERTENS, V16, P925, DOI 10.1097/00004872-199816070-00005; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Chen X, 2001, HYPERTENSION, V38, P606, DOI 10.1161/hy09t1.094005; D'Alessio M, 2003, ANN NY ACAD SCI, V1010, P449, DOI 10.1196/annals.1299.082; Dicks AP, 1996, CHEM BIOL, V3, P655, DOI 10.1016/S1074-5521(96)90133-7; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 2000, REGUL PEPTIDES, V90, P19, DOI 10.1016/S0167-0115(00)00105-1; Duvall WL, 2005, MT SINAI J MED, V72, P71; Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007; Foster D C, 1999, Rev Physiol Biochem Pharmacol, V135, P1, DOI 10.1007/BFb0033668; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Gandley RE, 2005, HYPERTENSION, V45, P21, DOI 10.1161/01.HYP.0000150158.42620.3e; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GHIGO D, 1993, AM J PHYSIOL, V265, pC728, DOI 10.1152/ajpcell.1993.265.3.C728; Gokce N, 1999, CIRCULATION, V99, P3234, DOI 10.1161/01.CIR.99.25.3234; Harrison D, 2003, AM J CARDIOL, V91, p7A; Hasnain BI, 2004, CLEV CLIN J MED, V71, P327, DOI 10.3949/ccjm.71.4.327; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Huang AN, 2001, AM J PHYSIOL-CELL PH, V281, pC719, DOI 10.1152/ajpcell.2001.281.2.C719; Jernigan NL, 2004, AM J PHYSIOL-LUNG C, V286, pL947, DOI 10.1152/ajplung.00215.2003; Ji YB, 1999, ARCH BIOCHEM BIOPHYS, V362, P67, DOI 10.1006/abbi.1998.1013; KashibaIwatsuki M, 1997, J BIOCHEM-TOKYO, V122, P1208; KEANEY JF, 1993, J CLIN INVEST, V91, P1582, DOI 10.1172/JCI116364; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; Khan BV, 1996, P NATL ACAD SCI USA, V93, P9114, DOI 10.1073/pnas.93.17.9114; Khaw KT, 2001, LANCET, V357, P657, DOI 10.1016/S0140-6736(00)04128-3; Laursen JB, 2001, FREE RADICAL RES, V35, P387, DOI 10.1080/10715760100300901; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Liuzzi F, 2003, ANN NY ACAD SCI, V1010, P441, DOI 10.1196/annals.1299.080; Massy ZA, 2004, J AM SOC NEPHROL, V15, P470, DOI 10.1097/01.ASN.0000106716.22153.BB; Matsumoto T, 2003, J PHARMACOL EXP THER, V306, P103, DOI 10.1124/jpet.103.049163; May JM, 2005, ARCH BIOCHEM BIOPHYS, V434, P178, DOI 10.1016/j.abb.2004.10.023; Moncada S, 1997, ANN NY ACAD SCI, V811, P60, DOI 10.1111/j.1749-6632.1997.tb51989.x; Moulton K S, 2001, Curr Atheroscler Rep, V3, P225, DOI 10.1007/s11883-001-0065-0; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; Naseem Khalid M., 2005, Molecular Aspects of Medicine, V26, P33, DOI 10.1016/j.mam.2004.09.003; Ness A R, 1996, J Cardiovasc Risk, V3, P373; Ness AR, 1996, J HYPERTENS, V14, P503; NUNES GL, 1995, ARTERIOSCL THROM VAS, V15, P156, DOI 10.1161/01.ATV.15.1.156; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; RAM FS, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000993.PUB2; Rossig L, 2001, CIRCULATION, V104, P2182, DOI 10.1161/hc4301.098284; Sato J, 2000, CARDIOVASC RES, V47, P697, DOI 10.1016/S0008-6363(00)00137-1; Sephel GC, 1996, MATRIX BIOL, V15, P263, DOI 10.1016/S0945-053X(96)90117-1; Sessa WC, 2004, J CELL SCI, V117, P2427, DOI 10.1242/jcs.01165; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Taniyama Y, 2003, HYPERTENSION, V42, P1075, DOI 10.1161/01.HYP.0000100443.09293.4F; Tsuboi H, 2004, J CELL BIOCHEM, V93, P162, DOI 10.1002/jcb.20134; WEDGWOOD S, 2005, AM J PHYSL LUNG CELL; Yang Y, 2005, P NATL ACAD SCI USA, V102, P117, DOI 10.1073/pnas.0405989102	57	26	26	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e25	10.1371/journal.pone.0000025	http://dx.doi.org/10.1371/journal.pone.0000025			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183652	gold, Green Published, Green Accepted			2022-12-25	WOS:000207443600025
J	Harris, JA; Arabzadeh, E; Fairhall, AL; Benito, C; Diamond, ME				Harris, Justin A.; Arabzadeh, Ehsan; Fairhall, Adrienne L.; Benito, Claire; Diamond, Mathew E.			Factors Affecting Frequency Discrimination of Vibrotactile Stimuli: Implications for Cortical Encoding	PLOS ONE			English	Article								Background. Measuring perceptual judgments about stimuli while manipulating their physical characteristics can uncover the neural algorithms underlying sensory processing. We carried out psychophysical experiments to examine how humans discriminate vibrotactile stimuli. Methodology/Principal Findings. Subjects compared the frequencies of two sinusoidal vibrations applied sequentially to one fingertip. Performance was reduced when (1) the root mean square velocity (or energy) of the vibrations was equated by adjusting their amplitudes, and (2) the vibrations were noisy (their temporal structure was irregular). These effects were super-additive when subjects compared noisy vibrations that had equal velocity, indicating that frequency judgments became more dependent on the vibrations' temporal structure when differential information about velocity was eliminated. To investigate which areas of the somatosensory system use information about velocity and temporal structure, we required subjects to compare vibrations applied sequentially to opposite hands. This paradigm exploits the fact that tactile input to neurons at early levels (e.g., the primary somatosensory cortex, SI) is largely confined to the contralateral side of the body, so these neurons are less able to contribute to vibration comparisons between hands. The subjects' performance was still sensitive to differences in vibration velocity, but became less sensitive to noise. Conclusions/Significance. We conclude that vibration frequency is represented in different ways by different mechanisms distributed across multiple cortical regions. Which mechanisms support the "readout'' of frequency varies according to the information present in the vibration. Overall, the present findings are consistent with a model in which information about vibration velocity is coded in regions beyond SI. While adaptive processes within SI also contribute to the representation of frequency, this adaptation is influenced by the temporal regularity of the vibration.	[Harris, Justin A.; Arabzadeh, Ehsan; Benito, Claire] Univ Sydney, Sch Psychol, Sydney, NSW 2006, Australia; [Fairhall, Adrienne L.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; [Diamond, Mathew E.] Scuola Int Super Studi Avanzati, Cognit Neurosci Sector, Trieste, Italy	University of Sydney; University of Washington; University of Washington Seattle; International School for Advanced Studies (SISSA)	Harris, JA (corresponding author), Univ Sydney, Sch Psychol, Sydney, NSW 2006, Australia.	justinh@psych.usyd.edu.au		Arabzadeh, Ehsan/0000-0001-9632-0735; Harris, Justin/0000-0003-3865-8097; DIAMOND, Mathew Ernest/0000-0003-2286-4566	Australian Research Council [DP0343552, DP0663086]; Telethon Foundation [GGP02459]; James S. McDonnell Foundation; Italian Institute of Technology; Human Frontiers Science Program [RG0043/2004-C]; Burroughs-Wellcome Careers at the Scientific Interface	Australian Research Council(Australian Research Council); Telethon Foundation(Fondazione Telethon); James S. McDonnell Foundation; Italian Institute of Technology(Istituto Italiano di Tecnologia - IIT); Human Frontiers Science Program(Human Frontier Science Program); Burroughs-Wellcome Careers at the Scientific Interface(Burroughs Wellcome Fund)	This work was supported by grants from the Australian Research Council (grants DP0343552 and DP0663086), the Telethon Foundation (grant GGP02459), the James S. McDonnell Foundation, the Italian Institute of Technology, the Human Frontiers Science Program (a postdoctoral fellowship to E. A., and grant RG0043/2004-C), and a Burroughs-Wellcome Careers at the Scientific Interface grant.	Arabzadeh E, 2004, J NEUROSCI, V24, P6011, DOI 10.1523/JNEUROSCI.1389-04.2004; Arabzadeh E, 2003, J NEUROSCI, V23, P9146; Burton H, 1999, CEREB CORTEX, V9, P662, DOI 10.1093/cercor/9.7.662; Fairhall AL, 2001, NATURE, V412, P787, DOI 10.1038/35090500; GOFF GD, 1967, J EXP PSYCHOL, V74, P294, DOI 10.1037/h0024561; Harris JA, 2002, J NEUROSCI, V22, P8720; Harris JA, 2001, J NEUROSCI, V21, P8262, DOI 10.1523/JNEUROSCI.21-20-08262.2001; HARRIS JA, 2006, PERCEPT DECISION ACT, P238; HEGNER YL, J NEUROPHYS IN PRESS, DOI DOI 10.1152/JN.00617.02006; Hernandez A, 1997, J NEUROSCI, V17, P6391; Hernandez A, 2000, P NATL ACAD SCI USA, V97, P6191, DOI 10.1073/pnas.120018597; Hlushchuk Y, 2006, J NEUROSCI, V26, P5819, DOI 10.1523/JNEUROSCI.5536-05.2006; IWAMURA Y, 1993, EXP BRAIN RES, V92, P360; Kontsevich LL, 1999, VISION RES, V39, P2729, DOI 10.1016/S0042-6989(98)00285-5; LAK A, RETUNING NEURO UNPUB; LAMOTTE RH, 1975, J NEUROPHYSIOL, V38, P539, DOI 10.1152/jn.1975.38.3.539; Lipton ML, 2006, J NEUROSCI, V26, P180, DOI 10.1523/JNEUROSCI.1073-05.2006; Luna R, 2005, NAT NEUROSCI, V8, P1210, DOI 10.1038/nn1513; MERZENICH MM, 1978, J COMP NEUROL, V181, P41, DOI 10.1002/cne.901810104; MOUNTCAS.VB, 1967, SCIENCE, V155, P597, DOI 10.1126/science.155.3762.597; MOUNTCASTLE VB, 1969, J NEUROPHYSIOL, V32, P452, DOI 10.1152/jn.1969.32.3.452; MOUNTCASTLE VB, 1990, J NEUROSCI, V10, P3032; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; Roder B, 2002, EXP BRAIN RES, V143, P453, DOI 10.1007/s00221-002-1019-7; Romo R, 2003, NAT REV NEUROSCI, V4, P203, DOI 10.1038/nrn1058; Romo R, 1998, NATURE, V392, P387, DOI 10.1038/32891; Romo R, 2001, ANNU REV NEUROSCI, V24, P107, DOI 10.1146/annurev.neuro.24.1.107; Romo R, 2002, NAT NEUROSCI, V5, P1217, DOI 10.1038/nn950; Salinas E, 2000, J NEUROSCI, V20, P5503, DOI 10.1523/JNEUROSCI.20-14-05503.2000; Shoham D, 2001, J NEUROSCI, V21, P6820, DOI 10.1523/JNEUROSCI.21-17-06820.2001; Tassinari G, 1996, NEUROPSYCHOLOGIA, V34, P235, DOI 10.1016/0028-3932(95)00085-2; THORSON J, 1974, SCIENCE, V183, P161, DOI 10.1126/science.183.4121.161; Tommerdahl M, 2006, J NEUROSCI, V26, P5970, DOI 10.1523/JNEUROSCI.5270-05.2006	34	33	33	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e100	10.1371/journal.pone.0000100	http://dx.doi.org/10.1371/journal.pone.0000100			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183633	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443600099
J	Khanna, R; Li, Q; Stanley, EF				Khanna, Rajesh; Li, Qi; Stanley, Elise F.			'Fractional Recovery' Analysis of a Presynaptic Synaptotagmin 1-Anchored Endocytic Protein Complex	PLOS ONE			English	Article								Background. The integral synaptic vesicle protein and putative calcium sensor, synaptotagmin 1 (STG), has also been implicated in synaptic vesicle (SV) recovery. However, proteins with which STG interacts during SV endocytosis remain poorly understood. We have isolated an STG-associated endocytic complex (SAE) from presynaptic nerve terminals and have used a novel fractional recovery (FR) assay based on electrostatic dissociation to identify SAE components and map the complex structure. The location of SAE in the presynaptic terminal was determined by high-resolution quantitative immunocytochemistry at the chick ciliary ganglion giant calyx-type synapse. Methodology/Principle Findings. The first step in FR analysis was to immunoprecipitate (IP) the complex with an antibody against one protein component (the IP-protein). The immobilized complex was then exposed to a high salt (1150 mM) stress-test that caused shedding of co-immunoprecipitated proteins (coIP-proteins). A Fractional Recovery ratio (FR: recovery after high salt/recovery with control salt as assayed by Western blot) was calculated for each co-IP-protein. These FR values reflect complex structure since an easily dissociated protein, with a low FR value, cannot be intermediary between the IP-protein and a salt-resistant protein. The structure of the complex was mapped and a blueprint generated with a pair of FR analyses generated using two different IP-proteins. The blueprint of SAE contains an AP180/X/STG/stonin 2/intersectin/epsin core (X is unknown and epsin is hypothesized), and an AP2 adaptor, H-/L-clathrin coat and dynamin scission protein perimeter. Quantitative immunocytochemistry (ICA/ICQ method) at an isolated calyx-type presynaptic terminal indicates that this complex is associated with STG at the presynaptic transmitter release face but not with STG on intracellular synaptic vesicles. Conclusions/Significance. We hypothesize that the SAE serves as a recognition site and also as a seed complex for clathrin-mediated synaptic vesicle recovery. The combination of FR analysis with quantitative immunocytochemistry provides a novel and effective strategy for the identification and characterization of biologically-relevant multi-molecular complexes.	[Khanna, Rajesh; Li, Qi; Stanley, Elise F.] Univ Hlth Network, Toronto Western Res Inst, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Stanley, EF (corresponding author), Univ Hlth Network, Toronto Western Res Inst, Toronto, ON, Canada.	estanley@uhnres.utoronto.ca		Khanna, Rajesh/0000-0002-9066-2969	CIHR [MOP57716]; Canada Research Chair; Tanenbaum chair	CIHR(Canadian Institutes of Health Research (CIHR)); Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); Tanenbaum chair	CIHR MOP57716, Canada Research Chair, Tanenbaum chair ( all to EFS). No other support, all experiments were carried out independently in the laboratory.	Augustine GJ, 2006, BIOCHEM SOC T, V34, P68, DOI 10.1042/BST0340068; Blondeau F, 2004, P NATL ACAD SCI USA, V101, P3833, DOI 10.1073/pnas.0308186101; Diril MK, 2006, DEV CELL, V10, P233, DOI 10.1016/j.devcel.2005.12.011; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Fernandez-Alfonso T, 2006, NEURON, V51, P179, DOI 10.1016/j.neuron.2006.06.008; Gentile L, 2005, EUR J NEUROSCI, V21, P278, DOI 10.1111/j.1460-9568.2004.03841.x; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; KEEN JH, 1987, J BIOL CHEM, V262, P3864; Kelly LE, 2005, BIOCHEM J, V388, P195, DOI 10.1042/BJ20041797; KHANNA R, 2006, NEUROSCIENCE; Koh TW, 2004, NEURON, V43, P193, DOI 10.1016/j.neuron.2004.06.029; Lafer EM, 2002, TRAFFIC, V3, P513, DOI 10.1034/j.1600-0854.2002.30801.x; Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; Marie B, 2004, NEURON, V43, P207, DOI 10.1016/j.neuron.2004.07.001; Martina JA, 2001, J CELL BIOL, V153, P1111, DOI 10.1083/jcb.153.5.1111; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; Mirotznik RR, 2000, J NEUROSCI, V20, P7614; Montesinos ML, 2005, BRAIN RES REV, V49, P416, DOI 10.1016/j.brainresrev.2005.06.002; Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000; Murthy VN, 2003, ANNU REV NEUROSCI, V26, P701, DOI 10.1146/annurev.neuro.26.041002.131445; Nicholson-Tomishima K, 2004, P NATL ACAD SCI USA, V101, P16648, DOI 10.1073/pnas.0406968101; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; Poskanzer KE, 2006, NEURON, V50, P49, DOI 10.1016/j.neuron.2006.02.021; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; STANLEY EF, 1991, J NEUROSCI, V11, P985; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; STANLEY EF, 1991, NEURON, V7, P585, DOI 10.1016/0896-6273(91)90371-6; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; Walther K, 2004, P NATL ACAD SCI USA, V101, P964, DOI 10.1073/pnas.0307862100; Walther K, 2001, EMBO REP, V2, P634, DOI 10.1093/embo-reports/kve134; Wienisch M, 2006, NAT NEUROSCI, V9, P1019, DOI 10.1038/nn1739; Willig KI, 2006, NATURE, V440, P935, DOI 10.1038/nature04592; Xiong X, 2006, BIOCHEM BIOPH RES CO, V347, P76, DOI 10.1016/j.bbrc.2006.06.045; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Yao PJ, 2005, J COMP NEUROL, V481, P58, DOI 10.1002/cne.20362; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	40	12	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e67	10.1371/journal.pone.0000067	http://dx.doi.org/10.1371/journal.pone.0000067			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183698	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600067
J	Sano, Y; Nakaya, T; Pedrini, S; Takeda, S; Iijima-Ando, K; Iijima, K; Mathews, PM; Itohara, S; Gandy, S; Suzuki, T				Sano, Yoshitake; Nakaya, Tadashi; Pedrini, Steve; Takeda, Shizu; Iijima-Ando, Kanae; Iijima, Koichi; Mathews, Paul M.; Itohara, Shigeyoshi; Gandy, Sam; Suzuki, Toshiharu			Physiological Mouse Brain A beta Levels Are Not Related to the Phosphorylation State of Threonine-668 of Alzheimer's APP	PLOS ONE			English	Article							AMYLOID PRECURSOR PROTEIN; CYTOPLASMIC DOMAIN; DISEASE; FE65; CLEAVAGE; SITE	Background. Amyloid-beta peptide species ending at positions 40 and 42 (A beta 40, A beta 42) are generated by the proteolytic processing of the Alzheimer's amyloid precursor protein (APP). A beta peptides accumulate in the brain early in the course of Alzheimer's disease (AD), especially A beta 42. The cytoplasmic domain of APP regulates intracellular trafficking and metabolism of APP and its carboxyl-terminal fragments (CTF alpha, CTF beta). The role of protein phosphorylation in general, and that of the phosphorylation state of APP at threonine-668 (Thr(668)) in particular, has been investigated in detail by several laboratories (including our own). Some investigators have recently proposed that the phosphorylation state of Thr(668) plays a pivotal role in governing brain A beta levels, prompting the current study. Methodology. In order to evaluate whether the phosphorylation state of Thr(668) controlled brain A beta levels, we studied the levels and subcellular distributions of holoAPP, sAPP alpha, sAPP beta, CTF alpha, CTF beta, A beta 40 and A beta 42 in brains from "knock-in'' mice in which a non-phosphorylatable alanyl residue had been substituted at position 668, replacing the threonyl residue present in the wild-type protein. Conclusions. The levels and subcellular distributions of holoAPP, sAPP alpha, sAPP beta, CTF alpha, CTF beta, A beta 40 and A beta 42 in the brains of Thr(668)Ala mutant mice were identical to those observed in wild-type mice. These results indicate that, despite speculation to the contrary, the phosphorylation state of APP at Thr(668) does not play an obvious role in governing the physiological levels of brain A beta 40 or A beta 42 in vivo.	[Pedrini, Steve; Iijima-Ando, Kanae; Iijima, Koichi; Gandy, Sam] Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA 19107 USA; [Sano, Yoshitake; Takeda, Shizu; Itohara, Shigeyoshi] RIKEN, Brain Sci Inst, Wako, Saitama, Japan; [Nakaya, Tadashi; Suzuki, Toshiharu] Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Sapporo, Hokkaido, Japan; [Iijima-Ando, Kanae; Iijima, Koichi] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Mathews, Paul M.] Nathan S Kline Inst Psychiat Res, Dementia Res Program, Orangeburg, NY 10962 USA	Jefferson University; RIKEN; Hokkaido University; Cold Spring Harbor Laboratory; Nathan Kline Institute for Psychiatric Research	Gandy, S (corresponding author), Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA 19107 USA.	samgandy@earthlink.net; tsuzuki@pharm.hokudai.ac.jp	Itohara, Shigeyoshi/I-8769-2012; Suzuki, Toshiharu/B-5342-2013	Itohara, Shigeyoshi/0000-0002-2410-9989; Mathews, Paul/0000-0003-1742-7687; Pedrini, Steve/0000-0002-6409-8022; Sano, Yoshitake/0000-0001-5188-3104	Ministry of Education, Science, Culture, Sports, Science, and Technology, Japan [17790046, 16029002, 17025002]; The Mitsubishi Foundation; USPHS [AG010491, AG023611, NS41017, NS45357]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS045357, R01NS041017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010491, R01AG023611] Funding Source: NIH RePORTER	Ministry of Education, Science, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); The Mitsubishi Foundation; USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the Ministry of Education, Science, Culture, Sports, Science, and Technology, Japan ( T. S., T. N.) including 17790046, 16029002, and 17025002, by a grant from The Mitsubishi Foundation ( T. S.), and by the USPHS ( S. G., P. M., S. P.), including AG010491, AG023611, and NS41017, and NS45357.	Akiyama H, 2005, BIOCHEM BIOPH RES CO, V336, P521, DOI 10.1016/j.bbrc.2005.08.130; Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Ando K, 1999, J NEUROSCI, V19, P4421; Aplin AE, 1996, J NEUROCHEM, V67, P699; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cruz JC, 2006, J NEUROSCI, V26, P10536, DOI 10.1523/JNEUROSCI.3133-06.2006; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; KAWASE E, 1994, INT J DEV BIOL, V38, P385; Kimberly WT, 2005, J NEUROSCI, V25, P5533, DOI 10.1523/JNEUROSCI.4883-04.2005; Lee MS, 2003, J CELL BIOL, V163, P83, DOI 10.1083/jcb.200301115; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Liu KN, 2002, BIOCHEMISTRY-US, V41, P3128, DOI 10.1021/bi015800g; Maudsley S, 2006, NAT MED, V12, P392, DOI 10.1038/nm0406-392; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Nakaya T, 2006, GENES CELLS, V11, P633, DOI 10.1111/j.1365-2443.2006.00968.x; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Pastorino L, 2006, NATURE, V440, P528, DOI 10.1038/nature04543; Ramelot TA, 2001, J MOL BIOL, V307, P871, DOI 10.1006/jmbi.2001.4535; Ramelot TA, 2000, BIOCHEMISTRY-US, V39, P2714, DOI 10.1021/bi992580m; SCHMIDT S, METHODS MOL BIOL, V299, P267; Seabrook GR, 1999, NEUROPHARMACOLOGY, V38, P349, DOI 10.1016/S0028-3908(98)00204-4; SILVER LM, MOUSE GENETICS CONCE; Small SA, 2006, NEURON, V52, P15, DOI 10.1016/j.neuron.2006.09.001; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; Sunaga S, 1997, MOL REPROD DEV, V46, P109, DOI 10.1002/(SICI)1098-2795(199702)46:2&lt;109::AID-MRD1&gt;3.0.CO;2-U; Suzuki T, 2006, J BIOCHEM, V139, P949, DOI 10.1093/jb/mvj121; Taru H, 2004, J BIOL CHEM, V279, P21628, DOI 10.1074/jbc.M312007200; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; Vingtdeux V, 2005, NEUROBIOL DIS, V20, P625, DOI 10.1016/j.nbd.2005.05.004; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	36	51	52	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e51	10.1371/journal.pone.0000051	http://dx.doi.org/10.1371/journal.pone.0000051			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183681	Green Submitted, gold, Green Published			2022-12-25	WOS:000207443600051
J	Rothhammer, T; Bataille, F; Spruss, T; Eissner, G; Bosserhoff, AK				Rothhammer, T.; Bataille, F.; Spruss, T.; Eissner, G.; Bosserhoff, A-K			Functional implication of BMP4 expression on angiogenesis in malignant melanoma	ONCOGENE			English	Article						malignant melanoma; endothelium; migration; invasion; angiogenesis	BONE MORPHOGENETIC PROTEIN-2; VASCULOGENIC MIMICRY; TUMOR ANGIOGENESIS; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; GENE-THERAPY; ID PROTEINS; IN-VITRO; GROWTH; CANCER	Analyses of malignant melanomas revealed a strong expression of bone morphogenic proteins (BMPs) and their autocrine effect in promoting cell invasion and migration. Here, we report a paracrine effect of BMPs on the vascular network. Both BMP2 and BMP4 induced tube formation as well as the migratory efficiency of microvascular endothelial cells. Melanoma cells with reduced BMP activity attracted less endothelial cells in invasion assays than control cells. Furthermore, reduction of BMPs in melanoma cells had a strong effect on vasculogenic mimicry. Tube formation on matrigel was analysed for melanoma cells as well as in co-cultures of endothelial and melanoma cells. Melanoma cells with reduced BMP activity were not capable of forming cordlike structures by themselves and additionally inhibited tube formation of the endothelial cells. Genes involved in angiogenesis turned out to be strongly downregulated in these cell clones. Tumors derived from cells with impaired BMP activity showed reduced tumor growth or large necrotic areas owing to lack of angiogenesis in in vivo analyses.	Univ Regensburg, Univ Hosp, Inst Pathol & Mol Pathol, D-93053 Regensburg, Germany; Univ Regensburg, Inst Pharm, D-93053 Regensburg, Germany; Univ Regensburg, Univ Hosp, Dept Hematol & Oncol, D-93053 Regensburg, Germany	University of Regensburg; University of Regensburg; University of Regensburg	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Alani RM, 2004, CANCER BIOL THER, V3, P498, DOI 10.4161/cbt.3.6.930; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Benezra R, 2001, TRENDS CARDIOVAS MED, V11, P237, DOI 10.1016/S1050-1738(01)00117-7; Botchkarev VA, 2004, DIFFERENTIATION, V72, P512, DOI 10.1111/j.1432-0436.2004.07209005.x; Cavallaro U, 2000, J NEURO-ONCOL, V50, P63, DOI 10.1023/A:1006414621286; Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545; Ding Z, 2005, LYMPHOLOGY, V38, P87; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; Folberg R, 2004, APMIS, V112, P508, DOI 10.1111/j.1600-0463.2004.apm11207-0810.x; Hatakeyama S, 1997, BIOCHEM MOL BIOL INT, V42, P497; HATAKEYAMA S, 1993, BIOCHEM BIOPH RES CO, V190, P695, DOI 10.1006/bbrc.1993.1105; Hendrix MJC, 2003, ONCOGENE, V22, P3070, DOI 10.1038/sj.onc.1206447; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Ide H, 1997, CANCER RES, V57, P5022; Jones N, 2000, CANCER METAST REV, V19, P13, DOI 10.1023/A:1026555121511; Kiyozuka Y, 2001, ANTICANCER RES, V21, P1723; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; McDonald DM, 2000, CANCER METAST REV, V19, P109, DOI 10.1023/A:1026529222845; McDonald DM, 2000, AM J PATHOL, V156, P383, DOI 10.1016/S0002-9440(10)64740-2; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Pache G, 2006, AM J PHYSIOL-RENAL, V291, pF654, DOI 10.1152/ajprenal.00214.2004; Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708; Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153; Peters KG, 2004, RECENT PROG HORM RES, V59, P51, DOI 10.1210/rp.59.1.51; Raida M, 2005, J CANCER RES CLIN, V131, P741, DOI 10.1007/s00432-005-0024-1; Rothhammer T, 2005, CANCER RES, V65, P448; Saalbach A, 2005, ONCOGENE, V24, P4710, DOI 10.1038/sj.onc.1208559; Seftor EA, 2002, CRIT REV ONCOL HEMAT, V44, P17, DOI 10.1016/S1040-8428(01)00199-8; Straume O, 2005, BRIT J CANCER, V93, P933, DOI 10.1038/sj.bjc.6602792; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Turgeman G, 2001, J GENE MED, V3, P240; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46; Vogt RR, 2006, J CELL BIOCHEM, V98, P1196, DOI 10.1002/jcb.20831; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; Ward NL, 2002, SEMIN CELL DEV BIOL, V13, P19, DOI 10.1006/scdb.2001.0288; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yamamoto Y, 2004, NATURWISSENSCHAFTEN, V91, P519, DOI 10.1007/s00114-004-0575-z	44	132	138	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4158	4170		10.1038/sj.onc.1210182	http://dx.doi.org/10.1038/sj.onc.1210182			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17173062				2022-12-25	WOS:000247252700011
J	Detarsio, E; Alvarez, CE; Saigo, M; Andreo, CS; Drincovich, MF				Detarsio, Enrique; Alvarez, Clarisa E.; Saigo, Mariana; Andreo, Carlos S.; Drincovich, Maria F.			Identification of domains involved in tetramerization and malate inhibition of maize C-4-NADP-malic enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADP-MALIC ENZYME; C4 PHOSPHOENOLPYRUVATE CARBOXYLASE; OXIDATIVE DECARBOXYLASES; SUBSTRATE-INHIBITION; PIGEON LIVER; FLAVERIA; SITES; BINDING; MECHANISM; EVOLUTION	C-4 photosynthetic NADP-malic enzyme (ME) has evolved from non-C-4 isoforms and gained unique kinetic and structural properties during this process. To identify the domains responsible for the structural and kinetic differences between maize C4 and non-C-4-NADP-ME several chimeras between these isoforms were constructed and analyzed. By using this approach, we found that the region flanked by amino acid residues 102 and 247 is critical for the tetrameric state of C-4-NADP-ME. In this way, the oligomerization strategy of these NADP-ME isoforms differs markedly from the one that present non-plant NADP-ME with known crystal structures. On the other hand, the region from residue 248 to the C-terminal end of the C-4 isoform is involved in the inhibition by high malate concentrations at pH 7.0. The inhibition pattern of the C-4-NADP-ME and some of the chimeras suggested an allosteric site responsible for such behavior. This pH-dependent inhibition could be important for regulation of the C-4 isoform in vivo, with the enzyme presenting maximum activity while photosynthesis is in progress.	Univ Nacl Rosario, Ctr Estudios Fotosintet & Bioquim, RA-2000 Rosario, Argentina	National University of Rosario	Andreo, CS (corresponding author), Univ Nacl Rosario, Ctr Estudios Fotosintet & Bioquim, Suipacha 531, RA-2000 Rosario, Argentina.	candreo@fbioyf.unr.edu.ar	Drincovich, Maria F/Q-4195-2019; Drincovich, Maria F/F-3902-2017	Drincovich, Maria F/0000-0003-4897-3285; Drincovich, Maria F/0000-0003-4897-3285; Saigo, Mariana/0000-0002-2312-8782				Ashton AR, 1997, ARCH BIOCHEM BIOPHYS, V345, P251, DOI 10.1006/abbi.1997.0260; Chang GG, 2003, BIOCHEMISTRY-US, V42, P12721, DOI 10.1021/bi035251+; Chang HC, 2003, J BIOL CHEM, V278, P23996, DOI 10.1074/jbc.M213242200; Detarsio E, 2003, J BIOL CHEM, V278, P13757, DOI 10.1074/jbc.M212530200; Dixon M., 1979, ENZYMES, Vthird; DRINCOVICH MF, 1991, PHYSIOL PLANTARUM, V81, P462; Drincovich MF, 2001, FEBS LETT, V490, P1, DOI 10.1016/S0014-5793(00)02331-0; EDWARDS GE, 1992, PHYTOCHEMISTRY, V31, P1845, DOI 10.1016/0031-9422(92)80322-6; Fridlyand LE, 1998, ARCH BIOCHEM BIOPHYS, V349, P290, DOI 10.1006/abbi.1997.0482; HSU RY, 1980, BIOCHEMISTRY-US, V19, P962, DOI 10.1021/bi00546a021; Hsu WC, 2004, BIOCHEMISTRY-US, V43, P7382, DOI 10.1021/bi049600r; Hung HC, 2005, BIOCHEM J, V392, P39, DOI 10.1042/BJ20050641; IGLESIAS AA, 1990, PLANT PHYSIOL, V92, P66, DOI 10.1104/pp.92.1.66; Karsten WE, 2003, BIOCHEMISTRY-US, V42, P9712, DOI 10.1021/bi034101w; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai LB, 2002, PLANT PHYSIOL, V128, P140, DOI 10.1104/pp.010449; Lai LB, 2002, PLANT PHYSIOL, V128, P125, DOI 10.1104/pp.010448; Lara MV, 2006, PLANT PHYSIOL, V142, P673, DOI 10.1104/pp.106.085829; Maurino VG, 2001, PLANT MOL BIOL, V45, P409, DOI 10.1023/A:1010665910095; PRY TA, 1980, BIOCHEMISTRY-US, V19, P951, DOI 10.1021/bi00546a020; REYNOLDS CH, 1978, ARCH BIOCHEM BIOPHYS, V189, P309, DOI 10.1016/0003-9861(78)90217-5; Saigo M, 2004, PLANT MOL BIOL, V55, P97, DOI 10.1007/s11103-004-0472-z; Svensson P, 2003, ARCH BIOCHEM BIOPHYS, V414, P180, DOI 10.1016/S0003-9861(03)00165-6; Tausta SL, 2002, PLANT MOL BIOL, V50, P635, DOI 10.1023/A:1019998905615; Westhoff P, 2004, ANN BOT-LONDON, V93, P13, DOI 10.1093/aob/mch003; Wheeler MCG, 2005, PLANT PHYSIOL, V139, P39, DOI 10.1104/pp.105.065953; Xu YW, 1999, STRUCT FOLD DES, V7, P877, DOI 10.1016/S0969-2126(99)80115-4; Yang ZR, 2002, PROTEIN SCI, V11, P332, DOI 10.1110/ps.38002; Yang ZR, 2002, STRUCTURE, V10, P951, DOI 10.1016/S0969-2126(02)00788-8	29	24	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6053	6060		10.1074/jbc.M609436200	http://dx.doi.org/10.1074/jbc.M609436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17150960	hybrid			2022-12-25	WOS:000244867200010
J	Carnevale, R; Pignatelli, P; Lenti, L; Buchetti, B; Sanguigni, V; Di Santo, S; Violi, F				Carnevale, R.; Pignatelli, P.; Lenti, L.; Buchetti, B.; Sanguigni, V.; Di Santo, S.; Violi, F.			LDL are oxidatively modified by platelets via GP91(phox) and accumulate in human monocytes	FASEB JOURNAL			English	Article						X-linked chronic granulomatous disease; ROS; gp91phox activation	LOW-DENSITY-LIPOPROTEIN; CHRONIC GRANULOMATOUS-DISEASE; SMOOTH-MUSCLE CELLS; CHOLESTERYL ESTERS; ENDOTHELIAL-CELLS; SUPEROXIDE ANION; DEGRADATION; MACROPHAGES; ACTIVATION; CLEAVAGE	Oxidative stress-mediated LDL modification has a key role in initiation of the atherosclerotic process. Platelets produce reactive oxidant species (ROS) upon stimulation with agonist, but it is uncertain whether they are able to oxidatively modify LDL. Human platelets taken from healthy subjects were incubated with LDL, then stimulated with collagen. Compared with unstimulated platelets, collagen-stimulated platelets induced LDL modification as shown by enhanced conjugated dienes and lysophosphatidylcholine formation, electrophoretic mobility, Apo B-100 degradation, and monocyte LDL uptake. Activated platelets also induced a marked reduction of vitamin E contained in LDL. A significant inhibition of LDL oxidation was observed in platelets treated with arachidonyl trifluomethyl ketone (AACOCF3), an inhibitor of phospolipase A2. The experiments reported above were also conducted in patients with hereditary deficiency of gp91phox, the central core of NADPH oxidase, and in patients with hypercholesterolemia. Platelets from gp91 phox-deficient patients produced a small amount of ROS and weakly modified LDL. Conversely, platelets from hypercholesterolemic patients showed enhanced ROS formation and oxidized LDL more than platelets from healthy subjects. This study provides evidence that platelets modify LDL via NADPH oxidase-mediated oxidative stress, a phenomenon that could be dependent on arachidonic acid activation. This finding suggests a role for platelets in favoring LDL accumulation within atherosclerotic plaque.	Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Policlin Umberto, I-00185 Rome, Italy; Univ Roma Tor Vergata, Dept Internal Med, Rome, Italy	Sapienza University Rome; University Hospital Sapienza Rome; University of Rome Tor Vergata	Violi, F (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Policlin Umberto, I-00185 Rome, Italy.	francesco.violi@uniroma1.it	Carnevale, Roberto/K-1472-2016; Sanguigni, Valerio/AAH-2515-2020; Violi, Francesco/K-1509-2016; pignatelli, pasquale/K-2116-2016	Carnevale, Roberto/0000-0002-6216-9595; Violi, Francesco/0000-0002-6610-7068; pignatelli, pasquale/0000-0002-2265-7455				Aust O, 2001, J CHROMATOGR A, V936, P83, DOI 10.1016/S0021-9673(01)01269-9; Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P7; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; Burger PC, 2003, BLOOD, V101, P2661, DOI 10.1182/blood-2002-07-2209; ESTERBAUER H, 1987, J LIPID RES, V28, P495; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; FOLCH J, 1957, J BIOL CHEM, V226, P497; FONG LG, 1987, J LIPID RES, V28, P1466; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810; JULIANO L, 2000, CIRCULATION, V101, P1249; Krotz F, 2002, BLOOD, V100, P917, DOI 10.1182/blood.V100.3.917; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leo R, 1997, CIRCULATION, V95, P885; MARCUS AJ, 1977, J CLIN INVEST, V59, P149, DOI 10.1172/JCI108613; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; NOBLE RP, 1968, J LIPID RES, V9, P693; Pignatelli P, 1998, BLOOD, V91, P484, DOI 10.1182/blood.V91.2.484.484_484_490; Pignatelli P, 2004, CIRCULATION, V110, P1326, DOI 10.1161/01.CIR.0000134963.77201.55; PIGNATELLI P, 2002, AM J PHYSIOL-HEART C, V284, P41; PUHL H, 1994, METHOD ENZYMOL, V233, P425; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Rae J, 1998, AM J HUM GENET, V62, P1320, DOI 10.1086/301874; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; SKIPSKI VP, 1957, METHOD ENZYMOL, V35, P395; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Wagner DD, 2003, ARTERIOSCL THROM VAS, V23, P2131, DOI 10.1161/01.ATV.0000095974.95122.EC; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200	32	49	51	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					927	934		10.1096/fj.06-6908com	http://dx.doi.org/10.1096/fj.06-6908com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17194695				2022-12-25	WOS:000244686400029
J	Fitzpatrick, JM; Hirai, Y; Hirai, H; Hoffmann, KF				Fitzpatrick, Jennifer M.; Hirai, Yuriko; Hirai, Hirohisa; Hoffmann, Karl F.			Schistosome egg production is dependent upon the activities of two developmentally regulated tyrosinases	FASEB JOURNAL			English	Article						helminth; schistosoma; kojic acid; developmental regulation	EGGSHELL FORMATION; PHENOL OXIDASE; GENE-EXPRESSION; REPRODUCTIVE-SYSTEM; CRYSTAL-STRUCTURE; CATECHOL OXIDASE; MANSONI; PRAZIQUANTEL; JAPONICUM; INFECTIONS	Egg production is responsible for life cycle progression and host immunopathology during schistosomiasis, with the associated parasite molecules being investigated as potential novel chemotherapeutic targets. Here, we characterize two Schistosoma mansoni products, tyrosinase I and tyrosinase 2 (SmTYR1/SmTYR2) and show that their diphenol oxidase enzyme activities are critical for eggshell formation and production. The genes encoding these bifunctional enzymes (monophenol and diphenol oxidases) result from a duplication event that likely occurred before speciation and exist in the parasite's genome as multiple copies, which are linked and localized to chromosomes 4 and W. SmTYR1/SmTYR2 transcription and diphenol oxidase action are developmentally regulated with most enzyme activity localized to the eggshell-producing cells contained within the vitellaria of adult female worms. Importantly, kojic-acid mediated inhibition (IC50=0.5 mu M) of SmTYR1/SmTYR2's diphenol oxidase activity during in vitro culture of sexually mature adult worms resulted in a significant decrease in the production of phenotypically normal eggs. Therefore our data suggest that SmTYR1/2 inhibition represents a novel and potentially effective strategy for combating schistosomiasis and furthermore, it may point to new methods for combinatorial control of immunopathology and egg transmission during platyhelminth infection.	Univ Cambridge, Dept Pathol, Cambridge CB1 1QP, England; Kyoto Univ, Primate Res Inst, Inuyama, Aichi 484, Japan	University of Cambridge; Kyoto University	Hoffmann, KF (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB1 1QP, England.	kfh24@cam.ac.uk		Hoffmann, Karl/0000-0002-3932-5502	Wellcome Trust [RG35177] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alverson J, 2003, J INVERTEBR PATHOL, V83, P60, DOI 10.1016/S0022-2011(03)00040-5; Bergquist NR, 1998, PARASITOL TODAY, V14, P99, DOI 10.1016/S0169-4758(97)01207-6; Boonanuntanasarn S, 2004, PIGM CELL RES, V17, P413, DOI 10.1111/j.1600-0749.2004.00166.x; Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334; Cioli D, 2003, PARASITOL RES, V90, pS3, DOI 10.1007/s00436-002-0751-z; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Colhoun LM, 1998, PARASITOLOGY, V116, P555, DOI 10.1017/S0031182098002662; Doenhoff MJ, 2002, T ROY SOC TROP MED H, V96, P465, DOI 10.1016/S0035-9203(02)90405-0; Ebersberger I, 2005, DEV GENES EVOL, V215, P261, DOI 10.1007/s00427-005-0467-z; ERASMUS DA, 1973, PARASITOLOGY, V67, P165, DOI 10.1017/S0031182000046394; ESHETE F, 1993, J PARASITOL, V79, P309, DOI 10.2307/3283563; Fitzpatrick JM, 2006, INT J PARASITOL, V36, P1081, DOI 10.1016/j.ijpara.2006.06.007; Fitzpatrick JM, 2005, MOL BIOCHEM PARASIT, V141, P1, DOI 10.1016/j.molbiopara.2005.01.007; Fitzpatrick JM, 2004, MOL BIOCHEM PARASIT, V136, P191, DOI 10.1016/j.molbiopara.2004.03.014; Garcia-Borron JC, 2002, PIGM CELL RES, V15, P162, DOI 10.1034/j.1600-0749.2002.02012.x; GAYKEMA WPJ, 1986, J MOL BIOL, V187, P255, DOI 10.1016/0022-2836(86)90233-0; Greenberg RM, 2005, INT J PARASITOL, V35, P1, DOI 10.1016/j.ijpara.2004.09.004; Hagan P, 2004, TRENDS PARASITOL, V20, P92, DOI 10.1016/j.pt.2003.11.010; Hill DE, 1997, J PARASITOL, V83, P938, DOI 10.2307/3284293; HIRAI H, 1995, PARASITOL TODAY, V11, P310, DOI 10.1016/0169-4758(95)80048-4; Hoffmann KF, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-8-research0041; Hoffmann KF, 2002, ADV PARASIT, V52, P265, DOI 10.1016/S0065-308X(02)52014-5; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Kabatereine NB, 1999, PARASITOLOGY, V118, P101, DOI 10.1017/S0031182098003576; Kim YJ, 2005, BIOL PHARM BULL, V28, P323, DOI 10.1248/bpb.28.323; King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4; Klabunde T, 1998, NAT STRUCT BIOL, V5, P1084, DOI 10.1038/4193; Lei TC, 2002, ANAL BIOCHEM, V305, P260, DOI 10.1006/abio.2002.5665; Neves R, 2005, PARASITOL RES, V95, P43, DOI 10.1007/s00436-004-1241-2; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Olds GR, 1996, AM J TROP MED HYG, V55, P121; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; Ribeiro-dos-Santos G, 2006, PARASITOL RES, V99, P505, DOI 10.1007/s00436-006-0175-2; RIBEIROPAES JT, 1995, COMP BIOCHEM PHYS B, V111, P69, DOI 10.1016/0305-0491(94)00231-I; Sambrook J., 2002, MOL CLONING LAB MANU; SEED JL, 1980, EXP PARASITOL, V50, P33, DOI 10.1016/0014-4894(80)90005-3; SEED JL, 1980, EXP PARASITOL, V49, P430, DOI 10.1016/0014-4894(80)90077-6; SEED JL, 1978, J PARASITOL, V64, P283, DOI 10.2307/3279674; SHAW MK, 1987, J HELMINTHOL, V61, P253, DOI 10.1017/S0022149X00010117; SMYTH J. D., 1959, EXPTL PARASITOL, V8, P286, DOI 10.1016/0014-4894(59)90027-X; STURROCK RF, 1966, T ROY SOC TROP MED H, V60, P139, DOI 10.1016/0035-9203(66)90214-8; WANG FL, 1986, MOL BIOCHEM PARASIT, V18, P69, DOI 10.1016/0166-6851(86)90051-4; WELLS KE, 1991, EXP PARASITOL, V73, P295, DOI 10.1016/0014-4894(91)90101-2; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x	47	56	59	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					823	835		10.1096/fj.06-7314com	http://dx.doi.org/10.1096/fj.06-7314com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17167065				2022-12-25	WOS:000244686400020
J	Nakajima, T; Hayashi, K; Viswanathan, PC; Kim, MY; Anghelescu, M; Barksdale, KA; Shuai, W; Balser, JR; Kupershmidt, S				Nakajima, Tadashi; Hayashi, Kenshi; Viswanathan, Prakash C.; Kim, Min-Young; Anghelescu, Mircea; Barksdale, Kate A.; Shuai, Wen; Balser, Jeffrey R.; Kupershmidt, Sabina			HERG is protected from pharmacological block by alpha-1,2-glucosyltransferase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; DEFECTIVE PROTEIN TRAFFICKING; LIPID-LINKED OLIGOSACCHARIDE; POTASSIUM CHANNEL; ENDOPLASMIC-RETICULUM; CARDIAC-ARRHYTHMIA; I-KS; EXPRESSION; GLYCOSYLATION; RECTIFIER	The HERG (human ether-A-go-go-related gene) protein, which underlies the cardiac repolarizing current I-Kr is the unintended target for many pharmaceutical agents. Inadvertent block Of IKr, known as the acquired long QT syndrome (aLQTS), is a leading cause for drug withdrawal by the United States Food and Drug Administration. Hence, an improved understanding of the regulatory factors that protect most individuals from aLQTS is essential for advancing clinical therapeutics in broad areas, from cancer chemotherapy to antipsychotics and antidepressants. Here, we show that the K+ channel regulatory protein KCR1, which markedly reduces I,,, drug sensitivity, protects HERG through glucosyltransferase function. KCR1 and the yeast alpha-1,2-glucosyltransferaseALG10 exhibit sequence homology, and like KCR1, ALG10 diminished HERG block by dofetilide. Inhibition of cellular glycosylation pathways with tunicamycin abrogated the effects of KCR1 as did expression in Lec1 cells (deficient in glycosylation). Moreover, KCR1 complemented the growth defect of an alg10-deficient yeast strain and enhanced glycosylation of an Alg10 substrate in yeast. HERG itself is not the target for KCR1-mediated glycosylation because the dofetilide response of glycosylation-deficient HERG(N598Q) was still modulated by KCR1. Nonetheless, our data indicate that the alpha-1,2-glucosyltransferase function is a key component of the molecular pathway whereby KCR1 diminishes I,, drug response. Incorporation of in vitro data into a computational model indicated that KCR1 expression is protective against arrhythmias. These findings reveal a potential new avenue for targeted prevention of aLQTS.	Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Univ Pittsburgh, Cardiovasc Res Inst, Pittsburgh, PA 15213 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kupershmidt, S (corresponding author), Vanderbilt Univ, Sch Med, Dept Anesthesiol, 2220 Pierce Ave,554 Preston Res Bldg, Nashville, TN 37232 USA.	sabina.kupershmidt@vanderbilt.edu	Kupershmidt, Sabina/AAO-5464-2021	Kupershmidt, Sabina/0000-0002-8119-2723	NHLBI NIH HHS [HL69914, P01 PPG HL46681] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069914, P01HL046681] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Aerssens J, 2005, PHARMACOGENOMICS, V6, P259, DOI 10.1517/14622416.6.3.259; Burda P, 1998, GLYCOBIOLOGY, V8, P455, DOI 10.1093/glycob/8.5.455; Burda P, 1996, P NATL ACAD SCI USA, V93, P7160, DOI 10.1073/pnas.93.14.7160; Chen HJ, 2003, NEURON, V40, P15, DOI 10.1016/S0896-6273(03)00570-1; Chiang Chern-En, 2004, Cardiol Rev, V12, P222, DOI 10.1097/01.crd.0000123842.42287.cf; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Delisle BP, 2004, CIRC RES, V94, P1418, DOI 10.1161/01.RES.0000128561.28701.ea; Delisle BP, 2003, J BIOL CHEM, V278, P35749, DOI 10.1074/jbc.M305787200; Ficker E, 2003, CIRC RES, V92, pE87, DOI 10.1161/01.RES.0000079028.31393.15; Ficker E, 2000, J MOL CELL CARDIOL, V32, P2327, DOI 10.1006/jmcc.2000.1263; Ficker E, 2000, AM J PHYSIOL-HEART C, V279, pH1748, DOI 10.1152/ajpheart.2000.279.4.H1748; Gong QM, 2002, AM J PHYSIOL-HEART C, V283, pH77, DOI 10.1152/ajpheart.00008.2002; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hoshi N, 1998, J BIOL CHEM, V273, P23080, DOI 10.1074/jbc.273.36.23080; Jiang M, 2004, CIRCULATION, V109, P1783, DOI 10.1161/01.CIR.0000124225.43852.50; Kubota T, 2001, J CARDIOVASC ELECTR, V12, P1223, DOI 10.1046/j.1540-8167.2001.01223.x; Kupershmidt S, 2003, FASEB J, V17, P2263, DOI 10.1096/fj.02-1057fje; Kupershmidt S, 2002, CARDIOVASC RES, V56, P93, DOI 10.1016/S0008-6363(02)00498-4; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; Lundquist Andrew L, 2005, J Mol Cell Cardiol, V38, P277, DOI 10.1016/j.yjmcc.2004.11.012; LUO CH, 1994, CIRC RES, V74, P1071, DOI 10.1161/01.RES.74.6.1071; Mitcheson JS, 2000, J GEN PHYSIOL, V115, P229, DOI 10.1085/jgp.115.3.229; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Noble D, 2002, SCIENCE, V295, P1678, DOI 10.1126/science.1069881; Park KH, 2003, FASEB J, V17, DOI 10.1096/fj.03-0577fje; Paulussen ADC, 2004, J MOL MED, V82, P182, DOI 10.1007/s00109-003-0522-z; Petersen CI, 2004, P NATL ACAD SCI USA, V101, P11773, DOI 10.1073/pnas.0306005101; Priori SG, 1999, CIRCULATION, V99, P529, DOI 10.1161/01.CIR.99.4.529; Rajamani S, 2002, CIRCULATION, V105, P2830, DOI 10.1161/01.CIR.0000019513.50928.74; Roden DM, 2005, J CLIN INVEST, V115, P2025, DOI 10.1172/JCI25539; Roden DM, 2004, NEW ENGL J MED, V350, P1013, DOI 10.1056/NEJMra032426; Roti ECR, 2002, J BIOL CHEM, V277, P47779, DOI 10.1074/jbc.M206638200; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Schulze-Bahr E, 2001, EUR HEART J SUPPL, V3, pK48, DOI 10.1016/S1520-765X(01)90006-9; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Splawski I, 2002, SCIENCE, V297, P1333, DOI 10.1126/science.1073569; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; Thomas D, 2003, CARDIOVASC RES, V60, P235, DOI 10.1016/j.cardiores.2003.08.002; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Watanabe I, 2003, J PHYSIOL-LONDON, V550, P51, DOI 10.1113/jphysiol.2003.040337; Weerapura M, 2002, J PHYSIOL-LONDON, V540, P15, DOI 10.1113/jphysiol.2001.013296; Yang P, 2002, CIRCULATION, V105, P1943, DOI 10.1161/01.CIR.0000014448.19052.4C; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zou AR, 1997, AM J PHYSIOL-HEART C, V272, pH1309, DOI 10.1152/ajpheart.1997.272.3.H1309	48	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5506	5513		10.1074/jbc.M605976200	http://dx.doi.org/10.1074/jbc.M605976200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189275	hybrid			2022-12-25	WOS:000244482300045
J	Shikata, M; Ishikawa, F; Kanoh, J				Shikata, Miho; Ishikawa, Fuyuki; Kanoh, Junko			Te12 is required for activation of the Mrc1-mediated replication checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; TELOMERE LENGTH REGULATION; FORK PROTECTION COMPLEX; DOUBLE-STRAND BREAKS; CELL-CYCLE ARREST; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; S-PHASE; CAENORHABDITIS-ELEGANS; SACCHAROMYCES-CEREVISIAE	Proteins belonging to the Tel2/Rad-5/Clk-2 family are conserved among eukaryotes and are involved in various cellular processes, such as cell proliferation, telomere maintenance, the biological clock, and the DNA damage checkpoint. However, the molecular mechanisms underlying the functions of these molecules remain largely unclear. Here we report that in the fission yeast, Schizosaccharomycespombe, Te12 is required for efficient phosphorylation of Mrc1, a mediator of DNA replication checkpoint signaling, and for activation of Cds1, a replication checkpoint kinase, when DNA replication is blocked by hydroxyurea. In fact, Tel2 is required for survival of replication fork arrest and for the replication checkpoint in cells lacking Chk1, another checkpoint kinase the role of which overlaps that of Cds1 in cell cycle arrest by replication block. in addition, Tel2 plays important roles in entry into S phase and in genome stability. Tel2 is essential for vegetative cell growth, and the tel2A strain accumulated cells with IC DNA content after germination. In the absence of hydroxyurea, Tel2 is vital in the mutant lacking Swil, a component of the replication fork protection complex, and multiple Rad22 DNA repair foci were frequently observed in Tel2-repressed swil A cells especially at S phase. In contrast, the cds1 Delta swi1 Delta mutant did not show such lethality. These results indicate that S. pombe Tel2 plays important roles in the Mrc1-mediated replication checkpoint as well as in the Cds1-independent regulation of genome integrity.	Kyoto Univ, Grad Sch Biostudies, Dept Gene Mechanisms, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Kanoh, J (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Gene Mechanisms, Sakyo Ku, Kitashirakawaoiwake Cho, Kyoto 6068502, Japan.	jkanoh@lif.kyoto-u.ac.jp	Ishikawa, Fuyuki/AAU-4056-2021; Kanoh, Junko/AGM-9632-2022	Ishikawa, Fuyuki/0000-0002-5580-2305; 				Ahmed S, 2001, CURR BIOL, V11, P1934, DOI 10.1016/S0960-9822(01)00604-2; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Alfa C, 1993, EXPT FISSION YEAST L; Baber-Furnari BA, 2000, MOL BIOL CELL, V11, P1; Banerjee D, 2005, DEV CELL, V8, P287, DOI 10.1016/j.devcel.2004.12.006; Barnes JW, 2003, SCIENCE, V302, P439, DOI 10.1126/science.1086593; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Benard C, 2001, DEVELOPMENT, V128, P4045; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Branzei D, 2005, CURR OPIN CELL BIOL, V17, P568, DOI 10.1016/j.ceb.2005.09.003; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Calzada A, 2005, GENE DEV, V19, P1905, DOI 10.1101/gad.337205; Capasso H, 2002, J CELL SCI, V115, P4555, DOI 10.1242/jcs.00133; Chan RC, 2003, NATURE, V423, P1002, DOI 10.1038/nature01697; Christensen PU, 2000, P NATL ACAD SCI USA, V97, P2579, DOI 10.1073/pnas.97.6.2579; Dalgaard JZ, 2000, CELL, V102, P745, DOI 10.1016/S0092-8674(00)00063-5; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Du LL, 2003, MOL CELL BIOL, V23, P6150, DOI 10.1128/MCB.23.17.6150-6158.2003; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Garcia-Muse T, 2005, EMBO J, V24, P4345, DOI 10.1038/sj.emboj.7600896; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; HARTMAN PS, 1982, GENETICS, V102, P159; Hatanaka M, 2001, YEAST, V18, P207, DOI 10.1002/1097-0061(200102)18:3<207::AID-YEA661>3.0.CO;2-I; HEKIMI S, 1995, GENETICS, V141, P1351; Jiang N, 2003, J BIOL CHEM, V278, P21678, DOI 10.1074/jbc.M300286200; Kanoh J, 2001, CURR BIOL, V11, P1624, DOI 10.1016/S0960-9822(01)00503-6; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kota RS, 1998, NUCLEIC ACIDS RES, V26, P1528, DOI 10.1093/nar/26.6.1528; Kota RS, 1999, CHROMOSOMA, V108, P278, DOI 10.1007/s004120050379; Krings G, 2004, P NATL ACAD SCI USA, V101, P14085, DOI 10.1073/pnas.0406037101; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lambert S, 2005, BIOCHIMIE, V87, P591, DOI 10.1016/j.biochi.2004.10.020; Lee J, 2005, MOL BIOL CELL, V16, P5269, DOI 10.1091/mbc.E05-07-0671; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lim CS, 2001, CURR BIOL, V11, P1706, DOI 10.1016/S0960-9822(01)00526-7; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; Matsumoto S, 2005, J BIOL CHEM, V280, P42536, DOI 10.1074/jbc.M510575200; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Mayer ML, 2004, MOL BIOL CELL, V15, P1736, DOI 10.1091/mbc.E03-08-0619; Mochida S, 2004, EMBO J, V23, P418, DOI 10.1038/sj.emboj.7600018; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Nedelcheva MN, 2005, J MOL BIOL, V347, P509, DOI 10.1016/j.jmb.2005.01.041; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Noguchi E, 2004, MOL CELL BIOL, V24, P8342, DOI 10.1128/MCB.24.19.8342-8355.2004; Noguchi E, 2003, MOL CELL BIOL, V23, P7861, DOI 10.1128/MCB.23.21.7861-7874.2003; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; OSTERMANN K, 1993, NUCLEIC ACIDS RES, V21, P5940, DOI 10.1093/nar/21.25.5940; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rhind N, 2000, J CELL SCI, V113, P3889; Runge KW, 1996, MOL CELL BIOL, V16, P3094; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sommariva E, 2005, MOL CELL BIOL, V25, P2770, DOI 10.1128/MCB.25.7.2770-2784.2005; Szyjka SJ, 2005, MOL CELL, V19, P691, DOI 10.1016/j.molcel.2005.06.037; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tanaka K, 2004, J BIOL CHEM, V279, P32079, DOI 10.1074/jbc.M404834200; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tanaka K, 2001, MOL CELL BIOL, V21, P3398, DOI 10.1128/MCB.21.10.3398-3404.2001; Tourriere H, 2005, MOL CELL, V19, P699, DOI 10.1016/j.molcel.2005.07.028; Unsal-Kacmaz K, 2005, MOL CELL BIOL, V25, P3109, DOI 10.1128/MCB.25.8.3109-3116.2005; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wolkow TD, 2002, MOL BIOL CELL, V13, P480, DOI 10.1091/mbc.01-03-0104; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhao H, 2003, MOL CELL BIOL, V23, P8395, DOI 10.1128/MCB.23.22.8395-8403.2003	71	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5346	5355		10.1074/jbc.M607432200	http://dx.doi.org/10.1074/jbc.M607432200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189249	hybrid			2022-12-25	WOS:000244482300030
J	Cougot, D; Wu, YF; Cair, S; Caramel, J; Renard, CA; Levy, L; Buendia, MA; Neuveut, C				Cougot, Delphine; Wu, Yuanfei; Cair, Stefano; Caramel, Julie; Renard, Claire-Angelique; Levy, Laurence; Buendia, Marie Annick; Neuveut, Christine			The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGET GENE ACTIVATION; DNA-BINDING; HBX PROTEIN; TRANSGENIC MICE; TRANSACTIVATION FUNCTION; BASIC REGION; PIVOTAL ROLE; CELL-DEATH; IN-VIVO; REPLICATION	The hepatitis B virus infects more than 350 million people worldwide and is a leading cause of liver cancer. The virus encodes a multifunctional regulator, the hepatitis B virus X protein (HBx), that is essential for virus replication. HBx is involved in modulating signal transduction pathways and transcription mediated by various factors, notably CREB that requires the recruitment of the coactivators CREB-binding protein (CBP)/p300. Here we investigated the role of HBx and its potential interaction with CBP/p300 in regulating CREB transcriptional activity. We show that HBx and CBP/p300 synergistically enhanced CREB, activity and that CREB phosphorylation by protein kinase A was a prerequisite for the cooperative action of HBx and CBP/p300. We further show that HBx interacted directly with CBP/p300 in vitro and in vivo. Using chromatin immunoprecipitation, we provide evidence that HBx physically occupied the CREB-binding domain of CREB-responsive promoters of endogenous cellular genes such as interleukin 8 and proliferating cell nuclear antigen. Moreover expression of HBx increased the recruitment of p300 to the interleukin 8 and proliferating cell nuclear antigen promoters in cells, and this is associated with increased gene expression. As recruitment of CBP/p300 is known to represent the limiting event for activating CREB target genes, HBx may disrupt this cellular regulation, thus predisposing cells to transformation.	Inst Pasteur, INSERM, U576, Unite Oncogenese & Virol Mol, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Neuveut, C (corresponding author), Inst Pasteur, INSERM, U576, Unite Oncogenese & Virol Mol, F-75724 Paris 15, France.	cneuveut@pasteur.fr	Cairo, Stefano/O-2831-2016; LEVY, Laurence/AAF-5672-2021	Cairo, Stefano/0000-0002-4725-5970; Neuveut, Christine/0000-0001-6520-271X; Caramel, Julie/0000-0002-8883-918X				Abramovitch R, 2004, CANCER RES, V64, P1338, DOI 10.1158/0008-5472.CAN-03-2089; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barnabas S, 1997, J BIOL CHEM, V272, P20684, DOI 10.1074/jbc.272.33.20684; Barnabas S, 2000, J VIROL, V74, P83, DOI 10.1128/JVI.74.1.83-90.2000; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Bischof O, 2006, MOL CELL, V22, P783, DOI 10.1016/j.molcel.2006.05.016; Bouchard M, 2001, J VIROL, V75, P4247, DOI 10.1128/JVI.75.9.4247-4257.2001; Bouchard MJ, 2004, J VIROL, V78, P12725, DOI 10.1128/JVI.78.23.12725-12734.2004; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brockmann D, 2003, CURR TOP MICROBIOL, V272, P97; Cairo S, 2005, ONCOGENE, V24, P2195, DOI 10.1038/sj.onc.1208338; Chan HM, 2001, J CELL SCI, V114, P2363; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Conkright MD, 2005, TRENDS CELL BIOL, V15, P457, DOI 10.1016/j.tcb.2005.07.007; Cougot D, 2005, J CLIN VIROL, V34, pS75, DOI 10.1016/S1386-6532(05)80014-9; Forgues M, 2003, MOL CELL BIOL, V23, P5282, DOI 10.1128/MCB.23.15.5282-5292.2003; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Gatza ML, 2005, ENVIRON MOL MUTAGEN, V45, P304, DOI 10.1002/em.20088; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Kashanchi F, 2005, ONCOGENE, V24, P5938, DOI 10.1038/sj.onc.1208973; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; Labalette C, 2004, MOL CELL BIOL, V24, P10689, DOI 10.1128/MCB.24.24.10689-10702.2004; Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; Leupin O, 2005, J VIROL, V79, P4238, DOI 10.1128/JVI.79.7.4238-4245.2005; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100; Madden CR, 2001, J VIROL, V75, P3851, DOI 10.1128/JVI.75.8.3851-3858.2001; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MAURER RA, 1989, J BIOL CHEM, V264, P6870; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Nakamoto Y, 1998, J EXP MED, V188, P341, DOI 10.1084/jem.188.2.341; Neuveut C, 2002, FRONT BIOSCI-LANDMRK, V7, pD157, DOI 10.2741/neuveut; Perini G, 1999, J BIOL CHEM, V274, P13970, DOI 10.1074/jbc.274.20.13970; Pflum MKH, 2001, BIOCHEMISTRY-US, V40, P693, DOI 10.1021/bi0011936; Pollicino T, 2006, GASTROENTEROLOGY, V130, P823, DOI 10.1053/j.gastro.2006.01.001; Schneider TL, 2001, BIOCHEMISTRY-US, V40, P2835, DOI 10.1021/bi002450+; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; Sirven A, 2001, MOL THER, V3, P438, DOI 10.1006/mthe.2001.0282; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Tang H, 2005, J VIROL, V79, P5548, DOI 10.1128/JVI.79.9.5548-5556.2005; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TRUANT R, 1995, J VIROL, V69, P1951; TRUJILLO MA, 1991, P NATL ACAD SCI USA, V88, P3797, DOI 10.1073/pnas.88.9.3797; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Yoo YG, 2004, FEBS LETT, V577, P121, DOI 10.1016/j.febslet.2004.10.004; Yoo YG, 2004, J BIOL CHEM, V279, P36242, DOI 10.1074/jbc.M401290200; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	69	161	169	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4277	4287		10.1074/jbc.M606774200	http://dx.doi.org/10.1074/jbc.M606774200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158882	hybrid			2022-12-25	WOS:000244482000007
J	Fairn, GD; MacDonald, K; McMaster, CR				Fairn, Gregory D.; MacDonald, Kendra; McMaster, Christopher R.			A chemogenomic screen in Saccharomyces cerevisiae uncovers a primary role for the mitochondria in farnesol toxicity and its regulation by the Pkc1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; CELL INTEGRITY PATHWAY; PHOSPHATIDYLCHOLINE SYNTHESIS; CHEMICAL GENETICS; INDUCED APOPTOSIS; YEAST; INHIBITION; PROTEIN; CYTOTOXICITY; LOCALIZATION	The isoprenoid farnesol has been shown to preferentially induce apoptosis in cancerous cells; however, the mode of action of farnesol-induced death is not established. We used chemogenomic profiling using Saccharomyces cerevisiae to probe the core cellular processes targeted by farnesol. This screen revealed 48 genes whose inactivation increased sensitivity to farnesol. The gene set indicated a role for the generation of oxygen radicals by the Rieske iron-sulfur component of complex III of the electron transport chain as a major mediator of farnesol-induced cell death. Consistent with this, loss of mitochondrial DNA, which abolishes electron transport, resulted in robust resistance to farnesol. A genomic interaction map predicted interconnectedness between the Pkc1 signaling pathway and farnesol sensitivity via regulation of the generation of reactive oxygen species. Consistent with this prediction (i) Pkc1, Bck1, and Mkk1 relocalized to the mitochondria upon farnesol addition, (ii) inactivation of the only non-essential and non-redundant member of the Pkc1 signaling pathway, BCK1, resulted in farnesol sensitivity, and (iii) expression of activated alleles of PKC1, BCIC1, and MKK1 increased resistance to farnesol and hydrogen peroxide. Sensitivity to farnesol was not affected by the presence of the osmostabilizer sorbitol nor did farnesol affect phosphorylation of the ultimate Pkc1-responsive kinase responsible for controlling the cell wall integrity pathway, Slt2. The data indicate that the generation of reactive oxygen species by the electron transport chain is a primary mechanism by which farnesol kills cells. The Pkc1 signaling pathway regulates farnesol-mediated cell death through management of the generation of reactive oxygen species.	Dalhousie Univ, Dept Pediat & Biochem, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Mol Biol, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University	McMaster, CR (corresponding author), Dalhousie Univ, Dept Pediat & Biochem, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada.	christopher.mcmaster@dal.ca		McMaster, Christopher/0000-0003-0822-5776; Fairn, Greg/0000-0001-6508-168X				ADANY I, 1994, CANCER LETT, V79, P175, DOI 10.1016/0304-3835(94)90257-7; Anthony ML, 1999, J BIOL CHEM, V274, P19686, DOI 10.1074/jbc.274.28.19686; Beattie DS, 1999, J BIOENERG BIOMEMBR, V31, P215, DOI 10.1023/A:1005415611822; Breitkreutz BJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r23; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Fairn GD, 2005, METHODS, V36, P102, DOI 10.1016/j.ymeth.2004.11.005; Gille L, 2001, ARCH BIOCHEM BIOPHYS, V388, P34, DOI 10.1006/abbi.2000.2257; Harrison JC, 2001, NAT CELL BIOL, V3, P417, DOI 10.1038/35070104; Harrison JC, 2004, J BIOL CHEM, V279, P2616, DOI 10.1074/jbc.M306110200; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Lagace TA, 2002, MOL CELL BIOL, V22, P4851, DOI 10.1128/MCB.22.13.4851-4862.2002; Levin DE, 2005, MICROBIOL MOL BIOL R, V69, P262, DOI 10.1128/MMBR.69.2.262-291.2005; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Machida K, 1998, J BACTERIOL, V180, P4460, DOI 10.1128/JB.180.17.4460-4465.1998; Machida K, 1999, MICROBIOL-UK, V145, P293, DOI 10.1099/13500872-145-2-293; Mayer TU, 2003, TRENDS CELL BIOL, V13, P270, DOI 10.1016/S0962-8924(03)00077-1; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Nohl H, 2005, BIOCHEM PHARMACOL, V69, P719, DOI 10.1016/j.bcp.2004.12.002; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Parsons Ainslie B, 2003, Prog Cell Cycle Res, V5, P159; Rioja A, 2000, FEBS LETT, V467, P291, DOI 10.1016/S0014-5793(00)01168-6; Schmelzle T, 2002, MOL CELL BIOL, V22, P1329, DOI 10.1128/MCB.22.5.1329-1339.2002; TONG AH, 2005, METHOD MOL BIOL, V313, P717; Vilella F, 2005, J BIOL CHEM, V280, P9149, DOI 10.1074/jbc.M411062200; VOZIYAN PA, 1995, BIOCHEM BIOPH RES CO, V212, P479, DOI 10.1006/bbrc.1995.1995; Wild AC, 2004, J BIOL CHEM, V279, P17101, DOI 10.1074/jbc.M314035200; Wright MM, 2001, J BIOL CHEM, V276, P25254, DOI 10.1074/jbc.M011552200; WRIGHT MM, 2005, FEBS J, V272, P5056; Yang CF, 2003, TRENDS PHARMACOL SCI, V24, P602, DOI 10.1016/j.tips.2003.09.003; Zaremberg V, 2005, J BIOL CHEM, V280, P38047, DOI 10.1074/jbc.M502849200	34	48	50	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4868	4874		10.1074/jbc.M610575200	http://dx.doi.org/10.1074/jbc.M610575200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17164236	hybrid			2022-12-25	WOS:000244482000069
J	Jilaveanu, LB; Oliver, DB				Jilaveanu, Lucia B.; Oliver, Donald B.			In vivo membrane topology of Escherichia coli SecA ATPase reveals extensive periplasmic exposure of multiple functionally important domains clustering on one face of SecA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TRANSLOCATION; PREPROTEIN TRANSLOCASE; BACTERIAL-MEMBRANE; BINDING DOMAIN; SIGNAL PEPTIDE; INNER MEMBRANE; DIMERIC SECA; BOUND SECA; WILD-TYPE; SECYEG	The Sec-dependent protein translocation pathway promotes the transport of proteins into or across the bacterial plasma membrane. SecA ATPase has been shown to be a nanomotor that associates with its protein cargo as well as the SecYEG channel complex and to undergo ATP-driven cycles of membrane insertion and retraction that promote stepwise protein translocation. previous studies have shown that both the 65-kDa N-domain and 30-kDa C-domain of SecA appear to undergo such membrane cycling. In the present study we performed in vivo sulfhydryl labeling of an extensive collection of monocysteine secA mutants under topologically specific conditions to identify regions of SecA that are accessible to the trans side of the membrane in its membrane-integrated state. Our results show that distinct regions of five of six SecA domains were labeled under these conditions, and such labeling clusters to a single face of the SecA structure. Our results demarcate an extensive face of SecA that interacts with SecYEG and is in fluid contact with the protein-conducting channel. The observed domain-specific labeling patterns should also provide important constraints on model building efforts in this dynamic system.	Wesleyan Univ, Dept Biochem & Mol Biol, Middletown, CT 06457 USA	Wesleyan University	Oliver, DB (corresponding author), Wesleyan Univ, Dept Biochem & Mol Biol, Middletown, CT 06457 USA.	doliver@wesleyan.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baud C, 2002, J BIOL CHEM, V277, P13724, DOI 10.1074/jbc.M200047200; BAYER EA, 1985, ANAL BIOCHEM, V149, P529, DOI 10.1016/0003-2697(85)90609-8; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; Cannon KS, 2005, J CELL BIOL, V169, P219, DOI 10.1083/jcb.200412019; de Keyzer J, 2005, J BIOL CHEM, V280, P35255, DOI 10.1074/jbc.M506157200; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1998, J BACTERIOL, V180, P5776, DOI 10.1128/JB.180.21.5776-5779.1998; Eichler J, 1998, J BIOL CHEM, V273, P21675, DOI 10.1074/jbc.273.34.21675; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; Jilaveanu LB, 2006, J BACTERIOL, V188, P335, DOI 10.1128/JB.188.1.335-338.2006; Jilaveanu LB, 2005, P NATL ACAD SCI USA, V102, P7511, DOI 10.1073/pnas.0502774102; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; Karamyshev AL, 2005, J BIOL CHEM, V280, P37930, DOI 10.1074/jbc.M509100200; KIM YJ, 1994, CELL, V78, P845; KIMURA E, 1991, J BIOL CHEM, V266, P6600; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Mitra K, 2005, NATURE, V438, P318, DOI 10.1038/nature04133; Musial-Siwek M, 2005, BIOCHEMISTRY-US, V44, P13987, DOI 10.1021/bi050882k; Nakatogawa H, 2000, J BIOL CHEM, V275, P33209, DOI 10.1074/jbc.C000550200; Natale P, 2005, BIOCHEMISTRY-US, V44, P6424, DOI 10.1021/bi047488r; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; Or E, 2005, J BIOL CHEM, V280, P9097, DOI 10.1074/jbc.M413947200; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; Papanikou E, 2005, J BIOL CHEM, V280, P43209, DOI 10.1074/jbc.M509990200; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; Ramamurthy V, 1997, J BIOL CHEM, V272, P23239, DOI 10.1074/jbc.272.37.23239; Randall LL, 2002, CELL MOL LIFE SCI, V59, P1617, DOI 10.1007/PL00012488; SADAIE Y, 1991, GENE, V98, P101; Scheuring J, 2005, J MOL BIOL, V354, P258, DOI 10.1016/j.jmb.2005.09.058; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; Sharma V, 2003, P NATL ACAD SCI USA, V100, P2243, DOI 10.1073/pnas.0538077100; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; Stewart JB, 2003, J BACTERIOL, V185, P5234, DOI 10.1128/JB.185.17.5234-5239.2003; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Does C, 2003, METHOD ENZYMOL, V372, P86; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van Geest M, 2000, MICROBIOL MOL BIOL R, V64, P13, DOI 10.1128/MMBR.64.1.13-33.2000; van Voorst F, 1998, BIOCHEMISTRY-US, V37, P12261, DOI 10.1021/bi9809021; van Voorst F, 2000, FEBS LETT, V486, P57, DOI 10.1016/S0014-5793(00)02209-2; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; Veenendaal AKJ, 2004, BBA-MOL CELL RES, V1694, P81, DOI 10.1016/j.bbamcr.2004.02.009; Vrontou E, 2004, BBA-MOL CELL RES, V1694, P67, DOI 10.1016/j.bbamcr.2004.06.003; Wang LG, 2004, BIOCHEMISTRY-US, V43, P13185, DOI 10.1021/bi049485k; Zito CR, 2003, J BIOL CHEM, V278, P40640, DOI 10.1074/jbc.M308025200	60	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4661	4668		10.1074/jbc.M610828200	http://dx.doi.org/10.1074/jbc.M610828200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17166834	hybrid			2022-12-25	WOS:000244482000047
J	Gafvelin, G; Parmley, S; Neimert-Andersson, T; Blank, U; Eriksson, TLJ; van Hage, M; Punnonen, J				Gafvelin, Guro; Parmley, Stephen; Neimert-Andersson, Theresa; Blank, Ulrich; Eriksson, Tove L. J.; van Hage, Marianne; Punnonen, Juha			Hypoallergens for allergen-specific immunotherapy by directed molecular evolution of mite group 2 allergens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEP-D 2; BIRCH POLLEN ALLERGEN; IGE-BINDING-CAPACITY; LEPIDOGLYPHUS-DESTRUCTOR; ANTIBODY-RESPONSES; MAJOR ALLERGEN; 3-DIMENSIONAL STRUCTURE; DISULFIDE BONDS; CELL EPITOPES; IN-VITRO	Allergen-specific immunotherapy is the only treatment that provides long lasting relief of allergic symptoms. Currently, it is based on repeated administration of allergen extracts. To improve the safety and efficacy of allergen extract-based immunotherapy, application of hypoallergens, i.e. modified allergens with reduced IgE binding capacity but retained T-cell reactivity, has been proposed. It may, however, be difficult to predict how to modify an allergen to create a hypoallergen. Directed molecular evolution by DNA shuffling and screening provides a means by which to evolve proteins having novel or improved functional properties without knowledge of structure - function relationships of the target molecules. With the aim to generate hypoallergens we applied multigene DNA shuffling on three group 2 dust mite allergen genes, two isoforms of Lep d 2 and Gly d 2. DNA shuffling yielded a library of genes from which encoded shuffled allergens were expressed and screened. A positive selection was made for full-length, high-expressing clones, and screening for low binding to IgE from mite allergic patients was performed using an IgE bead-based binding assay. Nine selected shuffled allergens revealed 80-fold reduced to completely abolished IgE binding compared with the parental allergens in IgE binding competition experiments. Two hypoallergen candidates stimulated allergen-specific T-cell proliferation and cytokine production at comparable levels as the wildtype allergens in patient peripheral blood mononuclear cell cultures. The two candidates also induced blocking Lep d 2-specific IgG antibodies in immunized mice. We conclude that directed molecular evolution is a powerful approach to generate hypoallergens for potential use in allergen-specific immunotherapy.	Karolinska Inst, Dept Med Clin Immunol & Allergy, S-17176 Stockholm, Sweden; Maxygen Inc, Redwood City, CA 94063 USA; INSERM, U699, F-75018 Paris, France; Univ Paris 07, Fac Med, F-75018 Paris, France	Karolinska Institutet; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Gafvelin, G (corresponding author), Karolinska Univ Hosp, Dept Med, Clin Immunol & Allergy Unit, Karolinska Inst, S-17176 Stockholm, Sweden.	guro.gafvelin@ki.se	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Blank, Ulrich/0000-0002-2661-2983; Gafvelin, Guro/0000-0003-1618-4011				Adedoyin J, 2006, J IMMUNOL METHODS, V310, P117, DOI 10.1016/j.jim.2006.01.001; Akdis CA, 2001, TRENDS IMMUNOL, V22, P175, DOI 10.1016/S1471-4906(01)01862-2; Apt D, 2006, VACCINE, V24, P335, DOI 10.1016/j.vaccine.2005.07.100; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Beezhold DH, 2001, J ALLERGY CLIN IMMUN, V107, P1069, DOI 10.1067/mai.2001.115482; Chang CCJ, 1999, NAT BIOTECHNOL, V17, P793, DOI 10.1038/11737; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Drew AC, 2004, J IMMUNOL, V173, P5872, DOI 10.4049/jimmunol.173.9.5872; Elfman LHM, 1998, INT ARCH ALLERGY IMM, V117, P167, DOI 10.1159/000024006; Eriksson TLJ, 2001, CLIN EXP ALLERGY, V31, P1881, DOI 10.1046/j.1365-2222.2001.01242.x; Gafvelin G, 2005, INT ARCH ALLERGY IMM, V138, P59, DOI 10.1159/000087358; Gafvelin G, 2001, J ALLERGY CLIN IMMUN, V107, P511, DOI 10.1067/mai.2001.112264; Holm J, 2004, J IMMUNOL, V173, P5258, DOI 10.4049/jimmunol.173.8.5258; Johansson E, 1999, INT ARCH ALLERGY IMM, V120, P43, DOI 10.1159/000024218; Karamloo F, 2005, EUR J IMMUNOL, V35, P3268, DOI 10.1002/eji.200425522; Karisola P, 2004, J IMMUNOL, V172, P2621, DOI 10.4049/jimmunol.172.4.2621; Kronqvist M, 1999, CLIN EXP ALLERGY, V29, P35, DOI 10.1046/j.1365-2222.1999.00452.x; Kronqvist M, 2000, CLIN EXP ALLERGY, V30, P670, DOI 10.1046/j.1365-2222.2000.00822.x; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Lazetic S, 2002, J BIOL CHEM, V277, P38660, DOI 10.1074/jbc.M205808200; Leong SR, 2003, P NATL ACAD SCI USA, V100, P1163, DOI 10.1073/pnas.0237327100; Marchand F, 2003, ALLERGY, V58, P1037, DOI 10.1034/j.1398-9995.2003.00251.x; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Neudecker P, 2003, BIOCHEM J, V376, P97, DOI 10.1042/BJ20031057; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Olsson S, 1998, MOL IMMUNOL, V35, P1017, DOI 10.1016/S0161-5890(98)00101-1; Parvaneh S, 2002, CLIN EXP ALLERGY, V32, P80, DOI 10.1046/j.0022-0477.2001.01255.x; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Punnonen J, 2000, INT ARCH ALLERGY IMM, V121, P173, DOI 10.1159/000024315; Rabjohn P, 2002, INT ARCH ALLERGY IMM, V128, P15, DOI 10.1159/000057999; Robinson DS, 2003, PEDIATR PULM, V36, P369, DOI 10.1002/ppul.10375; Saarne T, 2005, CLIN EXP ALLERGY, V35, P657, DOI 10.1111/j.1365-2222.2005.02234.x; SCHMIDT M, 1995, FEBS LETT, V370, P11, DOI 10.1016/0014-5793(95)98164-E; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Soong NW, 2000, NAT GENET, V25, P436, DOI 10.1038/78132; Spangfort MD, 2003, J IMMUNOL, V171, P3084, DOI 10.4049/jimmunol.171.6.3084; Spiegelberg HL, 2002, CURR OPIN ALLERGY CL, V2, P547, DOI 10.1097/00130832-200212000-00012; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Swoboda I, 2002, EUR J IMMUNOL, V32, P270, DOI 10.1002/1521-4141(200201)32:1<270::AID-IMMU270>3.0.CO;2-X; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Westritschnig K, 2004, J IMMUNOL, V172, P5684, DOI 10.4049/jimmunol.172.9.5684; Wright A, 2005, HUM GENE THER, V16, P881, DOI 10.1089/hum.2005.16.881; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219	50	30	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3778	3787		10.1074/jbc.M607938200	http://dx.doi.org/10.1074/jbc.M607938200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17170112	hybrid			2022-12-25	WOS:000244481900041
J	Waldron, KJ; Tottey, S; Yanagisawa, S; Dennison, C; Robinson, NJ				Waldron, Kevin J.; Tottey, Stephen; Yanagisawa, Sachiko; Dennison, Christopher; Robinson, Nigel J.			A periplasmic iron-binding protein contributes toward inward copper supply	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; THYLAKOID MEMBRANE; TRANSPORT PROTEIN; TERMINAL DOMAIN; SYNECHOCYSTIS; PLASTOCYANIN; IDENTIFICATION; GENE; PHOTOSYNTHESIS; EXPRESSION	Periplasmic substrate binding proteins are known for iron, zinc, manganese, nickel, and molybdenum but not copper. Synechocystis PCC 6803 requires copper for thylakoid-localized plastocyanin and cytochrome oxidase. Here we show that mutants deficient in a periplasmic substrate binding protein FutA2 have low cytochrome oxidase activity and produce cytochrome c(6) when grown under copper conditions (150 nM) in which wild-type cells use plastocyanin rather than cytochrome c6. Anaerobic separation of extracts by two-dimensional native liquid chromatography followed by metal analysis and peptide mass-fingerprinting establish that accumulation of copper-plastocyanin is impaired, but iron-ferredoxin is unaffected in Delta futA2 grown in 150 nM copper. However, recombinant FutA2 binds iron in preference to copper in vitro with an apparent Fe(III) affinity similar to that of its paralog FutA1, the principal substrate binding protein for iron import. FutA2 is also associated with iron and not copper in periplasm extracts, and this Fe(III)-protein complex is absent in Delta futA2. There are differences in the soluble protein and small-molecule complexes of copper and iron, and the total amount of both elements increases in periplasm extracts of Delta futA2 relative to wild type. Changes in periplasm protein and small-molecule complexes for other metals are also observed in Delta futA2. It is proposed that FutA2 contributes to metal partitioning in the periplasm by sequestering Fe(III), which limits aberrant Fe(III) associations with vital binding sites for other metals, including copper.	Univ Newcastle, Sch Med, ICaMB, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Robinson, NJ (corresponding author), Univ Newcastle, Sch Med, ICaMB, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	n.j.robinson@ncl.ac.uk	Waldron, Kevin John/HHM-8983-2022; Robinson, Nigel J/J-6363-2012; Waldron, Kevin/J-2368-2016	Waldron, Kevin John/0000-0002-5577-7357; Robinson, Nigel J/0000-0001-5586-1092; Waldron, Kevin/0000-0002-5577-7357; Dennison, Christopher/0000-0001-8665-052X	Biotechnology and Biological Sciences Research Council [BBS/B/02576] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ALGE D, 1994, GENE, V138, P127, DOI 10.1016/0378-1119(94)90794-3; Banci L, 2004, J BIOL CHEM, V279, P27502, DOI 10.1074/jbc.M402005200; Banci L, 2006, P NATL ACAD SCI USA, V103, P8320, DOI 10.1073/pnas.0600142103; Banerjee S, 2003, J MOL BIOL, V333, P1061, DOI 10.1016/j.jmb.2003.09.008; BARTSEVICH VV, 1995, EMBO J, V14, P1845, DOI 10.1002/j.1460-2075.1995.tb07176.x; Bartsevich VV, 1996, J BIOL CHEM, V271, P26057, DOI 10.1074/jbc.271.42.26057; Borrelly GPM, 2004, MOL MICROBIOL, V53, P217, DOI 10.1111/j.1365-2958.2004.04106.x; Borrelly GPM, 2004, BIOCHEM J, V378, P293, DOI 10.1042/BJ20031669; BOTTIN H, 1992, BIOCHIM BIOPHYS ACTA, V1101, P48, DOI 10.1016/0167-4838(92)90465-P; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; CHEN CY, 1993, MOL MICROBIOL, V10, P311, DOI 10.1111/j.1365-2958.1993.tb01957.x; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; da Silva J. J. R. Frausto, 2001, BIOL CHEM ELEMENTS; Fulda S, 1999, ARCH MICROBIOL, V171, P214, DOI 10.1007/s002030050702; Fulda S, 2000, EUR J BIOCHEM, V267, P5900, DOI 10.1046/j.1432-1327.2000.01642.x; Gabricevic M, 2004, BIOCHEMISTRY-US, V43, P5811, DOI 10.1021/bi036217y; Herald VL, 2003, FEBS LETT, V537, P96, DOI 10.1016/S0014-5793(03)00101-7; Huang F, 2006, PROTEOMICS, V6, P910, DOI 10.1002/pmic.200500114; Huang F, 2002, MOL CELL PROTEOMICS, V1, P956, DOI 10.1074/mcp.M200043-MCP200; KANAMARU K, 1994, MOL MICROBIOL, V13, P369, DOI 10.1111/j.1365-2958.1994.tb00430.x; Katoh H, 2001, PLANT CELL PHYSIOL, V42, P823, DOI 10.1093/pcp/pce106; Katoh H, 2001, J BACTERIOL, V183, P2779, DOI 10.1128/JB.183.9.2779-2784.2001; Keren N, 2004, PLANT PHYSIOL, V135, P1666, DOI 10.1104/pp.104.042770; Keren N, 2002, BIOCHEMISTRY-US, V41, P15085, DOI 10.1021/bi026892s; Liberton M, 2006, PROTOPLASMA, V227, P129, DOI 10.1007/s00709-006-0145-7; Manna P, 1997, PLANT MOL BIOL, V35, P407, DOI 10.1023/A:1005875124387; MERCHANT S, 1987, EMBO J, V6, P2531, DOI 10.1002/j.1460-2075.1987.tb02540.x; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; Molina-Heredia FP, 2003, NATURE, V424, P33, DOI 10.1038/424033b; Moseley J, 2000, EMBO J, V19, P2139, DOI 10.1093/emboj/19.10.2139; PHUNG LT, 1994, P NATL ACAD SCI USA, V91, P9651, DOI 10.1073/pnas.91.20.9651; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Rosenzweig AC, 2002, CHEM BIOL, V9, P673, DOI 10.1016/S1074-5521(02)00156-4; Rukhman V, 2005, J MOL BIOL, V348, P961, DOI 10.1016/j.jmb.2005.03.006; Simon WJ, 2002, PROTEOMICS, V2, P1735, DOI 10.1002/1615-9861(200212)2:12<1735::AID-PROT1735>3.0.CO;2-K; Spence E, 2003, MOL MICROBIOL, V48, P1481, DOI 10.1046/j.1365-2958.2003.03519.x; Srivastava R, 2005, PROTEOMICS, V5, P4905, DOI 10.1002/pmic.200500111; Tolle J, 2002, MICROBIOL-SGM, V148, P3293, DOI 10.1099/00221287-148-10-3293; Tottey S, 2005, ACCOUNTS CHEM RES, V38, P775, DOI 10.1021/ar0300118; Tottey S, 2002, J BIOL CHEM, V277, P5490, DOI 10.1074/jbc.M105857200; Tottey S, 2001, J BIOL CHEM, V276, P19999, DOI 10.1074/jbc.M011243200; van de Meene AML, 2006, ARCH MICROBIOL, V184, P259, DOI 10.1007/s00203-005-0027-y; Wang HL, 2002, MOL MICROBIOL, V44, P1493, DOI 10.1046/j.1365-2958.2002.02983.x; Weigel M, 2003, J BIOL CHEM, V278, P31286, DOI 10.1074/jbc.M302876200; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350; ZHANG L, 1992, J BIOL CHEM, V267, P19054	47	37	42	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3837	3846		10.1074/jbc.M609916200	http://dx.doi.org/10.1074/jbc.M609916200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148438	hybrid			2022-12-25	WOS:000244481900047
J	Kopp, JL; Wilder, PJ; Desler, M; Kinarsky, L; Rizzino, A				Kopp, Janel L.; Wilder, Phillip J.; Desler, Michelle; Kinarsky, Leo; Rizzino, Angie			Different domains of the transcription factor ELF3 are required in a promoter-specific manner and multiple domains control its binding to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; BETA RECEPTOR GENE; ETS-FAMILY MEMBER; NF-KAPPA-B; AUTOINHIBITORY DOMAINS; II RECEPTOR; FUNCTIONAL-ANALYSIS; EPITHELIAL-CELLS; FACTOR ELK-1; EXPRESSION	Elf3 is an epithelially restricted member of the ETS transcription factor family, which is involved in a wide range of normal cellular processes. Elf3 is also aberrantly expressed in several cancers, including breast cancer. To better understand the molecular mechanisms by which Elf3 regulates these processes, we created a large series of Elf3 mutant proteins with specific domains deleted or targeted by point mutations. The modified forms of Elf3 were used to analyze the contribution of each domain to DNA binding and the activation of gene expression. Our work demonstrates that three regions of Elf3, in addition to its DNA binding domain ( ETS domain), influence Elf3 binding to DNA, including the transactivation domain that behaves as an autoinhibitory domain. Interestingly, disruption of the transactivation domain relieves the autoinhibition of Elf3 and enhances Elf3 binding to DNA. On the basis of these studies, we suggest a model for autoinhibition of Elf3 involving intramolecular interactions. Importantly, this model is consistent with our finding that the N-terminal region of Elf3, which contains the transactivation domain, interacts with its C terminus, which contains the ETS domain. In parallel studies, we demonstrate that residues flanking the N- and C-terminal sides of the ETS domain of Elf3 are crucial for its binding to DNA. Our studies also show that an AT-hook domain, as well as the serine- and aspartic acid-rich domain but not the pointed domain, is necessary for Elf3 activation of promoter activity. Unexpectedly, we determined that one of the AT-hook domains is required in a promoter-specific manner.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Rizzino, A (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	arizzino@unmc.edu			NCI NIH HHS [CA009476, CA36727] Funding Source: Medline; NCRR NIH HHS [RR16469] Funding Source: Medline; NIGMS NIH HHS [GM80751] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, T32CA009476] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER RR, 1990, DEVELOPMENT, V110, P211; Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Asada S, 2003, J AM CHEM SOC, V125, P4992, DOI 10.1021/ja0292703; Asada S, 2002, P NATL ACAD SCI USA, V99, P12747, DOI 10.1073/pnas.202162199; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Brembeck FH, 2000, ONCOGENE, V19, P1941, DOI 10.1038/sj.onc.1203441; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Buttice G, 1996, ONCOGENE, V13, P2297; Cabral A, 2003, J BIOL CHEM, V278, P17792, DOI 10.1074/jbc.M300508200; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; De Haro L, 2002, NUCLEIC ACIDS RES, V30, P2972; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Do HJ, 2006, FEBS LETT, V580, P1865, DOI 10.1016/j.febslet.2006.02.049; Eckel KL, 2003, DNA CELL BIOL, V22, P79, DOI 10.1089/104454903321515896; Feldman RJ, 2003, ANTICANCER RES, V23, P2125; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Grall FT, 2005, FEBS J, V272, P1676, DOI 10.1111/j.1742-4658.2005.04592.x; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Kelly D, 1998, J BIOL CHEM, V273, P21115, DOI 10.1074/jbc.273.33.21115; Kim JH, 2002, J BIOL CHEM, V277, P17520, DOI 10.1074/jbc.M110434200; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kopp JL, 2004, J BIOL CHEM, V279, P19407, DOI 10.1074/jbc.M314115200; Kwon JH, 2003, J BIOL CHEM, V278, P875, DOI 10.1074/jbc.M208241200; Laget MP, 1996, ONCOGENE, V12, P1325; Lamb KA, 1998, MOL REPROD DEV, V51, P218; Lee HJ, 2003, J EXP CLIN CANC RES, V22, P477; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; Neve RM, 2002, ONCOGENE, V21, P3934, DOI 10.1038/sj.onc.1205503; Ng AYN, 2002, GASTROENTEROLOGY, V122, P1455, DOI 10.1053/gast.2002.32990; Nowling T, 2002, MOL REPROD DEV, V63, P309, DOI 10.1002/mrd.90014; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Perrella MA, 1999, J BIOL CHEM, V274, P9045, DOI 10.1074/jbc.274.13.9045; Prescott JD, 2004, MOL CELL BIOL, V24, P5548, DOI 10.1128/MCB.24.12.5548-5564.2004; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Pufall MA, 2002, ANNU REV CELL DEV BI, V18, P421, DOI 10.1146/annurev.cellbio.18.031502.133614; Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310; Rizzino A, 2002, VITAM HORM, V64, P1, DOI 10.1016/S0083-6729(02)64001-4; Rudders S, 2001, J BIOL CHEM, V276, P3302, DOI 10.1074/jbc.M006507200; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Sieweke Michael H., 1997, Leukemia (Basingstoke), V11, P486; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Wang YZ, 2005, BIOCHEMISTRY-US, V44, P7095, DOI 10.1021/bi047352t; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Wiebe MS, 2003, J BIOL CHEM, V278, P17901, DOI 10.1074/jbc.M212211200; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 2002, MOL CELL BIOL, V22, P5036, DOI 10.1128/MCB.22.14.5036-5046.2002; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; Zhang XM, 1999, J BIOL CHEM, V274, P20235, DOI 10.1074/jbc.274.29.20235	72	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3027	3041		10.1074/jbc.M609907200	http://dx.doi.org/10.1074/jbc.M609907200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148437	hybrid			2022-12-25	WOS:000243793900029
J	Li, FC; Shetty, AK; Sugahara, K				Li, Fuchuan; Shetty, Ajaya Kumar; Sugahara, Kazuyuki			Neuritogenic activity of chondroitin/dermatan sulfate hybrid chains of embryonic pig brain and their mimicry from shark liver - Involvement of the pleiotrophin and hepatocyte growth factor signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-SCATTER FACTOR; ANAPLASTIC LYMPHOMA KINASE; PROTEIN LINKAGE REGION; L-IDURONIC ACID; NEURITE OUTGROWTH; DERMATAN SULFATE; FUNCTIONAL-CHARACTERIZATION; HIPPOCAMPAL-NEURONS; BINDING ACTIVITIES; HEPARAN-SULFATE	Accumulating evidence suggests the involvement of chondroitin sulfate (CS) and dermatan sulfate (DS) hybrid chains in the brain's development and critical roles for oversulfated disaccharides and IdoUA residues in the growth factor-binding and neuritogenic activities of these chains. In the pursuit of sources of CS/DS with unique structures, neuritogenic activity, and therapeutic potential, two novel CS/DS preparations were isolated from shark liver by anion exchange chromatography. The major (80%) low sulfated and minor (20%) highly sulfated fractions had an average molecular mass of 3.8-38.9 and 75.7 kDa, respectively. Digestion with various chondroitinases (CSases) revealed a large panel of disaccharides with either GlcUA or IdoUA scattered along the polysaccharide chains in both of the fractions. The higher M-r fraction, richer in IdoUA(2-O-sulfate) alpha 1-3GalNAc(4-O-sulfate) and GlcUA beta/IdoUA alpha 1-3GalNAc(4,6-O-disulfate) units, exerted greater neurite outgrowth-promoting (NOP) activity and better promoted the binding of various heparin-binding growth factors, including pleiotrophin (PTN), midkine, recombinant human heparin-binding epidermal growth factor-like growth factor, VEGF(165), fibroblast growth factor-2, fibroblast growth factor-7, and hepatocyte growth factor (HGF). These activities were largely abolished by digestion with CSase ABC or B but only moderately affected by a mixture of CSases AC-I and AC-II. In addition, the NOP activity of the larger fraction was markedly reduced by desulfation with alkali, suggesting a role for the 2-O-sulfate of IdoUA(2-O-sulfate) alpha 1-3GalNAc(4-O-sulfate). The NOP activity of the higher molecular weight fraction and that of the embryonic pig brain-derived CS/DS fraction were also suppressed to a large extent by antibodies against HGF, PTN, and their individual receptors cMet and anaplastic lymphoma kinase, revealing the involvement of the HGF and PTN signaling pathways in the activity.	Hokkaido Univ, Grad Sch Life Sci, Lab Proteoglycan Signaling & Therapeut, Frontier Res Ctr PostGenom Sci & Technol,Kita Ku, Sapporo, Hokkaido 0010021, Japan; Kobe Pharmaceut Univ, Dept Biochem, Kobe, Hyogo 6588558, Japan	Hokkaido University; Kobe Pharmaceutical University	Sugahara, K (corresponding author), Hokkaido Univ, Grad Sch Life Sci, Lab Proteoglycan Signaling & Therapeut, Frontier Res Ctr PostGenom Sci & Technol,Kita Ku, Nishi 11 Choume,Kita 21 Jo, Sapporo, Hokkaido 0010021, Japan.	k-sugar@sci.hokudai.ac.jp						Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bao XF, 2005, J BIOL CHEM, V280, P35318, DOI 10.1074/jbc.M507304200; Bao XF, 2005, J BIOL CHEM, V280, P9180, DOI 10.1074/jbc.M413423200; Bao XF, 2004, J BIOL CHEM, V279, P9765, DOI 10.1074/jbc.M310877200; Bergefall K, 2005, J BIOL CHEM, V280, P32193, DOI 10.1074/jbc.M503645200; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BLOCH B, 1992, DEV BRAIN RES, V70, P267, DOI 10.1016/0165-3806(92)90206-C; BOHLEN P, 1991, Progress in Growth Factor Research, V3, P143, DOI 10.1016/S0955-2235(05)80005-5; CACERES A, 1986, J NEUROSCI, V6, P714; CHANDRASEKHAR S, 1987, ANAL BIOCHEM, V161, P103, DOI 10.1016/0003-2697(87)90658-0; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Deakin JA, 1999, J CELL SCI, V112, P1999; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; ERNFORS P, 1990, J NEUROSCI RES, V27, P10, DOI 10.1002/jnr.490270103; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FERRO DR, 1986, J AM CHEM SOC, V108, P6773, DOI 10.1021/ja00281a052; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; HAYNES LW, 1988, MOL NEUROBIOL, V2, P263, DOI 10.1007/BF02935635; Helmbacher F, 2003, NEURON, V39, P767, DOI 10.1016/S0896-6273(03)00493-8; Hienola A, 2006, J CELL BIOL, V174, P569, DOI 10.1083/jcb.200602043; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; Hsiao JC, 1999, J VIROL, V73, P8750, DOI 10.1128/JVI.73.10.8750-8761.1999; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Kluppel M, 2005, DEVELOPMENT, V132, P3989, DOI 10.1242/dev.01948; LAFONT F, 1992, DEVELOPMENT, V114, P17; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maina F, 1999, NAT NEUROSCI, V2, P213, DOI 10.1038/6310; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Maina F, 1998, NEURON, V20, P835, DOI 10.1016/S0896-6273(00)80466-3; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MICHELACCI YM, 1975, BIOCHEM J, V151, P121, DOI 10.1042/bj1510121; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Nandi S, 2006, BLOOD, V107, P786, DOI 10.1182/blood-2005-05-1822; Nandini CD, 2005, J BIOL CHEM, V280, P4058, DOI 10.1074/jbc.M412074200; Nandini CD, 2004, J BIOL CHEM, V279, P50799, DOI 10.1074/jbc.M404746200; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; POOLE AR, 1986, BIOCHEM J, V236, P1; Properzi F, 2005, EUR J NEUROSCI, V21, P378, DOI 10.1111/j.1460-9568.2005.03876.x; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; RAUVALA H, 1994, DEV BRAIN RES, V79, P157, DOI 10.1016/0165-3806(94)90121-X; REJ R, 1989, THROMB HAEMOSTASIS, V61, P540; RODEN L, 1980, BIOCH GLYCOPROTEINS, P491; SCOTT JE, 1995, BIOCHEMISTRY-US, V34, P15467, DOI 10.1021/bi00047a011; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Taylor KR, 2006, FASEB J, V20, P9, DOI 10.1096/fj.05-4682rev; Thompson J, 2004, MOL CELL NEUROSCI, V27, P441, DOI 10.1016/j.mcn.2004.07.007; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; White J, 2003, CURR BIOL, V13, pR717, DOI 10.1016/j.cub.2003.08.048; Williams RK, 1997, J VIROL, V71, P1375, DOI 10.1128/JVI.71.2.1375-1380.1997; Yamada S, 2002, J BIOL CHEM, V277, P31877, DOI 10.1074/jbc.M205078200; Yang XM, 1998, J NEUROSCI, V18, P8369; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	67	64	66	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2956	2966		10.1074/jbc.M609296200	http://dx.doi.org/10.1074/jbc.M609296200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145750	hybrid			2022-12-25	WOS:000243793900022
J	Almeida, MC; Steiner, AA; Branco, LGS; Romanovsky, AA				Almeida, Maria C.; Steiner, Alexandre A.; Branco, Luiz G. S.; Romanovsky, Andrej A.			Neural Substrate of Cold-Seeking Behavior in Endotoxin Shock	PLOS ONE			English	Article								Systemic inflammation is a leading cause of hospital death. Mild systemic inflammation is accompanied by warmth-seeking behavior (and fever), whereas severe inflammation is associated with cold-seeking behavior (and hypothermia). Both behaviors are adaptive. Which brain structures mediate which behavior is unknown. The involvement of hypothalamic structures, namely, the preoptic area (POA), paraventricular nucleus (PVH), or dorsomedial nucleus (DMH), in thermoregulatory behaviors associated with endotoxin (lipopolysaccharide [LPS])-induced systemic inflammation was studied in rats. The rats were allowed to select their thermal environment by freely moving in a thermogradient apparatus. A low intravenous dose of Escherichia coli LPS (10 mu g/kg) caused warmth-seeking behavior, whereas a high, shock-inducing dose (5,000 mu g/kg) caused cold-seeking behavior. Bilateral electrocoagulation of the PVH or DMH, but not of the POA, prevented this cold-seeking response. Lesioning the DMH with ibotenic acid, an excitotoxin that destroys neuronal bodies but spares fibers of passage, also prevented LPS-induced cold-seeking behavior; lesioning the PVH with ibotenate did not affect it. Lesion of no structure affected cold-seeking behavior induced by heat exposure or by pharmacological stimulation of the transient receptor potential (TRP) vanilloid-1 channel ("warmth receptor''). Nor did any lesion affect warmth-seeking behavior induced by a low dose of LPS, cold exposure, or pharmacological stimulation of the TRP melastatin-8 ("cold receptor''). We conclude that LPS-induced cold-seeking response is mediated by neuronal bodies located in the DMH and neural fibers passing through the PVH. These are the first two landmarks on the map of the circuitry of cold-seeking behavior associated with endotoxin shock.	[Almeida, Maria C.; Steiner, Alexandre A.; Romanovsky, Andrej A.] St Josephs Hosp, Syst Inflammat Lab, Phoenix, AZ USA; [Almeida, Maria C.] Univ Sao Paulo, Med Sch Ribeirao Preto, Sao Paulo, Brazil; [Branco, Luiz G. S.] Univ Sao Paulo, Dent Sch Ribeirao Preto, Sao Paulo, Brazil	St. Joseph's Hospital and Medical Center; Universidade de Sao Paulo; Universidade de Sao Paulo	Romanovsky, AA (corresponding author), St Josephs Hosp, Syst Inflammat Lab, Phoenix, AZ USA.	aromano@chw.edu	Branco, Luiz/AAH-7589-2020; Almeida, Maria Camila/F-4443-2012; Branco, Luiz G S/N-6273-2014; Steiner, Alexandre A/G-1288-2012	Branco, Luiz/0000-0003-0292-4947; Almeida, Maria Camila/0000-0002-2012-3169; Steiner, Alexandre A/0000-0002-0802-4619; Romanovsky, Andrej/0000-0003-3772-8575	St. Joseph's Foundation; National Institute of Neurological Disorders and Stroke [NS-41233]; Arizona Disease Control Research Commission [8016]; CAPES Foundation, Brazil; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041233] Funding Source: NIH RePORTER	St. Joseph's Foundation; National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Arizona Disease Control Research Commission; CAPES Foundation, Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The study was funded by grants from the St. Joseph's Foundation (to A. A. R.), National Institute of Neurological Disorders and Stroke (grant NS-41233 to A. A. R.), and Arizona Disease Control Research Commission (category II grant #8016 to A. A. R.), and by a Visiting Ph. D. Student Fellowship from the CAPES Foundation, Brazil (to M. C. A.). None of the funding bodies had any involvement whatsoever in preparing this manuscript.	ALLEN GV, 1992, J COMP NEUROL, V315, P313, DOI 10.1002/cne.903150307; Almeida MC, 2006, EUR J NEUROSCI, V23, P3359, DOI 10.1111/j.1460-9568.2006.04854.x; AMIR S, 1990, BRAIN RES, V508, P152, DOI 10.1016/0006-8993(90)91129-5; Bicego KC, 2002, J EXP BIOL, V205, P3513; Caldeira JC, 1998, ANN NY ACAD SCI, V856, P294, DOI 10.1111/j.1749-6632.1998.tb08342.x; CARLISLE HJ, 1969, J COMP PHYSIOL PSYCH, V69, P391, DOI 10.1037/h0028170; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Craig AD, 2003, CURR OPIN NEUROBIOL, V13, P500, DOI 10.1016/S0959-4388(03)00090-4; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; CRAWSHAW LI, 1975, J PHYSIOL-LONDON, V244, P197, DOI 10.1113/jphysiol.1975.sp010791; de Menezes RCA, 2006, BRAIN RES, V1092, P129, DOI 10.1016/j.brainres.2006.03.080; DiMicco JA, 2002, PHARMACOL BIOCHEM BE, V71, P469, DOI 10.1016/S0091-3057(01)00689-X; Florez-Duquet M, 2001, AM J PHYSIOL-REG I, V280, pR1457, DOI 10.1152/ajpregu.2001.280.5.R1457; Gallagher M, 1996, CURR OPIN NEUROBIOL, V6, P221, DOI 10.1016/S0959-4388(96)80076-6; HART BL, 1988, NEUROSCI BIOBEHAV R, V12, P123, DOI 10.1016/S0149-7634(88)80004-6; Heimer L, 2006, NEUROSCI BIOBEHAV R, V30, P126, DOI 10.1016/j.neubiorev.2005.06.006; HORN T, 1994, AM J PHYSIOL, V267, pR323, DOI 10.1152/ajpregu.1994.267.1.R323; JARRARD LE, 1989, J NEUROSCI METH, V29, P251, DOI 10.1016/0165-0270(89)90149-0; Jhou T, 2005, J COMP NEUROL, V493, P111, DOI 10.1002/cne.20734; KLUGER MJ, 1991, PHYSIOL REV, V71, P93, DOI 10.1152/physrev.1991.71.1.93; KORNEVA EK, 1992, NEUROIMMUNOLOGY FEVE, P145; KRUEGER JM, 1994, CRIT REV IMMUNOL, V14, P355, DOI 10.1615/CritRevImmunol.v14.i3-4.70; Lee HS, 2005, J NEUROSCI, V25, P1304, DOI 10.1523/JNEUROSCI.4745.04.2005; LIPTON JM, 1974, AM J PHYSIOL, V226, P1356, DOI 10.1152/ajplegacy.1974.226.6.1356; LIPTON JM, 1968, PHYSIOL BEHAV, V3, P165, DOI 10.1016/0031-9384(68)90049-8; LIPTON JM, 1976, AM J PHYSIOL, V231, P1638, DOI 10.1152/ajplegacy.1976.231.6.1638; LOVICK TA, 1993, BEHAV BRAIN RES, V58, P19, DOI 10.1016/0166-4328(93)90087-7; Lu J, 2001, J NEUROSCI, V21, P4864, DOI 10.1523/JNEUROSCI.21-13-04864.2001; Madden CJ, 2004, AM J PHYSIOL-REG I, V286, pR320, DOI 10.1152/ajpregu.00515.2003; Maruyama M, 2003, AM J PHYSIOL-REG I, V285, pR1116, DOI 10.1152/ajpregu.00166.2002; MOGA MM, 1990, J COMP NEUROL, V295, P624, DOI 10.1002/cne.902950408; Moqrich A, 2005, SCIENCE, V307, P1468, DOI 10.1126/science.1108609; Morrison SR, 2004, NEWS PHYSIOL SCI, V19, P67, DOI 10.1152/nips.01502.2003; Nagashima K, 2000, AUTON NEUROSCI-BASIC, V85, P18, DOI 10.1016/S1566-0702(00)00216-2; NAGEL JA, 1980, SCIENCE, V208, P301, DOI 10.1126/science.7367860; Nakamura K, 2002, J NEUROSCI, V22, P4600, DOI 10.1523/JNEUROSCI.22-11-04600.2002; Nakamura Y, 2005, EUR J NEUROSCI, V22, P3137, DOI 10.1111/j.1460-9568.2005.04515.x; Oka T, 2000, J COMP NEUROL, V428, P20, DOI 10.1002/1096-9861(20001204)428:1<20::AID-CNE3>3.0.CO;2-X; Onat FY, 2002, CELLS TISSUES ORGANS, V172, P48, DOI 10.1159/000064385; Patapoutian A, 2003, NAT REV NEUROSCI, V4, P529, DOI 10.1038/nrn1141; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Petersen, 2006, LECT NOTES HUMAN PHY, P603; Phelps EA, 2005, NEURON, V48, P175, DOI 10.1016/j.neuron.2005.09.025; ROBERTS WW, 1974, J COMP PHYSIOL PSYCH, V86, P470, DOI 10.1037/h0036147; ROBERTS WW, 1977, PHYSIOL BEHAV, V19, P503, DOI 10.1016/0031-9384(77)90226-8; ROBERTS WW, 1988, ANN NY ACAD SCI, V525, P363, DOI 10.1111/j.1749-6632.1988.tb38620.x; Romanovsky AA, 1996, AM J PHYSIOL-REG I, V271, pR244, DOI 10.1152/ajpregu.1996.271.1.R244; Romanovsky AA, 1997, ANN NY ACAD SCI, V813, P733, DOI 10.1111/j.1749-6632.1997.tb51775.x; Romanovsky AA, 2002, J APPL PHYSIOL, V92, P2667, DOI 10.1152/japplphysiol.01173.2001; Romanovsky AA, 1996, AM J PHYSIOL-REG I, V270, pR693, DOI 10.1152/ajpregu.1996.270.4.R693; Rosenzweig M, 2005, GENE DEV, V19, P419, DOI 10.1101/gad.1278205; SAKAGUCHI T, 1988, BRAIN RES BULL, V20, P461, DOI 10.1016/0361-9230(88)90135-9; SAPER CB, 1994, NEW ENGL J MED, V330, P1880; SAPER CB, 1985, J COMP NEUROL, V237, P21, DOI 10.1002/cne.902370103; SATINOFF E, 1976, BRAIN RES BULL, V1, P553, DOI 10.1016/0361-9230(76)90082-4; SATINOFF E, 1970, J COMP PHYSIOL PSYCH, V71, P77, DOI 10.1037/h0028959; Scammell TE, 1996, J NEUROSCI, V16, P6246; SCHULZE G, 1981, N-S ARCH PHARMACOL, V318, P43, DOI 10.1007/BF00503311; Srividya R, 2006, NEUROSCIENCE, V139, P853, DOI 10.1016/j.neuroscience.2006.01.003; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; SZALLASI A, 1989, NEUROSCIENCE, V30, P515, DOI 10.1016/0306-4522(89)90269-8; SZEKELY M, 1979, ACTA PHYSIOL HUNG, V53, P265; SZYMUSIAK R, 1982, PHYSIOL BEHAV, V28, P161, DOI 10.1016/0031-9384(82)90118-4; TERHORST GJ, 1986, BRAIN RES BULL, V16, P231; Thompson RH, 1998, BRAIN RES REV, V27, P89, DOI 10.1016/S0165-0173(98)00010-1; Thompson RH, 1996, J COMP NEUROL, V376, P143, DOI 10.1002/(SICI)1096-9861(19961202)376:1<143::AID-CNE9>3.0.CO;2-3; VANZOEREN JG, 1976, AM J PHYSIOL, V230, P932, DOI 10.1152/ajplegacy.1976.230.4.932; Yoshida K, 2003, EUR J NEUROSCI, V18, P1848, DOI 10.1046/j.1460-9568.2003.02919.x; YOSHIMATSU H, 1993, BRAIN RES, V601, P121, DOI 10.1016/0006-8993(93)91702-T; Zaretskaia MV, 2003, NEUROSCI LETT, V340, P1, DOI 10.1016/S0304-3940(03)00047-8	70	81	82	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e1	10.1371/journal.pone.0000001	http://dx.doi.org/10.1371/journal.pone.0000001			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183631	Green Published, gold			2022-12-25	WOS:000207443600001
J	Goddard, MR; Leigh, J; Roger, AJ; Pemberton, AJ				Goddard, Matthew R.; Leigh, Jessica; Roger, Andrew J.; Pemberton, Andrew J.			Invasion and Persistence of a Selfish Gene in the Cnidaria	PLOS ONE			English	Article								Background. Homing endonuclease genes (HEGs) are superfluous, but are capable of invading populations that mix alleles by biasing their inheritance patterns through gene conversion. One model suggests that their long-term persistence is achieved through recurrent invasion. This circumvents evolutionary degeneration, but requires reasonable rates of transfer between species to maintain purifying selection. Although HEGs are found in a variety of microbes, we found the previous discovery of this type of selfish genetic element in the mitochondria of a sea anemone surprising. Methods/Principal Findings. We surveyed 29 species of Cnidaria for the presence of the COXIHEG. Statistical analyses provided evidence for HEG invasion. We also found that 96 individuals of Metridium senile, from five different locations in the UK, had identical HEG sequences. This lack of sequence divergence illustrates the stable nature of Anthozoan mitochondria. Our data suggests this HEG conforms to the recurrent invasion model of evolution. Conclusions. Ordinarily such low rates of HEG transfer would likely be insufficient to enable major invasion. However, the slow rate of Anthozoan mitochondrial change lengthens greatly the time to HEG degeneration: this significantly extends the periodicity of the HEG life-cycle. We suggest that a combination of very low substitution rates and rare transfers facilitated metazoan HEG invasion.	[Goddard, Matthew R.] Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand; [Goddard, Matthew R.] Univ London Imperial Coll Sci Technol & Med, Natl Environm Res Council Ctr Populat Biol, London, England; [Leigh, Jessica; Roger, Andrew J.] Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS, Canada; [Pemberton, Andrew J.] Marine Biol Assoc UK, Plymouth, Devon, England	University of Auckland; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); Dalhousie University; Marine Biological Association United Kingdom	Goddard, MR (corresponding author), Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand.	m.goddard@auckland.ac.nz	Goddard, Matthew/C-7462-2014	Goddard, Matthew/0000-0002-7482-4438	Canadian Institutes for Health Research [MOP-62809]; UK Natural Environment Research Council; University of Auckland Research [3606223]	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); UK Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); University of Auckland Research	The contributions of JL and AJR were supported by an operating grant(MOP-62809) from the Canadian Institutes for Health Research. This work was funded by the UK Natural Environment Research Council and a University of Auckland Research grant (3606223) to MG.	Beagley CT, 1996, P NATL ACAD SCI USA, V93, P5619, DOI 10.1073/pnas.93.11.5619; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; Bergthorsson U, 2004, P NATL ACAD SCI USA, V101, P17747, DOI 10.1073/pnas.0408336102; Bergthorsson U, 2003, NATURE, V424, P197, DOI 10.1038/nature01743; Berntson EA, 1999, MOL PHYLOGENET EVOL, V13, P417, DOI 10.1006/mpev.1999.0649; Burt A, 2004, CURR OPIN GENET DEV, V14, P609, DOI 10.1016/j.gde.2004.09.010; Chevalier BS, 2001, NUCLEIC ACIDS RES, V29, P3757, DOI 10.1093/nar/29.18.3757; Dalgaard JZ, 1997, NUCLEIC ACIDS RES, V25, P4626, DOI 10.1093/nar/25.22.4626; France SC, 2002, HYDROBIOLOGIA, V471, P149, DOI 10.1023/A:1016517724749; Fukami H, 2005, CORAL REEFS, V24, P410, DOI 10.1007/s00338-005-0023-3; Goddard MR, 1999, P NATL ACAD SCI USA, V96, P13880, DOI 10.1073/pnas.96.24.13880; Goddard MR, 2001, P ROY SOC B-BIOL SCI, V268, P2537, DOI 10.1098/rspb.2001.1830; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Haugen P, 2005, TRENDS GENET, V21, P111, DOI 10.1016/j.tig.2004.12.007; Haugen P, 2004, MOL BIOL EVOL, V21, P129, DOI 10.1093/molbev/msh005; Huelsenbeck JP, 1996, SYST BIOL, V45, P92, DOI 10.2307/2413514; Koufopanou V, 2002, MOL BIOL EVOL, V19, P239, DOI 10.1093/oxfordjournals.molbev.a004077; Lampe DJ, 2003, MOL BIOL EVOL, V20, P554, DOI 10.1093/molbev/msg069; Lartillot N, 2006, SYST BIOL, V55, P195, DOI 10.1080/10635150500433722; Loreto ELD, 2001, J HERED, V92, P375, DOI 10.1093/jhered/92.5.375; Medina M, 2006, P NATL ACAD SCI USA, V103, P9096, DOI 10.1073/pnas.0602444103; Nishimura Y, 2002, GENE DEV, V16, P1116, DOI 10.1101/gad.979902; Nylander J. A. A., 2004, MRMODELTEST V2; Nylander JAA, 2004, SYST BIOL, V53, P47, DOI 10.1080/10635150490264699; Page RDM, 1998, TRENDS ECOL EVOL, V13, P356, DOI 10.1016/S0169-5347(98)01438-4; Pagel M, 1999, NATURE, V401, P877, DOI 10.1038/44766; Pinto SM, 2000, GENET MOL BIOL, V23, P601, DOI 10.1590/S1415-47572000000300017; PONTKINGDOM G, 1997, J MOL EVOL, V46, P419; Rokas A, 2003, TRENDS ECOL EVOL, V18, P411, DOI 10.1016/S0169-5347(03)00125-3; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Shearer TL, 2002, MOL ECOL, V11, P2475, DOI 10.1046/j.1365-294X.2002.01652.x; Shimodaira H, 1999, MOL BIOL EVOL, V16, P1114, DOI 10.1093/oxfordjournals.molbev.a026201; Swofford D.L., 2002, PAUP PHYLOGENETIC AN, DOI 10.1111/j.0014-3820.2002.tb00191.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Waggoner B, 2004, J PALEONTOL, V78, P51, DOI 10.1666/0022-3360(2004)078<0051:RAATTE>2.0.CO;2; White T.J., 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1; WOLFRAM S, 1996, MATH 5 0; Won JH, 2001, CORAL REEFS, V20, P39	39	41	41	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e3	10.1371/journal.pone.0000003	http://dx.doi.org/10.1371/journal.pone.0000003			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183657	Green Submitted, Green Accepted, Green Published, gold			2022-12-25	WOS:000207443600003
J	Lian, QZ; Yeo, KS; Que, JW; Tan, EKW; Yu, FG; Yin, YJ; Salto-Tellez, M; El Oakley, RM; Lim, SK				Lian, Qizhou; Yeo, Keng Suan; Que, Jianwen; Tan, Eileen Khia Way; Yu, Fenggang; Yin, Yijun; Salto-Tellez, Manuel; El Oakley, Reida Menshawe; Lim, Sai-Kiang			Establishing Clonal Cell Lines with Endothelial-Like Potential from CD9(hi), SSEA-1(-) Cells in Embryonic Stem Cell-Derived Embryoid Bodies	PLOS ONE			English	Article								Background. Differentiation of embryonic stem cells (ESCs) into specific cell types with minimal risk of teratoma formation could be efficiently directed by first reducing the differentiation potential of ESCs through the generation of clonal, self-renewing lineage-restricted stem cell lines. Efforts to isolate these stem cells are, however, mired in an impasse where the lack of purified lineage-restricted stem cells has hindered the identification of defining markers for these rare stem cells and, in turn, their isolation. Methodology/Principal Findings. We describe here a method for the isolation of clonal lineage-restricted cell lines with endothelial potential from ESCs through a combination of empirical and rational evidence-based methods. Using an empirical protocol that we have previously developed to generate embryo-derived RoSH lines with endothelial potential, we first generated E-RoSH lines from mouse ESC-derived embryoid bodies (EBs). Despite originating from different mouse strains, RoSH and E-RoSH lines have similar gene expression profiles (r(2) = 0.93) while that between E-RoSH and ESCs was 0.83. In silico gene expression analysis predicted that like RoSH cells, E-RoSH cells have an increased propensity to differentiate into vasculature. Unlike their parental ESCs, E-RoSH cells did not form teratomas and differentiate efficiently into endothelial-like cells in vivo and in vitro. Gene expression and FACS analysis revealed that RoSH and E-RoSH cells are CD9(hi), SSEA-1(-) while ESCs are CD9(lo), SSEA-1(+). Isolation of CD9(hi), SSEA-1(-) cells that constituted 1%-10% of EB-derived cultures generated an E-RoSH-like culture with an identical E-RoSH-like gene expression profile (r(2) = 0.95) and a propensity to differentiate into endothelial-like cells. Conclusions. By combining empirical and rational evidence-based methods, we identified definitive selectable surface antigens for the isolation and propagation of lineage-restricted stem cells with endothelial-like potential from mouse ESCs.	[Lian, Qizhou; Yeo, Keng Suan; Que, Jianwen; Tan, Eileen Khia Way; El Oakley, Reida Menshawe; Lim, Sai-Kiang] Genome Inst Singapore, Singapore, Singapore; [Lian, Qizhou; Que, Jianwen; Tan, Eileen Khia Way; Yu, Fenggang] Natl Univ Singapore, Dept Surg, Singapore 117548, Singapore; [Yin, Yijun] Natl Univ Singapore, Dept Obstet & Gynaecol, Singapore 117548, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; [Salto-Tellez, Manuel] Natl Univ Singapore, Dept Pathol, Singapore 117548, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore	Lim, SK (corresponding author), Genome Inst Singapore, Singapore, Singapore.	limsk@gis.a-star.edu.sg	Lim, Sai Kiang/AEN-0252-2022; Lian, Qizhou/Y-1613-2019	Lim, Sai Kiang/0000-0002-5752-3297; Lian, Qizhou/0000-0001-8189-7160; Salto-Tellez, Manuel/0000-0001-8586-282X; El Oakley, Reida M/0000-0003-4101-8998	ASTAR-BMRC (Agency for Science and Technology-Biomedical Research Council) [01/1/21/17/045]	ASTAR-BMRC (Agency for Science and Technology-Biomedical Research Council)(Agency for Science Technology & Research (A*STAR))	This work was funded by an ASTAR-BMRC (Agency for Science and Technology-Biomedical Research Council) grant (BMRC Project No. 01/1/21/17/045) to SKL and RMO. ASTAR-BMRC did not participate in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript	Aberdam D, 2004, INT J DEV BIOL, V48, P203, DOI 10.1387/ijdb.15272386; Barberi T, 2005, PLOS MED, V2, P554, DOI 10.1371/journal.pmed.0020161; Barreiro O, 2005, BLOOD, V105, P2852, DOI 10.1182/blood-2004-09-3606; Breier G, 1997, THROMB HAEMOSTASIS, V78, P678; BROWN DG, 1993, HISTOCHEM J, V25, P452, DOI 10.1007/BF00157810; Chung S, 2006, J NEUROCHEM, V97, P1467, DOI 10.1111/j.1471-4159.2006.03841.x; Conti L, 2005, PLOS BIOL, V3, P1594, DOI 10.1371/journal.pbio.0030283; Cui L, 2004, J HISTOCHEM CYTOCHEM, V52, P1447, DOI 10.1369/jhc.3A6241.2004; FORSYTH KD, 1991, IMMUNOLOGY, V72, P292; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; Greenlee AR, 2005, TOXICOL IN VITRO, V19, P389, DOI 10.1016/j.tiv.2004.11.002; HASHEMI S, 1991, AM J HEMATOL, V38, P293, DOI 10.1002/ajh.2830380408; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hidaka K, 2003, FASEB J, V17, P740, DOI 10.1096/fj.02-0104fje; Hirai H, 2003, BLOOD, V101, P886, DOI 10.1182/blood-2002-02-0655; Keller G, 2005, GENE DEV, V19, P1129, DOI 10.1101/gad.1303605; Kouskoff V, 2005, P NATL ACAD SCI USA, V102, P13170, DOI 10.1073/pnas.0501672102; Kubo A, 2004, DEVELOPMENT, V131, P1651, DOI 10.1242/dev.01044; Lim SK, 1997, BLOOD, V90, P1291, DOI 10.1182/blood.V90.3.1291.1291_1291_1299; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Miyagi T, 2002, EXP HEMATOL, V30, P1444, DOI 10.1016/S0301-472X(02)00961-X; Nagano K, 2005, PROTEOMICS, V5, P1346, DOI 10.1002/pmic.200400990; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; Oka M, 2002, MOL BIOL CELL, V13, P1274, DOI 10.1091/mbc.02-01-0600; Otani T, 2005, EXP HEMATOL, V33, P632, DOI 10.1016/j.exphem.2005.03.006; Rao M, 2004, DEV BIOL, V275, P269, DOI 10.1016/j.ydbio.2004.08.013; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Rippon HJ, 2006, STEM CELLS, V24, P1389, DOI 10.1634/stemcells.2005-0465; RISAU W, 1988, DEVELOPMENT, V102, P471; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUIZARGUELLES GJ, 1994, MAYO CLIN PROC, V69, P684, DOI 10.1016/S0025-6196(12)61350-0; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; Tada S, 2005, DEVELOPMENT, V132, P4363, DOI 10.1242/dev.02005; Wei CL, 2005, STEM CELLS, V23, P166, DOI 10.1634/stemcells.2004-0162; Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003; Wynne F, 2006, REPRODUCTION, V131, P721, DOI 10.1530/rep.1.00869; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yin Y, 2002, STEM CELLS, V20, P338, DOI 10.1634/stemcells.20-4-338; Yin YJ, 2004, ARTERIOSCL THROM VAS, V24, P691, DOI 10.1161/01.ATV.0000120375.51196.73; ZHAO Y, 2006, EXP CELL RES; Zola H, 2000, J BIOL REG HOMEOS AG, V14, P218	41	7	12	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e6	10.1371/journal.pone.0000006	http://dx.doi.org/10.1371/journal.pone.0000006			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183690	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600006
J	Scobie, HM; Young, JAT				Scobie, Heather M.; Young, John A. T.			Divalent Metal Ion Coordination by Residue T118 of Anthrax Toxin Receptor 2 Is Not Essential for Protective Antigen Binding	PLOS ONE			English	Article								The protective antigen (PA) subunit of anthrax toxin interacts with the integrin-like I domains of either of two cellular receptors, ANTXR1 or ANTXR2. These I domains contain a metal ion-dependent adhesion site (MIDAS) made up of five nonconsecutive amino acid residues that coordinate a divalent metal ion that is important for PA-binding. The MIDAS residues of integrin I domains shift depending upon whether the domain exists in a closed (ligand-unbound) or open (ligand-bound) conformation. Of relevance to this study, the MIDAS threonine residue coordinates the metal ion only in the open I domain conformation. Previously it was shown that the MIDAS threonine is essential for PA interaction with ANTXR1, a result consistent with the requirement that the I domain of that receptor adopts an open conformation for PA-binding [1]. Here we have tested the requirement for the MIDAS threonine of ANTXR2 for PA-binding. We show that the toxin can bind to a mutant receptor lacking the MIDAS threonine and that it can use that mutant receptor to intoxicate cultured cells. These findings suggest that an open-like configuration of the ANTXR2 MIDAS is not essential for the interaction with PA.	[Scobie, Heather M.; Young, John A. T.] Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA	Salk Institute	Young, JAT (corresponding author), Salk Inst Biol Studies, Infect Dis Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jyoung@salk.edu		Young, John/0000-0003-1824-2561	NIH [A156013]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by NIH grant A156013.	Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Bradley KA, 2003, J BIOL CHEM, V278, P49342, DOI 10.1074/jbc.M307900200; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P13147, DOI 10.1073/pnas.0405405101; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; Rosovitz MJ, 2003, J BIOL CHEM, V278, P30936, DOI 10.1074/jbc.M301154200; Santelli E, 2004, NATURE, V430, P905, DOI 10.1038/nature02763; Scobie HM, 2006, PLOS PATHOG, V2, P949, DOI 10.1371/journal.ppat.0020111; Scobie HM, 2005, J INFECT DIS, V192, P1047, DOI 10.1086/432731; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; Wigelsworth DJ, 2004, J BIOL CHEM, V279, P23349, DOI 10.1074/jbc.M401292200	14	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e99	10.1371/journal.pone.0000099	http://dx.doi.org/10.1371/journal.pone.0000099			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183731	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600098
J	Loffler, KA; Biondi, CA; Gartside, MG; Serewko-Auret, MM; Duncan, R; Tonks, ID; Mould, AW; Waring, P; Muller, HK; Kay, GF; Hayward, NK				Loffler, K. A.; Biondi, C. A.; Gartside, M. G.; Serewko-Auret, M. M.; Duncan, R.; Tonks, I. D.; Mould, A. W.; Waring, P.; Muller, H. K.; Kay, G. F.; Hayward, N. K.			Lack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice	ONCOGENE			English	Article						endocrine; pancreas; pituitary; parathyroid; thyroid	MULTIPLE ENDOCRINE NEOPLASIA; CELL-CYCLE; CONDITIONAL INACTIVATION; RETINOBLASTOMA GENE; TYPE-1; SUPPRESSOR; GROWTH; TUMORIGENESIS; EXPRESSION; PROTEIN	To identify possible genetic interactions between the mechanisms of tumor suppression of menin and pRb, we intercrossed mice with targeted deletions of Men1 and Rb1, and compared tumor development in cohorts of animals carrying single or dual mutations of these tumor-suppressor genes. In mice lacking one copy of Men1, pancreatic islet and anterior pituitary adenomas are common. In animals lacking one copy of Rb1, intermediate pituitary and thyroid tumors occur at high frequency, with less frequent development of pancreatic islet hyperplasia and parathyroid lesions. In mice heterozygous for both Men1 and Rb1, pancreatic hyperplasia and tumors of the intermediate pituitary and thyroid occurred at high frequency. Serum measurements of calcium and glucose did not vary significantly between genotypic groups. Loss of heterozygosity at the Rb1 locus was common in pituitary and thyroid tumors, whereas loss of menin was observed in pancreatic and parathyroid lesions. The tumor spectrum in the double heterozygotes was a combination of pathologies seen in each of the individual heterozygotes, without decrease in age of onset, indicating independent, non-additive effects of the two mutations. Together with the lack of increased tumor spectrum, this suggests that menin and pRb function in a common pathway of tumor suppression.	Queensland Inst Med Res, Canc & Cell Biol Div, Herston, Qld 4029, Australia; Peter MacCallum Canc Inst, Dept Pathol, Melbourne, Vic, Australia; Univ Tasmania, Sch Med, Hobart, Tas, Australia	QIMR Berghofer Medical Research Institute; Peter Maccallum Cancer Center; University of Tasmania	Hayward, NK (corresponding author), Queensland Inst Med Res, Canc & Cell Biol Div, 300 Herston Rd, Herston, Qld 4029, Australia.	Nick.Hayward@qimr.edu.au	hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020; Kay, Graham F/A-4130-2011	hayward, nicholas k/0000-0003-4760-1033; Loffler, Kelly/0000-0003-3302-5995; Mould, Arne/0000-0002-2004-4348				Agarwal SK, 2003, P NATL ACAD SCI USA, V100, P10770, DOI 10.1073/pnas.1834524100; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; Biondi C, 2002, GENESIS, V32, P150, DOI 10.1002/gene.10061; Biondi CA, 2004, MOL CELL BIOL, V24, P3125, DOI 10.1128/MCB.24.8.3125-3131.2004; Busygina V, 2004, HUM MOL GENET, V13, P2399, DOI 10.1093/hmg/ddh271; Casanovas O, 2005, ONCOGENE, V24, P6597, DOI 10.1038/sj.onc.1208823; CHANDRASEKHARAP.S, 2003, J INTERN MED, V253, P599; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; CRYNS VL, 1994, NEW ENGL J MED, V330, P757, DOI 10.1056/NEJM199403173301105; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jin SH, 2003, CANCER RES, V63, P4204; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Karnik SK, 2005, P NATL ACAD SCI USA, V102, P14659, DOI 10.1073/pnas.0503484102; Kim H, 2003, CANCER RES, V63, P6135; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; LOFFLER KA, 2006, INT J CANC      1016; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; Ratineau C, 2004, J BIOL CHEM, V279, P24477, DOI 10.1074/jbc.M401835200; Schnepp RW, 2004, J BIOL CHEM, V279, P10685, DOI 10.1074/jbc.M308073200; Sowa H, 2004, J BIOL CHEM, V279, P40267, DOI 10.1074/jbc.M401312200; Sowa H, 2003, J BIOL CHEM, V278, P21058, DOI 10.1074/jbc.M302044200; Tonks ID, 2005, PIGM CELL RES, V18, P252, DOI 10.1111/j.1600-0749.2005.00245.x; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480	31	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					4009	4017		10.1038/sj.onc.1210163	http://dx.doi.org/10.1038/sj.onc.1210163			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17173065	Bronze			2022-12-25	WOS:000247144500011
J	Ayllon, V; O'Connor, R				Ayllon, V.; O'Connor, R.			TOPK promotes tumour cell proliferation through p38MAPK activity and regulation of the DNA damage response	ONCOGENE			English	Article						IGF-IR; p38; PBK; H2AX; tumour growth	INSULIN-LIKE-GROWTH; IGF-I RECEPTOR; PDZ-BINDING KINASE; NUCLEOTIDE EXCISION-REPAIR; DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION; PROTEIN-KINASE; MICROARRAY ANALYSIS; IONIZING-RADIATION; GENE-EXPRESSION	The contribution of the insulin-like growth-factor-I receptor (IGF-IR) to tumour progression is well documented. To identify new mediators of IGF-IR function in cancer, we recently isolated genes differentially expressed in cells overexpressing the IGF-IR. Among these was the serine/threonine kinase PBK/TOPK (PDZ-binding kinase/T-LAK cell-originated protein kinase), previously associated with highly proliferative cells and tissues. Here, we show that PBK is expressed at high levels in tumour cell lines compared with non-transformed cells. IGF-I could induce PBK expression only in transformed cells, whereas epidermal growth factor could induce PBK in non-transformed MCF-10A breast epithelial cells. Suppression of PBK expression using small interfering RNA did not prevent progression through the cell cycle, but caused decreased proliferation over time in culture, and reduced clonogenic growth in soft agarose. PBK knockdown impaired p38 activation after long-term stimulation with different growth factors and reduced DU145 cells motility. Suppressed PBK expression also resulted in an impaired response to DNA damage that was evident by the decreased generation of gamma-H2AX, increased DNA damage and decreased cell survival. Taken together, the data indicate that PBK is necessary for appropriate activation and function of the p38 pathway by growth factors. Thus, enhanced expression of PBK may facilitate tumour growth by mediating p38 activation and by helping cells to overcome DNA damage.	Natl Univ Ireland, BioSci Inst, Cell Biol Lab, Dept Biochem, Cork, Ireland	University College Cork	O'Connor, R (corresponding author), Natl Univ Ireland, BioSci Inst, Cell Biol Lab, Dept Biochem, Coll Rd, Cork, Ireland.	r.oconnor@ucc.ie	O'Connor, Rosemary/B-7902-2014; Ayllon, Veronica/L-7069-2014	O'Connor, Rosemary/0000-0002-0687-3422; Ayllon, Veronica/0000-0002-7322-9282				Abe Y, 2000, J BIOL CHEM, V275, P21525, DOI 10.1074/jbc.M909629199; Bartucci M, 2001, CANCER RES, V61, P6747; Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652; Cote S, 2002, CYTOKINE, V20, P113, DOI 10.1006/cyto.2002.1988; Dendouga N, 2005, MOL CELL BIOL, V25, P7569, DOI 10.1128/MCB.25.17.7569-7579.2005; Dougherty JD, 2005, J NEUROSCI, V25, P10773, DOI 10.1523/JNEUROSCI.3207-05.2005; Dupont J, 2003, RECENT PROG HORM RES, V58, P325, DOI 10.1210/rp.58.1.325; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Friedmann B, 2004, CLIN CANCER RES, V10, P6476, DOI 10.1158/1078-0432.CCR-04-0586; Fujibuchi T, 2005, DEV GROWTH DIFFER, V47, P637, DOI 10.1111/j.1440-169X.2005.00834.x; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Heron-Milhavet L, 2001, J BIOL CHEM, V276, P18185, DOI 10.1074/jbc.M011490200; Hofmann F, 2005, DRUG DISCOV TODAY, V10, P1041, DOI 10.1016/S1359-6446(05)03512-9; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Kim MS, 2003, CANCER RES, V63, P5454; Lee-Kwon W, 1998, EXP CELL RES, V241, P458, DOI 10.1006/excr.1998.4087; Lisby M, 2004, CURR OPIN CELL BIOL, V16, P328, DOI 10.1016/j.ceb.2004.03.011; Loughran G, 2005, ONCOGENE, V24, P6185, DOI 10.1038/sj.onc.1208772; Loughran G, 2005, MOL BIOL CELL, V16, P1811, DOI 10.1091/mbc.E04-12-1052; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; Madhusudan S, 2005, TRENDS MOL MED, V11, P503, DOI 10.1016/j.molmed.2005.09.004; Maldonado C, 2005, BIOCHEM BIOPH RES CO, V336, P1112, DOI 10.1016/j.bbrc.2005.08.245; Marti TM, 2006, P NATL ACAD SCI USA, V103, P9891, DOI 10.1073/pnas.0603779103; Matsumoto S, 2004, BIOCHEM BIOPH RES CO, V325, P997, DOI 10.1016/j.bbrc.2004.10.133; Mauro L, 2004, J MOL HISTOL, V35, P247; Mikhailov A, 2005, CELL CYCLE, V4, P57, DOI 10.4161/cc.4.1.1357; Mulligan C, 2002, J BIOL CHEM, V277, P42480, DOI 10.1074/jbc.M206206200; Nandi A, 2004, BLOOD CELL MOL DIS, V32, P240, DOI 10.1016/j.bcmd.2003.10.004; Nandi AK, 2006, LEUKEMIA RES, V30, P437, DOI 10.1016/j.leukres.2005.08.011; O'Connor R, 2003, HORM METAB RES, V35, P771; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Risinger MA, 2004, CANCER CELL, V6, P539, DOI 10.1016/j.ccr.2004.12.001; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; Sartor CI, 2004, NAT CLIN PRACT ONCOL, V1, P80, DOI 10.1038/ncponc0048; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shen WH, 2004, J BIOL CHEM, V279, P7438, DOI 10.1074/jbc.M310264200; Simons-Evelyn M, 2001, BLOOD CELL MOL DIS, V27, P825, DOI 10.1006/bcmd.2001.0452; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Speit G, 1999, METH MOL B, V113, P203; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Surmacz E, 2003, ONCOGENE, V22, P6589, DOI 10.1038/sj.onc.1206772; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Wang WD, 2005, CLIN CANCER RES, V11, P5140, DOI 10.1158/1078-0432.CCR-04-2548; Yacoub A, 2003, RADIAT RES, V159, P439, DOI 10.1667/0033-7587(2003)159[0439:EGFAIR]2.0.CO;2; Yang S, 2005, AM J PHYSIOL-RENAL, V289, pF1144, DOI 10.1152/ajprenal.00094.2005	49	111	118	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3451	3461		10.1038/sj.onc.1210142	http://dx.doi.org/10.1038/sj.onc.1210142			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160018				2022-12-25	WOS:000246799200001
J	Qiu, W; Zhou, M; Mazumdar, M; Azzi, A; Ghanmi, D; Luu-The, V; Labrie, F; Lin, SX				Qiu, Wei; Zhou, Ming; Mazumdar, Mausumi; Azzi, Arezki; Ghanmi, Dalila; Luu-The, Van; Labrie, Fernand; Lin, Sheng-Xiang			Structure-based inhibitor design for an enzyme that binds different steroids - A potent inhibitor for human type 5 17 beta-hydroxysteroid dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; KETO REDUCTASE AKR1C3; PROSTATE-CANCER; ESTROGENIC 17-BETA-HYDROXYSTEROID-DEHYDROGENASE; 3-BETA-HYDROXYSTEROID DEHYDROGENASE; CRYSTAL-STRUCTURES; LHRH AGONIST; EXPRESSION; LOCALIZATION; ESTRADIOL	Human type 5 17 beta-hydroxysteroid dehydrogenase plays a crucial role in local androgen formation in prostate tissue. Several chemicals were synthesized and tested for their ability to inhibit this enzyme, and a series of estradiol derivatives bearing a lactone on the D-ring were found to inhibit its activity efficiently. The crystal structure of the type 5 enzyme in complex with NADP and such a novel inhibitor, EM1404, was determined to a resolution of 1.30 angstrom. Significantly more hydrogen bonding and hydrophobic interactions were defined between EM1404 and the enzyme than in the substrate ternary complex. The lactone ring of EM1404 accounts for important interactions with the enzyme, whereas the amide group at the opposite end of the inhibitor contributes to the stability of three protein loops involved in the construction of the substrate binding site. EM1404 has a strong competitive inhibition, with a K-i of 6.9 +/- 1.4 nM, demonstrating 40 times higher affinity than that of the best inhibitor previously reported. This is observed despite the fact that the inhibitor occupies only part of the binding cavity. Attempts to soak the inhibitor into crystals of the binary complex with NADP were unsuccessful, yielding a structure with a polyethylene glycol fragment occupying the substrate binding site. The relative crystal packing is discussed. Combined studies of small molecule inhibitor synthesis, x-ray crystallography, enzyme inhibition, and molecular modeling make it possible to analyze the plasticity of the substrate binding site of the enzyme, which is essential for developing more potent and specific inhibitors for hormone-dependent cancer therapy.	Univ Laval, Res Ctr, CHU Quebec, Canadian Inst Hlth,Res Grp Mol Endocrinol, Quebec City, PQ G1V 4G2, Canada	Laval University	Lin, SX (corresponding author), Univ Laval, Res Ctr, CHU Quebec, Canadian Inst Hlth,Res Grp Mol Endocrinol, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	sxlin@crchul.ulaval.ca		Lin, Sheng-Xiang/0000-0001-9149-375X				ANDERSSON S, 1995, J ENDOCRINOL, V146, P197, DOI 10.1677/joe.0.1460197; Azzi A, 1996, NAT STRUCT BIOL, V3, P665, DOI 10.1038/nsb0896-665; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTSCH W, 1987, J STEROID BIOCHEM, V28, P35, DOI 10.1016/0022-4731(87)90121-X; Bauman DR, 2005, MOL PHARMACOL, V67, P60, DOI 10.1124/mol.104.006569; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; Burczynski ME, 1998, BIOCHEMISTRY-US, V37, P6781, DOI 10.1021/bi972725u; Denmeade SR, 1996, PROSTATE, V28, P251; Desmond JC, 2003, CANCER RES, V63, P505; Dufort I, 1999, ENDOCRINOLOGY, V140, P568, DOI 10.1210/en.140.2.568; El-Alfy M, 1999, ENDOCRINOLOGY, V140, P1481, DOI 10.1210/en.140.3.1481; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gangloff A, 2002, FASEB J, V16, P274, DOI 10.1096/fj.02-0397fje; Han Q, 2000, J BIOL CHEM, V275, P1105, DOI 10.1074/jbc.275.2.1105; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; Jez JM, 1997, BIOCHEM PHARMACOL, V54, P639, DOI 10.1016/S0006-2952(97)84253-0; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Koh E, 2002, PROSTATE, V53, P154, DOI 10.1002/pros.10139; Komoto J, 2004, BIOCHEMISTRY-US, V43, P2188, DOI 10.1021/bi036046x; Krazeisen A, 2002, ADV EXP MED BIOL, V505, P151; Krazeisen A, 2001, MOL CELL ENDOCRINOL, V171, P151, DOI 10.1016/S0303-7207(00)00422-6; LABRIE F, 1985, J STEROID BIOCHEM, V23, P833, DOI 10.1016/S0022-4731(85)80024-8; LABRIE F, 1982, CLIN INVEST MED, V5, P267; Labrie F, 2003, M S-MED SCI, V19, P910, DOI 10.1051/medsci/20031910910; Labrie F, 2002, UROLOGY, V60, P115, DOI 10.1016/S0090-4295(02)01639-4; LABRIE F, 1999, Patent No. 9946279; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Lin HK, 2004, STEROIDS, V69, P795, DOI 10.1016/j.steroids.2004.09.014; Lin HK, 1997, MOL ENDOCRINOL, V11, P1971, DOI 10.1210/me.11.13.1971; Lin SX, 2006, MOL CELL ENDOCRINOL, V248, P38, DOI 10.1016/j.mce.2005.11.035; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; Lovering AL, 2004, CANCER RES, V64, P1802, DOI 10.1158/0008-5472.CAN-03-2847; MARTEL C, 1992, J STEROID BIOCHEM, V41, P597, DOI 10.1016/0960-0760(92)90390-5; Matsuura K, 1998, J BIOCHEM-TOKYO, V124, P940, DOI 10.1093/oxfordjournals.jbchem.a022211; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nakamura Y, 2005, ENDOCR-RELAT CANCER, V12, P101, DOI 10.1677/erc.1.00914; Oduwole OO, 2004, CANCER RES, V64, P7604, DOI 10.1158/0008-5472.CAN-04-0446; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pelletier G, 1999, J HISTOCHEM CYTOCHEM, V47, P731, DOI 10.1177/002215549904700602; Pelletier G, 2001, J ENDOCRINOL, V171, P373, DOI 10.1677/joe.0.1710373; Penning TM, 2000, BIOCHEM J, V351, P67, DOI 10.1042/0264-6021:3510067; Penning TM, 2001, MOL CELL ENDOCRINOL, V171, P137, DOI 10.1016/S0303-7207(00)00426-3; Qiu W, 2004, MOL ENDOCRINOL, V18, P1798, DOI 10.1210/me.2004-0032; Qiu W, 2002, FASEB J, V16, P1829, DOI 10.1096/fj.02-0026fje; Qiu W, 1999, J STEROID BIOCHEM, V68, P239, DOI 10.1016/S0960-0760(99)00036-9; QIU W, 2002, THESIS LAVAL U QUEBE; Quinkler M, 2004, J ENDOCRINOL, V183, P331, DOI 10.1677/joe.1.05762; Rheault P, 1999, CYTOGENET CELL GENET, V84, P241, DOI 10.1159/000015267; SEGEL LA, 1976, J THEOR BIOL, V57, P23, DOI 10.1016/S0022-5193(76)80004-5; Soronen P, 2004, J STEROID BIOCHEM, V92, P281, DOI 10.1016/j.jsbmb.2004.10.004; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Wick M, 2002, MOL PHARMACOL, V62, P1207, DOI 10.1124/mol.62.5.1207; Zhou M, 2002, ACTA CRYSTALLOGR D, V58, P1048, DOI 10.1107/S0907444902005255; Zhu DW, 1996, J CRYST GROWTH, V168, P275, DOI 10.1016/0022-0248(96)00331-4	54	48	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8368	8379		10.1074/jbc.M606784200	http://dx.doi.org/10.1074/jbc.M606784200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17166832	hybrid			2022-12-25	WOS:000245081000070
J	Ning, Y; Buranda, T; Hudson, LG				Ning, Yan; Buranda, Tione; Hudson, Laurie G.			Activated epidermal growth factor receptor induces integrin alpha 2 internalization via caveolae/raft-dependent endocytic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN EPITHELIAL CARCINOMA; EGF-RECEPTOR; SURFACE EXPRESSION; MESOTHELIAL CELLS; PLASMA-MEMBRANE; ADHESION; MIGRATION; KINASE; COLLAGEN; TYROSINE	Elevated expression or activity of the epidermal growth factor (EGF) receptor is common in ovarian cancer and is associated with poor patient prognosis. Our previous studies demonstrated that expression of the constitutively active mutant form of the EGF receptor (EGFRvIII) in ovarian cancer cells led to reduction in integrin alpha 2 surface expression, defects in cell spreading, and disruption of focal adhesions. Inhibition of EGFRvIII catalytic activity reversed the response, suggesting that EGF receptor activation regulates integrin alpha 2. In this study we found that EGF treatment resulted in a transient loss of integrin alpha 2 from the cell surface. Before EGF stimulation, integrin alpha 2 and EGF receptors were associated based on biochemical and immuno-colocalization approaches. After EGF treatment, EGF receptor and integrin alpha 2 were internalized and segregated into different compartments. Integrin alpha 2, but not EGF receptor, was associated with caveolin-1 and GM1 (Gal_1,3GaINAc_1,4(Neu5Ac-_ 2,3)Gal_1,4GIc_1,1-ceramide) gangliosides, suggesting caveolae-mediated endocytosis. Moreover, integrin alpha 2 was subsequently targeted to the Golgi apparatus and the endoplasmic reticulum. Together, these findings demonstrate that activated EGF receptor transiently modulates integrin alpha 2 cell surface expression and stimulates integrin alpha 2 trafficking via caveolae/ raft-mediated endocytosis, representing a novel mechanism by which the EGF receptor may regulate integrin-mediated cell behavior.	Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico	Hudson, LG (corresponding author), Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA.	lhudson@salud.unm.edu			NATIONAL CANCER INSTITUTE [R01CA090492, P30CA118100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K25AI060036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES012072] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA118100, R01 CA90492] Funding Source: Medline; NIAID NIH HHS [K25 AI060036, K25 AI 60036] Funding Source: Medline; NIEHS NIH HHS [P30 ES-012072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abulrob A, 2004, ONCOGENE, V23, P6967, DOI 10.1038/sj.onc.1207911; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Auersperg N, 2003, GYNECOL ONCOL, V88, pS47, DOI 10.1006/gyno.2002.6683; Berryman S, 2005, J VIROL, V79, P8519, DOI 10.1128/JVI.79.13.8519-8534.2005; Burns AR, 2005, BIOPHYS J, V89, P1081, DOI 10.1529/biophysj.105.060327; Cabodi S, 2004, BIOCHEM SOC T, V32, P438, DOI 10.1042/BST0320438; CANNISTRA SA, 1995, GYNECOL ONCOL, V58, P216, DOI 10.1006/gyno.1995.1214; Caswell PT, 2006, TRAFFIC, V7, P14, DOI 10.1111/j.1600-0854.2005.00362.x; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Fabbri M, 2005, MOL BIOL CELL, V16, P5793, DOI 10.1091/mbc.E05-05-0413; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Fishman DA, 1998, INVAS METAST, V18, P15, DOI 10.1159/000024495; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HARVEY W, 1983, J PATHOL, V139, P337, DOI 10.1002/path.1711390309; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Imelli N, 2004, J VIROL, V78, P3089, DOI 10.1128/JVI.78.6.3089-3098.2004; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Klekotka PA, 2001, J BIOL CHEM, V276, P9503, DOI 10.1074/jbc.M006286200; Klekotka PA, 2001, J BIOL CHEM, V276, P32353, DOI 10.1074/jbc.M101921200; Krensel K, 1999, INT J CANCER, V80, P546, DOI 10.1002/(SICI)1097-0215(19990209)80:4<546::AID-IJC11>3.0.CO;2-9; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Li J, 1999, J BIOL CHEM, V274, P11209, DOI 10.1074/jbc.274.16.11209; Maihle N J, 2002, Cancer Treat Res, V107, P247; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Moser TL, 1996, INT J CANCER, V67, P695, DOI 10.1002/(SICI)1097-0215(19960904)67:5<695::AID-IJC18>3.3.CO;2-2; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; NIEDBALA MJ, 1987, CLIN EXP METASTAS, V5, P181, DOI 10.1007/BF00058063; Ning Y, 2005, CANCER RES, V65, P9280, DOI 10.1158/0008-5472.CAN-05-0407; Norkin LC, 2002, J VIROL, V76, P5156, DOI 10.1128/JVI.76.10.5156-5166.2002; Pang H, 2004, J CELL SCI, V117, P1421, DOI 10.1242/jcs.01009; Panicker AK, 2006, EXP CELL RES, V312, P299, DOI 10.1016/j.yexcr.2005.10.031; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Powelka AM, 2004, TRAFFIC, V5, P20, DOI 10.1111/j.1600-0854.2004.00150.x; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rezgui SS, 2000, INT J CANCER, V87, P360, DOI 10.1002/1097-0215(20000801)87:3<360::AID-IJC8>3.0.CO;2-9; Ringerike T, 2002, J CELL SCI, V115, P1331; SAWADA M, 1994, LAB INVEST, V70, P333; Sharma DK, 2005, CANCER RES, V65, P8233, DOI 10.1158/0008-5472.CAN-05-0803; Skubitz Amy P N, 2002, Cancer Treat Res, V107, P305; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SPIEGEL S, 1984, J CELL BIOL, V99, P1575, DOI 10.1083/jcb.99.5.1575; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Strobel T, 1997, CANCER RES, V57, P1228; Thyberg J, 2000, LAB INVEST, V80, P915, DOI 10.1038/labinvest.3780095; Upla P, 2004, MOL BIOL CELL, V15, P625, DOI 10.1091/mbc.E03-08-0588; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Wong Alice S T, 2003, Reprod Biol Endocrinol, V1, P70, DOI 10.1186/1477-7827-1-70; Yu X, 2000, J CELL SCI, V113, P2139; ZHU GG, 1993, CANCER RES, V53, P5028	61	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6380	6387		10.1074/jbc.M610915200	http://dx.doi.org/10.1074/jbc.M610915200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17179151	hybrid			2022-12-25	WOS:000244867200045
J	Zihni, C; Mitsopoulos, C; Tavares, IA; Baum, B; Ridley, AJ; Morris, JDH				Zihni, Ceniz; Mitsopoulos, Costas; Tavares, Ignatius A.; Baum, Buzz; Ridley, Anne J.; Morris, Jonathan D. H.			Prostate-derived sterile 20-like kinase 1-alpha induces apoptosis - JNK- and caspase-dependent nuclear localization is a requirement for membrane blebbing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; N-TERMINAL KINASE; PROTEIN-KINASE; STE20-RELATED KINASE; MEDIATED ACTIVATION; SCAFFOLD PROTEINS; HISTONE H2B; ROCK-I; CLEAVAGE; PHOSPHORYLATION	We have demonstrated previously that full-length prostate-derived sterile 20-like kinase 1-alpha (PSK1-alpha) binds to microtubules via its C terminus and regulates their organization and stability independently of its catalytic activity. Here we have shown that apoptotic and microtubule-disrupting agents promote catalytic activation, C-terminal cleavage, and nuclear translocation of endogenous phosphoserine 181 PSK1-a and activated N-terminal PSK1-alpha-induced apoptosis. PSK1-a, unlike its novel isoform PSK1-beta, stimulated the c-jun N-terminal kinase (JNK) pathway, and the nucleajr localization of PSK1-alpha and its induction of cell contraction, membrane blebbing, and apoptotic body formation were dependent on JNK activity. PSK1-alpha was also a caspase substrate, and the broad spectrum caspase inhibitor benzyloxycarbonyl-VAD-fluoromethyl ketone or mutation of a putative caspase recognition motif ((916)DPGD(919)) blocked nuclear localization of PSK1-a and its induction of membrane blebs. Additional inhibition of caspase 9 was needed to prevent cell contraction. PSK1-a is therefore a bifunctional kinase that associates with microtubules, and JNK-and caspase-mediated removal of its C-terminal microtubule-binding domain permits nuclear translocation of the N-terminal region of PSK1-alpha and its induction of apoptosis.	Kings Coll London, Rayne Inst, London SE5 9NU, England; UCL Branch, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; King's College London; Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Morris, JDH (corresponding author), Kings Coll London, Rayne Inst, 123 Coldharbour Lane, London SE5 9NU, England.	jonathan.morris@kcl.ac.uk		Baum, Buzz/0000-0002-9201-6186; Mitsopoulos, Costas/0000-0002-9116-5921; Ridley, Anne/0000-0001-8186-5708				Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Dan I, 2002, J BIOL CHEM, V277, P5929, DOI 10.1074/jbc.M110882200; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de la Barre AE, 2001, EMBO J, V20, P6383, DOI 10.1093/emboj/20.22.6383; Deng Y, 2003, J BIOL CHEM, V278, P11760, DOI 10.1074/jbc.M211085200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Flygare J, 1998, FEBS LETT, V427, P247, DOI 10.1016/S0014-5793(98)00433-5; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Huang CYF, 2002, J BIOL CHEM, V277, P34367, DOI 10.1074/jbc.M202468200; Kelkar N, 2005, MOL CELL BIOL, V25, P2733, DOI 10.1128/MCB.25.7.2733-2743.2005; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Leverrier Y, 2001, NAT CELL BIOL, V3, pE91, DOI 10.1038/35070151; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Mitsopoulos C, 2003, J BIOL CHEM, V278, P18085, DOI 10.1074/jbc.M213064200; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Schwab BL, 1998, EXP CELL RES, V238, P415, DOI 10.1006/excr.1997.3850; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Ura S, 2001, GENES CELLS, V6, P519, DOI 10.1046/j.1365-2443.2001.00439.x; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhou TJ, 2004, STRUCTURE, V12, P1891, DOI 10.1016/j.str.2004.07.021; Zihni C, 2006, J BIOL CHEM, V281, P7317, DOI 10.1074/jbc.M513769200	44	26	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6484	6493		10.1074/jbc.M608336200	http://dx.doi.org/10.1074/jbc.M608336200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17158878	hybrid			2022-12-25	WOS:000244867200056
J	Chauhan, A; Hahn, S; Gartner, S; Pardo, CA; Netesan, SK; McArthur, J; Nath, A				Chauhan, Ashok; Hahn, Sven; Gartner, Suzanne; Pardo, Carlos A.; Netesan, Senthil Kumar; McArthur, Justin; Nath, Avindra			Molecular programming of endothelin-1 in HIV-infected brain: role of Tat in up-regulation of ET-1 and its inhibition by statins	FASEB JOURNAL			English	Article						HIV-neuropathogenesis; nuclear Tat; ET-1 transcriptional regulation; NF-kappa B; simvastatin	HUMAN-IMMUNODEFICIENCY-VIRUS; FACTOR-KAPPA-B; HUMAN FETAL ASTROCYTES; NITRIC-OXIDE SYNTHASE; GENE-EXPRESSION; CEREBROSPINAL-FLUID; PROTEIN-KINASE; GLIAL-CELLS; FACTOR-I; ACTIVATION	Human Immune Deficiency Virus-1 (HIV-1) infection can induce severe and debilitating neurological problems, including behavioral abnormalities, motor dysfunction, and dementia. HIV can persistently infect astrocytes, during which viral accessory proteins are produced that are unaffected by current antiretroviral therapy. The effect of these proteins on astrocyte function remains unknown. Astrocytes are the predominant cells within the brain; thus, disruption of astrocyte function could influence the neuropathogenesis of HIV infection. To explore further these effects, we constitutively expressed HIV-Tat protein in astrocytes. Since the nuclear presence of Tat protein leads to alteration of host gene expression, we further analyzed the effects of Tat on host gene transcripts. Endothelin-1 (ET-1) was a significantly elevated transcript as verified by reverse transcription-polymerase chain reaction (RT-PCR), and it was subsequently released extracellularly in Tat-expressing and HIV-infected astrocytes. ET-I expression was also prominent in reactive astrocytes and neurons in brain tissues from basal ganglia and frontal lobes of HfV encephalitic patients. HIV-Tat regulated ET-I at the transcriptional level through NF-kappa B (NF-kappa B)-responsive sites in the ET-1 promoter. Intriguingly, simvastatin (10 mu M) down-regulated HIV-Tat-induced ET-1 and also inhibited activation of NF-kappa B in astrocytes. Our findings suggest that ET-1 may be critical in mediating the neuropathogenesis of HIV dementia and that statins may have therapeutic potential in these patients.	Johns Hopkins Univ, Dept Neurol, Richard Johnson Div Neuroimmunol & Neurol Infect, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Chauhan, A (corresponding author), Johns Hopkins Univ, Dept Neurol, Richard Johnson Div Neuroimmunol & Neurol Infect, 509 Pathol,600 N Wolfe St, Baltimore, MD 21287 USA.	achauha1@jhmi.edu	Pardo, Carlos A./A-5192-2008	Pardo, Carlos A./0000-0002-4128-5335	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH070306, P01MH070056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039253, R01NS050064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K08DA016160] Funding Source: NIH RePORTER; NIDA NIH HHS [K08DA16160, K08 DA016160-04, K08 DA016160] Funding Source: Medline; NIMH NIH HHS [P01MH070306, P01MH070056, P01 MH070056, P01 MH070306] Funding Source: Medline; NINDS NIH HHS [R01 NS050064, R01NS039253, R01 NS039253, R01 NS050064-02, R01NS050064] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson CE, 2003, NEUROPATH APPL NEURO, V29, P378, DOI 10.1046/j.1365-2990.2003.00475.x; Braun-Moscovici Y, 2004, SEMIN ARTHRITIS RHEU, V34, P442, DOI 10.1016/j.semarthrit.2003.11.003; Bruce-Keller AJ, 2003, J NEUROSCI, V23, P8417; Chauhan A, 2003, J BIOL CHEM, V278, P13512, DOI 10.1074/jbc.M209381200; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CHOWDHURY M, 1992, J VIROL, V66, P7355, DOI 10.1128/JVI.66.12.7355-7361.1992; Conant K, 1996, J VIROL, V70, P1384, DOI 10.1128/JVI.70.3.1384-1389.1996; del Real G, 2004, J EXP MED, V200, P541, DOI 10.1084/jem.20040061; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; DEWHURST S, 1987, FEBS LETT, V213, P138, DOI 10.1016/0014-5793(87)81479-5; Didier N, 2002, NEUROREPORT, V13, P1179, DOI 10.1097/00001756-200207020-00022; Doi M, 2000, HYPERTENS RES, V23, P643, DOI 10.1291/hypres.23.643; EHRENREICH H, 1993, J IMMUNOL, V150, P4601; EPSTEIN L G, 1984, AIDS Research, V1, P447; FARRE AL, 1993, CIRCULATION, V88, P1166, DOI 10.1161/01.CIR.88.3.1166; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; Gorry P, 1998, J NEUROVIROL, V4, P377, DOI 10.3109/13550289809114536; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hery C, 1997, NEUROPATH APPL NEURO, V23, P352, DOI 10.1111/j.1365-2990.1997.tb01307.x; Ho MCY, 2001, FASEB J, V15, P618, DOI 10.1096/fj.99-1022com; Hughes PM, 2003, J NEUROPATH EXP NEUR, V62, P1276, DOI 10.1093/jnen/62.12.1276; INOUE A, 1989, J BIOL CHEM, V264, P14954; Inoue I, 2002, BIOCHEM BIOPH RES CO, V290, P131, DOI 10.1006/bbrc.2001.6141; Ishizawa K, 2004, HYPERTENS RES, V27, P433, DOI 10.1291/hypres.27.433; Lin R, 2005, BIOL PHARM BULL, V28, P1630, DOI 10.1248/bpb.28.1630; Liu CA, 2004, ONCOGENE, V23, P8731, DOI 10.1038/sj.onc.1208106; Madonna R, 2005, J BIOL CHEM, V280, P13503, DOI 10.1074/jbc.M411859200; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; Matsuura S, 2002, GLIA, V37, P178, DOI 10.1002/glia.10020; Mattart M, 2003, BIORHEOLOGY, V40, P289; McArthur JC, 2004, ARCH NEUROL-CHICAGO, V61, P1687, DOI 10.1001/archneur.61.11.1687; Messam CA, 2000, J NEUROVIROL, V6, pS90; MINAMI M, 1995, PROG NEURO-PSYCHOPH, V19, P509, DOI 10.1016/0278-5846(95)00031-P; MOSQUEDAGARCIA R, 1993, CIRC RES, V72, P20, DOI 10.1161/01.RES.72.1.20; Mraiche F, 2005, BRIT J PHARMACOL, V144, P715, DOI 10.1038/sj.bjp.0706114; Naidoo V, 2004, J CHEM NEUROANAT, V27, P87, DOI 10.1016/j.jchemneu.2003.12.002; Narushima I, 2003, PHARMACOL TOXICOL, V92, P21, DOI 10.1034/j.1600-0773.2003.920104.x; NATH A, 1995, J NEUROPATH EXP NEUR, V54, P320, DOI 10.1097/00005072-199505000-00005; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; Nie XJ, 1996, REV NEUROSCIENCE, V7, P177; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Quehenberger P, 2000, DIABETES, V49, P1561, DOI 10.2337/diabetes.49.9.1561; RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004; RIECKMANN P, 1995, RES EXP MED, V195, P17, DOI 10.1007/BF02576770; Rolinski B, 1999, INFECTION, V27, P244, DOI 10.1007/s150100050020; Sabri F, 1999, VIROLOGY, V264, P370, DOI 10.1006/viro.1999.9998; Sacktor N, 2002, J NEUROVIROL, V8, P115, DOI 10.1080/13550280290101094; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; Sironi L, 2006, NEUROBIOL DIS, V22, P445, DOI 10.1016/j.nbd.2005.12.004; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; TENCE M, 1992, EUR J NEUROSCI, V4, P993, DOI 10.1111/j.1460-9568.1992.tb00125.x; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; TORNATORE C, 1994, J VIROL, V68, P93, DOI 10.1128/JVI.68.1.93-102.1994; Tsang MCS, 2001, NEUROREPORT, V12, P2265, DOI 10.1097/00001756-200107200-00044; Wei CY, 2006, MOL PHARMACOL, V69, P960, DOI 10.1124/mol.105.017368; WESSELINGH SL, 1994, ADV NEUROIMMUNOL, V4, P199, DOI 10.1016/S0960-5428(06)80258-5; Woods M, 2003, MOL PHARMACOL, V64, P923, DOI 10.1124/mol.64.4.923; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; Yeung AC, 2002, CIRCULATION, V105, P2937, DOI 10.1161/01.CIR.0000023397.12047.03; Yoon SS, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-4; Zhang GuiChang, 1997, Recent Research Developments in Plant Physiology, V1, P75	61	35	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					777	789		10.1096/fj.06-7054com	http://dx.doi.org/10.1096/fj.06-7054com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197385	Green Accepted			2022-12-25	WOS:000244686400016
J	Bayas, MV; Kearney, A; Avramovic, A; van der Merwe, PA; Leckband, DE				Bayas, Marco V.; Kearney, Alice; Avramovic, Adam; van der Merwe, P. Anton; Leckband, Deborah E.			Impact of salt bridges on the equilibrium binding and adhesion of human CD2 and CD58	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECT FORCE MEASUREMENTS; LOW-AFFINITY; PROTEIN INTERACTIONS; ANTIGEN RECOGNITION; CRYSTAL-STRUCTURE; CELL RECOGNITION; MOLECULE CD2; SURFACE; RECEPTOR; COMPLEX	This study describes quantitative investigations of the impact of single charge mutations on equilibrium binding, kinetics, and the adhesion strength of the CD2-CD58 interaction. Previously steered molecular dynamics simulations guided the selection of the charge mutants investigated, which include the CD2 mutants D31A, K41A, K51A, and K91A. This set includes mutations in which the previous cell aggregation and binding data either agreed or disagreed with the steered molecular dynamics predictions. Surface plasmon resonance measurements quantified the solution binding properties. Adhesion was quantified with the surface force apparatus, which was used previously to study the closely related CD2-CD48 interaction. The results reveal roles that these salt bridges play in equilibrium binding and adhesion. We discuss both the molecular basis of this behavior and its implications for cell adhesion.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA	University of Oxford; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	van der Merwe, PA (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	anton.vandermerwe@pathology.oxford.ac.uk; leckband@uiuc.edu			MRC [G9722488] Funding Source: UKRI; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051338] Funding Source: NIH RePORTER; Medical Research Council [G19/31, G9722488] Funding Source: Medline; NIGMS NIH HHS [R01 GM51338] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; ARULANANDAM ARN, 1994, J EXP MED, V180, P1861, DOI 10.1084/jem.180.5.1861; Bayas MV, 2003, BIOPHYS J, V84, P2223, DOI 10.1016/S0006-3495(03)75028-0; BEBBINGTON C R, 1991, Methods (Orlando), V2, P136, DOI 10.1016/S1046-2023(05)80214-2; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; Davis SJ, 1998, P NATL ACAD SCI USA, V95, P5490, DOI 10.1073/pnas.95.10.5490; Evans E, 1998, FARADAY DISCUSS, V111, P1; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Ikemizu S, 1999, P NATL ACAD SCI USA, V96, P4289, DOI 10.1073/pnas.96.8.4289; ISRAELAC.JN, 1973, J COLLOID INTERF SCI, V44, P259, DOI 10.1016/0021-9797(73)90218-X; ISRAELACHVILI JN, 1978, J CHEM SOC FARAD T 1, V74, P975, DOI 10.1039/f19787400975; Israelachvilli J.N., 1992, INTERMOLECULAR SURFA, P312; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; Kim M, 2001, J MOL BIOL, V312, P711, DOI 10.1006/jmbi.2001.4980; KOYASU S, 1990, P NATL ACAD SCI USA, V87, P2603, DOI 10.1073/pnas.87.7.2603; KRETSCHM.E, 1968, Z NATURFORSCH PT A, VA 23, P2135, DOI 10.1515/zna-1968-1247; Lavrik N, 2000, LANGMUIR, V16, P1842, DOI 10.1021/la9904612; LECKBAND DE, 1994, BIOCHEMISTRY-US, V33, P4611, DOI 10.1021/bi00181a023; Lee JK, 2004, J EXP MED, V200, P1455, DOI 10.1084/jem.20041251; Li F, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2372493; Martel L, 2002, J PHYS IV, V12, P365, DOI 10.1051/jp4:20020245; MOIGNEON P, 1989, NATURE, V339, P312; Socci ND, 1999, P NATL ACAD SCI USA, V96, P2031, DOI 10.1073/pnas.96.5.2031; TINOCO I, 2002, PHYS CHEM PRINCIPLES, P33; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; vanderMerwe PA, 1997, J EXP MED, V185, P393, DOI 10.1084/jem.185.3.393; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030; Zhu BR, 2002, BIOCHEMISTRY-US, V41, P12163, DOI 10.1021/bi020296g	34	23	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5589	5596		10.1074/jbc.M607968200	http://dx.doi.org/10.1074/jbc.M607968200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17172599	hybrid			2022-12-25	WOS:000244482300055
J	Lee, YH; Tamura, K; Maeda, M; Hoshino, M; Sakurai, K; Takahashi, S; Ikegami, T; Hase, T; Goto, Y				Lee, Young-Ho; Tamura, Kosuke; Maeda, Masahiro; Hoshino, Masaru; Sakurai, Kazumasa; Takahashi, Satoshi; Ikegami, Takahisa; Hase, Toshiharu; Goto, Yuji			Cores and pH-dependent dynamics of ferredoxin-NADP(+) reductase revealed by hydrogen/deuterium exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMIDE PROTON-EXCHANGE; HYDROGEN-EXCHANGE; PROTEIN DYNAMICS; NADP+ REDUCTASE; BINDING; STABILITY; IDENTIFICATION; DENATURATION; EVOLUTION; DOMAINS	NMR-detected hydrogen/deuterium (H/D) exchange of amide protons is a powerful way for investigating the residue-based conformational stability and dynamics of proteins in solution. Maize ferredoxin-NADP(+) reductase (FNR) is a relatively large protein with 314 amino acid residues, consisting of flavin adenine dinucleotide (FAD) and nicotinamide adenine dinucleotide phosphate (NADP(+))-binding domains. To address the structural stability and dynamics of FNR, H/D exchange of amide protons was performed using heteronuclear NMR at pD, values 8.0 and 6.0, physiologically relevant conditions mimicking inside of chloroplasts. At both pD, values, the exchange rate varied widely depending on the residues. The profiles of protected residues revealed that the highly protected regions matched well with the hydrophobic cores suggested from the crystal structure, and that the NADP(+)-binding domain can be divided into two subdomains. The global stability of FNR obtained by H/D exchange with NMR was higher than that by chemical denaturation, indicating that H/D exchange is especially useful for analyzing the residue-based conformational stability of large proteins, for which global unfolding is mostly irreversible. Interestingly, more dynamic conformation of the C-terminal subdomain of the NADP(+)-binding domain at pD, 8.0, the daytime pH in chloroplasts, than at pD, 6.0 is likely to be involved in the increased binding of NADP(+) for elevating the activity of FNR. In light of photosynthesis, the present study provides the first structure-based relationship of dynamics with function for the FNR-type family in solution.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, CREST, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Takahashi, Satoshi/AAC-5532-2019; Ikegami, Takahisa/I-9626-2017; Hase, Toshiharu/H-9271-2013	Takahashi, Satoshi/0000-0003-1506-9222; Ikegami, Takahisa/0000-0002-1429-1844; Tamura, Kousuke/0000-0002-3835-5507				Aliverti A, 2004, BBA-PROTEINS PROTEOM, V1696, P93, DOI 10.1016/j.bbapap.2003.09.011; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Bottoms CA, 2002, PROTEIN SCI, V11, P2125, DOI 10.1110/ps.0213502; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; CARRILLO N, 1981, J BIOL CHEM, V256, P6823; Carrillo N, 2003, EUR J BIOCHEM, V270, P1900, DOI 10.1046/j.1432-1033.2003.03566.x; CARRILLO N, 1981, J BIOL CHEM, V256, P1058; Cioni P, 2002, BIOPHYS J, V82, P3246, DOI 10.1016/S0006-3495(02)75666-X; CLAKE J, 1998, CURR OPIN STRUC BIOL, V8, P112; CLARKE J, 1993, P NATL ACAD SCI USA, V90, P9837, DOI 10.1073/pnas.90.21.9837; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Englander SW, 1996, CURR OPIN STRUC BIOL, V6, P18, DOI 10.1016/S0959-440X(96)80090-X; Freund C, 1996, BIOCHEMISTRY-US, V35, P8457, DOI 10.1021/bi952764a; GADDA G, 1990, J BIOL CHEM, V265, P11955; Gozu M, 2002, PROTEIN SCI, V11, P2792, DOI 10.1110/ps.0216602; Hocker B, 2001, CURR OPIN BIOTECH, V12, P376, DOI 10.1016/S0958-1669(00)00230-5; Huyghues-Despointes B M, 2001, Methods Mol Biol, V168, P69; Ishima R, 2000, NAT STRUCT BIOL, V7, P740, DOI 10.1038/78963; JANDU SK, 1990, BIOCHEMISTRY-US, V29, P6264, DOI 10.1021/bi00478a022; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Karplus PA, 2004, PHOTOSYNTH RES, V81, P303, DOI 10.1023/B:PRES.0000036884.57303.2e; Katou H, 2001, J MOL BIOL, V310, P471, DOI 10.1006/jmbi.2001.4777; Kay LE, 1998, NAT STRUCT BIOL, V5, P513, DOI 10.1038/755; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; Li RH, 1999, PROTEIN SCI, V8, P1571, DOI 10.1110/ps.8.8.1571; LOH SN, 1993, BIOCHEMISTRY-US, V32, P11022, DOI 10.1021/bi00092a011; LU JR, 1992, BIOCHEMISTRY-US, V31, P4749, DOI 10.1021/bi00135a002; Maeda M, 2005, BIOCHEMISTRY-US, V44, P10644, DOI 10.1021/bi050424b; Maeda M, 2002, J BIOL CHEM, V277, P17101, DOI 10.1074/jbc.M112002200; MAYO SL, 1993, SCIENCE, V262, P873, DOI 10.1126/science.8235609; Milne JS, 1999, J MOL BIOL, V290, P811, DOI 10.1006/jmbi.1999.2924; Pace C N, 1986, Methods Enzymol, V131, P266; Polshakov VI, 2006, J MOL BIOL, V356, P886, DOI 10.1016/j.jmb.2005.11.084; Popovych N, 2006, NAT STRUCT MOL BIOL, V13, P831, DOI 10.1038/nsmb1132; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SHORTLE D, 1989, ARCH BIOCHEM BIOPHYS, V272, P103, DOI 10.1016/0003-9861(89)90200-2; Steensma E, 1998, J MOL BIOL, V282, P653, DOI 10.1006/jmbi.1998.2045; SWINDELLS MB, 1995, PROTEIN SCI, V4, P103; SwintKruse L, 1996, BIOCHEMISTRY-US, V35, P171, DOI 10.1021/bi9517603; Whitten ST, 2005, P NATL ACAD SCI USA, V102, P4282, DOI 10.1073/pnas.0407499102; Williams DH, 2004, ANGEW CHEM INT EDIT, V43, P6596, DOI 10.1002/anie.200300644; ZEHFUS MH, 1995, PROTEIN SCI, V4, P1188, DOI 10.1002/pro.5560040617; Zehfus MH, 1997, PROTEIN SCI, V6, P1210, DOI 10.1002/pro.5560060609	46	22	24	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5959	5967		10.1074/jbc.M608417200	http://dx.doi.org/10.1074/jbc.M608417200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17192259	Green Published, hybrid			2022-12-25	WOS:000244482300091
J	Quintavalle, M; Sambucini, S; Summa, V; Orsatti, L; Talamo, F; De Francesco, R; Neddermann, P				Quintavalle, Manuela; Sambucini, Sonia; Summa, Vincenzo; Orsatti, Laura; Talamo, Fabio; De Francesco, Raffaele; Neddermann, Petra			Hepatitis C virus NS5A is a direct substrate of casein kinase I-alpha, a cellular kinase identified by inhibitor affinity chromatography using specific NS5A hyperphosphorylation inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTRUCTURAL PROTEIN 5A; RNA REPLICATION; PHOSPHORYLATION; CULTURE; CELLS; DETERMINANTS; POLYPROTEIN; REPLICON; COMPLEX; GENOME	The hepatitis C virus encodes a single polyprotein that is processed by host and viral proteases to yield at least 10 mature viral proteins. The nonstructural (NS) protein 5A is a phosphoprotein, and experimental data indicate that the phosphorylation state of NS5A is important for the outcome of viral RNA replication. We were able to identify kinase inhibitors that specifically inhibit the formation of the hyperphosphorylated form of NS5A I in cells. These kinase inhibitors were used for inhibitor affinity chromatography in order to identify the cellular targets of these compounds. The kinases casein kinase II (CKI) p38 MAPK, CIT (Citron Rho-interacting kinase), GAK, JNK2, PKA, RSK 1/2, and RIPK2 were identified in the high affinity binding fractions of two NS5A hyperphosphorylation inhibitors I p58-i). Even though these kinases are targets of the NS5A-p58-i, the only kinase showing an effect on NS5A hyperphosphorylation was confirmed to be CKI-alpha. Although this finding does not exclude the possibility that other kinase(s) might be involved in basal or regulatory phosphorylation of NS5A, we show here that NS5A is a direct substrate of CKI-alpha. Moreover, in vitro phosphorylation of NS5A by CKI-alpha resulted for the first time in the production of basal and hyperphosphorylated forms resembling those produced in cells. In vitro kinase reactions performed with NS5A peptides show that Ser-2204 is a preferred substrate residue for CKI-alpha after pre-phosphorylation of Ser-2201.	Ist Ric Biol Mol P Angeletti, I-00040 Rome, Italy	Merck & Company	Neddermann, P (corresponding author), Ist Ric Biol Mol P Angeletti, Via Pontina Km 30-6, I-00040 Rome, Italy.	Petra_Neddermann@merck.com	De Francesco, Raffaele/J-6003-2012; Summa, Vincenzo/AHE-9025-2022	De Francesco, Raffaele/0000-0001-8754-5123; Summa, Vincenzo/0000-0002-6288-2681				Appel N, 2005, J VIROL, V79, P896, DOI 10.1128/JVI.79.2.896-909.2005; Appel N, 2006, J BIOL CHEM, V281, P9833, DOI 10.1074/jbc.R500026200; Asabe SI, 1997, J VIROL, V71, P790, DOI 10.1128/JVI.71.1.790-796.1997; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Bukh J, 2002, P NATL ACAD SCI USA, V99, P14416, DOI 10.1073/pnas.212532699; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Coito C, 2004, J VIROL, V78, P3502, DOI 10.1128/JVI.78.7.3502-3513.2004; DEFRANCESCO R, 2006, Patent No. 2006021449; Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Godl K, 2003, P NATL ACAD SCI USA, V100, P15434, DOI 10.1073/pnas.2535024100; Gosert R, 2003, J VIROL, V77, P5487, DOI 10.1128/JVI.77.9.5487-5492.2003; Graziani R, 2004, J GEN VIROL, V85, P1867, DOI 10.1099/vir.0.80006-0; GROSS SD, 1995, J CELL BIOL, V130, P711, DOI 10.1083/jcb.130.3.711; Hidajat Rachmat, 2004, Kobe Journal of Medical Sciences, V50, P153; Huang LY, 2005, J BIOL CHEM, V280, P36417, DOI 10.1074/jbc.M508175200; Huang LY, 2004, PROTEIN EXPRES PURIF, V37, P144, DOI 10.1016/j.pep.2004.05.005; Ide Y, 1997, GENE, V201, P151, DOI 10.1016/S0378-1119(97)00440-X; Kalamvoki M, 2006, J BIOL CHEM, V281, P13449, DOI 10.1074/jbc.M601124200; KANEKO T, 1994, BIOCHEM BIOPH RES CO, V205, P320, DOI 10.1006/bbrc.1994.2667; Katze MG, 2000, VIROLOGY, V278, P501, DOI 10.1006/viro.2000.0662; Kim J, 1999, BIOCHEM BIOPH RES CO, V257, P777, DOI 10.1006/bbrc.1999.0460; Koch JO, 1999, J VIROL, V73, P7138; Lohmann V, 2003, J VIROL, V77, P3007, DOI 10.1128/JVI.77.5.3007-3019.2003; Macdonald A, 2004, J GEN VIROL, V85, P2485, DOI 10.1099/vir.0.80204-0; Neddermann P, 1999, J VIROL, V73, P9984, DOI 10.1128/JVI.73.12.9984-9991.1999; Neddermann P, 2004, J VIROL, V78, P13306, DOI 10.1128/JVI.78.23.13306-13314.2004; Quintavalle M, 2006, J VIROL, V80, P11305, DOI 10.1128/JVI.01465-06; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Shimakami T, 2004, J VIROL, V78, P2738, DOI 10.1128/JVI.78.6.2738-2748.2004; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; Tellinghuisen TL, 2004, J BIOL CHEM, V279, P48576, DOI 10.1074/jbc.M407787200; Tong X, 2006, VIRUS RES, V115, P122, DOI 10.1016/j.virusres.2005.07.012; Trozzi C, 2003, J VIROL, V77, P3669, DOI 10.1128/JVI.77.6.3669-3679.2003; Wissing J, 2004, MOL CELL PROTEOMICS, V3, P1181, DOI 10.1074/mcp.M400124-MCP200	36	73	76	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5536	5544		10.1074/jbc.M610486200	http://dx.doi.org/10.1074/jbc.M610486200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17166835	hybrid, Green Published			2022-12-25	WOS:000244482300049
J	Yun, HM; Kim, S; Kim, HJ; Kostenis, E; Kim, JI; Seong, JY; Baik, JH; Rhim, H				Yun, Hyung-Mun; Kim, Sunoh; Kim, Hyun-Ji; Kostenis, Evi; Kim, Jae Il; Seong, Jae Young; Baik, Ja-Hyun; Rhim, Hyewhon			The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM FACILITATION; TYROSINE KINASE; MAP KINASE; RAT-BRAIN; SEROTONIN RECEPTOR; ALZHEIMERS-DISEASE; MOLECULAR-CLONING; MESSENGER-RNA; WATER MAZE; CAMP	The human 5-HT6 receptor (5-HT6R) is one of the latest cloned receptors among the known 5-HT receptors. Its abundant distribution in the limbic region, which participates in the control of mood and emotion and is involved in nervous system diseases such as depression and Alzheimer disease, has caused it to generate much interest. However, the cellular mechanisms of 5-HT6R are poorly understood. In the present study we found, using a yeast two-hybrid assay, that the carboxyl-terminal region of 5-HT6R interacts with the Fyn-tyrosine kinase. We also determined using a glutathione S-transferase pulldown assay that this interaction was mediated through the SH3 domain of Fyn and confirmed this by co-immunoprecipitation assays in two different transfected cell lines as well as in adult rat brains. Immunocyto(histo)chemistry also showed prominent co-localization between 5-HT6R and Fyn in transfected cells and a similar distribution between 5-HT6R and Fyn in the rat brain. Based on this interaction, we further examined the modulation of 5-HT6R by Fyn and vice versa. In addition, we demonstrated that the activation of 5-HT6R activated the extracellular signal-regulated kinase 1/2 via an Fyn-dependent pathway. These findings suggest that Fyn may play an important role in 5-HT(6)Rmediated signaling pathways in the central nervous system.	Korea Inst Sci & Technol, Biomed Res Ctr, Seoul 136791, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Inst Pharmaceut Biol, D-53115 Bonn, Germany; Korea Univ, Coll Med, Grad Sch Med, Seoul 136705, South Korea	Korea Institute of Science & Technology (KIST); Korea University; Korea University; Korea University Medicine (KU Medicine)	Rhim, H (corresponding author), Korea Inst Sci & Technol, Biomed Res Ctr, 39-1 Hawholgok Dong, Seoul 136791, South Korea.	hrhim@kist.re.kr	Seong, Jae Young/A-5794-2012	Seong, Jae Young/0000-0002-3312-6924				BARE DJ, 1993, ONCOGENE, V8, P1429; Bhaskar K, 2005, J BIOL CHEM, V280, P35119, DOI 10.1074/jbc.M505895200; Boess FG, 1997, NEUROPHARMACOLOGY, V36, P713, DOI 10.1016/S0028-3908(97)00019-1; Chin J, 2005, J NEUROSCI, V25, P9694, DOI 10.1523/JNEUROSCI.2980-05.2005; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Fernandez-Ballester G, 2004, J MOL BIOL, V335, P619, DOI 10.1016/j.jmb.2003.10.060; Graeff FG, 1996, PHARMACOL BIOCHEM BE, V54, P129, DOI 10.1016/0091-3057(95)02135-3; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Grimaldi B, 1998, N-S ARCH PHARMACOL, V357, P393, DOI 10.1007/PL00005184; HOYER D, 1994, PHARMACOL REV, V46, P157; Kinsey AM, 2001, MOL BRAIN RES, V88, P194, DOI 10.1016/S0169-328X(01)00034-1; Klinger M, 2002, J BIOL CHEM, V277, P32490, DOI 10.1074/jbc.M200556200; Kohen R, 1996, J NEUROCHEM, V66, P47; Kostenis E, 2001, TRENDS PHARMACOL SCI, V22, P560, DOI 10.1016/S0165-6147(00)01810-1; Lee G, 2004, J NEUROSCI, V24, P2304, DOI 10.1523/JNEUROSCI.4162-03.2004; Lorke DE, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-36; Lu ZF, 2005, J BIOL CHEM, V280, P389, DOI 10.1074/jbc.M405973200; Ma YC, 2002, CELL MOL LIFE SCI, V59, P456, DOI 10.1007/s00018-002-8438-2; MARTIN GR, 1994, PHARMACOL THERAPEUT, V62, P283, DOI 10.1016/0163-7258(94)90048-5; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Michael D, 1998, P NATL ACAD SCI USA, V95, P1864, DOI 10.1073/pnas.95.4.1864; Mitchell ES, 2005, PHARMACOL THERAPEUT, V108, P320, DOI 10.1016/j.pharmthera.2005.05.001; MIYAKAWA T, 1994, MOL BRAIN RES, V27, P179, DOI 10.1016/0169-328X(94)90201-1; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; Norum JH, 2003, J BIOL CHEM, V278, P3098, DOI 10.1074/jbc.M206237200; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Resh MD, 1998, INT J BIOCHEM CELL B, V30, P1159, DOI 10.1016/S1357-2725(98)00089-2; Rogers DC, 2001, PSYCHOPHARMACOLOGY, V158, P114; ROTH BL, 1994, J PHARMACOL EXP THER, V268, P1403; RUAT M, 1993, P NATL ACAD SCI USA, V90, P8547, DOI 10.1073/pnas.90.18.8547; RUAT M, 1993, BIOCHEM BIOPH RES CO, V193, P268, DOI 10.1006/bbrc.1993.1619; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHEN Y, 1993, J BIOL CHEM, V268, P18200; Simansky KJ, 1996, BEHAV BRAIN RES, V73, P37, DOI 10.1016/0166-4328(96)00066-6; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Tomidokoro Y, 2001, NEUROSCI LETT, V299, P169, DOI 10.1016/S0304-3940(00)01767-5; Tsai SJ, 1999, NEUROSCI LETT, V276, P138, DOI 10.1016/S0304-3940(99)00802-2; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WARD RP, 1995, NEUROSCIENCE, V64, P1105, DOI 10.1016/0306-4522(94)00439-C; Woolley ML, 2004, CNS NEUROL DISORD-DR, V3, P59, DOI 10.2174/1568007043482561; Woolley ML, 2001, NEUROPHARMACOLOGY, V41, P210, DOI 10.1016/S0028-3908(01)00056-9; Yau JLW, 1997, MOL BRAIN RES, V45, P182, DOI 10.1016/S0169-328X(97)00026-0; Yoshioka M, 1998, LIFE SCI, V62, P1473, DOI 10.1016/S0024-3205(98)00092-7; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	47	115	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5496	5505		10.1074/jbc.M606215200	http://dx.doi.org/10.1074/jbc.M606215200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189269	hybrid			2022-12-25	WOS:000244482300044
J	Barbolina, MV; Adley, BP; Ariztia, EV; Liu, YY; Stack, MS				Barbolina, Maria V.; Adley, Brian P.; Ariztia, Edgardo V.; Liu, Yueying; Stack, M. Sharon			Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC TYROSINE KINASE; EXTRACELLULAR-MATRIX; MESSENGER-RNA; I COLLAGEN; TRANSCRIPTION FACTORS; EPITHELIAL CARCINOMA; SEGREGATION ANALYSIS; ENDOTHELIAL-CELLS; MESOTHELIAL CELLS; BREAST-CANCER	Late stage ovarian cancer is characterized by disseminated intraperitoneal metastasis as secondary lesions anchor in the type I and III collagen-rich submesothelial matrix. Ovarian carcinoma cells preferentially adhere to interstitial collagen, and collagen-induced integrin clustering up-regulates the expression of the transmembrane collagenase membrane type 1 matrix metalloproteinase (MT1-MMP). Collagenolytic activity is important in intraperitoneal metastasis, potentiating invasion through the mesothelial cell layer and colonization of the submesothelial collagen-rich matrix. The objective of this study was to elucidate a potential mechanistic link between collagen adhesion and MT1-MMP expression. Our results indicate that culturing cells on three-dimensional collagen gels, but not thin layer collagen or synthetic three-dimensional hydrogels, results in rapid induction of the transcription factor EGR1. Integrin signaling through a SRC kinase-dependent pathway is necessary for EGR1 induction. Silencing of EGR1 expression using small interfering RNA abrogated collagen-induced MT1-MMP expression and inhibited cellular invasion of three-dimensional collagen gels. These data support a model for intraperitoneal metastasis wherein collagen adhesion and clustering of collagen binding integrins activates integrin-mediated signaling via SRC kinases to induce expression of EGR1, resulting in transcriptional activation of the MT1-MMP promoter and subsequent MT1-MMP-catalyzed collagen invasion. This model highlights the role of unique interactions between ovarian carcinoma cells and interstitial collagens in the ovarian tumor microenvironment in inducing gene expression changes that potentiate intraperitoneal metastatic progression.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Robert H. Lurie Comprehensive Cancer Center	Stack, MS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA.	stackm@missouri.edu			NATIONAL CANCER INSTITUTE [R01CA109545, R01CA086984] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA086984-10, R01 CA109545-03, R01 CA109545-02, R01 CA086984-09, R01CA86984, R01 CA109545, R01 CA086984, R01 CA086984-07, R01 CA086984-06, R01 CA109545-04, R01 CA086984-08] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afzal S, 1998, HUM PATHOL, V29, P155, DOI 10.1016/S0046-8177(98)90226-X; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; AUERSPERG N, 1995, OVARIAN CANC, V3, P157; Auranen A, 1998, BRIT J CANCER, V77, P1537, DOI 10.1038/bjc.1998.252; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CANNISTRA SA, 1995, GYNECOL ONCOL, V58, P216, DOI 10.1006/gyno.1995.1214; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Davidson B, 2002, MOL CELL ENDOCRINOL, V187, P39, DOI 10.1016/S0303-7207(01)00709-2; Davidson B, 1999, CLIN EXP METASTAS, V17, P799, DOI 10.1023/A:1006723011835; Davidson B, 2001, AM J CLIN PATHOL, V115, P517; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; Fishman DA, 1998, INVAS METAST, V18, P15, DOI 10.1159/000024495; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; George JA, 2005, CANCER RES, V65, P10381, DOI 10.1158/0008-5472.CAN-05-1822; Ghosh Supurna, 2002, Cancer Treat Res, V107, P331; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Haas TL, 1999, J BIOL CHEM, V274, P22679, DOI 10.1074/jbc.274.32.22679; HARVEY W, 1983, J PATHOL, V139, P337, DOI 10.1002/path.1711390309; HOSKINS WJ, 1995, J CELL BIOCH S, V23, P189; HOULSTON RS, 1991, ANN HUM GENET, V55, P291, DOI 10.1111/j.1469-1809.1991.tb00856.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ingber DE, 2002, DIFFERENTIATION, V70, P547, DOI 10.1046/j.1432-0436.2002.700908.x; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lohi J, 2000, GENE, V242, P75, DOI 10.1016/S0378-1119(99)00549-1; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Masaki T, 1998, HEPATOLOGY, V27, P1257, DOI 10.1002/hep.510270511; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAZURENKO NN, 1992, EUR J CANCER, V28A, P372, DOI 10.1016/S0959-8049(05)80056-5; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Moser TL, 1996, INT J CANCER, V67, P695, DOI 10.1002/(SICI)1097-0215(19960904)67:5<695::AID-IJC18>3.3.CO;2-2; MOSER TL, 1994, INT J CANCER, V56, P552, DOI 10.1002/ijc.2910560415; Munshi HG, 2006, CANCER METAST REV, V25, P45, DOI 10.1007/s10555-006-7888-7; NAROD SA, 1994, CANCER-AM CANCER SOC, V74, P2341, DOI 10.1002/1097-0142(19941015)74:8<2341::AID-CNCR2820740819>3.0.CO;2-Z; NAROD SA, 1995, AM J HUM GENET, V56, P254; NIEDBALA MJ, 1987, CLIN EXP METASTAS, V5, P181, DOI 10.1007/BF00058063; Ning W, 2004, P NATL ACAD SCI USA, V101, P14895, DOI 10.1073/pnas.0401168101; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PATWARDHAN S, 1991, ONCOGENE, V6, P917; Pengetnze Y, 2003, BIOCHEM BIOPH RES CO, V309, P377, DOI 10.1016/j.bbrc.2003.08.012; Petrella BL, 2005, ONCOGENE, V24, P1043, DOI 10.1038/sj.onc.1208305; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, 1992, ONCOGENE, V7, P121; Roskelley CD, 2002, SEMIN CANCER BIOL, V12, P97, DOI 10.1006/scbi.2001.0417; Sakata K, 2000, INT J ONCOL, V17, P673; SAWADA M, 1994, LAB INVEST, V70, P333; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Sood AK, 2004, AM J PATHOL, V165, P1087, DOI 10.1016/S0002-9440(10)63370-6; STACK MS, 2002, OVARIAN CANC CANC TR, P99; STYLIANOU E, 1990, KIDNEY INT, V37, P1563, DOI 10.1038/ki.1990.150; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tatin F, 2006, J CELL SCI, V119, P769, DOI 10.1242/jcs.02787; Varon C, 2006, MOL CELL BIOL, V26, P3582, DOI 10.1128/MCB.26.9.3582-3594.2006; Wiener JR, 2003, GYNECOL ONCOL, V88, P73, DOI 10.1006/gyno.2002.6851; Yamaguchi S, 2002, LAB INVEST, V82, P949, DOI 10.1097/01.LAB.0000020408.77307.E9; ZHU GG, 1993, CANCER RES, V53, P5028; Zipfel PF, 1997, BBA-GENE STRUCT EXPR, V1354, P134, DOI 10.1016/S0167-4781(97)00084-5	68	72	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4924	4931		10.1074/jbc.M608428200	http://dx.doi.org/10.1074/jbc.M608428200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158885	hybrid			2022-12-25	WOS:000244482000075
J	Ye, ZY; Gan, YH				Ye, Zhiyong; Gan, Yunn-Hwen			Flagellin contamination of recombinant heat shock protein 70 is responsible for its activity on T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TUMOR-NECROSIS-FACTOR; DENDRITIC CELLS; BACTERIAL FLAGELLIN; MURINE MACROPHAGES; IMMUNE-SYSTEM; IN-VIVO; STIMULATION; ACTIVATION; ADJUVANT	Heat shock proteins (Hsp) 60 and 70 have been intensively studied for their ability to activate innate immunity. Heat shock proteins had been shown to induce the activation of dendritic cells, T cells, and B cells. However, the possible contamination of endotoxin in heat shock protein preparations makes their function as an activator of immune system ambiguous. Here, we examined the ability of bacterial Hsp60 and Hsp70 to activate Jurkat T cells and primary T cells. We found that Burkholderia pseudomallei Hsp70 and Mycobacterium tuberculosis Hsp70 could costimulate Jurkat T cells to make IL-2 and signal through TLR5. This costimulatory activity is not due to endotoxin or contaminants signaling via TLR2 nor TLR4. However, recombinant Hsp70 expressed in Escherichia coli Delta fliC strain completely lost its ability to costimulate T cells. Thus, the activation of T cells by recombinant Hsp70 is ascribed to flagellin contamination.	Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, Singapore 117597, Singapore; Natl Univ Singapore, Program Immunol, Yong Loo Lin Sch Med, Singapore 117597, Singapore	National University of Singapore; National University of Singapore	Gan, YH (corresponding author), Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, Block MD7,05-10,8 Med Dr, Singapore 117597, Singapore.	bchganyh@nus.edu.sg	Gan, Yunn-Hwen/AAH-8515-2021					Bates D, 2005, MOL MICROBIOL, V57, P380, DOI 10.1111/j.1365-2958.2005.04693.x; Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C; Bulut Y, 2005, J BIOL CHEM, V280, P20961, DOI 10.1074/jbc.M411379200; Caron G, 2005, J IMMUNOL, V175, P1551, DOI 10.4049/jimmunol.175.3.1551; Chen K, 2004, J LEUKOCYTE BIOL, V75, P260, DOI 10.1189/jlb.0703341; Cohen-Sfady M, 2005, J IMMUNOL, V175, P3594, DOI 10.4049/jimmunol.175.6.3594; Crellin NK, 2005, J IMMUNOL, V175, P8051, DOI 10.4049/jimmunol.175.12.8051; Floto RA, 2006, SCIENCE, V314, P454, DOI 10.1126/science.1133515; Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gobert AP, 2004, J BIOL CHEM, V279, P245, DOI 10.1074/jbc.M307858200; Habich C, 2005, J IMMUNOL, V174, P1298, DOI 10.4049/jimmunol.174.3.1298; Harmala LAE, 2002, J IMMUNOL, V169, P5622, DOI 10.4049/jimmunol.169.10.5622; Honko AN, 2006, INFECT IMMUN, V74, P1113, DOI 10.1128/IAI.74.2.1113-1120.2006; Huang Q, 2000, J EXP MED, V191, P403, DOI 10.1084/jem.191.2.403; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Lee SE, 2006, INFECT IMMUN, V74, P694, DOI 10.1128/IAI.74.1.694-702.2006; MacAry PA, 2004, IMMUNITY, V20, P95, DOI 10.1016/S1074-7613(03)00357-1; Means TK, 2003, J IMMUNOL, V170, P5165, DOI 10.4049/jimmunol.170.10.5165; Osterloh A, 2004, J BIOL CHEM, V279, P47906, DOI 10.1074/jbc.M408440200; Rock KL, 2005, SPRINGER SEMIN IMMUN, V26, P231, DOI 10.1007/s00281-004-0173-3; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Tsan MF, 2004, AM J PHYSIOL-CELL PH, V286, pC739, DOI 10.1152/ajpcell.00364.2003; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; Wang YF, 2002, J IMMUNOL, V169, P2422, DOI 10.4049/jimmunol.169.5.2422; Zanin-Zhorov A, 2003, FASEB J, V17, P1567, DOI 10.1096/fj.02-1139fje; Zanin-Zhorov A, 2006, J CLIN INVEST, V116, P2022, DOI 10.1172/JCI28423; Zhang HF, 2002, FEBS LETT, V532, P171, DOI 10.1016/S0014-5793(02)03669-4	30	62	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4479	4484		10.1074/jbc.M606802200	http://dx.doi.org/10.1074/jbc.M606802200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17178717	hybrid			2022-12-25	WOS:000244482000029
J	Harris, JE; Femandez-Vilaseca, M; Elkington, PTG; Horncastle, DE; Graeber, MB; Friedland, JS				Harris, James E.; Femandez-Vilaseca, Marc; Elkington, Paul T. G.; Horncastle, Donna E.; Graeber, Manuel B.; Friedland, Jon S.			IFN-gamma synergizes with IL-1 beta to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis	FASEB JOURNAL			English	Article						astrocyle; Mycobacterium; tuberculosis; monocyte; gelatinase B; AMP kinase; JAK-STAT	NECROSIS-FACTOR-ALPHA; INTERFERON-GAMMA; CEREBROSPINAL-FLUID; MATRIX-METALLOPROTEINASE; GENE-EXPRESSION; MYCOBACTERIUM-TUBERCULOSIS; HUMAN CHONDROCYTES; EPITHELIAL-CELLS; GELATINASE-B; ONCOSTATIN-M	Matrix metalloproteinase-9 (MMP-9) activity is implicated in pathogenesis of central nervous system tuberculosis (CNS-TB). IFN gamma, a key cytokine in TB, usually inhibits MMP-9 secretion. Addition of IFN gamma to conditioned media from M. tb-infected monocytes (CoMTB) resulted in a 7-fold increase in MMP-9 activity detected by gelatin zymography (P < 0.01). In contrast, tissue inhibitor of metalloproteinase (TIMP)-1 and -2 secretion, measured by ELISA, was suppressed. Dexamethasone abolished the synergistic increase in MMP-9 activity. Interleukin (IL)-1 beta in CoMTB is a critical mediator of synergy with IFN gamma, and IL-beta alone synergizes with IFN gamma to increase MMP-9 secretion from 51 +/- 31 to 762 +/- 136 U. IL-1 beta activity is dependent on p38 mitogen-activated protein (MAPK) kinase, which was found to be phosphorylated in tissue specimens from patients with CNS-TB. Extracellular signal regulated kinase (Erk) and p38 MAPK activation did not affect IFN gamma signaling pathways. Inhibition of janus-activated kinase (JAK)-2 by 50 mu M AG540 decreased MMP-9 secretion to 124 +/- 11.1 from 651 +/- 229 U of activity (P < 0.01). However, signal transducer and activator of transcription (STAT)-3 but not STAT-1 phosphorylation was synergistically up-regulated by IFN gamma and CoMTB. In summary, synergy between Il-1 beta and STAT-3 dependent IFN gamma signaling is key in control of up-regulation of MMP-9 activity in CNS-TB and may be a significant mechanism of brain tissue destruction.	Univ London Imperial Coll Sci & Technol, Dept Infect Dis & Immun, London W12 0NN, England; Univ London Imperial Coll Sci & Technol, Dept Histopathol, London W12 0NN, England; Univ London Imperial Coll Sci & Technol, Dept Neuropathol, London, England	Imperial College London; Imperial College London; Imperial College London	Friedland, JS (corresponding author), Univ London Imperial Coll Sci & Technol, Dept Infect Dis & Immun, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	j.friedland@imperial.ac.uk	Graeber, Manuel/H-3224-2011	Elkington, Paul/0000-0003-0390-0613; Friedland, Jonathan S/0000-0001-7789-9649; Harris, James/0000-0002-8542-3189	Department of Health [DHCS/06/05/012] Funding Source: Medline; National Institute for Health Research [DHCS/06/05/012] Funding Source: researchfish	Department of Health; National Institute for Health Research(National Institute for Health Research (NIHR))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; AKALIN H, 1994, SCAND J INFECT DIS, V26, P667, DOI 10.3109/00365549409008634; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Asahina M, 2001, CLIN NEUROPATHOL, V20, P60; Bartholome EJ, 2001, J INTERF CYTOK RES, V21, P495, DOI 10.1089/10799900152434367; Bianchini F, 2006, ONCOL REP, V15, P709; Cagatay T, 2005, RESPIROLOGY, V10, P290, DOI 10.1111/j.1440-1843.2005.00711.x; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; Catterall JB, 2001, ARTHRITIS RHEUM-US, V44, P2296, DOI 10.1002/1529-0131(200110)44:10<2296::AID-ART392>3.0.CO;2-9; Ceyhan M, 1997, TURKISH J PEDIATR, V39, P177; DASTUR DK, 1995, RADIOL CLIN N AM, V33, P733; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Dinney CPN, 1998, CANCER RES, V58, P808; DONALD PR, 1995, CLIN INFECT DIS, V21, P924, DOI 10.1093/clinids/21.4.924; Elkington PTG, 2006, THORAX, V61, P259, DOI 10.1136/thx.2005.051979; Elkington PTG, 2006, J IMMUNOL METHODS, V309, P115, DOI 10.1016/j.jim.2005.11.010; Elkington PTG, 2005, J IMMUNOL, V175, P5333, DOI 10.4049/jimmunol.175.8.5333; Ernst M, 2004, TRENDS GENET, V20, P23, DOI 10.1016/j.tig.2003.11.003; Fairbanks LD, 2004, NUCLEOS NUCLEOT NUCL, V23, P1185, DOI 10.1081/NCN-200027451; Fassbender K, 1999, NEUROLOGY, V53, P1104, DOI 10.1212/WNL.53.5.1104; Giannopoulou M, 2006, AM J PHYSIOL-RENAL, V290, pF1234, DOI 10.1152/ajprenal.00388.2005; GOTTSCHALL PE, 1995, J NEUROSCI RES, V42, P335, DOI 10.1002/jnr.490420307; Graeber MB, 1990, BRAIN PATHOL, V1, P2, DOI 10.1111/j.1750-3639.1990.tb00630.x; Helbecque N, 2003, NEUROSCI LETT, V350, P181, DOI 10.1016/S0304-3940(03)00905-4; Hickey WF, 2001, GLIA, V36, P118, DOI 10.1002/glia.1101; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Ivanoff A, 1999, CLIN EXP METASTAS, V17, P695, DOI 10.1023/A:1006749304315; Kaur N, 2003, J NEUROCHEM, V87, P437, DOI 10.1046/j.1471-4159.2003.02012.x; Koshy PJT, 2002, ARTHRITIS RHEUM, V46, P961, DOI 10.1002/art.10212; Kurisaki H, 2000, Rinsho Shinkeigaku, V40, P209; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; Levin M, 1999, P ASSOC AM PHYSICIAN, V111, P308, DOI 10.1046/j.1525-1381.1999.99242.x; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Ma ZD, 2005, J LEUKOCYTE BIOL, V78, P515, DOI 10.1189/jlb.0205112; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Mastroianni CM, 1997, CLIN IMMUNOL IMMUNOP, V84, P171, DOI 10.1006/clin.1997.4367; Matsuura E, 2000, J NEUROL SCI, V173, P45, DOI 10.1016/S0022-510X(99)00303-2; New L, 2003, MOL BIOL CELL, V14, P2603, DOI 10.1091/mbc.E02-08-0538; Novak U, 2000, J CLIN NEUROSCI, V7, P280, DOI 10.1054/jocn.1999.0212; OHGA S, 1994, ARCH DIS CHILD, V70, P123, DOI 10.1136/adc.70.2.123; Pereira CB, 2004, MICROBES INFECT, V6, P25, DOI 10.1016/j.micinf.2003.10.007; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Price NM, 2001, J IMMUNOL, V166, P4223, DOI 10.4049/jimmunol.166.6.4223; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Rivera S, 2004, M S-MED SCI, V20, P55, DOI 10.1051/medsci/200420155; Rock RB, 2005, J INFECT DIS, V192, P2054, DOI 10.1086/498165; Roy SK, 2002, P NATL ACAD SCI USA, V99, P7945, DOI 10.1073/pnas.122075799; Sanceau J, 2002, J BIOL CHEM, V277, P35766, DOI 10.1074/jbc.M202959200; Seternes OM, 2002, MOL CELL BIOL, V22, P6931, DOI 10.1128/MCB.22.20.6931-6945.2002; Shin KY, 2000, CANCER LETT, V159, P127, DOI 10.1016/S0304-3835(00)00522-X; Simmons CP, 2005, J IMMUNOL, V175, P579, DOI 10.4049/jimmunol.175.1.579; Svendsen CN, 2002, NATURE, V417, P29, DOI 10.1038/417029a; Thwaites G, 2000, J NEUROL NEUROSUR PS, V68, P289, DOI 10.1136/jnnp.68.3.289; Thwaites GE, 2004, NEW ENGL J MED, V351, P1741, DOI 10.1056/NEJMoa040573; Thwaites GE, 2005, LANCET NEUROL, V4, P160, DOI 10.1016/S1474-4422(05)01013-6; Uhm JH, 1998, GLIA, V22, P53, DOI 10.1002/(SICI)1098-1136(199801)22:1<53::AID-GLIA5>3.0.CO;2-9; Wu CY, 2004, J NEUROCHEM, V90, P1477, DOI 10.1111/j.1471-4159.2004.02682.x; Yong V W, 1999, Expert Opin Investig Drugs, V8, P255, DOI 10.1517/13543784.8.3.255; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhou M, 2003, J BIOL CHEM, V278, P45406, DOI 10.1074/jbc.M309075200	63	37	41	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					356	365		10.1096/fj.06-6925com	http://dx.doi.org/10.1096/fj.06-6925com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158965				2022-12-25	WOS:000244686300009
J	Glerup, S; Kloverpris, S; Laursen, LS; Dagnaes-Hansen, F; Thiel, S; Conover, CA; Oxvig, C				Glerup, Simon; Kloverpris, Sren; Laursen, Lisbeth S.; Dagnaes-Hansen, Frederik; Thiel, Steffen; Conover, Cheryl A.; Oxvig, Claus			Cell surface detachment of pregnancy-associated plasma protein-A requires the formation of intermolecular proteinase-inhibitor disulfide bonds and glycosaminoglycan covalently bound to the inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR BASIC-PROTEIN; MESSENGER-RIBONUCLEIC-ACID; PAPP-A; TERNARY COMPLEX; PROFORM; BINDING; PROTEOLYSIS; SPECIFICITY; EXPRESSION; MECHANISM	The metzincin metalloproteinase pregnancy-associated plasma protein-A (PAPP-A, pappalysin-1) promotes cell growth by proteolytic cleavage of insulin-like growth factor-binding proteins 4 and 5, causing the release of bound insulin-like growth factors. PAPP-A binds an unknown cell-surface heparan sulfate proteoglycan, suggesting that it controls insulin-like growth factor signaling spatially. In human pregnancy, the majority of PAPP-A circulates as a disulfide-bonded complex with its inhibitor, the proform of eosinophil major basic protein (proMBP). Interestingly, Ser-62 of proMBP is substituted with a glycosaminoglycan ( GAG) chain, possibly a heparan sulfate type, and the PAPP-A center dot proMBP complex is unable to bind to the cell surface. We show here that proMBP detaches surface-bound PAPP-A in a process that depends on the proMBP GAG and also on the formation of intermolecular disulfide bonds between PAPP-A and proMBP. Unlike what was expected, we demonstrate that the GAG of proMBP is not required for PAPP-A center dot proMBP complex formation and that proMBP residues His-137, Ser-178, Arg-179, and Asn-181 are important for the recognition of PAPP-A. Using a mouse model, we find that the half-life of circulating PAPP-A and proMBP in complex is severalfold higher than both of the uncomplexed proteins, further suggesting that the PAPP-A center dot proMBP complex is formed at the cell surface in vivo rather than in the circulation. Further supporting this, we show that formation of the PAPP-A center dot proMBP complex at the cell surface proceeds rapidly compared with the slow rate of complex formation in solution. Because both PAPP-A and proMBP are expressed ubiquitously, this model may be applicable to many tissues in which insulin-like growth factor bioavailability is locally regulated.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Immunol & Med Microbiol, DK-8000 Aarhus C, Denmark; Mayo Clin & Mayo Fdn, Coll Med, Dept Internal Med, Div Metab Endocrinol & Nutr, Rochester, MN 55905 USA	Aarhus University; Aarhus University; Mayo Clinic	Oxvig, C (corresponding author), Aarhus Univ, Dept Mol Biol, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	co@mb.au.dk		Thiel, Steffen/0000-0002-4817-155X; Laursen, Lisbeth Schmidt/0000-0002-8676-5869; Oxvig, Claus/0000-0002-4715-9719; Dagnaes-Hansen, Frederik/0000-0002-6622-0853				Bayes-Genis A, 2001, NEW ENGL J MED, V345, P1022, DOI 10.1056/NEJMoa003147; Boldt HB, 2001, BIOCHEM J, V358, P359, DOI 10.1042/0264-6021:3580359; BONNO M, 1994, LAB INVEST, V71, P560; Bunn RC, 2003, TRENDS ENDOCRIN MET, V14, P176, DOI 10.1016/S1043-2760(03)00049-3; Chen BK, 2003, J CLIN ENDOCR METAB, V88, P4465, DOI 10.1210/jc.2003-030193; Conover CA, 2004, DEVELOPMENT, V131, P1187, DOI 10.1242/dev.00997; Conover CA, 2001, ENDOCRINOLOGY, V142, P2155, DOI 10.1210/en.142.5.2155; Dementiev A, 2004, NAT STRUCT MOL BIOL, V11, P863, DOI 10.1038/nsmb810; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Ganesh VK, 2004, P NATL ACAD SCI USA, V101, P8924, DOI 10.1073/pnas.0400744101; GIUDICE LC, 2002, J CLIN ENDOCR METAB, V87, P2329; Glerup S, 2005, J BIOL CHEM, V280, P9823, DOI 10.1074/jbc.M413228200; Glerup S, 2006, J BIOL CHEM, V281, P31509, DOI 10.1074/jbc.M605824200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hogg PJ, 2003, TRENDS BIOCHEM SCI, V28, P210, DOI 10.1016/S0968-0004(03)00057-4; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; Laursen LS, 2002, J BIOL CHEM, V277, P47225, DOI 10.1074/jbc.M209155200; Laursen LS, 2002, BIOCHEM J, V367, P31, DOI 10.1042/BJ20020831; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Li W, 2004, NAT STRUCT MOL BIOL, V11, P857, DOI 10.1038/nsmb811; Overgaard MT, 2000, J BIOL CHEM, V275, P31128, DOI 10.1074/jbc.M001384200; Overgaard MT, 1999, BIOL REPROD, V61, P1083, DOI 10.1095/biolreprod61.4.1083; Overgaard MT, 2004, FEBS LETT, V560, P147, DOI 10.1016/S0014-5793(04)00095-X; Overgaard MT, 2003, J BIOL CHEM, V278, P2106, DOI 10.1074/jbc.M208777200; OXVIG C, 1994, BIOCHEM MOL BIOL INT, V33, P329; OXVIG C, 1993, J BIOL CHEM, V268, P12243; OXVIG C, 1994, BBA-GEN SUBJECTS, V1201, P415, DOI 10.1016/0304-4165(94)90071-X; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PIZZO SV, 1989, AM J MED, V87, pS10, DOI 10.1016/0002-9343(89)80524-8; Qin QP, 1997, CLIN CHEM, V43, P2323; Smith GCS, 2002, NATURE, V417, P916, DOI 10.1038/417916a; SOTTRUPJENSEN L, 1993, BIOCHEM MOL BIOL INT, V30, P789; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; Swaminathan GJ, 2001, J BIOL CHEM, V276, P26197, DOI 10.1074/jbc.M100848200; Wald NJ, 1999, NEW ENGL J MED, V341, P461, DOI 10.1056/NEJM199908123410701; Weyer K, 2004, EUR J BIOCHEM, V271, P1525, DOI 10.1111/j.1432-1033.2004.04061.x; Zhuo LS, 2004, J BIOL CHEM, V279, P38079, DOI 10.1074/jbc.R300039200	39	14	14	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1769	1778		10.1074/jbc.M608454200	http://dx.doi.org/10.1074/jbc.M608454200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17145752	hybrid			2022-12-25	WOS:000243451300028
J	Bacac, M; Provero, P; Mayran, N; Stehle, JC; Fusco, C; Stamenkovic, I				Bacac, Marina; Provero, Paolo; Mayran, Nathalie; Stehle, Jean-Christophe; Fusco, Carlo; Stamenkovic, Ivan			A Mouse Stromal Response to Tumor Invasion Predicts Prostate and Breast Cancer Patient Survival	PLOS ONE			English	Article								Primary and metastatic tumor growth induces host tissue responses that are believed to support tumor progression. Understanding the molecular changes within the tumor microenvironment during tumor progression may therefore be relevant not only for discovering potential therapeutic targets, but also for identifying putative molecular signatures that may improve tumor classification and predict clinical outcome. To selectively address stromal gene expression changes during cancer progression, we performed cDNA microarray analysis of laser-microdissected stromal cells derived from prostate intraepithelial neoplasia (PIN) and invasive cancer in a multistage model of prostate carcinogenesis. Human orthologs of genes identified in the stromal reaction to tumor progression in this mouse model were observed to be expressed in several human cancers, and to cluster prostate and breast cancer patients into groups with statistically different clinical outcomes. Univariate Cox analysis showed that overexpression of these genes is associated with shorter survival and recurrence-free periods. Taken together, our observations provide evidence that the expression signature of the stromal response to tumor invasion in a mouse tumor model can be used to probe human cancer, and to provide a powerful prognostic indicator for some of the most frequent human malignancies.	[Bacac, Marina; Mayran, Nathalie; Stehle, Jean-Christophe; Fusco, Carlo; Stamenkovic, Ivan] Inst Univ Pathol, Div Expt Pathol, Lausanne, Switzerland; [Provero, Paolo] Univ Turin, Dept Genet Biol & Biochem, Turin, Italy	University of Turin	Stamenkovic, I (corresponding author), Inst Univ Pathol, Div Expt Pathol, Lausanne, Switzerland.	Ivan.Stamenkovic@chuv.hospvd.ch	Provero, Paolo/AAC-1930-2019; Fusco, Carlo/AAC-7332-2022		Swiss National Science Foundation (SNSF) [3100-65090.01]; Molecular Oncology National Centre of Competence in Research (NCCR)	Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); Molecular Oncology National Centre of Competence in Research (NCCR)(Swiss National Science Foundation (SNSF))	Funding: This work was supported by the Swiss National Science Foundation (SNSF) grant 3100-65090.01 and a Molecular Oncology National Centre of Competence in Research (NCCR) grant. P. P. is a Lagrange Fellow of the CRT Foundation, Turin.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chantrain CF, 2004, CANCER RES, V64, P1675, DOI 10.1158/0008-5472.CAN-03-0160; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ein-Dor L, 2006, P NATL ACAD SCI USA, V103, P5923, DOI 10.1073/pnas.0601231103; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Hu Y, 2002, J BIOL CHEM, V277, P44462, DOI 10.1074/jbc.M205784200; Hubbard T, 2005, NUCLEIC ACIDS RES, V33, pD447, DOI 10.1093/nar/gki138; Ippolito JE, 2005, P NATL ACAD SCI USA, V102, P9901, DOI 10.1073/pnas.0500756102; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Joyce JA, 2004, CELL CYCLE, V3, P1516, DOI 10.4161/cc.3.12.1289; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kasprzyk A, 2004, GENOME RES, V14, P160, DOI 10.1101/gr.1645104; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Laurent-Matha V, 2005, J CELL BIOL, V168, P489, DOI 10.1083/jcb.200403078; Leung SY, 2002, P NATL ACAD SCI USA, V99, P16203, DOI 10.1073/pnas.212646299; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Littlepage LE, 2005, CANCER CELL, V7, P499, DOI 10.1016/j.ccr.2005.05.019; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Nadji M, 1996, HUM PATHOL, V27, P890, DOI 10.1016/S0046-8177(96)90214-2; Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1; Peeper D, 2006, CELL, V125, P1230, DOI 10.1016/j.cell.2006.06.018; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Skrzydlewska E, 2005, WORLD J GASTROENTERO, V11, P1251, DOI 10.3748/wjg.v11.i9.1251; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Tfelt-Hansen J, 2006, CLIN MED RES, V4, P130, DOI 10.3121/cmr.4.2.130; Tinker AV, 2006, CANCER CELL, V9, P333, DOI 10.1016/j.ccr.2006.05.001; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; West RB, 2005, PLOS BIOL, V3, P1101, DOI 10.1371/journal.pbio.0030187; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhao HJ, 2006, PLOS MED, V3, P115, DOI 10.1371/journal.pmed.0030013	47	47	47	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e32	10.1371/journal.pone.0000032	http://dx.doi.org/10.1371/journal.pone.0000032			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183660	Green Published, gold			2022-12-25	WOS:000207443600032
J	de Groot, P; Veldhuizen, RW				de Groot, Paul; Veldhuizen, R. W.			Human Coronary Artery Remodeling, Beginning and End of the Atherosclerotic Process	PLOS ONE			English	Article								Background, Aims of the Study. The objective of the study was to relate the progress of coronary artery remodeling to the earliest stages of the atherosclerotic process. For this purpose, a mathematical model for description of dimensional change of the coronary artery wall and its constituent components was developed and applied. Materials and Methods. The study used coronary artery samples randomly taken from each of 83 consecutive, unselected postmortems. All samples were routinely fixed and processed to paraffin for the preparation of right-angled, 5-micron sections, routinely stained and mounted for subsequent analysis. Computer assisted image analysis, using 32 systematic random, radial sampling lines, was used for interactive measurements of distance from centre of lumen to points defining intima, media and adventitia thickness along the radial intercept, which were subsequently tabled for analysis of variance, calculations of (group-vessel) means, and related to stage of pathology. Results. Pre-atherosclerotic changes, before any localised changes in especially intima dimensions, are found, consisting of a process of gradual vascular widening, associated with temporally at least partly dissociated increases in width, which as a fraction of total vessel radius show a phased process. In these, the intima first increases, subsequently remains stable, and finally reduces in width proportionally to the increasing diameter. The media shows a similar initial increase, on average stabilising in the third phase after reaching a plateau value in the second. The adventitia, already increasing in phase 1, continues to increase in phase 2, accelerating in phase 3. The complex process, as found, occurs systematically in all vessels, is distributed circumferentially, and precedes the development of localised lesions of the intima. Conclusions. The findings suggest the existence of a diffuse complex of changes, consisting of a gradual vascular widening followed by narrowing, with associated mural changes reflecting the atherosclerotic process.	[de Groot, Paul] MCH Hosp, Dept Cardiol, The Hague, Netherlands; [Veldhuizen, R. W.] MCH Hosp, Dept Pathol, The Hague, Netherlands		de Groot, P (corresponding author), MCH Hosp, Dept Cardiol, The Hague, Netherlands.	legrands@planet.nl						BOND MG, 1981, ARTERY, V9, P21; Clarijs JAGM, 1997, ARTERIOSCL THROM VAS, V17, P2617, DOI 10.1161/01.ATV.17.11.2617; DEGROOT P, 1994, THESIS LEIDEN U; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; Herity NA, 1999, J CARDIOVASC ELECTR, V10, P1016, DOI 10.1111/j.1540-8167.1999.tb01273.x; Labropoulos N, 1998, AM J SURG, V176, P140, DOI 10.1016/S0002-9610(98)00135-4; Varnava AM, 2001, HEART, V86, P207, DOI 10.1136/heart.86.2.207; ZARINS CK, 1988, J VASC SURG, V7, P386, DOI 10.1067/mva.1988.avs0070386	8	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e91	10.1371/journal.pone.0000091	http://dx.doi.org/10.1371/journal.pone.0000091			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183723	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443600090
J	Matoba, R; Niwa, H; Masui, S; Ohtsuka, S; Carter, MG; Sharov, AA; Ko, MSH				Matoba, Ryo; Niwa, Hitoshi; Masui, Shinji; Ohtsuka, Satoshi; Carter, Mark G.; Sharov, Alexei A.; Ko, Minoru S. H.			Dissecting Oct3/4-Regulated Gene Networks in Embryonic Stem Cells by Expression Profiling	PLOS ONE			English	Article							TRANSCRIPTION FACTOR; SELF-RENEWAL; MOUSE EMBRYOS; AKT KINASE; POU-DOMAIN; ES CELLS; OCT-4; DIFFERENTIATION; PLURIPOTENCY; NANOG	POU transcription factor Pou5f1 (Oct3/4) is required to maintain ES cells in an undifferentiated state. Here we show that global expression profiling of Oct3/4-manipulated ES cells delineates the downstream target genes of Oct3/4. Combined with data from genome-wide chromatin-immunoprecipitation (ChIP) assays, this analysis identifies not only primary downstream targets of Oct3/4, but also secondary or tertiary targets. Furthermore, the analysis also reveals that downstream target genes are regulated either positively or negatively by Oct3/4. Identification of a group of genes that show both activation and repression depending on Oct3/4 expression levels provides a possible mechanism for the requirement of appropriate Oct3/4 expression to maintain undifferentiated ES cells. As a proof-of-principle study, one of the downstream genes, Tcl1, has been analyzed in detail. We show that Oct3/4 binds to the promoter region of Tcl1 and activates its transcription. We also show that Tcl1 is involved in the regulation of proliferation, but not differentiation, in ES cells. These findings suggest that the global expression profiling of gene-manipulated ES cells can help to delineate the structure and dynamics of gene regulatory networks.	[Matoba, Ryo; Carter, Mark G.; Sharov, Alexei A.; Ko, Minoru S. H.] NIA, Dev Genom & Aging Sect, Genet Lab, NIH, Baltimore, MD 21224 USA; [Niwa, Hitoshi; Masui, Shinji; Ohtsuka, Satoshi] RIKEN, Ctr Dev Biol, Lab Pluripotent Cell Studies, Kobe, Hyogo, Japan	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); RIKEN	Ko, MSH (corresponding author), NIA, Dev Genom & Aging Sect, Genet Lab, NIH, Baltimore, MD 21224 USA.	kom@mail.nih.gov	Carter, Mark/B-5089-2010; Ko, Minoru S. H./B-7969-2009	Ko, Minoru S. H./0000-0002-3530-3015; Masui, Shinji/0000-0001-7417-0019	Intramural Research Program of the National Institute on Aging, NIH; NATIONAL INSTITUTE ON AGING [Z01AG000656, ZIAAG000656] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute on Aging, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported in part by the Intramural Research Program of the National Institute on Aging, NIH.	Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; Bortvin A, 2003, DEVELOPMENT, V130, P1673, DOI 10.1242/dev.00366; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Carter MG, 2003, GENOME RES, V13, P1011, DOI 10.1101/gr.878903; Catena R, 2004, J BIOL CHEM, V279, P41846, DOI 10.1074/jbc.M405514200; CAVALERI F, 2004, HDB STEM CELLS, P27; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Furukawa-Hibi Y, 2005, ANTIOXID REDOX SIGN, V7, P752, DOI 10.1089/ars.2005.7.752; Hamatani T, 2004, DEV CELL, V6, P117, DOI 10.1016/S1534-5807(03)00373-3; Hay DC, 2004, STEM CELLS, V22, P225, DOI 10.1634/stemcells.22-2-225; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kang SM, 2005, BLOOD, V105, P1288, DOI 10.1182/blood-2004-04-1453; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kishimoto H, 2003, CELL STRUCT FUNCT, V28, P11; Kraft HJ, 1996, J BIOL CHEM, V271, P12873, DOI 10.1074/jbc.271.22.12873; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Masui S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni043; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Narducci MG, 2002, P NATL ACAD SCI USA, V99, P11712, DOI 10.1073/pnas.182412399; Narducci MG, 1997, ONCOGENE, V15, P919, DOI 10.1038/sj.onc.1201246; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nishimoto M, 2003, BIOCHEM BIOPH RES CO, V302, P581, DOI 10.1016/S0006-291X(03)00218-3; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Okuda A, 1998, EMBO J, V17, P2019, DOI 10.1093/emboj/17.7.2019; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; PONGUBALA JMR, 1995, J BIOL CHEM, V270, P10304, DOI 10.1074/jbc.270.17.10304; Ramos-Mejia V, 2005, DEV DYNAM, V232, P180, DOI 10.1002/dvdy.20211; Roberts MS, 2004, MOL CELL BIOL, V24, P1505, DOI 10.1128/MCB.24.4.1505-1515.2004; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Saijoh Y, 1996, GENES CELLS, V1, P239, DOI 10.1046/j.1365-2443.1996.d01-237.x; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Sharov AA, 2003, PLOS BIOL, V1, P410, DOI 10.1371/journal.pbio.0000074; SHAROV AA, 2005, BIOINFORMATICS; Shimozaki K, 2003, DEVELOPMENT, V130, P2505, DOI 10.1242/dev.00476; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Stewart C. L., 2002, Gene expression at the beginning of animal development, P205; SUDA Y, 1987, J CELL PHYSIOL, V133, P197, DOI 10.1002/jcp.1041330127; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; TAKEUCHI T, 2006, DEV DYN; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Tanaka TS, 2002, GENOME RES, V12, P1921, DOI 10.1101/gr.670002; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Trewick SC, 2005, EMBO REP, V6, P315, DOI 10.1038/sj.embor.7400379; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Watanabe S, 2006, ONCOGENE, V25, P2697, DOI 10.1038/sj.onc.1209307; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yoshikawa T, 2006, GENE EXPR PATTERNS, V6, P213, DOI 10.1016/j.modgep.2005.06.003; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zhang GX, 2003, MOL CELL BIOL, V23, P6507, DOI 10.1128/MCB.23.18.6507-6519.2003	71	143	148	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e26	10.1371/journal.pone.0000026	http://dx.doi.org/10.1371/journal.pone.0000026			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183653	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600026
J	Vigne, P; Frelin, C				Vigne, Paul; Frelin, Christian			A Low Protein Diet Increases the Hypoxic Tolerance in Drosophila	PLOS ONE			English	Article								Dietary restriction is well known to increase the life span of a variety of organisms from yeast to mammals, but the relationships between nutrition and the hypoxic tolerance have not yet been considered. Hypoxia is a major cause of cell death in myocardial infarction and stroke. Here we forced hypoxia-related death by exposing one-day-old male Drosophila to chronic hypoxia (5% O-2) and analysed their survival. Chronic hypoxia reduced the average life span from 33.6 days to 6.3 days when flies were fed on a rich diet. A demographic analysis indicated that chronic hypoxia increased the slope of the mortality trajectory and not the short-term risk of death. Dietary restriction produced by food dilution, by yeast restriction, or by amino acid restriction partially reversed the deleterious action of hypoxia. It increased the life span of hypoxic flies up to seven days, which represented about 25% of the life time of an hypoxic fly. Maximum survival of hypoxic flies required only dietary sucrose, and it was insensitive to drugs such as rapamycin and resveratrol, which increase longevity of normoxic animals. The results thus uncover a new link between protein nutrition, nutrient signalling, and resistance to hypoxic stresses.	[Vigne, Paul; Frelin, Christian] Fac Med Nice, INSERM, F-06034 Nice, France; [Vigne, Paul; Frelin, Christian] Univ Nice Sophia Antipolis, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur	Frelin, C (corresponding author), Fac Med Nice, INSERM, U210, F-06034 Nice, France.	cfrelin@unice.fr			Institut National de la Sante et de la Recherche Medicale; Federation pour la Recherche sur le Cerveau; University of Nice Sophia Antipolis	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Federation pour la Recherche sur le Cerveau; University of Nice Sophia Antipolis	This work was supported by the Institut National de la Sante et de la Recherche Medicale, Federation pour la Recherche sur le Cerveau, and the University of Nice Sophia Antipolis.	Ahmet I, 2005, CIRCULATION, V112, P3115, DOI 10.1161/CIRCULATIONAHA.105.563817; Arquier N, 2006, BIOCHEM J, V393, P471, DOI 10.1042/BJ20050675; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; CARVALHO GB, 2005, NAT METH, V2, P755; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Haddad GG, 1997, P NATL ACAD SCI USA, V94, P10809, DOI 10.1073/pnas.94.20.10809; HOLLINGS.MJ, 1970, J INSECT PHYSIOL, V16, P1017, DOI 10.1016/0022-1910(70)90195-2; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Mair W, 2005, PLOS BIOL, V3, P1305, DOI 10.1371/journal.pbio.0030223; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; Mattson Mark P, 2004, NeuroRx, V1, P111, DOI 10.1007/BF03206571; Min KJ, 2006, MECH AGEING DEV, V127, P93, DOI 10.1016/j.mad.2005.09.004; Min KJ, 2006, MECH AGEING DEV, V127, P643, DOI 10.1016/j.mad.2006.02.005; O'Farrell PH, 2001, J CLIN INVEST, V107, P671, DOI 10.1172/JCI12562; Partridge L, 2005, MECH AGEING DEV, V126, P938, DOI 10.1016/j.mad.2005.03.023; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; VANHERREWEGE J, 1974, EXP GERONTOL, V9, P191; Walker DW, 2006, CURR BIOL, V16, P674, DOI 10.1016/j.cub.2006.01.057; Walker G, 2005, MECH AGEING DEV, V126, P929, DOI 10.1016/j.mad.2005.03.014; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789	27	18	20	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e56	10.1371/journal.pone.0000056	http://dx.doi.org/10.1371/journal.pone.0000056			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183686	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600056
J	Jiao, R; Harrigan, JA; Shevelev, I; Dietschy, T; Selak, N; Indig, FE; Piotrowski, J; Janscak, P; Bohr, VA; Stagljar, I				Jiao, R.; Harrigan, J. A.; Shevelev, I.; Dietschy, T.; Selak, N.; Indig, F. E.; Piotrowski, J.; Janscak, P.; Bohr, V. A.; Stagljar, I.			The Werner syndrome protein is required for recruitment of chromatin assembly factor 1 following DNA damage	ONCOGENE			English	Article						WRN; CAF-1; DNA damage; chromatin assembly; genome stability	SYNDROME GENE-PRODUCT; NUCLEOTIDE EXCISION-REPAIR; BLOOM-SYNDROME HELICASES; FUNCTIONAL INTERACTION; IN-VIVO; HUMAN-CELLS; FLAP ENDONUCLEASE-1; POLYMERASE-BETA; WRN HELICASES; STRAND BREAKS	The Werner syndrome protein (WRN) and chromatin assembly factor 1 (CAF-1) are both involved in the maintenance of genome stability. In response to DNA-damaging signals, both of these proteins relocate to sites where DNA synthesis occurs. However, the interaction between WRN and CAF-1 has not yet been investigated. In this report, we show that WRN interacts physically with the largest subunit of CAF-1, hp150, in vitro and in vivo. Although hp150 does not alter WRN catalytic activities in vitro, and the chromatin assembly activity of CAF-1 is not affected in the absence of WRN in vivo, this interaction may have an important role during the cellular response to DNA replication fork blockage and/or DNA damage signals. In hp150 RNA-mediated interference (RNAi) knockdown cells, WRN partially formed foci following hydroxyurea (HU) treatment. However, in the absence of WRN, hp150 did not relocate to form foci following exposure to HU and ultraviolet light. Thus, our results demonstrate that WRN responds to DNA damage before CAF-1 and suggest that WRN may recruit CAF-1, via interaction with hp150, to DNA damage sites during DNA synthesis.	Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, Dept Biochem, Toronto, ON M5S 3E1, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 3E1, Canada; Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, Beijing 100080, Peoples R China; Chinese Acad Sci, State Key Lab Brain & Cognit Sci, Inst Biophys, Beijing 100080, Peoples R China; NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M4X 1K9, Canada; Friedrich Miescher Inst Biomed Res, Basel, Switzerland; NIA, Res Resources Branch, NIH, Baltimore, MD 21224 USA; Univ Zurich, Inst Mol Canc Res, CH-8006 Zurich, Switzerland	University of Toronto; University of Toronto; Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Toronto; Friedrich Miescher Institute for Biomedical Research; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Zurich	Jiao, R (corresponding author), Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, Dept Biochem, 160 Coll St, Toronto, ON M5S 3E1, Canada.	rjiao@sun5.ibp.ac.cn; igor.stagljar@utoronto.ca	Bohr, Vilhelm/AAP-5931-2020; Jiao, Renjie/AAE-8902-2019; Janscak, Pavel/G-6189-2014; Janscak, Pavel/Q-3795-2018	Janscak, Pavel/0000-0002-1748-7789	NATIONAL INSTITUTE ON AGING [Z01AG000615, ZICAG000615] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Bohr VA, 2005, MUTAT RES-FUND MOL M, V577, P252, DOI 10.1016/j.mrfmmm.2005.03.021; Bradshaw PS, 2005, NAT GENET, V37, P193, DOI 10.1038/ng1506; Cheng WH, 2004, J BIOL CHEM, V279, P21169, DOI 10.1074/jbc.M312770200; Doherty KM, 2005, J BIOL CHEM, V280, P29494, DOI 10.1074/jbc.M500653200; Franchitto A, 2004, CELL CYCLE, V3, P1331, DOI 10.4161/cc.3.10.1185; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; Garcia PL, 2004, NUCLEIC ACIDS RES, V32, P3771, DOI 10.1093/nar/gkh709; Green CM, 2003, EMBO J, V22, P5163, DOI 10.1093/emboj/cdg478; Guay D, 2006, INT J BIOCHEM CELL B, V38, P1300, DOI 10.1016/j.biocel.2006.01.008; Harrigan JA, 2006, NUCLEIC ACIDS RES, V34, P745, DOI 10.1093/nar/gkj475; Harrigan JA, 2003, J BIOL CHEM, V278, P22686, DOI 10.1074/jbc.M213103200; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Jiao RJ, 2004, MOL CELL BIOL, V24, P4710, DOI 10.1128/MCB.24.11.4710-4719.2004; Karmakar P, 2005, MECH AGEING DEV, V126, P1146, DOI 10.1016/j.mad.2005.06.004; Karmakar P, 2002, NUCLEIC ACIDS RES, V30, P3583, DOI 10.1093/nar/gkf482; Karmakar P, 2002, J BIOL CHEM, V277, P18291, DOI 10.1074/jbc.M111523200; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Krude T, 1999, EUR J BIOCHEM, V263, P1, DOI 10.1046/j.1432-1327.1999.00508.x; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Laud PR, 2005, GENE DEV, V19, P2560, DOI 10.1101/gad.1321305; Lee JW, 2005, J BIOL CHEM, V280, P39627, DOI 10.1074/jbc.M506112200; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; LI L, 2005, J CELL SCI, V118, P4153; Linger J, 2005, GENETICS, V171, P1513, DOI 10.1534/genetics.105.043000; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; Nabatiyan A, 2004, MOL CELL BIOL, V24, P2853, DOI 10.1128/MCB.24.7.2853-2862.2004; Nabatiyan A, 2006, MOL CELL BIOL, V26, P1839, DOI 10.1128/MCB.26.5.1839-1849.2006; Opresko PL, 2004, MOL CELL, V14, P763, DOI 10.1016/j.molcel.2004.05.023; Opresko PL, 2004, J BIOL CHEM, V279, P18099, DOI 10.1074/jbc.R300034200; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Oshima J, 2002, CANCER RES, V62, P547; Ozgenc A, 2005, MUTAT RES-FUND MOL M, V577, P237, DOI 10.1016/j.mrfmmm.2005.03.020; Pedrazzi G, 2003, BIOL CHEM, V384, P1155, DOI 10.1515/BC.2003.128; Petkovic M, 2005, J CELL SCI, V118, P4261, DOI 10.1242/jcs.02556; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; Rodriguez-Lopez AM, 2003, MECH AGEING DEV, V124, P167, DOI 10.1016/S0047-6374(02)00131-8; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; Sharma S, 2004, HUM MOL GENET, V13, P2247, DOI 10.1093/hmg/ddh234; Sharma S, 2005, NUCLEIC ACIDS RES, V33, P6769, DOI 10.1093/nar/gki1002; Sharma S, 2004, J BIOL CHEM, V279, P9847, DOI 10.1074/jbc.M309898200; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Tyler JK, 2001, MOL CELL BIOL, V21, P6574, DOI 10.1128/MCB.21.19.6574-6584.2001; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; von Kobbe C, 2004, NUCLEIC ACIDS RES, V32, P4003, DOI 10.1093/nar/gkh721; von Kobbe C, 2003, MOL CELL BIOL, V23, P8601, DOI 10.1128/MCB.23.23.8601-8613.2003; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wolffe A., 1998, CHROMATIN STRUCTURE; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Xue Y, 2002, BIOCHEMISTRY-US, V41, P2901, DOI 10.1021/bi0157161; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097-2765(03)00037-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	69	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3811	3822		10.1038/sj.onc.1210150	http://dx.doi.org/10.1038/sj.onc.1210150			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173071				2022-12-25	WOS:000247026400005
J	Takahashi, K; Akiyama, H; Shimazaki, K; Uchida, C; Akiyama-Okunuki, H; Tomita, M; Fukumoto, M; Uchida, T				Takahashi, K.; Akiyama, H.; Shimazaki, K.; Uchida, C.; Akiyama-Okunuki, H.; Tomita, M.; Fukumoto, M.; Uchida, T.			Ablation of a peptidyl prolyl isomerase Pin1 from p53-null mice accelerated thymic hyperplasia by increasing the level of the intracellular form of Notch1	ONCOGENE			English	Article						p53; Notch1; presenilin-1; thymocytes; hyperplasia	CELL-CYCLE; RETINOBLASTOMA PROTEIN; X-CHROMOSOME; P53 PROTEIN; DNA-DAMAGE; GROWTH; APOPTOSIS; GENE; PRESENILIN-1; EXPRESSION	Tumor suppressor p53 is essential for checkpoint control in response to a variety of genotoxics tresses. DNA damage leads to phosphorylation on the Ser/Thr-Pro motifs of p53, which facilitates interaction with Pin1, a pSer/pThr-Prospeci. c peptidyl prolyl isomerase. Pin1 is required for the timely activation of p53, resulting in apoptosis or cell cycle arrest. To investigate the physiological relationship between Pin1 and p53, we created Pin1-/-p53-/-mice. These p53-deficient mice spontaneously developed lymphomas, mainly of thymic origin, as well as generalized lymphoma infiltration into other organs, including the liver, kidneys and lungs. Ablation of Pin1, in addition to p53, accelerated the thymichy perplasia, but the thymocytes in these Pin1-/-p53-/- mice did not infiltrate other organs. The thymocytes in 12-week-old Pin1-/-p53-/- mic e were CD4(-)CD8(-) (double negative) and had significantly higher levels of the intracellular form of Notch1 (NIC) than the thymocytes of p53-/- or wild- type mice. Presenilin-1, a cleavage enzyme for NIC generation from full-length Notch1 was increased in the thymocytes of Pin1-/-p53-/- mice. Pin1 depletion also inhibited the degradation of NIC by proteasomes. These results suggest that both Pin1 and p53 control the normal proliferation and differentiation of thymocytes by regulating the NIC level.	Tohoku Univ, Grad Sch Agr Sci, Sendai, Miyagi 9818555, Japan; Tohoku Univ, Ctr Interdisciplinary Res, Sendai, Miyagi 9818555, Japan; Tohoku Univ, Inst Dev Aging & Canc, Sendai, Miyagi 9818555, Japan; Showa Univ, Sch Pharmaceut Sci, Tokyo 142, Japan; Ibaraki Univ, Univ Hlth Ctr, Mito, Ibaraki 310, Japan	Tohoku University; Tohoku University; Tohoku University; Showa University; Ibaraki University	Uchida, T (corresponding author), Tohoku Univ, Grad Sch Agr Sci, 1-1 Amamiya, Sendai, Miyagi 9818555, Japan.	uchidat@biochem.tohoku.ac.jp		Uchida, Takafumi/0000-0003-3665-4906				Akiyama H, 2005, BIOCHEM BIOPH RES CO, V336, P521, DOI 10.1016/j.bbrc.2005.08.130; Amson R, 2000, P NATL ACAD SCI USA, V97, P5346, DOI 10.1073/pnas.97.10.5346; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fowlkes BJ, 2002, J IMMUNOL, V169, P1817, DOI 10.4049/jimmunol.169.4.1817; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; Hasserjian RP, 1996, BLOOD, V88, P970, DOI 10.1182/blood.V88.3.970.bloodjournal883970; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jehn BM, 1999, J IMMUNOL, V162, P635; Katsuda K, 2002, ONCOGENE, V21, P2108, DOI 10.1038/sj.onc.1205272; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lai EC, 2002, CURR BIOL, V12, pR200, DOI 10.1016/S0960-9822(02)00749-2; Laws AM, 2004, EUR J IMMUNOL, V34, P726, DOI 10.1002/eji.200324772; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Lu KP, 1996, NATURE, V380, P544; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Maillard I, 2003, IMMUNITY, V19, P781, DOI 10.1016/S1074-7613(03)00325-X; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P8917, DOI 10.1128/MCB.24.20.8917-8928.2004; Nakase H, 1996, STROKE, V27, P720, DOI 10.1161/01.STR.27.4.720; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; PURDIE CA, 1994, ONCOGENE, V9, P603; Radtke F, 2004, NAT IMMUNOL, V5, P247, DOI 10.1038/ni1045; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROGEL A, 1988, BIOCHIM BIOPHYS ACTA, V950, P395; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; TAKAGI N, 1974, EXP CELL RES, V86, P127, DOI 10.1016/0014-4827(74)90657-0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl GM, 2002, NAT CELL BIOL, V4, P328; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	59	48	49	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3835	3845		10.1038/sj.onc.1210153	http://dx.doi.org/10.1038/sj.onc.1210153			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17160015				2022-12-25	WOS:000247026400007
J	Graessmann, M; Berg, B; Fuchs, B; Klein, A; Graessmann, A				Graessmann, M.; Berg, B.; Fuchs, B.; Klein, A.; Graessmann, A.			Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3	ONCOGENE			English	Article						breast cancer cells; therapy resistance; osteopontin; inhibition of apoptosis; caspase-3; microarray	MITOCHONDRIA; ACTIVATION; PROTEINS; STRESS; DEATH; RECEPTOR; PHOSPHORYLATION; IDENTIFICATION; CLUSTERS; BINDING	Impairment of the complex regulatory network of cell death and survival is frequently the reason for therapy resistance of breast cancer cells and a major cause of tumor progression. We established two independent cell lines from a fast growing mouse breast tumor (WAP-SVT/t transgenic animal). Cells from one line (ME-A cells) are sensitive to apoptotic stimuli such as growth factor depletion or treatment with antitumor agents (e.g. doxorubicin). Cells from the second line (ME-C cells), which carry a missense mutation at the p53 codon 242, are very insensitive to apoptotic stimuli. Co-cultivation experiments revealed that the ME-C cells mediate cell death resistance to the ME-A cells. Microarray and Western blot analysis showed that osteopontin (OPN) is selectively overexpressed by the ME-C cells. This glycoprotein is the most abundant protein secreted by the ME-C cells and we obtained strong indications that OPN is the main antiapoptotic factor. However, the OPN containing ME-C cell medium does not alter the expression level of pro- or antiapoptotic genes or known inhibitors of apoptosis (IAPs). Its signaling involves mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK)1/2 as the kinase inhibitor PD98059 restores apoptosis but not the Akt inhibitor. In the ME-A cells, mitochondrial cytochrome c release occurs with and without external apoptotic stimuli. OPN containing ME-C cell medium does not prevent the mitochondrial cytochrome c release and caspase-9 processing. In serum starved ME-A cells, the OPN containing ME-C cell medium prevents caspase-3 activation. However, in doxorubicin-treated cells, although apoptosis is blocked, it does not inhibit caspase-3. This indicates that the ME-A cells distinguish between the initial apoptotic stimuli and that the cells possess a further uncharacterized control element acting downstream from caspase-3.	Charite Univ Med Berlin, Inst Mol Biol & Bioinformat, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Graessmann, M (corresponding author), Charite Univ Med Berlin, Inst Mol Biol & Bioinformat, Arnimallee 22,Farbeckstr,30, D-14195 Berlin, Germany.	adolf.graessmann@charite.de	Klein, Andreas/AAG-4506-2021	Klein, Andreas/0000-0002-3496-7215				Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Caudevilla C, 2001, FEBS LETT, V507, P269, DOI 10.1016/S0014-5793(01)02957-X; Christensen B, 2005, BIOCHEM J, V390, P285, DOI 10.1042/BJ20050341; Costantini P, 2002, CELL DEATH DIFFER, V9, P82, DOI 10.1038/sj.cdd.4400932; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; FUJII S, 1999, J CHINESE I ENV ENG, V9, P9; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Gardai SJ, 2004, J BIOL CHEM, V279, P44695, DOI 10.1074/jbc.M405313200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; Hu P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Johnson CR, 2004, APOPTOSIS, V9, P423, DOI 10.1023/B:APPT.0000031457.90890.13; Kanda H, 2004, J BIOCHEM, V136, P1, DOI 10.1093/jb/mvh098; Khan SA, 2002, J CELL BIOCHEM, V85, P728, DOI 10.1002/jcb.10170; Klein A, 2005, J MOL MED, V83, P362, DOI 10.1007/s00109-004-0625-1; Kohlhoff S, 2000, FREE RADICAL BIO MED, V29, P497, DOI 10.1016/S0891-5849(00)00340-3; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lin YH, 2001, J BIOL CHEM, V276, P46024, DOI 10.1074/jbc.M105132200; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Schimmer AD, 2004, CANCER RES, V64, P7183, DOI 10.1158/0008-5472.CAN-04-1918; Shanmugam V, 1997, BIOCHEMISTRY-US, V36, P5729, DOI 10.1021/bi961687w; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tuck AB, 2001, J MAMMARY GLAND BIOL, V6, P419, DOI 10.1023/A:1014734930781; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; TZENG YJ, 1993, ONCOGENE, V8, P1965; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Wessel Ralf, 2006, In Silico Biology, V6, P61	46	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2840	2850		10.1038/sj.onc.1210096	http://dx.doi.org/10.1038/sj.onc.1210096			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17160024				2022-12-25	WOS:000246210800004
J	Morris, SA; Rao, B; Garcia, BA; Hake, SB; Diaz, RL; Shabanowitz, J; Hil, DF; Allis, CD; Lieb, JD; Strahl, BD				Morris, Stephanie A.; Rao, Bhargavi; Garcia, Benjamin A.; Hake, Sandra B.; Diaz, Robert L.; Shabanowitz, Jeffrey; Hil, Donald F.; Allis, C. David; Lieb, Jason D.; Strahl, Brian D.			Identification of histone H3 lysine 36 acetylation as a highly conserved histone modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; POSTTRANSLATIONAL MODIFICATIONS; TRANSCRIPTIONAL ELONGATION; ACETYLTRANSFERASE ACTIVITY; MASS-SPECTROMETRY; SAGA COMPLEX; GENOME-WIDE; METHYLATION; YEAST	Histone lysine acetylation is a major mechanism by which cells regulate the structure and function of chromatin, and new sites of acetylation continue to be discovered. Here we identify and characterize histone H3K36 acetylation (H3K36ac). By mass spectrometric analyses of H3 purified from Tetrahymena thermophila and Saccharomyces cerevisiae (yeast), we find that H3K36 can be acetylated or methylated. Using an antibody specific to H3K36ac, we show that this modification is conserved in mammals. In yeast, genome-wide ChIP-chip experiments show that H3K36ac is localized predominantly to the promoters of RNA polymerase II-transcribed genes, a pattern inversely related to that of H3K36 methylation. The pattern of H3K36ac localization is similar to that of other sites of H3 acetylation, including H3K9ac and H3K14ac. Using histone acetyltransferase complexes purified from yeast, we show that the Gcn5-containing SAGA complex that regulates transcription specifically acetylates H3K36 in vitro. Deletion of GCN5 completely abolishes H3K36ac in vivo. These data expand our knowledge of the genomic targets of Gcn5, show H3K36ac is highly conserved, and raise the intriguing possibility that the transition between H3K36ac and H3K36me acts as an "acetyl/methyl switch" governing chromatin function along transcription units.	Univ N Carolina, Dept Biochem & Biophys, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; Rockefeller Univ, Lab Chromatin Biol, New York, NY 10021 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of Virginia; Rockefeller University; University of Virginia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Strahl, BD (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Sch Med, Chapel Hill, NC 27599 USA.	brian_strahl@med.unc.edu	Strahl, Brian/C-7601-2012	Strahl, Brian/0000-0002-4947-6259; Lieb, Jason/0000-0001-7601-8061	NIGMS NIH HHS [GM 68088, R01 GM072518-01A1, GM 072518, R01 GM037537, R01 GM068088, R01 GM072518-02, R01 GM072518, R01 GM040922, GM 37537, R01 GM068088-04, GM 40922] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537, R01GM040922, R01GM068088, R01GM072518] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; BOHLANDER SK, 1992, GENOMICS, V13, P1322, DOI 10.1016/0888-7543(92)90057-Y; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Clements A, 2003, MOL CELL, V12, P461, DOI 10.1016/S1097-2765(03)00288-0; Cosgrove MS, 2004, NAT STRUCT MOL BIOL, V11, P1037, DOI 10.1038/nsmb851; Davie JR, 1999, J CELL BIOCHEM, P141; Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Garcia BA, 2007, J BIOL CHEM, V282, P7641, DOI 10.1074/jbc.M607900200; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; Grewal SIS, 2004, CURR OPIN CELL BIOL, V16, P230, DOI 10.1016/j.ceb.2004.04.002; Hake SB, 2006, J BIOL CHEM, V281, P559, DOI 10.1074/jbc.M509266200; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Joshi AA, 2005, MOL CELL, V20, P971, DOI 10.1016/j.molcel.2005.11.021; Keogh MC, 2005, CELL, V123, P593, DOI 10.1016/j.cell.2005.10.025; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005; Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008; Liu CL, 2005, PLOS BIOL, V3, P1753, DOI 10.1371/journal.pbio.0030328; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; Medzihradszky KF, 2004, MOL CELL PROTEOMICS, V3, P872, DOI 10.1074/mcp.M400041-MCP200; Mizzen CA, 1999, METHOD ENZYMOL, V304, P675; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nathan D, 2006, GENE DEV, V20, P966, DOI 10.1101/gad.1404206; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Poux AN, 2003, BIOCHEMISTRY-US, V42, P14366, DOI 10.1021/bi035632n; Rao B, 2005, MOL CELL BIOL, V25, P9447, DOI 10.1128/MCB.25.21.9447-9459.2005; Recht J, 2006, P NATL ACAD SCI USA, V103, P6988, DOI 10.1073/pnas.0601676103; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shilatifard A, 2004, BBA-GENE STRUCT EXPR, V1677, P79, DOI 10.1016/j.bbaexp.2003.11.013; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Syka JEP, 2004, J PROTEOME RES, V3, P621, DOI 10.1021/pr0499794; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Turner BM, 2005, NAT STRUCT MOL BIOL, V12, P110, DOI 10.1038/nsmb0205-110; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; VANHOLDE KE, 1988, CHROMATIN, P111; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Ye JX, 2005, MOL CELL, V18, P123, DOI 10.1016/j.molcel.2005.02.031; Yu YX, 2003, MOL CELL BIOL, V23, P1910, DOI 10.1128/MCB.23.6.1910-1921.2003; Zhang KL, 2002, ANAL BIOCHEM, V306, P259, DOI 10.1006/abio.2002.5719; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	69	104	116	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7632	7640		10.1074/jbc.M607909200	http://dx.doi.org/10.1074/jbc.M607909200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17189264	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000245080900076
J	Ramya, TNC; Karmodiya, K; Surolia, A; Surolia, N				Ramya, T. N. C.; Karmodiya, Krishanpal; Surolia, Avadhesha; Surolia, Namita			15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; ENOYL-ACP REDUCTASE; MALARIA; INHIBITION; SEQUENCE; PHOSPHORYLATION; DEOXYSPERGUALIN; IDENTIFICATION; BIOSYNTHESIS; LOCALIZATION	15-Deoxyspergualin, an immunosuppressant with tumoricidal and antimalarial properties, has been implicated in the inhibition of a diverse array of cellular processes including polyamine synthesis and protein synthesis. Endeavoring to identify the mechanism of antimalarial action of this molecule, we examined its effect on Plasmodiunifalciparum protein synthesis, polyamine biosynthesis, and transport. 15-Deoxyspergualin stalled protein synthesis in P.falciparum through Hsp70 sequestration and subsequent phosphorylation of the eukaryotic initiation factor eff2a. However, protein synthesis inhibition as well as polyamine depletion were invoked only by high micromolar concentrations of 15-deoxyspergualin, in contrast to the submicromolar concentrations sufficient to inhibit parasite growth. Further investigations demonstrated that 15-deoxyspergualin in the malaria parasite primarily targets the hitherto underexplored process of trafficking of nucleus-encoded proteins to the apicoplast. Our finding that 15-deoxyspergualin kills the malaria parasite by interfering with targeting of nucleus-encoded. proteins to the apicoplast not only exposes a chink in the armor of the malaria parasite, but also reveals new realms in our endeavors to study this intriguing biological process.	Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India; Indian Inst Sci, Bangalore 560012, Karnataka, India; Natl Inst Immunol, New Delhi 110067, India	Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Indian Institute of Science (IISC) - Bangalore; Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Surolia, N (corresponding author), Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India.	surolia@nii.res.in	Chakravarthy, Ramya/F-8924-2010; SUROLIA, AVADESHA/C-5442-2009; Chakravarthy, Ramya T. N./AAJ-7507-2021	Karmodiya, Krishanpal/0000-0002-5714-0587				AMORIM HV, 1977, J AGR FOOD CHEM, V25, P957, DOI 10.1021/jf60212a047; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; Foth BJ, 2003, SCIENCE, V299, P705, DOI 10.1126/science.1078599; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; HBATNAGAR P, 2001, PLANT PHYSIOL, V125, P2139; He CY, 2001, EMBO J, V20, P330, DOI 10.1093/emboj/20.3.330; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kapoor M, 2001, BIOCHEM BIOPH RES CO, V289, P832, DOI 10.1006/bbrc.2001.6061; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; MATTS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2559, DOI 10.1073/pnas.80.9.2559; McFadden GI, 1997, BIOESSAYS, V19, P1033, DOI 10.1002/bies.950191114; Midorikawa Y, 1998, CHEMOTHERAPY, V44, P409, DOI 10.1159/000007152; Midorikawa Y, 1997, CHEMOTHERAPY, V43, P31, DOI 10.1159/000239532; Mohrle JJ, 1997, BIOCHEM J, V328, P677; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; Nadler SG, 1998, BIOCHEM BIOPH RES CO, V253, P176, DOI 10.1006/bbrc.1998.9775; Nishimura K, 2002, BIOCHEM J, V363, P761, DOI 10.1042/0264-6021:3630761; PRICE NT, 1991, BIOCHEM BIOPH RES CO, V176, P993, DOI 10.1016/0006-291X(91)90380-P; Ramya TNC, 2007, BIOCHEM J, V401, P411, DOI 10.1042/BJ20060879; Ramya TNC, 2007, ANTIMICROB AGENTS CH, V51, P307, DOI 10.1128/AAC.00808-06; Ramya TNC, 2006, BIOCHEM BIOPH RES CO, V348, P585, DOI 10.1016/j.bbrc.2006.07.082; Ramya TNC, 2006, BIOCHEM BIOPH RES CO, V348, P579, DOI 10.1016/j.bbrc.2006.07.127; Rial DV, 2000, EUR J BIOCHEM, V267, P6239, DOI 10.1046/j.1432-1327.2000.01707.x; Sato S, 2002, CURR GENET, V40, P391, DOI 10.1007/s00294-002-0273-3; SUROLIA N, 1992, BIOCHEM BIOPH RES CO, V187, P744, DOI 10.1016/0006-291X(92)91258-R; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; SUROLIA N, 1991, P NATL ACAD SCI USA, V88, P4786, DOI 10.1073/pnas.88.11.4786; Thulasiraman V, 1998, EUR J BIOCHEM, V255, P552, DOI 10.1046/j.1432-1327.1998.2550552.x; Tonkin CJ, 2004, MOL BIOCHEM PARASIT, V137, P13, DOI 10.1016/j.molbiopara.2004.05.009; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; van Dooren GG, 2002, J BIOL CHEM, V277, P23612, DOI 10.1074/jbc.M201748200; van Dooren GG, 2001, BBA-MOL CELL RES, V1541, P34, DOI 10.1016/S0167-4889(01)00154-9; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wilson RJM, 2002, J MOL BIOL, V319, P257, DOI 10.1016/S0022-2836(02)00303-0; Zuegge J, 2001, GENE, V280, P19, DOI 10.1016/S0378-1119(01)00776-4	40	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6388	6397		10.1074/jbc.M610251200	http://dx.doi.org/10.1074/jbc.M610251200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17194705	hybrid			2022-12-25	WOS:000244867200046
J	Sen, A; Baxa, U; Simon, MN; Wall, JS; Sabate, R; Saupe, SJ; Steven, AC				Sen, Anindito; Baxa, Ulrich; Simon, Martha N.; Wall, Joseph S.; Sabate, Raimon; Saupe, Sven J.; Steven, Alasdair C.			Mass analysis by scanning transmission electron microscopy and electron diffraction validate predictions of stacked beta-solenoid model of HET-s prion fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS PODOSPORA-ANSERINA; IN-VITRO; HETEROKARYON INCOMPATIBILITY; HYDROGEN/DEUTERIUM EXCHANGE; PROTEIN; DOMAIN; URE2P; SUP35; FILAMENTS; ORGANIZATION	Fungal prions are infectious filamentous polymers of proteins that are soluble in uninfected cells. In its prion form, the HET-s protein of Podospora anserina participates in a fungal self/nonself recognition phenomenon called heterokaryon incompatibility. Like other prion proteins, HET-s has a so-called "prion domain" (its C-terminal region, HET-s-(218-289)) that is responsible for induction and propagation of the prion in vivo and for fibril formation in vitro. Prion fibrils are thought to have amyloid backbones of polymerized prion domains. A relatively detailed model has been proposed for prion domain fibrils of HET-s based on a variety of experimental constraints (Ritter, C., Maddelein, M. L., Siemer, A. B., Luhrs, T., Ernst, M., Meier, B. H., Saupe, S. J., and Riek, R. (2005) Nature 435, 844 - 848). To test specific predictions of this model, which envisages axial stacking of beta-solenoids with two coils per subunit, we examined fibrils by electron microscopy. Electron diffraction gave a prominent meridional reflection at (0.47 nm)(-1), indicative of cross-P structure, as predicted. STEM (scanning transmission electron microscopy) mass-per-unit-length measurements yielded 1.02 +/- 0.16 subunits per 0.94 nm, in agreement with the model prediction (I subunit per 0.94 nm). This is half the packing density of similar to I subunit per 0.47 nm previously obtained for fibrils of the yeast prion proteins, Ure2p and Sup35p, whence it follows that the respective amyloid architectures are basically different.	NIH, Struct Biol Lab, Bethesda, MD 20892 USA; NIH, NIAMSD, Bethesda, MD 20892 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Univ Bordeaux 2, CNRS, UMR 5095,Inst Biochim & Genet Cellulaire, Lab Genet Mol Champignons, F-33077 Bordeaux, France	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); United States Department of Energy (DOE); Brookhaven National Laboratory; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Steven, AC (corresponding author), NIH, Struct Biol Lab, Bldg 50,Rm 1517,50 S Dr MSC 8025, Bethesda, MD 20892 USA.	Alasdair_Steven@nih.gov	; sabate, raimon/I-7849-2014	Baxa, Ulrich/0000-0002-7263-5078; sabate, raimon/0000-0003-3894-2362; saupe, sven/0000-0002-5589-721X	Intramural NIH HHS Funding Source: Medline; NIBIB NIH HHS [5 P41 EB2181] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002181] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Balguerie A, 2004, J CELL SCI, V117, P2599, DOI 10.1242/jcs.01116; Balguerie A, 2003, EMBO J, V22, P2071, DOI 10.1093/emboj/cdg213; Baxa U, 2005, J STRUCT BIOL, V150, P170, DOI 10.1016/j.jsb.2005.02.007; Baxa U, 2002, P NATL ACAD SCI USA, V99, P5253, DOI 10.1073/pnas.082097899; Baxa U, 2006, ADV PROTEIN CHEM, V73, P125, DOI 10.1016/S0065-3233(06)73005-4; Brachmann A, 2005, EMBO J, V24, P3082, DOI 10.1038/sj.emboj.7600772; Chien P, 2004, ANNU REV BIOCHEM, V73, P617, DOI 10.1146/annurev.biochem.72.121801.161837; Coustou V, 1997, P NATL ACAD SCI USA, V94, P9773, DOI 10.1073/pnas.94.18.9773; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; Derkatch IL, 1996, GENETICS, V144, P1375; Diaz-Avalos R, 2005, P NATL ACAD SCI USA, V102, P10165, DOI 10.1073/pnas.0504599102; Dos Reis S, 2002, J BIOL CHEM, V277, P5703, DOI 10.1074/jbc.M110183200; Edskes HK, 2002, P NATL ACAD SCI USA, V99, P16384, DOI 10.1073/pnas.162349599; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Heymann JB, 2001, J STRUCT BIOL, V133, P156, DOI 10.1006/jsbi.2001.4339; Kajava AV, 2006, ADV PROTEIN CHEM, V73, P55, DOI 10.1016/S0065-3233(06)73003-0; Kajava AV, 2004, P NATL ACAD SCI USA, V101, P7885, DOI 10.1073/pnas.0402427101; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Kishimoto A, 2004, BIOCHEM BIOPH RES CO, V315, P739, DOI 10.1016/j.bbrc.2004.01.117; Kobe B, 2000, TRENDS BIOCHEM SCI, V25, P509, DOI 10.1016/S0968-0004(00)01667-4; Maddelein ML, 2002, P NATL ACAD SCI USA, V99, P7402, DOI 10.1073/pnas.072199199; Muller SA, 2001, MICRON, V32, P21, DOI 10.1016/S0968-4328(00)00022-6; Nazabal A, 2005, J BIOL CHEM, V280, P13220, DOI 10.1074/jbc.M413185200; Nazabal A, 2003, BIOCHEMISTRY-US, V42, P8852, DOI 10.1021/bi0344275; Pierce MM, 2005, BIOCHEMISTRY-US, V44, P321, DOI 10.1021/bi047964d; Ritter C, 2005, NATURE, V435, P844, DOI 10.1038/nature03793; Ross ED, 2005, P NATL ACAD SCI USA, V102, P12825, DOI 10.1073/pnas.0506136102; Ross ED, 2004, MOL CELL BIOL, V24, P7206, DOI 10.1128/MCB.24.16.7206-7213.2004; Saupe SJ, 2000, MICROBIOL MOL BIOL R, V64, P489, DOI 10.1128/MMBR.64.3.489-502.2000; Schlumpberger M, 2001, MOL CELL BIOL, V21, P7035, DOI 10.1128/MCB.21.20.7035-7046.2001; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Siemer AB, 2006, J AM CHEM SOC, V128, P13224, DOI 10.1021/ja063639x; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; THOMAS D, 1994, BIOL CELL, V80, P181, DOI 10.1016/0248-4900(94)90041-8; Trus BL, 1996, J STRUCT BIOL, V116, P61, DOI 10.1006/jsbi.1996.0011; TURCQ B, 1991, MOL GEN GENET, V228, P265, DOI 10.1007/BF00282475; Wall JS, 2000, METH MOL B, V148, P589; YODER MD, 1995, FASEB J, V9, P335, DOI 10.1096/fasebj.9.5.7896002	41	71	71	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5545	5550		10.1074/jbc.M611464200	http://dx.doi.org/10.1074/jbc.M611464200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17178708	hybrid			2022-12-25	WOS:000244482300050
J	Wu, CY; Chen, CL; Lee, YH; Cheng, YC; Wu, YC; Shu, HY; Gotz, F; Liu, ST				Wu, Cheng-Yeu; Chen, Chyi-Liang; Lee, Yu-Hsiu; Cheng, Yu-Chieh; Wu, Ying-Chung; Shu, Hung-Yu; Goetz, Friedrich; Liu, Shih-Tung			Nonribosomal synthesis of fengycin on an enzyme complex formed by fengycin synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PEPTIDE SYNTHETASES; GRAMICIDIN-S-SYNTHETASE; BACILLUS-SUBTILIS F-29-3; BIOCHEMICAL-CHARACTERIZATION; MACROCYCLIC PEPTIDES; CONDENSATION DOMAIN; POLYACRYLAMIDE-GELS; MODULAR STRUCTURE; ESCHERICHIA-COLI; BIOSYNTHESIS	Fengycin, a lipopeptidic antibiotic, is synthesized nonribosomally by five fengycin synthetases (FenC, FenD, FenE, FenA, and FenB) in Bacillus subtilis F29-3. This work demonstrates that these fengycin synthetases interlock to form a chain, which coils into a 14.5-nm structure. In this chain, fengycin synthetases are linked in the order FenC-FenD-FenE-FenA-FenB by interactions between the C-terminal region of an upstream enzyme and the N-terminal region of its downstream partner enzyme, with their amino acid activation modules arranged colinearly with the amino acids in fengycin. This work also reveals that fengycin is synthesized on this fengycin synthetase chain, explaining how fengycin is synthesized efficiently and accurately. The results from this investigation demonstrate that forming a peptide synthetase complex is crucial to nonribosomal peptide synthesis.	Chang Gung Univ, Dept Microbiol & Immunol, Mol Genet Lab, Tao Yuan 333, Taiwan; Univ Tubingen, Inst Biol, AG Mikbrobielle Genet, D-70276 Tubingen, Germany	Chang Gung University; Eberhard Karls University of Tubingen	Liu, ST (corresponding author), Chang Gung Univ, Dept Microbiol & Immunol, Mol Genet Lab, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.	cgliu@mail.cgu.edu.tw	Chen, Chyi-Liang/GVT-1758-2022	Shu, Hung-Yu/0000-0002-2213-9324; Chen, Chyi-Liang/0000-0003-4591-0924; Wu, Cheng-Yeu/0000-0002-1545-0835				BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; Chang LK, 2004, J BIOL CHEM, V279, P38803, DOI 10.1074/jbc.M405470200; CHANG LK, 1994, GENE, V150, P129; CHEN CL, 1995, MOL GEN GENET, V248, P121, DOI 10.1007/BF02190792; Chiocchini C, 2006, CHEM BIOL, V13, P899, DOI 10.1016/j.chembiol.2006.06.015; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P1293, DOI 10.1073/pnas.70.5.1293; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Finking R, 2004, ANNU REV MICROBIOL, V58, P453, DOI 10.1146/annurev.micro.58.030603.123615; Grunewald J, 2006, MICROBIOL MOL BIOL R, V70, P121, DOI 10.1128/MMBR.70.1.121-146.2006; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; Hoppert M, 2001, ARCH MICROBIOL, V176, P285, DOI 10.1007/s002030100324; Hori K, 1997, J BIOCHEM-TOKYO, V122, P606; IMANAKA T, 1982, J BACTERIOL, V149, P824, DOI 10.1128/JB.149.3.824-830.1982; Klein DL, 1995, MICROB DRUG RESIST, V1, P49, DOI 10.1089/mdr.1995.1.49; Kleinkauf H, 1997, Prog Drug Res, V48, P27; Kleinkauf Horst, 2000, Biofactors, V11, P91; KOISCHWITZ H, 1976, BIOCHIM BIOPHYS ACTA, V429, P1041, DOI 10.1016/0005-2744(76)90349-1; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; Li GH, 1998, J BACTERIOL, V180, P1338, DOI 10.1128/JB.180.5.1338-1341.1998; Lin TP, 2005, BBA-GENE STRUCT EXPR, V1730, P159, DOI 10.1016/j.bbaexp.2005.02.005; Lin TP, 1999, J BACTERIOL, V181, P5060, DOI 10.1128/JB.181.16.5060-5067.1999; Linne U, 2000, BIOCHEMISTRY-US, V39, P10439, DOI 10.1021/bi000768w; Linne U, 2003, BIOCHEMISTRY-US, V42, P5114, DOI 10.1021/bi034223o; LOEFFLER W, 1986, J PHYTOPATHOL, V115, P204, DOI 10.1111/j.1439-0434.1986.tb00878.x; Luo LS, 2002, BIOCHEMISTRY-US, V41, P9184, DOI 10.1021/bi026047+; Mootz HD, 1997, J BACTERIOL, V179, P6843, DOI 10.1128/jb.179.21.6843-6850.1997; Sambrook J, 2001, MOL CLONING LAB MANU; Samel SA, 2006, J MOL BIOL, V359, P876, DOI 10.1016/j.jmb.2006.03.062; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; Schwarzer D, 2003, NAT PROD REP, V20, P275, DOI 10.1039/b111145k; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shu HY, 2002, BIOCHEM BIOPH RES CO, V292, P789, DOI 10.1006/bbrc.2002.6729; Sieber SA, 2004, ANGEW CHEM INT EDIT, V43, P493, DOI 10.1002/anie.200352787; Sieber SA, 2003, J BACTERIOL, V185, P7036, DOI 10.1128/JB.185.24.7036-7043.2003; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; Stachelhaus T, 1996, CHEM BIOL, V3, P913, DOI 10.1016/S1074-5521(96)90180-5; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1016/0378-1097(94)00459-5; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; Tschen J. S. M., 1987, Transactions of the Mycological Society of Japan, V28, P483; VANITTANAKOM N, 1986, J ANTIBIOT, V39, P888, DOI 10.7164/antibiotics.39.888; vonDohren H, 1997, CHEM REV, V97, P2675, DOI 10.1021/cr9600262	43	43	54	5	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5608	5616		10.1074/jbc.M609726200	http://dx.doi.org/10.1074/jbc.M609726200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17182617	hybrid			2022-12-25	WOS:000244482300057
J	Zhang, LL; Pan, XY; Hershey, JWB				Zhang, Lili; Pan, Xiaoyu; Hershey, John W. B.			Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PROTEIN-SYNTHESIS; NEOPLASTIC TRANSFORMATION; BINDING PROTEIN; TUMOR-FORMATION; UP-REGULATION; HELA-CELLS; EXPRESSION; AMPLIFICATION; BREAST	Transcriptional and post-transcriptional regulatory mechanisms are commonly accepted paradigms of tumorigenesis. The view is emerging that deregulation of translation contributes importantly to cancer development, a role not generally appreciated before. Eukaryotic initiation factor eIF3 contains at least thirteen non-identical subunits, named from eIF3a to eIF3m, and plays an essential role in the rate-limiting initiation phase of translation. Increased mRNA and protein levels of the eIF3a, -3b, -3c, -3h, and -3i subunits have been detected in a wide variety of human tumors and are frequently identified as prognostic biomarkers for poor clinical outcome. However, it remains to be established whether up-regulation of eIF3 subunits is a consequence or a cause of the malignant phenotypes. Here we report that ectopic expression of eIF3a, -3b, -3c, -3h, or -3i in stably transfected NlH3T3 cells leads to a number of oncogenic properties: decreased doubling times, increased clonogenicity and viability, facilitated S-phase entry, attenuation of apoptosis, formation of transformed foci, and anchorage-independent growth. Only overexpression of the transforming subunits results in a stimulation of initiation and global protein synthesis rates and enhanced translation of poorly translated mRNAs that encode growth-regulating proteins, including cyclinD1, c-Myc, fibroblast growth factor-2, and ornithine decarboxylase, which may be responsible for oncogenic malignancy in the transformed cell lines. Based on these results, we hypothesize that eIF3 contributes to hyperactivation of the translation initiation machinery and thereby may play an important role in neoplasia. Cancer cells appear to require an aberrantly activated translational state to survive, suggesting that the initiation factors may be promising therapeutic targets for treating cancer.	Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Mol & Cell Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Hershey, JWB (corresponding author), Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, 1 Shields Ave, Davis, CA 95616 USA.	jwhershey@ucdavis.edu						AVDULOV S, 2004, CANCER CELL, P553; Bachmann F, 1997, CANCER RES, V57, P988; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; Buttitta F, 2005, CLIN CANCER RES, V11, P3198, DOI 10.1158/1078-0432.CCR-04-2308; CHANG H, 1976, P NATL ACAD SCI USA, V73, P3206, DOI 10.1073/pnas.73.9.3206; Chen GP, 1999, INT J CANCER, V84, P95, DOI 10.1002/(SICI)1097-0215(19990420)84:2<95::AID-IJC1>3.0.CO;2-N; Choy L, 1998, J BIOL CHEM, V273, P31455, DOI 10.1074/jbc.273.47.31455; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; Dellas A, 1998, CANCER, V83, P1376, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1376::AID-CNCR15>3.0.CO;2-1; Dong ZZ, 2004, ONCOGENE, V23, P3790, DOI 10.1038/sj.onc.1207465; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Fraser CS, 2004, J BIOL CHEM, V279, P8946, DOI 10.1074/jbc.M312745200; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hui DJ, 2003, J BIOL CHEM, V278, P39477, DOI 10.1074/jbc.M305038200; Joseph P, 2004, MOL CELL BIOCHEM, V255, P93, DOI 10.1023/B:MCBI.0000007265.38475.f7; Joseph P, 2002, CANCER RES, V62, P703; Kim TH, 2004, PLANT CELL, V16, P3341, DOI 10.1105/tpc.104.026880; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lin L, 2001, J CELL BIOCHEM, V80, P483, DOI 10.1002/1097-4644(20010315)80:4<483::AID-JCB1002>3.0.CO;2-B; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Marchetti A, 2001, INT J ONCOL, V18, P175; Mayeur GL, 2003, EUR J BIOCHEM, V270, P4133, DOI 10.1046/j.1432-1033.2003.03807.x; Miyazaki S, 1997, GENOMICS, V46, P155, DOI 10.1006/geno.1997.4996; Morris-Desbois C, 2001, J BIOL CHEM, V276, P45988, DOI 10.1074/jbc.M104966200; Nielsen KH, 2006, MOL CELL BIOL, V26, P2984, DOI 10.1128/MCB.26.8.2984-2998.2006; Nupponen NN, 2000, GENE CHROMOSOME CANC, V28, P203; Nupponen NN, 1999, AM J PATHOL, V154, P1777, DOI 10.1016/S0002-9440(10)65433-8; Okamoto H, 2003, HEPATOLOGY, V38, P1242, DOI 10.1053/jhep.2003.50457; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Pincheira R, 2001, BRIT J CANCER, V84, P1520, DOI 10.1054/bjoc.2001.1828; Raught B, 1996, CANCER RES, V56, P4382; Rosenwald IB, 2004, ONCOGENE, V23, P3230, DOI 10.1038/sj.onc.1207552; Rothe M, 2000, AM J PATHOL, V157, P1597, DOI 10.1016/S0002-9440(10)64797-9; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Saramaki O, 2001, AM J PATHOL, V159, P2089, DOI 10.1016/S0002-9440(10)63060-X; Savinainen KJ, 2004, BRIT J CANCER, V90, P1041, DOI 10.1038/sj.bjc.6601648; Siridechadilok B, 2005, SCIENCE, V310, P1513, DOI 10.1126/science.1118977; Unbehaun A, 2004, GENE DEV, V18, P3078, DOI 10.1101/gad.1255704; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6; Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	48	151	164	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5790	5800		10.1074/jbc.M606284200	http://dx.doi.org/10.1074/jbc.M606284200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17170115	hybrid			2022-12-25	WOS:000244482300075
J	Chou, TF; Wagner, CR				Chou, Tsui-Fen; Wagner, Carston R.			Lysyl-tRNA synthetase-generated lysyl-adenylate is a substrate for histidine triad nucleotide binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-INTERACTING PROTEIN-1; TRANSCRIPTIONAL ACTIVITY; ACTIVE-SITE; HIT FAMILY; HIV-1 GAG; HINT; FHIT; MECHANISM; ENZYME; GENE	Histidine triad nucleotide binding proteins (Hints) are the most ancient members of the histidine triad protein superfamily of nucleotidyltransferases and hydrolyases. Protein-protein interaction studies have found that complexes of the transcription factors MITE or USF2 and lysyl-tRNA synthetase (LysRS) are associated with human Hintl. Therefore, we hypothesized that lysyl-AMP or the LysRS center dot lysyl-AMP may be a native substrate for Hints. To explore the biochemical relationship between Hintl and LysRS, a series of catalytic radiolabeling, mutagenesis, and kinetic experiments was conducted with purified LysRSs and Hints from human and Escherichia coli. After incubation of the E. coli or human LysRS with Hints and [alpha-P-32]ATP, but not [alpha-P-32]GTP, P-32-labeled Hints were observed. By varying time and the concentrations of lysine, Mg2+, or LysRS, the adenylation of Hint was found to be dependent on the formation of lysyl-AMP. Site-directed mutagenesis studies of the active site histidine triad revealed that Hint labeling could be abolished by substitution of either His-101 of E. coli hinT or His-112 of human Hintl by either alanine or glycine. Ap(4)A, believed to be synthesized by LysRS in vivo, and Zn2+ were shown to inhibit the formation of Hint-AMP with an IC50 value in the low micromolar range. Consistent with pyrophosphate being an inhibitor for aminoacyl-tRNA synthetase, incubations in the presence of pyrophosphatase resulted in enhanced formation of Hint-AMP. These results demonstrate that the lysyl-AMP intermediate formed by LysRS is a natural substrate for Hints and suggests a potential highly conserved regulatory role for Hints on LysRS and possibly other aminoacyl-tRNA synthetases.	Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Wagner, CR (corresponding author), Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA.	wagne003@umn.edu						Ahel I, 2006, NATURE, V443, P713, DOI 10.1038/nature05164; Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BREVET A, 1995, J BIOL CHEM, V270, P14439, DOI 10.1074/jbc.270.24.14439; BREVET A, 1989, P NATL ACAD SCI USA, V86, P8275, DOI 10.1073/pnas.86.21.8275; Bullock TL, 2003, J MOL BIOL, V328, P395, DOI 10.1016/S0022-2836(03)00305-X; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; Chou TF, 2005, J BIOL CHEM, V280, P15356, DOI 10.1074/jbc.M500434200; CHOU TF, 2006, IN PRESS MOL PHARM; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; Desogus G, 2000, BIOCHEMISTRY-US, V39, P8418, DOI 10.1021/bi0006722; FREY PA, 1982, METHOD ENZYMOL, V87, P20; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; Geeganage S, 1998, BIOCHEMISTRY-US, V37, P14500, DOI 10.1021/bi9815546; Hati S, 2006, J BIOL CHEM, V281, P27862, DOI 10.1074/jbc.M605856200; Howard OMZ, 2002, J EXP MED, V196, P781, DOI 10.1084/jem.20020186; Huang K, 2004, BIOCHEMISTRY-US, V43, P7637, DOI 10.1021/bi049762n; Huang KS, 2005, EUR J ORG CHEM, V2005, P5198, DOI 10.1002/ejoc.200500499; Hughes SJ, 2006, PROTEINS, V62, P649, DOI 10.1002/prot.20609; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Jakubowski H, 1999, BIOCHEMISTRY-US, V38, P8088, DOI 10.1021/bi990629i; Javanbakht H, 2003, J BIOL CHEM, V278, P27644, DOI 10.1074/jbc.M301840200; Khvorova A, 1999, NUCLEIC ACIDS RES, V27, P4451, DOI 10.1093/nar/27.22.4451; Kijas AW, 2006, J BIOL CHEM, V281, P13939, DOI 10.1074/jbc.M507946200; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; Kovaleski BJ, 2006, J BIOL CHEM, V281, P19449, DOI 10.1074/jbc.M601189200; Krakowiak A, 2004, J BIOL CHEM, V279, P18711, DOI 10.1074/jbc.M314271200; Kwasnicka DA, 2003, J BIOL CHEM, V278, P39051, DOI 10.1074/jbc.M306355200; LEDNEVA RK, 1967, DOKL AKAD NAUK SSSR+, V172, P977; Lee YN, 2005, MOL CELL BIOL, V25, P8904, DOI 10.1128/MCB.25.20.8904-8912.2005; Lee YN, 2004, IMMUNITY, V20, P145, DOI 10.1016/S1074-7613(04)00020-2; Li H, 2006, ONCOGENE, V25, P713, DOI 10.1038/sj.onc.1209111; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Liu HD, 2002, EMBO J, V21, P4699, DOI 10.1093/emboj/cdf448; Martin J, 2006, GASTROENTEROLOGY, V130, P2179, DOI 10.1053/j.gastro.2006.03.024; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Park SG, 2005, TRENDS BIOCHEM SCI, V30, P569, DOI 10.1016/j.tibs.2005.08.004; Parks KP, 2004, PHYSIOL GENOMICS, V20, P12, DOI 10.1152/physiolgenomics.00204.2004; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; Stark LA, 1998, J VIROL, V72, P3037, DOI 10.1128/JVI.72.4.3037-3044.1998; Steer BA, 1999, BIOCHEMISTRY-US, V38, P4965, DOI 10.1021/bi990038s; THEOCLITOU ME, 1996, J CHEM SOC P1, V16, P123; Weiske J, 2006, J BIOL CHEM, V281, P27356, DOI 10.1074/jbc.M513452200; Wolfson AD, 2002, P NATL ACAD SCI USA, V99, P5965, DOI 10.1073/pnas.092152799; Yuan BZ, 2004, NEOPLASIA, V6, P412, DOI 10.1593/neo.03490; ZAMECNIK PC, 1966, BIOCHEM BIOPH RES CO, V24, P91, DOI 10.1016/0006-291X(66)90415-3	51	50	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4719	4727		10.1074/jbc.M610530200	http://dx.doi.org/10.1074/jbc.M610530200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158446	hybrid, Green Accepted			2022-12-25	WOS:000244482000053
J	Xiong, Y; Collins, QF; An, J; Lupo, E; Liu, HY; Liu, DL; Robidoux, J; Liu, ZQ; Cao, WH				Xiong, Yan; Collins, Qu Fan; An, Jie; Lupo, Edgar, Jr.; Liu, Hui-Yu; Liu, Delong; Robidoux, Jacques; Liu, Zhenqi; Cao, Wenhong			p38 mitogen-activated protein kinase plays an inhibitory role in hepatic lipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-2; FATTY-ACID SYNTHESIS; STIMULATED GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; MAP-KINASE; RAT HEPATOCYTES; TRANSGENIC MICE; GLUT4 TRANSLOCATION; COACTIVATOR PGC-1	Hepatic lipogenesis is the principal route to convert excess carbohydrates into fatty acids and is mainly regulated by two opposing hormones, insulin and glucagon. Although insulin stimulates hepatic lipogenesis, glucagon inhibits it. However, the mechanism by which glucagon suppresses lipogenesis remains poorly understood. In this study, we have observed that p38 mitogen-activated protein kinase plays an inhibitory role in hepatic lipogenesis. Levels of plasma triglyceride and triglyceride accumulation in the liver were both elevated when p38 activation was blocked. Expression levels of central lipogenic genes, including sterol regulatory element-binding protein-1 (SREBP-1), fatty acid synthase, hydroxy-3-methylglutaryl coenzyme A reductase, farnesyl pyrophosphate synthase, and cytochrome P-450-51, were decreased in liver by fasting and in primary hepatocytes by glucagon but increased by the inhibition of p38. In addition, we have shown that p38 can inhibit insulin-induced expression of key lipogenic genes in isolated hepatocytes. Our results in hepatoma cells demonstrate that p38 plays an inhibitory role in the activation of the SREBP-1c promoter. Finally, we have shown that transcription of the PGC-1 beta gene, a key coactivator of SREBP-lc, was reduced in liver by fasting and in isolated hepatocytes by glucagon. This reduction was significantly reversed by the blockade of p38. Insulin-induced expression of the PGC-1 gamma gene was enhanced by the inhibition of p38 but suppressed by the activation of p38. Together, we have identified an inhibitory role for p38 in the transcription of central lipogenic genes, SREBPs, and PGC-1 beta and hepatic lipogenesis.	Hammer Inst Hlth Sci, Endocrine Biol Program, Res Triangle Pk, NC 27709 USA; Hammer Inst Hlth Sci, Ctr Integrated Genom, Res Triangle Pk, NC 27709 USA; Cent S Univ, Sarah W Stedman Ctr Nutr & Metab, Changsha 410078, Peoples R China; Cent S Univ, Dept Pharmacol, Sch Pharmaceut Sci, Changsha 410078, Peoples R China; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Endocrinol, Charlottesville, VA 22908 USA; Duke Univ, Med Ctr, Dept Internal Med, Div Endocrinol, Durham, NC 27710 USA	The Hamner Institutes for Health Sciences; The Hamner Institutes for Health Sciences; Central South University; Central South University; University of Virginia; Duke University	Cao, WH (corresponding author), Hammer Inst Hlth Sci, Endocrine Biol Program, 6 Davis Dr,POB 12137, Res Triangle Pk, NC 27709 USA.	wcao@thehamner.org		Robidoux, JAcques/0000-0002-4809-4734				Accili D, 2004, DIABETES, V53, P1633, DOI 10.2337/diabetes.53.7.1633; Akimoto T, 2005, J BIOL CHEM, V280, P19587, DOI 10.1074/jbc.M408862200; Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; Bazuine M, 2003, EUR J BIOCHEM, V270, P3891, DOI 10.1046/j.1432-1033.2003.03771.x; Cagen LM, 2005, BIOCHEM J, V385, P207, DOI 10.1042/BJ20040162; Cahill GF., 1976, GLUCONEOGENESIS ITS, P515; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; Cao WH, 2005, J BIOL CHEM, V280, P42731, DOI 10.1074/jbc.M506223200; Cao WH, 2001, J BIOL CHEM, V276, P27077, DOI 10.1074/jbc.M101049200; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Collins QF, 2006, J BIOL CHEM, V281, P24336, DOI 10.1074/jbc.M602177200; COOPER AD, 1996, HEPATOLOGY TXB LIVER, V1, P92; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; Fan M, 2004, GENE DEV, V18, P278, DOI 10.1101/gad.1152204; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Harris R A, 1979, Adv Exp Med Biol, V111, P17; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Herzig S, 2003, NATURE, V426, P190, DOI 10.1038/nature02110; Horton JD, 2003, J BIOL CHEM, V278, P36652, DOI 10.1074/jbc.M306540200; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; KEDDERIS GL, 1988, TOXICOL APPL PHARM, V93, P403, DOI 10.1016/0041-008X(88)90043-9; Konrad D, 2002, DIABETES, V51, P2719, DOI 10.2337/diabetes.51.9.2719; Kotzka J, 2000, J LIPID RES, V41, P99; Kotzka J, 2004, J BIOL CHEM, V279, P22404, DOI 10.1074/jbc.M401198200; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; Kramer DK, 2005, DIABETES, V54, P1157, DOI 10.2337/diabetes.54.4.1157; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Lerin C, 2003, DIABETES, V52, P2221, DOI 10.2337/diabetes.52.9.2221; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Lin JD, 2003, J BIOL CHEM, V278, P30843, DOI 10.1074/jbc.M303643200; McGee SL, 2006, CLIN EXP PHARMACOL P, V33, P395, DOI 10.1111/j.1440-1681.2006.04362.x; McGee SL, 2004, DIABETES, V53, P1208, DOI 10.2337/diabetes.53.5.1208; Miserez AR, 1997, GENOMICS, V40, P31, DOI 10.1006/geno.1996.4525; Nagoshi E, 2001, MOL CELL BIOL, V21, P2779, DOI 10.1128/MCB.21.8.2779-2789.2001; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Richter EA, 2004, P NUTR SOC, V63, P211, DOI 10.1079/PNS2004343; Rincon M, 2000, IMMUNOL CELL BIOL, V78, P166, DOI 10.1046/j.1440-1711.2000.00900.x; SEGLEN PO, 1979, J TOXICOL ENV HEALTH, V5, P551, DOI 10.1080/15287397909529766; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Somwar R, 2002, J BIOL CHEM, V277, P50386, DOI 10.1074/jbc.M205277200; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; Suzuki T, 2001, J BIOL CHEM, V276, P27511, DOI 10.1074/jbc.M011726200; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; Xue BZ, 2005, MOL CELL BIOL, V25, P8311, DOI 10.1128/MCB.25.18.8311-8322.2005; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	60	75	88	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4975	4982		10.1074/jbc.M606742200	http://dx.doi.org/10.1074/jbc.M606742200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17172644	hybrid			2022-12-25	WOS:000244482000080
J	Wenz, T; Covian, R; Hellwig, P; MacMillan, F; Meunier, B; Trumpower, BL; Hunte, C				Wenz, Tina; Covian, Raul; Hellwig, Petra; MacMillan, Fraser; Meunier, Brigitte; Trumpower, Bernard L.; Hunte, Carola			Mutational analysis of cytochrome b at the ubiquinol oxidation site of yeast complex III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BC(1) COMPLEX; SACCHAROMYCES-CEREVISIAE; Q(O) SITE; QUINOL OXIDATION; MOLECULAR-BASIS; Q-CYCLE; RESISTANCE; INHIBITORS; PROTEIN; UBIHYDROQUINONE	The cytochrome bc(1) complex is a dimeric enzyme of the inner mitochondrial membrane that links electron transfer from ubiquinol to cytochrome c by a protonmotive Q cycle mechanism in which ubiquinol is oxidized at one center in the enzyme, referred to as center P, and ubiquinone is rereduced at a second center, referred to as center N. To better understand the mechanism of ubiquinol oxidation, we have examined catalytic activities and pre-steady-state reduction kinetics of yeast cytochrome bc(1) complexes with mutations in cytochrome b that we expected would affect oxidation of ubiquinol. We mutated two residues thought to be involved in proton conduction linked to ubiquinol oxidation, Tyr(132) and Glu(272), and two residues proposed to be involved in docking ubiquinol into the center P pocket, Phe(129) and Tyr(279). Substitution of Phe(129) by lysine or arginine yielded a respiration-deficient phenotype and lipid-dependent catalytic activity. Increased bypass reactions were detectable for both variants, with F129K showing the more severe effects. Substitution with lysine leads to a disturbed coordination of a b heme as deduced from changes in the midpoint potential and the EPR signature. Removal of the aromatic side chain in position Tyr(279) lowers the catalytic activity accompanied by a low level of bypass reactions. Pre-steady-state kinetics of the enzymes modified at Glu(272) and Tyr(132) confirmed the importance of their functional groups for electron transfer. Altered center N kinetics and activation of ubiquinol oxidation by binding of cytochrome c in the Y132F and E272D enzymes indicate long range effects of these mutations.	Max Planck Inst Biophys, Dept Mol Membrane Biol, D-60438 Frankfurt, Germany; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Univ Strasbourg 1, Inst Chim, UMR 7177, LC3, F-67000 Strasbourg, France; Univ Frankfurt, Inst Phys & Theoret Chem, D-60439 Frankfurt, Germany; Univ Frankfurt, Ctr Biomol Magnet Resonance, D-60439 Frankfurt, Germany; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	Max Planck Society; Dartmouth College; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Goethe University Frankfurt; Goethe University Frankfurt; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Hunte, C (corresponding author), Max Planck Inst Biophys, Dept Mol Membrane Biol, Max Von Laue Str 3, D-60438 Frankfurt, Germany.	Carola.Hunte@mpibp-frankfurt.mpg.de	MacMillan, Fraser/AAM-4483-2020; MacMillan, Fraser/B-7619-2011; Hunte, Carola/E-4071-2015	MacMillan, Fraser/0000-0002-2410-4790; MacMillan, Fraser/0000-0002-2410-4790; Hunte, Carola/0000-0002-0826-3986; hellwig, petra/0000-0001-6294-5163; Meunier, Brigitte/0000-0002-6988-4663	NIGMS NIH HHS [GM 20379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; Covian R, 2005, J BIOL CHEM, V280, P22732, DOI 10.1074/jbc.M413592200; Covian R, 2004, J BIOL CHEM, V279, P15040, DOI 10.1074/jbc.M400193200; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; Crofts AR, 1999, P NATL ACAD SCI USA, V96, P10021, DOI 10.1073/pnas.96.18.10021; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DIRAGO JP, 1989, J BIOL CHEM, V264, P14543; Esser L, 2004, J MOL BIOL, V341, P281, DOI 10.1016/j.jmb.2004.05.065; Fisher N, 2005, PEST MANAG SCI, V61, P973, DOI 10.1002/ps.1066; Fisher N, 2004, J BIOL CHEM, V279, P12951, DOI 10.1074/jbc.M313866200; GEIER BM, 1992, EUR J BIOCHEM, V208, P375, DOI 10.1111/j.1432-1033.1992.tb17197.x; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Hunte C, 2003, FEBS LETT, V545, P39, DOI 10.1016/S0014-5793(03)00391-0; Jordan DB, 1999, PESTIC SCI, V55, P105, DOI 10.1002/(SICI)1096-9063(199902)55:2&lt;105::AID-PS879&gt;3.0.CO;2-D; Kessl JJ, 2004, J BIOL CHEM, V279, P2817, DOI 10.1074/jbc.M309984200; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; Lebrun E, 2006, MOL BIOL EVOL, V23, P1180, DOI 10.1093/molbev/msk010; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Muller F, 2002, BIOCHEMISTRY-US, V41, P7866, DOI 10.1021/bi025581e; Osyczka A, 2005, TRENDS BIOCHEM SCI, V30, P176, DOI 10.1016/j.tibs.2005.02.001; Palsdottir H, 2004, BBA-BIOMEMBRANES, V1666, P2, DOI 10.1016/j.bbamem.2004.06.012; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; SARBIAS AS, 1992, BIOCHEMISTRY-US, V34, P16004; Silkstone GG, 2005, J AM CHEM SOC, V127, P92, DOI 10.1021/ja045719b; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; Wenz T, 2006, BIOCHEMISTRY-US, V45, P9042, DOI 10.1021/bi060280g; Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224	30	52	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3977	3988		10.1074/jbc.M606482200	http://dx.doi.org/10.1074/jbc.M606482200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17145759	hybrid			2022-12-25	WOS:000244481900062
J	Beach, D; Gonen, R; Bogin, Y; Reischl, IG; Yablonski, D				Beach, Dvora; Gonen, Ronnie; Bogin, Yaron; Reischl, Ilona G.; Yablonski, Deborah			Dual role of SLP-76 in mediating T cell receptor-induced activation of phospholipase C-gamma 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; ANTIGEN RECEPTOR; DIFFERENTIAL ROLE; PROTEIN NETWORKS; LIPID RAFTS; LAT LINKER; C-GAMMA; PLC-GAMMA-1; DOMAIN	Phospholipase C-gamma 1 (PLC-gamma 1) activation depends on a heterotrimeric complex of adaptor proteins composed of LAT, Gads, and SLP-76. Upon T cell receptor stimulation, a portion of PLC-gamma 1 is recruited to a detergent-resistant membrane fraction known as the glycosphingolipid-enriched membrane microdomains (GEMs), or lipid rafts, to which LAT is constitutively localized. In addition to LAT, PLC-gamma 1 GEM recruitment depended on SLP-76, and, in particular, required the Gads-binding domain of SLP-76. The N-terminal tyrosine phosphorylation sites and P-I region of SLP-76 were not required for PLC-gamma 1 GEM recruitment, but were required for PLC-gamma 1 phosphorylation at Tyr(783). Thus, GEM recruitment can be insufficient for full activation of PLC-gamma 1 in the absence of a second SLP-76-mediated event. Indeed, a GEM-targeted derivative of PLC-gamma 1 depended on SLP-76 for T cell receptor-induced phosphorylation at Tyr(783) and subsequent NFAT activation. On a biochemical level, SLP-76 inducibly associated with both Vav and catalytically active ITK, which efficiently phosphorylated a PLC-gamma 1 fragment at Tyr(783) in vitro. Both associations were disrupted upon mutation of the N-terminal tyrosine phosphorylation sites of SLP-76. The P-I region deletion disrupted Vav association and reduced SLP-76-associated kinase activity. A smaller deletion within the P-I region, which does not impair PLC-gamma 1 activation, did not impair the association with Vav, but reduced SLP-76-associated kinase activity. These results provide new insight into the multiple roles of SLP-76 and the functional importance of its interactions with other signaling proteins.	Technion Israel Inst Technol, Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; US FDA, Immunobiol Lab, Div Monoclonal Antibodies, Off Biotechnol Prod,Ctr Drug Evaluat & Res, Bethesda, MD 20892 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; US Food & Drug Administration (FDA)	Yablonski, D (corresponding author), Technion Israel Inst Technol, Rappaport Fac Med, Rappaport Family Inst Res Med Sci, POB 9649 Bat Galim, IL-31096 Haifa, Israel.	debya@tx.technion.ac.il		Yablonski, Deborah/0000-0003-2979-0440; Blecher, Ronnie/0000-0003-2847-1149				Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Braiman A, 2006, EMBO J, V25, P774, DOI 10.1038/sj.emboj.7600978; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Douglass AD, 2005, CELL, V121, P937, DOI 10.1016/j.cell.2005.04.009; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Gonen R, 2005, J BIOL CHEM, V280, P8364, DOI 10.1074/jbc.M409437200; Harder T, 2004, CURR OPIN IMMUNOL, V16, P353, DOI 10.1016/j.coi.2004.03.013; Hartgroves LC, 2003, J BIOL CHEM, V278, P20389, DOI 10.1074/jbc.M301212200; Houtman JCD, 2004, BIOCHEMISTRY-US, V43, P4170, DOI 10.1021/bi0357311; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Ishiai M, 2000, J EXP MED, V192, P847, DOI 10.1084/jem.192.6.847; Jia CYH, 2005, MOL CELL PROTEOMICS, V4, P1155, DOI 10.1074/mcp.M500108-MCP200; Jordan MS, 2006, J IMMUNOL, V176, P2430, DOI 10.4049/jimmunol.176.4.2430; Kettner A, 2003, MOL CELL BIOL, V23, P2395, DOI 10.1128/MCB.23.7.2395-2406.2003; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Koretzky GA, 2006, NAT REV IMMUNOL, V6, P67, DOI 10.1038/nri1750; Kumar L, 2002, P NATL ACAD SCI USA, V99, P884, DOI 10.1073/pnas.022619199; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Lin J, 2001, J BIOL CHEM, V276, P29588, DOI 10.1074/jbc.M102221200; Liu KQ, 1998, J EXP MED, V187, P1721, DOI 10.1084/jem.187.10.1721; Liu SKW, 2001, ONCOGENE, V20, P6284, DOI 10.1038/sj.onc.1204771; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Myung PS, 2001, IMMUNITY, V15, P1011, DOI 10.1016/S1074-7613(01)00253-9; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Paz PE, 2001, BIOCHEM J, V356, P461, DOI 10.1042/0264-6021:3560461; Poulin B, 2005, P NATL ACAD SCI USA, V102, P4276, DOI 10.1073/pnas.0409590102; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Schneider H, 2000, J BIOL CHEM, V275, P3835, DOI 10.1074/jbc.275.6.3835; Sekiya F, 2004, J BIOL CHEM, V279, P32181, DOI 10.1074/jbc.M405116200; Serrano CJ, 2005, J IMMUNOL, V174, P6233, DOI 10.4049/jimmunol.174.10.6233; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Singer AL, 2004, J BIOL CHEM, V279, P15481, DOI 10.1074/jbc.M313339200; Stoica B, 1998, J IMMUNOL, V160, P1059; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Veri MC, 2001, MOL CELL BIOL, V21, P6939, DOI 10.1128/MCB.21.20.6939-6950.2001; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Wonerow P, 2002, BIOCHEM J, V364, P755, DOI 10.1042/BJ20020128; Wong J, 2000, J BIOL CHEM, V275, P33116, DOI 10.1074/jbc.M004467200; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Xu Z, 2002, CELL GROWTH DIFFER, V13, P285; Yablonski D, 2001, ADV IMMUNOL, V79, P93, DOI 10.1016/S0065-2776(01)79003-7; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhu MH, 2005, J IMMUNOL, V174, P31, DOI 10.4049/jimmunol.174.1.31; Zhu NH, 2003, J IMMUNOL, V170, P325, DOI 10.4049/jimmunol.170.1.325	57	36	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2937	2946		10.1074/jbc.M606697200	http://dx.doi.org/10.1074/jbc.M606697200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148460	hybrid			2022-12-25	WOS:000243793900020
J	Chattopadhyay, S; Tracy, E; Liang, P; Robledo, O; Rose-John, S; Baumann, H				Chattopadhyay, Souvik; Tracy, Erin; Liang, Ping; Robledo, Olivier; Rose-John, Stefan; Baumann, Heinz			Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; T-CELLS; ALPHA(1)-PROTEINASE INHIBITOR; FIBRINOGEN BIOSYNTHESIS; STIMULATING FACTOR; GROWTH-INHIBITION; DESIGNER CYTOKINE; PLASMA-PROTEINS; IN-VIVO; RECEPTOR	Lung epithelial cells are primary targets of oncostatin M (OSM) and, to a lower degree, of interleukin (IL)-6 and IL-31, all members of the IL-6 cytokine family. The OSM receptor (OSMR) signals through activation of STAT and mitogen-activated protein kinase pathways to induce genes encoding differentiated cell functions, reduce cell-cell interaction, and suppress cell proliferation. IL-31 functions through the heteromeric IL-31 receptor, which shares with OSMR the OSMR beta subunit, but does not engage gp130, the common subunit of all other IL-6 cytokine receptors. Because the response of epithelial cells to IL-31 is unknown, the action of IL-31 was characterized in the human alveolar epithelial cell line A549 in which the expression of the ligand-binding IL-31R alpha subunit was increased. IL-31 initiated signaling that differed from other IL-6 cytokines by the particularly strong recruitment of the STAT3, ERK, JNK, and Akt pathways. IL-31 was highly effective in suppressing proliferation by altering expression of cell cycle proteins, including up-regulation of p27(Kip1) and down regulation of cyclin B1, CDC2, CDK6, MCM4, and retinoblastoma. A single STAT3 recruitment site (Tyr-721) in the cytoplasmic domain of IL-31R alpha exerts a dominant function in the entire receptor complex and is critical for gene induction, morphological changes, and growth inhibition. The data suggest that inflammatory and immune reactions involving activated T-cells regulate functions of epithelial cells by IL-6 cytokines through receptor-defined signaling reactions.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Univ Kiel, Dept Biochem, D-24098 Kiel, Germany	Roswell Park Cancer Institute; Roswell Park Cancer Institute; University of Kiel	Baumann, H (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	heinz.baumann@roswellpark.org	Rose-John, Stefan/A-7998-2010; Liang, Ping/D-2709-2009; Liang, Ping/S-3790-2018	Rose-John, Stefan/0000-0002-7519-3279; Liang, Ping/0000-0003-4423-0636; Liang, Ping/0000-0003-4423-0636	NATIONAL CANCER INSTITUTE [R01CA085580, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056, CA085580] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bando T, 2006, NEUROSCIENCE, V142, P1263, DOI 10.1016/j.neuroscience.2006.07.009; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; Bihl M, 1998, AM J RESP CELL MOL, V19, P606, DOI 10.1165/ajrcmb.19.4.3247; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200; Boutten A, 1998, AM J RESP CELL MOL, V18, P511, DOI 10.1165/ajrcmb.18.4.2772; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Cichy J, 1998, BIOCHEM J, V329, P335, DOI 10.1042/bj3290335; de Jager W, 2003, CLIN DIAGN LAB IMMUN, V10, P133, DOI 10.1128/CDLI.10.1.133-139.2003; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; DeMiguel F, 2002, PROSTATE, V52, P123, DOI 10.1002/pros.10110; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Diveu C, 2003, J BIOL CHEM, V278, P49850, DOI 10.1074/jbc.M307286200; Diveu C, 2004, EUR CYTOKINE NETW, V15, P291; Dreuw A, 2004, J BIOL CHEM, V279, P36112, DOI 10.1074/jbc.M401122200; duPont NC, 2005, J REPROD IMMUNOL, V66, P175, DOI 10.1016/j.jri.2005.03.005; Finelt N, 2005, CYTOKINE, V31, P305, DOI 10.1016/j.cyto.2005.05.005; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; FULLER GM, 1985, J CELL BIOL, V101, P1481, DOI 10.1083/jcb.101.4.1481; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; Gao LF, 2005, CLIN CANCER RES, V11, P6333, DOI 10.1158/1078-0432.CCR-05-0148; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Grant SL, 2001, GROWTH FACTORS, V19, P153, DOI 10.3109/08977190109001083; Greenberg AK, 2002, AM J RESP CELL MOL, V27, P320, DOI 10.1165/rcmb.4710; Haidaris PJS, 1997, BLOOD, V89, P873; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; Huising MO, 2006, J ENDOCRINOL, V189, P1, DOI 10.1677/joe.1.06591; Ishimi Y, 2003, J BIOL CHEM, V278, P24644, DOI 10.1074/jbc.M213252200; Jones SA, 2005, J INTERF CYTOK RES, V25, P241, DOI 10.1089/jir.2005.25.241; Kaido T, 2004, HEPATO-GASTROENTEROL, V51, P1667; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Kawada M, 2006, CANCER RES, V66, P2913, DOI 10.1158/0008-5472.CAN-05-3460; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Klein C, 2005, J CLIN INVEST, V115, P860, DOI 10.1172/JCI200523640; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Krebs DL, 2000, J CELL SCI, V113, P2813; Lai CF, 1999, J BIOL CHEM, V274, P7793, DOI 10.1074/jbc.274.12.7793; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Loewen GM, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-145; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Nakamura K, 2004, HEPATOLOGY, V39, P635, DOI 10.1002/hep.20086; Peters M, 1998, J IMMUNOL, V161, P3575; PIQUETPELLORCE C, 1994, EXP CELL RES, V213, P340, DOI 10.1006/excr.1994.1208; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Rose-John S, 2006, J LEUKOCYTE BIOL, V80, P227, DOI 10.1189/jlb.1105674; Sallenave JM, 1997, J INTERF CYTOK RES, V17, P337, DOI 10.1089/jir.1997.17.337; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P; Stross C, 2006, J BIOL CHEM, V281, P8458, DOI 10.1074/jbc.M511212200; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Viswanathan S, 2002, STEM CELLS, V20, P119, DOI 10.1634/stemcells.20-2-119; Wahl AF, 2001, ANN RHEUM DIS, V60, pIII75; Wallace PM, 1999, J IMMUNOL, V162, P5547; Wang YP, 2000, J BIOL CHEM, V275, P25273, DOI 10.1074/jbc.M002296200; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	66	85	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3014	3026		10.1074/jbc.M609655200	http://dx.doi.org/10.1074/jbc.M609655200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148439	hybrid			2022-12-25	WOS:000243793900028
J	Oertel, J; Villmann, C; Kettenmann, H; Kirchhoff, F; Becker, CM				Oertel, Jana; Villmann, Carmen; Kettenmann, Helmut; Kirchhoff, Frank; Becker, Cord-Michael			A novel glycine receptor beta subunit splice variant predicts an unorthodox transmembrane topology - Assembly into heteromeric receptor complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SPINAL-CORD; GLIAL-CELLS; NEUROTRANSMITTER RECEPTORS; NICOTINIC RECEPTORS; CHLORIDE CHANNELS; GABA RECEPTORS; MESSENGER-RNA; SPASTIC MOUSE; GEPHYRIN; EXPRESSION	The inhibitory glycine receptor is a ligand-gated ion channel with a pentameric assembly from ligand binding alpha and structural beta subunits. In addition to alpha subunit gene variants (alpha 1-alpha 4) and developmental alterations in subunit composition of the receptor protein complex, alternative splicing of alpha subunits has been found to contribute to glycine receptor heterogeneity. Here, we describe a novel splice variant of the glycine receptor beta subunit from mouse central nervous system, prevailing in macroglial cells, predominantly in astrocytes and extraneural tissues. As predicted by its cDNA sequence, the novel subunit beta Delta 7 lacks amino acid positions 251-302 encoded by exon 7 of the Glrb gene. Transcripts and antigen of beta Delta 7 were detected in cerebral cortex, liver, and heart. Lack of exon 7 results in a profoundly altered prediction of transmembrane topology as beta Delta 7 lacks TM1 and TM2 present in the full-length variant. Despite these topological alterations, in vitro studies showed that the beta Delta 7 polypeptide integrates into the plasma membrane, forming receptor complexes with the alpha 1 subunit and gephyrin. Our data demonstrate that a topology deviating from the classical four transmembrane-fold is compatible with formation of glycine receptor protein complexes. However, co-expression of alpha 1 with beta Delta 7 subunits did not change glycine receptor channel properties. Rather, the high level of expression in non- neuronal cells having intimate contact with synaptic regions may account for a yet unknown function of this splice variant beta Delta 7 in glycinergic neurotransmission.	Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, D-91054 Erlangen, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Max Planck Inst Expt Med, D-37075 Gottingen, Germany	University of Erlangen Nuremberg; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society	Becker, CM (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Fahrstr 17, D-91054 Erlangen, Germany.	cmb@biochem.uni-erlangen.de	Oertel, Jana/T-1048-2017; Kirchhoff, Frank/B-9335-2008; Kettenmann, Helmut/AAJ-5142-2021	Kirchhoff, Frank/0000-0002-2324-2761; Kettenmann, Helmut/0000-0001-8208-0291				AKAGI H, 1991, NEUROSCI RES, V11, P28, DOI 10.1016/0168-0102(91)90064-6; BECKER CM, 1992, NEURON, V8, P283, DOI 10.1016/0896-6273(92)90295-O; BECKER CM, 1988, EMBO J, V7, P3717, DOI 10.1002/j.1460-2075.1988.tb03255.x; BETZ H, 1991, TRENDS NEUROSCI, V14, P458, DOI 10.1016/0166-2236(91)90045-V; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; FRASER DD, 1994, GLIA, V11, P83, DOI 10.1002/glia.440110203; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Grudzinska J, 2005, NEURON, V45, P727, DOI 10.1016/j.neuron.2005.01.028; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hawthorne R, 2005, J BIOL CHEM, V280, P35836, DOI 10.1074/jbc.M506645200; JACKSON PS, 1993, AM J PHYSIOL, V265, pC1489, DOI 10.1152/ajpcell.1993.265.6.C1489; KIM EY, 2006, IN PRESS EMBO J; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; Kirchhoff F, 1996, J NEUROCHEM, V66, P1383; Kirsch J, 1996, MOL CELL NEUROSCI, V8, P93, DOI 10.1006/mcne.1996.0048; KIRSCH J, 1995, J NEUROSCI, V15, P4148; Kneussel M, 2000, TRENDS NEUROSCI, V23, P429, DOI 10.1016/S0166-2236(00)01627-1; Kneussel M, 1999, J NEUROCHEM, V72, P1323, DOI 10.1046/j.1471-4159.1999.0721323.x; Kneussel M, 2000, J PHYSIOL-LONDON, V525, P1, DOI 10.1111/j.1469-7793.2000.t01-4-00001.x; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUHSE J, 1990, NEURON, V5, P867, DOI 10.1016/0896-6273(90)90346-H; KUHSE J, 1990, J BIOL CHEM, V265, P22317; Kumar DV, 2002, J NEUROBIOL, V52, P156, DOI 10.1002/neu.10072; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; Makara JK, 2001, GLIA, V34, P52, DOI 10.1002/glia.1039; MALOSIO ML, 1991, EMBO J, V10, P2401, DOI 10.1002/j.1460-2075.1991.tb07779.x; Matthias K, 2003, J NEUROSCI, V23, P1750; Meier J, 2004, J NEUROSCI, V24, P1398, DOI 10.1523/JNEUROSCI.4260-03.2004; Meier J, 2001, NAT NEUROSCI, V4, P253, DOI 10.1038/85099; Meier JC, 2005, NAT NEUROSCI, V8, P736, DOI 10.1038/nn1467; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; MULHARDT C, 1994, NEURON, V13, P1003, DOI 10.1016/0896-6273(94)90265-8; Nikolic Z, 1998, J BIOL CHEM, V273, P19708, DOI 10.1074/jbc.273.31.19708; PASTOR A, 1995, EUR J NEUROSCI, V7, P1188, DOI 10.1111/j.1460-9568.1995.tb01109.x; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; Rees MI, 2003, J BIOL CHEM, V278, P24688, DOI 10.1074/jbc.M301070200; Rees MI, 2002, HUM MOL GENET, V11, P853, DOI 10.1093/hmg/11.7.853; Ren Z, 2003, J BIOL CHEM, V278, P52700, DOI 10.1074/jbc.M309585200; Ross ED, 2005, NAT CELL BIOL, V7, P1039, DOI 10.1038/ncb1105-1039; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; Rouzaire-Dubois B, 2000, PFLUG ARCH EUR J PHY, V440, P881, DOI 10.1007/s004240000371; SASSOEPOGNETTO M, 1995, J COMP NEUROL, V357, P1, DOI 10.1002/cne.903570102; Shan Q, 2001, J NEUROCHEM, V76, P1109, DOI 10.1046/j.1471-4159.2001.00124.x; Sola M, 2004, EMBO J, V23, P2510, DOI 10.1038/sj.emboj.7600256; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; Todd AJ, 1996, EUR J NEUROSCI, V8, P2492, DOI 10.1111/j.1460-9568.1996.tb01543.x; Unwin N, 2003, FEBS LETT, V555, P91, DOI 10.1016/S0014-5793(03)01084-6; van Zundert B, 2005, BRAIN RES, V1050, P40, DOI 10.1016/j.brainres.2005.05.014; Wassle H, 1998, VISION RES, V38, P1411, DOI 10.1016/s0042-6989(97)00300-3; Zhang XD, 2004, GLIA, V47, P46, DOI 10.1002/glia.20024	57	30	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2798	2807		10.1074/jbc.M608941200	http://dx.doi.org/10.1074/jbc.M608941200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145751	Green Submitted, hybrid			2022-12-25	WOS:000243793900006
J	Breuker, CJ; Patterson, JS; Klingenberg, CP				Breuker, Casper J.; Patterson, James S.; Klingenberg, Christian Peter			A Single Basis for Developmental Buffering of Drosophila Wing Shape	PLOS ONE			English	Article								The nature of developmental buffering processes has been debated extensively, based on both theoretical reasoning and empirical studies. In particular, controversy has focused on the question of whether distinct processes are responsible for canalization, the buffering against environmental or genetic variation, and for developmental stability, the buffering against random variation intrinsic in developmental processes. Here, we address this question for the size and shape of Drosophila melanogaster wings in an experimental design with extensively replicated and fully controlled genotypes. The amounts of variation among individuals and of fluctuating asymmetry differ markedly among genotypes, demonstrating a clear genetic basis for size and shape variability. For wing shape, there is a high correlation between the amounts of variation among individuals and fluctuating asymmetry, which indicates a correspondence between the two types of buffering. Likewise, the multivariate patterns of shape variation among individuals and of fluctuating asymmetry show a close association. For wing size, however, the amounts of individual variation and fluctuating asymmetry are not correlated. There was a significant link between the amounts of variation between wing size and shape, more so for fluctuating asymmetry than for variation among individuals. Overall, these experiments indicate a considerable degree of shared control of individual variation and fluctuating asymmetry, although it appears to differ between traits.	[Breuker, Casper J.; Patterson, James S.; Klingenberg, Christian Peter] Univ Manchester, Fac Life Sci, Manchester, Lancs, England	University of Manchester	Klingenberg, CP (corresponding author), Univ Manchester, Fac Life Sci, Manchester, Lancs, England.	cpk@manchester.ac.uk	Breuker, Casper/P-8270-2019; Klingenberg, Christian Peter/B-3470-2010; Breuker, Casper/N-6582-2013; Rohlf, F J/A-8710-2008	Breuker, Casper/0000-0001-7909-1950; Klingenberg, Christian Peter/0000-0002-8117-6141; Breuker, Casper/0000-0001-7909-1950; 	Marie Curie Intra-European Fellowship, 6th European Community; UK Biotechnology and Biological Sciences Research Council; Biotechnology and Biological Sciences Research Council [BBS/B/12253] Funding Source: researchfish	Marie Curie Intra-European Fellowship, 6th European Community; UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This research was supported by a Marie Curie Intra-European Fellowship within the 6th European Community Framework Programme and a research grant from the UK Biotechnology and Biological Sciences Research Council.	Badyaev AV, 2004, AM NAT, V163, P868, DOI 10.1086/386551; Baylac M, 1998, ACTA ZOOL ACAD SCI H, V44, P97; Bergman A, 2003, NATURE, V424, P549, DOI 10.1038/nature01765; Bookstein F. L., 1997, MORPHOMETRIC TOOLS L; Clarke GM, 1998, HEREDITY, V80, P562, DOI 10.1046/j.1365-2540.1998.00294.x; Debat V, 2000, P ROY SOC B-BIOL SCI, V267, P423, DOI 10.1098/rspb.2000.1017; Debat V, 2001, TRENDS ECOL EVOL, V16, P555, DOI 10.1016/S0169-5347(01)02266-2; Dryden I., 1998, STAT ANAL SHAPE; Dworkin I, 2005, EVOLUTION, V59, P1500; Flatt T, 2005, Q REV BIOL, V80, P287, DOI 10.1086/432265; Gibson G, 2004, NAT REV GENET, V5, P681, DOI 10.1038/nrg1426; Good P, 2000, PERMUTATION TESTS PR; Hallgrimmson B., 2005, VARIATION CENTRAL CO, P525; Hallgrimsson B, 2004, J EXP ZOOL PART B, V302B, P207, DOI 10.1002/jez.b.21002; Hallgrimsson B, 2003, J EXP ZOOL PART B, V296B, P40, DOI 10.1002/jez.b.00015; Hallgrimsson B, 2002, YEARB PHYS ANTHROPOL, V45, P131, DOI 10.1002/ajpa.10182; Hoffmann AA, 2001, ECOL LETT, V4, P97, DOI 10.1046/j.1461-0248.2001.00205.x; Houchmandzadeh B, 2002, NATURE, V415, P798, DOI 10.1038/415798a; Iriarte PF, 2003, J GENET, V82, P95, DOI 10.1007/BF02715812; Klingenberg Christian Peter, 2003, P14; Klingenberg CP, 2005, SYST BIOL, V54, P678, DOI 10.1080/10635150590947258; Klingenberg CP, 2003, EVOL DEV, V5, P522, DOI 10.1046/j.1525-142X.2003.03057.x; Klingenberg CP, 2002, EVOLUTION, V56, P1909; Klingenberg CP, 1999, EVOLUTION, V53, P358, DOI [10.2307/2640773, 10.1111/j.1558-5646.1999.tb03772.x]; Klingenberg CP, 1998, EVOLUTION, V52, P1363, DOI 10.1111/j.1558-5646.1998.tb02018.x; Klingenberg CP, 2001, AM NAT, V157, P11, DOI 10.1086/317002; Klingenberg CP, 2000, EVOLUTION, V54, P1273, DOI 10.1111/j.0014-3820.2000.tb00560.x; LEAMY L, 1993, GENETICA, V89, P139, DOI 10.1007/BF02424510; Leamy LJ, 2005, ANNU REV ECOL EVOL S, V36, P1, DOI 10.1146/annurev.ecolsys.36.102003.152640; Loy A, 1998, J MORPHOL, V237, P137, DOI 10.1002/(SICI)1097-4687(199808)237:2<137::AID-JMOR5>3.0.CO;2-Z; Mardia K., 1979, MULTIVARIATE ANAL, V15, P518; McKenzie John A., 2003, P135; Meiklejohn CD, 2002, TRENDS ECOL EVOL, V17, P468, DOI 10.1016/S0169-5347(02)02596-X; Milton CC, 2003, P NATL ACAD SCI USA, V100, P13396, DOI 10.1073/pnas.1835613100; Monteiro LR, 1999, SYST BIOL, V48, P192, DOI 10.1080/106351599260526; PALMER AR, 1986, ANNU REV ECOL SYST, V17, P391, DOI 10.1146/annurev.es.17.110186.002135; Parks AL, 2004, NAT GENET, V36, P288, DOI 10.1038/ng1312; Reale D, 2003, EVOLUTION, V57, P597, DOI 10.1111/j.0014-3820.2003.tb01551.x; Rego C, 2006, EVOLUTION, V60, P746, DOI 10.1111/j.0014-3820.2006.tb01153.x; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Santos M, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-7; Siegal ML, 2002, P NATL ACAD SCI USA, V99, P10528, DOI 10.1073/pnas.102303999; Trotta V, 2005, EVOL DEV, V7, P234, DOI 10.1111/j.1525-142X.2005.05026.x; Van Valen Leigh, 2005, P29, DOI 10.1016/B978-012088777-4/50005-3; Willmore KE, 2006, J ANAT, V208, P361, DOI 10.1111/j.1469-7580.2006.00527.x; Willmore KE, 2005, EVOLUTION, V59, P898; Windig JJ, 2000, J EVOLUTION BIOL, V13, P29, DOI 10.1046/j.1420-9101.2000.00143.x; Woods RE, 1999, EVOLUTION, V53, P493, DOI [10.2307/2640785, 10.1111/j.1558-5646.1999.tb03784.x]; Zelditch M.L., 2004, GEOMETRIC MORPHOMETR, DOI DOI 10.1016/B978-0-12-778460-1.X5000-5	49	113	113	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e7	10.1371/journal.pone.0000007	http://dx.doi.org/10.1371/journal.pone.0000007			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183701	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600007
J	Collins, C; Azmi, P; Berru, M; Zhu, XF; Shulman, MJ				Collins, Cathy; Azmi, Peter; Berru, Maribel; Zhu, Xiaofu; Shulman, Marc J.			A Weakened Transcriptional Enhancer Yields Variegated Gene Expression	PLOS ONE			English	Article							HEAVY-CHAIN LOCUS; MATRIX ATTACHMENT REGIONS; BINDING PROTEIN; IGH LOCUS; IMMUNOGLOBULIN; METHYLATION; CELLS; ELEMENTS; ABSENCE; SITES	Identical genes in the same cellular environment are sometimes expressed differently. In some cases, including the immunoglobulin heavy chain (IgH) locus, this type of differential gene expression has been related to the absence of a transcriptional enhancer. To gain additional information on the role of the IgH enhancer, we examined expression driven by enhancers that were merely weakened, rather than fully deleted, using both mutations and insulators to impair enhancer activity. For this purpose we used a LoxP/Cre system to place a reporter gene at the same genomic site of a stable cell line. Whereas expression of the reporter gene was uniformly high in the presence of the normal, uninsulated enhancer and undetectable in its absence, weakened enhancers yielded variegated expression of the reporter gene; i.e., the average level of expression of the same gene differed in different clones, and expression varied significantly among cells within individual clones. These results indicate that the weakened enhancer allows the reporter gene to exist in at least two states. Subtle aspects of the variegation suggest that the IgH enhancer decreases the average duration (half-life) of the silent state. This analysis has also tested the conventional wisdom that enhancer activity is independent of distance and orientation. Thus, our analysis of mutant (truncated) forms of the IgH enhancer revealed that the 250 bp core enhancer was active in its normal position, similar to 1.4 kb 3' of the promoter, but inactive,6 kb 3', indicating that the activity of the core enhancer was distance-dependent. A longer segment - the core enhancer plus, 1 kb of 3' flanking material, including the 3' matrix attachment region - was active, and the activity of this longer segment was orientation-dependent. Our data suggest that this 3' flank includes binding sites for at least two activators.	[Collins, Cathy; Azmi, Peter; Berru, Maribel; Zhu, Xiaofu; Shulman, Marc J.] Univ Toronto, Dept Immunol, Toronto, ON, Canada	University of Toronto	Shulman, MJ (corresponding author), Univ Toronto, Dept Immunol, Toronto, ON, Canada.	marc.shulman@utoronto.ca			Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Funding: This work was supported by grants from the Canadian Institutes of Health Research.	Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BERTRAND E, 1994, NUCLEIC ACIDS RES, V22, P293, DOI 10.1093/nar/22.3.293; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Cheng EY, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-27; Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003; Feng YQ, 1999, J MOL BIOL, V292, P779, DOI 10.1006/jmbi.1999.3113; Forrester WC, 1999, GENE DEV, V13, P3003, DOI 10.1101/gad.13.22.3003; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; GROSSCHEDL R, 1988, CELL, V55, P645, DOI 10.1016/0092-8674(88)90223-1; Guo LY, 2005, IMMUNITY, V23, P89, DOI 10.1016/j.immuni.2005.05.008; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Hume DA, 2000, BLOOD, V96, P2323, DOI 10.1182/blood.V96.7.2323.h8002323_2323_2328; JENUWEIN T, 1993, GENE DEV, V7, P2016, DOI 10.1101/gad.7.10.2016; KADESCH T, 1986, NUCLEIC ACIDS RES, V14, P8209, DOI 10.1093/nar/14.20.8209; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Kurakin A, 2005, DEV GENES EVOL, V215, P46, DOI 10.1007/s00427-004-0448-7; LEE JJ, 1987, METHOD ENZYMOL, V152, P633; Martin David I. K., 1996, Bioessays, V18, P919, DOI 10.1002/bies.950181111; Oancea AE, 1997, MOL CELL BIOL, V17, P2658, DOI 10.1128/MCB.17.5.2658; Palstra RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/ng1244; PORTON B, 1990, MOL CELL BIOL, V10, P1076, DOI 10.1128/MCB.10.3.1076; Ronai D, 1999, MOL CELL BIOL, V19, P7031; Ronai D, 2004, GENETICS, V167, P411, DOI 10.1534/genetics.167.1.411; Ronai D, 2002, J IMMUNOL, V169, P6919, DOI 10.4049/jimmunol.169.12.6919; Sakai E, 1999, P NATL ACAD SCI USA, V96, P1526, DOI 10.1073/pnas.96.4.1526; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; Serizawa SU, 2004, TRENDS GENET, V20, P648, DOI 10.1016/j.tig.2004.09.006; SKOG S, 1979, CELL TISSUE KINET, V12, P501, DOI 10.1111/j.1365-2184.1979.tb00172.x; Sutter NB, 2003, P NATL ACAD SCI USA, V100, P1105, DOI 10.1073/pnas.242732999; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; WASYLYK C, 1986, EMBO J, V5, P553, DOI 10.1002/j.1460-2075.1986.tb04246.x; Wiersma EJ, 1999, J BIOL CHEM, V274, P4858, DOI 10.1074/jbc.274.8.4858; Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426; Zhao H, 2004, NUCLEIC ACIDS RES, V32, P4903, DOI 10.1093/nar/gkh832	36	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e33	10.1371/journal.pone.0000033	http://dx.doi.org/10.1371/journal.pone.0000033			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183661	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600033
J	Goren, A; Simchen, G; Fibach, E; Szabo, PE; Tanimoto, K; Chakalova, L; Pfeifer, GP; Fraser, PJ; Engel, JD; Cedar, H				Goren, Alon; Simchen, Giora; Fibach, Eitan; Szabo, Piroska E.; Tanimoto, Keiji; Chakalova, Lyubomira; Pfeifer, Gerd P.; Fraser, Peter J.; Engel, James D.; Cedar, Howard			Fine Tuning of Globin Gene Expression by DNA Methylation	PLOS ONE			English	Article								Expression patterns in the globin gene cluster are subject to developmental regulation in vivo. While the gamma(A) and gamma(G) genes are expressed in fetal liver, both are silenced in adult erythrocytes. In order to decipher the role of DNA methylation in this process, we generated a gamma AC transgenic mouse system that allowed us to control gamma(A) methylation during development. DNA methylation causes a 20-fold repression of gamma(A) both in non-erythroid and adult erythroid cells. In erythroid cells this modification works as a dominant mechanism to repress gamma gene expression, probably through changes in histone acetylation that prevent the binding of erythroid transcription factors to the promoter. These studies demonstrate that DNA methylation serves as an elegant in vivo fine-tuning device for selecting appropriate genes in the globin locus. In addition, our findings provide a mechanism for understanding the high levels of gamma-globin transcription seen in patients with Hereditary Persistence of Fetal Hemoglobin, and help explain why 5azaC and butyrate compounds stimulate gamma-globin expression in patients with beta-hemoglobinopathies.	[Goren, Alon; Cedar, Howard] Hebrew Univ Jerusalem, Dept Cellular Biochem & Human Genet, Jerusalem, Israel; [Simchen, Giora] Hebrew Univ Jerusalem, Dept Genet, IL-91904 Jerusalem, Israel; [Fibach, Eitan] Hebrew Univ Jerusalem, Dept Hematol, IL-91904 Jerusalem, Israel; [Szabo, Piroska E.; Pfeifer, Gerd P.] City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA USA; [Tanimoto, Keiji] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki, Japan; [Chakalova, Lyubomira; Fraser, Peter J.] Babraham Inst, Lab Chromatin & Gene Express, Cambridge, England; [Engel, James D.] Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI USA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; City of Hope; Beckman Research Institute of City of Hope; University of Tsukuba; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Michigan System; University of Michigan	Cedar, H (corresponding author), Hebrew Univ Jerusalem, Dept Cellular Biochem & Human Genet, Jerusalem, Israel.	cedar@md.huji.ac.il	Chakalova, Lyubomira/C-6810-2012; Fraser, Peter/B-7549-2009; Tanimoto, Keiji/B-2600-2014	Fraser, Peter/0000-0002-0041-1227; Szabo, Piroska/0000-0001-9314-7009; Goren, Alon/0000-0001-5669-9357; Tanimoto, Keiji/0000-0003-1971-6546	NIH; Belfer Foundation; Israel Cancer Research Fund; Israel Ministry of Health; MRC [G117/530] Funding Source: UKRI; Medical Research Council [G117/530] Funding Source: researchfish	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Belfer Foundation; Israel Cancer Research Fund; Israel Ministry of Health; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Funding: This work was supported by NIH, Belfer Foundation, Israel Cancer Research Fund and Israel Ministry of Health.	BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BRANDEIS M, 1993, BIOESSAYS, V15, P1; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; COLLINS FS, 1987, BLOOD, V70, P1797; DHAR V, 1988, MOL CELL BIOL, V8, P4958, DOI 10.1128/MCB.8.11.4958; Duan ZJ, 2001, MOL CELL BIOL, V21, P3083, DOI 10.1128/MCB.21.9.3083-3095.2001; ELDER JT, 1990, MOL CELL BIOL, V10, P1382, DOI 10.1128/MCB.10.4.1382; EPNER E, 1988, P NATL ACAD SCI USA, V85, P8081, DOI 10.1073/pnas.85.21.8081; FEINGOLD EA, 1989, BLOOD, V74, P2178; FIBACH E, 1989, BLOOD, V73, P100; Forget BG, 1998, ANN NY ACAD SCI, V850, P38, DOI 10.1111/j.1749-6632.1998.tb10460.x; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; Fu XH, 2002, EXP CELL RES, V278, P1, DOI 10.1006/excr.2002.5555; GAENSLER KML, 1993, P NATL ACAD SCI USA, V90, P11381, DOI 10.1073/pnas.90.23.11381; Gilbert DM, 2002, NAT GENET, V32, P336, DOI 10.1038/ng1102-336; Goren A, 2003, NAT REV MOL CELL BIO, V4, P25, DOI 10.1038/nrm1008; Hajkova Petra, 2002, Methods Mol Biol, V200, P143; Hashimshony T, 2003, NAT GENET, V34, P187, DOI 10.1038/ng1158; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HUISMAN THJ, 1997, SICKLE CELL ANEMIA; Huxley C, 1998, METHODS, V14, P199, DOI 10.1006/meth.1997.0578; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; Ikuta T, 1996, J BIOL CHEM, V271, P14082, DOI 10.1074/jbc.271.24.14082; Ji YH, 2003, P NATL ACAD SCI USA, V100, P7557, DOI 10.1073/pnas.0932635100; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; LEY TJ, 1982, NEW ENGL J MED, V307, P1469, DOI 10.1056/NEJM198212093072401; Li F, 2001, J CELL BIOL, V154, P283, DOI 10.1083/jcb.200104043; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; OPPENHEIM A, 1985, BLOOD, V66, P1202; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; Peterson KR, 1998, HUM MOL GENET, V7, P2079, DOI 10.1093/hmg/7.13.2079; PONCZ M, 1987, NUCLEIC ACIDS RES, V15, P5169, DOI 10.1093/nar/15.13.5169; RONCHI AE, 1995, J BIOL CHEM, V270, P21934, DOI 10.1074/jbc.270.37.21934; Rupon JW, 2006, P NATL ACAD SCI USA, V103, P6617, DOI 10.1073/pnas.0509322103; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Simon I, 2001, EMBO J, V20, P6150, DOI 10.1093/emboj/20.21.6150; Szabo PE, 2000, ANAL BIOCHEM, V283, P112, DOI 10.1006/abio.2000.4631; Szabo PE, 2004, MOL CELL BIOL, V24, P4858, DOI 10.1128/MCB.24.11.4858-4868.2004; Tanimoto K, 1999, NUCLEIC ACIDS RES, V27, P3130, DOI 10.1093/nar/27.15.3130; Tanimoto K, 1999, NATURE, V398, P344, DOI 10.1038/18698; VANDERPLOEG LHT, 1980, CELL, V19, P947, DOI 10.1016/0092-8674(80)90086-0; Yeivin A, 1993, EXS, V64, P523; Zhang JM, 2002, NATURE, V420, P198, DOI 10.1038/nature01150	51	40	44	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e46	10.1371/journal.pone.0000046	http://dx.doi.org/10.1371/journal.pone.0000046			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183675	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600046
J	Marani, M; Zillio, T; Belluco, E; Silvestri, S; Maritan, A				Marani, Marco; Zillio, Tommaso; Belluco, Enrica; Silvestri, Sonia; Maritan, Amos			Non-Neutral Vegetation Dynamics	PLOS ONE			English	Article							RELATIVE SPECIES ABUNDANCE; BETA-DIVERSITY; PATTERNS; MODEL	The neutral theory of biodiversity constitutes a reference null hypothesis for the interpretation of ecosystem dynamics and produces relatively simple analytical descriptions of basic system properties, which can be easily compared to observations. On the contrary, investigations in non-neutral dynamics have in the past been limited by the complexity arising from heterogeneous demographic behaviours and by the relative paucity of detailed observations of the spatial distribution of species diversity (beta-diversity): These circumstances prevented the development and testing of explicit non-neutral mathematical descriptions linking competitive strategies and observable ecosystem properties. Here we introduce an exact non-neutral model of vegetation dynamics, based on cloning and seed dispersal, which yields closed-form characterizations of beta-diversity. The predictions of the non-neutral model are validated using new high-resolution remote-sensing observations of salt-marsh vegetation in the Venice Lagoon (Italy). Model expressions of beta-diversity show a remarkable agreement with observed distributions within the wide observational range of scales explored (5.10(-1) m divided by 10(3) m). We also consider a neutral version of the model and find its predictions to be in agreement with the more limited characterization of beta-diversity typical of the neutral theory (based on the likelihood that two sites be conspecific or heterospecific, irrespective of the species). However, such an agreement proves to be misleading as the recruitment rates by propagules and by seed dispersal assumed by the neutral model do not reflect known species characteristics and correspond to averages of those obtained under the more general non-neutral hypothesis. We conclude that non-neutral beta-diversity characterizations are required to describe ecosystem dynamics in the presence of species-dependent properties and to successfully relate the observed patterns to the underlying processes.	[Marani, Marco; Belluco, Enrica] Univ Padua, Dipartimento Ingn Idraul Marittima Ambientale & G, Padua, Italy; [Marani, Marco; Belluco, Enrica] Univ Padua, Int Ctr Hydrol, Padua, Italy; [Zillio, Tommaso] Int Sch Adv Studies SISSA, Trieste, Italy; [Silvestri, Sonia] CVN, Serv Informat, Venice, Italy; [Maritan, Amos] CNIS, Unita Padova, Padua, Italy	University of Padua; University of Padua; International School for Advanced Studies (SISSA)	Marani, M (corresponding author), Univ Padua, Dipartimento Ingn Idraul Marittima Ambientale & G, Padua, Italy.	marani@idra.unipd.it; amos.maritan@pd.infn.it	Marani, Marco/F-9451-2016	Belluco, Enrica/0000-0001-8094-0219; Marani, Marco/0000-0002-1493-6913; SILVESTRI, SONIA/0000-0002-5114-8633; Maritan, Amos/0000-0002-3535-7873	TIDE EU RTD [EVK3-CT-2001-00064]; NSF [DEB-0346488]	TIDE EU RTD; NSF(National Science Foundation (NSF))	This work was supported by the TIDE EU RTD Project (EVK3-CT-2001-00064) and by NSF grant DEB-0346488.	Abramowitz M., 1970, HDB MATH FUNCTIONS; Adam P., 1990, SALT MARSH ECOLOGY; Belluco E, 2006, REMOTE SENS ENVIRON, V105, P54, DOI 10.1016/j.rse.2006.06.006; CASTELLANOS EM, 1994, J ECOL, V82, P239, DOI 10.2307/2261292; Caylor KK, 2006, DRYLAND ECOHYDROLOGY, P259, DOI 10.1007/1-4020-4260-4_15; Chave J, 2002, THEOR POPUL BIOL, V62, P153, DOI 10.1006/tpbi.2002.1597; Condit R, 2002, SCIENCE, V295, P666, DOI 10.1126/science.1066854; Condit R, 2000, SCIENCE, V288, P1414, DOI 10.1126/science.288.5470.1414; Cronk J, 2001, WETLAND PLANTS BIOL; DACEY JWH, 1984, SCIENCE, V224, P487, DOI 10.1126/science.224.4648.487; Green JL, 2004, NATURE, V432, P747, DOI 10.1038/nature03034; Hubbell SP, 1997, CORAL REEFS, V16, pS9, DOI 10.1007/s003380050237; Hubbell Stephen P., 2001, V32, pi; KRUSE FA, 1993, REMOTE SENS ENVIRON, V44, P145, DOI 10.1016/0034-4257(93)90013-N; LEVIN SA, 1992, ECOLOGY, V73, P1943, DOI 10.2307/1941447; Marani M, 2004, J MARINE SYST, V51, P191, DOI 10.1016/j.jmarsys.2004.05.012; MARANI M, 2006, WATER RESOUR RES, V42, pD606, DOI DOI 10.1029/2005WR004582; Marani M, 2006, ESTUAR COAST SHELF S, V69, P414, DOI 10.1016/j.ecss.2006.05.021; Mitsch W., 2000, WETLANDS, V3rd; Pandolfi JM, 2006, NATURE, V440, P35, DOI 10.1038/440035a; Rodriguez-Iturbe I., 2005, ECOHYDROLOGY WATER C; Silvestri S, 2005, ESTUAR COAST SHELF S, V62, P119, DOI 10.1016/j.ecss.2004.08.010; Ursino N, 2004, WATER RESOUR RES, V40, DOI 10.1029/2003WR002702; Van Kampen NG, 1992, STOCHASTIC PROCESSES; Volkov I, 2003, NATURE, V424, P1035, DOI 10.1038/nature01883; Zillio T, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.098101	26	16	16	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e78	10.1371/journal.pone.0000078	http://dx.doi.org/10.1371/journal.pone.0000078			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183710	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600078
J	Rzhetsky, A; Zheng, T; Weinreb, C				Rzhetsky, Andrey; Zheng, Tian; Weinreb, Chani			Self-Correcting Maps of Molecular Pathways	PLOS ONE			English	Article							BAYESIAN NETWORKS; EXPRESSION; APOPTOSIS; PRESENILIN-1; KNOWLEDGE; MODELS	Reliable and comprehensive maps of molecular pathways are indispensable for guiding complex biomedical experiments. Such maps are typically assembled from myriads of disparate research reports and are replete with inconsistencies due to variations in experimental conditions and/or errors. It is often an intractable task to manually verify internal consistency over a large collection of experimental statements. To automate large-scale reconciliation efforts, we propose a random-arcs-and-nodes model where both nodes (tissue-specific states of biological molecules) and arcs (interactions between them) are represented with random variables. We show how to obtain a non-contradictory model of a molecular network by computing the joint distribution for arc and node variables, and then apply our methodology to a realistic network, generating a set of experimentally testable hypotheses. This network, derived from an automated analysis of over 3,000 full-text research articles, includes genes that have been hypothetically linked to four neurological disorders: Alzheimer's disease, autism, bipolar disorder, and schizophrenia. We estimated that approximately 10% of the published molecular interactions are logically incompatible. Our approach can be directly applied to an array of diverse problems including those encountered in molecular biology, ecology, economics, politics, and sociology.	[Rzhetsky, Andrey; Weinreb, Chani] Columbia Univ, Dept Biomed Informat, Ctr Computat Biol & Bioinformat, New York, NY 10027 USA; [Rzhetsky, Andrey; Weinreb, Chani] Columbia Univ, Joint Ctr Syst Biol, New York, NY USA; [Rzhetsky, Andrey] Columbia Univ, Judith P Sulzberger MD Columbia Genome Ctr, New York, NY USA; [Rzhetsky, Andrey] Columbia Univ, Dept Biol, New York, NY USA; [Zheng, Tian] Columbia Univ, Dept Stat, New York, NY USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Rzhetsky, A (corresponding author), Columbia Univ, Dept Biomed Informat, Ctr Computat Biol & Bioinformat, New York, NY 10027 USA.	andrey.rzhetsky@dbmi.columbia.edu	rzhetsky, andrey/B-6118-2012	rzhetsky, andrey/0000-0001-6959-7405; Zheng, Tian/0000-0003-4889-0391	National Institutes of Health [GM61372, GM070789]; National Science Foundation [0438291, 0121687, 0532231]; Cure Autism Now Foundation; Defense Advanced Research Projects Agency [FA8750-04-2-0123];  [5-T15-LM007079]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061372, R01GM070789] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007079] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Cure Autism Now Foundation; Defense Advanced Research Projects Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); ; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	This work was supported by the National Institutes of Health (GM61372 to A. R., GM070789 to T. Z., and training fellowship 5-T15-LM007079 to C. W.), the National Science Foundation ( 0438291 and 0121687 to A. R., and 0532231 to T. Z.), the Cure Autism Now Foundation to A. R., and the Defense Advanced Research Projects Agency (FA8750-04-2-0123 to A. R.).	Amson R, 2000, P NATL ACAD SCI USA, V97, P5346, DOI 10.1073/pnas.97.10.5346; Barabasi AL, 2005, SCIENCE, V308, P639, DOI 10.1126/science.1112554; Bascompte J, 2006, SCIENCE, V312, P431, DOI 10.1126/science.1123412; Cokol M, 2005, NAT BIOTECHNOL, V23, P1243, DOI 10.1038/nbt1005-1243; da Costa CA, 2003, J BIOL CHEM, V278, P12064, DOI 10.1074/jbc.M212379200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Frey BJ, 2005, NAT GENET, V37, P991, DOI 10.1038/ng1630; Friedman C, 2001, Bioinformatics, V17 Suppl 1, pS74; Friedman N, 2004, SCIENCE, V303, P799, DOI 10.1126/science.1094068; Friedman N, 2000, J COMPUT BIOL, V7, P601, DOI 10.1089/106652700750050961; Gilks WR, 1996, MARKOV CHAIN MONTE C; Hartemink A J, 2001, Pac Symp Biocomput, P422; HECKERMAN D, 1995, MACH LEARN, V20, P197, DOI 10.1007/BF00994016; HECKERMAN D, 1995, COMMUN ACM, V38, P27, DOI 10.1145/203330.203336; Hoff PD, 2004, POLIT ANAL, V12, P160, DOI 10.1093/pan/mph012; Kahn CE, 1997, COMPUT BIOL MED, V27, P19, DOI 10.1016/S0010-4825(96)00039-X; Krauthammer M, 2004, P NATL ACAD SCI USA, V101, P15148, DOI 10.1073/pnas.0404315101; Ligon KL, 2003, DEVELOPMENT, V130, P2275, DOI 10.1242/dev.00421; Liu J. S., 2001, SPRINGER SERIES STAT; Markowetz F, 2005, BIOINFORMATICS, V21, P4026, DOI 10.1093/bioinformatics/bti662; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; Pearl J., 2000, CAUSALITY MODELS REA, DOI DOI 10.1017/CBO9780511803161; PEARL J, 1988, M KAUFMANN SERIES RE; Rzhetsky A, 2004, J BIOMED INFORM, V37, P43, DOI 10.1016/j.jbi.2003.10.001; RZHETSKY A, 2006, P NATL ACAD SCI US; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; SZOLOVITS P, 1995, METHOD INFORM MED, V34, P111; Von Neumann J., 1956, AUTOM STUD, P43, DOI DOI 10.1515/9781400882618-003; Yeang CH, 2004, J COMPUT BIOL, V11, P243, DOI 10.1089/1066527041410382	29	9	10	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e61	10.1371/journal.pone.0000061	http://dx.doi.org/10.1371/journal.pone.0000061			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183692	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600061
J	Uht, RM; Amos, S; Martin, PM; Riggan, AE; Hussaini, IM				Uht, R. M.; Amos, S.; Martin, P. M.; Riggan, A. E.; Hussaini, I. M.			The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway	ONCOGENE			English	Article						PKC-eta; AP-1; ERK; Elk-1; glioblastoma; proliferation	SIGNAL-TRANSDUCTION; HUMAN GLIOMA; TRANSCRIPTION FACTORS; IN-VITRO; RECEPTOR TRANSACTIVATION; MALIGNANT GLIOMAS; GROWTH; AP-1; INHIBITION; EXPRESSION	Glioblastoma multiforme (GBM) is the highest grade of astrocytoma. GBM pathogenesis has been linked to receptor tyrosine kinases and kinases further down signal-transduction pathways - in particular, members of the protein kinase C (PKC) family. The expression and activity of various PKC isoforms are increased in malignant astrocytomas, but not in non-neoplastic astrocytes. This suggests that PKC activity contributes to tumor progression. The level of PKC-eta expressed correlates with the degree of phorbol-12-myristate-13-acetate (PMA)-induced proliferation of two glioblastoma cell lines, U-1242 MG and U-251 MG. Normally, U-1242 cells do not express PKC-eta, and PMA inhibits their proliferation. Conversely, PMA increases proliferation of U-1242 cells that are stably transfected with PKC-eta (U-1242-PKC-eta). PMA treatment also stimulates proliferation of U-251 cells, which express PKC-eta. Here, we determined that extracellular signal-regulated kinase (ERK) and Elk-1 are downstream targets of PKC-eta. Elk-1-mediated transcriptional activity correlates with the PKC-eta-mediated mitogenic response. Pretreatment of U-1242-PKC-eta cells with inhibitors of PKC or MAPK/ERK kinase (MEK) (bisindolyl maleimide (BIM) or U0126, respectively) blocked both PMA-induced Elk-1 transcriptional activity and PMA-stimulated proliferation. An overexpressed dominant-negative PKC-eta reduced the mitogenic response in U-251 cells, as did reduction of Elk-1 by small interfering RNA. Taken together, these results strongly suggest that PKC-eta-mediated glioblastoma proliferation involves MEK/mitogen-activated protein (MAP) kinase phosphorylation, activation of ERK and subsequently of Elk-1. Elk-1 target genes involved in GBM proliferative responses have yet to be identified.	Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Uht, RM (corresponding author), Univ Virginia, Sch Med, Dept Pathol, MR 5,Rm 3123,415 Lane Rd, Charlottesville, VA 22908 USA.	ruht@virginia.edu		Amos, Samson/0000-0003-2780-2276	NATIONAL CANCER INSTITUTE [R01CA090851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035122] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90851] Funding Source: Medline; NINDS NIH HHS [R01 NS35122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aeder SE, 2004, ONCOGENE, V23, P9062, DOI 10.1038/sj.onc.1208093; Amos S, 2005, J BIOL CHEM, V280, P7729, DOI 10.1074/jbc.M409056200; Baltuch GH, 1996, BRAIN RES, V710, P143, DOI 10.1016/0006-8993(95)01395-4; BALTUCH GH, 1995, CAN J NEUROL SCI, V22, P264, DOI 10.1017/S0317167100039457; BIGNER DD, 1981, J NEUROPATH EXP NEUR, V40, P201, DOI 10.1097/00005072-198105000-00001; BONGCAMRUDLOFF E, 1991, CANCER RES, V51, P1553; COULDWELL WT, 1990, J NEUROSURG, V73, P594, DOI 10.3171/jns.1990.73.4.0594; Dooley NP, 1998, NEUROREPORT, V9, P1727, DOI 10.1097/00001756-199806010-00011; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eller JL, 2005, NEUROSURGERY, V56, P155, DOI 10.1227/01.NEU.0000145865.25689.55; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Houillier C, 2006, CANCER-AM CANCER SOC, V106, P2218, DOI 10.1002/cncr.21819; Hussaini IM, 2000, J BIOL CHEM, V275, P22348, DOI 10.1074/jbc.M003203200; Hussaini IM, 1999, GLIA, V25, P71, DOI 10.1002/(SICI)1098-1136(19990101)25:1<71::AID-GLIA7>3.0.CO;2-0; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KLEIHEUS P, 1997, PATHOLOGY GENETICS T; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Mischel PS, 2003, BRAIN PATHOL, V13, P52; MISHIMA K, 1994, BIOCHEM BIOPH RES CO, V201, P363, DOI 10.1006/bbrc.1994.1710; Nozaki M, 1999, Neuro Oncol, V1, P124, DOI 10.1093/neuonc/1.2.124; POLLACK IF, 1991, J NEUROSURG, V75, P284, DOI 10.3171/jns.1991.75.2.0284; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sharif TR, 1999, INT J ONCOL, V14, P327; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shen L, 1998, BIOCHEM PHARMACOL, V55, P1711, DOI 10.1016/S0006-2952(98)00045-8; Szaniawska B, 1996, CANCER LETT, V107, P205, DOI 10.1016/0304-3835(96)04369-8; Tootle TL, 2005, BIOESSAYS, V27, P285, DOI 10.1002/bies.20198; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; *US CANC STAT WORK, 2005, US DEP HHS, P50; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; Zellner A, 1998, CLIN CANCER RES, V4, P1797	40	61	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2007	26	20					2885	2893		10.1038/sj.onc.1210090	http://dx.doi.org/10.1038/sj.onc.1210090			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17146445				2022-12-25	WOS:000246210800008
J	Nie, J; Pei, J; Blumenthal, M; Pei, DQ				Nie, Jing; Pei, Jing; Blumenthal, Malcolm; Pei, Duanqing			Complete restoration of cell surface activity of transmembrane-truncated MT1-MMP by a glycosylphosphatidylinositol anchor - Implications for MTI-MMP-mediated proMMP2 activation and collagenolysis in three-dimensions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; DOMAIN; INVASION; PROGELATINASE; MT3-MMP; ENZYME	MT1-MMP is a potent collagenase not only required for skeletal development but also implicated in tumor invasion and metastasis. The mechanism through which cellsdeploy MT1-MMP to mediate collagenolysis remains largely unknown. C-terminally truncated MT1-MMP lacking its transmembrane and cytoplasmic domains, although proteolytic active in purified forms, is known to be deficient in cell-mediated proMMP2 activation and collagenolysis, suggesting that cells regulate its activity through both domains. Indeed, the cytoplasmic domain is recognized by the trafficking machinery that mediates its internalization and recycling. Here we demonstrate that its transmembrane domain can be functionally substituted by the glycosylphosphatidylinositol (GPI)-anchor of MT6-MMP. The GPI-anchored MT1-MMP, orMT1-GPI, activates proMMP2 on the cell surface and promotes cell growth in a three-dimensional type I collagen matrix. On the other hand, a GPI-anchored MMP13 with a functional furin activation signal fails to promote cell growth in a three-dimensional collagen matrix, whereas remaining competent in collagenolysis on a two-dimensional collagen matrix under serum-free conditions. alpha(2) macroglobulin (alpha M-2) or serum is sufficient to inhibit the collagenase activity of GPI-anchored active MMP13. Our results suggest that both membrane-tethering and proteolytic activity encoded by MT1-MMP are required for its ability to promote cell growth and invasion in a three-dimensional collagen matrix.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Pei, DQ (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA.	peixx003@umn.edu			NCI NIH HHS [CA76308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076308, R29CA076308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kang TB, 2000, FASEB J, V14, P2559, DOI 10.1096/fj.00-0269com; Knauper V, 2002, FEBS LETT, V532, P127, DOI 10.1016/S0014-5793(02)03654-2; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Nie J, 2003, CANCER RES, V63, P6758; Pei DQ, 1998, PROTEIN EXPRES PURIF, V13, P277, DOI 10.1006/prep.1998.0894; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Toth M, 2003, BIOCHEM BIOPH RES CO, V308, P386, DOI 10.1016/S0006-291X(03)01405-0; TRAVIS J, 1988, AM J MED, V84, P37; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Wang P, 2004, J BIOL CHEM, V279, P51148, DOI 10.1074/jbc.M409074200; Wang P, 2004, J BIOL CHEM, V279, P20461, DOI 10.1074/jbc.M400264200; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Wang YH, 1999, J BIOL CHEM, V274, P33043, DOI 10.1074/jbc.274.46.33043; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	32	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6438	6443		10.1074/jbc.M607337200	http://dx.doi.org/10.1074/jbc.M607337200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17158888	hybrid			2022-12-25	WOS:000244867200051
J	Li, XQ; Zou, GZ; Yuan, WR; Lu, WY				Li, Xiangqun; Zou, Guozhang; Yuan, Weirong; Lu, Wuyuan			Defining the native disulfide topology in the somatomedin B domain of human vitronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; TOTAL CHEMICAL-SYNTHESIS; CELL-MIGRATION; STRUCTURAL REQUIREMENTS; UROKINASE RECEPTOR; BINDING-PROTEIN; TUMOR-GROWTH; HUMAN-PLASMA; S-PROTEIN; PAI-1	The N-terminal 44 amino acid residues of the human plasma glycoprotein vitronectin, known as the somatomedin B (SMB) domain, mediates the interaction between vitronectin and plasminogen activator inhibitor 1 (PAI-1) in a variety of important biological processes. Despite the functional importance of the Cys-rich SMB domain, how its four disulfide bridges are arranged in the molecule remains highly controversial, as evidenced by three different disulfide connectivities reported by several laboratories. Using native chemical ligation and orthogonal protection of selected Cys residues, we chemically synthesized all three topological analogs of SMB with predefined disulfide connectivities corresponding to those previously published. In addition, we oxidatively folded a fully reduced SMB in aqueous solution, and prepared, by CNBr cleavage, the N-terminal segment of 51 amino acid residues of intact vitronectin purified from human blood. Proteolysis coupled with mass spectrometric analysis and functional characterization using a surface plasmon resonance based vitronectin-PAI-1-SMB competition assay allowed us to conclude that 1) only the Cys(5)-Cys(21), Cys(9)-Cys(39), Cys(19)-Cys(32), and Cys(25)-Cys(31) connectivity is present in native vitronectin; 2) only the native disulfide connectivity is functional; and 3) the native disulfide pairings can be readily formed during spontaneous (oxidative) folding of the SMB domain in vitro. Our results unequivocally define the native disulfide topology in the SMB domain of human vitronectin, providing biochemical as well as functional support to the structural findings on a recombinant SMB domain by Read and colleagues.	Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Lu, WY (corresponding author), Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA.	luw@umbi.umd.edu	Lu, Wuyuan/J-8452-2017; Lu, Wuyuan/B-2268-2010	Lu, Wuyuan/0000-0003-1318-9968; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061482, R21AI058939] Funding Source: NIH RePORTER; NIAID NIH HHS [AI061482, AI058939] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Dawson PE, 2000, ANNU REV BIOCHEM, V69, P923, DOI 10.1146/annurev.biochem.69.1.923; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Dellas C, 2005, THROMB HAEMOSTASIS, V93, P631, DOI 10.1160/TH05-01-0033; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Deng G, 2001, J CELL PHYSIOL, V189, P23, DOI 10.1002/jcp.1133; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; FRYKLUND L, 1978, FEBS LETT, V87, P55, DOI 10.1016/0014-5793(78)80132-X; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Horn NA, 2004, J BIOL CHEM, V279, P35867, DOI 10.1074/jbc.M405716200; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; Kamikubo Y, 2006, BIOCHEMISTRY-US, V45, P3297, DOI 10.1021/bi052278f; Kamikubo Y, 2004, BIOCHEMISTRY-US, V43, P6519, DOI 10.1021/bi049647c; Kamikubo Y, 2002, J BIOL CHEM, V277, P27109, DOI 10.1074/jbc.M200354200; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Kohler HP, 2000, NEW ENGL J MED, V342, P1792, DOI 10.1056/NEJM200006153422406; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; Li XQ, 2005, BIOCHEMISTRY-US, V44, P14688, DOI 10.1021/bi051519g; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Mayasundari A, 2004, J BIOL CHEM, V279, P29359, DOI 10.1074/jbc.M401279200; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; MIMURO J, 1989, J BIOL CHEM, V264, P936; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Muir TW, 1997, METHOD ENZYMOL, V289, P266; Okumura Y, 2002, J BIOL CHEM, V277, P9395, DOI 10.1074/jbc.M111225200; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3; Royle G, 2001, ANAL BIOCHEM, V296, P245, DOI 10.1006/abio.2001.5316; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; WIMAN B, 1995, THROMB HAEMOSTASIS, V74, P71; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; WIMAN B, 1988, THROMB HAEMOSTASIS, V59, P392; Wu ZB, 2003, P NATL ACAD SCI USA, V100, P8880, DOI 10.1073/pnas.1533186100; Wu ZB, 2004, P NATL ACAD SCI USA, V101, P11587, DOI 10.1073/pnas.0404649101; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943	45	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5318	5326		10.1074/jbc.M611396200	http://dx.doi.org/10.1074/jbc.M611396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189256	hybrid			2022-12-25	WOS:000244482300027
J	Yanagida, K; Ishii, S; Hamano, F; Noguchi, K; Shimizu, T				Yanagida, Keisuke; Ishii, Satoshi; Hamano, Fumie; Noguchi, Kyoko; Shimizu, Takao			LPA(4)/p2y(9)/GPR23 mediates rho-dependent morphological changes in a rat neuronal cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTORS; NEURITE RETRACTION; PROSTANOID RECEPTOR; PROGENITOR CELLS; N1E-115 CELLS; BETA-CATENIN; P115 RHOGEF; ACTIVATION; G-ALPHA(13)	Lysophosphatidic acid (LPA) is a potent lipid mediator that evokes a variety of biological responses in many cell types via its specific G protein-coupled receptors. In particular, LPA affects cell morphology, cell survival, and cell cycle progression in neuronal cells. Recently, we identified p2y(9)/GPR23 as a novel fourth LPA receptor, LPA(4) (Noguchi, K., Ishii, S., and Shimizu, T. (2003) J. Biol. Chem. 278, 25600-25606). To assess the functions of LPA, in neuronal cells, we used rat neuroblastoma B103 cells that lack endogenous responses to LPA. In B103 cells stably expressing LPA(4), we observed G(q/11)-dependent calcium mobilization, but LPA did not affect adenylyl cyclase activity. In LPA, transfectants, LPA induced dramatic morphological changes, i.e. neurite retraction, cell aggregation, and cadherin-dependent cell adhesion, which involved Rho-mediated signaling pathways. Thus, our results demonstrated that LPA4 as well as LPA, couple to G(q/11) and G(12/13), whereas LPA(4) differs from LPA(1) in that it does not couple to G(i/o). Through neurite retraction and cell aggregation, LPA(4) may play a role in neuronal development such as neurogenesis and neuronal migration.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, PRESTO, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Ishii, S (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	mame@m.u-tokyo.ac.jp	Shimizu, Takao/AAV-7052-2021					An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chen Q, 2005, J NEUROSCI, V25, P281, DOI 10.1523/JNEUROSCI.3692-04.2005; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Chun J, 2005, PROSTAG OTH LIPID M, V77, P46, DOI 10.1016/j.prostaglandins.2004.09.009; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Couvillon AD, 2006, CELL SIGNAL, V18, P715, DOI 10.1016/j.cellsig.2005.06.012; DAS AK, 1989, LIPIDS, V24, P329, DOI 10.1007/BF02535172; Dawson J, 2003, J NEUROCHEM, V87, P947, DOI 10.1046/j.1471-4159.2003.02056.x; Fujino H, 2002, J BIOL CHEM, V277, P48786, DOI 10.1074/jbc.M209393200; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Fujiwara Y, 2003, J NEUROCHEM, V87, P1272, DOI 10.1046/j.1471-4159.2003.02106.x; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Fukushima N, 2004, J CELL BIOCHEM, V92, P993, DOI 10.1002/jcb.20093; Fukushima N, 2002, MOL CELL NEUROSCI, V20, P271, DOI 10.1006/mcne.2002.1123; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Govek EE, 2005, GENE DEV, V19, P1, DOI 10.1101/gad.1256405; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Harada J, 2004, J NEUROCHEM, V88, P1026, DOI 10.1046/j.1471-4159.2003.02219.x; Harrison SM, 2003, MOL CELL NEUROSCI, V24, P1170, DOI 10.1016/j.mcn.2003.09.001; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hasegawa H, 1997, BIOCHEM BIOPH RES CO, V234, P631, DOI 10.1006/bbrc.1997.6655; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Jaillard C, 2005, J NEUROSCI, V25, P1459, DOI 10.1523/JNEUROSCI.4645-04.2005; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Janssens R, 1997, BIOCHEM BIOPH RES CO, V236, P106, DOI 10.1006/bbrc.1997.6895; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Luo LQ, 2005, ANNU REV NEUROSCI, V28, P127, DOI 10.1146/annurev.neuro.28.061604.135632; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; ODowd BF, 1997, GENE, V187, P75, DOI 10.1016/S0378-1119(96)00722-6; Pierce KL, 1999, J BIOL CHEM, V274, P35944, DOI 10.1074/jbc.274.50.35944; Rhee HJ, 2006, NEUROREPORT, V17, P523; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; Sayas CL, 2002, J NEUROSCI, V22, P6863; Seasholtz TM, 2004, J NEUROCHEM, V91, P501, DOI 10.1111/j.1471-4159.2004.02749.x; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Sugiura T, 1999, BBA-MOL CELL BIOL L, V1440, P194, DOI 10.1016/S1388-1981(99)00127-4; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; TOKUMURA A, 1995, PROG LIPID RES, V34, P151, DOI 10.1016/0163-7827(95)00001-G; Toman RE, 2004, J CELL BIOL, V166, P381, DOI 10.1083/jcb.200402016; Tsukahara T, 2006, J BIOL CHEM, V281, P3398, DOI 10.1074/jbc.M510843200; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; von Kugelgen I, 2006, PHARMACOL THERAPEUT, V110, P415, DOI 10.1016/j.pharmthera.2005.08.014; Wanner IB, 2002, J NEUROSCI, V22, P4066, DOI 10.1523/JNEUROSCI.22-10-04066.2002; Weiner JA, 2001, J NEUROSCI, V21, P7069, DOI 10.1523/JNEUROSCI.21-18-07069.2001; Yamada T, 2004, J BIOL CHEM, V279, P6595, DOI 10.1074/jbc.M308133200; Ye XQ, 2002, NEUROREPORT, V13, P2169, DOI 10.1097/00001756-200212030-00002; ZUHERINGDORF DM, 2004, J CELL BIOCHEM, V92, P937	70	87	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5814	5824		10.1074/jbc.M610767200	http://dx.doi.org/10.1074/jbc.M610767200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17172642	hybrid			2022-12-25	WOS:000244482300077
J	Shen, YG; Lee, G; Choe, Y; Zoltewicz, JS; Peterson, AS				Shen, Yiguo; Lee, Gena; Choe, Youngshik; Zoltewicz, J. Susie; Peterson, Andrew S.			Functional architecture of atrophins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; GENE-PRODUCT; INTERACTS; POLYGLUTAMINE; POLARITY; DOMAIN; PML	Vertebrate genomes harbor two Atrophin genes, Atrophin-1 (Atn1) and Atrophin-2 (Atn2). The Atnl locus produces a single polypeptide, whereas two different protein products are expressed from the Atn2 (also known as Rere) locus. A long, or full-length, form contains an amino-terminal MTA-2-homologous domain followed by an Atrophin-1-related domain. A short form, expressed via an internal promoter, consists solely of the Atrophin domain. Atrophin-1 can be co-immunoprecipitated along with Atrophin-2, suggesting that the Atrophins ordinarily function together. Mutations that disrupt the expression of the long form of Atrophin-2 disrupt early embryonic development. To determine the requirement for Atrophin-1 during development we generated a null allele. Somewhat surprisingly we found that Atrophin-1 function is dispensable. To gain a better understanding of the requirement for Atrophin function during development, an analysis of the functional domains of the three different gene products was carried out. Taken together, these data suggest that Atrophins function as bifunctional transcriptional regulators. The long form of Atrophin-2 has a transcriptional repression activity that is not found in the other Atrophin polypeptides and that is required for normal embryogenesis. Atrophin-1 and the short form of Atrophin-2, on the other hand, can act as potent and evolutionarily conserved transcriptional activators.	Univ Calif San Francisco, Gallo Ctr, Oakland, CA 94608 USA; Univ Calif San Francisco, Dept Neurol, Oakland, CA 94608 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco	Peterson, AS (corresponding author), Genentech Inc, Dept Mol Biol, MS-37,1 DNA Way, San Francisco, CA 94080 USA.	Peterson.Andrew@gene.com			NIDA NIH HHS [7R01DA017627-09] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA017627] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Asai Y, 2006, P NATL ACAD SCI USA, V103, P9069, DOI 10.1073/pnas.0603453103; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Charroux B, 2006, DEV BIOL, V291, P278, DOI 10.1016/j.ydbio.2005.12.012; Fanto M, 2003, DEVELOPMENT, V130, P763, DOI 10.1242/dev.00304; Herman MA, 1999, DEVELOPMENT, V126, P1055; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Okamura-Oho Y, 1999, HUM MOL GENET, V8, P947, DOI 10.1093/hmg/8.6.947; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Takahashi J, 2003, NEUROBIOL DIS, V13, P230, DOI 10.1016/S0969-9961(03)00080-9; Waerner T, 2001, CELL GROWTH DIFFER, V12, P201; Wang L, 2006, GENE DEV, V20, P525, DOI 10.1101/gad.1393506; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Yamada M, 2001, ANN NEUROL, V49, P14, DOI 10.1002/1531-8249(200101)49:1<14::AID-ANA5>3.0.CO;2-X; Yanagisawa H, 2000, HUM MOL GENET, V9, P1433, DOI 10.1093/hmg/9.9.1433; Zhang S, 2002, CELL, V108, P45, DOI 10.1016/S0092-8674(01)00630-4; Zoltewicz JS, 2004, DEVELOPMENT, V131, P3, DOI 10.1242/dev.00908	18	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					5037	5044		10.1074/jbc.M610274200	http://dx.doi.org/10.1074/jbc.M610274200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17150957	hybrid			2022-12-25	WOS:000244482000086
J	Wu, Y; Termine, DJ; Swulius, MT; Moremen, KW; Sifers, RN				Wu, Ying; Termine, Daniel J.; Swulius, Matthew T.; Moremen, Kelley W.; Sifers, Richard N.			Human endoplasmic reticulum mannosidase I is subject to regulated proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN QUALITY-CONTROL; ALPHA-MANNOSIDASE; DEGRADATION; ER; ALPHA-1-ANTITRYPSIN; ALPHA(1)-ANTITRYPSIN; INHIBITORS; EXPRESSION; CATALYSIS; MEMBRANE	In the early secretory pathway, opportunistic cleavage of asparagine-linked ofigosaccharides by endoplasmic reticulum (ER) mannosidase I targets misfolded glycoproteins for dislocation into the cytosol and destruction by 26 S proteasomes. The low basal concentration of the glycosidase is believed to coordinate the glycan cleavage with prolonged conformation-based ER retention, ensuring that terminally misfolded glycoproteins are preferentially targeted for destruction. Herein the intracellular fate of human ER mannosidase I was monitored to determine whether a post-translational process might contribute to the regulation of its intracellular concentration. The transiently expressed recombinant human glycosidase was subject to rapid intracellular turnover in mouse hepatoma cells, as was the endogenous mouse ortholog. Incubation with either chloroquine or leupeptin, but not lactacystin, led to intracellular stabilization, implicating the involvement of lysosomal acid hydrolases. Inhibition of protein synthesis with cycloheximide led to intracellular depletion of the glycosidase and concomitant ablation of asparagine-linked glycoprotein degradation, confirming the physiologic relevance of the destabilization process. Metabolic incorporation of radiolabeled phosphate, detection by anti-phosphoserine antiserum, and the stabilizing effect of general serine kinase inhibition implied that ER mannosidase I is subjected to regulated proteolysis. Stabilization in response to genetically engineered removal of the amino-terminal cytoplasmic tail, a postulated regulatory domain, and colocalization of green fluorescent protein fusion proteins with Lamp1 provided two additional lines of evidence to support the hypothesis. A model is proposed in which proteolytically driven checkpoint control of ER mannosidase I contributes to the establishment of an equitable glycoprotein quality control standard by which the efficiency of asparagine-linked glycoprotein conformational maturation is measured.	Baylor Coll Med, Dept Pathol Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Physiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Biophys, Houston, TX 77030 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Sifers, RN (corresponding author), Baylor Coll Med, Dept Pathol Mol & Cellular Biol, Houston, TX 77030 USA.	rsifers@bcm.tmc.edu	Moremen, Kelley/AAD-4661-2019; Sifers, Richard Norman/AGQ-7262-2022		NCI NIH HHS [U01 CA091295] Funding Source: Medline; NCRR NIH HHS [P41 RR005351, RR005351] Funding Source: Medline; NHLBI NIH HHS [HL62553, R01 HL062553] Funding Source: Medline; NIDDK NIH HHS [DK064232, R01 DK064232, R01 DK075322] Funding Source: Medline; NIGMS NIH HHS [R01 GM047533, GM47533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA091295] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064232, R01DK075322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Amshoff C, 1999, BIOL CHEM, V380, P669, DOI 10.1515/BC.1999.083; Cabral CM, 2002, MOL BIOL CELL, V13, P2639, DOI 10.1091/mbc.E02-02-0068; Cabral CM, 2001, TRENDS BIOCHEM SCI, V26, P619, DOI 10.1016/S0968-0004(01)01942-9; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; Choudhury P, 1997, J BIOL CHEM, V272, P13446, DOI 10.1074/jbc.272.20.13446; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Fagioli C, 2001, J BIOL CHEM, V276, P12885, DOI 10.1074/jbc.M009603200; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Gerstein M, 2002, SCIENCE, V295, P284, DOI 10.1126/science.1068664; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; Gordon SR, 1999, EXP CELL RES, V246, P233, DOI 10.1006/excr.1998.4298; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Herscovics A, 2001, BIOCHIMIE, V83, P757, DOI 10.1016/S0300-9084(01)01319-0; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Hynes TR, 2004, J BIOL CHEM, V279, P44101, DOI 10.1074/jbc.M405151200; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Karaveg K, 2005, J BIOL CHEM, V280, P16197, DOI 10.1074/jbc.M500119200; Karaveg K, 2005, J BIOL CHEM, V280, P29837, DOI 10.1074/jbc.M505130200; Lederkremer GZ, 2005, TRENDS BIOCHEM SCI, V30, P297, DOI 10.1016/j.tibs.2005.04.010; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; Sekijima Y, 2005, CELL, V121, P73, DOI 10.1016/j.cell.2005.01.018; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P355, DOI 10.1038/nsb0595-355; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; Termine D, 2005, METHODS, V35, P348, DOI 10.1016/j.ymeth.2004.10.006; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Travers KJ, 2002, ADV PROTEIN CHEM, V59, P345; Tremblay LO, 1999, GLYCOBIOLOGY, V9, P1073, DOI 10.1093/glycob/9.10.1073; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida Y, 2003, J BIOL CHEM, V278, P43877, DOI 10.1074/jbc.M304157200; Zhao G, 2006, J BIOL CHEM, V281, P13751, DOI 10.1074/jbc.M600137200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	47	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4841	4849		10.1074/jbc.M607156200	http://dx.doi.org/10.1074/jbc.M607156200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17166854	Green Accepted, hybrid			2022-12-25	WOS:000244482000066
J	Feinberg, H; Castelli, R; Drickamer, K; Seeberger, PH; Weis, WI				Feinberg, Hadar; Castelli, Riccardo; Drickamer, Kurt; Seeberger, Peter H.; Weis, William I.			Multiple modes of binding enhance the affinity of DC-SIGN for high mannose N-linked glycans found on viral glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; ANTIBODY 2G12; RECOGNITION; RECEPTORS; VIRUS; OLIGOSACCHARIDES; MECHANISM; CLUSTER	The dendritic cell surface receptor DC-SIGN and the closely related endothelial cell receptor DC-SIGNR specifically recognize high mannose N-linked carbohydrates on viral pathogens. Previous studies have shown that these receptors bind the outer trimannose branch Man alpha 1-3[Manal-6]Man alpha present in high mannose structures. Although the trimannoside binds to DC-SIGN or DC-SIGNR more strongly than mannose, additional affinity enhancements are observed in the presence of one or more Man alpha 1-2Man alpha moieties on the nonreducing termini of oligomannose structures. The molecular basis of this enhancement has been investigated by determining crystal structures of DC-SIGN bound to a synthetic six-mannose fragment of a high mannose N-linked oligosaccharide, Man alpha 1-2Man alpha 1-3[Man alpha 1-2Man alpha 1-6]Man alpha-6Man and to the disaccharide Man alpha 1-2Man. The structures reveal mixtures of two binding modes in each case. Each mode features typical C-type lectin binding at the principal Ca2+-binding site by one mannose residue. In addition, other sugar residues form contacts unique to each binding mode. These results suggest that the affinity enhancement displayed toward oligosaccharides decorated with the Mana1-2Mana structure is due in part to multiple binding modes at the primary Ca 21 site, which provide both additional contacts and a statistical (entropic) enhancement of binding.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Cellular Physiol, Stanford, CA 94305 USA; ETH, Swiss Fed Inst Technol, Lab Organ Chem, CH-8093 Zurich, Switzerland; Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England	Stanford University; Stanford University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Imperial College London	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, 299 Campus Dr W, Stanford, CA 94305 USA.	bill.weis@stanford.edu	Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150	NIGMS NIH HHS [GM50569] Funding Source: Medline; Wellcome Trust [075565] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182; Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102; Cambi A, 2003, CURR OPIN CELL BIOL, V15, P539, DOI 10.1016/j.ceb.2003.08.004; Ding XL, 1997, CARBOHYD RES, V303, P445, DOI 10.1016/S0008-6215(97)00190-0; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Feinberg H, 2005, J BIOL CHEM, V280, P1327, DOI 10.1074/jbc.M409925200; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Ng KKS, 2002, J BIOL CHEM, V277, P16088, DOI 10.1074/jbc.M200493200; Pohlmann S, 2001, TRENDS IMMUNOL, V22, P643, DOI 10.1016/S1471-4906(01)02081-6; Ratner DM, 2004, CHEMBIOCHEM, V5, P379, DOI 10.1002/cbic.200300804; Ratner DM, 2002, EUR J ORG CHEM, V2002, P826; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730; SONDHEIMER SJ, 1978, CARBOHYD RES, V60, P187, DOI 10.1016/S0008-6215(00)83477-1; Steinman RM, 2000, CELL, V100, P491, DOI 10.1016/S0092-8674(00)80684-4; Tong L, 1996, ACTA CRYSTALLOGR A, V52, P782, DOI 10.1107/S010876739600548X; van Kooyk Y, 2003, TRENDS MOL MED, V9, P153, DOI 10.1016/S1471-4914(03)00027-3; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Woods RJ, 1998, EUR J BIOCHEM, V258, P372, DOI 10.1046/j.1432-1327.1998.2580372.x	28	123	131	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4202	4209		10.1074/jbc.M609689200	http://dx.doi.org/10.1074/jbc.M609689200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17150970	Green Accepted, hybrid			2022-12-25	WOS:000244481900083
J	He, JQ; Saha, SK; Kang, JR; Zarnegar, B; Cheng, GH				He, Jeannie Q.; Saha, Supriya K.; Kang, Jason R.; Zarnegar, Brian; Cheng, Genhong			Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; RING FINGER; SIGNAL TRANSDUCER; ADAPTER PROTEINS; ACTIVATION; KINASE; MICE; CD40; NF-KAPPA-B2; FAMILY	Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) are critical signaling adaptors downstream of many receptors in the TNF receptor and interleukin-1 receptor/Toll-like receptor superfamilies. Whereas TRAF2, 5, and 6 are activators of the canonical NF-kappa B signaling pathway, TRAF3 is an inhibitor of the noncanonical NF-kappa B pathway. The contribution of the different domains in TRAFs to their respective functions remains unclear. To elucidate the structural and functional specificities of TRAF3, we reconstituted TRAF3-deficient cells with a series of TRAF3 mutants and assessed their abilities to restore TRAF3-mediated inhibition of the noncanonical NF-kappa B pathway as measured by NF-kappa B-inducing kinase (NIK) protein levels and processing of p100 to p52. We found that a structurally intact RING finger domain of TRAF3 is required for inhibition of the noncanonical NF-kappa B pathway. In addition, the three N-terminal domains, but not the C-terminal TRAF domain, of the highly homologous TRAF5 can functionally replace the corresponding domains of TRAF3 in suppression of the noncanonical NF-kappa B pathway. This functional specificity correlates with the specific binding of TRAF3, but not TRAF5, to the previously reported TRAF3 binding motif in NIK. Our studies suggest that both the RING finger domain activity and the specific binding of the TRAF domain to NIK are two critical components of TRAF3 suppression of NIK protein levels and the processing of p100 to p52.	Univ Calif Los Angeles, Dept Microbiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Med Scientist Training Program, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Cheng, GH (corresponding author), Univ Calif Los Angeles, Dept Microbiol, 8-240 Factor Bldg,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	gcheng@mednet.ucla.edu	Saha, Supriya/AAC-5365-2019		NATIONAL CANCER INSTITUTE [R01CA087924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057559] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA87924] Funding Source: Medline; NIAID NIH HHS [AI07126-30, R01 AI056154] Funding Source: Medline; NIGMS NIH HHS [GM 08042, R01 GM57559] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Brink R, 1998, J BIOL CHEM, V273, P4129, DOI 10.1074/jbc.273.7.4129; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chung JY, 2002, J CELL SCI, V115, P679; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dadgostar H, 1998, J BIOL CHEM, V273, P24775, DOI 10.1074/jbc.273.38.24775; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Grech A, 2000, MOL IMMUNOL, V37, P721, DOI 10.1016/S0161-5890(00)00098-5; Grech AP, 2004, IMMUNITY, V21, P629, DOI 10.1016/j.immuni.2004.09.011; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; He JQ, 2006, J EXP MED, V203, P2413, DOI 10.1084/jem.20061166; Hu WH, 2004, J BIOL CHEM, V279, P35975, DOI 10.1074/jbc.M405699200; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Kim YS, 2005, MOL CELL BIOL, V25, P2130, DOI 10.1128/MCB.25.6.2130-2137.2005; Li CL, 2002, STRUCTURE, V10, P403, DOI 10.1016/S0969-2126(02)00733-5; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Qian YC, 2004, IMMUNITY, V21, P575, DOI 10.1016/j.immuni.2004.09.001; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Saha SK, 2006, EMBO J, V25, P3257, DOI 10.1038/sj.emboj.7601220; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tsitsikov EN, 2001, IMMUNITY, V15, P647, DOI 10.1016/S1074-7613(01)00207-2; Wajant H, 1998, J MOL EVOL, V47, P656, DOI 10.1007/PL00006423	38	83	88	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3688	3694		10.1074/jbc.M610271200	http://dx.doi.org/10.1074/jbc.M610271200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158868	hybrid			2022-12-25	WOS:000244481900031
J	Youn, H; Kerby, RL; Koh, J; Roberts, GP				Youn, Hwan; Kerby, Robert L.; Koh, Junseock; Roberts, Gary P.			A C-helix residue, Arg-123, has important roles in both the active and inactive forms of the cAMP receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CYCLIC-NUCLEOTIDE; TRANSCRIPTION ACTIVATION; ALLOSTERIC REGULATION; CRYSTAL-STRUCTURE; BINDING; DNA; MUTATIONS; CAP; CRP	The cAMP receptor protein I of Escherichia coli exists in an equilibrium between active and inactive forms, and the effector, cAMP, shifts that equilibrium to the active form, thereby allowing DNA binding. For this equilibrium shift, a C-helix repositioning around the C-helix residues Thr-127 and Ser-128 has been reported as a critical local event along with proper beta 4/beta 5 positioning. Here we show that another C-helix residue, Arg-123, has a unique role in cAMP-dependent CRP activation in two different ways. First, Arg-123 is important for proper cAMP affinity, although it is not critical for the conformational change with saturating amounts of cAMP. Second, Arg-123 is optimal for stabilizing the inactive conformation of CRP when cAMP is absent, thereby allowing a maximal range of regulation by cAMP. However, Arg-123 does not appear to be critical for a functional response to cAMP, as has been proposed previously (Berman, H. M., Ten Eyck, L. F., Goodsell, D. S., Haste, N. M., Korney, A., and Taylor, S. S. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 45-50). Based on mutagenic evidence, we also propose the basis for the stabilization of the inactive form to be through a salt interaction between Asp-68 and Arg-123.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Roberts, GP (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.	groberts@bact.wisc.edu			NIGMS NIH HHS [GM53228, R01 GM053228, GM23467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023467, R01GM053228, R37GM023467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1985, EMBO J, V4, P3329, DOI 10.1002/j.1460-2075.1985.tb04084.x; BELDUZ AO, 1993, NUCLEIC ACIDS RES, V21, P1827, DOI 10.1093/nar/21.8.1827; Berman HM, 2005, P NATL ACAD SCI USA, V102, P45, DOI 10.1073/pnas.0408579102; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CHENG XD, 1994, J BIOL CHEM, V269, P30781; Chiang L W, 1993, PCR Methods Appl, V2, P210; GARGES S, 1985, CELL, V41, P745, DOI 10.1016/S0092-8674(85)80055-6; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X; HARMAN JG, 1986, J BIOL CHEM, V261, P6332; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Lin SH, 2002, BIOCHEMISTRY-US, V41, P14935, DOI 10.1021/bi026756n; Lin SH, 2002, BIOCHEMISTRY-US, V41, P11857, DOI 10.1021/bi026099z; Malecki J, 2000, J BIOL CHEM, V275, P8480, DOI 10.1074/jbc.275.12.8480; Marvin JS, 2001, NAT STRUCT BIOL, V8, P795, DOI 10.1038/nsb0901-795; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MOORE J, 1992, J BACTERIOL, V174, P8030, DOI 10.1128/JB.174.24.8030-8035.1992; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Savery NJ, 2002, J BACTERIOL, V184, P2273, DOI 10.1128/JB.184.8.2273-2280.2002; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Shi Y, 2000, BIOCHEMISTRY-US, V39, P7300, DOI 10.1021/bi000225m; TAKAHASHI M, 1989, J MOL BIOL, V207, P783, DOI 10.1016/0022-2836(89)90244-1; Youn H, 2006, J BIOL CHEM, V281, P1119, DOI 10.1074/jbc.M509421200	27	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3632	3639		10.1074/jbc.M606602200	http://dx.doi.org/10.1074/jbc.M606602200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158453	hybrid			2022-12-25	WOS:000244481900025
J	Breuert, S; Allers, T; Spohn, G; Soppa, J				Breuert, Sebastian; Allers, Thorsten; Spohn, Gabi; Soppa, Joerg			Regulated Polyploidy in Halophilic Archaea	PLOS ONE			English	Article								Polyploidy is common in higher eukaryotes, especially in plants, but it is generally assumed that most prokaryotes contain a single copy of a circular chromosome and are therefore monoploid. We have used two independent methods to determine the genome copy number in halophilic archaea, 1) cell lysis in agarose blocks and Southern blot analysis, and 2) Real-Time quantitative PCR. Fast growing H. salinarum cells contain on average about 25 copies of the chromosome in exponential phase, and their ploidy is downregulated to 15 copies in early stationary phase. The chromosome copy number is identical in cultures with a twofold lower growth rate, in contrast to the results reported for several other prokaryotic species. Of three additional replicons of H. salinarum, two have a low copy number that is not growth-phase regulated, while one replicon even shows a higher degree of growth phase-dependent regulation than the main replicon. The genome copy number of H. volcanii is similarly high during exponential phase (on average 18 copies/cell), and it is also downregulated (to 10 copies) as the cells enter stationary phase. The variation of genome copy numbers in the population was addressed by fluorescence microscopy and by FACS analysis. These methods allowed us to verify the growth phase-dependent regulation of ploidy in H. salinarum, and they revealed that there is a wide variation in genome copy numbers in individual cells that is much larger in exponential than in stationary phase. Our results indicate that polyploidy might be more widespread in archaea (or even prokaryotes in general) than previously assumed. Moreover, the presence of so many genome copies in a prokaryote raises questions about the evolutionary significance of this strategy.	[Breuert, Sebastian; Spohn, Gabi; Soppa, Joerg] Goethe Univ Frankfurt, Inst Mol Biosci, Frankfurt, Germany; [Allers, Thorsten] Univ Nottingham, Inst Genet, Queens Med Ctr, Nottingham NG7 2RD, England	Goethe University Frankfurt; University of Nottingham	Soppa, J (corresponding author), Goethe Univ Frankfurt, Inst Mol Biosci, Frankfurt, Germany.	soppa@em.uni-frankfurt.de	Allers, Thorsten/G-5503-2010	Allers, Thorsten/0000-0002-7308-3332; Soppa, Jorg/0000-0002-6132-5840	Deutsche Forschungsgemeinschaft (German Research Council) [So264/7-2]; Royal Society University	Deutsche Forschungsgemeinschaft (German Research Council)(German Research Foundation (DFG)); Royal Society University(Royal Society of London)	This work was supported by the Deutsche Forschungsgemeinschaft (German Research Council) through grant No. So264/7-2 (to JS), and by a Royal Society University Research Fellowship (to TA).	Allers T, 2004, APPL ENVIRON MICROB, V70, P943, DOI 10.1128/AEM.70.2.943-953.2004; BACHMANN BJ, 1996, ESCHERICHIA COLI SAL, P2460; Bernander R, 1997, J BACTERIOL, V179, P4963, DOI 10.1128/jb.179.16.4963-4969.1997; Bitan-Banin G, 2003, J BACTERIOL, V185, P772, DOI 10.1128/JB.185.3.772-778.2003; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bremer H, 1996, ESCHERICHIA COLI SAL; CHANT J, 1986, SYST APPL MICROBIOL, V7, P106, DOI 10.1016/S0723-2020(86)80132-1; CLAVERO MRS, 1994, APPL ENVIRON MICROB, V60, P2069, DOI 10.1128/AEM.60.6.2069-2075.1994; CLINE SW, 1989, J BACTERIOL, V171, P4987, DOI 10.1128/jb.171.9.4987-4991.1989; Comai L, 2005, NAT REV GENET, V6, P836, DOI 10.1038/nrg1711; DALY MJ, 1994, J BACTERIOL, V176, P3508, DOI 10.1128/JB.176.12.3508-3517.1994; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HANSEN MT, 1978, J BACTERIOL, V134, P71, DOI 10.1128/JB.134.1.71-75.1978; Herrmann U, 2002, MOL MICROBIOL, V46, P395, DOI 10.1046/j.1365-2958.2002.03181.x; Hiraoka Y, 2002, APPL ENVIRON MICROB, V68, P5104, DOI 10.1128/AEM.68.10.5104-5112.2002; Hjort K, 1999, J BACTERIOL, V181, P5669, DOI 10.1128/JB.181.18.5669-5675.1999; Khakhlova O, 2006, PLANT J, V46, P85, DOI 10.1111/j.1365-313X.2006.02673.x; KITAYAMA HS, 1981, J BIOCHEM-TOKYO, V90, P877; KITTEN T, 1992, GENETICS, V132, P311; Kottemann M, 2005, EXTREMOPHILES, V9, P219, DOI 10.1007/s00792-005-0437-4; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Liao DQ, 2000, J MOL EVOL, V51, P305, DOI 10.1007/s002390010093; Maisnier-Patin S, 2002, MOL MICROBIOL, V45, P1443, DOI 10.1046/j.1365-2958.2002.03111.x; Majernik AI, 2005, J BACTERIOL, V187, P1856, DOI 10.1128/JB.187.5.1856-1858.2005; Malandrin L, 1999, GENETICS, V152, P1315; MALDONADO R, 1994, J BACTERIOL, V176, P3911, DOI 10.1128/JB.176.13.3911-3919.1994; MALDONADO R, 1992, GENETICS, V132, P869; Ng WV, 2000, P NATL ACAD SCI USA, V97, P12176, DOI 10.1073/pnas.190337797; Peck RF, 2000, MOL MICROBIOL, V35, P667, DOI 10.1046/j.1365-2958.2000.01739.x; POSTGATE JR, 1984, J GEN MICROBIOL, V130, P1597; PUNITA SJ, 1989, J BACTERIOL, V171, P3133, DOI 10.1128/jb.171.6.3133-3138.1989; ROSENSHINE I, 1991, NATO ADV SCI I A-LIF, V201, P265; RUEPP A, 1995, J BACTERIOL, V177, P1129, DOI 10.1128/jb.177.5.1129-1136.1995; Ruepp A, 1996, J BACTERIOL, V178, P4942, DOI 10.1128/jb.178.16.4942-4947.1996; Santoyo G, 2005, FEMS MICROBIOL REV, V29, P169, DOI 10.1016/j.femsre.2004.10.004; SKARSTAD K, 1986, EMBO J, V5, P1711, DOI 10.1002/j.1460-2075.1986.tb04415.x; SOPPA J, 1989, J BIOL CHEM, V264, P13049; Soppa J, 2006, MICROBIOL-SGM, V152, P585, DOI 10.1099/mic.0.28504-0; Soppa J, 1998, J MICROBIOL METH, V34, P41, DOI 10.1016/S0167-7012(98)00067-0; Tobiason DM, 2006, PLOS BIOL, V4, P1069, DOI 10.1371/journal.pbio.0040185; van Gerwen SJC, 1999, J FOOD PROTECT, V62, P1024, DOI 10.4315/0362-028X-62.9.1024; Wang GJ, 2004, J BACTERIOL, V186, P3187, DOI 10.1128/JB.186.10.3187-3194.2004; Webb CD, 1998, MOL MICROBIOL, V28, P883, DOI 10.1046/j.1365-2958.1998.00808.x; Wendel JF, 2000, PLANT MOL BIOL, V42, P225, DOI 10.1023/A:1006392424384; Wolfe KH, 2001, NAT REV GENET, V2, P333, DOI 10.1038/35072009	45	127	131	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e92	10.1371/journal.pone.0000092	http://dx.doi.org/10.1371/journal.pone.0000092			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183724	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600091
J	Nagaoka, M; Koshimizu, U; Yuasa, S; Hattori, F; Chen, H; Tanaka, T; Okabe, M; Fukuda, K; Akaike, T				Nagaoka, Masato; Koshimizu, Uichi; Yuasa, Shinsuke; Hattori, Fumiyuki; Chen, Hao; Tanaka, Tomofumi; Okabe, Masaru; Fukuda, Keiichi; Akaike, Toshihiro			E-Cadherin-Coated Plates Maintain Pluripotent ES Cells without Colony Formation	PLOS ONE			English	Article							EMBRYONIC STEM-CELLS; SELF-RENEWAL; EXPRESSION; DIFFERENTIATION; ADHESION; MAINTENANCE; ACTIVATION; INDUCTION; CULTURE; OCT-3/4	Embryonic stem (ES) cells cultured on gelatin-coated plates or feeder layers form tight aggregated colonies by the E-cadherin-mediated cell-cell adhesions. Here we show that murine ES cells do not make cell-cell contacts or form colonies when cultured on the plate coated with a fusion protein of E-cadherin and IgG Fc domain. The cells in culture retain all ES cell features including pluripotency to differentiate into cells of all three germ layers and germ-line transmission after extended culture. Furthermore, they show a higher proliferative ability, lower dependency on LIF, and higher transfection efficiency than colony-forming conditions. Our results suggest that aggregated colony formation might inhibit diffusion of soluble factors and increase cell-cell communication, which may result in a heterogeneous environment within and between surrounding cells of the colony. This method should enable more efficient and scalable culture of ES cells, an important step towards the clinical application of these cells.	[Nagaoka, Masato; Akaike, Toshihiro] Tokyo Inst Technol, Dept Biomol Engn, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa, Japan; [Koshimizu, Uichi; Hattori, Fumiyuki; Tanaka, Tomofumi] Daiichi Asubio Pharma Co Ltd, Biomed Res Labs, Osaka, Japan; [Yuasa, Shinsuke; Hattori, Fumiyuki; Chen, Hao; Fukuda, Keiichi] Keio Univ, Sch Med, Dept Regenerat Med & Adv Cardiac Therapeut, Tokyo, Japan; [Okabe, Masaru] Osaka Univ, Genome Informat Res Ctr, Osaka, Japan	Tokyo Institute of Technology; Asubio Pharma Co., Ltd.; Keio University; Osaka University	Akaike, T (corresponding author), Tokyo Inst Technol, Dept Biomol Engn, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa, Japan.	takaike@bio.titech.ac.jp	Yuasa, Shinsuke/L-8310-2013; Fukuda, Keiichi/L-3777-2013; Nagaoka, Masato/GRF-5030-2022; Nagaoka, Masato/J-1551-2014; Okabe, Masaru/B-6917-2015	Yuasa, Shinsuke/0000-0001-5593-7552; Okabe, Masaru/0000-0002-0803-9044	21st Century COE Program; Ministry of Education, Culture, Sports, Science and Technology of Japan	21st Century COE Program(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by a Grant of the 21st Century COE Program and a Grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (T. A.).	Amit M, 2004, BIOL REPROD, V70, P837, DOI 10.1095/biolreprod.103.021147; Beattie GM, 2005, STEM CELLS, V23, P489, DOI 10.1634/stemcells.2004-0279; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Cui L, 2004, J HISTOCHEM CYTOCHEM, V52, P1447, DOI 10.1369/jhc.3A6241.2004; Dang SM, 2004, STEM CELLS, V22, P275, DOI 10.1634/stemcells.22-3-275; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Larue L, 1996, DEVELOPMENT, V122, P3185; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nagaoka M, 2003, PROTEIN ENG, V16, P243, DOI 10.1093/proeng/gzg037; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Niewiadomska P, 1999, J CELL BIOL, V144, P533, DOI 10.1083/jcb.144.3.533; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2002, MOL CELL BIOL, V22, P1526, DOI 10.1128/MCB.22.5.1526-1536.2002; Ogawa K, 2004, GENES CELLS, V9, P471, DOI 10.1111/j.1356-9597.2004.00736.x; Ojima T, 2006, AM J PATHOL, V168, P331, DOI 10.2353/ajpath.2006.050435; Orsulic S, 2000, J CELL SCI, V113, P1793; Prudhomme W, 2004, P NATL ACAD SCI USA, V101, P2900, DOI 10.1073/pnas.0308768101; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; ROGERS MB, 1991, DEVELOPMENT, V113, P815; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Schroeder T, 2003, P NATL ACAD SCI USA, V100, P4018, DOI 10.1073/pnas.0438008100; SHIRAYOSHI Y, 1983, CELL, V35, P631, DOI 10.1016/0092-8674(83)90095-8; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X	34	96	103	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e15	10.1371/journal.pone.0000015	http://dx.doi.org/10.1371/journal.pone.0000015			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183641	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600015
J	Montano, MM; Chaplin, LJ; Deng, H; Mesia-Vela, S; Gaikwad, N; Zahid, M; Rogan, E				Montano, M. M.; Chaplin, L. J.; Deng, H.; Mesia-Vela, S.; Gaikwad, N.; Zahid, M.; Rogan, E.			Protective roles of quinone reductase and tamoxifen against estrogen-induced mammary tumorigenesis	ONCOGENE			English	Article						quinone reductase; oxidative damage; estrogen receptor beta; estrogen; antiestrogens; mammary gland	TRANSCRIPTIONAL REGULATION; FUNCTIONAL IMPLICATIONS; F344 RAT; CARCINOGEN; INDUCTION; RECEPTOR; CANCER; DAMAGE; BETA; SUSCEPTIBILITY	We previously reported that antiestrogen-liganded estrogen receptor beta (ER beta) transcriptionally activates the major detoxifying enzyme quinone reductase (QR) (NAD(P)H:quinone oxidoreductase). Further studies on the functional role of ERb-mediated upregulation of antioxidative enzymes indicated protective effects against estrogen induced oxidative DNA damage (ODD). We now report on in vivo and in vitro studies that show that ER beta-mediated upregulation of QR are involved in the protection against estrogen-induced mammary tumorigenesis. Using the August Copenhagen Irish (ACI) model of estrogen-induced carcinogenesis, we observed that increased ODD and decreased QR expression occur early in the process of estrogen-induced mammary tumorigenesis. Prevention of ACI mammary gland tumorigenesis by tamoxifen was accompanied by decreased ODD and increased QR levels. These correlative findings were supported by our findings that down regulation of QR levels led to increased levels of estrogen quinone metabolites and enhanced transformation potential of 17 beta-estradiol treated MCF10A non-tumorigenic breast epithelial cells. Concurrent expression of ER beta and treatment with 4-hydroxytamoxifen decreased tumorigenic potential of these MCF10A cells. We conclude that upregulation of QR, through induction by tamoxifen, can inhibit estrogen-induced ODD and mammary cell tumorigenesis, representing a possible novel mechanism of tamoxifen prevention against breast cancer.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Columbia Univ, Med Ctr, Emphysema & Canc Act Program, New York, NY USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68182 USA	Case Western Reserve University; Columbia University; University of Nebraska System; University of Nebraska Medical Center	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg Room W367,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@po.cwru.edu		zahid, Muhammad/0000-0002-9975-9476	NCI NIH HHS [CA92440, CA80959, P01 CA49210] Funding Source: Medline; NIEHS NIH HHS [ES05022] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092440, P01CA049210] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ansell PJ, 2004, ENDOCRINOLOGY, V145, P311, DOI 10.1210/en.2003-0817; Bianco NR, 2003, MOL ENDOCRINOL, V17, P1344, DOI 10.1210/me.2002-0382; Dawson PJ, 1996, AM J PATHOL, V148, P313; Guo M, 2001, BIOCHEM PHARMACOL, V62, P1449, DOI 10.1016/S0006-2952(01)00801-2; Harvell DME, 2000, P NATL ACAD SCI USA, V97, P2779, DOI 10.1073/pnas.050569097; Helbock HJ, 1999, METHOD ENZYMOL, V300, P156; Jefcoate C R, 2000, J Natl Cancer Inst Monogr, P95; Jones SB, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-62; Kassie F, 2003, CARCINOGENESIS, V24, P255, DOI 10.1093/carcin/24.2.255; Li JJ, 2002, MOL CARCINOGEN, V33, P56, DOI 10.1002/mc.10022; Li SA, 2002, J ENDOCRINOL, V175, P297, DOI 10.1677/joe.0.1750297; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Matusheski NV, 2001, J AGR FOOD CHEM, V49, P5743, DOI 10.1021/jf010809a; Montano MM, 2004, ONCOGENE, V23, P2442, DOI 10.1038/sj.onc.1207358; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Rogan EG, 2003, CARCINOGENESIS, V24, P697, DOI 10.1093/carcin/bgg004; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Thomas RD, 2006, CHEM-BIOL INTERACT, V160, P204, DOI 10.1016/j.cbi.2006.01.007	19	36	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3587	3590		10.1038/sj.onc.1210144	http://dx.doi.org/10.1038/sj.onc.1210144			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160017				2022-12-25	WOS:000246799200015
J	Prost, S; Lu, P; Caldwell, H; Harrison, D				Prost, S.; Lu, P.; Caldwell, H.; Harrison, D.			E2F regulates DDB2: consequences for DNA repair in Rb-deficient cells	ONCOGENE			English	Article						DDB2; retinoblastoma; E2F; transcription factor; hepatocytes; DNA repair	NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; BINDING-PROTEIN; IN-VIVO; TRANSCRIPTION FACTORS; UV-IRRADIATION; GENE-PRODUCT; MOUSE CELLS; WILD-TYPE; P53	DDB2, a gene mutated in XPE patients, is involved in global genomic repair especially the repair of cyclobutane pyrimidine dimers (CPDs), and is regulated by p53 in human cells. We show that DDB2 is expressed in mouse tissues and demonstrate, using primary mouse epithelial cells, that mouse DDB2 is regulated by E2F transcription factors. Retinoblastoma (Rb), a tumor suppressor critical for the control of cell cycle progression, regulates E2F activity. Using Cre-Lox technology to delete Rb in primary mouse hepatocytes, we show that DDB2 gene expression increases, leading to elevated DDB2 protein levels. Furthermore, we show that endogenous E2F1 and E2F3 bind to DDB2 promoter and that treatment with E2F1-antisense or E2F1-small interfering RNA (siRNA) decreases DDB2 transcription, demonstrating that E2F1 is a transcriptional regulator for DDB2. This has consequences for global genomic repair: in Rb-null cells, where E2F activity is elevated, global DNA repair is increased and removal of CPDs is more efficient than in wild-type cells. Treatment with DDB2-siRNA decreases DDB2 expression and abolishes the repair phenotype of Rb-null cells. In summary, these results identify a new regulatory pathway for DDB2 by E2F, which does not require but is potentiated by p53, and demonstrate that DDB2 is involved in global repair in mouse epithelial cells.	Univ Edinburgh, Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland	University of Edinburgh	Prost, S (corresponding author), Univ Edinburgh, Queens Med Res Inst, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	s.prost@ed.ac.uk		harrison, david/0000-0001-9041-9988; prost, sandrine/0000-0002-0140-7115	Medical Research Council [G9900991B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Adimoolam S, 2003, DNA REPAIR, V2, P947, DOI 10.1016/S1568-7864(03)00087-9; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Berton TR, 2005, ONCOGENE, V24, P2449, DOI 10.1038/sj.onc.1208462; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fitch ME, 2003, J BIOL CHEM, V278, P46906, DOI 10.1074/jbc.M307254200; Fitch ME, 2003, CARCINOGENESIS, V24, P843, DOI 10.1093/carcin/bgg031; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P283; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; Lin GY, 1998, VIROLOGY, V249, P189, DOI 10.1006/viro.1998.9317; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nicholson T, 2001, BMC Cardiovasc Disord, V1, P2, DOI 10.1186/1471-2261-1-2; Nishiwaki Y, 2004, J INVEST DERMATOL, V122, P526, DOI 10.1046/j.0022-202X.2004.22226.x; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Prost S, 1998, FASEB J, V12, P181, DOI 10.1096/fasebj.12.2.181; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Prost S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e80; PURDIE CA, 1994, ONCOGENE, V9, P603; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Sheahan S, 2004, ONCOGENE, V23, P1489, DOI 10.1038/sj.onc.1207280; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Stevceva L, 2004, CURR HIV RES, V2, P1, DOI 10.2174/1570162043485004; Takahashi Y, 2000, GENE DEV, V14, P804; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tang J, 2002, DNA REPAIR, V1, P601, DOI 10.1016/S1568-7864(02)00052-6; Vooijs M, 2002, ONCOGENE, V21, P4635, DOI 10.1038/sj.onc.1205575; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Wang QE, 2004, CARCINOGENESIS, V25, P1033, DOI 10.1093/carcin/bgh085; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492; Zolezzi F, 2000, GENE, V245, P151, DOI 10.1016/S0378-1119(00)00022-6	37	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3572	3581		10.1038/sj.onc.1210151	http://dx.doi.org/10.1038/sj.onc.1210151			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17173070				2022-12-25	WOS:000246799200013
J	Schiffer, NW; Broadley, SA; Hirschberger, T; Tavan, P; Kretzschmar, HA; Giese, A; Haass, C; Hartl, FU; Schmid, B				Schiffer, Niclas W.; Broadley, Sarah A.; Hirschberger, Thomas; Tavan, Paul; Kretzschmar, Hans A.; Giese, Armin; Haass, Christian; Hartl, F. Ulrich; Schmid, Bettina			Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; HUNTINGTONS-DISEASE; MUTANT HUNTINGTIN; IN-VIVO; MOLECULAR-DYNAMICS; DRUG DISCOVERY; BODY FORMATION; TOXICITY; THERAPEUTICS; DISORDERS	Several neurodegenerative diseases, including Huntington disease (HD), are associated with aberrant folding and aggregation of polyglutamine (polyQ expansion proteins. Here we established the zebrafish, Danio rerio, as a vertebrate HD model permitting the screening for chemical suppressors of polyQ aggregation and toxicity. Upon expression in zebrafish embryos, polyQ-expanded fragments of huntingtin (htt) accumulated in large SDS-insoluble inclusions, reproducing a key feature of HD pathology. Real time monitoring of inclusion formation in the living zebrafish indicated that inclusions grow by rapid incorporation of soluble htt species. Expression of mutant htt increased the frequency of embryos with abnormal morphology and the occurrence of apoptosis. Strikingly, apoptotic cells were largely devoid of visible aggregates, suggesting that soluble oligomeric precursors may instead be responsible for toxicity. As in nonvertebrate polyQ disease models, the molecular chaperones, Hsp40 and Hsp70, suppressed both polyQ aggregation and toxicity. Using the newly established zebrafish model, two compounds of the N'-benzylidene-benzohydrazide class directed against mammalian prion proved to be potent inhibitors of polyQ aggregation, consistent with a common structural mechanism of aggregation for prion and polyQ disease proteins.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Univ Munich, Ctr Neuropathol & Prion Res, D-80336 Munich, Germany; Univ Munich, Chair BioMol Opt, Dept Phys, D-80538 Munich, Germany	Max Planck Society; University of Munich; University of Munich; University of Munich	Hartl, FU (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Am Klopferspitz 18, D-82152 Martinsried, Germany.	uhartl@biochem.mpg.de; Bettina.Schmid@med.uni-muenchen.de	Giese, Armin/F-3271-2010; Hartl, F. Ulrich/Y-8206-2019	Giese, Armin/0000-0002-8238-4102; 				Aguzzi A, 2003, SCIENCE, V302, P814, DOI 10.1126/science.1087348; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Barral JM, 2004, SEMIN CELL DEV BIOL, V15, P17, DOI 10.1016/j.semcdb.2003.12.010; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; Bertsch U, 2005, J VIROL, V79, P7785, DOI 10.1128/JVI.79.12.7785-7791.2005; Bezprozvanny I, 2004, BIOCHEM BIOPH RES CO, V322, P1310, DOI 10.1016/j.bbrc.2004.08.035; Blader P, 1998, NATURE, V395, P112, DOI 10.1038/25836; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Creton R, 2004, DEV BRAIN RES, V151, P33, DOI 10.1016/j.devbrainres.2004.03.016; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DEWAR MJS, 1977, J AM CHEM SOC, V99, P4899, DOI 10.1021/ja00457a004; Di Prospero NA, 2005, NAT REV GENET, V6, P756, DOI 10.1038/nrg1690; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Evans TG, 2005, CELL STRESS CHAPERON, V10, P66, DOI 10.1379/CSC-79R.1; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Hazeki N, 2000, BIOCHEM BIOPH RES CO, V277, P386, DOI 10.1006/bbrc.2000.3682; Heiser V, 2002, P NATL ACAD SCI USA, V99, P16400, DOI 10.1073/pnas.182426599; Hockly E, 2006, NEUROBIOL DIS, V21, P228, DOI 10.1016/j.nbd.2005.07.007; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Karlovich CA, 1998, GENE, V217, P117, DOI 10.1016/S0378-1119(98)00342-4; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; Meriin AB, 2002, J CELL BIOL, V157, P997, DOI 10.1083/jcb.200112104; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; Nelson R, 2006, CURR OPIN STRUC BIOL, V16, P260, DOI 10.1016/j.sbi.2006.03.007; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Ross CA, 2005, NAT REV MOL CELL BIO, V6, P891, DOI 10.1038/nrm1742; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Stork M, 2005, BIOPHYS J, V88, P2442, DOI 10.1529/biophysj.104.052415; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang WF, 2005, NEUROBIOL DIS, V20, P500, DOI 10.1016/j.nbd.2005.03.026; Zon LI, 2005, NAT REV DRUG DISCOV, V4, P35, DOI 10.1038/nrd1606	37	79	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9195	9203		10.1074/jbc.M607865200	http://dx.doi.org/10.1074/jbc.M607865200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17170113	hybrid			2022-12-25	WOS:000245780300066
J	Grobler, JA; Dornadula, G; Rice, MR; Simcoe, AL; Hazuda, DJ; Miller, MD				Grobler, Jay A.; Dornadula, Geetha; Rice, Michele R.; Simcoe, Amy L.; Hazuda, Daria J.; Miller, Michael D.			HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(+)-STRAND DNA-SYNTHESIS; RIBONUCLEASE-H; MECHANISM; COMPLEX; ACID	Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are highly specific and potent allosteric inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. NNRTIs inhibit reverse transcription in a substrate length-dependent manner in biochemical assays and in cell-based HIV-1 replication assays, suggesting a stochastic inhibitory mechanism. Surprisingly, we observed that NNRTIs potently inhibited plus-strand initiation in vitro under conditions in which little or no inhibition of minus-strand DNA synthesis was observed. In assays that recapitulated the initiation of plus-strand DNA synthesis, greater inhibition was observed with an RNA PPT primer than with a DNA primer of corresponding sequence and with wild-type reverse transcriptase but not with NNRTI-resistant enzymes. Structural elements that dictate sensitivity to NNRTIs were revealed using modified plus-strand initiation substrates. The data presented here suggest that specific inhibition of plus-strand initiation may be an important mechanism by which NNRTIs block HIV-1 replication.	Merck Res Labs, Dept Antiviral Res, West Point, PA 19486 USA	Merck & Company	Grobler, JA (corresponding author), Merck Res Labs, Dept Antiviral Res, POB 4,WP26A-3000, West Point, PA 19486 USA.	jay_grobler@merck.com						CARROLL SS, 1993, J BIOL CHEM, V268, P276; DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOPALAKRISHNAN V, 1994, J BIOL CHEM, V269, P4110; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; Gotte M, 2001, J BIOL CHEM, V276, P6711, DOI 10.1074/jbc.M009097200; KOHISTAEDT LA, 1992, SCIENCE, V256, P1783; Kvaratskhelia M, 2002, J BIOL CHEM, V277, P16689, DOI 10.1074/jbc.M109914200; Palaniappan C, 1998, J BIOL CHEM, V273, P3808, DOI 10.1074/jbc.273.7.3808; PALANIAPPAN C, 1995, J BIOL CHEM, V270, P4861, DOI 10.1074/jbc.270.9.4861; Quan YD, 1999, J VIROL, V73, P6700, DOI 10.1128/JVI.73.8.6700-6707.1999; Quan YD, 1998, NUCLEIC ACIDS RES, V26, P5692, DOI 10.1093/nar/26.24.5692; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Shaw-Reid CA, 2005, BIOCHEMISTRY-US, V44, P1595, DOI 10.1021/bi0486740; Shaw-Reid CA, 2003, J BIOL CHEM, V278, P2777, DOI 10.1074/jbc.C200621200; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Telesnitsky A., 1997, P121	20	101	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8005	8010		10.1074/jbc.M608274200	http://dx.doi.org/10.1074/jbc.M608274200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17172472	hybrid			2022-12-25	WOS:000245081000031
J	Crepaldi, T; Bersani, F; Scuoppo, C; Accornero, P; Prunotto, C; Taulli, R; Forni, PE; Leo, C; Chiarle, R; Griffiths, J; Glass, DJ; Ponzetto, C				Crepaldi, Tiziana; Bersani, Francesca; Scuoppo, Claudio; Accornero, Paolo; Prunotto, Chiara; Taulli, Riccardo; Forni, Paolo E.; Leo, Christian; Chiarle, Roberto; Griffiths, Jennifer; Glass, David J.; Ponzetto, Carola			Conditional activation of MET in differentiated skeletal muscle induces atrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; GENE-EXPRESSION; UBIQUITIN LIGASES; AUTOCRINE LOOP; P38 MAPK; IN-VIVO; KAPPA-B; RECEPTOR; MICE; TRANSFORMATION	Skeletal muscle atrophy is a common debilitating feature of many systemic diseases, including cancer. Here we examined the effects of inducing expression of an oncogenic version of the Met receptor (Tpr-Met) in terminally differentiated skeletal muscle. A responder mouse containing the Tpr-Met oncogene and GFP (green fluorescent protein) as a reporter was crossed with a transactivator mouse expressing tTA under the control of the muscle creatine kinase promoter. Tpr-Met induction during fetal development and in young adult mice caused severe muscle wasting, with decreased fiber size and loss of myosin heavy chain protein. Concomitantly, in the Tpr-Met-expressing muscle the mRNA of the E3 ubiquitin ligases atrogin-1/MAFbx, MuRF1, and of the lysosomal protease cathepsin L, which are markers of skeletal muscle atrophy, was significantly increased. In the same muscles phosphorylation of the Met downstream effectors Akt, p38 MAPK, and I kappa B alpha was higher than in normal controls. Induction of Tpr-Met in differentiating satellite cells derived from the double transgenics caused aberrant cell fusion, protein loss, and myotube collapse. Increased phosphorylation of Met downstream effectors was also observed in the Tpr-Met-expressing myotubes cultures. Treatment of these cultures with either a proteasomal or a p38 inhibitor prevented Tpr-Met-mediated myotube breakdown, establishing accelerated protein degradation consequent to inappropriate activation of p38 as the major route for the Tpr-Met-induced muscle phenotype.	Univ Turin, Dept Anat Pharmacol & Forens Med, I-10126 Turin, Italy; Univ Turin, Dept Biomed Sci & Oncol, I-10126 Turin, Italy; Univ Turin, Ctr Expt Res & Med Studies, I-10126 Turin, Italy; Regeneron Pharmaceut Inc, Muscle Program, Tarrytown, NY 10591 USA	University of Turin; University of Turin; University of Turin; Regeneron	Crepaldi, T (corresponding author), Univ Turin, Dept Anat Pharmacol & Forens Med, Corso M DAzeglio 52, I-10126 Turin, Italy.	tiziana.crepaldi@unito.it	crepaldi, tiziana/AAY-7207-2020; Accornero, Paolo/B-1396-2008; TAULLI, Riccardo/J-7347-2018; Glass, David/AAI-3910-2021; FORNI, PAOLO/C-3533-2011; Glass, David/C-4782-2012	crepaldi, tiziana/0000-0003-3410-947X; TAULLI, Riccardo/0000-0003-1277-6263; Bersani, Francesca/0000-0002-0343-7078; Glass, David/0000-0001-6187-4164; Forni, Paolo E./0000-0001-6547-3464; CHIARLE, Roberto/0000-0003-1564-8531	Telethon [D.095] Funding Source: Medline	Telethon(Fondazione Telethon)		Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Argiles JM, 1999, MED RES REV, V19, P223, DOI 10.1002/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO;2-N; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Bechet D, 2005, INT J BIOCHEM CELL B, V37, P2098, DOI 10.1016/j.biocel.2005.02.029; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bischoff R, 1997, DEV DYNAM, V208, P505, DOI 10.1002/(SICI)1097-0177(199704)208:4<505::AID-AJA6>3.0.CO;2-M; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Di Giovanni S, 2004, ANN NEUROL, V55, P195, DOI 10.1002/ana.10811; Gal-Levi R, 1998, BBA-MOL CELL RES, V1402, P39, DOI 10.1016/S0167-4889(97)00124-9; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Halevy O, 2004, EXP CELL RES, V297, P224, DOI 10.1016/j.yexcr.2004.03.024; Jackman RW, 2004, AM J PHYSIOL-CELL PH, V287, pC834, DOI 10.1152/ajpcell.00579.2003; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Lai KMV, 2004, MOL CELL BIOL, V24, P9295, DOI 10.1128/MCB.24.21.9295-9304.2004; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Leshem Y, 2000, J CELL PHYSIOL, V184, P101, DOI 10.1002/(SICI)1097-4652(200007)184:1<101::AID-JCP11>3.0.CO;2-D; Li YP, 2005, FASEB J, V19, P362, DOI 10.1096/fj.04-2364com; LYONS GE, 1991, DEVELOPMENT, V113, P1017; Madhavan R, 2005, IUBMB LIFE, V57, P719, DOI 10.1080/15216540500338739; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Matsumoto T, 1999, BRIT J CANCER, V79, P764, DOI 10.1038/sj.bjc.6690123; Miller KJ, 2000, AM J PHYSIOL-CELL PH, V278, pC174, DOI 10.1152/ajpcell.2000.278.1.C174; Muller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Nagaraju K, 2000, P NATL ACAD SCI USA, V97, P9209, DOI 10.1073/pnas.97.16.9209; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prunotto C, 2004, DEV DYNAM, V231, P582, DOI 10.1002/dvdy.20177; Relaix F, 2003, GENE DEV, V17, P2950, DOI 10.1101/gad.281203; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tatsumi R, 2004, MUSCLE NERVE, V30, P654, DOI 10.1002/mus.20114; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; Taulli R, 2005, CANCER GENE THER, V12, P456, DOI 10.1038/sj.cgt.7700815; Taulli R, 2006, CANCER RES, V66, P4742, DOI 10.1158/0008-5472.CAN-05-4292; Vigna E, 2002, MOL THER, V5, P252, DOI 10.1006/mthe.2002.0542; Vigna E, 1999, ONCOGENE, V18, P4275, DOI 10.1038/sj.onc.1202791; Weston AD, 2003, J CELL SCI, V116, P2885, DOI 10.1242/jcs.00525; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000	56	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6812	6822		10.1074/jbc.M610916200	http://dx.doi.org/10.1074/jbc.M610916200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17194700	hybrid			2022-12-25	WOS:000244867200091
J	Shureiqi, I; Zuo, XS; Broaddus, R; Wu, Y; Guan, BX; Morris, JS; Lippman, SM				Shureiqi, Imad; Zuo, Xiangsheng; Broaddus, Russell; Wu, Yuanqing; Guan, Baoxiang; Morris, Jeffrey S.; Lippman, Scott M.			The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer	FASEB JOURNAL			English	Article						transcriptional regulation; apoptosis	CARCINOMA CELL-LINE; 15-LIPOXYGENASE-1 EXPRESSION; INDUCED APOPTOSIS; DIFFERENTIATION; ACTIVATION; INHIBITOR; CELECOXIB; CACO-2; GENES	Transcriptional suppression of 15-lipoxygenase (LOX)-1 (15-LOX-1) helps enable human colorectal cancer cells escape apoptosis, a critical mechanism for colonic tumorigenesis. GATA-6 is strongly expressed in vitro in cancer cells; its down-regulation by pharmaceuticals is associated with reversal of 15-LOX-1 transcriptional suppression. The mechanistic contribution of GATA-6 overexpression to colonic tumorigenesis, especially concerning 15-LOX-1 transcriptional suppression, remains unknown. We tested whether GATA-6 is differentially overexpressed in human colorectal cancers and whether reversing GATA-6 overexpression in colon cancer cells is sufficient to restore 15-LOX-1 expression and influence cell proliferation or apoptosis. The expression of GATA-6 RNA and protein was measured in paired human colorectal cancer and normal tissues from two separate patient groups. We used GATA-6 small interfering RNA transfection to down-regulate GATA-6 expression and examine the effects of this down-regulation on 15-LOX-1 expression, cell proliferation, and apoptosis in Caco-2 and HCT-116 colon cancer cells with and without the nonsteroidal antiinflammatory drug NS-398 or the histone deacetylase inhibitor sodium butyrate. GATA-6 mRNA and protein expressions were higher in cancer than normal epithelia of the colon. GATA-6 knockdown was insufficient by itself but contributed significantly to restoring 15-LOX-1 expression and inducing apoptosis by NS-398 or sodium butyrate. Maintaining 15-LOX-1 transcriptional silencing in cancer cells is a multifactorial process involving GATA-6 overexpression and other regulatory events.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Shureiqi, I (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, 1515 Holocombe Blvd, Houston, TX 77030 USA.	ishureiqi@mdanderson.org	Shureiqi, imad/T-6214-2019	Shureiqi, Imad/0000-0003-2019-938X; Zuo, Xiangsheng/0000-0002-8593-1132	NATIONAL CANCER INSTITUTE [R01CA106577] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Al-azzeh ED, 2000, BBA-GENE STRUCT EXPR, V1490, P324, DOI 10.1016/S0167-4781(00)00013-0; Conrad DJ, 2000, AM J RESP CELL MOL, V22, P226, DOI 10.1165/ajrcmb.22.2.3786; Deguchi A, 2005, CANCER RES, V65, P8442, DOI 10.1158/0008-5472.CAN-05-1109; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Grullich C, 2001, FEBS LETT, V489, P51, DOI 10.1016/S0014-5793(01)02080-4; Guo MZ, 2004, CLIN CANCER RES, V10, P7917, DOI 10.1158/1078-0432.CCR-04-1140; Hawk ET, 2005, J CLIN ONCOL, V23, P378, DOI 10.1200/JCO.2005.08.097; Heslin MJ, 2005, ANN SURG, V241, P941, DOI 10.1097/01.sla.0000164177.95620.c1; Hill EM, 1998, AM J RESP CELL MOL, V18, P662, DOI 10.1165/ajrcmb.18.5.2985; Hsi LC, 2005, MOL CANCER THER, V4, P1740, DOI 10.1158/1535-7163.MCT-05-0218; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; Kamitani H, 2000, FEBS LETT, V467, P341, DOI 10.1016/S0014-5793(00)01155-8; Kelly WK, 2005, NAT CLIN PRACT ONCOL, V2, P150, DOI 10.1038/ncponc0106; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morrison B, 1998, SWINE HEALTH PROD, V6, P4; Nixon JB, 2004, PROSTAG LEUKOTR ESS, V70, P7, DOI 10.1016/j.plefa.2003.06.001; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PINTO M, 1983, BIOL CELL, V47, P323; RAMITANI H, 2001, CARCINOGENESIS, V22, P187; Shankaranarayanan P, 2001, J BIOL CHEM, V276, P42753, DOI 10.1074/jbc.M102626200; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Shureiqi I, 1999, CARCINOGENESIS, V20, P1985, DOI 10.1093/carcin/20.10.1985; Shureiqi I, 2005, CANCER RES, V65, P11486, DOI 10.1158/0008-5472.CAN-05-2180; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Shureiqi I, 2002, CANCER RES, V62, P1178; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Yu JS, 2003, CANCER RES, V63, P6170; Zuo X, 2006, ONCOGENE, V25, P1225, DOI 10.1038/sj.onc.1209160	32	49	51	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					743	753		10.1096/fj.06-6830com	http://dx.doi.org/10.1096/fj.06-6830com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17167069	Green Accepted			2022-12-25	WOS:000244686400013
J	Chan, JYH; Cheng, HL; Chou, JLJ; Li, FCH; Dai, KY; Chan, SHH; Chang, AYW				Chan, Julie Y. H.; Cheng, Hsiao-Lei; Chou, Jimmy L. J.; Li, Faith C. H.; Dai, Kuang-Yu; Chan, Samuel H. H.; Chang, Alice Y. W.			Heat shock protein 60 or 70 activates nitric-oxide synthase (NOS) I- and inhibits NOSII-associated signaling and depresses the mitochondrial apoptotic cascade during brain stem death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROSTRAL VENTROLATERAL MEDULLA; SYSTEMIC ARTERIAL-PRESSURE; HEAT-SHOCK PROTEINS; ACUTE MEVINPHOS INTOXICATION; KAPPA-B ACTIVATION; CARDIOVASCULAR-RESPONSES; MESSENGER-RNA; GLUTAMATERGIC TRANSMISSION; NEURONAL APOPTOSIS; SPECTRAL-ANALYSIS	The cellular and molecular basis of brain stem death remains an enigma. As the origin of a "life-and-death" signal that reflects the progression toward brain stem death, the rostral ventrolateral medulla (RVLM) is a suitable neural substrate for mechanistic delineation of this phenomenon. Here, we evaluated the hypothesis that heat shock proteins (HSPs) play a neuroprotective role in the RVLM during brain stem death and delineated the underlying mechanisms, using a clinically relevant animal model that employed the organophosphate pesticide mev-inphos (Mev) as the experimental insult. In Sprague-Dawley rats, proteomic, Western blot, and real-time PCR analyses demonstrated that Mev induced de novo synthesis of HSP60 or HSP70 in the RVLM without affecting HSP90 level. Loss-of-function manipulations of HSP60 or HSP70 in the RVLM using antiserum or antisense oligonucleotide potentiated Mev-elicited cardiovascular depression alongside reduced nitric-oxide synthase (NOS) I/protein kinase G signaling, enhanced NOS II/peroxynitrite cascade, intensified nucleosomal DNA fragmentation, elevated cytoplasmic histone-associated DNA fragments or activated caspase-3, and augmented the cytochrome c/caspase-3 cascade of apoptotic signaling in the RVLM. Co-immunoprecipitation experiments further revealed a progressive increase in the complex formed between HSP60 and mitochondrial or cytosolic Bax or mitochondrial Bcl-2 during Mev intoxication, alongside a dissociation of the cytosolic HSP60-Bcl-2 complex. We conclude that HSP60 and HSP70 confer neuroprotection against Mev intoxication by ameliorating cardiovascular depression via an anti-apoptotic action in the RVLM. The possible underlying intracellular processes include enhancing NOS I/protein kinase G signaling and inhibiting the NOS II/peroxynitrite cascade. In addition, HSP60 exerts its effects against apoptosis by blunting Mev-induced activation of the Bax/cytochrome c/caspase-3 cascade.	Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung 80424, Taiwan; Kaohsiung Vet Gen hosp, Dept Med Educ & Res, Kaohsiung 81346, Taiwan; Natl Cheng Kung Univ, Ctr Gene Regulat & Signal Transduct Res, Tainan 70101, Taiwan	National Sun Yat Sen University; Kaohsiung Veterans General Hospital; National Cheng Kung University	Chang, AYW (corresponding author), Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung 80424, Taiwan.	achang@mail.nsysu.edu.tw	Chan, Julie/X-5253-2019					BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bulut Y, 2002, J IMMUNOL, V168, P1435, DOI 10.4049/jimmunol.168.3.1435; Chan JYH, 2005, PROG NEUROBIOL, V77, P396, DOI 10.1016/j.pneurobio.2005.11.004; Chan JYH, 2005, NEUROPHARMACOLOGY, V48, P161, DOI 10.1016/j.neuropharm.2004.08.012; Chan JYH, 2004, CIRCULATION, V110, P3560, DOI 10.1161/01.CIR.0000143082.63063.33; Chan JYH, 2004, NEUROPHARMACOLOGY, V46, P1184, DOI 10.1016/j.neuropharm.2004.01.017; Chan SHH, 2005, CIRC RES, V97, P772, DOI 10.1161/01.RES.0000185804.79157.C0; Chan SHH, 2005, FREE RADICAL BIO MED, V39, P603, DOI 10.1016/j.freeradbiomed.2005.04.012; Chan SHH, 2001, BRIT J PHARMACOL, V133, P606, DOI 10.1038/sj.bjp.0704105; Chang AYW, 2003, J BIOMED SCI, V10, P285, DOI 10.1159/000070093; Ciani E, 2002, J BIOL CHEM, V277, P49896, DOI 10.1074/jbc.M206177200; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; CORRERAS MC, 2004, MOL ASPECTS MED, V25, P125; Deans Z, 1996, J BIOL CHEM, V271, P32153, DOI 10.1074/jbc.271.50.32153; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; Emrich Thomas, 2002, Methods Mol Biol, V191, P99; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; Fernando LP, 2000, SHOCK, V14, P128, DOI 10.1097/00024382-200014020-00009; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Flohe SB, 2003, J IMMUNOL, V170, P2340, DOI 10.4049/jimmunol.170.5.2340; GENG Y, 1992, CIRC RES, V71, P1268, DOI 10.1161/01.RES.71.5.1268; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Gupta RC, 2001, ARCH TOXICOL, V75, P346, DOI 10.1007/s002040100249; Hauser GJ, 1996, AM J PHYSIOL-HEART C, V271, pH2529, DOI 10.1152/ajpheart.1996.271.6.H2529; Hirvonen MR, 1996, BIOCHEM J, V315, P845, DOI 10.1042/bj3150845; Hou Q, 2005, AM J PHYSIOL-HEART C, V289, pH477, DOI 10.1152/ajpheart.00879.2004; Huang CC, 2004, MOL PHARMACOL, V66, P492, DOI 10.1124/mol.104.000554; Huang CC, 2003, MOL PHARMACOL, V64, P521, DOI 10.1124/mol.64.2.521; Huang YH, 2002, PROTEOMICS, V2, P1220, DOI 10.1002/1615-9861(200209)2:9<1220::AID-PROT1220>3.0.CO;2-3; HUNG TP, 1995, J NEUROL NEUROSUR PS, V58, P75, DOI 10.1136/jnnp.58.1.75; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Kaetsu A, 2001, J APPL TOXICOL, V21, P425, DOI 10.1002/jat.774; Kirchhoff SR, 2002, CIRCULATION, V105, P2899, DOI 10.1161/01.CIR.0000019403.35847.23; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kuo TBJ, 1997, AM J PHYSIOL-HEART C, V272, pH485, DOI 10.1152/ajpheart.1997.272.1.H485; Kuo TBJ, 1997, AM J PHYSIOL-HEART C, V273, pH1291, DOI 10.1152/ajpheart.1997.273.3.H1291; Li FCH, 2005, MOL PHARMACOL, V68, P179, DOI 10.1124/mol.105.011684; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Lossi L, 2003, PROG NEUROBIOL, V69, P287, DOI 10.1016/S0301-0082(03)00051-0; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; Martinus RD, 1996, EUR J BIOCHEM, V240, P98, DOI 10.1111/j.1432-1033.1996.0098h.x; Meldrum KK, 2003, CIRC RES, V92, P293, DOI 10.1161/01.RES.0000057754.35180.99; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Oksala N, 2004, EUR SURG RES, V36, P67, DOI 10.1159/000076645; Pallis CA, 1983, ABC BRAIN STEM DEATH; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; PODCROSO JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85; Ramachandran A, 2002, FREE RADICAL BIO MED, V33, P1465, DOI 10.1016/S0891-5849(02)01142-5; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; Robertson JD, 1999, BIOCHEM J, V344, P477, DOI 10.1042/0264-6021:3440477; ROSS CA, 1984, J NEUROSCI, V4, P474; Ryan MT, 1997, GENE, V196, P9, DOI 10.1016/S0378-1119(97)00111-X; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Saur D, 2002, J BIOL CHEM, V277, P25798, DOI 10.1074/jbc.M109802200; Shan YX, 2003, J MOL CELL CARDIOL, V35, P1135, DOI 10.1016/S0022-2828(03)00229-3; Soltys BJ, 1996, EXP CELL RES, V222, P16, DOI 10.1006/excr.1996.0003; Szabo C, 1996, EUR J PHARMACOL, V315, P221, DOI 10.1016/S0014-2999(96)00628-0; Thippeswamy T, 2001, EUR J NEUROSCI, V14, P1229, DOI 10.1046/j.0953-816x.2001.01752.x; Todryk SM, 2000, IMMUNOLOGY, V99, P334, DOI 10.1046/j.1365-2567.2000.00002.x; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21, DOI 10.1615/CritRevNeurobiol.v13.i1.20; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Wu KLH, 2003, NEUROBIOL DIS, V14, P19, DOI 10.1016/S0969-9961(03)00078-0; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Yang CH, 1995, J PHARMACOL EXP THER, V275, P1568; Yen DHT, 2004, SHOCK, V21, P358, DOI 10.1097/00024382-200404000-00011; Yen DHT, 2001, SHOCK, V15, P35, DOI 10.1097/00024382-200115010-00006; Yen DHT, 2000, CRIT CARE MED, V28, P2805, DOI 10.1097/00003246-200008000-00021; Yien HW, 1997, CRIT CARE MED, V25, P258, DOI 10.1097/00003246-199702000-00011; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445; Zucchi I, 2002, P NATL ACAD SCI USA, V99, P8660, DOI 10.1073/pnas.132259399	75	58	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4585	4600		10.1074/jbc.M603394200	http://dx.doi.org/10.1074/jbc.M603394200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17150954	hybrid			2022-12-25	WOS:000244482000040
J	Debrincat, MA; Zhang, JG; Willson, TA; Silke, J; Connolly, LM; Simpson, RJ; Alexander, WS; Nicola, NA; Kile, BT; Hilton, DJ				Debrincat, Marlyse A.; Zhang, Jian-Guo; Willson, Tracy A.; Silke, John; Connolly, Lisa M.; Simpson, Richard J.; Alexander, Warren S.; Nicola, Nicos A.; Kile, Benjamin T.; Hilton, Douglas J.			Ankyrin repeat and suppressors of cytokine signaling box protein Asb-9 targets creatine kinase B for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOCS-BOX; ENERGY HOMEOSTASIS; MASS-SPECTROMETRY; UBIQUITIN LIGASE; IN-VIVO; GENE; CELLS; IDENTIFICATION; INHIBITION; LEUKEMIA	The suppressors of cytokine signaling (SOCS) proteins inhibit cytokine action by direct interaction with Janus kinases or activated cytokine receptors. In addition to the N-terminal and Src homology 2 domains that mediate these interactions, SOCS proteins contain a C-terminal SOCS box. DNA data base searches have identified a number of other protein families that possess a SOCS box, of which the ankyrin repeat and SOCS box-containing (Asb) proteins constitute the largest. Although it is known that the SOCS proteins are involved in the negative regulation of cytokine signaling, the biological and biochemical functions of the Asbs are largely undefined. Using a proteomics approach, we demonstrate that creatine kinase B (CKB) interacts with Asb-9 in a specific, SOCS box-independent manner. This interaction increases the polyubiquitylation of CKB and decreases total CKB levels within the cell. The targeting of CKB for degradation by Asb-9 was primarily SOCS box-dependent and suggests that Asb-9 acts as a specific ubiquitin ligase regulating levels of this evolutionarily conserved enzyme.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Canc & Haematol, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Mol Med, Parkville, Vic 3050, Australia; Univ Melbourne, Dept Med Biol, Parkville, Vic 3050, Australia; La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Joint Proteom Lab, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Melbourne; La Trobe University; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Hilton, DJ (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Canc & Haematol, 1G Royal Parade, Parkville, Vic 3050, Australia.	hilton@wehi.edu.au	Kile, Benjamin T/F-6593-2011; Hilton, Douglas J/C-7250-2013; Nicola, Nicos/D-2989-2011; Silke, John/B-7622-2008; Kile, Benjamin/GNP-3246-2022; Simpson, Richard/A-6947-2012	Kile, Benjamin T/0000-0002-8836-8947; Hilton, Douglas J/0000-0002-7698-2392; Nicola, Nicos/0000-0003-1054-7889; Silke, John/0000-0002-7611-5774; Kile, Benjamin/0000-0002-8836-8947; Simpson, Richard/0000-0002-9834-0796				ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; Boengler K, 2003, BIOCHEM BIOPH RES CO, V302, P17, DOI 10.1016/S0006-291X(03)00095-0; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Chen JS, 2001, BLOOD, V97, P2115, DOI 10.1182/blood.V97.7.2115; CHNG JLC, 1994, J BIOL CHEM, V269, P2336; Chung AS, 2005, MOL CELL BIOL, V25, P4716, DOI 10.1128/MCB.25.11.4716-4726.2005; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Diks SH, 2006, J CELL BIOL, V174, P581, DOI 10.1083/jcb.200601081; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Guibal FC, 2002, J BIOL CHEM, V277, P218, DOI 10.1074/jbc.M108476200; Haan S, 2003, J BIOL CHEM, V278, P31972, DOI 10.1074/jbc.M303170200; Heuze ML, 2005, J BIOL CHEM, V280, P5468, DOI 10.1074/jbc.M413040200; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Jost CR, 2002, EUR J NEUROSCI, V15, P1692, DOI 10.1046/j.1460-9568.2002.02001.x; KADDURAHDAOUK R, 1990, MOL CELL BIOL, V10, P1476, DOI 10.1128/MCB.10.4.1476; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kile BT, 2001, MOL CELL BIOL, V21, P6189, DOI 10.1128/MCB.21.18.6189-6197.2001; Kile BT, 2000, GENE, V258, P31, DOI 10.1016/S0378-1119(00)00402-9; Kohroki J, 2001, FEBS LETT, V505, P223, DOI 10.1016/S0014-5793(01)02829-0; Liu YZ, 2003, BIOCHEM BIOPH RES CO, V300, P972, DOI 10.1016/S0006-291X(02)02971-6; McDaneld TG, 2006, AM J PHYSIOL-REG I, V290, pR1672, DOI 10.1152/ajpregu.00239.2005; McDaneld TG, 2004, PHYSIOL GENOMICS, V16, P275, DOI 10.1152/physiolgenomics.00127.2003; MORITZ RL, 1992, J CHROMATOGR, V599, P119; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Silke J, 2005, P NATL ACAD SCI USA, V102, P16182, DOI 10.1073/pnas.0502828102; Silke J, 2004, J BIOL CHEM, V279, P4313, DOI 10.1074/jbc.M305661200; Simpson RJ, 2000, ELECTROPHORESIS, V21, P1707, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1707::AID-ELPS1707>3.0.CO;2-Q; SOMJEN D, 1989, P NATL ACAD SCI USA, V86, P3361, DOI 10.1073/pnas.86.9.3361; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tachikawa M, 2004, EUR J NEUROSCI, V20, P144, DOI 10.1111/j.1460-9568.2004.03478.x; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Vasilescu J, 2004, PROTEOMICS, V4, P3845, DOI 10.1002/pmic.200400856; WALLIMANN T, 1994, MOL CELL BIOCHEM, V133, P193, DOI 10.1007/BF01267955; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wang F, 2002, J CELL BIOCHEM, V84, P156, DOI 10.1002/jcb.1276; Wilcox A, 2004, J BIOL CHEM, V279, P38881, DOI 10.1074/jbc.M406101200; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang JG, 2001, P NATL ACAD SCI USA, V98, P13261, DOI 10.1073/pnas.231486498; ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483	50	41	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4728	4737		10.1074/jbc.M609164200	http://dx.doi.org/10.1074/jbc.M609164200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17148442	hybrid			2022-12-25	WOS:000244482000054
J	Borgono, CA; Michael, IP; Komatsu, N; Jayakumar, A; Kapadia, R; Clayman, GL; Sotiropoulou, G; Diamandis, EP				Borgono, Carla A.; Michael, Iacovos P.; Komatsu, Nahoko; Jayakumar, Arumugam; Kapadia, Ravi; Clayman, Gary L.; Sotiropoulou, Georgia; Diamandis, Eleftherios P.			A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEUM CHYMOTRYPTIC ENZYME; HUMAN STRATUM-CORNEUM; ELASTASE-SPECIFIC INHIBITOR; AMINO-ACID-SEQUENCE; NETHERTON-SYNDROME; HUMAN SKIN; PROTEINASE-INHIBITOR; TRYPSIN-LIKE; BIOCHEMICAL-CHARACTERIZATION; TERMINAL DIFFERENTIATION	Desquamation of the stratum corneum is a serine protease-dependent process. Two members of the human tissue kallikrein (KLK) family of (chymo)tryptic-like serine proteases, KLK5 and KLK7, are implicated in desquamation by digestion of (corneo)desmosomes and inhibition by desquamation-related serine protease inhibitors (SPIs). However, the epidermal localization and specificity of additional KLKs also supports a role for these enzymes in desquamation. This study aims to delineate the probable contribution of KLK1, KLK5, KLK6, KLK13, and KLK14 to desquamation by examining their interactions, in vitro, with: 1) colocalized SPI, lympho-epithelial Kazal-type-related inhibitor (LEKTI, four recombinant fragments containing inhibitory domains 1-6 (rLEKTI(1-6)), domains 6-8 and partial domain 9 (rLEKTI(6 -9')), domains 9-12 (rLEKTI(9-12)), and domains 12-15 (rLEKTI(12-15)), secretory leukocyte protease inhibitor, and elafin and 2) their ability to digest the (corneo)desmosomal cadherin, desmoglein 1.KLK1 was not inhibited by any SPI tested. KLK5, KLK6, KLK13, and KLK14 were potently inhibited by rLEKTI(1-6), rLEKTI(6-9'), and rLEKTI(9-12) with K-i values in the range of 2.3-28.4 nM, 6.1-221 nM, and 2.7-416 nM for each respective fragment. Only KLK5 was inhibited by rLEKTI(12-15) (K-i = 21.8 nM). No KLK was inhibited by secretory leukocyte protease inhibitor or elafin. Apart from KLK13, all KLKs digested the ectodomain of desmoglein 1 within cadherin repeats, Ca2+ binding sites, or in the juxtamembrane region. Our study indicates that multiple KLKs may participate in desquamation through cleavage of desmoglein 1 and regulation by LEKTI. These findings may have clinical implications for the treatment of skin disorders in which KLK activity is elevated.	Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada; Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Patras, Sch Hlth Sci, Dept Pharm, Patras 26500, Greece	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Patras	Diamandis, EP (corresponding author), Mt Sinai Hosp, Dept Pathol & Lab Med, 650 Univ Ave, Toronto, ON M5G 1X5, Canada.	ediamandis@mtsinai.on.ca	Michael, Iacovos P/C-8695-2016	Michael, Iacovos P/0000-0001-7674-1233; Diamandis, Eleftherios/0000-0002-1589-820X; Jayakumar, Arumugam/0000-0002-1284-4222				Ahmed A, 2001, J PROTEIN CHEM, V20, P273, DOI 10.1023/A:1010902815953; Bazzi H, 2006, DIFFERENTIATION, V74, P129, DOI 10.1111/j.1432-0436.2006.00061.x; Bernett MJ, 2002, J BIOL CHEM, V277, P24562, DOI 10.1074/jbc.M202392200; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BIETH JG, 1984, BIOCHEM MED METAB B, V32, P387, DOI 10.1016/0006-2944(84)90046-2; Bitoun E, 2003, HUM MOL GENET, V12, P2417, DOI 10.1093/hmg/ddg247; Borgono CA, 2004, MOL CANCER RES, V2, P257; Borgono CA, 2007, J BIOL CHEM, V282, P2405, DOI 10.1074/jbc.M608348200; Bourgeois L, 1997, J BIOL CHEM, V272, P29590, DOI 10.1074/jbc.272.47.29590; Brattsand M, 2005, J INVEST DERMATOL, V124, P198, DOI 10.1111/j.0022-202X.2004.23547.x; Brattsand M, 1999, J BIOL CHEM, V274, P30033, DOI 10.1074/jbc.274.42.30033; BRODY J, 1968, ACTA DERM-VENEREOL, V48, P290; Chao J., 2004, HDB PROTEOLYTIC ENZY, V2, P1577; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Chen VC, 2000, J BIOL CHEM, V275, P38457, DOI 10.1074/jbc.M005605200; Chitaev NA, 1997, J CELL BIOL, V138, P193, DOI 10.1083/jcb.138.1.193; COUBET C, 2004, J INVEST DERMATOL, V122, P1325; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Descargues P, 2006, J INVEST DERMATOL, V126, P1622, DOI 10.1038/sj.jid.5700284; Egelrud T, 2005, BRIT J DERMATOL, V153, P1200, DOI 10.1111/j.1365-2133.2005.06834.x; EGELRUD T, 1991, ARCH DERMATOL RES, V283, P108, DOI 10.1007/BF00371618; EISENBERG SP, 1990, J BIOL CHEM, V265, P7976; Ekholm IE, 2000, J INVEST DERMATOL, V114, P56, DOI 10.1046/j.1523-1747.2000.00820.x; Felber LM, 2005, BIOL CHEM, V386, P291, DOI 10.1515/BC.2005.035; FIEDLER F, 1987, EUR J BIOCHEM, V163, P303, DOI 10.1111/j.1432-1033.1987.tb10801.x; Franzke CW, 1996, J BIOL CHEM, V271, P21886, DOI 10.1074/jbc.271.36.21886; Galliano MF, 2006, J BIOL CHEM, V281, P5780, DOI 10.1074/jbc.M508017200; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; GREENE SL, 1985, J AM ACAD DERMATOL, V13, P329, DOI 10.1016/S0190-9622(85)70170-3; GRUTTER MG, 1988, EMBO J, V7, P345, DOI 10.1002/j.1460-2075.1988.tb02819.x; Hachem JP, 2006, J INVEST DERMATOL, V126, P1609, DOI 10.1038/sj.jid.5700288; Hanakawa Y, 2003, J INVEST DERMATOL, V121, P383, DOI 10.1046/j.1523-1747.2003.12362.x; Hanakawa Y, 2002, J CLIN INVEST, V110, P53, DOI 10.1172/JCI200215766; HANSSON L, 1994, J BIOL CHEM, V269, P19420; Hiemstra PS, 1996, INFECT IMMUN, V64, P4520, DOI 10.1128/IAI.64.11.4520-4524.1996; Ishida-Yamamoto A, 2005, J INVEST DERMATOL, V124, P360, DOI 10.1111/j.0022-202X.2004.23583.x; Ishida-Yamamoto A, 2004, J INVEST DERMATOL, V122, P1137, DOI 10.1111/j.0022-202X.2004.22515.x; Jayakumar A, 2005, ARCH BIOCHEM BIOPHYS, V435, P89, DOI 10.1016/j.abb.2004.12.012; Jayakumar A, 2004, PROTEIN EXPRES PURIF, V35, P93, DOI 10.1016/j.pep.2003.12.004; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; Kapadia C, 2004, CLIN CHIM ACTA, V339, P157, DOI 10.1016/j.cccn.2003.10.009; KING IA, 1987, J CELL BIOL, V105, P3053, DOI 10.1083/jcb.105.6.3053; KOCH PJ, 1992, P NATL ACAD SCI USA, V89, P353, DOI 10.1073/pnas.89.1.353; Komatsu N, 2005, J INVEST DERMATOL, V125, P1182, DOI 10.1111/j.0022-202X.2005.23933.x; Komatsu N, 2005, BRIT J DERMATOL, V153, P274, DOI 10.1111/j.1365-2133.2005.06754.x; Komatsu N, 2003, J INVEST DERMATOL, V121, P542, DOI 10.1046/j.1523-1747.2003.12363.x; Komatsu N, 2002, J INVEST DERMATOL, V118, P436, DOI 10.1046/j.0022-202x.2001.01663.x; Krebs M, 1999, J INVEST DERMATOL, V113, P32, DOI 10.1046/j.1523-1747.1999.00644.x; Kreutzmann P, 2004, J CHROMATOGR B, V803, P75, DOI 10.1016/j.jchromb.2003.07.016; Kurzen H, 1998, DIFFERENTIATION, V63, P295, DOI 10.1046/j.1432-0436.1998.6350295.x; Kuwae K, 2002, J CLIN PATHOL-MOL PA, V55, P235, DOI 10.1136/mp.55.4.235; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Laxmikanthan G, 2005, PROTEINS, V58, P802, DOI 10.1002/prot.20368; LUNDSTROM A, 1991, ACTA DERM-VENEREOL, V71, P471; LUNDSTROM A, 1988, J INVEST DERMATOL, V91, P340, DOI 10.1111/1523-1747.ep12475679; LUNDSTROM A, 1990, J INVEST DERMATOL, V94, P216, DOI 10.1111/1523-1747.ep12874531; Magert HJ, 1999, J BIOL CHEM, V274, P21499, DOI 10.1074/jbc.274.31.21499; Magert HJ, 2002, INT J BIOCHEM CELL B, V34, P573, DOI 10.1016/S1357-2725(01)00179-0; Magklara A, 2003, BIOCHEM BIOPH RES CO, V307, P948, DOI 10.1016/S0006-291X(03)01271-3; Michael IP, 2005, J BIOL CHEM, V280, P14628, DOI 10.1074/jbc.M408132200; Noe V, 2001, J CELL SCI, V114, P111; OHLSSON K, 1995, J ANDROL, V16, P64; OHMAN H, 1994, ACTA DERM-VENEREOL, V74, P375; Oji V, 2006, BRIT J DERMATOL, V154, P860, DOI 10.1111/j.1365-2133.2005.07109.x; Raghunath M, 2004, J INVEST DERMATOL, V123, P474, DOI 10.1111/j.0022-202X.2004.23220.x; Rawlings ND, 2004, BIOCHEM J, V378, P705, DOI 10.1042/BJ20031825; Schechter NM, 2005, BIOL CHEM, V386, P1173, DOI 10.1515/BC.2005.134; SERRE G, 1991, J INVEST DERMATOL, V97, P1061, DOI 10.1111/1523-1747.ep12492589; Shimomura Y, 2005, BRIT J DERMATOL, V153, P1026, DOI 10.1111/j.1365-2133.2005.06900.x; Simon M, 2001, J BIOL CHEM, V276, P20292, DOI 10.1074/jbc.M100201200; SKERROW CJ, 1989, J CELL SCI, V92, P667; SONDELL B, 1995, J INVEST DERMATOL, V104, P819, DOI 10.1111/1523-1747.ep12607007; SONDELL B, 1994, J HISTOCHEM CYTOCHEM, V42, P459, DOI 10.1177/42.4.7510318; Sotiropoulou G, 2003, ONCOL RES, V13, P381; Sprecher E, 2001, J INVEST DERMATOL, V117, P179, DOI 10.1046/j.1523-1747.2001.01389.x; Stefansson K, 2006, BIOL CHEM, V387, P761, DOI 10.1515/BC.2006.095; Suzuki Y, 1996, BRIT J DERMATOL, V134, P460, DOI 10.1046/j.1365-2133.1996.31794.x; Taggart CC, 2001, J BIOL CHEM, V276, P33345, DOI 10.1074/jbc.M103220200; Talas U, 2000, J INVEST DERMATOL, V114, P165, DOI 10.1046/j.1523-1747.2000.00825.x; Tartaglia-Polcini A, 2006, J INVEST DERMATOL, V126, P315, DOI 10.1038/sj.jid.5700015; Whittock NV, 2003, CLIN EXP DERMATOL, V28, P410, DOI 10.1046/j.1365-2230.2003.01311.x; WIEDOW O, 1993, J INVEST DERMATOL, V101, P305, DOI 10.1111/1523-1747.ep12365430; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; YING QL, 1993, BIOCHEMISTRY-US, V32, P1866, DOI 10.1021/bi00058a021	84	209	220	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3640	3652		10.1074/jbc.M607567200	http://dx.doi.org/10.1074/jbc.M607567200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158887	hybrid			2022-12-25	WOS:000244481900026
J	Luka, Z; Pakhomova, S; Loukachevitch, LV; Egli, M; Newcomer, ME; Wagner, C				Luka, Zigmund; Pakhomova, Svetlana; Loukachevitch, Lioudmila V.; Egli, Martin; Newcomer, Marcia E.; Wagner, Conrad			5-methyltetrahydrofolate is bound in intersubunit areas of rat liver folate-binding protein glycine N-methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; DIHYDROFOLATE-REDUCTASE; CATALYTIC MECHANISM; FOLIC-ACID; INHIBITION; DEFICIENCY; METABOLISM; ENZYMES; METHYLENETETRAHYDROFOLATE; PURIFICATION	Glycine N-methyltransferase (GNMT) is a key regulatory enzyme in methyl group metabolism. It is abundant in the liver, where it uses excess S-adenosylmethionine (AdoMet) to methylate glycine to N-methylglycine (sarcosine) and produces S-adenosylhomocysteine (AdoHcy), thereby controlling the methylating potential of the cell. GNMT also links utilization of preformed methyl groups, in the form of methionine, to their de novo synthesis, because it is inhibited by a specific form of folate, 5-methyltetrahydrofolate. Although the structure of the enzyme has been elucidated by x-ray crystallography of the apoenzyme and in the presence of the substrate, the location of the folate inhibitor in the tetrameric structure has not been identified. We report here for the first time the crystal structure of rat GNMT complexed with 5-methyltetrahydrofolate. In the GNMT-folate complex, two folate binding sites were located in the intersubunit areas of the tetramer. Each folate binding site is formed primarily by two 1-7 N-terminal regions of one pair of subunits and two 205-218 regions of the other pair of subunits. Both the pteridine and p-aminobenzoyl rings are located in the hydrophobic cavities formed by Tyr(5), Leu(207), and Met(215) residues of all subunits. Binding experiments in solution also confirm that one GNMT tetramer binds two folate molecules. For the enzymatic reaction to take place, the N-terminal fragments of GNMT must have a significant degree of conformational freedom to provide access to the active sites. The presence of the folate in this position provides a mechanism for its inhibition.	Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37212 USA; Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Louisiana State University System; Louisiana State University	Wagner, C (corresponding author), Vanderbilt Univ, Med Ctr, Dept Biochem, 620 Light Hall, Nashville, TN 37232 USA.	Conrad.Wagner@vanderbilt.edu			NIDDK NIH HHS [DK15289] Funding Source: Medline; NIGMS NIH HHS [GM55237] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015289, R01DK015289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055237] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BALAGHI M, 1993, AM J CLIN NUTR, V58, P198, DOI 10.1093/ajcn/58.2.198; Blakley R.L., 1969, N HOLLAND RES MONOGR, P1; BLUMENSTEIN J, 1960, BIOCHEM BIOPH RES CO, V3, P259, DOI 10.1016/0006-291X(60)90235-7; Brautigam CA, 2004, P NATL ACAD SCI USA, V101, P12142, DOI 10.1073/pnas.0404851101; CANTONI GL, 1978, TRANSMETHYLATION, P155; Chen SY, 2004, CANCER RES, V64, P3617, DOI 10.1158/0008-5472.CAN-03-3726; Clarke S, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P63; Cody V, 2004, ACTA CRYSTALLOGR D, V60, P646, DOI 10.1107/S0907444904002094; COOK RJ, 1984, P NATL ACAD SCI-BIOL, V81, P3631, DOI 10.1073/pnas.81.12.3631; Evans JC, 2004, P NATL ACAD SCI USA, V101, P3729, DOI 10.1073/pnas.0308082100; Fu ZJ, 1996, BIOCHEMISTRY-US, V35, P11985, DOI 10.1021/bi961068n; GUPTA VS, 1967, ARCH BIOCHEM BIOPHYS, V120, P712, DOI 10.1016/0003-9861(67)90536-X; HEADY JE, 1973, J BIOL CHEM, V248, P69; HORNE DW, 1988, CLIN CHEM, V34, P2357; Huang Y, 2000, J MOL BIOL, V298, P149, DOI 10.1006/jmbi.2000.3637; Hyatt DC, 1997, BIOCHEMISTRY-US, V36, P4585, DOI 10.1021/bi962936j; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLOTZ IM, 1946, ARCH BIOCHEM, V9, P109; Luka Z, 2003, PROTEIN EXPRES PURIF, V28, P280, DOI 10.1016/S1046-5928(02)00710-6; Luka Z, 2002, HUM GENET, V110, P68, DOI 10.1007/s00439-001-0648-4; Luka Z, 2006, TRANSGENIC RES, V15, P393, DOI 10.1007/s11248-006-0008-1; MATTHEWS DA, 1977, SCIENCE, V197, P452, DOI 10.1126/science.17920; Moreland JL, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-21; Mudd SH, 2001, J INHERIT METAB DIS, V24, P448, DOI 10.1023/A:1010577512912; OGAWA H, 1993, COMP BIOCHEM PHYS B, V106, P601, DOI 10.1016/0305-0491(93)90137-T; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pakhomova S, 2004, PROTEINS, V57, P331, DOI 10.1002/prot.20209; Pattanayek R, 1998, PROTEIN SCI, V7, P1326, DOI 10.1002/pro.5560070608; Pejchal R, 2005, BIOCHEMISTRY-US, V44, P11447, DOI 10.1021/bi050533q; POE M, 1980, BIOCHEMISTRY-US, V19, P4576, DOI 10.1021/bi00561a006; SUZUKI N, 1980, ARCH BIOCHEM BIOPHYS, V199, P236, DOI 10.1016/0003-9861(80)90277-5; Takata Y, 2003, BIOCHEMISTRY-US, V42, P8394, DOI 10.1021/bi034245a; Thomas AH, 2001, HELV CHIM ACTA, V84, P3849, DOI 10.1002/1522-2675(20011219)84:12<3849::AID-HLCA3849>3.0.CO;2-F; Thomas AH, 2002, HELV CHIM ACTA, V85, P2300, DOI 10.1002/1522-2675(200208)85:8<2300::AID-HLCA2300>3.0.CO;2-B; WAGNER C, 1985, BIOCHEM BIOPH RES CO, V127, P746, DOI 10.1016/S0006-291X(85)80006-1; Yeo EJ, 1999, J BIOL CHEM, V274, P37559, DOI 10.1074/jbc.274.53.37559; ZAMIEROWSKI MM, 1977, J BIOL CHEM, V252, P933	38	24	26	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4069	4075		10.1074/jbc.M610384200	http://dx.doi.org/10.1074/jbc.M610384200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158459	hybrid, Green Published			2022-12-25	WOS:000244481900070
J	Sun, L; Stoecklin, G; Van Way, S; Hinkovska-Galcheva, V; Guo, RF; Anderson, P; Shanley, TP				Sun, Lei; Stoecklin, Georg; Van Way, Susan; Hinkovska-Galcheva, Vania; Guo, Ren-Feng; Anderson, Paul; Shanley, Thomas Patrick			Tristetraprolin (TTP)-14-3-3 complex formation protects TTP from dephosphorylation by protein phosphatase 2a and stabilizes tumor necrosis factor-alpha mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENTS; BINDING PROTEIN; SERINE/THREONINE PHOSPHATASE; INFLAMMATORY MEDIATORS; 3'-UNTRANSLATED REGION; NUCLEOTIDE-SEQUENCE; KINASE P38; DEGRADATION; EXPRESSION; REGULATOR	Tumor necrosis factor (TNF)-alpha is a major cytokine produced by alveolar macrophages in response to pathogen-associated molecular patterns such as lipopolysaccharide. TNF-alpha secretion is regulated at both transcriptional and post-transcriptional levels. Posttranscriptional regulation occurs by modulation of TNF-alpha mRNA stability via the binding of tristetraprolin (TTP) to the adenosine/ uridine-rich elements found in the 3'-untranslated region of the TNF-alpha transcript. Phosphorylation plays important roles in modulating mRNA stability, because activation of p38 MAPK by lipopolysaccharide stabilizes TNF-alpha mRNA. We hypothesized that the protein phosphatase 2A (PP2A) regulates this signaling pathway. Our results show that inhibition of PP2A by okadaic acid or small interference RNA significantly enhanced the stability of TNF-alpha mRNA. This result was associated with increased phosphorylation of p38 MAPK and MAPK-activated kinase 2 (MK-2). PP2A inhibition increased TTP phosphorylation and enhanced complex formation with chaperone protein 14-3-3. TTP physically interacted with PP2A in transfected mammalian cells. A functional consequence of TTP-14-3-3 complex formation appeared to be protection of TTP from dephosphorylation by inhibition of the binding of PP2A to phosphorylated TTP. Mutation of the MK-2 phosphorylation sites of TTP did not influence TNF-alpha adenosine/ uridine-rich element binding and did not alter the increased TNF-alpha T-untranslated region-dependent luciferase activity induced by PP2A-small interference RNA silencing. Our data indicate that, although phosphorylation stabilizes TNF-alpha mRNA, PP2A regulates the mRNA stability by modulating the phosphorylation state of members of the p38/MK-2/TTP pathway.	Univ Michigan, Sch Med, Dept Pediat, Div Crit Care, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Shanley, TP (corresponding author), Univ Michigan, Sch Med, Dept Pediat, Div Crit Care, 109 Zina Pitcher Pl,4460 Basic Sci Res Bldg, Ann Arbor, MI 48109 USA.	tshanley@med.umich.edu	Huang, H/E-9490-2010	Stoecklin, Georg/0000-0001-9284-9834; Shanley, Thomas/0000-0001-8936-377X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066839] Funding Source: NIH RePORTER; NIGMS NIH HHS [7R01GM066839-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; BERG JT, 1993, J APPL PHYSIOL, V74, P2812, DOI 10.1152/jappl.1993.74.6.2812; Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491; Brook M, 2006, MOL CELL BIOL, V26, P2408, DOI 10.1128/MCB.26.6.2408-2418.2006; Brooks SA, 2002, ARTHRITIS RHEUM, V46, P1362, DOI 10.1002/art.10235; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; Cao HP, 2003, ARCH BIOCHEM BIOPHYS, V412, P106, DOI 10.1016/S0003-9861(03)00012-2; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; Cavaillon JM, 2003, SCAND J INFECT DIS, V35, P535, DOI 10.1080/00365540310015935; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chrestensen CA, 2004, J BIOL CHEM, V279, P10176, DOI 10.1074/jbc.M310486200; Clark AR, 2003, FEBS LETT, V546, P37, DOI 10.1016/S0014-5793(03)00439-3; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Gringhuis SI, 2005, MOL CELL BIOL, V25, P6454, DOI 10.1128/MCB.25.15.6454-6463.2005; Hitti E, 2006, MOL CELL BIOL, V26, P2399, DOI 10.1128/MCB.26.6.2399-2407.2006; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; Johnson BA, 2002, J BIOL CHEM, V277, P18029, DOI 10.1074/jbc.M110465200; Kray AE, 2005, J BIOL CHEM, V280, P35974, DOI 10.1074/jbc.M506093200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; Lykke-Andersen J, 2005, GENE DEV, V19, P351, DOI 10.1101/gad.1282305; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Murata T, 2002, BIOCHEM BIOPH RES CO, V293, P1242, DOI 10.1016/S0006-291X(02)00363-7; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Rigby WFC, 2005, J IMMUNOL, V174, P7883, DOI 10.4049/jimmunol.174.12.7883; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Schmidlin M, 2004, EMBO J, V23, P4760, DOI 10.1038/sj.emboj.7600477; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Shanley TP, 2001, J IMMUNOL, V166, P966, DOI 10.4049/jimmunol.166.2.966; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; Stoecklin G, 2004, EMBO J, V23, P1313, DOI 10.1038/sj.emboj.7600163; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Stoecklin G, 2006, EMBO REP, V7, P72, DOI 10.1038/sj.embor.7400572; Sun L, 2003, J BIOL CHEM, V278, P38301, DOI 10.1074/jbc.M212801200; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; Van Hoof C, 2003, BBA-MOL CELL RES, V1640, P97, DOI 10.1016/S0167-4889(03)00029-6; VARNUM BC, 1989, ONCOGENE, V4, P119; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200; Yu Q, 2003, J BIOL CHEM, V278, P1579, DOI 10.1074/jbc.M203526200; Zhu W, 2001, AM J PHYSIOL-LUNG C, V281, pL499, DOI 10.1152/ajplung.2001.281.2.L499	53	154	156	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3766	3777		10.1074/jbc.M607347200	http://dx.doi.org/10.1074/jbc.M607347200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17170118	hybrid			2022-12-25	WOS:000244481900040
J	Clough, RL; Stefanis, L				Clough, R. Lee; Stefanis, Leonidas			A novel pathway for transcriptional regulation of alpha-synuclein	FASEB JOURNAL			English	Article						Parkinson's disease; PC12 cells; ERK; PI3 kinase; NGF	NERVE GROWTH-FACTOR; FAMILIAL PARKINSONS-DISEASE; PC12 CELLS; GENE-EXPRESSION; NEURONAL DIFFERENTIATION; DOPAMINERGIC-NEURONS; UP-REGULATION; SUSCEPTIBILITY; POLYMORPHISM; NACP-REP1	alpha-Synuclein is an abundant neuronal protein that has been linked to both normal synaptic function and neurodegeneration-in particular, Parkinson's disease (PD). Uncovering mechanisms that control alpha-synuclein transcription is therefore critical for PD pathogenesis and synaptic function. We previously reported that in PC12 cells and primary neurons, alpha-synuclein is transcriptionally up-regulated after application of growth factors. In the current work we have characterized the pathway involved in this regulation in PC12 cells. The MAP/ERK pathway, and in particular Ras, is both sufficient and necessary for the NGF and basic fibroblast growth factor (bFGF) -mediated response. Significantly, response elements for this pathway, including a putative occult promoter, lie within intron 1, a hitherto unappreciated regulatory region of the gene that may be utilized in this or other settings. The PI3 kinase pathway is also involved in alpha-synuclein regulation, but response elements for this pathway appear to lie primarily outside of intron 1. These findings indicate that NGF- and bFGF-mediated signal transduction via the MAP/ERK and PI3 kinase pathways, and in part via regulatory regions within intron 1, may be involved in alpha-synuclein transcriptional regulation. Targeting of these pathways may serve to modulate alpha-synuclein so that it achieves desirable levels within neuronal cells.	Acad Athens, Fdn Biomed Res, IIBEAA, Div Basic Neurosci, GR-11527 Athens, Greece	Academy of Athens	Stefanis, L (corresponding author), Acad Athens, Fdn Biomed Res, IIBEAA, Div Basic Neurosci, GR-11527 Athens, Greece.	lstefanis@bioacademy.gr	Stefanis, Leonidas/AAD-7192-2019					Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Baptista MJ, 2003, J NEUROCHEM, V85, P957, DOI 10.1046/j.1471-4159.2003.01742.x; Chiba-Falek O, 2001, HUM MOL GENET, V10, P3101, DOI 10.1093/hmg/10.26.3101; Chong YH, 2006, J BIOL CHEM, V281, P20315, DOI 10.1074/jbc.M601016200; Conlon TM, 2006, EUR J IMMUNOL, V36, P139, DOI 10.1002/eji.200535219; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Gomez-Santos C, 2005, BRAIN RES BULL, V65, P87, DOI 10.1016/j.brainresbull.2004.11.008; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; Izumi Y, 2001, NEUROSCI LETT, V300, P125, DOI 10.1016/S0304-3940(01)01557-9; Kawamata T, 2003, NEUROCHEM RES, V28, P1221, DOI 10.1023/A:1024284529945; Khan N, 2001, ANN NEUROL, V49, P665; Kholodilov NG, 1999, J NEUROCHEM, V73, P2586, DOI 10.1046/j.1471-4159.1999.0732586.x; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Kruger R, 1999, ANN NEUROL, V45, P611, DOI 10.1002/1531-8249(199905)45:5<611::AID-ANA9>3.0.CO;2-X; Li WX, 2004, J NEUROSCI, V24, P7400, DOI 10.1523/JNEUROSCI.1370-04.2004; Madziar B, 2005, J NEUROCHEM, V92, P767, DOI 10.1111/j.1471-4159.2004.02908.x; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; Marek L, 2004, J CELL PHYSIOL, V201, P459, DOI 10.1002/jcp.20087; Mash DC, 2003, J NEUROSCI, V23, P2564; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Mellick GD, 2005, NEUROSCI LETT, V375, P112, DOI 10.1016/j.neulet.2004.10.078; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Mueller JC, 2005, ANN NEUROL, V57, P535, DOI 10.1002/ana.20438; Pals P, 2004, ANN NEUROL, V56, P591, DOI 10.1002/ana.20268; Parsian A, 1998, NEUROLOGY, V51, P1757, DOI 10.1212/WNL.51.6.1757; Pereira PS, 2006, DEV DYNAM, V235, P225, DOI 10.1002/dvdy.20606; Petersen K, 1999, NEUROSCIENCE, V91, P651, DOI 10.1016/S0306-4522(98)00596-X; Rideout HJ, 2003, J NEUROCHEM, V84, P803, DOI 10.1046/j.1471-4159.2003.01574.x; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Schafer G, 2003, J BIOL CHEM, V278, P8190, DOI 10.1074/jbc.M211999200; Schonhoff CM, 2001, J NEUROCHEM, V78, P631, DOI 10.1046/j.1471-4159.2001.00432.x; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spadafora P, 2003, NEUROSCI LETT, V351, P75, DOI 10.1016/S0304-3940(03)00859-0; Stefanis L, 2001, J NEUROCHEM, V76, P1165, DOI 10.1046/j.1471-4159.2001.00114.x; Subramaniam S, 2006, NEUROSCIENCE, V138, P1055, DOI 10.1016/j.neuroscience.2005.12.013; Tan EK, 2004, NEUROLOGY, V62, P128, DOI 10.1212/01.WNL.0000101721.25345.DC; Tan EK, 2003, NEUROSCI LETT, V336, P70, DOI 10.1016/S0304-3940(02)01178-3; Vekrellis K, 2004, MOL NEUROBIOL, V30, P1, DOI 10.1385/MN:30:1:001; Vila M, 2000, J NEUROCHEM, V74, P721, DOI 10.1046/j.1471-4159.2000.740721.x; Waetzig V, 2003, MOL CELL NEUROSCI, V24, P238, DOI 10.1016/S1044-7431(03)00126-X; Waetzig V, 2003, J BIOL CHEM, V278, P567, DOI 10.1074/jbc.M207391200; Xia Y, 1996, ANN NEUROL, V40, P207, DOI 10.1002/ana.410400212; Xia Y, 2001, J ALZHEIMERS DIS, V3, P485, DOI 10.3233/JAD-2001-3508	46	42	44	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					596	607		10.1096/fj.06-7111com	http://dx.doi.org/10.1096/fj.06-7111com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17167067				2022-12-25	WOS:000244686300032
J	Kappert, K; Paulsson, J; Sparwel, J; Leppanen, O; Hellberg, C; Ostman, A; Micke, P				Kappert, Kai; Paulsson, Janna; Sparwel, Jan; Leppanen, Olli; Hellberg, Carina; Ostman, Arne; Micke, Patrick			Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation	FASEB JOURNAL			English	Article						tissue remodeling; laser capture microdissection; vascular smooth muscle cell; protein tyrosine phosphalase	PROTEIN-TYROSINE PHOSPHATASES; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; BETA-RECEPTOR; PROLIFERATION; IDENTIFICATION; INSULIN; INJURY	Growth factor-dependent tissue remodeling, such as restenosis, is believed to be predominantly regulated by changes in expression of receptor-tyrosine-kinases (RTKs) and their ligands. As endogenous antagonists of RTKs, protein-tyrosine-phosphatases (PTPs) are additional candidate regulators of these processes. Using laser-capture-microdissection and quantitative RT-polymerase chain reaction (qRT-PCR), we investigated the layer-specific expression of the four platelet-derived growth factor (PDGF) isoforms, the PDGF-alpha and beta receptors, and five PTPs implied in control of PDGF-receptor signaling 8 and 14 days after balloon injury of the rat carotid. Results were correlated with analyses of PDGF-beta receptor phosphorylation and vascular smooth muscle cell (VSMC) proliferation in vivo. The expression levels of all components, as well as receptor activation and VSMC proliferation, showed specific changes, which varied between media and neointima. Interestingly, PTP expression-particularly, DEP-1 levels-appeared to be the dominating factor determining receptor-phosphorylation and VSMC proliferation. In support of these findings, cultured DEP-1(-/-) cells displayed increased PDGF-dependent cell signaling. Hyperactivation of PDGF-induced signaling was also observed after siRNA-down-regulation of DEP-1 in VSMCs. The results indicate a previously unrecognized role of PDGF-receptor-targeting PTPs in controlling neointima formation. In more general terms, the observations indicate transcriptional regulation of PTPs as an important mechanism for controlling onset and termination of RTK-dependent tissue remodeling.	Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden; Univ Uppsala Hosp, Div Vasc Surg, Uppsala, Sweden; Uppsala Univ, Ludwig Inst Canc Res, Uppsala, Sweden	Karolinska Institutet; Uppsala University; Uppsala University Hospital; Ludwig Institute for Cancer Research; Uppsala University	Ostman, A (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden.	arne.ostman@ki.se	Kappert, Kai/H-4116-2017	Kappert, Kai/0000-0001-6976-0428				Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Berset TA, 2005, GENE DEV, V19, P1328, DOI 10.1101/gad.333505; Bonner JC, 2004, CYTOKINE GROWTH F R, V15, P255, DOI 10.1016/j.cytogfr.2004.03.006; Borges LG, 1996, CIRC RES, V79, P570, DOI 10.1161/01.RES.79.3.570; Chang YZ, 2006, ARTERIOSCL THROM VAS, V26, P501, DOI 10.1161/01.ATV.0000201070.71787.b8; Chang YZ, 2004, AM J PHYSIOL-HEART C, V287, pH2201, DOI 10.1152/ajpheart.00520.2004; Chen JZ, 2005, BIOCHEM BIOPH RES CO, V329, P976, DOI 10.1016/j.bbrc.2005.02.062; CLOWES AW, 1983, LAB INVEST, V49, P327; Fukada T, 2003, EMBO J, V22, P479, DOI 10.1093/emboj/cdg067; Galic S, 2005, MOL CELL BIOL, V25, P819, DOI 10.1128/MCB.25.2.819-829.2005; Giese NA, 1999, ARTERIOSCL THROM VAS, V19, P900, DOI 10.1161/01.ATV.19.4.900; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; Heldin CH, 2002, ARCH BIOCHEM BIOPHYS, V398, P284, DOI 10.1006/abbi.2001.2707; Jandt E, 2003, ONCOGENE, V22, P4175, DOI 10.1038/sj.onc.1206652; Kappert K, 2006, AM J PHYSIOL-HEART C, V290, pH538, DOI 10.1152/ajpheart.00240.2005; Kappert K, 2005, CARDIOVASC RES, V65, P587, DOI 10.1016/j.cardiores.2004.08.016; Kokel M, 1998, GENE DEV, V12, P1425, DOI 10.1101/gad.12.10.1425; Levitzki A, 2004, CYTOKINE GROWTH F R, V15, P229, DOI 10.1016/j.cytogfr.2004.03.010; Lin J, 2004, J IMMUNOL, V173, P2324, DOI 10.4049/jimmunol.173.4.2324; Markova B, 2003, BIOCHEMISTRY-US, V42, P2691, DOI 10.1021/bi0265574; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Persson C, 2004, MOL CELL BIOL, V24, P2190, DOI 10.1128/MCB.24.5.2190-2201.2004; Persson C, 2002, FEBS LETT, V517, P27, DOI 10.1016/S0014-5793(02)02570-X; Ponten A, 2005, CIRC RES, V97, P1036, DOI 10.1161/01.RES.0000190590.31545.d4; Raines EW, 2004, CYTOKINE GROWTH F R, V15, P237, DOI 10.1016/j.cytogfr.2004.03.004; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; VACARESSE N, 2005, EMBO C FEBS WORKSH E	27	39	40	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					523	534		10.1096/fj.06-6219com	http://dx.doi.org/10.1096/fj.06-6219com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158785				2022-12-25	WOS:000244686300025
J	Bensch, S; Andren, H; Hansson, B; Pedersen, HC; Sand, H; Sejberg, D; Wabakken, P; Akesson, M; Liberg, O				Bensch, Staffan; Andren, Henrik; Hansson, Bengt; Pedersen, Hans Chr.; Sand, Hakan; Sejberg, Douglas; Wabakken, Petter; Akesson, Mikael; Liberg, Olof			Selection for Heterozygosity Gives Hope to a Wild Population of Inbred Wolves	PLOS ONE			English	Article								Recent analyses have questioned the usefulness of heterozygosity estimates as measures of the inbreeding coefficient (f), a finding that may have dramatic consequences for the management of endangered populations. We confirm that f and heterozygosity is poorly correlated in a wild and highly inbred wolf population. Yet, our data show that for each level of f, it was the most heterozygous wolves that established themselves as breeders, a selection process that seems to have decelerated the loss of heterozygosity in the population despite a steady increase of f. The markers contributing to the positive relationship between heterozygosity and breeding success were found to be located on different chromosomes, but there was a substantial amount of linkage disequilibrium in the population, indicating that the markers are reflecting heterozygosity over relatively wide genomic regions. Following our results we recommend that management programs of endangered populations include estimates of both f and heterozygosity, as they may contribute with complementary information about population viability.	[Bensch, Staffan; Hansson, Bengt; Sejberg, Douglas; Akesson, Mikael] Lund Univ, Dept Anim Ecol, S-22362 Lund, Sweden; [Andren, Henrik; Sand, Hakan; Liberg, Olof] Swedish Univ Agr Sci, Dept Conservat Biol, Grimso Wildlife Res Stn, Riddarhyttan, Sweden; [Pedersen, Hans Chr.] Norwegian Inst Nat Res, Div Terr Ecol, N-7004 Trondheim, Norway; [Wabakken, Petter] Hedmark Univ Coll, Fac Forestry & Wildlife Management, Koppang, Norway	Lund University; Swedish University of Agricultural Sciences; Norwegian Institute Nature Research; Inland Norway University of Applied Sciences	Bensch, S (corresponding author), Lund Univ, Dept Anim Ecol, S-22362 Lund, Sweden.	staffan.bensch@zooekol.lu.se	Hansson, Bengt/L-8874-2013; Åkesson, Mikael/K-5370-2014; Andrén, Henrik/C-8995-2015	Hansson, Bengt/0000-0001-6694-8169; Andren, Henrik/0000-0002-5616-2426	Swedish Research Council; Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning; Swedish Environmental Protection Agency; World Wide Fund for Nature ( Sweden); Swedish Association for Hunting and Wildlife Management; Olle och Signhild Engkvists Stiftelser; Norwegian Research Council; Norwegian Directorate for Nature Management; Norwegian Institute for Nature Research; Norwegian Ministry of Environment; Hedmark University College	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning(Swedish Research Council Formas); Swedish Environmental Protection Agency; World Wide Fund for Nature ( Sweden); Swedish Association for Hunting and Wildlife Management; Olle och Signhild Engkvists Stiftelser; Norwegian Research Council(Research Council of NorwayEuropean Commission); Norwegian Directorate for Nature Management; Norwegian Institute for Nature Research(Bioforsk); Norwegian Ministry of Environment; Hedmark University College	Funding was provided to SB and BH from the Swedish Research Council, to OL and SB from the the Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning, to OL, HA and HS by the Swedish Environmental Protection Agency, the World Wide Fund for Nature ( Sweden), the Swedish Association for Hunting and Wildlife Management, the private foundation "Olle och Signhild Engkvists Stiftelser'' to HCP and PW by the Norwegian Research Council, the Norwegian Directorate for Nature Management, the Norwegian Institute for Nature Research, Norwegian Ministry of Environment, and the Hedmark University College.	ANDREN H, 2006, GENETIC ASPECTS VIAB, P59; Aspi J, 2006, MOL ECOL, V15, P1561, DOI 10.1111/j.1365-294X.2006.02877.x; Balloux F, 2004, MOL ECOL, V13, P3021, DOI 10.1111/j.1365-294X.2004.02318.x; Bierne N, 1998, GENETICS, V148, P1893; David P, 1998, HEREDITY, V80, P531, DOI 10.1046/j.1365-2540.1998.00393.x; Dunning AM, 2000, AM J HUM GENET, V67, P1544, DOI 10.1086/316906; Ellegren H, 1999, HEREDITAS, V130, P239, DOI 10.1111/j.1601-5223.1999.00239.x; Falconer D. S, 1996, INTRO QUANTITATIVE G; Flagstad O, 2003, MOL ECOL, V12, P869, DOI 10.1046/j.1365-294X.2003.01784.x; Garner A, 2005, CONSERV BIOL, V19, P1215, DOI 10.1111/j.1523-1739.2005.00105.x; Gilpin M.E., 1986, P19; Hansson B, 2004, EVOLUTION, V58, P870; Hard D. L, 1997, PRINCIPLES POPULATIO; Hedrick PW, 2001, TRENDS ECOL EVOL, V16, P629, DOI 10.1016/S0169-5347(01)02282-0; JIMENEZ JA, 1994, SCIENCE, V266, P271, DOI 10.1126/science.7939661; Kalinowski ST, 1998, ZOO BIOL, V17, P481, DOI 10.1002/(SICI)1098-2361(1998)17:6<481::AID-ZOO2>3.0.CO;2-G; Kalinowski ST, 1999, CONSERV BIOL, V13, P1371, DOI 10.1046/j.1523-1739.1999.98346.x; KELLER LF, 1994, NATURE, V372, P356, DOI 10.1038/372356a0; Keller LF, 2002, TRENDS ECOL EVOL, V17, P230, DOI 10.1016/S0169-5347(02)02489-8; Kimura MA, 1985, NEUTRAL THEORY MOL E; Kingsolver JG, 2001, AM NAT, V157, P245, DOI 10.1086/319193; LACY RC, 1995, VORTEX STOCHASTIC SI; LANDE R, 1983, EVOLUTION, V37, P1210, DOI [10.1111/j.1558-5646.1983.tb00236.x, 10.2307/2408842]; LEARY RF, 1987, EVOLUTION, V41, P1413, DOI 10.1111/j.1558-5646.1987.tb02480.x; Leonard JA, 2005, MOL ECOL, V14, P9, DOI 10.1111/j.1365-294X.2004.02389.x; Liberg O, 2005, BIOL LETT-UK, V1, P17, DOI 10.1098/rsbl.2004.0266; Lucchini V, 2004, MOL ECOL, V13, P523, DOI 10.1046/j.1365-294X.2004.02077.x; Markert JA, 2004, HEREDITY, V92, P306, DOI 10.1038/sj.hdy.6800409; McKusick VA, 2000, NAT GENET, V24, P203, DOI 10.1038/73389; McRae AF, 2002, GENETICS, V160, P1113; MORTON NE, 1956, P NATL ACAD SCI USA, V42, P855, DOI 10.1073/pnas.42.11.855; Otto SP, 1997, GENETICS, V146, P723; Peel D., 2004, NEESTIMATOR SOFTWARE; Pemberton J, 2004, TRENDS ECOL EVOL, V19, P613, DOI 10.1016/j.tree.2004.09.010; Raikkonen J, 2006, MAMM BIOL, V71, P65, DOI 10.1016/j.mambio.2005.12.002; RALLS K, 1988, Conservation Biology, V2, P185, DOI 10.1111/j.1523-1739.1988.tb00169.x; SCHLUTER D, 1986, EVOLUTION, V40, P221, DOI 10.1111/j.1558-5646.1986.tb00465.x; Slate J, 2004, HEREDITY, V93, P255, DOI 10.1038/sj.hdy.6800485; Sutter NB, 2004, GENOME RES, V14, P2388, DOI 10.1101/gr.3147604; Taberlet P, 1999, TRENDS ECOL EVOL, V14, P323, DOI 10.1016/S0169-5347(99)01637-7; Vila C, 2003, P ROY SOC B-BIOL SCI, V270, P91, DOI 10.1098/rspb.2002.2184; Wabakken P, 2001, CAN J ZOOL, V79, P710, DOI 10.1139/cjz-79-4-710; WABAKKEN P, 2005, 62005 HOGSK HEDM	43	91	93	0	66	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e72	10.1371/journal.pone.0000072	http://dx.doi.org/10.1371/journal.pone.0000072			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183704	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600072
J	Demuth, JP; De Bie, T; Stajich, JE; Cristianini, N; Hahn, MW				Demuth, Jeffery P.; De Bie, Tijl; Stajich, Jason E.; Cristianini, Nello; Hahn, Matthew W.			The Evolution of Mammalian Gene Families	PLOS ONE			English	Article							POSITIVE SELECTION; GENOME SEQUENCE; CHIMPANZEE; DUPLICATION; HUMANS; NUMBER; MOUSE; REPERTOIRE; DIVERGENCE; ALGORITHM	Gene families are groups of homologous genes that are likely to have highly similar functions. Differences in family size due to lineage-specific gene duplication and gene loss may provide clues to the evolutionary forces that have shaped mammalian genomes. Here we analyze the gene families contained within the whole genomes of human, chimpanzee, mouse, rat, and dog. In total we find that more than half of the 9,990 families present in the mammalian common ancestor have either expanded or contracted along at least one lineage. Additionally, we find that a large number of families are completely lost from one or more mammalian genomes, and a similar number of gene families have arisen subsequent to the mammalian common ancestor. Along the lineage leading to modern humans we infer the gain of 689 genes and the loss of 86 genes since the split from chimpanzees, including changes likely driven by adaptive natural selection. Our results imply that humans and chimpanzees differ by at least 6% (1,418 of 22,000 genes) in their complement of genes, which stands in stark contrast to the oft-cited 1.5% difference between orthologous nucleotide sequences. This genomic "revolving door'' of gene gain and loss represents a large number of genetic differences separating humans from our closest relatives.	[Demuth, Jeffery P.; Hahn, Matthew W.] Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; [Demuth, Jeffery P.; Hahn, Matthew W.] Indiana Univ, Sch Informat, Bloomington, IN USA; [De Bie, Tijl] Univ Southampton, Sch Elect & Comp Sci, ISIS Grp, Southampton, Hants, England; [Stajich, Jason E.] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC USA; [Cristianini, Nello] Univ Calif Davis, Dept Stat, Davis, CA 95616 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; University of Southampton; Duke University; University of California System; University of California Davis	Hahn, MW (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	mwh@indiana.edu	Stajich, Jason Eric/C-7297-2008; De Bie, Tijl/B-2920-2013	Stajich, Jason Eric/0000-0002-7591-0020; Hahn, Matthew/0000-0002-5731-8808; De Bie, Tijl/0000-0002-2692-7504	National Science Foundation [MCB-0528465, DBI-0543586]; National Institutes of Health [R33HG003070-01]; CoE [EF/05/007]; Research Council K. U. Leuven; Indiana University; Lilly Endowment, Inc.;  [GOA/2005/04]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R33HG003070] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CoE(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Research Council K. U. Leuven(KU Leuven); Indiana University; Lilly Endowment, Inc.; ; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This work was supported by grants from the National Science Foundation (MCB-0528465 and DBI-0543586) to MWH and the National Institutes of Health (R33HG003070-01) to NC. TDB acknowledges support from the CoE EF/05/007 SymBioSys, and from GOA/2005/04, both from the Research Council K. U. Leuven. MWH and JPD are also supported by the METACyt Initiative of Indiana University, funded in part through a major grant from the Lilly Endowment, Inc. None of the sponsors played any role in any part of the study.	Bailey JA, 2006, NAT REV GENET, V7, P552, DOI 10.1038/nrg1895; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bergthorsson U, 2003, NATURE, V424, P197, DOI 10.1038/nature01743; Boussau B, 2004, P NATL ACAD SCI USA, V101, P9722, DOI 10.1073/pnas.0400975101; Britten RJ, 2002, P NATL ACAD SCI USA, V99, P13633, DOI 10.1073/pnas.172510699; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Bustamante CD, 2005, NATURE, V437, P1153, DOI 10.1038/nature04240; Carroll SB, 2005, PLOS BIOL, V3, P1159, DOI 10.1371/journal.pbio.0030245; Chen K, 2000, J COMPUT BIOL, V7, P429, DOI 10.1089/106652700750050871; Cheng Z, 2005, NATURE, V437, P88, DOI 10.1038/nature04000; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Copley RR, 2003, CURR OPIN GENET DEV, V13, P623, DOI 10.1016/j.gde.2003.10.004; De Bie T, 2006, BIOINFORMATICS, V22, P1269, DOI 10.1093/bioinformatics/btl097; Enard W, 2002, NATURE, V418, P869, DOI 10.1038/nature01025; Enright AJ, 2002, NUCLEIC ACIDS RES, V30, P1575, DOI 10.1093/nar/30.7.1575; Eystathioy T, 2000, J AUTOIMMUN, V14, P179, DOI 10.1006/jaut.1999.0359; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fortna A, 2004, PLOS BIOL, V2, P937, DOI 10.1371/journal.pbio.0020207; Francino MP, 2005, NAT GENET, V37, P573, DOI 10.1038/ng1579; Garczarek L, 2000, P NATL ACAD SCI USA, V97, P4098, DOI 10.1073/pnas.070040897; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Gilad Y, 2005, GENOME RES, V15, P224, DOI 10.1101/gr.2846405; Gilad Y, 2004, PLOS BIOL, V2, P120, DOI 10.1371/journal.pbio.0020005; Grus WE, 2005, P NATL ACAD SCI USA, V102, P5767, DOI 10.1073/pnas.0501589102; Hahn MW, 2005, GENOME RES, V15, P1153, DOI 10.1101/gr.3567505; Hahn MW, 2004, GENETICS, V167, P867, DOI 10.1534/genetics.103.025726; Hubbard T, 2005, NUCLEIC ACIDS RES, V33, pD447, DOI 10.1093/nar/gki138; Hughes AL, 2004, J MOL EVOL, V59, P827, DOI 10.1007/s00239-004-0115-7; Johnson ME, 2001, NATURE, V413, P514, DOI 10.1038/35097067; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Li W. H, 1997, MOL EVOLUTION; Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338; Long M, 2003, NAT REV GENET, V4, P865, DOI 10.1038/nrg1204; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Lynch Michael, 2003, Journal of Structural and Functional Genomics, V3, P35, DOI 10.1023/A:1022696612931; Malsam J, 2005, SCIENCE, V307, P1095, DOI 10.1126/science.1108061; McLysaght A, 2003, P NATL ACAD SCI USA, V100, P15655, DOI 10.1073/pnas.2136653100; Mikkelsen TS, 2005, NATURE, V437, P69, DOI 10.1038/nature04072; Nguyen DQ, 2006, PLOS GENET, V2, P198, DOI 10.1371/journal.pgen.0020020; Nielsen R, 2005, PLOS BIOL, V3, P976, DOI 10.1371/journal.pbio.0030170; Niimura Y, 2005, GENE, V346, P23, DOI 10.1016/j.gene.2004.09.027; Noonan JP, 2003, AM J HUM GENET, V72, P621, DOI 10.1086/368060; Ohno S., 1970, EVOLUTION GENE DUPLI; Olson MV, 1999, AM J HUM GENET, V64, P18, DOI 10.1086/302219; Ranson H, 2002, SCIENCE, V298, P179, DOI 10.1126/science.1076781; Rockman MV, 2005, PLOS BIOL, V3, P2208, DOI 10.1371/journal.pbio.0030387; Rouquier S, 2000, P NATL ACAD SCI USA, V97, P2870, DOI 10.1073/pnas.040580197; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Shiu SH, 2006, P NATL ACAD SCI USA, V103, P2232, DOI 10.1073/pnas.0510388103; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; Torrents D, 2003, GENOME RES, V13, P2559, DOI 10.1101/gr.1455503; Vallender EJ, 2006, HUM MOL GENET, V15, P3034, DOI 10.1093/hmg/ddl245; Wang XX, 2006, PLOS BIOL, V4, P366, DOI 10.1371/journal.pbio.0040052; Wassink TH, 2005, AM J MED GENET B, V136B, P36, DOI 10.1002/ajmg.b.30180; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Weider LJ, 2005, ANNU REV ECOL EVOL S, V36, P219, DOI 10.1146/annurev.ecolsys.36.102003.152620; Wooding S, 2006, BIOESSAYS, V28, P335, DOI 10.1002/bies.20385; Zhang JZ, 2002, GENETICS, V162, P1825; Zmasek CM, 2001, BIOINFORMATICS, V17, P821, DOI 10.1093/bioinformatics/17.9.821	59	225	231	1	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e85	10.1371/journal.pone.0000085	http://dx.doi.org/10.1371/journal.pone.0000085			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183716	Green Published, gold			2022-12-25	WOS:000207443600084
J	Spierings, E; Drabbels, J; Hendriks, M; Pool, J; Spruyt-Gerritse, M; Claas, F; Goulmy, E				Spierings, Eric; Drabbels, Jos; Hendriks, Matthijs; Pool, Jos; Spruyt-Gerritse, Marijke; Claas, Frans; Goulmy, Els			A Uniform Genomic Minor Histocompatibility Antigen Typing Methodology and Database Designed to Facilitate Clinical Applications	PLOS ONE			English	Article								Background. Minor Histocompatibility (H) antigen mismatches significantly influence the outcome of HLA-matched allogeneic stem cell transplantation. The molecular identification of human H antigens is increasing rapidly. In parallel, clinical application of minor H antigen typing has gained interest. So far, relevant and simple tools to analyze the minor H antigens in a quick and reliable way are lacking. Methodology and Findings. We developed a uniform PCR with sequence-specific primers (PCR-SSP) for 10 different autosomal minor H antigens and H-Y. This genomic minor H antigen typing methodology allows easy incorporation in the routine HLA typing procedures. DNA from previously typed EBV-LCL was used to validate the methodology. To facilitate easy interpretation for clinical purposes, a minor H database named dbMinor (http://www.lumc.nl/dbminor) was developed. Input of the minor H antigen typing results subsequently provides all relevant information for a given patient/donor pair and additional information on the putative graft-versus-host, graft-versus-tumor and host-versus-graft reactivities. Significance. A simple, uniform and rapid methodology was developed enabling determination of minor H antigen genotypes of all currently identified minor H antigens. A dbMinor database was developed to interpret the genomic typing for its potential clinical relevance. The combination of the minor H antigen genomic typing methodology with the online dbMinor database and applications facilitates the clinical application of minor H antigens anti-tumor targets after stem cell transplantation.	[Spierings, Eric; Drabbels, Jos; Hendriks, Matthijs; Pool, Jos; Spruyt-Gerritse, Marijke; Claas, Frans; Goulmy, Els] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Spierings, E (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands.	eric.spierings@lumc.nl	Spierings, Eric/AAU-5138-2021	Spierings, Eric/0000-0001-9441-1019; Hendriks, Matthijs/0000-0003-2334-9013	European Commission; Leiden University Medical Center, the Netherlands Organization for Scientific Research (NWO); Macropa Foundation	European Commission(European CommissionEuropean Commission Joint Research Centre); Leiden University Medical Center, the Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Macropa Foundation	Funding: This study was supported in part by grants of the Leukemia and Lymphoma Society of America, the 6th Framework Programme "Allostem" of the European Commission, the Leiden University Medical Center, the Netherlands Organization for Scientific Research (NWO) and the Macropa Foundation.	Akatsuka Y, 2003, J EXP MED, V197, P1489, DOI 10.1084/jem.20021925; Brickner AG, 2006, BLOOD, V107, P3779, DOI 10.1182/blood-2005-08-3501; Brickner AG, 2001, J EXP MED, V193, P195, DOI 10.1084/jem.193.2.195; Cai JC, 2004, J EXP MED, V199, P1017, DOI 10.1084/jem.20031012; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; den Haan JMM, 1998, SCIENCE, V279, P1054, DOI 10.1126/science.279.5353.1054; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; Dolstra H, 2002, EUR J IMMUNOL, V32, P2748, DOI 10.1002/1521-4141(2002010)32:10<2748::AID-IMMU2748>3.0.CO;2-T; Dolstra H, 1999, J EXP MED, V189, P301, DOI 10.1084/jem.189.2.301; Fujii N, 2002, TRANSPLANTATION, V73, P1137, DOI 10.1097/00007890-200204150-00022; GOULMY E, 1976, LANCET, V2, P1206; GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159a0; Goulmy E, 1996, CURR OPIN IMMUNOL, V8, P75, DOI 10.1016/S0952-7915(96)80108-7; Goulmy E, 1997, IMMUNOL REV, V157, P125, DOI 10.1111/j.1600-065X.1997.tb00978.x; Goulmy E, 2006, HUM IMMUNOL, V67, P433, DOI 10.1016/j.humimm.2006.03.012; Hambach L, 2005, CURR OPIN IMMUNOL, V17, P202, DOI 10.1016/j.coi.2005.01.010; Ivanov R, 2005, CLIN CANCER RES, V11, P1694, DOI 10.1158/1078-0432.CCR-04-1772; Klein CA, 2002, J EXP MED, V196, P359, DOI 10.1084/jem.20011838; Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; Mommaas B, 2002, J IMMUNOL, V169, P3131, DOI 10.4049/jimmunol.169.6.3131; Murata M, 2003, J EXP MED, V197, P1279, DOI 10.1084/jem.20030044; Nishida T, 2004, BRIT J HAEMATOL, V124, P629, DOI 10.1111/j.1365-2141.2004.04823.x; OLERUP O, 1991, TISSUE ANTIGENS, V37, P197, DOI 10.1111/j.1399-0039.1991.tb01872.x; Pierce RA, 1999, J IMMUNOL, V163, P6360; Rijke BC, 2005, J CLIN INVEST, V115, P3506, DOI 10.1172/JCI24832; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Spierings E, 2005, J CLIN INVEST, V115, P3397, DOI 10.1172/JCI27094; Spierings E, 2003, LANCET, V362, P610, DOI 10.1016/S0140-6736(03)14191-8; Spierings E, 2003, BLOOD, V102, P621, DOI 10.1182/blood-2003-01-0260; Torikai H, 2004, J IMMUNOL, V173, P7046, DOI 10.4049/jimmunol.173.11.7046; Tseng LH, 1998, TISSUE ANTIGENS, V52, P305, DOI 10.1111/j.1399-0039.1998.tb03052.x; Vogt MHJ, 2000, BLOOD, V96, P3126, DOI 10.1182/blood.V96.9.3126.h8003126_3126_3132; Vogt MHJ, 2000, BLOOD, V95, P1100, DOI 10.1182/blood.V95.3.1100.003k42_1100_1105; Vogt MHJ, 2002, BLOOD, V99, P3027, DOI 10.1182/blood.V99.8.3027; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640; Warren EH, 2006, SCIENCE, V313, P1444, DOI 10.1126/science.1130660; Warren EH, 2000, J IMMUNOL, V164, P2807, DOI 10.4049/jimmunol.164.5.2807; Warren EH, 1998, BLOOD, V91, P2197, DOI 10.1182/blood.V91.6.2197; Wilke M, 2002, TISSUE ANTIGENS, V59, P304, DOI 10.1034/j.1399-0039.2002.590408.x; Wilke M, 1998, TISSUE ANTIGENS, V52, P312, DOI 10.1111/j.1399-0039.1998.tb03053.x; Wilke Martina, 2003, Hematol J, V4, P315, DOI 10.1038/sj.thj.6200318; Zorn E, 2004, J EXP MED, V199, P1133, DOI 10.1084/jem.20031560	43	45	46	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e42	10.1371/journal.pone.0000042	http://dx.doi.org/10.1371/journal.pone.0000042			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183671	gold, Green Published, Green Submitted			2022-12-25	WOS:000207443600042
J	Uechi, T; Nakajima, Y; Nakao, A; Torihara, H; Chakraborty, A; Inoue, K; Kenmochi, N				Uechi, Tamayo; Nakajima, Yukari; Nakao, Akihiro; Torihara, Hidetsugu; Chakraborty, Anirban; Inoue, Kunio; Kenmochi, Naoya			Ribosomal Protein Gene Knockdown Causes Developmental Defects in Zebrafish	PLOS ONE			English	Article								The ribosomal proteins (RPs) form the majority of cellular proteins and are mandatory for cellular growth. RP genes have been linked, either directly or indirectly, to various diseases in humans. Mutations in RP genes are also associated with tissue-specific phenotypes, suggesting a possible role in organ development during early embryogenesis. However, it is not yet known how mutations in a particular RP gene result in specific cellular changes, or how RP genes might contribute to human diseases. The development of animal models with defects in RP genes will be essential for studying these questions. In this study, we knocked down 21 RP genes in zebrafish by using morpholino antisense oligos to inhibit their translation. Of these 21, knockdown of 19 RPs resulted in the development of morphants with obvious deformities. Although mutations in RP genes, like other housekeeping genes, would be expected to result in nonspecific developmental defects with widespread phenotypes, we found that knockdown of some RP genes resulted in phenotypes specific to each gene, with varying degrees of abnormality in the brain, body trunk, eyes, and ears at about 25 hours post fertilization. We focused further on the organogenesis of the brain. Each knocked-down gene that affected the morphogenesis of the brain produced a different pattern of abnormality. Among the 7 RP genes whose knockdown produced severe brain phenotypes, 3 human orthologs are located within chromosomal regions that have been linked to brain-associated diseases, suggesting a possible involvement of RP genes in brain or neurological diseases. The RP gene knockdown system developed in this study could be a powerful tool for studying the roles of ribosomes in human diseases.	[Uechi, Tamayo; Nakajima, Yukari; Nakao, Akihiro; Torihara, Hidetsugu; Chakraborty, Anirban; Kenmochi, Naoya] Miyazaki Univ, Frontier Sci Res Ctr, Miyazaki, Japan; [Inoue, Kunio] Kobe Univ, Grad Sch Sci & Technol, Dept Biol, Kobe, Hyogo 657, Japan	University of Miyazaki; Kobe University	Kenmochi, N (corresponding author), Miyazaki Univ, Frontier Sci Res Ctr, Miyazaki, Japan.	kenmochi@med.miyazaki-u.ac.jp	Kenmochi, Naoya/ABF-3564-2021; Chakraborty, Anirban/AAP-5348-2020	/0000-0003-3476-6576	Ministry of Education, Culture, Sports, Science, and Technology (MEXT) [14035103, 17790653, 188093]; Japan Society for the Promotion of Science (JSPS) [P06457]; Sasagawa Grants for Science Fellows (SGSF)	Ministry of Education, Culture, Sports, Science, and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Sasagawa Grants for Science Fellows (SGSF)	Funding: This study was supported by Grants-in-Aid for Scientific Research (14035103, 17790653, and 188093) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) and the Japan Society for the Promotion of Science (JSPS), and Sasagawa Grants for Science Fellows (SGSF). AC is a research fellow of JSPS (P06457).	Abidi F, 1999, AM J MED GENET, V85, P223, DOI 10.1002/(SICI)1096-8628(19990730)85:3<223::AID-AJMG8>3.0.CO;2-R; Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; AMSTERDAM A, 2004, P NATL ACAD SCI USA, V170, P245; CAVASLAR GN, 2002, AM J HUM GENET, V66, P1705; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Driever W, 1996, DEVELOPMENT, V123, P37; Golling G, 2002, NAT GENET, V31, P135, DOI 10.1038/ng896; Haffter P, 1996, DEVELOPMENT, V123, P1; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; Irobi J, 2004, NAT GENET, V36, P597, DOI 10.1038/ng1328; Ishijima J, 1998, GENOMICS, V49, P341, DOI 10.1006/geno.1998.5277; Kenmochi N, 1998, GENOME RES, V8, P509, DOI 10.1101/gr.8.5.509; Klein DJ, 2004, J MOL BIOL, V340, P141, DOI 10.1016/j.jmb.2004.03.076; Lambertsson A, 1998, ADV GENET, V38, P69, DOI 10.1016/S0065-2660(08)60142-X; Leegwater PAJ, 2001, NAT GENET, V29, P383, DOI 10.1038/ng764; Liu JM, 2006, BLOOD, V107, P4583, DOI 10.1182/blood-2005-12-4831; Matsson H, 2004, MOL CELL BIOL, V24, P4032, DOI 10.1128/MCB.24.9.4032-4037.2004; Nakao A, 2004, NUCLEIC ACIDS RES, V32, pD168, DOI 10.1093/nar/gkh004; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Noller HF, 2005, SCIENCE, V309, P1508, DOI 10.1126/science.1111771; Oliver ER, 2004, DEVELOPMENT, V131, P3907, DOI 10.1242/dev.01268; Ropers HH, 2006, CURR OPIN GENET DEV, V16, P260, DOI 10.1016/j.gde.2006.04.017; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Tang BS, 2005, HUM GENET, V116, P222, DOI 10.1007/s00439-004-1218-3; Uechi T, 2001, GENOMICS, V72, P223, DOI 10.1006/geno.2000.6470; van der Knaap MS, 2002, ANN NEUROL, V51, P264, DOI 10.1002/ana.10112; Willig TN, 1999, BLOOD, V94, P4294; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443; Yoshihama M, 2002, GENOME RES, V12, P379, DOI 10.1101/gr.214202	29	73	75	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e37	10.1371/journal.pone.0000037	http://dx.doi.org/10.1371/journal.pone.0000037			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183665	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600037
J	Aoki, K; Aoki, M; Sugai, M; Harada, N; Miyoshi, H; Tsukamoto, T; Mizoshita, T; Tatematsu, M; Seno, H; Chiba, T; Oshima, M; Hsieh, CL; Taketo, MM				Aoki, K.; Aoki, M.; Sugai, M.; Harada, N.; Miyoshi, H.; Tsukamoto, T.; Mizoshita, T.; Tatematsu, M.; Seno, H.; Chiba, T.; Oshima, M.; Hsieh, C-L; Taketo, M. M.			Chromosomal instability by beta-catenin/TCF transcription in APC or beta-catenin mutant cells	ONCOGENE			English	Article						APC; beta-catenin; chromosomal instability; cancer; Wnt signaling	ADENOMATOUS-POLYPOSIS-COLI; COLORECTAL TUMOR-CELLS; GASTRIC-CANCER; EXPRESSION; MUTATIONS; PROTEIN; MICE; GENE; TUMORIGENESIS; CARCINOMA	Adenomatous polyposis coli (APC/Apc) gene encodes a key tumor suppressor whose mutations activate beta-catenin/T-cell factor (TCF)-mediated transcription (canonical Wnt signaling). Here, we show that Wnt signaling can cause chromosomal instability (CIN). As an indicator of CIN, we scored anaphase bridge index (ABI) in mouse polyps and ES cells where Wnt signaling was activated by Apc or beta-catenin mutations. We found three to nine times higher ABI than in wild-type controls. Furthermore, karyotype analysis confirmed that the Wnt signal activated ES cells produced new chromosomal aberrations at higher rates; hence CIN. Consistently, expression of dominant-negative TCFs in these cells reduced their ABI. We also found that Wnt signal activation increased phosphorylation of Cdc2 (Cdk1) that inhibited its activity, and suppressed apoptosis upon exposure of the cells to nocodazole or colcemid. The data suggest that Wnt signaling stimulates the cells to escape from mitotic arrest and apoptosis, resulting in CIN. In human gastric cancer tissues with nuclear beta-catenin, ABI was significantly higher than in those without. These results collectively indicate that beta-catenin/TCF-mediated transcription itself increases CIN through dysregulation of G2/M progression.	Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Ctr Mol Biol & Genet, Kyoto 6068501, Japan; Banyu Tsukuba Res Inst Merck, Ibaraki, Japan; Aichi Canc Ctr, Res Inst, Div Oncol Pathol, Aichi, Japan; Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto 6068501, Japan; Univ So Calif, Dept Urol, Los Angeles, CA 90033 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Kyoto University; Kyoto University; Merck & Company; Aichi Cancer Center; Kyoto University; University of Southern California; University of Southern California	Taketo, MM (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	taketo@mfour.med.kyoto-u.ac.jp	Tsukamoto, Tetsuya/ABD-4397-2020; Oshima, Masanobu/F-9958-2014; Aoki, Masahiro/A-5149-2016; Harada, Naomoto/Y-4591-2019; Aoki, Kazuhiro/I-5483-2019	Tsukamoto, Tetsuya/0000-0002-7502-8724; Oshima, Masanobu/0000-0002-3304-0004; Aoki, Masahiro/0000-0003-4316-9490; Aoki, Kazuhiro/0000-0001-7263-1555; Miyoshi, Hiroyuki/0000-0001-7400-0714; Seno, Hiroshi/0000-0002-8509-8128; Harada, Naomoto/0000-0003-1083-7253; Sugai, Manabu/0000-0003-1668-7647				Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Danesi DT, 2000, CYTOMETRY, V42, P27, DOI 10.1002/(SICI)1097-0320(20000215)42:1<27::AID-CYTO5>3.0.CO;2-N; Dikovskaya D, 2004, MOL BIOL CELL, V15, P2978, DOI 10.1091/mbc.E03-08-0613; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gisselsson D, 2003, ADV CANCER RES, V87, P1; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Green RA, 2003, J CELL BIOL, V163, P949, DOI 10.1083/jcb.200307070; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Homfray TFR, 1998, HUM MUTAT, V11, P114, DOI 10.1002/(SICI)1098-1004(1998)11:2<114::AID-HUMU3>3.0.CO;2-J; HSIEH CL, 1997, CELL BIOL LAB HDB, P391; Ishikawa T, 2003, DEV BIOL, V253, P230, DOI 10.1016/S0012-1606(02)00020-9; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li Q, 2005, CANCER RES, V65, P8622, DOI 10.1158/0008-5472.CAN-05-2145; McCartney BM, 2006, DEVELOPMENT, V133, P2407, DOI 10.1242/dev.02398; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mizoshita T, 2003, J CANCER RES CLIN, V129, P727, DOI 10.1007/s00432-003-0499-6; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Sekiya T, 2004, J BIOL CHEM, V279, P6840, DOI 10.1074/jbc.M310876200; Sekiya T, 2002, CANCER RES, V62, P3322; Seno H, 2002, INT J ONCOL, V21, P769; Shih IM, 2001, CANCER RES, V61, P818; Shin HJ, 2003, CANCER CELL, V4, P483, DOI 10.1016/S1535-6108(03)00302-7; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Taketo MM, 2006, CANCER SCI, V97, P355, DOI 10.1111/j.1349-7006.2006.00190.x; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tighe A, 2004, J CELL SCI, V117, P6339, DOI 10.1242/jcs.01556; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0	42	57	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3511	3520		10.1038/sj.onc.1210141	http://dx.doi.org/10.1038/sj.onc.1210141			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160019				2022-12-25	WOS:000246799200007
J	Jacobson, F; Pistorius, A; Farkas, D; De Grip, W; Hansson, O; Sjolin, L; Neutze, R				Jacobson, Frida; Pistorius, Arthur; Farkas, Daniel; De Grip, Willem; Hansson, Orjan; Sjolin, Lennart; Neutze, Richard			pH dependence of copper geometry, reduction potential, and nitrite affinity in nitrite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCALIGENES-FAECALIS S-6; X-RAY-STRUCTURE; INTRAMOLECULAR ELECTRON-TRANSFER; ATOMIC-RESOLUTION STRUCTURES; TYPE-2 COPPER; ACHROMOBACTER-CYCLOCLASTES; ACTIVE-SITE; MOLECULAR REPLACEMENT; ANGSTROM RESOLUTION; SUBSTRATE-BINDING	Many properties of copper-containing nitrite reductase are pH-dependent, such as gene expression, enzyme activity, and substrate affinity. Here we use x-ray diffraction to investigate the structural basis for the pH dependence of activity and nitrite affinity by examining the type 2 copper site and its immediate surroundings in nitrite reductase from Rhodobacter sphaeroides 2.4.3. At active pH the geometry of the substrate-free oxidized type 2 copper site shows a near perfect tetrahedral geometry as defined by the positions of its ligands. At higher pH values the most favorable copper site geometry is altered toward a more distorted tetrahedral geometry whereby the solvent ligand adopts a position opposite to that of the His-131 ligand. This pH-dependent variation in type 2 copper site geometry is discussed in light of recent computational results. When co-crystallized with substrate, nitrite is seen to bind in a bidentate fashion with its two oxygen atoms ligating the type 2 copper, overlapping with the positions occupied by the solvent ligand in the high and low pH structures. Fourier transformation infrared spectroscopy is used to assign the pH dependence of the binding of nitrite to the active site, and EPR spectroscopy is used to characterize the pH dependence of the reduction potential of the type 2 copper site. Taken together, these spectroscopic and structural observations help to explain the pH dependence of nitrite reductase, highlighting the subtle relationship between copper site geometry, nitrite affinity, and enzyme activity.	Chalmers, Dept Chem & Biol Engn, SE-40530 Gothenburg, Sweden; Radboud Univ Nijmegen, Dept Biochem, UMC 286, Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Univ Gothenburg, Dept Chem, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Dept Chem, SE-41296 Gothenburg, Sweden	Chalmers University of Technology; Radboud University Nijmegen; University of Gothenburg; University of Gothenburg	Neutze, R (corresponding author), Chalmers, Dept Chem & Biol Engn, Box 462, SE-40530 Gothenburg, Sweden.	richard.neutze@chembio.chalmers.se	Neutze, Richard/A-7573-2010; Pistorius, Arthur/ABB-1229-2021; Pistorius, Arthur MA/P-5780-2015; Sjolin, Lennart G/B-2619-2010; Hansson, Orjan/D-1282-2009; DeGrip, Willem/L-4335-2015	Neutze, Richard/0000-0003-0986-6153; Pistorius, Arthur/0000-0003-1865-4961; DeGrip, Willem/0000-0001-7637-4920				Abraham ZHL, 1997, BIOCHEM J, V324, P511, DOI 10.1042/bj3240511; ADMAN ET, 1995, J BIOL CHEM, V270, P27458, DOI 10.1074/jbc.270.46.27458; Antonyuk SV, 2005, P NATL ACAD SCI USA, V102, P12041, DOI 10.1073/pnas.0504207102; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett ML, 2004, BIOCHEMISTRY-US, V43, P16311, DOI 10.1021/bi048682g; Beaumont HJE, 2004, MOL MICROBIOL, V54, P148, DOI 10.1111/j.1365-2958.2004.04248.x; Boulanger MJ, 2002, J MOL BIOL, V315, P1111, DOI 10.1006/jmbi.2001.5251; Boulanger MJ, 2001, BIOCHEMISTRY-US, V40, P9132, DOI 10.1021/bi0107400; Boulanger MJ, 2000, J BIOL CHEM, V275, P23957, DOI 10.1074/jbc.M001859200; Dodd FE, 1997, ACTA CRYSTALLOGR D, V53, P406, DOI 10.1107/S0907444997002667; Ellis MJ, 2003, J MOL BIOL, V328, P429, DOI 10.1016/S0022-2836(03)00308-5; Ellis MJ, 2002, J MOL BIOL, V316, P51, DOI 10.1006/jmbi.2001.5304; Ellis MJ, 2001, ACTA CRYSTALLOGR D, V57, P1110, DOI 10.1107/S0907444901008654; Evans W, 1997, CHEM BRIT, V33, P22; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; Impagliazzo A, 2005, CHEMBIOCHEM, V6, P1648, DOI 10.1002/cbic.200500082; Inoue T, 1998, J BIOCHEM, V124, P876, DOI 10.1093/oxfordjournals.jbchem.a022201; Jacobson F, 2005, ACTA CRYSTALLOGR D, V61, P1190, DOI 10.1107/S0907444905017488; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kallrot N, 2005, INT J QUANTUM CHEM, V102, P520, DOI 10.1002/qua.20386; Kobayashi K, 1999, J BIOCHEM, V126, P408, DOI 10.1093/oxfordjournals.jbchem.a022465; Kukimoto M, 1996, J BIOL CHEM, V271, P13680, DOI 10.1074/jbc.271.23.13680; KUKIMOTO M, 1994, BIOCHEMISTRY-US, V33, P5246, DOI 10.1021/bi00183a030; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LESLIE AGW, 1992, JNT CCP4 ESF EAMCB N, V26, P27; MURPHY MEP, 1995, BIOCHEMISTRY-US, V34, P12107, DOI 10.1021/bi00038a003; Murphy MEP, 1997, J BIOL CHEM, V272, P28455, DOI 10.1074/jbc.272.45.28455; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nurizzo D, 1997, STRUCTURE, V5, P1157, DOI 10.1016/S0969-2126(97)00267-0; Olesen K, 1998, BIOCHEMISTRY-US, V37, P6086, DOI 10.1021/bi971603z; SUZUKI S, 1994, J AM CHEM SOC, V116, P11145, DOI 10.1021/ja00103a035; Suzuki S, 1999, COORDIN CHEM REV, V190, P245, DOI 10.1016/S0010-8545(99)00069-7; Tocheva EI, 2004, SCIENCE, V304, P867, DOI 10.1126/science.1095109; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Veselov A, 1998, BIOCHEMISTRY-US, V37, P6095, DOI 10.1021/bi971604r; Wijma HJ, 2003, BIOCHEMISTRY-US, V42, P4075, DOI 10.1021/bi027270+; Zhao YW, 2002, BIOCHEMISTRY-US, V41, P7464, DOI 10.1021/bi0256274; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	40	62	61	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6347	6355		10.1074/jbc.M605746200	http://dx.doi.org/10.1074/jbc.M605746200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17148448	Green Published, hybrid			2022-12-25	WOS:000244867200041
J	Andriamampandry, C; Taleb, O; Kemmel, V; Humbert, JP; Aunis, D; Maitre, M				Andriamampandry, Christian; Taleb, Omar; Kemmel, Veronique; Humbert, Jean-Paul; Aunis, Dominique; Maitre, Michel			Cloning and functional characterization of a gamma-hydroxybutyrate receptor identified in the human brain	FASEB JOURNAL			English	Article						G-protein coupled receptors; electrophysiological characterization; functional expression; GHB	RAT-BRAIN; HIPPOCAMPAL-NEURONS; GABA(B) RECEPTORS; BINDING-SITES; ACID; DESENSITIZATION; CELLS; PIG	Two parent clones of a gamma-hydroxybutyrate (GHB) receptor, C12K32 and GHBh1, were isolated from a human frontal cortex cDNA library. The two clones differ by a deleted cytosine in C12K32. CHO cells transfected with either C12K32 or GHBh1 responded positively to submicromolar GHB stimulation. However, unlike C12K32, GHBh1 desensitizes rapidly on application of low concentrations of GHB. GHB receptor properties were then studied on C I 2K32 expressed in CHO cells. C12K32 bound GHB with a K-d of 114 nM and has no affinity for GABA or glutamate. GHB and NCS-382 displaced [H-3]GHB with an IC50 of 53 +/- 8 and 120 +/- 18 nM, respectively. In patch-clamp experiments, GHB induced a dose-dependent response with an EC50 of 130 nM. This response was antagonized by NCS-382, was not reproduced by GABA, and was sensitive to the addition of GTP-gamma-S in the recording pipette. CHO cells transfected with C12K32 exhibited GTP gamma-S-35 binding with an EC50 of 462 nM for GHB and an IC50 of 2.9 mu M for NCS-382. The present data led to the conclusion that both C12K32 and GHBh1 are two closely related isoforms of a human GHB receptor, GHBh1, that is described in the databank as the GPCR 172A.	Fac Med, INSERM, U575, F-67085 Strasbourg, France; INSERM, Inst Chim Biol, F-67085 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Maitre, M (corresponding author), Fac Med, INSERM, U575, 11 Rue Humann, F-67085 Strasbourg, France.	maitre@neurochem.u-strasbg.fr	Kemmel, Véronique/V-2590-2019; Taleb, Omar/K-1457-2016; Dominique, Aunis/W-1419-2019; Kemmel, Veronique/O-9018-2015; Maitre, Michel/J-9974-2016	Kemmel, Véronique/0000-0003-4680-4293; Taleb, Omar/0000-0003-2407-0380; Kemmel, Veronique/0000-0003-4680-4293; Maitre, Michel/0000-0003-1478-4806				Andriamampandry C, 2003, FASEB J, V17, P1691, DOI 10.1096/fj.02-0846fje; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; BENAVIDES J, 1982, LIFE SCI, V30, P953, DOI 10.1016/0024-3205(82)90624-5; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Castelli MP, 2000, MOL BRAIN RES, V78, P91, DOI 10.1016/S0169-328X(00)00078-4; Castelli MP, 2004, CNS DRUG REV, V10, P243; DOHERTY JD, 1978, J PHARMACOL EXP THER, V207, P130; Ericsson TA, 2003, P NATL ACAD SCI USA, V100, P6759, DOI 10.1073/pnas.1138025100; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; GALLIMBERTI L, 1989, LANCET, V2, P787; Gould GG, 2003, BRAIN RES, V979, P51, DOI 10.1016/S0006-8993(03)02865-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Kam PCA, 1998, ANAESTHESIA, V53, P1195, DOI 10.1046/j.1365-2044.1998.00603.x; Kaupmann K, 2003, EUR J NEUROSCI, V18, P2722, DOI 10.1111/j.1460-9568.2003.03013.x; LABORIT H, 1964, INT J NEUROPHARMACOL, V3, P433; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Letunic I, 2006, NUCLEIC ACIDS RES, V34, pD257, DOI 10.1093/nar/gkj079; Lingenhoehl K, 1999, NEUROPHARMACOLOGY, V38, P1667, DOI 10.1016/S0028-3908(99)00131-8; Lorente P, 2000, P NATL ACAD SCI USA, V97, P8664, DOI 10.1073/pnas.97.15.8664; MAITRE M, 1990, J PHARMACOL EXP THER, V255, P657; Maitre M, 1997, PROG NEUROBIOL, V51, P337, DOI 10.1016/S0301-0082(96)00064-0; MAMELAK M, 1986, SLEEP, V9, P285, DOI 10.1093/sleep/9.1.285; Muller C, 2002, J NEUROCHEM, V80, P899, DOI 10.1046/j.0022-3042.2002.00780.x; NELSON T, 1981, J NEUROCHEM, V37, P1345, DOI 10.1111/j.1471-4159.1981.tb04689.x; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schweitzer P, 2004, J PHARMACOL EXP THER, V311, P172, DOI 10.1124/jpet.104.069534; WILLIAMS SR, 1995, NEUROSCIENCE, V66, P133, DOI 10.1016/0306-4522(94)00604-4; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; XIE XM, 1992, EUR J PHARMACOL, V212, P291, DOI 10.1016/0014-2999(92)90347-7	30	59	61	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					885	895		10.1096/fj.06-6509com	http://dx.doi.org/10.1096/fj.06-6509com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197387				2022-12-25	WOS:000244686400025
J	Goossens, S; Janssens, B; Vanpoucke, G; De Rycke, R; van Hengel, J; van Roy, F				Goossens, Steven; Janssens, Barbara; Vanpoucke, Griet; De Rycke, Riet; van Hengel, Jolanda; van Roy, Frans			Truncated isoform of mouse alpha T-catenin is testis-restricted in expression and function	FASEB JOURNAL			English	Article						afadin; testis; spermatogenesis	CELL-CELL ADHESION; CADHERIN-ASSOCIATED PROTEIN; COLON-CANCER CELLS; BETA-CATENIN; INTERCELLULAR-ADHESION; ADHERENS JUNCTIONS; BINDING; COMPLEX; NECTIN; AFADIN	alpha T-Catenin is a recently identified member of the alpha-catenin family of cell-cell adhesion molecules. For decades it was thought that ot-catenins mediate solid cell-cell adhesion by linking the cadherin-mediated cell-cell adhesion complex with the actin cytoskeleton. However, the roles of (alpha-catenins in this classical adhesion model have been questioned recently. (alpha T-Catenin has a restricted expression pattern, in contrast to the ubiquitously expressed (alpha E-catenin. High levels of off-catenin were detected in heart and testis. Northern and Western blot experiments indicated that besides the standard full-length alpha T-catenin transcript, smaller alternative transcripts are expressed in testis. We report the cloning of two alternative transcripts of the mouse alpha T-catenin gene (transcript-B and -X), both of which are expressed in a testisrestricted manner from two putative alternative promoters. Alternative transcript-X encodes a smaller protein, isoform-X, which lacks the amino-terminal beta-catenin binding domain of the standard mouse alpha T-catenin protein, and is therefore unable to restore cell-cell adhesion in an alpha-catenin-negative colon carcinoma cell line. Immunohistochemical analysis showed specific localization of the alpha T-catenin isoform-X in the differentiating germ cells. In contrast to the standard full-length alpha T-catenin protein, this shortened isoform-X can bind to I-afadin, an important component of the nectin/afadin/ponsin adhesion complex that reportedly is essential for spermatogenesis.	Univ Ghent VIB, Dept Mol Biomed Res, B-9052 Ghent, Belgium; Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	van Roy, F (corresponding author), Univ Ghent VIB, Dept Mol Biomed Res, Technol Pk 927, B-9052 Ghent, Belgium.	f.vanroy@dmbr.ugent.be	van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039; Goossens, Steven/0000-0002-5693-8570				Asada M, 2003, J BIOL CHEM, V278, P4103, DOI 10.1074/jbc.M209832200; Busby V, 2004, NEUROMOL MED, V5, P133, DOI 10.1385/NMM:5:2:133; CLAVERIE JM, 1993, GENOMICS, V15, P13, DOI 10.1006/geno.1993.1004; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goossens S, 2005, FRONT BIOSCI-LANDMRK, V10, P398, DOI 10.2741/1537; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; Janssens B, 2003, HUM GENET, V112, P227, DOI 10.1007/s00439-002-0857-5; Janssens B, 2001, J CELL SCI, V114, P3177; Kierszenbaum AL, 2004, ARCH HISTOL CYTOL, V67, P271, DOI 10.1679/aohc.67.271; Kobielak A, 2004, NAT REV MOL CELL BIO, V5, P614, DOI 10.1038/nrm1433; Kobielak A, 2006, P NATL ACAD SCI USA, V103, P2322, DOI 10.1073/pnas.0510422103; Kobielak A, 2004, NAT CELL BIOL, V6, P21, DOI 10.1038/ncb1075; Kotaja N, 2004, NAT METHODS, V1, P249, DOI 10.1038/nmeth1204-249; Mueller S, 2003, BIOL REPROD, V69, P1330, DOI 10.1095/biolreprod.102.014670; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; Pokutta S, 2002, J BIOL CHEM, V277, P18868, DOI 10.1074/jbc.M201463200; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Vermeulen SJ, 1999, ONCOGENE, V18, P905, DOI 10.1038/sj.onc.1202348; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020; Zhang JY, 2005, ENDOCRINOLOGY, V146, P1268, DOI 10.1210/en.2004-1194	27	20	20	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					647	655		10.1096/fj.06-6066com	http://dx.doi.org/10.1096/fj.06-6066com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17185752				2022-12-25	WOS:000244686400004
J	Gupta, A; Decaillot, FM; Gomes, I; Tkalych, O; Heimann, AS; Ferro, ES; Devi, LA				Gupta, Achla; Decaillot, Fabien M.; Gomes, Ivone; Tkalych, Oleg; Heimann, Andrea S.; Ferro, Erner S.; Devi, Lakshmi A.			Conformation state-sensitive antibodies to G-protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT CHANGES; DELTA-OPIOID RECEPTORS; MONOCLONAL-ANTIBODY; STRUCTURAL FEATURES; TERMINAL SEQUENCE; RHODOPSIN; BINDING; MU; AGONIST; ACTIVATION	A growing body of evidence indicates that G-protein-coupled receptors undergo complex conformational changes upon agonist activation. It is likely that the extracellular region, including the N terminus, undergoes activation-dependent conformational changes. We examined this by generating antibodies to regions within the N terminus of mu-opioid receptors. We find that antibodies to the midportion of the N-terminal tail exhibit enhanced recognition of activated receptors, whereas those to the distal regions do not. The enhanced recognition is abolished upon treatment with agents that block G-protein coupling or deglycosylate the receptor. This suggests that the N-terminal region of mu receptors undergoes conformational changes following receptor activation that can be selectively detected by these region-specific antibodies. We used these antibodies to characterize,mu receptor type-specific ligands and find that the antibodies accurately differentiate ligands with varying efficacies. Next, we examined if these antibodies can be used to investigate the extent and duration of activation of endogenous receptors. We find that peripheral morphine administration leads to a time-dependent increase in antibody binding in the striatum and prefrontal cortex with a peak at about 30 min, indicating that these antibodies can be used to probe the spatio-temporal dynamics of native mu receptors. Finally, we show that this strategy of targeting the N-terminal region to generate receptor conformation-specific antisera can be applied to other G alpha(i)-coupled (delta-opioid, CB1 cannabinoid, alpha(2A)-adrenergic) as well as G alpha(s)- (beta(2)-adrenergic) and G alpha(q)-coupled (AT1 angiotensin) receptors. Taken together, these studies describe antisera as tools that allow, for the first time, studies probing differential conformation states of G-protein-coupled receptors, which could be used to identify molecules of therapeutic interest.	CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; Proteimax SC, BR-06700020 Cotia, SP, Brazil; Univ Sao Paulo, Dept Cell & Dev Biol, BR-05504900 Sao Paulo, Brazil	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Universidade de Sao Paulo	Devi, LA (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, 19-84 Annenberg Bldg,1 Gustave L Levy Pl, New York, NY 10029 USA.	lakshmi.devi@mssm.edu	Devi P, Lakshmi/GXM-5982-2022; Ferro, Emer S/D-3908-2012	Devi P, Lakshmi/0000-0001-9274-4776; Ferro, Emer S/0000-0003-1651-9192	NIDA NIH HHS [DA19521, R37 DA008863, R01 DA008863, R56 DA008863, K05 DA019521, DA08863] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA008863, R56DA008863, R01DA008863, K05DA019521] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7945, DOI 10.1021/bi990014l; Archer E, 2003, TRENDS PHARMACOL SCI, V24, P36, DOI 10.1016/S0165-6147(02)00009-3; Blanpain C, 2002, MOL BIOL CELL, V13, P723, DOI 10.1091/mbc.01-03-0129; Bozon V, 2002, RECEPTOR CHANNEL, V8, P113, DOI 10.1080/10606820212394; Cha KW, 2000, P NATL ACAD SCI USA, V97, P3016, DOI 10.1073/pnas.97.7.3016; Decaillot FM, 2003, NAT STRUCT BIOL, V10, P629, DOI 10.1038/nsb950; Dhawan BN, 1996, PHARMACOL REV, V48, P567; Eitan S, 2003, J NEUROSCI, V23, P8360; Fadhil I, 2004, J BIOL CHEM, V279, P21069, DOI 10.1074/jbc.M311468200; Fang F, 1996, BRAIN RES, V722, P95, DOI 10.1016/0006-8993(96)00198-9; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fujisawa Y, 1999, J NEUROSCI, V19, P9618; GARZON J, 1994, LIFE SCI, V54, pPL191, DOI 10.1016/0024-3205(94)90167-8; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gomes I, 2004, P NATL ACAD SCI USA, V101, P5135, DOI 10.1073/pnas.0307601101; Gomes I, 2002, METHODS, V27, P358, DOI 10.1016/S1046-2023(02)00094-4; Gomes I, 1999, FEBS LETT, V456, P126, DOI 10.1016/S0014-5793(99)00878-9; Gouarderes C, 2000, EUR J PHARMACOL, V406, P391, DOI 10.1016/S0014-2999(00)00716-0; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lebesgue D, 1998, EUR J PHARMACOL, V348, P123, DOI 10.1016/S0014-2999(98)00136-8; Lecat S, 2002, J BIOL CHEM, V277, P42034, DOI 10.1074/jbc.M203606200; Levin MC, 2002, J BIOL CHEM, V277, P30429, DOI 10.1074/jbc.M200681200; Lu J, 1998, J IMMUNOL, V160, P1782; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; MORGAN EL, 1993, J IMMUNOL, V151, P377; Mouledous L, 2000, J BIOL CHEM, V275, P29268, DOI 10.1074/jbc.M004971200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Peter JC, 2003, J BIOL CHEM, V278, P36740, DOI 10.1074/jbc.M306877200; Salle L, 2001, J MOL CELL CARDIOL, V33, P405, DOI 10.1006/jmcc.2000.1312; Scherrer G, 2004, EUR J NEUROSCI, V19, P2239, DOI 10.1111/j.0953-816X.2004.03339.x; Schmidt A, 2001, J BIOL CHEM, V276, P23373, DOI 10.1074/jbc.M100057200; Silve C, 2005, J BIOL CHEM, V280, P37917, DOI 10.1074/jbc.M506263200; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Takao M, 2002, ZOOL SCI, V19, P651, DOI 10.2108/zsj.19.651; Trapaidze N, 2000, DNA CELL BIOL, V19, P195, DOI 10.1089/104454900314465; Vaidehi N, 2002, P NATL ACAD SCI USA, V99, P12622, DOI 10.1073/pnas.122357199; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; Vignal E, 2001, MOL CELL BIOL, V21, P8022, DOI 10.1128/MCB.21.23.8022-8034.2001; Wang DX, 2004, J PHARMACOL EXP THER, V308, P512, DOI 10.1124/jpet.103.054049; Xu W, 2001, BIOCHEMISTRY-US, V40, P8018, DOI 10.1021/bi002490d; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u	43	81	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5116	5124		10.1074/jbc.M609254200	http://dx.doi.org/10.1074/jbc.M609254200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17148456	hybrid, Green Accepted			2022-12-25	WOS:000244482300005
J	Yao, PL; Lin, YC; Sawhney, P; Richburg, JH				Yao, Pei-Li; Lin, Yi-Chen; Sawhney, Pragati; Richburg, John H.			Transcriptional regulation of FasL expression and participation of sTNF-alpha in response to Sertoli cell injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; SITE-DIRECTED MUTAGENESIS; LIGAND GENE-EXPRESSION; YOUNG-RAT TESTES; MONO-(2-ETHYLHEXYL) PHTHALATE; TNF-ALPHA; INDUCED APOPTOSIS; INTERLEUKIN-8 EXPRESSION; PROTEIN EXPRESSION	The Fas/FasL signaling pathway has previously been demonstrated to be critical for triggering germ cell apoptosis in response to mono-(2-ethylhexyl)phthalate (MEHP)-induced Sertoli cell injury. Although Sertoli cells ubiquitously express the FasL protein, MEHP-induced germ cell apoptosis appears to tightly correlate with increased levels of Sertoli cell FasL. Here we characterize the transcriptional regulation of the murine FasL gene in Sertoli cells after MEHP exposure. A serial deletion strategy for 1.5 kb of the 5'-upstream activating sequence of the FasL promoter was used to determine transcriptional activity in response to MEHP. Luciferase activity of the FasL promoter in the rat Sertoli cell line ASC-17D revealed that two regions, - 500 to - 324 and - 1250 to - 1000, were necessary to drive the inducible transcription of FasL, Sequence analysis of these two regions revealed two cis-regulatory elements, NF-kappa B and Sp-1. By site-directed mutagenesis, electrophoretic mobility shift and chromatin immunoprecipitation assays, it was confirmed that MEHP-induced FasL expression is enhanced through the transcriptional regulation of both NF-kappa B and Sp-1. Experiments performed both in vitro and in vivo revealed that MEHP exposure results in an increased production of sTNF-alpha and that sTNF-alpha-mediated NF-kappa B activation causes robust increases in FasL levels in both the ASC-17D Sertoli cell line and in primary rat Sertoli cell/germ cell co-cultures. In the seminiferous epithelium, Sertoli cells express TNFR1, whereas germ cells produce TNF-alpha. Therefore, sTNF-alpha released by germ cells after MEHP-induced Sertoli cell injury acts upon Sertoli cell TNFRI and activates NF-kappa B and Sp-1 that consequently causes a robust induction of FasL expression. These novel findings point to a potential "feed-forward" signaling mechanism by which germ cells prompt Sertoli cells to trigger their apoptotic elimination.	Univ Texas, Coll Pharm, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, Coll Pharm, Div Pharmacol & Toxicol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Richburg, JH (corresponding author), 1 Univ Stn, Austin, TX 78712 USA.	john_richburg@mail.utexas.edu	Richburg, John H/P-4369-2014	Richburg, John H/0000-0001-6334-9777; Yao, Pei-Li/0000-0003-0832-3771	NIEHS NIH HHS [ES09145] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009145] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arnold R, 1999, J IMMUNOL, V162, P7140; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bhattacharya N, 2005, BIOL REPROD, V72, P745, DOI 10.1095/biolreprod.104.031583; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Boekhoudt GH, 2003, J IMMUNOL, V170, P4139, DOI 10.4049/jimmunol.170.8.4139; Chandrasekaran Y, 2005, BIOL REPROD, V72, P206, DOI 10.1095/biolreprod.104.030858; Chandrasekaran Y, 2006, BIOL REPROD, V74, P560, DOI 10.1095/biolreprod.105.045146; CHAPIN RE, 1988, TOXICOL APPL PHARM, V92, P467, DOI 10.1016/0041-008X(88)90186-X; Chen JJW, 2005, J CLIN ONCOL, V23, P953, DOI 10.1200/JCO.2005.12.172; Chen JJW, 2003, CLIN CANCER RES, V9, P729; Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512; Crist SA, 2003, J BIOL CHEM, V278, P35950, DOI 10.1074/jbc.M306220200; D'Abrizio P, 2004, INT J ANDROL, V27, P304, DOI 10.1111/j.1365-2605.2004.00483.x; D'Alessio A, 2001, P NATL ACAD SCI USA, V98, P3316, DOI 10.1073/pnas.051566098; DE SK, 1993, ENDOCRINOLOGY, V133, P389, DOI 10.1210/en.133.1.389; Delfino F, 1998, MOL ENDOCRINOL, V12, P1696, DOI 10.1210/me.12.11.1696; Delfino FJ, 1999, J BIOL CHEM, V274, P35607, DOI 10.1074/jbc.274.50.35607; Dunkel L, 1997, CELL DEATH DIFFER, V4, P171, DOI 10.1038/sj.cdd.4400234; Dzialo-Hatton R, 2001, J IMMUNOL, V166, P4534, DOI 10.4049/jimmunol.166.7.4534; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GEARING AJH, 1995, J LEUKOCYTE BIOL, V57, P774, DOI 10.1002/jlb.57.5.774; Giammona CJ, 2002, TOXICOL APPL PHARM, V185, P119, DOI 10.1006/taap.2002.9536; Hadziselimovic F, 1998, J UROLOGY, V160, P1158, DOI 10.1016/S0022-5347(01)62725-3; HALLECK MM, 1992, FREE RADICAL BIO MED, V12, P137, DOI 10.1016/0891-5849(92)90007-4; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hilton TL, 2003, J BIOL CHEM, V278, P12992, DOI 10.1074/jbc.M300412200; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Hong CY, 2004, MOL CELL BIOL, V24, P2593, DOI 10.1128/MCB.24.7.2593-2604.2004; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; Hu JH, 2003, CELL RES, V13, P361, DOI 10.1038/sj.cr.7290181; Hu XT, 1999, J IMMUNOL, V163, P3106; Ichimura T, 2003, TOXICOLOGY, V194, P35, DOI 10.1016/j.tox.2003.07.003; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Jing D, 2004, ELECTROPHORESIS, V25, P2439, DOI 10.1002/elps.200405994; Kavlock R, 2002, REPROD TOXICOL, V16, P529, DOI 10.1016/S0890-6238(02)00032-1; Kavurma MM, 2001, J BIOL CHEM, V276, P4964, DOI 10.1074/jbc.M009251200; Kavurma MM, 2003, CELL DEATH DIFFER, V10, P36, DOI 10.1038/sj.cdd.4401179; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kim T, 2006, BIOL REPROD, V74, P744, DOI 10.1095/biolreprod.105.048892; Koji T, 2003, ARCH HISTOL CYTOL, V66, P1, DOI 10.1679/aohc.66.1; Lee J, 1999, ENDOCRINOLOGY, V140, P852, DOI 10.1210/en.140.2.852; Lee JW, 1997, ENDOCRINOLOGY, V138, P2081, DOI 10.1210/en.138.5.2081; Li LH, 1998, TOXICOL APPL PHARM, V153, P258, DOI 10.1006/taap.1998.8550; Li SL, 1997, BIOTECHNIQUES, V23, P588, DOI 10.2144/97234bm05; Lin WW, 1997, FERTIL STERIL, V68, P1065, DOI 10.1016/S0015-0282(97)00372-5; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lysiak Jeffrey J, 2004, Reprod Biol Endocrinol, V2, P9, DOI 10.1186/1477-7827-2-9; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; Mauduit C, 1998, ENDOCRINOLOGY, V139, P2863, DOI 10.1210/en.139.6.2863; McClure RF, 1999, J BIOL CHEM, V274, P7756, DOI 10.1074/jbc.274.12.7756; Mir MA, 2003, BIOORGAN MED CHEM, V11, P2791, DOI 10.1016/S0968-0896(03)00211-6; Morales V, 2003, ENDOCRINOLOGY, V144, P4763, DOI 10.1210/en.2003-0569; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Ohta S, 2001, J RHEUMATOL, V28, P1756; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Ongeri EM, 2005, MOL ENDOCRINOL, V19, P1837, DOI 10.1210/me.2004-0487; Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525; Peng YH, 2006, J SURG RES, V130, P58, DOI 10.1016/j.jss.2005.07.030; Pentikainen V, 2002, AM J PATHOL, V160, P205, DOI 10.1016/S0002-9440(10)64364-7; Pentikainen V, 2001, J CLIN ENDOCR METAB, V86, P4480, DOI 10.1210/jc.86.9.4480; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; Pinkoski MJ, 2002, J BIOL CHEM, V277, P42380, DOI 10.1074/jbc.M208167200; Print CG, 2000, BIOESSAYS, V22, P423, DOI 10.1002/(SICI)1521-1878(200005)22:5&lt;423::AID-BIES4&gt;3.0.CO;2-0; Rasoulpour RJ, 2005, BIOL REPROD, V72, P479, DOI 10.1095/biolreprod.104.034363; RASOULPOUR RJ, 2006, IN PRESS BIOL REPROD; RICCIOLI A, 1995, P NATL ACAD SCI USA, V92, P5808, DOI 10.1073/pnas.92.13.5808; Riccioli A, 2003, ANDROLOGIA, V35, P64, DOI 10.1046/j.1439-0272.2003.00538.x; Richburg JH, 2003, TOXICOL LETT, V139, P1, DOI 10.1016/S0378-4274(02)00419-8; Richburg JH, 2002, TOXICOL LETT, V135, P167, DOI 10.1016/S0378-4274(02)00254-0; Richburg JH, 1999, TOXICOL APPL PHARM, V160, P271, DOI 10.1006/taap.1999.8786; Richburg JH, 1996, TOXICOL APPL PHARM, V137, P42, DOI 10.1006/taap.1996.0055; Richburg JH, 2000, TOXICOL LETT, V112, P79, DOI 10.1016/S0378-4274(99)00253-2; ROBERTS KP, 1995, BIOL REPROD, V53, P1446, DOI 10.1095/biolreprod53.6.1446; Ruby J, 1997, J EXP MED, V186, P1591, DOI 10.1084/jem.186.9.1591; Russell L. D., 1990, HISTOLOGICAL HISTOPA; Shishodia S, 2002, J BIOCHEM MOL BIOL, V35, P28; Siu MKY, 2004, BIOESSAYS, V26, P978, DOI 10.1002/bies.20099; Siu MKY, 2004, BIOL REPROD, V70, P945, DOI 10.1095/biolreprod.103.023606; Siu MKY, 2003, ENDOCRINOLOGY, V144, P371, DOI 10.1210/en.2002-220786; Slongo ML, 2002, BIOL CHEM, V383, P235, DOI 10.1515/BC.2002.025; Soond SM, 2003, MOL CELL BIOL, V23, P8334, DOI 10.1128/mcb.23.22.8334-8344.2003; Suominen JS, 2004, EUR J ENDOCRINOL, V151, P629, DOI 10.1530/eje.0.1510629; Teixeiro E, 1999, EUR J IMMUNOL, V29, P745, DOI 10.1002/(SICI)1521-4141(199903)29:03<745::AID-IMMU745>3.0.CO;2-0; Wang RA, 1998, BIOL REPROD, V58, P1250, DOI 10.1095/biolreprod58.5.1250; XIONG YT, 1993, ENDOCRINOLOGY, V133, P2568, DOI 10.1210/en.133.6.2568; XIONG YT, 1993, ENDOCRINOLOGY, V132, P2438, DOI 10.1210/en.132.6.2438; Xu JP, 1999, AM J REPROD IMMUNOL, V42, P381; Yao PL, 2005, AM J RESP CELL MOL, V32, P540, DOI 10.1165/rcmb.2004-0223OC; Ziparo E, 1995, ITALIAN JOURNAL OF ANATOMY AND EMBRYOLOGY, VOL 100 - SUPPLEMENT N.1 - 1995, P553	91	51	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5420	5431		10.1074/jbc.M609068200	http://dx.doi.org/10.1074/jbc.M609068200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17192273	hybrid			2022-12-25	WOS:000244482300037
J	Fardeau, V; Lelandais, G; Oldfield, A; Salin, H; Lemoine, S; Garcia, M; Tanty, V; Le Crom, S; Jacq, C; Devaux, F				Fardeau, Vivienne; Lelandais, Gaelle; Oldfield, Andrew; Salin, Helene; Lemoine, Sophie; Garcia, Mathilde; Tanty, Veronique; Le Crom, Stephane; Jacq, Claude; Devaux, Frederic			The central role of PDR1 in the foundation of yeast drug resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION DATA; SACCHAROMYCES-CEREVISIAE; MULTIDRUG-RESISTANCE; TRANSCRIPTION FACTOR; GENOME-WIDE; NUCLEAR-LOCALIZATION; CANDIDA-ALBICANS; ABC TRANSPORTERS; IN-VIVO; STRESS	The widespread pleiotropic drug resistance (PDR) phenomenon is well described as the long term selection of genetic variants expressing constitutively high levels of membrane transporters involved in drug efflux. However, the transcriptional cascades leading to the PDR phenotype in wild-type cells are largely unknown, and the first steps of this phenomenon are poorly understood. We investigated the transcriptional mechanisms underlying the establishment of an efficient PDR response in budding yeast. We show that within a few minutes of drug sensing yeast elicits an effective PDR response, involving tens of PDR genes. This early PDR response (ePDR) is highly dependent on the Pdr1p transcription factor, which is also one of the major genetic determinants of long term PDR acquisition. The activity of Pdr1p in early drug response is not drug-specific, as two chemically unrelated drugs, benomyl and fluphenazine, elicit identical, Pdr1p-dependent, ePDR patterns. Our data also demonstrate that Pdr1p is an original stress response factor, the DNA binding properties of which do not depend on the presence of drugs. Thus, Pdr1p is a promoter-resident regulator involved in both basal expression and rapid drug-dependent induction of PDR genes.	Ecole Normale Super, Mol Genet Lab, CNRS, UMR8541, F-75230 Paris 05, France; INSERM, U368, Mol & Dev Biol Lab, F-75230 Paris 05, France; Ecole Normale Super, Plate Forme Transcriptome IFR36, F-75230 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Devaux, F (corresponding author), Ecole Normale Super, Mol Genet Lab, CNRS, UMR8541, F-75230 Paris 05, France.	devaux@biologie.ens.Fr	Oldfield, Andrew/ABF-1343-2021; Le Crom, Stéphane/P-4176-2016; DEVAUX, Frédéric/N-2288-2019; Oldfield, Andrew J./AAP-4354-2021	Oldfield, Andrew/0000-0002-5401-9909; Le Crom, Stéphane/0000-0002-0534-7797; DEVAUX, Frédéric/0000-0002-0039-9096; 				Akache B, 2002, J BIOL CHEM, V277, P21254, DOI 10.1074/jbc.M202566200; Azevedo D, 2003, FREE RADICAL BIO MED, V35, P889, DOI 10.1016/S0891-5849(03)00434-9; BALZI E, 1987, J BIOL CHEM, V262, P16871; Boorsma A, 2005, NUCLEIC ACIDS RES, V33, pW592, DOI 10.1093/nar/gki484; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; Cui Z, 1998, MOL MICROBIOL, V29, P1307, DOI 10.1046/j.1365-2958.1998.01027.x; Cyert MS, 2003, BIOCHEM BIOPH RES CO, V311, P1143, DOI 10.1016/S0006-291X(03)01552-3; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; Delahodde A, 2001, MOL MICROBIOL, V39, P304, DOI 10.1046/j.1365-2958.2001.02182.x; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Devaux F, 2002, FEBS LETT, V515, P25, DOI 10.1016/S0014-5793(02)02387-6; Devauz F, 2001, EMBO REP, V2, P493, DOI 10.1093/embo-reports/kve114; Edlind T, 2002, MOL MICROBIOL, V46, P257, DOI 10.1046/j.1365-2958.2002.03165.x; Gao C, 2004, J BIOL CHEM, V279, P42677, DOI 10.1074/jbc.M406363200; GARCIA M, 2007, YEAST MITOCHONDRIAL; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Golfier G, 2004, BIOINFORMATICS, V20, P1641, DOI 10.1093/bioinformatics/bth117; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Harismendy O, 2003, EMBO J, V22, P4738, DOI 10.1093/emboj/cdg466; Hellauer K, 2002, J BIOL CHEM, V277, P17671, DOI 10.1074/jbc.M201637200; Henry KW, 1999, ANTIMICROB AGENTS CH, V43, P1968, DOI 10.1128/AAC.43.8.1968; Hikkel I, 2003, J BIOL CHEM, V278, P11427, DOI 10.1074/jbc.M208549200; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Karababa M, 2006, MOL MICROBIOL, V59, P1429, DOI 10.1111/j.1365-2958.2005.05037.x; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Kellis M, 2004, J COMPUT BIOL, V11, P319, DOI 10.1089/1066527041410319; Kolaczkowska A, 1999, DRUG RESIST UPDATE, V2, P403, DOI 10.1054/drup.1999.0113; Kolaczkowski M, 2004, EUKARYOT CELL, V3, P880, DOI 10.1128/EC.3.4.880-892.2004; Kolaczkowski M, 1998, MICROB DRUG RESIST, V4, P143, DOI 10.1089/mdr.1998.4.143; Larochelle M, 2006, MOL CELL BIOL, V26, P6690, DOI 10.1128/MCB.02450-05; Le Crom S, 2002, MOL CELL BIOL, V22, P2642, DOI 10.1128/MCB.22.8.2642-2649.2002; Li XZ, 2004, DRUGS, V64, P159, DOI 10.2165/00003495-200464020-00004; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lucau-Danila A, 2005, MOL CELL BIOL, V25, P1860, DOI 10.1128/MCB.25.5.1860-1868.2005; Lucau-Danila A, 2003, J BIOL CHEM, V278, P52641, DOI 10.1074/jbc.M309580200; Mamnun YM, 2002, MOL MICROBIOL, V46, P1429, DOI 10.1046/j.1365-2958.2002.03262.x; Matta MAD, 2001, GENE, V272, P111, DOI 10.1016/S0378-1119(01)00558-3; Motohashi Noboru, 2000, Current Drug Targets, V1, P237, DOI 10.2174/1389450003349191; Moye-Rowley WS, 2003, PROG NUCLEIC ACID RE, V73, P251, DOI 10.1016/S0079-6603(03)01008-0; Onda M, 2004, GENE, V332, P51, DOI 10.1016/j.gene.2004.02.003; Owsianik G, 2002, MOL MICROBIOL, V43, P1295, DOI 10.1046/j.1365-2958.2002.02823.x; Prasad R, 2005, INT REV CYTOL, V242, P215; Sanglard D, 2003, MOL MICROBIOL, V48, P959, DOI 10.1046/j.1365-2958.2003.03495.x; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Souid AK, 2006, GENETICS, V173, P1919, DOI 10.1534/genetics.106.057596; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Teixeira MC, 2002, BIOCHEM BIOPH RES CO, V292, P530, DOI 10.1006/bbrc.2002.6691; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tutulan-Cunita AC, 2005, BIOSCI BIOTECH BIOCH, V69, P857, DOI 10.1271/bbb.69.857; Vaquerizas JM, 2005, NUCLEIC ACIDS RES, V33, pW616, DOI 10.1093/nar/gki500; Viladevall L, 2004, J BIOL CHEM, V279, P43614, DOI 10.1074/jbc.M403606200; Wehrschutz-Sigl E, 2004, EUR J BIOCHEM, V271, P1145, DOI 10.1111/j.1432-1033.2004.04018.x; WHITE CI, 1985, MOL GEN GENET, V201, P99, DOI 10.1007/BF00397993; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200; Zeitlinger J, 2003, CELL, V113, P395, DOI 10.1016/S0092-8674(03)00301-5; Zhang XT, 2001, J BIOL CHEM, V276, P8812, DOI 10.1074/jbc.M010686200	63	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					5063	5074		10.1074/jbc.M610197200	http://dx.doi.org/10.1074/jbc.M610197200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158869	hybrid			2022-12-25	WOS:000244482000089
J	Mouzat, K; Prod'Homme, M; Volle, DH; Sion, B; Dechelotte, P; Gauthier, K; Vanacker, JM; Lobaccaro, JMA				Mouzat, Kevin; Prod'Homme, Magali; Volle, David H.; Sion, Benoit; Dechelotte, Pierre; Gauthier, Karine; Vanacker, Jean-Marc; Lobaccaro, Jean-Marc A.			Oxysterol nuclear receptor LXR beta regulates cholesterol homeostasis and contractile function in mouse uterus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-X-RECEPTORS; UTERINE SMOOTH-MUSCLE; BODY-MASS INDEX; SKELETAL-MUSCLE; GENE-EXPRESSION; LIPID-ACCUMULATION; ALPHA; PREGNANCY; METABOLISM; MYOMETRIUM	The uterus is an organ where lipid distribution plays a critical role for its function. Here we show that nuclear receptor for oxysterols LXR beta prevents accumulation of cholesteryl esters in mouse myometrium by controlling expression of genes involved in cholesterol efflux and storage (abca1 and abcg1). Upon treatment with an LXR agonist that mimics activation by oxysterols, expression of these target genes was increased in wild-type mice, whereas under basal conditions, lxra;beta(-/-) mice exhibited a marked decrease in abcg1 accumulation. This change resulted in a phenotype of cholesteryl ester accumulation. Besides, a defect of contractile activity induced by oxytocin or PGF2 alpha was observed in mice lacking LXR beta. These results imply that LXR beta provides a safety valve to limit cholesteryl ester levels as a basal protective mechanism in the uterus against cholesterol accumulation and is necessary for a correct induction of contractions.	Univ Blaise Pascal, UMR 6547, CNRS, F-63177 Clermont Ferrand, France; Human Nutr Res Ctr, F-63177 Clermont Ferrand, France; Univ Auvergne, Lab Biol Dev & Reprod, F-63058 Clermont Ferrand, France; Hop Hotel Dieu, CHU Clermont Ferrand, Serv Anat Pathol, F-63058 Clermont Ferrand, France; EMI, INSERM, F-34298 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); Universite Clermont Auvergne (UCA); CHU Clermont Ferrand; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Lobaccaro, JMA (corresponding author), Univ Blaise Pascal, UMR 6547, CNRS, 24 Ave Landais, F-63177 Clermont Ferrand, France.	j-marc.lobaccaro@univ-bpclermont.fr	Lobaccaro, Jean-Marc/Q-3926-2019; Volle, David H/P-6155-2014; Lobaccaro, Jean-Marc A./U-1928-2019	Lobaccaro, Jean-Marc/0000-0001-9890-2392; Volle, David H/0000-0003-0843-0550; 				Andreasen KR, 2004, ACTA OBSTET GYN SCAN, V83, P1022, DOI 10.1111/j.0001-6349.2004.00624.x; Babiychuk EB, 2004, J MEMBRANE BIOL, V198, P95, DOI 10.1007/s00232-004-0663-1; Barau G, 2006, BJOG-INT J OBSTET GY, V113, P1173, DOI 10.1111/j.1471-0528.2006.01038.x; Barish GD, 2005, MOL ENDOCRINOL, V19, P2466, DOI 10.1210/me.2004-0529; Beaven SW, 2006, ANNU REV MED, V57, P313, DOI 10.1146/annurev.med.57.121304.131428; Berto AGA, 2003, BBA-GEN SUBJECTS, V1619, P98, DOI 10.1016/S0304-4165(02)00446-4; Brizzi P, 1999, AM J OBSTET GYNECOL, V181, P430, DOI 10.1016/S0002-9378(99)70574-0; Buxton ILO, 2005, P W PHARMACOL SOC, V48, P126; Chu K, 2006, MOL CELL BIOL, V26, P6786, DOI 10.1128/MCB.00077-06; Condon JC, 2004, P NATL ACAD SCI USA, V101, P4978, DOI 10.1073/pnas.0401124101; Costet P, 2000, J BIOL CHEM, V275, P28240; Cozzone D, 2006, DIABETOLOGIA, V49, P990, DOI 10.1007/s00125-006-0140-8; Cummins CL, 2006, J CLIN INVEST, V116, P1902, DOI 10.1172/JCI28400; DALLE M, 1992, ARCH INT PHYSIOL BIO, V100, P251, DOI 10.3109/13813459208998110; Davies JD, 2005, J BIOL CHEM, V280, P3911, DOI 10.1074/jbc.M410075200; Di Renzo GC, 2005, CURR OPIN OBSTET GYN, V17, P598, DOI 10.1097/01.gco.0000191899.84567.4d; DOCKERY P, 1989, BAILLIERE CLIN OB GY, V3, P227, DOI 10.1016/S0950-3552(89)80020-3; Doherty DA, 2006, INT J GYNECOL OBSTET, V95, P242, DOI 10.1016/j.ijgo.2006.06.021; Dreja K, 2002, ARTERIOSCL THROM VAS, V22, P1267, DOI 10.1161/01.ATV.0000023438.32585.A1; Frenoux JM, 2004, J MOL ENDOCRINOL, V33, P361, DOI 10.1677/jme.1.01515; Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629; Gimpl G, 2000, EUR J BIOCHEM, V267, P2483, DOI 10.1046/j.1432-1327.2000.01280.x; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Grizard G, 2000, J CHROMATOGR B, V740, P101, DOI 10.1016/S0378-4347(00)00039-6; HOLMAN RT, 1991, P NATL ACAD SCI USA, V88, P4835, DOI 10.1073/pnas.88.11.4835; Horard B, 2004, J MOL ENDOCRINOL, V33, P87, DOI 10.1677/jme.0.0330087; Hu X, 2003, MOL ENDOCRINOL, V17, P1019, DOI 10.1210/me.2002-0399; HUSZAR G, 1982, AM J OBSTET GYNECOL, V142, P225, DOI 10.1016/S0002-9378(16)32341-9; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Kabiru W, 2004, AM J OBSTET GYNECOL, V191, P928, DOI 10.1016/j.ajog.2004.06.051; Kase ET, 2005, DIABETES, V54, P1108, DOI 10.2337/diabetes.54.4.1108; Komuves LG, 2002, J INVEST DERMATOL, V118, P25, DOI 10.1046/j.0022-202x.2001.01628.x; Mascrez B, 2004, EMBO REP, V5, P285, DOI 10.1038/sj.embor.7400094; MCCORMACK SA, 1980, ENDOCRINOLOGY, V106, P1634, DOI 10.1210/endo-106-5-1634; Mendelson CR, 2005, J STEROID BIOCHEM, V93, P113, DOI 10.1016/j.jsbmb.2004.12.027; Muscat GEO, 2002, J BIOL CHEM, V277, P40722, DOI 10.1074/jbc.M206681200; Myatt L, 2004, PROSTAG LEUKOTR ESS, V70, P137, DOI 10.1016/j.plefa.2003.04.004; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; POTTER J, 1978, CLIN CHIM ACTA, V87, P57, DOI 10.1016/0009-8981(78)90057-8; Pulkkinen MO, 1998, GYNECOL OBSTET INVES, V46, P220, DOI 10.1159/000010038; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Robertson KM, 2005, ENDOCRINOLOGY, V146, P2519, DOI 10.1210/en.2004-1413; Smith RD, 2005, AM J PHYSIOL-CELL PH, V288, pC982, DOI 10.1152/ajpcell.00120.2004; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Volle DH, 2004, MOL ENDOCRINOL, V18, P888, DOI 10.1210/me.2003-0338; Wagner BL, 2003, MOL CELL BIOL, V23, P5780, DOI 10.1128/MCB.23.16.5780-5789.2003	52	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4693	4701		10.1074/jbc.M606718200	http://dx.doi.org/10.1074/jbc.M606718200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17166844	hybrid			2022-12-25	WOS:000244482000050
J	Whitney, SM; Sharwood, RE				Whitney, Spencer M.; Sharwood, Robert E.			Linked Rubisco subunits can assemble into functional oligomers without impeding catalytic performance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; ESCHERICHIA-COLI; TOBACCO CHLOROPLASTS; KINETIC-PROPERTIES; PLASTID GENOME; RBCS GENE; PHOTOSYNTHESIS; OXYGENASE; 1,5-BISPHOSPHATE	Although transgenic manipulation in higher plants of the catalytic large subunit (L) of the photosynthetic CO2-fixing enzyme ribulose 1,5-bisphospahte carboxylase/oxygenase (Rubisco) is now possible, the manipulation of its cognate small subunit (S) is frustrated by the nuclear location of its multiple gene copies. To examine whether L and S can be engineered simultaneously by fusing them together, the subunits from Synechococcus PCC6301 Rubisco were tethered together by different linker sequences, producing variant fusion peptides. In Escherichia coli the variant PCC6301 LS fusions assembled into catalytically functional octameric ([LS](8)) and hexadecameric ([[LS](8)](2)) quaternary structures that excluded the integration of co-expressed unfused S. Assembly of the LS fusions into Rubisco complexes was impaired 50-90% relative to the assembly of unlinked L and S into L8S8. enzyme. Assembly in E. coli was not emulated using tobacco SL fusions that accumulated entirely as insoluble protein. Catalytic measurements showed the CO2/O-2 specificity, carboxylation rate, and Michaelis constants for CO2 and ribulose 1,5-bisphosphate for the cyanobacterial Rubisco complexes comprising fusions where the S was linked to the N terminus of L closely matched those of the wild-type L,S, enzyme. In contrast, the substrate affinities and carboxylation rate of the Rubisco complexes comprising fusions where L was fused to the N terminus of S or a six-histidine tag was appended to the C terminus of L were compromised. Overall this work provides a framework for implementing an alternative strategy for exploring simultaneous engineering of modified, or foreign, Rubisco L and S subunits in higher plant plastids.	Australian Natl Univ, Res Sch Biol Sci, M, Canberra, ACT 2601, Australia	Australian National University	Whitney, SM (corresponding author), Australian Natl Univ, Res Sch Biol Sci, M, POB 475, Canberra, ACT 2601, Australia.	spencer.whitney@anu.edu.au	Whitney, Spencer M/C-9266-2009	Whitney, Spencer M/0000-0003-2954-2359; Sharwood, Robert/0000-0003-4993-3816				Andrews TJ, 2003, ARCH BIOCHEM BIOPHYS, V414, P159, DOI 10.1016/S0003-9861(03)00100-0; ANDREWS TJ, 1988, J BIOL CHEM, V263, P12213; Dhingra A, 2004, P NATL ACAD SCI USA, V101, P6315, DOI 10.1073/pnas.0400981101; Duff AP, 2000, J MOL BIOL, V298, P903, DOI 10.1006/jmbi.2000.3724; Emlyn-Jones D, 2006, PLANT CELL PHYSIOL, V47, P1630, DOI 10.1093/pcp/pcl028; Farr GW, 2003, EMBO J, V22, P3220, DOI 10.1093/emboj/cdg313; GATENBY AA, 1992, PLANT MOL BIOL, V19, P677, DOI 10.1007/BF00026793; GATENBY AA, 1984, EUR J BIOCHEM, V144, P361, DOI 10.1111/j.1432-1033.1984.tb08472.x; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GUTTERIDGE S, 1986, BIOCHEM SOC T, V14, P28, DOI 10.1042/bst0140028; Houtz RL, 2003, ARCH BIOCHEM BIOPHYS, V414, P150, DOI 10.1016/S0003-9861(03)00122-X; Kane HJ, 1998, PLANT PHYSIOL, V117, P1059, DOI 10.1104/pp.117.3.1059; KANE HJ, 1994, AUST J PLANT PHYSIOL, V21, P449, DOI 10.1071/PP9940449; Kanevski I, 1999, PLANT PHYSIOL, V119, P133, DOI 10.1104/pp.119.1.133; KANEVSKI I, 1994, P NATL ACAD SCI USA, V91, P1969, DOI 10.1073/pnas.91.5.1969; KETTLEBOROUGH CA, 1990, J EXP BOT, V41, P1287, DOI 10.1093/jxb/41.10.1287; LARIMER FW, 1993, GENE, V126, P85, DOI 10.1016/0378-1119(93)90593-R; Long SP, 2006, PLANT CELL ENVIRON, V29, P315, DOI 10.1111/j.1365-3040.2005.01493.x; MORELL MK, 1994, J BIOL CHEM, V269, P8091; MORELL MK, 1992, AUST J BOT, V40, P431, DOI 10.1071/BT9920431; Parry MAJ, 2003, J EXP BOT, V54, P1321, DOI 10.1093/jxb/erg141; PAUL K, 1991, BIOCHEMISTRY-US, V30, P10019, DOI 10.1021/bi00105a029; Pearce FG, 2006, BIOCHEM J, V399, P525, DOI 10.1042/BJ20060430; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; PORTIS AR, 1990, ARCH BIOCHEM BIOPHYS, V283, P397, DOI 10.1016/0003-9861(90)90660-Q; Raines CA, 2006, PLANT CELL ENVIRON, V29, P331, DOI 10.1111/j.1365-3040.2005.01488.x; Roy Harry, 2000, VVolume 9, P53; Ruuska S, 1998, AUST J PLANT PHYSIOL, V25, P859, DOI 10.1071/PP98079; Spreitzer RJ, 2005, P NATL ACAD SCI USA, V102, P17225, DOI 10.1073/pnas.0508042102; Spreitzer RJ, 2003, ARCH BIOCHEM BIOPHYS, V414, P141, DOI 10.1016/S0003-9861(03)00171-1; Spreitzer RJ, 2002, ANNU REV PLANT BIOL, V53, P449, DOI 10.1146/annurev.arplant.53.100301.135233; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Taylor TC, 1997, J MOL BIOL, V265, P432, DOI 10.1006/jmbi.1996.0738; Tcherkez GGB, 2006, P NATL ACAD SCI USA, V103, P7246, DOI 10.1073/pnas.0600605103; Whitney SM, 1999, PLANT PHYSIOL, V121, P579, DOI 10.1104/pp.121.2.579; Whitney SM, 2003, PLANT PHYSIOL, V133, P287, DOI 10.1104/pp.103.026146; Whitney SM, 2001, P NATL ACAD SCI USA, V98, P14738, DOI 10.1073/pnas.261417298; Whitney SM, 2001, PLANT J, V26, P535, DOI 10.1046/j.1365-313x.2001.01056.x; Whitney SM, 2001, PLANT CELL, V13, P193, DOI 10.1105/tpc.13.1.193; Zhang XH, 2002, PLANT CELL PHYSIOL, V43, P1302, DOI 10.1093/pcp/pcf158; Zhu GH, 1998, PHOTOSYNTH RES, V57, P71, DOI 10.1023/A:1006020424581; Zhu XG, 2004, PLANT CELL ENVIRON, V27, P155, DOI 10.1046/j.1365-3040.2004.01142.x	42	33	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3809	3818		10.1074/jbc.M610479200	http://dx.doi.org/10.1074/jbc.M610479200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17150955	hybrid			2022-12-25	WOS:000244481900044
J	Harris, EN; Kyosseva, SV; Weigel, JA; Weigel, PH				Harris, Edward N.; Kyosseva, Svetlana V.; Weigel, Janet A.; Weigel, Paul H.			Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ENDOTHELIAL-CELLS; CHONDROITIN SULFATE PROTEOGLYCAN; RAT-LIVER; LIGAND-BINDING; PROTEINS; TISSUE; IDENTIFICATION; STABILIN-1; HYPEROSMOLARITY; LOCALIZATION	The hyaluronic acid ( HA) receptor for endocytosis ( HARE; also designated stabilin-2 and FEEL-2) mediates systemic clearance of glycosaminoglycans from the circulatory and lymphatic systems via coated pit-mediated uptake. HARE is primarily found as two isoforms (315- and 190-kDa) in sinusoidal endothelial cells of the liver, lymph node, and spleen. Here we characterize the ligand specificity and function of the large stably expressed 315- HARE isoform in Flp-In 293 cell lines. Like human spleen sinusoidal endothelial cells, Flp-In 293 cell lines transfected with a single cDNA encoding the full-length 315- HARE express both the 315-kDa and the proteolytically truncated 190-kDa isoforms in a ratio of similar to 3-4:1. The 190-kDa HARE isoform generated from the 315-kDa HARE and the 315-kDa HARE specifically bound I-125-HA. Like the 190-kDa HARE expressed alone (Harris, E. N., Weigel, J. A., and Weigel, P. H. (2004) J. Biol. Chem. 279, 36201-36209), the 190- and 315-kDa HARE isoforms expressed in 315-HARE cell lines were recognized by anti-HARE monoclonal antibodies 30, 154, and 159. All 315-HARE cell lines could endocytose and degrade I-125-HA. Competition studies with live cells indicate that 190- HARE and 315- HARE bind HA with higher apparent affinity (Kd similar to 10-20 nM) than chondroitin sulfate (CS) types A, C, D, or E. Only slight competition of HA endocytosis was observed with CS-B (dermatan sulfate) and chondroitin. Direct binding assays with the 315-HARE ectodomain revealed high affinity HA binding, and lower binding affinities for CS-C, CS-D, and CS-E. A majority of each HARE isoform was intracellular, within the endocytic system, suggesting transient surface residency typical of an active endocytic recycling receptor.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@ouhc.edu	Harris, Edward N/A-1596-2011		NIGMS NIH HHS [GM69961] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069961] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abatangelo G., 2000, REDEFINING HYALURONA; ASARI A, 1994, J HISTOCHEM CYTOCHEM, V42, P513, DOI 10.1177/42.4.8126377; Balazs E A, 1972, Mod Probl Ophthalmol, V10, P3; Blundell CD, 2005, J BIOL CHEM, V280, P18189, DOI 10.1074/jbc.M414343200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; ERIKSSON S, 1983, EXP CELL RES, V144, P223, DOI 10.1016/0014-4827(83)90458-5; Falkowski M, 2003, HISTOCHEM CELL BIOL, V120, P361, DOI 10.1007/s00418-003-0585-5; FRASER JRE, 1983, CELL TISSUE RES, V233, P285; FRASER JRE, 1981, BIOCHEM J, V200, P415, DOI 10.1042/bj2000415; FRASER JRE, 1985, CELL TISSUE RES, V242, P505; Hansen B, 2005, EXP CELL RES, V303, P160, DOI 10.1016/j.yexcr.2004.09.017; Harris EN, 2004, J BIOL CHEM, V279, P36201, DOI 10.1074/jbc.M405322200; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Laabs T, 2005, CURR OPIN NEUROBIOL, V15, P116, DOI 10.1016/j.conb.2005.01.014; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laurent T.C., 1991, DEGRADATION BIOACTIV, P249; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1986, BIOCHEM J, V234, P653, DOI 10.1042/bj2340653; Matsui Fumiko, 2004, Congenital Anomalies, V44, P181, DOI 10.1111/j.1741-4520.2004.00038.x; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; McGary CT, 2003, METHOD ENZYMOL, V363, P354; MCGARY CT, 1993, HEPATOLOGY, V18, P1465, DOI 10.1002/hep.1840180628; Meyer K, 1934, J BIOL CHEM, V107, P629; Moller HJ, 1998, SCAND J CLIN LAB INV, V58, P269, DOI 10.1080/00365519850186445; Nishida Y, 2005, EXP CELL RES, V307, P194, DOI 10.1016/j.yexcr.2005.03.026; OKA JA, 1989, J BIOL CHEM, V264, P12016; OKA JA, 1988, J CELL BIOCHEM, V36, P169, DOI 10.1002/jcb.240360208; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; Prevo R, 2004, J BIOL CHEM, V279, P52580, DOI 10.1074/jbc.M406897200; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; Rapp A, 2006, BIOCHIMIE, V88, P473, DOI 10.1016/j.biochi.2005.10.007; SMEDSROD B, 1990, BIOCHEM J, V266, P313, DOI 10.1042/bj2660313; Smedsrod B, 2003, GLYCOBIOLOGY, V13, p11G, DOI 10.1093/glycob/cwg056; SMEDSROD B, 1988, CELL TISSUE RES, V253, P39; Tamura Y, 2003, J BIOL CHEM, V278, P12613, DOI 10.1074/jbc.M210211200; Tonnaer ELGM, 2006, MICROBES INFECT, V8, P316, DOI 10.1016/j.micinf.2005.06.028; Toole BP, 2002, AM J PATHOL, V161, P745, DOI 10.1016/S0002-9440(10)64232-0; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; TZAICOS C, 1989, BIOCHEM J, V264, P823, DOI 10.1042/bj2640823; Ulbrich SE, 2004, MOL CELL ENDOCRINOL, V214, P9, DOI 10.1016/j.mce.2003.12.002; Weigel JA, 2003, J BIOL CHEM, V278, P42802, DOI 10.1074/jbc.M307201200; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9; Weigel PH, 2003, GLYCOBIOLOGY, V13, p12G, DOI 10.1093/glycob/cwg057; Weigel PH, 2002, BBA-GEN SUBJECTS, V1572, P341, DOI 10.1016/S0304-4165(02)00318-5; WEISSMANN B, 1954, J BIOL CHEM, V208, P417; YannarielloBrown J, 1997, GLYCOBIOLOGY, V7, P15, DOI 10.1093/glycob/7.1.15; YannarielloBrown J, 1996, BIOCHEM BIOPH RES CO, V218, P314, DOI 10.1006/bbrc.1996.0055; YANNARIELLOBROWN J, 1992, J CELL BIOCHEM, V48, P73, DOI 10.1002/jcb.240480111; YU Q, 1995, BIOTECHNIQUES, V19, P122; Zhou B, 1999, J BIOL CHEM, V274, P33831, DOI 10.1074/jbc.274.48.33831; Zhou B, 2003, GLYCOBIOLOGY, V13, P339, DOI 10.1093/glycob/cwg029; Zhou B, 2002, MOL BIOL CELL, V13, P2853, DOI 10.1091/mbc.02-03-0048; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200	57	94	96	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2785	2797		10.1074/jbc.M607787200	http://dx.doi.org/10.1074/jbc.M607787200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145755	hybrid, Green Submitted			2022-12-25	WOS:000243793900005
J	Kwon, O; Eck, P; Chen, SL; Corpe, CP; Lee, JH; Kruhlak, M; Levine, M				Kwon, Oran; Eck, Peter; Chen, Shenglin; Corpe, Christopher P.; Lee, Je-Hyuk; Kruhlak, Michael; Levine, Mark			Inhibition of the intestinal glucose transporter GLUT2 by flavonoids	FASEB JOURNAL			English	Article						intestinal sugar transporter; polyphenols; intraluminal flavonoids; Xenopus laevis	BRUSH-BORDER-MEMBRANE; DIFFUSIVE COMPONENT; DIETARY FLAVONOIDS; FRUCTOSE TRANSPORT; ABSORPTION; QUERCETIN; RAT; POLYPHENOLS; CACO-2; COTRANSPORTER	We tested whether the dominant intestinal sugar transporter GLUT2 was inhibited by intestinal luminal compounds that are inefficiently absorbed and naturally present in foods. Because of their abundance in fruits and vegetables, flavonoids were selected as model compounds. Robust inhibition of glucose and fructose transport by GLUT2 expressed in Xenopus laevis oocytes was produced by the flavonols myricetin, fisetin, the widely consumed flavonoid quercetin, and its glucoside precursor isoquercetrin. IC(50)s for quercetin, myricetin, and isoquercetirin were similar to 200- to 1000-fold less than glucose or fructose concentrations, and noncompetitive inhibition was observed. The two other major intestinal sugar transporters, GLUT5 and SGLT1, were unaffected by flavonoids. Sugar transport by GLUT2 overexpressed in pituitary cells and naturally present in Caco-2E intestinal cells was similarly inhibited by quercetin. GLUT2 was detected on the apical side of Caco-2E cells, indicating that GLUT2 was in the correct orientation to be inhibited by luminal compounds. Quercetin itself was not transported by the three major intestinal glucose transporters. Because the flavonoid quercetin, a food component with an excellent pharmacology safety profile, might act as a potent luminal inhibitor of sugar absorption independent of its own transport, flavonols show promise as new pharmacologic agents in the obesity epidemic.	NIDDKD, NIH, Mol & Clin Nutr Sect, Digest Dis Branch,Intramural Res Program, Bethesda, MD 20892 USA; NCI, Expt Immunol Branch, Intramural Res Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Levine, M (corresponding author), NIDDKD, NIH, Mol & Clin Nutr Sect, Digest Dis Branch,Intramural Res Program, Bethesda, MD 20892 USA.	markl@mail.nih.gov	Chen, Shenglin/B-4049-2010	corpe, christopher/0000-0003-1994-8312; Eck, Peter/0000-0003-2371-9774; Levine, Michael/0000-0003-0036-7809	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK053214, Z01DK053214] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ANSHIMA H, 2005, J AGR FOOD CHEM, V53, P1955; Beecher GR, 2003, J NUTR, V133, p3248S; Bissonnette P, 1996, AM J PHYSIOL-GASTR L, V270, pG833, DOI 10.1152/ajpgi.1996.270.5.G833; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; Cermak R, 2004, BRIT J NUTR, V91, P849, DOI 10.1079/BJN20041128; CHANTRET I, 1994, J CELL SCI, V107, P213; CHANTRET I, 1988, CANCER RES, V48, P1936; Corpe CP, 1996, PFLUG ARCH EUR J PHY, V432, P192, DOI 10.1007/s004240050124; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; Dandona P, 2005, CIRCULATION, V111, P1448, DOI 10.1161/01.CIR.0000158483.13093.9D; DEBNAM ES, 1975, J PHYSIOL-LONDON, V246, P181, DOI 10.1113/jphysiol.1975.sp010885; DELEZAY O, 1995, J CELL PHYSIOL, V163, P120, DOI 10.1002/jcp.1041630114; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Grundy SM, 2005, AM J CARDIOL, V96, p47D, DOI 10.1016/j.amjcard.2005.03.020; Helliwell PA, 2000, BIOCHEM J, V350, P149, DOI 10.1042/0264-6021:3500149; Helliwell PA, 2002, J PHYSIOL-LONDON, V544, P579, DOI 10.1113/jphysiol.2002.028209; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; Hossain SJ, 2002, J AGR FOOD CHEM, V50, P5215, DOI 10.1021/jf020252e; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; Johnston K, 2005, FEBS LETT, V579, P1653, DOI 10.1016/j.febslet.2004.12.099; Kellett GL, 2000, BIOCHEM J, V350, P155, DOI 10.1042/0264-6021:3500155; Kellett GL, 2005, DIABETES, V54, P3056, DOI 10.2337/diabetes.54.10.3056; Kobayashi Y, 2000, J AGR FOOD CHEM, V48, P5618, DOI 10.1021/jf0006832; Kroon PA, 2004, AM J CLIN NUTR, V80, P15; MAHRAOUI L, 1992, AM J PHYSIOL, V263, pG312, DOI 10.1152/ajpgi.1992.263.3.G312; McGovern SL, 2003, J MED CHEM, V46, P1478, DOI 10.1021/jm020427b; Murota K, 2003, ARCH BIOCHEM BIOPHYS, V417, P12, DOI 10.1016/S0003-9861(03)00284-4; Okamoto T, 2005, INT J MOL MED, V16, P275; OLEFSKY JM, 1978, BIOCHEM J, V172, P137, DOI 10.1042/bj1720137; Park JB, 2000, J NUTR, V130, P1297, DOI 10.1093/jn/130.5.1297; Plat J, 2005, AM J CARDIOL, V96, p15D, DOI 10.1016/j.amjcard.2005.03.015; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Scalbert A, 2005, AM J CLIN NUTR, V81, p215S, DOI 10.1093/ajcn/81.1.215S; Scalbert A, 2000, J NUTR, V130, p2073S, DOI 10.1093/jn/130.8.2073S; Scheepers A, 2004, JPEN-PARENTER ENTER, V28, P364, DOI 10.1177/0148607104028005364; Song J, 2002, J BIOL CHEM, V277, P15252, DOI 10.1074/jbc.M110496200; Strobel P, 2005, BIOCHEM J, V386, P471, DOI 10.1042/BJ20040703; THORENS B, 1990, AM J PHYSIOL, V259, P279; Uldry M, 2004, PFLUG ARCH EUR J PHY, V447, P480, DOI 10.1007/s00424-003-1085-0; van de Laar FA, 2005, DIABETES CARE, V28, P154, DOI 10.2337/diacare.28.1.154; Vera JC, 2001, BIOCHEMISTRY-US, V40, P777, DOI 10.1021/bi001660j; Walgren RA, 2000, J PHARMACOL EXP THER, V294, P837; Walle T, 2004, FREE RADICAL BIO MED, V36, P829, DOI 10.1016/j.freeradbiomed.2004.01.002; Walle T, 2003, DRUG METAB DISPOS, V31, P1288, DOI 10.1124/dmd.31.11.1288; Williams RJ, 2004, FREE RADICAL BIO MED, V36, P838, DOI 10.1016/j.freeradbiomed.2004.01.001; Williamson G, 2005, AM J CLIN NUTR, V81, p243S, DOI [10.1093/ajcn/81.1.243S, 10.1093/ajcn/81.1.230S]; Wolffram S, 2002, J NUTR, V132, P630, DOI 10.1093/jn/132.4.630; Wright EM, 2003, BEST PRACT RES CL GA, V17, P943, DOI 10.1016/S1521-6918(03)00107-0; Yanovski SZ, 2002, NEW ENGL J MED, V346, P591, DOI 10.1056/NEJMra012586	51	292	306	5	74	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					366	377		10.1096/fj.06-6620com	http://dx.doi.org/10.1096/fj.06-6620com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17172639				2022-12-25	WOS:000244686300010
J	Llorens, JV; Navarro, JA; Martinez-Sebastian, MJ; Baylies, MR; Schneuwly, S; Botella, JA; Molto, MD				Llorens, Jose V.; Navarro, Juan A.; Martinez-Sebastian, Maria J.; Baylies, Mary R.; Schneuwly, S.; Botella, Jose A.; Molto, Maria D.			Causative role of oxidative stress in a Drosophila model of Friedreich ataxia	FASEB JOURNAL			English	Article						frataxin; aconitase; mitochondrial respiration; hyperoxia; RNAi	CITRIC-ACID CYCLE; YEAST FRATAXIN; MITOCHONDRIAL ACONITASE; ELECTRON-TRANSPORT; IRON HOMEOSTASIS; GENE-EXPRESSION; IN-VITRO; PROTEIN; MELANOGASTER; HOMOLOG	Friedreich ataxia (FA), the most common form of hereditary ataxia, is caused by a deficit in the mitochondrial protein frataxin. While several hypotheses have been suggested, frataxin function is not well understood. Oxidative stress has been suggested to play a role in the pathophysiology of FA, but this view has been recently questioned, and its link to frataxin is unclear. Here, we report the use of RNA interference (RNAi) to suppress the Drosophila frataxin gene (fh) expression. This model system parallels the situation in FA patients, namely a moderate systemic reduction of frataxin levels compatible with normal embryonic development. Under these conditions, fh-RNAi flies showed a shortened life span, reduced climbing abilities, and enhanced sensitivity to oxidative stress. Under hyperoxia, fh-RNAi flies also showed a dramatic reduction of aconitase activity that seriously impairs the mitochondrial respiration while the activities of succinate dehydrogenase, respiratory complex I and II, and indirectly complex III and IV are normal. Remarkably, frataxin overexpression also induced the oxidative-mediated inactivation of mitochondrial aconitase. This work demonstrates, for the first time, the essential function of frataxin in protecting aconitase from oxidative stress-dependent inactivation in a multicellular organism. Moreover our data support an important role of oxidative stress in the progression of FA and suggest a tissue-dependent sensitivity to frataxin imbalance. We propose that in FA, the oxidative mediated inactivation of aconitase, which occurs normally during the aging process, is enhanced due to the lack of frataxin.	Univ Valencia, Dept Genet, Fac Ciencias Biol, E-46100 Valencia, Spain; Univ Regensburg, Inst Zool, D-8400 Regensburg, Germany; Mem Sloan Kettering Canc Ctr, Dev Biol Program, New York, NY 10021 USA	University of Valencia; University of Regensburg; Memorial Sloan Kettering Cancer Center	Molto, MD (corresponding author), Univ Valencia, Dept Genet, Fac Ciencias Biol, Carrer Doctor Moliner 50, E-46100 Valencia, Spain.	dmolto@uv.es	Langa, Juan Antonio Navarro/AAA-8013-2020	Langa, Juan Antonio Navarro/0000-0003-2266-728X; Schneuwly, Stephan/0000-0001-7711-8902; Llorens, Jose V./0000-0001-9823-6246; Martinez-Sebastian, Maria-Jose/0000-0001-5549-7921; Molto, Maria Dolores/0000-0001-5219-2022				Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Anderson PR, 2005, HUM MOL GENET, V14, P3397, DOI 10.1093/hmg/ddi367; Botella JA, 2004, CURR BIOL, V14, P782, DOI 10.1016/j.cub.2004.04.036; Bradley JL, 2004, NEUROCHEM RES, V29, P561, DOI 10.1023/B:NERE.0000014826.00881.c3; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brazzolotto X, 1999, J BIOL CHEM, V274, P21625, DOI 10.1074/jbc.274.31.21625; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Canizares J, 2000, GENE, V256, P35, DOI 10.1016/S0378-1119(00)00343-7; Chantrel-Groussard K, 2001, HUM MOL GENET, V10, P2061, DOI 10.1093/hmg/10.19.2061; Chen OS, 2002, P NATL ACAD SCI USA, V99, P16922, DOI 10.1073/pnas.232392299; Coppola G, 2006, NEUROBIOL DIS, V22, P302, DOI 10.1016/j.nbd.2005.11.014; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; Cripps RM, 2002, DEV BIOL, V246, P14, DOI 10.1006/dbio.2002.0666; Das N, 2001, BIOCHEM J, V360, P209, DOI 10.1042/0264-6021:3600209; Delatycki MB, 2000, J MED GENET, V37, P1, DOI 10.1136/jmg.37.1.1; Delaval E, 2004, EUR J BIOCHEM, V271, P4559, DOI 10.1111/j.1432-1033.2004.04422.x; Drysdale RA, 2005, NUCLEIC ACIDS RES, V33, pD390, DOI 10.1093/nar/gki046; Emond M, 2000, NEUROLOGY, V55, P1752, DOI 10.1212/WNL.55.11.1752; Ferguson M, 2005, BIOCHEM J, V390, P501, DOI 10.1042/BJ20042130; Gakh O, 2006, HUM MOL GENET, V15, P467, DOI 10.1093/hmg/ddi461; Gakh O, 2002, BIOCHEMISTRY-US, V41, P6798, DOI 10.1021/bi025566+; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gibson TJ, 1996, TRENDS NEUROSCI, V19, P465, DOI 10.1016/S0166-2236(96)20054-2; Gonzalez-Cabo P, 2005, HUM MOL GENET, V14, P2091, DOI 10.1093/hmg/ddi214; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; HARDING AE, 1993, ADV NEUROL, V61, P1; HARDING AE, 1983, Q J MED, V52, P489; IAZUSTA V, 2006, J BIOL CHEM, V281, P12227; Janero DR, 1996, AM J PHYSIOL-CELL PH, V270, pC1735, DOI 10.1152/ajpcell.1996.270.6.C1735; Kaplan J, 1999, P NATL ACAD SCI USA, V96, P10948, DOI 10.1073/pnas.96.20.10948; Kimbrell DA, 2002, GENESIS, V34, P23, DOI 10.1002/gene.10134; Kirby K, 2002, P NATL ACAD SCI USA, V99, P16162, DOI 10.1073/pnas.252342899; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492; Mockett RJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P260, DOI 10.1006/abbi.1999.1460; Mockett RJ, 2001, EXP GERONTOL, V36, P441, DOI 10.1016/S0531-5565(00)00258-8; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; MUNUJOS P, 1993, ANAL BIOCHEM, V212, P506, DOI 10.1006/abio.1993.1360; Nie GJ, 2005, BLOOD, V105, P2161, DOI 10.1182/blood-2004-07-2722; Park S, 2003, J BIOL CHEM, V278, P31340, DOI 10.1074/jbc.M303158200; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; Pianese L, 2004, J NEUROL NEUROSUR PS, V75, P1061, DOI 10.1136/jnnp.2003.028605; Pianese L, 2002, HUM MOL GENET, V11, P2989, DOI 10.1093/hmg/11.23.2989; Piccin A, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.12.e55; Piemonte F, 2001, EUR J CLIN INVEST, V31, P1007, DOI 10.1046/j.1365-2362.2001.00922.x; PRABHU HR, 1993, INDIAN J BIOCHEM BIO, V30, P289; Puccio H, 2002, CURR OPIN GENET DEV, V12, P272, DOI 10.1016/S0959-437X(02)00298-8; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Ristow M, 2000, P NATL ACAD SCI USA, V97, P12239, DOI 10.1073/pnas.220403797; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Schulz JB, 2000, NEUROLOGY, V55, P1719, DOI 10.1212/WNL.55.11.1719; Seznec H, 2005, HUM MOL GENET, V14, P463, DOI 10.1093/hmg/ddi042; Shoichet SA, 2002, HUM MOL GENET, V11, P815, DOI 10.1093/hmg/11.7.815; Tan GL, 2003, HUM MOL GENET, V12, P1699, DOI 10.1093/hmg/ddg187; Vazquez-Manrique RP, 2005, FASEB J, V19, P172, DOI 10.1096/fj.05-4212fje; Vorgerd M, 2000, NEUROMUSCULAR DISORD, V10, P430, DOI 10.1016/S0960-8966(00)00108-5; Williamson D. H., 1974, METHODS ENZYMATIC AN, P2266, DOI [10.1016/B978-0-12-091304-6.50093-8, DOI 10.1016/B978-0-12-091304-6.50093-8]; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; Yarian CS, 2006, MECH AGEING DEV, V127, P79, DOI 10.1016/j.mad.2005.09.028; Yarian CS, 2005, J BIOENERG BIOMEMBR, V37, P91, DOI 10.1007/s10863-005-4132-z; Yoon T, 2004, J BIOL CHEM, V279, P25943, DOI 10.1074/jbc.C400107200; Zahavi M., 1965, Journal of Insect Physiology, V11, P811, DOI 10.1016/0022-1910(65)90160-5	68	99	99	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					333	344		10.1096/fj.05-5709com	http://dx.doi.org/10.1096/fj.05-5709com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17167074				2022-12-25	WOS:000244686300007
J	Carey, CC; Gorman, KF; Rutherford, S				Carey, Charles C.; Gorman, Kristen F.; Rutherford, Suzannah			Modularity and Intrinsic Evolvability of Hsp90-Buffered Change	PLOS ONE			English	Article								Hsp90 controls dramatic phenotypic transitions in a wide array of morphological features of many organisms. The genetic-background dependence of specific abnormalities and their response to laboratory selection suggested Hsp90 could be an 'evolutionary capacitor', allowing developmental variation to accumulate as neutral alleles under normal conditions and manifest selectable morphological differences during environmental stress. The relevance of Hsp90-buffered variation for evolution has been most often challenged by the idea that large morphological changes controlled by Hsp90 are unconditionally deleterious. To address this issue, we tested an Hsp90-buffered abnormality in Drosophila for unselected pleiotropic effects and correlated fitness costs. Up to 120-fold differences in penetrance among six highly related selection lines, started from an initially small number of flies and rapidly selected for and against a deformed eye trait (dfe), did not translate into measurable differences in any of several tests of viability, lifespan or competitive fitness. Nor were 17 dfe Quantitative Trait Loci (QTL) associated with fitness effects in over 1,400 recombinant lines. Our ability to detect measurable effects of inbreeding, media environment and the white mutation in the selection line backgrounds independent of dfe penetrance suggests that, within the limitations of laboratory tests of fitness, this large morphological change controlled by Hsp90 was selectable independent of strong, correlated and unconditionally deleterious effects-abundant, polygenic variation hidden by Hsp90 allows potentially deleterious alleles to be readily replaced during selection by less deleterious alleles with similar phenotypic effects. Hsp90 links environmental stress with the expression of developmental variation controlling unprecedented morphological plasticity. As outlined here and in the companion paper of this issue, the complex genetic architecture of Hsp90-buffered variation supports a remarkable modularity of Hsp90 effects on quantitative and qualitative phenotypes, consistent with the 'Hsp90 capacitor hypothesis' and standard quantitative genetic models of threshold traits.	[Carey, Charles C.; Gorman, Kristen F.; Rutherford, Suzannah] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center	Rutherford, S (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1124 Columbia St, Seattle, WA 98104 USA.	srutherf@fhcrc.org	Rutherford, Suzannah/L-7355-2019	Rutherford, Suzannah/0000-0002-7809-3337	Damon Runyon Walter Winchel Foundation Scholar Award NIH [R01 GM068873]; NIH [F32 GM07542, T32 CA80416]; NATIONAL CANCER INSTITUTE [T32CA080416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068873] Funding Source: NIH RePORTER	Damon Runyon Walter Winchel Foundation Scholar Award NIH; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Damon Runyon Walter Winchel Foundation Scholar Award NIH R01 GM068873. Chuck Carey was funded by NIH F32 GM07542 and NIH T32 CA80416.	Ashburner M., 1989, DROSOPHILA; Bergman A, 2003, NATURE, V424, P549, DOI 10.1038/nature01765; Bishop CD, 2002, DEV GENES EVOL, V212, P70, DOI 10.1007/s00427-002-0212-9; CLARK AG, 1995, GENETICA, V96, P225, DOI 10.1007/BF01439576; DEBAT V, 2006, EVOLUTION IN PRESS; Dickinson WJ, 1999, NATURE, V399, P30, DOI 10.1038/19894; Dietrich MR, 2003, NAT REV GENET, V4, P68, DOI 10.1038/nrg979; Fisher R. A., 1932, GENETICAL THEORY NAT; Frankel J, 2001, J EUKARYOT MICROBIOL, V48, P147, DOI 10.1111/j.1550-7408.2001.tb00297.x; Frankel J, 2001, J EUKARYOT MICROBIOL, V48, P135, DOI 10.1111/j.1550-7408.2001.tb00296.x; Gibson G, 2000, BIOESSAYS, V22, P372, DOI 10.1002/(SICI)1521-1878(200004)22:4<372::AID-BIES7>3.0.CO;2-J; Kimura M, 1983, NEUTRAL THEORY MOL E, pXV; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Loubradou G, 1997, GENETICS, V147, P581; Loubradou G, 1999, GENETICS, V152, P519; Meiklejohn CD, 2002, TRENDS ECOL EVOL, V17, P468, DOI 10.1016/S0169-5347(02)02596-X; Milton CC, 2003, P NATL ACAD SCI USA, V100, P13396, DOI 10.1073/pnas.1835613100; Milton CC, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000075; Nollen EAA, 2002, J CELL SCI, V115, P2809; Orr HA, 1998, EVOLUTION, V52, P935, DOI [10.2307/2411226, 10.1111/j.1558-5646.1998.tb01823.x]; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Roberts SP, 1999, OECOLOGIA, V121, P323, DOI 10.1007/s004420050935; RUTHERFORD S, 2007, MOL ASPECTS STRESS R; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Rutherford SL, 2000, BIOESSAYS, V22, P1095, DOI 10.1002/1521-1878(200012)22:12&lt;1095::AID-BIES7&gt;3.0.CO;2-A; Rutherford SL, 2003, NAT REV GENET, V4, P263, DOI 10.1038/nrg1041; Wagner GP, 1999, J EXP ZOOL, V285, P116, DOI 10.1002/(SICI)1097-010X(19990815)285:2<116::AID-JEZ3>3.0.CO;2-P; Wiesgigl M, 2001, MOL BIOL CELL, V12, P3307, DOI 10.1091/mbc.12.11.3307; WRIGHT SEWALL, 1932, PROC SIXTH INTERNAT CONGR GENETICS ITHACA NEW YORK, V1, P356	29	16	16	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e76	10.1371/journal.pone.0000076	http://dx.doi.org/10.1371/journal.pone.0000076			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183708	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443600076
J	Graefe, SEB; Streichert, T; Budde, BS; Nurnberg, P; Steeg, C; Muller-Myhsok, B; Fleischer, B				Graefe, Sebastian E. B.; Streichert, Thomas; Budde, Birgit S.; Nuernberg, Peter; Steeg, Christiane; Mueller-Myhsok, Bertram; Fleischer, Bernhard			Genes from Chagas Susceptibility Loci That Are Differentially Expressed in T-cruzi-Resistant Mice Are Candidates Accounting for Impaired Immunity	PLOS ONE			English	Article								Variation between inbred mice of susceptibility to experimental Trypanosoma cruzi infection has frequently been described, but the immunogenetic background is poorly understood. The outcross of the susceptible parental mouse strains C57BL/6 (B6) and DBA/2 (D2), B6D2F1 (F1) mice, is highly resistant to this parasite. In the present study we show by quantitative PCR that the increase of tissue parasitism during the early phase of infection is comparable up to day 11 between susceptible B6 and resistant F1 mice. A reduction of splenic parasite burdens occurs thereafter in both strains but is comparatively retarded in susceptible mice. Splenic microarchitecture is progressively disrupted with loss of follicles and B lymphocytes in B6 mice, but not in F1 mice. By genotyping of additional backcross offspring we corroborate our earlier findings that susceptibility maps to three loci on Chromosomes 5, 13 and 17. Analysis of gene expression of spleen cells from infected B6 and F1 mice with microarrays identifies about 0.3% of transcripts that are differentially expressed. Assuming that differential susceptibility is mediated by altered gene expression, we propose that the following differentially expressed transcripts from these loci are strong candidates for the observed phenotypic variation: H2-E alpha, H2-D1, Ng23, Msh5 and Tubb5 from Chromosome 17; and Cxcl11, Bmp2k and Spp1 from Chromosome 5. Our results indicate that innate mechanisms are not of primary relevance to resistance of F1 mice to T. cruzi infection, and that differential susceptibility to experimental infection with this protozoan pathogen is not paralleled by extensive variation of the transcriptome.	[Graefe, Sebastian E. B.; Fleischer, Bernhard] Univ Hosp Eppendorf, Inst Immunol, Hamburg, Germany; [Graefe, Sebastian E. B.; Steeg, Christiane; Fleischer, Bernhard] Bernhard Nocht Inst Trop Med, Dept Med Microbiol & Immunol, Hamburg, Germany; [Streichert, Thomas] Univ Hosp, Inst Clin Chem, Hamburg, Germany; [Budde, Birgit S.] Univ Cologne, Cologne Ctr Genom, Cologne, Germany; [Budde, Birgit S.; Nuernberg, Peter] Univ Cologne, Inst Genet, D-5000 Cologne, Germany; [Mueller-Myhsok, Bertram] Max Planck Inst Expt Psychiat, Munich, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Bernhard Nocht Institut fur Tropenmedizin; University of Cologne; University of Cologne; Max Planck Society	Graefe, SEB (corresponding author), Univ Hosp Eppendorf, Inst Immunol, Hamburg, Germany.	graefe@bni-hamburg.de	Müller-Myhsok, Bertram/A-3289-2013	Budde, Birgit/0000-0001-9385-4168	German Federal Ministry of Science and Education through the National Genome Research Network	German Federal Ministry of Science and Education through the National Genome Research Network	This work was supported by the German Federal Ministry of Science and Education through the National Genome Research Network.	Abel B, 2005, J IMMUNOL, V175, P6006, DOI 10.4049/jimmunol.175.9.6006; Allcock RJN, 2000, IMMUNOL TODAY, V21, P328, DOI 10.1016/S0167-5699(00)01654-6; Andrade LO, 2002, EXP PARASITOL, V100, P269, DOI 10.1016/S0014-4894(02)00024-3; ANDRADE V, 1985, BRAZ J MED BIOL RES, V18, P499; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Bonner AE, 2003, J MED GENET, V40, P408, DOI 10.1136/jmg.40.6.408; Buckner FS, 1999, INFECT IMMUN, V67, P403, DOI 10.1128/IAI.67.1.403-409.1999; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Campbell DA, 2004, CURR MOL MED, V4, P549, DOI 10.2174/1566524043360249; Casadevall A, 2001, J INFECT DIS, V184, P337, DOI 10.1086/322044; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Colorado IA, 2000, HUM IMMUNOL, V61, P320, DOI 10.1016/S0198-8859(99)00177-9; Cooke GS, 2001, NAT REV GENET, V2, P967, DOI 10.1038/35103577; de Vries SS, 1999, GENE DEV, V13, P523, DOI 10.1101/gad.13.5.523; Deghaide NHS, 1998, DIGEST DIS SCI, V43, P246, DOI 10.1023/A:1018829600200; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3; Fernandez-Mestre MT, 1998, PARASITE IMMUNOL, V20, P197; Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208; Graefe SEB, 2003, MICROBES INFECT, V5, P833, DOI 10.1016/S1286-4579(03)00176-X; Graefe SEB, 2003, GENES IMMUN, V4, P321, DOI 10.1038/sj.gene.6363972; Guarner J, 2001, AM J TROP MED HYG, V65, P152, DOI 10.4269/ajtmh.2001.65.152; Hardison JL, 2006, INFECT IMMUN, V74, P135, DOI 10.1128/IAI.74.1.135-143.2006; Hardison JL, 2006, INFECT IMMUN, V74, P125, DOI 10.1128/IAI.74.1.125-134.2006; HOFF R, 1974, J PARASITOL, V60, P527, DOI 10.2307/3278377; Holscher C, 1998, INFECT IMMUN, V66, P1208; JONES PP, 1981, IMMUNOGENETICS, V12, P321, DOI 10.1007/BF01561674; Kearns AE, 2001, J BIOL CHEM, V276, P42213, DOI 10.1074/jbc.M106163200; Kellam P, 2006, CELL, V124, P695, DOI 10.1016/j.cell.2006.02.003; KNUDSEN S, GUIDE ANAL DNA MICRO, P184; Koguchi Y, 2003, AM J RESP CRIT CARE, V167, P1355, DOI 10.1164/rccm.200209-1113OC; Kumar S, 1998, PARASITE IMMUNOL, V20, P207, DOI 10.1046/j.1365-3024.1998.00154.x; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Liao GC, 2004, SCIENCE, V306, P690, DOI 10.1126/science.1100636; Liaw L, 1998, J CLIN INVEST, V101, P1468; Loetscher P, 2001, J BIOL CHEM, V276, P2986, DOI 10.1074/jbc.M005652200; Luduena RF, 1998, INT REV CYTOL, V178, P207; Machado FS, 2005, J INFECT DIS, V191, P627, DOI 10.1086/427515; Maeno Y, 2006, ACTA TROP, V98, P305, DOI 10.1016/j.actatropica.2006.05.001; Marinho CRF, 1999, INFECT IMMUN, V67, P308, DOI 10.1128/IAI.67.1.308-318.1999; Marinho CRF, 2004, INFECT IMMUN, V72, P2350, DOI 10.1128/IAI.72.4.2350-2357.2004; Messaoudi I, 2002, SCIENCE, V298, P1797, DOI 10.1126/science.1076064; *MGD, 2006, MOUS GEN INF WEB SIT; Michailowsky V, 2001, AM J PATHOL, V159, P1723, DOI 10.1016/S0002-9440(10)63019-2; MILES MA, 2005, TOPLEY WILSONS MICRO, P376; MORGADO MG, 1989, EMBO J, V8, P3245, DOI 10.1002/j.1460-2075.1989.tb08484.x; Nau GJ, 1999, INFECT IMMUN, V67, P4223, DOI 10.1128/IAI.67.8.4223-4230.1999; Nieto A, 2000, TISSUE ANTIGENS, V55, P195, DOI 10.1034/j.1399-0039.2000.550301.x; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; Petkovic V, 2004, J LEUKOCYTE BIOL, V76, P701, DOI 10.1189/jlb.1103570; POTTS WK, 1995, IMMUNOL REV, V143, P181, DOI 10.1111/j.1600-065X.1995.tb00675.x; POWELL MR, 1993, PARASITE IMMUNOL, V15, P215, DOI 10.1111/j.1365-3024.1993.tb00603.x; Rajagopalan D, 2003, BIOINFORMATICS, V19, P1469, DOI 10.1093/bioinformatics/btg202; ROTTENBERG ME, 1993, INFECT IMMUN, V61, P5129, DOI 10.1128/IAI.61.12.5129-5133.1993; Sedy JR, 2005, NAT IMMUNOL, V6, P90, DOI 10.1038/ni1144; Shinohara ML, 2006, NAT IMMUNOL, V7, P498, DOI 10.1038/ni1327; SILVA JS, 1991, J EXP MED, V174, P539, DOI 10.1084/jem.174.3.539; SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169; SINGH RP, 1990, J EXP MED, V171, P1931, DOI 10.1084/jem.171.6.1931; Soares MBP, 2001, AM J PATHOL, V159, P703, DOI 10.1016/S0002-9440(10)61741-5; Soto CDA, 2003, INFECT IMMUN, V71, P1194, DOI 10.1128/IAI.71.3.1194-1199.2003; Talvani A, 2000, MICROBES INFECT, V2, P851, DOI 10.1016/S1286-4579(00)00388-9; Tarleton RL, 1997, P NATL ACAD SCI USA, V94, P3932, DOI 10.1073/pnas.94.8.3932; TARLETON RL, 1992, NATURE, V356, P338, DOI 10.1038/356338a0; TRISCHMANN TM, 1982, INFECT IMMUN, V35, P546, DOI 10.1128/IAI.35.2.546-551.1982; TRISCHMANN TM, 1984, PARASITE IMMUNOL, V6, P561, DOI 10.1111/j.1365-3024.1984.tb00825.x; TRISCHMANN TM, 1983, J IMMUNOL, V130, P1953; Vago AR, 1996, LANCET, V348, P891, DOI 10.1016/S0140-6736(05)64761-7; WilliamsBlangero S, 1997, AM J TROP MED HYG, V57, P538, DOI 10.4269/ajtmh.1997.57.538; WRIGHTSMAN R, 1982, INFECT IMMUN, V36, P637, DOI 10.1128/IAI.36.2.637-644.1982; WRIGHTSMAN RA, 1984, INFECT IMMUN, V44, P351, DOI 10.1128/IAI.44.2.351-354.1984; Xanthou G, 2003, EUR J IMMUNOL, V33, P2241, DOI 10.1002/eji.200323787; Zhang L, 1996, EUR J IMMUNOL, V26, P102, DOI 10.1002/eji.1830260116; Zhang L, 1999, J INFECT DIS, V180, P480, DOI 10.1086/314889; Zuniga E, 2000, CLIN EXP IMMUNOL, V119, P507, DOI 10.1046/j.1365-2249.2000.01150.x	76	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e57	10.1371/journal.pone.0000057	http://dx.doi.org/10.1371/journal.pone.0000057			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183687	Green Published, gold, Green Accepted			2022-12-25	WOS:000207443600057
J	Hill, PC; Brookes, RH; Fox, A; Jackson-Sillah, D; Lugos, MD; Jeffries, DJ; Donkor, SA; Adegbola, RA; McAdam, KPWJ				Hill, Philip C.; Brookes, Roger H.; Fox, Annette; Jackson-Sillah, Dolly; Lugos, Moses D.; Jeffries, David J.; Donkor, Simon A.; Adegbola, Richard A.; McAdam, Keith P. W. J.			Surprisingly High Specificity of the PPD Skin Test for M-tuberculosis Infection from Recent Exposure in The Gambia	PLOS ONE			English	Article								Background. Options for intervention against Mycobacterium tuberculosis infection are limited by the diagnostic tools available. The Purified Protein Derivative (PPD) skin test is thought to be non-specific, especially in tropical settings. We compared the PPD skin test with an ELISPOT test in The Gambia. Methodology/Principal Findings. Household contacts over six months of age of sputum smear positive TB cases and community controls were recruited. They underwent a PPD skin test and an ELISPOT test for the T cell response to PPD and ESAT-6/CFP10 antigens. Responsiveness to M. tuberculosis exposure was analysed according to sleeping proximity to an index case using logistic regression. 615 household contacts and 105 community controls were recruited. All three tests assessed increased significantly in positivity with increasing M. tuberculosis exposure, the PPD skin test most dramatically (OR 15.7; 95% CI 6.6-35.3). While the PPD skin test positivity continued to trend downwards in the community with increasing distance from a known case (61.9% to 14.3%), the PPD and ESAT-6/CFP-10 ELISPOT positivity did not. The PPD skin test was more in agreement with ESAT-6/CFP-10 ELISPOT (75%, p = 0.01) than the PPD ELISPOT (53%, p < 0.0001). With increasing M. tuberculosis exposure, the proportion of ESAT-6/CFP-10 positive contacts who were PPD skin test positive increased (p < 0.0001), and the proportion of ESAT-6/CFP-10 negative contacts that were PPD skin test negative decreased (p < 0.0001); the converse did not occur. Conclusions/Significance. The PPD skin test has surprisingly high specificity for M. tuberculosis infection from recent exposure in The Gambia. In this setting, anti-tuberculous prophylaxis in PPD skin test positive individuals should be revisited.	[Hill, Philip C.; Brookes, Roger H.; Fox, Annette; Jackson-Sillah, Dolly; Lugos, Moses D.; Jeffries, David J.; Donkor, Simon A.; Adegbola, Richard A.; McAdam, Keith P. W. J.] MRC Unit, Bacterial Dis Programme, Banjul, Gambia	University of London; London School of Hygiene & Tropical Medicine	Hill, PC (corresponding author), MRC Unit, Bacterial Dis Programme, Banjul, Gambia.	phill@mrc.gm	Lugos, Moses D/AAZ-5179-2020	Lugos, Moses D/0000-0002-4921-2691; Brookes, Roger/0000-0002-5361-0617; Fox, Annette/0000-0002-0565-7146	The Medical Research Council (UK); European Commission; MRC [MC_U190071468] Funding Source: UKRI; Medical Research Council [MC_U190071468] Funding Source: researchfish	The Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Commission(European CommissionEuropean Commission Joint Research Centre); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The Medical Research Council (UK) and the European Commission. Neither had any role in the design or conduct or collection analysis and interpretation of the data, or in the preparation, review or approval of the manuscript.	Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390; ANDERSEN P, 1995, J IMMUNOL, V154, P3359; [Anonymous], 1956, Br Med J, V1, P413; Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195; Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8; Black GF, 2001, INT J TUBERC LUNG D, V5, P664; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; COMSTOCK GW, 1969, AM REV RESPIR DIS, V100, P839; Crampin AC, 2001, T ROY SOC TROP MED H, V95, P481, DOI 10.1016/S0035-9203(01)90009-4; DEJONG BC, 2006, J INFECT DI IN PRESS; Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9; Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192; Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962; Floyd S, 2002, J INFECT DIS, V186, P807, DOI 10.1086/342416; Guwatudde D, 2003, AM J EPIDEMIOL, V158, P887, DOI 10.1093/aje/kwg227; Hill PC, 2005, J CLIN MICROBIOL, V43, P2070, DOI 10.1128/JCM.43.5.2070-2074.2005; Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362; Hill PC, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-156; Hoft DF, 2000, CLIN INFECT DIS, V30, pS217, DOI 10.1086/313864; Jeffries DJ, 2004, INT J TUBERC LUNG D, V8, P1095; Koch R., 1891, DEUT MED WOCHENSCHR, V17, P101, DOI [10.1055/s-0029-1206198, DOI 10.1055/S-0029-1206198]; Kunkel EJ, 2002, IMMUNITY, V16, P1, DOI 10.1016/S1074-7613(01)00261-8; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Lawn SD, 2006, CLIN INFECT DIS, V42, P1040, DOI 10.1086/501018; Lienhardt C, 2003, PEDIATRICS, V111, pE608, DOI 10.1542/peds.111.5.e608; Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066; Maher D, 2005, CLIN CHEST MED, V26, P167, DOI 10.1016/j.ccm.2005.02.009; Marshall RJ, 2001, STAT MED, V20, P1077, DOI 10.1002/sim.747; Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746; Pitman R, 2002, INT J TUBERC LUNG D, V6, P485; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; Sester M, 2004, KIDNEY INT, V65, P1826, DOI 10.1111/j.1523-1755.2004.00586.x	32	18	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e68	10.1371/journal.pone.0000068	http://dx.doi.org/10.1371/journal.pone.0000068			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183699	Green Published, gold			2022-12-25	WOS:000207443600068
J	Jensen, ML; Dave, S; van der Loeff, MS; da Costa, C; Vincent, T; Leligdowicz, A; Benn, CS; Roth, A; Ravn, H; Lisse, IM; Whittle, H; Aaby, P				Jensen, Mette Lundsby; Dave, Sangeeta; van der Loeff, Maarten Schim; da Costa, Carlos; Vincent, Tim; Leligdowicz, Aleksandra; Benn, Christine Stabell; Roth, Adam; Ravn, Henrik; Lisse, Ida Maria; Whittle, Hilton; Aaby, Peter			Vaccinia Scars Associated with Improved Survival among Adults in Rural Guinea-Bissau	PLOS ONE			English	Article							MEASLES IMMUNIZATION; MALIGNANT-MELANOMA; CHILD-MORTALITY; HIV-2 INFECTION; PROVIRUS LOAD; COMMUNITY; SMALLPOX; BCG; VACCINATIONS; COHORT	Background. In urban Guinea-Bissau, adults with a vaccinia scar had better survival but also a higher prevalence of HIV-2 infection. We therefore investigated the association between vaccinia scar and survival and HIV infection in a rural area of Guinea-Bissau. Methodology/Principal Findings. In connection with a study of HIV in rural Guinea-Bissau, we assessed vaccinia and BCG scars in 193 HIV-1 or HIV-2 infected and 174 uninfected participants. Mortality was assessed after 2 1/2-3 years of follow-up. The analyses were adjusted for age, sex, village, and HIV status. The prevalence of vaccinia scar was associated with age, village, and HIV-2 status but not with sex and schooling. Compared with individuals without any scar, individuals with a vaccinia scar had better survival (mortality rate ratio (MR) = 0.22 (95% CI 0.08-0.61)), the MR being 0.19 (95% CI 0.06-0.57) for women and 0.40 (95% CI 0.04-3.74) for men. Estimates were similar for HIV-2 infected and HIV-1 and HIV-2 uninfected individuals. The HIV-2 prevalence was higher among individuals with a vaccinia scar compared to individuals without a vaccinia scar (RR = 1.57 (95% CI 1.02-2.36)). Conclusion. The present study supports the hypothesis that vaccinia vaccination may have a non-specific beneficial effect on adult survival.	[Jensen, Mette Lundsby; da Costa, Carlos; Benn, Christine Stabell; Roth, Adam; Ravn, Henrik; Aaby, Peter] Statens Serum Inst, Projecto Saude Bandim, Bissau, Guinea Bissau; [Dave, Sangeeta; van der Loeff, Maarten Schim; Vincent, Tim; Leligdowicz, Aleksandra; Whittle, Hilton] MRC Labs, Fajara, Gambia; [Lisse, Ida Maria] Herlev Univ Hosp, Dept Pathol, Copenhagen, Denmark	Statens Serum Institut; MRC Laboratory Molecular Biology; University of Copenhagen; Herlev & Gentofte Hospital	Aaby, P (corresponding author), Statens Serum Inst, Projecto Saude Bandim, Bissau, Guinea Bissau.	p.aaby@bandim.org	Leligdowicz, Aleksandra/Q-2494-2016; Leligdowicz, Aleksandra/GLS-9028-2022	Leligdowicz, Aleksandra/0000-0001-6055-4644; Leligdowicz, Aleksandra/0000-0001-6055-4644; Aaby, Peter/0000-0001-8331-1389	British Medical Research Council; Danish Medical Research Council; DANIDA; Novo Nordisk Foundation; Danish National Research Foundation	British Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); DANIDA; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish National Research Foundation(Danmarks Grundforskningsfond)	The study received financial support from the British Medical Research Council and the Danish Medical Research Council, DANIDA, Novo Nordisk Foundation and Danish National Research Foundation. PA holds a research professorship grant from the Novo Nordisk Foundation. These institutions played no role in the conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	AABY P, 1993, AM J EPIDEMIOL, V138, P746, DOI 10.1093/oxfordjournals.aje.a116912; AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481; Aaby P, 1996, AIDS, V10, P1585, DOI 10.1097/00002030-199611000-00019; Aaby P, 2006, VACCINE, V24, P5718, DOI 10.1016/j.vaccine.2006.04.045; Ariyoshi K, 2003, J INFECT DIS, V188, P1648, DOI 10.1086/379780; Ariyoshi K, 1996, J INFECT DIS, V173, P245, DOI 10.1093/infdis/173.1.245; Ashorn P, 2002, ARCH DIS CHILD, V87, P386, DOI 10.1136/adc.87.5.386; Bager P, 2003, J ALLERGY CLIN IMMUN, V111, P1227, DOI 10.1067/mai.2003.1483; Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904; Cox D. R., 1984, ANAL SURVIVAL DATA; Demkowicz WE, 1996, J VIROL, V70, P2627, DOI 10.1128/JVI.70.4.2627-2631.1996; DEMKOWICZ WE, 1993, J VIROL, V67, P1538, DOI 10.1128/JVI.67.3.1538-1544.1993; FINE PEM, 1989, B WORLD HEALTH ORGAN, V67, P35; Frey SE, 2002, NEW ENGL J MED, V346, P1275, DOI 10.1056/NEJMoa013431; Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; GRUFFERMAN S, 1982, JNCI-J NATL CANCER I, V68, P107; HENDERSON DA, 1999, VACCINES, P74; Jaffar S, 2005, AIDS RES HUM RETROV, V21, P560, DOI 10.1089/aid.2005.21.560; Knudsen KM, 1996, INT J EPIDEMIOL, V25, P665, DOI 10.1093/ije/25.3.665; Kolmel KF, 2005, EUR J CANCER, V41, P118, DOI 10.1016/j.ejca.2004.09.023; KOLMEL KF, 1992, MELANOMA RES, V2, P207; Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435; Kurtzke JF, 1997, ACTA NEUROL SCAND, V96, P149; Mercer A, 1990, DIS MORTALITY POPULA; Moore ZS, 2006, LANCET, V367, P425, DOI 10.1016/S0140-6736(06)68143-9; Pfahlberg A, 2002, J INVEST DERMATOL, V119, P570, DOI 10.1046/j.1523-1747.2002.00643.x; Poulsen AG, 2000, SCAND J INFECT DIS, V32, P169, DOI 10.1080/003655400750045286; RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016; Shann F, 2004, PEDIATR INFECT DIS J, V23, P555, DOI 10.1097/01.inf.0000130155.42392.04; van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012; VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474; Welsh RM, 2002, NAT REV IMMUNOL, V2, P417, DOI 10.1038/nri820; WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015	34	40	41	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e101	10.1371/journal.pone.0000101	http://dx.doi.org/10.1371/journal.pone.0000101			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183634	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443600100
J	Russell, CA; Real, LA; Smith, DL				Russell, Colin A.; Real, Leslie A.; Smith, David L.			Spatial Control of Rabies on Heterogeneous Landscapes	PLOS ONE			English	Article							RACCOON RABIES; METAPOPULATION DYNAMICS; TRAVELING-WAVES; SPREAD; HIERARCHIES; EPIDEMIC; MODEL	Rabies control in terrestrial wildlife reservoirs relies heavily on an oral rabies vaccine (ORV). In addition to direct ORV delivery to protect wildlife in natural habitats, vaccine corridors have been constructed to control the spread; these corridors are often developed around natural barriers, such as rivers, to enhance the effectiveness of vaccine deployment. However, the question of how to optimally deploy ORV around a river (or other natural barrier) to best exploit the barrier for rabies control has not been addressed using mathematical models. Given an advancing epidemic wave, should the vaccine be distributed on both sides of barrier, behind the barrier, or in front of it? Here, we introduce a new mathematical model for the dynamics of raccoon rabies on a spatially heterogeneous landscape that is both simple and realistic. We demonstrate that the vaccine should always be deployed behind a barrier to minimize the recurrence of subsequent epidemics. Although the oral rabies vaccine is sufficient to induce herd immunity inside the vaccinated area, it simultaneously creates a demographic refuge. When that refuge is in front of a natural barrier, seasonal dispersal from the vaccine corridor into an endemic region sustains epidemic oscillations of raccoon rabies. When the vaccine barrier creates a refuge behind the river, the low permeability of the barrier to host movement limits dispersal of the host population from the protected populations into the rabies endemic area and limits subsequent rabies epidemics.	[Russell, Colin A.] Univ Cambridge, Dept Zool, Cambridge, England; [Real, Leslie A.] Emory Univ, Dept Biol, Atlanta, GA 30322 USA; [Smith, David L.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA	University of Cambridge; Emory University; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)	Russell, CA (corresponding author), Univ Cambridge, Dept Zool, Cambridge, England.	car44@cam.ac.uk	Smith, David L/L-8850-2013; Russell, Colin/ABE-7106-2020	Smith, David L/0000-0003-4367-3849; Russell, Colin/0000-0002-2113-162X	Gates Cambridge Trust	Gates Cambridge Trust	Funding: This work was supported by a Gates Cambridge Trust Fellowship to CAR.	ANDERSON RM, 1986, NATURE, V322, P304, DOI 10.1038/322304a0; Bourhy H, 1999, J GEN VIROL, V80, P2545, DOI 10.1099/0022-1317-80-10-2545; BROADFOOT J, 2000, ECOLOGICAL APPL, V11, P295; Childs JE, 2000, P NATL ACAD SCI USA, V97, P13666, DOI 10.1073/pnas.240326697; COYNE MJ, 1989, AM J VET RES, V50, P2148; Cummings DAT, 2004, NATURE, V427, P344, DOI 10.1038/nature02225; Grenfell B, 1997, TRENDS ECOL EVOL, V12, P395, DOI 10.1016/S0169-5347(97)01174-9; Grenfell BT, 2001, NATURE, V414, P716, DOI 10.1038/414716a; KAUFMANN J, 1982, WILD MAMMALS N AM BI; Keeling MJ, 2000, NATURE, V407, P903, DOI 10.1038/35038073; Krebs J W, 1998, J Public Health Manag Pract, V4, P56; Lucey BT, 2002, VECTOR-BORNE ZOONOT, V2, P77, DOI 10.1089/153036602321131878; MURRAY JD, 1986, PROC R SOC SER B-BIO, V229, P111, DOI 10.1098/rspb.1986.0078; Ostfeld RS, 2005, TRENDS ECOL EVOL, V20, P328, DOI 10.1016/j.tree.2005.03.009; Roscoe DE, 1998, J WILDLIFE DIS, V34, P752, DOI 10.7589/0090-3558-34.4.752; Russell CA, 2005, PLOS BIOL, V3, P382, DOI 10.1371/journal.pbio.0030088; Selhorst T, 1999, ECOL MODEL, V124, P221, DOI 10.1016/S0304-3800(99)00170-2; Smith DL, 2005, PREV VET MED, V71, P225, DOI 10.1016/j.prevetmed.2005.07.009; Smith DL, 2002, P NATL ACAD SCI USA, V99, P3668, DOI [10.1073/pnas.042400799, 10.1073/pnas.132272199]; SMITH G, 1995, J AM VET MED ASSOC, V208, P1666; SMITH GC, 2002, ECOLOGICAL MODELLING, V150, P129; Thulke HH, 1999, ECOL MODEL, V117, P179, DOI 10.1016/S0304-3800(98)00198-7; Viboud C, 2006, SCIENCE, V312, P447, DOI 10.1126/science.1125237; Walsh PD, 2005, PLOS BIOL, V3, P1946, DOI 10.1371/journal.pbio.0030371; Xia YC, 2004, AM NAT, V164, P267, DOI 10.1086/422341	25	51	53	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e27	10.1371/journal.pone.0000027	http://dx.doi.org/10.1371/journal.pone.0000027			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183654	gold, Green Published			2022-12-25	WOS:000207443600027
J	Strathdee, D; Ibbotson, H; Grant, SGN				Strathdee, Douglas; Ibbotson, Helen; Grant, Seth G. N.			Expression of Transgenes Targeted to the Gt(ROSA)26Sor Locus Is Orientation Dependent	PLOS ONE			English	Article							EMBRYONIC STEM-CELLS; GENE-EXPRESSION; HPRT LOCUS; TRANSCRIPTIONAL INTERFERENCE; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; MOUSE; MICE; ACTIVATION; PROMOTERS	Background. Targeting transgenes to a chosen location in the genome has a number of advantages. A single copy of the DNA construct can be inserted by targeting into regions of chromatin that allow the desired developmental and tissue-specific expression of the transgene. Methodology. In order to develop a reliable system for reproducibly expressing trangenes it was decided to insert constructs at the Gt(ROSA)26Sor locus. A cytomegalovirus (CMV) promoter was used to drive expression of the Tetracycline (tet) transcriptional activator, rtTA2(s)-M2, and test the effectiveness of using the ROSA26 locus to allow transgene expression. The tet operator construct was inserted into one allele of ROSA26 and a tet responder construct controlling expression of EGFP was inserted into the other allele. Conclusions. Expression of the targeted transgenes was shown to be affected by both the presence of selectable marker cassettes and by the orientation of the transgenes with respect to the endogenous ROSA26 promoter. These results suggest that transcriptional interference from the endogenous gene promoter or from promoters in the selectable marker cassettes may be affecting transgene expression at the locus. Additionally we have been able to determine the optimal orientation for transgene expression at the ROSA26 locus.	[Strathdee, Douglas; Grant, Seth G. N.] Wellcome Trust Sanger Inst, Cambridge, England; [Strathdee, Douglas; Ibbotson, Helen; Grant, Seth G. N.] Univ Edinburgh, Neurosci Res Ctr, Edinburgh, Midlothian, Scotland	Wellcome Trust Sanger Institute; University of Edinburgh	Strathdee, D (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge, England.	ds10@sanger.ac.uk		Grant, Seth/0000-0001-8732-8735	Gatsby Charitable Foundation; Wellcome Trust	Gatsby Charitable Foundation; Wellcome Trust(Wellcome TrustEuropean Commission)	This work was supported by a grant from the Gatsby Charitable Foundation and the Wellcome Trust.	Awatramani R, 2001, NAT GENET, V29, P257, DOI 10.1038/ng1101-257; Bagchi B, 2006, CELL BIOL INT, V30, P505, DOI 10.1016/j.cellbi.2006.01.008; Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; Belteki G, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni051; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bronson SK, 1996, P NATL ACAD SCI USA, V93, P9067, DOI 10.1073/pnas.93.17.9067; Bryja V, 2003, REPROD NUTR DEV, V43, P477, DOI 10.1051/rnd:2004001; Chiaromonte F, 2003, GENOME RES, V13, P2602, DOI 10.1101/gr.1169203; Chung SM, 2002, STEM CELLS, V20, P139, DOI 10.1634/stemcells.20-2-139; CLARK AJ, 1994, REPROD FERT DEVELOP, V6, P589, DOI 10.1071/RD9940589; Cvetkovic B, 2000, J BIOL CHEM, V275, P1073, DOI 10.1074/jbc.275.2.1073; Dorer DR, 1997, TRANSGENIC RES, V6, P3, DOI 10.1023/A:1018460413680; Eszterhas SK, 2002, MOL CELL BIOL, V22, P469, DOI 10.1128/MCB.22.2.469-479.2002; Evans V, 2000, PHYSIOL GENOMICS, V2, P67, DOI 10.1152/physiolgenomics.2000.2.2.67; Feng YQ, 2005, MOL CELL BIOL, V25, P3864, DOI 10.1128/MCB.25.10.3864-3874.2005; Fiering S, 1999, METHOD ENZYMOL, V306, P42; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gossen M, 2002, ANNU REV GENET, V36, P153, DOI 10.1146/annurev.genet.36.041002.120114; Greger IH, 1998, NUCLEIC ACIDS RES, V26, P1294, DOI 10.1093/nar/26.5.1294; Guillot PV, 2000, PHYSIOL GENOMICS, V2, P77, DOI 10.1152/physiolgenomics.2000.2.2.77; Hasegawa K, 2002, FEBS LETT, V520, P47, DOI 10.1016/S0014-5793(02)02761-8; Heaney JD, 2004, GENOMICS, V83, P1072, DOI 10.1016/j.ygeno.2003.12.015; Herrera FJ, 2004, J VIROL, V78, P9689, DOI 10.1128/JVI.78.18.9689-9696.2004; Kisseberth WC, 1999, DEV BIOL, V214, P128, DOI 10.1006/dbio.1999.9417; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; Liu WM, 2006, J MOL MED, V84, P57, DOI 10.1007/s00109-005-0711-z; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; Mao XH, 2001, BLOOD, V97, P324, DOI 10.1182/blood.V97.1.324; Martin David I. K., 1996, Bioessays, V18, P919, DOI 10.1002/bies.950181111; Masui S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni043; Misra RP, 2002, ENDOCRINE, V19, P229, DOI 10.1385/ENDO:19:3:229; Miyazaki S, 2005, BIOCHEM BIOPH RES CO, V338, P1083, DOI 10.1016/j.bbrc.2005.10.054; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Yata Y, 2003, HEPATOLOGY, V37, P267, DOI 10.1053/jhep.2003.50067; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	43	43	50	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e4	10.1371/journal.pone.0000004	http://dx.doi.org/10.1371/journal.pone.0000004			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183668	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600004
J	Mitra, S; Holz, RC				Mitra, Sanghamitra; Holz, Richard C.			Unraveling the catalytic mechanism of nitrile hydratases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONHEME IRON; CRYSTAL-STRUCTURE; AEROMONAS-PROTEOLYTICA; INDUSTRIAL-PRODUCTION; ELECTRONIC-STRUCTURE; ACTIVE-SITE; SUBSTRATE; BIOTRANSFORMATION; AMINOPEPTIDASE; DEHYDROGENASE	To elucidate a detailed catalytic mechanism for nitrile hydratases (NHases), the pH and temperature dependence of the kinetic constants k(cat) and K-m for the cobalt-type NHase from Pseudonocardia thermophila JCM 3095 (PtNHase) were examined. PtNHase was found to exhibit a bell-shaped curve for plots of relative activity versus PH at pH 3.2-11 and was found to display maximal activity between PH 7.2 and 7.8. Fits of these data provided pK(ES1) and pK(ES2) values of 5.9 +/- 0.1 and 9.2 +/- 0.1 (k(cat)' = 130 +/- 1 s(-1)), respectively, and pK(E1) and pK(E2) values of 5.8 +/- 0.1 and 9.1 +/- 0.1 (k(cat)'/K-m' = (6.5 +/- 0.1) X 10(3)s(-1) mM(-1)), respectively. Proton inventory studies indicated that two protons are transferred in the rate-limiting step of the reaction at pH 7.6. Because PtNHase is stable at 60 degrees C, an Arrhenius plot was constructed by plotting In(k(cat)) versus 1/T, providing E-a = 23.0 +/- 1.2 kJ/mol. The thermal stability of PtNHase also allowed Delta H-0 ionization values to be determined, thus helping to identify the ionizing groups exhibiting the pK(ES1) and pK(ES2) values. Based on Delta H-ion(0) data, pK(ES1) is assigned to beta Tyr(68), whereas pK(ES2) is assigned to beta Arg(52), beta Arg(157), or alpha Ser(112) (NHases are alpha(2)beta(2)-heterotetramers). A combination of these data with those previously reported for NHases and synthetic model complexes, along with sequence comparisons of both iron- and cobalt-type NHases, allowed a novel catalytic mechanism for NHases to be proposed.	Loyola Univ, Dept Chem, Chicago, IL 60626 USA; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Loyola University Chicago; Utah System of Higher Education; Utah State University	Mitra, S (corresponding author), Loyola Univ, Dept Chem, 1068 W Sheridan Rd, Chicago, IL 60626 USA.	rholz1@luc.edu						ALBERY WJ, 1975, PROTON TRANSFER REAC; Alfani F, 2001, J MOL CATAL B-ENZYM, V11, P687, DOI 10.1016/S1381-1177(00)00160-0; Banerjee A, 2002, APPL MICROBIOL BIOT, V60, P33, DOI 10.1007/s00253-002-1062-0; Bienvenue DL, 2002, J BIOL INORG CHEM, V7, P129, DOI 10.1007/s007750100280; Boone AJ, 2001, INORG CHEM, V40, P1837, DOI 10.1021/ic0009021; Chen GJ, 1997, BIOCHEMISTRY-US, V36, P4278, DOI 10.1021/bi9618676; Clark DD, 2004, BIOCHEMISTRY-US, V43, P6763, DOI 10.1021/bi049783h; Clark DD, 2002, BIOCHEMISTRY-US, V41, P2727, DOI 10.1021/bi0118005; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; CLELAND WW, 1982, CRC CR REV BIOCH MOL, V13, P385; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; Dadd MR, 2001, ENZYME MICROB TECH, V29, P20, DOI 10.1016/S0141-0229(01)00337-4; Desai LV, 2004, DALTON T, P872, DOI 10.1039/b313380j; Dey A, 2006, J AM CHEM SOC, V128, P533, DOI 10.1021/ja0549695; Dixon M., 1979, ENZYMES, Vthird; ELROD JP, 1980, J AM CHEM SOC, V102, P3917, DOI 10.1021/ja00531a039; Endo I, 2001, J INORG BIOCHEM, V83, P247, DOI 10.1016/S0162-0134(00)00171-9; Greene SN, 2006, INORG CHEM, V45, P17, DOI 10.1021/ic050965p; Harrop TC, 2004, ACCOUNTS CHEM RES, V37, P253, DOI 10.1021/ar0301532; Hourai S, 2003, BIOCHEM BIOPH RES CO, V312, P340, DOI 10.1016/j.bbrc.2003.10.124; Huang WJ, 1997, STRUCTURE, V5, P691, DOI 10.1016/S0969-2126(97)00223-2; IZATT RM, 1976, HEATS PROTON IONIZAT; JIN HY, 1993, J AM CHEM SOC, V115, P5290, DOI 10.1021/ja00065a048; Jones S, 2004, CURR OPIN CHEM BIOL, V8, P3, DOI 10.1016/j.cbpa.2003.11.001; KOBAYASHI M, 1992, TRENDS BIOTECHNOL, V10, P402, DOI 10.1016/0167-7799(92)90283-2; Kovacs JA, 2004, CHEM REV, V104, P825, DOI 10.1021/cr020619e; Martinkova L, 1998, BIOTECHNOL LETT, V20, P909, DOI 10.1023/A:1005306723601; Martinkova L, 2003, CURR ORG CHEM, V7, P1279, DOI 10.2174/1385272033486486; Miyanaga A, 2004, EUR J BIOCHEM, V271, P429, DOI 10.1046/j.1432-1033.2003.03943.x; Miyanaga A, 2001, BIOCHEM BIOPH RES CO, V288, P1169, DOI 10.1006/bbrc.2001.5897; NAGASAWA T, 1993, APPL MICROBIOL BIOT, V40, P189; NAGASAWA T, 1988, APPL ENVIRON MICROB, V54, P1766, DOI 10.1128/AEM.54.7.1766-1769.1988; NAGASAWA T, 1995, PURE APPL CHEM, V67, P1241, DOI 10.1351/pac199567071241; Nagashima S, 1998, NAT STRUCT BIOL, V5, P347, DOI 10.1038/nsb0598-347; Nakasako M, 1999, BIOCHEMISTRY-US, V38, P9887, DOI 10.1021/bi982753s; Padmakumar R, 1999, APPL BIOCHEM BIOTECH, V77-9, P671; Payne MS, 1997, BIOCHEMISTRY-US, V36, P5447, DOI 10.1021/bi962794t; Petrillo KL, 2005, APPL MICROBIOL BIOT, V67, P664, DOI 10.1007/s00253-004-1842-9; SALOMAA P, 1964, J AM CHEM SOC, V86, P1, DOI 10.1021/ja01055a001; Segel IH., 1993, ENZYME KINETICS BEHA; Segel IH, 1975, ENZYME KINETICS BEHA; Shaw NM, 2003, ADV SYNTH CATAL, V345, P425, DOI 10.1002/adsc.200390049; Shearer J, 2002, J AM CHEM SOC, V124, P11417, DOI 10.1021/ja012555f; Shearer J, 2001, J AM CHEM SOC, V123, P463, DOI 10.1021/ja002642s; SUGIURA Y, 1987, J AM CHEM SOC, V109, P5848, DOI 10.1021/ja00253a046; Tsujimura M, 2003, J AM CHEM SOC, V125, P11532, DOI 10.1021/ja035018z; VENKATASUBBAN KS, 1984, CRC CR REV BIOCH MOL, V17, P1, DOI 10.3109/10409238409110268; Wu ZL, 2003, CHEM COMMUN, P386, DOI 10.1039/b210743k; Yamada H, 1996, BIOSCI BIOTECH BIOCH, V60, P1391, DOI 10.1271/bbb.60.1391; Yamaki T, 1997, J FERMENT BIOENG, V83, P474, DOI 10.1016/S0922-338X(97)83004-8	50	51	51	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7397	7404		10.1074/jbc.M604117200	http://dx.doi.org/10.1074/jbc.M604117200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17150969	Green Published, hybrid			2022-12-25	WOS:000245080900051
J	Eto, K; Kaur, V; Thomas, MK				Eto, Kazuhiro; Kaur, Varinderpal; Thomas, Melissa K.			Regulation of pancreas duodenum homeobox-1 expression by early growth response-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC TRANSCRIPTION; NUCLEAR FACTOR 3-BETA; INSULIN GENE-TRANSCRIPTION; PROMOTER FACTOR-I; PDX-1 GENE; TARGET GENES; BETA; EGR-1; GLUCOSE; PATHWAYS	The homeodomain transcription factor pancreas duodenum homeobox-1 (PDX-1) is a key regulator of pancreatic beta-cell development, function, and survival. Deficits in PDX-1 expression result in insulin deficiency and hyperglycemia. We previously found that the glucose-responsive transcription factor early growth response-1 (Egr-1) activates the insulin promoter in part by increasing expression levels of PDX-1. We now report that Egr-1 binds and activates multiple regulatory sites within the pdx-1 promoter. We identified consensus Egr-1 recognition sequences within proximal and distal. regions of the mouse pdx-1 promoter and demonstrated specific binding of Egr-1 by chromatin immunoprecipitation and electrophoretic mobility shift assays. Overexpression of Egr-1 increased transcriptional activation of the -4500 proximal pdx-1 promoter and of the highly conserved regulatory Areas I, II, and Ill. Mutagenesis of a specific Egr-1 binding site within Area III substantially decreased Egr-1-mediated activation. Egr-1 increased the transcriptional activation of Areas I and II, despite the absence of Egr-1 recognition sequences within this promoter segment, suggesting that Egr-1 also can regulate the pdx-1 promoter indirectly. Egr-1 increased, and a dominant-negative Egr-1 mutant repressed, the transcriptional activation of distal pdx-1 promoter sequences. Mutagenesis of a specific Egr-1 binding site within regulatory Area IV reduced basal and Egr-1-mediated transcriptional activation. Our data indicate that Egr-1 regulates expression of PDX-1 in pancreatic P-cells by both direct and indirect activation of the pdx-1 promoter. We propose that Egr-1 expression levels may act as a sensor in pancreatic P-cells to translate extracellular signals into changes in PDX-1 expression levels and pancreatic beta-cell function.	Massachusetts Gen Hosp, Mol Endocrinol Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Thomas, MK (corresponding author), Massachusetts Gen Hosp, Mol Endocrinol Lab, Thier 340,50 Blossom St, Boston, MA 02114 USA.	mthomas1@partners.org			NIDDK NIH HHS [P30DK057521] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057521] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Bae SK, 1999, CANCER RES, V59, P5989; Ben-Shushan E, 2001, J BIOL CHEM, V276, P17533, DOI 10.1074/jbc.M009088200; Bernal-Mizrachi E, 2000, J BIOL CHEM, V275, P25681, DOI 10.1074/jbc.M003424200; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Chapman NR, 2000, J BIOL CHEM, V275, P4719, DOI 10.1074/jbc.275.7.4719; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; Elbein SC, 2004, DIABETES CARE, V27, P1968, DOI 10.2337/diacare.27.8.1968; Eto K, 2006, ENDOCRINOLOGY, V147, P2923, DOI 10.1210/en.2005-1336; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; Fu MG, 2003, GENE, V315, P33, DOI 10.1016/S0378-1119(03)00730-3; Garnett KE, 2005, J MOL ENDOCRINOL, V35, P13, DOI 10.1677/jme.1.01792; Gerrish K, 2004, MOL ENDOCRINOL, V18, P533, DOI 10.1210/me.2003-0371; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Gerrish K, 2001, J BIOL CHEM, V276, P47775, DOI 10.1074/jbc.M109244200; Gousseva N, 2001, J CELL BIOCHEM, V81, P523, DOI 10.1002/1097-4644(20010601)81:3<523::AID-JCB1066>3.0.CO;2-E; Gragnoli C, 2005, METABOLISM, V54, P983, DOI 10.1016/j.metabol.2005.01.037; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Harada S, 2001, DNA CELL BIOL, V20, P223, DOI 10.1089/104454901750219107; Holland AM, 2002, P NATL ACAD SCI USA, V99, P12236, DOI 10.1073/pnas.192255099; JHUN BH, 1995, BIOCHEMISTRY-US, V34, P7996, DOI 10.1021/bi00025a005; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Josefsen K, 1999, DIABETOLOGIA, V42, P195, DOI 10.1007/s001250051139; Kang JH, 2006, DIABETOLOGIA, V49, P969, DOI 10.1007/s00125-006-0179-6; Keeton AB, 2003, ENDOCRINOLOGY, V144, P5402, DOI 10.1210/en.2003-0592; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; Leung-Theung-Long S, 2005, J BIOL CHEM, V280, P7976, DOI 10.1074/jbc.M407485200; LIN YL, 1995, ENDOCRINOLOGY, V136, P2922, DOI 10.1210/en.136.7.2922; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mosley AL, 2004, MOL ENDOCRINOL, V18, P2279, DOI 10.1210/me.2003-0463; Offield MF, 1996, DEVELOPMENT, V122, P983; Ohsugi M, 2004, DIABETES, V53, P1496, DOI 10.2337/diabetes.53.6.1496; Owen KR, 2004, DIABETOLOGIA, V47, P957, DOI 10.1007/s00125-004-1397-4; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Samaras SE, 2003, J BIOL CHEM, V278, P12263, DOI 10.1074/jbc.M210801200; Samaras SE, 2002, MOL CELL BIOL, V22, P4702, DOI 10.1128/MCB.22.13.4702-4713.2002; Sartipy P, 2003, J BIOL CHEM, V278, P52298, DOI 10.1074/jbc.M306922200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwitzgebel VM, 2003, J CLIN ENDOCR METAB, V88, P4398, DOI 10.1210/jc.2003-030046; Sharma S, 1996, J BIOL CHEM, V271, P2294, DOI 10.1074/jbc.271.4.2294; Sharma S, 1997, MOL CELL BIOL, V17, P2598, DOI 10.1128/MCB.17.5.2598; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Silverman ES, 1998, BIOCHEM J, V336, P183, DOI 10.1042/bj3360183; Stanojevic V, 2004, ENDOCRINOLOGY, V145, P2918, DOI 10.1210/en.2003-1188; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Taub R, 1999, SEMIN LIVER DIS, V19, P117, DOI 10.1055/s-2007-1007104; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Thomas Melissa K., 2004, P552; Thomas MK, 2001, J CLIN INVEST, V108, P319, DOI 10.1172/JCI200112029; Thomas MK, 2001, ENDOCRINOLOGY, V142, P1033, DOI 10.1210/en.142.3.1033; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Tsuruzoe K, 2001, MOL CELL BIOL, V21, P26, DOI 10.1128/MCB.21.1.26-38.2001; Van Velkinburgh JC, 2005, J BIOL CHEM, V280, P38438, DOI 10.1074/jbc.M508594200; Weng JP, 2002, DIABETES CARE, V25, P68, DOI 10.2337/diacare.25.1.68; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002	64	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					5973	5983		10.1074/jbc.M607288200	http://dx.doi.org/10.1074/jbc.M607288200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17150967	hybrid			2022-12-25	WOS:000244867200002
J	Horigome, D; Satoh, H; Itoh, N; Mitsunaga, K; Oonishi, I; Nakagawa, A; Uchida, A				Horigome, Daisuke; Satoh, Hiroyuki; Itoh, Nobue; Mitsunaga, Katsuyoshi; Oonishi, Isao; Nakagawa, Atsushi; Uchida, Akira			Structural mechanism and photoprotective function of water-soluble chlorophyll-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; LEPIDIUM-VIRGINICUM; ANGSTROM RESOLUTION; SINGLET OXYGEN; PHOTOSYSTEM-I; SYSTEM; CRYSTALLIZATION; PHOTOSYNTHESIS; FLUORESCENCE; SPECTROSCOPY	A water-soluble chlorophyll-binding protein (WSCP) is the single known instance of a putative chlorophyll (Chl) carrier in green plants. Recently the photoprotective function of WSCP has been demonstrated by EPR measurements; the light-induced singlet-oxygen formation of Chl in the WSCP tetramer is about four times lower than that of unbound Chl. This paper describes the crystal structure of the WSCP-Chl complex purified from leaves of Lepidium virginicum (Virginia pepperweed) to clarify the mechanism of its photoprotective function. The WSCP-Chl complex is a homotetramer comprising four protein chains of 180 amino acids and four Chl molecules. At the center of the complex one hydrophobic cavity is formed in which all of the four Chl molecules are tightly packed and isolated from bulk solvent. With reference to the novel Chl-binding mode, we propose that the photoprotection mechanism may be based on the inhibition of physical contact between the Chl molecules and molecular oxygen.	Toho Univ, Dept Biomol Sci, Funabashi, Chiba 2748510, Japan; Toho Univ, Fac Sci, Funabashi, Chiba 2748510, Japan; Toho Univ, Sch Pharmaceut Sci, Funabashi, Chiba 2748510, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Toho University; Toho University; Toho University; Osaka University	Uchida, A (corresponding author), Toho Univ, Dept Biomol Sci, 2-2-1 Miyama, Funabashi, Chiba 2748510, Japan.	auchida@biomol.sci.toho-u.ac.jp	Nakagawa, Atsushi/M-5731-2019; Nakagawa, Atsushi/D-4329-2009	Nakagawa, Atsushi/0000-0002-1700-7861; Nakagawa, Atsushi/0000-0002-1700-7861				Amerongen H, 2001, J PHYS CHEM B, V105, P604; Balaban TS, 2002, BBA-BIOENERGETICS, V1556, P197, DOI 10.1016/S0005-2728(02)00363-8; BEDDARD GS, 1976, NATURE, V260, P366, DOI 10.1038/260366a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Dashdorj N, 2005, BIOPHYS J, V88, P4178, DOI 10.1529/biophysj.104.058693; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Drzewiecka-Matuszek A, 2005, J BIOL INORG CHEM, V10, P453, DOI 10.1007/s00775-005-0652-6; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; HOOFT RW, 1996, NATURE, V381, P27; Horigome D, 2003, ACTA CRYSTALLOGR D, V59, P2283, DOI 10.1107/S0907444903019127; Hortensteiner S, 1999, CELL MOL LIFE SCI, V56, P330, DOI 10.1007/s000180050434; Hughes JL, 2006, J AM CHEM SOC, V128, P3649, DOI 10.1021/ja056576b; Ilami G, 1997, PHYTOCHEMISTRY, V45, P1, DOI 10.1016/S0031-9422(96)00788-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kamimura Y, 1997, PLANT CELL PHYSIOL, V38, P133, DOI 10.1093/oxfordjournals.pcp.a029143; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Krauchenco S, 2003, BIOCHEM BIOPH RES CO, V312, P1303, DOI 10.1016/j.bbrc.2003.11.062; Krieger-Liszkay A, 2005, J EXP BOT, V56, P337, DOI 10.1093/jxb/erh237; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li YF, 1997, J MOL BIOL, V271, P456, DOI 10.1006/jmbi.1997.1189; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Matile P, 1997, PLANTA, V201, P96, DOI 10.1007/BF01258685; MURATA T, 1981, BIOCHIM BIOPHYS ACTA, V635, P341, DOI 10.1016/0005-2728(81)90032-3; MURATA T, 1980, BIOCHIM BIOPHYS ACTA, V593, P167, DOI 10.1016/0005-2728(80)90018-3; Nishio N, 1997, PLANT PHYSIOL, V115, P841, DOI 10.1104/pp.115.2.841; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; Oba T, 2002, PHOTOSYNTH RES, V74, P1, DOI 10.1023/A:1020816128794; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peterman EJG, 1998, BIOPHYS J, V75, P389, DOI 10.1016/S0006-3495(98)77523-X; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Satoh H, 1998, J BIOL CHEM, V273, P30568, DOI 10.1074/jbc.273.46.30568; Satoh H, 2001, PLANT CELL PHYSIOL, V42, P906, DOI 10.1093/pcp/pce117; Schmidt K, 2003, BIOCHEMISTRY-US, V42, P7427, DOI 10.1021/bi034207r; SPIKES JD, 1991, CHLOROPHYLLS, P1181; SUGIYAMA KI, 1978, BIOCHIM BIOPHYS ACTA, V503, P107, DOI 10.1016/0005-2728(78)90165-2; Szabo I, 2005, EMBO REP, V6, P629, DOI 10.1038/sj.embor.7400460; Takamiya K, 2000, TRENDS PLANT SCI, V5, P426, DOI 10.1016/S1360-1385(00)01735-0; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; Zhong DP, 2001, P NATL ACAD SCI USA, V98, P11867, DOI 10.1073/pnas.211440398	41	79	83	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6525	6531		10.1074/jbc.M609458200	http://dx.doi.org/10.1074/jbc.M609458200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17170107	hybrid, Green Published			2022-12-25	WOS:000244867200060
J	Matsushita, M; Suzuki, NN; Obara, K; Fujioka, Y; Ohsumi, Y; Inagaki, F				Matsushita, Minako; Suzuki, Nobuo N.; Obara, Keisuke; Fujioka, Yuko; Ohsumi, Yoshinori; Inagaki, Fuyuhiko			Structure of Atg5 center dot Atg16, a complex essential for autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR GRAPHICS; CRYSTAL-STRUCTURE; PROTEIN; SYSTEM; YEAST; MEMBRANE; MUTANTS; CELLS; CONJUGATE	Atg5 is covalently modified with a ubiquitin-like modifier, Atg12, and the Atg12-Atg5 conjugate further forms a complex with the multimeric protein Atg16. The Atg12-Atg5 center dot Atg16 multimeric complex plays an essential role in autophagy, the bulk degradation system conserved in all eukaryotes. We have reported here the crystal structure of Atg5 complexed with the N-terminal region of Atg16 at 1.97 angstrom resolution. Atg5 comprises two ubiquitin-like domains that flank a helix-rich domain. The N-terminal region of Atg16 has a helical structure and is bound to the groove formed by these three domains. In vitro analysis showed that Arg-35 and Phe-46 of Atg16 are crucial for the interaction. Atg16, with a mutation at these residues, failed to localize to the pre-autophagosomal structure and could not restore autophagy in Atg16-deficient yeast strains. Furthermore, these Atg16 mutants could not restore a severe reduction in the formation of the Atg8-phosphatidylethanolamine conjugate, another essential factor for autophagy, in Atg16-deficient strains under starvation conditions. These results taken together suggest that the direct interaction between Atg5 and Atg16 is crucial to the performance of their roles in autophagy.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Kita Ku, Sapporo, Hokkaido 0010021, Japan; Natl Inst Basic Biol, Div Mol Cell Biol, Okazaki, Aichi 4448585, Japan	Hokkaido University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Inagaki, F (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Kita Ku, N-21,W-11, Sapporo, Hokkaido 0010021, Japan.	finagaki@pharm.hokudai.ac.jp	Obara, Keisuke/A-3824-2012; Ohsumi, Yoshinori/C-6449-2009; Noda, Nobuo/P-1397-2015	Ohsumi, Yoshinori/0000-0003-2384-2166; Noda, Nobuo/0000-0002-6940-8069; Fujioka, Yuko/0000-0002-6905-0669				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Hanada T, 2005, AUTOPHAGY, V1, P110, DOI 10.4161/auto.1.2.1858; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ichimura Y, 2004, J BIOL CHEM, V279, P40584, DOI 10.1074/jbc.M405860200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200; Matsushita M, 2006, ACTA CRYSTALLOGR F, V62, P1021, DOI 10.1107/S1744309106036232; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Obara K, 2006, MOL BIOL CELL, V17, P1527, DOI 10.1091/mbc.E05-09-0841; Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Stroupe ME, 2003, NAT STRUCT BIOL, V10, P1064, DOI 10.1038/nsb1007; Sugawara K, 2004, GENES CELLS, V9, P611, DOI 10.1111/j.1356-9597.2004.00750.x; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Suzuki NN, 2005, AUTOPHAGY, V1, P119, DOI 10.4161/auto.1.2.1859; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009	34	177	191	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6763	6772		10.1074/jbc.M609876200	http://dx.doi.org/10.1074/jbc.M609876200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17192262	Green Published, hybrid			2022-12-25	WOS:000244867200086
J	Shraga-Heled, N; Kessler, O; Prahst, C; Kroll, J; Augustin, H; Neufeld, G				Shraga-Heled, Niva; Kessler, Ofra; Prahst, Claudia; Kroll, Jens; Augustin, Hellmut; Neufeld, Gera			Neuropilin-1 and neuropilin-2 enhance VEGF(121) stimulated signal transduction by the VEGFR-2 receptor	FASEB JOURNAL			English	Article						angiogenesis; semaphorin; endothelial cells; vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE; TUMOR ANGIOGENESIS; BINDING; CELLS; MICE; FORM; ISOFORM; KDR; VASCULOGENESIS	The neuropilin-1 (np1) receptor binds the 165 amino-acid form of vascular endothelial growth factor(165) (VEGF(165)) and functions as an enhancer that potentiates VEGF(165) signaling via the VEGFR-2 tyrosine-kinase receptor. To study the mechanism by which neuropilins potentiate VEGF activity we produced a VEGF(165) mutant (VEGF(165KF)) that binds to neuropilins but displays a much lower affinity toward VEGFR-1 and VEGFR-2. VEGF(165KF) failed to induce VEGFR-2 phosphorylation in cells lacking neuropilins. However, in the presence of np1, VEGF(165KF) bound weakly to VEGFR-2, induced VEGFR-2 phosphorylation, and activated ERK1/2. Interestingly, VEGF(165KF) did not promote formation of VEGFR-2/np1 complexes nor did high concentrations of VEGF(165KF) inhibit VEGF165 induced formation of such complexes, suggesting that VEGF(165) does not stabilize VEGFR-2/np1 complexes by forming bridges spanning VEGFR-2 and np1. VEGF(121) is a VEGF form that does not bind to neuropilins. Surprisingly, both np1 and neuropilin-2 (np2) enhanced VEGF(121)-induced phosphorylation of VEGFR-2 and VEGF121-induced proliferation of endothelial cells. The enhancement of VEGF(121) activity by np1 was accompanied by a 10-fold increase in binding affinity. to, VEGFR-2 and was not associated with the formation of new VEGFR-2/np1 complexes. These observations suggest that neuropilins enhance the activity of VEGF forms that do not bind to neuropilins, indicate that np2 is a functional VEGF receptor, and imply that spontaneously formed VEGFR-2/np1 complexes suffice for efficient neuropilin mediated enhancement of VEGF activity.	Technion Israel Inst Technol, Rappaport Res Inst Med Sci, Canc & Vasc Biol Res Ctr, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; Tumor Biol Ctr, Dept Vasc Biol & Angiogenesis Res, Freiburg, Germany	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Neufeld, G (corresponding author), Technion Israel Inst Technol, Rappaport Res Inst Med Sci, Canc & Vasc Biol Res Ctr, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel.	gera@tx.technion.ac.il	Augustin, Hellmut/AAA-5246-2020; Neufeld, Gera/F-1524-2019	Augustin, Hellmut/0000-0002-7173-4242; 				COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Gluzman-Poltorak Z, 2001, J BIOL CHEM, V276, P18688, DOI 10.1074/jbc.M006909200; Hiratsuka S, 2005, MOL CELL BIOL, V25, P346, DOI 10.1128/MCB.25.1.346-354.2005; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kessler O, 2004, CANCER RES, V64, P1008, DOI 10.1158/0008-5472.CAN-03-3090; Korff T, 2001, FASEB J, V15, P447, DOI 10.1096/fj.00-0139com; Korff T, 1999, J CELL SCI, V112, P3249; Lange T, 2003, J BIOL CHEM, V278, P17164, DOI 10.1074/jbc.M212224200; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Liu WB, 2005, CYTOKINE, V32, P206, DOI 10.1016/j.cyto.2005.09.009; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Prewett M, 1999, CANCER RES, V59, P5209; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen JK, 2004, MOL MED, V10, P12, DOI 10.2119/2004-00017.Campochiaro; SHIBUYA M, 1990, ONCOGENE, V5, P519; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; West DC, 2005, J BIOL CHEM, V280, P13457, DOI 10.1074/jbc.M410924200; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Yuan L, 2002, DEVELOPMENT, V129, P4797	36	55	57	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					915	926		10.1096/fj.06-6277com	http://dx.doi.org/10.1096/fj.06-6277com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17185751				2022-12-25	WOS:000244686400028
J	Kimura, K; Tanaka, N; Nakamura, N; Takano, S; Ohkuma, S				Kimura, Kenji; Tanaka, Nozomu; Nakamura, Nobuhiro; Takano, Syuichi; Ohkuma, Shoji			Knockdown of mitochondrial heat shock protein 70 promotes progeria-like phenotypes in Calenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMATIC RNAI SCREEN; HEAT-SHOCK FACTOR; CAENORHABDITIS-ELEGANS; LIFE-SPAN; RESPIRATORY-CHAIN; OXIDATIVE STRESS; MOLECULAR CHAPERONES; ELECTRON-TRANSPORT; ENERGY-METABOLISM; SENSITIVE MUTANT	Mitochondrial heat shock protein 70 (mthsp70) functions as a mitochondrial import motor and is essential in mitochondrial biogenesis and energy generation in eukaryotic cells. HSP-6 (hsp70F) is a nematode orthologue of mthsp70. Knockdown of HSP-6 by RNA interference in young adult nematodes caused a reduction in the levels of ATP-2, HSP-60 and CLK-1, leading to abnormal mitochondrial morphology and lower ATP levels. As a result, RNA interference-treated worms had lower motility, defects in oogenesis, earlier accumulation of autofluorescent material, and a shorter life span. These are the major phenotypes observed during the aging of worms, suggesting that the reduction of HSP-6 causes early aging or progeria-like phenotypes. The amount of HSP-6 became dramatically reduced at the expected mean life span in not only wild-type but also in long and short life span mutant worms (wild-type, daf-2, and daf-16). Mitochondrial HSP-60 and ATP-2 were also reduced following the reduction of HSP-6 during aging. These results suggest that the reduction of HSP-6 causes defects in mitochondrial function at the final stage of aging, leading to mortality.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Life Sci, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University	Nakamura, N (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Life Sci, Kanazawa, Ishikawa 9201192, Japan.	osaru3@kenroku.kanazawa-u.ac.jp; takano@uthscsa.edu	Nakamura, Nobuhiro/F-7811-2011	Nakamura, Nobuhiro/0000-0002-8836-6714; Kimura, Kenji/0000-0002-0290-9627				Bakala H, 2003, EUR J BIOCHEM, V270, P2295, DOI 10.1046/j.1432-1033.2003.03598.x; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2; Braeckman BP, 2002, MECH AGEING DEV, V123, P105, DOI 10.1016/S0047-6374(01)00331-1; Chaturvedi S, 2005, MED SCI MONITOR, V11, pRA238; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; Cummins JM, 2001, HUM REPROD UPDATE, V7, P217, DOI 10.1093/humupd/7.2.217; Curran SP, 2004, J BIOL CHEM, V279, P54655, DOI 10.1074/jbc.M409618200; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Enns GM, 2005, CLIN GENET, V68, P337, DOI 10.1111/j.1399-0004.2005.00499.x; Farr CL, 2004, J BIOL CHEM, V279, P17047, DOI 10.1074/jbc.M400283200; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; Garigan D, 2002, GENETICS, V161, P1101; Gerstbrein B, 2005, AGING CELL, V4, P127, DOI 10.1111/j.1474-9726.2005.00153.x; GuhaThakurta D, 2002, GENOME RES, V12, P701, DOI 10.1101/gr.228902; Hamilton B, 2005, GENE DEV, V19, P1544, DOI 10.1101/gad.1308205; Hartman PS, 2001, MECH AGEING DEV, V122, P1187, DOI 10.1016/S0047-6374(01)00259-7; Herlan M, 2004, J CELL BIOL, V165, P167, DOI 10.1083/jcb.200403022; Herndon LA, 2002, NATURE, V419, P808, DOI 10.1038/nature01135; HOSOKAWA H, 1994, MECH AGEING DEV, V74, P161, DOI 10.1016/0047-6374(94)90087-6; HOSONO R, 1980, EXP GERONTOL, V15, P285, DOI 10.1016/0531-5565(80)90032-7; Huang C, 2004, P NATL ACAD SCI USA, V101, P8084, DOI 10.1073/pnas.0400848101; Ishihara N, 2006, EMBO J, V25, P2966, DOI 10.1038/sj.emboj.7601184; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Jansen RPS, 1998, MOL CELL ENDOCRINOL, V145, P81, DOI 10.1016/S0303-7207(98)00173-7; Jezek P, 2005, INT J BIOCHEM CELL B, V37, P2478, DOI 10.1016/j.biocel.2005.05.013; Jin JH, 2006, MOL CELL PROTEOMICS, V5, P1193, DOI 10.1074/mcp.M500382-MCP200; Jonassen T, 2002, J BIOL CHEM, V277, P45020, DOI 10.1074/jbc.M204758200; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kaul SC, 2003, EXP CELL RES, V286, P96, DOI 10.1016/S0014-4827(03)00101-0; Kawai A, 2001, J CELL SCI, V114, P3565; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Kondo M, 2005, MECH AGEING DEV, V126, P637, DOI 10.1016/j.mad.2004.11.011; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Liu Y, 2005, MOL CELL BIOCHEM, V268, P45, DOI 10.1007/s11010-005-2996-1; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Morley JF, 2004, MOL BIOL CELL, V15, P657, DOI 10.1091/mbc.E03-07-0532; Ostergaard E, 2005, NEUROLOGY, V65, P931, DOI 10.1212/01.wnl.0000176065.80560.26; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Senoo-Matsuda N, 2003, J BIOL CHEM, V278, P22031, DOI 10.1074/jbc.M211377200; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; Strub A, 2003, J MOL BIOL, V334, P1087, DOI 10.1016/j.jmb.2003.10.023; STUART RA, 1994, EXPERIENTIA, V50, P1002, DOI 10.1007/BF01923454; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; TROCKEL U, 1986, J NEUROL NEUROSUR PS, V49, P645, DOI 10.1136/jnnp.49.6.645; Tsang WY, 2003, DEV DYNAM, V226, P719, DOI 10.1002/dvdy.10272; Tsang WY, 2001, J BIOL CHEM, V276, P32240, DOI 10.1074/jbc.M103999200; Vazquez-Manrique RP, 2005, FASEB J, V19, P172, DOI 10.1096/fj.05-4212fje; Ventura N, 2005, AGING CELL, V4, P109, DOI 10.1111/j.1474-9726.2005.00149.x; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; Voos W, 2002, BBA-MOL CELL RES, V1592, P51, DOI 10.1016/S0167-4889(02)00264-1; Wadhwa R, 2004, J GENE MED, V6, P439, DOI 10.1002/jgm.530; Wadhwa R, 2003, EMBO REP, V4, P595, DOI 10.1038/sj.embor.embor855; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Yokoyama K, 2002, FEBS LETT, V516, P53, DOI 10.1016/S0014-5793(02)02470-5	62	81	90	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5910	5918		10.1074/jbc.M609025200	http://dx.doi.org/10.1074/jbc.M609025200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189267	hybrid			2022-12-25	WOS:000244482300087
J	Ponighaus, C; Ambrosius, M; Casanova, JC; Prante, C; Kuhn, J; Esko, JD; Kleesiek, K; Gotting, C				Poenighaus, Claudia; Ambrosius, Michael; Casanova, Javier Carrera; Prante, Christian; Kuhn, Joachim; Esko, Jeffrey D.; Kleesiek, Knut; Goetting, Christian			Human xylosyltransferase II is involved in the biosynthesis of the uniform tetrasaccharide linkage region in chondroitin sulfate and heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-D-XYLOSYLTRANSFERASE; UDP-D-XYLOSE; PSEUDOXANTHOMA ELASTICUM PXE; PEPTIDE O-XYLOSYLTRANSFERASE; JAR CHORIOCARCINOMA CELLS; SERUM XYLOSYLTRANSFERASE; FIBROSIS MARKER; XT-II; EXPRESSION; POLYMORPHISMS	Human xylosyltransferase I (XT-I) initiates the biosynthesis of the glycosaminoglycan (GAG) linkage tetrasaccharide in proteoglycans. Xylosyltransferase 11 (XT-II) is a protein homologous to XT-I but with hitherto unknown activity or physiological function. Here, we report the enzymatic activity of XT-II and provide evidence that XT-II initiates the biosynthesis of both heparan sulfate and chondroitin sulfate GAGs. Transfection of the xylosyltransferase-deficient Chinese hamster ovary mutant pgsA-745 with XT-I or XT-II coding cDNA completely restored GAG biosynthesis. GAG disaccharide analysis revealed that XT-I- and XT-II-transfected pgsA-745 cells produced similar amounts of chondroitin sulfate and heparan sulfate. Furthermore, a high xylosyltransferase activity was measured after transfection with cDNAs encoding either isozyme. Analysis of the enzyme activity revealed that XT-II catalyzes the transfer of xylose to similar peptide acceptors as XT-I but with different efficiency. The optimal XT-II acceptor was observed using a bikunin-related peptide (K-m 5.2 mu m). Analysis of XT-I and XT-II mRNA expression in murine tissues showed a differential expression pattern for both enzymes. In particular, XT-II is highly expressed in liver tissue, where XT-I transcripts were not detected. This is the first report on the enzyme activity of XT-II and its involvement in chondroitin sulfate and heparan sulfate biosynthesis.	Ruhr Univ Bochum, Inst Lab & Transfus Med, Herz & Diabeteszentrum Nordrhein Westfalen, D-32545 Bad Oeynhausen, Germany; Univ Calif San Diego, Dept Cellular & Mol Biol, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA	Ruhr University Bochum; University of California System; University of California San Diego	Gotting, C (corresponding author), Ruhr Univ Bochum, Inst Lab & Transfus Med, Herz & Diabeteszentrum Nordrhein Westfalen, Georgstr 11, D-32545 Bad Oeynhausen, Germany.	cgoetting@hdz-nrw.de			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063, R01GM033063] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33063] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Brunner A, 2006, GLYCOCONJUGATE J, V23, P543, DOI 10.1007/s10719-006-7633-z; Byers PH, 2002, J CLIN INVEST, V109, P3, DOI 10.1172/JCI14841; CAMPBELL P, 1984, ANAL BIOCHEM, V137, P505, DOI 10.1016/0003-2697(84)90119-2; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Gotting C, 2004, J BIOL CHEM, V279, P42566, DOI 10.1074/jbc.M401340200; Gotting C, 1999, J INVEST DERMATOL, V112, P919, DOI 10.1046/j.1523-1747.1999.00590.x; Gotting C, 2005, J MOL MED, V83, P984, DOI 10.1007/s00109-005-0693-x; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Hwang HY, 2003, J BIOL CHEM, V278, P11735, DOI 10.1074/jbc.C200518200; KITAGAWA H, 1995, ANAL BIOCHEM, V232, P114, DOI 10.1006/abio.1995.9952; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kuhn J, 2003, J BIOTECHNOL, V103, P191, DOI 10.1016/S0168-1656(03)00102-0; Kuhn J, 2003, BIOCHEM BIOPH RES CO, V312, P537, DOI 10.1016/j.bbrc.2003.10.157; Kuhn J, 2005, BIOCHEM BIOPH RES CO, V333, P156, DOI 10.1016/j.bbrc.2005.05.087; Kuhn J, 2001, J BIOL CHEM, V276, P4940, DOI 10.1074/jbc.M005111200; Kuhn J, 2006, CLIN CHEM, V52, P2243, DOI 10.1373/clinchem.2006.071167; LOZZO RV, 1998, ANNU REV BIOCHEM, V67, P609; Muller S, 2005, BIOCHEM J, V386, P227, DOI 10.1042/BJ20041206; Schon S, 2006, J MED GENET, V43, P745, DOI 10.1136/jmg.2006.040972; Schon S, 2006, OSTEOARTHR CARTILAGE, V14, P442, DOI 10.1016/j.joca.2005.11.004; Schon S, 2006, J BIOL CHEM, V281, P14224, DOI 10.1074/jbc.M510690200; Schon S, 2005, KIDNEY INT, V68, P1483, DOI 10.1111/j.1523-1755.2005.00561.x; Schottler M, 2005, CLIN BIOCHEM, V38, P486, DOI 10.1016/j.clinbiomed.2005.02.004; Seo NS, 2005, J BIOL CHEM, V280, P42774, DOI 10.1074/jbc.M511531200; Vogel K, 2006, ELECTROPHORESIS, V27, P1363, DOI 10.1002/elps.200500578; Weilke C, 1997, CLIN CHEM, V43, P45; Wilson IBH, 2002, J BIOL CHEM, V277, P21207, DOI 10.1074/jbc.M201634200; Wilson IBH, 2004, CELL MOL LIFE SCI, V61, P794, DOI 10.1007/s00018-003-3278-2; Zhang LJ, 2001, J BIOL CHEM, V276, P28806, DOI 10.1074/jbc.M100204200	30	78	80	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5201	5206		10.1074/jbc.M611665200	http://dx.doi.org/10.1074/jbc.M611665200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189265	hybrid			2022-12-25	WOS:000244482300014
J	Ray, K; Adipietro, KA; Chen, C; Northup, JK				Ray, Kausik; Adipietro, Kaylin A.; Chen, Claudia; Northup, John K.			Elucidation of the role of peptide linker in calcium-sensing receptor activation process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CA2+ RECEPTOR; METABOTROPIC GLUTAMATE-RECEPTOR; CALCIMIMETIC COMPOUND; TRANSMEMBRANE DOMAIN; SIGNAL-TRANSDUCTION; CHIMERIC RECEPTORS; DIMERIZATION; RECOGNITION; EXPRESSION; MUTATIONS	Family 3 G-protein-coupled receptors (GPCRs), which includes metabotropic glutamate receptors (mGluRs), sweet and "umami" taste receptors (T1Rs), and the extracellular calcium-sensing receptor (CaR), represent a distinct group among the superfamily of GPCRs characterized by large amino-terminal extracellular ligand-binding domains (ECD) with homology to bacterial periplasmic amino acid-binding proteins that are responsible for signal detection and receptor activation through as yet unresolved mechanism(s) via the seven-transmembrane helical domain (7TMD) common to all GPCRs. To address the mechanism(s) by which ligand-induced conformational changes are conveyed from the ECD to the 7TMD for G-protein activation, we altered the length and composition of a 14-amino acid linker segment common to all family 3 GPCRs except GABA(B) receptor, in the CaR by insertion, deletion, and site-directed mutagenesis of specific highly conserved residues. Small alterations in the length and composition of the linker impaired cell surface expression and abrogated signaling of the chimeric receptors. The exchange of nine amino acids within the linker of CaR with the homologous sequence of mGluR1, however, preserved receptor function. Ala substitution for the four highly conserved residues within this amino acid sequence identified a Len at position 606 of the CaR critical for cell surface expression and signaling. Substitution of Leu(606) for Ala resulted in impaired cell surface expression. However, Ile and Val substitutions displayed strong activating phenotypes. Disruption of the linker by insertion of nine amino acids of a random-coiled structure uncoupled the ECD from regulating the 7TMD. These data are consistent with a model of receptor activation in which the peptide linker, and particularly Leu(606), provides a critical interaction for the CaR signal transmission, a finding likely to be relevant for all family 3 GPCRs containing this conserved motif.	NIDCD, Lab Cellular Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Ray, K (corresponding author), 5 Res Ct,Rm 2A11, Rockville, MD 20850 USA.	rayk@nidcd.nih.gov	Ray, Kausik/Z-2055-2019		Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000068, Z01DC000068] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Goudet C, 2004, P NATL ACAD SCI USA, V101, P378, DOI 10.1073/pnas.0304699101; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Hauache OM, 2000, ENDOCRINOLOGY, V141, P4156, DOI 10.1210/en.141.11.4156; Hu JX, 2000, J BIOL CHEM, V275, P16382, DOI 10.1074/jbc.M000277200; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14643, DOI 10.1073/pnas.251554798; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Miedlich SU, 2004, J BIOL CHEM, V279, P7254, DOI 10.1074/jbc.M307191200; Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Ray K, 2000, J BIOL CHEM, V275, P34245, DOI 10.1074/jbc.M005581200; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Ray K, 2005, J BIOL CHEM, V280, P37013, DOI 10.1074/jbc.M506681200; Ray K, 2002, J BIOL CHEM, V277, P18908, DOI 10.1074/jbc.M202113200; RAY K, 2001, INT ARCH BIOSCI, P1027; Romano C, 2001, MOL PHARMACOL, V59, P46, DOI 10.1124/mol.59.1.46; Yu L, 2004, TRENDS BIOCHEM SCI, V29, P458, DOI 10.1016/j.tibs.2004.07.009	21	14	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5310	5317		10.1074/jbc.M609610200	http://dx.doi.org/10.1074/jbc.M609610200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189274	hybrid			2022-12-25	WOS:000244482300026
J	Corzo, G; Sabo, JK; Bosmans, F; Billen, B; Villegas, E; Tytgat, J; Norton, RS				Corzo, Gerardo; Sabo, Jennifer K.; Bosmans, Frank; Billen, Bert; Villegas, Elba; Tytgat, Jan; Norton, Raymond S.			Solution structure and alanine scan of a spider toxin that affects the activation of mammalian voltage-gated sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SCORPION TOXIN; OMEGA-CONOTOXIN GVIA; NA+ CHANNELS; DOMAIN-II; RAT-BRAIN; FUNCTIONAL EXPRESSION; MOLECULAR-MECHANISMS; TITYUS-SERRULATUS; NMR-SPECTROSCOPY; MEMBRANE-PROTEIN	Magi 5, from the hexathelid spider Macrothele gigas, is a 29-residue polypeptide containing three disulfide bridges. It binds specifically to receptor site 4 on mammalian voltage-gated sodium channels and competes with scorpion beta-toxins, such as Css IV from Centruroides suffusus suffusus. As a consequence, Magi 5 shifts the activation voltage of the mammalian rNav1.2a channel to more hyperpolarized voltages, whereas the insect channel, DmNav1, is not affected. To gain insight into toxin-channel interactions, Magi 5 and 23 analogues were synthesized. The three-dimensional structure of Magi 5 in aqueous solution was determined, and its voltage-gated sodium channel-binding surfaces were mapped onto this structure using data from electrophysiological measurements on a series of Ala-substituted analogues. The structure clearly resembles the inhibitor cystine knot structural motif, although the triple-stranded beta-sheet typically found in that motif is partially distorted in Magi 5. The interactive surface of Magi 5 toward voltage-gated sodium channels resembles in some respects the Janus-faced atracotoxins, with functionally important charged residues on one face of the toxin and hydrophobic residues on the other. Magi 5 also resembles the scorpion beta-toxin Css IV, which has distinct nonpolar and charged surfaces that are critical for channel binding and has a key Glu involved in voltage sensor trapping. These two distinct classes of toxin, with different amino acid sequences and different structures, may utilize similar groups of residues on their surface to achieve the common end of modifying voltage-gated sodium channel function.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Nacl Autonoma Mexico, Inst Biotechnol, Cuernavaca 61500, Morelos, Mexico; Suntory Inst Bioorgan Res, Osaka 6188503, Japan; Univ Leuven, Toxicol Lab, B-3000 Louvain, Belgium; Univ Auton Estado mexico, Ctr Invest Biotecnol, Cuernavaca 62210, Morelos, Mexico	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Universidad Nacional Autonoma de Mexico; Suntory Holdings Ltd; KU Leuven	Norton, RS (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.	Ray.Norton@wehi.edu.au	Tytgat, Jan/F-1560-2010; Corzo, Gerardo/B-3778-2014; Bosmans, Frank/A-9660-2013; Bosmans, Frank/T-5589-2017	Corzo, Gerardo/0000-0002-9513-1622; Bosmans, Frank/0000-0002-6476-235X; Bosmans, Frank/0000-0002-6476-235X; Norton, Raymond/0000-0001-8893-0584; Bosmans, Frank/0000-0002-0451-6050; Villegas Villarreal, Elba Cristina/0000-0003-1795-0427; Tytgat, Jan/0000-0003-1778-6022				BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bernard C, 2001, BIOCHEMISTRY-US, V40, P12795, DOI 10.1021/bi015537j; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2001, J GEN PHYSIOL, V118, P291, DOI 10.1085/jgp.118.3.291; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Cestele S, 2006, J BIOL CHEM, V281, P21332, DOI 10.1074/jbc.M603814200; Cohen L, 2005, J BIOL CHEM, V280, P5045, DOI 10.1074/jbc.M408427200; Cohen L, 2004, J BIOL CHEM, V279, P8206, DOI 10.1074/jbc.M307531200; Corzo G, 2003, FEBS LETT, V547, P43, DOI 10.1016/S0014-5793(03)00666-5; DINGLEY AJ, 1995, J BIOMOL NMR, V6, P321; FENG GP, 1995, CELL, V82, P1001, DOI 10.1016/0092-8674(95)90279-1; Froy O, 1999, J BIOL CHEM, V274, P5769, DOI 10.1074/jbc.274.9.5769; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GIBBS SJ, 1991, J MAGN RESON, V93, P395, DOI 10.1016/0022-2364(91)90014-K; Gordon Dalia, 1997, Invertebrate Neuroscience, V3, P103, DOI 10.1007/BF02480365; Hassani O, 1999, EUR J BIOCHEM, V260, P76, DOI 10.1046/j.1432-1327.1999.00152.x; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Karbat I, 2004, FASEB J, V18, P683, DOI 10.1096/fj.03-0733com; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lew MJ, 1997, J BIOL CHEM, V272, P12014, DOI 10.1074/jbc.272.18.12014; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Little MJ, 1998, FEBS LETT, V439, P246, DOI 10.1016/S0014-5793(98)01378-7; LUDVIGSEN S, 1992, J BIOMOL NMR, V2, P227, DOI 10.1007/BF01875318; Mantegazza M, 2005, J PHYSIOL-LONDON, V568, P13, DOI 10.1113/jphysiol.2005.093484; Marcotte P, 1997, CIRC RES, V80, P363, DOI 10.1161/01.RES.80.3.363; MERUTKA G, 1995, J BIOMOL NMR, V5, P14, DOI 10.1007/BF00227466; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; Norton RS, 1998, TOXICON, V36, P1573, DOI 10.1016/S0041-0101(98)00149-4; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Pallaghy PK, 1999, J PEPT RES, V53, P343, DOI 10.1034/j.1399-3011.1999.00040.x; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Sabo JK, 2007, INFECT IMMUN, V75, P61, DOI 10.1128/IAI.01041-06; Scanlon MJ, 1997, STRUCTURE, V5, P1585, DOI 10.1016/S0969-2126(97)00307-9; Schulz G. E., 1979, PRINCIPLES PROTEIN S; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SEAVEY B R, 1991, Journal of Biomolecular NMR, V1, P217, DOI 10.1007/BF01875516; Shichor I, 2002, J NEUROSCI, V22, P4364, DOI 10.1523/JNEUROSCI.22-11-04364.2002; Tan JG, 2002, J NEUROSCI, V22, P5300; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; Tong XT, 2006, BIOCHEM BIOPH RES CO, V349, P890, DOI 10.1016/j.bbrc.2006.08.131; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Warmke JW, 1997, J GEN PHYSIOL, V110, P119, DOI 10.1085/jgp.110.2.119; Waxman SG, 2002, NOVART FDN SYMP, V241, P34; Yao SG, 2000, J BIOMOL NMR, V16, P109, DOI 10.1023/A:1008382624724; Zeng XZ, 2003, TOXICON, V41, P651, DOI 10.1016/S0041-0101(02)00361-6	51	32	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4643	4652		10.1074/jbc.M605403200	http://dx.doi.org/10.1074/jbc.M605403200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17148449	hybrid			2022-12-25	WOS:000244482000045
J	Friedrich, ML; Cui, M; Hernandez, JB; Weist, BM; Andersen, HM; Zhang, XW; Huang, L; Walsh, CM				Friedrich, Monica L.; Cui, Meng; Hernandez, Jeniffer B.; Weist, Brian M.; Andersen, Hilde-Marie; Zhang, Xiaowu; Huang, Lan; Walsh, Craig M.			Modulation of DRAK2 autophosphorylation by antigen receptor signaling in primary lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; DAP KINASE; HOMOLOGOUS PROTEIN; T-CELLS; IN-VIVO; ACTIVATION; PHOSPHORYLATION; APOPTOSIS; BINDING; FAMILY	Death-associated protein-related apoptotic kinase-2 (DRAK2), a member of the death-associated protein-like family of serine/threonine kinases, is highly expressed in lymphoid organs and is a negative regulator of T cell activation. To investigate the regulation of DRAK2 activity in primary lymphocytes, we employed mass spectrometry to identify sites of autophosphorylation on DRAK2. These studies have revealed a key site of autophosphorylation on serine 12. Using a phospho-specific antibody to detect Ser(12) phosphorylation, we found that autophosphorylation is induced by antigen receptor stimulation in T and B cells. In Jurkat T cells, resting B cells and thymocytes, DRAK2 was hypophosphorylated on Ser(12) but rapidly phosphorylated with antigen receptor ligation. This increase in phosphorylation was dependent on intracellular calcium mobilization, because BAPTA-AM blocked DRAK2 kinase activity, whereas the SERCA inhibitor thapsigargin promoted Ser(12) phosphorylation. Our results show that DRAK2 kinase activity is regulated in a calcium-dependent manner and that Ser(12) phosphorylation is necessary for optimal suppression of T cell activation by this kinase, suggesting a potential feedback loop may act to modulate the activity of this kinase following antigen receptor signaling.	Univ Calif Irvine, Ctr Immunol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Phys & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Canc Res, Irvine, CA 92697 USA; Cell Signaling Technol Inc, Danvers, MA 01923 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Huang, L (corresponding author), Univ Calif Irvine, Ctr Immunol, 3215 McGaugh Hall, Irvine, CA 92697 USA.	lanhuang@uci.edu; cwalsh@uci.edu	Huang, Lan/C-3618-2011	Walsh, Craig/0000-0001-7808-2817	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063419] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007311, R01GM074830] Funding Source: NIH RePORTER; NIAID NIH HHS [AI063419] Funding Source: Medline; NIGMS NIH HHS [GM074830, T32GM007311] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arechiga AF, 2005, J IMMUNOL, V175, P7800, DOI 10.4049/jimmunol.175.12.7800; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1023, DOI 10.1002/elps.11501401163; Chalkley RJ, 2005, MOL CELL PROTEOMICS, V4, P1194, DOI 10.1074/mcp.D500002-MCP200; Feske S, 2005, J EXP MED, V202, P651, DOI 10.1084/jem.20050687; Friedrich ML, 2005, INT IMMUNOL, V17, P1379, DOI 10.1093/intimm/dxh315; Graves PR, 2005, J BIOL CHEM, V280, P9363, DOI 10.1074/jbc.M412538200; Guerrero C, 2006, MOL CELL PROTEOMICS, V5, P366, DOI 10.1074/mcp.M500303-MCP200; Kogel D, 2001, BIOESSAYS, V23, P352, DOI 10.1002/bies.1050; Kuwahara H, 2003, J BIOCHEM, V134, P245, DOI 10.1093/jb/mvg137; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Matsumoto M, 2001, J BIOCHEM, V130, P217, DOI 10.1093/oxfordjournals.jbchem.a002975; McGargill MA, 2004, IMMUNITY, V21, P781, DOI 10.1016/j.immuni.2004.10.008; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Rosado JA, 2001, J BIOL CHEM, V276, P15659, DOI 10.1074/jbc.M009218200; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Schaefer BC, 2001, ANAL BIOCHEM, V297, P86, DOI 10.1006/abio.2001.5327; Schumacher AM, 2004, BIOCHEMISTRY-US, V43, P8116, DOI 10.1021/bi049589v; Shani G, 2004, MOL CELL BIOL, V24, P8611, DOI 10.1128/MCB.24.19.8611-8626.2004; Shani G, 2001, EMBO J, V20, P1099, DOI 10.1093/emboj/20.5.1099; Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200; Tian JH, 2003, J BIOL CHEM, V278, P26265, DOI 10.1074/jbc.M300492200; Wilcox HM, 2003, J BIOL CHEM, V278, P37112, DOI 10.1074/jbc.M304811200; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	29	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4573	4584		10.1074/jbc.M606675200	http://dx.doi.org/10.1074/jbc.M606675200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17182616	hybrid			2022-12-25	WOS:000244482000039
J	Lee, CW; Rivera, R; Dubin, AE; Chun, J				Lee, Chang-Wook; Rivera, Richard; Dubin, Adrienne E.; Chun, Jerold			LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BETA-GAMMA-SUBUNITS; LYSOPHOSPHOLIPASE-D; CELLULAR-RESPONSES; ADENYLYL-CYCLASE; P115 RHOGEF; AUTOTAXIN; IDENTIFICATION; MOTILITY; STIMULATION	Lysophosphatidic acid (LPA) is a bioactive lysophospholipid that signals through G protein-coupled receptors (GPCRs) to produce a range of biological responses. A recently reported fourth receptor, LPA(4)/GPR23, was notable for its low homology to the previously identified receptors LPA(1-3) and for its ability to increase intracellular concentrations of cAMP and calcium. However, the signaling pathways leading to LPA(4)-mediated induction of cAMP and calcium levels have not been reported. Using epitope-tagged LPA(4), pharmacological intervention, and G protein mini-genes, we provide independent confirmatory evidence that supports LPA(4) as a fourth LPA receptor, including LPA concentration-dependent responses and specific membrane binding. Importantly, we further demonstrate new LPA-dependent activities of LPA, that include the following: receptor internalization; G(12/13)- and Rho-mediated neurite retraction and stress fiber formation; G(q) protein and pertussis toxin-sensitive calcium mobilization and activation of a nonselective cation conductance; and cAMP increases mediated by G(s). The receptor is broadly expressed in embryonic tissues, including brain, as determined by Northern blot and reverse transcription-PCR analysis. Adult tissues have increased expression in skin, heart, and to a lesser extent, thymus. These data confirm the identification and extend the functionality of LPA(4) as an LPA receptor, bringing the number of independently verified LPA receptors to five, with both overlapping and distinct signaling properties and tissue expression.			Chun, J (corresponding author), Scripps Res Inst, Dept Mol Biol, Helen Lab Dorris Inst Neurol & Psychiat Disorders, 10550 N Torrey Pines Rd,ICND-118, La Jolla, CA 92037 USA.	jchun@scripps.edu	Chun, Jerold/Y-4670-2019	Lee, Chang-Wook/0000-0002-0907-8475	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD050685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051699, K02MH001723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048478] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD050685] Funding Source: Medline; NIMH NIH HHS [R01-MH51699, K02-MH01723] Funding Source: Medline; NINDS NIH HHS [R01-NS048478] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Dubin AE, 1999, J NEUROSCI, V19, P1371; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fukushima N, 2000, DEV BIOL, V228, P6, DOI 10.1006/dbio.2000.9930; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Fukushima N, 2002, MOL CELL NEUROSCI, V20, P271, DOI 10.1006/mcne.2002.1123; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Gardell SE, 2006, TRENDS MOL MED, V12, P65, DOI 10.1016/j.molmed.2005.12.001; Gilchrist A., 2002, SCI STKE, pPL1; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Kawasawa Y, 2000, BIOCHEM BIOPH RES CO, V276, P957, DOI 10.1006/bbrc.2000.3570; Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157; Kotarsky K, 2006, J PHARMACOL EXP THER, V318, P619, DOI 10.1124/jpet.105.098848; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Murakami N, 2004, J BIOL CHEM, V279, P42484, DOI 10.1074/jbc.M406561200; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Pear Warren S., 1997, P41; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419-05; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Witte Owen N, 2005, Science, V307, P206; Xu Y, 2006, NAT CELL BIOL, V8, P299; Ye XQ, 2005, NATURE, V435, P104, DOI 10.1038/nature03505; Ye XQ, 2002, BBA-MOL CELL BIOL L, V1585, P108, DOI 10.1016/S1388-1981(02)00330-X; Zhu K, 2005, J BIOL CHEM, V280, P43280	49	128	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4310	4317		10.1074/jbc.M610826200	http://dx.doi.org/10.1074/jbc.M610826200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17166850	hybrid			2022-12-25	WOS:000244482000010
J	Mori, S; Shirahige, K				Mori, Saori; Shirahige, Katsuhiko			Perturbation of the activity of replication origin by meiosis-specific transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEIOTIC DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; S-PHASE; YEAST; PROTEINS; IDENTIFICATION; SPORULATION; INITIATION; COMPLEXES; DYNAMICS	We have determined the activity of all ARSs on the Saccharomyces cerevisiae chromosome VI as chromosomal replication origins in premeiotic S-phase by neutral/neutral two-dimensional gel electrophoresis. The comparison of origin activity of each origin in mitotic and premeiotic S-phase showed that one of the most efficient origins in mitotic S-phase, ARS605, was completely inhibited in premeiotic S-phase. ARS605 is located within the open reading frame of MSH4 gene that is transcribed specifically during an early stage of meiosis. Systematic analysis of relationships between MSH4 transcription and ARS605 origin activity revealed that transcription of MSH4 inhibited the ARS605 origin activity by removing origin recognition complex from ARS605. Deletion of UME6, a transcription factor responsible for repressing MSH4 during mitotic S-phase, resulted in inactivation of ARS605 in mitosis. Our finding is the first demonstration that the transcriptional regulation on the replication origin activity is related to changes in cell physiology. These results may provide insights into changes in replication origin activity in embryonic cell cycle during early developmental stages.	Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Kanagawa 2300045, Japan; Tokyo Inst Technol, Ctr Biol Resources & Informat, Div Gene Res, Lab Genome Struct & Funct, Kanagawa 2268501, Japan	Yokohama City University; Tokyo Institute of Technology	Shirahige, K (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, 1-7-29 Suehiro Cho, Kanagawa 2300045, Japan.	kshirahi@bio.titech.ac.jp		Shirahige, Katsuhiko/0000-0002-7862-1144				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Borde V, 2000, SCIENCE, V290, P806, DOI 10.1126/science.290.5492.806; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BUDD ME, 1989, MOL CELL BIOL, V9, P365, DOI 10.1128/MCB.9.2.365; Cha RS, 2000, GENE DEV, V14, P493; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; COLLINS I, 1994, MOL CELL BIOL, V14, P3524, DOI 10.1128/MCB.14.5.3524; De Antoni A, 2000, GENE, V246, P179, DOI 10.1016/S0378-1119(00)00083-4; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; Friedman KL, 1997, GENES CELLS, V2, P667, DOI 10.1046/j.1365-2443.1997.1520350.x; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HOLLINGSWORTH RE, 1993, CHROMOSOMA, V102, P415, DOI 10.1007/BF00360406; Hori Y, 1996, MOL BIOL CELL, V7, P409, DOI 10.1091/mbc.7.3.409; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; KUPIEC M, 1997, MOL CELLULAR BIOL YE, V3, P889; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; Murakami H, 2001, NAT GENET, V28, P290, DOI 10.1038/90142; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Ofir Y, 2004, MOL BIOL CELL, V15, P2230, DOI 10.1091/mbc.E03-08-0617; Ohta K, 1998, P NATL ACAD SCI USA, V95, P646, DOI 10.1073/pnas.95.2.646; Raghuraman MK, 2001, SCIENCE, V294, P115, DOI 10.1126/science.294.5540.115; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; SHIRAHIGE K, 1993, MOL CELL BIOL, V13, P5043, DOI 10.1128/MCB.13.8.5043; SNYDER M, 1988, MOL CELL BIOL, V8, P2184, DOI 10.1128/MCB.8.5.2184; Washburn BK, 2001, MOL CELL BIOL, V21, P2057, DOI 10.1128/MCB.21.6.2057-2069.2001; Williams RM, 2002, P NATL ACAD SCI USA, V99, P13431, DOI 10.1073/pnas.202495299; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6; Yamashita M, 1997, GENES CELLS, V2, P655, DOI 10.1046/j.1365-2443.1997.1530351.x	34	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4447	4452		10.1074/jbc.M609671200	http://dx.doi.org/10.1074/jbc.M609671200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17170106	hybrid			2022-12-25	WOS:000244482000025
J	Tatituri, RVV; Illarionov, PA; Dover, LG; Nigou, J; Gilleron, M; Hitchen, P; Krumbach, K; Morris, HR; Spencer, N; Dell, A; Eggeling, L; Besra, GS				Tatituri, Raju V. V.; Illarionov, Petr A.; Dover, Lynn G.; Nigou, Jerome; Gilleron, Martine; Hitchen, Paul; Krumbach, Karin; Morris, Howard R.; Spencer, Neil; Dell, Anne; Eggeling, Lothar; Besra, Gurdyal S.			Inactivation of Corynebacterium glutamicum NCgI0452 and the role of MgtA in the biosynthesis of a novel mannosylated glycolipid involved in-lipomannan biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODERATELY HALOPHILIC BACTERIUM; MYCOBACTERIUM-TUBERCULOSIS H37RV; MEMBRANE-ASSOCIATED LIPOMANNAN; CELL-WALL ARABINOGALACTAN; BACILLUS-CALMETTE-GUERIN; MYO-INOSITOL ANCHOR; PHOSPHATIDYLINOSITOL MANNOSIDE; MONOPHOSPHOMANNOSE SYNTHASE; CORYNEFORM BACTERIA; MICROCOCCUS-LUTEUS	Mycobacterium tuberculosis PimB has been demonstrated to catalyze the addition of a mannose residue from GDP-mannose to a monoacylated phosphatidyl-myo-inositol mannoside (Ac1PIM1) to generate Ac1PIM2. Herein, we describe the disruption of its probable orthologue Cg-pimB and the chemical analysis of glycolipids and lipoglycans isolated from wild type Corynebacterium glutamicum and the C. glutamicum::pimB mutant. Following a careful analysis, two related glycolipids, Gl-A and Gl-X, were found in the parent strain, but Gl-X was absent from the mutant. The biosynthesis of Gl-X was restored in the mutant by complementation with either Cg-pimB or Mt-pimB. Subsequent chemical analyses established Gl-X as 1,2-diO-C-16/C-18:1-(alpha-D-mannopyranosyl)-(1 -> 4)-(alpha-D-glucopyranosyluronic acid)-(1 -> 3)-glycerol (ManGlcAGroAc(2)) and Gl-A as the precursor, GlcAGroAc(2). In addition, C. glutamicum::pimB was still able to produce Ac1PIM2, suggesting that Cg-PimB catalyzes the synthesis of ManGlcAGroAc2 from GlcAGroAc(2). Isolation of lipoglycans from C. glutamicum led to the identification of two related lipoglycans. The larger lipoglycan possessed a lipoarabinomannan-like structure, whereas the smaller lipoglycan was similar to lipomannan (LM). The absence of MariGlcAGroAc(2) in C. glutamicum::pimB led to a severe reduction in LM. These results suggested that ManGlcAGroAc(2) was further extended to an LM-like molecule. Complementation of C. glutamicum::pimB with Cg-pimB and Mt-pimB led to the restoration of LM biosynthesis. As a result, Cg-PimB, which we have assigned as MgtA, is now clearly defined as a GDP-mannose-dependent alpha-mannosyltransferase from our in vitro analyses and is involved in the biosynthesis of ManGlcAGroAc(2).	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; CNRS, Inst Pharmacol & Biol Struct, UMR 5089, Toulouse, France; Res Ctr Juelich, Inst Biotechnol 1, D-52425 Julich, Germany; Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, Fac Nat Sci, London SW7 2AZ, England; MSCAN Mass Spect Res & Training Ctr, Wokingham RG41 2TZ, Berks, England; Univ Birmingham, Sch Chem, Birmingham B15 2TT, W Midlands, England	University of Birmingham; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Helmholtz Association; Research Center Julich; Imperial College London; University of Birmingham	Besra, GS (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	g.besra@bham.ac.uk	Dover, Lynn G/F-3021-2010; Dover, Lynn George/Q-6778-2019; Nigou, Jérôme/D-6802-2019	Dover, Lynn G/0000-0002-4776-2665; Dover, Lynn George/0000-0002-4776-2665; Nigou, Jérôme/0000-0002-6233-2487; Besra, Gurdyal/0000-0002-5605-0395; GILLERON, Martine/0000-0002-2581-3302	MRC [G0500590] Funding Source: UKRI; Medical Research Council [G0500590] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alderwick LJ, 2005, J BIOL CHEM, V280, P32362, DOI 10.1074/jbc.M506339200; Allard STM, 2001, CELL MOL LIFE SCI, V58, P1650, DOI 10.1007/PL00000803; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; BRENNAN P, 1968, J BIOL CHEM, V243, P2975; Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHATTERJEE D, 1988, J BIOL CHEM, V263, P4092; CHATTERJEE D, 1987, J BIOL CHEM, V262, P3528; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COYLE MB, 1990, CLIN MICROBIOL REV, V3, P227, DOI 10.1128/CMR.3.3.227-246.1990; DAFFE M, 1990, J BIOL CHEM, V265, P6734; Dinadayala P, 2006, J BIOL CHEM, V281, P20027, DOI 10.1074/jbc.M603395200; Dmitriev BA, 2000, INT J MED MICROBIOL, V290, P251; Dobson G., 1985, CHEM METHODS BACTERI, P237; Dover LG, 2004, FEMS MICROBIOL REV, V28, P225, DOI 10.1016/j.femsre.2003.10.001; Eggeling L, 2005, HDB CORYNEBACTERIUM, P535; Funke G, 1997, CLIN MICROBIOL REV, V10, P125, DOI 10.1128/CMR.10.1.125; Gibson KJC, 2003, J BIOL CHEM, V278, P40842, DOI 10.1074/jbc.M307988200; Gibson KJC, 2003, MICROBIOL-SGM, V149, P1437, DOI 10.1099/mic.0.26161-0; Gilleron M, 2000, J BIOL CHEM, V275, P677, DOI 10.1074/jbc.275.1.677; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Gurcha SS, 2002, BIOCHEM J, V365, P441, DOI 10.1042/BJ20020107; HILL DL, 1966, J BIOL CHEM, V241, P895; HUNTER SW, 1986, J BACTERIOL, V168, P917, DOI 10.1128/jb.168.2.917-922.1986; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; Kaur D, 2006, P NATL ACAD SCI USA, V103, P13664, DOI 10.1073/pnas.0603049103; Khoo KH, 1996, J BIOL CHEM, V271, P12333, DOI 10.1074/jbc.271.21.12333; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; LEOPOLD K, 1993, ANAL BIOCHEM, V208, P57, DOI 10.1006/abio.1993.1008; Ludwiczak P, 2002, MICROBIOL-SGM, V148, P3029, DOI 10.1099/00221287-148-10-3029; Luneberg E, 2000, INT J MED MICROBIOL, V290, P37; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; MCNEIL M, 1989, METHOD ENZYMOL, V179, P215; MINNIKIN DE, 1971, BIOCHIM BIOPHYS ACTA, V249, P651, DOI 10.1016/0005-2736(71)90148-9; Morita YS, 2006, J BIOL CHEM, V281, P25143, DOI 10.1074/jbc.M604214200; Morita YS, 2004, BIOCHEM J, V378, P589, DOI 10.1042/BJ20031372; Nakamura Y, 2003, GENE, V317, P149, DOI 10.1016/S0378-1119(03)00653-X; Nigou J, 2000, J MOL BIOL, V299, P1353, DOI 10.1006/jmbi.2000.3821; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Pakkiri LS, 2005, GLYCOBIOLOGY, V15, P291, DOI 10.1093/glycob/cwi003; Pakkiri LS, 2004, GLYCOBIOLOGY, V14, P73, DOI 10.1093/glycob/cwh012; PELEG E, 1971, FEBS LETT, V15, P309, DOI 10.1016/0014-5793(71)80645-2; PIERINGER RA, 1989, MICROBIAL LIPIDS, V2, P51; RYU EK, 1979, J LIPID RES, V20, P561; Sahm H, 2000, BIOL CHEM, V381, P899, DOI 10.1515/BC.2000.111; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Stackebrandt E, 1997, INT J SYST BACTERIOL, V47, P479, DOI 10.1099/00207713-47-2-479; STERN N, 1973, BIOCHIM BIOPHYS ACTA, V296, P136, DOI 10.1016/0005-2760(73)90053-2; STERN N, 1971, FEBS LETT, V19, P217, DOI 10.1016/0014-5793(71)80517-3; STERN N, 1973, BIOCHIM BIOPHYS ACTA, V296, P130, DOI 10.1016/0005-2760(73)90052-0; WILKINSON GS, 1968, BIOCHIM BIOPHYS ACTA, V152, P227; WILKINSON SG, 1968, BIOCHIM BIOPHYS ACTA, V164, P148, DOI 10.1016/0005-2760(68)90141-0; WILKINSON SG, 1969, BIOCHIM BIOPHYS ACTA, V187, P492, DOI 10.1016/0005-2760(69)90046-0; WOLUCKA BA, 1993, BIOCHIM BIOPHYS ACTA, V1170, P131, DOI 10.1016/0005-2760(93)90062-E	63	60	63	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4561	4572		10.1074/jbc.M608695200	http://dx.doi.org/10.1074/jbc.M608695200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17179146	hybrid			2022-12-25	WOS:000244482000038
J	Clarke, E; Reichard, UH; Zuberbuhler, K				Clarke, Esther; Reichard, Ulrich H.; Zuberbuehler, Klaus			The Syntax and Meaning of Wild Gibbon Songs	PLOS ONE			English	Article								Spoken language is a result of the human capacity to assemble simple vocal units into more complex utterances, the basic carriers of semantic information. Not much is known about the evolutionary origins of this behaviour. The vocal abilities of non-human primates are relatively unimpressive in comparison, with gibbon songs being a rare exception. These apes assemble a repertoire of call notes into elaborate songs, which function to repel conspecific intruders, advertise pair bonds, and attract mates. We conducted a series of field experiments with white-handed gibbons at Khao Yai National Park, Thailand, which showed that this ape species uses songs also to protect themselves against predation. We compared the acoustic structure of predatory-induced songs with regular songs that were given as part of their daily routine. Predator-induced songs were identical to normal songs in the call note repertoire, but we found consistent differences in how the notes were assembled into songs. The responses of out-of-sight receivers demonstrated that these syntactic differences were meaningful to conspecifics. Our study provides the first evidence of referential signalling in a free-ranging ape species, based on a communication system that utilises combinatorial rules.	[Clarke, Esther; Zuberbuehler, Klaus] Univ St Andrews, Sch Psychol, St Andrews, Scotland; [Reichard, Ulrich H.] Max Planck Inst Evolutionary Anthropol, Leipzig, Germany; [Reichard, Ulrich H.] So Illinois Univ, Dept Anthropol, Carbondale, IL 62901 USA	University of St Andrews; Max Planck Society; Southern Illinois University System; Southern Illinois University	Zuberbuhler, K (corresponding author), Univ St Andrews, Sch Psychol, St Andrews, Scotland.	kz3@st-and.ac.uk	Zuberbühler, Klaus/A-9053-2011; Clarke, Esther/AAH-3822-2019	Zuberbühler, Klaus/0000-0001-8378-088X; Clarke, Esther/0000-0002-9002-9223; Reichard, Ulrich H./0000-0002-5564-3922	Khao Yai white-handed gibbon project; University of St Andrews; BBSRC studentship	Khao Yai white-handed gibbon project; University of St Andrews; BBSRC studentship(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The Max-Planck-Institute for Evolutionary Anthropology, Leipzig, has provided generous long-term support of the Khao Yai white-handed gibbon project. This research was funded by the University of St Andrews and by a BBSRC studentship to Esther Clarke.	Arnold K, 2006, NATURE, V441, P303, DOI 10.1038/441303a; ARNOLD K, MONKEYS APE IN PRESS; BARELLI C, HORMONES BE IN PRESS; Bartlett Thad Q., 2007, P274; Brockelman WY, 1998, BEHAV ECOL SOCIOBIOL, V42, P329, DOI 10.1007/s002650050445; Catchpole C., 1995, BIRD SONG BIOL THEME; Cowlishaw G, 1996, ETHOLOGY, V102, P272; Fichtel C, 2005, ANIM BEHAV, V70, P165, DOI 10.1016/j.anbehav.2004.09.020; Geissmann T, 2000, ANIM BEHAV, V60, P805, DOI 10.1006/anbe.2000.1540; Geissmann T, 1999, BEHAVIOUR, V136, P1005, DOI 10.1163/156853999501694; GRICE HP, 1969, PHILOS REV, V78, P147, DOI 10.2307/2184179; Haraway MM, 1998, PRIMATES, V39, P1, DOI 10.1007/BF02557739; Leighton D. R., 1986, PRIMATE SOC, P135; Marler P., 1977, RECOGNITION COMPLEX, P17; MARSHALL JT, 1976, SCIENCE, V193, P235, DOI 10.1126/science.193.4249.235; MAYNARDSMITH J, 1965, AM NAT, V99, P59; MITANI JC, 1985, BEHAVIOUR, V92, P59, DOI 10.1163/156853985X00389; PALOMBIT RA, 1994, ANIM BEHAV, V47, P721, DOI 10.1006/anbe.1994.1097; RAEMAEKERS JJ, 1985, ANIM BEHAV, V33, P481, DOI 10.1016/S0003-3472(85)80071-3; RAEMAEKERS JJ, 1984, BEHAVIOUR, V91, P146, DOI 10.1163/156853984X00263; REICHARD U, 1995, ETHOLOGY, V100, P99; Reichard U, 1998, AM J PRIMATOL, V46, P35, DOI 10.1002/(SICI)1098-2345(1998)46:1<35::AID-AJP4>3.0.CO;2-W; Reichard U. H., 2003, MONOGAMY MATING STRA; Reichard Ulrich H., 2003, P190; SAVINI T, AM J PHYS A IN PRESS; SEYFARTH RM, 1980, ANIM BEHAV, V28, P1070, DOI 10.1016/S0003-3472(80)80097-2; Slocombe KE, 2006, ANIM BEHAV, V72, P989, DOI 10.1016/j.anbehav.2006.01.030; Slocombe KE, 2005, CURR BIOL, V15, P1779, DOI 10.1016/j.cub.2005.08.068; Snowdon Charles T., 2004, P57, DOI 10.1017/CBO9780511542459.006; Sommer V, 2000, PRIMATE MALES, P159; Sunquist ME, 2002, WILD CATS WORLD; TENAZA RR, 1977, NATURE, V268, P233, DOI 10.1038/268233a0; Todd NPM, 2004, J ACOUST SOC AM, V115, P3077, DOI 10.1121/1.1736273; Uhde NL, 2002, EAT OR BE EATEN, P268, DOI 10.1017/CBO9780511610233.017; VANSCHAIK CP, 1983, BEHAVIOUR, V85, P91, DOI 10.1163/156853983X00057; *WILDL CONS SOC, 2001, STAT EC CONS TIG THE; Zuberbuhler K, 1999, ETHOLOGY, V105, P477, DOI 10.1046/j.1439-0310.1999.00396.x; Zuberbuhler K, 2001, BEHAV ECOL SOCIOBIOL, V50, P414, DOI 10.1007/s002650100383; Zuberbuhler K, 1997, ANIM BEHAV, V53, P589, DOI 10.1006/anbe.1996.0334; Zuberbuhler K., 2006, ENCY LANGUAGE LINGUI, P143	40	153	157	0	83	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e73	10.1371/journal.pone.0000073	http://dx.doi.org/10.1371/journal.pone.0000073			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183705	gold, Green Published, Green Accepted, Green Submitted			2022-12-25	WOS:000207443600073
J	Franscini, N; El Gedaily, A; Matthey, U; Franitza, S; Sy, MS; Burkle, A; Groschup, M; Braun, U; Zahn, R				Franscini, Nicola; El Gedaily, Ahmed; Matthey, Ulrich; Franitza, Susanne; Sy, Man-Sun; Buerkle, Alexander; Groschup, Martin; Braun, Ueli; Zahn, Ralph			Prion Protein in Milk	PLOS ONE			English	Article								Background. Prions are known to cause transmissible spongiform encephalopathies (TSE) after accumulation in the central nervous system. There is increasing evidence that prions are also present in body fluids and that prion infection by blood transmission is possible. The low concentration of the proteinaceous agent in body fluids and its long incubation time complicate epidemiologic analysis and estimation of spreading and thus the risk of human infection. This situation is particularly unsatisfactory for food and pharmaceutical industries, given the lack of sensitive tools for monitoring the infectious agent. Methodology/Principal Findings. We have developed an adsorption matrix, Alicon PrioTrap (R), which binds with high affinity and specificity to prion proteins. Thus we were able to identify prion protein (PrPC)-the precursor of prions (PrPSc)-in milk from humans, cows, sheep, and goats. The absolute amount of PrPC differs between the species (from mu g/l range in sheep to ng/l range in human milk). PrPC is also found in homogenised and pasteurised off-the-shelf milk, and even ultrahigh temperature treatment only partially diminishes endogenous PrPC concentration. Conclusions/Significance. In view of a recent study showing evidence of prion replication occurring in the mammary gland of scrapie infected sheep suffering from mastitis, the appearance of PrPC in milk implies the possibility that milk of TSE-infected animals serves as source for PrPSc.	[Franscini, Nicola; El Gedaily, Ahmed; Matthey, Ulrich; Franitza, Susanne; Zahn, Ralph] Alicon AG, Schlieren, Switzerland; [Sy, Man-Sun] Case Western Univ, Sch Med, Inst Pathol, Cleveland, OH USA; [Buerkle, Alexander] Univ Konstanz, Lehrstuhl Mol Toxikol, Constance, Germany; [Groschup, Martin] Bundesforschungsinst Tiergesundheit, Friedrich Loeffler Inst, Greifswald, Germany; [Braun, Ueli] Univ Zurich, Dept Nutztiere, Zurich, Switzerland	Case Western Reserve University; University of Konstanz; Friedrich Loeffler Institute; University of Zurich	Zahn, R (corresponding author), Alicon AG, Schlieren, Switzerland.	info@alicon.ch						Barclay GR, 2002, TRANSFUSION, V42, P517, DOI 10.1046/j.1537-2995.2002.00095.x; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BRADLEY R, 1993, BRIT MED BULL, V49, P932, DOI 10.1093/oxfordjournals.bmb.a072654; Buschmann A, 2005, J INFECT DIS, V192, P934, DOI 10.1086/431602; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; Castilla J, 2005, NAT MED, V11, P982, DOI 10.1038/nm1286; *EC, 1997, VI819796 EC; *EC MULT SCI COMM, 1997, OP POSS RISKS REL US; HADLOW WJ, 1980, VET PATHOL, V17, P187, DOI 10.1177/030098588001700207; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; Ironside JW, 2004, HAEMOPHILIA, V10, P64, DOI 10.1111/j.1365-2516.2004.00982.x; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; Laffont-Proust I, 2005, FEBS LETT, V579, P6333, DOI 10.1016/j.febslet.2005.10.013; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; Ligios C, 2005, NAT MED, V11, P1137, DOI 10.1038/nm1105-1137; MacGregor I, 1999, VOX SANG, V77, P88; MANSON J, 1992, DEVELOPMENT, V115, P117; MOBLEY WC, 1988, P NATL ACAD SCI USA, V85, P9811, DOI 10.1073/pnas.85.24.9811; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; *STAT EUR FOOD SAF, 2004, BSE TSE SCI PAN BIOL; TAYLOR DM, 1995, VET REC, V136, P592, DOI 10.1136/vr.136.23.592; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	29	24	26	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e71	10.1371/journal.pone.0000071	http://dx.doi.org/10.1371/journal.pone.0000071			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183703	Green Published, Green Accepted, gold			2022-12-25	WOS:000207443600071
J	Leppanen, P; Kholova, I; Mahonen, AJ; Airenne, K; Koota, S; Mansukoski, H; Narvainen, J; Wirzenius, M; Alhonen, L; Janne, J; Alitalo, K; Yla-Herttuala, S				Leppanen, Pia; Kholova, Ivana; Mahonen, Anssi J.; Airenne, Kari; Koota, Suvi; Mansukoski, Hannu; Narvainen, Johanna; Wirzenius, Maria; Alhonen, Leena; Janne, Juhani; Alitalo, Kari; Yla-Herttuala, Seppo			Short and Long-Term Effects of hVEGF-A(165) in Cre-Activated Transgenic Mice	PLOS ONE			English	Article								We have generated a transgenic mouse where hVEGF-A(165) expression has been silenced with loxP-STOP fragment, and we used this model to study the effects of hVEGF-A(165) over-expression in mice after systemic adenovirus mediated Cre-gene transfer. Unlike previous conventional transgenic models, this model leads to the expression of hVEGF-A(165) in only a low number of cells in the target tissues in adult mice. Levels of hVEGF-A(165) expression were moderate and morphological changes were found mainly in the liver, showing typical signs of active angiogenesis. Most mice were healthy without any major consequences up to 18 months after the activation of hVEGF-A(165) expression. However, one mouse with a high plasma hVEGF-A(165) level died spontaneously because of bleeding into abdominal cavity and having liver hemangioma, haemorrhagic paratubarian cystic lesions and spleen peliosis. Also, two mice developed malignant tumors (hepatocellular carcinoma and lung adenocarcinoma), which were not seen in control mice. We conclude that long-term uncontrolled hVEGF-A(165) expression in only a limited number of target cells in adult mice can be associated with pathological changes, including possible formation of malignant tumors and uncontrolled bleeding in target tissues. These findings have implications for the design of long-term clinical trials using hVEGF-A(165) gene and protein.	[Leppanen, Pia; Kholova, Ivana; Mahonen, Anssi J.; Airenne, Kari; Koota, Suvi; Alhonen, Leena; Janne, Juhani; Yla-Herttuala, Seppo] Univ Kuopio, AI Virtanen Inst, Dept Biotechnol & Mol Med, FIN-70211 Kuopio, Finland; [Wirzenius, Maria; Alitalo, Kari] Univ Helsinki, Biomedicum, Lab Mol Canc Biol, Helsinki, Finland; [Yla-Herttuala, Seppo] Kuopio Univ Hosp, Dept Med, SF-70210 Kuopio, Finland; [Yla-Herttuala, Seppo] Kuopio Univ Hosp, Gene Therapy Unit, SF-70210 Kuopio, Finland; [Mansukoski, Hannu] Tech Univ Dresden, Dresden, Germany; [Narvainen, Johanna] Univ Manchester, Fac Life Sci, Manchester, Lancs, England	University of Eastern Finland; University of Helsinki; Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Technische Universitat Dresden; University of Manchester	Yla-Herttuala, S (corresponding author), Univ Kuopio, AI Virtanen Inst, Dept Biotechnol & Mol Med, FIN-70211 Kuopio, Finland.	Seppo.Ylaherttuala@uku.fi	Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Yla-Herttuala, Seppo/0000-0001-7593-2708	Sigrid Juselius Foundation; Finnish Foundation for Cardiovascular Research, Finnish Academy and European Union (Lymphangiogenenomics) [LSHG-CT-2004-503573]; European Vascular Genomics Network (EVGN) [LSHM-CT-2003-503254]	Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Foundation for Cardiovascular Research, Finnish Academy and European Union (Lymphangiogenenomics); European Vascular Genomics Network (EVGN)	This work was supported by grants from Sigrid Juselius Foundation, Finnish Foundation for Cardiovascular Research, Finnish Academy and European Union (Lymphangiogenenomics LSHG-CT-2004-503573) and European Vascular Genomics Network (EVGN, LSHM-CT-2003-503254).	Baldwin ME, 2005, MOL CELL BIOL, V25, P2441, DOI 10.1128/MCB.25.6.2441-2449.2005; Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29; Belteki G, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni051; Bhardwaj S, 2003, HUM GENE THER, V14, P1451, DOI 10.1089/104303403769211664; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cursiefen C, 2002, INVEST OPHTH VIS SCI, V43, P2127; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FRITH CH, 1982, LAB ANIM SCI, V32, P157; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Hiltunen MO, 2000, FASEB J, V14, P2230, DOI 10.1096/fj.00-0145com; Hiltunen MO, 2003, FASEB J, V17, P1147, DOI 10.1096/fj.02-0514fje; Jalkanen J, 2003, ATHEROSCLEROSIS, V169, P95, DOI 10.1016/S0021-9150(03)00155-2; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1996, EMBO J, V15, P290; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Leppanen P, 2005, CIRCULATION, V112, P1347, DOI 10.1161/CIRCULATIONAHA.105.534107; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Odorisio T, 2002, J CELL SCI, V115, P2559; Okamoto N, 1997, AM J PATHOL, V151, P281; Puumalainen AM, 1998, HUM GENE THER, V9, P1769, DOI 10.1089/hum.1998.9.12-1769; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Vogel J, 2004, J CEREBR BLOOD F MET, V24, P849, DOI 10.1097/01.WCB.0000126564.89011.11; Yla-Herttuala S, 2000, LANCET, V355, P213, DOI 10.1016/S0140-6736(99)04180-X; Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694; Zeng X, 1998, DEV DYNAM, V211, P215, DOI 10.1002/(SICI)1097-0177(199803)211:3<215::AID-AJA3>3.0.CO;2-K	36	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e13	10.1371/journal.pone.0000013	http://dx.doi.org/10.1371/journal.pone.0000013			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183639	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443600013
J	Neyrolles, O; Hernandez-Pando, R; Pietri-Rouxel, F; Fornes, P; Tailleux, L; Payan, JAB; Pivert, E; Bordat, Y; Aguilar, D; Prevost, MC; Petit, C; Gicquel, B				Neyrolles, Olivier; Hernandez-Pando, Rogelio; Pietri-Rouxel, France; Fornes, Paul; Tailleux, Ludovic; Barrios Payan, Jorge Alberto; Pivert, Elisabeth; Bordat, Yann; Aguilar, Diane; Prevost, Marie-Christine; Petit, Caroline; Gicquel, Brigitte			Is Adipose Tissue a Place for Mycobacterium tuberculosis Persistence?	PLOS ONE			English	Article								Background. Mycobacterium tuberculosis, the etiological agent of tuberculosis (TB), has the ability to persist in its human host for exceptionally long periods of time. However, little is known about the location of the bacilli in latently infected individuals. Long-term mycobacterial persistence in the lungs has been reported, but this may not sufficiently account for strictly extra-pulmonary TB, which represents 10-15% of the reactivation cases. Methodology/Principal Findings. We applied in situ and conventional PCR to sections of adipose tissue samples of various anatomical origins from 19 individuals from Mexico and 20 from France who had died from causes other than TB. M. tuberculosis DNA could be detected by either or both techniques in fat tissue surrounding the kidneys, the stomach, the lymph nodes, the heart and the skin in 9/57 Mexican samples (6/19 individuals), and in 8/26 French samples (6/20 individuals). In addition, mycobacteria could be immuno-detected in perinodal adipose tissue of 1 out of 3 biopsy samples from individuals with active TB. In vitro, using a combination of adipose cell models, including the widely used murine adipose cell line 3T3-L1, as well as primary human adipocytes, we show that after binding to scavenger receptors, M. tuberculosis can enter within adipocytes, where it accumulates intracytoplasmic lipid inclusions and survives in a non-replicating state that is insensitive to the major anti-mycobacterial drug isoniazid. Conclusions/Significance. Given the abundance and the wide distribution of the adipose tissue throughout the body, our results suggest that this tissue, among others, might constitute a vast reservoir where the tubercle bacillus could persist for long periods of time, and avoid both killing by antimicrobials and recognition by the host immune system. In addition, M. tuberculosis-infected adipocytes might provide a new model to investigate dormancy and to evaluate new drugs for the treatment of persistent infection.	[Neyrolles, Olivier] CNRS, Paris, France; [Neyrolles, Olivier; Tailleux, Ludovic; Pivert, Elisabeth; Bordat, Yann; Gicquel, Brigitte] Inst Pasteur, Unit Mycobacterial Genet, Paris, France; [Hernandez-Pando, Rogelio; Barrios Payan, Jorge Alberto; Aguilar, Diane] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Pathol, Tlalpan, Mexico; [Pietri-Rouxel, France; Petit, Caroline] Inst Cochin, Dept Infect Dis, Paris, France; [Fornes, Paul] Hop Europeen Georges Pompidou, AP HP, Dept Anatomopathol, Paris, France; [Prevost, Marie-Christine] Inst Pasteur, Electron Microscopy Lab, Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Neyrolles, O (corresponding author), CNRS, Paris, France.	neyrolle@pasteur.fr	Neyrolles, Olivier/AAG-3692-2019; Neyrolles, Olivier B/A-3184-2011	Neyrolles, Olivier/0000-0003-0047-5885; BORDAT, Yann/0000-0001-8616-6498; Hernandez-Pando, Rogelio/0000-0003-1292-3833; Pietri-Rouxel, France/0000-0002-6258-7594; Tailleux, Ludovic/0000-0003-3931-1052	Institut Pasteur	Institut Pasteur(European Commission)	Funding: This work was funded by Institut Pasteur.	Alvarez HM, 2002, APPL MICROBIOL BIOT, V60, P367, DOI 10.1007/s00253-002-1135-0; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Byrd TF, 1998, INFECT IMMUN, V66, P5132, DOI 10.1128/IAI.66.11.5132-5139.1998; Charriere G, 2003, J BIOL CHEM, V278, P9850, DOI 10.1074/jbc.M210811200; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cousin B, 1999, FASEB J, V13, P305, DOI 10.1096/fasebj.13.2.305; DEWIT D, 1992, TUBERCLE LUNG DIS, V73, P262, DOI 10.1016/0962-8479(92)90130-C; FARER LS, 1979, AM J EPIDEMIOL, V109, P205, DOI 10.1093/oxfordjournals.aje.a112675; Fine PEM, 1999, NEW ENGL J MED, V341, P1226, DOI 10.1056/NEJM199910143411609; Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4; Garton NJ, 2002, MICROBIOL-SGM, V148, P2951, DOI 10.1099/00221287-148-10-2951; Godard C M, 1993, Acta Leprol, V8, P133; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Hart PD, 1996, INFECT IMMUN, V64, P1491, DOI 10.1128/IAI.64.4.1491-1493.1996; Hernandez-Pando R, 2000, LANCET, V356, P2133, DOI 10.1016/S0140-6736(00)03493-0; Hopewell Philip C., 1994, P25; Hu Y, 2006, INT J TUBERC LUNG D, V10, P317; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V963, P192, DOI 10.1016/0005-2760(88)90280-9; Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558; Kuniyasu A, 2003, FEBS LETT, V537, P85, DOI 10.1016/S0014-5793(03)00096-6; Kuniyasu A, 2002, BIOCHEM BIOPH RES CO, V295, P319, DOI 10.1016/S0006-291X(02)00666-6; Mehta PK, 1996, INFECT IMMUN, V64, P2673, DOI 10.1128/IAI.64.7.2673-2679.1996; Munoz-Elias EJ, 2005, INFECT IMMUN, V73, P546, DOI 10.1128/IAI.73.1.546-551.2005; Opie EL, 1927, ARCH PATHOL LAB MED, V4, P1; Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5; RASTOGI N, 1992, CURR MICROBIOL, V25, P203, DOI 10.1007/BF01570720; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Seiler P, 2003, J INFECT DIS, V188, P1326, DOI 10.1086/378563; Stewart GR, 2003, NAT REV MICROBIOL, V1, P97, DOI 10.1038/nrmicro749; Stute N, 2004, EXP HEMATOL, V32, P1212, DOI 10.1016/j.exphem.2004.09.003; Tailleux L, 2003, TRENDS MICROBIOL, V11, P259, DOI 10.1016/S0966-842X(03)00102-1; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; TYRRELL DAJ, 1975, BRIT J EXP PATHOL, V56, P99; Ulrichs T, 2005, J PATHOL, V205, P633, DOI 10.1002/path.1728; Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602; Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zimmerli S, 1996, AM J RESP CELL MOL, V15, P760, DOI 10.1165/ajrcmb.15.6.8969271	38	231	239	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e43	10.1371/journal.pone.0000043	http://dx.doi.org/10.1371/journal.pone.0000043			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183672	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600043
J	dela Paz, NG; Simeonidis, S; Leo, C; Rose, DW; Collins, T				dela Paz, Nathaniel G.; Simeonidis, Simos; Leo, Christopher; Rose, David W.; Collins, Tucker			Regulation of NF-kappa B-dependent gene expression by the POU domain transcription factor Oct-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; HUMAN ENDOTHELIAL-CELLS; CREB-BINDING PROTEIN; E-SELECTIN; INTERLEUKIN-6 GENE; KINASE IKK; FACTOR-I; ACTIVATION; RECEPTOR; IL-6	Maintenance of the cells of the vessel wall in a quiescent state is an important aspect of normal vascular physiology. Transcriptional repressors are widely believed to regulate this process, yet the exact factors involved and the mechanism of repression are not known. Here, we report that the POU domain transcription factor Oct-1 represses the expression of E-selectin and vascular cell adhesion molecule (VCAM-1), two cytokine-inducible, NF-kappa B-dependent endothelial-leukocyte adhesion molecules that participate in the leukocyte recruitment phase of the inflammatory response. Co-transfection and microinjection studies demonstrate that Oct-1 blocks tumor necrosis factor alpha-stimulated E-selectin and VCAM-1 expression. Gene expression arrays indicate that control of tumor necrosis factor alpha-induced, NF-kappa B-dependent gene expression by Oct-1 is promoter-specific. A DNA-binding mutant of Oct-1 represses NF-kappa B-dependent reporter gene expression. Biochemically, Oct-1 interacts with p65, suggesting that Oct-1 is involved in the regulation of NF-kappa B transactivation function. NF-kappa B-dependent gene expression is more pronounced in Oct-1-deficient than in wild-type murine embryonic fibroblasts, and reintroduction of human Oct-1 abolishes these differences. Finally, the cytokine interleukin-6 induces Oct-1 gene expression, providing a biologically relevant means by which NF-kappa B-dependent gene expression can be selectively reverted by Oct-1 to quiescent levels.	Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Calif San Diego, Sch Med, Mol Pathol Grad Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Collins, T (corresponding author), Childrens Hosp, Dept Pathol, 300 Longwood Ave, Boston, MA 02115 USA.	tcollins@rics.bwh.harvard.edu			NHLBI NIH HHS [T32 HL076115, F31HL-74452, HL-45462] Funding Source: Medline; NIDDK NIH HHS [DK-54802] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F31HL074452] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054802] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUER J, 1988, BLOOD, V72, P1134; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Edelstein LC, 2005, J BIOL CHEM, V280, P11192, DOI 10.1074/jbc.M412997200; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Glass CK, 2000, GENE DEV, V14, P121; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HSU W, 1993, MOL CELL BIOL, V13, P2515, DOI 10.1128/MCB.13.4.2515; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; JIRIK FR, 1989, J IMMUNOL, V142, P144; Kakizawa T, 1999, J BIOL CHEM, V274, P19103, DOI 10.1074/jbc.274.27.19103; Kakizawa T, 2001, J BIOL CHEM, V276, P9720, DOI 10.1074/jbc.M008531200; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; Kumbrink J, 2005, J BIOL CHEM, V280, P42785, DOI 10.1074/jbc.M511079200; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MARCINKIEWICZ J, 1991, CYTOKINE, V3, P327, DOI 10.1016/1043-4666(91)90501-4; Matthias P, 1998, SEMIN IMMUNOL, V10, P155, DOI 10.1006/smim.1998.0117; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Modur V, 1997, J CLIN INVEST, V100, P2752, DOI 10.1172/JCI119821; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PODOR TJ, 1989, ANN NY ACAD SCI, V557, P374; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Read MA, 1996, J IMMUNOL, V157, P3472; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; SIRONI M, 1989, J IMMUNOL, V142, P549; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Tantin D, 2005, CANCER RES, V65, P10750, DOI 10.1158/0008-5472.CAN-05-2399; van Heel DA, 2002, HUM MOL GENET, V11, P1281, DOI 10.1093/hmg/11.11.1281; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Wang VEH, 2004, MOL CELL BIOL, V24, P1022, DOI 10.1128/MCB.24.3.1022-1032.2004; Waxman AB, 2003, AM J RESP CELL MOL, V29, P513, DOI 10.1165/rcmb.2002-0044OC; Weiser MCM, 1997, MOL BIOL CELL, V8, P999, DOI 10.1091/mbc.8.6.999; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WIDMER U, 1993, J IMMUNOL, V150, P4996; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	62	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8424	8434		10.1074/jbc.M606923200	http://dx.doi.org/10.1074/jbc.M606923200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17192276	hybrid			2022-12-25	WOS:000245081000075
J	Laramee, M; Chabot, C; Cloutier, M; Stenne, R; Holgado-Madruga, M; Wong, AJ; Royal, I				Laramee, Melanie; Chabot, Catherine; Cloutier, Monikca; Stenne, Raphaelle; Holgado-Madruga, Marina; Wong, Albert J.; Royal, Isabelle			The scaffolding adapter Gab1 mediates vascular endothelial growth factor signaling and is required for endothelial cell migration and capillary formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-2; DOCKING PROTEIN GAB1; PHOSPHOLIPASE C-GAMMA; NITRIC-OXIDE SYNTHASE; KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITE; FACTOR RECEPTOR-2; PH DOMAIN; ACTIVATION	Vascular endothelial growth factor (VEGF) is involved in the promotion of endothelial cell proliferation, migration, and capillary formation. These activities are mainly mediated by the VEGFR2 receptor tyrosine kinase that upon stimulation, promotes the activation of numerous proteins including phospholipase C gamma (PLC gamma), phosphatidylinositol 3-kinase (PI3K), Akt, Src, and ERK1/2. However, the VEGFR2-proximal signaling events leading to the activation of these targets remain ill defined. We have identified the Gab1 adapter as a novel tyrosine-phosphorylated protein in VEGF-stimulated cells. In bovine aortic endothelial cells, Gab1 associates with VEGFR2, Grb2, PI3K, SHP2, Shc, and PLC gamma, and its overexpression enhances VEGF-dependent cell migration. Importantly, silencing of Gab1 using small interfering RNAs leads to the impaired activation of PLC gamma, ERK1/2, Src, and Akt; blocks VEGF-induced endothelial cell migration; and perturbs actin reorganization and capillary formation. In addition, co-expression of VEGFR2 with Gab1 mutants unable to bind SHP2 or PI3K in human embryonic kidney 293 cells and bovine aortic endothelial cells mimics the defects observed in Gab1-depleted cells. Our work thus identifies Gabl as a novel critical regulatory component of endothelial cell migration and capillary formation and reveals its key role in the activation of VEGF-evoked signaling pathways required for angiogenesis.	CHUM, Ctr Rech, Hop Notre Dame de Bon Secours, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H2L 4M1, Canada; Stanford Univ, Med Ctr, Dept Neurosurg, Stanford, CA 94305 USA	Universite de Montreal; Universite de Montreal; Stanford University	Royal, I (corresponding author), CHUM, Ctr Rech, Hop Notre Dame de Bon Secours, Inst Canc Montreal, Pavillon JA Seve Y-4605,1560 Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.	isabelle.royal@umontreal.ca		Royal, Isabelle/0000-0002-7548-1182				Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Claesson-Welsh L, 2003, BIOCHEM SOC T, V31, P20, DOI 10.1042/bst0310020; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Criscuoli ML, 2005, BLOOD, V105, P1508, DOI 10.1182/blood-2004-06-2246; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Dance M, 2006, J BIOL CHEM, V281, P23285, DOI 10.1074/jbc.M600987200; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dixit M, 2005, CIRC RES, V97, P1236, DOI 10.1161/01.RES.0000195611.59811.ab; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Ferrara N, 2005, EXP SUPPL, V94, P209; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Holgado-Madruga M, 2004, CANCER RES, V64, P2007, DOI 10.1158/0008-5472.CAN-03-2886; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Ingham RJ, 2001, J BIOL CHEM, V276, P12257, DOI 10.1074/jbc.M010590200; Jin ZG, 2005, J BIOL CHEM, V280, P12305, DOI 10.1074/jbc.M500294200; KACHARY L, 2001, CARDIOVASC RES, V9, P568; Kallin A, 2004, J BIOL CHEM, V279, P17897, DOI 10.1074/jbc.M312996200; Kendall RL, 1999, J BIOL CHEM, V274, P6453, DOI 10.1074/jbc.274.10.6453; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamothe B, 2004, MOL CELL BIOL, V24, P5657, DOI 10.1128/MCB.24.13.5657-5666.2004; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lock LS, 2002, MOL BIOL CELL, V13, P2132, DOI 10.1091/mbc.02-02-0031; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maeda K, 2004, BIOCHEM BIOPH RES CO, V323, P345, DOI 10.1016/j.bbrc.2004.08.095; Manes S, 1999, MOL CELL BIOL, V19, P3125; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsumoto T, 2005, EMBO J, V24, P2342, DOI 10.1038/sj.emboj.7600709; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zachary I, 2005, EXP SUPPL, V94, P267; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	71	88	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					7758	7769		10.1074/jbc.M611327200	http://dx.doi.org/10.1074/jbc.M611327200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17178724	hybrid			2022-12-25	WOS:000245081000003
J	Wolde, M; Fellows, A; Cheng, J; Kivenson, A; Coutermarsh, B; Talebian, L; Karlson, K; Piserchio, A; Mierke, DF; Stanton, BA; Guggino, WB; Madden, DR				Wolde, Michael; Fellows, Abigail; Cheng, Jie; Kivenson, Aleksandr; Coutermarsh, Bonita; Talebian, Laleh; Karlson, Katherine; Piserchio, Andrea; Mierke, Dale F.; Stanton, Bruce A.; Guggino, William B.; Madden, Dean R.			Targeting CAL as a negative regulator of Delta F508-CFTR cell-surface expression - An RNA interference and structure-based muta genetic approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE-CONDUCTANCE-REGULATOR; AIRWAY EPITHELIAL-CELLS; CYSTIC-FIBROSIS GENE; PLASMA-MEMBRANE; PDZ PROTEINS; FUNCTIONAL EXPRESSION; APICAL MEMBRANE; HALF-LIFE; CFTR; DOMAIN	PDZ domains are ubiquitous peptide-binding modules that mediate protein-protein interactions in a wide variety of intracellular trafficking and localization processes. These include the pathways that regulate the membrane trafficking and endocytic recycling of the cystic fibrosis transmembrane conductance regulator (CFTR), an epithelial chloride channel mutated in patients with cystic fibrosis. Correspondingly, a number of PDZ proteins have now been identified that directly or indirectly interact with the C terminus of CFTR. One of these is CAL, whose overexpression in heterologous cells directs the lysosomal degradation of WT-CFTR in a dose-dependent fashion and reduces the amount of CFTR found at the cell surface. Here, we show that RNA interference targeting endogenous CAL specifically increases cell-surface expression of the disease-associated Delta F508-CFTR mutant and thus enhances transepithelial chloride currents in a polarized human patient bronchial epithelial cell line. We have reconstituted the CAL-CFTR interaction in vitro from purified components, demonstrating for the first time that the binding is direct and allowing us to characterize its components biochemically and biophysically. To test the hypothesis that inhibition of the binding site could also reverse CAL-mediated suppression of CFTR, a three-dimensional homology model of the CAL-CFTR complex was constructed and used to generate a CAL mutant whose binding pocket is correctly folded but has lost its ability to bind CFTR. Although produced at the same levels as wild-type protein, the mutant does not affect CFTR expression levels. Taken together, our data establish CAL as a candidate therapeutic target for correction of post-maturational trafficking defects in cystic fibrosis.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Brown Univ, Div Biol & Med, Dept Mol Pharmacol, Providence, RI 02912 USA	Dartmouth College; Dartmouth College; Johns Hopkins University; Brown University	Madden, DR (corresponding author), 7200 Vail Bldg, Hanover, NH 03755 USA.	drm0001@dartmouth.edu			NCRR NIH HHS [1 P20 RR018787] Funding Source: Medline; NHLBI NIH HHS [R01 HL47122] Funding Source: Medline; PHS HHS [R01 45881] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018787] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bebok Z, 2005, J PHYSIOL-LONDON, V569, P601, DOI 10.1113/jphysiol.2005.096669; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; Brone B, 2005, AM J PHYSIOL-CELL PH, V288, pC20, DOI 10.1152/ajpcell.00368.2004; Bruscia E, 2002, GENE THER, V9, P683, DOI 10.1038/sj.gt.3301741; Cheng J, 2005, J BIOL CHEM, V280, P3731, DOI 10.1074/jbc.M410026200; Cheng J, 2004, J BIOL CHEM, V279, P1892, DOI 10.1074/jbc.M308640200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Gruenert D C, 2004, J Cyst Fibros, V3 Suppl 2, P191, DOI 10.1016/j.jcf.2004.05.040; Guerra L, 2005, J BIOL CHEM, V280, P40925, DOI 10.1074/jbc.M505103200; Guggino WB, 2006, NAT REV MOL CELL BIO, V7, P426, DOI 10.1038/nrm1949; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Harris BZ, 2001, J CELL SCI, V114, P3219; He JQ, 2004, J BIOL CHEM, V279, P50190, DOI 10.1074/jbc.M404876200; Heda GD, 2001, AM J PHYSIOL-CELL PH, V280, pC166, DOI 10.1152/ajpcell.2001.280.1.C166; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; KOPITO RR, 1999, PHYSIOL REV, V79, P167; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kunzelmann K, 2001, NEWS PHYSIOL SCI, V16, P167; Li CY, 2005, PHARMACOL THERAPEUT, V108, P208, DOI 10.1016/j.pharmthera.2005.04.004; Li Y, 2006, AM J RESP CELL MOL, V34, P600, DOI 10.1165/rcmb.2005-0421OC; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; Maliepaard M, 2001, CANCER RES, V61, P3458; Milewski MI, 2001, J CELL SCI, V114, P719; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; Piserchio A, 2005, BIOCHEMISTRY-US, V44, P16158, DOI 10.1021/bi0516475; Piserchio A, 2002, J BIOL CHEM, V277, P6967, DOI 10.1074/jbc.M109453200; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Swiatecka-Urban A, 2006, AM J PHYSIOL-CELL PH, V290, pC862, DOI 10.1152/ajpcell.00108.2005; Swiatecka-Urban A, 2005, J BIOL CHEM, V280, P36762, DOI 10.1074/jbc.M508944200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Taddei A, 2004, FEBS LETT, V558, P52, DOI 10.1016/S0014-5793(04)00011-0; Tuma PL, 2002, MOL BIOL CELL, V13, P3400, DOI 10.1091/mbc.02-04-0054; Van Goor F, 2006, AM J PHYSIOL-LUNG C, V290, pL1117, DOI 10.1152/ajplung.00169.2005; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wente W, 2005, J BIOL CHEM, V280, P32419, DOI 10.1074/jbc.M507198200; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	53	55	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8099	8109		10.1074/jbc.M611049200	http://dx.doi.org/10.1074/jbc.M611049200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17158866	hybrid			2022-12-25	WOS:000245081000042
J	Ouchane, S; Picaud, M; Therizols, P; Reiss-Husson, F; Astier, C				Ouchane, Soufian; Picaud, Martine; Therizols, Pierre; Reiss-Husson, Francoise; Astier, Chantal			Global regulation of photosynthesis and respiration by FnrL - The first two targets in the tetrapyrrole pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-SPHAEROIDES 2.4.1; COPROPORPHYRINOGEN-III OXIDASE; ISOCYCLIC RING FORMATION; GENE-EXPRESSION; RUBRIVIVAX-GELATINOSUS; HEME-BIOSYNTHESIS; ESCHERICHIA-COLI; CHLAMYDOMONAS-REINHARDTII; TRANSCRIPTION FACTOR; PURPLE BACTERIA	Fur is a regulator that controls the expression of a variety of genes in response to oxygen limitation in bacteria. To assess the role of Fnr in photosynthesis in Rubrivivax gelatinosus, a strain carrying a null mutation in fnrL was constructed. It was unable to grow anaerobically in the light, but, intriguingly, it was able to produce photosynthetic complexes under high oxygenation conditions. The mutant lacked all c-type cytochromes normally detectable in microaerobically-grown wild type cells and accumulated coproporphyrin Ill. These data suggested that the pleiotropic phenotype observed in FNR is primarily due to the control at the level of the HemN oxygen-independent coproporphyrinogen III dehydrogenase. hemN expression in trans partially suppressed the FNR phenotype, as it rescued heme and cytochrome syntheses. Nevertheless, these cells were photosynthetically deficient, and pigment analyses showed that they were blocked at the level of Mg2+-protoporphyrin monomethyl ester. Expression of both hemN and bchE in the FNR mutant restored synthesis of Mg2+-protochlorophyllide. We, therefore, conclude that FnrL controls respiration by regulating hemN expression and controls photosynthesis by regulating both hemN and bchE expression. A comprehensive picture of the control points of microaerobic respiration and photosynthesis by FnrL is provided, and the prominent role of this factor in activating alternative gene programs after reduction of oxygen tension in facultative aerobes is discussed.	Univ Paris 06, UPR 2167, Ctr Genet Mol, CNRS, F-91198 Gif Sur Yvette, France; Univ Paris 11, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Ouchane, S (corresponding author), Univ Paris 06, UPR 2167, Ctr Genet Mol, CNRS, Batiment 26,Ave Terrasse, F-91198 Gif Sur Yvette, France.	souchane@cgm.cnrs-gif.fr	Therizols, Pierre/AAA-5515-2021; OUCHANE, Soufian/HHM-5430-2022; Ouchane, Soufian/ABE-2609-2020	Ouchane, Soufian/0000-0002-8161-3866; Therizols, Pierre/0000-0002-5916-0987				Bauer C, 2003, PHILOS T R SOC B, V358, P147, DOI 10.1098/rstb.2002.1189; Bauer CE, 1999, ANNU REV MICROBIOL, V53, P495, DOI 10.1146/annurev.micro.53.1.495; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; Gough SP, 2000, P NATL ACAD SCI USA, V97, P6908, DOI 10.1073/pnas.97.12.6908; HORIUCHI K, 1991, CLIN CHEM, V37, P1173; Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1111/j.1574-6976.1998.tb00375.x; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; Mason MG, 2001, APPL ENVIRON MICROB, V67, P4512, DOI 10.1128/AEM.67.10.4512-4519.2001; Moore LJ, 2001, J BIOL CHEM, V276, P45744, DOI 10.1074/jbc.M106569200; Moseley J, 2000, EMBO J, V19, P2139, DOI 10.1093/emboj/19.10.2139; Mouncey NJ, 1998, J BACTERIOL, V180, P2228, DOI 10.1128/JB.180.8.2228-2231.1998; O'Brian MR, 2002, ADV MICROB PHYSIOL, V46, P257, DOI 10.1016/S0065-2911(02)46006-7; Oh JI, 2001, MOL MICROBIOL, V39, P1116, DOI 10.1046/j.1365-2958.2001.02299.x; Oh JI, 2000, J BACTERIOL, V182, P3081, DOI 10.1128/JB.182.11.3081-3087.2000; Ouchane S, 2004, J BIOL CHEM, V279, P6385, DOI 10.1074/jbc.M309851200; Ouchane S, 1996, MOL GEN GENET, V252, P379, DOI 10.1007/BF02173002; Panek H, 2002, MICROBIOL-SGM, V148, P2273, DOI 10.1099/00221287-148-8-2273; Pinta V, 2002, J BACTERIOL, V184, P746, DOI 10.1128/JB.184.3.746-753.2002; Porra RJ, 1998, EUR J BIOCHEM, V257, P185, DOI 10.1046/j.1432-1327.1998.2570185.x; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Quinn JM, 2002, PLANT PHYSIOL, V128, P463, DOI 10.1104/pp.010694; Raymond J, 2004, GEOBIOLOGY, V2, P199, DOI 10.1111/j.1472-4677.2004.00037.x; Roh JH, 2002, J BACTERIOL, V184, P5330, DOI 10.1128/JB.184.19.5330-5338.2002; Salmon K, 2003, J BIOL CHEM, V278, P29837, DOI 10.1074/jbc.M213060200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schobert M, 2002, J MOL MICROB BIOTECH, V4, P287; Smart JL, 2004, J MOL BIOL, V342, P1171, DOI 10.1016/j.jmb.2004.08.007; SMITH KM, 1975, PORPHYRINS METALLOPO, P872; Steunou AS, 2004, J BACTERIOL, V186, P3133, DOI 10.1128/JB.186.10.3133-3142.2004; Suzuki JY, 1997, ANNU REV GENET, V31, P61, DOI 10.1146/annurev.genet.31.1.61; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; TROUP B, 1994, J BACTERIOL, V176, P673, DOI 10.1128/jb.176.3.673-680.1994; TROUP B, 1995, J BACTERIOL, V177, P3326, DOI 10.1128/jb.177.11.3326-3331.1995; UFFEN RL, 1976, P NATL ACAD SCI USA, V73, P3298, DOI 10.1073/pnas.73.9.3298; VERNON LP, 1966, CHLOROPHYLLS      ED, P147; Zeilstra-Ryalls JH, 1998, J BACTERIOL, V180, P1496, DOI 10.1128/JB.180.6.1496-1503.1998; Zeilstra-Ryalls JH, 1998, METHOD ENZYMOL, V297, P151; ZeilstraRyalls JH, 1996, J BACTERIOL, V178, P985, DOI 10.1128/jb.178.4.985-993.1996; ZEILSTRARYALLS JH, 1995, J BACTERIOL, V177, P6422, DOI 10.1128/jb.177.22.6422-6431.1995; ZeilstraRyalls JH, 1997, J BACTERIOL, V179, P7264, DOI 10.1128/jb.179.23.7264-7273.1997	41	14	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7690	7699		10.1074/jbc.M605985200	http://dx.doi.org/10.1074/jbc.M605985200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17178720	hybrid			2022-12-25	WOS:000245080900081
J	Gillet, R; Kaur, S; Li, W; Hallier, M; Felden, B; Frank, J				Gillet, Reynald; Kaur, Sukhjit; Li, Wen; Hallier, Marc; Felden, Brice; Frank, Joachim			Scaffolding as an organizing principle in trans-translation - The roles of small protein band ribosomal protein S1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-MESSENGER-RNA; STALLED RIBOSOME; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; SMPB SYSTEM; TMRNA; BINDING; SUBUNIT; VISUALIZATION; RESCUE	A eubacterial ribosome stalled on a defective mRNA can be released through a quality control mechanism referred to as trans-translation, which depends on the coordinating binding actions of transfer-messenger RNA, small protein B, and ribosome protein S1. By means of cryo-electron microscopy, we obtained a map of the complex composed of a stalled ribosome and small protein B, which appears near the decoding center. This result suggests that, when lacking a codon, the A-site on the small subunit is a target for small protein B. To investigate the role of S1 played in trans-translation, we obtained a cryo-electron microscopic map, including a stalled ribosome, transfermessenger RNA, and small protein Bs but in the absence of SI. In this complex, several connections between the 30 S subunit and transfer-messenger RNA that appear in the +S1 complex are no longer found. We propose the unifying concept of scaffolding for the roles of small protein B and S1 in binding of transfer-messenger RNA to the ribosome during trans-translation, and we infer a pathway of sequential binding events in the initial phase of trans-translation.	Univ Rennes 1, IFR 140, UPRES JE 2311, INSERM,U835, F-35043 Rennes, France; Hlth Res Inc, Howard Hughes Med Inst, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Wadsworth Ctr, Albany, NY 12201 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Health Research Inc; Howard Hughes Medical Institute; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Wadsworth Center	Gillet, R (corresponding author), Univ Rennes 1, IFR 140, UPRES JE 2311, INSERM,U835, 2 Ave Prof Leon Bernard, F-35043 Rennes, France.	bfelden@univ-rennes1.fr; joachim@wadsworth.org	Hallier, Marc/L-2031-2015; felden, brice/L-4825-2015		NIGMS NIH HHS [R37 GM029169-23, GM55440, R01 GM055440-08, GM 67624, R01 GM067624, R37 GM29169, R37 GM029169, R01 GM055440-09A1, R01 GM029169, R01 GM029169-29, R01 GM055440, R37 GM029169-24] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055440, R01GM029169, R01GM067624, R37GM029169] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bordeau V, 2002, BIOCHIMIE, V84, P723, DOI 10.1016/S0300-9084(02)01442-6; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P103; Clemons WM, 2001, J MOL BIOL, V310, P827, DOI 10.1006/jmbi.2001.4778; Cochella L, 2005, SCIENCE, V308, P1178, DOI 10.1126/science.1111408; de Novoa PG, 2004, NUCLEIC ACIDS RES, V32, pD104, DOI 10.1093/nar/gkh102; Dong G, 2002, EMBO J, V21, P1845, DOI 10.1093/emboj/21.7.1845; Felden B, 1997, RNA, V3, P89; Frank J, 2006, 3 DIMENSIONAL ELECT; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; Gutmann S, 2003, NATURE, V424, P699, DOI 10.1038/nature01831; Hallier M, 2006, NUCLEIC ACIDS RES, V34, P1935, DOI 10.1093/nar/gkl097; Hallier M, 2004, J BIOL CHEM, V279, P25978, DOI 10.1074/jbc.M314086200; Hanawa-Suetsugu K, 2002, NUCLEIC ACIDS RES, V30, P1620, DOI 10.1093/nar/30.7.1620; Ivanova N, 2005, NUCLEIC ACIDS RES, V33, P3529, DOI 10.1093/nar/gki666; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Kaur S, 2006, P NATL ACAD SCI USA, V103, P16484, DOI 10.1073/pnas.0607438103; Keiler KC, 2000, P NATL ACAD SCI USA, V97, P7778, DOI 10.1073/pnas.97.14.7778; Maivali U, 2004, RNA, V10, P600, DOI 10.1261/rna.5220504; McGinness KE, 2004, P NATL ACAD SCI USA, V101, P13454, DOI 10.1073/pnas.0405521101; Metzinger L, 2005, NUCLEIC ACIDS RES, V33, P2384, DOI 10.1093/nar/gki534; Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3; Okada T, 2004, BIOSCI BIOTECH BIOCH, V68, P2319, DOI 10.1271/bbb.68.2319; Saguy M, 2005, BIOCHIMIE, V87, P897, DOI 10.1016/j.biochi.2005.03.014; Sengupta J, 2001, P NATL ACAD SCI USA, V98, P11991, DOI 10.1073/pnas.211266898; Shimizu Y, 2002, FEBS LETT, V514, P74, DOI 10.1016/S0014-5793(02)02333-5; Stagg SM, 2001, J MOL BIOL, V309, P727, DOI 10.1006/jmbi.2001.4632; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; Wower IK, 2000, EMBO J, V19, P6612, DOI 10.1093/emboj/19.23.6612; Wower J, 2002, BIOCHEMISTRY-US, V41, P8826, DOI 10.1021/bi0201365	30	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6356	6363		10.1074/jbc.M609658200	http://dx.doi.org/10.1074/jbc.M609658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17179154	hybrid, Green Accepted			2022-12-25	WOS:000244867200042
J	Kapoor, M; Kojima, F; Qian, M; Yang, LH; Crofford, LJ				Kapoor, Mohit; Kojima, Fumiaki; Qian, Min; Yang, Lihua; Crofford, Leslie J.			Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma - Regulation by prostaglandin E-2 via the phosphatidylinositol 3-kinase and Akt pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RANDOMIZED CONTROLLED-TRIAL; RHEUMATOID SYNOVIAL-CELLS; NITRIC-OXIDE; MICE LACKING; PPAR-GAMMA; EXPRESSION; CYCLOOXYGENASE-2; ARTHRITIS; INFLAMMATION; BIOSYNTHESIS	mPGES-1 (microsomal PGE synthase-1) is an inducible enzyme that acts downstream of cyclooxygenase (COX) and specifically catalyzes the conversion of prostaglandin (PG) H-2 to PGE(2) under basal as well as inflammatory conditions. In this study, using mouse embryo fibroblasts (MEFs) isolated from mice genetically deficient for the mPges-1 gene, we show basal elevation of peroxisome proliferator-activated receptor gamma (PPAR gamma) expression (protein and mRNA) and transcriptional activity associated with reduced basal PGE(2). We further show that basal mPGES-1-derived PGE, suppresses the expression of PPAR gamma through a cAMP-independent pathway involving phosphatidylinositol 3-kinase and Akt signaling. Using specific PPAR gamma agonist (rosiglitazone), PPAR gamma ligand (15-deoxy-Delta 12,14-PGJ(2)), and PPAR gamma inhibitor (GW9662), we confirm that activation of PPAR gamma blocks interleukin-1 beta-induced up-regulation of COX-2, mPGES-1, and their derived PGE(2). Furthermore, we demonstrate that up-regulation of PPAR gamma upon genetic deletion of mPGES-1 is responsible for reduced COX-2 expression under basal as well as interleukin-1 beta-stimulated conditions. This study provides evidence for the first time that mPGES-1 deletion not only decreases proinflammatory PGE(2) but also up-regulates anti-inflammatory PPAR gamma, which has the ability to suppress COX-2 and mPGES-1 expression and PGE(2) production. Thus, mPGES- I inhibition may limit inflammation by multiple mechanisms and is a potential therapeutic target.	Univ Kentucky, Div Rheumatol, Dept Internal Med, KY Clin, Lexington, KY 40536 USA; Univ Michigan, Sch Med, Div Cell & Dev Biol, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA	University of Kentucky; University of Michigan System; University of Michigan	Crofford, LJ (corresponding author), Univ Kentucky, Div Rheumatol, Dept Internal Med, KY Clin, Rm J-509, Lexington, KY 40536 USA.	lcrofford@uky.edu	Crofford, Leslie J/J-8010-2013	Crofford, Leslie J/0000-0002-6347-5738	NIAMS NIH HHS [R01 AR049010, R01 AR 049010] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049010] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Caristi S, 2005, J BIOL CHEM, V280, P14433, DOI 10.1074/jbc.M410725200; Cheng Y, 2006, J CLIN INVEST, V116, P1391, DOI 10.1172/JCI27540; Cheon H, 2006, J IMMUNOL, V177, P1092, DOI 10.4049/jimmunol.177.2.1092; Crofford LJ, 2003, ARTHRITIS RES THER, V5, P25, DOI 10.1186/ar620; Crofford LJ, 2001, GASTROENTEROL CLIN N, V30, P863, DOI 10.1016/S0889-8553(05)70217-X; Cuzzocrea S, 2002, MOL PHARMACOL, V61, P997, DOI 10.1124/mol.61.5.997; Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#; Farrajota K, 2005, ARTHRITIS RHEUM-US, V52, P94, DOI 10.1002/art.20714; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Gomez-Hernandez A, 2006, J CARDIOVASC PHARM, V47, P60; HONDA A, 1993, J BIOL CHEM, V268, P7759; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kamei D, 2003, J BIOL CHEM, V278, P19396, DOI 10.1074/jbc.M213290200; Kamei D, 2004, J BIOL CHEM, V279, P33684, DOI 10.1074/jbc.M400199200; Kapoor Mohit, 2005, Curr Opin Investig Drugs, V6, P461; Kapoor M, 2006, FASEB J, V20, P2387, DOI 10.1096/fj.06-6366fje; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kino Y, 2005, PROSTAG LEUKOTR ESS, V73, P103, DOI 10.1016/j.plefa.2005.04.014; Kojima F, 2005, FUND CLIN PHARMACOL, V19, P255, DOI 10.1111/j.1472-8206.2005.00316.x; Kojima F, 2004, ARTHRITIS RES THER, V6, pR355, DOI 10.1186/ar1195; Kojima F, 2003, ARTHRITIS RHEUM, V48, P2819, DOI 10.1002/art.11261; Kojima F, 2002, J RHEUMATOL, V29, P1836; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Moulin D, 2006, BIORHEOLOGY, V43, P561; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Namkoong S, 2005, EXP MOL MED, V37, P588, DOI 10.1038/emm.2005.72; Olschewski H, 1996, ANN INTERN MED, V124, P820, DOI 10.7326/0003-4819-124-9-199605010-00006; Peng Youming, 2005, Hemodial Int, V9 Suppl 1, pS15, DOI 10.1111/j.1542-4758.2005.01165.x; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Ricote M, 1999, J LEUKOCYTE BIOL, V66, P733, DOI 10.1002/jlb.66.5.733; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Saha S, 2005, AM J PHYSIOL-REG I, V288, pR1100, DOI 10.1152/ajpregu.00872.2004; Sanchez-Hidalgo M, 2005, BIOCHEM PHARMACOL, V69, P1733, DOI 10.1016/j.bcp.2005.03.024; Satoh K, 2000, NEUROSCI LETT, V283, P221, DOI 10.1016/S0304-3940(00)00926-5; Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140-6736(04)16893-1; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shiojiri T, 2002, EUR J PHARMACOL, V448, P231, DOI 10.1016/S0014-2999(02)01946-5; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Wang M, 2006, P NATL ACAD SCI USA, V103, P14507, DOI 10.1073/pnas.0606586103; White WB, 2003, AM J CARDIOL, V92, P411, DOI 10.1016/S0002-9149(03)00659-3; Willoughby DA, 2000, INT J IMMUNOPHARMACO, V22, P1131, DOI 10.1016/S0192-0561(00)00064-3	48	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5356	5366		10.1074/jbc.M610153200	http://dx.doi.org/10.1074/jbc.M610153200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17186945	hybrid			2022-12-25	WOS:000244482300031
J	Paro, S; Rancour, DM; Bednarek, SY				Paro, Sookhee; Rancour, David M.; Bednarek, Sebastian Y.			Protein domain-domain interactions and requirements for the negative regulation of Arabidopsis CDC48/p97 by the plant ubiquitin regulatory X (UBX) domain-containing protein, PUX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AAA ATPASE P97/VCP; CONFORMATIONAL-CHANGES; P97-UFD1-NPL4 COMPLEX; MEMBRANE-FUSION; P97; BINDING; ER; P47; DEGRADATION; INVOLVEMENT	CDC48/p97 is an essential AAA-ATPase chaperone that functions in numerous diverse cellular activities through its interaction with specific adapter proteins. The ubiquitin regulatory X (UBX)-containing protein, PUX1, functions to regulate the hexameric structure and ATPase activity of AtCDC48. To characterize the biochemical mechanism of PUX1 action on AtCDC48, we have defined domains of both PUX1 and AtCDC48 that are critical for interaction and oligomer disassembly. Binding of PUX1 to AtCDC48 was mediated through a region containing both the UBX domain and the immediate C-terminal flanking amino acids (UBX-C). Like other UBX domains, the primary binding site for the UBX-C of PUX1 is the N-a domain of AtCDC48. Alternative plant PUX protein UBX domains also bind AtCDC48 through the N terminus but were found not to be able to substitute for the action imparted by the UBX-C of PUX1 in hexamer disassembly, suggesting unique features for the UBX-C of PUX1. We propose that the PUX1 UBX-C domain modulates a second binding site on AtCDC48 required for the N-terminal domain of PUX1 to interact with and promote dissociation of the AtCDC48 hexamer. Utilizing Atcdc48 ATP hydrolysis and binding mutants, we demonstrate that PUX1 binding was not affected but that hexamer disassembly was significantly influenced by the ATP status of AtCDC48. ATPase activity in both the D I and the D2 domains was critical for PUX1-mediated AtCDC48 hexamer disassembly. Together these results provide new mechanistic insight into how the hexameric status and ATPase activity of AtCDC48 are modulated.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Cell & Mol Biol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Bednarek, SY (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	bednarek@biochem.wisc.edu		Rancour, David/0000-0002-3624-5750				Allen MD, 2006, J BIOL CHEM, V281, P25502, DOI 10.1074/jbc.M601173200; Alzayady KJ, 2005, J BIOL CHEM, V280, P34530, DOI 10.1074/jbc.M508890200; Beuron F, 2003, J MOL BIOL, V327, P619, DOI 10.1016/S0022-2836(03)00178-5; Bruderer RM, 2004, J BIOL CHEM, V279, P49609, DOI 10.1074/jbc.M408695200; Buchberger A, 2001, J MOL BIOL, V307, P17, DOI 10.1006/jmbi.2000.4462; Cao K, 2003, CELL, V115, P355, DOI 10.1016/S0092-8674(03)00815-8; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; Dalal S, 2004, MOL BIOL CELL, V15, P637, DOI 10.1091/mbc.E03-02-0097; Davies JM, 2005, STRUCTURE, V13, P183, DOI 10.1016/j.str.2004.11.014; Decottignies A, 2004, YEAST, V21, P127, DOI 10.1002/yea.1071; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; DeLaBarre B, 2006, MOL CELL, V22, P451, DOI 10.1016/j.molcel.2006.03.036; Dreveny I, 2004, EMBO J, V23, P1030, DOI 10.1038/sj.emboj.7600139; Gerega A, 2005, J BIOL CHEM, V280, P42856, DOI 10.1074/jbc.M510592200; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Lamb JR, 2001, J BIOL CHEM, V276, P21512, DOI 10.1074/jbc.M100235200; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Meyer HH, 2005, BBA-MOL CELL RES, V1744, P108, DOI 10.1016/j.bbamcr.2005.03.011; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; Rancour DM, 2004, J BIOL CHEM, V279, P54264, DOI 10.1074/jbc.M405498200; Rancour DM, 2002, PLANT PHYSIOL, V130, P1241, DOI 10.1104/pp.011742; Rienties IM, 2005, PLANTA, V221, P394, DOI 10.1007/s00425-004-1447-7; Rockel B, 2002, J MOL BIOL, V317, P673, DOI 10.1006/jmbi.2002.5448; Romisch K, 2006, TRENDS BIOCHEM SCI, V31, P24, DOI 10.1016/j.tibs.2005.11.004; Rouiller I, 2002, NAT STRUCT BIOL, V9, P950, DOI 10.1038/nsb872; Rouiller I, 2000, MOL CELL, V6, P1485, DOI 10.1016/S1097-2765(00)00144-1; Roy L, 2000, MOL BIOL CELL, V11, P2529, DOI 10.1091/mbc.11.8.2529; Schuberth C, 2005, NAT CELL BIOL, V7, P999, DOI 10.1038/ncb1299; Schuberth C, 2004, EMBO REP, V5, P818, DOI 10.1038/sj.embor.7400203; Song CC, 2003, J BIOL CHEM, V278, P3648, DOI 10.1074/jbc.M208422200; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wang Q, 2003, J BIOL CHEM, V278, P32784, DOI 10.1074/jbc.M303869200; Wang Q, 2003, BIOCHEM BIOPH RES CO, V300, P253, DOI 10.1016/S0006-291X(02)02840-1; Woodman PG, 2003, J CELL SCI, V116, P4283, DOI 10.1242/jcs.00817; Yamada K, 2003, SCIENCE, V302, P842, DOI 10.1126/science.1088305; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Yuan XM, 2001, J MOL BIOL, V311, P255, DOI 10.1006/jmbi.2001.4864; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	43	37	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5217	5224		10.1074/jbc.M609042200	http://dx.doi.org/10.1074/jbc.M609042200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17190830	hybrid			2022-12-25	WOS:000244482300016
J	Du, JX; Yun, CC; Bialkowska, A; Yang, VW				Du, James X.; Yun, C. Chris; Bialkowska, Agnieszka; Yang, Vincent W.			Protein inhibitor of activated STAT1 interacts with and up-regulates activities of the pro-proliferative transcription factor Kruppel-like factor 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR-5; RNA-POLYMERASE-II; INTERCHROMATIN GRANULE CLUSTERS; INTESTINAL EPITHELIAL-CELLS; TATA-BINDING PROTEIN; CELLULAR PROLIFERATION; DEOXYCYTIDINE KINASE; RIBONUCLEOPROTEIN F; SUMO-1 MODIFICATION; GENE-ACTIVATION	Kruppel-like factor 5 (KLF5) is a zinc finger-containing transcription factor that regulates proliferation of various cell types, including fibroblasts, smooth muscle cells, and intestinal epithelial cells. To identify proteins that interact with KLF5, we performed a yeast two-hybrid screen of a 17-day mouse embryo cDNA library with KLF5 as bait. The screen revealed 21 preys clustered in four groups as follows: proteins mediating gene expression, metabolism, trafficking, and signaling. Among them was protein inhibitor of activated STAT1(PIAS1), a small ubiquitin-like modifier (SUMO) ligase that regulates transcription factors through SUMOylation or physical interaction. Association between PIAS1 and KLF5 was verified by co-immunoprecipitation. Structural determination showed that the acidic domain of PIAS1 bound to both the amino- and carboxyl-terminal regions of KLF5 and that this interaction was inhibited by the amino terminus of PIAS1. Indirect immunofluorescence demonstrated that PIAS1 and KLF5 co-localized to the nucleus. Furthermore, the PIAS1-KLF5 complex was co-localized with the TATA-binding protein and was enriched in RNA polymerase II foci. Transient transfection of COS-7 cells by PIAS1 and KLF5 significantly increased the steady-state protein levels of each other. Luciferase reporter and chromatin immunoprecipitation assays showed that PIAS1 significantly activated the promoters of KLFS and PIAS1 and synergistically increased the transcriptional activity of KLF5 in activating the cyclin D1 and Cdc2 promoters. Importantly, PIAS1 increased the ability of KLF5 to enhance cell proliferation in transfected cells. These results indicate that PIAS1 is a functional partner of KLF5 and enhances the ability of KLF5 to promote proliferation.	Emory Univ, Sch Med, Div Digest Dis, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Hematol & Oncol, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Div Digest Dis, Dept Med, Atlanta, GA 30322 USA.	vyang@emory.edu			NCI NIH HHS [R01 CA084197-07, R01 CA084197, R01 CA084197-08, CA84197, R01 CA084197-09] Funding Source: Medline; NIDDK NIH HHS [R01 DK052230-11, R01 DK071597-01A2, R01 DK052230, R01 DK061418, R24 DK064399-03, R01 DK052230-09, R24 DK064399, R24 DK064399-04, R01 DK071597-02, R24 DK064399-05, DK64399, R01 DK071597, R01 DK061418-05, DK52230, R01 DK052230-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230, R01DK071597, R24DK064399, R01DK061418] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Antoine M, 2005, BIOCHEM BIOPH RES CO, V335, P146, DOI 10.1016/j.bbrc.2005.07.069; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Chanchevalap S, 2004, FEBS LETT, V578, P99, DOI 10.1016/j.febslet.2004.10.079; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Cromphout K, 2005, EUR J NEUROSCI, V22, P991, DOI 10.1111/j.1460-9568.2005.04266.x; Damen G, 2004, J PEDIATR GASTR NUTR, V38, P282, DOI 10.1097/00005176-200403000-00010; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dohmen RJ, 2004, BBA-MOL CELL RES, V1695, P113, DOI 10.1016/j.bbamcr.2004.09.021; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; ERIKSSON S, 1991, FEBS LETT, V280, P363, DOI 10.1016/0014-5793(91)80332-W; Ferrier V, 2002, NAT CELL BIOL, V4, pE57, DOI 10.1038/ncb0302-e57; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Gamachi A, 2003, MODERN PATHOL, V16, P1124, DOI 10.1097/01.MP.0000092953.20717.48; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Grishin NV, 2001, NUCLEIC ACIDS RES, V29, P638, DOI 10.1093/nar/29.3.638; Handwerger KE, 2003, J CELL BIOL, V160, P495, DOI 10.1083/jcb.200212024; Hari KL, 2001, GENE DEV, V15, P1334, DOI 10.1101/gad.877901; Hatzis P, 1998, J BIOL CHEM, V273, P30239, DOI 10.1074/jbc.273.46.30239; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Iborra FJ, 1996, J CELL SCI, V109, P1427; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kawai-Kowase K, 1999, CIRC RES, V85, P787, DOI 10.1161/01.RES.85.9.787; Kawai-Kowase K, 2005, MOL CELL BIOL, V25, P8009, DOI 10.1128/MCB.25.18.8009-8023.2005; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Komatsu T, 2004, MOL ENDOCRINOL, V18, P2451, DOI 10.1210/me.2004-0173; Lee YS, 2005, EMBO REP, V6, P949, DOI 10.1038/sj.embor.7400511; Liang M, 2004, J BIOL CHEM, V279, P22857, DOI 10.1074/jbc.M401554200; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liu B, 2004, NAT IMMUNOL, V5, P891, DOI 10.1038/ni1104; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu XQ, 2001, FEBS LETT, V490, P79, DOI 10.1016/S0014-5793(01)02134-2; Liu Y, 2003, J BIOL CHEM, V278, P48004, DOI 10.1074/jbc.M301902200; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Mintz PJ, 2000, J STRUCT BIOL, V129, P241, DOI 10.1006/jsbi.2000.4213; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Morikawa Y, 1998, BLOOD, V92, P129, DOI 10.1182/blood.V92.1.129.413k07_129_135; Munarriz E, 2004, MOL CELL BIOL, V24, P10593, DOI 10.1128/MCB.24.24.10593-10610.2004; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; Nandan MO, 2005, FEBS LETT, V579, P4757, DOI 10.1016/j.febslet.2005.07.053; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Nogami S, 2003, GENES CELLS, V8, P17, DOI 10.1046/j.1365-2443.2003.00612.x; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Okubo S, 2004, J BIOL CHEM, V279, P31455, DOI 10.1074/jbc.M403561200; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Pirard M, 1999, BIOCHEM J, V339, P201, DOI 10.1042/0264-6021:3390201; Prigge JR, 2006, J BIOL CHEM, V281, P12260, DOI 10.1074/jbc.M510835200; Saitoh N, 2004, MOL BIOL CELL, V15, P3876, DOI 10.1091/mbc.E04-03-0253; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Silins G, 1998, BIOCHEM BIOPH RES CO, V243, P273, DOI 10.1006/bbrc.1997.8091; Smith RK, 2002, DEVELOPMENT, V129, P71; Song J, 2005, J BIOL CHEM, V280, P40122, DOI 10.1074/jbc.M507059200; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; Watt AJ, 2001, MECH DEVELOP, V100, P205, DOI 10.1016/S0925-4773(00)00530-X; Whitney EM, 2006, GENE EXPRESSION, V13, P85, DOI 10.3727/000000006783991908; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Yoshida T, 1999, GENES CELLS, V4, P707, DOI 10.1046/j.1365-2443.1999.00295.x; Yoshida T, 1999, FEBS LETT, V457, P251, DOI 10.1016/S0014-5793(99)01048-0; Yu VWC, 2006, ANN NY ACAD SCI, V1068, P131, DOI 10.1196/annals.1346.027; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zhang QB, 2005, GENE, V348, P25, DOI 10.1016/j.gene.2004.12.050	85	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4782	4793		10.1074/jbc.M603413200	http://dx.doi.org/10.1074/jbc.M603413200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17178721	hybrid, Green Accepted			2022-12-25	WOS:000244482000060
J	Koide, K; Maegawa, S; Ito, K; Akiyama, Y				Koide, Kayo; Maegawa, Saki; Ito, Koreaki; Akiyama, Yoshinori			Environment of the active site region of RseP, an Escherichia coli regulated intramembrane proteolysis protease, assessed by site-directed cysteine alkylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; EXTRACYTOPLASMIC-STRESS-RESPONSE; GAMMA-SECRETASE COMPLEX; WATER-FILLED CHANNEL; ANTI-SIGMA FACTOR; PDZ DOMAIN; MEMBRANE; YAEL; CLEAVAGE; DEGRADATION	Regulated intramembrane proteolysis (RIP) plays crucial roles in both prokaryotic and eukaryotic organisms. Proteases for RIP cleave transmembrane regions of substrate membrane proteins. However, the molecular mechanisms for the proteolysis of membrane-embedded transmembrane sequences are largely unknown. Here we studied the environment surrounding the active site region of RseP, an Escherichia coli S2P ortholog involved in the sigma(E) pathway of extracytoplasmic stress responses. RseP has two presumed active site motifs, HEXXH and LDG, located in membrane-cytoplasm boundary regions. We examined the reactivity of cysteine residues introduced within or in the vicinity of these two active site motifs with membrane-impermeable thiol-alkylating reagents under various conditions. The active site positions were inaccessible to the reagents in the native state, but many of them became partially modifiable in the presence of a chaotrope, while requiring simultaneous addition of a chaotrope and a detergent for full modification. These results suggest that the active site of RseP is not totally embedded in the lipid phase but located within a proteinaceous structure that is partially exposed to the aqueous milieu.	Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan	Kyoto University	Akiyama, Y (corresponding author), Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan.	yakiyama@virus.kyoto-u.ac.jp						AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; Akiyama Y, 2004, EMBO J, V23, P4434, DOI 10.1038/sj.emboj.7600449; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; Alba BM, 2002, GENE DEV, V16, P2156, DOI 10.1101/gad.1008902; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Bohn C, 2004, MOL MICROBIOL, V52, P427, DOI 10.1111/j.1365-2958.2004.03985.x; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chen JC, 2005, MOL MICROBIOL, V55, P1085, DOI 10.1111/j.1365-2958.2004.04443.x; Davis R., 1980, ADV BACTERIAL GENETI; DeLasPenas A, 1997, MOL MICROBIOL, V24, P373, DOI 10.1046/j.1365-2958.1997.3611718.x; Ermolova N, 2006, BIOCHEMISTRY-US, V45, P4182, DOI 10.1021/bi052631h; Flynn JM, 2004, GENE DEV, V18, P2292, DOI 10.1101/gad.1240104; Grigorova IL, 2004, GENE DEV, V18, P2686, DOI 10.1101/gad.1238604; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Kanehara K, 2003, EMBO J, V22, P6389, DOI 10.1093/emboj/cdg602; Kanehara K, 2001, GENE, V281, P71, DOI 10.1016/S0378-1119(01)00823-X; Kanehara K, 2002, GENE DEV, V16, P2147, DOI 10.1101/gad.1002302; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura-Someya T, 1998, J BIOL CHEM, V273, P32806, DOI 10.1074/jbc.273.49.32806; Kinch LN, 2006, PROTEIN SCI, V15, P84, DOI 10.1110/ps.051766506; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kuwabara N, 2004, J BIOL CHEM, V279, P40567, DOI 10.1074/jbc.M401132200; Lazarov VK, 2006, P NATL ACAD SCI USA, V103, P6889, DOI 10.1073/pnas.0602321103; Makinoshima H, 2006, MICROBES INFECT, V8, P1882, DOI 10.1016/j.micinf.2006.02.021; Matson JS, 2005, P NATL ACAD SCI USA, V102, P16403, DOI 10.1073/pnas.0505818102; Missiakas D, 1997, MOL MICROBIOL, V24, P355, DOI 10.1046/j.1365-2958.1997.3601713.x; Ogura T, 2006, BIOCHEM BIOPH RES CO, V343, P525, DOI 10.1016/j.bbrc.2006.02.158; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rudner DZ, 1999, P NATL ACAD SCI USA, V96, P14765, DOI 10.1073/pnas.96.26.14765; Sato C, 2006, J NEUROSCI, V26, P12081, DOI 10.1523/JNEUROSCI.3614-06.2006; SAWANO A, 2000, NUCLEIC ACIDS RES, V28, P78, DOI DOI 10.1093/NAR/28.16.E78; Schobel S, 2004, MOL MICROBIOL, V52, P1091, DOI 10.1111/j.1365-2958.2004.04031.x; Tolia A, 2006, J BIOL CHEM, V281, P27633, DOI 10.1074/jbc.M604997200; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; Wang YC, 2006, NATURE, V444, P179, DOI 10.1038/nature05255; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wu ZR, 2006, NAT STRUCT MOL BIOL, V13, P1084, DOI 10.1038/nsmb1179; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7	41	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4553	4560		10.1074/jbc.M607339200	http://dx.doi.org/10.1074/jbc.M607339200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17179147	hybrid			2022-12-25	WOS:000244482000037
J	Yang, YZ; Goldstein, BG; Nakagawa, H; Katz, JP				Yang, Yizeng; Goldstein, Bree G.; Nakagawa, Hiroshi; Katz, Jonathan P.			Kruppel-like factor 5 activates MEK/ERK signaling via EGFR in primary squamous epithelial cells	FASEB JOURNAL			English	Article						keratinocytes; proliferation	KRUPPEL-LIKE FACTOR-5; EPIDERMAL-GROWTH-FACTOR; KLF5 TRANSCRIPTION FACTOR; ESOPHAGEAL KERATINOCYTES; STEM-CELLS; RECEPTOR; EXPRESSION; CANCER; PROLIFERATION; REGULATOR	Rapid cell proliferation is a hallmark of transit amplifying cells, but the mechanisms of this localized proliferation are not well understood. The Kruppel-like factor family member Klf5 (IKLF; BTEB2) promotes cell proliferation and is highly expressed in squamous epithelia, in regions of active proliferation. Here, using mouse primary esophageal keratinocytes as a model, we identify a critical role for Klf5 in regulating squamous epithelial proliferation via the epidermal growth factor receptor (EGFR), which, like Klf5, is localized to basal cells in squamous epithelia. We show that Klf5 increases proliferation, transcriptionally upregulates EGFR, and activates MEK/ERK signaling, as indicated by increased phosphorylation of MEK and ERK. By chromatin immunoprecipitation, we demonstrate that Klf5 binds directly to the 5' regulatory region of EGFR. In addition, we show that regulation of proliferation by Klf5 is dependent on EGFR and MEK/ ERK signaling, as the proliferative response to Klf5 is blocked by pharmacologic inhibition of EGFR or MEK. Inhibition of EGFR or MEK also decreases Klf5 expression. Thus, Klf5 regulates MEK/ERK signaling via EGFR and is also downstream of MAPK signaling, providing a novel mechanism for signal amplification or suppression and control of proliferation in basal cells.	Univ Penn, Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA	University of Pennsylvania	Katz, JP (corresponding author), Univ Penn, Sch Med, Dept Med, Div Gastroenterol, 600 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	jpkatz@mail.med.upenn.edu			NCI NIH HHS [P01-CA098101] Funding Source: Medline; NIDDK NIH HHS [P30 DK050306, R21 DK073888] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA098101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK073888, P30DK050306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALYASSIN TM, 1977, J ANAT, V123, P705; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Calabro A, 1997, HISTOCHEM J, V29, P745, DOI 10.1023/A:1026469219190; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen CH, 2006, INT J CANCER, V118, P1346, DOI 10.1002/ijc.21533; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Dikic I, 2003, BIOCHEM SOC T, V31, P1178; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Fujiwara Y, 2002, ALIMENT PHARM THERAP, V16, P52, DOI 10.1046/j.1365-2036.16.s2.29.x; Goessel G, 2005, P NATL ACAD SCI USA, V102, P15599, DOI 10.1073/pnas.0409730102; Harada H, 2003, MOL CANCER RES, V1, P729; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Karam Sherif M., 1999, Frontiers in Bioscience, V4, pD286, DOI 10.2741/Karam; Katz JP, 2002, GASTROENTEROL CLIN N, V31, P379, DOI 10.1016/S0889-8553(02)00006-7; Mandard AM, 2000, MUTAT RES-REV MUTAT, V462, P335, DOI 10.1016/S1383-5742(00)00019-3; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nandan MO, 2005, FEBS LETT, V579, P4757, DOI 10.1016/j.febslet.2005.07.053; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Ohlstein B, 2004, CURR OPIN CELL BIOL, V16, P693, DOI 10.1016/j.ceb.2004.09.003; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005; Pandey PK, 2005, MOL CELL BIOL, V25, P10695, DOI 10.1128/MCB.25.24.10695-10710.2005; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seery JP, 2002, J CELL SCI, V115, P1783; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Takaoka M, 2004, CANCER RES, V64, P7711, DOI 10.1158/0008-5472.CAN-04-0715; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Usui S, 2004, J BIOL CHEM, V279, P12300, DOI 10.1074/jbc.M305025200; Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090	40	66	69	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					543	550		10.1096/fj.06-6694com	http://dx.doi.org/10.1096/fj.06-6694com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158781				2022-12-25	WOS:000244686300027
J	Cochrane, DR; Wang, Z; Muramaki, M; Gleave, ME; Nelson, CC				Cochrane, Dawn R.; Wang, Zhou; Muramaki, Motosugu; Gleave, Martin E.; Nelson, Colleen C.			Differential regulation of clusterin and its Isoforms by androgens in prostate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRAL PROSTATE; STEROID-HORMONE RECEPTORS; BREAST-CANCER CELLS; GROWTH-FACTOR-BETA; RETE TESTIS FLUID; GENE-EXPRESSION; EPITHELIAL-CELLS; IN-VITRO; ANTISENSE OLIGONUCLEOTIDES; MEDIATED APOPTOSIS	Clusterin mRNA levels were shown to increase dramatically in rat ventral prostate following castration, and clusterin was therefore originally thought to be repressed by androgens. It was later discovered that the increased clusterin levels are most likely due to castration-induced apoptosis of the prostatic epithelium rather than direct action of the androgen receptor (AR). In the studies presented here, LNCaP cells in culture and rat prostate organ culture were treated with androgens. Clusterin mRNA and protein are shown to increase with androgen treatment in a time- and dose-dependent manner. This induction of clusterin requires AR and can be inhibited by casodex, an AR antagonist. We have found that the first intron of the clusterin gene contains putative androgen response elements. The intronic region is shown to be bound by AR in chromatin immunoprecipitation assays and is transactivated by AR in reporter assays. Two isoforms of clusterin result from alternate transcriptional start sites. Both isoforms are cytoprotective; however, Isoform 1 has the capacity to produce a splice variant that is apoptotic. Real time PCR was used to determine the response of the two isoforms to androgens. Intriguingly, these results illustrated that Isoform 2 was up-regulated, whereas Isoform 1 was down-regulated by androgens. Isoform 2 was also increased as the LNCaP xenograft tumor progressed to androgen-independence, whereas Isoform 1 was unaltered. This androgen regulation of clusterin may underline the cytoprotective role of androgens in normal prostate physiology as well as play an antiapoptotic role in prostate cancer progression.	VGH, Prostate Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Genet, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Urol Sci, Vancouver, BC V6T 1Z3, Canada; Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA 15232 USA	University of British Columbia; University of British Columbia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Nelson, CC (corresponding author), VGH, Prostate Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	colleen.nelson@ubc.ca						AHUJA HS, 1994, BIOCHEM CELL BIOL, V72, P523, DOI 10.1139/o94-070; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERCHEM GJ, 1995, CANCER RES, V55, P735; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; Buchanan G, 2001, CANCER METAST REV, V20, P207, DOI 10.1023/A:1015531326689; BURKEY BF, 1992, J LIPID RES, V33, P1517; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; Caccamo AE, 2003, ANN NY ACAD SCI, V1010, P514, DOI 10.1196/annals.1299.095; Carson JP, 1999, CANCER RES, V59, P1449; Coffey RNT, 2002, PROSTATE, V53, P300, DOI 10.1002/pros.10159; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; DVERGSTEN J, 1994, KIDNEY INT, V45, P828, DOI 10.1038/ki.1994.109; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; FREEMAN AE, 1986, P NATL ACAD SCI USA, V83, P2694, DOI 10.1073/pnas.83.8.2694; FRENCH LE, 1992, J CLIN INVEST, V90, P1919, DOI 10.1172/JCI116069; FRENCH LE, 1994, J CLIN INVEST, V93, P877, DOI 10.1172/JCI117043; FRITZ IB, 1983, BIOL REPROD, V28, P1173, DOI 10.1095/biolreprod28.5.1173; Gelissen IC, 1998, BIOCHEM J, V331, P231, DOI 10.1042/bj3310231; Gleave ME, 2001, UROLOGY, V58, P39, DOI 10.1016/S0090-4295(01)01241-9; Gleave ME, 2002, INVEST NEW DRUG, V20, P145, DOI 10.1023/A:1015694802521; GLEAVE ME, 1992, CANCER RES, V52, P1598; Gutacker C, 1999, BIOCHEM J, V339, P759, DOI 10.1042/0264-6021:3390759; Heikaus S, 2002, J MOL ENDOCRINOL, V29, P239, DOI 10.1677/jme.0.0290239; Hough CD, 2001, CANCER RES, V61, P3869; James SY, 1996, J STEROID BIOCHEM, V58, P395, DOI 10.1016/0960-0760(96)00048-9; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; Jin G, 1999, EUR J BIOCHEM, V263, P534, DOI 10.1046/j.1432-1327.1999.00533.x; July LV, 2002, PROSTATE, V50, P179, DOI 10.1002/pros.10047; Kimura K, 2001, CANCER RES, V61, P5611; Lee C, 2000, PROSTATE, P21; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; LEGER JG, 1988, PROSTATE, V13, P131, DOI 10.1002/pros.2990130205; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P1268, DOI 10.1210/endo-127-3-1268; Michel D, 1997, BIOCHEM J, V328, P45, DOI 10.1042/bj3280045; Miyake H, 2000, CANCER RES, V60, P170; Miyake H, 2001, MOL UROL, V5, P105, DOI 10.1089/10915360152559585; MONTPETIT ML, 1986, PROSTATE, V8, P25, DOI 10.1002/pros.2990080105; Pewitt EB, 1999, ENDOCRINOLOGY, V140, P2382, DOI 10.1210/en.140.5.2382; Poon S, 2000, BIOCHEMISTRY-US, V39, P15953, DOI 10.1021/bi002189x; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Reid KJ, 2001, J BIOL CHEM, V276, P2943, DOI 10.1074/jbc.M009170200; RENNIE PS, 1994, J STEROID BIOCHEM, V50, P31, DOI 10.1016/0960-0760(94)90169-4; RENNIE PS, 1988, CANCER RES, V48, P6309; RENNIE PS, 1989, MOL ENDOCRINOL, V3, P703, DOI 10.1210/mend-3-4-703; ROSEMBLIT N, 1994, J MOL ENDOCRINOL, V13, P69, DOI 10.1677/jme.0.0130069; ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pW249, DOI 10.1093/nar/gkh372; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Silkensen JR, 1995, J CLIN INVEST, V96, P2646, DOI 10.1172/JCI118330; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; Steinberg J, 1997, CLIN CANCER RES, V3, P1707; SYLVESTER SR, 1991, BIOL REPROD, V45, P195, DOI 10.1095/biolreprod45.1.195; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Waters KM, 2001, TOXICOL SCI, V63, P47, DOI 10.1093/toxsci/63.1.47; WONG P, 1994, EUR J BIOCHEM, V221, P917, DOI 10.1111/j.1432-1033.1994.tb18807.x; WONG P, 1993, J BIOL CHEM, V268, P5021; WONG P, 1994, BIOCHEM CELL BIOL, V72, P439, DOI 10.1139/o94-058; Wunsche W, 1998, INT J CANCER, V76, P684; Xie MJ, 2002, PANCREAS, V25, P234, DOI 10.1097/00006676-200210000-00004; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Yeung LHY, 2003, BIOCHEM J, V371, P843, DOI 10.1042/BJ20021816; Zellweger T, 2002, CLIN CANCER RES, V8, P3276; Zhang Q, 2006, BJU INT, V98, P452, DOI 10.1111/j.1464-410X.2006.06263.x; Zhu N, 1998, ENDOCRINOLOGY, V139, P4337, DOI 10.1210/en.139.10.4337	66	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2278	2287		10.1074/jbc.M608162200	http://dx.doi.org/10.1074/jbc.M608162200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17148459	Green Published, hybrid			2022-12-25	WOS:000243593200019
J	Lemjabbar-Alaoui, H; Dasari, V; Sidhu, SS; Mengistab, A; Finkbeiner, W; Gallup, M; Basbaum, C				Lemjabbar-Alaoui, Hassan; Dasari, Vijay; Sidhu, Sukhvinder S.; Mengistab, Aklilu; Finkbeiner, Walter; Gallup, Marianne; Basbaum, Carol			Wnt and Hedgehog Are Critical Mediators of Cigarette Smoke-Induced Lung Cancer	PLOS ONE			English	Article								Background. Lung cancer is the leading cause of cancer death in the world, and greater than 90% of lung cancers are cigarette smoke-related. Current treatment options are inadequate, because the molecular basis of cigarette-induced lung cancer is poorly understood. Methodology/Principal Findings. Here, we show that human primary or immortalized bronchial epithelial cells exposed to cigarette smoke for eight days in culture rapidly proliferate, show anchorage-independent growth, and form tumors in nude mice. Using this model of the early stages of smoke-induced tumorigenesis, we examined the molecular changes leading to lung cancer. We observed that the embryonic signaling pathways mediated by Hedgehog and Wnt are activated by smoke. Pharmacological inhibition of these pathways blocked the transformed phenotype. Conclusions/Significance. These experiments provide a model in which the early stages of smoke-induced tumorigenesis can be elicited, and should permit us to identify molecular changes driving this process. Results obtained so far indicate that smoke-induced lung tumors are driven by activation of two embryonic regulatory pathways, Hedgehog (Hh) and Wnt. Based on the current and emerging availability of drugs to inhibit Hh and Wnt signaling, it is possible that an understanding of the role of Hh and Wnt in lung cancer pathogenesis will lead to the development of new therapies.	[Lemjabbar-Alaoui, Hassan; Dasari, Vijay; Sidhu, Sukhvinder S.; Mengistab, Aklilu; Gallup, Marianne; Basbaum, Carol] Univ Calif San Francisco, Cardiovasc Res Inst, Program Biomed Sci, San Francisco, CA 94143 USA; [Lemjabbar-Alaoui, Hassan; Dasari, Vijay; Sidhu, Sukhvinder S.; Mengistab, Aklilu; Gallup, Marianne; Basbaum, Carol] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [Sidhu, Sukhvinder S.] Univ Calif San Francisco, Div Pulm & Crit Care, Dept Med, San Francisco, CA 94143 USA; [Sidhu, Sukhvinder S.] Univ Calif San Francisco, Div Allergy Immunol, Dept Med, San Francisco, CA 94143 USA; [Finkbeiner, Walter] San Francisco Gen Hosp, Dept Anat Pathol, San Francisco, CA 94110 USA; [Finkbeiner, Walter] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California Davis	Lemjabbar-Alaoui, H (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Program Biomed Sci, San Francisco, CA 94143 USA.	Hassan.alaoui@yahoo.com		Sidhu, Sukhvinder/0000-0002-2999-4358	National Institutes of Health [R01 HL075602, P01 HL024136]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075602, P01HL024136] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by grants R01 HL075602 and P01 HL024136 from the National Institutes of Health.	Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Boon EMJ, 2002, CANCER RES, V62, P5126; Clark AT, 2004, HUM MOL GENET, V13, P727, DOI 10.1093/hmg/ddh088; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Fujita E, 1997, BIOCHEM BIOPH RES CO, V238, P658, DOI 10.1006/bbrc.1997.7262; HAN W, 2005, MOL CARCINOG; Hecht SS, 2005, CARCINOGENESIS, V26, P1488, DOI 10.1093/carcin/bgi148; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kim Y, 2006, CANCER LETT, V234, P209, DOI 10.1016/j.canlet.2005.03.052; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Polakis P, 2000, GENE DEV, V14, P1837; Proctor RN, 2001, NAT REV CANCER, V1, P82, DOI 10.1038/35094091; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Schuller HM, 2005, LUNG CANCER, V49, P35, DOI 10.1016/j.lungcan.2004.12.012; Shapiro SD, 2004, AM J RESP CELL MOL, V31, P481, DOI 10.1165/rcmb.F285; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Uren A, 2005, CANCER RES, V65, P6199, DOI 10.1158/0008-5472.CAN-05-0455; van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Vassallo R, 2005, J IMMUNOL, V175, P2684, DOI 10.4049/jimmunol.175.4.2684; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wetmore C, 2003, CURR OPIN GENET DEV, V13, P34, DOI 10.1016/S0959-437X(03)00002-9; *WHO, 2000, 11 C TOB OR HLTH; Witschi H, 1997, CARCINOGENESIS, V18, P2035, DOI 10.1093/carcin/18.11.2035; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219	31	90	93	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e93	10.1371/journal.pone.0000093	http://dx.doi.org/10.1371/journal.pone.0000093			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183725	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443600092
J	Nahrendorf, M; Weissleder, R; Ertl, G				Nahrendorf, Matthias; Weissleder, Ralph; Ertl, Georg			Does FXIII Deficiency Impair Wound Healing after Myocardial Infarction?	PLOS ONE			English	Article								Inadequate healing of myocardial infarction may contribute to local expansion of the infarct, frequently leading to chamber dilation, heart failure, or myocardial rupture. Experimental evidence in mouse models suggests that Factor XIII might play a key role in wound healing, and low persistent values lead to increased incidence of cardiac rupture following myocardial infarction. Here we would like to share our initial clinical experiences with strikingly similar observations in patients with this grave disease, and compare these observations to experimental findings.	[Nahrendorf, Matthias; Ertl, Georg] Univ Wurzburg, Med Klin & Poliklin 1, Wurzburg, Germany; [Nahrendorf, Matthias; Weissleder, Ralph] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA USA	University of Wurzburg; Harvard University; Massachusetts General Hospital	Ertl, G (corresponding author), Univ Wurzburg, Med Klin & Poliklin 1, Wurzburg, Germany.	Ertl_G@medizin.uni-wuerzburg.de		/0000-0003-0828-4143				GAUDRON P, 1993, CIRCULATION, V87, P755, DOI 10.1161/01.CIR.87.3.755; Inbal A, 2005, THROMB HAEMOSTASIS, V94, P432, DOI 10.1160/TH05-04-0291; Nahrendorf M, 2006, CIRCULATION, V113, P1196, DOI 10.1161/CIRCULATIONAHA.105.602094	3	16	17	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e48	10.1371/journal.pone.0000048	http://dx.doi.org/10.1371/journal.pone.0000048			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183677	Green Published, gold			2022-12-25	WOS:000207443600048
J	Zhu, JC; Jambhekar, A; Sarver, A; DeRisi, J				Zhu, Jingchun; Jambhekar, Ashwini; Sarver, Aaron; DeRisi, Joseph			A Bayesian Network Driven Approach to Model the Transcriptional Response to Nitric Oxide in Saccharomyces cerevisiae	PLOS ONE			English	Article							GENE-EXPRESSION; NITROSATIVE STRESS; REACTIVE OXYGEN	The transcriptional response to exogenously supplied nitric oxide in Saccharomyces cerevisiae was modeled using an integrated framework of Bayesian network learning and experimental feedback. A Bayesian network learning algorithm was used to generate network models of transcriptional output, followed by model verification and revision through experimentation. Using this framework, we generated a network model of the yeast transcriptional response to nitric oxide and a panel of other environmental signals. We discovered two environmental triggers, the diauxic shift and glucose repression, that affected the observed transcriptional profile. The computational method predicted the transcriptional control of yeast flavohemoglobin YHB1 by glucose repression, which was subsequently experimentally verified. A freely available software application, ExpressionNet, was developed to derive Bayesian network models from a combination of gene expression profile clusters, genetic information and experimental conditions.	[Zhu, Jingchun; Jambhekar, Ashwini; Sarver, Aaron; DeRisi, Joseph] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; [DeRisi, Joseph] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	DeRisi, J (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	joe@derisilab.ucsf.edu		Jambhekar, Ashwini/0000-0003-1078-6601	Burroughs Wellcome Fund; National Science Foundation; David and Lucile Packard Foundation; Howard Hughes Medical Institute	Burroughs Wellcome Fund(Burroughs Wellcome Fund); National Science Foundation(National Science Foundation (NSF)); David and Lucile Packard Foundation(The David & Lucile Packard Foundation); Howard Hughes Medical Institute(Howard Hughes Medical Institute)	This work was supported by the Burroughs Wellcome Fund (JZ, JDR), the National Science Foundation (AJ), the David and Lucile Packard Foundation (AS, JDR), and the Howard Hughes Medical Institute (JDR).	Beer MA, 2004, CELL, V117, P185, DOI 10.1016/S0092-8674(04)00304-6; BROACH JR, 1991, MOL CELLULAR BIOL YE, pR5; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fang FC, 2004, NAT REV MICROBIOL, V2, P820, DOI 10.1038/nrmicro1004; FANG FC, 1999, NITRIC OXIDE INFECT, pR25; Friedman N, 2000, J COMPUT BIOL, V7, P601, DOI 10.1089/106652700750050961; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Hartemink A J, 2001, Pac Symp Biocomput, P422; HECKERMAN D, 1995, MACH LEARN, V20, P197, DOI 10.1007/BF00994016; Heckerman D., 1999, LEARNING GRAPHICAL M, P301; Hoeting JA, 1999, STAT SCI, V14, P382, DOI 10.1214/ss/1009212519; HROMATKA BS, 2005, MOL BIOL CELL; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; JORDAN MI, 1999, LEARNING GRAPHICAL M, pR7; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; Missall TA, 2004, EUKARYOT CELL, V3, P835, DOI 10.1128/EC.3.4.835-846.2004; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; NITTLER MP, 2005, MOL BIOL CELL; Pe'er D, 2001, Bioinformatics, V17 Suppl 1, pS215; PEARL J, 1988, PROBABILISTIC REASON, pR19; Sachs K, 2005, SCIENCE, V308, P523, DOI 10.1126/science.1105809; SARVER A, 2005, MOL BIOL CELL; Segal E, 2003, BIOINFORMATICS, V19, pi273, DOI 10.1093/bioinformatics/btg1038; Segal E, 2003, NAT GENET, V34, P166, DOI 10.1038/ng1165; SEGAL E, 2003, BIOINFORMATICS, V1, P1; Shiloh MU, 2000, CURR OPIN MICROBIOL, V3, P35, DOI 10.1016/S1369-5274(99)00048-X; Zhao XJ, 1996, J BIOL CHEM, V271, P25131, DOI 10.1074/jbc.271.41.25131	28	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e94	10.1371/journal.pone.0000094	http://dx.doi.org/10.1371/journal.pone.0000094			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183726	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600093
J	Yoo, YG; Na, TY; Yang, WK; Kim, HJ; Lee, IK; Kong, G; Chung, JH; Lee, MO				Yoo, Y-G; Na, T-Y; Yang, W-K; Kim, H-J; Lee, I-K; Kong, G.; Chung, J-H; Lee, M-O			6-Mercaptopurine, an activator of Nur77, enhances transcriptional activity of HIF-1 alpha resulting in new vessel formation	ONCOGENE			English	Article						6-mercaptopurine; Nur77; hypoxia-inducible factor-1 alpha; vascular endothelial growth factor	HYPOXIA-INDUCIBLE-FACTOR; UBIQUITIN-PROTEASOME PATHWAY; VASCULAR ENDOTHELIAL-CELLS; SERUM GROWTH-FACTORS; ORPHAN RECEPTOR TR3; NUCLEAR RECEPTOR; PROTEIN-KINASE; FACTOR 1-ALPHA; NGFI-B; EXPRESSION	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) plays a central role in oxygen homeostasis. Previously, we reported that the orphan nuclear receptor Nur77 functions in stabilizing HIF-1 alpha. Here, we demonstrate that 6-mercaptopurine (6-MP), an activator of the NR4A family members, enhances transcriptional activity of HIF-1. 6-MP enhanced the protein-level of HIF-1 alpha as well as vascular endothelial growth factor (VEGF) in a dose- and time-dependent manner. The induction of HIF-1 alpha was abolished by the transfection of either a dominant-negative Nur77 mutant or si-Nur77, indicating a critical role of Nur77 in the 6-MP action. The HIF-1 alpha protein level remained up to 60 min in the presence of 6-MP when de novo protein synthesis was blocked by cycloheximide, suggesting that 6-MP induces stabilization of the HIF-1 alpha protein. The fact that 6-MP decreased the association of HIF-1 alpha with von Hippel - Lindau protein and the acetylation of HIF-1 alpha, may explain how 6-MP induced stability of HIF-1 alpha. Further, 6-MP induced the transactivation function of HIF-1 alpha by recruiting co-activator cyclic-AMP-response-element- binding protein. Finally, 6-MP enhanced the expression of HIF-1 alpha and VEGF, and the formation of capillary tubes in human umbilical vascular endothelial cells. Together, our results provide a new insight for 6-MP action in the stabilization of HIF-1a and imply a potential application of 6-MP in hypoxia-associated human vascular diseases.	Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; Seoul Natl Univ, Bio MAX Inst, Seoul 151742, South Korea; Hanyang Univ, Coll Med, Dept Pathol, Seoul 133791, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Taegu, South Korea	Seoul National University (SNU); Seoul National University (SNU); Hanyang University; Kyungpook National University	Lee, MO (corresponding author), Seoul Natl Univ, Coll Pharm, San 56-1 Shillim Dong, Seoul 151742, South Korea.	molee@snu.ac.kr	Lee, In-Kyu/AAR-6374-2021					Aarbakke J, 1997, TRENDS PHARMACOL SCI, V18, P3, DOI 10.1016/S0165-6147(96)01007-3; Arkenbout EK, 2003, ARTERIOSCL THROM VAS, V23, P1535, DOI 10.1161/01.ATV.0000084639.16462.7A; Arkenbout EK, 2002, CIRCULATION, V106, P1530, DOI 10.1161/01.CIR.0000028811.03056.BF; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bilton R, 2005, J BIOL CHEM, V280, P31132, DOI 10.1074/jbc.M504482200; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chintharlapalli S, 2005, J BIOL CHEM, V280, P24903, DOI 10.1074/jbc.M500107200; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Cuenda A, 2000, METH MOL B, V99, P161; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Erez N, 2003, CANCER RES, V63, P8777; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; Gruber F, 2003, BLOOD, V101, P3042, DOI 10.1182/blood-2002-07-2331; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; Hsu Hui-Chen, 2004, Current Drug Targets - Inflammation and Allergy, V3, P413, DOI 10.2174/1568010042634523; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kim SH, 2006, BIOCHEM BIOPH RES CO, V340, P422, DOI 10.1016/j.bbrc.2005.12.018; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Kong TQ, 2004, P NATL ACAD SCI USA, V101, P10440, DOI 10.1073/pnas.0401339101; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li MH, 2004, CLIN CANCER RES, V10, P8266, DOI 10.1158/1078-0432.CCR-04-0951; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Maddika S, 2005, J CELL SCI, V118, P4485, DOI 10.1242/jcs.02580; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Martinez-Gonzalez J, 2005, CARDIOVASC RES, V65, P609, DOI 10.1016/j.cardiores.2004.10.002; Martinez-Gonzalez J, 2003, CIRC RES, V92, P96, DOI 10.1161/01.ES.0000050921.53008.47; Murphy EP, 2001, ARTHRITIS RHEUM-US, V44, P782, DOI 10.1002/1529-0131(200104)44:4<782::AID-ANR134>3.3.CO;2-8; MURRAY JE, 1963, NEW ENGL J MED, V268, P1315, DOI 10.1056/NEJM196306132682401; Ordentlich P, 2003, J BIOL CHEM, V278, P24791, DOI 10.1074/jbc.M302167200; RICHTER JE, 1999, CLIN PRACTICE GASTRO, V1, P1; Rius J, 2006, ATHEROSCLEROSIS, V184, P276, DOI 10.1016/j.atherosclerosis.2005.04.008; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tiede I, 2003, J CLIN INVEST, V111, P1133, DOI 10.1172/JCI200316432; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wansa KDSA, 2003, J BIOL CHEM, V278, P24776, DOI 10.1074/jbc.M300088200; Weigel G, 1999, THROMB RES, V94, P87, DOI 10.1016/S0049-3848(98)00199-6; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; Winoto A, 1997, Semin Immunol, V9, P51, DOI 10.1006/smim.1996.0053; Yoo YG, 2004, J BIOL CHEM, V279, P53365, DOI 10.1074/jbc.M408554200; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhang QZ, 2005, MOL CANCER THER, V4, P1465, DOI 10.1158/1535-7163.MCT-05-0198; Zhou T, 1996, J EXP MED, V183, P1879, DOI 10.1084/jem.183.4.1879	57	35	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3823	3834		10.1038/sj.onc.1210149	http://dx.doi.org/10.1038/sj.onc.1210149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17146432				2022-12-25	WOS:000247026400006
J	Burwell, EA; McCarty, GP; Simpson, LA; Thompson, KA; Loeb, DM				Burwell, E. A.; McCarty, G. P.; Simpson, L. A.; Thompson, K. A.; Loeb, D. M.			Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells	ONCOGENE			English	Article						breast cancer; oncogene; epithelial-mesenchymal transition; cell cycle; alternative splicing	BREAST-CANCER; EXPRESSION; DIFFERENTIATION; TRANSCRIPTION; INTERACTS; PRODUCT; TARGET; EXON; DNA	The role of WT1 (Wilm's tumor suppressor gene) in breast cancer is controversial, with evidence for both tumor-promoting and tumor-suppressing activities. In order to address this question, we expressed different WT1 isoforms in the mammary epithelial cell line H16N-2, which does not express endogenous WT1. Cells were stably transfected with either WT1 (- Ex5/ - KTS) or WT1 ( + Ex5/ + KTS) under the control of the inducible metallothionein promoter. Induction of WT1 (- Ex5/ - KTS) upregulated p21, causing a slowing of proliferation and a G2-phase cell cycle arrest. In artificial basement membrane, the WT1 (- Ex5/ - KTS) isoform promoted the appearance of highly organized acinar cellular aggregates. In contrast, WT1 (+ Ex5/ + KTS) had no effect on p21 or proliferation, but rather caused an epithelial-mesenchymal transition and a redistribution of E-cadherin from the cell membrane to the cytoplasm. This isoform also causes the cellular aggregates growing in artificial basement membrane to appear significantly less organized than control cells. Thus, different WT1 isoforms have distinct effects in this cell line, suggesting that depending on the ratio of WT1 isoform expression in mammary epithelial cells, WT1 could function to either promote or suppress a transformed phenotype.	Johns Hopkins Univ, Div Pediat Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Loeb, DM (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Sidney Kimmel Comprehens Canc Ctr, Bunting Blaustein Canc Res Bldg, Baltimore, MD 21231 USA.	dmloeb@jhmi.edu			NATIONAL CANCER INSTITUTE [T32CA060441] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA60441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Englert C, 1997, CANCER RES, V57, P1429; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Hewitt SM, 1996, ANTICANCER RES, V16, P621; Inoue K, 1998, BLOOD, V91, P2969, DOI 10.1182/blood.V91.8.2969.2969_2969_2976; KOLCH W, 1995, BREAST CANCER RES TR, V36, P139, DOI 10.1007/BF00666036; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LO HW, 2005, BREAST CANC RES TREA, V95, P1; Loeb DM, 2001, CANCER RES, V61, P921; Loeb DM, 2006, CELL CYCLE, V5, P1249, DOI 10.4161/cc.5.12.2807; Loeb DM, 2003, LEUKEMIA, V17, P965, DOI 10.1038/sj.leu.2402906; Loeb DM, 2002, J BIOL CHEM, V277, P19627, DOI 10.1074/jbc.M201336200; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; Natoli TA, 2002, MOL CELL BIOL, V22, P4433, DOI 10.1128/MCB.22.12.4433-4438.2002; Reizner N, 2005, J MOL ENDOCRINOL, V35, P135, DOI 10.1677/jme.1.01761; Reynolds PA, 2003, GENE DEV, V17, P2094, DOI 10.1101/gad.1110703; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026; Velona T, 1999, PEDIATR RES, V45, P658, DOI 10.1203/00006450-199905010-00008; Zapata-Benavides P, 2002, BIOCHEM BIOPH RES CO, V295, P784, DOI 10.1016/S0006-291X(02)00751-9; Zhang TF, 2003, ANTICANCER RES, V23, P3575	24	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2007	26	23					3423	3430		10.1038/sj.onc.1210127	http://dx.doi.org/10.1038/sj.onc.1210127			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17160023				2022-12-25	WOS:000246579600012
J	Kurbanov, BM; Fecker, LF; Geilen, CC; Sterry, W; Eberle, J				Kurbanov, B. M.; Fecker, L. F.; Geilen, C. C.; Sterry, W.; Eberle, J.			Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappa B but is related to downregulation of initiator caspases and DR4	ONCOGENE			English	Article						melanoma; apoptosis; TRAIL; TRAIL-R1/DR4; initiator caspases	APOPTOSIS-INDUCING LIGAND; CANCER-CELLS; (TRAIL)-INDUCED APOPTOSIS; DEATH RECEPTORS; MALIGNANT-MELANOMA; CARCINOMA CELLS; IN-VIVO; PROTEASOME; EXPRESSION; OVERCOMES	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted considerable attention as a novel anticancer agent. However, its efficiency may be diminished by occurring resistance in cancer cells. The mechanisms of TRAIL resistance in melanoma are still unsolved. Here we show for the first time that TRAIL-induced activation of NF-kappa B occurs in apoptosis-sensitive melanoma cell lines through TRAIL receptor 1/death receptor 4 (TRAIL-R1/DR4), whereas TRAIL failed to activate nuclear factor kappa B (NF-kappa B) in melanoma cells positive only for TRAIL receptor 2/death receptor 5 (TRAIL-R2/DR5). However, activation of NF-kappa B by TRAIL was not associated with enhanced expression of antiapoptotic factors: cellular FLICE-inhibitory protein (c-FLIP), Bcl-X-L, X-linked inhibitor of apoptosis protein (XIAP), Survivin, Livin. Rather in one of the cell lines, TRAIL induced the downregulation of DR4. In an established cell culture model for TRAIL resistance and regained TRAIL sensitivity, resistance was neither associated with increased NF-kappa B activity by TRAIL nor by an increased expression of antiapoptotic proteins. However, significant downregulation of caspase-8, caspase-10 and of DR4 was characteristic for TRAIL-resistant, DR4-positive melanoma cells, and regained TRAIL sensitivity coincided with re-expression of these factors. Sensitivity was also largely retained after their exogenous overexpression. Thus, initiator caspases and DR4 rather than NF-kappa B may control melanoma cell sensitivity to TRAIL, and strategies, which result in their upregulation, may be useful for enhancement of TRAIL sensitivity.	Univ Med Berlin, Skin Canc Ctr, Dept Dermatol & Allergy, D-12203 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Eberle, J (corresponding author), Univ Med Berlin, Skin Canc Ctr, Dept Dermatol & Allergy, Hindenburgdamm 30, D-12203 Berlin, Germany.	juergen.eberle@charite.de		Eberle, Jurgen/0000-0001-8533-1519				Bai JR, 2005, CANCER RES, V65, P2344, DOI 10.1158/0008-5472.CAN-04-3502; Chawla-Sarkar M, 2002, J IMMUNOL, V169, P847, DOI 10.4049/jimmunol.169.2.847; Chen XF, 2003, CANCER RES, V63, P1059; Di Pietro R, 2004, J CELL PHYSIOL, V201, P331, DOI 10.1002/jcp.20099; Eberle J, 1999, J INVEST DERMATOL, V112, P925, DOI 10.1046/j.1523-1747.1999.00598.x; Eberle J, 2003, ONCOGENE, V22, P9131, DOI 10.1038/sj.onc.1207228; Eggert A, 2001, CANCER RES, V61, P1314; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Fecker LF, 2006, J INVEST DERMATOL, V126, P1366, DOI 10.1038/sj.jid.5700192; Fischer U, 2005, CELL DEATH DIFFER, V12, P942, DOI 10.1038/sj.cdd.4401556; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Fulda S, 2006, ONCOGENE, V25, P5125, DOI 10.1038/sj.onc.1209518; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Ganten TM, 2005, HEPATOLOGY, V42, P588, DOI 10.1002/hep.20807; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Jin ZY, 2004, J BIOL CHEM, V279, P35829, DOI 10.1074/jbc.M405538200; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kurbanov BM, 2005, J INVEST DERMATOL, V125, P1010, DOI 10.1111/j.0022-202X.2005.23900.x; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lens MB, 2004, BRIT J DERMATOL, V150, P179, DOI 10.1111/j.1365-2133.2004.05708.x; Leverkus M, 2003, J INVEST DERMATOL, V121, P149, DOI 10.1046/j.1523-1747.2003.12332.x; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Li-Weber M, 2003, SEMIN IMMUNOL, V15, P145, DOI 10.1016/S1044-5323(03)00030-7; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Nguyen T, 2001, CLIN CANCER RES, V7, p966S; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Ravi R, 2004, DRUG RESIST UPDATE, V7, P53, DOI 10.1016/j.drup.2004.01.003; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Secchiero P, 2003, J LEUKOCYTE BIOL, V74, P223, DOI 10.1189/jlb.0103004; Singh TR, 2003, CANCER RES, V63, P5390; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SH, 2004, ONCOGENE, V23, P928, DOI 10.1038/sj.onc.1207213; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Zauli G, 2005, J CELL PHYSIOL, V202, P900, DOI 10.1002/jcp.20202; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427; Zhang XD, 2006, CLIN CANCER RES, V12, P1355, DOI 10.1158/1078-0432.CCR-05-2084; Zhu HB, 2005, CANCER BIOL THER, V4, P781, DOI 10.4161/cbt.4.7.1897	52	73	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2007	26	23					3364	3377		10.1038/sj.onc.1210134	http://dx.doi.org/10.1038/sj.onc.1210134			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17160022				2022-12-25	WOS:000246579600006
J	Mateos, S; Amarir, S; Laugier, D; Marx, M; Calothy, G				Mateos, S.; Amarir, S.; Laugier, D.; Marx, M.; Calothy, G.			Stable expression of intracellular Notch suppresses v-Src-induced transformation in avian neural cells	ONCOGENE			English	Article						cell transformation; differentiation; Src; Notch; tumor suppressor; paracrine activity	RETINAL PROGENITOR CELLS; QUAIL NEURORETINA CELLS; PROTEIN-KINASE; CHICK-EMBRYO; NEOPLASTIC TRANSFORMATION; TRANSCRIPTION FACTOR; VIRAL ONCOGENES; GROWTH ARREST; CANCER CELLS; CYCLE ARREST	Understanding how disruption of differentiation contributes to the cancer cell phenotype is required to identify alterations essential for malignant transformation and provide experimental basis for their correction. We investigated whether primary quail neuroretina cells, transformed by a conditional v-Src mutant (QNR/v-src(ts)), could revert to a normal phenotype, in response to the stable expression of constitutively active Notch1 intracellular domain (ICN). This model system was chosen because Notch signaling plays an instructive role in cell fate determination during NR development, and because the intrinsic capacity of QNR cultures to differentiate is blocked by v-Src.We report that stable ICN expression results in suppression of QNR/v-src(ts) cell transformation in the presence of an active oncoprotein. This phenotypic reversion coincides with a major switch in cell identity, as these undifferentiated cells acquire glial differentiation traits. Both changes appear to be mediated by CBF, a transcription factor that binds to ICN and activates target genes. Cells restored to a normal and differentiated phenotype have undergone changes in the functioning of signaling effectors, essentially regulating cell morphology and cytoskeleton organization. This dominant interference may be partially mediated by an autocrine/paracrine mechanism, as revertant cells secrete a factor(s), which inhibits transformation properties of QNR/v-src(ts) cells.	Ctr Univ Paris Sud, Inst CURIE, CNTS, UMR 146, F-91405 Orsay, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Calothy, G (corresponding author), Ctr Univ Paris Sud, Inst CURIE, CNTS, UMR 146, F-91405 Orsay, France.	georges.calothy@curie.u-psud.fr						ADLER V, 1992, J BIOL CHEM, V267, P17001; ALVAREZBUYLLA A, 1987, J COMP NEUROL, V264, P159, DOI 10.1002/cne.902640203; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Aouacheria A, 2002, ONCOGENE, V21, P1171, DOI 10.1038/sj.onc.1205170; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bao ZZ, 1997, J NEUROSCI, V17, P1425; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BeleckyAdams T, 1997, INVEST OPHTH VIS SCI, V38, P1293; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bernardos RL, 2005, DEV BIOL, V278, P381, DOI 10.1016/j.ydbio.2004.11.018; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Bocchetta M, 2003, ONCOGENE, V22, P81, DOI 10.1038/sj.onc.1206097; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chen CB, 2002, DEVELOPMENT, V129, P2401; Chen CMA, 2000, MECH DEVELOP, V90, P293; COMBES PC, 1977, CELL TISSUE RES, V185, P159; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; Douer D, 2002, INT J HEMATOL, V76, P179, DOI 10.1007/BF03165115; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Faigle R, 2004, MOL CELL BIOL, V24, P280, DOI 10.1128/MCB.24.1.280-293.2004; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; Fincham VJ, 1999, J CELL SCI, V112, P947; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Galy A, 2002, DEV BIOL, V248, P251, DOI 10.1006/dbio.2002.0736; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Henrique D, 1997, CURR BIOL, V7, P661, DOI 10.1016/S0960-9822(06)00293-4; Huang C, 2004, CELL CYCLE, V3, P4, DOI 10.4161/cc.3.1.601; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jean D, 1998, MECH DEVELOP, V76, P3, DOI 10.1016/S0925-4773(98)00117-8; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KAHN P, 1984, P NATL ACAD SCI-BIOL, V81, P7122, DOI 10.1073/pnas.81.22.7122; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; Kim JW, 2005, P NATL ACAD SCI USA, V102, P14308, DOI 10.1073/pnas.0501600102; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; Kopan R, 2002, J CELL SCI, V115, P1095; LAYER PG, 1989, CELL TISSUE RES, V258, P233; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Marquardt T, 2002, TRENDS NEUROSCI, V25, P32, DOI 10.1016/S0166-2236(00)02028-2; Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MARX M, 1988, J VIROL, V62, P4627, DOI 10.1128/JVI.62.12.4627-4633.1988; Mateos S, 2003, ONCOGENE, V22, P740, DOI 10.1038/sj.onc.1206213; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; Mey J, 2000, BRAIN RES REV, V32, P343, DOI 10.1016/S0165-0173(99)00022-3; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; OKADA TS, 1983, CELL DIFFER DEV, V12, P85, DOI 10.1016/0045-6039(83)90060-X; Oren A, 1999, MOL CELL BIOL, V19, P1742; Pawlak G, 2002, J BIOL CHEM, V277, P26927, DOI 10.1074/jbc.M202261200; Perron M, 2000, CELL MOL LIFE SCI, V57, P215, DOI 10.1007/PL00000685; PESSAC B, 1983, NATURE, V302, P616, DOI 10.1038/302616a0; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; Prada FA, 1995, GLIA, V15, P389, DOI 10.1002/glia.440150404; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Souopgui J, 2002, EMBO J, V21, P6429, DOI 10.1093/emboj/cdf644; Spira AI, 2003, CURR OPIN PHARMACOL, V3, P338, DOI 10.1016/S1471-4892(03)00081-X; Sriuranpong V, 2001, CANCER RES, V61, P3200; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tanaka M, 1999, J NEUROBIOL, V41, P524, DOI 10.1002/(SICI)1097-4695(199912)41:4<524::AID-NEU8>3.3.CO;2-9; TROTTER J, 1989, ONCOGENE, V4, P457; Vadlamudi RK, 2005, ONCOGENE, V24, P4591, DOI 10.1038/sj.onc.1208672; Wakamatsu Y, 2000, DEVELOPMENT, V127, P2811; Waltzer L, 1995, NUCLEIC ACIDS RES, V23, P4939, DOI 10.1093/nar/23.24.4939; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	85	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3338	3351		10.1038/sj.onc.1210124	http://dx.doi.org/10.1038/sj.onc.1210124			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17146440				2022-12-25	WOS:000246579600004
J	Narisawa-Saito, M; Handa, K; Yugawa, T; Ohno, S; Fujita, M; Kiyono, T				Narisawa-Saito, M.; Handa, K.; Yugawa, T.; Ohno, S.; Fujita, M.; Kiyono, T.			HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes	ONCOGENE			English	Article						HPV16 E6; ErbB2; primary human cervical keratinocytes; cervical cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; GROWTH-FACTOR RECEPTOR; PROGNOSTIC-SIGNIFICANCE; HER-2/NEU ONCOGENE; E6 ONCOPROTEIN; CARCINOMA; PROTEIN; CELLS; EXPRESSION; CANCER	Whether ErbB2 receptor tyrosine kinase contributes to cervical cancer is controversial. We have examined the effects of E6 and E7 genes of human papillomaviruses type 16 ( HPV-16) on ErbB2 expression in primary human cervical keratinocytes ( HCK) immortalized with hTERT ( HCK1T). In E6-positive cells ( HCK1T-E6 and HCK1T-E6E7), ErbB2 expression levels increased with the cell density. HCK1T-E6E7 showed impaired contact inhibition and anchorage-independent growth in soft agar which were abrogated with introduction of ErbB2-specific short hairpin RNA ( shRNA) or an ErbB2 specific inhibitor AG825. Furthermore, increased ErbB2 expression was also observed in HPV16 positive cervical cancer cell lines and this was diminished by introduction of HPV16E6- or E6AP-shRNA. At post-confluence cell densities, ErbB2 protein was stabilized in the presence of E6 whereas increased ErbB2 expression was not obvious with E6 mutants incapable of degrading p53. Furthermore, introduction of p53-shRNA to HCK1T resulted in increased ErbB2 protein stability, indicating possible ErbB2 regulation through p53. Finally, we showed that tumor formation of ErbB2-shRNA introduced SiHa cells were almost abolished. Taken together, these data indicate an important role of ErbB2 regulation by HPV16 E6 in oncogenic transformation of human cervical keratinocytes.	Natl Canc Ctr, Res Inst, Virol Div, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Kiyono, T (corresponding author), Natl Canc Ctr, Res Inst, Virol Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tkiyono@gan2.res.ncc.go.jp	Kiyono, Tohru/H-5834-2011	Fujita, Masatoshi/0000-0001-6617-2452				Al Moustafa AE, 2004, ONCOGENE, V23, P350, DOI 10.1038/sj.onc.1207148; Beger M, 2001, J MOL MED, V79, P314, DOI 10.1007/s001090100211; Bellone S, 2003, GYNECOL ONCOL, V91, P231, DOI 10.1016/S0090-8258(03)00460-8; Gewin L, 2004, GENE DEV, V18, P2269, DOI 10.1101/gad.1214704; Hudelist G, 2005, CANCER GENET CYTOGEN, V158, P35, DOI 10.1016/j.cancergencyto.2004.08.007; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ignatoski KMW, 2005, NEOPLASIA, V7, P788, DOI 10.1593/neo.05106; Kansra S, 2004, MOL BIOL CELL, V15, P4299, DOI 10.1091/mbc.E04-03-0233; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; KIHANA T, 1994, CANCER, V73, P148, DOI 10.1002/1097-0142(19940101)73:1<148::AID-CNCR2820730125>3.0.CO;2-C; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Kyo S, 2003, AM J PATHOL, V163, P2259, DOI 10.1016/S0002-9440(10)63583-3; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Nakano T, 1997, CANCER, V79, P513, DOI 10.1002/(SICI)1097-0142(19970201)79:3<513::AID-CNCR13>3.0.CO;2-6; Ndubisi B, 1997, ANN CLIN LAB SCI, V27, P396; Ngan HYS, 2001, TUMOR BIOL, V22, P176, DOI 10.1159/000050613; Niibe Y, 2003, INT J GYNECOL CANCER, V13, P849, DOI 10.1111/j.1525-1438.2003.13397.x; PINION SB, 1991, LANCET, V337, P819, DOI 10.1016/0140-6736(91)92518-7; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V319, P1, DOI 10.1016/j.bbrc.2004.04.150; Rosty C, 2004, INT J GYNECOL PATHOL, V23, P13, DOI 10.1097/01.pgp.0000092137.88121.8d; Sawada M, 2004, CELL DEATH DIFFER, V11, P997, DOI 10.1038/sj.cdd.4401438; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sharma A, 1999, ONCOLOGY-BASEL, V56, P83, DOI 10.1159/000011934; Takeda Y, 2004, J GENE MED, V6, P833, DOI 10.1002/jgm.583; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	32	42	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					2988	2996		10.1038/sj.onc.1210118	http://dx.doi.org/10.1038/sj.onc.1210118			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17146442				2022-12-25	WOS:000246395400004
J	Wyatt, CN; Mustard, KJ; Pearson, SA; Dallas, ML; Atkinson, L; Kumar, P; Peers, C; Hardie, DG; Evans, AM				Wyatt, Christopher N.; Mustard, Kirsty J.; Pearson, Selina A.; Dallas, Mark L.; Atkinson, Lucy; Kumar, Prem; Peers, Chris; Hardie, D. Grahame; Evans, A. Mark			AMP-activated protein kinase mediates carotid body excitation by hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OXIDATIVE-PHOSPHORYLATION; I CELLS; LARGE-CONDUCTANCE; POTASSIUM CHANNEL; K+ CURRENTS; ADENOSINE; CHEMORECEPTORS; IDENTIFICATION; SENSITIVITY; INHIBITION	Early detection of an O-2 deficit in the bloodstream is essential to initiate corrective changes in the breathing pattern of mammals. Carotid bodies serve an essential role in this respect; their type I cells depolarize when O-2 levels fall, causing voltage-gated Ca2+ entry. Subsequent neurosecretion elicits increased afferent chemosensory fiber discharge to induce appropriate changes in respiratory function (1). Although depolarization of type I cells by hypoxia is known to arise from K+ channel inhibition, the identity of the signaling pathway has been contested, and the coupling mechanism is unknown (2). We tested the hypothesis that AMP-activated protein kinase (AMPK) is the effector of hypoxic chemotransduction. AMPK is co-localized at the plasma membrane of type I cells with O-2-sensitive K+ channels. In isolated type I cells, activation of AMPK using 5-aminoimidazole-4-carboxamide riboside (AICAR) inhibited O-2-sensitive K+ currents (carried by large conductance Ca2+-activated (BKCa) channels and TASK (tandem pore, acid-sensing potassium channel)-like channels, leading to plasma membrane depolarization, Ca2+ influx, and increased chemosensory fiber discharge. Conversely, the AMPK antagonist compound C reversed the effects of hypoxia and AICAR on type I cell and carotid body activation. These results suggest that AMPK activation is both sufficient and necessary for the effects of hypoxia. Furthermore, AMPK activation inhibited currents carried by recombinant BKCa channels, whereas purified AMPK phosphorylated the a subunit of the channel in immunoprecipitates, an effect that was stimulated by AMP and inhibited by compound C. Our findings demonstrate a central role for AMPK in stimulus-response coupling by hypoxia and identify for the first time a link between metabolic stress and ion channel regulation in an O-2-sensing system.	Univ St Andrews, Div Biomed Sci, Sch Biol, St Andrews KY16 9TS, Fife, Scotland; Univ Dundee, Div Mol Physiol, Coll Life Sci, Sir James Black Ctr, Dundee DD1 5EH, Scotland; Univ Birmingham, Sch Med, Dept Physiol, Birmingham B15 2TT, W Midlands, England; Univ Leeds, Sch Med, Leeds LS2 9JT, W Yorkshire, England	University of St Andrews; University of Dundee; University of Birmingham; University of Leeds	Evans, AM (corresponding author), Univ St Andrews, Div Biomed Sci, Sch Biol, Bute Bldg, St Andrews KY16 9TS, Fife, Scotland.	ame3@st-andrews.ac.uk	Hardie, David/Z-1979-2019; Dallas, Mark L/A-6654-2013; Dallas, Mark/Q-6117-2019	Dallas, Mark/0000-0002-5190-0522; Peers, Chris/0000-0002-8354-346X; Hardie, Grahame/0000-0002-8373-7379; Kumar, Prem/0000-0001-7524-6046	Wellcome Trust [070772] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahring PK, 1997, FEBS LETT, V415, P67, DOI 10.1016/S0014-5793(97)01096-X; Buckler KJ, 1997, J PHYSIOL-LONDON, V498, P649, DOI 10.1113/jphysiol.1997.sp021890; Conde SV, 2006, ADV EXP MED BIOL, V580, P179, DOI 10.1007/0-387-31311-7_27; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Desmond DW, 2002, STROKE, V33, P2254, DOI 10.1161/01.STR.0000028235.91778.95; Donnelly DF, 1999, RESP PHYSIOL, V115, P151, DOI 10.1016/S0034-5687(99)00021-3; Evans AM, 2005, J BIOL CHEM, V280, P41504, DOI 10.1074/jbc.M510040200; Gadalla AE, 2004, J NEUROCHEM, V88, P1272, DOI 10.1046/j.1471-4159.2003.02253.x; GONZALEZ C, 1994, PHYSIOL REV, V74, P829, DOI 10.1152/physrev.1994.74.4.829; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Hartness ME, 2003, J BIOL CHEM, V278, P51422, DOI 10.1074/jbc.M309463200; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Lewis A, 2002, J PHYSIOL-LONDON, V540, P771, DOI 10.1113/jphysiol.2001.013888; McCartney CE, 2005, P NATL ACAD SCI USA, V102, P17870, DOI 10.1073/pnas.0505270102; PEPPER DR, 1995, J PHYSIOL-LONDON, V485, P531, DOI 10.1113/jphysiol.1995.sp020749; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Prabhakar NR, 2006, EXP PHYSIOL, V91, P17, DOI 10.1113/expphysiol.2005.031922; Vandier C, 1999, J PHYSIOL-LONDON, V515, P419, DOI 10.1111/j.1469-7793.1999.419ac.x; VOELKEL NF, 1986, AM REV RESPIR DIS, V133, P1186; Weir EK, 2005, NEW ENGL J MED, V353, P2042, DOI 10.1056/NEJMra050002; Williams SEJ, 2004, SCIENCE, V306, P2093, DOI 10.1126/science.1105010; Wyatt CN, 2006, ADV EXP MED BIOL, V580, P191, DOI 10.1007/0-387-31311-7_29; Wyatt CN, 2004, J PHYSIOL-LONDON, V556, P175, DOI 10.1113/jphysiol.2003.058131; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	35	118	120	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8092	8098		10.1074/jbc.M608742200	http://dx.doi.org/10.1074/jbc.M608742200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17179156	Green Accepted, hybrid			2022-12-25	WOS:000245081000041
J	Kim, HM; Oh, SC; Lim, KJ; Kasamatsu, J; Heo, JY; Park, BS; Lee, H; Yoo, OJ; Kasahara, M; Lee, JO				Kim, Ho Min; Oh, Se Cheol; Lim, Ki Jung; Kasamatsu, Jun; Heo, Jin Young; Park, Beom Seok; Lee, Hayyoung; Yoo, Ook Joon; Kasahara, Masanori; Lee, Jie-Oh			Structural diversity of the hagfish variable lymphocyte receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; PROTEIN BINDING-SITES; TOLL-LIKE RECEPTOR-3; RIBONUCLEASE INHIBITOR; MOLECULAR RECOGNITION; CRYSTAL-STRUCTURE; PREDICTION; ECTODOMAIN; SCAFFOLDS; SEQUENCES	Variable lymphocyte receptors (VLRs) are recently discovered leucine-rich repeat (LRR) family proteins that mediate adaptive immune responses in jawless fish. Phylogenetically it is the oldest adaptive immune receptor and the first one with a non-immunoglobulin fold. We present the crystal structures of one VLR-A and two VLR-B clones from the inshore hagfish. The hagfish VLRs have the characteristic horseshoe-shaped structure of LRR family proteins. The backbone structures of their LRR modules are highly homologous, and the sequence variation is concentrated on the concave surface of the protein. The conservation of key residues suggests that our structures are likely to represent the LRR structures of the entire repertoire of jawless fish VLRs. The analysis of sequence variability, prediction of protein interaction surfaces, amino acid composition analysis, and structural comparison with other LRR proteins suggest that the hypervariable concave surface is the most probable antigen binding site of the VLR.	Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Sci Biol, Taejon 305701, South Korea; Hokkaido Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido 0608638, Japan; Chungnam Natl Univ, Inst Biotechnol, Taejon 305764, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); Hokkaido University; Chungnam National University	Lee, JO (corresponding author), Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea.	jieoh.lee@kaist.ac.kr	Yoo, Ook Joon/C-1860-2011; Lee, Jie-Oh/AAG-4302-2020; Kim, Ho Min/G-2712-2011; Lee, Jie-Oh/C-1581-2011; Kang, Jin Young/E-4384-2019; Kasahara, Masanori/G-7651-2011	Lee, Jie-Oh/0000-0001-6519-6049				Alder MN, 2005, SCIENCE, V310, P1970, DOI 10.1126/science.1119420; Bell JK, 2006, P NATL ACAD SCI USA, V103, P8792, DOI 10.1073/pnas.0603245103; Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9; Bradford JR, 2005, BIOINFORMATICS, V21, P1487, DOI 10.1093/bioinformatics/bti242; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Collis AVJ, 2003, J MOL BIOL, V325, P337, DOI 10.1016/S0022-2836(02)01222-6; Delarbre C, 2002, MOL PHYLOGENET EVOL, V22, P184, DOI 10.1006/mpev.2001.1045; Fan QR, 2005, NATURE, V433, P269, DOI 10.1038/nature03206; Forrer P, 2003, FEBS LETT, V539, P2, DOI 10.1016/S0014-5793(03)00177-7; GILBERTSON P, 1986, DEV COMP IMMUNOL, V10, P1, DOI 10.1016/0145-305X(86)90039-X; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; He XLL, 2003, NEURON, V38, P177, DOI 10.1016/S0896-6273(03)00232-0; Howitt JA, 2004, EMBO J, V23, P4406, DOI 10.1038/sj.emboj.7600446; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jung D, 2006, ANNU REV IMMUNOL, V24, P541, DOI 10.1146/annurev.immunol.23.021704.115830; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; Kim JI, 2005, J BIOL CHEM, V280, P11347, DOI 10.1074/jbc.M414607200; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Mayer WE, 2002, P NATL ACAD SCI USA, V99, P14350, DOI 10.1073/pnas.212527499; Neuvirth H, 2004, J MOL BIOL, V338, P181, DOI 10.1016/j.jmb.2004.02.040; Nygren PA, 1997, CURR OPIN STRUC BIOL, V7, P463, DOI 10.1016/S0959-440X(97)80108-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pancer Z, 2005, P NATL ACAD SCI USA, V102, P9224, DOI 10.1073/pnas.0503792102; Pancer Z, 2004, NATURE, V430, P174, DOI 10.1038/nature02740; Pancer Z, 2006, ANNU REV IMMUNOL, V24, P497, DOI 10.1146/annurev.immunol.24.021605.090542; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Reche PA, 2003, J MOL BIOL, V331, P623, DOI 10.1016/S0022-2836(03)00750-2; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Skerra A, 2000, J MOL RECOGNIT, V13, P167, DOI 10.1002/1099-1352(200007/08)13:4<167::AID-JMR502>3.3.CO;2-0; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Stumpp MT, 2003, J MOL BIOL, V332, P471, DOI 10.1016/S0022-2836(03)00897-0; Takezaki N, 2003, MOL BIOL EVOL, V20, P287, DOI 10.1093/molbev/msg040; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ZAPATA A, 1984, CELL TISSUE RES, V235, P691	38	91	100	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6726	6732		10.1074/jbc.M608471200	http://dx.doi.org/10.1074/jbc.M608471200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17192264	hybrid			2022-12-25	WOS:000244867200082
J	Chen, L; Xiong, SG; She, HY; Lin, SW; Wang, JH; Tsukamoto, H				Chen, Li; Xiong, Shigang; She, Hongyun; Lin, Sharon W.; Wang, Jiaohong; Tsukamoto, Hidekazu			Iron causes interactions of TAK1, p21ras, and phosphatidylinositol 3-kinase in caveolae to activate I kappa B kinase in hepatic macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR IRON; FREE-RADICALS; SURVIVAL; PATHWAY; LIPOPOLYSACCHARIDE; EXPRESSION; P21(RAS); ALPHA; BAD; NO	We recently discovered a novel signaling phenomenon involving a rapid and transient rise in intracellular low molecular weight iron complex(es) in activation of licB kinase (IKK) in hepatic macrophages. We also showed direct treatment with ferrous iron substitutes for this event to activate IKK. The present study used this model to identify upstream kinases responsible for IKK activation. IKK activation induced by iron is abrogated by overexpression of a dominant negative mutant (DN) for transforming growth factor beta-activated kinase-1 (TAK1), NF-kappa B-inducing kinase, or phosphatidylinositol 3-kinase (PI3K) and by treatment with the mitogen-activated protein kinase (MAPK) kinase-1 (MEK1) inhibitor. Iron increases AKT phosphorylation that is prevented by DNTAK1 or DNp21ras. Iron causes ERK1/2 phosphorylation that is attenuated by DN-PI3K, prevented by DNp21ras, but unaffected by DNTAK1. Iron-induced TAK1 activity is not affected by the PI3K or MEK1 inhibitor, suggesting TAK1 is upstream of PI3K and MEK1. Iron increases interactions of TAK1 and PI3K with p21ras as demonstrated by co-immunoprecipitation and co-localization of these proteins with caveolin-1 as shown by immunofluorescent microscopy. Finally, filipin III, a caveolae inhibitor, abrogates iron-induced TAK1 and IKK activation. In conclusion, MEK1, TAK1, NF-kappa B-inducing kinase, and PI3K are required for iron-induced IKK activation in hepatic macrophages and TAK1, PI3K, and p21ras physically interact in caveolae to initiate signal transduction.	Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90033 USA; Dept Vet Affairs, Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	University of Southern California; University of Southern California	Tsukamoto, H (corresponding author), Univ So Calif, Keck Sch Med, Dept Pathol, 1333 San Pablo St,MMR-402, Los Angeles, CA 90033 USA.	htsukamo@usc.edu			NIAAA NIH HHS [R24AA12885, P50AA11999] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA011999, R24AA012885] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Atkinson PGP, 1999, IMMUNOLOGY, V96, P656; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bonkovsky HL, 2002, J HEPATOL, V37, P848, DOI 10.1016/S0168-8278(02)00305-7; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Graham JM, 2000, BRAIN, V123, P2423, DOI 10.1093/brain/123.12.2423; Grethe S, 2006, CELL SIGNAL, V18, P531, DOI 10.1016/j.cellsig.2005.05.023; Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200; KENNEDY JI, 1986, CHEST, V89, pS123, DOI 10.1378/chest.89.3_Supplement.123S; Krajewska WM, 2004, CELL MOL BIOL LETT, V9, P195; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102; Li SP, 2003, CANCER RES, V63, P3473; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Park YC, 1997, BIOCHEM BIOPH RES CO, V240, P692, DOI 10.1006/bbrc.1997.7722; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; She HY, 2002, AM J PHYSIOL-GASTR L, V283, pG719, DOI 10.1152/ajpgi.00108.2002; Stojanovic S, 2004, NITRIC OXIDE-BIOL CH, V11, P256, DOI 10.1016/j.niox.2004.09.007; Thomas KW, 2002, J BIOL CHEM, V277, P492, DOI 10.1074/jbc.M108107200; Tsukamoto H, 1999, AM J PHYSIOL-GASTR L, V277, pG1240, DOI 10.1152/ajpgi.1999.277.6.G1240; Uraz S, 2005, DIGEST DIS SCI, V50, P964, DOI 10.1007/s10620-005-2672-z; Xiong SG, 2003, J BIOL CHEM, V278, P17646, DOI 10.1074/jbc.M210905200; Yuan XM, 1999, FREE RADICAL RES, V30, P221, DOI 10.1080/10715769900300241; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	37	50	50	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5582	5588		10.1074/jbc.M609273200	http://dx.doi.org/10.1074/jbc.M609273200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17172471	hybrid			2022-12-25	WOS:000244482300054
J	Im, YJ; Davis, AJ; Perera, IY; Johannes, E; Allen, NS; Boss, WF				Im, Yang Ju; Davis, Amanda J.; Perera, Imara Y.; Johannes, Eva; Allen, Nina S.; Boss, Wendy F.			The N-terminal membrane occupation and recognition nexus domain of Arabidopsis phosphatidylinositol phosphate kinase 1 regulates enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE D-ALPHA; PLASMA-MEMBRANE; PHOSPHOINOSITIDE KINASES; ENDOSOME TRAFFICKING; HYPEROSMOTIC STRESS; SUSPENSION-CULTURE; PROTEIN; CELLS; 4,5-BISPHOSPHATE; THALIANA	The type I B family of phosphatidylinositol phosphate kinases (PIPKs) contain a characteristic region of Membrane Occupation and Recognition Nexus (MORN) motifs at the N terminus. These MORN motifs are not found in PIPKs from other eukaryotes. To understand the impact of the additional N-terminal domain on protein function and subcellular distribution, we expressed truncated and full-length versions of AtPIPKI, one member of this family of PIPKs, in Escherichia coli and in tobacco cells grown in suspension culture. Deletion of the N-terminal MORN domain (amino acids 1-251) of AtPIPKI increased the specific activity of the remaining C-terminal peptide (Delta MORN) > 4-fold and eliminated activation by phosphatidic acid (PtdOH). PtdOH activation could also be eliminated by mutating Pro(396) to Ala (P396A) in the predicted linker region between the MORN and the kinase homology domains. AtPIPKI is product-activated and the MORN domain binds PtdIns(4,5)P-2. Adding back the MORN peptide to Delta MORN or to the PtdOH-activated full-length protein increased activity similar to 2-fold. Furthermore, expressing the MORN domain in vivo increased the plasma membrane PtdInsP kinase activity. When cells were exposed to hyperosmotic stress, the MORN peptide redistributed from the plasma membrane to a lower phase or endomembrane fraction. In addition, endogenous PtdInsP kinase activity increased in the endomembrane fraction of hyperosmotically stressed cells. We conclude that the MORN peptide can regulate both the function and distribution of the enzyme in a manner that is sensitive to the lipid environment.	N Carolina State Univ, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Boss, WF (corresponding author), N Carolina State Univ, Plant Biol Box 7649, Raleigh, NC 27695 USA.	wendy_boss@ncsu.edu		Johannes, Eva/0000-0001-6489-1015; Perera, Imara/0000-0001-9421-1420				CHEN H, 1994, BIOTECHNIQUES, V16, P664; CHO MH, 1993, PLANT PHYSIOL, V103, P637, DOI 10.1104/pp.103.2.637; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; Ciruela A, 2000, BIOCHEM J, V346, P587, DOI 10.1042/0264-6021:3460587; Davis AJ, 2004, J LIPID RES, V45, P1783, DOI 10.1194/jlr.D400005-JLR200; DeWald DB, 2001, PLANT PHYSIOL, V126, P759, DOI 10.1104/pp.126.2.759; Downes CP, 2005, TRENDS CELL BIOL, V15, P259, DOI 10.1016/j.tcb.2005.03.008; Gonzales ML, 2006, J CELL BIOCHEM, V97, P252, DOI 10.1002/jcb.20655; Gubbels MJ, 2006, J CELL SCI, V119, P2236, DOI 10.1242/jcs.02949; Hadano S, 2006, HUM MOL GENET, V15, P233, DOI 10.1093/hmg/ddi440; Hinchliffe KA, 1999, CURR BIOL, V9, P983, DOI 10.1016/S0960-9822(99)80429-1; IMAI A, 1986, BIOCHEM J, V240, P341, DOI 10.1042/bj2400341; Jin JB, 2001, PLANT CELL, V13, P1511, DOI 10.1105/tpc.13.7.1511; Jones DH, 2000, J BIOL CHEM, V275, P13962, DOI 10.1074/jbc.C901019199; Jurgens G, 2004, ANNU REV CELL DEV BI, V20, P481, DOI 10.1146/annurev.cellbio.20.082503.103057; Kunita R, 2004, J BIOL CHEM, V279, P38626, DOI 10.1074/jbc.M406120200; Kunz J, 2002, J BIOL CHEM, V277, P5611, DOI 10.1074/jbc.M110775200; Lee EY, 2002, SCIENCE, V297, P1193, DOI 10.1126/science.1071362; Li WQ, 2004, NAT BIOTECHNOL, V22, P427, DOI 10.1038/nbt949; LING LE, 1989, J BIOL CHEM, V264, P5080; Ma H, 2004, PLANT MOL BIOL, V54, P295, DOI 10.1023/B:PLAN.0000028796.14336.24; Ma H, 2006, CELL RES, V16, P466, DOI 10.1038/sj.cr.7310058; McLaughlin S, 2005, NATURE, V438, P605, DOI 10.1038/nature04398; Meijer HJG, 2003, ANNU REV PLANT BIOL, V54, P265, DOI 10.1146/annurev.arplant.54.031902.134748; Mueller-Roeber B, 2002, PLANT PHYSIOL, V130, P22, DOI 10.1104/pp.004770; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Perera IY, 1999, P NATL ACAD SCI USA, V96, P5838, DOI 10.1073/pnas.96.10.5838; Perera IY, 2005, FEBS LETT, V579, P3427, DOI 10.1016/j.febslet.2005.05.018; Perera IY, 2002, PLANT PHYSIOL, V129, P1795, DOI 10.1104/pp.003426; Persson S, 2002, PLANT PHYSIOL, V128, P341, DOI 10.1104/pp.010840; Pical C, 1999, J BIOL CHEM, V274, P38232, DOI 10.1074/jbc.274.53.38232; Preuss ML, 2006, J CELL BIOL, V172, P991, DOI 10.1083/jcb.200508116; Qin WS, 1997, J BIOL CHEM, V272, P28267, DOI 10.1074/jbc.272.45.28267; SANDELIUS AS, 1986, FEBS LETT, V201, P282, DOI 10.1016/0014-5793(86)80624-X; Sang YM, 2001, PLANT J, V28, P135, DOI 10.1046/j.1365-313X.2001.01138.x; Shimada H, 2004, PLANT CELL PHYSIOL, V45, P960, DOI 10.1093/pcp/pch130; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Tudor EL, 2005, J BIOL CHEM, V280, P34735, DOI 10.1074/jbc.M506216200; Vincent P, 2005, J CELL BIOL, V168, P801, DOI 10.1083/jcb.200412074; Wang XM, 2002, CURR OPIN PLANT BIOL, V5, P408, DOI 10.1016/S1369-5266(02)00283-2; Welti R, 2002, J BIOL CHEM, V277, P31994, DOI 10.1074/jbc.M205375200; Westergren T, 2001, BIOCHEM J, V359, P583, DOI 10.1042/0264-6021:3590583; Yamamoto M, 2006, J BIOL CHEM, V281, P32630, DOI 10.1074/jbc.M605928200; Zhang WH, 2004, P NATL ACAD SCI USA, V101, P9508, DOI 10.1073/pnas.0402112101	45	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5443	5452		10.1074/jbc.M611342200	http://dx.doi.org/10.1074/jbc.M611342200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17197438	hybrid			2022-12-25	WOS:000244482300039
J	Shajahan, AN; Wang, AF; Decker, M; Minshall, RD; Liu, MC; Clarke, R				Shajahan, Ayesha N.; Wang, Aifen; Decker, Markus; Minshall, Richard D.; Liu, Minetta C.; Clarke, Robert			Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; UP-REGULATION; EPITHELIAL-CELLS; EXPRESSION; TAXOL; GROWTH; ACTIVATION; APOPTOSIS; P53; MICROTUBULES	Caveolin-1 (CAV1), a highly conserved membrane-associated protein, is a putative regulator of cellular transformation. CAV1 is localized in the plasmalemma, secretory vesicles, Golgi, mitochondria, and endoplasmic reticulum membrane and associates with the microtubule cytoskeleton. Taxanes such as paclitaxel (Taxol) are potent anti-tumor agents that repress the dynamic instability of microtubules and arrest cells in the G(2)/M phase. Src phosphorylation of Tyr-14 on CAV1 regulates its cellular localization and function. We report that phosphorylation of CAV1 on Tyr-14 regulates paclitaxel-mediated apoptosis in MCF-7 breast cancer cells. Befitting its role as a multitasking molecule, we show that CAV1 sensitizes cells to apoptosis by regulating cell cycle progression and activation of the apoptotic signaling molecules BCL2, p53, and p21. We demonstrate that phosphorylated CAV1 triggers apoptosis by inactivating BCL2 and increasing mitochondrial permeability more efficiently than non-phosphorylated CAV1. Furthermore, expression of p21, which correlates with taxane sensitivity, is regulated by CAV1 phosphorylation in a p53-dependent manner. Collectively, our findings underscore the importance of CAV1 phosphorylation in apoptosis and suggest that events that negate CAV1 tyrosine phosphorylation may contribute to anti-microtubule drug resistance.	Georgetown Univ, Coll Med, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; Georgetown Univ, Coll Med, Dept Physiol, Washington, DC 20057 USA; Georgetown Univ, Coll Med, Dept Biophys, Washington, DC 20057 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Dept Anesthesiol, Chicago, IL 60612 USA	Georgetown University; Georgetown University; Georgetown University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Clarke, R (corresponding author), Georgetown Univ, Coll Med, Dept Oncol, Lombardi Comprehens Canc Ctr, 3970 Reservoir Rd NW,NRB W405, Washington, DC 20057 USA.	clarker@georgeotown.edu	Clarke, Robert/A-6485-2008	Clarke, Robert/0000-0002-9278-0854; Shajahan-Haq, Ayesha/0000-0001-7616-320X				Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; Belanger MM, 2003, ANTI-CANCER DRUG, V14, P281, DOI 10.1097/00001813-200304000-00005; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1997, CANCER RES, V57, P130; Boudny V, 2002, BRIT J CANCER, V86, P463, DOI 10.1038/sj.bjc.6600080; Chen T, 2005, MOL CANCER THER, V4, P217; Clavarezza M, 2006, ANN ONCOL, V17, pVII22, DOI 10.1093/annonc/mdl944; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Gargalovic P, 2003, J LIPID RES, V44, P1622, DOI 10.1194/jlr.M300140-JLR200; Ghersi D, 2005, BRIT J CANCER, V93, P293, DOI 10.1038/sj.bjc.6602680; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; Gligorov J, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9-suppl_2-3; Haldar S, 1997, CANCER RES, V57, P229; Heliez C, 2003, ONCOGENE, V22, P3260, DOI 10.1038/sj.onc.1206409; Kim YN, 2002, EXP CELL RES, V280, P134, DOI 10.1006/excr.2002.5623; Kiss AL, 2005, MOL CELL ENDOCRINOL, V245, P128, DOI 10.1016/j.mce.2005.11.005; Ko YG, 1998, J CELL BIOCHEM, V71, P524, DOI 10.1002/(SICI)1097-4644(19981215)71:4<524::AID-JCB7>3.3.CO;2-2; Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; MANFREDI JJ, 1984, PHARMACOL THERAPEUT, V25, P83, DOI 10.1016/0163-7258(84)90025-1; MATSUOKA H, 1994, ANTICANCER RES, V14, P163; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Orlichenko L, 2006, J BIOL CHEM, V281, P4570, DOI 10.1074/jbc.M512088200; Panno ML, 2006, FEBS LETT, V580, P2371, DOI 10.1016/j.febslet.2006.03.055; Ravid D, 2005, ONCOGENE, V24, P1338, DOI 10.1038/sj.onc.1208337; Roussel E, 2004, ANTI-CANCER DRUG, V15, P961, DOI 10.1097/00001813-200411000-00005; Sagara Y, 2004, BRIT J CANCER, V91, P959, DOI 10.1038/sj.bjc.6602029; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Shajahan AN, 2004, J BIOL CHEM, V279, P48055, DOI 10.1074/jbc.M405837200; Sloan EK, 2004, ONCOGENE, V23, P7893, DOI 10.1038/sj.onc.1208062; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Trock BJ, 1997, J NATL CANCER I, V89, P917, DOI 10.1093/jnci/89.13.917; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Xie ZH, 2003, CANCER RES, V63, P5370; Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4; Yeung TK, 1999, BIOCHEM BIOPH RES CO, V263, P398, DOI 10.1006/bbrc.1999.1375; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947; Zajchowski DA, 2001, CANCER RES, V61, P5168	49	60	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5934	5943		10.1074/jbc.M608857200	http://dx.doi.org/10.1074/jbc.M608857200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17190831	hybrid			2022-12-25	WOS:000244482300089
J	Anderson, GR; Semenov, A; Song, JH; Martemyanov, KA				Anderson, Garret R.; Semenov, Arthur; Song, Joseph H.; Martemyanov, Kirill A.			The membrane anchor R7BP controls the proteolytic stability of the striatal specific RGS protein, RGS9-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE ACCELERATING PROTEIN; IN-VIVO; NERVOUS-SYSTEM; SIGNALING RGS; MICE LACKING; DEP DOMAIN; REGULATORS; R9AP; EXPRESSION; COMPLEX	A member of the RGS ((r) under bar egulators of (G) under bar protein (s) under bar ignaling) family, RGS9-2 is a critical regulator of G protein signaling pathways that control locomotion and reward signaling in the brain. RGS9-2 is specifically expressed in striatal neurons where it forms complexes with its newly discovered partner, R7BP ((R7) under bar family binding protein). Interaction with R7BP is important for the subcellular targeting of RGS9-2, which in native neurons is found in plasma membrane and its specializations, postsynaptic densities. Here we report that R7BP plays an additional important role in determining proteolytic stability of RGS9-2. We have found that co-expression with R7BP dramatically elevates the levels of RGS9-2 and its constitutive subunit, G beta 5. Measurement of the RGS9-2 degradation kinetics in cells indicates that R7BP markedly reduces the rate of RGS9-2-G beta 5 proteolysis. Lentivirus-mediated RNA interference knockdown of the R7BP expression in native striatal neurons results in the corresponding decrease in RGS9-2 protein levels. Analysis of the molecular determinants that mediate R7BP/RGS9-2 binding to result in proteolytic protection have identified that the binding site for R7BP in RGS proteins is formed by pairing of the DEP ((D) under bar isheveled, (E) under bar GL-10, Pleckstrin) domain with the R7H ((R7 h) under bar omology), a domain of previously unknown function that interacts with four putative a-helices of the R7BP core. These findings provide a mechanism for the regulation of the RGS9 protein stability in the striatal neurons.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Martemyanov, KA (corresponding author), Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA.	martemyanov@umn.edu	Anderson, Garret/B-1316-2011; Anderson, Garret/AAX-7011-2021		NIDA NIH HHS [DA011806] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; Baker SA, 2006, BIOCHEMISTRY-US, V45, P10690, DOI 10.1021/bi060376a; Burchett SA, 1998, J NEUROCHEM, V70, P2216; Burns ME, 2003, NEURON, V38, P853, DOI 10.1016/S0896-6273(03)00361-1; Cabrera-Vera TM, 2004, P NATL ACAD SCI USA, V101, P16339, DOI 10.1073/pnas.0407416101; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Chen CK, 2003, P NATL ACAD SCI USA, V100, P6604, DOI 10.1073/pnas.0631825100; Coleman JE, 2003, PHYSIOL GENOMICS, V12, P221, DOI 10.1152/physiolgenomics.00135.2002; Cullen BR, 2004, VIRUS RES, V102, P3, DOI 10.1016/j.virusres.2004.01.009; Drenan RM, 2005, J CELL BIOL, V169, P623, DOI 10.1083/jcb.200502007; Drenan RM, 2006, J BIOL CHEM, V281, P28222, DOI 10.1074/jbc.M604428200; Garzon J, 2001, EUR J NEUROSCI, V13, P801, DOI 10.1046/j.0953-816x.2000.01444.x; Gold SJ, 1997, J NEUROSCI, V17, P8024; Heximer SP, 2003, J CLIN INVEST, V111, P1259, DOI 10.1172/JCI200318099C; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hu G, 2003, J BIOL CHEM, V278, P14550, DOI 10.1074/jbc.M212046200; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; Huang XY, 2006, MOL CELL BIOL, V26, P6870, DOI 10.1128/MCB.00314-06; Ivkovic S, 1999, J NEUROSCI, V19, P5409; Keresztes G, 2004, J BIOL CHEM, V279, P1581, DOI 10.1074/jbc.C300456200; Keresztes G, 2003, MOL CELL NEUROSCI, V24, P687, DOI 10.1016/S1044-7431(03)00231-8; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; Kovoor A, 2005, J NEUROSCI, V25, P2157, DOI 10.1523/JNEUROSCI.2840-04.2005; Krispel CM, 2006, NEURON, V51, P409, DOI 10.1016/j.neuron.2006.07.010; Krispel CM, 2003, J NEUROSCI, V23, P6965, DOI 10.1523/JNEUROSCI.23-18-06965.2003; LEFEBVRE B, 1995, BIOTECHNIQUES, V19, P186; Lishko PV, 2002, J BIOL CHEM, V277, P24376, DOI 10.1074/jbc.M203237200; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Martemyanov KA, 2005, J BIOL CHEM, V280, P5133, DOI 10.1074/jbc.C400596200; Martemyanov KA, 2003, J NEUROSCI, V23, P10175; Nishiguchi KM, 2004, NATURE, V427, P75, DOI 10.1038/nature02170; Rahman Z, 2003, NEURON, V38, P941, DOI 10.1016/S0896-6273(03)00321-0; Rojkova AM, 2003, J BIOL CHEM, V278, P12507, DOI 10.1074/jbc.M207302200; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Siderovski DP, 2005, INT J BIOL SCI, V1, P51, DOI 10.7150/ijbs.1.51; Skiba NP, 2001, J BIOL CHEM, V276, P37365, DOI 10.1074/jbc.M106431200; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Song JH, 2006, J BIOL CHEM, V281, P15361, DOI 10.1074/jbc.M600749200; Svenningsson P, 2004, ANNU REV PHARMACOL, V44, P269, DOI 10.1146/annurev.pharmtox.44.101802.121415; Tekumalla PK, 2001, BIOL PSYCHIAT, V50, P813, DOI 10.1016/S0006-3223(01)01234-3; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Witherow DS, 2003, RECEPTOR CHANNEL, V9, P205, DOI 10.1080/10606820390203848; Zachariou V, 2003, P NATL ACAD SCI USA, V100, P13656, DOI 10.1073/pnas.2232594100	44	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4772	4781		10.1074/jbc.M610518200	http://dx.doi.org/10.1074/jbc.M610518200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158100	hybrid			2022-12-25	WOS:000244482000059
J	Van Themsche, C; Mathieu, I; Parent, S; Asselin, E				Van Themsche, Celine; Mathieu, Isabelle; Parent, Sophie; Asselin, Eric			Transforming growth factor-beta 3 increases the invasiveness of endometrial carcinoma cells through phosphatidylinositol 3-kinase-dependent up-regulation of X-linked inhibitor of apoptosis and protein kinase C-dependent induction of matrix metalloproteinase-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; SIGNAL-TRANSDUCTION; CANCER-CELLS; IN-VITRO; EXPRESSION; INVASION; ADENOCARCINOMA; ANGIOGENESIS; ACTIVATION	dTumor cells often acquire intrinsic resistance to the growth inhibitory and pro-apoptotic effects of transforming growth factor-beta (TGF-beta); moreover, TGF-beta can confer invasive properties to established tumor cells. In the present study, we show that TGF-beta isoforms (TGF-beta 1, TGF-beta 2, and TGF-beta 3) trigger proper Smad signaling in human endometrial carcinoma cell lines and efficiently inhibit cellular proliferation. These cells, however, exhibit a high degree of resistance to TGF-beta pro-apoptotic effects; we found that this resistant phenotype would be acquired through up-regulation of X-linked inhibitor of apoptosis protein (XIAP) levels. In addition, using RNA interference and pharmacological inhibitors, we show that TGF-beta increases cellular invasiveness via two distinct signaling pathways in endometrial carcinoma cells: phosphatidylinositol 3-kinase/AKT-dependent up-regulation of XIAP and protein kinase C-dependent induction of matrix-metalloproteinase-9 (MMP-9) expression. Additionally, these findings were correlated with clinical observations showing abundant TGF-beta immunoreactivity in human endometrial carcinoma tumors in vivo, extending from the epithelial compartment to the stroma upon acquisition of an invasive phenotype (gradually from grades I to III). Collectively our results describe for the first time a role for TGF-beta 3 in tumor invasiveness.	Univ Quebec, Dept Biol Chem, Trois Rivieres, PQ G9A 5H7, Canada	University of Quebec; University of Quebec Trois Rivieres	Asselin, E (corresponding author), Univ Quebec, Dept Biol Chem, Trois Rivieres, PQ G9A 5H7, Canada.	eric.asselin@uqtr.ca						Aglund K, 2004, GYNECOL ONCOL, V94, P699, DOI 10.1016/j.ygyno.2004.06.028; Alabert C, 2006, ONCOGENE, V25, P3387, DOI 10.1038/sj.onc.1209385; Arends MJ, 1999, HISTOPATHOLOGY, V35, P174, DOI 10.1046/j.1365-2559.1999.00756.x; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; del Re E, 2004, J BIOL CHEM, V279, P22765, DOI 10.1074/jbc.M401350200; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Farina AR, 1998, INT J CANCER, V75, P721; GOLD LI, 1994, CANCER RES, V54, P2347; Gold LI, 1999, SEMIN REPROD ENDOCR, V17, P73, DOI 10.1055/s-2007-1016214; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; Javelaud D, 2005, ONCOGENE, V24, P7624, DOI 10.1038/sj.onc.1208900; Jin X, 2004, BRIT J CANCER, V91, P1808, DOI 10.1038/sj.bjc.6602214; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; Leivonen SK, 2006, ONCOGENE, V25, P2588, DOI 10.1038/sj.onc.1209291; Maliekal TT, 2003, ONCOGENE, V22, P4889, DOI 10.1038/sj.onc.1206806; Parekh TV, 2002, CANCER RES, V62, P2778; Park DW, 2003, CANCER LETT, V195, P185, DOI 10.1016/S0304-3835(03)00131-9; Perlino E, 1998, BRIT J CANCER, V77, P1260, DOI 10.1038/bjc.1998.211; Qian SW, 1999, GROWTH FACTORS, V17, P63, DOI 10.3109/08977199909001063; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Schrantz N, 1999, ONCOGENE, V18, P3511, DOI 10.1038/sj.onc.1202718; Shigeoka Y, 2004, J CANCER RES CLIN, V130, P146, DOI 10.1007/s00432-003-0520-0; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Shooner C, 2005, REPROD BIOL ENDOCRIN, V3, P1, DOI 10.1186/1477-7827-3-20; Watanabe Y, 2003, CLIN CANCER RES, V9, P6497; Woo JH, 2004, ONCOGENE, V23, P1845, DOI 10.1038/sj.onc.1207307; Yabushita H, 2000, J Obstet Gynaecol Res, V26, P163; Yu Q, 2000, GENE DEV, V14, P163; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200	30	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4794	4802		10.1074/jbc.M608497200	http://dx.doi.org/10.1074/jbc.M608497200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17150964	hybrid			2022-12-25	WOS:000244482000061
J	Mazurov, D; Heidecker, G; Derse, D				Mazurov, Dmitriy; Heidecker, Gisela; Derse, David			The inner loop of tetraspanins CD82 and CD81 mediates interactions with human T cell lymphotrophic virus type 1 Gag protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE-4 SUPERFAMILY; PLASMA-MEMBRANE; METASTASIS SUPPRESSOR; ENRICHED MICRODOMAINS; SYNCYTIUM FORMATION; MOLECULAR CLONE; MATRIX PROTEIN; C33 ANTIGEN; HTLV-1 GAG; PALMITOYLATION	The tetraspanin superfamily proteins play important roles in organizing membrane protein complexes, modulating integrin function, and controlling T cell adhesion. Tetraspanins such as CD82 contain two extracellular loops with its N terminus, C terminus, and inner loop exposed to the cytoplasm. The matrix (MA) domain of human T cell lymphotrophic virus, type 1 (HTLV-1), Gag interacts with the cytoplasmic face of the plasma membrane and is concentrated at tetraspanin-enriched microdomains. To understand the basis of this association, we generated site-directed mutations in the various domains of CD82 and used coimmunoprecipitation and colocalization approaches to examine interactions with HTLV-1 MA. The large extracellular loop of CD82, which is important for interactions with integrins, was not required for the association with HTLV-1 MA. The cytoplasmic N terminus and C terminus of CD82 were also dispensable for CD82-MA interactions. In contrast, mutations of conserved amino acids in the inner loop of CD82 or of palmitoylated cysteines that flank the inner loop diminished CD82 association with MA. HTLV-1 MA also interacted with the inner loop of CD81. Thus, association of HTLV-1 Gag with tetraspanin-enriched microdomains is mediated by the inner loops of CD81 and CD82.	NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Derse, D (corresponding author), NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA.	derse@ncifcrf.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010003, ZIABC010003] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 2002, J BIOL CHEM, V277, P36991, DOI 10.1074/jbc.M205265200; Berditchevski F, 2001, J CELL SCI, V114, P4143; Bienstock RJ, 2001, MOL CARCINOGEN, V32, P139, DOI 10.1002/mc.1073; Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Cannon KS, 2001, EMBO J, V20, P2443, DOI 10.1093/emboj/20.10.2443; Charrin S, 2003, BIOCHEM BIOPH RES CO, V304, P107, DOI 10.1016/S0006-291X(03)00545-X; Charrin S, 2002, FEBS LETT, V516, P139, DOI 10.1016/S0014-5793(02)02522-X; Christensen AM, 1996, J MOL BIOL, V264, P1117, DOI 10.1006/jmbi.1996.0700; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Delamater AM, 2002, HA CL HE PS, V1, P443; DERSE D, 1995, J VIROL, V69, P1907, DOI 10.1128/JVI.69.3.1907-1912.1995; Derse D, 2001, J VIROL, V75, P8461, DOI 10.1128/JVI.75.18.8461-8468.2001; Derse D, 1996, J ACQ IMMUN DEF SYND, V12, P1, DOI 10.1097/00042560-199605010-00001; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; Heidecker G, 2004, J VIROL, V78, P6636, DOI 10.1128/JVI.78.12.6636-6648.2004; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; IMAI T, 1993, J IMMUNOL, V151, P6470; Lagaudriere-Gesbert C, 1998, EUR J IMMUNOL, V28, P4332, DOI 10.1002/(SICI)1521-4141(199812)28:12<4332::AID-IMMU4332>3.0.CO;2-8; Le Blanc I, 2002, J VIROL, V76, P905, DOI 10.1128/JVI.76.2.905-911.2002; Le Blanc I, 1999, J VIROL, V73, P1860, DOI 10.1128/JVI.73.3.1860-1867.1999; Levy S, 2005, PHYSIOLOGY, V20, P218, DOI 10.1152/physiol.00015.2005; Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548; Manns A, 1999, LANCET, V353, P1951, DOI 10.1016/S0140-6736(98)09460-4; Mazurov D, 2006, VIROLOGY, V346, P194, DOI 10.1016/j.virol.2005.10.033; Nydegger S, 2006, J CELL BIOL, V173, P795, DOI 10.1083/jcb.200508165; Ono A, 2004, P NATL ACAD SCI USA, V101, P14889, DOI 10.1073/pnas.0405596101; Pique C, 2000, VIROLOGY, V276, P455, DOI 10.1006/viro.2000.0538; Rayne F, 2004, J MOL BIOL, V343, P903, DOI 10.1016/j.jmb.2004.09.013; Rous BA, 2002, MOL BIOL CELL, V13, P1071, DOI 10.1091/mbc.01-08-0409; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Saad JS, 2006, P NATL ACAD SCI USA, V103, P11364, DOI 10.1073/pnas.0602818103; Stipp CS, 2003, TRENDS BIOCHEM SCI, V28, P106, DOI 10.1016/S0968-0004(02)00014-2; Tarrant JM, 2003, TRENDS IMMUNOL, V24, P610, DOI 10.1016/j.it.2003.09.011; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Vogt AB, 2002, IMMUNOL REV, V189, P136, DOI 10.1034/j.1600-065X.2002.18912.x; Wright MD, 2004, TISSUE ANTIGENS, V64, P533, DOI 10.1111/j.1399-0039.2004.00321.x; Yang XW, 2004, J CELL BIOL, V167, P1231, DOI 10.1083/jcb.200404100; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 2000, BIOCHEM J, V351, P629, DOI 10.1042/0264-6021:3510629; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhou B, 2004, CANCER RES, V64, P7455, DOI 10.1158/0008-5472.CAN-04-1574	45	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3896	3903		10.1074/jbc.M607322200	http://dx.doi.org/10.1074/jbc.M607322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17166843	hybrid			2022-12-25	WOS:000244481900054
J	Nieves-Cintron, M; Amberg, GC; Nichols, CB; Molkentin, JD; Santana, LF				Nieves-Cintron, Madeline; Amberg, Gregory C.; Nichols, C. Blake; Molkentin, Jeffery D.; Santana, Luis F.			Activation of NFATc3 down-regulates the beta 1 subunit of large conductance, calcium-activated K+ channels in arterial smooth muscle and contributes to hypertension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ACCUMULATION; CARDIAC-HYPERTROPHY; RECEPTORS; CURRENTS; CELLS	Large conductance, Ca2+-activated K+ (BK) channels modulate the excitability and contractile state of arterial smooth muscle. Recently, we demonstrated that during hypertension, expression of the accessory beta 1 subunit was decreased relative to the pore-forming alpha subunit of the BK channel. Reduced beta 1 subunit expression resulted in BK channels with impaired function due to lowered sensitivity to Ca2+. Here, we tested the hypothesis that activation of the calcineurin/NFATc3 signaling pathway down-regulates beta 1 expression during angiotensin II-induced hypertension. Consistent with this hypothesis, we found that in vivo administration of angiotensin II-activated calcineurin/NFATc3 signaling in arterial smooth muscle. During angiotensin II infusion, arterial smooth muscle BK channel function was decreased in wild type (WT) but not in NFATc3 null (NFATc3(-/-)) mice. Accordingly, beta 1 expression was decreased in WT but not in NFATc3(-/-) arteries. Angiotensin II-induced down-regulation of the beta 1 subunit required Ca2+ influx via L-type Ca2+ channels. However, in the absence of angiotensin II, moderate elevation of [Ca2+](i) alone was not sufficient to activate NFAT transcriptional activity and, thus, decrease beta 1 subunit expression. Importantly, angiotensin II infusion increased systemic blood pressure to a lower extent in NFATc3(-/-) than in WT mice, indicating that this transcription factor is required for the development of severe hypertension during chronic angiotensin II signaling activation. We conclude that activation of calcineurin and NFATc3 during sustained angiotensin II signaling down-regulates the expression of the beta 1 subunit of the BK channel, which in turn contributes to arterial dysfunction and the development of hypertension.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Childrens Hosp, Med Ctr Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	University of Washington; University of Washington Seattle; Cincinnati Children's Hospital Medical Center	Santana, LF (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357290, Seattle, WA 98195 USA.	santana@u.washington.edu		Molkentin, Jeffery/0000-0002-3558-6529; Santana, Luis/0000-0002-4297-8029; Amberg, Gregory/0000-0001-6094-1185	NHLBI NIH HHS [HL077115, HL085870] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085870, R01HL077115] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amberg GC, 2004, J BIOL CHEM, V279, P47326, DOI 10.1074/jbc.M408789200; Amberg GC, 2003, J CLIN INVEST, V112, P717, DOI 10.1172/JC1200318684; Amberg GC, 2003, CIRC RES, V93, P965, DOI 10.1161/01.RES.0000100068.43006.36; Bayguinov O, 2001, AM J PHYSIOL-CELL PH, V281, pC1512, DOI 10.1152/ajpcell.2001.281.5.C1512; Bosc LVG, 2004, J BIOL CHEM, V279, P10702, DOI 10.1074/jbc.M312920200; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; Bueno OF, 2004, CIRC RES, V94, P91, DOI 10.1161/01.RES.0000107197.99679.77; Cox DH, 2000, J GEN PHYSIOL, V116, P411, DOI 10.1085/jgp.116.3.411; Crowley SD, 2006, P NATL ACAD SCI USA, V103, P17985, DOI 10.1073/pnas.0605545103; Gomez MF, 2003, J BIOL CHEM, V278, P46847, DOI 10.1074/jbc.M304765200; Gomez MF, 2002, J BIOL CHEM, V277, P37756, DOI 10.1074/jbc.M203596200; Hagen BM, 2003, AM J PHYSIOL-CELL PH, V285, pC1270, DOI 10.1152/ajpcell.00153.2003; HARDER DR, 1985, CIRC RES, V57, P319, DOI 10.1161/01.RES.57.2.319; Hayabuchi Y, 2001, AM J PHYSIOL-HEART C, V281, pH2480, DOI 10.1152/ajpheart.2001.281.6.H2480; Kleppisch T, 1996, AM J PHYSIOL-HEART C, V271, pH2462, DOI 10.1152/ajpheart.1996.271.6.H2462; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; Kubo M, 1997, J PHYSIOL-LONDON, V503, P489, DOI 10.1111/j.1469-7793.1997.489bg.x; Maravall M, 2000, BIOPHYS J, V78, P2655, DOI 10.1016/S0006-3495(00)76809-3; Meera P, 1996, FEBS LETT, V385, P127; Navedo MF, 2006, J GEN PHYSIOL, V127, P611, DOI 10.1085/jgp.200609519; Navedo MF, 2005, P NATL ACAD SCI USA, V102, P11112, DOI 10.1073/pnas.0500360102; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Ni YG, 2006, CIRCULATION, V114, P1159, DOI 10.1161/CIRCULATIONAHA.106.637124; Pluger S, 2000, CIRC RES, V87, pE53, DOI 10.1161/01.RES.87.11.e53; Rossow CF, 2004, CIRC RES, V94, P1340, DOI 10.1161/01.RES.0000128406.08418.34; Rossow CF, 2006, CIRC RES, V98, P1306, DOI 10.1161/01.RES.0000222028.92993.10; Shipston MJ, 1996, J PHYSIOL-LONDON, V493, P665, DOI 10.1113/jphysiol.1996.sp021413; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Tanaka Y, 1997, J PHYSIOL-LONDON, V502, P545, DOI 10.1111/j.1469-7793.1997.545bj.x; Wellman GC, 2001, AM J PHYSIOL-HEART C, V281, pH2559, DOI 10.1152/ajpheart.2001.281.6.H2559; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Yang L, 2005, J BIOL CHEM, V280, P207, DOI 10.1074/jbc.M410509200	32	93	96	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3231	3240		10.1074/jbc.M608822200	http://dx.doi.org/10.1074/jbc.M608822200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148444	hybrid			2022-12-25	WOS:000243793900050
J	Bloch, I; Quintana, FJ; Gerber, D; Cohen, T; Cohen, IR; Shai, Y				Bloch, Itai; Quintana, Francisco J.; Gerber, Doron; Cohen, Tomer; Cohen, Irun R.; Shai, Yechiel			T-Cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif	FASEB JOURNAL			English	Article						membrane proteins; protein-membrane interaction; peptide-membrane interaction; transmembrane domain; recognition within membranes	TERMINAL HEPTAD REPEAT; TRANSFORM INFRARED-SPECTROSCOPY; FUSION PEPTIDE; MEMBRANE-FUSION; DC-SIGN; UNILAMELLAR VESICLES; RECEPTOR-CD3 COMPLEX; ADJUVANT ARTHRITIS; HELIX INTERACTIONS; ENVELOPE PROTEIN	Fusion peptide (FP) of the HIV gp41 molecule inserts into the T cell membrane during virus-cell fusion. FP also blocks the TCR/CD3 interaction needed for antigen-triggered T cell activation. Here we used in vitro (fluorescence and immunoprecipitation), in vivo (T cell mediated autoinumme disease adjuvant arthritis), and in silico methods to identify the FP-TCR novel interaction motif: the alpha-helical transmembrane domain (TMD) of the TCR alpha chain, and the beta-sheet 5-13 region of the 16 N-terminal aa of FP (FP1-16). Deciphering the molecular mechanism of the immunosuppressive activity of FP provides a new potential target to overcome the immunosuppressant activity of HIV, and in addition a tool for down-regulating immune mediated inflammation.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	yechiel.shai@weizmann.ac.il	Cohen, Irun R/B-3542-2009; Quintana, Francisco Javier/AAB-6915-2020					Adachi T, 1996, EMBO J, V15, P1534, DOI 10.1002/j.1460-2075.1996.tb00497.x; Agirre A, 2000, BBA-BIOMEMBRANES, V1467, P153, DOI 10.1016/S0005-2736(00)00214-5; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Call ME, 2004, EMBO J, V23, P2348, DOI 10.1038/sj.emboj.7600245; Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002; Chang DK, 1997, J VIROL, V71, P6593, DOI 10.1128/JVI.71.9.6593-6602.1997; Chang DK, 1997, EUR J BIOCHEM, V247, P896, DOI 10.1111/j.1432-1033.1997.00896.x; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Epand RM, 2003, BBA-BIOMEMBRANES, V1614, P116, DOI 10.1016/S0005-2736(03)00169-X; Fleming KG, 2001, P NATL ACAD SCI USA, V98, P14340, DOI 10.1073/pnas.251367498; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; Garcia E, 2005, TRAFFIC, V6, P488, DOI 10.1111/j.1600-0854.2005.00293.x; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; Gerber D, 2005, FASEB J, V19, P1190, DOI 10.1096/fj.04-3498fje; Gordon LM, 2002, BBA-BIOMEMBRANES, V1559, P96, DOI 10.1016/S0005-2736(01)00443-6; Gordon LM, 2004, PROTEIN SCI, V13, P1012, DOI 10.1110/ps.03407704; GORDON SM, 1992, J EXPO ANAL ENV EP S, V1, P41; Gorfe AA, 2004, J AM CHEM SOC, V126, P15277, DOI 10.1021/ja046607n; HAYNES BF, 1993, J EXP MED, V177, P717, DOI 10.1084/jem.177.3.717; Johnson WE, 2002, ANNU REV MED, V53, P499, DOI 10.1146/annurev.med.53.082901.104053; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; Kliger Y, 2000, J MOL BIOL, V301, P905, DOI 10.1006/jmbi.2000.4004; Kucerka N, 2005, BIOPHYS J, V88, P2626, DOI 10.1529/biophysj.104.056606; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; Manolios N, 1997, NAT MED, V3, P84, DOI 10.1038/nm0197-84; McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238; Mobley PW, 1999, BBA-BIOMEMBRANES, V1418, P1, DOI 10.1016/S0005-2736(99)00014-0; Nagle JF, 2000, CURR OPIN STRUC BIOL, V10, P474, DOI 10.1016/S0959-440X(00)00117-2; Nagle JF, 2000, BBA-REV BIOMEMBRANES, V1469, P159, DOI 10.1016/S0304-4157(00)00016-2; Peisajovich SG, 2000, BIOCHEMISTRY-US, V39, P1826, DOI 10.1021/bi991887i; Peisajovich SG, 2002, TRENDS BIOCHEM SCI, V27, P183, DOI 10.1016/S0968-0004(01)02050-3; Peisajovich SG, 2003, BBA-BIOMEMBRANES, V1614, P122, DOI 10.1016/S0005-2736(03)00170-6; Petrache HI, 1998, CHEM PHYS LIPIDS, V95, P83, DOI 10.1016/S0009-3084(98)00068-1; Petrache HI, 2000, BIOPHYS J, V79, P3172, DOI 10.1016/S0006-3495(00)76551-9; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Quintana FJ, 2005, J CLIN INVEST, V115, P2149, DOI 10.1172/JCI23956; Quintana FJ, 2003, J IMMUNOL, V171, P3533, DOI 10.4049/jimmunol.171.7.3533; Quintana FJ, 2002, J IMMUNOL, V169, P3422, DOI 10.4049/jimmunol.169.6.3422; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; Sackett K, 2002, BIOCHEMISTRY-US, V41, P4678, DOI 10.1021/bi0255322; Sackett K, 2005, J MOL BIOL, V350, P790, DOI 10.1016/j.jmb.2005.05.030; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; SLEPUSHKIN VA, 1992, AIDS RES HUM RETROV, V8, P9, DOI 10.1089/aid.1992.8.9; Sugaya M, 2004, J IMMUNOL, V172, P2219, DOI 10.4049/jimmunol.172.4.2219; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; Wexler-Cohen Y, 2005, BIOCHEMISTRY-US, V44, P5853, DOI 10.1021/bi047666g; Woods TC, 1997, BLOOD, V89, P1635, DOI 10.1182/blood.V89.5.1635.1635_1635_1641; Yang J, 2001, BIOCHEMISTRY-US, V40, P8126, DOI 10.1021/bi0100283; Yang J, 2001, J MOL GRAPH MODEL, V19, P129, DOI 10.1016/S1093-3263(00)00128-5	53	35	41	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					393	401		10.1096/fj.06-7061com	http://dx.doi.org/10.1096/fj.06-7061com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17185749				2022-12-25	WOS:000244686300013
J	Lindholm, E; Melander, O; Almgren, P; Berglund, G; Agardh, CD; Groop, L; Orho-Melander, M				Lindholm, Eero; Melander, Olle; Almgren, Peter; Berglund, Goran; Agardh, Carl-David; Groop, Leif; Orho-Melander, Marju			Polymorphism in the MHC2TA Gene Is Associated with Features of the Metabolic Syndrome and Cardiovascular Mortality	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; DIABETIC-NEPHROPATHY; RISK-FACTORS; MICROALBUMINURIA; SUSCEPTIBILITY; INFLAMMATION; MULTIPLE; HISTORY; DESIGN	Background. Recently, a -168A -> G polymorphism in the MHC class II transactivator gene (MHC2TA) was shown to be associated with increased susceptibility to myocardial infarction (MI). Aim. To confirm the association between the MHC2TA -168A -> G polymorphism and MI and to study its putative role for microalbuminuria, the metabolic syndrome (MetS) and cardiovascular mortality. Materials and Methods. Using an allelic discrimination method we genotyped 11,064 individuals from three study populations: 1) 4,432 individuals from the Botnia type 2 diabetes (T2D) study, 2) 1,222 patients with MI and 2,345 control subjects participating in the Malmo "Diet and Cancer study and comprising an MI case-control sample, and 3) 3,065 T2D patients from the Local Swedish Diabetes registry. Results. No association between the -168A -> G polymorphism in MHC2TA and MI was observed. However, in the Botnia cohort the AG/GG genotypes were associated with cardiovascular mortality after MI (1.78 [1.09-2.92], p = 0.02). In addition, the AG/GG genotypes were more common in subjects with MetS (40.1% vs. 36.9%, p = 0.03) and in non-diabetic subjects with microalbuminuria (45.4% vs. 36.5%, p = 0.003) compared to control subjects. Conclusions. A polymorphism in MHC2TA was associated with cardiovascular mortality and predictors of cardiovascular mortality, microalbuminuria and MetS.	[Lindholm, Eero; Melander, Olle; Almgren, Peter; Berglund, Goran; Agardh, Carl-David; Groop, Leif; Orho-Melander, Marju] Lund Univ, Dept Clin Sci, Clin Res Ctr, Univ Hosp Malmo MAS, Malmo, Sweden	Lund University	Lindholm, E (corresponding author), Lund Univ, Dept Clin Sci, Clin Res Ctr, Univ Hosp Malmo MAS, Malmo, Sweden.	Eero.Lindholm@lu.se		Lindholm, Eero/0000-0002-8869-681X; Melander, Olle/0000-0002-2581-484X	Diabetes Program at Lund University (DPLU); Foundation for Strategic Research through the National Network for Cardiovascular Research; Swedish Medical Research Council; Albert Pa hlssons Foundation; Malmo University Hospital Foundations; Crafoord Foundation; Novo Nordisk Foundation; Swedish Heart and Lung Foundation; Medical Faculty of Lund University; Skane County Council Research and Development Foundation; Sigrid Juselius Foundation; Academy of Finland; Finnish Diabetes Research Foundation; Folkhalsan Research Foundation; Viktor Ollqvist Foundation	Diabetes Program at Lund University (DPLU); Foundation for Strategic Research through the National Network for Cardiovascular Research; Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Albert Pa hlssons Foundation; Malmo University Hospital Foundations; Crafoord Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Medical Faculty of Lund University; Skane County Council Research and Development Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Academy of Finland(Academy of Finland); Finnish Diabetes Research Foundation; Folkhalsan Research Foundation; Viktor Ollqvist Foundation	This work was supported by grants from the Diabetes Program at Lund University (DPLU), the Foundation for Strategic Research through the National Network for Cardiovascular Research, the Swedish Medical Research Council, the Albert Pa hlssons Foundation, the Malmo University Hospital Foundations, the Crafoord Foundation, the Novo Nordisk Foundation, the Swedish Heart and Lung Foundation, the Medical Faculty of Lund University and the Skane County Council Research and Development Foundation. The Botnia Study is principally supported by the Sigrid Juselius Foundation, the Academy of Finland, the Finnish Diabetes Research Foundation, the Folkhalsan Research Foundation, and the Viktor Ollqvist Foundation.	Aso Y, 2004, CLIN CHIM ACTA, V348, P139, DOI 10.1016/j.cccn.2004.05.006; BERGLUND G, 1993, J INTERN MED, V233, P45, DOI 10.1111/j.1365-2796.1993.tb00647.x; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42; Greenland P, 2003, JAMA-J AM MED ASSOC, V290, P891, DOI 10.1001/jama.290.7.891; Groop L, 1996, DIABETES, V45, P1585, DOI 10.2337/diabetes.45.11.1585; Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683; Khot UN, 2003, JAMA-J AM MED ASSOC, V290, P898, DOI 10.1001/jama.290.7.898; Lee SH, 2005, NEPHROLOGY, V10, pS32, DOI 10.1111/j.1440-1797.2005.00454.x; Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878; Lindholm E, 2001, EUR J EPIDEMIOL, V17, P983, DOI 10.1023/A:1020036805655; MOGENSEN CE, 1995, DIABETES CARE, V18, P572, DOI 10.2337/diacare.18.4.572; MOGENSEN CE, 1985, UREMIA INVEST, V9, P85, DOI 10.3109/08860228509088195; Ozaki K, 2004, NATURE, V429, P72, DOI 10.1038/nature02502; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Pasternak Richard C., 2003, Cardiology Clinics, V21, P393, DOI 10.1016/S0733-8651(03)00080-8; Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149; Swanberg M, 2005, NAT GENET, V37, P486, DOI 10.1038/ng1544; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; von Wowern F, 2005, KIDNEY INT, V68, P2164, DOI 10.1111/j.1523-1755.2005.00672.x; Wang Q, 2005, CURR OPIN CARDIOL, V20, P182, DOI 10.1097/01.hco.0000160373.77190.f1; YUDKIN JS, 1988, LANCET, V2, P530	23	18	19	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e64	10.1371/journal.pone.0000064	http://dx.doi.org/10.1371/journal.pone.0000064			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183695	gold, Green Published, Green Submitted			2022-12-25	WOS:000207443600064
J	Roord, STA; Zonneveld-Huijssoon, E; Le, T; Yung, GP; Koffeman, E; Ronaghy, A; Ghahramani, N; Lanza, P; Billetta, R; Prakken, BJ; Albani, S				Roord, Sarah T. A.; Zonneveld-Huijssoon, Evelien; Le, Tho; Yung, Gisella Puga; Koffeman, Eva; Ronaghy, Arash; Ghahramani, Negar; Lanza, Paola; Billetta, Rosario; Prakken, Berent J.; Albani, Salvatore			Modulation of T Cell Function by Combination of Epitope Specific and Low Dose Anticytokine Therapy Controls Autoimmune Arthritis	PLOS ONE			English	Article								Innate and adaptive immunity contribute to the pathogenesis of autoimmune arthritis by generating and maintaining inflammation, which leads to tissue damage. Current biological therapies target innate immunity, eminently by interfering with single pro-inflammatory cytokine pathways. This approach has shown excellent efficacy in a good proportion of patients with Rheumatoid Arthritis (RA), but is limited by cost and side effects. Adaptive immunity, particularly T cells with a regulatory function, plays a fundamental role in controlling inflammation in physiologic conditions. A growing body of evidence suggests that modulation of T cell function is impaired in autoimmunity. Restoration of such function could be of significant therapeutic value. We have recently demonstrated that epitope-specific therapy can restore modulation of T cell function in RA patients. Here, we tested the hypothesis that a combination of anti-cytokine and epitope-specific immunotherapy may facilitate the control of autoimmune inflammation by generating active T cell regulation. This novel combination of mucosal tolerization to a pathogenic T cell epitope and single low dose anti-TNF alpha was as therapeutically effective as full dose anti-TNFa treatment. Analysis of the underlying immunological mechanisms showed induction of T cell immune deviation.	[Roord, Sarah T. A.; Le, Tho; Yung, Gisella Puga; Koffeman, Eva; Ronaghy, Arash; Albani, Salvatore] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Roord, Sarah T. A.; Le, Tho; Yung, Gisella Puga; Koffeman, Eva; Albani, Salvatore] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Roord, Sarah T. A.; Zonneveld-Huijssoon, Evelien; Prakken, Berent J.] Wilhelmina Childrens Hosp, Univ Med Ctr Utrecht, Dept Pediat Immunol, Utrecht, Netherlands; [Ghahramani, Negar; Lanza, Paola; Billetta, Rosario; Albani, Salvatore] Androclus Therapeut, San Diego, CA USA; [Roord, Sarah T. A.; Zonneveld-Huijssoon, Evelien; Le, Tho; Yung, Gisella Puga; Koffeman, Eva; Prakken, Berent J.; Albani, Salvatore] EUREKA Inst Translat Med, Immunol Adv Ctr, Preclin Immunogenom Project, Siracusa, Italy	University of California System; University of California San Diego; University of California System; University of California San Diego; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Albani, S (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	salbani@ucsd.edu		, Gisella/0000-0002-2283-7798	Royal Netherlands Academy of Arts and Sciences; Dutch Society of Scientific Research (NWO); NIAMS and NIAD, NIH	Royal Netherlands Academy of Arts and Sciences; Dutch Society of Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); NIAMS and NIAD, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Roord was supported by a grant from the Ter Meulen Fund of the Royal Netherlands Academy of Arts and Sciences and the Dutch Society of Scientific Research (NWO). The work was in part supported by grants from the NIAMS and NIAD branches of the NIH, and by a gift from Associazione Italiana per la Ricerca contro l'Artrite. Prakken and Zonneveld-Huijssoon are supported by an Innovation Grant from the Dutch Society for Scientific Research (NWO). Koffeman is supported by a Grant from the Ter Meulen Fund from the Royal Netherlands Academy for Arts and Sciences.	ALBANI S, 1994, J PEDIATR-US, V124, P561, DOI 10.1016/S0022-3476(05)83134-8; Albani S, 1996, IMMUNOL TODAY, V17, P466, DOI 10.1016/0167-5699(96)20029-G; ALBANI S, 1995, NAT MED, V1, P448, DOI 10.1038/nm0595-448; ALBANI S, 1994, CLIN EXP RHEUMATOL, V12, pS35; Anderson PO, 2006, EUR J IMMUNOL, V36, P1374, DOI 10.1002/eji.200635883; ANDERTON SM, 1995, J EXP MED, V181, P943, DOI 10.1084/jem.181.3.943; Bach JF, 2003, NAT REV IMMUNOL, V3, P189, DOI 10.1038/nri1026; Baecher-Allan C, 2004, SEMIN IMMUNOL, V16, P89, DOI 10.1016/j.smim.2003.12.005; Banchereau J, 2004, IMMUNITY, V20, P539, DOI 10.1016/S1074-7613(04)00108-6; Bendele AM, 1999, CLIN EXP RHEUMATOL, V17, P553; Bloom BJ, 2000, ARTHRITIS RHEUM, V43, P2606, DOI 10.1002/1529-0131(200011)43:11<2606::AID-ANR31>3.0.CO;2-X; Bluestone JA, 2006, SEMIN IMMUNOL, V18, P77, DOI 10.1016/j.smim.2006.01.003; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Bresson D, 2006, J CLIN INVEST, V116, P1371, DOI 10.1172/JCI27191; Cope AP, 2004, CURR OPIN IMMUNOL, V16, P780, DOI 10.1016/j.coi.2004.09.005; de Kleer I, 2006, BLOOD, V107, P1696, DOI 10.1182/blood-2005-07-2800; de Kleer IM, 2003, ARTHRITIS RHEUM, V48, P2001, DOI 10.1002/art.11174; Dekker L, 2004, CLIN EXP RHEUMATOL, V22, P252; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; Ehrenstein MR, 2004, J EXP MED, V200, P277, DOI 10.1084/jem.20040165; Garrood T, 2006, ARTHRITIS RHEUM-US, V54, P1055, DOI 10.1002/art.21720; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; Kamphuis S, 2005, LANCET, V366, P50, DOI 10.1016/S0140-6736(05)66827-4; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; LaCava A, 1997, J CLIN INVEST, V100, P658, DOI 10.1172/JCI119577; Larche M, 2006, IMMUNOL ALLERGY CLIN, V26, P321, DOI 10.1016/j.iac.2006.02.005; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Masteller EL, 2006, SEMIN IMMUNOL, V18, P103, DOI 10.1016/j.smim.2006.01.004; Nolte-'t Hoen ENM, 2004, EUR J IMMUNOL, V34, P3016, DOI 10.1002/eji.200324725; Olsen NJ, 2004, NEW ENGL J MED, V350, P2167, DOI 10.1056/NEJMra032906; Prakken ABJ, 1996, ARTHRITIS RHEUM-US, V39, P1826, DOI 10.1002/art.1780391108; Prakken BJ, 2001, CURR DIRECT AUTOIMMU, V3, P51; Prakken BJ, 2004, P NATL ACAD SCI USA, V101, P4228, DOI 10.1073/pnas.0400061101; Prakken BJ, 2003, SPRINGER SEMIN IMMUN, V25, P47, DOI 10.1007/s00281-003-0128-7; Prakken BJ, 1997, P NATL ACAD SCI USA, V94, P3284, DOI 10.1073/pnas.94.7.3284; Prakken BJ, 2002, ARTHRITIS RHEUM, V46, P1937, DOI 10.1002/art.10366; Sakaguchi S, 2003, J CLIN INVEST, V112, P1310, DOI 10.1172/JCI200320274; Schotte H, 2004, RHEUMATOLOGY, V43, P960, DOI 10.1093/rheumatology/keh178; Tarzi M, 2006, CLIN EXP ALLERGY, V36, P465, DOI 10.1111/j.1365-2222.2006.02469.x; Taylor PC, 2001, CURR OPIN RHEUMATOL, V13, P164, DOI 10.1097/00002281-200105000-00003; Valencia X, 2006, BLOOD, V108, P253, DOI 10.1182/blood-2005-11-4567; van Eden W, 1998, IMMUNOL TODAY, V19, P303, DOI 10.1016/S0167-5699(98)01283-3; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441; Zanin-Zhorov A, 2006, J CLIN INVEST, V116, P2022, DOI 10.1172/JCI28423; Zou J, 2003, ANN RHEUM DIS, V62, P561, DOI 10.1136/ard.62.6.561	49	29	32	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e87	10.1371/journal.pone.0000087	http://dx.doi.org/10.1371/journal.pone.0000087			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183718	gold, Green Submitted, Green Published			2022-12-25	WOS:000207443600086
J	Fan, Y; Gelinas, C				Fan, Y.; Gelinas, C.			An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation	ONCOGENE			English	Article						Rel; NF-kappa B; transcription; transactivation; transformation	CLASSICAL HODGKIN LYMPHOMA; CHICKEN SPLEEN-CELLS; V-REL; TRANSACTIVATION DOMAIN; MALIGNANT TRANSFORMATION; BREAST-CANCER; DNA-BINDING; EXPRESSION; MUTATIONS; PROTEIN	c-Rel is overexpressedin several B-cell lymphomas and c-rel gene overexpression can transform primary chicken lymphoid cells and induce tumors in animals. Although c-Rel is generally a stronger transcriptional activator than its viral derivative v-Rel, its oncogenic activity is significantly weaker. Among the mutations acquired during c-Rel's evolution into v-Rel are deletion of c-Rel's transactivation domain 2 ( cTAD2) and mutations in cTAD1. Given the critical role of the Rel TADs in cell transformation, we investigated how mutations in c-Rel's cTAD1 and cTAD2 contribute to its oncogenicity and that of v-Rel. Mutations in cTAD2 noticeably increased c-Rel's transforming activity by promoting its nuclear localization and gene-specific transactivation, despite an overall decrease in kappa B site-dependent transactivation potency. Conversely, substitution of vTAD by cTAD1 increased v-Rel's transactivation and transforming efficiencies, whereas its substitution by the stronger cTAD2 compromised activation of mip-1b but not irf-4 and was detrimental to cell transformation. These results suggest that the Rel TADs differentially contribute to gene specific activation and that an optimal range of transcription potency is necessary for efficient transformation. These findings may have important implications for understanding how Rel TAD mutations can lead to a more oncogenic phenotype.	Rutgers State Univ, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Canc Inst New Jersey, New Brunswick, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Gelinas, C (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, 679 Hoes Lane, Piscataway, NJ 08854 USA.	gelinas@cabm.rutgers.edu			NCI NIH HHS [CA54999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054999, R29CA054999] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; Carrasco D, 1998, J EXP MED, V187, P973, DOI 10.1084/jem.187.7.973; Chen CL, 1999, MOL CELL BIOL, V19, P307; Chen CL, 2001, MOL CELL BIOL, V21, P7115; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; Fan YJ, 2004, ONCOGENE, V23, P1030, DOI 10.1038/sj.onc.1207221; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HRDLICKOVA R, 1994, J VIROL, V68, P308; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Iwai K, 2005, FEBS LETT, V579, P141, DOI 10.1016/j.febslet.2004.11.060; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Petrenko O, 1997, ONCOGENE, V15, P1671, DOI 10.1038/sj.onc.1201334; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Savage KJ, 2003, BLOOD, V102, P3871, DOI 10.1182/blood-2003-06-1841; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Starczynowski DT, 2005, ONCOGENE, V24, P7355, DOI 10.1038/sj.onc.1208902; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; STARCZYNOWSKI DT, 2006, ONCOGENE        1030	33	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					4038	4043		10.1038/sj.onc.1210164	http://dx.doi.org/10.1038/sj.onc.1210164			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17173064				2022-12-25	WOS:000247144500015
J	Cowling, VH; Cole, MD				Cowling, V. H.; Cole, M. D.			E-cadherin repression contributes to c-Myc-induced epithelial cell transformation	ONCOGENE			English	Article						c-Myc; E-cadherin; transformation; epithelial cell; EMT	TRANSCRIPTION FACTOR SNAIL; MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; METASTASIS; GROWTH	c-Myc oncoprotein is overexpressed in a significant proportion of human epithelial cancers, and experimental overexpression of c-Myc in epithelial cells promotes tumour formation. However, it is not known how c-Myc promotes epithelial cell tumour formation. We report that c-Myc expression in human mammary epithelial cells induces a dramatic change in cell morphology, with some characteristics of an 'epithelial to mesenchymal transition'. E-cadherin expression is repressed by a post-transcriptional mechanism in cells expressing c-Myc. Furthermore, E-cadherin repression is necessary for c-Myc-induced cell transformation.	Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Pharmacol, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Genet, Lebanon, NH 03756 USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center	Cole, MD (corresponding author), Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Pharmacol, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	mcole@dartmouth.edu		Cowling, Victoria/0000-0001-7638-4870	MRC [G0700240] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [R01CA080320] Funding Source: NIH RePORTER; Medical Research Council [G0700240] Funding Source: Medline; NCI NIH HHS [CA80320] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; DiRenzo J, 2002, CANCER RES, V62, P89; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; GRAFF JR, 1995, CANCER RES, V55, P5195; Niveditha S R, 2003, Indian J Pathol Microbiol, V46, P579; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822	18	49	50	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3582	3586		10.1038/sj.onc.1210132	http://dx.doi.org/10.1038/sj.onc.1210132			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17146437				2022-12-25	WOS:000246799200014
J	Ohkawa, Y; Yoshimura, S; Higashi, C; Marfella, CGA; Dacwag, CS; Tachibana, T; Imbalzano, AN				Ohkawa, Yasuyuki; Yoshimura, Saori; Higashi, Chiduru; Marfella, Concetta G. A.; Dacwag, Caroline S.; Tachibana, Taro; Imbalzano, Anthony N.			Myogenin and the SWI/SNF ATPase Brg1 maintain myogenic gene expression at different stages of skeletal myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEXES; MUSCLE DIFFERENTIATION; SATELLITE CELLS; STEM-CELLS; MYOD; SPECIFICATION; ACTIVATION; MUTATION; DISTINCT; FAMILY	Many studies have examined transcriptional regulation during the initiation of skeletal muscle differentiation; however, there is less information regarding transcriptional control during adult myogenesis and during the maintenance of the differentiated state. MyoD and the mammalian SWI/SNF chromatinremodeling enzymes containing the Brg1 ATPase are necessary to induce myogenesis in cell culture models and in developing embryonic tissue, whereas myogenin and Brg1 are critical for the expression of the late genes that induce terminal muscle differentiation. Here, we demonstrate that myogenin also binds to its own promoter during the late stages of embryonic muscle development. As is the case during embryonic myogenesis, MyoD and Brg1 co-localize to the myogenin promoter in primary adult muscle satellite cells. However, in mature myofibers, myogenin and Brg1 are preferentially co-localized to the myogenin promoter. Thus, the myogenin promoter is occupied by different myogenic factors at different times of myogenesis. The relevance of myogenin in the continued expression from its own promoter is demonstrated in culture, where we show that myogenin, in the absence of MyoD, is capable of maintaining its own expression by recruiting the Brg1 ATPase to modify promoter chromatin structure and facilitate myogenin expression. Finally, we utilized in vivo electroporation to demonstrate that Brg1 is required for the continued production of the myogenin protein in newborn skeletal muscle tissue. These findings strongly suggest that the skeletal muscle phenotype is maintained by myogenin and the continuous activity of Brg1-based SWI/SNF chromatin-remodeling enzymes.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Osaka City Univ, Dept Bioengn, Osaka 5588585, Japan	University of Massachusetts System; University of Massachusetts Worcester; Osaka Metropolitan University	Imbalzano, AN (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	anthony.imbalzano@umassmed.edu	Ohkawa, Yasuyuki/C-4087-2016; Ohkawa, Yasuyuki/ABG-1839-2021	Ohkawa, Yasuyuki/0000-0001-6440-9954; Ohkawa, Yasuyuki/0000-0001-6440-9954	NIGMS NIH HHS [GM56244, R01 GM056244] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056244] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432-0436.2001.680412.x; Bergstrom DA, 2001, MOL CELL BIOL, V21, P2404, DOI 10.1128/MCB.21.7.2404-2412.2001; Blais A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Cao Y, 2006, EMBO J, V25, P502, DOI 10.1038/sj.emboj.7600958; CHENG TC, 1995, P NATL ACAD SCI USA, V92, P561, DOI 10.1073/pnas.92.2.561; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; Dhawan J, 2005, TRENDS CELL BIOL, V15, P666, DOI 10.1016/j.tcb.2005.10.007; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Holterman CE, 2005, SEMIN CELL DEV BIOL, V16, P575, DOI 10.1016/j.semcdb.2005.07.004; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Knapp JR, 2006, DEVELOPMENT, V133, P601, DOI 10.1242/dev.02249; Konno D, 2005, J BIOL CHEM, V280, P5082, DOI 10.1074/jbc.M408251200; Lickert H, 2004, NATURE, V432, P107, DOI 10.1038/nature03071; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Ohkawa Y, 2006, EMBO J, V25, P490, DOI 10.1038/sj.emboj.7600943; Olguin HC, 2004, DEV BIOL, V275, P375, DOI 10.1016/j.ydbio.2004.08.015; Parker MH, 2006, MOL CELL BIOL, V26, P5771, DOI 10.1128/MCB.02404-05; Pownall ME, 2002, ANNU REV CELL DEV BI, V18, P747, DOI 10.1146/annurev.cellbio.18.012502.105758; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Roy K, 2002, J BIOL CHEM, V277, P33818, DOI 10.1074/jbc.M205159200; Saito T, 2001, DEV BIOL, V240, P237, DOI 10.1006/dbio.2001.0439; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; Tapscott SJ, 2005, DEVELOPMENT, V132, P2685, DOI 10.1242/dev.01874; Valdez MR, 2000, DEV BIOL, V219, P287, DOI 10.1006/dbio.2000.9621; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	38	61	64	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6564	6570		10.1074/jbc.M608898200	http://dx.doi.org/10.1074/jbc.M608898200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17194702	hybrid			2022-12-25	WOS:000244867200065
J	Ventadour, S; Jarzaguet, M; Wing, SS; Chambon, C; Combaret, L; Bechet, D; Attaix, D; Taillandier, D				Ventadour, Sophie; Jarzaguet, Marianne; Wing, Simon S.; Chambon, Christophe; Combaret, Lydie; Bechet, Daniel; Attaix, Didier; Taillandier, Daniel			A new method of purification of proteasome substrates reveals polyubiquitination of 20 S proteasome subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN; EXPRESSION; PROTEINS; BINDING	The 26 S proteasome is implicated in the control of many major biological functions but a reliable method for the identification of its major substrates, i.e. polyubiquitin (Ub) conjugates, is still lacking. Based on the steps present in cells, i.e. recognition and deubiquitination, we developed an affinity matrix-based purification of polyUb conjugates suitable for any biological sample. Ub-conjugates were first purified from proteasome inhibitor-treated C2C12 cells using the Ub binding domains of the S5a proteasome subunit bound to an affinity matrix and then deubiquitinated by the catalytic domain of the USP2 enzyme. This two step purification of proteasome substrates involving both protein-protein interactions and enzyme-mediated release allowed highly specific isolation of polyUb 26 S proteasome substrates, which were then resolved on two-dimensional gels post-deubiquitination. To establish our method, we focused on a gel area where spots were best resolved. Surprisingly, spot analysis by mass spectrometry identified alpha 2, alpha 6, alpha 7, beta 2, beta 3, beta 4, and beta 5 20 S proteasome subunits as potential substrates. Western blots using an anti-beta 3 proteasome subunit antibody confirmed that high molecular weight forms of beta 3 were present, particularly in proteasome inhibitor-treated cells. Sucrose gradients of cell lysates suggested that the proteasome was first disassembled before subunits were polyubiquitinated. Altogether, we provide a technique that enables large scale identification of 26 S proteasome substrates that should contribute to a better understanding of this proteolytic machinery in any living cell and/or organ/tissue. Furthermore, the data suggest that proteasome homeostasis involves an autoregulatory mechanism.	INRA, UMR1019, Human Nutr Unit, F-63122 Ceyrat, France; Human Nutr Res Ctr, Proteom Core Facil, F-63122 Ceyrat, France; McGill Univ, Dept Med, Montreal, PQ H3A 2B2, Canada	INRAE; McGill University	Taillandier, D (corresponding author), INRA, UMR1019, Human Nutr Unit, F-63122 Ceyrat, France.	taillandier@clermont.inra.fr	Bechet, Daniel/AAU-2874-2020; chambon, christophe/A-1788-2017; Attaix, Didier/H-5247-2011; Wing, Simon/D-2589-2012	Bechet, Daniel/0000-0002-3812-8099; chambon, christophe/0000-0003-0357-9807; Wing, Simon/0000-0001-8394-7563; Taillandier, Daniel/0000-0003-4520-0551; Attaix, Didier/0000-0002-0429-9957; Combaret, Lydie/0000-0001-6550-8700				Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Bose S, 2004, BIOCHEM J, V378, P177, DOI 10.1042/BJ20031122; Chondrogianni N, 2005, J BIOL CHEM, V280, P11840, DOI 10.1074/jbc.M413007200; Denison C, 2005, CURR OPIN CHEM BIOL, V9, P69, DOI 10.1016/j.cbpa.2004.10.010; Geetha T, 2005, EMBO J, V24, P3859, DOI 10.1038/sj.emboj.7600845; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hitchcock AL, 2003, P NATL ACAD SCI USA, V100, P12735, DOI 10.1073/pnas.2135500100; Holzl H, 2000, J CELL BIOL, V150, P119, DOI 10.1083/jcb.150.1.119; Hosoda M, 2005, ONCOGENE, V24, P7156, DOI 10.1038/sj.onc.1208872; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lin HJ, 2001, J BIOL CHEM, V276, P20357, DOI 10.1074/jbc.M008761200; Marotti LA, 2002, BIOCHEMISTRY-US, V41, P5067, DOI 10.1021/bi015940q; Matsumoto M, 2005, PROTEOMICS, V5, P4145, DOI 10.1002/pmic.200401280; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Piec I, 2005, FASEB J, V19, P1143, DOI 10.1096/fj.04-3084fje; Raasi S, 2004, J MOL BIOL, V341, P1367, DOI 10.1016/j.jmb.2004.06.057; Raasi S, 2005, NAT STRUCT MOL BIOL, V12, P708, DOI 10.1038/nsmb962; Somara S, 2004, AM J PHYSIOL-CELL PH, V286, pC1290, DOI 10.1152/ajpcell.00458.2003; Wang QH, 2005, J MOL BIOL, V348, P727, DOI 10.1016/j.jmb.2005.03.007; Weekes J, 2003, PROTEOMICS, V3, P208, DOI 10.1002/pmic.200390029; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158; ZHANG N, 1993, DEV BIOL, V157, P214, DOI 10.1006/dbio.1993.1125	25	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5302	5309		10.1074/jbc.M610005200	http://dx.doi.org/10.1074/jbc.M610005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189251	Green Published, hybrid			2022-12-25	WOS:000244482300025
J	Gong, HS; Murphy, A; McMaster, CR; Byers, DM				Gong, Huansheng; Murphy, Anne; McMaster, Christopher R.; Byers, David M.			Neutralization of acidic residues in helix II stabilizes the folded conformation of acyl carrier protein and variably alters its function with different enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGLUCOSAMINE; ESCHERICHIA-COLI; VIBRIO-HARVEYI; POLYKETIDE SYNTHASE; CATION-BINDING; BIOSYNTHESIS; SYNTHETASE; ACYLTRANSFERASE; IDENTIFICATION; SITE	Acyl carrier protein (ACP), a small protein essential for bacterial growth and pathogenesis, interacts with diverse enzymes during the biosynthesis of fatty acids, phospholipids, and other specialized products such as lipid A. NMR and hydrodynamic studies have previously shown that divalent cations stabilize native helical ACP conformation by binding to conserved acidic residues at two sites (A and B) at either end of the "recognition" helix II. To examine the roles of these amino acids in ACP structure and function, site-directed mutagenesis was used to replace individual site A (Asp-30, Asp-35, Asp-38) and site B (Glu-47, Glu-53, Asp-56) residues in recombinant Vibrio harveyi ACP with the corresponding amides, along with combined mutations at each site (SA, SB) or both sites (SA/SB). Like native V, harveyi ACP, all individual mutants were unfolded at neutral pH but adopted a helical conformation in the presence of millimolar Mg2+ or upon fatty acylation. Mg2+ binding to sites A or B independently stabilized native ACP conformation, whereas mutant SA/SB was folded in the absence of Mg2+, suggesting that charge neutralization is largely responsible for ACP stabilization by divalent cations. Asp-35 in site A was critical for holo-ACP synthase activity, while acyl-ACP synthetase and UDP-N-acetylglucosamine acyltransferase (LpxA) activities were more affected by mutations in site B. Both sites were required for fatty acid synthase activity. Overall, our results indicate that divalent cation binding site mutations have predicted effects on ACP conformation but unpredicted and variable consequences on ACP function with different enzymes.	Dalhousie Univ, Atlantic Res Ctr, Clin Res Ctr, Dept Pediat, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Atlantic Res Ctr, Clin Res Ctr, Dept Biochem, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Atlantic Res Ctr, Clin Res Ctr, Dept Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University; Dalhousie University	Byers, DM (corresponding author), Dalhousie Univ, Atlantic Res Ctr, Clin Res Ctr, Dept Pediat, Rm C-305,5849 Univ Ave, Halifax, NS B3H 4H7, Canada.	david.byers@dal.ca		McMaster, Christopher/0000-0003-0822-5776				ABITA JP, 1971, EUR J BIOCHEM, V23, P412, DOI 10.1111/j.1432-1033.1971.tb01635.x; ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ANDREC M, 1995, PROTEIN SCI, V4, P983; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; BYERS DM, 1985, P NATL ACAD SCI USA, V82, P6085, DOI 10.1073/pnas.82.18.6085; Crump MP, 1997, BIOCHEMISTRY-US, V36, P6000, DOI 10.1021/bi970006+; FICE D, 1993, J BACTERIOL, V175, P1865, DOI 10.1128/JB.175.7.1865-1870.1993; Flaman AS, 2001, J BIOL CHEM, V276, P35934, DOI 10.1074/jbc.M101849200; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; FREDERICK AF, 1988, FEBS LETT, V238, P43, DOI 10.1016/0014-5793(88)80222-9; GEIGER O, 1991, J BACTERIOL, V173, P2872, DOI 10.1128/JB.173.9.2872-2878.1991; Gong H, 2003, BIOCHEM BIOPH RES CO, V302, P35, DOI 10.1016/S0006-291X(03)00108-6; HEATON MP, 1994, J BACTERIOL, V176, P681, DOI 10.1128/jb.176.3.681-690.1994; Herald VL, 2003, FEBS LETT, V537, P96, DOI 10.1016/S0014-5793(03)00101-7; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; Jain NU, 2004, J MOL BIOL, V343, P1379, DOI 10.1016/j.jmb.2004.08.103; Jiang YF, 2006, BIOCHEMISTRY-US, V45, P10008, DOI 10.1021/bi060842w; Jordan SW, 1997, J BIOL CHEM, V272, P17903, DOI 10.1074/jbc.272.29.17903; Keating MM, 2002, BBA-PROTEINS PROTEOM, V1601, P208, DOI 10.1016/S1570-9639(02)00470-3; KIM Y, 1989, BIOCHEMISTRY-US, V28, P8792, DOI 10.1021/bi00448a017; Kim Y, 2006, BIOCHEM BIOPH RES CO, V341, P776, DOI 10.1016/j.bbrc.2006.01.025; KIM YM, 1990, J AM CHEM SOC, V112, P3707, DOI 10.1021/ja00165a092; Lambalot RH, 1997, METHOD ENZYMOL, V279, P254; McAllister KA, 2006, J BACTERIOL, V188, P4737, DOI 10.1128/JB.01917-05; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; ROCK CO, 1981, J BIOL CHEM, V256, P2669; ROCK CO, 1982, J BIOL CHEM, V257, P10759; Roujeinikova A, 2002, STRUCTURE, V10, P825, DOI 10.1016/S0969-2126(02)00775-X; RUMLEY MK, 1992, J BIOL CHEM, V267, P11806; Schaefer AL, 1996, P NATL ACAD SCI USA, V93, P9505, DOI 10.1073/pnas.93.18.9505; SCHULZ H, 1969, J BIOL CHEM, V244, P6577; SCHULZ H, 1975, J BIOL CHEM, V250, P2299; SHEN B, 1992, J BACTERIOL, V174, P3818, DOI 10.1128/JB.174.11.3818-3821.1992; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; Sweet CR, 2001, J BIOL CHEM, V276, P19565, DOI 10.1074/jbc.M101868200; TENER DM, 1990, EUR J BIOCHEM, V189, P559, DOI 10.1111/j.1432-1033.1990.tb15523.x; White SW, 2005, ANNU REV BIOCHEM, V74, P791, DOI 10.1146/annurev.biochem.74.082803.133524; Wong HC, 2002, J BIOL CHEM, V277, P15874, DOI 10.1074/jbc.M112300200; Worsham LAS, 2003, BIOCHEMISTRY-US, V42, P167, DOI 10.1021/bi0261950; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Xu GY, 2001, STRUCTURE, V9, P277, DOI 10.1016/S0969-2126(01)00586-X; Zhang YM, 2003, J LIPID RES, V44, P1, DOI 10.1194/jlr.R200016-JLR200; Zhang YM, 2003, J BIOL CHEM, V278, P52935, DOI 10.1074/jbc.M309874200; Zhang YM, 2001, J BIOL CHEM, V276, P8231, DOI 10.1074/jbc.M008042200; Zornetzer GA, 2006, BIOCHEMISTRY-US, V45, P5217, DOI 10.1021/bi052062d	48	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4494	4503		10.1074/jbc.M608234200	http://dx.doi.org/10.1074/jbc.M608234200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17179150	hybrid			2022-12-25	WOS:000244482000031
J	Cnop, M; Ladriere, L; Hekerman, P; Ortis, F; Cardozo, AK; Dogusan, Z; Flamez, D; Boyce, M; Yuan, JY; Eizirik, DL				Cnop, Miriam; Ladriere, Laurence; Hekerman, Paul; Ortis, Fernanda; Cardozo, Alessandra K.; Dogusan, Zeynep; Flamez, Daisy; Boyce, Michael; Yuan, Junying; Eizirik, Decio L.			Selective inhibition of eukaryotic translation initiation factor 2 alpha dephosphorylation potentiates fatty acid-induced endoplasmic reticulum stress and causes pancreatic beta-cell dysfunction and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; INSULIN-PRODUCING CELLS; FACTOR-KAPPA-B; MONOCYTE CHEMOATTRACTANT PROTEIN-1; WOLCOTT-RALLISON-SYNDROME; MESSENGER-RNA; ER STRESS; GLUCOSE-HOMEOSTASIS; PROMOTES SURVIVAL; ISLET CELLS	Free fatty acids cause pancreatic beta-cell apoptosis and may contribute to beta-cell loss in type 2 diabetes via the induction of endoplasmic reticulum stress. Reductions in eukaryotic translation initiation factor (eIF) 2 alpha phosphorylation trigger P-cell failure and diabetes. Salubrinal selectively inhibits eIF2 alpha dephosphorylation, protects other cells against endoplasmic reticulum stress-mediated apoptosis, and has been proposed as a beta-cell protector. Unexpectedly, salubrinal induced apoptosis in primary beta-cells, and it potentiated the deleterious effects of oleate and palmitate. Salubrinal induced a marked eIF2 alpha phosphorylation and potentiated the inhibitory effects of free fatty acids on protein synthesis and insulin release. The synergistic activation of the PERK-eIF2 alpha branch of the endoplasmic reticulum stress response, but not of the IRE1 and activating transcription factor-6 pathways, led to a marked induction of activating transcription factor-4 and the pro-apoptotic transcription factor CHOP. Our findings demonstrate that excessive eIF2 alpha phosphorylation is poorly tolerated by beta-cells and exacerbates free fatty acid-induced apoptosis. This modifies the present paradigm regarding the beneficial role of eIF2 alpha phosphorylation in beta-cells and must be taken into consideration when designing therapies to protect beta-cells in type 2 diabetes.	Free Univ Brussels, Erasmus Sch Med, Expt Med Lab, B-1070 Brussels, Belgium; Erasme Univ Hosp, Div Endocrinol, B-1070 Brussels, Belgium; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Harvard University; Harvard Medical School	Cnop, M (corresponding author), Free Univ Brussels, Erasmus Sch Med, Expt Med Lab, CP-618,Route Lennik 808, B-1070 Brussels, Belgium.	mcnop@ulb.ac.be	Ortis, Fernanda/M-7190-2019; Longo, Kenneth A/A-5631-2010; Ortis, Fernanda/K-7917-2014	Cnop, Miriam/0000-0002-5112-1692; Ortis, Fernanda/0000-0002-9551-2839; DOGUSAN, ZEYNEP/0000-0002-1506-669X; Boyce, Michael/0000-0002-2729-4876; Kupper Cardozo, Alessandra/0000-0001-7143-3696				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Cardozo AK, 2005, DIABETES, V54, P452, DOI 10.2337/diabetes.54.2.452; Chen MC, 2001, DIABETOLOGIA, V44, P325, DOI 10.1007/s001250051622; Cnop M, 2005, DIABETES, V54, pS97, DOI 10.2337/diabetes.54.suppl_2.S97; Cnop M, 2001, DIABETES, V50, P1771, DOI 10.2337/diabetes.50.8.1771; Cnop M, 2002, BIOCHEM PHARMACOL, V63, P1281, DOI 10.1016/S0006-2952(02)00860-2; Darville MI, 1998, DIABETOLOGIA, V41, P1101, DOI 10.1007/s001250051036; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; EIZIRIK DL, 1991, AUTOIMMUNITY, V10, P107, DOI 10.3109/08916939109004814; Eldor R, 2006, P NATL ACAD SCI USA, V103, P5072, DOI 10.1073/pnas.0508166103; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Heimberg H, 2001, DIABETES, V50, P2219, DOI 10.2337/diabetes.50.10.2219; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; Karaskov E, 2006, ENDOCRINOLOGY, V147, P3398, DOI 10.1210/en.2005-1494; Kessel D, 2006, BIOCHEM BIOPH RES CO, V346, P1320, DOI 10.1016/j.bbrc.2006.06.056; Kharroubi I, 2006, DIABETOLOGIA, V49, P2350, DOI 10.1007/s00125-006-0366-5; Kharroubi I, 2004, ENDOCRINOLOGY, V145, P5087, DOI 10.1210/en.2004-0478; Korth MJ, 1996, GENE, V170, P181, DOI 10.1016/0378-1119(95)00883-7; Kutlu B, 2003, DIABETES, V52, P348, DOI 10.2337/diabetes.52.2.348; Ladiges WC, 2005, DIABETES, V54, P1074, DOI 10.2337/diabetes.54.4.1074; LECLERCQMEYER V, 1985, ENDOCRINOLOGY, V116, P1168, DOI 10.1210/endo-116-3-1168; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LING Z, 1994, DIABETOLOGIA, V37, P15; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Maedler K, 2003, DIABETES, V52, P726, DOI 10.2337/diabetes.52.3.726; Mann JI, 2002, LANCET, V360, P783, DOI 10.1016/S0140-6736(02)09901-4; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Oakes SA, 2006, CURR MOL MED, V6, P99, DOI 10.2174/156652406775574587; Ortis F, 2006, MOL ENDOCRINOL, V20, P1867, DOI 10.1210/me.2005-0268; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; Pirot P, 2006, DIABETOLOGIA, V49, P1229, DOI 10.1007/s00125-006-0214-7; Porte D, 2001, DIABETES, V50, pS160, DOI 10.2337/diabetes.50.2007.S160; Rasschaert J, 2005, J BIOL CHEM, V280, P33984, DOI 10.1074/jbc.M502213200; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Scheuner D, 2005, NAT MED, V11, P757, DOI 10.1038/nm1259; Scheuner D, 2006, J BIOL CHEM, V281, P21458, DOI 10.1074/jbc.M603784200; Schroder M, 2006, CURR MOL MED, V6, P5, DOI 10.2174/156652406775574569; Senee V, 2004, DIABETES, V53, P1876, DOI 10.2337/diabetes.53.7.1876; Smith WW, 2005, HUM MOL GENET, V14, P3801, DOI 10.1093/hmg/ddi396; VALVERDE I, 1988, ENDOCRINOLOGY, V122, P1443, DOI 10.1210/endo-122-4-1443; Wang HY, 2005, J CELL SCI, V118, P3905, DOI 10.1242/jcs.02513; Wang Y, 2000, J BIOL CHEM, V275, P27013; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	58	250	262	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3989	3997		10.1074/jbc.M607627200	http://dx.doi.org/10.1074/jbc.M607627200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158450	hybrid, Green Published			2022-12-25	WOS:000244481900063
J	Drenkard, D; Becke, FM; Langstein, J; Spruss, T; Kunz-Schughart, LA; Tan, TE; Lim, YC; Schwarz, H				Drenkard, Daniela; Becke, Florian M.; Langstein, Joachim; Spruss, Thilo; Kunz-Schughart, Leoni A.; Tan, Teng Ee; Lim, Yaw Chyn; Schwarz, Herbert			CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity	FASEB JOURNAL			English	Article						extravasation; vascular biology	FACTOR-RECEPTOR FAMILY; DENDRITIC CELLS; 4-1BB LIGAND; LYMPHOCYTE-ACTIVATION; IN-VIVO; PROLIFERATION; SELECTINS; SURVIVAL; ADHESION; MEMBER	The cytokine receptor CD137 is a member of the TNF receptor family and a potent T cell costimulatory molecule. Its ligand is expressed on antigen presenting cells as a transmembrane protein and it too can deliver signals into the cells it is expressed on (reverse signaling). In monocytes, immobilized CD137 protein induces activation, prolongation of survival and proliferation. Here we show that recombinant immobilized CD137 protein enhances migration of monocytes in vitro. Further, CD137 expression on spheroids leads to a significantly enhanced infiltration by monocytes. The migration-inducing activity of CD137 could be confirmed in vivo. Matrigel, which was coated with recombinant CD137 protein and was inserted into the flanks of mice attracted large numbers of monocytes and was heavily infiltrated by these cells. In vivo, expression of CD137 by blood vessel walls at sites of inflammation was detectable by immunohistochemistry. CD 137 expression is inducible by proinflammatory cytokines in endothelial cells, suggesting that a physiological function of CD 137 may be the facilitation of monocyte extravasation in inflammatory tissues.	Natl Univ Singapore, Dept Physiol, Immunol Program, Singapore 117597, Singapore; Natl Univ Singapore, Dept Pathol, Singapore 117597, Singapore; Univ Regensburg, Dept Pathol, D-8400 Regensburg, Germany; Univ Regensburg, Vet Serv, D-8400 Regensburg, Germany	National University of Singapore; National University of Singapore; University of Regensburg; University of Regensburg	Schwarz, H (corresponding author), Natl Univ Singapore, Dept Physiol, Immunol Program, 2 Med Dr,MD 9, Singapore 117597, Singapore.	phssh@nus.edu.sg		Kunz-Schughart, Leoni/0000-0003-3912-6594				ANDREESEN R, 1990, J LEUKOCYTE BIOL, V47, P490, DOI 10.1002/jlb.47.6.490; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; Duffield JS, 2003, CLIN SCI, V104, P27, DOI 10.1042/CS20020240; Futagawa T, 2002, INT IMMUNOL, V14, P275, DOI 10.1093/intimm/14.3.275; Gonzalez-Amaro R, 1999, CRIT REV IMMUNOL, V19, P389; Guinn B, 1999, J IMMUNOL, V162, P5003; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; Kim YJ, 2002, J HEMATOTH STEM CELL, V11, P895, DOI 10.1089/152581602321080556; Laderach D, 2003, CELL IMMUNOL, V226, P37, DOI 10.1016/j.cellimm.2003.11.003; Langstein J, 2000, BIOCHEM BIOPH RES CO, V273, P117, DOI 10.1006/bbrc.2000.2889; Langstein J, 1999, BLOOD, V94, P3161, DOI 10.1182/blood.V94.9.3161.421k31_3161_3168; Langstein J, 1999, J LEUKOCYTE BIOL, V65, P829, DOI 10.1002/jlb.65.6.829; Langstein J, 1998, J IMMUNOL, V160, P2488; Lotz M, 1996, J LEUKOCYTE BIOL, V60, P1; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Melero I, 1998, EUR J IMMUNOL, V28, P1116, DOI 10.1002/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A; Michel J, 1999, IMMUNOLOGY, V98, P42; Mittler RS, 2004, IMMUNOL RES, V29, P197, DOI 10.1385/IR:29:1-3:197; Muller WA, 2003, TRENDS IMMUNOL, V24, P327, DOI 10.1016/S1471-4906(03)00117-0; Pauly S, 2002, J LEUKOCYTE BIOL, V72, P35; ROMEIS B, 1989, MIKROSKOPISCHE TECHN, P497; Rossiter H, 1997, MOL MED TODAY, V3, P214, DOI 10.1016/S1357-4310(97)01040-X; Schwarz H, 2005, J LEUKOCYTE BIOL, V77, P281, DOI 10.1189/jlb.0904558; Schwarz H, 1996, BLOOD, V87, P2839, DOI 10.1182/blood.V87.7.2839.bloodjournal8772839; SCHWARZ H, 1993, GENE, V134, P295, DOI 10.1016/0378-1119(93)90110-O; SCHWARZ H, 1995, BLOOD, V85, P1043, DOI 10.1182/blood.V85.4.1043.bloodjournal8541043; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; Sica G, 2000, ADV EXP MED BIOL, V465, P355; Tohka S, 2001, FASEB J, V15, P373, DOI 10.1096/fj.00-0240com; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Vestweber D, 2002, CURR OPIN CELL BIOL, V14, P587, DOI 10.1016/S0955-0674(02)00372-1	31	84	90	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					456	463		10.1096/fj.05-4739com	http://dx.doi.org/10.1096/fj.05-4739com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17167064				2022-12-25	WOS:000244686300019
J	Aguayo-Mazzucato, C; Sanchez-Soto, C; Godinez-Puig, V; Gutierrez-Ospina, G; Hiriart, M				Aguayo-Mazzucato, Cristina; Sanchez-Soto, Carmen; Godinez-Puig, Victoria; Gutierrez-Ospina, Gabriel; Hiriart, Marcia			Restructuring of Pancreatic Islets and Insulin Secretion in a Postnatal Critical Window	PLOS ONE			English	Article							ENDOCRINE PANCREAS; BETA-CELLS; GLUCOSE-METABOLISM; HIGH-CARBOHYDRATE; GENE-EXPRESSION; NEONATAL-RAT; B-CELLS; GLUCOKINASE; FETAL; INTERVENTION	Function and structure of adult pancreatic islets are determined by early postnatal development, which in rats corresponds to the first month of life. We analyzed changes in blood glucose and hormones during this stage and their association with morphological and functional changes of alpha and beta cell populations during this period. At day 20 (d20), insulin and glucose plasma levels were two- and six-fold higher, respectively, as compared to d6. Interestingly, this period is characterized by physiological hyperglycemia and hyperinsulinemia, where peripheral insulin resistance and a high plasmatic concentration of glucagon are also observed. These functional changes were paralleled by reorganization of islet structure, cell mass and aggregate size of alpha and beta cells. Cultured beta cells from d20 secreted the same amount of insulin in 15.6 mM than in 5.6 mM glucose (basal conditions), and were characterized by a high basal insulin secretion. However, beta cells from d28 were already glucose sensitive. Understanding and establishing morphophysiological relationships in the developing endocrine pancreas may explain how events in early life are important in determining adult islet physiology and metabolism.	[Aguayo-Mazzucato, Cristina; Sanchez-Soto, Carmen; Hiriart, Marcia] Univ Nacl Autonoma Mexico, Inst Cellular Physiol, Dept Biophys, Mexico City 04510, DF, Mexico; [Gutierrez-Ospina, Gabriel] Univ Nacl Autonoma Mexico, Biomed Res Inst, Dept Cell Biol & Physiol, Mexico City 04510, DF, Mexico; [Godinez-Puig, Victoria] Univ Nacl Autonoma Mexico, Fac Med, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Hiriart, M (corresponding author), Univ Nacl Autonoma Mexico, Inst Cellular Physiol, Dept Biophys, Mexico City 04510, DF, Mexico.	mhiriart@ifc.unam.mx	Hiriart, Marcia/A-3988-2008	Hiriart, Marcia/0000-0001-5711-8868; Gutierrez Ospina, Gabriel/0000-0002-6286-8281	CONACYT [D39822]; DGAPA [211800]	CONACYT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); DGAPA	Funding: This work was supported by CONACYT D39822 and DGAPA 211800. CAM is a fellow of CONACyT and DGEP.	Aalinkeel R, 2001, AM J PHYSIOL-ENDOC M, V281, pE640, DOI 10.1152/ajpendo.2001.281.3.E640; Aalinkeel R, 1999, AM J PHYSIOL-ENDOC M, V277, pE1061, DOI 10.1152/ajpendo.1999.277.6.E1061; ASPLUND K, 1972, DIABETOLOGIA, V8, P153, DOI 10.1007/BF01212254; ASPLUND K, 1969, DIABETOLOGIA, V5, P260, DOI 10.1007/BF01212095; BAETENS D, 1979, SCIENCE, V206, P1323, DOI 10.1126/science.390711; Bains RK, 2004, ENDOCRINOLOGY, V145, P2666, DOI 10.1210/en.2003-1608; Bonner-Weir S, 2001, DIABETES, V50, pS20, DOI 10.2337/diabetes.50.2007.S20; Cerf ME, 2005, AM J PHYSIOL-REG I, V288, pR1122, DOI 10.1152/ajpregu.00335.2004; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; HEINZE E, 1971, ENDOCRINOLOGY, V88, P1259, DOI 10.1210/endo-88-5-1259; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; HIRIART M, 1991, ENDOCRINOLOGY, V128, P3193, DOI 10.1210/endo-128-6-3193; HOLE RL, 1988, AM J PHYSIOL, V254, pE167, DOI 10.1152/ajpendo.1988.254.2.E167; HUGHES SJ, 1994, DIABETOLOGIA, V37, P134, DOI 10.1007/s001250050083; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; Lucas A, 1998, J NUTR, V128, p401S, DOI 10.1093/jn/128.2.401S; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Matschinsky FM, 2002, DIABETES, V51, pS394, DOI 10.2337/diabetes.51.2007.S394; Montanya E, 2000, DIABETES, V49, P1341, DOI 10.2337/diabetes.49.8.1341; MORLEY MG, 1982, AM J PHYSIOL, V242, pG354, DOI 10.1152/ajpgi.1982.242.4.G354; Navarro-Tableros V, 2004, DIABETES, V53, P2018, DOI 10.2337/diabetes.53.8.2018; Ong KK, 2004, DIABETOLOGIA, V47, P1064, DOI 10.1007/s00125-004-1405-8; Ozanne SE, 2002, TRENDS ENDOCRIN MET, V13, P368, DOI 10.1016/S1043-2760(02)00666-5; Petrik J, 2001, PEDIATR RES, V49, P84, DOI 10.1203/00006450-200101000-00019; Rosenbaum T, 2001, DIABETES, V50, P1755, DOI 10.2337/diabetes.50.8.1755; Scaglia L, 1997, ENDOCRINOLOGY, V138, P1736, DOI 10.1210/en.138.4.1736; Schuit F, 2002, DIABETES, V51, pS326, DOI 10.2337/diabetes.51.2007.S326; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SMITH PF, 1989, SELECTED METHODS ENZ, P205; Srinivasan M, 2003, EXP BIOL MED, V228, P15, DOI 10.1177/153537020322800102; Straub SG, 2004, AM J PHYSIOL-CELL PH, V287, pC565, DOI 10.1152/ajpcell.00079.2004; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; TIEDGE M, 1993, BIOCHEM MOL BIOL INT, V29, P161; TRIMBLE ER, 1982, J CLIN INVEST, V69, P405, DOI 10.1172/JCI110464; Vidaltamayo R, 1996, ENDOCRINE, V4, P19, DOI 10.1007/BF02738870; Yajnik CS, 2004, J NUTR, V134, P205, DOI 10.1093/jn/134.1.205	36	64	67	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e35	10.1371/journal.pone.0000035	http://dx.doi.org/10.1371/journal.pone.0000035			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183663	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600035
J	Colosimo, PF; Tolwinski, NS				Colosimo, Pamela F.; Tolwinski, Nicholas S.			Wnt, Hedgehog and Junctional Armadillo/beta-Catenin Establish Planar Polarity in the Drosophila Embryo	PLOS ONE			English	Article								To generate specialized structures, cells must obtain positional and directional information. In multi-cellular organisms, cells use the non-canonical Wnt or planar cell polarity (PCP) signaling pathway to establish directionality within a cell. In vertebrates, several Wnt molecules have been proposed as permissible polarity signals, but none has been shown to provide a directional cue. While PCP signaling components are conserved from human to fly, no PCP ligands have been reported in Drosophila. Here we report that in the epidermis of the Drosophila embryo two signaling molecules, Hedgehog (Hh) and Wingless (Wg or Wnt1), provide directional cues that induce the proper orientation of Actin-rich structures in the larval cuticle. We further find that proper polarity in the late embryo also involves the asymmetric distribution and phosphorylation of Armadillo (Arm or beta-catenin) at the membrane and that interference with this Arm phosphorylation leads to polarity defects. Our results suggest new roles for Hh and Wg as instructive polarizing cues that help establish directionality within a cell sheet, and a new polarity-signaling role for the membrane fraction of the oncoprotein Arm.	[Colosimo, Pamela F.; Tolwinski, Nicholas S.] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Dev Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Tolwinski, NS (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Dev Biol, 1275 York Ave, New York, NY 10021 USA.	tolwinsn@mskcc.org	Tolwinski, Nicholas/Q-5782-2019; Tolwinski, Nicholas/D-1481-2014	Tolwinski, Nicholas/0000-0002-8507-2737; 	Howard Fellows program at Sloan-Kettering Institute	Howard Fellows program at Sloan-Kettering Institute	The funding for this project comes from the Howard Fellows program at Sloan-Kettering Institute. The funding is entirely institutional, and the Institute does not interfere in the running of individual laboratories.	Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Amonlirdviman K, 2005, SCIENCE, V307, P423, DOI 10.1126/science.1105471; Arias AM, 2006, NAT REV GENET, V7, P34, DOI 10.1038/nrg1750; Axelrod Jeffrey D, 2002, ScientificWorldJournal, V2, P434; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; Bek S, 2002, J CELL SCI, V115, P4743, DOI 10.1242/jcs.00154; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Cadigan KM, 2006, J CELL SCI, V119, P395, DOI 10.1242/jcs.02826; Casal J, 2002, CURR BIOL, V12, P1189, DOI 10.1016/S0960-9822(02)00974-0; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1998, DEVELOPMENT, V125, P4943; Choi HJ, 2006, J BIOL CHEM, V281, P1027, DOI 10.1074/jbc.M511338200; CHOU TB, 1992, GENETICS, V131, P643; Collier S, 2005, GENETICS, V169, P2035, DOI 10.1534/genetics.104.033381; Dawes-Hoang RE, 2005, DEVELOPMENT, V132, P4165, DOI 10.1242/dev.01938; DINARDO S, 1994, CURR OPIN GENET DEV, V4, P529, DOI 10.1016/0959-437X(94)90068-E; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Dumstrei K, 2002, DEVELOPMENT, V129, P3983; Gates J, 2005, CELL, V123, P769, DOI 10.1016/j.cell.2005.11.009; Goldstein B, 2006, DEV CELL, V10, P391, DOI 10.1016/j.devcel.2005.12.016; Gritzan U, 1999, DEVELOPMENT, V126, P4107; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Harris TJC, 2004, J CELL BIOL, V167, P135, DOI 10.1083/jcb.200406024; Hatini V, 2001, TRENDS GENET, V17, P574, DOI 10.1016/S0168-9525(01)02448-9; Hays R, 1997, DEVELOPMENT, V124, P3727; Hayward P, 2005, DEVELOPMENT, V132, P1819, DOI 10.1242/dev.01724; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Hilliard MA, 2006, DEV CELL, V10, P379, DOI 10.1016/j.devcel.2006.01.013; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Kalderon D, 2002, TRENDS CELL BIOL, V12, P523, DOI 10.1016/S0962-8924(02)02388-7; Klein TJ, 2005, ANNU REV CELL DEV BI, V21, P155, DOI 10.1146/annurev.cellbio.21.012704.132806; Kobielak A, 2006, P NATL ACAD SCI USA, V103, P2322, DOI 10.1073/pnas.0510422103; Larsen CW, 2003, DEVELOPMENT, V130, P5625, DOI 10.1242/dev.00867; Lawrence PA, 2004, DEVELOPMENT, V131, P4651, DOI 10.1242/dev.01351; Lawrence PA, 2002, DEVELOPMENT, V129, P2749; Lawrence PA, 1996, DEVELOPMENT, V122, P4095; Lele Z, 2001, GENESIS, V30, P190, DOI 10.1002/gene.1063; Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Morel V, 2004, DEVELOPMENT, V131, P3273, DOI 10.1242/dev.01217; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pacquelet A, 2005, J CELL BIOL, V170, P803, DOI 10.1083/jcb.200506131; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Price MH, 2006, J CELL SCI, V119, P403, DOI 10.1242/jcs.02761; SAMPEDRO J, 1993, DEVELOPMENT, V117, P677; Sanson B, 1999, CELL, V98, P207, DOI 10.1016/S0092-8674(00)81015-6; Scholey JM, 2006, CELL, V125, P439, DOI 10.1016/j.cell.2006.04.013; Simon MA, 2004, DEVELOPMENT, V131, P6175, DOI 10.1242/dev.01550; Szuts D, 1997, DEVELOPMENT, V124, P3209; Tada M, 2000, DEVELOPMENT, V127, P2227; Tolwinski NS, 2004, PLOS BIOL, V2, P486, DOI 10.1371/journal.pbio.0020095; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Walters JW, 2005, DEV BIOL, V286, P415, DOI 10.1016/j.ydbio.2005.06.031; WALTERS JW, 2006, DEV BIOL; Wehrli M, 1998, DEVELOPMENT, V125, P1421; WEHRLI M, 1995, DEVELOPMENT, V121, P2451; Westfall TA, 2003, J CELL BIOL, V162, P889, DOI 10.1083/jcb.200303107; WODRAZ A, 2006, J CELL SCI; WU M, 2006, DEV BIOL; XU T, 1993, DEVELOPMENT, V117, P1223; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020	70	34	35	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e9	10.1371/journal.pone.0000009	http://dx.doi.org/10.1371/journal.pone.0000009			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183721	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600009
J	Kashiwagi, A; Urabe, I; Kaneko, K; Yomo, T				Kashiwagi, Akiko; Urabe, Itaru; Kaneko, Kunihiko; Yomo, Tetsuya			Adaptive Response of a Gene Network to Environmental Changes by Fitness-Induced Attractor Selection	PLOS ONE			English	Article							ESCHERICHIA-COLI; CELL-DIFFERENTIATION; SINGLE-CELL; NOISE; EXPRESSION; DIVERSIFICATION; MULTISTABILITY; CONSTRUCTION; DEGRADATION; PLASTICITY	Cells switch between various stable genetic programs (attractors) to accommodate environmental conditions. Signal transduction machineries efficiently convey environmental changes to the gene regulation apparatus in order to express the appropriate genetic program. However, since the number of environmental conditions is much larger than that of available genetic programs so that the cell may utilize the same genetic program for a large set of conditions, it may not have evolved a signaling pathway for every environmental condition, notably those that are rarely encountered. Here we show that in the absence of signal transduction, switching to the appropriate attractor state expressing the genes that afford adaptation to the external condition can occur. In a synthetic bistable gene switch in Escherichia coli in which mutually inhibitory operons govern the expression of two genes required in two alternative nutritional environments, cells reliably selected the "adaptive attractor" driven by gene expression noise. A mathematical model suggests that the "non-adaptive attractor" is avoided because in unfavorable conditions, cellular activity is lower, which suppresses mRNA metabolism, leading to larger fluctuations in gene expression. This, in turn, renders the non-adaptive state less stable. Although attractor selection is not as efficient as signal transduction via a dedicated cascade, it is simple and robust, and may represent a primordial mechanism for adaptive responses that preceded the evolution of signaling cascades for the frequently encountered environmental changes.	[Kashiwagi, Akiko; Yomo, Tetsuya] Osaka Univ, Grad Sch Informat Sci & Technol, Dept Bioinformat Engn, Osaka, Japan; [Urabe, Itaru] Osaka Univ, Grad Sch Engn, Dept Biotechnol, Osaka, Japan; [Kaneko, Kunihiko; Yomo, Tetsuya] Osaka Univ, Grad Sch Frontier Biosci, Osaka, Japan; [Yomo, Tetsuya] Osaka Univ, Japan Sci & Technol Agcy, Complex Syst Biol Project, Osaka, Japan; [Kaneko, Kunihiko] Univ Tokyo, Dept Pure & Appl Sci, Tokyo, Japan; [Kaneko, Kunihiko] Univ Tokyo, Japan Sci & Technol Agcy, Complex Syst Biol Project, Tokyo, Japan	Osaka University; Osaka University; Osaka University; Japan Science & Technology Agency (JST); Osaka University; University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo	Yomo, T (corresponding author), Osaka Univ, Grad Sch Informat Sci & Technol, Dept Bioinformat Engn, Osaka, Japan.	yomo@ist.osaka-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [11CE2006, 15207020, 15013235]; Takeda Science Foundation; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL [U17CE002006] Funding Source: NIH RePORTER	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Funding: This work was supported in part by Grants-in-Aid (Nos. 11CE2006, 15207020, and 15013235), "The 21st Century Center of Excellence Program" and "Special Coordination Funds for Promoting Science and Technology: Yuragi Project" of the Ministry of Education, Culture, Sports, Science and Technology, Japan, and by a grant from Takeda Science Foundation.	Acar M, 2005, NATURE, V435, P228, DOI 10.1038/nature03524; Albert B., 2002, MOL BIOL CELL, V4th ed.; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; APPLEMAN JR, 1988, J BIOL CHEM, V263, P10304; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Bar-Even A, 2006, NAT GENET, V38, P636, DOI 10.1038/ng1807; Becskei A, 2001, EMBO J, V20, P2528, DOI 10.1093/emboj/20.10.2528; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; BROSIUS J, 1981, PLASMID, V6, P112, DOI 10.1016/0147-619X(81)90058-5; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dublanche Y, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100081; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Forgacs G, 2005, BIOLOGICAL PHYSICS OF THE DEVELOPING EMBRYO, P1, DOI 10.1017/CBO9780511755576; Furusawa Chikara, 2005, Biophysics (Nagoya-shi), V1, P25, DOI 10.2142/biophysics.1.25; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Gerhardt P., 1994, METHODS GEN MOL BACT; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hasty J, 2002, NATURE, V420, P224, DOI 10.1038/nature01257; Hasty J, 2000, P NATL ACAD SCI USA, V97, P2075, DOI 10.1073/pnas.040411297; Hooshangi S, 2005, P NATL ACAD SCI USA, V102, P3581, DOI 10.1073/pnas.0408507102; Huang S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.128701; Huang S, 2000, EXP CELL RES, V261, P91, DOI 10.1006/excr.2000.5044; Isaacs FJ, 2003, P NATL ACAD SCI USA, V100, P7714, DOI 10.1073/pnas.1332628100; Kaneko K, 1997, B MATH BIOL, V59, P139, DOI 10.1016/S0092-8240(96)00044-4; Kaneko K, 1997, PHYS REV LETT, V78, P2736, DOI 10.1103/PhysRevLett.78.2736; Kaneko K, 2000, P ROY SOC B-BIOL SCI, V267, P2367, DOI 10.1098/rspb.2000.1293; Kaneko K, 2006, LIFE INTRO COMPLEX S; Kashiwagi A, 2001, J MOL EVOL, V52, P502, DOI 10.1007/s002390010180; KAUFFMAN SA, 1993, ORIGIN ORDER; Laurent M, 1999, TRENDS BIOCHEM SCI, V24, P418, DOI 10.1016/S0968-0004(99)01473-5; Ozbudak EM, 2004, NATURE, V427, P737, DOI 10.1038/nature02298; PLATT T, 1970, NATURE, V228, P1154, DOI 10.1038/2281154a0; Press W., 1986, NUMERICAL RECIPES; Rosenfeld N, 2005, SCIENCE, V307, P1962, DOI 10.1126/science.1106914; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLOTMANN M, 1979, EUR J BIOCHEM, V95, P39, DOI 10.1111/j.1432-1033.1979.tb12937.x; SKERRA A, 1994, GENE, V151, P131, DOI 10.1016/0378-1119(94)90643-2; Willeboordse FH, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.026207; XU WZ, 1994, J FERMENT BIOENG, V77, P252, DOI 10.1016/0922-338X(94)90229-1	42	183	189	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e49	10.1371/journal.pone.0000049	http://dx.doi.org/10.1371/journal.pone.0000049			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183678	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600049
J	Kluiver, J; van den Berg, A; de Jong, D; Blokzijl, T; Harms, G; Bouwman, E; Jacobs, S; Poppema, S; Kroesen, BJ				Kluiver, J.; van den Berg, A.; de Jong, D.; Blokzijl, T.; Harms, G.; Bouwman, E.; Jacobs, S.; Poppema, S.; Kroesen, B-J			Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma	ONCOGENE			English	Article						BIC; microRNA-155; Burkitt lymphoma; microRNA processing; B-cell receptor; ADAR	VIRUS-INDUCED LYMPHOMAS; B-CELL LYMPHOMAS; HIGH EXPRESSION; RNA; MIR-155; IDENTIFICATION; MODULATION; ONCOGENES; PRECURSOR; COMPLEX	BIC is a primary microRNA (pri-miR-155) that can be processed to mature miR-155. In this study, we show the crucial involvement of protein kinase C (PKC) and nuclear factor-kappa B (NF-kappa B) in the regulation of BIC expression upon B-cell receptor triggering. Surprisingly, Northern blot analysis did not reveal any miR-155 expression upon induction of BIC expression in the Burkitt lymphoma-derived Ramos cell line, whereas other microRNAs were clearly detectable. Ectopic expression of BIC in Ramos and HEK293 cells resulted in miR-155 expression in HEK293, but not in Ramos cells, suggesting a specific block of BIC to miR-155 processing in Ramos. In line with the results obtained with Ramos, lack of miR-155 expression after induction of BIC expression was also observed in other Burkitt lymphoma cell lines, indicating a generic and specific blockade in the processing of BIC in Burkitt lymphoma. In contrast, induction of BIC expression in normal tonsillar B cells resulted in very high levels of miR-155 expression and induction of BIC expression in Hodgkin's lymphoma cell lines. It also resulted in elevated levels of miR-155. Our data provide evidence for two levels of regulation for mature miR-155 expression: one at the transcriptional level involving PKC and NF-kappa B, and one at the processing level. Burkitt lymphoma cells not only express low levels of BIC, but also prevent processing of BIC via an, as yet, unknown mechanism.	Univ Groningen, Med Ctr, Dept Pathol & Lab Med, Sect Med Biol, NL-9713 GZ Groningen, Netherlands; Univ Groningen, Med Ctr, Dept Pathol & Lab Med, Sect Pathol, NL-9713 GZ Groningen, Netherlands	University of Groningen; University of Groningen	Kroesen, BJ (corresponding author), Univ Groningen, Med Ctr, Dept Pathol & Lab Med, Sect Med Biol, Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.	b.j.kroesen@med.umcg.nl	van den Berg, Anke/H-1718-2011; Poppema, Sibrand/D-1204-2012; Jones, Jeffrey A/E-9827-2013; Kluiver, Joost/G-6406-2014	van den Berg, Anke/0000-0002-8894-2638; Kluiver, Joost/0000-0001-7650-2937				Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; CLURMAN BE, 1989, MOL CELL BIOL, V9, P2657, DOI 10.1128/MCB.9.6.2657; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Haasch D, 2002, CELL IMMUNOL, V217, P78, DOI 10.1016/S0008-8749(02)00506-3; Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jiang JM, 2006, GENE CHROMOSOME CANC, V45, P103, DOI 10.1002/gcc.20264; Kluiver J, 2006, GENE CHROMOSOME CANC, V45, P147, DOI 10.1002/gcc.20273; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Luciano DJ, 2004, RNA, V10, P1174, DOI 10.1261/rna.7350304; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Obernosterer G, 2006, RNA, V12, P1161, DOI 10.1261/rna.2322506; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Ramkissoon SH, 2006, LEUKEMIA RES, V30, P643, DOI 10.1016/j.leukres.2005.09.001; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Specht K, 2001, AM J PATHOL, V158, P419, DOI 10.1016/S0002-9440(10)63985-5; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Tam W, 2002, J VIROL, V76, P4275, DOI 10.1128/JVI.76.9.4275-4286.2002; van den Berg A, 2003, GENE CHROMOSOME CANC, V37, P20, DOI 10.1002/gcc.10186; Yang WD, 2006, NAT STRUCT MOL BIOL, V13, P13, DOI 10.1038/nsmb1041; Zeng Y, 2005, J BIOL CHEM, V280, P27595, DOI 10.1074/jbc.M504714200	30	109	130	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3769	3776		10.1038/sj.onc.1210147	http://dx.doi.org/10.1038/sj.onc.1210147			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173072				2022-12-25	WOS:000247026400001
J	Toualbi, K; Guller, MC; Mauriz, JL; Labalette, C; Buendia, MA; Mauviel, A; Bernuau, D				Toualbi, K.; Guller, M. C.; Mauriz, J-L; Labalette, C.; Buendia, M-A; Mauviel, A.; Bernuau, D.			Physical and functional cooperation between AP-1 and beta-catenin for the regulation of TCF-dependent genes	ONCOGENE			English	Article						AP-1; beta-catenin; Fos; Jun; cyclin D1; hepatoma cells	GROWTH-FACTOR-BETA; ONLY PROTEIN FHL2; C-FOS EXPRESSION; NF-KAPPA-B; CYCLIN D1; TRANSCRIPTIONAL COACTIVATOR; SIGNALING PATHWAY; MESENCHYMAL TRANSITION; BINDING PROTEIN; ACTIVATION	Stabilization of cytoplasmic beta-catenin is a hallmark of a variety of cancers. The stabilized beta-catenin is able to translocate to the nucleus, where it acts as a transcriptional activator of T-cell factor (TCF)-regulated genes. beta-Catenin may cross-talk with many signalling cascades to activate target genes. Whether beta-catenin cooperates with AP-1, another transcriptional complex activated during tumorigenesis is not fully clarified. We show that alpha-catenin co-immunoprecipitates with c-Jun and c- os. GST pull-down experiments indicate a physical association of the armadillo repeat domain of b-catenin with the DNA-binding domain of c-Jun and of the C-terminal domain of beta- catenin with the N-terminal domain of c-Fos. Promoter studies indicate that overexpression of AP-1 activates the transcription of two beta-catenin target genes, cyclin D1 and c-myc, by a mechanism independent of the AP-1 site, and fully dependent on the TCF-binding site. We further demonstrate that AP-1/beta-catenin synergism is involved during serum-induced cyclin D1 transcriptional activation. We identify a TCF-binding site on the cyclin D1 promoter which binds in vivo a complex induced by serum, containing beta- catenin, TCF4, c-Fos, c-Jun, JunB and JunD. This novel mechanism of interaction between two signalling cascades might contribute to the potentiation of malignancy.	INSERM, U697, Paris, France; Univ Paris 07, Paris, France; Inst Pasteur, Unite Recombinaison & Express Genet, Paris, France; INSERM, U163, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bernuau, D (corresponding author), Hop St Louis, Unite INSERM, U 697, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	bernuau@stlouis.inserm.fr	Mauriz, Jose L/G-9970-2014; MAUVIEL, Alain/F-6251-2013	Mauriz, Jose L/0000-0003-3160-8599; Mauviel, Alain/0000-0002-0438-2793				Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Carruba G, 1999, ANN NY ACAD SCI, V886, P212, DOI 10.1111/j.1749-6632.1999.tb09419.x; Chakladar A, 2005, BIOCHEM BIOPH RES CO, V336, P190, DOI 10.1016/j.bbrc.2005.08.061; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eger A, 2004, ONCOGENE, V23, P2672, DOI 10.1038/sj.onc.1207416; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007; Ferrara P, 2003, ONCOGENE, V22, P1461, DOI 10.1038/sj.onc.1206266; Ferrigno O, 2002, ONCOGENE, V21, P4879, DOI 10.1038/sj.onc.1205623; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; Grueneberg DA, 2003, MOL CELL BIOL, V23, P3936, DOI 10.1128/MCB.23.11.3936-3950.2003; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Harris TJC, 2005, TRENDS CELL BIOL, V15, P234, DOI 10.1016/j.tcb.2005.03.002; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Iavarone C, 2003, J BIOL CHEM, V278, P50024, DOI 10.1074/jbc.M308617200; Ishikawa T, 2000, MOL CELL ENDOCRINOL, V164, P77, DOI 10.1016/S0303-7207(00)00241-0; Iwahashi H, 2000, J IMMUNOL, V164, P5403, DOI 10.4049/jimmunol.164.10.5403; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Peron P, 2001, J BIOL CHEM, V276, P10524, DOI 10.1074/jbc.M005919200; Rahmani M, 2001, ONCOGENE, V20, P5132, DOI 10.1038/sj.onc.1204678; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sasaki T, 2003, CANCER RES, V63, P801; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; SIMONSON MS, 1994, EXP CELL RES, V215, P137, DOI 10.1006/excr.1994.1325; Sparks AB, 1998, CANCER RES, V58, P1130; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200; Zhurinsky J, 2000, J CELL SCI, V113, P3127	52	64	67	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3492	3502		10.1038/sj.onc.1210133	http://dx.doi.org/10.1038/sj.onc.1210133			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17146436				2022-12-25	WOS:000246799200005
J	Chubanov, V; Schlingmann, KP; Waring, J; Heinzinger, J; Kaske, S; Waidegger, S; Schnitzler, MMY; Gudermann, T				Chubanov, Vladimir; Schlingmann, Karl P.; Waering, Janine; Heinzinger, Jolanta; Kaske, Silke; Waidegger, Siegfried; Schnitzler, Michael Mederos y; Gudermann, Thomas			Hypomagnesemia with secondary hypocalcemia due to a missense mutation in the putative pore-forming region of TRPM6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL KINASES TRPM6; MAGNESIUM; PROTEIN; CHANNELOPATHIES; ACTIVATION; MECHANISM; INSIGHTS; MUSCLE; GENES	Hypomagnesemia with secondary hypocalcemia is an autosomal recessive disorder caused by mutations in the TRPM6 gene. Current experimental evidence suggests that TRPM6 may function in a specific association with TRPM7 by means of heterooligomeric channel complex formation. Here, we report the identification and functional characterization of a new hypomagnesemia with secondary hypocalcemia missense mutation in TRPM6. The affected subject presented with profound hypomagnesemia and hypocalcemia caused by compound heterozygous mutation in the TRPM6 gene: 1208(-1)G > A affecting the acceptor splice site preceding exon 11, and 3050C > G resulting in the amino acid change (P1017R) in the putative pore-forming region of TRPM6. To assess the functional consequences of the P1017R mutation, TRPM6(P1017R) and wild-type TRPM6 were co-expressed with TRPM7 in Xenopus oocytes and HEK 293 cells, and currents were assessed by two-electrode voltage clamp and whole cell patch clamp measurements, respectively. Co-expression of wild-type TRPM6 and TRPM7 resulted in a significant increase in the amplitude of TRPM7-like currents. In contrast, TRPM6(P1017R) suppressed TRPM7 channel activity. In line with these observations, TRPM7, containing the corresponding mutation P1040R, displayed a dominant-negative effect upon co-expression with wild-type TRPM7. Confocal microscopy and fluorescence resonance energy transfer recordings demonstrated that the P1017R mutation neither affects assembly of TRPM6 with TRPM7, nor co-trafficking of heteromultimeric channel complexes to the cell surface. We conclude that a functional defect in the putative pore of TRPM6/7 channel complexes is sufficient to impair body magnesium homeostasis.	Univ Marburg, Inst Pharmacol & Toxicol, D-35033 Marburg, Germany; Univ Marburg, Univ Childrens Hosp, D-35033 Marburg, Germany	Philipps University Marburg; Philipps University Marburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Gudermann, T (corresponding author), Univ Marburg, Inst Pharmacol & Toxicol, Karl von Frisch Str 1, D-35033 Marburg, Germany.	guderman@staff.uni-marburg.de						Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Ashcroft FM, 2006, NATURE, V440, P440, DOI 10.1038/nature04707; Cannon SC, 2006, ANNU REV NEUROSCI, V29, P387, DOI 10.1146/annurev.neuro.29.051605.112815; Chubanov V, 2005, PFLUG ARCH EUR J PHY, V451, P228, DOI 10.1007/s00424-005-1470-y; Chubanov V, 2005, N-S ARCH PHARMACOL, V371, P334, DOI 10.1007/s00210-005-1056-4; Chubanov V, 2004, P NATL ACAD SCI USA, V101, P2894, DOI 10.1073/pnas.0305252101; Clark K, 2006, EMBO J, V25, P290, DOI 10.1038/sj.emboj.7600931; Demeuse P, 2006, J GEN PHYSIOL, V127, P421, DOI 10.1085/jgp.200509410; Dorovkov MV, 2004, J BIOL CHEM, V279, P50643, DOI 10.1074/jbc.C400441200; Drennan D, 2004, PROG BIOPHYS MOL BIO, V85, P1, DOI 10.1016/S0079-6107(03)00060-9; Elizondo MR, 2005, CURR BIOL, V15, P667, DOI 10.1016/j.cub.2005.02.050; Fleig A, 2004, TRENDS PHARMACOL SCI, V25, P633, DOI 10.1016/j.tips.2004.10.004; Fonfria E, 2006, J RECEPT SIG TRANSD, V26, P159, DOI 10.1080/10799890600637506; Furney SJ, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-165; Groenestege WMT, 2006, J AM SOC NEPHROL, V17, P1035, DOI 10.1681/ASN.2005070700; Gums JG, 2004, AM J HEALTH-SYST PH, V61, P1569, DOI 10.1093/ajhp/61.15.1569; Hanna MG, 2006, NAT CLIN PRACT NEURO, V2, P252, DOI 10.1038/ncpneuro0178; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Hermosura MC, 2005, P NATL ACAD SCI USA, V102, P11510, DOI 10.1073/pnas.0505149102; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Jiang JM, 2005, J GEN PHYSIOL, V126, P137, DOI 10.1085/jgp.200409185; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Kass RS, 2005, J CLIN INVEST, V115, P1986, DOI 10.1172/JCI26011; Konrad M, 2004, AM J PHYSIOL-RENAL, V286, pF599, DOI 10.1152/ajprenal.00312.2003; Kozak JA, 2005, J GEN PHYSIOL, V126, P499, DOI 10.1085/jgp.200509324; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; Kunert-Keil C, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-159; Langeslag M, 2007, J BIOL CHEM, V282, P232, DOI 10.1074/jbc.M605300200; Li M, 2006, J GEN PHYSIOL, V127, P525, DOI 10.1085/jgp.200609502; Liu D, 2005, J BIOL CHEM, V280, P20691, DOI 10.1074/jbc.M414072200; Matsushita M, 2005, J BIOL CHEM, V280, P20793, DOI 10.1074/jbc.M413671200; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Nilius B, 2005, J BIOL CHEM, V280, P22899, DOI 10.1074/jbc.M501686200; Owsianik G, 2006, ANNU REV PHYSIOL, V68, P685, DOI 10.1146/annurev.physiol.68.040204.101406; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pieper U, 2006, NUCLEIC ACIDS RES, V34, pD291, DOI 10.1093/nar/gkj059; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Schlingmann KP, 2005, J AM SOC NEPHROL, V16, P3061, DOI 10.1681/ASN.2004110989; Schlingmann KP, 2005, J PHYSIOL-LONDON, V566, P301, DOI 10.1113/jphysiol.2004.080200; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Schmitz C, 2005, J BIOL CHEM, V280, P37763, DOI 10.1074/jbc.M509175200; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Su LT, 2006, J BIOL CHEM, V281, P11260, DOI 10.1074/jbc.M512885200; Takezawa R, 2004, P NATL ACAD SCI USA, V101, P6009, DOI 10.1073/pnas.0307565101; Touyz RM, 2006, AM J PHYSIOL-REG I, V290, pR73, DOI 10.1152/ajpregu.00515.2005; Voets T, 2004, J BIOL CHEM, V279, P19, DOI 10.1074/jbc.M311201200; Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901	49	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7656	7667		10.1074/jbc.M611117200	http://dx.doi.org/10.1074/jbc.M611117200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17197439	hybrid			2022-12-25	WOS:000245080900078
J	Garcia, BA; Hake, SB; Diaz, RL; Kauer, M; Morris, SA; Recht, J; Shabanowitz, J; Mishra, N; Strahl, BD; Allis, CD; Hunt, DF				Garcia, Benjamin A.; Hake, Sandra B.; Diaz, Robert L.; Kauer, Monika; Morris, Stephanie A.; Recht, Judith; Shabanowitz, Jeffrey; Mishra, Nilamadhab; Strahl, Brian D.; Allis, C. David; Hunt, Donald F.			Organismal differences in post-translational modifications in histones H3 and H4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; SACCHAROMYCES-CEREVISIAE; LYSINE METHYLATION; ACTIVE CHROMATIN; DNA ELIMINATION; VARIANT H3.3; SET DOMAIN; ACETYLATION; HETEROCHROMATIN; TETRAHYMENA	Post-translational modifications (PTMs) of histories play an important role in many cellular processes, notably gene regulation. Using a combination of mass spectrometric and immunobiochemical approaches, we show that the PTM profile of histone H3 differs significantly among the various model organisms examined. Unicellular eukaryotes, such as Saccharomyces cerevisiae (yeast) and Tetrahymena thermophila (Tet), for example, contain more activation than silencing marks as compared with mammalian cells (mouse and human), which are generally enriched in PTMs more often associated with gene silencing. Close examination reveals that many of the better-known modified lysines (Lys) can be either methylated or acetylated and that the overall modification patterns become more complex from unicellular eukaryotes to mammals. Additionally, novel species-specific H3 PTMs from wild-type asynchronously grown cells are also detected by mass spectrometry. Our results suggest that some PTMs are more conserved than previously thought, including H3K9me1 and H4K20me2 in yeast and H3K27me1, -me2, and -me3 in Tet. On histone H4, methylation at Lys-20 showed a similar pattern as H3 methylation at Lys-9, with mammals containing more methylation than the unicellular organisms. Additionally, modification profiles of H4 acetylation were very similar among the organisms examined.	Rockefeller Univ, Lab Chromatin Biol, New York, NY 10021 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sect Rheumatol & Clin Immunol, Winston Salem, NC 27157 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA	Rockefeller University; University of Virginia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Wake Forest University; Wake Forest Baptist Medical Center; University of Virginia	Hunt, DF (corresponding author), Rockefeller Univ, Lab Chromatin Biol, Box 78,1230 York Ave, New York, NY 10021 USA.	dfh@virginia.edu	Strahl, Brian/C-7601-2012; Hunt, Donald F/I-6936-2012	Strahl, Brian/0000-0002-4947-6259; Hunt, Donald F/0000-0003-2815-6368; Recht, Judith/0000-0003-3572-0457	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068088, R01GM037537] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 68088, GM 40922, GM 37537] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Avramova ZV, 2002, PLANT PHYSIOL, V129, P40, DOI 10.1104/pp.010981; Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Cheung P, 2005, MOL ENDOCRINOL, V19, P563, DOI 10.1210/me.2004-0496; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Chow JC, 2003, CELL MOL LIFE SCI, V60, P2586, DOI 10.1007/s00018-003-3121-9; Daury L, 2006, EMBO REP, V7, P66, DOI 10.1038/sj.embor.7400561; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Garcia BA, 2005, J PROTEOME RES, V4, P2032, DOI 10.1021/pr050188r; Hake SB, 2006, P NATL ACAD SCI USA, V103, P6428, DOI 10.1073/pnas.0600803103; Hake SB, 2006, J BIOL CHEM, V281, P559, DOI 10.1074/jbc.M509266200; Hake SB, 2005, P NATL ACAD SCI USA, V102, P6344, DOI 10.1073/pnas.0502413102; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Jin C, 2006, P NATL ACAD SCI USA, V103, P574, DOI 10.1073/pnas.0509974103; Johnson L, 2004, NUCLEIC ACIDS RES, V32, P6511, DOI 10.1093/nar/gkh992; Kamakaka RT, 2005, GENE DEV, V19, P295, DOI 10.1101/gad.1272805; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Madireddi MT, 1996, CELL, V87, P75, DOI 10.1016/S0092-8674(00)81324-0; Martin SE, 2000, ANAL CHEM, V72, P4266, DOI 10.1021/ac000497v; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; Medzihradszky KF, 2004, MOL CELL PROTEOMICS, V3, P872, DOI 10.1074/mcp.M400041-MCP200; Morris SA, 2007, J BIOL CHEM, V282, P7632, DOI 10.1074/jbc.M607909200; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; Pusarla RH, 2005, FEBS J, V272, P5149, DOI 10.1111/j.1742-4658.2005.04930.x; Recht J, 2006, P NATL ACAD SCI USA, V103, P6988, DOI 10.1073/pnas.0601676103; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Syka JEP, 2004, J PROTEOME RES, V3, P621, DOI 10.1021/pr0499794; Taverna SD, 2002, CELL, V110, P701, DOI 10.1016/S0092-8674(02)00941-8; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Yang YW, 2003, ENDOCRINOLOGY, V144, P5658, DOI 10.1210/en.2003-0798; Zhang KL, 2002, MOL CELL PROTEOMICS, V1, P500, DOI 10.1074/mcp.M200031-MCP200; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6	52	237	252	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7641	7655		10.1074/jbc.M607900200	http://dx.doi.org/10.1074/jbc.M607900200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17194708	hybrid, Green Published			2022-12-25	WOS:000245080900077
J	Li, HM; Zhao, YW; Guo, Y; Li, Z; Eisele, L; Mourad, W				Li, Hongmin; Zhao, Yiwei; Guo, Yi; Li, Zhong; Eisele, Leslie; Mourad, Walid			Zinc induces dimerization of the class II major histocompatibility complex molecule that leads to cooperative binding to a superantigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTHRITIDIS-DERIVED MITOGEN; TOXIC-SHOCK-SYNDROME; CELL-RECEPTOR-BINDING; MHC CLASS; CRYSTAL-STRUCTURE; HLA-DR; BACTERIAL SUPERANTIGENS; 3-DIMENSIONAL STRUCTURE; IMMUNOLOGICAL SYNAPSE; HIGH-AFFINITY	Dimerization of class 11 major histocompatibility complex (MHC) plays an important role in the MHC biological function. Mycoplasma arthritidis-derived mitogen (MAM) is a superantigen that can activate large fractions of T cells bearing specific T cell receptor V beta elements. Here we have used structural, sedimentation, and surface plasmon resonance detection approaches to investigate the molecular interactions between MAM and the class 11 MHC molecule HLA-DR1 in the context of a hemagglutinin peptide-(306-318) (HA). Our results revealed that zinc ion can efficiently induce the dimerization of the HLA-DR1/HA complex. Because the crystal structure of the MAM/HLA-DR1/hemagglutinin complex in the presence of EDTA is nearly identical to the structure of the complex crystallized in the presence of zinc ion, Zn2+ is evidently not directly involved in the binding between MAM and HLA-DRI. Sedimentation and surface plasmon resonance studies further revealed that MAM binds the HLA-DR1/HA complex with high affinity in a 1:1 stoichiometry, in the absence of Zn2+. However, in the presence of Zn2+, a dimerized MAM/HLA-DR1/HA complex can arise through the Zn2+-induced DR1 dimer. In the presence of Zn2+, cooperative binding of MAM to the DR1 dimer was also observed.	New York State Dept Hlth, Wadsworth ctr, Albany, NY 12208 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12208 USA; Univ Montreal, CHU Montreal, Montreal, PQ H2X 1P1, Canada	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Universite de Montreal	Li, HM (corresponding author), New York State Dept Hlth, Wadsworth ctr, 120 New Scotland Ave, Albany, NY 12208 USA.	lih@wadsworth.org	Li, Hongmin/ABI-2439-2020	Li, Hongmin/0000-0002-8684-5308; Mourad, Walid/0000-0002-1859-9387; Li, Zhong/0000-0002-1039-7000	NIAID NIH HHS [R21 AI064637-01, AI64637, R01 AI050628, R01 AI050628-01, AI50628, R21 AI064637] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050628, R21AI064637] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE J, 1992, P NATL ACAD SCI USA, V89, P4066, DOI 10.1073/pnas.89.9.4066; Baker HM, 2004, J BIOL CHEM, V279, P38571, DOI 10.1074/jbc.M406695200; Baker M, 2001, PROTEIN SCI, V10, P1268, DOI 10.1110/ps.330101; Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921; Bernatchez C, 1997, INFECT IMMUN, V65, P2000, DOI 10.1128/IAI.65.6.2000-2005.1997; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMBIER JC, 1991, J IMMUNOL, V146, P2075; CHEN ZZ, 1987, J IMMUNOL, V138, P2345; Cherry RJ, 1998, J CELL BIOL, V140, P71, DOI 10.1083/jcb.140.1.71; Cole B C, 1991, Curr Top Microbiol Immunol, V174, P107; COLE BC, 1991, IMMUNOL TODAY, V12, P271, DOI 10.1016/0167-5699(91)90125-D; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAMRUNDLES S, 1980, CLIN IMMUNOL IMMUNOP, V16, P115, DOI 10.1016/0090-1229(80)90172-5; Etongue-Mayer P, 2002, EUR J IMMUNOL, V32, P50, DOI 10.1002/1521-4141(200201)32:1<50::AID-IMMU50>3.0.CO;2-A; Fan QR, 2000, J BIOL CHEM, V275, P23700, DOI 10.1074/jbc.M003318200; Frayser M, 1999, PROTEIN EXPRES PURIF, V15, P105, DOI 10.1006/prep.1998.0987; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; GOODMAN S, 1995, J IMMUNOL, V155, P1210; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HARRISON RT, 1987, HARRISONS PRINCIPLES, V1, P455; Hayball JD, 2005, MOL CELL BIOCHEM, V273, P1, DOI 10.1007/s11010-005-5281-4; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILL CP, 1991, BIOCHEMISTRY-US, V30, P917, DOI 10.1021/bi00218a006; Hitzel C, 1999, J IMMUNOL, V162, P4671; HUDSON KR, 1995, J EXP MED, V182, P711, DOI 10.1084/jem.182.3.711; HURLEY JM, 1995, J EXP MED, V181, P2229, DOI 10.1084/jem.181.6.2229; Ibs KH, 2003, J NUTR, V133, p1452S, DOI 10.1093/jn/133.5.1452S; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; Kadima W, 1999, BIOCHEMISTRY-US, V38, P13443, DOI 10.1021/bi9903188; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; Kitamura H, 2006, NAT IMMUNOL, V7, P971, DOI 10.1038/ni1373; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; KOZONO H, 1995, IMMUNITY, V3, P187, DOI 10.1016/1074-7613(95)90088-8; Langlois MA, 2000, EUR J IMMUNOL, V30, P1748, DOI 10.1002/1521-4141(200006)30:6<1748::AID-IMMU1748>3.0.CO;2-J; Langlois MA, 2003, J BIOL CHEM, V278, P22309, DOI 10.1074/jbc.M300823200; LENTNER C, 1981, GEIGY SCI TABLES, V3, P78; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; Li HM, 2007, MOL IMMUNOL, V44, P763, DOI 10.1016/j.molimm.2006.04.010; Li PL, 1997, J EXP MED, V186, P375, DOI 10.1084/jem.186.3.375; Li YL, 2001, IMMUNITY, V14, P93, DOI 10.1016/S1074-7613(01)00092-9; Lindstedt R, 2001, J IMMUNOL, V166, P800, DOI 10.4049/jimmunol.166.2.800; MALCHIODI EL, 1995, J EXP MED, V182, P1833, DOI 10.1084/jem.182.6.1833; McCormick JK, 2001, ANNU REV MICROBIOL, V55, P77, DOI 10.1146/annurev.micro.55.1.77; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Nydam T, 1998, INT IMMUNOL, V10, P1237, DOI 10.1093/intimm/10.8.1237; PAPAGEORGIOU AC, 1995, STRUCTURE, V3, P769, DOI 10.1016/S0969-2126(01)00212-X; Petersson K, 2002, STRUCTURE, V10, P1619, DOI 10.1016/S0969-2126(02)00895-X; Petersson K, 2001, EMBO J, V20, P3306, DOI 10.1093/emboj/20.13.3306; PLOEGH H, 1993, NATURE, V364, P16, DOI 10.1038/364016d0; Renno T, 1996, IMMUNOL REV, V154, P175, DOI 10.1111/j.1600-065X.1996.tb00934.x; Roucard C, 1996, J BIOL CHEM, V271, P13993, DOI 10.1074/jbc.271.24.13993; Saito T, 2006, CURR OPIN IMMUNOL, V18, P305, DOI 10.1016/j.coi.2006.03.014; Schafer P H, 1995, Semin Immunol, V7, P389, DOI 10.1006/smim.1995.0043; SCHAFER PH, 1994, IMMUNITY, V1, P699, DOI 10.1016/1074-7613(94)90040-X; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Sundstrom M, 1996, EMBO J, V15, P6832, DOI 10.1002/j.1460-2075.1996.tb01074.x; THORLACIUSUSSING O, 1987, NEUROENDOCRINOLOGY, V45, P233, DOI 10.1159/000124731; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920; Yadati S, 1999, IMMUNOL LETT, V67, P47, DOI 10.1016/S0165-2478(98)00146-1; Yang JY, 2003, J BIOL CHEM, V278, P50412, DOI 10.1074/jbc.M306848200; Zhao YW, 2004, STRUCTURE, V12, P277, DOI 10.1016/j.str.2004.01.008; Zhao YW, 2004, ACTA CRYSTALLOGR D, V60, P353, DOI 10.1107/S090744490302763X	68	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					5991	6000		10.1074/jbc.M608482200	http://dx.doi.org/10.1074/jbc.M608482200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17166841	Green Accepted, hybrid			2022-12-25	WOS:000244867200004
J	Mesleh, MF; Shirley, WA; Heise, CE; Ling, N; Maki, RA; Laura, RP				Mesleh, Michael F.; Shirley, William A.; Heise, Christopher E.; Ling, Nicholas; Maki, Richard A.; Laura, Richard P.			NMR structural characterization of a minimal peptide antagonist bound to the extracellular domain of the corticotropin-releasing factor(1) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; TRANSFER DIFFERENCE NMR; PULSED-FIELD GRADIENTS; LIGAND-BINDING; G-PROTEIN; COMPETITIVE ANTAGONISTS; NONPEPTIDE ANTAGONISTS; DISULFIDE PATTERN; HORMONE-RECEPTOR; CRF RECEPTORS	Natural peptide agonists of corticotrophin-releasing factor (CRF) receptors bind to the receptor by a two-site mechanism as follows: the carboxyl end of the ligand binds the N-terminal extracellular domain (ECD) of the receptor and the amino portion of the ligand binds the extracellular face of the seven transmembrane region. Recently, peptide antagonists homologous to the 12 C-terminal residues of CRF have been derived, which bind the CRF1 receptor through an interaction with the ECD. Here we characterized the binding of a minimal 12-residue peptide antagonist while bound to the isolated ECD of the CRF, receptor. We have expressed and purified soluble and properly folded ECD independent from the seven-transmembrane region as a thioredoxin fusion protein in Escherichia coli. A model of the peptide antagonist, cyclic corticotrophin-releasing factor residues 30 - 41(cCRF(30 - 41)), was calculated while bound to the recombinant ECD using transferred nuclear Overhauser effect spectroscopy. Although the peptide is unstructured in solution, it adopts an a-helical conformation when bound to the ECD. Residues of cCRF(30-41) comprising the binding interface with the ECD were mapped using saturation transfer difference NMR. Two hydrophobic residues (Met(38) and Ile(41)) as well as two amide groups (Asn(34) and the C-terminal amide) on one face of the helix defined the binding epitope of the antagonist. This epitope may be used as a starting point for development of nonpeptide antagonists targeting the ECD of this receptor.	Neurosci Biosci Inc, Dept Discovery Biol, San Diego, CA 92130 USA; Neurosci Biosci Inc, Dept Med Chem, San Diego, CA 92130 USA; Neurosci Biosci Inc, Dept Pharmacol, San Diego, CA 92130 USA; Neurosci Biosci Inc, Dept Biol Chem, San Diego, CA 92130 USA	Neurocrine Biosciences; Neurocrine Biosciences; Neurocrine Biosciences; Neurocrine Biosciences	Maki, RA (corresponding author), Neurosci Biosci Inc, Dept Discovery Biol, 12790 El Camino Real, San Diego, CA 92130 USA.	rmaki@neurocrine.com						Barsukov IL, 1996, J MOL BIOL, V262, P543, DOI 10.1006/jmbi.1996.0534; Bazarsuren A, 2002, BIOPHYS CHEM, V96, P305, DOI 10.1016/S0301-4622(02)00023-6; Behan DP, 1996, MOL PSYCHIATR, V1, P265; Blank T, 2003, J NEUROSCI, V23, P700, DOI 10.1523/JNEUROSCI.23-02-00700.2003; Chalmers DT, 1996, TRENDS PHARMACOL SCI, V17, P166, DOI 10.1016/0165-6147(96)81594-X; *CHEM COMP GROUP I, 2006, MOL OP ENV MOE; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; Dautzenberg FM, 1998, P NATL ACAD SCI USA, V95, P4941, DOI 10.1073/pnas.95.9.4941; Goddard T. D., 2006, SPARKY; Grace CRR, 2004, P NATL ACAD SCI USA, V101, P12836, DOI 10.1073/pnas.0404702101; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Grigoriadis DE, 2005, EXPERT OPIN THER TAR, V9, P651, DOI 10.1517/14728222.9.4.651; GULYAS J, 1995, P NATL ACAD SCI USA, V92, P10575, DOI 10.1073/pnas.92.23.10575; HAWKINS GD, 1995, CHEM PHYS LETT, V246, P122, DOI 10.1016/0009-2614(95)01082-K; Heinrichs SC, 2004, J PHARMACOL EXP THER, V311, P427, DOI 10.1124/jpet.103.052092; Hoare SRJ, 2005, DRUG DISCOV TODAY, V10, P417, DOI 10.1016/S1359-6446(05)03370-2; Hoare SRJ, 2004, BIOCHEMISTRY-US, V43, P3996, DOI 10.1021/bi036110a; Hoare SRJ, 2003, MOL PHARMACOL, V63, P751, DOI 10.1124/mol.63.3.751; Hofmann BA, 2001, PROTEIN SCI, V10, P2050, DOI 10.1110/ps.12101; Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; Inooka H, 2001, NAT STRUCT BIOL, V8, P161, DOI 10.1038/84159; Kehne J, 2002, CNS NEUROL DISORD-DR, V1, P467, DOI 10.2174/1568007023339049; Klose J, 2005, BIOCHEMISTRY-US, V44, P1614, DOI 10.1021/bi049022e; Klose J, 2004, PROTEIN SCI, V13, P2470, DOI 10.1110/ps.04835904; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORNREICH WD, 1992, J MED CHEM, V35, P1870, DOI 10.1021/jm00088a024; Lewis K, 2001, P NATL ACAD SCI USA, V98, P7570, DOI 10.1073/pnas.121165198; Maaheimo H, 2000, BIOCHEMISTRY-US, V39, P12778, DOI 10.1021/bi000780o; Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; McCarthy JR, 1999, CURR PHARM DESIGN, V5, P289; Megy S, 2005, J BIOL CHEM, V280, P29107, DOI 10.1074/jbc.M501628200; Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233; Nemeroff CB, 2005, J CLIN PSYCHIAT, V66, P5; NI F, 1994, PROG NUCL MAG RES SP, V26, P517, DOI 10.1016/0079-6565(94)90000-0; Nielsen SM, 2000, P NATL ACAD SCI USA, V97, P10277, DOI 10.1073/pnas.97.18.10277; Onufriev A, 2000, J PHYS CHEM B, V104, P3712, DOI 10.1021/jp994072s; PALLAI PV, 1983, P NATL ACAD SCI-BIOL, V80, P6770, DOI 10.1073/pnas.80.22.6770; Perrin MH, 2003, J BIOL CHEM, V278, P15595, DOI 10.1074/jbc.M210476200; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Perrin MH, 1998, ENDOCRINOLOGY, V139, P566, DOI 10.1210/en.139.2.566; Perry SJ, 2005, J BIOL CHEM, V280, P11560, DOI 10.1074/jbc.M412914200; Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398; Rijkers DTS, 2004, CHEMBIOCHEM, V5, P340, DOI 10.1002/cbic.200300769; RIVIER J, 1984, SCIENCE, V224, P889, DOI 10.1126/science.6326264; Saunders J, 2003, PROGR MED CHEM, V41, P195, DOI 10.1016/S0079-6468(02)41006-5; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; SPIESS J, 1981, P NATL ACAD SCI-BIOL, V78, P6517, DOI 10.1073/pnas.78.10.6517; Wietfeld D, 2004, J BIOL CHEM, V279, P38386, DOI 10.1074/jbc.M405335200; Wille S, 1999, J NEUROCHEM, V72, P388, DOI 10.1046/j.1471-4159.1999.0720388.x; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yamada Y, 2004, J MED CHEM, V47, P1075, DOI 10.1021/jm034180+	56	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6338	6346		10.1074/jbc.M609816200	http://dx.doi.org/10.1074/jbc.M609816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17192263	hybrid			2022-12-25	WOS:000244867200040
J	Tanaka, Y; Morikawa, K; Ohki, Y; Yao, M; Tsumoto, K; Watanabe, N; Ohta, T; Tanaka, I				Tanaka, Yoshikazu; Morikawa, Kazuya; Ohki, Yu; Yao, Min; Tsumoto, Kouhei; Watanabe, Nobuhisa; Ohta, Toshiko; Tanaka, Isao			Structural and mutational analyses of Drp35 from Staphylococcus aureus - A possible mechanism for its lactonase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOLIGO-VULGARIS; PYROCOCCUS-HORIKOSHII; SERUM PARAOXONASES; CRYSTAL-STRUCTURE; CALCIUM; DENSITY; RESOLUTION; BINDING; PON1; ATHEROSCLEROSIS	Drp35 is a protein induced by cell wall-affecting antibiotics or detergents; it possesses calcium-dependent lactonase activity. To determine the molecular basis of the lactonase activity, we first solved the crystal structures of Drp35 with and without Ca2+; these showed that the molecule has a six-bladed beta-propeller structure with two calcium ions bound at the center of the beta-propeller and surface region. Mutational analyses of evolutionarily conserved residues revealed that the central calcium-binding site is essential for the enzymatic activity of Drp35. Substitution of some other amino acid residues for the calcium-binding residues demonstrated the critical contributions of Glu(48), Asp(138), and Asp(236) to the enzymatic activity. Differential scanning calorimetric analysis revealed that the loss of activity of E48Q and D236N, but not D138N, was attributed to their inability to hold the calcium ion. Further structural analysis of the D138N mutant indicates that it lacks a water molecule bound to the calcium ion rather than the calcium ion itself. Based on these observations and structural information, a possible catalytic mechanism in which the calcium ion and its binding residues play direct roles was proposed for the lactonase activity of Drp35.	Hokkaido Univ, Fac Adv Life Sci, Sapporo, Hokkaido 0600810, Japan; Univ Tokyo, Frad Sch Frontier Sci, Dept Med Genome Sci, Tokyo 2778562, Japan; Univ Tsukuba, Grad Sch Comprehens Human Sci, Inst Basic Med Sci, Dept Microbiol, Tsukuba, Ibaraki 3058575, Japan	Hokkaido University; University of Tokyo; University of Tsukuba	Tanaka, I (corresponding author), Hokkaido Univ, Fac Adv Life Sci, Sapporo, Hokkaido 0600810, Japan.	tanaka@castor.sci.hokudai.ac.jp	yao, min/F-5287-2011; Watanabe, Nobuhisa/B-1187-2008; Ohki, Yu/U-2946-2019	yao, min/0000-0003-1687-5904; Watanabe, Nobuhisa/0000-0002-0118-5815; Morikawa, Kazuya/0000-0002-1503-7151; Tanaka, Yoshikazu/0000-0002-7893-3236				Aharoni A, 2004, P NATL ACAD SCI USA, V101, P482, DOI 10.1073/pnas.2536901100; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 2000, BIOCHEMISTRY-US, V39, P9099, DOI 10.1021/bi0000317; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; Draganov DI, 2004, N-S ARCH PHARMACOL, V369, P78, DOI 10.1007/s00210-003-0833-1; Fujino A, 2004, J MOL BIOL, V341, P999, DOI 10.1016/j.jmb.2004.06.062; Gonzalvo MC, 1998, J BIOCHEM MOL TOXIC, V12, P61, DOI 10.1002/(SICI)1099-0461(1998)12:1<61::AID-JBT8>3.0.CO;2-N; Harel M, 2004, NAT STRUCT MOL BIOL, V11, P412, DOI 10.1038/nsmb767; Hartleib J, 2001, BBA-PROTEIN STRUCT M, V1546, P312, DOI 10.1016/S0167-4838(01)00153-4; Hartleib J, 2001, BIOCHEM J, V353, P579, DOI 10.1042/0264-6021:3530579; Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8; Jawad Z, 2002, STRUCTURE, V10, P447, DOI 10.1016/S0969-2126(02)00750-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Karaveg K, 2005, J BIOL CHEM, V280, P16197, DOI 10.1074/jbc.M500119200; Khersonsky O, 2006, J BIOL CHEM, V281, P7649, DOI 10.1074/jbc.M512594200; Khersonsky O, 2005, BIOCHEMISTRY-US, V44, P6371, DOI 10.1021/bi047440d; Kuo CL, 1998, DRUG METAB DISPOS, V26, P653; Kuroda M, 2003, MOL MICROBIOL, V49, P807, DOI 10.1046/j.1365-2958.2003.03599.x; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903; Laskowski RA, 1996, PROTEIN SCI, V5, P2438; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Morikawa K, 2005, FEMS MICROBIOL LETT, V249, P185, DOI 10.1016/j.femsle.2005.06.038; Murakami H, 1999, BIOCHEM BIOPH RES CO, V264, P348, DOI 10.1006/bbrc.1999.1388; Ng CJ, 2005, FREE RADICAL BIO MED, V38, P153, DOI 10.1016/j.freeradbiomed.2004.09.035; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pidcock E, 2001, J BIOL INORG CHEM, V6, P479, DOI 10.1007/s007750100214; Rosenblat M, 2006, J BIOL CHEM, V281, P7657, DOI 10.1074/jbc.M512595200; Sakai N, 2004, PROTEINS, V57, P869, DOI 10.1002/prot.20259; Scharff EI, 2001, STRUCTURE, V9, P493, DOI 10.1016/S0969-2126(01)00610-4; Schuller DJ, 1996, ACTA CRYSTALLOGR D, V52, P425, DOI 10.1107/S0907444995013291; SCHUTZBACH JS, 1990, J BIOL CHEM, V265, P2546; Sheldrick G.M, 2001, International Tables for Macromolecular Crystallography, P333; Szuwart M, 2006, PHYTOCHEMISTRY, V67, P1476, DOI 10.1016/j.phytochem.2006.05.021; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1872, DOI 10.1107/S090744499901029X; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P45, DOI 10.1107/S0907444902018048; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Versees W, 2003, CURR OPIN STRUC BIOL, V13, P731, DOI 10.1016/j.sbi.2003.10.002; Versees W, 2001, J MOL BIOL, V307, P1363, DOI 10.1006/jmbi.2001.4548; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEBER DJ, 1994, BIOCHEMISTRY-US, V33, P8017, DOI 10.1021/bi00192a005; WILLIAMS RJP, 1992, CELL CALCIUM, V13, P355, DOI 10.1016/0143-4160(92)90049-X; Yao M, 2006, ACTA CRYSTALLOGR D, V62, P189, DOI 10.1107/S0907444905038965; Yu BZ, 1998, BIOCHEMISTRY-US, V37, P12576, DOI 10.1021/bi9728607	51	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5770	5780		10.1074/jbc.M607340200	http://dx.doi.org/10.1074/jbc.M607340200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17166853	hybrid			2022-12-25	WOS:000244482300073
J	Lee, D; Schultz, JB; Knauf, PA; King, MR				Lee, Dooyoung; Schultz, Joanne B.; Knauf, Philip A.; King, Michael R.			Mechanical shedding of L-selectin from the neutrophil surface during rolling on sialyl Lewis x under flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; LYMPHOCYTE HOMING RECEPTOR; CELL-ADHESION; IN-VITRO; HYDRODYNAMIC SHEAR; DOWN-MODULATION; DEFICIENT MICE; CROSS-LINKING; IDENTIFICATION	The interaction of L-selectin expressed on leukocytes with endothelial cells leads to capture and rolling and is critical for the recruitment of leukocytes into sites of inflammation. It is known that leukocyte activation by chemoattractants, the change of osmotic pressure in cell media, or cross-linking of L-selectin all result in rapid shedding of L-selectin. Here we present a novel mechanism for surface cleavage of L-selectin on neutrophils during rolling on a sialyl Lewis x-coated surface that involves mechanical force. Flow cytometry and rolling of neutrophils labeled with Qdot (R)-L-selectin antibodies in an in vitro flow chamber showed that the mechanical shedding of L-selectin occurs during rolling and depends on the amount of shear applied. In addition, the mechanical L-selectin shedding causes an increase in cell rolling velocity with rolling duration, suggesting a gradual loss of L-selectin and is mediated by p38 mitogen-activated protein kinase activation. Thus, these data show that mechanical force induces the cleavage of L-selectin from the neutrophil surface during rolling and therefore decreases the adhesion of cells to a ligand-presenting surface in flow.	Univ Rochester, Dept Chem Engn, Rochester, NY 14642 USA; Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Dept Biomed Engn, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	King, MR (corresponding author), Univ Rochester, Dept Chem Engn, 601 Elmwood Ave, Rochester, NY 14642 USA.	mike_king@urmc.rochester.edu	Lee, Dooyoung/B-9925-2008; King, Michael/A-1138-2007		NHLBI NIH HHS [HL018208] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018208] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander SR, 2000, J LEUKOCYTE BIOL, V67, P415, DOI 10.1002/jlb.67.3.415; Allport JR, 1997, J IMMUNOL, V158, P4365; Bennett TA, 2000, J IMMUNOL, V164, P4120, DOI 10.4049/jimmunol.164.8.4120; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Cara DC, 2001, J IMMUNOL, V167, P6552, DOI 10.4049/jimmunol.167.11.6552; Chang KC, 2000, P NATL ACAD SCI USA, V97, P11262, DOI 10.1073/pnas.200240897; Detmers PA, 1998, J IMMUNOL, V161, P1921; Eilers PHC, 2004, BIOINFORMATICS, V20, P623, DOI 10.1093/bioinformatics/btg454; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Fu H, 1997, IMMUNOL LETT, V59, P71, DOI 10.1016/S0165-2478(97)00103-X; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; Green CE, 2003, AM J PHYSIOL-CELL PH, V284, pC705, DOI 10.1152/ajpcell.00331.2002; Greenberg AW, 2000, BIOPHYS J, V79, P2391, DOI 10.1016/S0006-3495(00)76484-8; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; Jasuja RR, 2000, INT J IMMUNOPATH PH, V13, P1; JUTILA MA, 1989, J IMMUNOL, V143, P3318; Kaba NK, 2001, AM J PHYSIOL-CELL PH, V281, pC1403, DOI 10.1152/ajpcell.2001.281.4.C1403; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; MCEVER RP, 1997, J CLIN INVEST, V100, P97; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mowery P, 2004, CHEM BIOL, V11, P725, DOI 10.1016/j.chembiol.2004.03.027; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Rizoli SB, 1999, J BIOL CHEM, V274, P22072, DOI 10.1074/jbc.274.31.22072; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; Smolen JE, 2000, J BIOL CHEM, V275, P15876, DOI 10.1074/jbc.M906232199; SPERTINI O, 1994, BLOOD, V84, P1249, DOI 10.1182/blood.V84.4.1249.bloodjournal8441249; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steeber DA, 1996, J IMMUNOL, V157, P1096; Stoddart JH, 1996, J IMMUNOL, V157, P5653; SUZUKI Y, 1993, BIOCHEM BIOPH RES CO, V190, P426, DOI 10.1006/bbrc.1993.1065; Taylor AD, 1996, BIOPHYS J, V71, P3488, DOI 10.1016/S0006-3495(96)79544-9; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; VARKI A, 1997, J CLIN INVEST, V100, P31; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Wang LC, 2005, NAT IMMUNOL, V6, P902, DOI 10.1038/ni1233; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0	46	66	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4812	4820		10.1074/jbc.M609994200	http://dx.doi.org/10.1074/jbc.M609994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17172469	hybrid			2022-12-25	WOS:000244482000063
J	Montaville, P; Schlicker, C; Leonov, A; Zweckstetter, M; Sheldrick, GM; Becker, S				Montaville, Pierre; Schlicker, Christine; Leonov, Andrei; Zweckstetter, Markus; Sheldrick, George M.; Becker, Stefan			The C2A-C2B linker defines the high affinity Ca2+ binding mode of rabphilin-3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C2B DOMAIN; PROTEIN; SYNAPTOTAGMIN; VESICLES; EXOCYTOSIS; SENSORS; SITES; IONS	The Ca2+ binding properties of C2 domains are essential for the function of their host proteins. We present here the first crystal structures showing an unexpected Ca2+ binding mode of the C2B domain of rabphilin-3A in atomic detail. Acidic residues from the linker region between the C2A and C2B domains of rabphilin-3A interact with the Ca2+-binding region of the C2B domain. Because of these interactions, the coordination sphere of the two bound Ca2+ ions is almost complete. Mutation of these acidic residues to alanine resulted in a 10-fold decrease in the intrinsic Ca2+ binding affinity of the C2B domain. Using NMR spectroscopy, we show that this interaction occurred only in the Ca2+-bound state of the C2B domain. In addition, this Ca2+ binding mode was maintained in the C2 domain tandem fragment. In NMR-based liposome binding assays, the linker was not released upon phospholipid binding. Therefore, this unprecedented Ca2+ binding mode not only shows how a C2 domain increases its intrinsic Ca2+ affinity, but also provides the structural base for an atypical protein-Ca2+-phospholipid binding mode of rabphilin-3A.	Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany; Univ Gottingen, Dept Struct Chem, D-37077 Gottingen, Germany	Max Planck Society; University of Gottingen	Becker, S (corresponding author), Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, Fassberg 11, D-37077 Gottingen, Germany.	sabe@nmr.mpibpc.mpg.de		montaville, Pierre/0000-0002-9931-3482; Zweckstetter, Markus/0000-0002-2536-6581				Arribas M, 1997, EUR J CELL BIOL, V74, P209; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cheng Y, 2004, PROTEIN SCI, V13, P2665, DOI 10.1110/ps.04832604; Chung SH, 1998, J BIOL CHEM, V273, P10240, DOI 10.1074/jbc.273.17.10240; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; Coppola T, 2001, J CELL SCI, V114, P1757; Dai H, 2004, NAT STRUCT MOL BIOL, V11, P844, DOI 10.1038/nsmb817; Deak F, 2006, EMBO J, V25, P2856, DOI 10.1038/sj.emboj.7601165; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Fukuda M, 2000, BIOCHEM BIOPH RES CO, V276, P626, DOI 10.1006/bbrc.2000.3520; FYKSE EM, 1995, J NEUROSCI, V15, P2385, DOI 10.1523/JNEUROSCI.15-03-02385.1995; Garcia J, 2004, NAT STRUCT MOL BIOL, V11, P45, DOI 10.1038/nsmb707; GODDARD TD, 1989, SPARKY VERSION 3; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; Groffen AJA, 2006, J NEUROCHEM, V97, P818, DOI 10.1111/j.1471-4159.2006.03755.x; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Joberty G, 1999, J CELL SCI, V112, P3579; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Malmberg NJ, 2005, ANNU REV BIOPH BIOM, V34, P71, DOI 10.1146/annurev.biophys.34.040204.144534; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ochoa WF, 2002, J MOL BIOL, V320, P277, DOI 10.1016/S0022-2836(02)00464-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SCOLASTICO C, 1987, Patent No. 8705024; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; Shin OH, 2004, P NATL ACAD SCI USA, V101, P2554, DOI 10.1073/pnas.0308477100; Staunton J, 2001, J NEUROSCI, V21, P9255, DOI 10.1523/JNEUROSCI.21-23-09255.2001; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Sugita S, 2002, EMBO J, V21, P270, DOI 10.1093/emboj/21.3.270; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; Tsuboi T, 2005, J BIOL CHEM, V280, P39253, DOI 10.1074/jbc.M507173200; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Ubach J, 1999, NAT CELL BIOL, V1, P106, DOI 10.1038/10076; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329	42	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					5015	5025		10.1074/jbc.M606746200	http://dx.doi.org/10.1074/jbc.M606746200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17166855	Green Published, hybrid			2022-12-25	WOS:000244482000084
J	Wang, X; Smith, DR; Jones, JW; Chapman, MR				Wang, Xuan; Smith, Daniel R.; Jones, Jonathan W.; Chapman, Matthew R.			In vitro polymerization of a functional Escherichia coli amyloid protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN AGGREGATIVE FIMBRIAE; CURLI FIBERS; ALZHEIMERS-DISEASE; COMMON MECHANISM; OLIGOMERS IMPLIES; BETA-PROTEIN; FIBRILS; FIBRILLOGENESIS; PEPTIDES; INTERNALIZATION	Amyloid formation is characterized by the conversion of Soluble proteins into biochemically and structurally distinct fibers. Although amyloid formation is traditionally associated with diseases such as Alzheimer disease, a number of biologically functional amyloids have recently been described. Curli are amyloid fibers produced by Escherichia coli that contribute to biofilm formation and other important physiological processes. We characterized the polymerization properties of the major curli subunit protein CsgA. CsgA polymerizes into an amyloid fiber in a sigmoidal kinetic fashion with a distinct lag, growth, and stationary phase. Adding sonicated preformed CsgA fibers to the polymerization reaction can significantly shorten the duration of the lag phase. We also demonstrate that the conversion of soluble CsgA into an insoluble fiber involves the transient formation of an intermediate similar to that characterized for several disease-associated amyloids. The CsgA core amyloid domain can be divided into five repeating units that share sequence and structural hallmarks. We show that peptides representing three of these repeating units are amyloidogenic in vitro. Although the defining characteristics of CsgA polymerization appear conserved with disease-associated amyloids, these proteins evolved in diverse systems and for different purposes. Therefore, amyloidogenesis appears to be an innate protein folding pathway that can be capitalized on to fulfill normal physiological tasks.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Chapman, MR (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ, Ann Arbor, MI 48109 USA.	chapmanm@umich.edu		Wang, Xuan/0000-0002-2910-8598; Chapman, Matthew/0000-0002-2645-1294	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073847] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI073847, R01 AI073847-01] Funding Source: Medline; PHS HHS [K22A1054967, P50-A608671] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Austin JW, 1998, FEMS MICROBIOL LETT, V162, P295, DOI 10.1016/S0378-1097(98)00137-2; Barnhart MM, 2006, ANNU REV MICROBIOL, V60, P131, DOI 10.1146/annurev.micro.60.080805.142106; Barnhart MM, 2006, J BACTERIOL, V188, P5212, DOI 10.1128/JB.00234-06; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; Bian Z, 2000, J INFECT DIS, V181, P602, DOI 10.1086/315233; Bian Z, 2001, J INFECT DIS, V183, P612, DOI 10.1086/318528; Bieler S, 2005, J BIOL CHEM, V280, P26880, DOI 10.1074/jbc.M502031200; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; Chen SM, 2001, PROTEIN SCI, V10, P887, DOI 10.1110/ps.42301; Cherny I, 2005, J MOL BIOL, V352, P245, DOI 10.1016/j.jmb.2005.07.028; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Collinson SK, 1999, J MOL BIOL, V290, P741, DOI 10.1006/jmbi.1999.2882; Coustou-Linares V, 2001, MOL MICROBIOL, V42, P1325, DOI 10.1046/j.1365-2958.2001.02707.x; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Elliot MA, 2003, GENE DEV, V17, P1727, DOI 10.1101/gad.264403; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Fowler DM, 2006, PLOS BIOL, V4, P100, DOI 10.1371/journal.pbio.0040006; Galzitskaya OV, 2006, PROTEINS, V63, P144, DOI 10.1002/prot.20851; Gebbink MFBG, 2005, NAT REV MICROBIOL, V3, P333, DOI 10.1038/nrmicro1127; Glabe CG, 2006, NEUROLOGY, V66, pS74, DOI 10.1212/01.wnl.0000192103.24796.42; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Gophna U, 2001, INFECT IMMUN, V69, P2659, DOI 10.1128/IAI.69.4.2659-2665.2001; Gophna U, 2002, FEMS MICROBIOL LETT, V212, P55, DOI 10.1111/j.1574-6968.2002.tb11244.x; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Hammar M, 1996, P NATL ACAD SCI USA, V93, P6562, DOI 10.1073/pnas.93.13.6562; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hurshman AR, 2004, BIOCHEMISTRY-US, V43, P7365, DOI 10.1021/bi049621l; Johansson C, 2001, FEMS IMMUNOL MED MIC, V30, P21, DOI 10.1111/j.1574-695X.2001.tb01545.x; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kisilevsky R, 2000, J STRUCT BIOL, V130, P99, DOI 10.1006/jsbi.2000.4222; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; LeVine H, 1999, METHOD ENZYMOL, V309, P274; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Liu JJ, 1999, NATURE, V400, P573, DOI 10.1038/23048; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; Lundmark K, 2005, P NATL ACAD SCI USA, V102, P6098, DOI 10.1073/pnas.0501814102; Nelson R, 2006, CURR OPIN STRUC BIOL, V16, P260, DOI 10.1016/j.sbi.2006.03.007; Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680; Olsen A, 2002, J BIOL CHEM, V277, P34568, DOI 10.1074/jbc.M206353200; Prusiner SB, 1998, BRAIN PATHOL, V8, P499; Quist A, 2005, P NATL ACAD SCI USA, V102, P10427, DOI 10.1073/pnas.0502066102; Rhoades E, 2003, BIOPHYS J, V84, P3480, DOI 10.1016/S0006-3495(03)70068-X; Ross ED, 2005, NAT CELL BIOL, V7, P1039, DOI 10.1038/ncb1105-1039; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; Shorter J, 2005, NAT REV GENET, V6, P435, DOI 10.1038/nrg1616; True HL, 2000, NATURE, V407, P477, DOI 10.1038/35035005; Tukel C, 2005, MOL MICROBIOL, V58, P289, DOI 10.1111/j.1365-2958.2005.04825.x; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Wright CF, 2005, NATURE, V438, P878, DOI 10.1038/nature04195; Zogaj X, 2001, MOL MICROBIOL, V39, P1452, DOI 10.1046/j.1365-2958.2001.02337.x; Zogaj X, 2003, INFECT IMMUN, V71, P4151, DOI 10.1128/IAI.71.7.4151-4158.2003	56	142	146	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3713	3719		10.1074/jbc.M609228200	http://dx.doi.org/10.1074/jbc.M609228200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17164238	Green Accepted, hybrid			2022-12-25	WOS:000244481900034
J	Guo, Z; Shao, LF; Du, Q; Park, KS; Geller, DA				Guo, Zhong; Shao, Lifang; Du, Qiang; Park, Kyung Soo; Geller, David A.			Identification of a classic cytokine-induced enhancer upstream in the human iNOS promoter	FASEB JOURNAL			English	Article						NO; ChIP	NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; GENE-TRANSCRIPTION; MOLECULAR-CLONING; MOUSE MACROPHAGES; CELL-LINE; CHROMATIN STRUCTURE; HUMAN HEPATOCYTES; INTERFERON-GAMMA; RESPONSE ELEMENT	The human inducible NOS (iNOS) promoter transcriptionally regulated by 5' flanking region extending 16 kb upstream that contains cytokine-responsive DNA motifs. In this study, we further identified a classic inducible enhancer located between -5 and -6 kb in the hiNOS upstream promoter. This 1 kb promoter sequence functions as a cytokine-inducible enhancer in an orientation- and position-independent manner in human lung A549 and liver AKN1 cells. This DNA enhancer also confers cytokine inducibility to the heterologous thymidine kinase (TK) promoter. Chromatin immunoprecipitation (ChIP) analysis was applied, and confirmed cytokine-inducible in vivo DNA-protein interactions within this enhancer region. In vivo functional binding of both NF-kappa B (p65/p50) and Stat-1 alpha at the -5.8 kb human iNOS promoter site was significantly increased in A549 cells after cytokine stimulation, while only Stat-1 alpha bound at the -5.2 kb site. These results identify the -5 to -6 kb promoter region as a classic transcriptional enhancer for the human iNOS gene and provide definitive in vivo evidence of specific NF-kappa B and Stat-1 nuclear protein binding that mediates transcription of the hiNOS gene under cytokine stimulation.	Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Geller, DA (corresponding author), Univ Pittsburgh, Dept Surg, Kaufmann Med Bldg,Ste 300,3471 5th Ave, Pittsburgh, PA 15213 USA.	gellerda@upmc.edu			NIDDK NIH HHS [R01-DK62313] Funding Source: Medline; NIGMS NIH HHS [R01-GM52021] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052021] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Burgess-Beusse B, 2002, P NATL ACAD SCI USA, V99, P16433, DOI 10.1073/pnas.162342499; Chan GC, 2005, J IMMUNOL, V175, P3846, DOI 10.4049/jimmunol.175.6.3846; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; Chu SC, 1998, BIOCHEM BIOPH RES CO, V248, P871, DOI 10.1006/bbrc.1998.9062; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Du QA, 2006, CANCER RES, V66, P7024, DOI 10.1158/0008-5472.CAN-05-4110; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Feng XS, 2002, P NATL ACAD SCI USA, V99, P14212, DOI 10.1073/pnas.212306199; Ganster R. W., 2000, NITRIC OXIDE; Ganster RW, 2005, J INTERF CYTOK RES, V25, P707, DOI 10.1089/jir.2005.25.707; Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GELLER DA, 1995, J IMMUNOL, V155, P4890; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Guo Z, 2003, FASEB J, V17, P1718, DOI 10.1096/fj.02-1172fje; Hausding M, 2000, BRIT J PHARMACOL, V131, P553, DOI 10.1038/sj.bjp.0703607; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; Linn SC, 1997, AM J PHYSIOL-GASTR L, V272, pG1499, DOI 10.1152/ajpgi.1997.272.6.G1499; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Mellott JK, 2001, AM J PHYSIOL-LUNG C, V280, pL390, DOI 10.1152/ajplung.2001.280.3.L390; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Nussler AK, 1999, IN VITRO CELL DEV-AN, V35, P190, DOI 10.1007/s11626-999-0026-4; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; Suschek CV, 2004, CURR MOL MED, V4, P763, DOI 10.2174/1566524043359908; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Taylor BS, 2000, SHOCK, V13, P413, DOI 10.1097/00024382-200006000-00001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	37	52	56	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					535	542		10.1096/fj.06-6739com	http://dx.doi.org/10.1096/fj.06-6739com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158780				2022-12-25	WOS:000244686300026
J	Kalisch, T; Wilimzig, C; Kleibel, N; Tegenthoff, M; Dinse, HR				Kalisch, Tobias; Wilimzig, Claudia; Kleibel, Nadine; Tegenthoff, Martin; Dinse, Hubert R.			Age-Related Attenuation of Dominant Hand Superiority	PLOS ONE			English	Article								Background. The decline of motor performance of the human hand-arm system with age is well-documented. While dominant hand performance is superior to that of the non-dominant hand in young individuals, little is known of possible age-related changes in hand dominance. We investigated age-related alterations of hand dominance in 20 to 90 year old subjects. All subjects were unambiguously right-handed according to the Edinburgh Handedness Inventory. In Experiment 1, motor performance for aiming, postural tremor, precision of arm-hand movement, speed of arm-hand movement, and wrist-finger speed tasks were tested. In Experiment 2, accelerometer-sensors were used to obtain objective records of hand use in everyday activities. Principal Findings. Our data confirm previous findings of a general task-dependent decline in motor performance with age. Analysis of the relationship between right/left-hand performances using a laterality index showed a loss of right hand dominance with advancing age. The clear right-hand advantage present at younger ages changed to a more balanced performance in advanced age. This shift was due to a more pronounced age-related decline of right hand performance. Accelerometer-sensor measurements supported these findings by demonstrating that the frequency of hand use also shifted from a clear right hand preference in young adults to a more balanced usage of both hands in old age. Despite these age-related changes in the relative level of performance in defined motor tasks and in the frequency of hand use, elderly subjects continued to rate themselves as unambiguous right-handers. Conclusion. The discrepancy between hand-specific practical performance in controlled motor tests as well as under everyday conditions and the results of questionnaires concerning hand use and hand dominance suggests that most elderly subjects are unaware of the changes in hand dominance that occur over their lifespan, i.e., a shift to ambidexterity.	[Kalisch, Tobias; Wilimzig, Claudia; Kleibel, Nadine; Dinse, Hubert R.] Ruhr Univ Bochum, Dept Theoret Biol, Neural Plast Lab, Inst Neuroinformat, Bochum, Germany; [Wilimzig, Claudia] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Tegenthoff, Martin] Ruhr Univ Bochum, Dept Neurol, BG Kliniken Bergmannsheil, Bochum, Germany	Ruhr University Bochum; California Institute of Technology; Ruhr University Bochum	Dinse, HR (corresponding author), Ruhr Univ Bochum, Dept Theoret Biol, Neural Plast Lab, Inst Neuroinformat, Bochum, Germany.	hubert.dinse@neuroinformatik.rub.de	Kalisch, Tobias/AAY-4182-2021	Kalisch, Tobias/0000-0003-4206-4283; dinse, hubert/0000-0001-9024-0451	DFG [Di 334/10-4, Te 315/2-1]; Schering Stiftung; Studienstiftung des Deutschen Volkes	DFG(German Research Foundation (DFG)); Schering Stiftung; Studienstiftung des Deutschen Volkes	This research was supported by grants from the DFG awarded to HRD (Di 334/10-4) and MT (Te 315/2-1), a grant from the Schering Stiftung awarded to TK, and a grant from the Studienstiftung des Deutschen Volkes awarded to CW.	Albert M. S., 1988, GERIATRIC NEUROPSYCH; Amunts K, 2000, NEUROPSYCHOLOGIA, V38, P304, DOI 10.1016/S0028-3932(99)00075-5; ANNETT M, 1970, BRIT J PSYCHOL, V61, P303, DOI 10.1111/j.2044-8295.1970.tb01248.x; Bishop DVM, 1996, BRIT J PSYCHOL, V87, P269, DOI 10.1111/j.2044-8295.1996.tb02590.x; BOLTZ MG, 1994, J EXP PSYCHOL LEARN, V20, P1154, DOI 10.1037/0278-7393.20.5.1154; BROWN JW, 1975, NEUROPSYCHOLOGIA, V13, P107, DOI 10.1016/0028-3932(75)90054-8; Cabeza R, 1997, J NEUROSCI, V17, P391; Cabeza R, 2002, PSYCHOL AGING, V17, P85, DOI 10.1037//0882-7974.17.1.85; CARELLA J, 1990, HDB PSYCHOL AGING, P201; Carmeli E, 2003, J GERONTOL A-BIOL, V58, P146, DOI 10.1093/gerona/58.2.M146; Carmelli D, 2000, J APPL PHYSIOL, V89, P1879, DOI 10.1152/jappl.2000.89.5.1879; Cavill S, 2003, BRAIN COGNITION, V53, P149, DOI 10.1016/S0278-2626(03)00098-8; Chan KM, 2000, CAN J NEUROL SCI, V27, P220, DOI 10.1017/S0317167100000858; CHODZKOZAJKO WJ, 1991, MED SCI SPORT EXER, V23, P868; Civardi C, 2000, CLIN NEUROPHYSIOL, V111, P624, DOI 10.1016/S1388-2457(99)00301-6; COLE KJ, 1991, J MOTOR BEHAV, V23, P251, DOI 10.1080/00222895.1991.9942036; Corey DM, 2001, NEUROPSY NEUROPSY BE, V14, P144; DENNER B, 1964, PERCEPT MOTOR SKILL, V19, P723, DOI 10.2466/pms.1964.19.3.723; Dik MG, 2003, J CLIN EXP NEUROPSYC, V25, P643, DOI 10.1076/jcen.25.5.643.14583; DIXIT NK, 2000, NEUROIMAGE, V5, P94; Dolcos F, 2002, NEUROSCI BIOBEHAV R, V26, P819, DOI 10.1016/S0149-7634(02)00068-4; Elias LJ, 1998, NEUROPSYCHOLOGIA, V36, P37, DOI 10.1016/S0028-3932(97)00107-3; Fleishman E.A., 1972, PSYCHOMOTOR DOMAIN, P78; FLEMINGER JJ, 1977, NEUROPSYCHOLOGIA, V15, P471, DOI 10.1016/0028-3932(77)90101-4; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Francis KL, 2000, EXP AGING RES, V26, P169, DOI 10.1080/036107300243632; FROLKIS VV, 1976, GERONTOLOGY, V22, P244, DOI 10.1159/000212143; GALGANSKI ME, 1993, J NEUROPHYSIOL, V69, P2108, DOI 10.1152/jn.1993.69.6.2108; GOLDSTEIN G, 1981, Journal of Clinical Neuropsychology, V3, P65, DOI 10.1080/01688638108403114; GRADY CL, 1995, SCIENCE, V269, P218, DOI 10.1126/science.7618082; Grady CL, 1998, NEUROIMAGE, V8, P409, DOI 10.1006/nimg.1998.0376; Grady CL, 2000, CURR OPIN NEUROBIOL, V10, P224, DOI 10.1016/S0959-4388(00)00073-8; GRIMBY G, 1982, ACTA PHYSIOL SCAND, V115, P125, DOI 10.1111/j.1748-1716.1982.tb07054.x; Hausmann M, 2003, LATERALITY, V8, P277, DOI 10.1080/13576500244000201; Henkel V, 2001, NEUROPSYCHOLOGIA, V39, P1158, DOI 10.1016/S0028-3932(01)00043-4; HORN JL, 1977, AM PSYCHOL, V31, P269; Hughes S, 1997, J AM GERIATR SOC, V45, P905, DOI 10.1111/j.1532-5415.1997.tb02957.x; Hutchinson S, 2002, NEUROIMAGE, V17, P1720, DOI 10.1006/nimg.2002.1309; JAGACINSKI RJ, 1995, PSYCHOL AGING, V10, P8, DOI 10.1037/0882-7974.10.1.8; JEBSEN R H, 1969, Archives of Physical Medicine and Rehabilitation, V50, P311; KEEN DA, 1994, J APPL PHYSIOL, V77, P2648, DOI 10.1152/jappl.1994.77.6.2648; Kinoshita H, 1996, EUR J APPL PHYSIOL, V74, P450; KOCEL KM, 1980, NEUROPSYCHOLOGY LEFT, P293; Krampe RT, 2002, NEUROSCI BIOBEHAV R, V26, P769, DOI 10.1016/S0149-7634(02)00064-7; Kraus PH, 2000, J NEURAL TRANSM, V107, P73, DOI 10.1007/s007020050006; Laidlaw DH, 2000, MUSCLE NERVE, V23, P600, DOI 10.1002/(SICI)1097-4598(200004)23:4<600::AID-MUS20>3.3.CO;2-4; Liao MJ, 1997, J EXP PSYCHOL HUMAN, V23, P1644, DOI 10.1037/0096-1523.23.6.1644; Mattay VS, 2002, NEUROLOGY, V58, P630, DOI 10.1212/WNL.58.4.630; MCFIE J, 1975, ASSESSMENT ORGANIC I; MEUDELL PR, 1987, CORTEX, V23, P431; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; MURRAY MP, 1980, PHYS THER, V60, P412, DOI 10.1093/ptj/60.4.412; Nielson KA, 2002, PSYCHOL AGING, V17, P56, DOI 10.1037//0882-7974.17.1.56; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Peters A, 2002, NEUROSCI BIOBEHAV R, V26, P733, DOI 10.1016/S0149-7634(02)00060-X; Peters M, 1998, Laterality, V3, P77, DOI 10.1080/713754291; PORAC C, 1993, CAN J EXP PSYCHOL, V47, P697, DOI 10.1037/h0078873; Ranganathan VK, 2001, J AM GERIATR SOC, V49, P1478, DOI 10.1046/j.1532-5415.2001.4911240.x; Sailer A, 2000, NEUROLOGY, V55, P979, DOI 10.1212/WNL.55.7.979; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; SAND PL, 1973, PERCEPT MOTOR SKILL, V36, P1343, DOI 10.2466/pms.1973.36.3c.1343; Schut LJ, 1998, GERIATRICS, V53, pS16; Smith CD, 1999, NEUROLOGY, V53, P1458, DOI 10.1212/WNL.53.7.1458; SPERLING L, 1980, SCAND J REHABIL MED, V12, P139; Triggs WJ, 2000, CORTEX, V36, P679, DOI 10.1016/S0010-9452(08)70545-8; WARABI T, 1986, EXP NEUROL, V92, P686, DOI 10.1016/0014-4886(86)90309-2; Wechsler D, 1958, MEASUREMENT APPRAISA; WELLER MPI, 1985, PSYCHOL MED, V15, P867, DOI 10.1017/S0033291700005109; Weuve J, 2004, JAMA-J AM MED ASSOC, V292, P1454, DOI 10.1001/jama.292.12.1454	69	72	73	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e90	10.1371/journal.pone.0000090	http://dx.doi.org/10.1371/journal.pone.0000090			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183722	Green Published, gold, Green Accepted			2022-12-25	WOS:000207443600089
J	Grabarczyk, P; Przybylski, GK; Depke, M; Volker, U; Bahr, J; Assmus, K; Broker, BM; Walther, R; Schmidt, CA				Grabarczyk, P.; Przybylski, G. K.; Depke, M.; Voelker, U.; Bahr, J.; Assmus, K.; Broeker, B. M.; Walther, R.; Schmidt, C. A.			Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells	ONCOGENE			English	Article						BCL11B; T-ALL; apoptosis; TRAIL; Bcl-xL	ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTIONAL REPRESSION; THYMIC LYMPHOMAS; BINDING PROTEIN; NURD COMPLEX; GENE; PROMOTER; LYMPHOCYTES; BCL-X(L); TRAIL	The B-cell chronic lymphocytic leukemia (CLL)/lymphoma 11B gene (BCL11B) encodes a Kruppel-like zinc. finger protein, which plays a crucial role in thymopoiesis and has been associated with hematopoietic malignancies. It was hypothesized that BCL11B may act as a tumor-suppressor gene, but its precise function has not yet been elucidated. Here, we demonstrate that the survival of human T-cell leukemia and lymphoma cell lines is critically dependent on Bcl11b. Suppression of Bcl11b by RN A interference selectively induced apoptosis in transformed T cells whereas normal mature T cells remained unaffected. The apoptosis was effected by simultaneous activation of death receptor-mediated and intrinsic apoptotic pathways, most likely as a result of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) upregulation and suppression of the Bcl-xL antiapoptotic protein. Our data indicate an antiapoptotic function of Bcl11b. The resistance of normal mature T lymphocytes to Bcl11b suppression-induced apoptosis and restricted expression pattern make it an attractive therapeutic target in T-cell malignancies.	Ernst Moritz Arndt Univ Greifswald, Clin Internal Med C, D-17475 Greifswald, Germany; Polish Acad Sci, Inst Human Genet, PL-00901 Poznan, Poland; Ernst Moritz Arndt Univ Greifswald, Lab Funct Genom, D-17475 Greifswald, Germany; Ernst Moritz Arndt Univ Greifswald, Inst Immunol & Transfus Med, D-17475 Greifswald, Germany; Ernst Moritz Arndt Univ Greifswald, Dept Med Biochem & Mol Biol, D-17475 Greifswald, Germany	Ernst Moritz Arndt Universitat Greifswald; Polish Academy of Sciences; Institute of Human Genetics of the Polish Academy of Sciences; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald	Schmidt, CA (corresponding author), Ernst Moritz Arndt Univ Greifswald, Clin Internal Med C, Sauerbruch Str, D-17475 Greifswald, Germany.	christian.schmidt@uni-greifswald.de	Bröker, Barbara M/O-4850-2015	Bröker, Barbara M/0000-0002-5020-8542; Volker, Uwe/0000-0002-5689-3448; Przybylski, Grzegorz/0000-0001-5783-1567				Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Avram D, 2002, BIOCHEM J, V368, P555, DOI 10.1042/BJ20020496; Bezrookove V, 2004, CANCER GENET CYTOGEN, V149, P72, DOI 10.1016/S0165-4608(03)00302-9; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Broome HE, 2002, LEUKEMIA RES, V26, P311, DOI 10.1016/S0145-2126(01)00118-7; Cismasiu VB, 2006, BLOOD, V108, P2695, DOI 10.1182/blood-2006-05-021790; Cismasiu VB, 2005, ONCOGENE, V24, P6753, DOI 10.1038/sj.onc.1208904; Ehrlich S, 2003, CYTOKINE, V24, P244, DOI 10.1016/S1043-4666(03)00094-2; Gesk S, 2003, LEUKEMIA, V17, P738, DOI 10.1038/sj.leu.2402884; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; Inoue J, 2006, J IMMUNOL, V176, P5871, DOI 10.4049/jimmunol.176.10.5871; Insinga A, 2005, CELL CYCLE, V4, P741, DOI 10.4161/cc.4.6.1717; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Kim KI, 2003, BRIT J CANCER, V88, P910, DOI 10.1038/sj.bjc.6600795; Klose R, 2005, TRANSPLANTATION, V80, P222, DOI 10.1097/01.TP.0000164817.59006.C2; Leid M, 2004, GENE EXPR PATTERNS, V4, P733, DOI 10.1016/j.modgep.2004.03.009; MacLeod RAF, 2003, GENE CHROMOSOME CANC, V37, P84, DOI 10.1002/gcc.10194; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nagel S, 2003, CANCER RES, V63, P5329; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Oshiro A, 2006, BLOOD, V107, P4500, DOI 10.1182/blood-2005-09-3801; Przybylski GK, 2005, LEUKEMIA, V19, P201, DOI 10.1038/sj.leu.2403619; Sakata J, 2004, CARCINOGENESIS, V25, P1069, DOI 10.1093/carcin/bgh094; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Senawong T, 2005, ARCH BIOCHEM BIOPHYS, V434, P316, DOI 10.1016/j.abb.2004.10.028; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Simon AK, 2001, P NATL ACAD SCI USA, V98, P5158, DOI 10.1073/pnas.091100398; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Topark-Ngarm A, 2006, J BIOL CHEM, V281, P32272, DOI 10.1074/jbc.M602776200; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zhang N, 2005, J IMMUNOL, V174, P6967, DOI 10.4049/jimmunol.174.11.6967	36	56	61	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3797	3810		10.1038/sj.onc.1210152	http://dx.doi.org/10.1038/sj.onc.1210152			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173069				2022-12-25	WOS:000247026400004
J	Portal, MM; Ferrero, GO; Caputto, BL				Portal, M. M.; Ferrero, G. O.; Caputto, B. L.			N-terminal c-Fos tyrosine phosphorylation regulates c-Fos/ER association and c-Fos-dependent phospholipid synthesis activation	ONCOGENE			English	Article						cytoplasmic c-Fos; phospholipid synthesis regulation; c-Fos/endoplasmic reticulum association; c-Fos-regulated lipid metabolism; c-Fos tyr phosphorylation; tyr-phosphorylation	TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; JUN; PROTEINS; BINDING; KINASE; CELLS; LIGHT; AP-1; DEGRADATION	c-Fos dephosphorylated on tyrosine (c-Fos), a component of the activator protein-1 (AP-1) family of transcription factors, is expressed at very low levels in resting cells. However, its expression is rapidly upregulated in cells undergoing G(0) to S phase transition leading to AP-1-dependent gene transcription responses. In addition, cytoplasmic c-Fos associates to the endoplasmic reticulum (ER) membranes and activates phospholipid synthesis during cell growth and differentiation. Herein, it is shown that in T98G cells, c-Fos/ER association and consequently phospholipid synthesis activation is regulated by the phosphorylated state of c-Fos tyrosine (tyr) residues. The small amount of c-Fos present in quiescent T98G cells is tyr-phosphorylated and not ER-membrane bound. In growing cells, it is dephosphorylated, associated to ER membranes and promotes phospholipid synthesis activation. Impairing tyr-dephosphorylation abrogates phospholipid synthesis activation and reduces proliferation rates to those of quiescent cells. Substitution of tyr residues 10, 30, 106 and 337 evidence tyr 10 and 30 as relevant for this regulatory phenomenon. It is concluded that phosphorylation of tyr residues 10 and 30 of c-Fos regulate the rate of synthesis of phospholipids by regulating c-Fos/ER association.	Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC,CONICET, RA-5000 Cordoba, Argentina	National University of Cordoba	Caputto, BL (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC,CONICET, Pabellon Argentina,Ciudad Univ, RA-5000 Cordoba, Argentina.	bcaputto@dqb.fcq.unc.edu.ar		PORTAL, Maximiliano/0000-0002-2884-6900				ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; Acquaviva C, 2001, ONCOGENE, V20, P942, DOI 10.1038/sj.onc.1204155; ALITALO R, 1990, BLOOD, V75, P1974; ALLEGRETTO EA, 1990, J CELL BIOCHEM, V42, P193, DOI 10.1002/jcb.240420403; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Borioli GA, 2005, BBA-BIOMEMBRANES, V1668, P41, DOI 10.1016/j.bbamem.2004.11.007; Borioli GA, 2004, FEBS LETT, V570, P82, DOI 10.1016/j.febslet.2004.06.033; Borioli GA, 2001, BIOCHEM BIOPH RES CO, V280, P9, DOI 10.1006/bbrc.2000.4081; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bussolino DF, 2001, FASEB J, V15, P556; Bussolino DF, 1998, MOL BRAIN RES, V58, P10, DOI 10.1016/S0169-328X(98)00065-5; Coronella-Wood J, 2004, J BIOL CHEM, V279, P33567, DOI 10.1074/jbc.M404013200; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; Gil GA, 2004, MOL BIOL CELL, V15, P1881, DOI 10.1091/mbc.e03-09-0705; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GUIDO ME, 1990, J NEUROCHEM, V55, P1855, DOI 10.1111/j.1471-4159.1990.tb05768.x; Guido ME, 1996, J NEUROSCI RES, V43, P93, DOI 10.1002/jnr.490430112; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kaludov NK, 1996, P NATL ACAD SCI USA, V93, P4465, DOI 10.1073/pnas.93.9.4465; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Stork PJS, 2002, CELL CYCLE, V1, P315, DOI 10.4161/cc.1.5.145; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Zerpa GAD, 1999, J NEUROCHEM, V73, P1228, DOI 10.1046/j.1471-4159.1999.0731228.x	29	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3551	3558		10.1038/sj.onc.1210137	http://dx.doi.org/10.1038/sj.onc.1210137			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160021				2022-12-25	WOS:000246799200011
J	Chen, BPC; Uematsu, N; Kobayashi, J; Lerenthal, Y; Krempler, A; Yajima, H; Lobrich, M; Shiloh, Y; Chen, DJ				Chen, Benjamin P. C.; Uematsu, Naoya; Kobayashi, Junya; Lerenthal, Yaniv; Krempler, Andrea; Yajima, Hirohiko; Loebrich, Markus; Shiloh, Yosef; Chen, David J.			Ataxia telangiectasia mutated (ATM) is essential for DNA-PKcs phosphorylations at the Thr-2609 cluster upon DNA double strand break	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; CELLULAR-RESPONSE; DAMAGE-RESPONSE; REPAIR; IDENTIFICATION; AUTOPHOSPHORYLATION; ARTEMIS; CELLS; CONNECTION	The catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) is rapidly phosphorylated at the Thr-2609 cluster and Ser-2056 upon ionizing radiation (IR). Furthermore, DNA-PKcs phosphorylation at both regions is critical for its role in DNA double strand break (DSB) repair as well as cellular resistance to radiation. IR-induced DNA-PKcs phosphorylation at Thr-2609 and Ser-2056, however, exhibits distinct kinetics indicating that they are differentially regulated. Although DNA-PKcs autophosphorylates itself at Ser-2056 after IR, we have reported here that ATM mediates DNA-PKcs phosphorylation at Thr-2609 as well as at the adjacent (S/T)Q motifs within the Thr-2609 cluster. In addition, our data suggest that DNA-PKcs and ATM-mediated DNA-PKcs phosphorylations are cooperative and required for the full activation of DNA-PKcs and the subsequent DSB repair. Elimination of DNA-PKcs phosphorylation at both regions severely compromises radioresistance and DSB repair. Finally, our result provides a possible mechanism for the direct involvement of ATM in non-homologous end joining-mediated DSB repair.	Univ Texas, SW Med Ctr Dallas, Dept Radiat Oncol, Div Mol Radiat Biol, Dallas, TX 75390 USA; Kyoto Univ, Ctr Radiat Biol, Dept Genome Dynam, Kyoto 6068501, Japan; Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet, IL-69978 Tel Aviv, Israel; Univ Saarland, Fachrichtung Biophys, D-66421 Homburg Saar, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Kyoto University; Tel Aviv University; Sackler Faculty of Medicine; Saarland University	Chen, DJ (corresponding author), Univ Texas, SW Med Ctr Dallas, Dept Radiat Oncol, Div Mol Radiat Biol, 2201 Inwood Rd, Dallas, TX 75390 USA.	david.chen@utsouthwestern.edu	Kobayashi, Junya/AAX-6390-2021; Classen, Scott/AAY-8176-2020	Kobayashi, Junya/0000-0003-4645-7500; 	NATIONAL CANCER INSTITUTE [R37CA050519, P01CA092584, R01CA086936, R01CA050519] Funding Source: NIH RePORTER; NCI NIH HHS [CA86936, CA50519, P01-CA92584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Bassing CH, 2004, DNA REPAIR, V3, P781, DOI 10.1016/j.dnarep.2004.06.001; Biton S, 2006, J BIOL CHEM, V281, P17482, DOI 10.1074/jbc.M601895200; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Goodarzi AA, 2006, EMBO J, V25, P3880, DOI 10.1038/sj.emboj.7601255; Gurley KE, 2001, CURR BIOL, V11, P191, DOI 10.1016/S0960-9822(01)00048-3; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Leahy JJJ, 2004, BIOORG MED CHEM LETT, V14, P6083, DOI 10.1016/j.bmcl.2004.09.060; Ma YM, 2005, J BIOL CHEM, V280, P33839, DOI 10.1074/jbc.M507113200; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Peng YL, 2005, CANCER RES, V65, P1670, DOI 10.1158/0008-5472.CAN-04-3451; Pike BL, 2004, MOL CELL BIOL, V24, P2779, DOI 10.1128/MCB.24.7.2779-2788.2004; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Soubeyrand S, 2003, CANCER RES, V63, P1198; Traven A, 2005, BIOESSAYS, V27, P397, DOI 10.1002/bies.20204; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; Wyman C, 2006, ANNU REV GENET, V40, P363, DOI 10.1146/annurev.genet.40.110405.090451; Ye RQ, 2001, J BIOL CHEM, V276, P4828, DOI 10.1074/jbc.M004894200; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753	31	225	232	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6582	6587		10.1074/jbc.M611605200	http://dx.doi.org/10.1074/jbc.M611605200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17189255	hybrid			2022-12-25	WOS:000244867200067
J	Vacher, H; Mohapatra, DP; Misonou, H; Trimmer, JS				Vacher, Helene; Mohapatra, Durga P.; Misonou, Hiroaki; Trimmer, Jaimes S.			Regulation of Kv1 channel trafficking by the mamba snake neurotoxin dendrotoxin K	FASEB JOURNAL			English	Article						potassium channel; neuron; endoplasmic reticulum	BETA-SUBUNIT POLYPEPTIDES; POTASSIUM CHANNEL; SURFACE EXPRESSION; CELL-SURFACE; MOLECULAR-PROPERTIES; MAMMALIAN BRAIN; ALPHA-SUBUNIT; ION CHANNELS; AMINO-ACIDS; IDENTIFICATION	Modulation of voltage-gated potassium (Kv) channel surface expression can profoundly affect neuronal excitability. Some, but not all, mammalian Shaker or Kv1 alpha subunits contain a dominant endoplasmic reticulum (ER) retention signal in their pore region, preventing surface expression of Kv1.1 homotetrameric channels and of heteromeric Kv1 channels containing more than one Kv1.1 subunit. The critical amino acid residues within this ER pore-region retention signal are also critical for high-affinity binding of snake dendrotoxins (DTX). This suggests that ER retention may be mediated by an ER protein with a domain structurally similar to that of DTX. One facet of such a model is that expression of soluble DTX in the ER lumen should compete for binding to the retention protein and allow for surface expression of retained Kv1.1. Here, we show that luminal DTX expression dramatically increased both the level of cell surface Kv1.1 immunofluorescence staining and the proportion of Kv1.1 with processed N-linked oligosaccharides. Electrophysiological analyses showed that luminal DTX expression led to significant increases in Kv1.1 currents. Together, these data showed that luminal DTX expression increases surface expression of functional Kv1.1 homotetrameric channels and support a model whereby a DTX-like ER protein regulates abundance of cell surface Kv1 channels.	Univ Calif Davis, Sch Med, Dept Pharmacol, Davis, CA 95616 USA	University of California System; University of California Davis	Trimmer, JS (corresponding author), Univ Calif Davis, Sch Med, Dept Pharmacol, 3502 GBSF,451 W Hlth Sci Dr,1 Shields Ave, Davis, CA 95616 USA.	jtrimmer@ucdavis.edu	Durga, Mohapatra/B-3620-2008; Mohapatra, Durga/M-2133-2017	Mohapatra, Durga/0000-0001-5016-1281; Misono, Hiroaki/0000-0001-5892-1804	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034383, R01NS034383] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS034383, R37 NS034383, NS34383, R37 NS034383-12] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BekeleArcuri Z, 1996, NEUROPHARMACOLOGY, V35, P851, DOI 10.1016/0028-3908(96)00128-1; Campomanes CR, 2002, J BIOL CHEM, V277, P8298, DOI 10.1074/jbc.M110276200; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Dolly JO, 1996, J BIOENERG BIOMEMBR, V28, P231, DOI 10.1007/BF02110698; Fu W, 2002, BIOPHYS J, V83, P2370, DOI 10.1016/S0006-3495(02)75251-X; Harvey AL, 2001, TOXICON, V39, P15, DOI 10.1016/S0041-0101(00)00162-8; Hille B., 2001, IONIC CHANNELS EXCIT, P814; HURST RS, 1991, MOL PHARMACOL, V40, P572; Imredy JP, 2000, J MOL BIOL, V296, P1283, DOI 10.1006/jmbi.2000.3522; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Koch RO, 1997, J BIOL CHEM, V272, P27577, DOI 10.1074/jbc.272.44.27577; Lopantsev V, 2003, EPILEPSIA, V44, P1506, DOI 10.1111/j.0013-9580.2003.44602.x; Manganas LN, 2001, P NATL ACAD SCI USA, V98, P14055, DOI 10.1073/pnas.241403898; Manganas LN, 2001, J BIOL CHEM, V276, P49427, DOI 10.1074/jbc.M109325200; Manganas LN, 2000, J BIOL CHEM, V275, P29685, DOI 10.1074/jbc.M005010200; Misonou H, 2005, J NEUROSCI METH, V144, P165, DOI 10.1016/j.jneumeth.2004.11.007; Miwa JM, 1999, NEURON, V23, P105, DOI 10.1016/S0896-6273(00)80757-6; Mohapatra DP, 2006, J NEUROSCI, V26, P685, DOI 10.1523/JNEUROSCI.4620-05.2006; Ohno M, 1998, PROG NUCLEIC ACID RE, V59, P307; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RHODES KJ, 1995, J NEUROSCI, V15, P5360; Robertson GA, 2006, HANDB EXP PHARMACOL, V171, P349; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Smart SL, 1998, NEURON, V20, P809, DOI 10.1016/S0896-6273(00)81018-1; Smith LA, 1997, BIOCHEMISTRY-US, V36, P7690, DOI 10.1021/bi963105g; SMITH LA, 1993, BIOCHEMISTRY-US, V32, P5692, DOI 10.1021/bi00072a026; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Trimmer JS, 2004, ANNU REV PHYSIOL, V66, P477, DOI 10.1146/annurev.physiol.66.032102.113328; TYTGAT J, 1995, J BIOL CHEM, V270, P24776, DOI 10.1074/jbc.270.42.24776; Wang FC, 1999, EUR J BIOCHEM, V263, P222, DOI 10.1046/j.1432-1327.1999.00494.x; Zhu J, 2005, BIOCHEM J, V388, P355, DOI 10.1042/BJ20041447; Zhu J, 2003, J BIOL CHEM, V278, P25558, DOI 10.1074/jbc.M207984200; Zhu J, 2001, J BIOL CHEM, V276, P39419, DOI 10.1074/jbc.M107399200	35	27	27	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					906	914		10.1096/fj.06-7229com	http://dx.doi.org/10.1096/fj.06-7229com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17185748	Green Accepted			2022-12-25	WOS:000244686400027
J	Burkhalter, J; Fiumelli, H; Erickson, JD; Martin, JL				Burkhalter, Julia; Fiumelli, Hubert; Erickson, Jeffrey D.; Martin, Jean-Luc			A critical role for system A amino acid transport in the regulation of dendritic development by brain-derived neurotrophic factor (BDNF)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; LONG-TERM POTENTIATION; MOUSE CORTICAL-NEURONS; VISUAL-CORTEX; MICE LACKING; MOLECULAR-BIOLOGY; PROTEIN-SYNTHESIS; MAMMALIAN TARGET; CRITICAL PERIOD; LATE-PHASE	Dendritic development is essential for the establishment of a functional nervous system. Among factors that control dendritic development, brain-derived neurotrophic factor (BDNF) has been shown to regulate dendritic length and complexity of cortical neurons. However, the cellular and molecular mechanisms that underlie these effects remain poorly understood. In this study, we examined the role of amino acid transport in mediating the effects of]BDNF on dendritic development. We show that BDNF increases System A amino acid transport in cortical neurons by selective up-regulation of the sodium-coupled neutral amino acid transporter (SNAT)1. Up-regulation of SNAT1 expression and System A activity is required for the effects of BDNF on dendritic growth and branching of cortical neurons. Further analysis revealed that induction of SNAT1 expression and System A activity by BDNF is necessary in particular to enhance synthesis of tissue-type plasminogen activator, a protein that we demonstrate to be essential for the effects of BDNF on cortical dendritic morphology. Together, these data reveal that stimulation of neuronal differentiation by BDNF requires the up-regulation of SNAT1 expression and System A amino acid transport to meet the increased metabolic demand associated with the enhancement of dendritic growth and branching.	Univ Lausanne, Dept Physiol, CH-1005 Lausanne, Switzerland; Louisiana State Univ, Hlth Sci Ctr, Ctr Neurosci, New Orleans, LA 70112 USA; Univ Lausanne, Dept Psychiat, Ctr Psychiat Neurosci, CH-1008 Prilly, Switzerland	University of Lausanne; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of Lausanne	Martin, JL (corresponding author), Univ Lausanne, Dept Physiol, Rue Bugnon 7, CH-1005 Lausanne, Switzerland.	jean-luc.martin@unil.ch		Martin, Jean-Luc/0000-0002-5082-4687				Armano S, 2002, J BIOL CHEM, V277, P10467, DOI 10.1074/jbc.M110942200; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Burkhalter J, 2003, J NEUROSCI, V23, P8212; CHRISTENSEN HN, 1965, J BIOL CHEM, V240, P3609; Cramer S, 2002, AM J PHYSIOL-CELL PH, V282, pC153, DOI 10.1152/ajpcell.2002.282.1.C153; Dijkhuizen PA, 2005, PROG BRAIN RES, V147, P17, DOI 10.1016/S0079-6123(04)47002-2; Fiumelli H, 1999, EUR J NEUROSCI, V11, P1639, DOI 10.1046/j.1460-9568.1999.00580.x; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Horch HW, 1999, NEURON, V23, P353; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; JESSELL TM, 2000, PRINCIPLES NEURAL SC, P1019; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P784, DOI 10.1007/s00424-003-1117-9; Mackenzie B, 2003, J BIOL CHEM, V278, P23720, DOI 10.1074/jbc.M212718200; Mataga N, 2004, NEURON, V44, P1031, DOI 10.1016/j.neuron.2004.11.028; Mataga N, 2002, P NATL ACAD SCI USA, V99, P7717, DOI 10.1073/pnas.102088899; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; McAllister AK, 1997, NEURON, V18, P767, DOI 10.1016/S0896-6273(00)80316-5; McAllister AK, 2000, CEREB CORTEX, V10, P963, DOI 10.1093/cercor/10.10.963; Melone M, 2004, CEREB CORTEX, V14, P562, DOI 10.1093/cercor/bhh018; Miller FD, 2003, CURR OPIN NEUROBIOL, V13, P391, DOI 10.1016/s0959-4388(03)00072-2; Muller CM, 1998, NAT NEUROSCI, V1, P47, DOI 10.1038/248; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Schratt GM, 2004, J NEUROSCI, V24, P7366, DOI 10.1523/JNEUROSCI.1739-04.2004; Seeds NW, 1999, P NATL ACAD SCI USA, V96, P14118, DOI 10.1073/pnas.96.24.14118; STELLA N, 1995, J NEUROSCI, V15, P3307; STURZEBECHER J, 1992, PROTEIN SCI, V1, P1007; Su TZ, 1997, BRAIN RES, V757, P69, DOI 10.1016/S0006-8993(97)00139-X; Taha S, 2002, NEURON, V34, P425, DOI 10.1016/S0896-6273(02)00673-6; Takei N, 2004, J NEUROSCI, V24, P9760, DOI 10.1523/JNEUROSCI.1427-04.2004; Whitford KL, 2002, ANNU REV NEUROSCI, V25, P127, DOI 10.1146/annurev.neuro.25.112701.142932; Zhang Y, 2005, J NEUROSCI, V25, P1797, DOI 10.1523/jneurosci.4850-04.2005	38	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5152	5159		10.1074/jbc.M608548200	http://dx.doi.org/10.1074/jbc.M608548200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17179157	hybrid			2022-12-25	WOS:000244482300009
J	Ragas, A; Roussel, L; Puzo, G; Riviere, M				Ragas, Aude; Roussel, Lucie; Puzo, Germain; Riviere, Michel			The Mycobacterium tuberculosis cell-surface glycoprotein Apa as a potential adhesin to colonize target cells via the innate immune system pulmonary C-type lectin surfactant protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; HUMAN DENDRITIC CELLS; MYO-INOSITOL ANCHOR; CARBOHYDRATE RECOGNITION; ATTENUATED STRAINS; MASS-SPECTROMETRY; MANNOSE RECEPTOR; IL-12 PRODUCTION; ANTIGEN COMPLEX; BOVIS BCG	Tuberculosis is still a major health problem, and understanding the mechanism by which Mycobacterium tuberculosis (Mtb) invades and colonizes its host target cells remains an important issue for the control of infection. The innate immune system C-type lectins (C-TLs), including the human pulmonary surfactant protein A (PSP-A), have been recently identified as determinant players in the early recognition of the invading pathogen and in mounting the host defense response. Although the antigenic lipoglycan mannosylated lipoarabinomannan is currently considered to be the major C-TL target on the mycobacterial surface, the recognition by some C-TLs of the only mycobacterial species composing the "Mtb complex" indicates that mannosylated lipoarabinomannan cannot account alone for this specificity. Thus, we searched for the mycobacterial molecules targeted by human PSP-A, focusing our attention on the Mtb surface glycoproteins. We developed an original functional proteomic approach based on a lectin blot assay using crude human bronchoalveolar lavage fluid as a source of physiological PSP-A. Combined with selective cell-surface protein extraction and mass spectrometry peptide mapping, this strategy allowed us to identify the Apa (alanine-and proline-rich antigenic) glycoprotein as new potential target for PSP-A. This result was supported by direct binding of PSP-A to purified Apa. Moreover, EDTA addition or deglycosylation of purified Apa samples completely abolished the interaction, demonstrating that the interaction is calcium- and mannose-dependent, as expected. Finally, we provide convincing evidence that Apa, formerly considered as mainly secreted, is associated with the cell wall for a sufficiently long time to aid in the attachment of PSP-A. Because, to date, Apa seems to be restricted to the Mtb complex strains, we propose that it may account for the selective recognition of those strains by PSP-A and other immune system C-TLs containing homologous functional domains.	CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse 4, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Riviere, M (corresponding author), CNRS, Inst Pharmacol & Biol Struct, 205 Narbonne, F-31077 Toulouse 4, France.	Michel.Riviere@ipbs.fr						Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Dobos KM, 1996, J BACTERIOL, V178, P2498, DOI 10.1128/jb.178.9.2498-2506.1996; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Ferguson JS, 1999, J IMMUNOL, V163, P312; Garapin AC, 2001, VACCINE, V19, P2830, DOI 10.1016/S0264-410X(01)00012-3; Gatfield J, 2003, ADV IMMUNOL, V81, P45, DOI 10.1016/S0065-2776(03)81002-7; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; GILLERON M, 2001, GLYCANS CELL INTERAC, P113; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Horn C, 1999, J BIOL CHEM, V274, P32023, DOI 10.1074/jbc.274.45.32023; Ibango HB, 2006, LANCET INFECT DIS, V6, P522, DOI 10.1016/S1473-3099(06)70552-7; Johansson U, 2001, IMMUNOL LETT, V77, P63, DOI 10.1016/S0165-2478(01)00190-0; Jouanguy E, 1999, CURR OPIN IMMUNOL, V11, P346, DOI 10.1016/S0952-7915(99)80055-7; Kumar P, 2003, INFECT IMMUN, V71, P1929, DOI 10.1128/IAI.71.4.1929-1937.2003; LAQUEYRERIE A, 1995, INFECT IMMUN, V63, P4003, DOI 10.1128/IAI.63.10.4003-4010.1995; Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200; Michell SL, 2003, J BIOL CHEM, V278, P16423, DOI 10.1074/jbc.M207959200; Monsarrat B, 1999, GLYCOBIOLOGY, V9, P335, DOI 10.1093/glycob/9.4.335; Nguyen L, 2005, TRENDS CELL BIOL, V15, P269, DOI 10.1016/j.tcb.2005.03.009; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; ORTALOMAGNE A, 1995, MICROBIOL-UK, V141, P1609, DOI 10.1099/13500872-141-7-1609; Pasula R, 1997, AM J RESP CELL MOL, V17, P209, DOI 10.1165/ajrcmb.17.2.2469; Pitarque S, 2005, BIOCHEM J, V392, P615, DOI 10.1042/BJ20050709; Romain F, 1999, INFECT IMMUN, V67, P5567, DOI 10.1128/IAI.67.11.5567-5572.1999; Schlesinger LS, 1996, J IMMUNOL, V157, P4568; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; Sharon N, 2006, BBA-GEN SUBJECTS, V1760, P527, DOI 10.1016/j.bbagen.2005.12.008; Sidobre S, 2002, BIOCHEM J, V365, P89, DOI 10.1042/BJ20011659; Sidobre S, 2000, J BIOL CHEM, V275, P2415, DOI 10.1074/jbc.275.4.2415; Ting LM, 1999, J IMMUNOL, V163, P3898; VanderVen BC, 2005, SCIENCE, V309, P941, DOI 10.1126/science.1114347; VENISSE A, 1993, J BIOL CHEM, V268, P12401; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x	37	86	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5133	5142		10.1074/jbc.M610183200	http://dx.doi.org/10.1074/jbc.M610183200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17158455	hybrid			2022-12-25	WOS:000244482300007
J	Jacobs, RL; Lingrell, S; Dyck, JRB; Vance, DE				Jacobs, Rene L.; Lingrell, Susanne; Dyck, Jason R. B.; Vance, Dennis E.			Inhibition of hepatic phosphatidylcholine synthesis by 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside is independent of AMP-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; CHINESE-HAMSTER OVARY; RAT-LIVER; CHOLINE DEFICIENCY; PHOSPHATIDYLETHANOLAMINE; CELLS; BIOSYNTHESIS; TRANSLOCATION; METABOLISM; METHYLATION	5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAr), a commonly used indirect activator of AMP-activated protein kinase (AMPK), inhibits phosphatidylcholine (PC) biosynthesis in freshly isolated hepatocytes. In all nucleated mammalian cells, PC is synthesized from choline via the Kennedy (CDP-choline) pathway. The purpose of our study was to provide direct evidence that AMPK regulates phospholipid biosynthesis and to elucidate the mechanism(s) by which AMPK inhibits hepatic PC synthesis. Incubations of hepatocytes with AICAr resulted in a dose-dependent activation of AMPK and inhibition of PC biosynthesis. Surprisingly, adenoviral delivery of constitutively active AMPK did not alter PC biosynthesis. In addition, expression of dominant negative mutants of AMPK was unable to block the AICAr-dependent inhibition of PC biosynthesis, indicating that AICAr was acting independently of AMPK activation. Determination of aqueous intermediates of the CDPcholine pathway indicated that choline kinase, the first enzyme in the pathway, was inhibited by AICAr administration. Flux through the CDP-choline pathway was directly correlated to the level of intracellular ATP concentrations. Therefore, it is possible that inhibition of PC biosynthesis is another process by which the cell can reduce ATP consumption in times of energetic stress. However, unlike cholesterol and triacylglycerol biosynthesis, PC production is not regulated by AMPK.	Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Cardiovasc Res Grp, Dept Pediat, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada.	dennis.vance@ualberta.ca		Jacobs, Rene/0000-0002-5525-1355; Dyck, Jason/0000-0002-7045-2884				Aoyama C, 2000, J LIPID RES, V41, P452; Bergeron R, 2001, DIABETES, V50, P1076, DOI 10.2337/diabetes.50.5.1076; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Delgado-Reyes CV, 2001, ARCH BIOCHEM BIOPHYS, V393, P184, DOI 10.1006/abbi.2001.2474; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Dolinsky VW, 2006, AM J PHYSIOL-HEART C, V291, pH2557, DOI 10.1152/ajpheart.00329.2006; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223; FOLCH J, 1957, J BIOL CHEM, V226, P497; Guigas B, 2006, DIABETES, V55, P865, DOI 10.2337/diabetes.55.04.06.db05-1178; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Henin N, 1996, BBA-GEN SUBJECTS, V1290, P197, DOI 10.1016/0304-4165(96)00021-9; Houweling M, 1997, BBA-LIPID LIPID MET, V1346, P1, DOI 10.1016/S0005-2760(97)00011-8; Houweling M, 2002, BIOCHEM J, V362, P97, DOI 10.1042/0264-6021:3620097; ISHIDATE K, 1992, METHOD ENZYMOL, V209, P121; Jacobs RL, 2004, J BIOL CHEM, V279, P47402, DOI 10.1074/jbc.M404027200; Jacobs RL, 2005, J BIOL CHEM, V280, P28299, DOI 10.1074/jbc.M501971200; JASWAL JS, 2006, AM J PHYSIOL, V291, pH188; JOHNSON JE, 1992, BIOCHEM J, V285, P815, DOI 10.1042/bj2850815; Kitos TE, 2006, BBA-MOL CELL BIOL L, V1761, P272, DOI 10.1016/j.bbalip.2006.02.014; Kuipers F, 1997, Subcell Biochem, V28, P295; Li ZY, 2006, CELL METAB, V3, P321, DOI 10.1016/j.cmet.2006.03.007; Lykidis A, 2001, J BIOL CHEM, V276, P2174, DOI 10.1074/jbc.M008794200; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P447, DOI 10.1016/0005-2760(84)90171-1; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; RIDGWAY ND, 1989, J BIOL CHEM, V264, P1203; RIDGWAY ND, 1992, METHOD ENZYMOL, V209, P366; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Rutter GA, 2003, BIOCHEM J, V375, P1, DOI 10.1042/BJ20030048; SABINA RL, 1985, J BIOL CHEM, V260, P6107; Samari HR, 1998, J BIOL CHEM, V273, P23758, DOI 10.1074/jbc.273.37.23758; SCHNEIDER WJ, 1978, EUR J BIOCHEM, V85, P181, DOI 10.1111/j.1432-1033.1978.tb12226.x; Sher RB, 2006, J BIOL CHEM, V281, P4938, DOI 10.1074/jbc.M512578200; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; Sugiyama K, 1998, LIPIDS, V33, P235, DOI 10.1007/s11745-998-0201-2; Sugiyama K, 1997, J NUTR, V127, P600, DOI 10.1093/jn/127.4.600; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; Taneva S, 2003, BIOCHEMISTRY-US, V42, P11768, DOI 10.1021/bi035234k; UTAL AK, 1991, J BIOL CHEM, V266, P24084; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P225; Vincent MF, 1996, DIABETOLOGIA, V39, P1148, DOI 10.1007/BF02658500; WEINHOLD PA, 1974, BIOCHEMISTRY-US, V13, P5135, DOI 10.1021/bi00722a013; WRIGHT PS, 1985, J BIOL CHEM, V260, P7919; YAO ZM, 1990, J BIOL CHEM, V265, P4326; Zang MW, 2004, J BIOL CHEM, V279, P47898, DOI 10.1074/jbc.M408149200	51	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4516	4523		10.1074/jbc.M605702200	http://dx.doi.org/10.1074/jbc.M605702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17179149	hybrid			2022-12-25	WOS:000244482000033
J	Hong-Brown, LQ; Brown, CR; Huber, DS; Lang, CH				Hong-Brown, Ly Q.; Randell Brown, C.; Huber, Danuta S.; Lang, Charles H.			Alcohol regulates eukaryotic elongation factor 2 phosphorylation via an AMP-activated protein kinase-dependent mechanism in C2C12 skeletal myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II; MAMMALIAN TARGET; TRANSLATION ELONGATION; GENE-EXPRESSION; RAPAMYCIN; MTOR; EEF2; INHIBITION; GLUCOSE; MUSCLE	Ethanol decreases protein synthesis in cells, although the underlying regulatory mechanisms of this process are not fully established. In the present study incubation of C2C12 myocytes with 100 mm EtOH decreased protein synthesis while markedly increasing the phosphorylation of eukaryortic elongation factor 2 (eEF2), a key component of the translation machinery. Both mTOR and MEK pathways were found to play a role in regulating the effect of EtOH on eEF2 phosphorylation. Rapamycin, an inhibitor of mammalian target of rapamycin, and the MEK inhibitor PD98059 blocked the EtOH-induced phosphorylation of eEF2, whereas the p38 MAPK inhibitor SB202190 had no effect. Unexpectedly, EtOH decreased the phosphorylation and activity of the eEF2 upstream regulator eEF2 kinase. Likewise, treatment of cells with the inhibitor rottlerin did not block the stimulatory effect of EtOH on eEF2, suggesting that eEF2 kinase (eEF2K) does not play a role in regulating eEF2. In contrast, increased eEF2 phosphorylation was correlated with an increase in AMP-activated protein kinase (AMPK) phosphorylation and activity. Compound C, an inhibitor of AMPK, suppressed the effects of EtOH on eEF2 phosphorylation but had no effect on eEF2K, indicating that AMPK regulates eEF2 independent of eEF2K. Finally, EtOH decreased protein phosphatase 2A activity when either eEF2 or AMPK was used as the substrate. Thus, this later action may partially account for the increased phosphorylation of eEF2 in response to EtOH and the observed sensitivity of AMPK to rapamycin and PD98059 treatments. Collectively, the induction of eEF2 phosphorylation by EtOH is controlled by an increase in AMPK and a decrease in protein phosphatase 2A activity.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Hong-Brown, LQ (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.	lqh10@psu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK072909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011290] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA11209, R01 AA011290] Funding Source: Medline; NIDDK NIH HHS [DK072909-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atherton PJ, 2005, FASEB J, V19, P786, DOI 10.1096/fj.04-2179fje; Browne GJ, 2004, J BIOL CHEM, V279, P12220, DOI 10.1074/jbc.M309773200; Browne GJ, 2002, EUR J BIOCHEM, V269, P5360, DOI 10.1046/j.1432-1033.2002.03290.x; CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x; Carroll M, 2004, J NEUROCHEM, V90, P1464, DOI 10.1111/j.1471-4159.2004.02634.x; CELIS JE, 1990, P NATL ACAD SCI USA, V87, P4231, DOI 10.1073/pnas.87.11.4231; Chan AYM, 2004, J BIOL CHEM, V279, P32771, DOI 10.1074/jbc.M403528200; Cheng SWY, 2004, J BIOL CHEM, V279, P15719, DOI 10.1074/jbc.C300534200; Crozier SJ, 2005, AM J PHYSIOL-HEART C, V289, pH1242, DOI 10.1152/ajpheart.00859.2004; Dorovkov MV, 2002, BIOCHEMISTRY-US, V41, P13444, DOI 10.1021/bi026494p; Fujii N, 2005, J BIOL CHEM, V280, P39033, DOI 10.1074/jbc.M504208200; Gimeno-Alcaniz JV, 2003, J MOL BIOL, V333, P201, DOI 10.1016/j.jmb.2003.08.022; Hait WN, 1996, FEBS LETT, V397, P55, DOI 10.1016/S0014-5793(96)01140-4; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Hong-Brown LQ, 2001, ALCOHOL CLIN EXP RES, V25, P1373; Hong-Brown LQ, 2006, ALCOHOL CLIN EXP RES, V30, P1297, DOI 10.1111/j.1530-0277.2006.00157.x; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Horman S, 2003, J BIOL CHEM, V278, P41970, DOI 10.1074/jbc.M302403200; Hue L, 2003, BIOCHEM SOC T, V31, P213, DOI 10.1042/bst0310213; Inamura N, 2005, J NEUROCHEM, V95, P1438, DOI 10.1111/j.1471-4159.2005.03466.x; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kim J, 2001, J BIOL CHEM, V276, P19102, DOI 10.1074/jbc.M011579200; Kimball SR, 2004, J BIOL CHEM, V279, P54103, DOI 10.1074/jbc.M410755200; Knebel A, 2002, BIOCHEM J, V367, P525, DOI 10.1042/BJ20020916; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; Lang CH, 2003, AM J PHYSIOL-ENDOC M, V285, pE1205, DOI 10.1152/ajpendo.00177.2003; Lenz G, 2005, J BIOL CHEM, V280, P38121, DOI 10.1074/jbc.C500363200; McLeod LE, 2002, FEBS LETT, V531, P448, DOI 10.1016/S0014-5793(02)03582-2; MERRICK WC, 2000, TRANSLATIONAL CONTRO, P59; MITSUI K, 1993, J BIOL CHEM, V268, P13422; Parmer TG, 1999, BRIT J CANCER, V79, P59, DOI 10.1038/sj.bjc.6690012; Parmer TG, 1997, CELL GROWTH DIFFER, V8, P327; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PRICE NT, 1991, FEBS LETT, V282, P253, DOI 10.1016/0014-5793(91)80489-P; Proud CG, 2003, CURR TOP MICROBIOL, V279, P215; Ravnskjaer K, 2006, J MOL ENDOCRINOL, V36, P289, DOI 10.1677/jme.1.01965; REDPATH NT, 1990, BIOCHEM J, V272, P175, DOI 10.1042/bj2720175; REDPATH NT, 1993, EUR J BIOCHEM, V213, P689, DOI 10.1111/j.1432-1033.1993.tb17809.x; Ren HN, 2005, CANCER RES, V65, P5841, DOI 10.1158/0008-5472.CAN-04-3141; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; Rose AJ, 2005, J PHYSIOL-LONDON, V569, P223, DOI 10.1113/jphysiol.2005.097154; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; RYAZANOV AG, 1991, FEBS LETT, V285, P170, DOI 10.1016/0014-5793(91)80798-8; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Sans MD, 2004, BIOCHEM BIOPH RES CO, V319, P144, DOI 10.1016/j.bbrc.2004.04.164; Terai K, 2005, MOL CELL BIOL, V25, P9554, DOI 10.1128/MCB.25.21.9554-9575.2005; Wang LJ, 2002, FEBS LETT, V531, P285, DOI 10.1016/S0014-5793(02)03536-6; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370	48	41	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3702	3712		10.1074/jbc.M606593200	http://dx.doi.org/10.1074/jbc.M606593200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17164244	hybrid			2022-12-25	WOS:000244481900033
J	Mei, G; Di Venere, A; Gasperi, V; Nicolai, E; Masuda, KR; Finazzi-Agro, A; Cravatt, BF; Maccarrone, M				Mei, Giampiero; Di Venere, Almerinda; Gasperi, Valeria; Nicolai, Eleonora; Masuda, Kim R.; Finazzi-Agro, Alessandro; Cravatt, Benjamin F.; Maccarrone, Mauro			Closing the gate to the active site - Effect of the inhibitor methoxyarachidonyl fluorophosphonate on the conformation and membrane binding of fatty acid amide hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANANDAMIDE; TARGET	Fatty acid amide hydrolase (FAAH) is a dimeric, membrane-bound enzyme that degrades neuromodulatory fatty acid amides and esters and is expressed in mammalian brain and peripheral tissues. The cleavage of 30 amino acids from each subunit creates an FAAH variant that is soluble and homogeneous in detergent-containing buffers, opening the avenue to the in vitro mechanistic and structural studies. Here we have studied the stability of FAAH as a function of guanidinium hydrochloride concentration and of hydrostatic pressure. The unfolding transition was observed to be complex and required a fitting procedure based on a three-state process with a monomeric intermediate. The first transition was characterized by dimer dissociation, with a free energy change of approximate to 11 kcal/mol that accounted for approximate to 80% of the total stabilization energy. This process was also paralleled by a large change in the solvent-accessible surface area, because of the hydration occurring both at the dimeric interface and within the monomers. As a consequence, the isolated subunits were found to be much less stable (Delta G approximate to 3 kcal/mol). The addition of methoxyarachidonyl fluorophosphonate, an irreversible inhibitor of FAAH activity, enhanced the stability of the dimer by approximate to 2 kcal/mol, toward denaturant- and pressure-induced unfolding. FAAH inhibition by methoxyarachidonyl fluorophosphonate also reduced the ability of the protein to bind to the membranes. These findings suggest that local conformational changes at the level of the active site might induce a tighter interaction between the subunits of FAAH, affecting the enzymatic activity and the interaction with membranes.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Roma Tor Vergata, INFM, I-00133 Rome, Italy; Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy; European Ctr Brain Res, Ist Ric & Cura, S Lucia Fdn, I-00143 Rome, Italy; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Chem, La Jolla, CA 92037 USA	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Rome Tor Vergata; University of Teramo; IRCCS Santa Lucia; Scripps Research Institute; Scripps Research Institute	Mei, G (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Montpellier 1, I-00133 Rome, Italy.	mei@med.uniroma2.it; mmaccarrone@unite.it	Gasperi, Valeria/AAN-9210-2021; Nicolai, Eleonora/AAR-4554-2020; gasperi, valeria/AGO-4500-2022	Nicolai, Eleonora/0000-0003-1415-9808; gasperi, valeria/0000-0003-3200-8093; Di Venere, Almerinda/0000-0002-9493-0270				Bari M, 2006, MINI-REV MED CHEM, V6, P257, DOI 10.2174/138955706776073466; Battista N, 2004, CURR NEUROVASC RES, V1, P129, DOI 10.2174/1567202043480107; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; Chebrou H, 1996, BBA-PROTEIN STRUCT M, V1298, P285, DOI 10.1016/S0167-4838(96)00145-8; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Cravatt BF, 2003, CURR OPIN CHEM BIOL, V7, P469, DOI 10.1016/S1367-5931(03)00079-6; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; FONTANA A, 1995, PROSTAG LEUKOTR ESS, V53, P301, DOI 10.1016/0952-3278(95)90130-2; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P3; Li WF, 2005, BIOTECHNOL ADV, V23, P271, DOI 10.1016/j.biotechadv.2005.01.002; Maccarrone M, 2003, J BIOL CHEM, V278, P32726, DOI 10.1074/jbc.M302123200; Maccarrone M, 2006, CURR PHARM DESIGN, V12, P759, DOI 10.2174/138161206775474279; Maccarrone M, 2001, BIOCHEMISTRY-US, V40, P6819, DOI 10.1021/bi010187m; Marianayagam NJ, 2004, TRENDS BIOCHEM SCI, V29, P618, DOI 10.1016/j.tibs.2004.09.006; May C, 2000, EUR J BIOCHEM, V267, P1100, DOI 10.1046/j.1432-1327.2000.01105.x; McKinney MK, 2005, ANNU REV BIOCHEM, V74, P411, DOI 10.1146/annurev.biochem.74.082803.133450; Mei G, 2005, FEBS J, V272, P16, DOI 10.1111/j.1432-1033.2004.04407.x; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Patricelli MP, 1998, BIOCHEMISTRY-US, V37, P15177, DOI 10.1021/bi981733n; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Royer CA, 2002, BBA-PROTEIN STRUCT M, V1595, P201, DOI 10.1016/S0167-4838(01)00344-2; SILVA JL, 1993, ANNU REV PHYS CHEM, V50, P245; Sipe JC, 2002, P NATL ACAD SCI USA, V99, P8394, DOI 10.1073/pnas.082235799; THOMSON JA, 1989, J BIOL CHEM, V264, P11614	26	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3829	3836		10.1074/jbc.M605653200	http://dx.doi.org/10.1074/jbc.M605653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158103	hybrid			2022-12-25	WOS:000244481900046
J	O'Brien, EM; Gomes, DA; Sehgal, S; Nathanson, MH				O'Brien, Elizabeth M.; Gomes, Dawidson A.; Sehgal, Sona; Nathanson, Michael H.			Hormonal regulation of nuclear permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; PROTEIN-KINASE-C; PORE COMPLEX; VASOPRESSIN RECEPTOR; TRANSCRIPTION FACTOR; CYTOSOLIC CALCIUM; CA2+ SPIKES; CELLS; ACTIVATION; TRANSPORT	Transport into the nucleus is critical for regulation of gene transcription and other intranuclear events. Passage of molecules into the nucleus depends in part upon their size and the presence of appropriate targeting sequences. However, little is known about the effects of hormones or their second messengers on transport across the nuclear envelope. We used localized two-photon activation of a photoactivatable green fluorescent protein to investigate whether hormones, via their second messengers, could alter nuclear permeability. Vasopressin and other hormones that increase cytosolic Ca2+ and activate protein kinase C increased permeability across the nuclear membrane of SKHep1 liver cells in a rapid unidirectional manner. An increase in cytosolic Ca2+ was both necessary and sufficient for this process. Furthermore, localized photorelease of caged Ca2+ near the nuclear envelope resulted in a local increase in nuclear permeability. Neither activation nor inhibition of protein kinase C affected nuclear permeability. These findings provide evidence that hormones linking to certain G protein-coupled receptors increase nuclear permeability via cytosolic Ca2+. Short term regulation of nuclear permeability may provide a novel mechanism by which such hormones permit transcription factors and other regulatory molecules to enter the nucleus, thereby regulating gene transcription in target cells.	Yale Univ, Sch Med, Sect Digest Dis, Dept Med, New Haven, CT 06520 USA	Yale University	Nathanson, MH (corresponding author), Yale Univ, Sch Med, Sect Digest Dis, Dept Med, 1 Gilbert St,Rm TAC S241D, New Haven, CT 06520 USA.	michael.nathanson@yale.edu	Gomes, Dawidson Assis/O-1372-2013	Gomes, Dawidson Assis/0000-0001-7714-991X; O'Brien, Elizabeth/0000-0003-4648-8358	NIDDK NIH HHS [DK07356, T32 DK007356, R01 DK045710-06A2, DK57751, DK34989, DK45710, R01 DK045710, P30 DK034989-169004, P01 DK057751, T32 DK007356-27, P01 DK057751-01A1, P30 DK034989] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989, R01DK045710, T32DK007356, P01DK057751, R29DK045710] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; Belov GA, 2004, J VIROL, V78, P10166, DOI 10.1128/JVI.78.18.10166-10177.2004; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; Brasier AR, 2000, MOL CELL BIOCHEM, V212, P155, DOI 10.1023/A:1007133710837; Brown EB, 1999, BIOPHYS J, V76, P489, DOI 10.1016/S0006-3495(99)77217-6; Buchholz I, 2004, J MEMBRANE BIOL, V199, P135, DOI 10.1007/s00232-004-0684-9; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; CHENOY SK, 2005, SCI STJE, pCM14; Craske ML, 2005, J CELL BIOL, V170, P1147, DOI 10.1083/jcb.200503118; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Dyachok O, 2006, NATURE, V439, P349, DOI 10.1038/nature04410; Echevarria W, 2003, NAT CELL BIOL, V5, P440, DOI 10.1038/ncb980; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fox JL, 1997, BIOCHEM J, V326, P491, DOI 10.1042/bj3260491; GREBER UF, 1992, J CELL BIOL, V116, P15, DOI 10.1083/jcb.116.1.15; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hirata K, 1998, P NATL ACAD SCI USA, V95, P8381, DOI 10.1073/pnas.95.14.8381; Howell JL, 2002, BIOTECHNIQUES, V32, P80, DOI 10.2144/02321st04; Ito K, 1997, EMBO J, V16, P242, DOI 10.1093/emboj/16.2.242; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; Leite MF, 2003, P NATL ACAD SCI USA, V100, P2975, DOI 10.1073/pnas.0536590100; Leite MF, 2002, GASTROENTEROLOGY, V122, P415, DOI 10.1053/gast.2002.30982; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Markou T, 2004, J MOL CELL CARDIOL, V37, P1001, DOI 10.1016/j.yjmcc.2004.08.002; Minagawa N, 2005, J BIOL CHEM, V280, P33637, DOI 10.1074/jbc.M503210200; Moore-Nichols D, 2002, BIOPHYS J, V83, P1421, DOI 10.1016/S0006-3495(02)73913-1; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; Nicou Alexandra, 2003, FASEB Journal, V17, P1901; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; Pante N, 2002, MOL BIOL CELL, V13, P425, DOI 10.1091/mbc.01-06-0308; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Potter SM, 1996, CURR BIOL, V6, P1595, DOI 10.1016/S0960-9822(02)70782-3; Pusl T, 2002, J BIOL CHEM, V277, P27517, DOI 10.1074/jbc.M203002200; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; Shahin V, 2005, J CELL SCI, V118, P2881, DOI 10.1242/jcs.02429; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Thevananther S, 2004, HEPATOLOGY, V39, P393, DOI 10.1002/hep.20075; THORGATE R, 2006, CALCIUM BINDING PROT, V1, P36; Thorogate R, 2004, J CELL SCI, V117, P5923, DOI 10.1242/jcs.01510; Wei XB, 2003, BIOPHYS J, V84, P1317, DOI 10.1016/S0006-3495(03)74947-9; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551	51	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4210	4217		10.1074/jbc.M606300200	http://dx.doi.org/10.1074/jbc.M606300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158097	Green Accepted, hybrid			2022-12-25	WOS:000244481900084
J	Weitz, D; Harder, D; Casagrande, F; Fotiadis, D; Obrdlik, P; Kelety, B; Daniel, H				Weitz, Dietmar; Harder, Daniel; Casagrande, Fabio; Fotiadis, Dimitrios; Obrdlik, Petr; Kelety, Bela; Daniel, Hannelore			Functional and structural characterization of a prokaryotic peptide transporter with features similar to mammalian PEPT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; DIPEPTIDE TRANSPORTER; H+/PEPTIDE COTRANSPORTER; CHARGE TRANSLOCATION; IDENTIFICATION; SUBSTRATE; PURIFICATION; RECOGNITION; PHYSIOLOGY; HISTIDINE	The ydgR gene of Escherichia coli encodes a protein of the proton-dependent oligopeptide transporter (POT) family. We cloned YdgR and overexpressed the His-tagged fusion protein in E. coli BL21 cells. Bacterial growth inhibition in the presence of the toxic phosphonopeptide alafosfalin established YgdR functionality. Transport was abolished in the presence of the proton ionophore carbonyl cyanide p-chlorophenylhydrazone, suggesting a proton-coupled transport mechanism. YdgR transports selectively only di- and tripeptides and structurally related peptidomimetics (such as aminocephalosporins) with a substrate recognition pattern almost identical to the mammalian peptide transporter PEPT1. The YdgR protein was purified to homogeneity from E. coli membranes. Blue native-polyacrylamide gel electrophoresis and transmission electron microscopy of detergent-solubilized YdgR suggest that it exists in monomeric form. Transmission electron microscopy revealed a crown-like structure with a diameter of similar to 8 nm and a central density. These are the first structural data obtained from a proton-dependent peptide transporter, and the YgdR protein seems an excellent model for studies on substrate and inhibitor interactions as well as on the molecular architecture of cell membrane peptide transporters.	Tech Univ Munich, Dept Food & Nutr, Mol Nutr Unit, D-85350 Freising Weihenstephan, Germany; Univ Basel, Biozentrum, ME Muller Inst Struct Biol, CH-4056 Basel, Switzerland; Iongate Biosci GmbH, D-65926 Frankfurt, Germany	Technical University of Munich; University of Basel	Daniel, H (corresponding author), Tech Univ Munich, Dept Food & Nutr, Mol Nutr Unit, Forum 5, D-85350 Freising Weihenstephan, Germany.	daniel@wzw.tum.de	Daniel, Hannelore/B-8982-2009	Harder, Daniel/0000-0003-4226-9748				Bolger MB, 1998, J PHARM SCI-US, V87, P1286, DOI 10.1021/js980090u; Brandsch M, 2004, EUR J PHARM SCI, V21, P53, DOI 10.1016/S0928-0987(03)00142-8; Chen XZ, 2000, BIOCHEM BIOPH RES CO, V272, P726, DOI 10.1006/bbrc.2000.2851; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Covitz KMY, 1998, BIOCHEMISTRY-US, V37, P15214, DOI 10.1021/bi981128k; Daniel H, 2004, PFLUG ARCH EUR J PHY, V447, P610, DOI 10.1007/s00424-003-1101-4; Daniel H, 2004, ANNU REV PHYSIOL, V66, P361, DOI 10.1146/annurev.physiol.66.032102.144149; DEKKER JP, 1988, BIOCHIM BIOPHYS ACTA, V936, P307, DOI 10.1016/0005-2728(88)90006-0; Dieck ST, 1999, GLIA, V25, P10, DOI 10.1002/(SICI)1098-1136(19990101)25:1<10::AID-GLIA2>3.0.CO;2-Y; Doring F, 1996, J PHYSIOL-LONDON, V497, P773; Doring F, 1998, J BIOL CHEM, V273, P23211, DOI 10.1074/jbc.273.36.23211; Fei YJ, 1997, BIOCHEMISTRY-US, V36, P452, DOI 10.1021/bi962058p; Fei YJ, 1998, BIOCHEM BIOPH RES CO, V246, P39, DOI 10.1006/bbrc.1998.8566; Ganapathy ME, 1998, BIOCHEM BIOPH RES CO, V246, P470, DOI 10.1006/bbrc.1998.8628; Geibel S, 2006, J BIOMOL SCREEN, V11, P262, DOI 10.1177/1087057105285110; GIBSON MM, 1984, J BACTERIOL, V160, P122, DOI 10.1128/JB.160.1.122-130.1984; Goh EB, 2004, J BACTERIOL, V186, P4019, DOI 10.1128/JB.186.12.4019-4024.2004; Heuberger EHML, 2002, J MOL BIOL, V317, P591, DOI 10.1006/jmbi.2002.5416; HIGGINS CF, 1986, METHOD ENZYMOL, V125, P365; Meyer-Lipp K, 2004, BIOCHEMISTRY-US, V43, P12606, DOI 10.1021/bi0489053; Otto C, 1996, AM J PHYSIOL, V271, P210; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; STEINER HY, 1995, MOL MICROBIOL, V16, P825, DOI 10.1111/j.1365-2958.1995.tb02310.x; Tamai I, 1998, J PHARM SCI-US, V87, P1542, DOI 10.1021/js980186o; Terada T, 1996, FEBS LETT, V394, P196, DOI 10.1016/0014-5793(96)00952-0; Terada T, 2004, CURR DRUG METAB, V5, P85, DOI 10.2174/1389200043489153; Theis S, 2002, MOL PHARMACOL, V61, P214, DOI 10.1124/mol.61.1.214; Theis S, 2001, PROTEIN EXPRES PURIF, V22, P436, DOI 10.1006/prep.2001.1455; Yeung AK, 1998, BIOCHEM BIOPH RES CO, V250, P103, DOI 10.1006/bbrc.1998.9283; Zhuang JP, 1999, J STRUCT BIOL, V125, P63, DOI 10.1006/jsbi.1998.4059; Zuber D, 2005, BBA-BIOENERGETICS, V1709, P240, DOI 10.1016/j.bbabio.2005.07.009	32	61	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2832	2839		10.1074/jbc.M604866200	http://dx.doi.org/10.1074/jbc.M604866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17158458	hybrid			2022-12-25	WOS:000243793900009
J	de la Fuente-Fernandez, R				de la Fuente-Fernandez, Raul			Impact of Neuroprotection on Incidence of Alzheimer's Disease	PLOS ONE			English	Article							VASCULAR DEMENTIA; COMMUNITY POPULATION; COGNITIVE FUNCTION; AFRICAN-AMERICANS; ENTORHINAL CORTEX; RURAL-COMMUNITY; NEURONAL LOSS; RISK-FACTORS; AGE; MILD	Converging evidence suggests that high levels of education and intellectual activity increase the cognitive reserve and reduce the risk of dementia. However, little is known about the impact that different neuroprotective strategies may have on the incidence of Alzheimer's disease. Using a simple mathematical regression model, it is shown here that age-specific counts of basic cognitive units (surrogate of neurons or synapses) in the normal population can be estimated from Alzheimer's incidence rates. Hence, the model can be used to test the effect of neuroprotection on Alzheimer's incidence. It was found that the number of basic cognitive units decreases with age, but levels off in older people. There were no gender differences after correcting for survival. The model shows that even modest neuroprotective effects on basic cognitive units can lead to dramatic reductions in the number of Alzheimer's cases. Most remarkably, a 5% increase in the cognitive reserve would prevent one third of Alzheimer's cases. These results suggest that public health policies aimed at increasing the cognitive reserve in the general population (e.g., implementing higher levels of education) are likely the most effective strategy for preventing Alzheimer's disease.	Hosp A Marcide, Neurol Sect, Ferrol, Spain	Complejo Hospitalario Universitario de Ferrol	de la Fuente-Fernandez, R (corresponding author), Hosp A Marcide, Neurol Sect, Ferrol, Spain.	rfuente@medynet.com						Aevarsson O, 1996, J AM GERIATR SOC, V44, P1455, DOI 10.1111/j.1532-5415.1996.tb04070.x; Andersen K, 1999, NEUROLOGY, V52, P85, DOI 10.1212/WNL.52.1.85; Arias Elizabeth, 2004, Natl Vital Stat Rep, V53, P1; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Bennett DA, 2003, NEUROLOGY, V60, P1909, DOI 10.1212/01.WNL.0000069923.64550.9F; Bowman AW, 1997, APPL SMOOTHING TECHN; Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; BRAYNE C, 1995, BRIT J PSYCHIAT, V167, P255, DOI 10.1192/bjp.167.2.255; CALNE DB, 1991, ANN NEUROL, V30, P206, DOI 10.1002/ana.410300213; Chandra V, 2001, NEUROLOGY, V57, P985, DOI 10.1212/WNL.57.6.985; Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098; Cleveland W.S., 1996, P STAT THEORY COMPUT, P10; Copeland JRM, 1999, BRIT J PSYCHIAT, V175, P433, DOI 10.1192/bjp.175.5.433; Di Carlo A, 2002, J AM GERIATR SOC, V50, P41, DOI 10.1046/j.1532-5415.2002.50006.x; Esiri MM, 2001, LANCET, V357, P169; Evans DA, 2003, ARCH NEUROL-CHICAGO, V60, P185, DOI 10.1001/archneur.60.2.185; Falke E, 2003, AM J PATHOL, V163, P1615, DOI 10.1016/S0002-9440(10)63518-3; Fitzpatrick AL, 2004, J AM GERIATR SOC, V52, P195, DOI 10.1111/j.1532-5415.2004.52058.x; Fratiglioni L, 2000, NEUROLOGY, V54, pS10; Fratiglioni L, 1997, NEUROLOGY, V48, P132, DOI 10.1212/WNL.48.1.132; Fukunishi I, 1991, Int J Soc Psychiatry, V37, P51, DOI 10.1177/002076409103700107; Ganguli M, 2000, NEUROLOGY, V54, P1109, DOI 10.1212/WNL.54.5.1109; Gao S, 1998, ARCH GEN PSYCHIAT, V55, P809, DOI 10.1001/archpsyc.55.9.809; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; GomezIsla T, 1996, J NEUROSCI, V16, P4491; Grady CL, 2000, CURR OPIN NEUROBIOL, V10, P224, DOI 10.1016/S0959-4388(00)00073-8; HAGNELL O, 1992, NEUROEPIDEMIOLOGY, V11, P61, DOI 10.1159/000110981; HEBERT LE, 1995, JAMA-J AM MED ASSOC, V273, P1354, DOI 10.1001/jama.273.17.1354; Hendrie HC, 2001, JAMA-J AM MED ASSOC, V285, P739, DOI 10.1001/jama.285.6.739; Hills, 1993, STAT MODELS EPIDEMIO; Irizarry MC, 2001, PRINCIPLES OF NEUROEPIDEMIOLOGY, P69; Jorm AF, 1998, NEUROLOGY, V51, P728, DOI 10.1212/WNL.51.3.728; Kubis N, 2000, BRAIN, V123, P366, DOI 10.1093/brain/123.2.366; Kukull WA, 2002, ARCH NEUROL-CHICAGO, V59, P1737, DOI 10.1001/archneur.59.11.1737; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; LETENNEUR L, 1994, INT J EPIDEMIOL, V23, P1256, DOI 10.1093/ije/23.6.1256; Liu CK, 1998, NEUROLOGY, V50, P1572, DOI 10.1212/WNL.50.6.1572; Lopez-Pousa S, 2004, NEUROEPIDEMIOLOGY, V23, P170, DOI 10.1159/000078502; McDowell I, 2000, NEUROLOGY, V55, P66; Miech RA, 2002, NEUROLOGY, V58, P209, DOI 10.1212/WNL.58.2.209; Morris JC, 1999, J CLIN INVEST, V104, P1171, DOI 10.1172/JCI8560; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Nitrini R, 2004, ALZ DIS ASSOC DIS, V18, P241; Ott A, 1998, AM J EPIDEMIOL, V147, P574; Price JL, 2001, ARCH NEUROL-CHICAGO, V58, P1395, DOI 10.1001/archneur.58.9.1395; Ravaglia G, 2005, NEUROLOGY, V64, P1525, DOI 10.1212/01.WNL.0000160107.02316.BF; Riley KP, 2005, NEUROBIOL AGING, V26, P341, DOI 10.1016/j.neurobiolaging.2004.06.019; RITCHIE K, 1995, LANCET, V346, P931, DOI 10.1016/S0140-6736(95)91556-7; Rocca WA, 2000, NEUROLOGY, V54, pS38; Scarmeas Nikolaos, 2004, Curr Neurol Neurosci Rep, V4, P374, DOI 10.1007/s11910-004-0084-7; Scrucca L., 2001, J STAT SOFTW, V6, P1; Shoulson I, 1998, SCIENCE, V282, P1072, DOI 10.1126/science.282.5391.1072; Simic G, 1997, J COMP NEUROL, V379, P482, DOI 10.1002/(SICI)1096-9861(19970324)379:4<482::AID-CNE2>3.0.CO;2-Z; Small SA, 2001, ARCH NEUROL-CHICAGO, V58, P360, DOI 10.1001/archneur.58.3.360; Spector A, 2003, BRIT J PSYCHIAT, V183, P248, DOI 10.1192/bjp.183.3.248; Tang MX, 2001, NEUROLOGY, V56, P49, DOI 10.1212/WNL.56.1.49; Terry RD, 2001, NEUROBIOL AGING, V22, P347, DOI 10.1016/S0197-4580(00)00250-5; *US BUR CENS, 2006, IDB POP PYR; Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252; Waite LM, 2001, INT J GERIATR PSYCH, V16, P680, DOI 10.1002/gps.404; Wang JYJ, 2006, NEUROLOGY, V66, P911, DOI 10.1212/01.wnl.0000192165.99963.2a; WEST MJ, 1994, LANCET, V344, P769, DOI 10.1016/S0140-6736(94)92338-8; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161	63	9	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e52	10.1371/journal.pone.0000052	http://dx.doi.org/10.1371/journal.pone.0000052			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183682	Green Published, gold			2022-12-25	WOS:000207443600052
J	Mahenthiralingam, E; Baldwin, A; Drevinek, P; Vanlaere, E; Vandamme, P; LiPuma, JJ; Dowson, CG				Mahenthiralingam, Eshwar; Baldwin, Adam; Drevinek, Pavel; Vanlaere, Elke; Vandamme, Peter; LiPuma, John J.; Dowson, Chris G.			Multilocus Sequence Typing Breathes Life into a Microbial Metagenome	PLOS ONE			English	Article								Shot-gun sequencing of DNA isolated from the environment and the assembly of metagenomes from the resulting data has considerably advanced the study of microbial diversity. However, the subsequent matching of these hypothetical metagenomes to cultivable microorganisms is a limitation of such cultivation-independent methods of population analysis. Using a nucleotide sequence-based genetic typing method, multilocus sequence typing, we were able for the first time to match clonal cultivable isolates to a published and controversial bacterial metagenome, Burkholderia SAR-1, which derived from analysis of the Sargasso Sea. The matching cultivable isolates were all associated with infection and geographically widely distributed; taxonomic analysis demonstrated they were members of Burkholderia cepacia complex Group K. Comparison of the Burkholderia SAR-1 metagenome to closely related B. cepacia complex genomes indicated that it was greater than 98% intact in terms of conserved genes, and it also shared complete sequence identity with the cultivable isolates at random loci beyond the genes sampled by the multilocus sequence typing. Two features of the extant cultivable clones support the argument that the Burkholderia SAR-1 sequence may have been a contaminant in the original metagenomic survey: (i) their growth in conditions reflective of sea water was poor, suggesting the ocean was not their preferred habitat, and (ii) several of the matching isolates were epidemiologically linked to outbreaks of infection that resulted from contaminated medical devices or products, indicating an adaptive fitness of this bacterial strain towards contamination-associated environments. The ability to match identical cultivable strains of bacteria to a hypothetical metagenome is a unique feature of nucleotide sequence-based microbial typing methods; such matching would not have been possible with more traditional methods of genetic typing, such as those based on pattern matching of genomic restriction fragments or amplified DNA fragments. Overall, we have taken the first steps in moving the status of the Burkholderia SAR-1 metagenome from a hypothetical entity towards the basis for life of cultivable strains that may now be analysed in conjunction with the assembled metagenomic sequence data by the wider scientific community.	[Baldwin, Adam; Dowson, Chris G.] Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; [Mahenthiralingam, Eshwar; Drevinek, Pavel] Cardiff Univ, Cardiff Sch Biosci, Cardiff, S Glam, Wales; [Vanlaere, Elke; Vandamme, Peter] Univ Ghent, Microbiol Lab, B-9000 Ghent, Belgium; [LiPuma, John J.] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA	University of Warwick; Cardiff University; Ghent University; University of Michigan System; University of Michigan	Mahenthiralingam, E (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Cardiff, S Glam, Wales.	MahenthiralingamE@cardiff.ac.uk	Vandamme, Peter AR/B-7967-2009; Dowson, Chris/N-6195-2014; Dowson, Christopher/ABG-5083-2021; Mahenthiralingam, Eshwar/D-3333-2009; Vandamme, Peter/ABG-3431-2021	Vandamme, Peter AR/0000-0002-5581-7937; Dowson, Chris/0000-0002-8294-8836; Dowson, Christopher/0000-0002-8294-8836; Mahenthiralingam, Eshwar/0000-0001-9014-3790; Vandamme, Peter/0000-0002-5581-7937	Wellcome Trust [072853]; Natural Environment Research Council [NER/T/S/2001/0299]; Nederlandse Cystic Fibrosis Stichting; Cystic Fibrosis Foundation (US);  [075586]	Wellcome Trust(Wellcome TrustEuropean Commission); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Nederlandse Cystic Fibrosis Stichting; Cystic Fibrosis Foundation (US); 	C. G. D., A. B., and E. M. thank the Wellcome Trust (grant 072853) for funding the MLST analysis; E. M. and P. D. also acknowledge additional funding from this charity (grant 075586). E. M. is also grateful for financial support from the Natural Environment Research Council (grant NER/T/S/2001/0299). P. V. is indebted to the Stichting Kapteinfonds and the Nederlandse Cystic Fibrosis Stichting for financial support for the European B. 21 cepacia complex Referral Laboratory and Repository. J.J.L. is indebted to the Cystic Fibrosis Foundation (US) for financial support.	ANDERSON RL, 1991, INFECT CONT HOSP EP, V12, P297; Baldwin A, 2005, J CLIN MICROBIOL, V43, P4665, DOI 10.1128/JCM.43.9.4665-4673.2005; Baldwin A, 2004, INFECT IMMUN, V72, P1537, DOI 10.1128/IAI.72.3.1537-1547.2004; Berriatua E, 2001, J CLIN MICROBIOL, V39, P990, DOI 10.1128/JCM.39.3.990-994.2001; Campana S, 2005, J CLIN MICROBIOL, V43, P5136, DOI 10.1128/JCM.43.10.5136-5142.2005; Carver TJ, 2005, BIOINFORMATICS, V21, P3422, DOI 10.1093/bioinformatics/bti553; Coenye T, 2003, ENVIRON MICROBIOL, V5, P719, DOI 10.1046/j.1462-2920.2003.00471.x; Coenye T, 2001, J CLIN MICROBIOL, V39, P3427, DOI 10.1128/JCM.39.10.3427-3436.2001; De Boeck K, 2004, EUR RESPIR J, V23, P851, DOI 10.1183/09031936.04.00118804; DeLong EE, 2005, NAT REV MICROBIOL, V3, P459, DOI 10.1038/nrmicro1158; Enright MC, 1999, TRENDS MICROBIOL, V7, P482, DOI 10.1016/S0966-842X(99)01609-1; Handelsman J, 2004, MICROBIOL MOL BIOL R, V68, P669, DOI 10.1128/MMBR.68.4.669-685.2004; HARELAND WA, 1975, J BACTERIOL, V121, P272, DOI 10.1128/JB.121.1.272-285.1975; Hicks CL, 2000, AUST VET J, V78, P193, DOI 10.1111/j.1751-0813.2000.tb10593.x; Holden MTG, 2004, P NATL ACAD SCI USA, V101, P14240, DOI 10.1073/pnas.0403302101; Kimata N, 2004, MICROBIAL ECOL, V47, P41, DOI 10.1007/s00248-003-1032-9; LEFF LG, 1995, APPL ENVIRON MICROB, V61, P1634, DOI 10.1128/AEM.61.4.1634-1636.1995; Lewis DA, 2005, AM J RESP CELL MOL, V33, P56, DOI 10.1165/rcmb.2004-0352OC; LiPuma JJ, 2001, AM J RESP CRIT CARE, V164, P92, DOI 10.1164/ajrccm.164.1.2011153; Mahenthiralingam E, 2000, J CLIN MICROBIOL, V38, P3165, DOI 10.1128/JCM.38.9.3165-3173.2000; Mahenthiralingam E, 2005, NAT REV MICROBIOL, V3, P144, DOI 10.1038/nrmicro1085; Mahenthiralingam E, 2000, J CLIN MICROBIOL, V38, P910, DOI 10.1128/JCM.38.2.910-913.2000; Mahenthiralingam E, 1996, J CLIN MICROBIOL, V34, P2914, DOI 10.1128/JCM.34.12.2914-2920.1996; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; O'Sullivan LA, 2005, LETT APPL MICROBIOL, V41, P8, DOI 10.1111/j.1472-765X.2005.01758.x; Payne GW, 2005, APPL ENVIRON MICROB, V71, P3917, DOI 10.1128/AEM.71.7.3917-3927.2005; PERRY B, 2001, MICROBIOL TODAY, V28, P185; Sambrook J., 2002, MOL CLONING LAB MANU; SHIRAKI M, 1995, J ENVIRON POLYM DEGR, V3, P13, DOI 10.1007/BF02067789; Souza AV, 2004, J MED MICROBIOL, V53, P999, DOI 10.1099/jmm.0.45702-0; STANIER RY, 1966, J GEN MICROBIOL, V43, P159, DOI 10.1099/00221287-43-2-159; Vandamme P, 2000, J CLIN MICROBIOL, V38, P1042, DOI 10.1128/JCM.38.3.1042-1047.2000; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Vermis K, 2002, J MED MICROBIOL, V51, P937, DOI 10.1099/0022-1317-51-11-937; Wolfgang MC, 2003, P NATL ACAD SCI USA, V100, P8484, DOI 10.1073/pnas.0832438100; 2004, MORBID MORTALITY WEE	36	48	50	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e17	10.1371/journal.pone.0000017	http://dx.doi.org/10.1371/journal.pone.0000017			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183643	gold, Green Submitted, Green Published			2022-12-25	WOS:000207443600017
J	Pang, YP				Pang, Yuan-Ping			Novel Acetylcholinesterase Target Site for Malaria Mosquito Control	PLOS ONE			English	Article								Current anticholinesterase pesticides were developed during World War II and are toxic to mammals because they target a catalytic serine residue of acetylcholinesterases (AChEs) in insects and in mammals. A sequence analysis of AChEs from 73 species and a three-dimensional model of a malaria-carrying mosquito (Anopheles gambiae) AChE (AgAChE) reported here show that C286 and R339 of AgAChE are conserved at the opening of the active site of AChEs in 17 invertebrate and four insect species, respectively. Both residues are absent in the active site of AChEs of human, monkey, dog, cat, cattle, rabbit, rat, and mouse. The 17 invertebrates include house mosquito, Japanese encephalitis mosquito, African malaria mosquito, German cockroach, Florida lancelet, rice leaf beetle, African bollworm, beet armyworm, codling moth, diamondback moth, domestic silkworm, honey bee, oat or wheat aphid, the greenbug, melon or cotton aphid, green peach aphid, and English grain aphid. The four insects are house mosquito, Japanese encephalitis mosquito, African malaria mosquito, and German cockroach. The discovery of the two invertebrate-specific residues enables the development of effective and safer pesticides that target the residues present only in mosquito AChEs rather than the ubiquitous serine residue, thus potentially offering an effective control of mosquito-borne malaria. Anti-AgAChE pesticides can be designed to interact with R339 and subsequently covalently bond to C286. Such pesticides would be toxic to mosquitoes but not to mammals.	Mayo Clin, Coll Med, Comp Aided Mol Design Lab, Rochester, MN 55905 USA	Mayo Clinic	Pang, YP (corresponding author), Mayo Clin, Coll Med, Comp Aided Mol Design Lab, Rochester, MN 55905 USA.	pang@mayo.edu		Pang, Yuan-Ping/0000-0003-0838-2560	Mayo Foundation for Medical Education and Research	Mayo Foundation for Medical Education and Research	This work was supported by the Mayo Foundation for Medical Education and Research.	BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Bourne Y, 1999, J BIOL CHEM, V274, P30370, DOI 10.1074/jbc.274.43.30370; Bourne Y, 2003, EMBO J, V22, P1, DOI 10.1093/emboj/cdg005; Boyd AE, 2000, J BIOL CHEM, V275, P22401, DOI 10.1074/jbc.M000606200; Caves LSD, 1998, PROTEIN SCI, V7, P649, DOI 10.1002/pro.5560070314; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106; CORNELL WD, 1995, J AM CHEM SOC, V117, P5197; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dooley AJ, 2006, BIOORG MED CHEM LETT, V16, P830, DOI 10.1016/j.bmcl.2005.11.018; Erlanson DA, 2000, P NATL ACAD SCI USA, V97, P9367, DOI 10.1073/pnas.97.17.9367; Fialka J. J., 2006, WALL STREET J, pA4; Filler Scott J., 2006, Morbidity and Mortality Weekly Report, V55, P1; Frisch M J, 1999, GAUSSIAN 98 REVISION; Johnson JL, 2003, J BIOL CHEM, V278, P38948, DOI 10.1074/jbc.M304797200; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Oelschlaeger P, 2003, BIOCHEMISTRY-US, V42, P8945, DOI 10.1021/bi0300332; Pang YP, 2004, PROTEINS, V57, P747, DOI 10.1002/prot.20249; Pang YP, 2001, FEBS LETT, V502, P93, DOI 10.1016/S0014-5793(01)02672-2; Pang YP, 1996, J BIOL CHEM, V271, P23646, DOI 10.1074/jbc.271.39.23646; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Perola E, 2000, J MED CHEM, V43, P401, DOI 10.1021/jm990408a; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Smith LJ, 2002, PROTEINS, V48, P487, DOI 10.1002/prot.10144; Snow CD, 2002, NATURE, V420, P102, DOI 10.1038/nature01160; Weill M, 2004, INSECT MOL BIOL, V13, P1, DOI 10.1111/j.1365-2583.2004.00452.x; Weill M, 2003, NATURE, V423, P136, DOI 10.1038/423136b; Zagrovic B, 2002, J MOL BIOL, V323, P927, DOI 10.1016/S0022-2836(02)00997-X; Zauhar RJ, 2000, BIOPOLYMERS, V53, P233, DOI 10.1002/(SICI)1097-0282(200003)53:3<233::AID-BIP3>3.3.CO;2-W	30	39	40	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e58	10.1371/journal.pone.0000058	http://dx.doi.org/10.1371/journal.pone.0000058			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183688	gold, Green Published, Green Submitted			2022-12-25	WOS:000207443600058
J	Sonoyama, W; Liu, Y; Fang, DAJ; Yamaza, T; Seo, BM; Zhang, CM; Liu, H; Gronthos, S; Wang, CY; Shi, ST; Wang, SL				Sonoyama, Wataru; Liu, Yi; Fang, Dianji; Yamaza, Takayoshi; Seo, Byoung-Moo; Zhang, Chunmei; Liu, He; Gronthos, Stan; Wang, Cun-Yu; Shi, Songtao; Wang, Songlin			Mesenchymal Stem Cell-Mediated Functional Tooth Regeneration in Swine	PLOS ONE			English	Article								Mesenchymal stem cell-mediated tissue regeneration is a promising approach for regenerative medicine for a wide range of applications. Here we report a new population of stem cells isolated from the root apical papilla of human teeth (SCAP, stem cells from apical papilla). Using a minipig model, we transplanted both human SCAP and periodontal ligament stem cells (PDLSCs) to generate a root/periodontal complex capable of supporting a porcelain crown, resulting in normal tooth function. This work integrates a stem cell-mediated tissue regeneration strategy, engineered materials for structure, and current dental crown technologies. This hybridized tissue engineering approach led to recovery of tooth strength and appearance.	[Liu, Yi; Fang, Dianji; Zhang, Chunmei; Shi, Songtao] Capital Med Univ, Sch Stomatol, Salivary Gland Dis Ctr, Beijing, Peoples R China; [Liu, Yi; Fang, Dianji; Zhang, Chunmei; Shi, Songtao] Capital Med Univ, Sch Stomatol, Mol Lab Gene Therapy, Beijing, Peoples R China; [Sonoyama, Wataru; Yamaza, Takayoshi; Wang, Songlin] Univ So Calif, Ctr Craniofacial Mol Biol, Sch Dent, Los Angeles, CA 90033 USA; [Sonoyama, Wataru] Okayama Univ, Dept Oral & Maxillofacial Rehabil, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan; [Seo, Byoung-Moo] Seoul Natl Univ, Dept Oral & Maxillofacial Rehabil, Sch Dent, Dent Res Inst, Seoul, South Korea; [Liu, He] Peking Univ, Sch Stomatol, Beijing 100871, Peoples R China; [Gronthos, Stan] Inst Med & Vet Sci, Div Haematol, Mesenchymal Stem Cell Grp, Adelaide, SA 5000, Australia; [Wang, Cun-Yu] Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; [Wang, Cun-Yu] Univ Michigan, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA	Capital Medical University; Capital Medical University; University of Southern California; Okayama University; Seoul National University (SNU); Peking University; Institute Medical & Veterinary Science Australia; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Shi, ST (corresponding author), Capital Med Univ, Sch Stomatol, Salivary Gland Dis Ctr, Beijing, Peoples R China.	songtaos@usc.edu; songlinwang@dentist.org.cn	Gronthos, Stan/Y-4419-2019; Sonoyama, Wataru/B-2160-2011	Gronthos, Stan/0000-0002-6225-3084; Yamaza, Takayoshi/0000-0001-7055-3370	University of Southern California School of Dentistry; National Natural Science Foundation of China [30428009]; Beijing Major Scientific program [D0906007000091]; Division of Intramural Research; National Institute of Dental and Craniofacial Research, National Institutes of Health; Department of Health and Human Service	University of Southern California School of Dentistry; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Major Scientific program; Division of Intramural Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Dental and Craniofacial Research, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Department of Health and Human Service	This study was sponsored by the University of Southern California School of Dentistry, grants from the National Natural Science Foundation of China (30428009), the Beijing Major Scientific program grant (D0906007000091), and the Division of Intramural Research, the National Institute of Dental and Craniofacial Research, the National Institutes of Health, Department of Health and Human Service.	Blazer S, 2002, BIOCHEM BIOPH RES CO, V296, P93, DOI 10.1016/S0006-291X(02)00818-5; Chai Y, 2003, MICROSC RES TECHNIQ, V60, P469, DOI 10.1002/jemt.10287; Duailibi MT, 2004, J DENT RES, V83, P523, DOI 10.1177/154405910408300703; Eckert SE, 2005, INT J ORAL MAX IMPL, V20, P406; Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797; Heitz-Mayfield LJA, 2004, INT J ORAL MAX IMPL, V19, P128; Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890-199704270-00003; Larsen MO, 2004, ILAR J, V45, P303, DOI 10.1093/ilar.45.3.303; MILLIKAN LE, 1974, J INVEST DERMATOL, V62, P20, DOI 10.1111/1523-1747.ep12676714; Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100; Ohazama A, 2004, J DENT RES, V83, P518, DOI 10.1177/154405910408300702; Park Sang-Hoon, 2005, Implant Dent, V14, P211, DOI 10.1097/01.id.0000173334.60107.1a; Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140-6736(04)16627-0; Shi S, 2005, Orthod Craniofac Res, V8, P191, DOI 10.1111/j.1601-6343.2005.00331.x; Shi S, 2001, BONE, V29, P532, DOI 10.1016/S8756-3282(01)00612-3; Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696; Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602-587; Thesleff I, 2003, QUINTESSENCE INT, V34, P613; Tummers M, 2003, DEVELOPMENT, V130, P1049, DOI 10.1242/dev.00332; Yen AHH, 2006, EXPERT OPIN BIOL TH, V6, P9, DOI 10.1517/14712598.6.1.9; Young CS, 2005, TISSUE ENG, V11, P1599, DOI 10.1089/ten.2005.11.1599	21	819	891	3	118	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e79	10.1371/journal.pone.0000079	http://dx.doi.org/10.1371/journal.pone.0000079			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183711	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443600079
J	Xing, Y; Kapur, K; Wong, WH				Xing, Yi; Kapur, Karen; Wong, Wing Hung			Probe Selection and Expression Index Computation of Affymetrix Exon Arrays	PLOS ONE			English	Article							MICROARRAY DATA; PREDICTION; CANCER	Background. There is great current interest in developing microarray platforms for measuring mRNA abundance at both gene level and exon level. The Affymetrix Exon Array is a new high-density gene expression microarray platform, with over six million probes targeting all annotated and predicted exons in a genome. An important question for the analysis of exon array data is how to compute overall gene expression indexes. Because of the complexity of the design of exon array probes, this problem is different in nature from summarizing gene-level expression from traditional 39 expression arrays. Methodology/Principal Findings. In this manuscript, we use exon array data from 11 human tissues to study methods for computing gene-level expression. We showed that for most genes there is a subset of exon array probes having highly correlated intensities across multiple samples. We suggest that these probes could be used as reliable indicators of overall gene expression levels. We developed a probe selection algorithm to select such a subset of highly correlated probes for each gene, and computed gene expression indexes using the selected probes. Conclusions/Significance. Our results demonstrate that probe selection improves gene expression estimates from exon arrays. The selected probes can be used in future analyses of other exon array datasets to compute gene expression indexes.	[Xing, Yi; Kapur, Karen; Wong, Wing Hung] Stanford Univ, Dept Stat, Stanford, CA 94305 USA; [Xing, Yi] Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA	Stanford University; University of Iowa	Wong, WH (corresponding author), Stanford Univ, Dept Stat, Stanford, CA 94305 USA.	whwong@stanford.edu	Xing, yi/E-2884-2010		NIH [HG02341]; NSF [DMS0505732]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002341] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	NIH HG02341, NSF DMS0505732	*AFF, GEN SIGN EST EX ARR; *AFF, EX ARR DES DAT; *AFF, GUID PROB LOG INT ER; *AFF, EX ARR PROB ANN; Allison DB, 2006, NAT REV GENET, V7, P55, DOI 10.1038/nrg1749; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023; Clark TA, 2002, SCIENCE, V296, P907, DOI 10.1126/science.1069415; Gupta S, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-72; Hardiman G, 2004, PHARMACOGENOMICS, V5, P487, DOI 10.1517/14622416.5.5.487; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Le K, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh173; Lee C, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-7-231; Lee C, 2003, NUCLEIC ACIDS RES, V31, P101, DOI 10.1093/nar/gkg029; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li HR, 2006, CANCER RES, V66, P4079, DOI 10.1158/0008-5472.CAN-05-4264; Lynch KW, 2004, NAT REV IMMUNOL, V4, P931, DOI 10.1038/nri1497; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; Nagase T, 2000, DNA RES, V7, P273; Pan Q, 2004, MOL CELL, V16, P929, DOI 10.1016/j.molcel.2004.12.004; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Sorek R, 2003, CANCER RES, V63, P6996; Stoughton RB, 2005, ANNU REV BIOCHEM, V74, P53, DOI 10.1146/annurev.biochem.74.082803.133212; Wu ZJ, 2005, J COMPUT BIOL, V12, P882, DOI 10.1089/cmb.2005.12.882; Zhu J, 2003, SCIENCE, V301, P836, DOI 10.1126/science.1085792	28	53	54	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e88	10.1371/journal.pone.0000088	http://dx.doi.org/10.1371/journal.pone.0000088			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183719	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600087
J	Barrientos, T; Frank, D; Kuwahara, K; Bezprozvannaya, S; Pipes, GCT; Bassel-Duby, R; Richardson, JA; Katus, HA; Olson, EN; Frey, N				Barrientos, Tomasa; Frank, Derk; Kuwahara, Koichiro; Bezprozvannaya, Svetlana; Pipes, G. C. Teg; Bassel-Duby, Rhonda; Richardson, James A.; Katus, Hugo A.; Olson, Eric N.; Frey, Norbert			Two novel members of the ABLIM protein family, ABLIM-2 and -3, associate with STARS and directly bind F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; GENE-EXPRESSION; PRESSURE-OVERLOAD; Z-DISC; CARDIAC MYOCYTES; RHO-GTPASES; C-ELEGANS; ACTIVATION; TRANSCRIPTION; RECEPTOR	In addition to regulating cell motility, contractility, and cytokinesis, the actin cytoskeleton plays a critical role in the regulation of transcription and gene expression. We have previously identified a novel muscle-specific actin-binding protein, STARS (striated muscle activator of Rho signaling), which directly binds actin and stimulates serum-response factor (SRF)-dependent transcription. To further dissect the STARS/SRF pathway, we performed a yeast two-hybrid screen of a skeletal muscle cDNA library using STARS as bait, and we identified two novel members of the ABLIM protein family, ABLIM-2 and -3, as STARS-interacting proteins. ABLIM-1, which is expressed in retina, brain, and muscle tissue, has been postulated to function as a tumor suppressor. ABLIM-2 and -3 display distinct tissue-specific expression patterns with the highest expression levels in muscle and neuronal tissue. Moreover, these novel ABLIM proteins strongly bind F-actin, are localized to actin stress fibers, and synergistically enhance STARS-dependent activation of SRF. Conversely, knockdown of endogenous ABLIM expression utilizing small interfering RNA significantly blunted SRF-dependent transcription in C2C12 skeletal muscle cells. These findings suggest that the members of the novel ABLIM protein family may serve as a scaffold for signaling modules of the actin cytoskeleton and thereby modulate transcription.	Univ Texas, SW Med Ctr, Dept Biol Mol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Heidelberg Univ, Dept Internal Med 3, D-69115 Heidelberg, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Ruprecht Karls University Heidelberg	Frey, N (corresponding author), Univ Texas, SW Med Ctr, Dept Biol Mol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Norbert.Frey@med.uni-heidelberg.de	Frey, Norbert/M-7749-2019; Kuwahara, Koichiro/AFK-1723-2022; Frey, Norbert/A-9695-2010	Frey, Norbert/0000-0001-7611-378X; Kuwahara, Koichiro/0000-0003-2670-7170; 				Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; Arai A, 2002, J BIOL CHEM, V277, P24453, DOI 10.1074/jbc.M202216200; Brancaccio M, 2003, NAT MED, V9, P68, DOI 10.1038/nm805; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Carlier MF, 2003, BIOESSAYS, V25, P336, DOI 10.1002/bies.10257; Chen H, 2000, TRENDS BIOCHEM SCI, V25, P19, DOI 10.1016/S0968-0004(99)01511-X; Erkman L, 2000, NEURON, V28, P779, DOI 10.1016/S0896-6273(00)00153-7; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Frank D, 2006, J MOL MED, V84, P446, DOI 10.1007/s00109-005-0033-1; Frey N, 2004, NAT MED, V10, P1336, DOI 10.1038/nm1132; Frey N, 2002, J BIOL CHEM, V277, P13998, DOI 10.1074/jbc.M200712200; Frey N, 2000, P NATL ACAD SCI USA, V97, P14632, DOI 10.1073/pnas.260501097; Geiger B, 2002, CELL, V110, P139, DOI 10.1016/S0092-8674(02)00831-0; Gitai Z, 2003, NEURON, V37, P53, DOI 10.1016/S0896-6273(02)01149-2; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hines WA, 1998, J MOL CELL CARDIOL, V30, P485, DOI 10.1006/jmcc.1997.0613; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; Kim AC, 1997, GENOMICS, V46, P291, DOI 10.1006/geno.1997.5029; Klimov E, 2005, BBA-GENE STRUCT EXPR, V1730, P1, DOI 10.1016/j.bbaexp.2005.05.001; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/s0092-8674(02)01226-6; Kuwahara K, 2005, MOL CELL BIOL, V25, P3173, DOI 10.1128/MCB.25.8.3173-3181.2005; Lin Chi-Hung, 1994, Current Opinion in Neurobiology, V4, P640, DOI 10.1016/0959-4388(94)90004-3; Lu JR, 1998, MECH DEVELOP, V73, P23, DOI 10.1016/S0925-4773(98)00030-6; Lu X, 2003, NEUROSCIENCE, V120, P121, DOI 10.1016/S0306-4522(03)00263-X; Lundquist EA, 1998, NEURON, V21, P385, DOI 10.1016/S0896-6273(00)80547-4; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Mahadeva H, 2002, FEBS LETT, V521, P100, DOI 10.1016/S0014-5793(02)02833-8; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Pan J, 2005, J CELL PHYSIOL, V202, P536, DOI 10.1002/jcp.20151; Philippar U, 2004, MOL CELL, V16, P867, DOI 10.1016/j.molcel.2004.11.039; Posern G, 2004, EMBO J, V23, P3973, DOI 10.1038/sj.emboj.7600404; Pyle WG, 2004, CIRC RES, V94, P296, DOI 10.1161/01.RES.0000116143.74830.A9; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roof DJ, 1997, J CELL BIOL, V138, P575, DOI 10.1083/jcb.138.3.575; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Shibata M, 2004, J BIOL CHEM, V279, P40084, DOI 10.1074/jbc.M403844200; Sorokina EM, 2005, J CELL BIOCHEM, V94, P225, DOI 10.1002/jcb.20327; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Souchet M, 2002, J CELL SCI, V115, P629; Struckhoff EC, 2003, DEVELOPMENT, V130, P693, DOI 10.1242/dev.00300; Ting HJ, 2002, P NATL ACAD SCI USA, V99, P661, DOI 10.1073/pnas.022469899; Torsoni AS, 2003, AM J PHYSIOL-CELL PH, V284, pC1411, DOI 10.1152/ajpcell.00098.2002; Vardar D, 2002, CELL MOTIL CYTOSKEL, V52, P9, DOI 10.1002/cm.10027; Vermeulen W, 2004, PROTEIN SCI, V13, P1276, DOI 10.1110/ps.03518104; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wear MA, 2000, CURR BIOL, V10, pR891, DOI 10.1016/S0960-9822(00)00845-9; Wei L, 2001, DEVELOPMENT, V128, P2953; Wulfkuhle JD, 1999, J CELL SCI, V112, P2125	52	60	68	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8393	8403		10.1074/jbc.M607549200	http://dx.doi.org/10.1074/jbc.M607549200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17194709	hybrid			2022-12-25	WOS:000245081000072
J	Little, GH; Bai, Y; Williams, T; Poizat, C				Little, Gillian H.; Bai, Yan; Williams, Tyisha; Poizat, Coralie			Nuclear calcium/calmodulin-dependent protein kinase II delta preferentially transmits signals to histone deacetylase 4 in cardiac cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEF2 TRANSCRIPTION FACTOR; CAM KINASE; DILATED CARDIOMYOPATHY; LOCALIZATION SIGNAL; HEART-FAILURE; RAT-HEART; HYPERTROPHY; PHOSPHORYLATION; EXPRESSION; ISOFORM	Class II histone deacetylases (HDACs) act as repressors of cardiac hypertrophy, an adaptative response of the heart characterized by a reprogramming of fetal cardiac genes. Prolonged hypertrophy often leads to dilated cardiomyopathy and heart failure. Upstream endogenous regulators of class II HDACs that regulate hypertrophic growth are just beginning to emerge. Here we demonstrate that the delta B isoform of calcium/calmodulin-dependent protein kinase II (CaMKII delta B), known to promote cardiac hypertrophy, transmits signals specifically to HDAC4 but not other class II HDACs. CaMKII delta B efficiently phosphorylates both a glutathione S-transferase (GST)-HDAC4 fragment spanning amino acids 207-311 and full-length FLAG-HDAC4 but not the equivalents in HDAC5. Although previous studies in skeletal muscle cells have shown that HDAC4 lacking serine 246 cannot be phosphorylated by CaMKI/IV, a similar mutant is still phosphorylated by CaMKII delta B. Importantly, mutation of serine 210 to alanine totally abolishes phosphorylation of the GST fragment and significantly reduces phosphorylation of full-length HDAC by CaMKII delta B. RNA interference knockdown of CaMKII delta B prevents the effects of hypertrophic stimuli. Overexpression of CaMKII delta B in primary neonatal cardiomyocytes increases the activity of the Mef2 transcription factor and completely rescues HDAC4-mediated repression of MEF2 but only partially rescues inhibition by HDAC5 or the HDAC4 S210A mutant. CaMKII delta B strongly interacts with HDAC4 in cells but not with HDAC5. These results demonstrate that CaMKII delta B preferentially targets HDAC4, and this involves serine 210. These findings identify HDAC4 as a specific downstream substrate of CaMKII delta B in cardiac cells and have broad applications for the signaling pathways leading to cardiac hypertrophy and heart failure.	Univ So Calif, Keck Sch Med, Inst Genet Med, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Poizat, C (corresponding author), Univ So Calif, Keck Sch Med, Inst Genet Med, Los Angeles, CA 90033 USA.	poizat@usc.edu			NCI NIH HHS [C06 CA62528-01] Funding Source: Medline; NCRR NIH HHS [C06 RR014514-01, C06 RR10600-01] Funding Source: Medline; NHLBI NIH HHS [HL-052771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [C06CA062528] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR010600, C06RR014514] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Backs J, 2006, J CLIN INVEST, V116, P1853, DOI 10.1172/JCI27438; BALTAS LG, 1995, FEBS LETT, V373, P71, DOI 10.1016/0014-5793(95)00981-E; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BROCKE L, 1995, J NEUROSCI, V15, P6797; Chang SR, 2005, P NATL ACAD SCI USA, V102, P8120, DOI 10.1073/pnas.0503275102; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Chawla S, 2003, J NEUROCHEM, V85, P151, DOI 10.1046/j.1471-4159.2003.01648.x; EDMAN CF, 1994, BBA-MOL CELL RES, V1221, P89, DOI 10.1016/0167-4889(94)90221-6; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Hagemann D, 1999, J CELL BIOCHEM, V74, P202; Harrison BC, 2006, MOL CELL BIOL, V26, P3875, DOI 10.1128/MCB.26.10.3875-3888.2006; Heist EK, 1998, J BIOL CHEM, V273, P19763, DOI 10.1074/jbc.273.31.19763; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kolodziejczyk SM, 1999, CURR BIOL, V9, P1203, DOI 10.1016/S0960-9822(00)80027-5; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Li XF, 2004, J BIOL CHEM, V279, P34201, DOI 10.1074/jbc.M405179200; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Linseman DA, 2003, J BIOL CHEM, V278, P41472, DOI 10.1074/jbc.M307245200; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; MAYER P, 1995, BASIC RES CARDIOL, V90, P372, DOI 10.1007/BF00788498; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2005, J CLIN INVEST, V115, P538, DOI 10.1172/JCI200524144; McKinsey TA, 1999, CURR OPIN GENET DEV, V9, P267, DOI 10.1016/S0959-437X(99)80040-9; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Poizat C, 2005, MOL CELL BIOL, V25, P2673, DOI 10.1128/MCB.25.7.2673-2687.2005; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; SMITH DB, 1991, CURRENT PROTOCOLS MO, V2; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wu X, 2006, J CLIN INVEST, V116, P675, DOI 10.1172/JCI27374; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang R, 2005, NAT MED, V11, P409, DOI 10.1038/nm1215; Zhang T, 2004, CARDIOVASC RES, V63, P476, DOI 10.1016/j.cardiores.2004.04.026; Zhang T, 2003, CIRC RES, V92, P912, DOI 10.1161/01.RES.0000069686.31472.C5; Zhang T, 2002, J BIOL CHEM, V277, P1261, DOI 10.1074/jbc.M108525200	42	73	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7219	7231		10.1074/jbc.M604281200	http://dx.doi.org/10.1074/jbc.M604281200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17179159	hybrid			2022-12-25	WOS:000245080900034
J	Hart, LS; Ornelles, D; Koumenis, C				Hart, Lori S.; Ornelles, David; Koumenis, Constantinos			The adenoviral E4orf6 protein induces atypical apoptosis in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; V(D)J RECOMBINATION; POLY(ADP-RIBOSE) POLYMERASE-1; CATALYTIC SUBUNIT; KINASE-ACTIVITY; CELL-DEATH; DEGRADATION; COMPLEX; P53; AUTOPHOSPHORYLATION	Adenoviral proteins interact with host-cell proteins to either exploit or inhibit cellular functions for the purpose of viral propagation. E4orf6, the 34-kDa gene product of the E4 gene, interacts with the double-strand break repair (DSBR) protein DNA-dependent protein kinase and cooperates with binding partner E1B-55K to degrade MIZE 11, preventing viral DNA concatemer formation. We previously demonstrated that E4orf6 radiosensitizes human tumor cells through the inhibition of DSBR, notably in the absence of E1B-55K. Here, we report that E4orf6 prolongs the signaling of DNA damage by inhibiting the activity of protein phosphatase 2A (PP2A), the phosphatase responsible for dephosphorylating gamma H2AX. The inhibition of PP2A occurs without significant disruption of the DNA re-ligation rate. Prolonged signaling of DNA damage in the presence of E4orf6 initiates caspase-dependent and independent cell death. This is accompanied by poly(ADP-ribose) polymerase (PARP) hyper-activation and the translocation of apoptosis-inducing factor (AIF) from the mitochondria to the nucleus. Knockdown of AIF by shRNA rescues the radiosensitization induced by E4orf6. Taken together, these data suggest that E4orf6 disrupts cellular DSBR signaling by inhibiting PP2A, leading to prolonged H2AX phosphorylation, hyperactivation of PARP, and AIF translocation to the nucleus. The function of E4orf6 as an inhibitor of PP2A and activator of PARP in the absence of other adenoviral gene products is of importance in delineating the adenovirus-host cell interplay.	Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Neurosurg, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Radiat Oncol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University	Koumenis, C (corresponding author), Univ Penn, Sch Med, Dept Radiat Oncol, 185 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	koumenis@xrt.upenn.edu	Koumenis, Constantinos/B-2002-2008	Koumenis, Costas/0000-0001-5945-4726	NCI NIH HHS [CA77342S1, CA77342] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077342] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Bernardi RJ, 2001, CLIN CANCER RES, V7, P4164; Block WD, 2004, NUCLEIC ACIDS RES, V32, P4351, DOI 10.1093/nar/gkh761; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Frank-Vaillant M, 2002, MOL CELL, V10, P1189, DOI 10.1016/S1097-2765(02)00705-0; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Hart LS, 2005, J BIOL CHEM, V280, P1474, DOI 10.1074/jbc.M409934200; Kienker LJ, 2000, NUCLEIC ACIDS RES, V28, P2752, DOI 10.1093/nar/28.14.2752; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Kubota N, 2000, CANCER LETT, V161, P141, DOI 10.1016/S0304-3835(00)00614-5; Martin NMB, 2001, J PHOTOCH PHOTOBIO B, V63, P162, DOI 10.1016/S1011-1344(01)00213-5; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Sekiguchi JM, 1999, COLD SPRING HARB SYM, V64, P169, DOI 10.1101/sqb.1999.64.169; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yu SW, 2003, NEUROBIOL DIS, V14, P303, DOI 10.1016/j.nbd.2003.08.008; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	30	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6061	6067		10.1074/jbc.M610405200	http://dx.doi.org/10.1074/jbc.M610405200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17172468	hybrid			2022-12-25	WOS:000244867200011
J	Jagnandan, D; Church, JE; Banfi, B; Stuehr, DJ; Marrero, MB; Fulton, DJR				Jagnandan, Davin; Church, Jarrod E.; Banfi, Botond; Stuehr, Dennis J.; Marrero, Mario B.; Fulton, David J. R.			Novel mechanism of activation of NADPH oxidase 5 - Calcium sensitization via phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; REACTIVE OXYGEN; SUPEROXIDE; LOCALIZATION; PROTEIN; EXPRESSION; GENERATION; P67(PHOX); P47(PHOX); NOX3	In contrast to other Nox isoforms, the activity of Nox5 does not require the presence of accessory proteins and is entirely dependent on the elevation of intracellular calcium. Previous studies have shown that the EC50 of Nox5 for calcium is relatively high and raises the question of whether Nox5 can be sufficiently activated in cells that do not experience extreme elevations of intracellular calcium. In the current study, we have identified a novel mechanism governing the activity of Nox5. Exposure of cells expressing Nox5 to phorbol 12-myristate 13-acetate (PMA) resulted in a slow and sustained increase in ROS, which was markedly different from the rapid response to ionomycin. PMA greatly potentiated the activity of Nox5 in response to low concentrations of ionomycin. The ability of PMA to increase Nox5 activity was abolished by calcium chelation and was a direct effect on enzyme activity, since PMA increased the calcium sensitivity of Nox5 in a cell-free assay. PMA stimulated the time-dependent phosphordation of Nox5 on Thr(494) and Ser(498). Mutation of these residues to alanine abolished both PMA-dependent phosphorylation and calcium sensitization. Conversely, mutation of Thr(494) and Ser(498) to glutamic acid produced a gain of function mutant that had increased activity at low concentrations of ionomycin. Within the cell, Nox5 was detected in detergent-resistant microdomains of the endoplasmic reticulum. In summary, the phosphorylation of Nox5 at key residues facilitates enzyme activation at lower levels of intracellular calcium and may provide an avenue for enzyme activation in response to a greater variety of extracellular stimuli.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol, Augusta, GA 30912 USA; Univ Iowa, Coll Med, Dept Anat, Coralville, IA 52241 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44195 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University of Iowa; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Fulton, DJR (corresponding author), Med Coll Georgia, Vasc Biol Ctr, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.	dfulton@mcg.edu		Church, Jarrod/0000-0001-8266-4043; Banfi, Botond/0000-0001-9273-1318	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074279] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL74279] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Ameziane-El-Hassani R, 2005, J BIOL CHEM, V280, P30046, DOI 10.1074/jbc.M500516200; Armstrong JS, 2002, INT J ANDROL, V25, P223, DOI 10.1046/j.1365-2605.2002.00351.x; Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; Banfi B, 2004, J BIOL CHEM, V279, P46065, DOI 10.1074/jbc.M403046200; Banfi B, 2004, J BIOL CHEM, V279, P18583, DOI 10.1074/jbc.M310268200; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Bayraktutan U, 2000, ARTERIOSCL THROM VAS, V20, P1903, DOI 10.1161/01.ATV.20.8.1903; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Cheng GJ, 2004, J BIOL CHEM, V279, P34250, DOI 10.1074/jbc.M400660200; Church JE, 2006, J BIOL CHEM, V281, P1477, DOI 10.1074/jbc.M505968200; Daiber A, 2004, FREE RADICAL BIO MED, V36, P101, DOI 10.1016/j.freeradbiomed.2003.10.012; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Jagnandan D, 2005, AM J PHYSIOL-CELL PH, V289, pC1024, DOI 10.1152/ajpcell.00162.2005; Kamiguti AS, 2005, J IMMUNOL, V175, P8424, DOI 10.4049/jimmunol.175.12.8424; Kawahara T, 2005, J BIOL CHEM, V280, P31859, DOI 10.1074/jbc.M501882200; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Snapp EL, 2003, J CELL BIOL, V163, P257, DOI 10.1083/jcb.200306020; Sumimoto H, 2005, BIOCHEM BIOPH RES CO, V338, P677, DOI 10.1016/j.bbrc.2005.08.210; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Van Buul JD, 2005, ANTIOXID REDOX SIGN, V7, P308, DOI 10.1089/ars.2005.7.308; Zhang Q, 2006, ARTERIOSCL THROM VAS, V26, P1015, DOI 10.1161/01.ATV.0000216044.49494.c4	23	164	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6494	6507		10.1074/jbc.M608966200	http://dx.doi.org/10.1074/jbc.M608966200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17164239	hybrid			2022-12-25	WOS:000244867200057
J	Jones, MA; Feeney, KA; Kelly, SM; Christie, JM				Jones, Matthew A.; Feeney, Kevin A.; Kelly, Sharon M.; Christie, John M.			Mutational analysis of phototropin 1 provides insights into the mechanism underlying LOV2 signal transmission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE-LIGHT RECEPTOR; INDUCED STRUCTURAL-CHANGES; PAS DOMAIN; PHOTORECEPTOR PHOTOTROPIN; PHOT-LOV1 DOMAIN; ARABIDOPSIS NPH1; BINDING DOMAINS; KINASE; OXYGEN; PHOTOCYCLE	Phototropins (phot1 and phot2) are blue light-activated serine/threonine protein kinases that elicit a variety of photoresponses in plants. Light sensing by the phototropins is mediated by two flavin mononucleotide (FMN)-binding domains, designated LOV1 and LOV2, located in the N-terminal region of the protein. Exposure to light results in the formation of a covalent adduct between the FMN chromophore and a conserved cysteine residue within the LOV domain. LOV2 photoexcitation is essential for phot1 function in Arabidopsis and is necessary to activate photl kinase activity through light-induced structural changes within a conserved a-helix situated C-terminal to LOV2. Here we have used site-directed mutagenesis to identify further amino acid residues that are important for photl activation by light. Mutagenesis of bacterially expressed LOV2 and full-length phot1 expressed in insect cells indicates that perturbation of the conserved salt bridge on the surface of LOV2 does not play a role in receptor activation. However, mutation of a conserved glutamine residue (Gln 575) within LOV2, reported previously to be required to propagate structural changes at the LOV2 surface, attenuates light-induced autophosphorylation of photl expressed in insect cells without compromising FMN binding. These findings, in combination with double mutant analyses, indicate that Gln"' plays an important role in coupling light-driven cysteinyl adduct formation from within LOV2 to structural changes at the LOV2 surface that lead to activation of the C-terminal kinase domain.	Univ Glasgow, Plant Sci Grp, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Christie, JM (corresponding author), Univ Glasgow, Plant Sci Grp, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.	J.Christie@bio.gla.ac.uk	Jones, Matt/W-8210-2019; Kelly, Sharon/K-4611-2013	Jones, Matt/0000-0002-3943-3968; Kelly, Sharon/0000-0002-3516-1387; Christie, John/0000-0002-9976-0055				Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; Ataka K, 2003, BIOPHYS J, V84, P466, DOI 10.1016/S0006-3495(03)74866-8; Bednarz T, 2004, PHOTOCH PHOTOBIO SCI, V3, P575, DOI 10.1039/b400976b; Briggs WR, 2002, TRENDS PLANT SCI, V7, P204, DOI 10.1016/S1360-1385(02)02245-8; Celaya RB, 2005, PHOTOCHEM PHOTOBIOL, V81, P73, DOI 10.1562/2004-08-22-IR-282.1; Christie JM, 1999, P NATL ACAD SCI USA, V96, P8779, DOI 10.1073/pnas.96.15.8779; Christie JM, 2002, PLANT J, V32, P205, DOI 10.1046/j.1365-313X.2002.01415.x; Christie JM, 2001, J BIOL CHEM, V276, P11457, DOI 10.1074/jbc.R100004200; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; Corchnoy SB, 2003, J BIOL CHEM, V278, P724, DOI 10.1074/jbc.M209119200; Crosson S, 2003, BIOCHEMISTRY-US, V42, P2, DOI 10.1021/bi026978l; Crosson S, 2002, PLANT CELL, V14, P1067, DOI 10.1105/tpc.010475; Eitoku T, 2005, J AM CHEM SOC, V127, P13238, DOI 10.1021/ja052523i; Erbel PJA, 2003, P NATL ACAD SCI USA, V100, P15504, DOI 10.1073/pnas.2533374100; Fedorov R, 2003, BIOPHYS J, V84, P2474, DOI 10.1016/S0006-3495(03)75052-8; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Harper SM, 2004, BIOCHEMISTRY-US, V43, P16184, DOI 10.1021/bi048092i; Harper SM, 2003, SCIENCE, V301, P1541, DOI 10.1126/science.1086810; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; Iwata T, 2002, J AM CHEM SOC, V124, P11840, DOI 10.1021/ja020834c; Iwata T, 2003, BIOCHEMISTRY-US, V42, P8183, DOI 10.1021/bi0345135; Jarillo JA., 1998, PLANT PHYSIOL, V117, P719; Kagawa T, 2001, SCIENCE, V291, P2138, DOI 10.1126/science.291.5511.2138; Kagawa T, 2004, PLANT CELL PHYSIOL, V45, P416, DOI 10.1093/pcp/pch045; Kasahara M, 2002, PLANT PHYSIOL, V129, P762, DOI 10.1104/pp.002410; Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005; Kumar S, 1999, J MOL BIOL, V293, P1241, DOI 10.1006/jmbi.1999.3218; Lin CT, 2003, ANNU REV PLANT BIOL, V54, P469, DOI 10.1146/annurev.arplant.54.110901.160901; Losi A, 2005, PHOTOCHEM PHOTOBIOL, V81, P1145, DOI 10.1562/2005-05-25-RA-541; Losi A, 2004, PHOTOCH PHOTOBIO SCI, V3, P566, DOI 10.1039/b400728j; Losi A, 2003, PHOTOCH PHOTOBIO SCI, V2, P759, DOI 10.1039/b301782f; Matsuoka D, 2005, P NATL ACAD SCI USA, V102, P13337, DOI 10.1073/pnas.0506402102; Nakasako M, 2004, BIOCHEMISTRY-US, V43, P14881, DOI 10.1021/bi0485530; Nozaki D, 2004, BIOCHEMISTRY-US, V43, P8373, DOI 10.1021/bi0494727; Ohgishi M, 2004, P NATL ACAD SCI USA, V101, P2223, DOI 10.1073/pnas.0305984101; Rutter J, 2001, P NATL ACAD SCI USA, V98, P8991, DOI 10.1073/pnas.161284798; Sakai T, 2001, P NATL ACAD SCI USA, V98, P6969, DOI 10.1073/pnas.101137598; Sakamoto K, 2002, PLANT CELL, V14, P1723, DOI 10.1105/tpc.003293; Salomon M, 2000, BIOCHEMISTRY-US, V39, P9401, DOI 10.1021/bi000585+; Salomon M, 2004, FEBS LETT, V572, P8, DOI 10.1016/j.febslet.2004.06.081; Swartz TE, 2002, BIOCHEMISTRY-US, V41, P7183, DOI 10.1021/bi025861u; Swartz TE, 2001, J BIOL CHEM, V276, P36493, DOI 10.1074/jbc.M103114200; Takemiya A, 2005, PLANT CELL, V17, P1120, DOI 10.1105/tpc.104.030049; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Watts KJ, 2006, J BACTERIOL, V188, P2154, DOI 10.1128/JB.188.6.2154-2162.2006; WISLON W, 2005, P NATL ACAD SCI USA, V102, P16596	46	72	77	0	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6405	6414		10.1074/jbc.M605969200	http://dx.doi.org/10.1074/jbc.M605969200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17164248	hybrid			2022-12-25	WOS:000244867200048
J	Sidani, SM; Kirchhoff, P; Socrates, T; Stelter, L; Ferreira, E; Caputo, C; Roberts, KE; Bell, RL; Egan, ME; Geibel, JP				Sidani, Shafik M.; Kirchhoff, Philipp; Socrates, Thenral; Stelter, Lars; Ferreira, Elisa; Caputo, Christina; Roberts, Kurt E.; Bell, Robert L.; Egan, Marie E.; Geibel, John P.			Delta F508 mutation results in impaired gastric acid secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CALCIUM-SENSING RECEPTOR; CYSTIC-FIBROSIS GENE; RECTIFYING CHLORIDE CHANNELS; PARIETAL-CELL; K+ CHANNEL; APICAL MEMBRANE; CL-CONDUCTANCES; HCO3-SECRETION; CFTR	The cystic fibrosis transmembrane conductance regulator (CFTR) is recognized as a multifunctional Protein that is involved in Cl- secretion, as well as acting as a regulatory protein. In order for acid secretion to take place a complex interaction of transport proteins and channels must occur at the apical pole of the parietal cell. Included in this process is at least one K+ and Cl- channel, allowing for both recycling of K+ for the H,K-ATPase, and Cl- secretion, necessary for the generation of concentrated HCl in the gastric gland lumen. We have previously shown that an ATP-sensitive potassium channel (K-ATP) is expressed in parietal cells. In the present study we measured secretagogue-induced acid secretion from wild-type and Delta F508-deficient mice in isolated gastric glands and whole stomach preparations. Secretagogue-induced acid secretion in wildtype mouse gastric glands could be significantly reduced with either glibenclamide or the specific inhibitor CFTR-inh172. In Delta F508-deficient mice, however, histamine-induced acid secretion was significantly less than in wild-type mice. Furthermore, immunofluorescent localization of sulfonylurea 1 and 2 failed to show expression of a sulfonylurea receptor in the parietal cell, thus further implicating CFTR as the ATP-binding cassette transporter associated with the K-ATP channels. These results demonstrate a regulatory role for the CFTR protein in normal gastric acid secretion.	Yale Univ, Dept Surg, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Dept Pediat, New Haven, CT 06520 USA; Univ Zurich, Dept Visceral & Transplantat Surg, CH-8091 Zurich, Switzerland	Yale University; Yale University; University of Zurich	Geibel, JP (corresponding author), Yale Univ, Dept Surg, Dept Cellular & Mol Physiol, BML 265,310 Cedar St, New Haven, CT 06520 USA.	john.geibel@yale.edu	Roberts, Kurt E/I-2226-2012		NIDDK NIH HHS [DK17433, DK53428, DK07017-29, DK007259-26, DK50230] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053428, R01DK050230, P01DK017433, T32DK007017, T32DK007259] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiba Y, 2005, AM J PHYSIOL-GASTR L, V289, pG753, DOI 10.1152/ajpgi.00130.2005; Ammar DA, 2002, AM J PHYSIOL-GASTR L, V282, pG23, DOI 10.1152/ajpgi.00277.2002; Armand M, 2004, PEDIATR RES, V55, P457, DOI 10.1203/01.PDR.0000110522.78194.5B; ATERMAN K, 1961, AM J DIS CHILD, V101, P210, DOI 10.1001/archpedi.1961.04020030074012; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; Busque SM, 2005, AM J PHYSIOL-GASTR L, V289, pG664, DOI 10.1152/ajpgi.00096.2005; Cahill P, 2000, J BIOL CHEM, V275, P16697, DOI 10.1074/jbc.M910205199; Cheng I, 1999, GASTROENTEROLOGY, V116, P118, DOI 10.1016/S0016-5085(99)70235-0; Clarke L L, 2001, JOP, V2, P263; Clarke LL, 1996, LAB ANIM SCI, V46, P612; Clarke LL, 1998, AM J PHYSIOL-GASTR L, V274, pG718, DOI 10.1152/ajpgi.1998.274.4.G718; Coakley R D, 2001, JOP, V2, P294; Coakley RD, 2003, P NATL ACAD SCI USA, V100, P16083, DOI 10.1073/pnas.2634339100; Cohn JA, 2005, J CLIN GASTROENTEROL, V39, pS70, DOI 10.1097/01.mcg.0000155522.89005.bf; COX KL, 1982, J PEDIATR GASTR NUTR, V1, P559, DOI 10.1097/00005176-198212000-00019; CUPPOLETTI J, 1993, AM J PHYSIOL, V264, pC1609, DOI 10.1152/ajpcell.1993.264.6.C1609; DiMagno EP, 2001, BEST PRACT RES CL GA, V15, P477, DOI 10.1053/bega.2001.0195; Dufner MM, 2005, AM J PHYSIOL-GASTR L, V289, pG1084, DOI 10.1152/ajpgi.00571.2004; Duman JG, 2002, J CELL SCI, V115, P1251; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; Egan ME, 2002, NAT MED, V8, P485, DOI 10.1038/nm0502-485; FIEDLER MA, 1992, AM J PHYSIOL, V262, pL779, DOI 10.1152/ajplung.1992.262.6.L779; Finberg KE, 2005, P NATL ACAD SCI USA, V102, P13616, DOI 10.1073/pnas.0506769102; Forte JG, 2004, AM J PHYSIOL-CELL PH, V286, pC478, DOI 10.1152/ajpcell.00531.2003; Forte JG, 1996, TRENDS CELL BIOL, V6, P45, DOI 10.1016/0962-8924(96)81009-9; FORTE TM, 1977, GASTROENTEROLOGY, V73, P941; Fujita A, 2002, J PHYSIOL-LONDON, V540, P85, DOI 10.1113/jphysiol.2001.013439; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; Geibel JP, 2005, WORLD J GASTROENTERO, V11, P5259, DOI 10.3748/wjg.v11.i34.5259; Geibel JP, 2001, J BIOL CHEM, V276, P39549, DOI 10.1074/jbc.M107315200; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Hallberg K, 2001, SCAND J GASTROENTERO, V36, P121, DOI 10.1080/003655201750065852; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; HONGRE AS, 1994, PFLUG ARCH EUR J PHY, V426, P284, DOI 10.1007/BF00374783; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; Kaur S, 2004, AM J PHYSIOL-GASTR L, V287, pG480, DOI 10.1152/ajpgi.00035.2004; KELLEY KA, 1992, GENOMICS, V13, P381, DOI 10.1016/0888-7543(92)90257-S; Kirchhoff P, 2006, PFLUG ARCH EUR J PHY, V451, P738, DOI 10.1007/s00424-005-1507-2; Kirchhoff P, 2003, AM J PHYSIOL-GASTR L, V285, pG1242, DOI 10.1152/ajpgi.00165.2003; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; Lambrecht NWG, 2005, PHYSIOL GENOMICS, V21, P81, DOI 10.1152/physiolgenomics.00212.2004; Li CY, 2005, PHARMACOL THERAPEUT, V108, P208, DOI 10.1016/j.pharmthera.2005.04.004; LLOYDSTILL JD, 1983, TXB CYSTIC FIBROSIS, P227; Loussouarn G, 1996, AM J PHYSIOL-CELL PH, V271, pC1565, DOI 10.1152/ajpcell.1996.271.5.C1565; Malinowska DH, 2004, AM J PHYSIOL-CELL PH, V286, pC495, DOI 10.1152/ajpcell.00386.2003; MALINOWSKA DH, 1995, AM J PHYSIOL-CELL PH, V268, pC191, DOI 10.1152/ajpcell.1995.268.1.C191; McDaniel N, 2005, AM J PHYSIOL-GASTR L, V289, pG550, DOI 10.1152/ajpgi.00095.2005; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; McNicholas CM, 1997, AM J PHYSIOL-RENAL, V273, pF843, DOI 10.1152/ajprenal.1997.273.5.F843; Mickle JE, 1998, CLIN CHEST MED, V19, P443, DOI 10.1016/S0272-5231(05)70092-7; Pratha VS, 2000, GASTROENTEROLOGY, V118, P1051, DOI 10.1016/S0016-5085(00)70358-1; REENSTRA WW, 1990, AM J PHYSIOL, V259, pG850, DOI 10.1152/ajpgi.1990.259.5.G850; Riordan JR, 2005, ANNU REV PHYSIOL, V67, P701, DOI 10.1146/annurev.physiol.67.032003.154107; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROCH B, 1995, PFLUG ARCH EUR J PHY, V429, P355, DOI 10.1007/BF00374150; Roepke TK, 2006, J BIOL CHEM, V281, P23740, DOI 10.1074/jbc.M604155200; ROULET M, 1980, PEDIATR RES, V14, P1360, DOI 10.1203/00006450-198012000-00019; Rowe SM, 2005, NEW ENGL J MED, V352, P1992, DOI 10.1056/NEJMra043184; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; Sangan P, 2002, J BIOL CHEM, V277, P9668, DOI 10.1074/jbc.M110852200; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; Sherry AM, 2001, AM J PHYSIOL-CELL PH, V280, pC1599, DOI 10.1152/ajpcell.2001.280.6.C1599; SINAASAPPEL M, 1995, NETH J MED, V46, P275, DOI 10.1016/0300-2977(95)00019-J; SINGH SK, 1995, P NATL ACAD SCI USA, V92, P11573, DOI 10.1073/pnas.92.25.11573; Song YL, 2006, AM J PHYSIOL-CELL PH, V290, pC741, DOI 10.1152/ajpcell.00379.2005; STRONG TV, 1994, J CLIN INVEST, V93, P347, DOI 10.1172/JCI116966; Thiagarajah JR, 2004, FASEB J, V18, P875, DOI 10.1096/fj.03-1248fje; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Vankeerberghen Anne, 2002, J Cyst Fibros, V1, P13, DOI 10.1016/S1569-1993(01)00003-0; WAISBREN SJ, 1994, NATURE, V368, P332, DOI 10.1038/368332a0; WAISBREN SJ, 1994, AM J PHYSIOL, V266, pC1013, DOI 10.1152/ajpcell.1994.266.4.C1013; Winter C, 2004, P NATL ACAD SCI USA, V101, P2636, DOI 10.1073/pnas.0307321101; Witt H, 2003, GUT, V52, pII31, DOI 10.1136/gut.52.suppl_2.ii31; WOLOSIN JM, 1984, AM J PHYSIOL, V246, pC537, DOI 10.1152/ajpcell.1984.246.5.C537; Yao XB, 2003, ANNU REV PHYSIOL, V65, P103, DOI 10.1146/annurev.physiol.65.072302.114200; ZEIHER BG, 1995, J CLIN INVEST, V96, P2051, DOI 10.1172/JCI118253; Zeitlin PL, 2000, KIDNEY INT, V57, P832, DOI 10.1046/j.1523-1755.2000.00922.x; Zerhusen B, 1999, J BIOL CHEM, V274, P7627, DOI 10.1074/jbc.274.12.7627	83	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6068	6074		10.1074/jbc.M608427200	http://dx.doi.org/10.1074/jbc.M608427200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17178714	hybrid			2022-12-25	WOS:000244867200012
J	Kerns, SL; Torke, SJ; Benjamin, JM; McGarry, TJ				Kerns, Sarah L.; Torke, Susanna J.; Benjamin, Jacqueline M.; McGarry, Thomas J.			Geminin prevents rereplication during Xenopus development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LICENSING FACTOR CDT1; DNA RE-REPLICATION; CELL-CYCLE; INHIBITION; DESTRUCTION; PROTEOLYSIS; HOMOLOG; DOMAINS; PCNA	To maintain a stable genome, it is essential that replication origins fire only once per cell cycle. The protein Geminin is thought to prevent a second round of DNA replication by inhibiting the essential replication factor Cdt1. Geminin also affects the development of several different organs by binding and inhibiting transcription factors and chromatin-remodeling proteins. It is not known if the defects in Geminin-deficient organisms are due to overreplication or to effects on cell differentiation. We previously reported that Geminin depletion in Xenopus causes early embryonic lethality due to a Chk1-dependent G, cell cycle arrest just after the midblastula transition. Here we report that expressing a non-Geminin-binding Cdt1 mutant in Xenopus embryos exactly reproduces the phenotype of geminin depletion. Expressing the same mutant in replication extracts induces a partial second round of DNA replication within a single S phase. We conclude that Geminin is required to suppress a second round of DNA replication in vivo and that the phenotype of Geminin-depleted Xenopus embryos is caused by abnormal Cdt1 regulation. Expressing a nondegradable Cdt1 mutant in embryos also reproduces the Geminin-deficient phenotype. In cell extracts' the nondegradable mutant has no effect by itself but augments the amount of rereplication observed when Geminin is depleted. We conclude that Cdt1 is regulated both by Geminin binding and by degradation.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Div Cardiol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Feinberg Cardiovasc Res Inst, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	McGarry, TJ (corresponding author), Tarry 15-703,300 E Super Ave, Chicago, IL 60611 USA.	t-mcgarry@northwestern.edu						Arias EE, 2006, NAT CELL BIOL, V8, P84, DOI 10.1038/ncb1346; Arias EE, 2005, GENE DEV, V19, P114, DOI 10.1101/gad.1255805; Benjamin JM, 2004, J BIOL CHEM, V279, P45957, DOI 10.1074/jbc.M407726200; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Del Bene F, 2004, NATURE, V427, P745, DOI 10.1038/nature02292; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Ferenbach A, 2005, NUCLEIC ACIDS RES, V33, P316, DOI 10.1093/nar/gki176; Gonzalez MA, 2006, GENE DEV, V20, P1880, DOI 10.1101/gad.379706; Harlow E., 1988, ANTIBODIES LAB MANUA; HEASMAN J, 1991, METHOD CELL BIOL, V36, P213; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; HUTCHISON CJ, 1993, CELL CYCLE PRACTICAL, P188; Iwao Y, 2005, DEV GROWTH DIFFER, V47, P283; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Lee C, 2004, NATURE, V430, P913, DOI 10.1038/nature02813; Li A, 2005, EMBO J, V24, P395, DOI 10.1038/sj.emboj.7600520; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Luo LF, 2004, NATURE, V427, P749, DOI 10.1038/nature02305; Maiorano D, 2005, CURR BIOL, V15, P146, DOI 10.1016/j.cub.2004.12.002; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry Thomas J., 2004, V296, P263; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nishitani H, 2004, J BIOL CHEM, V279, P30807, DOI 10.1074/jbc.M312644200; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Saxena S, 2004, MOL CELL, V15, P245, DOI 10.1016/j.molcel.2004.06.045; Senga T, 2006, J BIOL CHEM, V281, P6246, DOI 10.1074/jbc.M512705200; Seo S, 2005, GENE DEV, V19, P1723, DOI 10.1101/gad.1319105; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanagi K, 2005, J BIOL CHEM, V280, P19689, DOI 10.1074/jbc.C500070200; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747	34	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5514	5521		10.1074/jbc.M609289200	http://dx.doi.org/10.1074/jbc.M609289200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17179155	hybrid			2022-12-25	WOS:000244482300046
J	Kim, K; McCully, ME; Bhattacharya, N; Butler, B; Sept, D; Cooper, JA				Kim, Kyoungtae; McCully, Michelle E.; Bhattacharya, Nandini; Butler, Boyd; Sept, David; Cooper, John A.			Structure/function analysis of the interaction of phosphatidylinositol 4,5-bisphosphate with actin-capping protein - Implications for how capping protein binds the actin filament	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARBED-END; MOLECULAR-DYNAMICS; IDENTIFICATION; CYTOSKELETON; MICROSCOPY; MOTILITY; GELSOLIN; MUSCLE	The heterodimeric actin-capping protein (CP) can be inhibited by polyphosphoinositides, which may be important for actin polymerization at membranes in cells. Here, we have identified a conserved set of basic residues on the surface of CP that are important for the interaction with phosphaticlylinositol 4,5-bisphosphate (PIP2). Computational docking studies predicted the identity of residues involved in this interaction, and functional and physical assays with site-directed mutants of CP confirmed the prediction. The PIP2 binding site overlaps with the more important of the two known actin-binding sites of CP. Correspondingly, we observed that loss of PIP2 binding correlated with loss of actin binding among the mutants. Using TIRF (total internal reflection fluorescence) microscopy, we observed that PIP2 rapidly converted capped actin filaments to a growing state, consistent with uncapping. Together, these results extend our understanding of how CP binds to the barbed end of the actin filament, and they support the idea that CP can "wobble" when bound to the barbed end solely by the C-terminal "tentacle" of its beta-subunit.	Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Dept Biomed Engn, St Louis, MO 63110 USA; Washington Univ, Ctr Computat Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Cooper, JA (corresponding author), Campus Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	jcooper@wustl.edu	Sept, David/F-6497-2011; Cooper, John/E-9389-2012; Bhattacharya, Nandini/HGU-4374-2022; Cooper, John/D-4448-2014	Sept, David/0000-0003-3719-2483; Cooper, John/0000-0002-0933-4571	NHLBI NIH HHS [T32 HL007873] Funding Source: Medline; NIGMS NIH HHS [R01 GM038542, R01 GM067246, GM38542, GM067246, R01 GM038542-20] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007873] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038542, R01GM067246] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barkalow K, 1996, J CELL BIOL, V134, P389, DOI 10.1083/jcb.134.2.389; Bhattacharya N, 2006, J BIOL CHEM, V281, P31021, DOI 10.1074/jbc.M606278200; Bruck S, 2006, J BIOL CHEM, V281, P19196, DOI 10.1074/jbc.M600166200; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Canton DA, 2006, J BIOL CHEM, V281, P36347, DOI 10.1074/jbc.M607595200; DINUBILE MJ, 1995, MOL BIOL CELL, V6, P1659, DOI 10.1091/mbc.6.12.1659; Eddy RJ, 1997, J CELL BIOL, V139, P1243, DOI 10.1083/jcb.139.5.1243; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; Huang SJ, 2006, MOL BIOL CELL, V17, P1946, DOI 10.1091/mbc.E05-09-0840; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; HUXLEY HE, 1967, J MOL BIOL, V30, P383, DOI 10.1016/S0022-2836(67)80046-9; Janmey PA, 1999, CHEM PHYS LIPIDS, V101, P93, DOI 10.1016/S0009-3084(99)00058-4; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Kim K, 2006, MOL BIOL CELL, V17, P1354, DOI 10.1091/mbc.e05-10-0925; Kim SI, 2004, AM J TRANSPLANT, V4, P567; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; Kuhn JR, 2005, BIOPHYS J, V88, P1387, DOI 10.1529/biophysj.104.047399; Kumar N, 2004, J BIOL CHEM, V279, P3096, DOI 10.1074/jbc.M308878200; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Mejillano MR, 2004, CELL, V118, P363, DOI 10.1016/j.cell.2004.07.019; Mitra A, 2004, BIOCHEMISTRY-US, V43, P13955, DOI 10.1021/bi0487387; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Narita A, 2006, EMBO J, V25, P5626, DOI 10.1038/sj.emboj.7601395; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 2003, CELL, V4, P463; REBECCHI MJ, 1993, J BIOL CHEM, V268, P1735; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Schafer DA, 1998, J CELL BIOL, V143, P1919, DOI 10.1083/jcb.143.7.1919; Smith J, 2006, THEOR BIOL MED MODEL, V3, DOI 10.1186/1742-4682-3-30; Soeno Y, 1998, J MUSCLE RES CELL M, V19, P639, DOI 10.1023/A:1005329114263; Wear MA, 2003, CURR BIOL, V13, P1531, DOI 10.1016/S0960-9822(03)00559-1; Wear MA, 2004, TRENDS BIOCHEM SCI, V29, P418, DOI 10.1016/j.tibs.2004.06.003; Wear MA, 2004, J BIOL CHEM, V279, P14382, DOI 10.1074/jbc.M313412200; Yamashita A, 2003, EMBO J, V22, P1529, DOI 10.1093/emboj/cdg167; Yang CS, 2005, DEV CELL, V9, P209, DOI 10.1016/j.devcel.2005.06.008; YU FX, 1992, J BIOL CHEM, V267, P14616	38	63	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5871	5879		10.1074/jbc.M609850200	http://dx.doi.org/10.1074/jbc.M609850200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17182619	Green Accepted, hybrid			2022-12-25	WOS:000244482300083
J	Ma, DH; Tang, XD; Rogers, TB; Welling, PA				Ma, Donghui; Tang, Xiang D.; Rogers, Terry B.; Welling, Paul A.			An Andersen-Tawil syndrome mutation in Kir2.1 (V302M) alters the G-loop cytoplasmic K+ conduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; INWARD RECTIFICATION; KCNJ2 MUTATIONS; CLOSED STATE; PORE; DETERMINANTS; LOCALIZATION; TRAFFICKING; ACTIVATION; POLYAMINES	Loss-of-function mutations in the inward rectifier potassium channel, Kir2.1, cause Andersen-Tawil syndrome (ATS-1), an inherited disorder of periodic paralysis and ventricular arrhythmias. Here, we explore the mechanism by which a specific ATS-1 mutation (V302M) alters channel function. Val-302 is located in the G-loop, a structure that is believed to form a flexible barrier for potassium permeation at the apex of the cytoplasmic pore. Consistent with a role in stabilizing the G-loop in an open conformation, we found the V302M mutation specifically renders the channel unable to conduct potassium without altering subunit assembly or attenuating cell surface expression. As predicted by the position of the Val-302 side chain in the crystal structure, amino acid substitution analysis revealed that channel activity and phosphatidylinositol 4,5-bisphosphate (PIP2) sensitivity are profoundly sensitive to alterations in the size, shape, and hydrophobicity of side chains at the Val-302 position. The observations establish that the Val-302 side chain is a critical determinant of potassium conduction through the G-loop. Based on our functional studies and the cytoplasmic domain crystal structure, we suggest that Val-302 may influence PIP2 gating indirectly by translating PIP2 binding to conformational changes in the G-loop pore.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Welling, PA (corresponding author), Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA.	pwelling@umaryland.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054231] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL70709] Funding Source: Medline; NIDDK NIH HHS [R01 DK54231] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN ED, 1971, ACTA PAEDIATR SCAND, V60, P559, DOI 10.1111/j.1651-2227.1971.tb06990.x; Bendahhou S, 2003, J BIOL CHEM, V278, P51779, DOI 10.1074/jbc.M310278200; Chen L, 2002, P NATL ACAD SCI USA, V99, P8430, DOI 10.1073/pnas.122682899; Cukras CA, 2002, J GEN PHYSIOL, V119, P581, DOI 10.1085/jgp.20028562; Donaldson MR, 2003, NEUROLOGY, V60, P1811, DOI 10.1212/01.WNL.0000072261.14060.47; Dong K, 2002, J BIOL CHEM, V277, P49366, DOI 10.1074/jbc.M208679200; Du XO, 2004, J BIOL CHEM, V279, P37271, DOI 10.1074/jbc.M403413200; Enkvetchakul D, 2000, BIOPHYS J, V78, P2334, DOI 10.1016/S0006-3495(00)76779-8; Flagg TP, 1999, J GEN PHYSIOL, V114, P685, DOI 10.1085/jgp.114.5.685; Fujiwara Y, 2006, J GEN PHYSIOL, V127, P401, DOI 10.1085/jgp.200509434; Gigena MS, 2005, AM J PHYSIOL-HEART C, V289, pH285, DOI 10.1152/ajpheart.01291.2004; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; LOPATIN AN, 1995, J GEN PHYSIOL, V106, P923, DOI 10.1085/jgp.106.5.923; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Nichols CG, 1996, CIRC RES, V78, P1, DOI 10.1161/01.RES.78.1.1; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; Pegan S, 2005, NAT NEUROSCI, V8, P279, DOI 10.1038/nn1411; Pegan S, 2006, BIOCHEMISTRY-US, V45, P8599, DOI 10.1021/bi060653d; Phillips LR, 2003, NEURON, V37, P953, DOI 10.1016/S0896-6273(03)00155-7; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Preisig-Muller R, 2002, P NATL ACAD SCI USA, V99, P7774, DOI 10.1073/pnas.102609499; Proks P, 2005, EMBO REP, V6, P470, DOI 10.1038/sj.embor.7400393; Sadja R, 2001, NEURON, V29, P669, DOI 10.1016/S0896-6273(01)00242-2; Sansone V, 1997, ANN NEUROL, V42, P305, DOI 10.1002/ana.410420306; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Tang XD, 2004, NAT STRUCT MOL BIOL, V11, P171, DOI 10.1038/nsmb725; Tristani-Firouzi M, 2002, J CLIN INVEST, V110, P381, DOI 10.1172/JCI200215183; Welling PA, 1997, AM J PHYSIOL-RENAL, V273, pF825, DOI 10.1152/ajprenal.1997.273.5.F825; Xiao J, 2003, NAT NEUROSCI, V6, P811, DOI 10.1038/nn1090; Yi BA, 2001, NEURON, V29, P657, DOI 10.1016/S0896-6273(01)00241-0; Yoo D, 2005, J BIOL CHEM, V280, P35281, DOI 10.1074/jbc.M504836200; Yoo D, 2004, J BIOL CHEM, V279, P6863, DOI 10.1074/jbc.M311599200; Zaritsky JJ, 2001, J PHYSIOL-LONDON, V533, P697, DOI 10.1111/j.1469-7793.2001.t01-1-00697.x; Zhang L, 2005, CIRCULATION, V111, P2720, DOI 10.1161/CIRCULATIONAHA.104.472498; Zhang YY, 2004, J GEN PHYSIOL, V124, P729, DOI 10.1085/jgp.200409166; Zobel C, 2003, J PHYSIOL-LONDON, V550, P365, DOI 10.1113/jphysiol.2002.036400	39	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5781	5789		10.1074/jbc.M608776200	http://dx.doi.org/10.1074/jbc.M608776200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17166852	hybrid			2022-12-25	WOS:000244482300074
J	Sarkar, S; Davies, JE; Huang, ZB; Tunnacliffe, A; Rubinsztein, DC				Sarkar, Sovan; Davies, Janet E.; Huang, Zebo; Tunnacliffe, Alan; Rubinsztein, David C.			Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCULOPHARYNGEAL MUSCULAR-DYSTROPHY; AGGREGATE-PRONE PROTEINS; CELL-DEATH; POLYGLUTAMINE EXPANSIONS; PARKINSONS-DISEASE; PHOSPHATE SYNTHASE; MOUSE MODEL; GENE; DEGRADATION; INHIBITION	Trehalose, a disaccharide present in many non-mammalian species, protects cells against various environmental stresses. Whereas some of the protective effects may be explained by its chemical chaperone properties, its actions are largely unknown. Here we report a novel function of trehalose as an mTOR-independent autophagy activator. Trehalose-induced autophagy enhanced the clearance of autophagy substrates like mutant huntingtin and the A30P and A53T mutants of alpha-synuclein, associated with Huntington disease (HD) and Parkinson disease (PD), respectively. Furthermore, trehalose and mTOR inhibition by rapamycin together exerted an additive effect on the clearance of these aggregate-prone proteins because of increased autophagic activity. By inducing autophagy, we showed that trehalose also protects cells against subsequent pro-apoptotic insults via the mitochondrial pathway. The dual protective properties of trehalose (as an inducer of autophagy and chemical chaperone) and the combinatorial strategy with rapamycin may be relevant to the treatment of HD and related diseases, where the mutant proteins are autophagy substrates.	Univ Cambridge, Dept Med Genet, Cambridge Inst Med Res, Addenbrookes Hosp, Cambridge B2 2XY, England; Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	Rubinsztein, DC (corresponding author), Univ Cambridge, Dept Med Genet, Cambridge Inst Med Res, Addenbrookes Hosp, Hills Rd, Cambridge B2 2XY, England.	dcr1000@cam.ac.uk	Rubinsztein, David C/C-3472-2011; Sarkar, Sovan/F-8486-2017; Huang, Zebo/AAF-2382-2019	Sarkar, Sovan/0000-0002-9456-4362; Huang, Zebo/0000-0003-2431-3741; Tunnacliffe, Alan/0000-0001-8570-125X	Medical Research Council [G0600194(77639), G0000872, G0600194] Funding Source: Medline; Wellcome Trust [064354] Funding Source: Medline; MRC [G0600194, G0000872] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arora A, 2004, FEBS LETT, V564, P121, DOI 10.1016/S0014-5793(04)00326-6; Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495; Berger Z, 2006, HUM MOL GENET, V15, P433, DOI 10.1093/hmg/ddi458; Calado A, 2000, HUM MOL GENET, V9, P2321, DOI 10.1093/oxfordjournals.hmg.a018924; Chen QF, 2004, J EXP BIOL, V207, P3125, DOI 10.1242/jeb.01133; Chen QF, 2003, J BIOL CHEM, V278, P49113, DOI 10.1074/jbc.M308652200; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Davies JE, 2006, HUM MOL GENET, V15, P23, DOI 10.1093/hmg/ddi422; de Castro AG, 2000, FEBS LETT, V487, P199, DOI 10.1016/S0014-5793(00)02340-1; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; EKSTROM P, 1984, J NEUROCHEM, V43, P1342, DOI 10.1111/j.1471-4159.1984.tb05392.x; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Iwata A, 2005, P NATL ACAD SCI USA, V102, P13135, DOI 10.1073/pnas.0505801102; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kandror O, 2004, MOL CELL, V13, P771, DOI 10.1016/S1097-2765(04)00148-0; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Liu R, 2005, NEUROBIOL DIS, V20, P74, DOI 10.1016/j.nbd.2005.02.003; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Murphy MP, 2001, BBA-BIOENERGETICS, V1504, P1, DOI 10.1016/S0005-2728(00)00234-6; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Narain Y, 1999, J MED GENET, V36, P739, DOI 10.1136/jmg.36.10.739; Oesterreicher TJ, 2001, GENE, V270, P211, DOI 10.1016/S0378-1119(01)00474-7; Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036; Oliver A. E., 2004, CELL PRESERV TECHNOL, V2, P35, DOI DOI 10.1089/153834404322708745; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rankin J, 2000, BIOCHEM J, V348, P15, DOI 10.1042/0264-6021:3480015; Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Ravikumar B, 2003, HUM MOL GENET, V12, P985, DOI 10.1093/hmg/ddg109; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Rubinsztein DC, 2002, TRENDS GENET, V18, P202, DOI 10.1016/S0168-9525(01)02625-7; Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Simonson OE, 2005, CURR PHARM DESIGN, V11, P3671, DOI 10.2174/138161205774580813; Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200; Tanaka M, 2004, NAT MED, V10, P148, DOI 10.1038/nm985; Tanida I, 2004, J BIOL CHEM, V279, P36268, DOI 10.1074/jbc.M401461200; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; Wolkers WF, 2003, BBA-BIOMEMBRANES, V1612, P154, DOI 10.1016/S0005-2736(03)00114-7; Wolkers WF, 2001, CRYOBIOLOGY, V42, P79, DOI 10.1006/cryo.2001.2306; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33	48	836	872	3	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5641	5652		10.1074/jbc.M609532200	http://dx.doi.org/10.1074/jbc.M609532200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17182613	hybrid			2022-12-25	WOS:000244482300061
J	Shimazu, T; Horinouchi, S; Yoshida, M				Shimazu, Tadahiro; Horinouchi, Sueharu; Yoshida, Minoru			Multiple histone deacetylases and the CREB-binding protein regulate pre-mRNA 3 '-end processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I-M; LARGE T-ANTIGEN; POLY(A) POLYMERASE; TRICHOSTATIN-A; ACETYLATION; CLEAVAGE; P53; TRANSCRIPTION; ACTIVATION; SUBUNIT	Trichostatin A (TSA), a specific inhibitor of histone deacetylases (HDACs), induces acetylation of various non-histone proteins such as p53 and alpha-tubulin. We purified several acetylated proteins by the affinity to an anti-acetylated lysine (AcLys) antibody from cells treated with TSA and identified them by mass spectrometry. Here we report on acetylation of CFIm25, a component of mammalian cleavage factor Im (CF Im), and poly(A) polymerase (PAP), a polyadenylating enzyme for the pre-mRNA 3'-end. The residues acetylated in these proteins were mapped onto the regions required for interaction with each other. Whereas CBP acetylated these proteins, HDAC1, HDAC3, HDAC10, SIRT1, and SIRT2 were involved in in vivo deacetylation. Acetylation of the CFIm25 occurred depending on the cleavage factor complex formation. Importantly, the interaction between PAP and CIF Im complex was decreased by acetylation. We also demonstrated that acetylation of PAP inhibited the nuclear localization of PAP by inhibiting the binding to the importin alpha/beta complex. These results suggest that C]BP and HDACs regulate the X-end processing machinery and modulate the localization of PAP through the acetylation and deacetylation cycle.	RIKEN, Chem Genet Lab, Discovery Res Inst, Wako, Saitama 3510198, Japan; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	RIKEN; University of Tokyo	Yoshida, M (corresponding author), RIKEN, Chem Genet Lab, Discovery Res Inst, Wako, Saitama 3510198, Japan.	yoshidam@riken.jp	SHIMAZU, Tadahiro/ABC-3950-2020; Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				Akakura S, 2001, J BIOL CHEM, V276, P14649, DOI 10.1074/jbc.M100200200; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; Dettwiler S, 2004, J BIOL CHEM, V279, P35788, DOI 10.1074/jbc.M403927200; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; IMAMOTO N, 1995, FEBS LETT, V368, P415; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kim H, 2001, BIOCHEM BIOPH RES CO, V289, P513, DOI 10.1006/bbrc.2001.5992; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Marmorstein R, 2001, CURR OPIN GENET DEV, V11, P155, DOI 10.1016/S0959-437X(00)00173-8; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Poulin DL, 2004, J VIROL, V78, P8245, DOI 10.1128/JVI.78.15.8245-8253.2004; Proudfoot N, 2004, CURR OPIN CELL BIOL, V16, P272, DOI 10.1016/j.ceb.2004.03.007; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; Ruegsegger U, 1998, MOL CELL, V1, P243, DOI 10.1016/S1097-2765(00)80025-8; Shimazu T, 2006, ONCOGENE, V25, P7391, DOI 10.1038/sj.onc.1209731; Takahashi H, 2006, MOL CELL, V23, P207, DOI 10.1016/j.molcel.2006.05.040; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zhao WQ, 1998, MOL CELL BIOL, V18, P5010, DOI 10.1128/MCB.18.9.5010	25	47	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4470	4478		10.1074/jbc.M609745200	http://dx.doi.org/10.1074/jbc.M609745200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17172643	hybrid			2022-12-25	WOS:000244482000028
J	Balasubramanian, S; Fam, SR; Hall, RA				Balasubramanian, Srividya; Fam, Sami R.; Hall, Randy A.			GABA(B) receptor association with the PDZ scaffold Mupp1 alters receptor stability and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN PROTEIN-1 MUPP1; B-RECEPTOR; KINASE-ACTIVITY; PHOSPHORYLATION; INTERACTS; ALCOHOL; TRAFFICKING; COMPLEXES; BACLOFEN; SUBUNITS	gamma-Aminobutyric acid, type B (GABA(B)) receptors are heterodimeric G protein-coupled receptors that mediate slow inhibitory synaptic transmission in the central nervous system. To identify novel interacting partners that might regulate GABAB receptor (GABA(B)R) functionality, we screened the GABA(B)R2 carboxyl terminus against a recently created proteomic array of 96 distinct PDZ (PSD-95/Dlg/ZO-1 homology) domains. The screen identified three specific PDZ domains that exhibit interactions with GABABR2: Mupp1 PDZ13, PAPIN PDZ1, and Erbin PDZ. Biochemical analysis confirmed that full-length Mupp1 and PAPIN interact with GABABR2 in cells. Disruption of the GABABR2 interaction with PDZ scaffolds by a point mutation to the carboxyl terminus of the receptor dramatically decreased receptor stability and attenuated the duration of GABAB receptor signaling. The effects of mutating the GABABR2 carboxyl terminus on receptor stability and signaling were mimicked by small interference RNA knockdown of endogenous Mupp1. These findings reveal that GABA, receptor stability and signaling can be modulated via GABABR2 interactions with the PDZ scaffold protein Mupp1, which may contribute to cell-specific regulation of GABA, receptors in the central nervous system.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Hall, RA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 5113 Rollins Res Ctr,1510 Clifton Rd, Atlanta, GA 30322 USA.	rhall@pharm.emory.edu		Hall, Randy/0000-0002-8318-8728	NINDS NIH HHS [NS45644] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045644] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Addolorato G, 2000, ALCOHOL CLIN EXP RES, V24, P67, DOI 10.1097/00000374-200001000-00011; Addolorato G, 2002, ALCOHOL ALCOHOLISM, V37, P504, DOI 10.1093/alcalc/37.5.504; Balasubramanian S, 2004, J BIOL CHEM, V279, P18840, DOI 10.1074/jbc.M313470200; Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Bettler B, 1998, CURR OPIN NEUROBIOL, V8, P345, DOI 10.1016/S0959-4388(98)80059-7; Bowery NG, 2006, CURR OPIN PHARMACOL, V6, P37, DOI 10.1016/j.coph.2005.10.002; Bowery NG, 2002, PHARMACOL REV, V54, P247, DOI 10.1124/pr.54.2.247; Brock C, 2005, MOL BIOL CELL, V16, P5572, DOI 10.1091/mbc.E05-05-0400; Burman KJ, 2003, BRAIN RES, V970, P35, DOI 10.1016/S0006-8993(02)04269-5; Chen ZJ, 2006, J BIOL CHEM, V281, P12414, DOI 10.1074/jbc.M508651200; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Colombo G, 2004, NEUROTOX RES, V6, P403, DOI 10.1007/BF03033315; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Couve A, 2004, J BIOL CHEM, V279, P13934, DOI 10.1074/jbc.M311737200; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; Deguchi M, 2000, J BIOL CHEM, V275, P29875, DOI 10.1074/jbc.M005384200; Dev KK, 2004, NAT REV DRUG DISCOV, V3, P1047, DOI 10.1038/nrd1578; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Enna SJ, 2004, BIOCHEM PHARMACOL, V68, P1541, DOI 10.1016/j.bcp.2004.06.037; Fairfax BP, 2004, J BIOL CHEM, V279, P12565, DOI 10.1074/jbc.M311389200; Fam SR, 2005, P NATL ACAD SCI USA, V102, P8042, DOI 10.1073/pnas.0408818102; Fehr C, 2002, J NEUROSCI, V22, P3730; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; GODFREY PP, 1988, EUR J PHARMACOL, V152, P185, DOI 10.1016/0014-2999(88)90854-0; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Harris BZ, 2001, J CELL SCI, V114, P3219; Havlickova M, 2002, MOL PHARMACOL, V62, P343, DOI 10.1124/mol.62.2.343; He JQ, 2006, J BIOL CHEM, V281, P2820, DOI 10.1074/jbc.M509503200; Jeansonne B, 2003, CELL MOL BIOL, V49, P13; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kimber WA, 2002, BIOCHEM J, V361, P525, DOI 10.1042/0264-6021:3610525; Krapivinsky G, 2004, NEURON, V43, P563, DOI 10.1016/j.neuron.2004.08.003; Mancini A, 2000, FEBS LETT, V482, P54, DOI 10.1016/S0014-5793(00)02036-6; Margeta-Mitrovic M, 1999, J COMP NEUROL, V405, P299, DOI 10.1002/(SICI)1096-9861(19990315)405:3<299::AID-CNE2>3.0.CO;2-6; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; Munehira Y, 2004, J BIOL CHEM, V279, P15091, DOI 10.1074/jbc.M313436200; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; Pagano A, 2001, J NEUROSCI, V21, P1189; Parker LL, 2003, J BIOL CHEM, V278, P21576, DOI 10.1074/jbc.M210973200; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shirley RL, 2004, NAT NEUROSCI, V7, P699, DOI 10.1038/nn1271; Sitek B, 2003, BRAIN RES, V970, P178, DOI 10.1016/S0006-8993(03)02338-2; Slattery DA, 2005, J PHARMACOL EXP THER, V312, P290, DOI 10.1124/jpet.104.073536; Torres-Escalante JL, 2004, J NEUROSCI RES, V78, P268, DOI 10.1002/jnr.20247; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197; Zaleski MJB, 2001, PSYCHOPHARMACOLOGY, V153, P415, DOI 10.1007/s002130000581	56	68	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4162	4171		10.1074/jbc.M607695200	http://dx.doi.org/10.1074/jbc.M607695200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17145756	hybrid			2022-12-25	WOS:000244481900079
J	Farjo, R; Skaggs, J; Quiambao, AB; Cooper, MJ; Naash, MI				Farjo, Rafal; Skaggs, Jeff; Quiambao, Alexander B.; Cooper, Mark J.; Naash, Muna I.			Efficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles	PLOS ONE			English	Article								Background. The eye is an excellent candidate for gene therapy as it is immune privileged and much of the disease-causing genetics are well understood. Towards this goal, we evaluated the efficiency of compacted DNA nanoparticles as a system for non-viral gene transfer to ocular tissues. The compacted DNA nanoparticles examined here have been shown to be safe and effective in a human clinical trial, have no theoretical limitation on plasmid size, do not provoke immune responses, and can be highly concentrated. Methods and Findings. Here we show that these nanoparticles can be targeted to different tissues within the eye by varying the site of injection. Almost all cell types of the eye were capable of transfection by the nanoparticle and produced robust levels of gene expression that were dose-dependent. Most impressively, subretinal delivery of these nanoparticles transfected nearly all of the photoreceptor population and produced expression levels almost equal to that of rod opsin, the highest expressed gene in the retina. Conclusions. As no deleterious effects on retinal function were observed, this treatment strategy appears to be clinically viable and provides a highly efficient non-viral technology to safely deliver and express nucleic acids in the retina and other ocular tissues.	[Farjo, Rafal; Skaggs, Jeff; Quiambao, Alexander B.; Naash, Muna I.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73190 USA; [Cooper, Mark J.] Copernicus Therapeut Inc, Cleveland, OH USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Naash, MI (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73190 USA.	muna-naash@ouhsc.edu			National Institutes of Health [EY016201, EY10609, EY12190]; Foundation Fighting Blindness; Oklahoma Center for the Advancement of Science and Technology; Research to Prevent Blindness James S. Adams Scholar; NATIONAL EYE INSTITUTE [R01EY010609, R56EY010609, P30EY012190, R55EY010609, R03EY016201] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation Fighting Blindness(European Commission); Oklahoma Center for the Advancement of Science and Technology; Research to Prevent Blindness James S. Adams Scholar; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	Funding: This study was supported by grants from the National Institutes of Health (EY016201 and EY10609, and Core Grant for Vision Research EY12190), the Foundation Fighting Blindness, and the Oklahoma Center for the Advancement of Science and Technology. M. I. Naash is a recipient of the Research to Prevent Blindness James S. Adams Scholar Award.	Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008; Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; Aguirre G D, 1998, Mol Vis, V4, P23; Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068; Atencio IA, 2004, CURR OPIN MOL THER, V6, P624; Batten ML, 2005, PLOS MED, V2, P1177, DOI 10.1371/journal.pmed.0020333; Bauer S, 2005, DNA CELL BIOL, V24, P381, DOI 10.1089/dna.2005.24.381; Baum C, 2006, HUM GENE THER, V17, P253, DOI 10.1089/hum.2006.17.253; Bennett J, 2006, HUM GENE THER, V17, P177, DOI 10.1089/hum.2006.17.177; Bennett J, 1999, P NATL ACAD SCI USA, V96, P9920, DOI 10.1073/pnas.96.17.9920; Bennett J, 1996, NAT MED, V2, P649, DOI 10.1038/nm0696-649; Berry V, 2000, NAT GENET, V25, P15, DOI 10.1038/75538; Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026; Brooks AR, 2004, J GENE MED, V6, P395, DOI 10.1002/jgm.516; Cashman SM, 2005, GENE THER, V12, P1223, DOI 10.1038/sj.gt.3302512; Chen Y, 2006, INVEST OPHTH VIS SCI, V47, P1177, DOI 10.1167/iovs.05-0965; Chen ZY, 2004, GENE THER, V11, P856, DOI 10.1038/sj.gt.3302231; Dinculescu A, 2005, HUM GENE THER, V16, P649, DOI 10.1089/hum.2005.16.649; Drenser KA, 1998, INVEST OPHTH VIS SCI, V39, P681; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Farjo R, 2006, J CELL BIOL, V173, P59, DOI 10.1083/jcb.200509036; Farrar GJ, 2002, EMBO J, V21, P857, DOI 10.1093/emboj/21.5.857; Ferreira PA, 2005, HUM MOL GENET, V14, pR259, DOI 10.1093/hmg/ddi272; FINK TL, 2006, GENE THER EPUB; Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916; Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Halbert CL, 2006, HUM GENE THER, V17, P440, DOI 10.1089/hum.2006.17.440; Hong DH, 2005, INVEST OPHTH VIS SCI, V46, P435, DOI 10.1167/iovs.04-1065; Jun AS, 2003, EYE, V17, P906, DOI 10.1038/sj.eye.6700565; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Konstan MW, 2004, HUM GENE THER, V15, P1255, DOI 10.1089/hum.2004.15.1255; Kowalczyk T, 2001, MOL THER, V3, pS359; Kube D, 2003, MOL THER, V7, pS371; Lewin AS, 1998, NAT MED, V4, P967, DOI 10.1038/nm0898-967; Liu G, 2003, J BIOL CHEM, V278, P32578, DOI 10.1074/jbc.M305776200; Liu G, 2001, J BIOL CHEM, V276, P34379, DOI 10.1074/jbc.M105250200; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Martin AC, 2004, INVEST OPHTH VIS SCI, V45, P3387, DOI 10.1167/iovs.04-0349; Martin KRG, 2004, EYE, V18, P1049, DOI 10.1038/sj.eye.6701579; Martin KRG, 2003, INVEST OPHTH VIS SCI, V44, P4357, DOI 10.1167/iovs.02-1332; Mohan RR, 2005, PROG RETIN EYE RES, V24, P537, DOI 10.1016/j.preteyeres.2005.04.001; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; NAASH MI, 2006, MOL THER, pS882; Narfstrom K, 2005, DOC OPHTHALMOL, V111, P39, DOI [10.1007/s10633-005-3159-0, 10.1007/S10633-005-3159-0]; Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955; Nour M, 2004, INVEST OPHTH VIS SCI, V45, P15, DOI 10.1167/iovs.03-0663; Nour M, 2003, INVEST OPHTH VIS SCI, V44, P4505, DOI 10.1167/iovs.03-0453; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Pan QW, 2006, MOL THER, V13, pS398, DOI 10.1016/j.ymthe.2006.08.1133; Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165; Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016; Rolling F, 2004, GENE THER, V11, pS26, DOI 10.1038/sj.gt.3302366; Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027; Sarra GM, 2001, HUM MOL GENET, V10, P2353, DOI 10.1093/hmg/10.21.2353; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066; Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701; Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154; Ziady AG, 2003, MOL THER, V8, P936, DOI 10.1016/j.ymthe.2003.07.007; Ziady AG, 2003, MOL THER, V8, P948, DOI 10.1016/j.ymthe.2003.09.002	61	164	173	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e38	10.1371/journal.pone.0000038	http://dx.doi.org/10.1371/journal.pone.0000038			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183666	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600038
J	Yan, JZ; Chen, YX; Desmond, A; Silva, A; Yang, YQ; Wang, HR; Hua, XX				Yan, Jizhou; Chen, Ya-Xiong; Desmond, Angela; Silva, Albert; Yang, Yuqing; Wang, Haoren; Hua, Xianxin			Cdx4 and Menin Co-Regulate Hoxa9 Expression in Hematopoietic Cells	PLOS ONE			English	Article								Background. Transcription factor Cdx4 and transcriptional coregulator menin are essential for Hoxa9 expression and normal hematopoiesis. However, the precise mechanism underlying Hoxa9 regulation is not clear. Methods and Findings. Here, we show that the expression level of Hoxa9 is correlated with the location of increased trimethylated histone 3 lysine 4 (H3K4M3). The active and repressive histone modifications co-exist along the Hoxa9 regulatory region. We further demonstrate that both Cdx4 and menin bind to the same regulatory region at the Hoxa9 locus in vivo, and co-activate the reporter gene driven by the Hoxa9 cis-elements that contain Cdx4 binding sites. Ablation of menin abrogates Cdx4 access to the chromatin target and significantly reduces both active and repressive histone H3 modifications in the Hoxa9 locus. Conclusion. These results suggest a functional link among Cdx4, menin and histone modifications in Hoxa9 regulation in hematopoietic cells.	[Yan, Jizhou; Chen, Ya-Xiong; Desmond, Angela; Silva, Albert; Yang, Yuqing; Wang, Haoren; Hua, Xianxin] Univ Penn, Abramson Canc Ctr, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Hua, XX (corresponding author), Univ Penn, Abramson Canc Ctr, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	huax@mail.med.upenn.edu		Yan, Jizhou/0000-0001-7482-7842	NIH [CA100912]; Burroughs Wellcome Career Award; NATIONAL CANCER INSTITUTE [R01CA100912] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Career Award(Burroughs Wellcome Fund); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding: This work was in part supported by NIH grant (CA100912 to XH) and the Burroughs Wellcome Career Award (XH).	Araten DJ, 2005, CANCER RES, V65, P8111, DOI 10.1158/0008-5472.CAN-04-1198; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Chen YX, 2006, P NATL ACAD SCI USA, V103, P1018, DOI 10.1073/pnas.0510347103; Davidson AJ, 2003, NATURE, V425, P300, DOI 10.1038/nature01973; Dehe PM, 2005, J MOL BIOL, V353, P477, DOI 10.1016/j.jmb.2005.08.059; Deschamps J, 2005, DEVELOPMENT, V132, P2931, DOI 10.1242/dev.01897; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gaunt SJ, 2005, INT J DEV BIOL, V49, P901, DOI 10.1387/ijdb.052021sg; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gregory PA, 2006, PHARMACOGENET GENOM, V16, P527, DOI 10.1097/01.fpc.0000215068.06471.35; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Jin SH, 2003, CANCER RES, V63, P4204; Johnson JJ, 2003, BLOOD, V101, P3229, DOI 10.1182/blood-2002-05-1515; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Kumar AR, 2004, BLOOD, V103, P1823, DOI 10.1182/blood-2003-07-2582; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lawrence HJ, 2005, BLOOD, V106, P3988, DOI 10.1182/blood-2005-05-2003; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Luzzatto L, 2001, EUR J CANCER, V37, pS114; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; Milne TA, 2005, CANCER RES, V65, P11367, DOI 10.1158/0008-5472.CAN-05-1041; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Moore MAS, 2005, EXP HEMATOL, V33, P719, DOI 10.1016/j.exphem.2005.04.011; Morillon A, 2005, MOL CELL, V18, P723, DOI 10.1016/j.molcel.2005.05.009; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Pollard SL, 2000, CURR BIOL, V10, P1059, DOI 10.1016/S0960-9822(00)00676-X; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Schnepp RW, 2004, CANCER RES, V64, P6791, DOI 10.1158/0008-5472.CAN-04-0724; Schnepp RW, 2004, J BIOL CHEM, V279, P10685, DOI 10.1074/jbc.M308073200; SORENSEN PHB, 1994, J CLIN INVEST, V93, P429, DOI 10.1172/JCI116978; Tabaries S, 2005, MOL CELL BIOL, V25, P1389, DOI 10.1128/MCB.25.4.1389-1401.2005; van Dijk K, 2005, PLANT CELL, V17, P2439, DOI 10.1105/tpc.105.034165; Wang Y, 2005, P NATL ACAD SCI USA, V102, P19081, DOI 10.1073/pnas.0506127102; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015	59	24	26	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e47	10.1371/journal.pone.0000047	http://dx.doi.org/10.1371/journal.pone.0000047			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183676	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600047
J	Zaleskas, VM; Krause, DS; Lazarides, K; Patel, N; Hu, YG; Li, SG; Van Etten, RA				Zaleskas, Virginia M.; Krause, Daniela S.; Lazarides, Katherine; Patel, Nihal; Hu, Yiguo; Li, Shaoguang; Van Etten, Richard A.			Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F	PLOS ONE			English	Article								Background. A somatic activating mutation (V617F) in the JAK2 tyrosine kinase was recently discovered in the majority of patients with polycythemia vera (PV), and some with essential thrombocythemia (ET) and chronic idiopathic myelofibrosis. However, the role of mutant JAK2 in disease pathogenesis is unclear. Methods and Findings. We expressed murine JAK2 WT or V617F via retroviral bone marrow transduction/transplantation in the hematopoietic system of two different inbred mouse strains, Balb/c and C57Bl/6 (B6). In both strains, JAK2 V617F, but not JAK2 WT, induced non-fatal polycythemia characterized by increased hematocrit and hemoglobin, reticulocytosis, splenomegaly, low plasma erythropoietin (Epo), and Epo-independent erythroid colonies. JAK2 V617F also induced leukocytosis and neutrophilia that was much more prominent in Balb/c mice than in B6. Platelet counts were not affected in either strain despite expression of JAK2 V617F in megakaryocytes and markedly prolonged tail bleeding times. The polycythemia tended to resolve after several months, coincident with increased spleen and marrow fibrosis, but was resurrected by transplantation to secondary recipients. Using donor mice with mutations in Lyn, Hck, and Fgr, we demonstrated that the polycythemia was independent of Src kinases. Polycythemia and reticulocytosis responded to treatment with imatinib or a JAK2 inhibitor, but were unresponsive to the Src inhibitor dasatinib. Conclusions. These findings demonstrate that JAK2 V617F induces Epo-independent expansion of the erythroid lineage in vivo. The fact that the central erythroid features of PV are recapitulated by expression of JAK2 V617F argues that it is the primary and direct cause of human PV. The lack of thrombocytosis suggests that additional events may be required for JAK2 V617F to cause ET, but qualitative platelet abnormalities induced by JAK2 V617F may contribute to the hemostatic complications of PV. Despite the role of Src kinases in Epo signaling, our studies predict that Src inhibitors will be ineffective for therapy of PV. However, we provide proof-of-principle that a JAK2 inhibitor should have therapeutic effects on the polycythemia, and perhaps myelofibrosis and hemostatic abnormalities, suffered by MPD patients carrying the JAK2 V617F mutation.	[Zaleskas, Virginia M.; Krause, Daniela S.; Lazarides, Katherine; Patel, Nihal; Van Etten, Richard A.] Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; [Hu, Yiguo; Li, Shaoguang] Jackson Lab, Bar Harbor, ME 04609 USA	Tufts Medical Center; Jackson Laboratory	Van Etten, RA (corresponding author), Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA.	rvanetten@tufts-nemc.org			NIH [CA90576, HL56949, T32CA009429, CA11419]; Leukemia and Lymphoma Society; NATIONAL CANCER INSTITUTE [R01CA090576, T32CA009429] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056949] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by NIH grants CA90576 and HL56949 (to R. A. V.), T32CA009429 (to V.Z.) and CA11419 (to S. L.), and by a SCOR grant from the Leukemia and Lymphoma Society (to R. A. V.).	Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bellanne-Chantelot C, 2006, BLOOD, V108, P346, DOI 10.1182/blood-2005-12-4852; Campbell PJ, 2006, METH MOLEC MED, V125, P253; Campbell PJ, 2006, BLOOD, V107, P2098, DOI 10.1182/blood-2005-08-3395; Campbell PJ, 2005, LANCET, V366, P1945, DOI 10.1016/S0140-6736(05)67785-9; Cario H, 2005, BRIT J HAEMATOL, V130, P800, DOI 10.1111/j.1365-2141.2005.05683.x; CORREA PN, 1994, BLOOD, V83, P99; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DAMESHEK W, 1951, BLOOD, V6, P372, DOI 10.1182/blood.V6.4.372.372; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1037; Friedman JS, 2001, J EXP MED, V193, P925, DOI 10.1084/jem.193.8.925; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Ingley E, 2005, ONCOGENE, V24, P336, DOI 10.1038/sj.onc.1208199; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jones AV, 2006, BLOOD, V107, P3339, DOI 10.1182/blood-2005-09-3917; Jones AV, 2005, BLOOD, V106, P2162, DOI 10.1182/blood-2005-03-1320; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Levine RL, 2006, BLOOD, V107, P4139, DOI 10.1182/blood-2005-09-3900; Lu XH, 2005, P NATL ACAD SCI USA, V102, P18962, DOI 10.1073/pnas.0509714102; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Moliterno AR, 1998, NEW ENGL J MED, V338, P572, DOI 10.1056/NEJM199802263380903; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; Ramakrishnan V, 1999, P NATL ACAD SCI USA, V96, P13336, DOI 10.1073/pnas.96.23.13336; Richmond TD, 2005, TRENDS CELL BIOL, V15, P146, DOI 10.1016/j.tcb.2005.01.007; Roumiantsev S, 2004, CANCER CELL, V5, P287, DOI 10.1016/S1535-6108(04)00053-4; Schittenhelm MM, 2006, CANCER RES, V66, P473, DOI 10.1158/0008-5472.CAN-05-2050; Scott LM, 2005, BLOOD, V106, P2920, DOI 10.1182/blood-2005-05-2087; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Spivak JL, 2002, BLOOD, V100, P4272, DOI 10.1182/blood-2001-12-0349; Steensma DP, 2005, BLOOD, V106, P1207, DOI 10.1182/blood-2005-03-1183; Tefferi A, 2006, CANCER-AM CANCER SOC, V106, P631, DOI 10.1002/cncr.21645; Temerinac S, 2000, BLOOD, V95, P2569; Thompson JE, 2002, BIOORG MED CHEM LETT, V12, P1219, DOI 10.1016/S0960-894X(02)00106-3; Ugo V, 2004, EXP HEMATOL, V32, P179, DOI 10.1016/j.exphem.2003.11.003; Van Etten RA, 2004, CANCER CELL, V6, P547, DOI 10.1016/j.ccr.2004.12.004; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Westervelt P, 1999, BLOOD, V93, P2143, DOI 10.1182/blood.V93.7.2143.407a32_2143_2148; Wolff NC, 2005, BLOOD, V105, P3995, DOI 10.1182/blood-2004-09-3534; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942; Xu MJ, 2003, BLOOD, V102, P4354, DOI 10.1182/blood-2003-04-1308; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200	48	186	195	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e18	10.1371/journal.pone.0000018	http://dx.doi.org/10.1371/journal.pone.0000018			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183644	gold, Green Published			2022-12-25	WOS:000207443600018
J	Ababou, A; Gautel, M; Pfuhl, M				Ababou, Abdessamad; Gautel, Mathias; Pfuhl, Mark			Dissecting the N-terminal myosin binding site of human cardiac myosin-binding protein C - Structure and myosin binding of domain C2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; MODEL-FREE APPROACH; MUSCLE PROTEIN; REGULATORY DOMAIN; THICK FILAMENTS; MYBP-C; PHOSPHORYLATION; TITIN; SEQUENCE; MACROMOLECULES	Myosin-binding protein C (MyBP-C) binds to myosin with two binding sites, one close to the N terminus and the other at the C terminus. Here we present the solution structure of one part of the N-terminal binding site, the third immunoglobulin domain of the cardiac isoform of human MyBP-C (cC2) together with a model of its interaction with myosin. Domain cC2 has the beta-sandwich structure expected from a member of the immunoglobulin fold. The C-terminal part of the structure of cC2 is very closely related to telokin, the myosin binding fragment of myosin light chain kinase. Domain cC2 also contains two cysteines on neighboring strands F and G, which would be able to form a disulfide bridge in a similar position as in telokin. Using NMR spectroscopy and isothermal titration calorimetry we demonstrate that cC2 alone binds to a fragment of myosin, S2 Delta, with low affinity (k(D) = 1.1 mm) but exhibits a highly specific binding site. This consists of the C-terminal surface of the C'CFGA' beta-sheet, which includes Glu(301), a residue mutated to Gln in the disease familial hypertrophic cardiomyopathy. The binding site on S2 was identified by a combination of NMR binding experiments of cC2 with S2 Delta containing the cardiomyopathy-linked mutation R870H and molecular modeling. This mutation lowers the binding affinity and changes the arrangement of side chains at the interface. Our model of the cC2-S2 Delta complex gives a first glimpse of details of the MyBP-C-myosin interaction. Using this model we suggest that most key interactions are between polar amino acids, explaining why the mutations E301Q in cC2 and R870H in S2 Delta could be involved in cardiomyopathy. We expect that this model will stimulate future research to further refine the details of this interaction and their importance for cardiomyopathy.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Kings Coll London, Randall Ctr, Div Cardiovasc, London SE1 1L, England	University of Leicester	Pfuhl, M (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	mp84@le.ac.uK	Gautel, Mathias/AAB-9860-2019	Gautel, Mathias/0000-0003-4027-9803; Pfuhl, Mark/0000-0001-9592-6639	MRC [G0600251] Funding Source: UKRI; Medical Research Council [G0600251] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anan R, 2000, Hum Mutat, V15, P584, DOI 10.1002/1098-1004(200006)15:6<584::AID-HUMU25>3.0.CO;2-R; Bennett PM, 1999, REV PHYSIOL BIOCH P, V138, P203, DOI 10.1007/BF02346664; Blankenfeldt W, 2006, P NATL ACAD SCI USA, V103, P17713, DOI 10.1073/pnas.0606741103; Carrier L, 1997, CIRC RES, V80, P427, DOI 10.1161/01.res.0000435859.24609.b3; Case DAPD, 1999, AMBER 6; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DEBRA LS, 1997, J BIOL CHEM, V272, P25353; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dixon SL, 1997, J CHEM PHYS, V107, P879, DOI 10.1063/1.474386; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Fong S, 1996, J MOL BIOL, V264, P624, DOI 10.1006/jmbi.1996.0665; Freiburg A, 1996, EUR J BIOCHEM, V235, P317, DOI 10.1111/j.1432-1033.1996.00317.x; GAUTEL M, 1995, EMBO J, V14, P1952, DOI 10.1002/j.1460-2075.1995.tb07187.x; Gogonea V, 1999, J PHYS CHEM A, V103, P5171, DOI 10.1021/jp990266w; Gruen M, 1999, FEBS LETT, V453, P254, DOI 10.1016/S0014-5793(99)00727-9; Gruen M, 1999, J MOL BIOL, V286, P933, DOI 10.1006/jmbi.1998.2522; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; Idowu SM, 2003, J MOL BIOL, V329, P745, DOI 10.1016/S0022-2836(03)00425-X; Improta S, 1996, STRUCTURE, V4, P323, DOI 10.1016/S0969-2126(96)00036-6; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; Kreishman-Deitrick M, 2003, BIOCHEMISTRY-US, V42, P8579, DOI 10.1021/bi034536j; Kunst G, 2000, CIRC RES, V86, P51, DOI 10.1161/01.RES.86.1.51; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LANGE G, 1994, STRUCTURE, V2, P469, DOI 10.1016/S0969-2126(00)00048-4; LE HB, 1994, J BIOMOL NMR, V4, P341; Levine R, 2001, BIOPHYS J, V81, P1070, DOI 10.1016/S0006-3495(01)75764-5; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Mayans O, 2001, STRUCTURE, V9, P331, DOI 10.1016/S0969-2126(01)00591-3; McClellan G, 2001, BIOPHYS J, V81, P1083, DOI 10.1016/S0006-3495(01)75765-7; Miyamoto CA, 1999, J MUSCLE RES CELL M, V20, P703, DOI 10.1023/A:1005513312939; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; PFUHL M, 1995, STRUCTURE, V3, P391, DOI 10.1016/S0969-2126(01)00170-8; Politou AS, 1996, J MOL BIOL, V255, P604, DOI 10.1006/jmbi.1996.0050; Pope BJ, 2004, J BIOL CHEM, V279, P4840, DOI 10.1074/jbc.M310148200; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thomsen NK, 1996, NAT STRUCT BIOL, V3, P581, DOI 10.1038/nsb0796-581; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; TRINICK J, 1994, TRENDS BIOCHEM SCI, V19, P405, DOI 10.1016/0968-0004(94)90088-4; Turnbull WB, 2003, J AM CHEM SOC, V125, P14859, DOI 10.1021/ja036166s; VAJDA S, 1994, BIOCHEMISTRY-US, V33, P13977, DOI 10.1021/bi00251a004; Vaynberg J, 2005, MOL CELL, V17, P513, DOI 10.1016/j.molcel.2004.12.031; Velyvis A, 2003, NAT STRUCT BIOL, V10, P558, DOI 10.1038/nsb938; Weisberg A, 1996, P NATL ACAD SCI USA, V93, P8999, DOI 10.1073/pnas.93.17.8999; Winegrad S, 1999, CIRC RES, V84, P1117, DOI 10.1161/01.RES.84.10.1117; Winegrad S, 2000, CIRC RES, V86, P6, DOI 10.1161/01.RES.86.1.6; Woodhead JL, 2005, NATURE, V436, P1195, DOI 10.1038/nature03920	54	57	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9204	9215		10.1074/jbc.M610899200	http://dx.doi.org/10.1074/jbc.M610899200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17192269	hybrid			2022-12-25	WOS:000245780300067
J	Shindou, H; Hishikawa, D; Nakanishiu, H; Harayama, T; Ishii, S; Taguchi, R; Shimizu, T				Shindou, Hideo; Hishikawa, Daisuke; Nakanishiu, Hiroki; Harayama, Takeshi; Ishii, Satoshi; Taguchi, Ryo; Shimizu, Takao			A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells - Cloning and characterization of acetyl-CoA : lyso-PAF acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); NF-KAPPA-B; FACTOR RECEPTOR; HUMAN-NEUTROPHILS; LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE; FACTOR ACETYLHYDROLASE; P388D(1) MACROPHAGES; II CELLS; LIPOPOLYSACCHARIDE; BIOSYNTHESIS	Platelet-activating factor (PAF) is a potent proinflammatory lipid mediator eliciting a variety of cellular functions. Lipid mediators, including PAF are produced from membrane phospholipids by enzymatic cascades. Although a G protein-coupled PAF receptor and degradation enzymes have been cloned and characterized, the PAF biosynthetic enzyme, aceyl-CoAdyso-PAF acetyltransferase, has not been identified. Here, we cloned lyso-PAF acetyltransferase, which is critical in stimulus-dependent formation of PAF. The enzyme is a 60-kDa microsomal protein with three putative membrane-spanning domains. The enzyme was induced by bacterial endotoxin (lipopolysaccharide), which was suppressed by dexamethasone treatment. Surprisingly, the enzyme catalyzed not only biosynthesis of PAF from lyso-PAF but also incorporation of arachidonoyl-CoA to produce PAF precursor membrane glycerophospholipids (lysophosphatidylcholine acyltransferase activity). Under resting conditions, the enzyme prefers arachidonoyl-CoA and contributes to membrane biogenesis. Upon acute inflammatory stimulation with lipopolysaccharide, the activated enzyme utilizes acetyl-CoA more efficiently and produces PAF. Thus, our findings provide a novel concept that a single enzyme catalyzes membrane biogenesis of inflammatory cells while producing prophlogistic mediator in response to external stimuli.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Dept Metabolome, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, CREST, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, PRESTO, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Shimizu, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	tshimizu@m.u-tokyo.ac.jp	Harayama, Takeshi/AAD-8852-2022; Shimizu, Takao/AAV-7052-2021	Harayama, Takeshi/0000-0003-2255-4197; Nakanishi, Hiroki/0000-0002-5108-1598				Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; AOKI Y, 1995, J IMMUNOL METHODS, V186, P225, DOI 10.1016/0022-1759(95)00147-3; Arai H, 2002, PROSTAG OTH LIPID M, V68-9, P83, DOI 10.1016/S0090-6980(02)00023-0; Balsinde J, 2000, J BIOL CHEM, V275, P4783, DOI 10.1074/jbc.275.7.4783; BENIGNI A, 1992, LANCET, V339, P835, DOI 10.1016/0140-6736(92)90281-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen XN, 2006, P NATL ACAD SCI USA, V103, P11724, DOI 10.1073/pnas.0604946103; DOEBBER TW, 1987, P NATL ACAD SCI USA, V84, P7557, DOI 10.1073/pnas.84.21.7557; Fragopoulou E, 2005, MEDIAT INFLAMM, P263, DOI 10.1155/MI.2005.263; GOMEZCAMBRONERO J, 1986, BIOCHEM J, V237, P439, DOI 10.1042/bj2370439; Han SJ, 1999, EUR J IMMUNOL, V29, P1334, DOI 10.1002/(SICI)1521-4141(199904)29:04<1334::AID-IMMU1334>3.0.CO;2-0; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Houjou T, 2004, RAPID COMMUN MASS SP, V18, P3123, DOI 10.1002/rcm.1737; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; KENNEDY EP, 1961, FED PROC, V20, P934; Kihara Y, 2005, J EXP MED, V202, P853, DOI 10.1084/jem.20050660; Kume K, 1997, ANAL BIOCHEM, V246, P118, DOI 10.1006/abio.1996.9959; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; LANDS WEM, 1963, J BIOL CHEM, V238, P898; LEE TC, 1984, J BIOL CHEM, V259, P5526; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Li D, 2003, J HUM GENET, V48, P438, DOI 10.1007/s10038-003-0045-z; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; MERKL I, 1963, J BIOL CHEM, V238, P905; Nakanishi H, 2006, J BIOL CHEM, V281, P20140, DOI 10.1074/jbc.M600225200; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nixon AB, 1999, J BIOL CHEM, V274, P5469, DOI 10.1074/jbc.274.9.5469; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Owen JS, 2005, BBA-MOL CELL BIOL L, V1733, P120, DOI 10.1016/j.bbalip.2004.12.016; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; REINHOLD SL, 1989, J BIOL CHEM, V264, P21652; REMY E, 1989, BIOCHIM BIOPHYS ACTA, V1005, P87, DOI 10.1016/0005-2760(89)90035-0; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Shikano S, 2003, P NATL ACAD SCI USA, V100, P5783, DOI 10.1073/pnas.1031748100; Shimizu T, 2006, IUBMB LIFE, V58, P328, DOI 10.1080/15216540600702289; Shindou H, 2005, J IMMUNOL, V175, P1177, DOI 10.4049/jimmunol.175.2.1177; Shindou H, 2000, BIOCHEM BIOPH RES CO, V271, P812, DOI 10.1006/bbrc.2000.2723; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Smith JM, 2002, PEDIATR NEPHROL, V17, P1047, DOI 10.1007/s00467-002-0970-7; SNYDER F, 1995, BBA-LIPID LIPID MET, V1254, P231, DOI 10.1016/0005-2760(94)00192-2; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VENABLE ME, 1993, J BIOL CHEM, V268, P7965; WYKLE RL, 1980, J BIOL CHEM, V255, P256; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262	53	168	177	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6532	6539		10.1074/jbc.M609641200	http://dx.doi.org/10.1074/jbc.M609641200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17182612	hybrid			2022-12-25	WOS:000244867200061
J	Bonfils, C; Bec, N; Lacroix, B; Harricane, MC; Larroque, C				Bonfils, Claude; Bec, Nicole; Lacroix, Benjamin; Harricane, Marie-Cecile; Larroque, Christian			Kinetic analysis of tubulin assembly in the presence of the microtubule-associated protein TOGp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANOSINE 5'-TRIPHOSPHATE HYDROLYSIS; KINESIN-RELATED PROTEIN; MITOTIC SPINDLE; GTP HYDROLYSIS; FISSION YEAST; XENOPUS EGGS; PLUS-END; POLYMERIZATION; NUCLEATION; COMPONENT	The microtubule-associated protein TOGp, which belongs to a widely distributed protein family from yeasts to humans, is highly expressed in human tumors and brain tissue. From purified components we have determined the effect of TOGp on thermally induced tubulin association in vitro in the presence of 1 mm GTP and 3.4 m glycerol. Physicochemical parameters describing the mechanism of tubulin polymerization were deduced from the kinetic curves by application of the classical theoretical models of tubulin assembly. We have calculated from the polymerization time curves a range of parameters characteristic of nucleation, elongation, or steady state phase. In addition, the tubulin subunits turnover at microtubule ends was deduced from tubulin GTPase activity. For comparison, parallel experiments were conducted with colichicine and taxol, two drugs active on microtubules and with tau, a structural microtubule-associated protein from brain tissue. TOGp, which decreases the nucleus size and the tenth time of the reaction (the time required to produce 10% of the final amount of polymer), shortens the nucleation phase of microtubule assembly. In addition, TOGp favors microtubule formation by increasing the apparent first order rate constant of elongation. Moreover, TOGp increases the total amount of polymer by decreasing the tubulin critical concentration and by inhibiting depolymerization during the steady state of the reaction.	CLRC Val Aurelle Paul Lamarque, INSERM, EMI 229, F-34298 Montpellier 5, France; CNRS, Ctr Rech Biochim Macromol, F-34293 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Bonfils, C (corresponding author), CLRC Val Aurelle Paul Lamarque, INSERM, EMI 229, Rue Apothicaires, F-34298 Montpellier 5, France.	bonfils@valdorel.fnclcc.fr	Lacroix, Benjamin/AAL-8428-2020	Lacroix, Benjamin/0000-0003-2533-9150; bec, nicole/0000-0001-7608-2434				Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; CARLIER MF, 1983, BIOCHEMISTRY-US, V22, P4814, DOI 10.1021/bi00289a031; CARLIER MF, 1981, BIOCHEMISTRY-US, V20, P1918, DOI 10.1021/bi00510a030; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; Caudron N, 2002, J BIOL CHEM, V277, P50973, DOI 10.1074/jbc.M209753200; Charrasse S, 1998, J CELL SCI, V111, P1371; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; Cullen CF, 1999, J CELL BIOL, V146, P1005, DOI 10.1083/jcb.146.5.1005; Cullen CF, 2001, NAT CELL BIOL, V3, P637, DOI 10.1038/35083025; DAVIDPFEUTY T, 1977, P NATL ACAD SCI USA, V74, P5372, DOI 10.1073/pnas.74.12.5372; DAVIDPFEUTY T, 1979, J BIOL CHEM, V254, P1696; Dionne MA, 2000, J BIOL CHEM, V275, P12346, DOI 10.1074/jbc.275.16.12346; ERICKSON HP, 1981, BIOPHYS J, V34, P293, DOI 10.1016/S0006-3495(81)84850-3; Flyvbjerg H, 1996, P NATL ACAD SCI USA, V93, P5975, DOI 10.1073/pnas.93.12.5975; Garcia MA, 2002, EMBO J, V21, P6015, DOI 10.1093/emboj/cdf611; Garcia MA, 2001, EMBO J, V20, P3389, DOI 10.1093/emboj/20.13.3389; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; Graf R, 2000, J CELL SCI, V113, P1747; Hall D, 2003, BIOPHYS CHEM, V104, P655, DOI 10.1016/S0301-4622(03)00040-1; HOUMEIDA A, 1995, BIOPHYS CHEM, V56, P201, DOI 10.1016/0301-4622(95)00038-Y; Hunter AW, 2003, MOL CELL, V11, P445, DOI 10.1016/S1097-2765(03)00049-2; JOHNSON KA, 1977, J MOL BIOL, V117, P1, DOI 10.1016/0022-2836(77)90020-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; LIN CM, 1981, J BIOL CHEM, V256, P9242; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; Matthews LR, 1998, J CELL BIOL, V141, P1159, DOI 10.1083/jcb.141.5.1159; Muller-Reichert T, 1998, P NATL ACAD SCI USA, V95, P3661, DOI 10.1073/pnas.95.7.3661; OHKURA H, 1988, EMBO J, V7, P1465, DOI 10.1002/j.1460-2075.1988.tb02964.x; Ohkura H, 2001, J CELL SCI, V114, P3805; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; Popov AV, 2001, EMBO J, V20, P397, DOI 10.1093/emboj/20.3.397; RAGE F, 1992, ENDOCRINOLOGY, V130, P1056, DOI 10.1210/en.130.2.1056; ROBINSON J, 1982, J BIOL CHEM, V257, P5367; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SANDOVAL IV, 1981, J BIOL CHEM, V256, P8795; Sever S, 2002, CURR OPIN CELL BIOL, V14, P463, DOI 10.1016/S0955-0674(02)00347-2; Shirasu-Hiza M, 2003, J CELL BIOL, V161, P349, DOI 10.1083/jcb.200211095; Spittle C, 2000, J BIOL CHEM, V275, P20748, DOI 10.1074/jbc.M002597200; STERNLICHT H, 1979, J BIOL CHEM, V254, P540; Suarez I, 2002, NEUROCHEM INT, V41, P123, DOI 10.1016/S0197-0186(02)00033-5; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; VOTER WA, 1984, J BIOL CHEM, V259, P430; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Wang PJJ, 1997, J CELL BIOL, V139, P1271, DOI 10.1083/jcb.139.5.1271; WEGNER A, 1975, BIOPHYS CHEM, V3, P215, DOI 10.1016/0301-4622(75)80013-5; Whittington AT, 2001, NATURE, V411, P610, DOI 10.1038/35079128; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376	50	21	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5570	5581		10.1074/jbc.M605641200	http://dx.doi.org/10.1074/jbc.M605641200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17178729	hybrid, Green Accepted, Green Submitted			2022-12-25	WOS:000244482300053
J	Kang, SH; Kim, GR; Seong, M; Baek, SH; Seol, JH; Bang, OS; Ovaa, H; Tatsumi, K; Komatsu, M; Tanaka, K; Chung, CH				Kang, Sung Hwan; Kim, Gi Ryang; Seong, Minu; Baek, Sung Hee; Seol, Jae Hong; Bang, Ok Sun; Ovaa, Huib; Tatsumi, Kanako; Komatsu, Masaaki; Tanaka, Keiji; Chung, Chin Ha			Two novel ubiquitin-fold modifier 1 (Ufm1)-specific proteases, UfSP1 and UfSP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEUBIQUITINATING ENZYMES; UBIQUITIN; PROTEIN; SUMO; UFM1	Ubiquitin-fold modifier I (Ufm1) is a recently identified new ubiquitin-like protein, whose tertiary structure displays a striking resemblance to ubiquitin. Similar to ubiquitin, it has a Gly residue conserved across species at the C-terminal region with extensions of various amino acid sequences that need to be processed in vivo prior to conjugation to target proteins. Here we report the isolation, cloning, and characterization of two novel mouse Ufm1-specific proteases, named UfSP1 and UfSP2. UfSP1 and UfSP2 are composed of 217 and 461 amino acids, respectively, and they have no sequence homology with previously known proteases. UfSP2 is present in most, if not all, of multicellular organisms including plant, nematode, fly, and mammal, whereas UfSP1 could not be found in plant and nematode upon data base search. UfSP1 and UfSP2 cleaved the C-terminal extension of Ufm1 but not that of ubiquitin or other ubiquitin-like proteins, such as SUMO-1 and ISG15. Both were also capable of releasing Ufm1 from Ufm1-conjugated cellular proteins. They were sensitive to inhibition by sulfhydryl-blocking agents, such as N-ethylmaleimide, and their active site Cys could be labeled with Ufm1-vinylmethylester. Moreover, replacement of the conserved Cys residue by Ser resulted in a complete loss of the UfSP1 and UfSP2 activities. These results indicate that UfSP1 and UfSP2 are novel thiol proteases that specifically process the C terminus of Ufm1.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Bunkyo Ku, Tokyo 1138613, Japan	Seoul National University (SNU); Netherlands Cancer Institute; Tokyo Metropolitan Institute of Medical Science	Chung, CH (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.	chchung@snu.ac.kr	Komatsu, Masaaki/B-8321-2011; ovaa, huib/M-2334-2016	Komatsu, Masaaki/0000-0001-7672-7722; ovaa, huib/0000-0002-0068-054X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Balakirev MY, 2003, EMBO REP, V4, P517, DOI 10.1038/sj.embor.embor824; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; CHUNG CH, 1983, J BIOL CHEM, V258, P1032; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dohmen RJ, 2004, BBA-MOL CELL RES, V1695, P113, DOI 10.1016/j.bbamcr.2004.09.021; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hemelaar J, 2004, MOL CELL BIOL, V24, P84, DOI 10.1128/MCB.24.1.84-95.2004; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kang SH, 2005, METHOD ENZYMOL, V398, P500, DOI 10.1016/S0076-6879(05)98041-5; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Kim JH, 2003, J BIOCHEM, V134, P9, DOI 10.1093/jb/mvg107; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Komatsu M, 2004, EMBO J, V23, P1977, DOI 10.1038/sj.emboj.7600205; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Sasakawa H, 2006, BIOCHEM BIOPH RES CO, V343, P21, DOI 10.1016/j.bbrc.2006.02.107; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Tanaka K, 1998, MOL CELLS, V8, P503; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	31	91	99	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5256	5262		10.1074/jbc.M610590200	http://dx.doi.org/10.1074/jbc.M610590200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17182609	hybrid			2022-12-25	WOS:000244482300020
J	Otter, S; Grimmler, M; Neuenkirchen, N; Chari, A; Sickmann, A; Fischer, U				Otter, Simon; Grimmler, Matthias; Neuenkirchen, Nils; Chari, Ashwin; Sickmann, Albert; Fischer, Utz			A comprehensive interaction map of the human survival of motor neuron (SMN) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; SNRNP PROTEINS; GENE-PRODUCT; U-SNRNPS; IN-VITRO; COMPONENT; IDENTIFICATION; SPECIFICITY; EXPRESSION; SEVERITY	Assembly of the Sm-class of U-rich small nuclear ribonucleoprotein particles (U snRNPs) is a process facilitated by the macromolecular survival of motor neuron (SMN) complex. This entity promotes the binding of a set of factors, termed LSm/Sm proteins, onto snRNA to form the core structure of these particles. Nine factors, including the SMN protein, the product of the spinal muscular atrophy (SMA) disease gene, Gemins 2-8 and unrip have been identified as the major components of the SMN complex. So far, however, only little is known about the architecture of this complex and the contribution of individual components to its function. Here, we present a comprehensive interaction map of all core components of the SMN complex based upon in vivo and in vitro methods. Our studies reveal a modular composition of the SMN complex with the three proteins SMN, Gemin8, and Gemin7 in its center. Onto this central building block the other components are bound via multiple interactions. Furthermore, by employing a novel assay, we were able to reconstitute the SMN complex from individual components and confirm the interaction map. Interestingly, SMN protein carrying an SMA-causing mutation was severely impaired in formation of the SMN complex. Finally, we show that the peripheral component Gemin5 contributes an essential activity to the SMN complex, most likely the transfer of Sm proteins onto the U snRNA. Collectively, the data presented here provide a basis for the detailed mechanistic and structural analysis of the assembly machinery of U snRNPs.	Univ Wurzburg, Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany; Deutsch Forschungsgemeinschaft Res Ctr Expt Biome, Rudolf Virchow Ctr, D-97078 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Fischer, U (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany.	utz.fischer@biozentrum.uni-wuerzburg.de	Fischer, Utz/AAT-8422-2020; Chari, Ashwin/ABC-5304-2020; Sickmann, Albert/A-1010-2011; Fischer, Utz/A-4090-2016	Fischer, Utz/0000-0002-1465-6591; Chari, Ashwin/0000-0001-6220-9828; Sickmann, Albert/0000-0002-2388-5265; Fischer, Utz/0000-0002-1465-6591; Grimmler, Matthias/0000-0003-2860-3391				Achsel T, 2001, P NATL ACAD SCI USA, V98, P3685, DOI 10.1073/pnas.071033998; Baccon J, 2002, J BIOL CHEM, V277, P31957, DOI 10.1074/jbc.M203478200; Battle DJ, 2006, MOL CELL, V23, P273, DOI 10.1016/j.molcel.2006.05.036; Berger I, 2004, NAT BIOTECHNOL, V22, P1583, DOI 10.1038/nbt1036; Campbell L, 2000, HUM MOL GENET, V9, P1093, DOI 10.1093/hmg/9.7.1093; Carissimi C, 2006, J BIOL CHEM, V281, P8126, DOI 10.1074/jbc.M512243200; Carissimi C, 2005, FEBS LETT, V579, P2348, DOI 10.1016/j.febslet.2005.03.034; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Feng WQ, 2005, HUM MOL GENET, V14, P1605, DOI 10.1093/hmg/ddi168; GOLEMIS EA, 1999, CURRENT PROTOCOLS MO, V4, P40; Grimmler M, 2005, HUM MOL GENET, V14, P3099, DOI 10.1093/hmg/ddi343; Grimmler M, 2005, EMBO REP, V6, P70, DOI 10.1038/sj.embor.7400301; Gubitz AK, 2004, EXP CELL RES, V296, P51, DOI 10.1016/j.yexcr.2004.03.022; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hebert MD, 2001, GENE DEV, V15, P2720, DOI 10.1101/gad.908401; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; Meister G, 2002, EMBO J, V21, P5853, DOI 10.1093/emboj/cdf585; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Narayanan U, 2004, MOL CELL, V16, P223, DOI 10.1016/j.molcel.2004.09.024; Narayanan U, 2002, HUM MOL GENET, V11, P1785, DOI 10.1093/hmg/11.15.1785; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Pillai RS, 2003, GENE DEV, V17, P2321, DOI 10.1101/gad.274403; Raker VA, 1999, MOL CELL BIOL, V19, P6554; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; Shpargel KB, 2005, P NATL ACAD SCI USA, V102, P17372, DOI 10.1073/pnas.0508947102	35	103	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5825	5833		10.1074/jbc.M608528200	http://dx.doi.org/10.1074/jbc.M608528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17178713	hybrid, Green Published			2022-12-25	WOS:000244482300078
J	Bonshtien, AL; Weiss, C; Vitlin, A; Niv, A; Lorimer, GH; Azem, A				Bonshtien, Anat L.; Weiss, Celeste; Vitlin, Anna; Niv, Adina; Lorimer, George H.; Azem, Abdussalam			Significance of the N-terminal domain for the function of chloroplast cpn20 chaperonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ARABIDOPSIS-THALIANA; MOLECULAR CHAPERONES; PROTEIN; GROES; BINDING; OVEREXPRESSION; IDENTIFICATION; AGGREGATION; SEQUENCE	Chaperonins cpn60 and cpn10 are essential proteins involved in cellular protein folding. Plant chloroplasts contain a unique version of the cpn10 co-chaperonin, cpn20, which consists of two homologous cpn10-like domains (N-cpn20 and C-cpn20) that are connected by a short linker region. Although cpn20 seems to function like other single domain cpn10 oligomers, the structure and specific functions of the domains are not understood. We mutated amino acids in the "mobile loop" regions of N-cpn20, C-cpn20 or both: a highly conserved glycine, which was shown to be important for flexibility of the mobile loop, and a leucine residue shown to be involved in binding of co-chaperonin to chaperonin. The mutant proteins were purified and their oligomeric structure validated by gel filtration, native gel electrophoresis, and circular dichroism. Functional assays of protein refolding and inhibition of GroEL ATPase both showed (i) mutation of the conserved glycine reduced the activity of cpn20, whether in N-cpn20 (G32A) or C-cpn20 (G130A). The same mutation in the bacterial cpn10 (GroES G24A) had no effect on activity. (ii) Mutations in the highly conserved leucine of N-cpn20 (L35A) and in the corresponding L27A of GroES resulted in inactive protein. (iii) In contrast, mutant L133A, in which the conserved leucine of C-cpn20 was altered, retained 55% activity. We conclude that the structure of cpn20 is much more sensitive to alterations in the mobile loop than is the structure of GroES. Moreover, only N-cpn20 is necessary for activity of cpn20. However, full and efficient functioning requires both domains.	Tel Aviv Univ, Dept Biochem, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel; Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	Tel Aviv University; University System of Maryland; University of Maryland College Park	Weiss, C (corresponding author), Tel Aviv Univ, Dept Biochem, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel.	celeste@post.tau.ac.il; azema@tauex.tau.ac.il						AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BANEYX F, 1995, J BIOL CHEM, V270, P10695, DOI 10.1074/jbc.270.18.10695; BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; Bertsch U, 1995, PLANT MOL BIOL, V29, P1039, DOI 10.1007/BF00014976; Boston RS, 1996, PLANT MOL BIOL, V32, P191, DOI 10.1007/BF00039383; Boudker O, 1997, J MOL BIOL, V272, P770, DOI 10.1006/jmbi.1997.1263; Dickson R, 2000, J BIOL CHEM, V275, P11829, DOI 10.1074/jbc.275.16.11829; Eisenstein E, 1998, METHOD ENZYMOL, V290, P119, DOI 10.1016/S0076-6879(98)90011-8; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; Goloubinoff P, 1997, FEBS LETT, V407, P215, DOI 10.1016/S0014-5793(97)00348-7; Gur E, 2002, MOL MICROBIOL, V46, P1391, DOI 10.1046/j.1365-2958.2002.03257.x; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hill JE, 2001, CELL STRESS CHAPERON, V6, P190, DOI 10.1379/1466-1268(2001)006<0190:ATTIAI>2.0.CO;2; Hirohashi T, 1999, BBA-PROTEIN STRUCT M, V1429, P512, DOI 10.1016/S0167-4838(98)00268-4; Koumoto Y, 1999, PLANT J, V17, P467, DOI 10.1046/j.1365-313X.1999.00388.x; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; Levy-Rimler G, 2002, FEBS LETT, V529, P1, DOI 10.1016/S0014-5793(02)03178-2; MILOS P, 1984, J CELL BIOCHEM, V24, P153, DOI 10.1002/jcb.240240206; Richardson A, 1999, GENETICS, V152, P1449; Richardson A, 2001, J BIOL CHEM, V276, P4981, DOI 10.1074/jbc.M008628200; Sharkia R, 2003, BBA-PROTEINS PROTEOM, V1651, P76, DOI 10.1016/S1570-9639(03)00237-1; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VIITANEN PV, 1995, J BIOL CHEM, V270, P18158, DOI 10.1074/jbc.270.30.18158	28	18	20	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4463	4469		10.1074/jbc.M606433200	http://dx.doi.org/10.1074/jbc.M606433200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17178727	hybrid			2022-12-25	WOS:000244482000027
J	Herget, M; Oancea, G; Schrodt, S; Karas, M; Tampe, R; Abele, R				Herget, Meike; Oancea, Giani; Schrodt, Susanne; Karas, Michael; Tampe, Robert; Abele, Rupert			Mechanism of substrate sensing and signal transmission within an ABC transporter - Use of a trojan horse strategy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN-PROCESSING TAP; MYOSIN MOTOR DOMAIN; PEPTIDE-BINDING; TRANSMEMBRANE DOMAINS; ARTIFICIAL PROTEASE; MEMBRANE-PROTEINS; ESCHERICHIA-COLI; P-GLYCOPROTEIN; ATP HYDROLYSIS; COMPLEX	By translocating proteasomal degradation products into the endoplasmic reticulum for loading of major histocompatibility complex I molecules, the ABC transporter TAP plays a focal role in the adaptive immunity against infected or malignantly transformed cells. A key question regarding the transport mechanism is how the quality of the incoming peptide is detected and how this information is transmitted to the ATPase domains. To identify residues involved in this process, we evolved a Trojan horse strategy in which a small artificial protease is inserted into antigenic epitopes. After binding, the TAP backbone in contact is cleaved, allowing the peptide sensor site to be mapped by mass spectrometry. Within this sensor site, we identified residues that are essential for tight coupling of peptide binding and transport. This sensor and transmission interface is restructured during the ATP hydrolysis cycle, emphasizing its important function in the cross-talk between the transmembrane and the nucleotide-binding domains. This allocrite sensor may be similarly positioned in other members of the ABC exporter family.	Univ Frankfurt, Inst Biochem, D-60438 Frankfurt, Germany; Univ Frankfurt, Inst Pharmaceut Chem, Bioctr, D-60438 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Tampe, R (corresponding author), Univ Frankfurt, Inst Biochem, Max Von Laue Str 9, D-60438 Frankfurt, Germany.	tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Abele R, 2004, PHYSIOLOGY, V19, P216, DOI 10.1152/physiol.00002.2004; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; Cresswell P, 2005, IMMUNOL REV, V207, P145, DOI 10.1111/j.0105-2896.2005.00316.x; Dalmas O, 2005, J BIOL CHEM, V280, P36857, DOI 10.1074/jbc.M503266200; Datwyler SA, 2000, TRENDS BIOCHEM SCI, V25, P408, DOI 10.1016/S0968-0004(00)01652-2; Datwyler SA, 2001, MET IONS BIOL SYST, V38, P213; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GHAIM JB, 1995, BIOCHEMISTRY-US, V34, P11311, DOI 10.1021/bi00036a002; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; Gromme M, 1997, EUR J IMMUNOL, V27, P898, DOI 10.1002/eji.1830270415; HAYWARD MM, 1995, J ORG CHEM, V60, P3924, DOI 10.1021/jo00117a056; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Koch J, 2004, J BIOL CHEM, V279, P10142, DOI 10.1074/jbc.M312816200; Koopmann JO, 1996, EUR J IMMUNOL, V26, P1720, DOI 10.1002/eji.1830260809; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; Neumann L, 2002, J MOL BIOL, V324, P965, DOI 10.1016/S0022-2836(02)01148-8; Neumann L, 1999, J MOL BIOL, V294, P1203, DOI 10.1006/jmbi.1999.3329; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; RANA TM, 1991, P NATL ACAD SCI USA, V88, P10578, DOI 10.1073/pnas.88.23.10578; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Sankaran B, 1997, ARCH BIOCHEM BIOPHYS, V341, P160, DOI 10.1006/abbi.1997.9944; Schmidt BD, 2002, BIOCHEMISTRY-US, V41, P4186, DOI 10.1021/bi015582r; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; Schrodt S, 2006, J BIOL CHEM, V281, P6455, DOI 10.1074/jbc.M509784200; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Uebel S, 1997, P NATL ACAD SCI USA, V94, P8976, DOI 10.1073/pnas.94.17.8976; Uebel S, 1999, CURR OPIN IMMUNOL, V11, P203, DOI 10.1016/S0952-7915(99)80034-X; UEBEL S, 1995, J BIOL CHEM, V270, P18512, DOI 10.1074/jbc.270.31.18512; van Endert PM, 2002, TRENDS BIOCHEM SCI, V27, P454, DOI 10.1016/S0968-0004(02)02090-X; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wu JH, 1996, P NATL ACAD SCI USA, V93, P14498, DOI 10.1073/pnas.93.25.14498	41	37	37	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3871	3880		10.1074/jbc.M608480200	http://dx.doi.org/10.1074/jbc.M608480200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17164240	hybrid			2022-12-25	WOS:000244481900051
J	Schwarzer, D; Stummeyer, K; Gerardy-Schahn, R; Muhlenhoff, M				Schwarzer, David; Stummeyer, Katharina; Gerardy-Schahn, Rita; Muehlenhoff, Martina			Characterization of a novel intramolecular chaperone domain conserved in endosialidases and other bacteriophage tail spike and fiber proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P22 TAILSPIKE PROTEIN; ESCHERICHIA-COLI K1; CAPSULAR POLYSACCHARIDE; CRYSTAL-STRUCTURE; POLYSIALIC ACID; KINETIC STABILITY; BACILLUS-SUBTILIS; EVOLUTION; CLEAVAGE; CLONING	Folding and assembly of endosialidases, the trimeric tail spike proteins of Escherichia coli K1-specific bacteriophages, crucially depend on their C-terminal domain (CTD). Homologous CTDs were identified in phage proteins belonging to three different protein families: neck appendage proteins of several Bacillus phages, L-shaped tail fibers of coliphage T5, and K5 lyases, the tail spike proteins of phages infecting E. coli K5. By analyzing a representative of each family, we show that in all cases, the CTD is cleaved off after a strictly conserved serine residue and alanine substitution prevented cleavage. Further structural and functional analyses revealed that (i) CTDs are autonomous domains with a high alpha-helical content; (ii) proteolytically released CTDs assemble into hexamers, which are most likely dimers of trimers; (iii) highly conserved amino acids within the CTD are indispensable for CTD-mediated folding and complex formation; (iv) CTDs can be exchanged between proteins of different families; and (v) proteolytic cleavage is essential to stabilize the native protein complex. Data obtained for full-length and proteolytically processed endosialidase variants suggest that release of the CTD increases the unfolding barrier, trapping the mature trimer in a kinetically stable conformation. In summary, we characterize the CTD as a novel C-terminal chaperone domain, which assists folding and assembly of unrelated phage proteins.	Hannover Med Sch, Abt Zellulare Chem, Zentrum Biochem, D-30625 Hannover, Germany	Hannover Medical School	Muhlenhoff, M (corresponding author), Hannover Med Sch, Abt Zellulare Chem, Zentrum Biochem, Carl Neuberg Str 1, D-30625 Hannover, Germany.	muehlenhoff.martina@mh-hannover.de	Schwarzer, David/C-1939-2012					Ackermann HW, 1999, ADV VIRUS RES, V51, P135; Ali SA, 2003, BIOPHYS J, V85, P2606, DOI 10.1016/S0006-3495(03)74683-9; Botstein D, 1980, Ann N Y Acad Sci, V354, P484, DOI 10.1111/j.1749-6632.1980.tb27987.x; Burda MR, 1999, EUR J BIOCHEM, V265, P771, DOI 10.1046/j.1432-1327.1999.00782.x; CARRASCOSA JL, 1976, EUR J BIOCHEM, V66, P229, DOI 10.1111/j.1432-1033.1976.tb10512.x; Casjens SR, 2005, CURR OPIN MICROBIOL, V8, P451, DOI 10.1016/j.mib.2005.06.014; Clarke BR, 2000, J BACTERIOL, V182, P3761, DOI 10.1128/JB.182.13.3761-3766.2000; CONWAY JF, 1995, J MOL BIOL, V253, P86, DOI 10.1006/jmbi.1995.0538; Cunningham EL, 1999, P NATL ACAD SCI USA, V96, P11008, DOI 10.1073/pnas.96.20.11008; DICKSON RC, 1973, J MOL BIOL, V79, P633, DOI 10.1016/0022-2836(73)90068-5; Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644; Gage MJ, 2003, PROTEIN SCI, V12, P2732, DOI 10.1110/ps.03150303; GERARDYSCHAHN R, 1995, MOL MICROBIOL, V16, P441, DOI 10.1111/j.1365-2958.1995.tb02409.x; GROSS RJ, 1977, J CLIN MICROBIOL, V6, P548; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HELLER K, 1979, J BACTERIOL, V139, P32, DOI 10.1128/JB.139.1.32-38.1979; KALIMAN AV, 1995, FEBS LETT, V366, P46, DOI 10.1016/0014-5793(95)00482-O; Kanamaru S, 2002, NATURE, V415, P553, DOI 10.1038/415553a; Kreisberg JF, 2002, PROTEIN SCI, V11, P820, DOI 10.1110/ps.3440102; KWIATKOWSKI B, 1983, J VIROL, V45, P367, DOI 10.1128/JVI.45.1.367-374.1983; KWIATKOWSKI B, 1982, J VIROL, V43, P697, DOI 10.1128/JVI.43.2.697-704.1982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYING H, 1990, INFECT IMMUN, V58, P222, DOI 10.1128/IAI.58.1.222-227.1990; Lindberg AA, 1977, SURFACE CARBOHYDRATE, P289; Manning M, 2004, BIOCHEMISTRY-US, V43, P11248, DOI 10.1021/bi0491898; MARVIK OJ, 1994, VIROLOGY, V205, P51, DOI 10.1006/viro.1994.1619; Meijer WJJ, 2001, MICROBIOL MOL BIOL R, V65, P261, DOI 10.1128/MMBR.65.2.261-287.2001; Miller ES, 2003, MICROBIOL MOL BIOL R, V67, P86, DOI 10.1128/MMBR.67.1.86-156.2003; Miroshnikov KA, 1998, PROTEIN ENG, V11, P329, DOI 10.1093/protein/11.4.329; Miyake K, 1997, J FERMENT BIOENG, V84, P90, DOI 10.1016/S0922-338X(97)82793-6; Muhlenhoff M, 2003, J BIOL CHEM, V278, P12634, DOI 10.1074/jbc.M212048200; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Papanikolopoulou K, 2004, J BIOL CHEM, V279, P8991, DOI 10.1074/jbc.M311791200; PELKONEN S, 1989, J VIROL, V63, P4409, DOI 10.1128/JVI.63.10.4409-4416.1989; Peterson C, 2001, J STRUCT BIOL, V135, P18, DOI 10.1006/jsbi.2001.4375; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; SARFF LD, 1975, LANCET, V1, P1099; Scholl D, 2001, J VIROL, V75, P2509, DOI 10.1128/JVI.75.6.2509-2515.2001; SMITH HW, 1982, J GEN MICROBIOL, V128, P307; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 2004, METHOD ENZYMOL, V383, P318; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STIRM S, 1971, J VIROL, V8, P330, DOI 10.1128/JVI.8.3.330-342.1971; Stummeyer K, 2005, NAT STRUCT MOL BIOL, V12, P90, DOI 10.1038/nsmb874; Stummeyer K, 2006, MOL MICROBIOL, V60, P1123, DOI 10.1111/j.1365-2958.2006.05173.x; Tao YZ, 1998, CELL, V95, P431, DOI 10.1016/S0092-8674(00)81773-0; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; TOSI ME, 1975, J VIROL, V16, P1282, DOI 10.1128/JVI.16.5.1282-1295.1975; van Raaij MJ, 2001, J MOL BIOL, V314, P1137, DOI 10.1006/jmbi.2000.5204; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; Wang JB, 2005, VIROLOGY, V332, P45, DOI 10.1016/j.virol.2004.10.049; Wang SF, 2003, VIROLOGY, V314, P1, DOI 10.1016/S0042-6822(03)00375-1; Weigele PR, 2003, J BACTERIOL, V185, P4022, DOI 10.1128/JB.185.14.4022-4030.2003; Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002; Zhang YM, 2000, NAT BIOTECHNOL, V18, P1314, DOI 10.1038/82449	55	54	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2821	2831		10.1074/jbc.M609543200	http://dx.doi.org/10.1074/jbc.M609543200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17158460	hybrid			2022-12-25	WOS:000243793900008
J	Hayashi, Y; Aita, T; Toyota, H; Husimi, Y; Urabe, I; Yomo, T				Hayashi, Yuuki; Aita, Takuyo; Toyota, Hitoshi; Husimi, Yuzuru; Urabe, Itaru; Yomo, Tetsuya			Experimental Rugged Fitness Landscape in Protein Sequence Space	PLOS ONE			English	Article							THERMODYNAMICAL INTERPRETATION; EVOLUTIONARY DYNAMICS; ARBITRARY SEQUENCE; ESCHERICHIA-COLI; STRUCTURAL UNITS; INFECTION; SELECTION; REACTOR	The fitness landscape in sequence space determines the process of biomolecular evolution. To plot the fitness landscape of protein function, we carried out in vitro molecular evolution beginning with a defective fd phage carrying a random polypeptide of 139 amino acids in place of the g3p minor coat protein D2 domain, which is essential for phage infection. After 20 cycles of random substitution at sites 12-130 of the initial random polypeptide and selection for infectivity, the selected phage showed a 1.7x10(4)-fold increase in infectivity, defined as the number of infected cells per ml of phage suspension. Fitness was defined as the logarithm of infectivity, and we analyzed (1) the dependence of stationary fitness on library size, which increased gradually, and (2) the time course of changes in fitness in transitional phases, based on an original theory regarding the evolutionary dynamics in Kauffman's n-k fitness landscape model. In the landscape model, single mutations at single sites among n sites affect the contribution of k other sites to fitness. Based on the results of these analyses, k was estimated to be 18-24. According to the estimated parameters, the landscape was plotted as a smooth surface up to a relative fitness of 0.4 of the global peak, whereas the landscape had a highly rugged surface with many local peaks above this relative fitness value. Based on the landscapes of these two different surfaces, it appears possible for adaptive walks with only random substitutions to climb with relative ease up to the middle region of the fitness landscape from any primordial or random sequence, whereas an enormous range of sequence diversity is required to climb further up the rugged surface above the middle region.	[Hayashi, Yuuki; Yomo, Tetsuya] Osaka Univ, Dept Bioinformat Engn, Osaka, Japan; [Aita, Takuyo] Saitama Small Enterprise Promot Corp SKIP City, Rat Evolutionary Design Adv Biomol REDS Grp JST, Kawaguchi, Saitama, Japan; [Aita, Takuyo; Husimi, Yuzuru] Saitama Univ, Dept Funct Mat Sci, Saitama 3388570, Japan; [Toyota, Hitoshi; Urabe, Itaru] Osaka Univ, Dept Biotechnol, Osaka, Japan; [Yomo, Tetsuya] Osaka Univ, Grad Sch Frontier Biosci, Osaka, Japan; [Yomo, Tetsuya] Japan Sci & Technol Agcy JST, Expoloratory Res Adv Technol ERATO, Osaka, Japan	Osaka University; Saitama University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Yomo, T (corresponding author), Osaka Univ, Dept Bioinformat Engn, Osaka, Japan.	yomo@ist.osaka-u.ac.jp	Husimi, Yuzuru/L-5536-2019; Hayashi, Yuuki/Q-7515-2019	Hayashi, Yuuki/0000-0002-7073-0151	21st Century Center of Excellence Program; Ministry of Education, Culture, Sports, Science and Technology, Japan	21st Century Center of Excellence Program(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This research was supported in part by "The 21st Century Center of Excellence Program" and "Special Coordination Funds for Promoting Science and Technology: Yuragi Project" of the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Aita T, 2005, B MATH BIOL, V67, P613, DOI 10.1016/j.bulm.2004.09.004; Aita T, 2004, B MATH BIOL, V66, P1371, DOI 10.1016/j.bulm.2004.01.004; Aita T, 2003, J THEOR BIOL, V225, P215, DOI 10.1016/S0022-5193(03)00240-6; Aita T, 2002, BIOPOLYMERS, V64, P95, DOI 10.1002/bip.10126; Arakawa T, 1996, DNA Res, V3, P87, DOI 10.1093/dnares/3.2.87; Bogarad LD, 1999, P NATL ACAD SCI USA, V96, P2591, DOI 10.1073/pnas.96.6.2591; Chaput JC, 2004, CHEM BIOL, V11, P865, DOI 10.1016/j.chembiol.2004.04.006; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; EIGEN M, 1985, BER BUNSEN PHYS CHEM, V89, P658, DOI 10.1002/bbpc.19850890619; GO M, 1983, P NATL ACAD SCI-BIOL, V80, P1964, DOI 10.1073/pnas.80.7.1964; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; Hayashi Y, 2003, J MOL EVOL, V56, P162, DOI 10.1007/s00239-002-2389-y; Huynen MA, 1996, P NATL ACAD SCI USA, V93, P397, DOI 10.1073/pnas.93.1.397; Ito Y, 2004, J MOL EVOL, V58, P196, DOI 10.1007/s00239-003-2542-2; KAUFFMAN SA, 1989, J THEOR BIOL, V141, P211, DOI 10.1016/S0022-5193(89)80019-0; Kauffman Stuart A., 1993; Keefe AD, 2001, NATURE, V410, P715, DOI 10.1038/35070613; Lipovsek D, 2004, J IMMUNOL METHODS, V290, P51, DOI 10.1016/j.jim.2004.04.008; Marvin DA, 1998, CURR OPIN STRUC BIOL, V8, P150, DOI 10.1016/S0959-440X(98)80032-8; Matsuura T, 1998, PROTEIN ENG, V11, P789, DOI 10.1093/protein/11.9.789; Novella IS, 1999, J VIROL, V73, P1668, DOI 10.1128/JVI.73.2.1668-1671.1999; NOVELLA IS, 1995, P NATL ACAD SCI USA, V92, P5841, DOI 10.1073/pnas.92.13.5841; Prijambada ID, 1996, FEBS LETT, V382, P21, DOI 10.1016/0014-5793(96)00123-8; PrugelBennett A, 1997, J THEOR BIOL, V185, P81, DOI 10.1006/jtbi.1996.0295; Riechmann L, 1997, CELL, V90, P351, DOI 10.1016/S0092-8674(00)80342-6; Roberts RW, 1999, CURR OPIN CHEM BIOL, V3, P268, DOI 10.1016/S1367-5931(99)80042-8; Sambrook J, 2001, MOL CLONING LAB MANU; Schultes EA, 2000, SCIENCE, V289, P448, DOI 10.1126/science.289.5478.448; SCHUSTER P, 1995, J BIOTECHNOL, V41, P239, DOI 10.1016/0168-1656(94)00085-Q; TRAKULNALEAMSAI S, 1995, J FERMENT BIOENG, V79, P107, DOI 10.1016/0922-338X(95)94076-4; Voigt CA, 2001, ADV PROTEIN CHEM, V55, P79; WAGNER CR, 1995, BIOCHEMISTRY-US, V34, P15671, DOI 10.1021/bi00048a011; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; Woodcock G, 1996, J THEOR BIOL, V179, P61, DOI 10.1006/jtbi.1996.0049; Wright S, 1931, GENETICS, V16, P0097; Yamauchi A, 2002, PROTEIN ENG, V15, P619, DOI 10.1093/protein/15.7.619; ZACHER AN, 1980, GENE, V9, P127, DOI 10.1016/0378-1119(80)90171-7	37	37	40	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e96	10.1371/journal.pone.0000096	http://dx.doi.org/10.1371/journal.pone.0000096			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183728	gold, Green Published, Green Submitted			2022-12-25	WOS:000207443600095
J	Klinkenberg, D; Fraser, C; Heesterbeek, H				Klinkenberg, Don; Fraser, Christophe; Heesterbeek, Hans			The Effectiveness of Contact Tracing in Emerging Epidemics	PLOS ONE			English	Article								Background. Contact tracing plays an important role in the control of emerging infectious diseases, but little is known yet about its effectiveness. Here we deduce from a generic mathematical model how effectiveness of tracing relates to various aspects of time, such as the course of individual infectivity, the (variability in) time between infection and symptom-based detection, and delays in the tracing process. In addition, the possibility of iteratively tracing of yet asymptomatic infecteds is considered. With these insights we explain why contact tracing was and will be effective for control of smallpox and SARS, only partially effective for foot-and-mouth disease, and likely not effective for influenza. Methods and Findings. We investigate contact tracing in a model of an emerging epidemic that is flexible enough to use for most infections. We consider isolation of symptomatic infecteds as the basic scenario, and express effectiveness as the proportion of contacts that need to be traced for a reproduction ratio smaller than 1. We obtain general results for special cases, which are interpreted with respect to the likely success of tracing for influenza, smallpox, SARS, and foot-and-mouth disease epidemics. Conclusions. We conclude that (1) there is no general predictive formula for the proportion to be traced as there is for the proportion to be vaccinated; (2) variability in time to detection is favourable for effective tracing; (3) tracing effectiveness need not be sensitive to the duration of the latent period and tracing delays; (4) iterative tracing primarily improves effectiveness when single-step tracing is on the brink of being effective.	[Klinkenberg, Don; Heesterbeek, Hans] Univ Utrecht, Fac Vet Med, Dept Farm Anim Hlth, Utrecht, Netherlands; [Fraser, Christophe] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England	Utrecht University; Imperial College London	Klinkenberg, D (corresponding author), Univ Utrecht, Fac Vet Med, Dept Farm Anim Hlth, Utrecht, Netherlands.	d.klinkenberg@vet.uu.nl	Fraser, Christophe/A-8109-2008	Fraser, Christophe/0000-0003-2399-9657; Heesterbeek, Hans/0000-0001-8537-6418; Klinkenberg, Don/0000-0002-9449-6873	EU Sixth Framework Programme [SP22-CT-2004-511066]; Netherlands Organisation for Scientific Research (NWO) [918.56.620]	EU Sixth Framework Programme(European Commission); Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	The research of D. K. is supported by the EU Sixth Framework Programme for research for policy support (contract SP22-CT-2004-511066). The research of H. H. is supported by the Netherlands Organisation for Scientific Research (NWO grant 918.56.620).	Aldis GK, 2005, MATH BIOSCI, V195, P1, DOI 10.1016/j.mbs.2005.01.006; Becker NG, 2005, MATH BIOSCI, V193, P205, DOI 10.1016/j.mbs.2004.07.006; Bell D, 2006, EMERG INFECT DIS, V12, P81; Diekmann O., 2000, MATH EPIDEMIOLOGY IN; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Eames KTD, 2003, P ROY SOC B-BIOL SCI, V270, P2565, DOI 10.1098/rspb.2003.2554; Eichner M, 2003, AM J EPIDEMIOL, V158, P118, DOI 10.1093/aje/kwg104; Ferguson NM, 2001, NATURE, V413, P542, DOI 10.1038/35097116; Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017; Fraser C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/pnas.0307506101; Jezek Z, 1988, HUMAN MONKEYPOX; Kiss IZ, 2005, P ROY SOC B-BIOL SCI, V272, P1407, DOI 10.1098/rspb.2005.3092; Lloyd-Smith JO, 2003, P ROY SOC B-BIOL SCI, V270, P1979, DOI 10.1098/rspb.2003.2481; Muller J, 2000, MATH BIOSCI, V164, P39, DOI 10.1016/S0025-5564(99)00061-9; Porco TC, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-34	15	128	129	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e12	10.1371/journal.pone.0000012	http://dx.doi.org/10.1371/journal.pone.0000012			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183638	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600012
J	Kang, SG; Brown, AL; Chung, JH				Kang, Sung Gyun; Brown, Alexandra L.; Chung, Jay H.			Oxygen tension regulates the stability of insulin receptor substrate-1 (IRS-1) through caspase-mediated cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATES PHOSPHATIDYLINOSITOL 3-KINASE; COOH-TERMINAL TRUNCATION; OBSTRUCTIVE SLEEP-APNEA; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; 3T3-L1 ADIPOCYTES; SERINE/THREONINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; INDUCED DEGRADATION	The insulin and insulin-like growth factor-1 (IGF-1) receptors mediate signaling for energy uptake and growth through insulin receptor substrates (IRSs), which interact with these receptors as well as with downstream effectors. Oxygen is essential not only for ATP production through oxidative phosphorylation but also for many cellular processes, particularly those involved in energy homeostasis. The oxygen tension in vivo is significantly lower than that in the air and can vary widely depending on the tissue as well as on perfusion and oxygen consumption. How oxygen tension affects IRSs and their functions is poorly understood. Our findings indicate that transient hypoxia (1% oxygen) leads to caspase-mediated cleavage of IRS-1 without inducing cell death. The IRS-1 protein level rebounds rapidly upon return to normoxia. Protein tyrosine phosphatases (PTPs) appear to be important for the IRS-1 cleavage because tyrosine phosphorylation of the insulin receptor was decreased in hypoxia and IRS-1 cleavage could be blocked either with H2O2 or with vanadate, each of which inhibits PTPs. Activity of Akt, a downstream effector of insulin and IGF-1 signaling that is known to suppress caspase activation, was suppressed in hypoxia. Overexpression of dominant-negative Akt led to IRS-1 cleavage even in normoxia, and overexpression of constitutively active Akt partially suppressed IRS-1 cleavage in hypoxia, suggesting that hypoxiamediated suppression of Akt may induce caspase-mediated IRS-1 cleavage. In conclusion, our study elucidates a mechanism by which insulin and IGF-1 signaling can be matched to the oxygen level that is available to support growth and energy metabolism.	NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA; Korea Ocean Res & Dev Inst, Marine Biotechnol Ctr, Seoul 425600, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Korea Institute of Ocean Science & Technology (KIOST)	Chung, JH (corresponding author), NHLBI, Lab Biochem Genet, NIH, Bldg 10,Rm 7D14,10 Ctr Dr, Bethesda, MD 20892 USA.	chungj@nhlbi.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002243, ZIAHL002243] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ANDO S, 1992, J BIOL CHEM, V267, P25709; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Delahaye L, 1998, ENDOCRINOLOGY, V139, P4911, DOI 10.1210/en.139.12.4911; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; FEENER EP, 1993, J BIOL CHEM, V268, P11256; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; Goldstein BJ, 1998, MOL CELL BIOCHEM, V182, P91, DOI 10.1023/A:1006812218502; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Hale LP, 2002, AM J PHYSIOL-HEART C, V282, pH1467, DOI 10.1152/ajpheart.00682.2001; Harsch IA, 2004, AM J RESP CRIT CARE, V169, P156, DOI 10.1164/rccm.200302-206OC; Hartman ME, 2001, BIOCHEM BIOPH RES CO, V280, P776, DOI 10.1006/bbrc.2000.4214; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; KELLER SR, 1993, MOL REPROD DEV, V35, P346, DOI 10.1002/mrd.1080350405; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TIIHONEN M, 1993, J SLEEP RES, V2, P56, DOI 10.1111/j.1365-2869.1993.tb00062.x; Tsai AG, 2003, PHYSIOL REV, V83, P933, DOI 10.1152/physrev.00034.2002; Vasilakos JP, 1997, APOPTOSIS, V2, P289, DOI 10.1023/A:1026489104188; Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	58	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6090	6097		10.1074/jbc.M610659200	http://dx.doi.org/10.1074/jbc.M610659200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17179152	hybrid			2022-12-25	WOS:000244867200014
J	Tsang, VL; Chen, AA; Cho, LM; Jadin, KD; Sah, RL; DeLong, S; West, JL; Bhatia, SN				Tsang, Valerie Liu; Chen, Alice A.; Cho, Lisa M.; Jadin, Kyle D.; Sah, Robert L.; DeLong, Solitaire; West, Jennifer L.; Bhatia, Sangeeta N.			Fabrication of 3D hepatic tissues by additive photopatterning of cellular hydrogels	FASEB JOURNAL			English	Article						tissue engineering; liver; hepatic; PEG; microscale	POLY(VINYL ALCOHOL) HYDROGELS; SOLID FREEFORM FABRICATION; IN-VITRO CULTURE; EXTRACELLULAR-MATRIX; RAT HEPATOCYTES; ADHESION PEPTIDES; SANDWICH CONFIGURATION; BIODEGRADABLE POLYMERS; INTEGRIN EXPRESSION; GLYCOL) HYDROGELS	We have fabricated a hepatic tissue construct using a multilayer photopatteming platform for embedding cells in hydrogels of complex architecture. We first explored the potential of established hepatocyte culture models to stabilize isolated hepatocytes for photoencapsulation (e.g., double gel, Matrigel, cocultivation with nonparenchymal cells). Using photopolymerizable PEG hydrogels, we then tailored both the chemistry and architecture of the hydrogels to further support hepatocyte survival and liver-specific function. Specifically, we incorporated adhesive peptides to ligate key integrins on these adhesion-dependent cells. To identify the appropriate peptides for incorporation, the integrin expression of cultured hepatocytes was monitored by flow cytometry and their functional role in cell adhesion was assessed on full-length extracellular matrix (ECM) molecules and their adhesive peptide domains. In addition, we modified the hydrogel architecture to minimize barriers to nutrient transport for these highly metabolic cells. Viability of encapsulated cells was improved in photopatterned hydrogels with structural features of 500 mu m in width over unpatterned, bulk hydrogels. Based on these findings, we fabricated a multilayer photopatterned PEG hydrogel structure containing the adhesive RGD peptide sequence to ligate the 01501 integrin of cocultured hepatocytes. Three-dimensional photopatterned constructs were visualized by digital volumetric imaging and cultured in a continuous flow bioreactor for 12 d where they performed favorably in comparison to unpatterned, unperfused constructs. These studies will have impact in the field of liver biology as well as provide enabling tools for tissue engineering of other organs.	MIT, Cambridge, MA 02139 USA; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Harvard Mit Div Hlth Sci & Technol, Brigham & Womens Hosp, Div Hlth Sci & Technol, Boston, MA USA; Brigham & Womens Hosp, Dept Elect Engn & Comp Sci, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Med, Boston, MA 02115 USA; Rice Univ, Dept Bioengn, Houston, TX 77251 USA	Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Rice University	Bhatia, SN (corresponding author), MIT, E19-502D,77 Massachusetts Ave, Cambridge, MA 02139 USA.	sbhatia@mit.edu	West, Jennifer L/A-4582-2008	West, Jennifer L/0000-0001-8550-2875				Albrecht DR, 2005, LAB CHIP, V5, P111, DOI 10.1039/b406953f; Albrecht DR, 2006, NAT METHODS, V3, P369, DOI 10.1038/NMETH873; Alhadlaq A, 2005, TISSUE ENG, V11, P556, DOI 10.1089/ten.2005.11.556; Allen JW, 2003, BIOTECHNOL BIOENG, V82, P253, DOI 10.1002/bit.10569; Alsberg E, 2002, P NATL ACAD SCI USA, V99, P12025, DOI 10.1073/pnas.192291499; Aucoin L, 2002, J BIOMAT SCI-POLYM E, V13, P447, DOI 10.1163/156856202320253956; Balis UJ, 1999, METAB ENG, V1, P49, DOI 10.1006/mben.1998.0105; Behravesh E, 2003, J BIOMED MATER RES A, V65A, P260, DOI 10.1002/jbm.a.10461; Bhadriraju K, 2000, BIOMATERIALS, V21, P267, DOI 10.1016/S0142-9612(99)00175-1; Bhatia SN, 1998, J BIOMAT SCI-POLYM E, V9, P1137, DOI 10.1163/156856298X00695; Boland T, 2003, ANAT REC PART A, V272A, P497, DOI 10.1002/ar.a.10059; Brown LA, 2003, IN VITRO CELL DEV-AN, V39, P13; Bryant SJ, 2002, J BIOMED MATER RES, V59, P63, DOI 10.1002/jbm.1217; Bryant SJ, 2003, J BIOMED MATER RES A, V64A, P70, DOI 10.1002/jbm.a.10319; Carlisle ES, 2000, TISSUE ENG, V6, P45, DOI 10.1089/107632700320883; Catapano G, 1996, INT J ARTIF ORGANS, V19, P61, DOI 10.1177/039139889601900110; Cooke MN, 2003, J BIOMED MATER RES B, V64B, P65, DOI 10.1002/jbm.b.10485; Cruise GM, 1998, BIOMATERIALS, V19, P1287, DOI 10.1016/S0142-9612(98)00025-8; Cutler SM, 2003, BIOMATERIALS, V24, P1759, DOI 10.1016/S0142-9612(02)00570-7; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; Davis MW, 1996, BIOMATERIALS, V17, P365, DOI 10.1016/0142-9612(96)85575-X; DEMETRIOU AA, 1986, SCIENCE, V233, P1190, DOI 10.1126/science.2426782; DIXIT V, 1990, HEPATOLOGY, V12, P1342, DOI 10.1002/hep.1840120615; DUNKELMAN NS, 1995, BIOTECHNOL BIOENG, V46, P299, DOI 10.1002/bit.260460402; DUNN JCY, 1989, FASEB J, V3, P174, DOI 10.1096/fasebj.3.2.2914628; DUNN JCY, 1989, FASEB J, V3, P1873; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; Dvir-Ginzberg M, 2003, TISSUE ENG, V9, P757, DOI 10.1089/107632703768247430; Elisseeff J, 2000, J BIOMED MATER RES, V51, P164, DOI 10.1002/(SICI)1097-4636(200008)51:2<164::AID-JBM4>3.0.CO;2-W; Ewald AJ, 2002, DEV DYNAM, V225, P369, DOI 10.1002/dvdy.10169; Garcia AJ, 2002, BIOCHEMISTRY-US, V41, P9063, DOI 10.1021/bi025752f; Gobin AS, 2002, FASEB J, V16, P751, DOI 10.1096/fj.01-0759fje; Gobin AS, 2003, BIOTECHNOL PROGR, V19, P1781, DOI 10.1021/bp0341390; Griffith LG, 2002, ANN NY ACAD SCI, V961, P83, DOI 10.1111/j.1749-6632.2002.tb03056.x; Halstenberg S, 2002, BIOMACROMOLECULES, V3, P710, DOI 10.1021/bm015629o; Hamazaki K, 2002, HEPATO-GASTROENTEROL, V49, P1514; HANSEN LK, 1994, MOL BIOL CELL, V5, P967, DOI 10.1091/mbc.5.9.967; Hasirci V, 2001, TISSUE ENG, V7, P385, DOI 10.1089/10763270152436445; Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B; Houseman BT, 2001, BIOMATERIALS, V22, P943, DOI 10.1016/S0142-9612(00)00259-3; Hutmacher DW, 2001, J BIOMAT SCI-POLYM E, V12, P107, DOI 10.1163/156856201744489; Hwang NS, 2006, STEM CELLS, V24, P284, DOI 10.1634/stemcells.2005-0024; Itle LJ, 2005, BIOTECHNOL PROGR, V21, P926, DOI 10.1021/bp049681i; Jakab K, 2004, P NATL ACAD SCI USA, V101, P2864, DOI 10.1073/pnas.0400164101; Kaihara S, 2000, J PEDIATR SURG, V35, P1287, DOI 10.1053/jpsu.2000.9298; Kaihara S, 2000, TISSUE ENG, V6, P105, DOI 10.1089/107632700320739; Kantlehner M, 2000, CHEMBIOCHEM, V1, P107, DOI 10.1002/1439-7633(20000818)1:2<107::AID-CBIC107>3.0.CO;2-4; Kao WYJ, 1998, BIOTECHNOL BIOENG, V59, P2, DOI 10.1002/(SICI)1097-0290(19980705)59:1<2::AID-BIT2>3.3.CO;2-N; Kato M, 2004, BIOCHEMISTRY-US, V43, P2699, DOI 10.1021/bi0352670; Kim SH, 2003, J BIOMED MATER RES A, V67A, P1351, DOI 10.1002/jbm.a.10166; Kim SS, 2000, TISSUE ENG, V6, P39, DOI 10.1089/107632700320874; Klein TJ, 2003, OSTEOARTHR CARTILAGE, V11, P595, DOI 10.1016/S1063-4584(03)00090-6; Kong HJ, 2005, P NATL ACAD SCI USA, V102, P4300, DOI 10.1073/pnas.0405873102; Koo LY, 2002, J CELL SCI, V115, P1423; Lee H, 2002, TRANSPLANTATION, V73, P1589, DOI 10.1097/00007890-200205270-00011; Leong KF, 2003, BIOMATERIALS, V24, P2363, DOI 10.1016/S0142-9612(03)00030-9; Li Q, 2004, J BIOMED MATER RES A, V68A, P28, DOI 10.1002/jbm.a.20007; Liu VA, 2002, BIOMED MICRODEVICES, V4, P257, DOI 10.1023/A:1020932105236; Lutolf MP, 2003, P NATL ACAD SCI USA, V100, P5413, DOI 10.1073/pnas.0737381100; Mahoney MJ, 2006, BIOMATERIALS, V27, P2265, DOI 10.1016/j.biomaterials.2005.11.007; Mann BK, 2001, BIOMATERIALS, V22, P3045, DOI 10.1016/S0142-9612(01)00051-5; Mann BK, 2001, BIOMATERIALS, V22, P439, DOI 10.1016/S0142-9612(00)00196-4; Mann BK, 1999, BIOMATERIALS, V20, P2281, DOI 10.1016/S0142-9612(99)00158-1; Merzkirch C, 2001, ANAT RECORD, V263, P379, DOI 10.1002/ar.1118; MIYAZAKI M, 1988, ACTA MED OKAYAMA, V42, P351; MOONEY D, 1992, J CELL PHYSIOL, V151, P497, DOI 10.1002/jcp.1041510308; MOONEY DJ, 1995, J CELL SCI, V108, P2311; Mooney DJ, 1997, J BIOMED MATER RES, V37, P413, DOI 10.1002/(SICI)1097-4636(19971205)37:3<413::AID-JBM12>3.0.CO;2-C; Nejjari M, 1999, INT J CANCER, V83, P518, DOI 10.1002/(SICI)1097-0215(19991112)83:4<518::AID-IJC14>3.3.CO;2-H; Nishimura I, 2003, TISSUE ENG, V9, pS77; Nuttelman CR, 2002, BIOMATERIALS, V23, P3617, DOI 10.1016/S0142-9612(02)00093-5; Nuttelman CR, 2001, J BIOMED MATER RES, V57, P217, DOI 10.1002/1097-4636(200111)57:2<217::AID-JBM1161>3.0.CO;2-I; Park KH, 2005, BIOTECHNOL LETT, V27, P1081, DOI 10.1007/s10529-005-8453-0; Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939-6411(00)00090-4; PIERSCHBACHER M, 1983, P NATL ACAD SCI-BIOL, V80, P1224, DOI 10.1073/pnas.80.5.1224; Raeber GP, 2005, BIOPHYS J, V89, P1374, DOI 10.1529/biophysj.104.050682; Sachlos E, 2003, BIOMATERIALS, V24, P1487, DOI 10.1016/S0142-9612(02)00528-8; SAWHNEY AS, 1994, J BIOMED MATER RES, V28, P831, DOI 10.1002/jbm.820280710; Schmedlen KH, 2002, BIOMATERIALS, V23, P4325, DOI 10.1016/S0142-9612(02)00177-1; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shu XZ, 2004, BIOMATERIALS, V25, P1339, DOI 10.1016/j.biomaterials.2003.08.014; Sodian R, 2002, ASAIO J, V48, P12, DOI 10.1097/00002480-200201000-00004; Sun W, 2002, COMPUT METH PROG BIO, V67, P85, DOI 10.1016/S0169-2607(01)00116-X; Taboas JM, 2003, BIOMATERIALS, V24, P181, DOI 10.1016/S0142-9612(02)00276-4; Takezawa T, 2000, TISSUE ENG, V6, P641, DOI 10.1089/10763270050199587; ter Brugge PJ, 2002, TISSUE ENG, V8, P615, DOI 10.1089/107632702760240535; Uyama S, 2001, TRANSPLANTATION, V71, P1226, DOI 10.1097/00007890-200105150-00008; VACANTI JP, 1988, J PEDIATR SURG, V23, P3, DOI 10.1016/S0022-3468(88)80529-3; WEIGEL PH, 1980, J CELL BIOL, V87, P855, DOI 10.1083/jcb.87.3.855; Yoon JJ, 2002, BIOTECHNOL BIOENG, V78, P1, DOI 10.1002/bit.10239; Zajaczkowski MB, 2003, TISSUE ENG, V9, P525, DOI 10.1089/107632703322066705; Zein I, 2002, BIOMATERIALS, V23, P1169, DOI 10.1016/S0142-9612(01)00232-0	93	332	359	3	121	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					790	801		10.1096/fj.06-7117com	http://dx.doi.org/10.1096/fj.06-7117com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197384				2022-12-25	WOS:000244686400017
J	Gautron, J; Murayama, E; Vignal, A; Morisson, M; McKee, MD; Rehault, S; Labas, V; Belghazi, M; Vidal, ML; Nys, Y; Hincke, MT				Gautron, Joel; Murayama, Emi; Vignal, Alain; Morisson, Mireille; McKee, Marc D.; Rehault, Sophie; Labas, Valerie; Belghazi, Maya; Vidal, Mary-Laure; Nys, Yves; Hincke, Maxwell T.			Cloning of ovocalyxin-36, a novel chicken eggshell protein related to lipopolysaccharide-binding proteins, bactericidal permeability-increasing proteins, and plunc family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEINS; ULTRASTRUCTURAL-LOCALIZATION; PROTEOMIC ANALYSIS; GENE-EXPRESSION; HEN; COMPONENT; OVIDUCT; CDNA; BPI; PURIFICATION	The avian eggshell is a composite biomaterial composed of noncalcifying eggshell membranes and the overlying calcified shell matrix. The shell is deposited in a uterine fluid where the concentration of different protein species varies at different stages of its formation. The role of avian eggshell proteins during shell formation remains poorly understood, and we have sought to identify and characterize the individual components in order to gain insight into their function during elaboration of the eggshell. In this study, we have used direct sequencing, immunochemistry, expression screening, and EST data base mining to clone and characterize a 1995-bp full-length cDNA sequence corresponding to a novel chicken eggshell protein that we have named Ovocalyxin-36 (OCX-36). Ovocalyxin-36 protein was only detected in the regions of the oviduct where eggshell formation takes place; uterine OCX-36 message was strongly up-regulated during eggshell calcification. OCX-36 localized to the calcified eggshell predominantly in the inner part of the shell, and to the shell membranes. BlastN data base searching indicates that there is no mammalian version of OCX-36; however, the protein sequence is 20-25% homologous to proteins associated with the innate immune response as follows: lipopolysaccharide-binding proteins, bactericidal permeability-increasing proteins, and Plunc family proteins. Moreover, the genomic organization of these proteins and OCX-36 appears to be highly conserved. These observations suggest that OCX-36 is a novel and specific chicken eggshell protein related to the superfamily of lipopolysaccharide-binding proteins/bactericidal permeability-increasing proteins and Plunc proteins. OCX-36 may therefore participate in natural defense mechanisms that keep the egg free of pathogens.	INRA, UR83, Unite Rech Avicoles, F-37380 Nouzilly, France; Inst Pasteur, Unite Macrophages & Dev Immun, F-75724 Paris, France; INRA, UR 444, Lab Genet Cellulaire, F-31326 Castanet Tolosan, France; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Fac Dent, Montreal, PQ H3A 2B2, Canada; INRA, UMR85, Serv Spectrometrie Masse & Proteom, F-37380 Nouzilly, France; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada	INRAE; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; INRAE; McGill University; McGill University; INRAE; University of Ottawa	Gautron, J (corresponding author), INRA, UR83, Unite Rech Avicoles, F-37380 Nouzilly, France.	gautron@tours.inra.fr	McKee, Marc D/E-2187-2011; REHAULT-GODBERT, Sophie/Y-3890-2019; GAUTRON, Joël/A-1753-2017; Vignal, Alain/AAJ-5697-2021; Vignal, Alain/I-6253-2017	McKee, Marc D/0000-0001-8349-965X; GAUTRON, Joël/0000-0001-7800-0578; Vignal, Alain/0000-0002-6797-2125; Vignal, Alain/0000-0002-6797-2125; Murayama, Emi/0000-0002-5311-1594; Rehault-Godbert, Sophie/0000-0003-2800-3417				Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; Bingle CD, 2004, TRENDS IMMUNOL, V25, P53, DOI 10.1016/j.it.2003.11.007; Boardman PE, 2002, CURR BIOL, V12, P1965, DOI 10.1016/S0960-9822(02)01296-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cabra V, 2006, BBA-PROTEINS PROTEOM, V1764, P1110, DOI 10.1016/j.bbapap.2006.04.002; Carre W, 2006, PHYSIOL GENOMICS, V25, P514, DOI 10.1152/physiolgenomics.00207.2005; Carrino DA, 1997, CONNECT TISSUE RES, V36, P175, DOI 10.3109/03008209709160219; Fernandez MS, 2003, J STRUCT BIOL, V143, P171, DOI 10.1016/j.jsb.2003.08.007; Fernandez MS, 2001, MATRIX BIOL, V19, P793, DOI 10.1016/S0945-053X(00)00128-1; Gautron J, 2001, CONNECT TISSUE RES, V42, P255, DOI 10.3109/03008200109016840; Gautron J, 2001, J BIOL CHEM, V276, P39243, DOI 10.1074/jbc.M104543200; Gautron J, 1997, CONNECT TISSUE RES, V36, P195, DOI 10.3109/03008209709160220; Gautron J., 2003, P 8 INT S BIOM KAN J, P163; GRAY PW, 1989, J BIOL CHEM, V264, P9505; Guerin-Dubiard C, 2006, J AGR FOOD CHEM, V54, P3901, DOI 10.1021/jf0529969; HARRIS ED, 1980, SCIENCE, V208, P55, DOI 10.1126/science.6102412; Hincke M.T., 2000, CHEM BIOL MINERALIZE, P13; Hincke MT, 2003, CONNECT TISSUE RES, V44, P16, DOI 10.1080/03008200390152025; HINCKE MT, 1995, CALCIFIED TISSUE INT, V56, P578, DOI 10.1007/BF00298593; Hincke MT, 1999, J BIOL CHEM, V274, P32915, DOI 10.1074/jbc.274.46.32915; Hincke MT, 1995, CONNECT TISSUE RES, V31, P227, DOI 10.3109/03008209509010814; Hincke MT, 2000, MATRIX BIOL, V19, P443, DOI 10.1016/S0945-053X(00)00095-0; Hubacek JA, 1997, BIOCHEM BIOPH RES CO, V236, P427, DOI 10.1006/bbrc.1997.6970; *I NAT RECH AGR, 1989, AL AN MOIN PORC LAP; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lavelin I, 2002, AM J PHYSIOL-REG I, V283, pR853, DOI 10.1152/ajpregu.00088.2002; Lavelin I, 2001, AM J PHYSIOL-REG I, V281, pR1169, DOI 10.1152/ajpregu.2001.281.4.R1169; Lavelin I, 1998, MATRIX BIOL, V17, P615, DOI 10.1016/S0945-053X(98)90112-3; Mann K, 2003, MATRIX BIOL, V22, P397, DOI 10.1016/S0945-053X(03)00072-6; Mann K, 1999, BIOCHEM MOL BIOL INT, V47, P997; Mann K, 1999, FEBS LETT, V463, P12, DOI 10.1016/S0014-5793(99)01586-0; Mann K, 2006, PROTEOMICS, V6, P3801, DOI 10.1002/pmic.200600120; MCKEE MD, 1995, MICROSC RES TECHNIQ, V31, P44, DOI 10.1002/jemt.1070310105; Messens W, 2005, WORLD POULTRY SCI J, V61, P71, DOI 10.1079/WPS200443; Mine Y, 2003, J AGR FOOD CHEM, V51, P249, DOI 10.1021/jf020597x; Morisson M, 2002, GENET SEL EVOL, V34, P521, DOI [10.1051/gse:2002021, 10.1186/1297-9686-34-4-521]; NAU F, 2002, 11 EUR POULTR C BREM; Nys Y, 2004, CR PALEVOL, V3, P549, DOI 10.1016/j.crpv.2004.08.002; Pines M, 1995, MATRIX BIOL, V14, P765, DOI 10.1016/S0945-053X(05)80019-8; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; THIEDE MA, 1991, ENDOCRINOLOGY, V129, P1958, DOI 10.1210/endo-129-4-1958	42	91	98	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5273	5286		10.1074/jbc.M610294200	http://dx.doi.org/10.1074/jbc.M610294200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17179153	hybrid, Green Published			2022-12-25	WOS:000244482300022
J	Raman, P; Krukovets, I; Marinic, TE; Bornstein, P; Stenina, OI				Raman, Priya; Krukovets, Irene; Marinic, Tina E.; Bornstein, Paul; Stenina, Olga I.			Glycosylation mediates up-regulation of a potent antiangiogenic and proatherogenic protein, thrombospondin-1, by glucose in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; MYOCARDIAL-INFARCTION; HEXOSAMINE PATHWAY; INSULIN-RESISTANCE; DIABETES-MELLITUS; MESANGIAL CELLS; EXPRESSION; PROLIFERATION; STIMULATION; POLYMORPHISMS	Accelerated development of atherosclerotic lesions remains the most frequent and dangerous complication of diabetes, accounting for 80% of deaths among diabetics. However, our understanding of the pathways mediating glucose-induced gene expression in vascular cells remains controversial and incomplete. We have identified an intracellular metabolic pathway activated by high glucose in human aortic smooth muscle cells that mediates up-regulation of thrombospondin-1 (TSP-1). TSP-1 is a potent antiangiogenic and proatherogenic protein that may represent an important link between diabetes and vascular complications. Using different glucose analogs and metabolites sharing distinct, limited metabolic steps with glucose, we demonstrated that activation of TSP-1 transcription is mediated by the hexosamine pathway of glucose catabolism, possibly resulting in modulation of the activity of nuclear proteins activity through their glycosylation. Specific inhibitors of glutamine: fructose 6-phosphate amidotransferase (GFAT), an enzyme controlling the hexosamine pathway, as well as direct inhibitors of protein glycosylation efficiently inhibited TSP-1 transcription and the activity of a TSP-1 promoter-reporter construct stimulated by high glucose. Overexpression of recombinant GFAT resulted in increased TSP-1 levels. Pharmacological inhibition of GFAT or protein glycosylation inhibited increased proliferation of human aortic smooth muscle cells caused by glucose. We have demonstrated that the hexosamine metabolic pathway mediates up-regulation of TSP-1 by high glucose. Our results suggest that the hexosamine pathway and intracellular glycosylation may control important steps in initiation and development of atherosclerotic lesions.	Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA	Cleveland Clinic Foundation; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Stenina, OI (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, 9500 Euclid Ave,NB50, Cleveland, OH 44195 USA.	stenino@ccf.org		, Olga/0000-0002-1256-0545	NHLBI NIH HHS [P50 HL077107] Funding Source: Medline; NIDDK NIH HHS [R01 DK067532, K01 DK62128] Funding Source: Medline; PHS HHS [R01 45418] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL077107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK062128, R01DK067532] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Armstrong LC, 2002, MOL BIOL CELL, V13, P1893, DOI 10.1091/mbc.E01-09-0066; Aronson D, 1996, J AM COLL CARDIOL, V27, P528, DOI 10.1016/0735-1097(95)00496-3; Barzilay JI, 2001, DIABETES CARE, V24, P1233, DOI 10.2337/diacare.24.7.1233; BAYRAKTAR M, 1994, J INT MED RES, V22, P90, DOI 10.1177/030006059402200204; Boekholdt SM, 2002, ARTERIOSCL THROM VAS, V22, pE24, DOI 10.1161/01.ATV.0000046235.22451.66; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Carpentier M, 2005, BIOCHEMISTRY-US, V44, P5804, DOI 10.1021/bi047831s; Chen GL, 2003, FEBS LETT, V534, P54, DOI 10.1016/S0014-5793(02)03774-2; CODY M, 2005, CIRCULATION, V112, P164; Cui JX, 2004, ARTERIOSCL THROM VAS, V24, pE183, DOI 10.1161/01.ATV.0000147304.67100.ee; Faries PL, 2001, J VASC SURG, V33, P601, DOI 10.1067/mva.2001.111806; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Guo NH, 1997, CANCER RES, V57, P1735; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Isenberg JS, 2005, MATRIX BIOL, V24, P110, DOI 10.1016/j.matbio.2005.01.002; James LR, 2000, AM J PHYSIOL-RENAL, V279, pF718, DOI 10.1152/ajprenal.2000.279.4.F718; James LR, 2002, DIABETES, V51, P1146, DOI 10.2337/diabetes.51.4.1146; Kato T, 2003, CIRCULATION, V108, P712; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; Marso S P, 1999, Semin Interv Cardiol, V4, P129; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; Musicki B, 2005, P NATL ACAD SCI USA, V102, P11870, DOI 10.1073/pnas.0502488102; Nathan DM, 2003, NEW ENGL J MED, V348, P761; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Olson BA, 1999, PHARMACOLOGY, V58, P200, DOI 10.1159/000028282; Poczatek MH, 2000, AM J PATHOL, V157, P1353, DOI 10.1016/S0002-9440(10)64649-4; POLET H, 1988, J CELL PHYSIOL, V135, P47, DOI 10.1002/jcp.1041350107; RAUGI GJ, 1990, AM J PATHOL, V137, P179; Ridnour LA, 2005, P NATL ACAD SCI USA, V102, P13147, DOI 10.1073/pnas.0502979102; Riessen R, 1998, AM HEART J, V135, P357, DOI 10.1016/S0002-8703(98)70105-X; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; Sajid M, 2001, J INVEST MED, V49, P398, DOI 10.2310/6650.2001.33784; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; Sheetz MJ, 2002, JAMA-J AM MED ASSOC, V288, P2579, DOI 10.1001/jama.288.20.2579; Stenina OI, 2005, CURR PHARM DESIGN, V11, P2367, DOI 10.2174/1381612054367283; Stenina OI, 2003, CIRCULATION, V107, P3209, DOI 10.1161/01.CIR.0000074223.56882.97; Stouffer GA, 1998, CIRCULATION, V97, P907, DOI 10.1161/01.CIR.97.9.907; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; Tschoepe D, 1997, HORM METAB RES, V29, P631, DOI 10.1055/s-2007-979115; Walton B, 2003, CIRCULATION, V108, P771; Wang SX, 2004, J BIOL CHEM, V279, P34311, DOI 10.1074/jbc.M401629200; Wang SX, 2003, DIABETES, V52, P2144, DOI 10.2337/diabetes.52.8.2144; Weigert C, 2004, J BIOL CHEM, V279, P15908, DOI 10.1074/jbc.M313524200; Weigert C, 2003, DIABETOLOGIA, V46, P852, DOI 10.1007/s00125-003-1122-8; Wells L, 2003, FEBS LETT, V546, P154, DOI 10.1016/S0014-5793(03)00641-0; Wessel J, 2004, AM HEART J, V147, P905, DOI 10.1016/j.ahj.2003.12.013; Whelan SA, 2003, CIRC RES, V93, P1047, DOI 10.1161/01.RES.0000103190.20260.37; Yamada Y, 2002, NEW ENGL J MED, V347, P1916, DOI 10.1056/NEJMoa021445; Zhao XM, 2001, CIRCULATION, V103, P525, DOI 10.1161/01.CIR.103.4.525; Zwicker JI, 2006, BLOOD, V108, P1280, DOI 10.1182/blood-2006-04-015701	58	67	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5704	5714		10.1074/jbc.M610965200	http://dx.doi.org/10.1074/jbc.M610965200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17178709	hybrid			2022-12-25	WOS:000244482300067
J	Saigusa, K; Imoto, I; Tanikawa, C; Aoyagi, M; Ohno, K; Nakamura, Y; Inazawa, J				Saigusa, K.; Imoto, I.; Tanikawa, C.; Aoyagi, M.; Ohno, K.; Nakamura, Y.; Inazawa, J.			RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest	ONCOGENE			English	Article						RGC32; p53; Plk1; glioma; array-CGH	COMPARATIVE GENOMIC HYBRIDIZATION; POLO-LIKE KINASES; MULTIPLE-MYELOMA; CHROMOSOME 13Q; CANCER-CELLS; TUMOR; PLK1; P53; AMPLIFICATION; GLIOBLASTOMAS	To identify target genes for the hemizygous deletions of chromosome 13 that are recurrently observed in malignant gliomas, we performed genome-wide DNA copy-number analysis using array-based comparative genomic hybridization and gene expression analysis using an oligonucleotide-array. The response gene to complement 32 (RGC32) at 13q14.11 was identified as a deletion target, and its expression was frequently silenced in glioma cell lines compared with normal brain. Levels of RGC32 mRNA tended to decrease toward higher grades of primary astrocytomas, especially in tumors with mutations of p53. Expression of RGC32 mRNA was dramatically increased by exogenous p53 in a p53-mutant glioma cell line, and also by endogenous p53 in response to DNA damage in p53(+/+) colon-cancer cells, but not in isogenic p53(-/-) cells. Chromatin immunoprecipitation and reporter assays demonstrated binding of endogenous p53 protein to the promoter region of the RGC32 gene, implying p53-dependent transcriptional activity. Transiently and stably overexpressed RGC32 suppressed the growth of glioma cells, probably owing to induction of G2/M arrest. Immunocytochemical analysis revealed a concentration of RGC32 protein at the centrosome during mitosis. RGC32 formed a protein complex with polo-like kinase 1 and was phosphorylated in vitro. These observations implied a novel mechanism by which p53 might negatively regulate cell-cycle progression by way of this newly identified transcriptional target. Our results provide the first evidence that RGC32 might be a possible tumor-suppressor for glioma, that it is directly induced by p53, and that it mediates the arrest of mitotic progression.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Neurosurg, Tokyo 1138510, Japan; Japan Sci & Technol Corp, JST, CREST, Tokyo, Japan; Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1138510, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo, Japan; Tokyo Med & Dent Univ, Century Ctr Excellence Program Mol Destruct & Rec, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU); University of Tokyo; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Imoto, Issei/AAD-5799-2020	Tanikawa, Chizu/0000-0003-4759-4793				Badea T, 2002, J BIOL CHEM, V277, P502, DOI 10.1074/jbc.M109354200; Badea TC, 1998, J BIOL CHEM, V273, P26977, DOI 10.1074/jbc.273.41.26977; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Burns KL, 1998, J NEUROPATH EXP NEUR, V57, P122, DOI 10.1097/00005072-199802000-00003; Dietzmann K, 2001, J NEURO-ONCOL, V53, P1, DOI 10.1023/A:1011808200978; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Imoto I, 2003, CANCER RES, V63, P5691; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Inda MD, 2003, MOL CARCINOGEN, V36, P6, DOI 10.1002/mc.10085; Inoue J, 2004, AM J PATHOL, V165, P71, DOI 10.1016/S0002-9440(10)63276-2; Jongsma APM, 2002, J CLIN PATHOL-MOL PA, V55, P305, DOI 10.1136/mp.55.5.305; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kunwar S, 2001, CANCER RES, V61, P7683; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Lu W, 2006, PROSTATE, V66, P405, DOI 10.1002/pros.20363; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; MIYASHITA T, 1995, CELL, V80, P293; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nakamura M, 2001, CARCINOGENESIS, V22, P1715, DOI 10.1093/carcin/22.10.1715; Nishizaki T, 1998, GENE CHROMOSOME CANC, V21, P340, DOI 10.1002/(SICI)1098-2264(199804)21:4<340::AID-GCC8>3.0.CO;2-Z; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Okamoto Y, 2004, ACTA NEUROPATHOL, V108, P49, DOI 10.1007/s00401-004-0861-z; Pan HJ, 2005, CANCER RES, V65, P1664, DOI 10.1158/0008-5472.CAN-04-3297; Saigusa K, 2005, CANCER SCI, V96, P676, DOI 10.1111/j.1349-7006.2005.00099.x; SATO T, 1991, CANCER RES, V51, P5794; Shaughnessy J, 2000, BLOOD, V96, P1505, DOI 10.1182/blood.V96.4.1505.h8001505_1505_1511; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Takada H, 2005, CANCER SCI, V96, P100, DOI 10.1111/j.1349-7006.2005.00016.x; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	41	59	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1110	1121		10.1038/sj.onc.1210148	http://dx.doi.org/10.1038/sj.onc.1210148			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	17146433				2022-12-25	WOS:000244406400002
J	Operana, TN; Tukey, RH				Operana, Theresa N.; Tukey, Robert H.			Oligomerization of the UDP-glucuronosyltransferase 1A proteins - Homo- and heterodimerization analysis by fluorescence resonance energy transfer and co-immunoprecipitation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-METABOLIZING-ENZYMES; CYTOCHROME P450 REDUCTASE; HUMAN BILIRUBIN; LIVING CELLS; EXPRESSION; LOCALIZATION; ISOZYMES; PHENOL; GENE; INHIBITION	UDP-glucuronosyltransferases (UGTs) are membrane-bound proteins localized to the endoplasmic reticulum and catalyze the formation of beta-D-glucopyranosiduronic acids (glucuronides) using UDP-glucuronic acid and acceptor substrates such as drugs, steroids, bile acids, xenobiotics, and dietary nutrients. Recent biochemical evidence indicates that the UGT proteins may oligomerize in the membrane, but conclusive evidence is still lacking. In the present study, we have used fluorescence resonance energy transfer (FRET) to study UGT1A oligomerization in live cells. This technique demonstrated that UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, and UGT1A10 self-oligomerize (homodimerize). Heterodimer interactions were also explored, and it was determined that UGT1A1 was capable of binding with UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, and UGT1A10. In addition to the in vivo FRET analysis, UGT1A protein-protein interactions were demonstrated through co-immunoprecipitation experiments. Co-expression of hemagglutinin-tagged and cyan fluorescent protein-tagged UGT1A proteins, followed by immunoprecipitation with anti-hemagglutinin beads, illustrated the potential of each UGT1A protein to homodimerize. Co-immunoprecipitation results also confirmed that UGT1A1 was capable of forming heterodimer complexes with all of the UGT1A proteins, corroborating the FRET results in live cells. These preliminary studies suggest that the UGT1A family of proteins form oligomerized complexes in the membrane, a property that may influence function and substrate selectivity.	Univ Calif San Diego, Dept Chem & Biochem, Lab Environm Toxicol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, Lab Environm Toxicol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Tukey, RH (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Lab Environm Toxicol, La Jolla, CA 92093 USA.	rtukey@ucsd.edu			NIGMS NIH HHS [GM49135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Backes WL, 1998, BIOCHEMISTRY-US, V37, P12852, DOI 10.1021/bi980674a; Beaulieu M, 1997, DNA CELL BIOL, V16, P1143, DOI 10.1089/dna.1997.16.1143; BOSMA PJ, 1994, J BIOL CHEM, V269, P17960; CAWLEY GF, 1995, BIOCHEMISTRY-US, V34, P1244, DOI 10.1021/bi00004a018; CHEN F, 1993, BIOCHEMISTRY-US, V32, P10648, DOI 10.1021/bi00091a015; Chouinard S, 2006, MOL PHARMACOL, V69, P908, DOI 10.1124/mol.105.015891; Clegg R.M., 1996, FLUORESCENCE IMAGING; Dutton G.F., 1980, GLUCURONIDATION DRUG; Fremont JJ, 2005, MOL PHARMACOL, V67, P260, DOI 10.1124/mol.104.006361; Ghosh SS, 2001, J BIOL CHEM, V276, P42108, DOI 10.1074/jbc.M106742200; HARDING D, 1990, ANN HUM GENET, V54, P17, DOI 10.1111/j.1469-1809.1990.tb00356.x; Heydel JM, 2001, MOL BRAIN RES, V90, P83, DOI 10.1016/S0169-328X(01)00080-8; Hum DW, 1999, J STEROID BIOCHEM, V69, P413, DOI 10.1016/S0960-0760(99)00061-8; Ikushiro S, 1997, BIOCHEMISTRY-US, V36, P7154, DOI 10.1021/bi9702344; Ishii Y, 2005, FRONT BIOSCI-LANDMRK, V10, P887, DOI 10.2741/1583; Koiwai O, 1996, HUM MOL GENET, V5, P645, DOI 10.1093/hmg/5.5.645; Kurkela M, 2004, BIOCHEM PHARMACOL, V68, P2443, DOI 10.1016/j.bcp.2004.08.019; Kurkela M, 2003, J BIOL CHEM, V278, P3536, DOI 10.1074/jbc.M206136200; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Latif R, 2002, J BIOL CHEM, V277, P45059, DOI 10.1074/jbc.M206693200; Li Q, 1997, J BIOL CHEM, V272, P3272, DOI 10.1074/jbc.272.6.3272; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; Meech R, 1997, J BIOL CHEM, V272, P26913, DOI 10.1074/jbc.272.43.26913; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Monaghan G, 1997, MAMM GENOME, V8, P692, DOI 10.1007/s003359900539; MONAGHAN G, 1994, GENOMICS, V23, P496, DOI 10.1006/geno.1994.1531; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; RITTER JK, 1992, J BIOL CHEM, V267, P3257; Schmid JA, 2001, BIOCHEM SOC T, V29, P732, DOI 10.1042/0300-5127:0290732; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; SIEGEL RM, 2000, SCI STKE, pL1; SRIVASTAVA DK, 1987, BIOCHEMISTRY-US, V26, P1240, DOI 10.1021/bi00379a006; Szczesna-Skorupa E, 2003, J BIOL CHEM, V278, P31269, DOI 10.1074/jbc.M301489200; Takeda S, 2006, DRUG METAB DISPOS, V34, P1277, DOI 10.1124/dmd.106.009738; Tan YZ, 1997, ARCH BIOCHEM BIOPHYS, V342, P82, DOI 10.1006/abbi.1997.9995; Taura K, 2000, BIOCHEM BIOPH RES CO, V273, P1048, DOI 10.1006/bbrc.2000.3076; Thibaudeau J, 2006, CANCER RES, V66, P125, DOI 10.1158/0008-5472.CAN-05-2857; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Tukey RH, 2001, MOL PHARMACOL, V59, P405, DOI 10.1124/mol.59.3.405; van Kuppeveld FJM, 2002, J VIROL, V76, P9446, DOI 10.1128/JVI.76.18.9446-9456.2002; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465; Yamazaki H, 1997, ARCH BIOCHEM BIOPHYS, V342, P329, DOI 10.1006/abbi.1997.0125; Youvan D. C., 1997, BIOTECHNOLOGY, V3, P1; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	45	57	58	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4821	4829		10.1074/jbc.M609417200	http://dx.doi.org/10.1074/jbc.M609417200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17179145	hybrid			2022-12-25	WOS:000244482000064
J	Sanchez, M; Sauve, K; Picard, N; Tremblay, A				Sanchez, Melanie; Sauve, Karine; Picard, Nathalie; Tremblay, Andre			The hormonal response of estrogen receptor beta is decreased by the phosphatidylinositol 3-kinase/Akt pathway via a phosphorylation-dependent release of CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; ERBB RECEPTORS; TRANSCRIPTIONAL COACTIVATOR; NEOPLASTIC TRANSFORMATION; KINASE PATHWAY; LIVING CELLS; ALPHA; ACTIVATION; CBP; PROTEASOME	The hormonal response of estrogen receptors (ER) a and ER beta is controlled by a number of cofactors, including the general transcriptional coactivator CREB-binding protein (CBP). Growing evidence suggests that specific kinase signaling events also modulate the formation and activity of the ER coactivation complex. Here we show that ER beta activity and target gene expression are decreased upon activation of ErbB2/ErbB3 receptors despite the presence of CBP. This inhibition of ER beta involved activation of the phosphatidylinositol 3-kinase/Akt pathway, abrogating the potential of CBP to facilitate ER beta response to estrogen. Such reduced activity was associated with an impaired ability of ER beta to recruit CBP upon activation of Akt. Mutation of serine 255, an Akt consensus site contained in the hinge region of ERP, prevented the release of CBP and rendered ER beta transcriptionally more responsive to CBP coactivation, suggesting that Ser-255 may serve as a regulatory site to restrain ER beta activity in Akt-activated cells. In contrast, we found that CBP intrinsic activity was increased by Akt through threonine 1872, a consensus site for Akt in the cysteine- and histidine-rich 3 domain of CBP, indicating that such enhanced transcriptional potential of CBP did not serve to activate ER beta. Interestingly, nuclear receptors sharing a conserved Akt consensus site with ER beta also exhibit a reduced ability to be coactivated by CBP, whereas others missing that site were able to benefit from the activation of CBP by Akt. These results therefore outline a regulatory mechanism by which the phosphatidylinositol 3-kinase/Akt pathway may discriminate nuclear receptor response through coactivator transcriptional competence.	Hop St Justine, Ctr Rech, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Obstet & Gynecol, Montreal, PQ H3T 1C5, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Tremblay, A (corresponding author), Hop St Justine, Ctr Rech, Montreal, PQ H3T 1C5, Canada.	andre.tremblay@recherche-ste-justine.qc.ca						Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Ariazi EA, 2006, CURR TOP MED CHEM, V6, P203, DOI 10.2174/1568026610606030203; Avallone R, 2006, MOL ENDOCRINOL, V20, P3165, DOI 10.1210/me.2006-0146; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Cvoro A, 2006, MOL CELL, V21, P555, DOI 10.1016/j.molcel.2006.01.014; deFazio A, 2000, INT J CANCER, V87, P487, DOI 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J; DeFranco DB, 2002, MOL ENDOCRINOL, V16, P1449, DOI 10.1210/me.16.7.1449; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Driggers PH, 2001, J BIOL CHEM, V276, P46792, DOI 10.1074/jbc.M106927200; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Garat CV, 2006, MOL CELL BIOL, V26, P4934, DOI 10.1128/MCB.02477-05; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; Goodman RH, 2000, GENE DEV, V14, P1553; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jaber Basem M, 2006, Mol Endocrinol, V20, P2695, DOI 10.1210/me.2005-0218; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; McManus KJ, 2001, BIOCHEM CELL BIOL, V79, P253, DOI 10.1139/bcb-79-3-253; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nicholson KM, 2003, BREAST CANCER RES TR, V81, P117, DOI 10.1023/A:1025765215765; Pearce ST, 2004, CRIT REV ONCOL HEMAT, V50, P3, DOI 10.1016/j.critrevonc.2003.09.003; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; SANCHEZ M, 2005, MOL GENETICS CANC, P149; Schaufele F, 2000, MOL ENDOCRINOL, V14, P2024, DOI 10.1210/me.14.12.2024; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; St-Laurent V, 2005, J STEROID BIOCHEM, V94, P23, DOI 10.1016/j.jsbmb.2005.02.001; Stal O, 2003, BREAST CANCER RES, V5, pR37, DOI 10.1186/bcr569; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Stenoien DL, 2001, MOL CELL BIOL, V21, P4404, DOI 10.1128/MCB.21.13.4404-4412.2001; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tremblay A, 2001, J STEROID BIOCHEM, V77, P19, DOI 10.1016/S0960-0760(01)00031-0; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; Vilgelm A, 2006, CANCER RES, V66, P3375, DOI 10.1158/0008-5472.CAN-05-4019; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Weatherman RV, 2002, MOL ENDOCRINOL, V16, P487, DOI 10.1210/me.16.3.487; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401	60	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4830	4840		10.1074/jbc.M607908200	http://dx.doi.org/10.1074/jbc.M607908200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17166829	hybrid			2022-12-25	WOS:000244482000065
J	Bhaskaran, M; Kolliputi, N; Wang, Y; Gou, DM; Chintagari, NR; Liu, L				Bhaskaran, Manoj; Kolliputi, Narasaiah; Wang, Yang; Gou, Deming; Chintagari, Narendranath Reddy; Liu, Lin			Trans-differentiation of alveolar epithelial type II cells to type I cells involves autocrine signaling by transforming growth factor beta 1 through the Smad pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; PULMONARY-FIBROSIS; C-MYC; MONOCLONAL-ANTIBODIES; CYCLE ARREST; EXPRESSION; RAT; PROLIFERATION; REPRESSION; INHIBITOR	Type II alveolar epithelial cells (AEC II) proliferate and trans-differentiate into type I alveolar epithelial cells (AEC I) when the normal AEC I population is damaged in the lung alveoli. We hypothesized that signaling by transforming growth factor beta 1 (TGF beta 1), through its downstream Smad proteins, is involved in keeping AEC II quiescent in normal cells and its altered signaling may be involved in the trans-differentiation of AEC II to AEC I. In the normal lung, TGF beta 1 and Smad4 were highly expressed in AEC II. Using an in vitro cell culture model, we demonstrated that the trans-differentiation of AEC II into AEC I-like cells began with a proliferative phase, followed by a differentiation phase. The expression of TGF beta 1, Smad2, and Samd3 and their phosphorylated protein forms, and cell cycle inhibitors, p15(Ink4b) and p21(Cip1), was lower during the proliferative phase but higher during the differentiation phase. Furthermore, cyclin-dependent kinases 2, 4, and 6 showed an opposite trend of expression. TGF beta 1 secretion into the media increased during the differentiation phase, indicating an autocrine regulation. The addition of TGF beta 1 neutralizing antibody after the proliferative phase and silencing of Smad4 by RNA interference inhibited the trans-differentiation process. In summary, our results suggest that the trans-differentiation of AEC II to AEC I is modulated by signaling through the Smad-dependent TGF beta 1 pathway by altering the expression of proteins that control the G, to S phase entry in the cell cycle.	Oklahoma State Univ, Coll Vet Med, Dept Physiol Sci, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Liu, L (corresponding author), 246 McElroy Hall, Stillwater, OK 74078 USA.	lin.liu@okstate.edu	Wang, Yang/G-4496-2014; Kolliputi, Narasaiah/I-6050-2012	Wang, Yang/0000-0002-2626-478X; Kolliputi, Narasaiah/0000-0002-2654-1900	NHLBI NIH HHS [R01 HL-052146, R01 HL-071628, R01 HL-083188] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083188, R01HL052146, R01HL071628] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON IYR, 1974, LAB INVEST, V30, P35; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Borok Z, 1998, AM J RESP CELL MOL, V18, P554, DOI 10.1165/ajrcmb.18.4.2838; Borok Z, 1998, AM J PHYSIOL-LUNG C, V275, pL155, DOI 10.1152/ajplung.1998.275.1.L155; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; Buckley S, 1996, AM J PHYSIOL-LUNG C, V271, pL54, DOI 10.1152/ajplung.1996.271.1.L54; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen JW, 2004, LAB INVEST, V84, P727, DOI 10.1038/labinvest.3700095; Chen ZM, 2004, BIOCHEM BIOPH RES CO, V319, P774, DOI 10.1016/j.bbrc.2004.05.048; CORRIN B, 1994, HISTOPATHOLOGY, V24, P145, DOI 10.1111/j.1365-2559.1994.tb01293.x; DANTO SI, 1995, AM J RESP CELL MOL, V12, P497, DOI 10.1165/ajrcmb.12.5.7742013; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DOBBS LG, 1988, BIOCHIM BIOPHYS ACTA, V970, P146, DOI 10.1016/0167-4889(88)90173-5; EVANS MJ, 1973, AM J PATHOL, V70, P175; Fehrenbach H, 2001, RESP RES, V2, P33, DOI 10.1186/rr36; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Gonzalez R, 2005, AM J PHYSIOL-LUNG C, V288, pL179, DOI 10.1152/ajplung.00272.2004; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Huang SS, 2005, J CELL BIOCHEM, V96, P447, DOI 10.1002/jcb.20558; Iavarone A, 1997, NATURE, V387, P417; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Khalil N, 1996, AM J RESP CELL MOL, V14, P131, DOI 10.1165/ajrcmb.14.2.8630262; KHALIL N, 1993, J CLIN INVEST, V92, P1812, DOI 10.1172/JCI116771; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Moustakas A, 2001, J CELL SCI, V114, P4359; Narasaraju TA, 2006, J CELL BIOCHEM, V97, P984, DOI 10.1002/jcb.20653; Paine R, 1996, AM J PHYSIOL-LUNG C, V270, pL484, DOI 10.1152/ajplung.1996.270.4.L484; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Selman M, 2003, AM J RESP CELL MOL, V29, pS93; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Uhal BD, 1997, AM J PHYSIOL-LUNG C, V272, pL1031, DOI 10.1152/ajplung.1997.272.6.L1031; Venkatesan N, 2004, AM J PHYSIOL-LUNG C, V287, pL1342, DOI 10.1152/ajplung.00035.2004; Venkatesan N, 2002, AM J PHYSIOL-LUNG C, V283, pL806, DOI 10.1152/ajplung.00061.2002; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Warburton David, 2004, Paediatr Respir Rev, V5 Suppl A, pS283, DOI 10.1016/S1526-0542(04)90052-8; Williams MC, 2003, ANNU REV PHYSIOL, V65, P669, DOI 10.1146/annurev.physiol.65.092101.142446; Xu YD, 2003, AM J PHYSIOL-LUNG C, V285, pL527, DOI 10.1152/ajplung.00298.2002; YAMAMOTO T, 1994, EUR J ENDOCRINOL, V130, P302, DOI 10.1530/eje.0.1300302; Zen K, 1998, AM J PHYSIOL-LUNG C, V275, pL172, DOI 10.1152/ajplung.1998.275.1.L172; Zhang FJ, 2004, AM J RESP CELL MOL, V31, P679, DOI 10.1165/rcmb.2004-0182OC	50	65	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3968	3976		10.1074/jbc.M609060200	http://dx.doi.org/10.1074/jbc.M609060200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158884	hybrid			2022-12-25	WOS:000244481900061
J	Koncarevic, A; Jackman, RW; Kandarian, SC				Koncarevic, Alan; Jackman, Robert W.; Kandarian, Susan C.			The ubiquitin-protein ligase Nedd4 targets Notch1 in skeletal muscle and distinguishes the subset of atrophies caused by reduced muscle tension	FASEB JOURNAL			English	Article						hind limb unloading; denervation; starvation; diabetes; ubiquitination	DIRECT GENE-TRANSFER; END RULE PATHWAY; DENERVATION ATROPHY; CELL-ACTIVATION; WW DOMAINS; DEGRADATION; EXPRESSION; GROWTH; PROTEOLYSIS; INVIVO	Ubiquitination-dependent proteolysis is a fundamental process underlying skeletal muscle atrophy. Thus, the role of ubiquitin ligases is of great interest. There are no focused studies in muscle on the ubiquitin ligase Nedd4. We first confirmed increased mRNA expression in rat soleus muscles due to 1-14 days of hind limb unloading. Nedd4 protein localized to the sarcolemmal region of muscle fibers. Hind limb unloading, sciatic nerve denervation, starvation, and diabetes led to atrophy of soleus, plantaris, and gastrocnemius muscles, but only unloaded and denervated muscles showed a marked increase in Nedd4 protein expression. This increase was strongly correlated with decreased Notch1 expression, a known target of Nedd4 in other cell types. Overexpression of dominant negative Nedd4 in soleus muscles completely reversed the unloading-induced decrease of Notch1 expression, indicating that Nedd4 is required for Notch1 inactivation. Overexpression of wild-type Nedd4 in soleus muscles of weight bearing rats caused a decrease in Notch1 protein, indicating that Nedd4 is sufficient for Notch1 down-regulation. To further show that Notch1 is a Nedd4 substrate in muscle, conditional overexpression of Nedd4 in C2C12 myotubes induced ubiquitination of Notch1. This is the first finding of a Nedd4 substrate in muscle and of an ubiquitin ligase, the activity of which distinguishes disuse from cachexia atrophy.	Boston Univ, Dept Hlth Sci, Boston, MA 02215 USA	Boston University	Kandarian, SC (corresponding author), Boston Univ, Dept Hlth Sci, Boston, MA 02215 USA.	skandar@bu.edu			NIAMS NIH HHS [R01 AR41705] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041705] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACSADI G, 1991, NEW BIOL, V3, P71; Anan T, 1998, GENES CELLS, V3, P751, DOI 10.1046/j.1365-2443.1998.00227.x; Ardley HC, 2005, ESSAYS BIOCHEM, V41, P15, DOI 10.1042/EB0410015; Batt J, 2005, FASEB J, V19, P115, DOI 10.1096/fj.04-3640fje; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Boppart MD, 2006, AM J PHYSIOL-CELL PH, V290, pC1660, DOI 10.1152/ajpcell.00317.2005; Cao PR, 2005, INT J BIOCHEM CELL B, V37, P2088, DOI 10.1016/j.biocel.2004.11.010; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; Costelli P, 2003, CURR OPIN CLIN NUTR, V6, P407, DOI 10.1097/01.mco.0000078984.18774.02; d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x; DARR KC, 1989, J APPL PHYSIOL, V67, P1827, DOI 10.1152/jappl.1989.67.5.1827; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Dupont-Versteegden EE, 2006, J APPL PHYSIOL, V101, P202, DOI 10.1152/japplphysiol.01540.2005; Flores SY, 2003, PFLUG ARCH EUR J PHY, V446, P334, DOI 10.1007/s00424-003-1027-x; FURUNO K, 1990, J BIOL CHEM, V265, P8550; GOLDSPINK DF, 1983, BIOCHEM J, V210, P89, DOI 10.1042/bj2100089; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Hansson EM, 2004, SEMIN CANCER BIOL, V14, P320, DOI 10.1016/j.semcancer.2004.04.011; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Heissmeyer V, 2004, NAT IMMUNOL, V5, P255, DOI 10.1038/ni1047; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Huang J, 1998, P NATL ACAD SCI USA, V95, P12100, DOI 10.1073/pnas.95.21.12100; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; JASPERS SR, 1984, J APPL PHYSIOL, V57, P1472, DOI 10.1152/jappl.1984.57.5.1472; Jehn BM, 2002, J BIOL CHEM, V277, P8033, DOI 10.1074/jbc.M108552200; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kandarian SC, 2006, MUSCLE NERVE, V33, P155, DOI 10.1002/mus.20442; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Kwon YT, 2001, MOL CELL BIOL, V21, P8007, DOI 10.1128/MCB.21.23.8007-8021.2001; Lange S, 2005, SCIENCE, V308, P1599, DOI 10.1126/science.1110463; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Li HH, 2004, J CLIN INVEST, V114, P1058, DOI 10.1172/JCl200422220; MEDINA R, 1991, BIOMED BIOCHIM ACTA, V50, P347; Mitchell-Felton H, 1999, AM J PHYSIOL-CELL PH, V277, pC1269, DOI 10.1152/ajpcell.1999.277.6.C1269; Morris CA, 2005, J APPL PHYSIOL, V99, P1719, DOI 10.1152/japplphysiol.01419.2004; Murdaca J, 2004, J BIOL CHEM, V279, P26754, DOI 10.1074/jbc.M311802200; Peters DG, 1999, AM J PHYSIOL-CELL PH, V276, pC1218, DOI 10.1152/ajpcell.1999.276.5.C1218; Pham N, 2001, J BIOL CHEM, V276, P46995, DOI 10.1074/jbc.M108373200; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Price S R, 1998, Curr Opin Clin Nutr Metab Care, V1, P79, DOI 10.1097/00075197-199801000-00013; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; Radtke F, 2005, EMBO REP, V6, P1120, DOI 10.1038/sj.embor.7400585; Sakata T, 2004, CURR BIOL, V14, P2228, DOI 10.1016/j.cub.2004.12.028; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Scharschmidt E, 2004, MOL CELL BIOL, V24, P3860, DOI 10.1128/MCB.24.9.3860-3873.2004; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, AM J PHYSIOL-CELL PH, V272, pC1871, DOI 10.1152/ajpcell.1997.272.6.C1871; Stevenson EJ, 2003, J PHYSIOL-LONDON, V551, P33, DOI 10.1113/jphysiol.2003.044701; STPIERRE BA, 1994, AM J PATHOL, V145, P1463; Tidball JG, 2002, J PHYSIOL-LONDON, V545, P819, DOI 10.1113/jphysiol.2002.024935; TIDBALL JG, 1995, MED SCI SPORT EXER, V27, P1022, DOI 10.1249/00005768-199507000-00011; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Wilkin MB, 2004, CURR BIOL, V14, P2237, DOI 10.1016/j.cub.2004.11.030; Witt SH, 2005, J MOL BIOL, V350, P713, DOI 10.1016/j.jmb.2005.05.021; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	62	64	66	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					427	437		10.1096/fj.06-6665com	http://dx.doi.org/10.1096/fj.06-6665com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17172638				2022-12-25	WOS:000244686300016
J	Shimanuki, T; Hara, T; Furuya, T; Imamura, T; Miyazono, K				Shimanuki, T.; Hara, T.; Furuya, T.; Imamura, T.; Miyazono, K.			Modulation of the functional binding sites for TGF-beta on the type II receptor leads to suppression of TGF-beta signaling	ONCOGENE			English	Article						tGF-beta; TGF-beta receptor; homology modeling; antagonist	GROWTH-FACTOR-BETA; DEPENDENT KINASE INHIBITOR; CRYSTAL-STRUCTURE; TRANSFORMING GROWTH-FACTOR-BETA-2; SMAD PROTEINS; ACTIVIN; COMPLEX; SUPERFAMILY; FLAVOPIRIDOL; MEMBRANE	Transforming growth factor-beta (TGF-beta) binds to two different types of serine/threonine kinase receptors termed type II (T beta R-II) and type I (T beta R-I). TGF-beta is unable to bind to T beta R-I in the absence of T beta R-II, and initiates receptor assembly by binding with high affinity to T beta beta R-II. Previous structural analysis of the TGF-beta 3-T beta R-II complex has suggested that two charged amino acid residues, D55 and E142 of T beta R-II, are binding sites of TGF-beta. In the present study, we have shown that mutations of the amino-acid residues, D55 and E142 of T beta R-II, resulted in loss of TGF-beta binding and downstream signaling activity. Moreover, we found that 3,5,7,2',4'-pentahydroxyflavone (Morin) inhibits TGF-beta binding to T beta R-II, and suppresses phosphorylation of Smad2 and expression of a TGF-beta target gene Smad7 induced by TGF-beta. Our findings may thus provide useful information for designing therapeutic agents for various diseases induced by TGF-beta, including advanced cancers.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo, Japan; JFCR, Canc Inst, Koto Ku, Tokyo, Japan; POLA Chem Inst Ltd, Cutaneous Drug Res, Totsuka Ku, Kanagawa, Japan; PharmaDesign Inc, Chuo Ku, Tokyo, Japan	University of Tokyo; University of Tokyo; Japanese Foundation for Cancer Research; Pola Chemical Industries Inc.	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp						Allendorph GP, 2006, P NATL ACAD SCI USA, V103, P7643, DOI 10.1073/pnas.0602558103; Bandyopadhyay A, 2006, CANCER RES, V66, P6714, DOI 10.1158/0008-5472.CAN-05-3565; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; BIRT DF, 1990, CHEMOPREVENTION NONN, P221; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DE AWJ, 1996, P NATL ACAD SCI USA, V93, P2735; De Crescenzo G, 2006, J MOL BIOL, V355, P47, DOI 10.1016/j.jmb.2005.10.022; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ebisawa T, 1999, J CELL SCI, V112, P3519; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; EWING T, 1998, DOCK VERSION 4 0 REF; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Greenwald J, 2004, MOL CELL, V15, P485, DOI 10.1016/j.molcel.2004.07.011; Harrison CA, 2003, J BIOL CHEM, V278, P21129, DOI 10.1074/jbc.M302015200; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Hsiang CY, 2005, BIOCHEM PHARMACOL, V69, P1603, DOI 10.1016/j.bcp.2005.03.008; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kelland LR, 2000, EXPERT OPIN INV DRUG, V9, P2903, DOI 10.1517/13543784.9.12.2903; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oeda E, 1998, J BIOL CHEM, V273, P9353, DOI 10.1074/jbc.273.16.9353; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Qian SW, 1996, J BIOL CHEM, V271, P30656, DOI 10.1074/jbc.271.48.30656; Qian SW, 1999, GROWTH FACTORS, V17, P63, DOI 10.3109/08977199909001063; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; Schwartz GK, 2001, J CLIN ONCOL, V19, P1985, DOI 10.1200/JCO.2001.19.7.1985; Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; Tojo M, 2005, CANCER SCI, V96, P791, DOI 10.1111/j.1349-7006.2005.00103.x; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	39	6	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2007	26	23					3311	3320		10.1038/sj.onc.1210123	http://dx.doi.org/10.1038/sj.onc.1210123			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17146441				2022-12-25	WOS:000246579600001
J	Ishizawar, RC; Miyake, T; Parsons, SJ				Ishizawar, R. C.; Miyake, T.; Parsons, S. J.			c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function	ONCOGENE			English	Article						c-Src; ErbB2; ErbB3; HRG; PI3-kinase; heterocomplex formation	HUMAN-BREAST-CANCER; GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; PROTEIN; ACTIVATION; ONCOGENE; AUTOPHOSPHORYLATION; PHOSPHORYLATION; INVOLVEMENT	Overexpression and/or gene amplification of c-Src and members of the epidermal growth factor receptor (EGFR/ErbB) family have been implicated in the pathogenesis of breast cancer. Although members of the EGFR family are known to form heterocomplexes with one another, c-Src has also been shown to physically interact with members ofthis family in breast cancer cell lines and tumors. This paper investigates the role of c-Src in modulating the physical and functional interaction between ErbB2 and ErbB3, two family members that preferentially associate with one another and together exhibit high oncogenic potential. We show that overexpressed wild-type c-Src enhances heterocomplex formation of ErbB2 and ErbB3 that results in increased basal and/or heregulin induced activation of recept ors, and their downstream intracellular effectors. Expression of a kinase-inactive form of c-Src (K- c-Src) or pharmacological inhibition of c-Src by PP2 negatively affects these events. Furthermore, cellular motility and anchorage-independent growth promoted by the ErbB2/ ErbB3 heterocomplex are dependent upon c- Src, as demonstrated by the effects of K- c-Src overexpression or treatment with PP2. In contrast to previous studies that de. ned a role for c-Src downstream of ErbB2/ErbB3, the current work suggests an upstream mechanism, whereby c-Src enhances ErbB2/ErbB3 signaling and biological functions by positively modulating the association between ErbB2 and ErbB3.	Univ Virginia, Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Ctr Canc, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Parsons, SJ (corresponding author), Univ Virginia, Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA.	sap@virginia.edu		Ishizawar, Rumey/0000-0001-5952-7884	NCI NIH HHS [CA71449] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071449] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Fan YX, 2004, J BIOL CHEM, V279, P38143, DOI 10.1074/jbc.M405760200; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	27	77	82	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3503	3510		10.1038/sj.onc.1210138	http://dx.doi.org/10.1038/sj.onc.1210138			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17173075				2022-12-25	WOS:000246799200006
J	Pushkar, Y; Yano, J; Glatzel, P; Messinger, J; Lewis, A; Sauer, K; Bergmann, U; Yachandra, V				Pushkar, Yulia; Yano, Junko; Glatzel, Pieter; Messinger, Johannes; Lewis, Azul; Sauer, Kenneth; Bergmann, Uwe; Yachandra, Vittal			Structure and orientation of the Mn4Ca cluster in plant photosystem II membranes studied by polarized range-extended X-ray absorption spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; ELECTRON-PARAMAGNETIC-RES; MANGANESE MODEL COMPOUNDS; WATER-OXIDATION COMPLEX; EXCHANGE INTERACTIONS; MN CLUSTER; CALCIUM; EXAFS; EPR; EVOLUTION	X-ray absorption spectroscopy has provided important insights into the structure and function of the Mn4Ca cluster in the oxygen-evolving complex of Photosystem II (PS II). The range of manganese extended x-ray absorption fine structure data collected from PS II until now has been, however, limited by the presence of iron in PS II. Using a crystal spectrometer with high energy resolution to detect solely the manganese K alpha fluorescence, we are able to extend the extended x-ray absorption fine structure range beyond the onset of the iron absorption edge. This results in improvement in resolution of the manganese-backscatterer distances in PS II from 0.14 to 0.09 angstrom. The high resolution data obtained from oriented spinach PS II membranes in the S-1 state show that there are three di-mu-oxo-bridged manganese-manganese distances of similar to 2.7 and similar to 2.8 angstrom in a 2:1 ratio and that these three manganese-manganese vectors are aligned at an average orientation of similar to 60 degrees relative to the membrane normal. Furthermore, we are able to observe the separation of the Fourier peaks corresponding to the similar to 3.2 angstrom manganese-manganese and the similar to 3.4 angstrom manganese-calcium interactions in oriented PS II samples and determine their orientation relative to the membrane normal. The average of the manganese-calcium vectors at similar to 3.4 angstrom is aligned along the membrane normal, while the similar to 3.2 angstrom manganese-manganese vector is oriented near the membrane plane. A comparison of this structural information with the proposed Mn4Ca cluster models based on spectroscopic and diffraction data provides input for refining and selecting among these models.	Lawrence Berkeley Natl Lab, Melvin Calvin Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Max Planck Inst Bioanorgan Chem, D-45470 Mulheim, Germany; Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; European Synchrotron Radiation Facility (ESRF); Max Planck Society; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Yano, J (corresponding author), Lawrence Berkeley Natl Lab, Melvin Calvin Lab, Phys Biosci Div, 1 Cyclotron Rd, Berkeley, CA 94720 USA.	jyano@lbl.gov; vkyachandra@lbl.gov	Glatzel, Pieter/E-9958-2010; Messinger, Johannes/AAC-4221-2019	Glatzel, Pieter/0000-0001-6532-8144; Messinger, Johannes/0000-0003-2790-7721	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM055302, R01GM065440, R01GM055302] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-08630, P41 RR008630] Funding Source: Medline; NIGMS NIH HHS [GM-65440, R01 GM065440, R56 GM055302, R01 GM055302] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ananyev GM, 1997, BIOCHEMISTRY-US, V36, P11342, DOI 10.1021/bi970626a; BALDWIN MJ, 1994, J AM CHEM SOC, V116, P11349, DOI 10.1021/ja00104a014; BERGMANN U, 1998, SPIE P, V3448, P198; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOUSSAC A, 1988, CHEM SCRIPTA, V28A, P123; Boussac A, 2004, J BIOL CHEM, V279, P22809, DOI 10.1074/jbc.M401677200; BOUSSAC A, 1989, BIOCHEMISTRY-US, V28, P8984, DOI 10.1021/bi00449a005; BOUSSAC A, 1988, BIOCHEMISTRY-US, V27, P3476, DOI 10.1021/bi00409a052; BOUSSAC A, 1985, BIOCHIM BIOPHYS ACTA, V808, P231, DOI 10.1016/0005-2728(85)90004-0; Britt RD, 2004, BBA-BIOENERGETICS, V1655, P158, DOI 10.1016/j.bbabio.2003.11.009; Carrell TG, 2002, J BIOL INORG CHEM, V7, P2, DOI 10.1007/s00775-001-0305-3; CHEN CG, 1995, BIOCHEMISTRY-US, V34, P13511, DOI 10.1021/bi00041a031; CHRISTOU G, 1988, METAL CLUSTERS PROTE, P238; Chu HA, 2001, BBA-BIOENERGETICS, V1503, P69, DOI 10.1016/S0005-2728(00)00216-4; Cinco RM, 1999, INORG CHEM, V38, P5988, DOI 10.1021/ic991003j; Cinco RM, 2004, BIOCHEMISTRY-US, V43, P13271, DOI 10.1021/bi036308v; Cinco RM, 2002, BIOCHEMISTRY-US, V41, P12928, DOI 10.1021/bi026569p; CRAMER SP, 1988, XRAY ABSORPTION, P257; Darovsky A, 1996, INORG CHEM, V35, P6916, DOI 10.1021/ic9610391; DAU H, 1995, BIOCHEMISTRY-US, V34, P5274, DOI 10.1021/bi00015a043; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEROSE VJ, 1994, J AM CHEM SOC, V116, P5239, DOI 10.1021/ja00091a031; DEROSE VJ, 1995, CHEM PHYS, V194, P443, DOI 10.1016/0301-0104(95)00043-N; DUA H, 2001, BIOCHIM BIOPHYS ACTA, V1503, P24; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; GEORGE GN, 1989, SCIENCE, V243, P789, DOI 10.1126/science.2916124; Glatzel P, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.014117; Glatzel P, 2004, J AM CHEM SOC, V126, P9946, DOI 10.1021/ja038579z; Grove GN, 1998, BIOCHEMISTRY-US, V37, P1532, DOI 10.1021/bi971356z; Hasegawa K, 1999, CHEM PHYS LETT, V300, P9, DOI 10.1016/S0009-2614(98)01369-4; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; Kulik LV, 2005, J AM CHEM SOC, V127, P2392, DOI 10.1021/ja043012j; Kusunoki M, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P251; Latimer MJ, 1998, J PHYS CHEM B, V102, P8257, DOI 10.1021/jp981668r; Law NA, 1999, ADV INORG CHEM, V46, P305; LIANG W, 1994, BIOCHEMISTRY-US, V33, P4923, DOI 10.1021/bi00182a022; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; Messinger J, 2001, J AM CHEM SOC, V123, P7804, DOI 10.1021/ja004307+; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; MUKERJI I, 1994, BIOCHEMISTRY-US, V33, P9712, DOI 10.1021/bi00198a042; Mukhopadhyay S, 2004, CHEM REV, V104, P3981, DOI 10.1021/cr0206014; ONO T, 1988, FEBS LETT, V227, P147, DOI 10.1016/0014-5793(88)80886-X; ORT DR, 1996, OXYGENIC PHOTOSYNTHE; Peloquin JM, 2001, BBA-BIOENERGETICS, V1503, P96, DOI 10.1016/S0005-2728(00)00219-X; Pence LE, 1996, INORG CHEM, V35, P3069, DOI 10.1021/ic951448h; Penner-Hahn JE, 1998, STRUCT BOND, V90, P1; Pizarro SA, 2004, J BIOL INORG CHEM, V9, P247, DOI 10.1007/s00775-003-0520-1; Rehr JJ, 2000, REV MOD PHYS, V72, P621, DOI 10.1103/RevModPhys.72.621; Robblee JH, 2002, J AM CHEM SOC, V124, P7459, DOI 10.1021/ja011621a; Rutherford A.W., 1992, PHOTOSYSTEMS STRUCTU, P179; RUTHERFORD AW, 1985, BIOCHIM BIOPHYS ACTA, V807, P189, DOI 10.1016/0005-2728(85)90122-7; Sauer K, 2005, PHOTOSYNTH RES, V85, P73, DOI 10.1007/s11120-005-0638-9; Schiller H, 1998, BIOCHEMISTRY-US, V37, P7340, DOI 10.1021/bi972329b; SCOTT RA, 1984, STRUCTURAL RESONANCE, P295; Teo, 1986, EXAFS BASIC PRINCIPL; VINCENT JB, 1987, J CHEM SOC CHEM COMM, P236, DOI 10.1039/c39870000236; WIEGHARDT K, 1989, ANGEW CHEM INT EDIT, V28, P1153, DOI 10.1002/anie.198911531; Wydrzynski T. J., 2005, PHOTOSYSTEM; Yachandra VK, 1996, CHEM REV, V96, P2927, DOI 10.1021/cr950052k; Yachandra VK, 2005, ADV PHOTO RESPIRAT, V22, P235; YACHANDRA VK, 1995, METHOD ENZYMOL, V246, P638; YACHANDRA VK, 1993, SCIENCE, V260, P675, DOI 10.1126/science.8480177; Yano J, 2005, J AM CHEM SOC, V127, P14974, DOI 10.1021/ja054873a; Yano J, 2005, P NATL ACAD SCI USA, V102, P12047, DOI 10.1073/pnas.0505207102; Yano J, 2006, SCIENCE, V314, P821, DOI 10.1126/science.1128186	66	83	83	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7198	7208		10.1074/jbc.M610505200	http://dx.doi.org/10.1074/jbc.M610505200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17190828	Green Accepted, hybrid			2022-12-25	WOS:000245080900032
J	Balasubramanian, S; Eckert, RL				Balasubramanian, Sivaprakasam; Eckert, Richard L.			Curcumin suppresses AP1 transcription factor-dependent differentiation and activates apoptosis in human epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INVOLUCRIN PROMOTER; NF-KAPPA-B; GREEN TEA POLYPHENOL; 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED TUMOR PROMOTION; PROTEIN-KINASE-C; CELL-PROLIFERATION; GENE-EXPRESSION; PROTEASOMAL DEGRADATION; DERIVATIVES INHIBIT; DIETARY CURCUMIN	The diet-derived cancer preventive agent, curcumin, inhibits skin cancer cell proliferation and tumor formation. However, its effect on normal human keratinocyte differentiation, proliferation, and apoptosis has not been adequately studied. Involucrin (hINV) is a marker of keratinocyte differentiation and a useful model for the study of chemopreventive agent action. We show that curcumin suppresses the differentiation agent-dependent activation of hINV gene expression and that an AP1 transcription factor DNA binding site in the hINV gene is required for this regulation. A protein kinase C, Ras, MEKK1, MEK3 signaling cascade controls hINV expression by regulating AP1 factor level. Curcumin treatment inhibits the novel protein kinase C-, Ras-, and MEKK1-dependent activation of hINV promoter activity and reduces the differentiation agent-dependent increase in AP1 factor level and DNA binding. This reduction requires proteasome function. In addition, curcumin treatment reduces cell number, which is associated with a reduced cyclin and cdk1 levels. Curcumin treatment also suppresses the Bcl-xL level, leading to reduced mitochondrial membrane potential and increased cleavage of procaspases and poly(ADP-ribose) polymerase. These studies provide important insights regarding the mechanism whereby curcumin acts as a chemopreventive agent in normal human epidermis.	Case Western Reserve Univ, Sch Med, Dept Physiol Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol Biophys, 2109 Adelbert Rd, Cleveland, OH 44106 USA.	rle2@po.cwru.edu			NATIONAL CANCER INSTITUTE [R01CA092201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750, R01AR046494] Funding Source: NIH RePORTER; NCI NIH HHS [CA92201] Funding Source: Medline; NIAMS NIH HHS [AR046494, AR39750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Acquaviva C, 2001, ONCOGENE, V20, P7563, DOI 10.1038/sj.onc.1204880; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 2002, CURR OPIN CELL BIOL, V14, P715, DOI 10.1016/S0955-0674(02)00381-2; Aggarwal BB, 2003, ANTICANCER RES, V23, P363; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Balasubramanian S, 2005, ONCOGENE, V24, P4257, DOI 10.1038/sj.onc.1208586; Balasubramanian S, 2005, CARCINOGENESIS, V26, P1100, DOI 10.1093/carcin/bgi048; Balasubramanian S, 2004, J BIOL CHEM, V279, P24007, DOI 10.1074/jbc.M314331200; Balasubramanian S, 2002, J BIOL CHEM, V277, P1828, DOI 10.1074/jbc.M110376200; Berse M, 2004, J MOL BIOL, V343, P361, DOI 10.1016/j.jmb.2004.08.043; Cho JW, 2005, EXP MOL MED, V37, P186, DOI 10.1038/emm.2005.25; Choudhuri T, 2005, J BIOL CHEM, V280, P20059, DOI 10.1074/jbc.M410670200; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; Crish JF, 2002, ONCOGENE, V21, P738, DOI 10.1038/sj.onc.1205038; Dikshit P, 2006, NEUROTOX RES, V9, P29, DOI 10.1007/BF03033305; Dikshit P, 2006, BIOCHEM BIOPH RES CO, V342, P1323, DOI 10.1016/j.bbrc.2006.02.104; Eckert RL, 2006, MOL NUTR FOOD RES, V50, P123, DOI 10.1002/mnfr.200500125; Eckert RL, 2004, J INVEST DERMATOL, V123, P13, DOI 10.1111/j.0022-202X.2004.22723.x; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Gafner S, 2004, PHYTOCHEMISTRY, V65, P2849, DOI 10.1016/j.phytochem.2004.08.008; Grandjean-Laquerriere A, 2002, CYTOKINE, V18, P168, DOI 10.1006/cyto.2002.0888; Hahm ER, 2004, BIOCHEM BIOPH RES CO, V321, P337, DOI 10.1016/j.bbrc.2004.06.119; Hahm ER, 2002, CANCER LETT, V184, P89, DOI 10.1016/S0304-3835(02)00170-2; Hour TC, 2002, PROSTATE, V51, P211, DOI 10.1002/pros.10089; Huang MT, 1997, CARCINOGENESIS, V18, P83, DOI 10.1093/carcin/18.1.83; HUANG MT, 1995, CARCINOGENESIS, V16, P2493, DOI 10.1093/carcin/16.10.2493; Jana NR, 2004, J BIOL CHEM, V279, P11680, DOI 10.1074/jbc.M310369200; Jost M, 1999, J INVEST DERMATOL, V112, P443, DOI 10.1046/j.1523-1747.1999.00543.x; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; KAKAR SS, 1994, CANCER LETT, V87, P85, DOI 10.1016/0304-3835(94)90413-8; Kawasaki H, 2003, ONCOGENE, V22, P6839, DOI 10.1038/sj.onc.1206903; Krishnaswamy K, 1998, NUTR CANCER, V30, P163, DOI 10.1080/01635589809514657; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Limtrakul P, 1997, CANCER LETT, V116, P197, DOI 10.1016/S0304-3835(97)00187-0; Limtrakul PN, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-1; LU YP, 1994, CARCINOGENESIS, V15, P2363, DOI 10.1093/carcin/15.10.2363; Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Park CH, 2005, J BIOCHEM MOL BIOL, V38, P474; Prusty BK, 2005, INT J CANCER, V113, P951, DOI 10.1002/ijc.20668; Rinaldi AL, 2002, CANCER RES, V62, P5451; Santibanez JF, 2000, NUTR CANCER, V37, P49, DOI 10.1207/S15327914NC3701_6; Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010; Shishodia S, 2003, CARCINOGENESIS, V24, P1269, DOI 10.1093/carcin/bgg078; Singletary K, 1998, CARCINOGENESIS, V19, P1039, DOI 10.1093/carcin/19.6.1039; STONER GD, 1995, J CELL BIOCHEM, P169; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Wyke SM, 2004, BRIT J CANCER, V91, P1742, DOI 10.1038/sj.bjc.6602165; Yan CH, 2005, MOL CANCER THER, V4, P233	57	74	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6707	6715		10.1074/jbc.M606003200	http://dx.doi.org/10.1074/jbc.M606003200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17148446	hybrid			2022-12-25	WOS:000244867200080
J	Serrano, M; Robatzek, S; Torres, M; Kombrink, E; Somssich, IE; Robinson, M; Schulze-Lefert, P				Serrano, Mario; Robatzek, Silke; Torres, Martha; Kombrink, Erich; Somssich, Imre E.; Robinson, Mike; Schulze-Lefert, Paul			Chemical interference of pathogen-associated molecular pattern-triggered immune responses in Arabidopsis reveals a potential role for fatty-acid synthase type II complex-derived lipid signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; PHOSPHATIDIC-ACID; GENE-EXPRESSION; BACTERIAL FLAGELLIN; DISEASE RESISTANCE; INNATE IMMUNITY; THALIANA; PLANTS; ENDOCYTOSIS; SYSTEM	We describe an experimental setup using submerged cultures of Arabidopsis seedlings in 96-well microtiter plates that permits chemical intervention of rapid elicitor-mediated immune responses. Screening of a chemical library comprising 120 small molecules with known biological activities revealed four compounds reducing cellulysin- or flg22-activated gene expression of the early pathogen-associated molecular patterns (PAMP)responsive ATL2 gene. One chemical, oxytriazine, was found to induce ATL2 gene expression in the absence of PAMP. By monitoring additional flg22-triggered immediate early plant responses, we present evidence that two compounds, triclosan and fluazinam, interfere with the accumulation of reactive oxygen species and internalization of the activated plasma membrane resident FLS2 immune receptor. Using triclosan structure types and enzyme activity inhibition assays, Arabidopsis MOD1 enoyl-acyl carrier protein reductase, a subunit of the fatty-acid synthase type II (FAS II) complex, was identified as a likely cellular target of triclosan. Inhibition of all tested elicitor-triggered early immune responses by triclosan indicates a potential role for signaling lipids in flg22-triggered immunity. Chemical profiling of eca mutants, each showing deregulated ATL2 gene expression, with the identified compounds revealed mutant-specific response patterns and allowed us to deduce tentative action sites of ECA genes relative to the compound targets.	Max Planck Inst Plant Breeding Res, Dept Plant Microbe Interact, D-50829 Cologne, Germany; Syngenta Jealotts Hill Int Res Ctr, Bracknell RG42 6EY, Berks, England	Max Planck Society; Syngenta	Schulze-Lefert, P (corresponding author), Max Planck Inst Plant Breeding Res, Dept Plant Microbe Interact, Carl von Linne Weg 10, D-50829 Cologne, Germany.	schlef@mpiz-koeln.mpg.de	Somssich, Imre/GLT-3738-2022; Serrano, Mario/E-8719-2012; Schulze-Lefert, Paul/A-7746-2008; Bruening, Stefan/B-8505-2011; Robatzek, Silke/B-6844-2013; Schulze-Lefert, Paul/B-6707-2011	Somssich, Imre/0000-0003-3066-5794; Serrano, Mario/0000-0002-1510-756X; 				Affleck JG, 2006, TOXICOL SCI, V89, P495, DOI 10.1093/toxsci/kfj036; Armstrong JI, 2004, P NATL ACAD SCI USA, V101, P14978, DOI 10.1073/pnas.0404312101; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; Blackwell HE, 2003, PLANT PHYSIOL, V133, P448, DOI 10.1104/pp.103.031138; Blakley R L, 1995, Adv Enzymol Relat Areas Mol Biol, V70, P23; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; de Jong CF, 2004, PLANT J, V39, P1, DOI 10.1111/j.1365-313X.2004.02110.x; Durrant WE, 2000, PLANT CELL, V12, P963, DOI 10.1105/tpc.12.6.963; Ehlting J, 1999, PLANT J, V19, P9, DOI 10.1046/j.1365-313X.1999.00491.x; Eulgem T, 2000, TRENDS PLANT SCI, V5, P199, DOI 10.1016/S1360-1385(00)01600-9; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; Gomez-Gomez L, 2001, PLANT CELL, V13, P1155, DOI 10.1105/tpc.13.5.1155; Gomez-Gomez L, 1999, PLANT J, V18, P277, DOI 10.1046/j.1365-313X.1999.00451.x; Gross A, 2005, NEW PHYTOL, V165, P215, DOI 10.1111/j.1469-8137.2004.01245.x; Gutierrez RA, 2002, P NATL ACAD SCI USA, V99, P11513, DOI 10.1073/pnas.152204099; Heath RJ, 2002, APPL MICROBIOL BIOT, V58, P695, DOI 10.1007/s00253-001-0918-z; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Husebye H, 2006, EMBO J, V25, P683, DOI 10.1038/sj.emboj.7600991; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; KATER MM, 1994, PLANT MOL BIOL, V25, P771, DOI 10.1007/BF00028873; KEPPLER LD, 1989, PHYTOPATHOLOGY, V79, P974, DOI 10.1094/Phyto-79-974; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; Lee CS, 2006, NAT CELL BIOL, V8, P477, DOI 10.1038/ncb1401; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; Mou ZL, 2000, PLANT CELL, V12, P405, DOI 10.1105/tpc.12.3.405; Navarro L, 2004, PLANT PHYSIOL, V135, P1113, DOI 10.1104/pp.103.036749; Nurnberger T, 2004, IMMUNOL REV, V198, P249, DOI 10.1111/j.0105-2896.2004.0119.x; Poghosyan ZP, 2005, PLANT PHYSIOL BIOCH, V43, P37, DOI 10.1016/j.plaphy.2004.12.002; Robatzek S, 2006, GENE DEV, V20, P537, DOI 10.1101/gad.366506; Salinas-Mondragon RE, 1999, PLANT MOL BIOL, V40, P579, DOI 10.1023/A:1006267201855; Sasaki Y, 2004, BIOSCI BIOTECH BIOCH, V68, P1175, DOI 10.1271/bbb.68.1175; Serrano M, 2006, J MOL EVOL, V62, P434, DOI 10.1007/s00239-005-0038-y; Serrano M, 2004, GENETICS, V167, P919, DOI 10.1534/genetics.104.028043; Shah K, 2002, GENE DEV, V16, P1707, DOI 10.1101/gad.220402; SLABAS AR, 1986, BIOCHIM BIOPHYS ACTA, V877, P271, DOI 10.1016/0005-2760(86)90304-8; Smukste I, 2005, ANNU REV GENOM HUM G, V6, P261, DOI 10.1146/annurev.genom.6.080604.162136; Sprenger-Haussels M, 2000, PLANT J, V22, P1, DOI 10.1046/j.1365-313x.2000.00687.x; Surpin M, 2005, P NATL ACAD SCI USA, V102, P4902, DOI 10.1073/pnas.0500222102; Testerink C, 2005, TRENDS PLANT SCI, V10, P368, DOI 10.1016/j.tplants.2005.06.002; Ulker B, 2004, CURR OPIN PLANT BIOL, V7, P491, DOI 10.1016/j.pbi.2004.07.012; van der Luit AH, 2000, PLANT PHYSIOL, V123, P1507, DOI 10.1104/pp.123.4.1507; Zhao YD, 2003, SCIENCE, V301, P1107, DOI 10.1126/science.1084161; Zipfel C, 2005, CURR OPIN PLANT BIOL, V8, P353, DOI 10.1016/j.pbi.2005.05.004; Zipfel C, 2004, NATURE, V428, P764, DOI 10.1038/nature02485	45	59	63	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6803	6811		10.1074/jbc.M608792200	http://dx.doi.org/10.1074/jbc.M608792200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17166839	hybrid			2022-12-25	WOS:000244867200090
J	Deka, RK; Brautigam, CA; Tomson, FL; Lumpkins, SB; Tomchick, DR; Machius, M; Norgard, MV				Deka, Rani K.; Brautigam, Chad A.; Tomson, Farol L.; Lumpkins, Sarah B.; Tomchick, Diana R.; Machius, Mischa; Norgard, Michael V.			Crystal structure of the Tp34 (TP0971) lipoprotein of Treponema pallidum - Implications of its metal-bound state and affinity for human lactoferrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORRELIA-BURGDORFERI LIPOPROTEINS; 34-KILODALTON MEMBRANE IMMUNOGEN; MEDIATED ELECTRON-TRANSFER; OUTER-MEMBRANE; SUPEROXIDE REDUCTASE; BINDING PROTEIN; ATP-BINDING; IRON ACQUISITION; L-METHIONINE; SEQUENCE	The Tp34 (TP0971) membrane lipoprotein of Treponema pallidum, an obligate human pathogen and the agent of syphilis, was previously reported to have lactoferrin binding properties. Given the non-cultivatable nature of T. pallidum, a structure-to-function approach was pursued to clarify further potential relationships between the Tp34 structural and biochemical properties and its propensity to bind human lactorferrin. The crystal structure of a nonacylated, recombinant form of Tp34 (rTp34), solved to a resolution of 1.9 angstrom, revealed two metal-occupied binding sites within a dimer; the identity of the ion most likely was zinc. Residues from both of the monomers contributed to the interfacial metal-binding sites; a novel feature was that the delta-sulfur of methionine coordinated the zinc ion. Analytical ultracentrifugation showed that, in solution, rTp34 formed a metal-stabilized dimer and that rTp34 bound human lactorferrin with a stoichiometry of 2:1. Isothermal titration calorimetry further revealed that rTp34 bound human lactoferrin at high (submicromolar) affinity. Finally, membrane topology studies revealed that native Tp34 is not located on the outer surface (outer membrane) of T. pallidum but, rather, is periplasmic. How propensity of Tp34 to bind zinc and the iron-sequestering lactoferrin may relate overall to the biology of T. pallidum infection in humans is discussed.	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Oklahoma, Norman, OK 73019 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Oklahoma System; University of Oklahoma - Norman	Norgard, MV (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	michael.norgard@utsouthwestern.edu	Tomchick, Diana/HGV-2018-2022	Tomchick, Diana/0000-0002-7529-4643; Brautigam, Chad/0000-0001-6563-1338	NIAID NIH HHS [AI-56305] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056305] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akins DR, 1997, J BACTERIOL, V179, P5076, DOI 10.1128/jb.179.16.5076-5086.1997; ALDERETE JF, 1988, GENITOURIN MED, V64, P359; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; Auchere F, 2006, J BIOL INORG CHEM, V11, P433, DOI 10.1007/s00775-006-0090-0; Auchere F, 2004, J BIOL INORG CHEM, V9, P839, DOI 10.1007/s00775-004-0584-6; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; Balbo A, 2005, P NATL ACAD SCI USA, V102, P81, DOI 10.1073/pnas.0408399102; BECKER PS, 1994, INFECT IMMUN, V62, P1381, DOI 10.1128/IAI.62.4.1381-1391.1994; BELTRAMI JF, 2006, MMWR-MORBID MORTAL W, V55, P269; Bertini I., 1994, BIOINORG CHEM, P37; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Brautigam CA, 2004, J BIOL CHEM, V279, P11948, DOI 10.1074/jbc.M312015200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLEN JJ, 1981, REV INFECT DIS, V3, P1127; Castagnetto JM, 2002, NUCLEIC ACIDS RES, V30, P379, DOI 10.1093/nar/30.1.379; CHAKRABARTI P, 1989, BIOCHEMISTRY-US, V28, P6081, DOI 10.1021/bi00440a052; CHAMBERLAIN NR, 1989, INFECT IMMUN, V57, P2872, DOI 10.1128/IAI.57.9.2872-2877.1989; Clarke Teresa E., 2001, Current Topics in Medicinal Chemistry, V1, P7, DOI 10.2174/1568026013395623; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; COX DL, 1990, APPL ENVIRON MICROB, V56, P3063, DOI 10.1128/AEM.56.10.3063-3072.1990; COX DL, 1995, MOL MICROBIOL, V15, P1151, DOI 10.1111/j.1365-2958.1995.tb02288.x; COX DL, 1992, INFECT IMMUN, V60, P1076, DOI 10.1128/IAI.60.3.1076-1083.1992; Cox DL, 1996, P NATL ACAD SCI USA, V93, P7973, DOI 10.1073/pnas.93.15.7973; Dam J, 2005, BIOPHYS J, V89, P619, DOI 10.1529/biophysj.105.059568; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398; Deka RK, 2006, J BIOL CHEM, V281, P8072, DOI 10.1074/jbc.M511405200; Deka RK, 2004, J BIOL CHEM, V279, P55644, DOI 10.1074/jbc.M409263200; Deka RK, 2002, J BIOL CHEM, V277, P41857, DOI 10.1074/jbc.M207402200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dufayard JF, 2005, BIOINFORMATICS, V21, P2596, DOI 10.1093/bioinformatics/bti325; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Farnaud S, 2003, MOL IMMUNOL, V40, P395, DOI 10.1016/S0161-5890(03)00152-4; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Gerbase AC, 1998, SEX TRANSM INFECT, V74, pS12; Gordon JC, 2005, NUCLEIC ACIDS RES, V33, pW368, DOI 10.1093/nar/gki464; GrayOwen SD, 1996, TRENDS MICROBIOL, V4, P185, DOI 10.1016/0966-842X(96)10025-1; Haake DA, 2000, MICROBIOL-SGM, V146, P1491, DOI 10.1099/00221287-146-7-1491; Hardham JM, 1997, GENE, V197, P47, DOI 10.1016/S0378-1119(97)00234-5; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; Hazlett KRO, 2005, J BACTERIOL, V187, P6499, DOI 10.1128/JB.187.18.6499-6508.2005; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; JONES SA, 1984, J EXP MED, V160, P1404, DOI 10.1084/jem.160.5.1404; Jovanovic T, 2000, J BIOL CHEM, V275, P28439, DOI 10.1074/jbc.M003314200; Kanyshkova TG, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1, DOI 10.1023/A:1002817226110; LaFond RE, 2006, CLIN MICROBIOL REV, V19, P29, DOI 10.1128/CMR.19.1.29-49.2006; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; LEVAY PF, 1995, HAEMATOLOGICA, V80, P252; Lombard M, 2000, J BIOL CHEM, V275, P27021; MASSON PL, 1968, EUR J BIOCHEM, V6, P579, DOI 10.1111/j.1432-1033.1968.tb00484.x; MIETZNER TA, 1994, ANNU REV NUTR, V14, P471, DOI 10.1146/annurev.nu.14.070194.002351; Moore SA, 1997, J MOL BIOL, V274, P222, DOI 10.1006/jmbi.1997.1386; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; Ochsner UA, 1999, J BACTERIOL, V181, P1099, DOI 10.1128/JB.181.4.1099-1109.1999; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Payne Shelley M., 1993, Trends in Microbiology, V1, P66, DOI 10.1016/0966-842X(93)90036-Q; Peeling RW, 2006, J PATHOL, V208, P224, DOI 10.1002/path.1903; Perkins-Balding D, 2004, MICROBIOL MOL BIOL R, V68, P154, DOI 10.1128/MMBR.68.1.154-171.2004; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; RADOLF JD, 1995, J IMMUNOL, V154, P2866; RADOLF JD, 1988, INFECT IMMUN, V56, P490, DOI 10.1128/IAI.56.2.490-498.1988; RADOLF JD, 1995, MOL MICROBIOL, V16, P1067, DOI 10.1111/j.1365-2958.1995.tb02332.x; Radolf Justin D., 1994, Trends in Microbiology, V2, P307, DOI 10.1016/0966-842X(94)90446-4; ROBERTSON SM, 1982, INFECT IMMUN, V36, P1076, DOI 10.1128/IAI.36.3.1076-1085.1982; Santos-Silva T, 2006, J BIOL INORG CHEM, V11, P548, DOI 10.1007/s00775-006-0104-y; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Setubal JC, 2006, MICROBIOL-SGM, V152, P113, DOI 10.1099/mic.0.28317-0; Simms I, 2005, SEX TRANSM DIS, V32, P220, DOI 10.1097/01.olq.0000149848.03733.c1; STAGGS TM, 1994, MOL MICROBIOL, V12, P613, DOI 10.1111/j.1365-2958.1994.tb01048.x; Stauber DJ, 2006, P NATL ACAD SCI USA, V103, P2788, DOI 10.1073/pnas.0511161103; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; SWANCUTT MA, 1989, INFECT IMMUN, V57, P3314, DOI 10.1128/IAI.57.11.3314-3323.1989; SWANCUTT MA, 1990, INFECT IMMUN, V58, P384, DOI 10.1128/IAI.58.2.384-392.1990; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Theil E. C., 1994, BIOINORG CHEM, P1; THURNIGER A, 2006, PROTEINS, V62, P827; WEIGEL LM, 1994, P NATL ACAD SCI USA, V91, P11611, DOI 10.1073/pnas.91.24.11611; Yee A, 2002, P NATL ACAD SCI USA, V99, P1825, DOI 10.1073/pnas.042684599; Zhang ZG, 2003, ARCH MICROBIOL, V180, P88, DOI 10.1007/s00203-003-0561-4	89	37	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5944	5958		10.1074/jbc.M610215200	http://dx.doi.org/10.1074/jbc.M610215200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17192261	hybrid			2022-12-25	WOS:000244482300090
J	Gusdon, AM; Votyakova, TV; Reynolds, IJ; Mathews, CE				Gusdon, Aaron M.; Votyakova, Tatyana V.; Reynolds, Ian J.; Mathews, Clayton E.			Nuclear and mitochondrial interaction involving mt-Nd2 leads to increased mitochondrial reactive oxygen species production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME GENE-EXPRESSION; BETA-CELL DESTRUCTION; UBIQUINONE OXIDOREDUCTASE; NITRIC-OXIDE; COMPLEX-I; ANTIOXIDANT DEFENSE; FAS LIGAND; AUTOIMMUNE DESTRUCTION; ALLOXAN-RESISTANT; PANCREATIC-ISLETS	NADH dehydrogenase subunit 2, encoded by the mtDNA, has been associated with resistance to autoimmune type I diabetes (T1D) in a case control study. Recently, we confirmed a role for the mouse ortholog of the protective allele (mt-Nd2(a)) in resistance to T1D using genetic analysis of outcrosses between T1D-resistant ALR and T1D-susceptible NOD mice. We sought to determine the mechanism of disease protection by elucidating whether mt-Nd2(a) affects basal mitochondrial function or mitochondrial function in the presence of oxidative stress. Two fines of reciprocal conplastic mouse strains were generated: one with ALR nuclear DNA and NOD mtDNA (ALR.Mt(NOD)) and the reciprocal with NOD nuclear DNA and ALR mtDNA (NOD.Mt(ALR)). Basal mitochondrial respiration, transmembrane potential, and electron transport system enzymatic activities showed no difference among the strains. However, ALR.MtNOD mitochondria supported by either complex I or complex 11 substrates produced significantly more reactive oxygen species when compared with both parental strains, NOD.mt(ALR) or C57BL/6 controls. Nitric oxide inhibited respiration to a similar extent for mitochondria from the five strains due to competitive antagonism with molecular oxygen at complex IV. Superoxide and hydrogen peroxide generated by xanthine oxidase did not significantly decrease complex I function. The protein nitrating agents peroxynitrite or nitrogen dioxide radicals significantly decreased complex I function but with no significant difference among the five strains. In summary, mt-Nd2(a) does not confer elevated resistance to oxidative stress; however, it plays a critical role in the control of the mitochondrial reactive oxygen species production.	Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat,Diabet Inst,Rangos Res Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Mathews, CE (corresponding author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat,Diabet Inst,Rangos Res Ctr, 3460 5th Ave, Pittsburgh, PA 15213 USA.	cem65@pitt.edu	Reynolds, Ian Jeffery/ABH-3197-2020; Reynolds, Ian/C-4358-2008	Reynolds, Ian/0000-0003-3028-5070	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI056374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074656, R56DK074656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020899] Funding Source: NIH RePORTER; NIAID NIH HHS [AI056374] Funding Source: Medline; NIA NIH HHS [AG20899] Funding Source: Medline; NIDDK NIH HHS [DK074656, R01 DK074656] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Bertera S, 2003, DIABETES, V52, P387, DOI 10.2337/diabetes.52.2.387; BIRCHMACHIN M, 2001, MITOCHONDRIA; Briehl M M, 1995, Cell Death Differ, V2, P41; Briehl MM, 1996, CELL DEATH DIFFER, V3, P63; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; Flemming D, 2005, J MOL MICROB BIOTECH, V10, P208, DOI 10.1159/000091566; Friedrich T, 1998, BBA-BIOENERGETICS, V1365, P215, DOI 10.1016/S0005-2728(98)00070-X; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; Gabaldon T, 2005, J MOL BIOL, V348, P857, DOI 10.1016/j.jmb.2005.02.067; Gale E A, 1996, Horm Res, V45 Suppl 1, P39; Genova MW, 2003, EXP BIOL MED, V228, P506, DOI 10.1177/15353702-0322805-14; Ho E, 1999, FASEB J, V13, P1845, DOI 10.1096/fasebj.13.13.1845; HORIO F, 1994, DIABETOLOGIA, V37, P22; Hotta M, 1998, J EXP MED, V188, P1445, DOI 10.1084/jem.188.8.1445; Itoh N, 1997, J EXP MED, V186, P613, DOI 10.1084/jem.186.4.613; Jekabsone A, 2003, J MOL CELL CARDIOL, V35, P803, DOI 10.1016/S0022-2828(03)00137-8; Kokaze A, 2004, J HUM HYPERTENS, V18, P41, DOI 10.1038/sj.jhh.1001632; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5; Lizard G, 1998, FASEB J, V12, P1651, DOI 10.1096/fasebj.12.15.1651; Marques FD, 2003, BRAIN RES, V964, P153, DOI 10.1016/S0006-8993(02)04118-5; Mathews CE, 2005, J IMMUNOL, V175, P1248, DOI 10.4049/jimmunol.175.2.1248; Mathews CE, 2005, DIABETOLOGIA, V48, P261, DOI 10.1007/s00125-004-1644-8; Mathews CE, 2003, IMMUNOGENETICS, V55, P491, DOI 10.1007/s00251-003-0603-8; Mathews CE, 1999, DIABETES, V48, P2189, DOI 10.2337/diabetes.48.11.2189; Mathews CE, 2001, P NATL ACAD SCI USA, V98, P235, DOI 10.1073/pnas.98.1.235; Mathews CE, 1999, FREE RADICAL BIO MED, V27, P449, DOI 10.1016/S0891-5849(99)00084-2; Mathiesen C, 2002, BBA-BIOENERGETICS, V1556, P121, DOI 10.1016/S0005-2728(02)00343-2; Matsunaga H, 2001, DIABETES CARE, V24, P500, DOI 10.2337/diacare.24.3.500; NERUP J, 1988, DIABETES CARE, V11, P16; Nomura K, 2001, BIOL SIGNAL RECEPT, V10, P81; Petrovsky N, 2002, ANN NY ACAD SCI, V958, P204; Pomerleau DP, 2005, DIABETES, V54, P1603, DOI 10.2337/diabetes.54.5.1603; Raha S, 2002, FREE RADICAL BIO MED, V32, P421, DOI 10.1016/S0891-5849(01)00816-4; Ringquist S, 2004, HUM IMMUNOL, V65, P163, DOI 10.1016/j.humimm.2003.11.003; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SEKIGUCHI F, 1990, EXP ANIM TOKYO, V39, P269, DOI 10.1538/expanim1978.39.2_269; Silva DG, 2003, ANN NY ACAD SCI, V1005, P161, DOI 10.1196/annals.1288.018; Silva DG, 2003, J IMMUNOL, V170, P4996, DOI 10.4049/jimmunol.170.10.4996; Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649; Suarez-Pinzon WL, 2000, DIABETOLOGIA, V43, P1149, DOI 10.1007/s001250051506; Suarez-Pinzon WL, 2001, J AUTOIMMUN, V16, P449, DOI 10.1006/jaut.2001.0507; Tabatabaie T, 2000, BIOCHEM BIOPH RES CO, V273, P699, DOI 10.1006/bbrc.2000.2959; Takagi K, 2004, ATHEROSCLEROSIS, V175, P281, DOI 10.1016/j.atherosclerosis.2004.03.008; Tanaka M, 1998, LANCET, V351, P185, DOI 10.1016/S0140-6736(05)78211-8; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; Turko IV, 2003, J BIOL CHEM, V278, P33972, DOI 10.1074/jbc.M303734200; Uchigata Y, 2002, DIABETES CARE, V25, P2106, DOI 10.2337/diacare.25.11.2106; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; Votyakova TV, 2005, J NEUROCHEM, V93, P526, DOI 10.1111/j.1471-4159.2005.03042.x; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Wollheim CB, 2002, DIABETES, V51, pS37, DOI 10.2337/diabetes.51.2007.S37; Yao YG, 2002, HUM GENET, V111, P462, DOI 10.1007/s00439-002-0826-z; Zhang J, 2006, P NATL ACAD SCI USA, V103, P16212, DOI 10.1073/pnas.0604567103	60	50	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5171	5179		10.1074/jbc.M609367200	http://dx.doi.org/10.1074/jbc.M609367200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189252	hybrid			2022-12-25	WOS:000244482300011
J	Fang, Z; Park, CK; Li, HY; Kim, HY; Park, SH; Jung, SJ; Kim, JS; Monteil, A; Oh, SB; Miller, RJ				Fang, Zhi; Park, Chul-Kyu; Li, Hai Ying; Kim, Hyun Yeong; Park, Seong-Hae; Jung, Sung Jun; Kim, Joong Soo; Monteil, Arnaud; Oh, Seog Bae; Miller, Richard J.			Molecular basis of Ca(V)2.3 calcium channels in rat nociceptive neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; CA2+ CHANNELS; ALPHA(1) SUBUNITS; SENSORY NEURONS; PAIN; CELL; RECEPTOR; CURRENTS; MECHANISMS; AXOTOMY	Ca(v)2.3 calcium channels play an important role in pain transmission in peripheral sensory neurons. Six Ca(v)23 isoforms resulting from different combinations of three inserts (inserts I and II in the II-III loop and insert III in the carboxyl-terminal region) have been identified in different mammalian tissues. To date, however, Ca(v)23 isoforms unique to primary sensory neurons have not been identified. In this study, we determined Cav2.3 isoforms expressed in the rat trigeminal ganglion neurons. Whole tissue reverse transcription (RT)-PCR analyses revealed that only two isoforms, Ca(v)2.3a and Ca(v)23e, are present in TG neurons. Using single cell RT-PCR, we found that Ca(v)23e is the major isoform, whereas Ca(v)2.3e expression is highly restricted to small (< 16 mu m) isolectin B4-negative and tyrosine kinase A-positive neurons. Ca(v)23e was also preferentially detected in neurons expressing the nociceptive marker, transient receptor potential vanilloid 1. Single cell RT-PCR following calcium imaging and whole-cell patch clamp recordings provided evidence of an association between an R-type calcium channel component and Ca(v)2.3e expression. Our results suggest that Ca(v)2.3e in sensory neurons may be a potential target for the treatment of pain.	Seoul Natl Univ, Dept Physiol, Sch Dent & Dent Res Inst, Seoul 110749, South Korea; Seoul Natl Univ, Program Mol & Cellular Neurosci, Seoul 110749, South Korea; Kangwon Natl Univ, Dept Physiol, Coll Med, Chunchon 200710, South Korea; Inst Genom Fonct, Dept Physiol, CNRS UMR 5203, F-34396 Montpellier 5, France; Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA	Seoul National University (SNU); Seoul National University (SNU); Kangwon National University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Northwestern University; Feinberg School of Medicine	Oh, SB (corresponding author), Seoul Natl Univ, Dept Physiol, Sch Dent & Dent Res Inst, Seoul 110749, South Korea.	odolbae@snu.ac.kr	Monteil, Arnaud/G-3113-2012; OH, Seog Bae/AAQ-2478-2020	Monteil, Arnaud/0000-0003-1632-7318; 	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013141] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA013141-06A2, R01 DA013141] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bell TJ, 2004, NEURON, V41, P127, DOI 10.1016/S0896-6273(03)00801-8; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Bradbury EJ, 1998, MOL CELL NEUROSCI, V12, P256, DOI 10.1006/mcne.1998.0719; Brown SP, 2004, J NEUROSCI, V24, P5623, DOI 10.1523/JNEUROSCI.0918-04.2004; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Dietrich D, 2003, NEURON, V39, P483, DOI 10.1016/S0896-6273(03)00430-6; DUNLAP K, 1994, SCIENCE, V266, P828, DOI 10.1126/science.7973643; Foehring RC, 2000, J NEUROPHYSIOL, V84, P2225, DOI 10.1152/jn.2000.84.5.2225; Ikeda M, 2003, LIFE SCI, V73, P1175, DOI 10.1016/S0024-3205(03)00414-4; ISHIBASHI H, 1995, NEUROREPORT, V6, P1621, DOI 10.1097/00001756-199508000-00008; Ji RR, 2001, NEUROBIOL DIS, V8, P1, DOI 10.1006/nbdi.2000.0360; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Lambert RC, 1998, J NEUROSCI, V18, P8605; Lee SC, 2002, P NATL ACAD SCI USA, V99, P3276, DOI 10.1073/pnas.052697799; McCleskey EW, 1999, ANNU REV PHYSIOL, V61, P835, DOI 10.1146/annurev.physiol.61.1.835; Michael GJ, 1997, J NEUROSCI, V17, P8476; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Murakami M, 2004, BRAIN RES, V1024, P122, DOI 10.1016/j.brainres.2004.07.066; Murakami M, 2001, BRAIN RES, V903, P231, DOI 10.1016/S0006-8993(01)02427-1; Murray SS, 2003, J ANAT, V202, P227, DOI 10.1046/j.1469-7580.2003.00151.x; NAGY JI, 1982, NEUROSCIENCE, V7, P89, DOI 10.1016/0306-4522(82)90155-5; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; Pereverzev A, 2002, MOL CELL NEUROSCI, V21, P352, DOI 10.1006/mcne.2002.1179; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Piedras-Renteria ES, 1998, P NATL ACAD SCI USA, V95, P7760, DOI 10.1073/pnas.95.13.7760; Saegusa H, 2000, P NATL ACAD SCI USA, V97, P6132, DOI 10.1073/pnas.100124197; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; Schramm M, 1999, NEUROSCIENCE, V92, P565, DOI 10.1016/S0306-4522(99)00013-5; Sessle Barry J, 2002, J Dent Educ, V66, P108; Silbert SC, 2003, J NEUROSCI, V23, P34; Snider WD, 1998, NEURON, V20, P629, DOI 10.1016/S0896-6273(00)81003-X; Stucky CL, 1999, J NEUROSCI, V19, P6497; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tottene A, 2000, J NEUROSCI, V20, P171, DOI 10.1523/JNEUROSCI.20-01-00171.2000; Vajna R, 1998, EUR J BIOCHEM, V257, P274, DOI 10.1046/j.1432-1327.1998.2570274.x; Vanegas H, 2000, PAIN, V85, P9, DOI 10.1016/S0304-3959(99)00241-9; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Wilson SM, 2000, J NEUROSCI, V20, P8566; Yaksh TL, 2006, J PAIN, V7, pS13, DOI 10.1016/j.jpain.2005.09.007; Yang BH, 2003, J DENT RES, V82, P781, DOI 10.1177/154405910308201004; Yusaf SP, 2001, NEUROSCI LETT, V311, P137, DOI 10.1016/S0304-3940(01)02038-9; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	45	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4757	4764		10.1074/jbc.M605248200	http://dx.doi.org/10.1074/jbc.M605248200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17145762	Green Accepted, hybrid			2022-12-25	WOS:000244482000057
J	Kruglik, SG; Lambry, JC; Cianetti, S; Martin, JL; Eady, RR; Andrew, CR; Negrerie, M				Kruglik, Sergei G.; Lambry, Jean-Christophe; Cianetti, Simona; Martin, Jean-Louis; Eady, Robert R.; Andrew, Colin R.; Negrerie, Michel			Molecular basis for nitric oxide dynamics and affinity with Alcaligenes xylosoxidans cytochrome c '	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; RESOLVED RESONANCE RAMAN; HEME-BASED SENSORS; SP NCIB 11015; LIGAND-BINDING; GEMINATE RECOMBINATION; RHODOBACTER-CAPSULATUS; MYOGLOBIN MUTANT; NO; SPECTROSCOPY	The bacterial heme protein cytochrome c' from Alcaligenes xylosoxidans (AXCP) reacts with nitric oxide (NO) to form a 5-coordinate ferrous nitrosyl heme complex. The crystal structure of ferrous nitrosyl AXCP has previously revealed that NO is bound in an unprecedented manner on the proximal side of the heme. To understand how the protein structure of AXCP controls NO dynamics, we performed absorption and Raman time-resolved studies at the heme level as well as a molecular computational dynamics study at the entire protein structure level. We found that after NO dissociation from the heme iron, the structure of the proximal heme pocket of AXCP confines NO close to the iron so that an ultrafast (7 ps) and complete (99 +/- 1%) geminate rebinding occurs, whereas the proximal histidine does not rebind to the heme iron on the timescale of NO geminate rebinding. The distal side controls the initial NO binding, whereas the proximal heme pocket controls its release. These dynamic properties allow the trapping of NO within the protein core and represent an extreme behavior observed among heme proteins.	Ecole Polytech, Lab Opt Biosci, INSERM, U696, F-91128 Palaiseau, France; Univ Paris 06, CNRS, UMR 7033, BioMoCeTi, F-91030 Evry, France; INSERM, U696, F-91128 Palaiseau, France; John Innes Ctr, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England; Eastern Oregon Univ, Dept Chem & Biochem, La Grande, OR 97850 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Eastern Oregon University	Negrerie, M (corresponding author), Ecole Polytech, Lab Opt Biosci, INSERM, U696, F-91128 Palaiseau, France.	michel.negrerie@polytechnique.fr	Negrerie, Michel/L-2283-2018; Kruglik, Sergei/F-7042-2012	Negrerie, Michel/0000-0001-9918-031X; Kruglik, Sergei/0000-0002-2945-3092; Lambry, Jean-Christophe/0000-0001-8264-0391				ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; AMBLER RP, 1973, BIOCHEM J, V135, P751, DOI 10.1042/bj1350751; Andrew CR, 2005, BIOCHEMISTRY-US, V44, P8664, DOI 10.1021/bi050428g; Andrew CR, 2003, J AM CHEM SOC, V125, P9548, DOI 10.1021/ja035105r; Andrew CR, 2002, BIOCHEMISTRY-US, V41, P2353, DOI 10.1021/bi011419k; Andrew CR, 2001, BIOCHEMISTRY-US, V40, P4115, DOI 10.1021/bi0023652; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunori M, 1999, BIOPHYS J, V76, P1259, DOI 10.1016/S0006-3495(99)77289-9; CARVER TE, 1990, J BIOL CHEM, V265, P20007; Choi PS, 2005, J BACTERIOL, V187, P4077, DOI 10.1128/JB.187.12.4077-4085.2005; Chowdhury PK, 2003, J PHYS CHEM B, V107, P9122, DOI 10.1021/jp030106r; Cianetti S, 2004, J AM CHEM SOC, V126, P13932, DOI 10.1021/ja046442i; Cross R, 2000, J BACTERIOL, V182, P1442, DOI 10.1128/JB.182.5.1442-1447.2000; Cross R, 2001, J BACTERIOL, V183, P3050, DOI 10.1128/JB.183.10.3050-3054.2001; Decatur SM, 1996, BIOCHEMISTRY-US, V35, P4939, DOI 10.1021/bi951661p; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DUPRAT AF, 1995, BIOCHEMISTRY-US, V34, P2634, DOI 10.1021/bi00008a030; FINDSEN EW, 1988, J PHYS CHEM-US, V92, P307, DOI 10.1021/j100313a014; Franzen S, 2002, P NATL ACAD SCI USA, V99, P16754, DOI 10.1073/pnas.252590999; George SJ, 2001, J AM CHEM SOC, V123, P9683, DOI 10.1021/ja0158307; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; Ionascu D, 2005, J AM CHEM SOC, V127, P16921, DOI 10.1021/ja054249y; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; Kholodenko Y, 1999, BIOCHEMISTRY-US, V38, P5918, DOI 10.1021/bi983022v; Kruglik SG, 2001, J PHYS CHEM B, V105, P5018, DOI 10.1021/jp004207q; LAMBRY JC, 1997, THESIS PARIS SUD U O; Lawson DM, 2000, EMBO J, V19, P5661, DOI 10.1093/emboj/19.21.5661; Liebl U, 2003, BIOCHEMISTRY-US, V42, P6527, DOI 10.1021/bi027359f; Liebl U, 2002, P NATL ACAD SCI USA, V99, P12771, DOI 10.1073/pnas.192311699; Liu Y, 1999, BIOCHEMISTRY-US, V38, P3733, DOI 10.1021/bi982707s; Marti MA, 2005, J AM CHEM SOC, V127, P7721, DOI 10.1021/ja042870c; MARTIN JL, 1992, ANNU REV BIOPH BIOM, V21, P199, DOI 10.1146/annurev.bb.21.060192.001215; Mayburd AL, 2002, BIOCHEMISTRY-US, V41, P11582, DOI 10.1021/bi020058l; Meuwly M, 2002, BIOPHYS CHEM, V98, P183, DOI 10.1016/S0301-4622(02)00093-5; Negrerie M, 2006, J BIOL CHEM, V281, P10389, DOI 10.1074/jbc.M513375200; Negrerie M, 2001, J BIOL CHEM, V276, P46815, DOI 10.1074/jbc.M102224200; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; Negrerie M, 2006, J PHYS CHEM B, V110, P12766, DOI 10.1021/jp0559377; Nioche P, 2004, SCIENCE, V306, P1550, DOI 10.1126/science.1103596; NORRIS GE, 1979, J MOL BIOL, V135, P309, DOI 10.1016/0022-2836(79)90357-7; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; PARTHASARATHI N, 1987, J AM CHEM SOC, V109, P3865, DOI 10.1021/ja00247a009; PETRICH JW, 1994, J MOL BIOL, V238, P437, DOI 10.1006/jmbi.1994.1302; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Romao M. J., 2001, HDB METALLOPROTEINS, P44; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Wasser IM, 2002, CHEM REV, V102, P1201, DOI 10.1021/cr0006627; Ye X, 2002, J AM CHEM SOC, V124, P5914, DOI 10.1021/ja017359n; YOSHIMURA T, 1986, BIOCHEMISTRY-US, V25, P2436, DOI 10.1021/bi00357a021; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753	54	35	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					5053	5062		10.1074/jbc.M604327200	http://dx.doi.org/10.1074/jbc.M604327200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158883	hybrid			2022-12-25	WOS:000244482000088
J	Visser, F; Valsecchi, V; Annunziato, L; Lytton, J				Visser, Frank; Valsecchi, Valeria; Annunziato, Lucio; Lytton, Jonathan			Analysis of ion interactions with the K+-dependent Na+/Ca2+ exchangers NCKX2, NCKX3, and NCKX4 - Identification of THR-551 as a key residue in defining the apparent K+ affinity of NCKX2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; BINDING POCKET; GENE FAMILY; CA2+; TOPOLOGY; MUTAGENESIS; TRANSPORT; SEGMENTS	K+-dependent Na+/Ca2+ exchangers (NCKX) catalyze cytosolic Ca2+ extrusion and are particularly important for neuronal Ca2+ signaling. Of the five mammalian isoforms, the detailed functional characteristics have only been reported for NCKX1 and -2. In the current study, the functional characteristics of recombinant NCKX3 and -4 expressed in HEK293 cells were determined and compared with those of NCKX2. Although the apparent affinities of the three isoforms for Ca2+ and Na+ were similar, NCKX3 and -4 displayed similar to 40-fold higher affinities for K+ ions than NCKX2. Functional analysis of various NCKX2 mutants revealed that mutation of Thr-551 to Ala, the corresponding residue in NCKX4, resulted in an apparent K+ affinity shift to one similar to that of NCKX4 without a parallel shift in apparent Ca2+ affinity. In the converse situation, when Gln-476 of NCKX4 was converted to Lys, the corresponding residue in NCKX2, both the K+ and Ca2+ affinities were reduced. These results indicate that the apparently low K+ affinity of NCKX2 requires a Thr residue at position 551 that may reduce the conformational flexibility and/or K+ liganding strength of side-chain moieties on critical neighboring residues. This interaction appears to be specific to the structural context of the NCKX2 K+ binding pocket, because it was not possible to recreate the K+-specific low affinity phenotype with reciprocal mutations in NCKX4. The results of this study provide important information about the structure and function of NCKX proteins and will be critical to understanding their roles in neuronal Ca2+ signaling.	Univ Calgary, Libin Cardiovasc Inst Alberta, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Hotchkiss Brain Inst, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Naples Federico II, Div Pharmacol, Dept Neurosci, Sch Med, I-80131 Naples, Italy	Libin Cardiovascular Institute Of Alberta; University of Calgary; University of Calgary; University of Naples Federico II	Lytton, J (corresponding author), Univ Calgary, Libin Cardiovasc Inst Alberta, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.	jlytton@ucalgary.ca		Lytton, Jonathan/0000-0003-4770-2512; valsecchi, valeria/0000-0003-3625-8495; ANNUNZIATO, LUCIO/0000-0002-8534-8270				Augustine GJ, 2003, NEURON, V40, P331, DOI 10.1016/S0896-6273(03)00639-1; AUSUBEL FM, 2006, CURRNET PROTOCOLS MO; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Cai XJ, 2004, MOL BIOL EVOL, V21, P1692, DOI 10.1093/molbev/msh177; Cai XJ, 2002, J BIOL CHEM, V277, P48923, DOI 10.1074/jbc.M208818200; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; Dong H, 2001, J BIOL CHEM, V276, P25919, DOI 10.1074/jbc.M103401200; FONTANA G, 1995, J PHYSIOL-LONDON, V485, P349, DOI 10.1113/jphysiol.1995.sp020734; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iwamoto T, 1999, J BIOL CHEM, V274, P23094, DOI 10.1074/jbc.274.33.23094; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Kang K, 2003, BIOCHEMISTRY-US, V42, P9438, DOI 10.1021/bi0342261; Kang KJ, 2005, J BIOL CHEM, V280, P6834, DOI 10.1074/jbc.M412933200; Kang KJ, 2005, J BIOL CHEM, V280, P6823, DOI 10.1074/jbc.M407933200; Kinjo TG, 2005, BIOCHEMISTRY-US, V44, P7787, DOI 10.1021/bi0502442; Kinjo TG, 2003, BIOCHEMISTRY-US, V42, P2485, DOI 10.1021/bi0270788; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; Kraev A, 2001, J BIOL CHEM, V276, P23161, DOI 10.1074/jbc.M102314200; Lamason RL, 2005, SCIENCE, V310, P1782, DOI 10.1126/science.1116238; Lee JY, 2006, J BIOL CHEM, V281, P39205, DOI 10.1074/jbc.M606287200; Lee SH, 2002, J NEUROSCI, V22, P6891; Li XF, 2002, J BIOL CHEM, V277, P48410, DOI 10.1074/jbc.M210011200; Li XF, 2006, J BIOL CHEM, V281, P6273, DOI 10.1074/jbc.M512137200; LI ZP, 1994, J BIOL CHEM, V269, P17434; Linck B, 1998, AM J PHYSIOL-CELL PH, V274, pC415, DOI 10.1152/ajpcell.1998.274.2.C415; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Ottolia M, 2005, J BIOL CHEM, V280, P1061, DOI 10.1074/jbc.M411899200; Prinsen CFM, 2000, J NEUROSCI, V20, P1424; Quednau BD, 2004, PFLUG ARCH EUR J PHY, V447, P543, DOI 10.1007/s00424-003-1065-4; REEVES JP, 1983, J BIOL CHEM, V258, P3178; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P189; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22975; Schnetkamp PPM, 2004, PFLUG ARCH EUR J PHY, V447, P683, DOI 10.1007/s00424-003-1069-0; Szerencsei RT, 2000, J BIOL CHEM, V275, P669, DOI 10.1074/jbc.275.1.669; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Winkfein RJ, 2003, BIOCHEMISTRY-US, V42, P543, DOI 10.1021/bi026982x	41	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4453	4462		10.1074/jbc.M610582200	http://dx.doi.org/10.1074/jbc.M610582200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17172467	hybrid			2022-12-25	WOS:000244482000026
J	Altimimi, HF; Schnetkamp, PPM				Altimimi, Haider F.; Schnetkamp, Paul P. M.			Na+-dependent inactivation of the retinal cone/brain Na+/Ca2+-K+ exchanger NCKX2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; SODIUM-CALCIUM EXCHANGER; NA/CA-K EXCHANGER; MOLECULAR-CLONING; NA+-CA2+ EXCHANGER; POSTTETANIC POTENTIATION; CONE PHOTORECEPTORS; CA2+ CONCENTRATION; BINDING POCKET; AXON TERMINALS	The SLC24 gene family Na+/Ca2+-K+ exchangers (NCKX) are bidirectional plasma membrane transporters whose main function is the extrusion of Ca2+ from the cytosol. In this study, we used human embryonic kidney 293 cells expressing human retinal cone/brain NCKX2 to examine its Na+ affinity and kinetic parameters of Ca2+ transport. With the use of the ionophore gramicidin to control alkali cation concentrations across the plasma membrane, application of high intracellular Na+ promoted large NCKX2-mediated increases in intracellular free Ca2+ in the 15-20 mu M range; this also resulted in inactivation of NCKX2 transport, the first description of this novel kinetic state. The affinity of NCKX2 for internal Na+ was found to be sigmoidal, with a Hill coefficient of 2.6 and K-d = 50 mm. The time-dependent (t1/2 similar to 40s) inactivation of NCKX2 required high intracellular Na+ levels (K-d > 50 mM) as well as high occupancy of the extracellular Ca2+-binding site. Also reported are two residues whose substitution resulted in an increase in internal Na+ affinity to values of similar to 19 mm; these mutants also displayed enhanced inactivation, suggesting that inactivation requires binding of Na+ to its intracellular transport sites. These findings are the first report of a regulatory kinetic state of Ca2+ transport via NCKX2 Na+/Ca2+-K+ exchangers that may play a prominent role in regulation of Ca2+ extrusion in cellular environments such as neuronal synapses that experience frequent and dynamic Ca2+ fluxes.	Univ Calgary, Dept Physiol & Biophys, Fac Med, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada	University of Calgary	Schnetkamp, PPM (corresponding author), Univ Calgary, Dept Physiol & Biophys, Fac Med, Hotchkiss Brain Inst, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	pschnetk@ucalgary.ca	Altimimi, Haider/K-8658-2012	Altimimi, Haider/0000-0002-4516-141X				Bogeski I, 2006, CELL CALCIUM, V40, P1, DOI 10.1016/j.ceca.2006.03.003; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; Cooper CB, 2000, METHOD ENZYMOL, V315, P847; Dong H, 2001, J BIOL CHEM, V276, P25919, DOI 10.1074/jbc.M103401200; Garcia-Chacon LE, 2006, J PHYSIOL-LONDON, V574, P663, DOI 10.1113/jphysiol.2006.110841; Habets RLP, 2005, J PHYSIOL-LONDON, V564, P173, DOI 10.1113/jphysiol.2004.079160; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; Kang K, 2003, BIOCHEMISTRY-US, V42, P9438, DOI 10.1021/bi0342261; Kang KJ, 2005, J BIOL CHEM, V280, P6834, DOI 10.1074/jbc.M412933200; Kang KJ, 2005, J BIOL CHEM, V280, P6823, DOI 10.1074/jbc.M407933200; Kim MH, 2005, J NEUROSCI, V25, P6057, DOI 10.1523/JNEUROSCI.0454-05.2005; Kim MH, 2003, J NEUROSCI, V23, P11673; Kinjo TG, 2005, BIOCHEMISTRY-US, V44, P7787, DOI 10.1021/bi0502442; Kinjo TG, 2003, BIOCHEMISTRY-US, V42, P2485, DOI 10.1021/bi0270788; Kraev A, 2001, J BIOL CHEM, V276, P23161, DOI 10.1074/jbc.M102314200; Lamason RL, 2005, SCIENCE, V310, P1782, DOI 10.1126/science.1116238; Lee SH, 2002, J NEUROSCI, V22, P6891; LEE SL, 1994, J BIOL CHEM, V269, P14849; Li XF, 2002, J BIOL CHEM, V277, P48410, DOI 10.1074/jbc.M210011200; Li XF, 2006, J BIOL CHEM, V281, P6273, DOI 10.1074/jbc.M512137200; LI ZP, 1994, J BIOL CHEM, V269, P17434; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; Opuni K, 2000, J BIOL CHEM, V275, P21549, DOI 10.1074/jbc.M003158200; Paillart C, 2007, J GEN PHYSIOL, V129, P1, DOI 10.1085/jgp.200609652; Prinsen CFM, 2000, J NEUROSCI, V20, P1424; Prinsen CFM, 2002, ADV EXP MED BIOL, V514, P237; Quednau BD, 2004, PFLUG ARCH EUR J PHY, V447, P543, DOI 10.1007/s00424-003-1065-4; REGEHR WG, 1994, J NEUROSCI, V14, P523; SCHNETKAMP PPM, 1991, J GEN PHYSIOL, V98, P555, DOI 10.1085/jgp.98.3.555; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P189; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22983; SCHNETKAMP PPM, 1995, AM J PHYSIOL-CELL PH, V269, pC1153, DOI 10.1152/ajpcell.1995.269.5.C1153; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22975; Schnetkamp PPM, 2004, PFLUG ARCH EUR J PHY, V447, P683, DOI 10.1007/s00424-003-1069-0; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; SCHNETKAMP PPM, 1995, CELL CALCIUM, V18, P322, DOI 10.1016/0143-4160(95)90028-4; SCHNETKAMP PPM, 1995, J BIOL CHEM, V270, P13231, DOI 10.1074/jbc.270.22.13231; SCHNETKAMP PPM, 1986, J PHYSIOL-LONDON, V373, P25, DOI 10.1113/jphysiol.1986.sp016033; SCHNETKAMP PPM, 1995, BIOCHEMISTRY-US, V34, P7282, DOI 10.1021/bi00021a045; Sheng JZ, 2000, BIOPHYS J, V79, P1945, DOI 10.1016/S0006-3495(00)76443-5; Tang YG, 1997, NEURON, V18, P483, DOI 10.1016/S0896-6273(00)81248-9; Tanneur V, 2002, PFLUG ARCH EUR J PHY, V445, P74, DOI 10.1007/s00424-002-0859-0; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Winkfein RJ, 2003, BIOCHEMISTRY-US, V42, P543, DOI 10.1021/bi026982x; YAU KW, 1984, NATURE, V309, P352, DOI 10.1038/309352a0; Zhong N, 2001, J NEUROSCI, V21, P9598, DOI 10.1523/JNEUROSCI.21-24-09598.2001	47	18	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3720	3729		10.1074/jbc.M609285200	http://dx.doi.org/10.1074/jbc.M609285200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17164249	hybrid			2022-12-25	WOS:000244481900035
J	Frugier, G; Coussen, F; Giraud, MF; Odessa, MF; Emerit, MB; Boue-Grabot, E; Garret, M				Frugier, Guillaume; Coussen, Francoise; Giraud, Marie-France; Odessa, Marie-Francoise; Emerit, Michel B.; Boue-Grabot, Eric; Garret, Maurice			A gamma 2(R43Q) mutation, linked to epilepsy in humans, alters GABA(A) receptor assembly and modifies subunit composition on the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID TYPE-A; CHILDHOOD ABSENCE EPILEPSY; FEBRILE SEIZURES; INHIBITORY SYNAPSES; EXPRESSION; GAMMA-2-SUBUNIT; TRAFFICKING; MODEL; OVEREXPRESSION; LOCALIZATION	Genetic defects leading to epilepsy have been identified in gamma 2 GABA(A) receptor subunit. A gamma 2(R43Q) substitution is linked to childhood absence epilepsy and febrile seizure, and a gamma 2(K289M) mutation is associated with generalized epilepsy with febrile seizures plus. To understand the effect of these mutations, surface targeting of GABAA receptors was analyzed by subunit-specific immunofluorescent labeling of living cells. We first transfected hippocampal neurons in culture with recombinant gamma 2 constructs and showed that the gamma 2(R43Q) mutation prevented surface expression of the subunit, unlike gamma 2(K289M) substitution. Several gamma 2-subunit constructs, bearing point mutations within the Arg-43 domain, were expressed in COS-7 cells with alpha 3- and beta 3-subunits. R43Q and R43A substitutions dramatically reduced surface expression of the gamma 2-subunit, whereas R43K, P44A, and D39A substitutions had a lesser, but still significant, impact and K289M substitution had no effect. Whereas the mutant gamma 2(R43Q) was retained within intracellular compartments, alpha beta complexes were still targeted at the cell membrane. Coimmunoprecipitation experiments showed that gamma 2(R43Q) was able to associate with alpha 3- or beta 3-subunits, although the stoichiometry of the complex with alpha 3 was altered. Our data show that gamma 2(R43Q) is not a dominant negative and that the mutation leads to a modification of GABAA receptor subunit composition on the cell surface that impairs the synaptic targeting in neurons. This study reveals an involvement of the gamma 2-Arg-43 domain in the control of receptor assembly that may be relevant to the effect of the heterozygous gamma 2(R43Q) mutation leading to childhood absence epilepsy and febrile seizure.	Univ Bordeaux 2, CNRS, UMR 5543, Neurophysiol Lab, F-33076 Bordeaux, France; Inst F Magendie, UMR 5091, F-33077 Bordeaux, France; CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Inst Natl Sante & Rech Med, U288, F-75013 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Garret, M (corresponding author), Univ Bordeaux 2, CNRS, UMR 5543, Neurophysiol Lab, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	maurice.garret@u-bordeaux2.fr	Boué-Grabot, Eric/AAQ-2061-2020; Scheffer, Ingrid/G-1668-2013	Boué-Grabot, Eric/0000-0003-2187-9037; Scheffer, Ingrid/0000-0002-2311-2174; Emerit, Michel Boris/0000-0003-4824-535X				Alldred MJ, 2005, J NEUROSCI, V25, P594, DOI 10.1523/JNEUROSCI.4011-04.2005; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; Baumann SW, 2002, J BIOL CHEM, V277, P46020, DOI 10.1074/jbc.M207663200; Bianchi MT, 2002, J NEUROSCI, V22, P5321; Bollan K, 2003, J BIOL CHEM, V278, P4747, DOI 10.1074/jbc.M210229200; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Boue-Grabot E, 2004, J BIOL CHEM, V279, P52517, DOI 10.1074/jbc.M410223200; Boue-Grabot E, 2004, J BIOL CHEM, V279, P6967, DOI 10.1074/jbc.M307772200; Bowser DN, 2002, P NATL ACAD SCI USA, V99, P15170, DOI 10.1073/pnas.212320199; Connolly CN, 1999, MOL CELL NEUROSCI, V13, P259, DOI 10.1006/mcne.1999.0746; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Cossart R, 2005, TRENDS NEUROSCI, V28, P108, DOI 10.1016/j.tins.2004.11.011; Cossette P, 2002, NAT GENET, V31, P184, DOI 10.1038/ng885; Coussen F, 2002, J NEUROSCI, V22, P6426, DOI 10.1523/jneurosci.22-15-06426.2002; Crestani F, 1999, NAT NEUROSCI, V2, P833, DOI 10.1038/12207; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; EUGENE E, 2006, FENS, V3; Feng HJ, 2006, J NEUROSCI, V26, P1499, DOI 10.1523/JNEUROSCI.2913-05.2006; Fritschy JM, 2003, PHARMACOL THERAPEUT, V98, P299, DOI 10.1016/S0163-7258(03)00037-8; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUNTHER U, 1995, P NATL ACAD SCI USA, V92, P7749, DOI 10.1073/pnas.92.17.7749; Hales TG, 2005, MOL CELL NEUROSCI, V29, P120, DOI 10.1016/j.mcn.2005.01.002; Hanchar HJ, 2005, NAT NEUROSCI, V8, P339, DOI 10.1038/nn1398; Jacobs C, 2003, MOL CELL ENDOCRINOL, V209, P71, DOI 10.1016/j.mce.2003.07.002; Jaskolski F, 2004, J NEUROSCI, V24, P2506, DOI 10.1523/JNEUROSCI.5116-03.2004; Jin P, 2004, J BIOL CHEM, V279, P14179, DOI 10.1074/jbc.M313411200; KAIN SR, 1994, BIOTECHNIQUES, V17, P982; Kananura C, 2002, ARCH NEUROL-CHICAGO, V59, P1137, DOI 10.1001/archneur.59.7.1137; Kang JQ, 2006, J NEUROSCI, V26, P2590, DOI 10.1523/JNEUROSCI.4243-05.2006; Kang JQ, 2004, J NEUROSCI, V24, P8672, DOI 10.1523/JNEUROSCI.2717-04.2004; Klausberger T, 2001, J NEUROSCI, V21, P9124, DOI 10.1523/JNEUROSCI.21-23-09124.2001; Korpi ER, 2006, PHARMACOL THERAPEUT, V109, P12, DOI 10.1016/j.pharmthera.2005.05.009; Li HF, 2006, NEUROPHARMACOLOGY, V51, P121, DOI 10.1016/j.neuropharm.2006.03.003; Luscher B, 2004, PHARMACOL THERAPEUT, V102, P195, DOI 10.1016/j.pharmthera.2004.04.003; Maljevic S, 2006, ANN NEUROL, V59, P983, DOI 10.1002/ana.20874; Milligan CJ, 2004, J NEUROSCI, V24, P7241, DOI 10.1523/JNEUROSCI.1979-04.2004; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Noebels JL, 2003, ANNU REV NEUROSCI, V26, P599, DOI 10.1146/annurev.neuro.26.010302.081210; O'Mara M, 2005, BIOPHYS J, V88, P3286, DOI 10.1529/biophysj.104.051664; Sancar F, 2004, J BIOL CHEM, V279, P47034, DOI 10.1074/jbc.M403388200; Semyanov A, 2004, TRENDS NEUROSCI, V27, P262, DOI 10.1016/j.tins.2004.03.005; TAN HO, 2005, 2005 ABSTR VIEW IT P; Taylor AB, 2006, J NEUROSCI, V26, P1154, DOI 10.1523/JNEUROSCI.4424-05.2006; Thomas P, 2005, NAT NEUROSCI, V8, P889, DOI 10.1038/nn1483; Thompson SA, 2002, NEUROPHARMACOLOGY, V43, P662, DOI 10.1016/S0028-3908(02)00162-4; Toulme E, 2006, MOL PHARMACOL, V69, P576, DOI 10.1124/mol.105.018812; VANGUNSTEREN WF, 1996, GROMOS 96 MANUAL USE; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/ng0501-49; Wanamaker CP, 2003, ANN NY ACAD SCI, V998, P66, DOI 10.1196/annals.1254.009	50	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3819	3828		10.1074/jbc.M608910200	http://dx.doi.org/10.1074/jbc.M608910200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148443	hybrid			2022-12-25	WOS:000244481900045
J	Ma, CP; Lu, XZ; Shi, C; Li, JB; Gu, YC; Ma, YM; Chu, Y; Han, F; Gong, QH; Yu, WG				Ma, Cuiping; Lu, Xinzhi; Shi, Chao; Li, Jingbao; Gu, Yuchao; Ma, Yiming; Chu, Yan; Han, Feng; Gong, Qianhong; Yu, Wengong			Molecular cloning and characterization of a novel beta-agarase, AgaB, from marine Pseudoalteromonas sp CY24	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SEQUENCE-BASED CLASSIFICATION; SP STRAIN JT0107; PSEUDOMONAS-ATLANTICA; GLYCOSYL HYDROLASES; BACILLUS-LICHENIFORMIS; ALPHA-AGARASE; ACTIVE-SITE; CARBOXYLIC RESIDUES; NUCLEOTIDE-SEQUENCE	Agarases are generally classified into glycoside hydrolase families 16, 50, and 86 and are found to degrade agarose to frequently generate neoagarobiose, neoagarotetraose, or neoagarohexaose as the main products. In this study we have cloned a novel endo-type beta-agarase gene, agaB, from marine Pseudoalteromonas sp. CY24. The novel agarase encoded by agaB gene has no significant sequence similarity with any known proteins including all glycoside hydrolases. It degrades agarose to generate neoagarooctaose and neoagarodecaose as the main end products. Based on the analyses of enzymatic kinetics and degradation patterns of different oligosaccharides, the agarase AgaB appears to have a large substrate binding cleft that accommodates 12 sugar units, with 8 sugar units toward the reducing end spanning subsites + 1 to + 8 and 4 sugar units toward the non-reducing end spanning subsites -4 to -1, and enzymatic cleavage taking place between subsites -1 and +1. In addition, H-1 NMR analysis shows that this enzyme hydrolyzes the glycosidic bond with inversion of anomeric configuration, in contrast to other known agarases that are retaining. Altogether, AgaB is structurally and functionally different from other known agarases and appears to represent a new family of glycoside hydrolase.	Ocean Univ China, Dept Mol Biol, Marine Drug & Food Inst, Qingdao 266003, Peoples R China	Ocean University of China	Yu, WG (corresponding author), Ocean Univ China, Dept Mol Biol, Marine Drug & Food Inst, 5 Yushan Rd, Qingdao 266003, Peoples R China.	yuwg66@ouc.edu.cn		Ma, Cuiping/0000-0001-5491-7269				Allouch J, 2003, J BIOL CHEM, V278, P47171, DOI 10.1074/jbc.M308313200; Araki T, 1998, J MAR BIOTECHNOL, V6, P193; ARNOTT S, 1974, J MOL BIOL, V90, P269, DOI 10.1016/0022-2836(74)90372-6; BELAS R, 1989, J BACTERIOL, V171, P602, DOI 10.1128/jb.171.1.602-605.1989; BELAS R, 1988, APPL ENVIRON MICROB, V54, P30, DOI 10.1128/AEM.54.1.30-37.1988; BUTTNER MJ, 1987, MOL GEN GENET, V209, P101, DOI 10.1007/BF00329843; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DUCKWORTH M, 1969, BIOCHEM J, V113, P693, DOI 10.1042/bj1130693; GEBLER J, 1992, J BIOL CHEM, V267, P12559; GROLEAU D, 1977, CAN J MICROBIOL, V23, P672, DOI 10.1139/m77-100; Ha JC, 1997, BIOTECHNOL APPL BIOC, V26, P1; Hassairi I, 2001, BIORESOURCE TECHNOL, V79, P47, DOI 10.1016/S0960-8524(01)00037-2; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Henrissat B, 2000, PLANT PHYSIOL, V124, P1515, DOI 10.1104/pp.124.4.1515; Jam M, 2005, BIOCHEM J, V385, P703, DOI 10.1042/BJ20041044; JUNCOSA M, 1994, J BIOL CHEM, V269, P14530; Kandra L, 2003, FEBS LETT, V544, P194, DOI 10.1016/S0014-5793(03)00495-2; Kandra L, 2002, FEBS LETT, V518, P79, DOI 10.1016/S0014-5793(02)02649-2; Kobayashi R, 1997, BIOSCI BIOTECH BIOCH, V61, P162, DOI 10.1271/bbb.61.162; Krah M, 1998, EUR J BIOCHEM, V257, P101, DOI 10.1046/j.1432-1327.1998.2570101.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHAYE M, 1989, CARBOHYD RES, V190, P249, DOI 10.1016/0008-6215(89)84129-1; LAHAYE M, 1986, THESIS MCGILL U; MALMQVIST M, 1978, BIOCHIM BIOPHYS ACTA, V537, P31, DOI 10.1016/0005-2795(78)90600-1; MEULEN HJ, 1975, ANTON LEEUW INT J G, V41, P431; Michel G, 2001, STRUCTURE, V9, P513, DOI 10.1016/S0969-2126(01)00612-8; Michel G, 2001, J BIOL CHEM, V276, P40202, DOI 10.1074/jbc.M100670200; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; MORRICE LM, 1983, EUR J BIOCHEM, V137, P149, DOI 10.1111/j.1432-1033.1983.tb07808.x; MORRICE LM, 1983, EUR J BIOCHEM, V135, P553, DOI 10.1111/j.1432-1033.1983.tb07688.x; Ohta Y, 2004, APPL MICROBIOL BIOT, V64, P505, DOI 10.1007/s00253-004-1573-y; Ohta Y, 2005, CURR MICROBIOL, V50, P212, DOI 10.1007/s00284-004-4435-z; OLIVER JD, 1982, DEEP-SEA RES, V29, P795, DOI 10.1016/0198-0149(82)90007-3; OSCAR L, 1992, APPL ENVIRON MICROB, V58, P4060; Pitson SM, 1997, CARBOHYD RES, V303, P207, DOI 10.1016/S0008-6215(97)00159-6; PLANAS A, 1992, FEBS LETT, V308, P141, DOI 10.1016/0014-5793(92)81262-K; Polz MF, 1998, APPL ENVIRON MICROB, V64, P3724; POTIN P, 1993, EUR J BIOCHEM, V214, P599, DOI 10.1111/j.1432-1033.1993.tb17959.x; ROCHAS C, 1986, CARBOHYD RES, V148, P199, DOI 10.1016/S0008-6215(00)90388-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schroeder DC, 2003, MICROBIOL-SGM, V149, P2919, DOI 10.1099/mic.0.26513-0; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SUGANO Y, 1993, APPL ENVIRON MICROB, V59, P1549; SUGANO Y, 1994, BBA-GENE STRUCT EXPR, V1218, P105, DOI 10.1016/0167-4781(94)90109-0; Vera J, 1998, APPL ENVIRON MICROB, V64, P4378; Weinberger F, 2001, J PHYCOL, V37, P418, DOI 10.1046/j.1529-8817.2001.037003418.x; YOSHIZAWA Y, 1995, BIOSCI BIOTECH BIOCH, V59, P1933, DOI 10.1271/bbb.59.1933; Yu GL, 2002, CARBOHYD RES, V337, P433, DOI 10.1016/S0008-6215(02)00009-5; Zhong ZP, 2001, APPL ENVIRON MICROB, V67, P5771, DOI 10.1128/AEM.67.12.5771-5779.2001; Zverlov VV, 1998, FEMS MICROBIOL LETT, V164, P337, DOI 10.1016/S0378-1097(98)00236-5	52	77	90	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3747	3754		10.1074/jbc.M607888200	http://dx.doi.org/10.1074/jbc.M607888200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17166842	hybrid			2022-12-25	WOS:000244481900038
J	Xia, DR; Srinivas, H; Ahn, YH; Sethi, G; Sheng, XY; Yung, WKA; Xia, QH; Chiao, PJ; Kim, H; Brown, PH; Wistuba, II; Aggarwal, BB; Kurie, JM				Xia, Dianren; Srinivas, Harish; Ahn, Young-Ho; Sethi, Gautam; Sheng, Xiaoyang; Yung, W. K. Alfred; Xia, Qianghua; Chiao, Paul J.; Kim, Heetae; Brown, Powel H.; Wistuba, Ignacio I.; Aggarwal, Bharat B.; Kurie, Jonathan M.			Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; TUMOR-SUPPRESSOR; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; MICE LACKING; GENE; INHIBITION; JNK; MUTATIONS; APOPTOSIS	Mitogen-activated protein kinase kinase-4 (MKK4/SEK1) cooperates with phosphatidylinositol 3-kinase to maintain the survival of non-small cell lung cancer (NSCLC) cells, but the biochemical basis of this phenomenon has not been elucidated. Here we used genetic approaches to modulate MKK4 expression in mouse embryo fibroblasts (MEF cells) and NSCLC cells to identify prosurvival signals downstream of MKK4. Relative to wild-type MEF cells, MKK4-null MEF cells were highly susceptible to apoptosis by LY294002, paclitaxel, or serum starvation. MKK4 promoted the survival of MEF cells by decreasing the expression of phosphatase and tensin homologue deleted from chromosome 10 (PTEN). MKK4 inhibited PTEN transcription by activating NF kappa B, a transcriptional suppressor of PTEN. MKK4 was required for nuclear translocation of RelA/p65 and processing of the NF kappa B2 precursor (p100) into the mature form (p52). Studies on a panel of NSCLC cell lines revealed a subset with high MKK4/high NF kappa B/low PTEN that was relatively resistant to apoptosis. Thus, MKK4 promotes cell survival by activating phosphatidylinositol 3-kinase through an NF kappa B/PTEN-dependent pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Kurie, JM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jkurie@mdanderson.org	Sethi, Gautam/F-2372-2011; Aggarwal, Bharat B/G-3388-2013	Sethi, Gautam/0000-0002-8677-8475; 	NCI NIH HHS [P50 CA070907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bost F, 1999, MOL CELL BIOL, V19, P1938; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200; Lee HY, 2003, J BIOL CHEM, V278, P23630, DOI 10.1074/jbc.M300997200; Lee HY, 2002, CLIN CANCER RES, V8, P2970; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Massion PP, 2002, CANCER RES, V62, P3636; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1999, DEVELOPMENT, V126, P505; OHSHIMA S, 1994, VIRCHOWS ARCH, V424, P129; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Sheng XY, 2002, BIOCHEM BIOPH RES CO, V292, P422, DOI 10.1006/bbrc.2002.6662; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Su Gloria H, 2002, Hum Mutat, V19, P81, DOI 10.1002/humu.9002; Tas F, 2005, MED ONCOL, V22, P353, DOI 10.1385/MO:22:4:353; Teng DHF, 1997, CANCER RES, V57, P4177; Tsurutani J, 2005, CARCINOGENESIS, V26, P1182, DOI 10.1093/carcin/bgi072; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Wang L, 2004, ONCOGENE, V23, P5978, DOI 10.1038/sj.onc.1207802; Watanabe T, 2002, DEV BIOL, V250, P332, DOI 10.1006/dbio.2002.0781; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yoshida BA, 1999, CANCER RES, V59, P5483; Zhang WZ, 2002, AM J PHYSIOL-RENAL, V283, pF904, DOI 10.1152/ajprenal.00156.2002	39	79	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3507	3519		10.1074/jbc.M610141200	http://dx.doi.org/10.1074/jbc.M610141200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158870	hybrid			2022-12-25	WOS:000244481900013
J	Ambrosini, G; Sambol, EB; Carvajal, D; Vassilev, LT; Singer, S; Schwartz, GK				Ambrosini, G.; Sambol, E. B.; Carvajal, D.; Vassilev, L. T.; Singer, S.; Schwartz, G. K.			Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1	ONCOGENE			English	Article						MDM2; nutlin-3a; E2F1; DNA damage; apoptosis	UBIQUITIN LIGASE ACTIVITY; DNA-DAMAGE; MDM2 ANTAGONISTS; E2F-1-INDUCED APOPTOSIS; S-PHASE; PATHWAY; PROTEIN; P73; DEGRADATION; ONCOPROTEIN	MDM2 is a critical negative regulator of the p53 tumor suppressor protein. Recently, small-molecule antagonists of MDM2, the Nutlins, have been developed to inhibit the p53-MDM2 interaction and activate p53 signaling. However, half of human cancers have mutated p53 and they are resistant to Nutlin treatment. Here, we report that treatment of the p53-mutant malignant peripheral nerve sheath (MPNST) and p53-null HCT116 cells with cisplatin (Cis) and Nutlin-3a induced a degree of apoptosis that was significantly greater than either drug alone. Nutlin-3a also increased the cytotoxicity of both carboplatin and doxorubicin in a series of p53-mutant human tumor cell lines. In the human dedifferentiated liposarcoma cell line (LS141) and the p53 wild-type HCT116 cells, Nutlin-3a induced downregulation of E2F1 and this effect appeared to be proteasome dependent. In contrast, in MPNST and HCTp53-/- cells, Nutlin-3a inhibited the binding of E2F1 to MDM2 and induced transcriptional activation of free E2F1 in the presence of Cis-induced DNA damage. Downregulation of E2F1 by small interfering RNA significantly decreased the level of apoptosis induced by Cis and Nutlin-3a treatment. Moreover, expression of a dominant-negative form of E2F1 rescued cells from apoptosis, whereas cells overexpressing wildtype E2F1 showed an increase in cell death. This correlated with the induction of the proapoptotic proteins p73 alpha and Noxa, which are both regulated by E2F1. These results indicate that antagonism of MDM2 by Nutlin-3a in cells with mutant p53 enhances chemosensitivity in an E2F1- dependent manner. Nutlin-3a therefore may provide a therapeutic benefit in tumors with mutant p53 provided it is combined with chemotherapy.	Mem Sloan Kettering Canc Ctr, Dept Med, Lab New Drug Dev, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, Sarcoma Dis Management Program Lab, New York, NY 10021 USA; F Hoffmann La Roche & Co Ltd, Roche Res Ctr, Discovery Oncol, Nutley, NJ USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Roche Holding	Schwartz, GK (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Lab New Drug Dev, 1275 York Ave, New York, NY 10021 USA.	Schwartg@mskcc.org		Singer, Samuel/0000-0001-9713-8230				Banerjee D, 1998, CANCER RES, V58, P4292; Bianco R, 2005, CURR CANCER DRUG TAR, V5, P51, DOI 10.2174/1568009053332681; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Carvajal D, 2005, CANCER RES, V65, P1918, DOI 10.1158/0008-5472.CAN-04-3576; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang YY, 1997, CANCER RES, V57, P3640; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lin WC, 2001, GENE DEV, V15, P1833; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Meng RD, 1999, INT J ONCOL, V14, P5; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Muller M J, 2001, Obes Rev, V2, P15; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stuhmer T, 2005, BLOOD, V106, P3609, DOI 10.1182/blood-2005-04-1489; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Vassilev LT, 2005, J MED CHEM, V48, P4491, DOI 10.1021/jm058174k; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhang Z, 2005, ONCOGENE, V24, P7238, DOI 10.1038/sj.onc.1208814	36	131	138	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3473	3481		10.1038/sj.onc.1210136	http://dx.doi.org/10.1038/sj.onc.1210136			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17146434				2022-12-25	WOS:000246799200003
J	Hebbar, PB; Archer, TK				Hebbar, Pratibha B.; Archer, Trevor K.			Chromatin-dependent cooperativity between site-specific transcription factors in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-2; TUMOR VIRUS PROMOTER; BREAST-CANCER CELLS; GLUCOCORTICOID-RECEPTOR; GENE FAMILY; NUCLEAR RECEPTORS; SWI/SNF COMPLEX; MAMMARY-GLAND; ACTIVATION; EXPRESSION	Accessing binding sites in DNA wrapped around histories in condensed chromatin is an obstacle that transcription factors must overcome to regulate gene expression. Here we demonstrate cooperativity between two transcription factors, the glucocorticoid receptor (GR) and nuclear factor 1 (NF1) to bind the mouse mammary tumor virus promoter organized as regular chromatin in vivo. This cooperativity is not observed when the promoter is introduced transiently into cells. Using RNA interference to deplete NF1 protein levels in the cells, we confirmed that NF1 promotes binding of GR to the promoter. Furthermore, we observed a similar synergism between GR and NF1 binding on the endogenous 11 beta-hydroxysteroid dehydrogenase promoter, also regulated by GR and NF1. Our results suggest that the chromatin architecture of the promoters does not permit strong association of GR in the absence of NF1. Therefore we propose that cooperativity among DNA binding factors in binding to their cognate recognition sites in chromatin may be an important feature in the regulation of gene expression.	Natl Inst Environm Hlth Sci, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Archer, TK (corresponding author), Natl Inst Environm Hlth Sci, Mol Carcinogenesis Lab, NIH, 111 Alexander Dr,MD D4-01,POB 12233, Res Triangle Pk, NC 27709 USA.	archer1@niehs.nih.gov	Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071006] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 ES999999, Z01 ES071006-09] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; Alikhani-Koopaei R, 2004, J CLIN INVEST, V114, P1146, DOI 10.1172/JCI200421647; Archer TK, 1997, METHODS, V11, P235, DOI 10.1006/meth.1996.0410; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Chen WW, 2006, MOL ENDOCRINOL, V20, P560, DOI 10.1210/me.2005-0318; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Ferrari S, 2004, J BIOL CHEM, V279, P55520, DOI 10.1074/jbc.M410346200; Fletcher TM, 2000, MOL CELL BIOL, V20, P6466, DOI 10.1128/MCB.20.17.6466-6475.2000; Fryer CJ, 1998, J BIOL CHEM, V273, P1175, DOI 10.1074/jbc.273.2.1175; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Hager GL, 2000, BIOCHEM SOC T, V28, P405, DOI 10.1042/0300-5127:0280405; Hebbar PB, 2003, CHROMOSOMA, V111, P495, DOI 10.1007/s00412-003-0232-x; Hebbar PB, 2003, MOL CELL BIOL, V23, P887, DOI 10.1128/MCB.23.3.887-898.2003; Kane R, 2000, ADV EXP MED BIOL, V480, P117; Kinyamu HK, 2000, J BIOL CHEM, V275, P20061, DOI 10.1074/jbc.M001142200; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; LANGST G, 2004, BIOCHIM BIOPHYS ACTA, V677, P58; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miller JA, 2003, MOL CELL BIOL, V23, P1623, DOI 10.1128/MCB.23.5.1623-1632.2003; Murtagh J, 2003, J MAMMARY GLAND BIOL, V8, P241, DOI 10.1023/A:1025909109843; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Saitoh N, 2000, EMBO J, V19, P2315, DOI 10.1093/emboj/19.10.2315; SCHMID W, 1995, J STEROID BIOCHEM, V53, P33, DOI 10.1016/0960-0760(95)00038-2; Stafford JM, 2001, J BIOL CHEM, V276, P39885, DOI 10.1074/jbc.M105370200; Steele-Perkins G, 2005, MOL CELL BIOL, V25, P685, DOI 10.1128/MCB.25.2.685-698.2005; Trotter KW, 2004, MOL CELL BIOL, V24, P3347, DOI 10.1128/MCB.24.8.3347-3358.2004; van Beek JP, 2004, J CLIN ENDOCR METAB, V89, P5614, DOI 10.1210/jc.2004-0113; Wan YH, 2002, MOL ENDOCRINOL, V16, P1204, DOI 10.1210/me.16.6.1204; Wang JC, 2006, GENE DEV, V20, P689, DOI 10.1101/gad.1400506; Wang JC, 2004, P NATL ACAD SCI USA, V101, P15603, DOI 10.1073/pnas.0407008101; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217	36	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8284	8291		10.1074/jbc.M610554200	http://dx.doi.org/10.1074/jbc.M610554200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17186943	Green Accepted, hybrid			2022-12-25	WOS:000245081000061
J	Williams, LM; Sarma, U; Willets, K; Smallie, T; Brennan, F; Foxwell, BMJ				Williams, Lynn M.; Sarma, Usha; Willets, Kate; Smallie, Tim; Brennan, Fionula; Foxwell, Brian M. J.			Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; TNF-ALPHA PRODUCTION; RHEUMATOID-ARTHRITIS; TYROSINE PHOSPHORYLATION; INFLAMMATORY CYTOKINE; DNA-BINDING; CHRONIC ENTEROCOLITIS; INTRACELLULAR DOMAIN; DENDRITIC CELLS	There is general agreement that signal transducer and activation of transcription 3 (STAT3) is required to mediate the antiinflammatory activities of interleukin (IL)-10. However, STAT3 is activated by multiple factors that do not share the anti-inflammatory activity of IL-10. The question remains whether STAT3 is sufficient for the anti-inflammatory effects or whether there are other signals required, as had been suggested previously. We set out to map the human IL-10 receptor and to identify the key elements involved in transducing the cytokine-suppressive effects of IL-10. We were able to show an absolute requirement for both of the tyrosine residues found within the YXXQ-STAT3-docking site within the IL-10 receptor I and that no other signals appeared to be required. We used a constitutively active STAT3 to determine whether expression of this factor could suppress lipopolysaccharide-induced tumor necrosis factor and IL-6 production. Our data show that STAT3 activity can suppress both IL-6 and tumor necrosis factor production in lipopolysaccharide-stimulated macrophages. However, in synovial fibroblasts, STAT3 did not suppress IL-6 production, suggesting that the cellular environment plays an important role in dictating whether STAT3 drives a pro- or anti-inflammatory response.	Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol Div, London W6 8LH, England	Imperial College London; University of Oxford	Williams, LM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol Div, ARC Bldg,1 Aspenlea Rd, London W6 8LH, England.	b.foxwell@imperial.ac.uk			Medical Research Council [G0700128] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0700128] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andreakos E, 2003, ARTHRITIS RHEUM, V48, P1901, DOI 10.1002/art.11044; Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936; Besser D, 1999, MOL CELL BIOL, V19, P1401; Biswas R, 2003, J IMMUNOL, V170, P6202, DOI 10.4049/jimmunol.170.12.6202; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BUELENS C, 1995, EUR J IMMUNOL, V25, P2668, DOI 10.1002/eji.1830250940; CHANG CH, 1995, EUR J IMMUNOL, V25, P394, DOI 10.1002/eji.1830250213; Clarke CJP, 1998, EUR J IMMUNOL, V28, P1719, DOI 10.1002/(SICI)1521-4141(199805)28:05<1719::AID-IMMU1719>3.0.CO;2-Q; Crawley JB, 1996, J BIOL CHEM, V271, P16357, DOI 10.1074/jbc.271.27.16357; Cua DJ, 1996, J IMMUNOL, V157, P2830; Cua DJ, 1999, J EXP MED, V189, P1005, DOI 10.1084/jem.189.6.1005; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; Denys A, 2002, J IMMUNOL, V168, P4837, DOI 10.4049/jimmunol.168.10.4837; DING L, 1993, J IMMUNOL, V151, P1224; Fedorak RN, 2000, GASTROENTEROLOGY, V119, P1473, DOI 10.1053/gast.2000.20229; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; Foey AD, 1998, J IMMUNOL, V160, P920; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; GERARD C, 1993, J EXP MED, V177, P547, DOI 10.1084/jem.177.2.547; Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HO ASY, 1995, MOL CELL BIOL, V15, P5043; Hoentjen F, 2005, BLOOD, V105, P689, DOI 10.1182/blood-2004-04-1309; JOYCE DA, 1994, EUR J IMMUNOL, V24, P2699, DOI 10.1002/eji.1830241119; KATSIKIS PD, 1994, J EXP MED, V179, P1517, DOI 10.1084/jem.179.5.1517; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Keystone E, 1998, RHEUM DIS CLIN N AM, V24, P629, DOI 10.1016/S0889-857X(05)70030-2; Kolb H, 1997, AUTOIMMUNITY, V26, P1, DOI 10.3109/08916939709009544; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kuwata H, 2003, BLOOD, V102, P4123, DOI 10.1182/blood-2003-04-1228; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li L, 2006, J BIOL CHEM, V281, P33172, DOI 10.1074/jbc.M606940200; Liddle FJ, 2006, BIOCHEMISTRY-US, V45, P5599, DOI 10.1021/bi0525674; LIU Y, 1994, J IMMUNOL, V152, P1821; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; MALEFYT RD, 1993, J IMMUNOL, V150, P4754; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Murray PJ, 2005, P NATL ACAD SCI USA, V102, P8686, DOI 10.1073/pnas.0500419102; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Rajasingh J, 2006, FASEB J, V20, P2112, DOI 10.1096/fj.06-6084fje; Renauld JC, 2003, NAT REV IMMUNOL, V3, P667, DOI 10.1038/nri1153; Ricchetti GA, 2004, J LEUKOCYTE BIOL, V76, P719, DOI 10.1189/jlb.0104046; Riley JK, 1999, J BIOL CHEM, V274, P16513, DOI 10.1074/jbc.274.23.16513; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; TAN JC, 1995, J BIOL CHEM, V270, P12906, DOI 10.1074/jbc.270.21.12906; Walmsley M, 1996, ARTHRITIS RHEUM-US, V39, P495, DOI 10.1002/art.1780390318; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WeberNordt RM, 1996, BLOOD, V88, P809; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Williams L, 2004, J IMMUNOL, V172, P567, DOI 10.4049/jimmunol.172.1.567; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938	61	80	86	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					6965	6975		10.1074/jbc.M609101200	http://dx.doi.org/10.1074/jbc.M609101200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17194701	hybrid			2022-12-25	WOS:000245080900008
J	Gimenez, I; Forbush, B				Gimenez, Ignacio; Forbush, Biff			The residues determining differences in ion affinities among the alternative splice variants F, A, and B of the mammalian renal Na-K-Cl cotransporter (NKCC2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MECHANISMS; CATION-TRANSPORT; REVEALS; CHANNEL; BINDING; DOMAIN; TOPOLOGY; HOMOLOG; KINASE; LOCUS	Three alternatively spliced variants of the renal Na-K-Cl cotransporter (NKCC2) are found in distinct regions of the thick ascending limb of the mammalian kidney; these variants mediate Na(+)K(+)2Cl(-) transport with different ion affinities. Here, we examine the specific residues involved in the variant-specific affinity differences, utilizing a mutagenic approach to change the NKCC2B variant into the A or F variant, with functional expression in Xenopus oocytes. The splice region contains the second transmembrane domain (TM2) and the putative intracellular loop (ICL1) connecting TM2 and TM3. It is found that the B variant is functionally changed to the F variant by replacement of six residues, half of the effect brought about by three TM2 residues and half by three ICL1 residues. The involvement of the ICL1 residues strongly suggests that this region of ICL1 may actually be part of a membrane-embedded domain. Changing six residues is also sufficient to bring about the smaller functional change from the B to the A variant; three residues in TM2 appear to be primarily responsible, two of which correspond to residues involved in the B-to-F changes. A B-variant mutation reported in a mild case of Bartter disease was found to render the cotransporter inactive. These results identify the combination of amino acid variations responsible for the differences among the three splice variants of NKCC2, and they support a model in which a reentrant loop following TM2 contributes to the chloride binding and translocation domains.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06511 USA	Yale University	Gimenez, I (corresponding author), Univ Zaragoza, Fac Med, Dept Physiol & Pharmacol, Domingo Miral SN, E-50009 Zaragoza, Spain.	igimenez@unizar.es	Giménez, Ignacio/B-6322-2013	Giménez, Ignacio/0000-0002-6043-4869	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-17433] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Castrop H, 2005, AM J PHYSIOL-RENAL, V289, pF1185, DOI 10.1152/ajprenal.00455.2004; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Dowd BFX, 2003, J BIOL CHEM, V278, P27347, DOI 10.1074/jbc.M301899200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Gagnon E, 2005, J BIOL CHEM, V280, P32555, DOI 10.1074/jbc.M505511200; Gagnon E, 2004, J BIOL CHEM, V279, P5648, DOI 10.1074/jbc.M311218200; Gagnon E, 2003, AM J PHYSIOL-CELL PH, V284, pC365, DOI 10.1152/ajpcell.00262.2002; Gasol E, 2004, J BIOL CHEM, V279, P31228, DOI 10.1074/jbc.M402428200; Gerelsaikhan T, 2006, BIOCHEMISTRY-US, V45, P12060, DOI 10.1021/bi061126x; Gimenez I, 2002, FASEB J, V16, pA52; Gimenez I, 2002, J BIOL CHEM, V277, P8767, DOI 10.1074/jbc.C200021200; Grant GA, 2000, BIOCHEMISTRY-US, V39, P7316, DOI 10.1021/bi000218y; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Kim SY, 2005, P NATL ACAD SCI USA, V102, P16524, DOI 10.1073/pnas.0505454102; Kolbe M, 2000, SCIENCE, V288, P1390, DOI 10.1126/science.288.5470.1390; Lytle C, 1998, AM J PHYSIOL-CELL PH, V274, pC299, DOI 10.1152/ajpcell.1998.274.2.C299; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Piechotta K, 2002, J BIOL CHEM, V277, P50812, DOI 10.1074/jbc.M208108200; Plata C, 2002, J BIOL CHEM, V277, P11004, DOI 10.1074/jbc.M110442200; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Vargas-Poussou R, 1998, AM J HUM GENET, V62, P1332, DOI 10.1086/301872; Vila R, 2002, PROTEIN SCI, V11, P214, DOI 10.1110/ps.29602; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018	35	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6540	6547		10.1074/jbc.M610780200	http://dx.doi.org/10.1074/jbc.M610780200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17186942	hybrid			2022-12-25	WOS:000244867200062
J	Imai, H; Kefalov, V; Sakurai, K; Chisaka, O; Ueda, Y; Onishi, A; Morizumi, T; Fu, YB; Ichikawa, K; Nakatani, K; Honda, Y; Chen, J; Yau, KW; Shichida, Y				Imai, Hiroo; Kefalov, Vladimir; Sakurai, Keisuke; Chisaka, Osamu; Ueda, Yoshiki; Onishi, Akishi; Morizumi, Takefumi; Fu, Yingbin; Ichikawa, Kazuhisa; Nakatani, Kei; Honda, Yoshihito; Chen, Jeannie; Yau, King-Wai; Shichida, Yoshinori			Molecular properties of rhodopsin and rod function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISUAL PIGMENT; ABSORPTION MAXIMUM; METARHODOPSIN-II; BINDING PROTEIN; DARK-ADAPTATION; TRANSGENIC MICE; AMINO-ACIDS; LIGHT; CONES; PHOTOTRANSDUCTION	Signal transduction in rod cells begins with photon absorption by rhodopsin and leads to the generation of an electrical response. The response profile is determined by the molecular properties of the phototransduction components. To examine how the molecular properties of rhodopsin correlate with the rod-response profile, we have generated a knock-in mouse with rhodopsin replaced by its E122Q mutant, which exhibits properties different from those of wild-type (WT) rhodopsin. Knock-in mouse rods with E122Q rhodopsin exhibited a photosensitivity about 70% of WT. Correspondingly, their single-photon response had an amplitude about 80% of WT, and a rate of decline from peak about 1.3 times of WT. The overall 30% lower photosensitivity of mutant rods can be explained by a lower pigment photosensitivity (0.9) and the smaller single-photon response (0.8). The slower decline of the response, however, did not correlate with the 10-fold shorter lifetime of the meta-II state of E122Q rhodopsin. This shorter lifetime became evident in the recovery phase of rod cells only when arrestin was absent. Simulation analysis of the photoresponse profile indicated that the slower decline and the smaller amplitude of the single-photon response can both be explained by the shift in the meta-I/meta-II equilibrium of E122Q rhodopsin toward meta-I. The difference in meta-III lifetime between WT and E122Q mutant became obvious in the recovery phase of the dark current after moderate photobleaching of rod cells. Thus, the present study clearly reveals how the molecular properties of rhodopsin affect the amplitude, shape, and kinetics of the rod response.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kyoto 6068502, Japan; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Kyoto 6068507, Japan; Kanazawa Inst Technol, Dept Brain & Bioinformat Sci, Ishikawa 9240838, Japan; Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Tsukuba, Ibaraki 3058572, Japan; Univ So Calif, Keck Sch Med, Doheny Eye Inst, Mary D Allen Lab Vis Res, Los Angeles, CA 90033 USA	Kyoto University; Japan Science & Technology Agency (JST); Johns Hopkins University; Kyoto University; Kyoto University; Kanazawa Institute of Technology; University of Tsukuba; Japan Science & Technology Agency (JST); Doheny Eye Institute; University of Southern California	Shichida, Y (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan.	shichida@vision-kyoto-u.jp	Morizumi, Takefumi/AAA-2063-2021	Morizumi, Takefumi/0000-0002-2785-209X; Kefalov, Vladimir/0000-0002-1659-008X; Imai, Hiroo/0000-0003-0729-0322	NEI NIH HHS [R01 EY006837, R01 EY006837-19, R01 EY014596-05, F32 EY006837, R01 EY006837-20A1, R01 EY014596-02, R01 EY006837-18, R01 EY014596, R01 EY014596-03, R01 EY014596-01, R01 EY006837-17, R37 EY006837, R01 EY006837-16A1, R01 EY014596-04, EY 06837] Funding Source: Medline; NIDCD NIH HHS [R01 DC006904-02, R01 DC006904, R01 DC006904-01, R01 DC006904-03] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY014596, R37EY006837, F32EY006837, R01EY006837] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006904] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Burns ME, 2002, NEURON, V36, P81, DOI 10.1016/S0896-6273(02)00911-X; Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897; Calvert PD, 2001, NATURE, V411, P90, DOI 10.1038/35075083; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; Cha KW, 1997, P NATL ACAD SCI USA, V94, P10577, DOI 10.1073/pnas.94.20.10577; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DOWLING JE, 1963, J GEN PHYSIOL, V46, P1287, DOI 10.1085/jgp.46.6.1287; Govardovskii VI, 2000, J GEN PHYSIOL, V116, P791, DOI 10.1085/jgp.116.6.791; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; ICHIKAWA K, 1994, NEUROSCI RES, V19, P201, DOI 10.1016/0168-0102(94)90144-9; Ichikawa K, 2005, NEUROINFORMATICS, V3, P49, DOI 10.1385/NI:3:1:049; Ichikawa K, 2001, BIOINFORMATICS, V17, P483, DOI 10.1093/bioinformatics/17.5.483; IMAI H, 1994, BIOCHEMISTRY-US, V33, P14351, DOI 10.1021/bi00251a049; Imai H, 2005, PHOTOCH PHOTOBIO SCI, V4, P667, DOI 10.1039/b416731g; Imai H, 1997, P NATL ACAD SCI USA, V94, P2322, DOI 10.1073/pnas.94.6.2322; Imai H, 1997, BIOCHEMISTRY-US, V36, P12773, DOI 10.1021/bi970809x; JONES GJ, 1993, J GEN PHYSIOL, V102, P483, DOI 10.1085/jgp.102.3.483; Kefalov V, 2003, NATURE, V425, P526, DOI 10.1038/nature01992; Kefalov VJ, 2001, NEURON, V29, P749, DOI 10.1016/S0896-6273(01)00249-5; Kennedy MJ, 2001, NEURON, V31, P87, DOI 10.1016/S0896-6273(01)00340-3; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; Kuwayama S, 2005, BIOCHEMISTRY-US, V44, P2208, DOI 10.1021/bi047994g; Kuwayama S, 2002, BIOCHEMISTRY-US, V41, P15245, DOI 10.1021/bi026444k; Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; Liang Y, 2004, J BIOL CHEM, V279, P48189, DOI 10.1074/jbc.M408362200; Makino CL, 2004, J GEN PHYSIOL, V123, P729, DOI 10.1085/jgp.200308994; MATTINGLY M, 1999, JUVENILE JUSTICE UPD, V5, P13; Morizumi T, 2005, BIOCHEMISTRY-US, V44, P9936, DOI 10.1021/bi0504512; Nagata T, 1998, BIOCHEMISTRY-US, V37, P17216, DOI 10.1021/bi9810149; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P937, DOI 10.1021/bi00456a013; OKANO T, 1992, PHOTOCHEM PHOTOBIOL, V56, P995, DOI 10.1111/j.1751-1097.1992.tb09722.x; Onishi A, 2005, ZOOL SCI, V22, P1145, DOI 10.2108/zsj.22.1145; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; SAKAMOTO T, 1995, P NATL ACAD SCI USA, V92, P249, DOI 10.1073/pnas.92.1.249; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; Shichida Y, 2000, METHOD ENZYMOL, V315, P347; Shichida Y, 1998, CELL MOL LIFE SCI, V54, P1299, DOI 10.1007/s000180050256; SHICHIDA Y, 1987, BIOCHEMISTRY-US, V26, P4422, DOI 10.1021/bi00388a035; SHICHIDA Y, 1994, BIOCHEMISTRY-US, V33, P9040, DOI 10.1021/bi00197a002; Sommer ME, 2006, VISION RES, V46, P4532, DOI 10.1016/j.visres.2006.08.031; SUZUKI T, 1993, ZOOL SCI, V10, P425; Tachibanaki S, 2005, P NATL ACAD SCI USA, V102, P9329, DOI 10.1073/pnas.0501875102; Wang ZY, 2005, J BIOL CHEM, V280, P24293, DOI 10.1074/jbc.M502588200; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068; YAU KW, 1994, INVEST OPHTH VIS SCI, V35, P9; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154; Zimmermann K, 2004, J BIOL CHEM, V279, P48112, DOI 10.1074/jbc.M406856200	51	56	56	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6677	6684		10.1074/jbc.M610086200	http://dx.doi.org/10.1074/jbc.M610086200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17194706	hybrid, Green Accepted			2022-12-25	WOS:000244867200077
J	Kasahara, K; Nakayama, Y; Nakazato, Y; Ikeda, K; Kuga, T; Yamaguchi, N				Kasahara, Kousuke; Nakayama, Yuji; Nakazato, Yoshimi; Ikeda, Kikuko; Kuga, Takahisa; Yamaguchi, Naoto			Src signaling regulates completion of abscission in cytokinesis through ERK/MAPK activation at the midbody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYN TYROSINE KINASE; MAP KINASE; C-SRC; MITOTIC ACTIVATION; CLEAVAGE FURROW; RECEPTOR; REQUIREMENT; PHOSPHORYLATION; INHIBITOR; MITOSIS	Src family non-receptor-type tyrosine kinases regulate a wide variety of cellular events including cell cycle progression in G(2)/M phase. Here, we show that Src signaling regulates the terminal step in cytokinesis called abscission in HeLa cells. Abscission failure with an unusually elongated intercellular bridge containing the midbody is induced by treatment with the chemical Src inhibitors PP2 and SU6656 or expression of membrane-anchored Csk chimeras. By anti-phosphotyrosine immunofluorescence and live cell imaging, completion of abscission requires Src-mediated tyrosine phosphorylation during early stages of mitosis (before cleavage furrow formation), which is subsequently delivered to the midbody through Rab11-driven vesicle transport. Treatment with U0126, a MEK inhibitor, decreases tyrosine phosphorylation levels at the midbody, leading to abscission failure. Activated ERK by MEK-catalyzed dual phosphorylation on threonine and tyrosine residues in the TEY sequence, which is strongly detected by anti-phosphotyrosine antibody, is transported to the midbody in a Rab11-dependent manner. Src kinase activity during the early mitosis mediates ERK activation in late cytokinesis, indicating that Src-mediated signaling for abscission is spatially and temporally transmitted. Thus, these results suggest that recruitment of activated ERK, which is phosphorylated by MEK downstream of Src kinases, to the midbody plays an important role in completion of abscission.	Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Cell Biol, Chiba 2608675, Japan	Chiba University	Yamaguchi, N (corresponding author), Inohana 1-8-1,Chuo Ku, Chiba 2608675, Japan.	nyama@p.chiba-u.ac.jp	Kuga, Takahisa/AAX-9334-2020	Nakayama, Yuji/0000-0001-7882-0066				Akiyama N, 2005, CELL SIGNAL, V17, P597, DOI 10.1016/j.cellsig.2004.10.005; Albertson R, 2005, TRENDS CELL BIOL, V15, P92, DOI 10.1016/j.tcb.2004.12.008; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; Finger FP, 2002, CELL, V108, P727, DOI 10.1016/S0092-8674(02)00668-2; Gromley A, 2005, CELL, V123, P75, DOI 10.1016/j.cell.2005.07.027; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hirao A, 1998, J BIOL CHEM, V273, P10004, DOI 10.1074/jbc.273.16.10004; Hirao A, 1997, EMBO J, V16, P2342, DOI 10.1093/emboj/16.9.2342; Honda Z, 1997, J BIOL CHEM, V272, P25753, DOI 10.1074/jbc.272.41.25753; Horne MM, 2003, J CELL BIOL, V161, P1021, DOI 10.1083/jcb.200304144; Kasahara K, 2004, J CELL BIOL, V165, P641, DOI 10.1083/jcb.200403011; Kasahara K, 2007, J CELL PHYSIOL, V211, P220, DOI 10.1002/jcp.20931; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LAW CL, 1994, J BIOL CHEM, V269, P12310; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; Matsuda D, 2006, EXP CELL RES, V312, P1205, DOI 10.1016/j.yexcr.2006.02.003; Mera A, 1999, J BIOL CHEM, V274, P15766, DOI 10.1074/jbc.274.22.15766; Moasser MM, 1999, CANCER RES, V59, P6145; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nakayama Y, 2005, EXP CELL RES, V304, P570, DOI 10.1016/j.yexcr.2004.11.027; Nakayama Y, 2006, EXP CELL RES, V312, P2252, DOI 10.1016/j.yexcr.2006.03.021; Ng MM, 2005, DEV CELL, V9, P781, DOI 10.1016/j.devcel.2005.11.002; OHSATO Y, 1994, JPN J CANCER RES, V85, P1023, DOI 10.1111/j.1349-7006.1994.tb02900.x; Otegui MS, 2005, TRENDS CELL BIOL, V15, P404, DOI 10.1016/j.tcb.2005.06.003; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Sandilands E, 2004, DEV CELL, V7, P855, DOI 10.1016/j.devcel.2004.09.019; Sasabe M, 2006, GENE DEV, V20, P1004, DOI 10.1101/gad.1408106; Schweitzer JK, 2005, J BIOL CHEM, V280, P41628, DOI 10.1074/jbc.M504497200; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Skop AR, 2004, SCIENCE, V305, P61, DOI 10.1126/science.1097931; Skop AR, 2001, CURR BIOL, V11, P735, DOI 10.1016/S0960-9822(01)00231-7; Soyano T, 2003, GENE DEV, V17, P1055, DOI 10.1101/gad.1071103; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Tada J, 1999, BLOOD, V93, P3723, DOI 10.1182/blood.V93.11.3723.411k02_3723_3735; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tomas A, 2004, J CELL BIOL, V165, P813, DOI 10.1083/jcb.200311054; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Uyeda TQP, 2004, CURR OPIN CELL BIOL, V16, P55, DOI 10.1016/j.ceb.2003.11.004; Willard FS, 2001, CELL SIGNAL, V13, P653, DOI 10.1016/S0898-6568(01)00185-1; Wilson GM, 2005, MOL BIOL CELL, V16, P849, DOI 10.1091/mbc.e04-10-0927; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170; Yamaguchi N, 2001, J CELL SCI, V114, P1631; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037	56	82	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5327	5339		10.1074/jbc.M608396200	http://dx.doi.org/10.1074/jbc.M608396200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189253	hybrid			2022-12-25	WOS:000244482300028
J	Wrzaczek, M; Rozhon, W; Jonak, C				Wrzaczek, Michael; Rozhon, Wilfried; Jonak, Claudia			A proteasome-regulated glycogen synthase kinase-3 modulates disease response in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; PSEUDOMONAS-SYRINGAE; ARABIDOPSIS-THALIANA; SUBSTRATE-SPECIFICITY; SIGNALING PATHWAY; MULTIGENE FAMILY; GENE-EXPRESSION; INNATE IMMUNITY; 26S PROTEASOME; RESISTANCE	Glycogen synthase kinase-3 (GSK-3) is a key player in various important signaling pathways in animals. The activity of GSK-3 is known to be modulated by protein phosphorylation and differential complex formation. However, little information is available regarding the function and regulation of plant GSK-3/shaggy-like kinases (GSKs). Analysis of the in vivo kinase activity of MsK1, a GSK from Medicago sativa, revealed that MsK1 is active in healthy plants and that MsK1 activity is down-regulated by the elicitor cellulase in a time- and dose-dependent manner. Surprisingly, cellulase treatment triggered the degradation of the MsK1 protein in a proteasome-dependent manner suggesting a novel mechanism of GSK-3 regulation. Inhibition of MsK1 kinase activity and degradation of the protein were two successive processes that could be uncoupled. In a transgenic approach, stimulus-induced inhibition of MsK1 was impeded by constant replenishment of MsK1 by a strong constitutive promoter. MsK1 overexpressing plants exhibited enhanced disease susceptibility to the virulent bacterial pathogen Pseudomonas syringae. MAP kinase activation in response to pathogen infection was compromised in plants with elevated MsK1 levels. These data strongly suggest that tight regulation of the plant GSK-3, MsK1, may be important for innate immunity to limit the severity of virulent bacterial infection.	Univ Vienna, Max F Perutz Labs, Vienna Bioctr, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Jonak, C (corresponding author), Austrian Acad Sci, Gregor Mendel Inst Mol Plant Biol, Vienna Bioctr, Dr Bohrgasse 3, A-1030 Vienna, Austria.	claudia.jonak@gmi.oeaw.ac.at	Wrzaczek, Michael/AAU-5105-2020; Rozhon, Wilfried/AFK-4445-2022; Rozhon, Wilfried/AAG-3162-2022; Jonak, Claudia/G-1362-2016	Wrzaczek, Michael/0000-0002-5946-9060; Rozhon, Wilfried/0000-0003-0659-0593; Rozhon, Wilfried/0000-0003-0659-0593; Jonak, Claudia/0000-0001-9605-6751				Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Austin MJ, 2002, SCIENCE, V295, P2077, DOI 10.1126/science.1067747; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; Buell CR, 2003, P NATL ACAD SCI USA, V100, P10181, DOI 10.1073/pnas.1731982100; Cardinale F, 2000, J BIOL CHEM, V275, P36734, DOI 10.1074/jbc.M007418200; Charrier B, 2002, PLANT PHYSIOL, V130, P577, DOI 10.1104/pp.009175; Choe S, 2002, PLANT PHYSIOL, V130, P1506, DOI 10.1104/pp.010496; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUPPELS DA, 1986, APPL ENVIRON MICROB, V51, P323, DOI 10.1128/AEM.51.2.323-327.1986; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DECROOCQFERRANT V, 1995, PLANT J, V7, P897, DOI 10.1046/j.1365-313X.1995.07060897.x; Desikan R, 2001, PLANT PHYSIOL, V126, P1579, DOI 10.1104/pp.126.4.1579; Dornelas MC, 1999, PLANT MOL BIOL, V39, P137, DOI 10.1023/A:1006102812280; Dornelas MC, 2000, PLANT J, V21, P419, DOI 10.1046/j.1365-313x.2000.00691.x; EINZENBERGER E, 1995, BBA-GENE STRUCT EXPR, V1260, P315, DOI 10.1016/0167-4781(94)00229-V; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; He JX, 2005, SCIENCE, V307, P1634, DOI 10.1126/science.1107580; HE JX, 2002, P NATL ACAD SCI USA, V11, P11; Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160; Jing H, 2004, J BIOL CHEM, V279, P55176, DOI 10.1074/jbc.M409816200; Jonak C, 2000, PLANT CELL, V12, P1467, DOI 10.1105/tpc.12.8.1467; Jonak C, 2002, TRENDS PLANT SCI, V7, P457, DOI 10.1016/S1360-1385(02)02331-2; Jonak C, 1996, P NATL ACAD SCI USA, V93, P11274, DOI 10.1073/pnas.93.20.11274; JONAK C, 1995, PLANT MOL BIOL, V27, P217, DOI 10.1007/BF00019194; Jones DA, 2004, CURR OPIN IMMUNOL, V16, P48, DOI 10.1016/j.coi.2003.11.016; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; KEMPA S, 2007, IN PRESS PLANT J; Kim HS, 2002, PLANT CELL, V14, P1469, DOI 10.1105/tpc.001867; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Kinoshita T, 2005, NATURE, V433, P167, DOI 10.1038/nature03227; Kloek AP, 2001, PLANT J, V26, P509, DOI 10.1046/j.1365-313x.2001.01050.x; Kunkel BN, 2002, CURR OPIN PLANT BIOL, V5, P325, DOI 10.1016/S1369-5266(02)00275-3; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; Li JM, 2002, SCIENCE, V295, P1299; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liu Y, 2002, PLANT CELL, V14, P1483, DOI 10.1105/tpc.002493; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; Menke FLH, 2004, PLANT CELL, V16, P897, DOI 10.1105/tpc.015552; Moon J, 2004, PLANT CELL, V16, P3181, DOI 10.1105/tpc.104.161220; Nakagami H, 2005, TRENDS PLANT SCI, V10, P339, DOI 10.1016/j.tplants.2005.05.009; Nuhse TS, 2000, J BIOL CHEM, V275, P7521, DOI 10.1074/jbc.275.11.7521; PAY A, 1993, PLANT J, V3, P847, DOI 10.1111/j.1365-313X.1993.00847.x; Pedley KF, 2005, CURR OPIN PLANT BIOL, V8, P541, DOI 10.1016/j.pbi.2005.07.006; Perez-Perez JM, 2002, DEV BIOL, V242, P161, DOI 10.1006/dbio.2001.0543; Piao HL, 1999, PLANT PHYSIOL, V119, P1527, DOI 10.1104/pp.119.4.1527; Piao HL, 2001, PLANT J, V27, P305, DOI 10.1046/j.1365-313x.2001.01099.x; Rentel MC, 2004, NATURE, V427, P858, DOI 10.1038/nature02353; Richard O, 2005, J MOL EVOL, V61, P99, DOI 10.1007/s00239-004-0302-6; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Smalle J, 2004, ANNU REV PLANT BIOL, V55, P555, DOI 10.1146/annurev.arplant.55.031903.141801; Sullivan JA, 2003, NAT REV GENET, V4, P948, DOI 10.1038/nrg1228; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Thordal-Christensen H, 2003, CURR OPIN PLANT BIOL, V6, P351, DOI 10.1016/S1369-5266(03)00063-3; Tichtinsky G, 1998, BBA-GENE STRUCT EXPR, V1442, P261, DOI 10.1016/S0167-4781(98)00187-0; van Amerongen R, 2005, CELL CYCLE, V4, pE89; Veronese P, 2006, PLANT CELL, V18, P257, DOI 10.1105/tpc.105.035576; Vert G, 2006, NATURE, V441, P96, DOI 10.1038/nature04681; Volko SM, 1998, GENETICS, V149, P537; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WOODGETT JR, 1984, BIOCHIM BIOPHYS ACTA, V788, P339, DOI 10.1016/0167-4838(84)90047-5; WRZACZEK M, 2004, MSKI GLYCOGEN SYNTHA; Xie DX, 1998, SCIENCE, V280, P1091, DOI 10.1126/science.280.5366.1091; Yin YH, 2005, CELL, V120, P249, DOI 10.1016/j.cell.2004.11.044; Yin YH, 2002, CELL, V109, P181, DOI 10.1016/S0092-8674(02)00721-3; Yoo MJ, 2006, BMC PLANT BIOL, V6, DOI 10.1186/1471-2229-6-3; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yu IC, 1998, P NATL ACAD SCI USA, V95, P7819, DOI 10.1073/pnas.95.13.7819; Zhang YL, 2005, CELL MOL IMMUNOL, V2, P20; Zhao J, 2002, PLANT PHYSIOL, V130, P1221, DOI 10.1104/pp.102.010918	74	26	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5249	5255		10.1074/jbc.M610135200	http://dx.doi.org/10.1074/jbc.M610135200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17179144	Green Published, hybrid			2022-12-25	WOS:000244482300019
J	Li, Z; Xu, MJ; Xing, S; Ho, WT; Ishii, T; Li, QS; Fu, XQ; Zhao, ZZJ				Li, Zhe; Xu, Mingjiang; Xing, Shu; Ho, Wanting Tina; Ishii, Takefumi; Li, Qingshan; Fu, Xueqi; Zhao, Zhizhuang Joe			Erlotinib effectively inhibits JAK2(V617F) activity and polycythemia vera cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE MUTATION; ABL-POSITIVE CELLS; MYELOPROLIFERATIVE-DISORDERS; JAK2 MUTATION; ACTIVATING MUTATION; MYELOID-LEUKEMIA; LUNG-CANCER; IMATINIB; MYELOFIBROSIS; IDENTIFICATION	JAK2(V617F), a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The JAK2 mutant displays a much increased kinase activity and generates a PV-like phenotype in mouse bone marrow transplant models. This study shows that the anticancer drug erlotinib (Tarceva (TM)) is a potent inhibitor of JAK2(V617F) activity. In vitro colony culture assays revealed that erlotinib at micro-molar concentrations effectively suppresses the growth and expansion of PV hematopoietic progenitor cells while having little effect on normal cells. Furthermore, JAK2(V617F)-positive cells from PV patients show greater susceptibility to the inhibitor than their negative counterparts. Similar inhibitory effects were found with the JAK2(V617F)-positive human erythroleukemia HEL cell line. These data suggest that erlotinib may be used for treatment of JAK2(V617F)-positive PV and other myeloproliferative disorders.	Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA; Jilin Univ, Coll Life Sci, Edmond H Fischer Signal Transduct Lab, Changchun 130023, Peoples R China; Univ Illinois, Coll Med, Ctr Canc, Hematol Oncol Sect, Chicago, IL 60612 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Jilin University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Zhao, ZZJ (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA.	joe-zhao@ouhsc.edu	li, zhe/B-6882-2011	Xing, Shu/0000-0001-5449-4497	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076309, R01HL079441] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL079441-02, R01 HL076309, HL076309, R01 HL079441, R01 HL076309-05, HL079441] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jelinek J, 2005, BLOOD, V106, P3370, DOI 10.1182/blood-2005-05-1800; Jones AV, 2006, BLOOD, V107, P3339, DOI 10.1182/blood-2005-09-3917; Jones AV, 2005, BLOOD, V106, P2162, DOI 10.1182/blood-2005-03-1320; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; Levine RL, 2005, BLOOD, V106, P3377, DOI 10.1182/blood-2005-05-1898; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Oehler L, 2003, BLOOD, V102, P2240, DOI 10.1182/blood-2003-03-0676; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Quentmeier H, 2006, LEUKEMIA, V20, P471, DOI 10.1038/sj.leu.2404081; Sandberg EM, 2005, J MED CHEM, V48, P2526, DOI 10.1021/jm049470k; Scott LM, 2005, BLOOD, V106, P2920, DOI 10.1182/blood-2005-05-2087; Silver RT, 2003, LEUKEMIA, V17, P1186, DOI 10.1038/sj.leu.2402938; Steensma DP, 2005, BLOOD, V106, P1207, DOI 10.1182/blood-2005-03-1183; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Xu XS, 2007, BLOOD, V109, P339, DOI 10.1182/blood-2006-03-009472; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200	26	96	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3428	3432		10.1074/jbc.C600277200	http://dx.doi.org/10.1074/jbc.C600277200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17178722	Green Accepted, hybrid			2022-12-25	WOS:000244481900004
J	Qi, W; Yu, HT				Qi, Wei; Yu, Hongtao			KEN-box-dependent degradation of the Bub1 spindle checkpoint kinase by the anaphase-promoting complex/cyclosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; KINETOCHORE LOCALIZATION; ASSEMBLY CHECKPOINT; BUDDING YEAST; MITOTIC EXIT; CENP-E; PROTEOLYSIS; MITOSIS; PHOSPHORYLATION; CDC20	The spindle checkpoint is a cell cycle surveillance mechanism that ensures the fidelity of chromosome segregation during mitosis and meiosis. Bub1 is a protein serine-threonine kinase that plays multiple roles in chromosome segregation and the spindle checkpoint. In response to misaligned chromosomes, Bub1 directly inhibits the ubiquitin ligase activity of the anaphase-promoting complex or cyclosome (APC/C) by phosphorylating its activator Cdc20. The protein level and the kinase activity of Bub1 are regulated during the cell cycle; they peak in mitosis and are low in G(1)/S phase. Here we show that Bub1 is degraded during mitotic exit and that degradation of Bub1 is mediated by APC/C in complex with its activator Cdh1 (APC/C-Cdh1). Overexpression of Cdh1 reduces the protein levels of ectopically expressed Bub1, whereas depletion of Cdh1 by RNA interference increases the level of the endogenous Bub1 protein. Bub1 is ubiquitinated by immunopurified APC/C-Cdh1 in vitro. We further identify two KEN-box motifs on Bub1 that are required for its degradation in vivo and ubiquitination in vitro. A Bub1 mutant protein with both KEN-boxes mutated is stable in cells but fails to elicit a cell cycle phenotype, indicating that degradation of Bub1 by APC/C-Cdh1 is not required for mitotic exit. Nevertheless, our study clearly demonstrates that Bub1, an APC/C inhibitor, is also an APC/C substrate. The antagonistic relationship between Bub1 and APC/C may help to prevent the premature accumulation of Bub1 during G(1).	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yu, HT (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA.	hongtao.yu@utsouthwestern.edu	Pillay, Nischalan/F-9536-2012	Yu, Hongtao/0000-0002-8861-049X; Qi, Wei/0000-0003-0813-5316	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061542] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61542] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araki M, 2005, GENE DEV, V19, P2458, DOI 10.1101/gad.1361905; Bernard P, 1998, J CELL BIOL, V143, P1775, DOI 10.1083/jcb.143.7.1775; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Chen RH, 2004, EMBO J, V23, P3113, DOI 10.1038/sj.emboj.7600308; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Farr KA, 1998, MOL CELL BIOL, V18, P2738, DOI 10.1128/MCB.18.5.2738; Gillett ES, 2004, J CELL BIOL, V164, P535, DOI 10.1083/jcb.200308100; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Johnson VL, 2004, J CELL SCI, V117, P1577, DOI 10.1242/jcs.01006; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Palframan WJ, 2006, SCIENCE, V313, P680, DOI 10.1126/science.1127205; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Prinz S, 1998, CURR BIOL, V8, P750, DOI 10.1016/S0960-9822(98)70298-2; Qi W, 2006, MOL BIOL CELL, V17, P3705, DOI 10.1091/mbc.E06-03-0240; Schwab MS, 2001, CURR BIOL, V11, P141, DOI 10.1016/S0960-9822(01)00045-8; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; Shin HJ, 2003, CANCER CELL, V4, P483, DOI 10.1016/S1535-6108(03)00302-7; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Tanaka K, 1998, MOL CELLS, V8, P503; Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 2001, J CELL SCI, V114, P4385; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Yamaguchi S, 2003, EMBO J, V22, P1075, DOI 10.1093/emboj/cdg100; Yu HT, 2005, CELL CYCLE, V4, P262; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	36	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3672	3679		10.1074/jbc.M609376200	http://dx.doi.org/10.1074/jbc.M609376200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158872	hybrid			2022-12-25	WOS:000244481900029
J	Cannavo, E; Gerrits, B; Marra, G; Schlapbach, R; Jiricny, J				Cannavo, Elda; Gerrits, Bertran; Marra, Giancarlo; Schlapbach, Ralph; Jiricny, Josef			Characterization of the interactome of the human MutL homologues MLH1, PMS1, and PMS2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH-REPAIR; CHROMATIN REMODELING COMPLEX; FANCONI-ANEMIA; HUMAN-CELLS; C-MYC; ONCOGENIC TRANSFORMATION; DIRECT ASSOCIATION; MASS-SPECTROMETRY; HELICASE BRIP1; PROTEIN HMLH1	Postreplicative mismatch repair (MMR) involves the concerted action of at least 20 polypeptides. Although the minimal human MMR system has recently been reconstituted in vitro, genetic evidence from different eukaryotic organisms suggests that some steps of the MMR process may be carried out by more than one protein. Moreover, MMR proteins are involved also in other pathways of DNA metabolism, but their exact role in these processes is unknown. In an attempt to gain novel insights into the function of MMR proteins in human cells, we searched for interacting partners of the MutL homologues MLH1 and PMS2 by tandem affinity purification and of PMS1 by large scale immunoprecipitation. In addition to proteins known to interact with the MutL homologues during MMR, mass spectrometric analyses identified a number of other polypeptides, some of which bound to the above proteins with very high affinity. Whereas some of these interactors may represent novel members of the mismatch repairosome, others appear to implicate the MutL homologues in biological processes ranging from intracellular transport through cell signaling to cell morphology, recombination, and ubiquitylation.	Univ Zurich, Inst Mol Canc Res, CH-8057 Zurich, Switzerland; Univ Zurich, Funct Genom Ctr Zurich, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich	Jiricny, J (corresponding author), Univ Zurich, Inst Mol Canc Res, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	jiricny@imcr.unizh.ch	Schlapbach, Ralph/R-8234-2016	Schlapbach, Ralph/0000-0002-7488-4262				Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bratt A, 2005, J BIOL CHEM, V280, P34859, DOI 10.1074/jbc.M503915200; Brieger A, 2005, MOL CARCINOGEN, V43, P51, DOI 10.1002/mc.20081; Cannavo E, 2005, CANCER RES, V65, P10759, DOI 10.1158/0008-5472.CAN-05-2528; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Cejka P, 2003, EMBO J, V22, P2245, DOI 10.1093/emboj/cdg216; Chen PC, 2005, CANCER RES, V65, P8662, DOI 10.1158/0008-5472.CAN-05-0742; Cho SG, 2001, MOL CELL BIOL, V21, P8398, DOI 10.1128/MCB.21.24.8398-8413.2001; Ciotta C, 1998, J MOL BIOL, V276, P705, DOI 10.1006/jmbi.1997.1559; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Dugan KA, 2002, ONCOGENE, V21, P5835, DOI 10.1038/sj.onc.1205763; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; Dziembowski A, 2004, FEBS LETT, V556, P1, DOI 10.1016/S0014-5793(03)01357-7; El-Shemerly M, 2005, CANCER RES, V65, P3604, DOI 10.1158/0008-5472.CAN-04-4069; Ernkvist M, 2006, FEBS J, V273, P2000, DOI 10.1111/j.1742-4658.2006.05216.x; Feng Y, 2003, CANCER RES, V63, P8726; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Garcia V, 2000, NUCLEIC ACIDS RES, V28, P1692, DOI 10.1093/nar/28.8.1692; Gingras AC, 2005, J PHYSIOL-LONDON, V563, P11, DOI 10.1113/jphysiol.2004.080440; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Her CT, 2002, DNA REPAIR, V1, P719, DOI 10.1016/S1568-7864(02)00079-4; Hoffmann ER, 2004, CYTOGENET GENOME RES, V107, P232, DOI 10.1159/000080601; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Irminger-Finger I, 2006, NAT REV CANCER, V6, P382, DOI 10.1038/nrc1878; Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907; Jiricny J, 2006, CELL, V126, P239, DOI 10.1016/j.cell.2006.07.003; Jonsson ZO, 2004, MOL CELL, V16, P465, DOI 10.1016/j.molcel.2004.09.033; Kadyrov FA, 2006, CELL, V126, P297, DOI 10.1016/j.cell.2006.05.039; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kinch LN, 2005, NUCLEIC ACIDS RES, V33, P3598, DOI 10.1093/nar/gki676; Kondo E, 2001, NUCLEIC ACIDS RES, V29, P1695, DOI 10.1093/nar/29.8.1695; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Lipkin SM, 2002, NAT GENET, V31, P385, DOI 10.1038/ng931; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Neuberger MS, 2005, NAT REV IMMUNOL, V5, P171, DOI 10.1038/nri1553; Nielsen FC, 2004, ONCOGENE, V23, P1457, DOI 10.1038/sj.onc.1207265; Owen BAL, 2005, NAT STRUCT MOL BIOL, V12, P663, DOI 10.1038/nsmb965; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Pedrazzi G, 2001, NUCLEIC ACIDS RES, V29, P4378, DOI 10.1093/nar/29.21.4378; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Raschle M, 2002, J BIOL CHEM, V277, P21810, DOI 10.1074/jbc.M108787200; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SCHAR P, 1998, NUCL ACID M, V12, P199; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Sourisseau T, 2006, MOL CELL BIOL, V26, P2387, DOI 10.1128/MCB.26.6.2387-2398.2006; Stojic L, 2004, GENE DEV, V18, P1331, DOI 10.1101/gad.294404; Sugawara N, 2004, P NATL ACAD SCI USA, V101, P9315, DOI 10.1073/pnas.0305749101; Trojan J, 2002, GASTROENTEROLOGY, V122, P211, DOI 10.1053/gast.2002.30296; Tronchere H, 2003, CELL MOL LIFE SCI, V60, P2084, DOI 10.1007/s00018-003-3062-3; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wang Y, 2000, GENE DEV, V14, P927; Wei K, 2002, TRENDS MOL MED, V8, P346, DOI 10.1016/S1471-4914(02)02359-6; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Wu XS, 2003, MOL CELL BIOL, V23, P3320, DOI 10.1128/MCB.23.9.3320-3328.2003; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhang YB, 2005, CELL, V122, P693, DOI 10.1016/j.cell.2005.06.027	74	111	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2976	2986		10.1074/jbc.M609989200	http://dx.doi.org/10.1074/jbc.M609989200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148452	hybrid, Green Accepted			2022-12-25	WOS:000243793900024
J	Fiser, R; Masin, J; Basler, M; Krusek, J; Spulakova, V; Konopasek, I; Sebo, P				Fiser, Radovan; Masin, Jiri; Basler, Marek; Krusek, Jan; Spulakova, Veronika; Konopasek, Ivo; Sebo, Peter			Third activity of Bordetella adenylate cyclase (AC) toxin-hemolysin - Membrane translocation of AC domain polypeptide promotes calcium influx into CD11b(+) monocytes independently of the catalytic and hemolytic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL EPITOPES; CALMODULIN-BINDING; INVASIVE ACTIVITY; PERTUSSIS TOXIN; FATTY-ACYLATION; ALPHA-HEMOLYSIN; TARGET-CELLS; IDENTIFICATION; CYTOTOXICITY; RECEPTORS	The Bordetella adenylate cyclase toxin-hemolysin (CyaA) targets phagocytes expressing the alpha(M)beta(2) integrin (CD11b/CD18), permeabilizes their membranes by forming small cation-selective pores, and delivers into cells a calmodulin-activated adenylate cyclase (AC) enzyme that dissipates cytosolic ATP into cAMP. We describe here a third activity of CyaA that yields elevation of cytosolic calcium concentration ([Ca2+](i)) in target cells. The CyaA-mediated [Ca2+](i) increase in CD11b(+) J774A. 1 monocytes was inhibited by extracellular La3+ ions but not by nifedipine, SK&F 96365, flunarizine, 2-aminoethyl diphenyl-borinate, or thapsigargin, suggesting that influx of Ca2+ into cells was not because of receptor signaling or opening of conventional calcium channels by cAMP. Compared with intact CyaA, a CyaA-AC(-) toxoid unable to generate cAMP promoted a faster, albeit transient, elevation of [Ca2+](i). This was not because of cell permeabilization by the CyaA hemolysin pores, because a mutant exhibiting a strongly enhanced pore-forming activity (CyaA-E509K/E516K), but unable to deliver the AC domain into cells, was also unable to elicit a [Ca2+](i) increase. Further mutations interfering with AC translocation into cells, such as proline substitutions of glutamate residues 509 or 570 or deletion of the AC domain as such, reduced or ablated the [Ca2+](i)-elevating capacity of CyaA. Moreover, structural alterations within the AC domain, because of insertion of various oligopeptides, differently modulated the kinetics and extent of Ca2+ influx elicited by the respective AC(-) toxoids. Hence, the translocating AC polypeptide itself appears to participate in formation of a novel type of membrane path for calcium ions, contributing to action of CyaA in an unexpected manner.	Acad Sci Czech Republ, Lab Mol Biol Bacterial Pathogens, Inst Microbiol, CZ-14220 Prague 4, Czech Republic; Acad Sci Czech Republ, Inst Physiol, Dept Cellular Neurophysiol, CZ-14220 Prague 4, Czech Republic; Charles Univ Prague, Fac Sci, Dept Genet & Microbiol, CZ-12844 Prague 2, Czech Republic	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Charles University Prague	Sebo, P (corresponding author), Acad Sci Czech Republ, Lab Mol Biol Bacterial Pathogens, Inst Microbiol, CZ-14220 Prague 4, Czech Republic.	sebo@biomed.cas.cz	SEBO, Peter/N-2043-2019; Fiser, Radovan/E-4908-2012; Masin, Jiri/H-3125-2014; SEBO, Peter/F-7423-2011; Krusek, Jan/B-6341-2012; Basler, Marek/A-3559-2012; Konopásek, Ivo/AAE-9034-2021	SEBO, Peter/0000-0002-9755-7715; Fiser, Radovan/0000-0003-4516-0086; SEBO, Peter/0000-0002-9755-7715; Krusek, Jan/0000-0002-4820-0947; Basler, Marek/0000-0001-5414-2088; Konopásek, Ivo/0000-0002-6824-5974				Azenabor AA, 2004, BIOL CHEM, V385, P67, DOI 10.1515/BC.2004.009; Bagley KC, 2002, J LEUKOCYTE BIOL, V72, P962; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; Basar T, 1999, J BIOL CHEM, V274, P10777, DOI 10.1074/jbc.274.16.10777; Basler M, 2006, INFECT IMMUN, V74, P2207, DOI 10.1128/IAI.74.4.2207-2214.2006; Bassinet L, 2004, INFECT IMMUN, V72, P5530, DOI 10.1128/IAI.72.9.5530-5533.2004; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; Bennett DL, 1998, BIOCHEM J, V329, P349; BENZ R, 1994, J BIOL CHEM, V269, P27231; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Boyd AP, 2005, J IMMUNOL, V175, P730, DOI 10.4049/jimmunol.175.2.730; Bruce JIE, 2002, J BIOL CHEM, V277, P1340, DOI 10.1074/jbc.M106609200; CARONI P, 1981, J BIOL CHEM, V256, P3263; CHEN CF, 1988, SCIENCE, V239, P1024, DOI 10.1126/science.2449730; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; Delvig AA, 1999, EUR J IMMUNOL, V29, P2414, DOI 10.1002/(SICI)1521-4141(199908)29:08<2414::AID-IMMU2414>3.0.CO;2-P; Dib K, 2000, FRONT BIOSCI-LANDMRK, V5, pD438, DOI 10.2741/Pathology; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; El-Azami-El-Idrissi M, 2003, J BIOL CHEM, V278, P38514, DOI 10.1074/jbc.M304387200; Fong KP, 2006, CELL MICROBIOL, V8, P1753, DOI 10.1111/j.1462-5822.2006.00746.x; FRIEDMAN RL, 1987, INFECT IMMUN, V55, P135, DOI 10.1128/IAI.55.1.135-140.1987; Gao ZY, 2002, BIOCHEM J, V368, P397, DOI 10.1042/BJ20020999; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GOODWIN MS, 1990, INFECT IMMUN, V58, P3445, DOI 10.1128/IAI.58.10.3445-3447.1990; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; Gray M, 1998, J BIOL CHEM, V273, P18260, DOI 10.1074/jbc.273.29.18260; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guermonprez P, 2001, J EXP MED, V193, P1035, DOI 10.1084/jem.193.9.1035; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HACKETT M, 1995, J BIOL CHEM, V270, P20250, DOI 10.1074/jbc.270.35.20250; HANSKI E, 1985, J BIOL CHEM, V260, P5526; Harvill ET, 1999, INFECT IMMUN, V67, P1493, DOI 10.1128/IAI.67.3.1493-1500.1999; Heveker N, 1997, EUR J BIOCHEM, V243, P643, DOI 10.1111/j.1432-1033.1997.00643.x; HEWLETT E, 1976, J BACTERIOL, V127, P890, DOI 10.1128/JB.127.2.890-898.1976; HEWLETT EL, 1983, CLIN RES, V31, pA365; Hewlett EL, 2006, MOL MICROBIOL, V59, P447, DOI 10.1111/j.1365-2958.2005.04958.x; IWAKI M, 1995, MOL MICROBIOL, V17, P1015, DOI 10.1111/j.1365-2958.1995.mmi_17061015.x; Karimova G, 1998, P NATL ACAD SCI USA, V95, P12532, DOI 10.1073/pnas.95.21.12532; KHELEF N, 1993, INFECT IMMUN, V61, P4064, DOI 10.1128/IAI.61.10.4064-4071.1993; KHELEF N, 1995, FEMS MICROBIOL LETT, V134, P27, DOI 10.1016/0378-1097(95)00375-F; Koschinski A, 2006, FASEB J, V20, P973, DOI 10.1096/fj.05-4561fje; Kumar P, 2002, INFECT IMMUN, V70, P4997, DOI 10.1128/IAI.70.9.4997-5007.2002; LADANT D, 1988, J BIOL CHEM, V263, P2612; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Masin J, 2005, BIOCHEMISTRY-US, V44, P12759, DOI 10.1021/bi050459b; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; Nhieu GT, 2004, BIOL CELL, V96, P93, DOI 10.1016/j.biocel.2003.10.006; Njamkepo E, 2000, J CELL PHYSIOL, V183, P91, DOI 10.1002/(SICI)1097-4652(200004)183:1<91::AID-JCP11>3.0.CO;2-S; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Osicka R, 2000, INFECT IMMUN, V68, P247; Osickova A, 1999, J BIOL CHEM, V274, P37644; OTERO AS, 1995, J BIOL CHEM, V270, P9695, DOI 10.1074/jbc.270.17.9695; PEARSON RD, 1987, J IMMUNOL, V139, P2749; Persechini A, 2002, TRENDS CARDIOVAS MED, V12, P32, DOI 10.1016/S1050-1738(01)00144-X; Rhodes CR, 2001, ARCH BIOCHEM BIOPHYS, V395, P169, DOI 10.1006/abbi.2001.2553; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROSE T, 1995, J BIOL CHEM, V270, P26370, DOI 10.1074/jbc.270.44.26370; Ross PJ, 2004, INFECT IMMUN, V72, P1568, DOI 10.1128/IAI.72.3.1568-1579.2004; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; Schlecht G, 2004, J IMMUNOL, V173, P6089, DOI 10.4049/jimmunol.173.10.6089; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; Shen YQ, 2002, EMBO J, V21, P6721, DOI 10.1093/emboj/cdf681; Skinner LJ, 2003, J NEUROPHYSIOL, V90, P320, DOI 10.1152/jn.01155.2002; SZABO G, 1994, J BIOL CHEM, V269, P22496; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; Valeva A, 2005, J BIOL CHEM, V280, P36657, DOI 10.1074/jbc.M507690200; Vojtova J, 2006, CURR OPIN MICROBIOL, V9, P69, DOI 10.1016/j.mib.2005.12.011; Weingart CL, 2000, INFECT IMMUN, V68, P1735, DOI 10.1128/IAI.68.3.1735-1739.2000; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	72	60	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2808	2820		10.1074/jbc.M609979200	http://dx.doi.org/10.1074/jbc.M609979200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148436	hybrid			2022-12-25	WOS:000243793900007
J	Knoblauch, A; Will, C; Goncharenko, G; Ludwig, S; Wixler, V				Knoblauch, Alexander; Will, Carola; Goncharenko, Grigori; Ludwig, Stephan; Wixler, Viktor			The binding of Mss4 to alpha-integrin subunits regulates matrix metalloproteinase remodeling	FASEB JOURNAL			English	Article						integrin cytodomain; integrin-binding proteins; MT1-MMP; myoblast differentiation	MEMBRANE-PROXIMAL REGION; INSIDE-OUT ACTIVATION; PROTEIN TRANSDUCTION; NUCLEOTIDE EXCHANGE; CYTOPLASMIC DOMAINS; SKELETAL-MUSCLE; IN-VITRO; MT1-MMP; FIBRONECTIN; EXPRESSION	In four independent yeast two-hybrid screens with the integrin alpha-subunits alpha 3A, alpha 6A, alpha 7A, and alpha 7B, we identified the Mss4 protein, a nucleotide exchange factor for exocytic Rab GTPases, as a novel integrin interacting protein. We have previously shown that it binds to the conserved KXGFFKR region of integrin a-subunits located directly beneath the cell membrane. Here we show that the binding site for integrins on Mss4 is overlapping with those for Rab GTPases. Functional analysis of the Mss4/integrin interaction revealed its importance for activation of matrix metalloproteinases (MMPs) and remodeling of secreted extracellular matrix (ECM) proteins. The exocytosis of all the proteins analyzed, however, was unaffected. Furthermore, our data suggest that Mss4 drives the coordinated action of the MT1-MMP/integrin protein complex, thus regulating the presence and activation of MT1-MMP at newly formed filopodia and lamellipodia. This in turn facilitates the conversion of pro-MMPs to MMPs, resulting in cleavage and remodeling of ECM proteins. C2C12 myoblasts with stably down-regulated Mss4 showed a disturbed fibronectin remodeling during differentiation, resulting in malfunctioned myotube formation.	Munster Univ Hosp, Sch Med, Inst Mol Virol, D-48149 Munster, Germany; Univ Gomel, Dept Genet, Gomel, BELARUS	University of Munster; Francisk Skorina Gomel State University	Wixler, V (corresponding author), Munster Univ Hosp, Sch Med, Inst Mol Virol, Von Esmarch Str 56, D-48149 Munster, Germany.	vwixler@uni-muenster.de	Goncharenko, Grigori G./ABD-5708-2020	Goncharenko, Grigori G./0000-0003-1408-8843; Ludwig, Stephan/0000-0003-4490-3052				Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Briesewitz R, 1996, MOL BIOL CELL, V7, P1499, DOI 10.1091/mbc.7.10.1499; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Calderwood DA, 2004, J CELL SCI, V117, P657, DOI 10.1242/jcs.01014; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Carmeli E, 2004, MUSCLE NERVE, V29, P191, DOI 10.1002/mus.10529; CHUNG CY, 1990, J CELL PHYSIOL, V142, P392, DOI 10.1002/jcp.1041420224; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; deMelker AA, 1997, BIOCHEM J, V328, P529, DOI 10.1042/bj3280529; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; El Mourabit H, 2002, MATRIX BIOL, V21, P207, DOI 10.1016/S0945-053X(01)00198-6; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Ginsberg MH, 2001, J BIOL CHEM, V276, P22514, DOI 10.1074/jbc.M101915200; Gullberg G, 1999, CELL MOL LIFE SCI, V56, P442, DOI 10.1007/PL00000616; Hintermann E, 2004, MATRIX BIOL, V23, P75, DOI 10.1016/j.matbio.2004.03.001; Ho A, 2001, CANCER RES, V61, P474; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Itzen A, 2006, EMBO J, V25, P1445, DOI 10.1038/sj.emboj.7601044; Jones CB, 2003, CARDIOVASC RES, V59, P812, DOI 10.1016/S0008-6363(03)00516-9; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Kherif S, 1999, DEV BIOL, V205, P158, DOI 10.1006/dbio.1998.9107; KUHL U, 1984, DIFFERENTIATION, V28, P164, DOI 10.1111/j.1432-0436.1984.tb00279.x; Leeman MF, 2003, J PATHOL, V201, P528, DOI 10.1002/path.1466; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Lluri G, 2005, MUSCLE NERVE, V32, P492, DOI 10.1002/mus.20383; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Ma YQ, 2006, BIOCHEMISTRY-US, V45, P6656, DOI 10.1021/bi060279h; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Remacle AG, 2005, J CELL SCI, V118, P4975, DOI 10.1242/jcs.02610; Samson T, 2004, J BIOL CHEM, V279, P28641, DOI 10.1074/jbc.M312894200; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Sato H, 2005, CANCER SCI, V96, P212, DOI 10.1111/j.1349-7006.2005.00039.x; SCHULER F, 1995, J CELL SCI, V108, P3795; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; Strongin AY, 2006, CANCER METAST REV, V25, P87, DOI 10.1007/s10555-006-7892-y; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Takino T, 2006, EXP CELL RES, V312, P1381, DOI 10.1016/j.yexcr.2006.01.008; Thaw P, 2001, NAT STRUCT BIOL, V8, P701, DOI 10.1038/90415; Travis MA, 2003, TRENDS PHARMACOL SCI, V24, P192, DOI 10.1016/S0165-6147(03)00069-5; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; Wixler V, 1999, FEBS LETT, V445, P351, DOI 10.1016/S0014-5793(99)00151-9; Yamanouchi J, 2004, BIOCHEM J, V379, P317, DOI 10.1042/BJ20031753; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0; YU HT, 1995, BIOCHEMISTRY-US, V34, P9103, DOI 10.1021/bi00028a020; Zhu ZY, 2001, BIOCHEMISTRY-US, V40, P3027, DOI 10.1021/bi002680o	56	17	19	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					497	510		10.1096/fj.06-7022com	http://dx.doi.org/10.1096/fj.06-7022com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17172637				2022-12-25	WOS:000244686300023
J	Canamero, RC; Boccalandro, H; Casal, J; Serna, L				Canamero, Roberto C.; Boccalandro, Hernan; Casal, Jorge; Serna, Laura			Use of Confocal Laser as Light Source Reveals Stomata-Autonomous Function	PLOS ONE			English	Article							PLASMA-MEMBRANE PROTEIN; BLUE-LIGHT; INDUCED PHOSPHORYLATION; ACTION SPECTRUM; PHOTOTROPIN-2; MEDIATE; NPH1; NPL1	In most terrestrial plants, stomata open during the day to maximize the update of CO2 for photosynthesis, but they close at night to minimize water loss. Blue light, among several environmental factors, controls this process. Stomata response to diverse stimuli seems to be dictated by the behaviour of neighbour stomata creating leaf areas of coordinated response. Here individual stomata of Arabidopsis leaves were illuminated with a short blue-light pulse by focusing a confocal argon laser. Beautifully, the illuminated stomata open their pores, whereas their dark-adapted neighbours unexpectedly experience no change. This induction of individual stomata opening by low fluence rates of blue light was disrupted in the phototropin1 phototropin2 (phot1 phot2) double mutant, which exhibits insensitivity of stomatal movements in blue-illuminated epidermal strips. The irradiation of all epidermal cells making direct contact with a given stoma in both wild type and phot1 phot2 plants does not trigger its movement. These results unravel the stoma autonomous function in the blue light response and illuminate the implication of PHOT1 and/or PHOT2 in such response. The micro spatial heterogeneity that solar blue light suffers in partially shaded leaves under natural conditions highlights the physiological significance of the autonomous stomatal behaviour.	[Canamero, Roberto C.; Boccalandro, Hernan; Serna, Laura] Univ Castilla La Mancha, Environm Sci Fac, Toledo, Spain; [Boccalandro, Hernan; Casal, Jorge] Univ Buenos Aires, Fac Agron, Inst Invest Fisiol & Ecol Vinculadas Agr IFEVA, Buenos Aires, DF, Argentina; [Boccalandro, Hernan; Casal, Jorge] Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina	Universidad de Castilla-La Mancha; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Serna, L (corresponding author), Univ Castilla La Mancha, Environm Sci Fac, Toledo, Spain.	laura.serna@uclm.es		Casal, Jorge/0000-0001-6525-8414; Serna, Laura/0000-0002-4705-3519	Castilla-La Mancha University [PAI-05-058]; Ministry of Education and Culture of Spain [BIO2005-04493]	Castilla-La Mancha University; Ministry of Education and Culture of Spain(Spanish Government)	Funding: This work was supported by grants from the Castilla-La Mancha University (to LS, JC and HB), and both the Communities Council of Castilla-La Mancha (PAI-05-058) and the Ministry of Education and Culture of Spain (BIO2005-04493) (to LS). RCC was supported by a Communities Council of Castilla-La Mancha fellowship. HB was supported by a grant from the Castilla-La Mancha University.	Briggs WR, 2002, TRENDS PLANT SCI, V7, P204, DOI 10.1016/S1360-1385(02)02245-8; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; Chen M, 2004, ANNU REV GENET, V38, P87, DOI 10.1146/annurev.genet.38.072902.092259; Christie JM, 1999, P NATL ACAD SCI USA, V96, P8779, DOI 10.1073/pnas.96.15.8779; Eisinger W, 2000, PLANT PHYSIOL, V122, P99, DOI 10.1104/pp.122.1.99; Fan LM, 2004, CURR OPIN PLANT BIOL, V7, P537, DOI 10.1016/j.pbi.2004.07.009; GALLAGHER S, 1988, P NATL ACAD SCI USA, V85, P8003, DOI 10.1073/pnas.85.21.8003; HAGER A, 1993, PLANTA, V189, P567, DOI 10.1007/BF00198221; Hetherington AM, 2003, NATURE, V424, P901, DOI 10.1038/nature01843; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; Kagawa T, 2001, SCIENCE, V291, P2138, DOI 10.1126/science.291.5511.2138; KARLSSON PE, 1986, PHYSIOL PLANTARUM, V66, P207, DOI 10.1111/j.1399-3054.1986.tb02410.x; Kinoshita T, 2001, NATURE, V414, P656, DOI 10.1038/414656a; Kong SG, 2006, PLANT J, V45, P994, DOI 10.1111/j.1365-313X.2006.02667.x; Leckie CP, 1998, P NATL ACAD SCI USA, V95, P15837, DOI 10.1073/pnas.95.26.15837; Mao J, 2005, P NATL ACAD SCI USA, V102, P12270, DOI 10.1073/pnas.0501011102; Mott KA, 2000, TRENDS PLANT SCI, V5, P258, DOI 10.1016/S1360-1385(00)01648-4; Mott KA, 1997, PLANT CELL ENVIRON, V20, P1098, DOI 10.1046/j.1365-3040.1997.d01-138.x; Mott KA, 2001, PLANT CELL ENVIRON, V24, P657, DOI 10.1046/j.0016-8025.2001.00705.x; PALMER JM, 1993, PLANT PHYSIOL, V102, P1211, DOI 10.1104/pp.102.4.1211; Sakai T, 2001, P NATL ACAD SCI USA, V98, P6969, DOI 10.1073/pnas.101137598; Sakamoto K, 2002, PLANT CELL, V14, P1723, DOI 10.1105/tpc.003293; Salomon M, 1996, PLANTA, V199, P336, DOI 10.1007/BF00195724; Schroeder JI, 2001, ANNU REV PLANT PHYS, V52, P627, DOI 10.1146/annurev.arplant.52.1.627; Serna L, 2000, PHYSIOL PLANTARUM, V109, P351, DOI 10.1034/j.1399-3054.2000.100317.x; Sharma VK, 1997, PHYTOCHEMISTRY, V44, P775, DOI 10.1016/S0031-9422(96)00624-3; SHORT TW, 1993, PLANT PHYSIOL, V101, P647, DOI 10.1104/pp.101.2.647; Talbott LD, 2003, PLANT PHYSIOL, V133, P1522, DOI 10.1104/pp.103.029587; Talbott LD, 2002, AM J BOT, V89, P366, DOI 10.3732/ajb.89.2.366; ZEIGER E, 1977, SCIENCE, V196, P887, DOI 10.1126/science.196.4292.887; ZEIGER E, 1983, ANNU REV PLANT PHYS, V34, P441, DOI 10.1146/annurev.pp.34.060183.002301	31	4	4	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e36	10.1371/journal.pone.0000036	http://dx.doi.org/10.1371/journal.pone.0000036			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183664	gold, Green Published, Green Submitted			2022-12-25	WOS:000207443600036
J	Carmena, A; Speicher, S; Baylies, M				Carmena, Ana; Speicher, Stephan; Baylies, Mary			The PDZ Protein Canoe/AF-6 Links Ras-MAPK, Notch and Wingless/Wnt Signaling Pathways by Directly Interacting with Ras, Notch and Dishevelled	PLOS ONE			English	Article								Over the past few years, it has become increasingly apparent that signal transduction pathways are not merely linear cascades; they are organized into complex signaling networks that require high levels of regulation to generate precise and unique cell responses. However, the underlying regulatory mechanisms by which signaling pathways cross-communicate remain poorly understood. Here we show that the Ras-binding protein Canoe (Cno)/AF-6, a PDZ protein normally associated with cellular junctions, is a key modulator of Wingless (Wg)/Wnt, Ras-Mitogen Activated Protein Kinase (MAPK) and Notch (N) signaling pathways cross-communication. Our data show a repressive effect of Cno/AF-6 on these three signaling pathways through physical interactions with Ras, N and the cytoplasmic protein Dishevelled (Dsh), a key Wg effector. We propose a model in which Cno, through those interactions, actively coordinates, at the membrane level, Ras-MAPK, N and Wg signaling pathways during progenitor specification.	[Carmena, Ana; Baylies, Mary] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Dev Biol, New York, NY 10021 USA; [Carmena, Ana; Speicher, Stephan] Univ Miguel Hernandez, CSIC, Inst Neurociencias Alicante, Unidad Neurobiol Desarrollo, Alicante, Spain	Memorial Sloan Kettering Cancer Center; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Carmena, A (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Dev Biol, 1275 York Ave, New York, NY 10021 USA.	acarmena@umh.es	Carmena, Ana/H-3506-2015	Carmena, Ana/0000-0003-1855-7934	National Institutes of Health [GM56989]; Human Frontiers Postdoctoral Fellowship; Generalitat Valenciana [GV05/075]; Marie Curie Program [MIRG-CT-2005016536]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056989] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Human Frontiers Postdoctoral Fellowship; Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission); Marie Curie Program(European Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	M. B. and A. C. were supported by National Institutes of Health Grant GM56989, a Human Frontiers Postdoctoral Fellowship and Grants from the Generalitat Valenciana GV05/075 and Marie Curie Program (MIRG-CT-2005016536).	Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Axelrod JD, 2001, GENE DEV, V15, P1182; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bate Michael, 1993, P1013; Baylies MK, 2001, CURR OPIN GENET DEV, V11, P431, DOI 10.1016/S0959-437X(00)00214-8; Baylies MK, 1998, CELL, V93, P921, DOI 10.1016/S0092-8674(00)81198-8; Bellotto M, 2002, INT J DEV BIOL, V46, P149; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Boettner B, 2003, GENETICS, V165, P159; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Buff E, 1998, DEVELOPMENT, V125, P2075; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Carmena A, 1998, GENE DEV, V12, P3910, DOI 10.1101/gad.12.24.3910; Carmena A, 2002, DEV BIOL, V244, P226, DOI 10.1006/dbio.2002.0606; CARMENA A, 1995, GENE DEV, V9, P2373, DOI 10.1101/gad.9.19.2373; Carmena A, 1998, GENE DEV, V12, P304, DOI 10.1101/gad.12.3.304; Cooper MTD, 2000, CURR BIOL, V10, P1507, DOI 10.1016/S0960-9822(00)00826-5; Culi J, 2001, DEVELOPMENT, V128, P299; DUNINBORKOWSKI OM, 1995, DEV BIOL, V168, P689, DOI 10.1006/dbio.1995.1115; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; Frasch M, 1999, CURR OPIN GENET DEV, V9, P522, DOI 10.1016/S0959-437X(99)00014-3; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gabay L, 1997, DEVELOPMENT, V124, P3535; Gaengel K, 2003, DEVELOPMENT, V130, P5413, DOI 10.1242/dev.00759; Gisselbrecht S, 1996, GENE DEV, V10, P3003, DOI 10.1101/gad.10.23.3003; Gomez MR, 1997, DEVELOPMENT, V124, P4857; Halfon MS, 2000, CELL, V103, P63, DOI 10.1016/S0092-8674(00)00105-7; Hasson P, 2005, NAT GENET, V37, P101, DOI 10.1038/ng1486; Hayward P, 2005, DEVELOPMENT, V132, P1819, DOI 10.1242/dev.01724; Ikeya T, 1999, DEVELOPMENT, V126, P4455; James P, 1996, GENETICS, V144, P1425; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Knirr S, 2001, DEV BIOL, V238, P13, DOI 10.1006/dbio.2001.0397; Kosman D, 1998, DEV GENES EVOL, V208, P290, DOI 10.1007/s004270050184; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Lawrence PA, 1995, DEVELOPMENT, V121, P4303; Le Borgne R, 2005, DEVELOPMENT, V132, P1751, DOI 10.1242/dev.01789; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Maitra S, 2006, CURR BIOL, V16, P702, DOI 10.1016/j.cub.2006.02.063; MARTINBERMUDO MD, 1991, DEVELOPMENT, V113, P445; Matsuo T, 1997, DEVELOPMENT, V124, P2671; Michelson AM, 1998, DEV GENET, V22, P212, DOI 10.1002/(SICI)1520-6408(1998)22:3<212::AID-DVG4>3.0.CO;2-9; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; PRASAD R, 1993, CANCER RES, V53, P5624; Radziwill G, 2003, MOL CELL BIOL, V23, P4663, DOI 10.1128/MCB.23.13.4663-4672.2003; Ramain P, 2001, CURR BIOL, V11, P1729, DOI 10.1016/S0960-9822(01)00562-0; Rohrbaugh M, 2002, CURR BIOL, V12, P576, DOI 10.1016/S0960-9822(02)00743-1; Shaye DD, 2002, NATURE, V420, P686, DOI 10.1038/nature01234; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shimada Y, 2001, CURR BIOL, V11, P859, DOI 10.1016/S0960-9822(01)00233-0; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Su MT, 1999, DEVELOPMENT, V126, P3241; Sundaram MV, 2005, GENE DEV, V19, P1825, DOI 10.1101/gad.1330605; Takahashi K, 1998, MECH DEVELOP, V78, P97, DOI 10.1016/S0925-4773(98)00151-8; Tepass U, 1996, DEV BIOL, V177, P217, DOI 10.1006/dbio.1996.0157; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; YAMAMOTO D, 1996, MOL DYNAMICS DEV DRO; Yamamoto T, 1999, BIOCHEM BIOPH RES CO, V259, P103, DOI 10.1006/bbrc.1999.0731; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yoo AS, 2004, SCIENCE, V303, P663, DOI 10.1126/science.1091639; zur Lage P, 1999, DEVELOPMENT, V126, P3149	74	39	41	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e66	10.1371/journal.pone.0000066	http://dx.doi.org/10.1371/journal.pone.0000066			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183697	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600066
J	Sausbier, M; Zhou, XB; Beier, C; Sausbier, U; Wolpers, D; Maget, S; Martin, C; Dietrich, A; Ressmeyer, AR; Renz, H; Schlossmann, J; Hofmann, F; Neuhuber, W; Gudermann, T; Uhlig, S; Korth, M; Ruth, P				Sausbier, Matthias; Zhou, Xiao-Bo; Beier, Caroline; Sausbier, Ulrike; Wolpers, Daniela; Maget, Syivi; Martin, Christian; Dietrich, Alexander; Ressmeyer, Anna-Rebekka; Renz, Harald; Schlossmann, Jens; Hofmann, Franz; Neuhuber, Winfried; Gudermann, Tbomas; Uhlig, Stefan; Korth, Michael; Ruth, Peter			Reduced rather than enhanced cholinergic airway constriction in mice with ablation of the large conductance Ca2+-activated K+ channel	FASEB JOURNAL			English	Article						knockout mice; BK channel; airway contractility; cyclic GMP/PKG signaling; cholinergic agonists	DEPENDENT PROTEIN-KINASE; TRACHEAL SMOOTH-MUSCLE; GUINEA-PIG TRACHEA; POTASSIUM CHANNELS; NITRIC-OXIDE; CALCIUM; CONTRACTION; RELAXATION; RECEPTOR; INHIBITION	The unique voltage- and Ca2+-dependent K+ (BK) channel, prominently expressed in airway smooth muscle cells, has been suggested as an important effector in controlling airway contractility. Its deletion in mice depolarized resting membrane potential of tracheal cells, suggesting an increased open-probability of voltage-gated Ca2+ channels. While carbachol concentration-dependently increased the tonic tension of wild-type (WT) trachea, mutant trachea showed a different response with rapid tension development followed by phasic contractions superimposed on a tonic component. Tonic contractions were substantially more dependent on 1-type Ca2+ current in mutant than in WT trachea, even though 1-type Ca2+ channels were not up-regulated. In the absence of 1-type Ca2+ current, half-maximal contraction of trachea was shifted from 0.51 to 1.7 mu M. In agreement, cholinergic bronchoconstriction was reduced in mutant lung slices, isolated-perfused lungs and, most impressively, in mutant mice analyzed by body plethysmography. Furthermore, isoprenaline-mediated airway relaxation was enhanced in mutants. In-depth analysis of cAMP and cGMP signaling revealed up-regulation of the cGMP pathway in mutant tracheal muscle. Inhibition of cGMP kinase reestablished normal sensitivity toward carbachol, indicating that up-regulation of cGMP signaling counterbalances for BK channel ablation, pointing to a predominant role of BK channel in regulation of airway tone.	Univ Hamburg, Klinikum Eppendorf, Inst Pharmacol & Pharmazeuten, D-20246 Hamburg, Germany; Univ Tubingen, Inst Pharmazeut, D-72074 Tubingen, Germany; Leibniz Zentrum Med & Biowissensch, Borstel, Germany; Univ Marburg, Inst Pharmacol & Toxicol, D-35032 Marburg, Germany; Univ Marburg, Inst Klin Chem & Mol Diagnost, D-35032 Marburg, Germany; Tech Univ Munich, Inst Pharmacol & Toxicol, D-8000 Munich, Germany; Univ Erlangen Nurnberg, Inst Anat, Erlangen, Germany; Rhein Westfal TH Aachen, Inst Pharmacol & Toxicol, D-5100 Aachen, Germany	University of Hamburg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Philipps University Marburg; Philipps University Marburg; Technical University of Munich; University of Erlangen Nuremberg; RWTH Aachen University	Korth, M (corresponding author), Univ Hamburg, Klinikum Eppendorf, Inst Pharmacol & Pharmazeuten, Martinistr 52, D-20246 Hamburg, Germany.	korth@uke.uni-hamburg.de	Dietrich, Alexander/G-8619-2013; Schlossmann, Jens/I-7743-2016; Uhlig, Stefan/A-7290-2014	Dietrich, Alexander/0000-0002-1168-8707; Schlossmann, Jens/0000-0002-2550-6839; Uhlig, Stefan/0000-0003-2332-1280				AHMED F, 1985, BRIT J PHARMACOL, V84, P861, DOI 10.1111/j.1476-5381.1985.tb17380.x; Barnes PJ, 1998, AM J RESP CRIT CARE, V158, pS123, DOI 10.1164/ajrccm.158.supplement_2.13tac800; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; BLACK JL, 1990, THORAX, V45, P213, DOI 10.1136/thx.45.3.213; Choi JW, 1998, J PHARMACOL EXP THER, V285, P588; Corompt E, 1998, N-S ARCH PHARMACOL, V357, P77; Dimitropoulou C, 2005, AM J RESP CELL MOL, V32, P239, DOI 10.1165/rcmb.2004-0331OC; Eglen RM, 1996, PHARMACOL REV, V48, P531; FLEISCHMANN BK, 1994, P NATL ACAD SCI USA, V91, P11914, DOI 10.1073/pnas.91.25.11914; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323; Geiselhoringer A, 2004, EMBO J, V23, P4222, DOI 10.1038/sj.emboj.7600440; Glaab T, 2001, AM J PHYSIOL-LUNG C, V280, pL565, DOI 10.1152/ajplung.2001.280.3.L565; Held HD, 1999, BRIT J PHARMACOL, V126, P1191, DOI 10.1038/sj.bjp.0702394; HUANG JC, 1993, EUR J PHARMACOL, V235, P37, DOI 10.1016/0014-2999(93)90817-2; Jaggar JH, 2000, AM J PHYSIOL-CELL PH, V278, pC235, DOI 10.1152/ajpcell.2000.278.2.C235; Janssen LJ, 2002, AM J PHYSIOL-LUNG C, V282, pL1161, DOI 10.1152/ajplung.00452.2001; JANSSEN LJ, 1992, J PHYSIOL-LONDON, V453, P197, DOI 10.1113/jphysiol.1992.sp019224; JIANG H, 1992, J BIOL CHEM, V267, P1015; Johnson M, 1998, AM J RESP CRIT CARE, V158, pS146, DOI 10.1164/ajrccm.158.supplement_2.13tac110; JONES TR, 1993, J APPL PHYSIOL, V74, P1879, DOI 10.1152/jappl.1993.74.4.1879; JONES TR, 1990, J PHARMACOL EXP THER, V255, P697; KANNAN MS, 1995, LIFE SCI, V56, P2229, DOI 10.1016/0024-3205(95)00212-O; KIRKPATRICK CT, 1975, J PHYSIOL-LONDON, V244, P263, DOI 10.1113/jphysiol.1975.sp010796; KUME H, 1994, J CLIN INVEST, V93, P371, DOI 10.1172/JCI116969; Laporte R, 2004, PHARMACOL REV, V56, P439, DOI 10.1124/pr.56.4.1; Li L, 1998, EUR J PHARMACOL, V346, P255, DOI 10.1016/S0014-2999(98)00074-0; Lincoln T M, 1995, Adv Pharmacol, V34, P305; Madison JM, 2000, AM J RESP CELL MOL, V22, P513, DOI 10.1165/ajrcmb.22.5.f183; Martin C, 2004, AM J PHYSIOL-LUNG C, V287, pL250, DOI 10.1152/ajplung.00420.2003; Meredith AL, 2004, J BIOL CHEM, V279, P36746, DOI 10.1074/jbc.M405621200; MIURA M, 1992, AM REV RESPIR DIS, V146, P132, DOI 10.1164/ajrccm/146.1.132; MURRAY MA, 1991, BRIT J PHARMACOL, V103, P1814, DOI 10.1111/j.1476-5381.1991.tb09868.x; NADEL JA, 1984, ANNU REV MED, V35, P451, DOI 10.1146/annurev.med.35.1.451; Neuhaus-Steinmetz U, 2000, INT ARCH ALLERGY IMM, V121, P57, DOI 10.1159/000024298; Oshiro T, 2000, AM J RESP CELL MOL, V22, P528, DOI 10.1165/ajrcmb.22.5.3837; Patel HJ, 1998, J PHARMACOL EXP THER, V286, P952; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Sausbier M, 2005, CIRCULATION, V112, P60, DOI 10.1161/01.CIR.0000156448.74296.FE; Sausbier M, 2004, P NATL ACAD SCI USA, V101, P9474, DOI 10.1073/pnas.0401702101; Sausbier U, 2006, HISTOCHEM CELL BIOL, V125, P725, DOI 10.1007/s00418-005-0124-7; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; SOMLYO AV, 1968, J PHARMACOL EXP THER, V159, P129; Stengel PW, 2002, AM J PHYSIOL-REG I, V282, pR1443, DOI 10.1152/ajpregu.00486.2001; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; von Bethmann AN, 1998, AM J RESP CRIT CARE, V157, P263, DOI 10.1164/ajrccm.157.1.9608052; WERNER ME, 2005, J PHYSL, V267, P545; WORLEY JF, 1990, AM J PHYSIOL, V259, pL468, DOI 10.1152/ajplung.1990.259.6.L468; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760; ZhuGe R, 2002, J GEN PHYSIOL, V120, P15, DOI 10.1085/jgp.20028571; ZhuGe RH, 1998, J PHYSIOL-LONDON, V513, P711, DOI 10.1111/j.1469-7793.1998.711ba.x; Zimmerman JL, 2000, AM J RESP CRIT CARE, V162, P512, DOI 10.1164/ajrccm.162.2.9910105	52	27	28	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					812	822		10.1096/fj.06-7167com	http://dx.doi.org/10.1096/fj.06-7167com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197382				2022-12-25	WOS:000244686400019
J	Wotzlaw, C; Otto, T; Berchner-Pfannschmidt, U; Metzen, E; Acker, H; Fandrey, J				Wotzlaw, Christoph; Otto, Teresa; Berchner-Pfannschmidt, Utta; Metzen, Eric; Acker, Helmut; Fandrey, Joachim			Optical analysis of the HIF-1 complex in living cells by FRET and FRAP	FASEB JOURNAL			English	Article						fluorescence resonance energy transfer; fluorescence recoveiy after pholobleaching; hypoxia-inducible factor-1; oxygen sensing	HYPOXIA-INDUCIBLE-FACTOR; STRUCTURAL BASIS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; LIVE CELLS; ACTIVATION; FACTOR-1-ALPHA; HYDROXYLASES; PROTEIN; HETERODIMERIZATION	Hypoxia-inducible factor-1 (HIF-1) coordinates the cellular response to a lack of oxygen by controlling the expression of hypoxia-inducible genes that ensure an adequate energy supply. Assembly of the HIF-1 complex by its oxygen-regulated subunit HIF-1 alpha and its constitutive 0 subunit also known as ARNT is the key event of the cellular genetic response to hypoxia. By two-photon microscopy, we studied HIF-1 assembly in living cells and the mobility of fluorophore-labeled HIF-1 subunits by fluorescence recovery after photobleaching. We found a significantly slower nuclear migration of HIF-1 alpha than of HIF-1 beta, indicating that each subunit can move independently. We applied fluorescence resonance energy transfer to calculate the nanometer distance between alpha and beta subunits of the transcriptionally active HIF-1 complex bound to DNA. Both N terirnini of the fluorophore-labeled HIF-1 subunits were localized as close as 6.2 run, but even the N and C terminus of the HIF-1 complex were not further apart than 7.4 nm. Our data suggest a more compact 3-dimensional organization of the HIF complex than described so far by 2-dimensional models.	Univ Duisburg Gesamthsch, Inst Physiol, D-45122 Essen, Germany; Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany	University of Duisburg Essen; University of Lubeck	Fandrey, J (corresponding author), Univ Duisburg Gesamthsch, Inst Physiol, Hufelandstr 55, D-45122 Essen, Germany.	joachim.fandrey@uni-due.de	Acker, Helmut/AAJ-8332-2020; Acker, Helmut Anton Josef/AAS-6841-2020; Fandrey, Joachim/AAA-3524-2021	Acker, Helmut Anton Josef/0000-0001-5589-5508; Fandrey, Joachim/0000-0001-9585-0531				Berchner-Pfannschmidt U, 2004, BIOL CHEM, V385, P231, DOI 10.1515/BC.2004.017; Berchner-Pfannschmidt U, 2004, J BIOL CHEM, V279, P44976, DOI 10.1074/jbc.M313995200; Berney C, 2003, BIOPHYS J, V84, P3992, DOI 10.1016/S0006-3495(03)75126-1; Berra E, 2006, EMBO REP, V7, P41, DOI 10.1038/sj.embor.7400598; Bestvater F, 2002, J MICROSC-OXFORD, V208, P108, DOI 10.1046/j.1365-2818.2002.01074.x; Card PB, 2005, J MOL BIOL, V353, P664, DOI 10.1016/j.jmb.2005.08.043; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erbel PJA, 2003, P NATL ACAD SCI USA, V100, P15504, DOI 10.1073/pnas.2533374100; Fandrey J, 2006, CARDIOVASC RES, V71, P642, DOI 10.1016/j.cardiores.2006.05.005; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hopfl G, 2004, AM J PHYSIOL-REG I, V286, pR608, DOI 10.1152/ajpregu.00538.2003; Houtsmuller AB, 2001, HISTOCHEM CELL BIOL, V115, P13, DOI 10.1007/s004180000234; Kietzmann T, 2005, SEMIN CELL DEV BIOL, V16, P474, DOI 10.1016/j.semcdb.2005.03.010; Lee C, 2003, J BIOL CHEM, V278, P7558, DOI 10.1074/jbc.M210385200; Liu Q, 2004, P NATL ACAD SCI USA, V101, P4302, DOI 10.1073/pnas.0400265101; Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Ruas JL, 2005, J CELL SCI, V118, P301, DOI 10.1242/jcs.01617; Rubart M, 2004, CIRC RES, V95, P1154, DOI 10.1161/01.RES.0000150593.30324.42; Schofield CJ, 2005, BIOCHEM BIOPH RES CO, V338, P617, DOI 10.1016/j.bbrc.2005.08.111; Semenza GL, 1997, KIDNEY INT, V51, P553, DOI 10.1038/ki.1997.77; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tramier M, 2002, BIOPHYS J, V83, P3570, DOI 10.1016/S0006-3495(02)75357-5; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	33	29	29	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2007	21	3					700	707		10.1096/fj.06-6280com	http://dx.doi.org/10.1096/fj.06-6280com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197389				2022-12-25	WOS:000244686400009
J	Harada, H; Takahashi, M				Harada, Hosami; Takahashi, Masaaki			CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAAGSIEKTE SHEEP RETROVIRUS; LYSOSOMAL HYALURONIDASE; PLASMA HYALURONIDASE; SYNOVIAL-FLUID; TUMOR-GROWTH; EXPRESSION; CELLS; RECEPTOR; HYAL2; CD44	Hyaluronic acid (HA) is a high molecular weight glycosaminoglycan involved in a wide variety of cellular functions. However, its turnover in living cells remains largely unknown. In this study, CD44, a receptor for HA, and hyaluronidase-1, -2, and -3 (Hyal-1, -2 and -3) were stably expressed in HEK 293 cells and the mechanism of HA catabolism was systematically investigated using fluorescein-labeled HA. CD44 was essential for HA degradation by both endogenous and exogenously expressed hyaluronidases. Hyal-1 was not able to cleave HA in living cells in the absence of CD44. Intracellular HA degradation was predominantly mediated by Hyal-1 after incorporation of HA by CD44. Although Hyal-1 was active only in intracellular space in vivo, a certain amount of the enzyme was secreted to extracellular space. This extracellular Hyal-1 was found to be incorporated by cells and such uptake of Hyal-1 was, in part, involved in the intracellular degradation of HA. Hyal-2 was involved in the extracellular degradation of HA. Hyal-2 activity was also dependent on the expression of CD44 in both living cells and enzyme assays. Immunofluorescent microscopy demonstrated that both Hyal-2 and CD44 are present on the cell surface. Without CD44 expression, Hyal-2 existed in a granular pattern, and did not show hyaluronidase activity, suggesting that localization change could contribute to Hyal-2 function. A convenient and quantitative enzyme assay was established for the measurement of Hyal-2 activity. Hyal-2 activity was detected in the membrane fraction of cells co-expressing Hyal-2 and CD44. The pH optimum for Hyal-2 was 6.0-7.0. The membrane fraction of cells expressing Hyal-2 alone did not show hyaluronidase activity. Hyal-3 did not show any hyaluronidase activity in our experimental conditions. Based on these findings, Hyal-1 and -2 contribute to intracellular and extracellular catabolism of HA, respectively, in a CD44-dependent manner, and their HA degradation occurs independently from one another.	Sankyo Co Ltd, Lead Discovery Res Labs, Shinagawa Ku, Tokyo 1408710, Japan	Daiichi Sankyo Company Limited	Takahashi, M (corresponding author), Sankyo Co Ltd, Lead Discovery Res Labs, Shinagawa Ku, 1-2-58 Hiromachi, Tokyo 1408710, Japan.	mtakah@sankyo.co.jp						AFIFY AM, 1993, ARCH BIOCHEM BIOPHYS, V305, P434, DOI 10.1006/abbi.1993.1443; Botzki A, 2004, J BIOL CHEM, V279, P45990, DOI 10.1074/jbc.M406146200; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Csoka AB, 1999, GENOMICS, V60, P356, DOI 10.1006/geno.1999.5876; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; DAHL LB, 1985, ANN RHEUM DIS, V44, P817, DOI 10.1136/ard.44.12.817; DAY AJ, 2002, J BIOL CHEM, V277, P4575; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; Fieber C, 2004, J CELL SCI, V117, P359, DOI 10.1242/jcs.00831; Flannery CR, 1998, BIOCHEM BIOPH RES CO, V251, P824, DOI 10.1006/bbrc.1998.9561; FRASER JRE, 1981, BIOCHEM J, V200, P415, DOI 10.1042/bj2000415; Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773; Ghiran I, 2003, J BIOL CHEM, V278, P21024, DOI 10.1074/jbc.M302306200; GHOSH P, 1994, CLIN EXP RHEUMATOL, V12, P75; HUA Q, 1993, J CELL SCI, V106, P365; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Lepperdinger G, 2001, MATRIX BIOL, V20, P509, DOI 10.1016/S0945-053X(01)00170-6; Lokeshwar VB, 2005, CANCER RES, V65, P2243, DOI 10.1158/0008-5472.CAN-04-2805; LONGAKER MT, 1991, ANN SURG, V213, P292, DOI 10.1097/00000658-199104000-00003; Maeda N, 2001, P NATL ACAD SCI USA, V98, P4449, DOI 10.1073/pnas.071547598; Majors AK, 2003, J BIOL CHEM, V278, P47223, DOI 10.1074/jbc.M304871200; Natowicz MR, 1996, AM J MED GENET, V65, P209, DOI 10.1002/(SICI)1096-8628(19961028)65:3<209::AID-AJMG7>3.0.CO;2-K; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Novak U, 1999, CANCER RES, V59, P6246; Rai SK, 2001, P NATL ACAD SCI USA, V98, P4443, DOI 10.1073/pnas.071572898; Sly W S, 1978, Prog Clin Biol Res, V23, P547; Stern R, 2004, EUR J CELL BIOL, V83, P317, DOI 10.1078/0171-9335-00392; Stern R, 2003, GLYCOBIOLOGY, V13, p105R, DOI 10.1093/glycob/cwg112; Strobl B, 1998, GENOMICS, V53, P214, DOI 10.1006/geno.1998.5472; Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200; Taylor KR, 2004, J BIOL CHEM, V279, P17079, DOI 10.1074/jbc.M310859200; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2002, AM J PATHOL, V161, P745, DOI 10.1016/S0002-9440(10)64232-0; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; TOOLE BP, 1991, CELL BIOL EXTRACELLU, P61; TURLEY EA, 1980, NATURE, V283, P268, DOI 10.1038/283268a0; Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026; WEIGEL PH, 1986, J THEOR BIOL, V119, P219, DOI 10.1016/S0022-5193(86)80076-5; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Yoshida M, 2004, ARTHRITIS RES THER, V6, pR514, DOI 10.1186/ar1223	43	235	248	3	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5597	5607		10.1074/jbc.M608358200	http://dx.doi.org/10.1074/jbc.M608358200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17170110	hybrid			2022-12-25	WOS:000244482300056
J	Burkhart, BA; Kennett, SB; Archer, TK				Burkhart, Barbara A.; Kennett, Sarah B.; Archer, Trevor K.			Osmotic stress-dependent repression is mediated by histone H3 phosphorylation and chromatin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TRANSFORMED MOUSE FIBROBLASTS; B-INDUCED PHOSPHORYLATION; GLUCOCORTICOID-RECEPTOR; CHROMOSOME CONDENSATION; MITOTIC PHOSPHORYLATION; SER-10 PHOSPHORYLATION; BETAINE TRANSPORTER; KIDNEY-CELLS; IN-VIVO	Histone H3 phosphorylation has been linked to various environmental stress responses and specific chromatin structure. The role of H3 phosphorylation in the osmotic stress response was investigated on the mouse mammary tumor virus (MMTV) promoter in different chromatin configurations. Hormone-dependent transcription from the MMTV promoter is repressed by osmotic stress when the promoter is integrated and has a normal chromatin structure. However, when the MMTV promoter is transiently transfected, the chromatin structure is less organized, and hormone induction is not affected by osmotic stress. On the integrated MMTV promoter, phosphorylation of histone H3 serine 10 and 28 increases in response to osmotic stress, but the transient promoter shows no change. Hormone-dependent glucocorticoid receptor binding is reduced on the repressed promoter, and elevated H3 phosphorylation is temporally correlated with maximal MMTV repression Additionally, the protein kinase C inhibitor rottlerin, but not other kinase inhibitors, blocks both histone H3 phosphorylation and osmotic repression of MMTV transcription. Glucocorticoid receptor binding is inversely correlated with H3 phosphorylation, suggesting that displacement of the glucocorticoid receptor from the promoter is due to H3 phosphorylation and is the mechanism for the osmotic repression of hormone-dependent transcription.	Interagcy Oncol Task Force Food & Drug Adm, Ctr Biol Evaluat & Res, NIH, Bethesda, MD 20892 USA; NCI, NIH, Bethesda, MD 20892 USA; NIEHS, Lab Mol Carcinogenesis, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Archer, TK (corresponding author), Interagcy Oncol Task Force Food & Drug Adm, Ctr Biol Evaluat & Res, NIH, Bethesda, MD 20892 USA.	archer1@niehs.nih.gov	Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071006, ZIAES071006] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bell LM, 2000, J BIOL CHEM, V275, P25262, DOI 10.1074/jbc.M002076200; Bhattacharjee RN, 2006, VIROLOGY, V346, P1, DOI 10.1016/j.virol.2005.12.034; BODE AM, 2005, SCI STKE, pRE4; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Clayton AL, 2003, FEBS LETT, V546, P51, DOI 10.1016/S0014-5793(03)00451-4; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; DeManno DA, 1999, MOL ENDOCRINOL, V13, P91, DOI 10.1210/me.13.1.91; Deroo BJ, 2001, ONCOGENE, V20, P3039, DOI 10.1038/sj.onc.1204328; Dihazi H, 2005, MOL CELL PROTEOMICS, V4, P1445, DOI 10.1074/mcp.M400184-MCP200; Ding HF, 1997, MOL CELL BIOL, V17, P5843, DOI 10.1128/MCB.17.10.5843; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Fryer CJ, 2000, J BIOL CHEM, V275, P17771, DOI 10.1074/jbc.M908729199; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; He ZW, 2003, J BIOL CHEM, V278, P10588, DOI 10.1074/jbc.M208581200; Hebbar PB, 2003, CHROMOSOMA, V111, P495, DOI 10.1007/s00412-003-0232-x; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Hsiao PW, 2002, BIOCHEM CELL BIOL, V80, P343, DOI 10.1139/O02-082; Huang W, 2004, J LIPID RES, V45, P1519, DOI 10.1194/jlr.M400088-JLR200; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; Lim JH, 2004, MOL CELL, V15, P573, DOI 10.1016/j.molcel.2004.08.006; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; Michea L, 2000, AM J PHYSIOL-RENAL, V278, pF209, DOI 10.1152/ajprenal.2000.278.2.F209; Mizuno H, 2001, GENES CELLS, V6, P261, DOI 10.1046/j.1365-2443.2001.00418.x; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Proft M, 2004, CELL, V118, P351, DOI 10.1016/j.cell.2004.07.016; Prymakowska-Bosak M, 2001, MOL CELL BIOL, V21, P5169, DOI 10.1128/MCB.21.15.5169-5178.2001; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Schmitt A, 2002, FEBS LETT, V518, P23, DOI 10.1016/S0014-5793(02)02630-3; Sheikh-Hamad D, 2004, AM J PHYSIOL-RENAL, V287, pF1102, DOI 10.1152/ajprenal.00225.2004; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strelkov IS, 2002, CANCER RES, V62, P75; Trieschmann L, 1998, P NATL ACAD SCI USA, V95, P5468, DOI 10.1073/pnas.95.10.5468; Trotter KW, 2004, MOL CELL BIOL, V24, P3347, DOI 10.1128/MCB.24.8.3347-3358.2004; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; UCHIDA S, 1993, J CLIN INVEST, V91, P1604, DOI 10.1172/JCI116367; Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; Zhao HY, 2002, AM J PHYSIOL-RENAL, V282, pF710, DOI 10.1152/ajprenal.00303.2001; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200; Zhu F, 2004, CARCINOGENESIS, V25, P1847, DOI 10.1093/carcin/bgh202; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V278, pC102, DOI 10.1152/ajpcell.2000.278.1.C102	44	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4400	4407		10.1074/jbc.M609041200	http://dx.doi.org/10.1074/jbc.M609041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158874	hybrid			2022-12-25	WOS:000244482000020
J	Cifuentes-Rojas, C; Pavia, P; Hernandez, A; Osterwisch, D; Puerta, C; Cruz-Reyes, J				Cifuentes-Rojas, Catherine; Pavia, Paula; Hernandez, Alfredo; Osterwisch, Daniel; Puerta, Concepcion; Cruz-Reyes, Jorge			Substrate determinants for RNA editing and editing complex interactions at a site for full-round U insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI MITOCHONDRIA; PRECURSOR MESSENGER-RNA; BINDING PROTEIN GBP21; IN-VITRO; LEISHMANIA-TARENTOLAE; EXORIBONUCLEASE ACTIVITY; BAND IV; DELETION; GRNA; DNA	Multisubunit RNA editing complexes catalyze uridylate insertion/deletion RNA editing directed by complementary guide RNAs (gRNAs). Editing in trypanosome mitochondria is transcript-specific and developmentally controlled, but the molecular mechanisms of substrate specificity remain unknown. Here we used a minimal A6 pre-mRNA/gRNA substrate to define functional determinants for full-round insertion and editing complex interactions at the editing site 2 (ES2). Editing begins with pre-mRNA cleavage within an internal loop flanked by upstream and downstream duplexes with gRNA. We found that substrate recognition around the internal loop is sequence-independent and that completely artificial duplexes spanning a single helical turn are functional. Furthermore, after our report of cross-linking interactions at the deletion ES1 (35), we show for the first time editing complex contacts at an insertion ES. Our studies using site-specific ribose 2' substitutions defined 2'-hydroxyls within the (a) gRNA loop region and (b) flanking helixes that markedly stimulate both pre-mRNA cleavage and editing complex interactions at ES2. Modification of the downstream helix affected scissile bond specificity. Notably, a single 2'-hydroxyl at ES2 is essential for cleavage but dispensable for editing complex cross-linking. This study provides new insights on substrate recognition during full-round editing, including the relevance of secondary structure and the first functional association of specific (pre-mRNA and gRNA) riboses with both endonuclease cleavage and cross-linking activities of editing complexes at an ES. Importantly, most observed cross-linking interactions are both conserved and relatively stable at ES2 and ES1 in hybrid substrates. However, they were also detected as transient low-stability contacts in a non-edited transcript.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Pontificia Univ Javeriana, Lab Parasitol Mol, Bogota, Colombia	Texas A&M University System; Texas A&M University College Station; Pontificia Universidad Javeriana	Cruz-Reyes, J (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, 2128 TAMU, College Stn, TX 77843 USA.	cruzrey@tamu.edu	Cruz-Reyes, Jorge/GQP-1338-2022; Hernandez, Alfredo/AAV-5584-2021; Puerta, Concepcion J/AAG-4912-2019; Hernandez, Alfredo J/ABC-8311-2020	Hernandez, Alfredo J/0000-0002-0903-8932; Puerta Bula, Concepcion Judith/0000-0002-3449-3961; Cruz-Reyes, Jorge/0000-0003-0545-1508	NIGMS NIH HHS [GM067130] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067130] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen TE, 1998, MOL CELL BIOL, V18, P6014, DOI 10.1128/MCB.18.10.6014; Aphasizhev R, 2003, RNA, V9, P62, DOI 10.1261/rna.2134303; Aphasizhev R, 2003, EMBO J, V22, P913, DOI 10.1093/emboj/cdg083; Arnott S, 1970, Prog Biophys Mol Biol, V21, P265, DOI 10.1016/0079-6107(70)90027-1; Blaszczyk J, 2001, STRUCTURE, V9, P1225, DOI 10.1016/S0969-2126(01)00685-2; Blom D, 2001, NUCLEIC ACIDS RES, V29, P2950, DOI 10.1093/nar/29.14.2950; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; Brecht M, 2005, MOL CELL, V17, P621, DOI 10.1016/j.molcel.2005.01.018; Carnes J, 2005, P NATL ACAD SCI USA, V102, P16614, DOI 10.1073/pnas.0506133102; Cifuentes-Rojas C, 2005, NUCLEIC ACIDS RES, V33, P6610, DOI 10.1093/nar/gki943; Cruz-Reyes J, 1998, NUCLEIC ACIDS RES, V26, P3634, DOI 10.1093/nar/26.16.3634; Cruz-Reyes J, 1998, MOL CELL, V1, P401, DOI 10.1016/S1097-2765(00)80040-4; Cruz-Reyes J, 2002, MOL CELL BIOL, V22, P4652, DOI 10.1128/MCB.22.13.4652-4660.2002; Cruz-Reyes J, 2001, MOL CELL BIOL, V21, P884, DOI 10.1128/MCB.21.3.884-892.2001; CruzReyes J, 1996, P NATL ACAD SCI USA, V93, P8901, DOI 10.1073/pnas.93.17.8901; Ernst NL, 2003, MOL CELL, V11, P1525, DOI 10.1016/S1097-2765(03)00185-0; Gan JH, 2006, CELL, V124, P355, DOI 10.1016/j.cell.2005.11.034; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; Huang CE, 2001, EMBO J, V20, P4694, DOI 10.1093/emboj/20.17.4694; Hudson BP, 2004, NAT STRUCT MOL BIOL, V11, P257, DOI 10.1038/nsmb738; Igo RP, 2000, MOL CELL BIOL, V20, P8447, DOI 10.1128/MCB.20.22.8447-8457.2000; Igo RP, 2002, MOL CELL BIOL, V22, P1567, DOI 10.1128/MCB.22.5.1567-1576.2002; Igo RP, 2002, EUKARYOT CELL, V1, P112, DOI 10.1128/EC.1.1.112-118.2002; Kabb AL, 2001, NUCLEIC ACIDS RES, V29, P2575, DOI 10.1093/nar/29.12.2575; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; Kang XD, 2005, P NATL ACAD SCI USA, V102, P1017, DOI 10.1073/pnas.0409275102; Kapushoc ST, 1999, RNA, V5, P656, DOI 10.1017/S1355838299982250; Koslowsky Donna J, 2004, RNA Biol, V1, P28; Lawson SD, 2001, RNA, V7, P1793, DOI 10.1017/S135583820101055X; Leung SS, 1999, NUCLEIC ACIDS RES, V27, P778, DOI 10.1093/nar/27.3.778; Madison-Antenucci S, 1998, EMBO J, V17, P6368, DOI 10.1093/emboj/17.21.6368; Madison-Antenucci S, 2002, CELL, V108, P435, DOI 10.1016/S0092-8674(02)00653-0; Madison-Antenucci S, 2001, MOL CELL, V7, P879, DOI 10.1016/S1097-2765(01)00231-3; McManus MT, 2001, RNA, V7, P167, DOI 10.1017/S1355838201002072; Messias AC, 2004, ACCOUNTS CHEM RES, V37, P279, DOI 10.1021/ar030034m; Miller MM, 2006, RNA, V12, P1292, DOI 10.1261/rna.2331506; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Missel A, 1997, MOL CELL BIOL, V17, P4895, DOI 10.1128/MCB.17.9.4895; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; Muller UF, 2001, EMBO J, V20, P1394, DOI 10.1093/emboj/20.6.1394; Nandakumar J, 2004, MOL CELL, V16, P211, DOI 10.1016/j.molcel.2004.09.022; Noy A, 2005, J AM CHEM SOC, V127, P4910, DOI 10.1021/ja043293v; Oppegard LM, 2000, J BIOL CHEM, V275, P33911, DOI 10.1074/jbc.M003002200; Pai RD, 2003, RNA, V9, P469, DOI 10.1261/rna.2175703; Panigrahi AK, 2003, RNA, V9, P484, DOI 10.1261/rna.2194603; Panigrahi AK, 2001, MOL CELL BIOL, V21, P380, DOI 10.1128/MCB.21.2.380-389.2001; Panigrahi AK, 2006, RNA, V12, P1038, DOI 10.1261/rna.45506; Pelletier M, 2003, RNA, V9, P457, DOI 10.1261/rna.2160803; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; Rusche LN, 1997, EMBO J, V16, P4069, DOI 10.1093/emboj/16.13.4069; Rusche LN, 2001, MOL CELL BIOL, V21, P979, DOI 10.1128/MCB.21.4.979-989.2001; Sacharidou A, 2006, RNA, V12, P1219, DOI 10.1261/rna.2295706; Salavati R, 2006, RNA, V12, P819, DOI 10.1261/rna.2244106; Schnaufer A, 2003, MOL CELL, V12, P307, DOI 10.1016/S1097-2765(03)00286-7; Schnaufer A, 2001, SCIENCE, V291, P2159, DOI 10.1126/science.1058655; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; Simpson L, 2004, RNA, V10, P159, DOI 10.1261/rna.5170704; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Stefl R, 2005, EMBO REP, V6, P33, DOI 10.1038/sj.embor.7400325; Stuart KD, 2005, TRENDS BIOCHEM SCI, V30, P97, DOI 10.1016/j.tibs.2004.12.006; Tian B, 2004, NAT REV MOL CELL BIO, V5, P1013, DOI 10.1038/nrm1528; Trotter JR, 2005, MOL CELL, V20, P403, DOI 10.1016/j.molcel.2005.09.016; Vanhamme L, 1998, J BIOL CHEM, V273, P21825, DOI 10.1074/jbc.273.34.21825; Vondruskova E, 2005, J BIOL CHEM, V280, P2429, DOI 10.1074/jbc.M405933200; WANG AHJ, 1982, NATURE, V299, P601, DOI 10.1038/299601a0; Yu LE, 2006, RNA, V12, P1050, DOI 10.1261/rna.3406; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	68	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4265	4276		10.1074/jbc.M605554200	http://dx.doi.org/10.1074/jbc.M605554200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158098	hybrid			2022-12-25	WOS:000244482000006
J	Larose, S; Laterreur, N; Ghazal, G; Gagnon, J; Wellinger, RJ; Abou Elela, S				Larose, Stephanie; Laterreur, Nancy; Ghazal, Ghada; Gagnon, Jules; Wellinger, Raymund J.; Abou Elela, Sherif			RNase III-dependent regulation of yeast telomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; SUBSTRATE RECOGNITION; EST GENES; DNA; DEGRADATION; RNT1P; PROTEINS; CLEAVAGE; IDENTIFICATION	In bakers' yeast, in vivo telomerase activity requires a ribonucleoprotein (RNP) complex with at least four associated proteins (Est2p, Est1p, Est3p, and Cdc13p) and one RNA species (Tlc1). The function of telomerase in maintaining chromosome ends, called telomeres, is tightly regulated and linked to the cell cycle. However, the mechanisms that regulate the expression of individual components of telomerase are poorly understood. Here we report that yeast RNase III (Rnt1p), a double-stranded RNA-specific endoribonuclease, regulates the expression of telomerase subunits and is required for maintaining normal telomere length. Deletion or inactivation of RNT1 induced the expression of Est1, Est2, Est3, and Tlc1 RNAs and increased telomerase activity, leading to elongation of telomeric repeat tracts. In silico analysis of the different RNAs coding for the telomerase subunits revealed a canonical Rnt1p cleavage site near the 3' end of Est1 mRNA. This predicted structure was cleaved by Rnt1p and its disruption abolished cleavage in vitro. Mutation of the Rnt1p cleavage signal in vivo impaired the cell cycle-dependent degradation of Est1 mRNA without affecting its steady-state level. These results reveal a new mechanism that influences telomeres length by controlling the expression of the telomerase subunits.	Univ Sherbrooke, Fac Med, Dept Microbiol & Infect, RNA Grp, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Abou Elela, S (corresponding author), 3001 12 Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	sherif.abou.elela@usherbrooke.ca	Wellinger, Raymund/K-3207-2019	Wellinger, Raymund/0000-0001-6670-2759; Abou Elela, Sherif/0000-0002-0630-3294				ABOUELELA S, 1998, EMBO J, V17, P3738, DOI DOI 10.1093/EMB0J/17.13.3738); Boule JB, 2005, NATURE, V438, P57, DOI 10.1038/nature04091; Brachmann CB, 1998, YEAST, V14, P115; Catala M, 2004, MOL BIOL CELL, V15, P3015, DOI 10.1091/mbc.E04-03-0183; Chanfreau G, 1997, GENE DEV, V11, P2741, DOI 10.1101/gad.11.20.2741; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; CHANFREU G, 2000, P NATL ACAD SCI USA, V97, P1342; Chapon C, 1997, RNA, V3, P1337; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; Dahlseid JN, 2003, EUKARYOT CELL, V2, P134, DOI 10.1128/EC.2.1.134-142.2003; Danin-Kreiselman M, 2003, MOL CELL, V11, P1279, DOI 10.1016/S1097-2765(03)00137-0; Das B, 2003, MOL CELL BIOL, V23, P5502, DOI 10.1128/MCB.23.16.5502-5515.2003; di Fagagna FD, 2004, GENE DEV, V18, P1781, DOI 10.1101/gad.1214504; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; ENGELKE DR, 1990, ANAL BIOCHEM, V191, P396, DOI 10.1016/0003-2697(90)90238-5; Evans SK, 2000, J CELL SCI, V113, P3357; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; Ge DL, 2005, CURR BIOL, V15, P140, DOI 10.1016/j.cub.2004.12.001; Ghazal G, 2005, MOL CELL BIOL, V25, P2981, DOI 10.1128/MCB.25.8.2981-2994.2005; Gill T, 2004, MOL CELL BIOL, V24, P945, DOI 10.1128/MCB.24.3.945-953.2004; Giorgi C, 2001, EMBO J, V20, P6856, DOI 10.1093/emboj/20.23.6856; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Guthrie C, 1991, GUIDE YEAST GENETICS; HENIKOFF S, 1987, GENETICS, V117, P711; Hug N, 2006, CHROMOSOMA, V115, P413, DOI 10.1007/s00412-006-0067-3; Lamontagne B, 2004, J MOL BIOL, V338, P401, DOI 10.1016/j.jmb.2004.02.059; Lamontagne B, 2003, J MOL BIOL, V327, P985, DOI 10.1016/S0022-2836(03)00231-6; Lamontagne B., 2001, PURIFICATION CHARACT; Larrivee M, 2004, GENE DEV, V18, P1391, DOI 10.1101/gad.1199404; Lebars I, 2001, EMBO J, V20, P7250, DOI 10.1093/emboj/20.24.7250; LeBel C, 2005, J CELL SCI, V118, P2785, DOI 10.1242/jcs.02394; LeBel Catherine, 2006, Methods Mol Biol, V313, P265; Lee A, 2005, MOL CELL, V19, P39, DOI 10.1016/j.molcel.2005.05.021; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Marcand S, 2000, CURR BIOL, V10, P487, DOI 10.1016/S0960-9822(00)00450-4; Nagel R, 2000, RNA, V6, P1142, DOI 10.1017/S1355838200000431; Osterhage JL, 2006, NAT STRUCT MOL BIOL, V13, P720, DOI 10.1038/nsmb1125; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Rose MD., 1990, METHODS YEAST GENETI; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Snow BE, 2003, CURR BIOL, V13, P698, DOI 10.1016/S0960-9822(03)00210-0; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Taggart AKP, 2003, CURR OPIN CELL BIOL, V15, P275, DOI 10.1016/S0955-0674(03)00040-1; Taggart AKP, 2002, SCIENCE, V297, P1023, DOI 10.1126/science.1074968; Teo SH, 2001, EMBO REP, V2, P197, DOI 10.1093/embo-reports/kve038; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tremblay A, 2002, MOL CELL BIOL, V22, P4792, DOI 10.1128/MCB.22.13.4792-4802.2002; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Yang D, 2000, CURR BIOL, V10, P1191, DOI 10.1016/S0960-9822(00)00732-6; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zer C, 2005, J BIOL CHEM, V280, P28997, DOI 10.1074/jbc.M505913200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	57	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4373	4381		10.1074/jbc.M607145200	http://dx.doi.org/10.1074/jbc.M607145200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158880	hybrid			2022-12-25	WOS:000244482000017
J	Besse, A; Lamothe, B; Campos, AD; Webster, WK; Maddineni, U; Lin, SC; Wu, H; Darnay, BG				Besse, Arnaud; Lamothe, Betty; Campos, Alejandro D.; Webster, William K.; Maddineni, Upendra; Lin, Su-Chang; Wu, Hao; Darnay, Bryant G.			TAK1-dependent signaling requires functional interaction with TAB2/TAB3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; KINASE KINASE KINASE; OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; NFATC1 INDUCTION; RAW264.7 CELLS; TAK1; TRAF6; PROTEIN	Transforming growth factor beta-activated kinase 1 (TAX1), a member of the MAPKKK family, was initially described to play an essential role in the transforming growth factor beta-signaling pathway, but recent evidence has emerged implicating TAK1 in the interleukin (IL)-1 and tumor necrosis factor (TNF) pathways. Notably, two homologous proteins, TAB2 and TAB3, have been identified as adaptors linking TAK1 to the upstream adaptors TRAFs. However, it remains unclear whether the interaction between TAB2/TAB3 and TAK1 is necessary for its kinase activation and subsequent activation of the IKK and MAPK pathways. Here, we characterized the TAB2/TAB3-binding domain in TAK1 and further examined the requirement of this interaction for IL-1, TNF, and RANKL signaling. Through deletion mapping experiments, we demonstrated that the binding motif for TAB2/TAB3 is a non-contiguous region located within the last C-terminal 100 residues of TAK1. However, residues 479-553 of TAK1. appear to be necessary and sufficient for TAB2/TAB3 interaction. Conversely, residues 574-693 of TAB2 were shown to interact with TAK1. A green fluorescent protein fusion protein containing the last 100 residues of TAK1 (TAK1-C100) abolished the interaction of endogenous TAB2/TAB3 with TAK1, the phosphorylation of TAK1, and prevented the activation of IKK and MAPK induced by IL-1, TNF, and RANKL. Furthermore, TAK1-C100 blocked RANKL-induced nuclear accumulation of NFATc1 and consequently osteoclast differentiation consistent with the ability of a catalytically inactive TAK1 to block RANKL-mediated signaling. Significantly, our study provides evidence that the TAB2/TAB3 interaction with TAK1 is crucial for the activation of signaling cascades mediated by IL-1, TNF, and RANKL.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	University of Texas System; UTMD Anderson Cancer Center; Cornell University	Darnay, BG (corresponding author), Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	bdarnay@mdanderson.org	Lin, SC/G-4666-2010; Lin, Su-Chang/F-2899-2016	Lin, Su-Chang/0000-0003-0687-3139	NCI NIH HHS [CA16672SAF, P30 CA016672] Funding Source: Medline; NIAID NIH HHS [R01 AI045937, R01-AI 45937] Funding Source: Medline; NIAMS NIH HHS [R01 AR053540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chen ZJ, 2006, CELL DEATH DIFFER, V13, P687, DOI 10.1038/sj.cdd.4401869; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Israel A, 2006, TRENDS IMMUNOL, V27, P395, DOI 10.1016/j.it.2006.07.003; Jin G, 2004, P NATL ACAD SCI USA, V101, P2028, DOI 10.1073/pnas.0307314101; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kishida S, 2005, GENES CELLS, V10, P447, DOI 10.1111/j.1365-2443.2005.00852.x; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kitamura T, 1998, INT J HEMATOL, V67, P351; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; LAMOTHE B, 2006, IN PRESS J BIOL CHEM; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Polek TC, 2003, J BIOL CHEM, V278, P32317, DOI 10.1074/jbc.M302518200; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Sanjo H, 2003, MOL CELL BIOL, V23, P1231, DOI 10.1128/MCB.23.4.1231-1238.2003; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109-004-0612-6; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Wald D, 2001, EUR J IMMUNOL, V31, P3747, DOI 10.1002/1521-4141(200112)31:12<3747::AID-IMMU3747>3.0.CO;2-E; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	47	107	114	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3918	3928		10.1074/jbc.M608867200	http://dx.doi.org/10.1074/jbc.M608867200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158449	Green Accepted, hybrid			2022-12-25	WOS:000244481900056
J	Danek, EI; Tcherkezian, J; Triki, I; Meriane, M; Lamarche-Vane, N				Danek, Eric Ian; Tcherkezian, Joseph; Triki, Ibtissem; Meriane, Mayya; Lamarche-Vane, Nathalie			Glycogen synthase kinase-3 phosphorylates CdGAP at a consensus ERK 1 regulatory site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; GTPASE-ACTIVATING PROTEIN; RHO GTPASES; GENE-EXPRESSION; GSK-3; CYTOKINESIS; INHIBITION; PATHWAY; LINK; RAC	Rho GTPases regulate a multitude of cellular processes from cytoskeletal reorganization to gene transcription and are negatively regulated by GTPase-activating proteins (GAPs). Cdc42 GTPase-activating protein (CdGAP) is a ubiquitously expressed GAP for Rac1 and Cdc42. In this study, we set out to identify CdGAP-binding partners and, using a yeast two-hybrid approach, glycogen synthase kinase 3 alpha (GSK-3 alpha) was identified as a partner for CdGAP. GSK-3 exists in two isoforms, alpha and beta, and is involved in regulating many cellular functions from insulin response to tumorigenesis. We show that GSK-3 alpha and -beta interact with CdGAP in mammalian cells. We also demonstrate that GSK-3 phosphorylates CdGAP both in vitro and in vivo on Thr-776, which we have previously shown to be an ERK 1/2 phosphorylation site involved in CdGAP regulation. We report that the mRNA and protein levels of CdGAP are increased upon serum stimulation and that GSK-3 activity is necessary for the up-regulation of the protein levels of CdGAP but not for the increase in mRNA. We conclude that GSK-3 is an important regulator of CdGAP and that regulation of CdGAP protein levels by serum presents a novel mechanism for cells to control Cdc42/Rac1 GTPase signaling pathways.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	McGill University	Lamarche-Vane, N (corresponding author), McGill Univ, Dept Anat & Cell Biol, 3640 Univ St, Montreal, PQ H3A 2B2, Canada.	nathalie.lamarche@mcgill.ca						Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o; ASPENSTROM P, 1995, METHOD ENZYMOL, V256, P228; Benitah SA, 2004, BBA-REV CANCER, V1705, P121, DOI 10.1016/j.bbcan.2004.10.002; Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200; LaLonde DP, 2006, CURR BIOL, V16, P1375, DOI 10.1016/j.cub.2006.05.057; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Ligeti E, 2006, METHOD ENZYMOL, V406, P104, DOI 10.1016/S0076-6879(06)06009-5; Litovchick L, 2004, MOL CELL BIOL, V24, P8970, DOI 10.1128/MCB.24.20.8970-8980.2004; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; Stryer L., 1988, BIOCHEMISTRY-US, P187; Su L, 2003, J CELL BIOL, V163, P571, DOI 10.1083/jcb.200308007; Tcherkezian J, 2005, MOL CELL BIOL, V25, P6314, DOI 10.1128/MCB.25.15.6314-6329.2005; Tcherkezian J, 2006, BIOL CELL, V98, P445, DOI 10.1042/BC20050101; Trivedi N, 2005, J CELL SCI, V118, P993, DOI 10.1242/jcs.01697; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yin L, 2006, SCIENCE, V311, P1002, DOI 10.1126/science.1121613; YU JS, 1994, J NEUROCHEM, V62, P1596	35	7	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3624	3631		10.1074/jbc.M610073200	http://dx.doi.org/10.1074/jbc.M610073200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158447	hybrid			2022-12-25	WOS:000244481900024
J	Krejci, P; Masri, B; Salazar, L; Farrington-Rock, C; Prats, H; Thompson, LM; Wilcox, WR				Krejci, Pavel; Masri, Bernard; Salazar, Lisa; Farrington-Rock, Claire; Prats, Herve; Thompson, Leslie Michels; Wilcox, William R.			Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; SIGNALING PATHWAY; FACTOR RECEPTOR-3; TYROSINE KINASE; PC12 CELLS; TRANSCRIPTIONAL ACTIVATION; POTENT INHIBITORS; ENDOTHELIAL-CELLS; FGF RECEPTORS	Fibroblast growth factors (FGFs) inhibit chondrocyte proliferation via the Erk MAP kinase pathway. Here, we explored the role of protein kinase C in FGF signaling in chondrocytes. Erk activity in FGF2-treated RCS (rat chondrosarcoma) chondrocytes or human primary chondrocytes was abolished by the protein kinase C inhibitor bisindolylmaleimide I (Bis I). Bis I inhibited FGF2-induced activation of MEK, Raf-1, and Ras members of Erk signaling module but not the FGF2-induced tyrosine phosphorylation of Frs2 or the kinase activity of FGFR3, demonstrating that it targets the Erk cascade immediately upstream of Ras. Indeed, Bis I abolished the FGF2-mediated association of Shp2 tyrosine phosphatase with Frs2 and Gab1 adaptor proteins necessary for proper Ras activation. We also determined which PKC isoform is involved in FGF2-mediated activation of Erk. When both conventional and novel PKCs expressed by RCS chondrocytes ( PKC alpha, -gamma, -delta, and -is an element of) were down-regulated by phorbol ester, cells remained responsive to FGF2 with Erk activation, and this activation was sensitive to Bis I. Moreover, treatment with PKC lambda/xi pseudosubstrate lead to significant reduction of FGF2-mediated activation of Erk, suggesting involvement of an atypical PKC.	Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA; Inst Louis Bugnard, INSERM, U589, F-31403 Toulouse, France; Univ Calif Irvine, Dept Psychiat, Irvine, CA 92697 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90095 USA	Cedars Sinai Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Krejci, P (corresponding author), Cedars Sinai Med Ctr, Inst Med Genet, 8700 Beverly Blvd,SSB-3, Los Angeles, CA 90048 USA.	pavel.krejci@cshs.org	Krejčí, Pavel/I-4285-2014; Masri, Bernard/N-9856-2018	Masri, Bernard/0000-0002-4027-2604; Prats, Herve/0000-0002-4861-2167; Krejci, Pavel/0000-0003-0618-9134	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD022657] Funding Source: NIH RePORTER; NICHD NIH HHS [5P01-HD22657] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; Agazie YM, 2003, ONCOGENE, V22, P6909, DOI 10.1038/sj.onc.1206798; Aikawa T, 2001, J BIOL CHEM, V276, P29347, DOI 10.1074/jbc.M101859200; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chen J, 2004, P NATL ACAD SCI USA, V101, P14479, DOI 10.1073/pnas.0404438101; Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690; Cho JY, 2004, P NATL ACAD SCI USA, V101, P609, DOI 10.1073/pnas.2237184100; Cross MJ, 2002, MOL BIOL CELL, V13, P2881, DOI 10.1091/mbc.E02-02-0103; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hanafusa H, 2004, J BIOL CHEM, V279, P22992, DOI 10.1074/jbc.M312498200; Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; Kampfer S, 2001, J BIOL CHEM, V276, P42834, DOI 10.1074/jbc.M102047200; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; KLEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Krejci P, 2005, J CELL SCI, V118, P5089, DOI 10.1242/jcs.02618; Krejci P, 2004, EXP CELL RES, V297, P152, DOI 10.1016/j.yexcr.2004.03.011; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Legeai-Mallet L, 2004, BONE, V34, P26, DOI 10.1016/j.bone.2003.09.002; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; MARQUARDT B, 1994, ONCOGENE, V9, P3213; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Monsonego-Ornan E, 2002, FEBS LETT, V528, P83, DOI 10.1016/S0014-5793(02)03255-6; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; Murakami S, 2004, GENE DEV, V18, P290, DOI 10.1101/gad.1179104; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Nowroozi N, 2005, HUM MOL GENET, V14, P1529, DOI 10.1093/hmg/ddi161; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Passos-Bueno MR, 1999, HUM MUTAT, V14, P115; PRESTA M, 1989, J CELL BIOL, V109, P1877, DOI 10.1083/jcb.109.4.1877; Raucci A, 2004, J BIOL CHEM, V279, P1747, DOI 10.1074/jbc.M310384200; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Skaletz-Rorowski A, 2005, CARDIOVASC RES, V67, P142, DOI 10.1016/j.cardiores.2005.03.009; Skaletz-Rorowski A, 1999, ARTERIOSCL THROM VAS, V19, P1608, DOI 10.1161/01.ATV.19.7.1608; Strack V, 2002, BIOCHEMISTRY-US, V41, P603, DOI 10.1021/bi011327v; SZALLASI Z, 1995, MOL PHARMACOL, V47, P258; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UBERALL F, 1994, CELL SIGNAL, V6, P285, DOI 10.1016/0898-6568(94)90033-7; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Yasoda A, 2004, NAT MED, V10, P80, DOI 10.1038/nm971; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	57	31	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2929	2936		10.1074/jbc.M606144200	http://dx.doi.org/10.1074/jbc.M606144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145761	hybrid			2022-12-25	WOS:000243793900019
J	Jones, A; Jonsson, AB; Aro, H				Jones, Allison; Jonsson, Ann-Beth; Aro, Helena			Neisseria gonorrhoeae infection causes a G1 arrest in human epithelial cells	FASEB JOURNAL			English	Article						gonococcal infection; cyclins; cell cycle; cell cycle arrest	HUMAN CYCLIN-A; CELLULAR PILUS RECEPTOR; PROGRESSION; PROTEIN; TRANSITION; G(1); CD46; PHOSPHORYLATION; ATTACHMENT; ADHERENCE	Pathogenic bacteria can modulate and interfere with human cell cycle progression. Here we study the human pathogen Neisseria gonorrhoeae and its ability to influence and affect the cell cycle in two human target cell lines. We found that bacteria adhere equally well to cells synchronized into the different cell cycle phases of G1, S, and G2, but were unable to adhere to cells in M phase or GO phase. In addition, using Western blot and/or flow cytometry analysis we demonstrate that bacterial infection for 24 h results in decreased levels of the cell cycle regulatory proteins cyclin B1, cyclin D1, and cyclin E. Further studies in N. gonorrhoeae-infected epithelial cells involving analysis of DNA content, bromodeoxyuridine (BrdU) incorporation, quantification of late mitotic cells and analysis of nuclear phenotype provide compelling evidence that a 24 h gonococcal infection arrests the cells in early G1 phase of the cell cycle. In summary, we present data showing that MS11 P+ strain of N. gonorrhoeae can down-regulate cyclins, important modulators of the cell cycle, and result in a G1 arrest.	Univ Uppsala, Dept Med Biochem & Microbiol, Uppsala Biomed Ctr, S-75123 Uppsala, Sweden	Uppsala University	Aro, H (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, Uppsala Biomed Ctr, Box 582, S-75123 Uppsala, Sweden.	helena.aro@imbim.uu.se						BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Chiou CC, 2003, SCAND J GASTROENTERO, V38, P147, DOI 10.1080/00365520310000627; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Edwards JL, 2005, CELL MICROBIOL, V7, P1197, DOI 10.1111/j.1462-5822.2005.00547.x; Edwards JL, 2002, CELL MICROBIOL, V4, P571, DOI 10.1046/j.1462-5822.2002.t01-1-00215.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Hu L, 1999, INFECT IMMUN, V67, P4171, DOI 10.1128/IAI.67.8.4171-4182.1999; Jacinto A, 2001, NAT CELL BIOL, V3, pE117, DOI 10.1038/35074643; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Johansson L, 2003, SCIENCE, V301, P373, DOI 10.1126/science.1086476; Kallstrom H, 1997, MOL MICROBIOL, V25, P639, DOI 10.1046/j.1365-2958.1997.4841857.x; Kallstrom H, 2001, CELL MICROBIOL, V3, P133, DOI 10.1046/j.1462-5822.2001.00095.x; KELLOGG DS, 1968, J BACTERIOL, V96, P596, DOI 10.1128/JB.96.3.596-605.1968; Koomey M, 2001, CURR OPIN MICROBIOL, V4, P53, DOI 10.1016/S1369-5274(00)00164-8; Lara-Tejero M, 2000, SCIENCE, V290, P354, DOI 10.1126/science.290.5490.354; Marches O, 2003, MOL MICROBIOL, V50, P1553, DOI 10.1046/j.1365-2958.2003.03821.x; McCaw SE, 2003, MOL MICROBIOL, V49, P623, DOI 10.1046/j.1365-2958.2003.03591.x; Merz AJ, 1996, MOL MED, V2, P745, DOI 10.1007/BF03401658; Nougayrede JP, 2005, TRENDS MICROBIOL, V13, P103, DOI 10.1016/j.tim.2005.01.002; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Oswald E, 2005, CURR OPIN MICROBIOL, V8, P83, DOI 10.1016/j.mib.2004.12.011; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; SACCO RE, 1994, J IMMUNOL, V153, P1714; Scanlon M, 2000, J EUKARYOT MICROBIOL, V47, P525, DOI 10.1111/j.1550-7408.2000.tb00085.x; Shirin H, 1999, CANCER RES, V59, P2277; Sommi P, 2002, EXP CELL RES, V281, P128, DOI 10.1006/excr.2002.5629; SWANSON J, 1986, CELL, V47, P267, DOI 10.1016/0092-8674(86)90449-6; SWANSON J, 1973, J EXP MED, V137, P571, DOI 10.1084/jem.137.3.571; SWANSON J, 1987, ANTON LEEUW INT J G, V53, P44144; Wessler S, 2005, BIOL CHEM, V386, P481, DOI 10.1515/BC.2005.057	34	26	26	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2007	21	2					345	355		10.1096/fj.06-6675com	http://dx.doi.org/10.1096/fj.06-6675com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17158783				2022-12-25	WOS:000244686300008
J	Beste, C; Saft, C; Andrich, J; Gold, R; Falkenstein, M				Beste, Christian; Saft, Carsten; Andrich, Juergen; Gold, Ralf; Falkenstein, Michael			Error Processing in Huntington's Disease	PLOS ONE			English	Article								Background. Huntington's disease (HD) is a genetic disorder expressed by a degeneration of the basal ganglia inter alia accompanied with dopaminergic alterations. These dopaminergic alterations are related to genetic factors i.e., CAG-repeat expansion. The error (related) negativity (Ne/ERN), a cognitive event-related potential related to performance monitoring, is generated in the anterior cingulate cortex (ACC) and supposed to depend on the dopaminergic system. The Ne is reduced in Parkinson's Disease (PD). Due to a dopaminergic deficit in HD, a reduction of the Ne is also likely. Furthermore it is assumed that movement dysfunction emerges as a consequence of dysfunctional error-feedback processing. Since dopaminergic alterations are related to the CAG-repeat, a Ne reduction may furthermore also be related to the genetic disease load. Methodology/Principle Findings. We assessed the error negativity (Ne) in a speeded reaction task under consideration of the underlying genetic abnormalities. HD patients showed a specific reduction in the Ne, which suggests impaired error processing in these patients. Furthermore, the Ne was closely related to CAG-repeat expansion. Conclusions/Significance. The reduction of the Ne is likely to be an effect of the dopaminergic pathology. The result resembles findings in Parkinson's Disease. As such the Ne might be a measure for the integrity of striatal dopaminergic output function. The relation to the CAG-repeat expansion indicates that the Ne could serve as a gene-associated "cognitive'' biomarker in HD.	[Beste, Christian; Falkenstein, Michael] WHO Collaborating Ctr Occupat Hlth & Human Factor, Leibniz Res Ctr Working Environm & Human Factors, Dortmund, Germany; [Beste, Christian; Saft, Carsten; Andrich, Juergen; Gold, Ralf] Ruhr Univ Bochum, Dept Neurol, Huntington Ctr NRW, St Josef Hosp, Bochum, Germany	Dortmund University of Technology; Leibniz Institut for Arbeitsforschung an der TU Dortmund (IFADO); Ruhr University Bochum	Beste, C (corresponding author), WHO Collaborating Ctr Occupat Hlth & Human Factor, Leibniz Res Ctr Working Environm & Human Factors, Dortmund, Germany.	beste@ifado.de	Falkenstein, Michael/ABA-7497-2020	Saft, Carsten/0000-0002-3983-7292	Univerisity of Bochum (FoRUM) [AZ-F479-2005]	Univerisity of Bochum (FoRUM)	The study was funded by a grant from the Univerisity of Bochum (FoRUM AZ-F479-2005). The funders played no role in design and conduction of the study, as well as in the collection, analysis or interpretation of the data. The same is the case for preparation, review and approval of the manuscript.	Antonini A, 1998, ANN NEUROL, V43, P253, DOI 10.1002/ana.410430216; Bartenstein P, 1997, BRAIN, V120, P1553, DOI 10.1093/brain/120.9.1553; Capuron L, 2005, BIOL PSYCHIAT, V58, P190, DOI 10.1016/j.biopsych.2005.03.033; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Cohen JD, 2000, NAT NEUROSCI, V3, P421, DOI 10.1038/74783; Craufurd D., 2002, HUNTINGTONS DIS, P62; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; Falkenstein M, 2005, J PSYCHOPHYSIOL, V19, P305, DOI 10.1027/0269-8803.19.4.305; Falkenstein M, 2001, NEUROREPORT, V12, P157, DOI 10.1097/00001756-200101220-00039; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Frodl-Bauch T, 1999, NEUROPSYCHOBIOLOGY, V40, P86, DOI 10.1159/000026603; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Gehring WJ, 2000, NAT NEUROSCI, V3, P516, DOI 10.1038/74899; Ginovart N, 1997, BRAIN, V120, P503, DOI 10.1093/brain/120.3.503; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Gutekunst CA, 2002, HUNTINGTONS DIS, P251; Holroyd CB, 2003, TRENDS NEUROSCI, V26, P402, DOI 10.1016/S0166-2236(03)00175-9; Holroyd CB, 2002, SCIENCE, V296, P1610, DOI 10.1126/science.296.5573.1610; Holroyd CB, 2002, NEUROPSYCHOLOGIA, V40, P2116, DOI 10.1016/S0028-3932(02)00052-0; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Jazbec S, 2005, BIOL PSYCHIAT, V58, P632, DOI 10.1016/j.biopsych.2005.04.010; Kieburtz K, 1996, MOVEMENT DISORD, V11, P136, DOI 10.1002/mds.870110204; Kopp B, 1996, PSYCHOPHYSIOLOGY, V33, P282, DOI 10.1111/j.1469-8986.1996.tb00425.x; Liotti M, 2005, CORTEX, V41, P377, DOI 10.1016/S0010-9452(08)70274-0; MELAMED E, 1982, NEUROLOGY, V32, P640, DOI 10.1212/WNL.32.6.640; Paulsen JS, 2001, NEUROLOGY, V57, P658, DOI 10.1212/WNL.57.4.658; Pavese N, 2003, BRAIN, V126, P1127, DOI 10.1093/brain/awg119; Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243; Rachakonda V, 2004, CELL RES, V14, P347, DOI 10.1038/sj.cr.7290235; RANEN NG, 1995, AM J HUM GENET, V57, P593; Reading SAJ, 2004, ANN NEUROL, V55, P879, DOI 10.1002/ana.20121; REYNOLDS GP, 1986, J NEURAL TRANSM, V65, P151, DOI 10.1007/BF01256491; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Ridderinkhof KR, 2002, SCIENCE, V298, P2209, DOI 10.1126/science.1076929; Sanchez-Pernaute R, 2000, NEUROLOGY, V54, P119, DOI 10.1212/WNL.54.1.119; Smith MA, 2000, NATURE, V403, P544, DOI 10.1038/35000576; Ullsperger M, 2006, INT J PSYCHOPHYSIOL, V59, P59, DOI 10.1016/j.ijpsycho.2005.06.010; Ullsperger M, 2006, J COGNITIVE NEUROSCI, V18, P651, DOI 10.1162/jocn.2006.18.4.651; van Oostrom JCH, 2005, NEUROLOGY, V65, P941, DOI 10.1212/01.wnl.0000176071.08694.cc; Wexler NS, 2004, P NATL ACAD SCI USA, V101, P3498, DOI 10.1073/pnas.0308479101; YOHRLING GJ, 2002, HUNTINGTONS DIS, P276; Zirnheld PJ, 2004, J COGNITIVE NEUROSCI, V16, P1098, DOI 10.1162/0898929041502779; 1993, CELL, V72, P971	44	55	55	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e86	10.1371/journal.pone.0000086	http://dx.doi.org/10.1371/journal.pone.0000086			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183717	gold, Green Published, Green Submitted			2022-12-25	WOS:000207443600085
J	Davids, BJ; Reiner, DS; Birkeland, SR; Preheim, SP; Cipriano, MJ; McArthur, AG; Gillin, FD				Davids, Barbara J.; Reiner, David S.; Birkeland, Shanda R.; Preheim, Sarah P.; Cipriano, Michael J.; McArthur, Andrew G.; Gillin, Frances D.			A New Family of Giardial Cysteine-Rich Non-VSP Protein Genes and a Novel Cyst Protein	PLOS ONE			English	Article							EARLY DIVERGING EUKARYOTE; ANTIGENIC VARIATION; SURFACE PROTEIN; PRIMITIVE EUKARYOTE; ENTAMOEBA-HISTOLYTICA; SECRETORY APPARATUS; ANCIENT EUKARYOTE; LAMBLIA; WALL; ENCYSTATION	Since the Giardia lamblia cyst wall is necessary for survival in the environment and host infection, we tested the hypothesis that it contains proteins other than the three known cyst wall proteins. Serial analysis of gene expression during growth and encystation revealed a gene, "HCNCp" (High Cysteine Non-variant Cyst protein), that was upregulated late in encystation, and that resembled the classic Giardia variable surface proteins (VSPs) that cover the trophozoite plasmalemma. HCNCp is 13.9% cysteine, with many "CxxC" tetrapeptide motifs and a transmembrane sequence near the C-terminus. However, HCNCp has multiple "CxC" motifs rarely found in VSPs, and does not localize to the trophozoite plasmalemma. Moreover, the HCNCp C-terminus differed from the canonical VSP signature. Full-length epitope-tagged HCNCp expressed under its own promoter was upregulated during encystation with highest expression in cysts, including 42 and 21 kDa C-terminal fragments. Tagged HCNCp targeted to the nuclear envelope in trophozoites, and co-localized with cyst proteins to encystation-specific secretory vesicles during encystation. HCNCp defined a novel trafficking pathway as it localized to the wall and body of cysts, while the cyst proteins were exclusively in the wall. Unlike VSPs, HCNCp is expressed in at least five giardial strains and four WB subclones expressing different VSPs. Bioinformatics identified 60 additional large high cysteine membrane proteins (HCMp) containing >= 20 CxxC/CxC's lacking the VSP-specific C-terminal CRGKA. HCMp were absent or rare in other model or parasite genomes, except for Tetrahymena thermophila with 30. MEME analysis classified the 61 gHCMp genes into nine groups with similar internal motifs. Our data suggest that HCNCp is a novel invariant cyst protein belonging to a new HCMp family that is abundant in the Giardia genome. HCNCp and the other HCMp provide a rich source for developing parasite-specific diagnostic reagents, vaccine candidates, and subjects for further research into Giardia biology.	[Davids, Barbara J.; Reiner, David S.; Gillin, Frances D.] Univ Calif San Diego, Dept Pathol, Div Infect Dis, San Diego, CA 92103 USA; [Birkeland, Shanda R.; Cipriano, Michael J.; McArthur, Andrew G.] Marine Biol Lab, Josephine Bay Paul Ctr Comparat Mol Biol & Evolut, Woods Hole, MA 02543 USA; [Preheim, Sarah P.] Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	University of California System; University of California San Diego; Marine Biological Laboratory - Woods Hole; Woods Hole Oceanographic Institution	Davids, BJ (corresponding author), Univ Calif San Diego, Dept Pathol, Div Infect Dis, San Diego, CA 92103 USA.	Bdavids@ucsd.edu	Preheim, Sarah P/B-3432-2010; Reiner, David S./F-6106-2012	Preheim, Sarah P/0000-0001-7365-2382; Reiner, David S./0000-0002-8289-7311; McArthur, Andrew/0000-0002-1142-3063; Cipriano, Michael/0000-0001-8163-8812	NIH [GM61896, AI51687, AI42488, DK35108, AI51089]; Ellison Medical Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042488, R01AI051687, R01AI051089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061896] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison Medical Foundation(Lawrence Ellison Foundation); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funding: BJD, DSR, and FDG were supported by NIH grants GM61896, AI51687, AI42488, and DK35108. AGM, SPP, SRB, and MJC were supported by NIH grant AI51089 and the Marine Biological Laboratory's Program in Global Infectious Diseases, funded by the Ellison Medical Foundation. Computational resources were provided by the Josephine Bay Paul Center for Comparative Molecular Biology and Evolution (Marine Biological Laboratory) through funds provided by the W. M. Keck Foundation and the G. Unger Vetlesen Foundation.	Abel ES, 2001, J BIOL CHEM, V276, P10320, DOI 10.1074/jbc.M006589200; ADAM RD, 1988, J EXP MED, V167, P109, DOI 10.1084/jem.167.1.109; Adam RD, 2000, INT J PARASITOL, V30, P475, DOI 10.1016/S0020-7519(99)00191-5; Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; AGGARWAL A, 1989, MOL BIOCHEM PARASIT, V32, P39, DOI 10.1016/0166-6851(89)90127-8; AGGARWAL A, 1988, INFECT IMMUN, V56, P1420, DOI 10.1128/IAI.56.6.1420-1423.1988; ALEY SB, 1995, INFECT AGENT DIS, V4, P161; ALEY SB, 1993, EXP PARASITOL, V77, P295, DOI 10.1006/expr.1993.1087; Bailey TL, 1998, BIOINFORMATICS, V14, P48, DOI 10.1093/bioinformatics/14.1.48; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Beck DL, 2005, EUKARYOT CELL, V4, P722, DOI 10.1128/EC.4.4.722-732.2005; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bernander R, 2001, CELL MICROBIOL, V3, P55, DOI 10.1046/j.1462-5822.2001.00094.x; Bienz M, 2001, INFECT IMMUN, V69, P5278, DOI 10.1128/IAI.69.9.5278-5285.2001; CAPON AG, 1989, INT J PARASITOL, V19, P91, DOI 10.1016/0020-7519(89)90026-X; DAS S, 1991, J BIOL CHEM, V266, P21318; Davids BJ, 2004, MOL BIOCHEM PARASIT, V136, P173, DOI 10.1016/j.molbiopara.2004.03.011; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Eichinger D, 2001, CURR OPIN MICROBIOL, V4, P421, DOI 10.1016/S1369-5274(00)00229-0; Eisen JA, 2006, PLOS BIOL, V4, P1620, DOI 10.1371/journal.pbio.0040286; GILLIN FD, 1987, SCIENCE, V235, P1040, DOI 10.1126/science.3547646; GILLIN FD, 1990, P NATL ACAD SCI USA, V87, P4463, DOI 10.1073/pnas.87.12.4463; GILLIN FD, 1981, EXP PARASITOL, V51, P382, DOI 10.1016/0014-4894(81)90125-9; GILLIN FD, 1981, EXP PARASITOL, V52, P9, DOI 10.1016/0014-4894(81)90055-2; Gillin FD, 1996, ANNU REV MICROBIOL, V50, P679, DOI 10.1146/annurev.micro.50.1.679; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gottig N, 2006, J BIOL CHEM, V281, P18156, DOI 10.1074/jbc.M602081200; Hehl AB, 2000, MOL BIOL CELL, V11, P1789, DOI 10.1091/mbc.11.5.1789; Hehl AB, 2004, MOL MICROBIOL, V53, P19, DOI 10.1111/j.1365-2958.2004.04115.x; Hiltpold A, 2000, MOL BIOCHEM PARASIT, V109, P61, DOI 10.1016/S0166-6851(00)00229-2; HOWARDTILL RA, 2006, MOL CELL BI IN PRESS; JARROLL EL, 1989, MOL BIOCHEM PARASIT, V32, P121, DOI 10.1016/0166-6851(89)90063-7; Karr CD, 2004, MICROBIOL-SGM, V150, P1237, DOI 10.1099/mic.0.26922-0; Knodler LA, 1999, MOL MICROBIOL, V34, P327, DOI 10.1046/j.1365-2958.1999.01602.x; Knodler LA, 1999, J BIOL CHEM, V274, P29805, DOI 10.1074/jbc.274.42.29805; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Larocque R, 2003, INFECT IMMUN, V71, P5662, DOI 10.1128/IAI.71.10.5662-5669.2003; Loftus B, 2005, NATURE, V433, P865, DOI 10.1038/nature03291; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; LUJAN HD, 1994, J EUKARYOT MICROBIOL, V41, P169, DOI 10.1111/j.1550-7408.1994.tb01491.x; Marshall MM, 1997, CLIN MICROBIOL REV, V10, P67, DOI 10.1128/CMR.10.1.67; Marti M, 2003, TRENDS PARASITOL, V19, P440, DOI 10.1016/S1471-4922(03)00201-0; Marti M, 2003, J BIOL CHEM, V278, P24837, DOI 10.1074/jbc.M302082200; Marti M, 2003, MOL BIOL CELL, V14, P1433, DOI 10.1091/mbc.E02-08-0467; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; MCCAFFERY JM, 1994, EXP PARASITOL, V79, P236, DOI 10.1006/expr.1994.1087; MENG TC, 1993, INFECT IMMUN, V61, P5394, DOI 10.1128/IAI.61.12.5394-5397.1993; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; MOWATT MR, 1994, INFECT IMMUN, V62, P1213, DOI 10.1128/IAI.62.4.1213-1218.1994; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; NASH T, 1992, PARASITOL TODAY, V8, P229, DOI 10.1016/0169-4758(92)90119-M; NASH TE, 1989, EXP PARASITOL, V68, P238, DOI 10.1016/0014-4894(89)90104-5; NASH TE, 1990, EXP PARASITOL, V71, P415, DOI 10.1016/0014-4894(90)90067-M; Nash TE, 2002, MOL MICROBIOL, V45, P585, DOI 10.1046/j.1365-2958.2002.03029.x; NASH TE, 1991, INFECT IMMUN, V59, P1334, DOI 10.1128/IAI.59.4.1334-1340.1991; NASH TE, 1988, J IMMUNOL, V141, P636; Nash TE, 2001, INFECT IMMUN, V69, P1922, DOI 10.1128/IAI.69.3.1922-1923.2001; NASH TE, 1985, J INFECT DIS, V152, P1166, DOI 10.1093/infdis/152.6.1166; ORTEGABARRIA E, 1990, MOL BIOCHEM PARASIT, V43, P151, DOI 10.1016/0166-6851(90)90141-8; REINER DS, 1990, EUR J CELL BIOL, V53, P142; Reiner DS, 2003, J BIOL CHEM, V278, P2533, DOI 10.1074/jbc.M208033200; RODNEY YM, 1995, J EUKARYOT MICROBIOL, V42, P439, DOI 10.1111/j.1550-7408.1995.tb05888.x; Savioli L, 2006, TRENDS PARASITOL, V22, P203, DOI 10.1016/j.pt.2006.02.015; Singer SM, 2001, J INFECT DIS, V183, P119, DOI 10.1086/317659; SMITH PD, 1982, GASTROENTEROLOGY, V83, P797; SMITH PD, 1982, INFECT IMMUN, V36, P714, DOI 10.1128/IAI.36.2.714-719.1982; Stefanic S, 2006, J BIOL CHEM, V281, P7595, DOI 10.1074/jbc.M510940200; Sun CH, 2003, J BIOL CHEM, V278, P21701, DOI 10.1074/jbc.M302023200; Sun CH, 2002, MOL MICROBIOL, V46, P971, DOI 10.1046/j.1365-2958.2002.03233.x; Svard SG, 1998, MOL MICROBIOL, V30, P979, DOI 10.1046/j.1365-2958.1998.01125.x; Svard SG, 2003, FEMS MICROBIOL LETT, V218, P3, DOI 10.1016/S0378-1097(02)01107-2; Thompson RCA, 2000, PARASITOL TODAY, V16, P210, DOI 10.1016/S0169-4758(99)01624-5; Touz MC, 2005, MOL MICROBIOL, V58, P999, DOI 10.1111/j.1365-2958.2005.04891.x; Touz MC, 2002, J BIOL CHEM, V277, P8474, DOI 10.1074/jbc.M110250200; WARD HD, 1990, BIOESSAYS, V12, P211, DOI 10.1002/bies.950120504; Weiland MEL, 2003, INT J PARASITOL, V33, P1341, DOI 10.1016/S0020-7519(03)00201-7; WOLFE MS, 1992, CLIN MICROBIOL REV, V5, P93, DOI 10.1128/CMR.5.1.93-100.1992; Woycechowsky KJ, 2003, BIOCHEMISTRY-US, V42, P5387, DOI 10.1021/bi026993q	81	68	79	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e44	10.1371/journal.pone.0000044	http://dx.doi.org/10.1371/journal.pone.0000044			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183673	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443600044
J	Forgber, M; Basu, R; Roychoudhury, K; Theinert, S; Roy, S; Sundar, S; Walden, P				Forgber, Michael; Basu, Rajatava; Roychoudhury, Kaushik; Theinert, Stephan; Roy, Syamal; Sundar, Shyam; Walden, Peter			Mapping the Antigenicity of the Parasites in Leishmania donovani Infection by Proteome Serology	PLOS ONE			English	Article							GLUCOSE-REGULATED PROTEIN-78; CONFERS PROTECTIVE IMMUNITY; VISCERAL LEISHMANIASIS; DRUG-RESISTANCE; KALA-AZAR; DNA; VACCINATION; HOST; IDENTIFICATION; EXPRESSION	Background. Leishmaniasis defines a cluster of protozoal diseases with diverse clinical manifestations. The visceral form caused by Leishmania donovani is the most severe. So far, no vaccines exist for visceral leishmaniasis despite indications of naturally developing immunity, and sensitive immunodiagnostics are still at early stages of development. Methodology/Principle Findings. Establishing a proteome-serological methodology, we mapped the antigenicity of the parasites and the specificities of the immune responses in human leishmaniasis. Using 2-dimensional Western blot analyses with sera and parasites isolated from patients in India, we detected immune responses with widely divergent specificities for up to 330 different leishmanial antigens. 68 antigens were assigned to proteins in silver- and fluorochrome-stained gels. The antigenicity of these proteins did not correlate with the expression levels of the proteins. Although some antigens are shared among different parasite isolates, there are extensive differences and no immunodominant antigens, but indications of antigenic drift in the parasites. Six antigens were identified by mass spectrometry. Conclusions/Significance. Proteomics-based dissection of the serospecificities of leishmaniasis patients provides a comprehensive inventory of the complexity and interindividual heterogeneity of the host-responses to and variations in the antigenicity of the Leishmania parasites. This information can be instrumental in the development of vaccines and new immune monitoring and diagnostic devices.	[Forgber, Michael; Theinert, Stephan; Walden, Peter] Humboldt Univ, Charite Univ Med, Dept Dermatol Venerol & Allergy, Berlin, Germany; [Basu, Rajatava; Roychoudhury, Kaushik; Roy, Syamal] Indian Inst Chem Biol, Dept Immunol, Kolkata 700032, W Bengal, India; [Sundar, Shyam] Banaras Hindu Univ, Kala Azar Med Res Ctr, Varanasi 221005, Uttar Pradesh, India	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Banaras Hindu University (BHU)	Walden, P (corresponding author), Humboldt Univ, Charite Univ Med, Dept Dermatol Venerol & Allergy, Berlin, Germany.	peter.walden@charite.de	BASU, RAJATAVA/F-2756-2014	Roychoudhury, Kaushik/0000-0002-9585-7722; BASU, RAJATAVA/0000-0003-4029-8043	Volkswagen Foundation, Hannover, Germany [I/77 908]; Deutsche Forschungsgemeinschaft (DFG), Germany [446 IND 121/3/03]	Volkswagen Foundation, Hannover, Germany(Volkswagen); Deutsche Forschungsgemeinschaft (DFG), Germany(German Research Foundation (DFG))	Funding: The work was supported by a grant from the Volkswagen Foundation, Hannover, Germany, grant I/77 908, and the Deutsche Forschungsgemeinschaft (DFG), Germany, grant 446 IND 121/3/03.	Berman J, 2006, INDIAN J MED RES, V123, P289; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bull PC, 2005, J INFECT DIS, V192, P1119, DOI 10.1086/432761; Campos-Neto A, 2002, INFECT IMMUN, V70, P2828, DOI 10.1128/IAI.70.6.2828-2836.2002; Chan C, 1999, ELECTROPHORESIS, V20, P3467, DOI 10.1002/(SICI)1522-2683(19991101)20:17<3467::AID-ELPS3467>3.3.CO;2-0; CHANG KP, 1976, SCIENCE, V193, P678, DOI 10.1126/science.948742; Coler RN, 2005, TRENDS PARASITOL, V21, P244, DOI 10.1016/j.pt.2005.03.006; Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI 10.1128/CMR.19.1.111-126.2006; Cunningham DA, 2005, MOL MICROBIOL, V58, P636, DOI 10.1111/j.1365-2958.2005.04840.x; Davidson RN, 1999, J INFECTION, V39, P112, DOI 10.1016/S0163-4453(99)90001-4; Demine R, 2004, RAPID COMMUN MASS SP, V18, P907, DOI 10.1002/rcm.1420; Dubois ME, 2005, INFECT IMMUN, V73, P2690, DOI 10.1128/IAI.73.5.2690-2697.2005; Frank SA, 2006, INFECT GENET EVOL, V6, P141, DOI 10.1016/j.meegid.2004.10.005; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Ghedin E, 1998, J BIOL CHEM, V273, P22997, DOI 10.1074/jbc.273.36.22997; Ghosh A, 2001, VACCINE, V19, P3169, DOI 10.1016/S0264-410X(01)00023-8; Gopal S, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-11-r95; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; Gupta S, 2005, CURR OPIN MICROBIOL, V8, P428, DOI 10.1016/j.mib.2005.06.011; Gurunathan S, 1997, J EXP MED, V186, P1137, DOI 10.1084/jem.186.7.1137; Hastings KEM, 2005, TRENDS GENET, V21, P240, DOI 10.1016/j.tig.2005.02.005; Hisaeda H, 2005, INT J BIOCHEM CELL B, V37, P700, DOI 10.1016/j.biocel.2004.10.009; Horn D, 2005, CHROMOSOME RES, V13, P525, DOI 10.1007/s10577-005-0991-8; JARDIM A, 1991, J IMMUNOL, V147, P3538; Jensen ATR, 2002, TROP MED INT HEALTH, V7, P471, DOI 10.1046/j.1365-3156.2002.00880.x; Jensen ATR, 2001, BBA-PROTEIN STRUCT M, V1549, P73, DOI 10.1016/S0167-4838(01)00240-0; Khalil EAG, 2000, LANCET, V356, P1565, DOI 10.1016/S0140-6736(00)03128-7; KILLICKKENDRICK R, 1990, ANN PARASIT HUM COMP, V65, P37, DOI 10.1051/parasite/1990651037; Krah Alexander, 2004, Methods Mol Med, V94, P19; Kumar R, 2006, TROP MED INT HEALTH, V11, P41, DOI 10.1111/j.1365-3156.2005.01538.x; Lopez-Fuertes L, 2002, VACCINE, V21, P247, DOI 10.1016/S0264-410X(02)00450-4; MACFARLANE J, 1990, EUR J BIOCHEM, V190, P377, DOI 10.1111/j.1432-1033.1990.tb15586.x; Mansfield JM, 2005, PARASITE IMMUNOL, V27, P361, DOI 10.1111/j.1365-3024.2005.00791.x; MCMAHONPRATT D, 1993, INFECT IMMUN, V61, P3351, DOI 10.1128/IAI.61.8.3351-3359.1993; Morrison LJ, 2005, INT J PARASITOL, V35, P961, DOI 10.1016/j.ijpara.2005.05.004; PEARSON RD, 1983, REV INFECT DIS, V5, P907; Rafati S, 2001, VACCINE, V19, P3369, DOI 10.1016/S0264-410X(01)00081-0; Requena JM, 2000, PARASITOL TODAY, V16, P246, DOI 10.1016/S0169-4758(00)01651-3; Requena JM, 2001, TRENDS PARASITOL, V17, P64, DOI 10.1016/S1471-4922(00)01769-4; RUSSO DM, 1991, J IMMUNOL, V147, P3575; Schallig HDFH, 2002, MEM I OSWALDO CRUZ, V97, P1015, DOI 10.1590/S0074-02762002000700015; Sjolander A, 1998, J IMMUNOL, V160, P3949; SKEIKY YAW, 1995, INFECT IMMUN, V63, P4105, DOI 10.1128/IAI.63.10.4105-4114.1995; SKEIKY YAW, 1994, INFECT IMMUN, V62, P1643, DOI 10.1128/IAI.62.5.1643-1651.1994; Sukumaran B, 2003, VACCINE, V21, P1292, DOI 10.1016/S0264-410X(02)00352-3; Sundar S, 2006, J CLIN MICROBIOL, V44, P251, DOI 10.1128/JCM.44.1.251-253.2006; Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x; Theinert SM, 2005, INFECT IMMUN, V73, P7018, DOI 10.1128/IAI.73.10.7018-7021.2005; TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267; YANG DM, 1990, J IMMUNOL, V145, P2281; Yao CQ, 2003, MOL BIOCHEM PARASIT, V132, P1, DOI 10.1016/S0166-6851(03)00211-1	51	45	50	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e40	10.1371/journal.pone.0000040	http://dx.doi.org/10.1371/journal.pone.0000040			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183669	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600040
J	Girelli, D; Martinelli, N; Olivieri, O; Pizzolo, F; Friso, S; Faccini, G; Bozzini, C; Tenuti, I; Lotto, V; Villa, G; Guarini, P; Trabetti, E; Pignatti, PF; Mazzucco, A; Corrocher, R				Girelli, Domenico; Martinelli, Nicola; Olivieri, Oliviero; Pizzolo, Francesca; Friso, Simonetta; Faccini, Giovanni; Bozzini, Claudia; Tenuti, Ilaria; Lotto, Valentina; Villa, Giuliano; Guarini, Patrizia; Trabetti, Elisabetta; Pignatti, Pier Franco; Mazzucco, Alessandro; Corrocher, Roberto			Hyperhomocysteinemia and Mortality after Coronary Artery Bypass Grafting	PLOS ONE			English	Article								Background. The independent prognostic impact, as well as the possible causal role, of hyperhomocysteinemia (HHcy) in coronary artery disease (CAD) is controversial. No previous study specifically has addressed the relationship between HHcy and mortality after coronary artery bypass grafting (CABG) surgery. The aim of this study is to evaluate the prognostic impact of HHcy after CABG surgery. Methodology and Principal Findings. We prospectively followed 350 patients who underwent elective CABG between May 1996 and May 1999. At baseline, fasting total homocysteine (tHcy) levels were measured in all participants, and a post-methionine loading (PML) test was performed in 77.7% of them (n = 272). After a median follow-up of 58 months, 33 patients (9.4%) had died, 25 because of cardiovascular events. HHcy, defined by levels higher than the 90(th) percentile (25.2 mmol/L) of the population's distribution, was significantly associated to total and cardiovascular mortality (P = 0.018 [log-rank test 5.57]; P = 0.002 [log-rank test 9.76], respectively). The PML test had no prognostic value. After multiple adjustment for other univariate predictors by Cox regression, including statin therapy (the most powerful predictor in uni-/multivariate analyses), high-sensitivity C Reactive Protein (hs-CRP) levels, and all known major genetic (MTHFR 677C -> T polymorphism) and non-genetic (B-group vitamin status and renal function) tHcy determinants, HHcy remained an independent prognostic factor for mortality (HRs: 5.02, 95% CIs 1.88 to 13.42, P = 0.001). Conclusions. HHcy is an important prognostic marker after CABG, independent of modern drug therapy and biomarkers.	[Girelli, Domenico; Martinelli, Nicola; Olivieri, Oliviero; Pizzolo, Francesca; Friso, Simonetta; Bozzini, Claudia; Tenuti, Ilaria; Lotto, Valentina; Villa, Giuliano; Guarini, Patrizia; Corrocher, Roberto] Univ Verona, Dept Clin & Expt Med, I-37100 Verona, Italy; [Faccini, Giovanni] Univ Verona, Inst Clin Chem, I-37100 Verona, Italy; [Trabetti, Elisabetta; Pignatti, Pier Franco] Univ Verona, Sect Biol & Genet, I-37100 Verona, Italy	University of Verona; University of Verona; University of Verona	Girelli, D (corresponding author), Univ Verona, Dept Clin & Expt Med, I-37100 Verona, Italy.	domenico.girelli@univr.it	Pizzolo, Francesca/AAF-6581-2020; Martinelli, Nicola/J-5622-2016; Olivieri, Oliviero/A-9126-2008; Girelli, Domenico/B-1183-2008; Friso, Simonetta/K-4715-2016	Pizzolo, Francesca/0000-0003-4419-3994; Martinelli, Nicola/0000-0001-6465-5119; Olivieri, Oliviero/0000-0001-8209-9056; Girelli, Domenico/0000-0001-9684-1899; 	Veneto Region; MIUR; Cariverona Foundation, Verona, Italy	Veneto Region(Regione Veneto); MIUR(Ministry of Education, Universities and Research (MIUR)); Cariverona Foundation, Verona, Italy(Fondazione Cariverona)	Supported by grants from the Veneto Region, MIUR, and the Cariverona Foundation, Verona, Italy.	Anderson JL, 2000, CIRCULATION, V102, P1227, DOI 10.1161/01.CIR.102.11.1227; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; Bonaa KH, 2006, NEW ENGL J MED, V354, P1578, DOI 10.1056/NEJMoa055227; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Campeau L, 1997, NEW ENGL J MED, V336, P153; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Eagle KA, 1999, CIRCULATION, V100, P1464, DOI 10.1161/01.CIR.100.13.1464; Ford ES, 2002, INT J EPIDEMIOL, V31, P59, DOI 10.1093/ije/31.1.59; Frederiksen J, 2004, BLOOD, V104, P3046, DOI 10.1182/blood-2004-03-0897; Friso S, 2004, AM J CLIN NUTR, V79, P992; Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299; Gersh BJ, 2005, NEW ENGL J MED, V352, P2235, DOI 10.1056/NEJMe058053; Girelli D, 1998, BLOOD, V91, P4158, DOI 10.1182/blood.V91.11.4158.411k23_4158_4163; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023; Lange H, 2004, NEW ENGL J MED, V350, P2673, DOI 10.1056/NEJMoa032845; Lewis SJ, 2005, BMJ-BRIT MED J, V331, P1053, DOI 10.1136/bmj.38611.658947.55; Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900; Loscalzo J, 2006, NEW ENGL J MED, V354, P1629, DOI 10.1056/NEJMe068060; MCCULLY KS, 1969, AM J PATHOL, V56, P111; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Refsum H, 2004, CLIN CHEM, V50, P3, DOI 10.1373/clinchem.2003.021634; Ridker PM, 2005, NEW ENGL J MED, V352, P20, DOI 10.1056/NEJMoa042378; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Smulders Yvo M, 2005, Semin Vasc Med, V5, P87, DOI 10.1055/s-2005-872395; Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565; Van Der Griend R, 1998, J LAB CLIN MED, V132, P67, DOI 10.1016/S0022-2143(98)90027-0; WELCH CN, 1998, NEW ENGL J MED, V388, P1042	30	13	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e83	10.1371/journal.pone.0000083	http://dx.doi.org/10.1371/journal.pone.0000083			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183715	gold, Green Submitted, Green Published			2022-12-25	WOS:000207443600083
J	Legrand, FA; Nixon, DF; Loo, CP; Ono, E; Chapman, JM; Miyamoto, M; Diaz, RS; Santos, AMN; Succi, RCM; Abadi, J; Rosenberg, MG; de Moraes-Pinto, MI; Kallas, EG				Legrand, Fatema A.; Nixon, Douglas F.; Loo, Christopher P.; Ono, Erika; Chapman, Joan M.; Miyamoto, Maristela; Diaz, Ricardo S.; Santos, Amelia M. N.; Succi, Regina C. M.; Abadi, Jacob; Rosenberg, Michael G.; de Moraes-Pinto, Maria Isabel; Kallas, Esper G.			Strong HIV-1-Specific T Cell Responses in HIV-1-Exposed Uninfected Infants and Neonates Revealed after Regulatory T Cell Removal	PLOS ONE			English	Article								Background. In utero transmission of HIV-1 occurs on average in only 3%-15% of HIV-1-exposed neonates born to mothers not on antiretroviral drug therapy. Thus, despite potential exposure, the majority of infants remain uninfected. Weak HIV-1specific T-cell responses have been detected in children exposed to HIV-1, and potentially contribute to protection against infection. We, and others, have recently shown that the removal of CD4(+)CD25(+) T-regulatory (Treg) cells can reveal strong HIV-1 specific T-cell responses in some HIV-1 infected adults. Here, we hypothesized that Treg cells could suppress HIV-1-specific immune responses in young children. Methodology/Principal Findings. We studied two cohorts of children. The first group included HIV-1-exposed-uninfected (EU) as well as unexposed (UNEX) neonates. The second group comprised HIV-1-infected and HIV-1-EU children. We quantified the frequency of Treg cells, T-cell activation, and cell-mediated immune responses. We detected high levels of CD4(+)CD25(+)CD127(-) Treg cells and low levels of CD4(+) and CD8(+) T cell activation in the cord blood of the EU neonates. We observed HIV-1-specific T cell immune responses in all of the children exposed to the virus. These T-cell responses were not seen in the cord blood of control HIV-1 unexposed neonates. Moreover, the depletion of CD4(+)CD25(+) Treg cells from the cord blood of EU newborns strikingly augmented both CD4(+) and CD8(+) HIV-1-specific immune responses. Conclusions/Significance. This study provides new evidence that EU infants can mount strong HIV-1-specific T cell responses, and that in utero CD4(+)CD25(+) T-regulatory cells may be contributing to the lack of vertical transmission by reducing T cell activation.	[Nixon, Douglas F.; Loo, Christopher P.; Chapman, Joan M.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA; [Legrand, Fatema A.] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA; [Ono, Erika; Miyamoto, Maristela; Diaz, Ricardo S.; Santos, Amelia M. N.; Succi, Regina C. M.; de Moraes-Pinto, Maria Isabel; Kallas, Esper G.] Univ Fed Sao Paulo, Sao Paulo, Brazil; [Abadi, Jacob; Rosenberg, Michael G.] Albert Einstein Coll Med, Jacobi Med Ctr, Bronx, NY USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes; Universidade Federal de Sao Paulo (UNIFESP); Jacobi Medical Center; Yeshiva University; Albert Einstein College of Medicine	Nixon, DF (corresponding author), Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA.	douglas.nixon@ucsf.edu	Diaz, Ricardo/K-3978-2012; Miyamoto, Maristela/B-3834-2013; Nixon, Douglas/AAU-5734-2020; Kallas, Esper G/C-9539-2012; dos Santos, Amelia MN/H-5986-2013	Nixon, Douglas/0000-0002-2801-1786; dos Santos, Amelia MN/0000-0002-8407-1556; Loo, Christopher/0000-0002-5302-8774; Kallas, Esper/0000-0003-2026-6925	Elizabeth Glaser Pediatric AIDS Foundation; National Institutes of Health [AI060379, AI060407]; John E. Fogarty International Center [D43 TW00003]; FAPESP [01/11011-6, 04/15317-0]; UC President's Postdoctoral; CAPES; FOGARTY INTERNATIONAL CENTER [D43TW000003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060379, R21AI060379, R21AI060407] Funding Source: NIH RePORTER	Elizabeth Glaser Pediatric AIDS Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); John E. Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); UC President's Postdoctoral; CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the Elizabeth Glaser Pediatric AIDS Foundation, the National Institutes of Health (AI060379 and AI060407), the John E. Fogarty International Center (D43 TW00003), and FAPESP, a Brazilian funding agency (01/11011-6). D. F. N. is an Elizabeth Glaser Scientist of the Elizabeth Glaser Pediatric AIDS Foundation. F. A. L. is supported by the UC President's Postdoctoral Fellowship. E. O. is supported by a CAPES (a Brazilian funding agency) MSc fellowship. M. M. is supported by a FAPESP PhD fellowship (04/15317-0).	Aandahl EM, 2004, J VIROL, V78, P2454, DOI 10.1128/JVI.78.5.2454-2459.2004; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; BURCHETT SK, 1992, J INFECT DIS, V165, P813, DOI 10.1093/infdis/165.5.813; BUSEYNE F, 1993, J IMMUNOL, V150, P3569; Chakraborty R, 2005, J IMMUNOL, V174, P8191, DOI 10.4049/jimmunol.174.12.8191; CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905; CLERICI M, 1993, AIDS, V7, P1427, DOI 10.1097/00002030-199311000-00004; CONNOR EM, 1994, PEDIATR INFECT DIS J, V13, P440, DOI 10.1097/00006454-199405000-00036; DEMARIA A, 1994, J INFECT DIS, V170, P1296, DOI 10.1093/infdis/170.5.1296; Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Frenkel LM, 1998, SCIENCE, V280, P1073, DOI 10.1126/science.280.5366.1073; Gibson L, 2004, J IMMUNOL, V172, P2256, DOI 10.4049/jimmunol.172.4.2256; Hermann E, 2002, BLOOD, V100, P2153, DOI 10.1182/blood.V100.6.2153.h81802002153_2153_2158; Hofmeister R, 1999, CYTOKINE GROWTH F R, V10, P41, DOI 10.1016/S1359-6101(98)00025-2; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kalams SA, 1999, J VIROL, V73, P6721, DOI 10.1128/JVI.73.8.6721-6728.1999; Kinter AL, 2004, J EXP MED, V200, P331, DOI 10.1084/jem.20032069; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lichterfeld M, 2004, BLOOD, V104, P487, DOI 10.1182/blood-2003-12-4341; LIU W, 2006, J EXP MED; Lohman BL, 2005, J VIROL, V79, P8121, DOI 10.1128/JVI.79.13.8121-8130.2005; Luzuriaga K, 2005, CLIN INFECT DIS, V40, P466; LUZURIAGA K, 1991, J PEDIATR-US, V119, P230, DOI 10.1016/S0022-3476(05)80732-2; Luzuriaga Katherine, 2002, AIDS Reviews, V4, P21; Magder LS, 2005, JAIDS-J ACQ IMM DEF, V38, P87, DOI 10.1097/00126334-200501010-00016; Malhotra I, 1999, J IMMUNOL, V162, P6843; Marchant A, 2005, CLIN EXP IMMUNOL, V141, P10, DOI 10.1111/j.1365-2249.2005.02799.x; Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI17470; Mascart F, 2003, J IMMUNOL, V170, P1504, DOI 10.4049/jimmunol.170.3.1504; MCFARLAND EJ, 1994, J INFECT DIS, V170, P766, DOI 10.1093/infdis/170.4.766; McGowan JP, 2000, J ANTIMICROB CHEMOTH, V46, P657, DOI 10.1093/jac/46.5.657; Michaelsson J, 2006, J IMMUNOL, V176, P5741, DOI 10.4049/jimmunol.176.10.5741; Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Sandberg JK, 2003, J IMMUNOL, V170, P4403, DOI 10.4049/jimmunol.170.8.4403; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Scott-Algara D, 2001, J INFECT DIS, V183, P1565, DOI 10.1086/320708; Somerset DA, 2004, IMMUNOLOGY, V112, P38, DOI 10.1111/j.1365-2567.2004.01869.x; Spiegel HML, 2000, J INFECT DIS, V182, P88, DOI 10.1086/315639; Tsaknaridis L, 2003, J NEUROSCI RES, V74, P296, DOI 10.1002/jnr.10766; Zhang QB, 2002, PEDIATR INFECT DIS J, V21, P209, DOI 10.1097/00006454-200203000-00010; Zimmerli SC, 2005, P NATL ACAD SCI USA, V102, P7239, DOI 10.1073/pnas.0502393102; CLIN INFECT DIS, V40, P458	53	114	115	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e102	10.1371/journal.pone.0000102	http://dx.doi.org/10.1371/journal.pone.0000102			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183635	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600101
J	Buschbeck, M; Uribesalgo, I; Ledl, A; Gutierrez, A; Minucci, S; Muller, S; Di Croce, L				Buschbeck, M.; Uribesalgo, I.; Ledl, A.; Gutierrez, A.; Minucci, S.; Muller, S.; Di Croce, L.			PML4 induces differentiation by Myc destabilization	ONCOGENE			English	Article						cancer; differentiation; gene repression; Myc; promyelocytic leukemia protein; protein degradation	RAR-ALPHA; ACUTE-LEUKEMIA; C-MYC; UBIQUITIN; EXPRESSION; DEGRADATION; PATHOGENESIS; ASSOCIATION; PROTEASOMES; BINDING	Opposing functions like oncogene and tumor suppressions have been established for c-Myc and promyelocytic leukemia (PML) protein, respectively. Myc is known to inhibit differentiation of hematopoietic precursor cells, and here we report that PML promotes cell differentiation. We further demonstrate that PML and Myc form a complex in vivo. The interaction of the two proteins leads to the destabilization of Myc in a manner dependent on the really interesting new gene (RING) domain of PML. Although several PML isoforms are able to interact with Myc, the ability to destabilize Myc is specific for PML4. Importantly, the PML-induced destabilization resulted in a reduction of promoter-bound Myc on Myc-repressed genes. Thereby, PML induced the re-activation of Myc-repressed target genes including the tumor, suppressive genes of the cell cycle inhibitors cdkn1a/p21 and cdkn2b/ p15. Together, these results establish PML-mediated destabilization of Myc and the derepression of cell cycle inhibitor genes as an important regulatory mechanism that allows cell differentiation and prevents aberrant proliferation driven by uncontrolled Myc activity.	PRBB, CRG, Barcelona, Spain; Univ Pompeu Fabra, Barcelona, Spain; Max Planck Inst Biochem, D-82152 Martinsried, Germany; IEO, Milan, Italy	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Max Planck Society; IRCCS European Institute of Oncology (IEO)	Di Croce, L (corresponding author), ICREA, C Dr Aiguaer 88, Barcelona 08003, Spain.	luciano.dicroce@crg.es	Gutierrez, Arantxa/K-8213-2015; Di Croce, Luciano/E-7759-2015; Minucci, Saverio/J-9669-2012; Buschbeck, Marcus/J-8204-2017	Gutierrez, Arantxa/0000-0001-9033-3834; Di Croce, Luciano/0000-0003-3488-6228; Buschbeck, Marcus/0000-0002-3218-4567; Muller, Stefan/0000-0002-8792-7700	ICREA Funding Source: Custom	ICREA(ICREA)		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Amati B, 2004, P NATL ACAD SCI USA, V101, P8843, DOI 10.1073/pnas.0403046101; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Buschbeck M, 2005, EMBO REP, V6, P63, DOI 10.1038/sj.embor.7400316; Cairo S, 2005, ONCOGENE, V24, P2195, DOI 10.1038/sj.onc.1208338; Di Croce L, 2005, HUM MOL GENET, V14, pR77, DOI 10.1093/hmg/ddi109; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Kanatani Y, 1999, CELL GROWTH DIFFER, V10, P705; Lafarga M, 2002, MOL BIOL CELL, V13, P2771, DOI 10.1091/mbc.E02-03-0122; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Rockel TD, 2005, J CELL SCI, V118, P5231, DOI 10.1242/jcs.02642; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Smith KP, 2004, J CELL BIOCHEM, V93, P1282, DOI 10.1002/jcb.20273; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Strudwick S, 2002, LEUKEMIA, V16, P1906, DOI 10.1038/sj.leu.2402724; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Villa R, 2006, P NATL ACAD SCI USA, V103, P1400, DOI 10.1073/pnas.0509343103; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145	29	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3415	3422		10.1038/sj.onc.1210128	http://dx.doi.org/10.1038/sj.onc.1210128			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17146439				2022-12-25	WOS:000246579600011
J	Gawenis, LR; Bradford, EM; Prasad, V; Lorenz, JN; Simpson, JE; Clarke, LL; Woo, AL; Grisham, C; Sanford, LP; Doetschman, T; Miller, ML; Shull, GE				Gawenis, Lara R.; Bradford, Emily M.; Prasad, Vikram; Lorenz, John N.; Simpson, Janet E.; Clarke, Lane L.; Woo, Alison L.; Grisham, Christina; Sanford, L. Philip; Doetschman, Thomas; Miller, Marian L.; Shull, Gary E.			Colonic anion secretory defects and metabolic acidosis in mice lacking the NBC1Na(+)/HCO3- cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL TUBULAR-ACIDOSIS; SODIUM-BICARBONATE COTRANSPORTER; CARBONIC-ANHYDRASE-IV; K-CL COTRANSPORTER; CYSTIC-FIBROSIS; MURINE DUODENUM; NA+/H+ EXCHANGER; ION-TRANSPORT; OCULAR ABNORMALITIES; FUNCTIONAL-ANALYSIS	The NBC1 Na+/HCO3- cotransporter is expressed in many tissues, including kidney and intestinal epithelia. NBC1 mutations cause proximal renal tubular acidosis in humans, consistent with its role in HCO3- absorption in the kidney. In intestinal and colonic epithelia, NBC1 localizes to basolateral membranes and is thought to function in anion secretion. To test the hypothesis that NBC1 plays a role in transepithelial HCO3- secretion in the intestinal tract, null mutant (NBC1(-/-)) mice were prepared by targeted disruption of its gene (Slc4a4). NBC1(-/-) mice exhibited severe metabolic acidosis, growth retardation, reduced plasma Na+, hyperaldosteronism, splenomegaly, abnormal dentition, intestinal obstructions, and death before weaning. Intracellular pH (pH;) was not altered in cAMP-stimulated epithelial cells of NBC1(-/-) cecum, but pH(i) regulation during sodium removal and readdition was impaired. Bioelectric measurements of NBC1(-/-) colons revealed increased amiloride-sensitive Na+ absorption. In Ringer solution containing both Cl- and HCO3-, the magnitude of cAMP-stimulated anion secretion was normal in NBC1(-/-) distal colon but increased in proximal colon, with the increase largely supported by enhanced activity of the basolateral NKCC1 Na+-K+-2Cl(-) cotransporter. Anion substitution studies in which carbonic anhydrase was inhibited and transepithelial anion conductance was limited to HCO3- revealed a sharp decrease in both cAMP-stimulated HCO3- secretion and SITS-sensitive current in NBC1(-/-) proximal colon. These results are consistent with the known function of NBC1 in HCO3- absorption in the kidney and demonstrate that NBC1 activity is a component of the basolateral mechanisms for HCO3- uptake during cAMP-stimulated anion secretion in the proximal colon.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol & Cellular Pharmacol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Missouri, Dept Biomed Sci, Columbia, MO 65211 USA; Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO 65211 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way,ML524, Cincinnati, OH 45267 USA.	shullge@ucmail.uc.edu	Clarke, Lane L/AAK-2866-2020	Clarke, Lane L/0000-0002-4938-6261; Bradford, Emily/0000-0002-4711-5628	NATIONAL CENTER FOR RESEARCH RESOURCES [T32RR007004] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK048816, R01DK050594, R01DK057552, R01DK048816, F32DK067749, R56DK048816, R37DK050594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NCRR NIH HHS [T32-RR-07004] Funding Source: Medline; NHLBI NIH HHS [HL61974] Funding Source: Medline; NIDDK NIH HHS [DK48816, DK57552, DK50594, DK67749] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abuladze N, 1998, J BIOL CHEM, V273, P17689, DOI 10.1074/jbc.273.28.17689; Alper SL, 2002, ANNU REV PHYSIOL, V64, P899, DOI 10.1146/annurev.physiol.64.092801.141759; Alvarez BV, 2003, BIOCHEMISTRY-US, V42, P12321, DOI 10.1021/bi0353124; Arquitt CK, 2002, J DENT RES, V81, P492, DOI 10.1177/154405910208100712; Bachmann O, 2006, AM J PHYSIOL-GASTR L, V291, pG650, DOI 10.1152/ajpgi.00376.2005; Bachmann O, 2003, AM J PHYSIOL-GASTR L, V284, pG37, DOI 10.1152/ajpgi.00209.2002; Baschat AA, 1999, AM J OBSTET GYNECOL, V181, P190, DOI 10.1016/S0002-9378(99)70458-8; Bok D, 2001, AM J PHYSIOL-RENAL, V281, pF920, DOI 10.1152/ajprenal.2001.281.5.F920; Bonillo A, 1998, AM J PERINAT, V15, P115, DOI 10.1055/s-2007-993909; Bonnici B, 2004, PFLUG ARCH EUR J PHY, V448, P16, DOI 10.1007/s00424-003-1227-4; Brandao-Burch A, 2005, CALCIFIED TISSUE INT, V77, P167, DOI 10.1007/s00223-004-0285-8; BUKHAVE K, 1980, GASTROENTEROLOGY, V78, P32; Clarke LL, 1996, LAB ANIM SCI, V46, P612; Clarke LL, 1998, AM J PHYSIOL-GASTR L, V274, pG718, DOI 10.1152/ajpgi.1998.274.4.G718; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Dinour D, 2004, J BIOL CHEM, V279, P52238, DOI 10.1074/jbc.M406591200; Epple HJ, 2000, AM J PHYSIOL-GASTR L, V278, pG718, DOI 10.1152/ajpgi.2000.278.5.G718; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; Flemmer AW, 2002, J BIOL CHEM, V277, P37551, DOI 10.1074/jbc.M206294200; Gawenis LR, 2005, GASTROENTEROLOGY, V128, pA44; Gawenis LR, 2003, GASTROENTEROLOGY, V125, P1148, DOI 10.1016/S0016-5085(03)01212-5; Gawenis LR, 2001, BIOL TRACE ELEM RES, V83, P69, DOI 10.1385/BTER:83:1:69; Gawenis LR, 2004, AM J PHYSIOL-GASTR L, V286, pG1015, DOI 10.1152/ajpgi.00468.2003; GAWENIS LR, 2002, AM J PHYSIOL-GASTR L, V282, pG766; Gross E, 2002, AM J PHYSIOL-RENAL, V283, pF876, DOI 10.1152/ajprenal.00148.2002; Gross E, 1996, J MEMBRANE BIOL, V152, P245, DOI 10.1007/s002329900102; Hanlon-Lundberg KM, 1999, AM J OBSTET GYNECOL, V181, P196, DOI 10.1016/S0002-9378(99)70459-X; Horita S, 2005, J AM SOC NEPHROL, V16, P2270, DOI 10.1681/ASN.2004080667; Igarashi T, 1999, NAT GENET, V23, P264, DOI 10.1038/15440; Igarashi T, 2001, J AM SOC NEPHROL, V12, P713, DOI 10.1681/ASN.V124713; Inatomi J, 2004, PFLUG ARCH EUR J PHY, V448, P438, DOI 10.1007/s00424-004-1278-1; Jacob P, 2000, GASTROENTEROLOGY, V119, P406, DOI 10.1053/gast.2000.9358; JENSEN OM, 1986, SCAND J HAEMATOL, V36, P263; Krieger NS, 2003, SEMIN DIALYSIS, V16, P463, DOI 10.1046/j.1525-139X.2003.16100.x; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; Lucioni A, 2002, AM J PHYSIOL-GASTR L, V283, pG51, DOI 10.1152/ajpgi.00529.2001; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; Praetorius J, 2001, AM J PHYSIOL-GASTR L, V280, pG332, DOI 10.1152/ajpgi.2001.280.3.G332; Pushkin A, 2000, BBA-GENE STRUCT EXPR, V1493, P215, DOI 10.1016/S0167-4781(00)00149-4; Romero MF, 1999, ANNU REV PHYSIOL, V61, P699, DOI 10.1146/annurev.physiol.61.1.699; Romero MF, 2004, PFLUG ARCH EUR J PHY, V447, P495, DOI 10.1007/s00424-003-1180-2; Roussa E, 2004, BIOCHEM BIOPH RES CO, V314, P382, DOI 10.1016/j.bbrc.2003.12.099; Satoh H, 2003, AM J PHYSIOL-CELL PH, V284, pC729, DOI 10.1152/ajpcell.00166.2002; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Schultheis PJ, 1998, J BIOL CHEM, V273, P29150, DOI 10.1074/jbc.273.44.29150; Seidler U, 2001, JOP, V2, P247; SHELDON RJ, 1989, J PHARMACOL EXP THER, V249, P572; Simpson JE, 2005, AM J PHYSIOL-GASTR L, V288, pG1241, DOI 10.1152/ajpgi.00493.2004; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; Soleimani M, 2001, J MEMBRANE BIOL, V183, P71, DOI 10.1007/s00232-001-0055-8; Spicer Z, 2001, AM J PHYSIOL-GASTR L, V281, pG1369, DOI 10.1152/ajpgi.2001.281.6.G1369; Sterling D, 2002, J BIOL CHEM, V277, P25239, DOI 10.1074/jbc.M202562200; Sui W, 2003, J DENT RES, V82, P388, DOI 10.1177/154405910308200512; Takahashi N, 2000, P NATL ACAD SCI USA, V97, P5434, DOI 10.1073/pnas.090091297; Vitari AC, 2006, BIOCHEM J, V397, P223, DOI 10.1042/BJ20060220; Walker NM, 2002, GASTROENTEROLOGY, V123, P531, DOI 10.1053/gast.2002.34757; WINSNES A, 1979, ACTA PAEDIATR SCAND, V68, P861	59	127	130	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9042	9052		10.1074/jbc.M607041200	http://dx.doi.org/10.1074/jbc.M607041200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17192275	hybrid			2022-12-25	WOS:000245780300051
J	Liao, H; Hyman, MC; Lawrence, DA; Pinsky, DJ				Liao, Hui; Hyman, Matthew C.; Lawrence, Daniel A.; Pinsky, David J.			Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1 alpha, and C/EBP alpha	FASEB JOURNAL			English	Article						C/EBP alpha overexpression; hypoxia sensitivity; HRE-1 and HRE-2 motifs; PAI-1 transcription	INDUCIBLE FACTOR-I; ENHANCER-BINDING-PROTEIN; ISCHEMIA/REPERFUSION INJURY; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; RESPONSE ELEMENTS; EXPRESSION; ACTIVATOR; FAMILY; GROWTH	Hypoxia, as occurs during tissue ischemia, tips the natural anticoagulant/procoagulant balance of the endovascular wall to favor activation of coagulation. Plasminogen activator inhibitor-1 (PAI-1) is an important factor suppressing fibrinolysis under conditions of low oxygen tension. We previously reported that hypoxia induced PAI-1 mRNA and antigen expression in murine macrophages secondary to increased de novo transcription as well as increased mRNA stability. We now show in RAW264.7 murine macrophages that the transcription factors early growth response gene-1 (Egr-1), hypoxia-inducible factor-1 alpha (HIF-1 alpha), and CCAAT/enhancer binding protein cl (C/EBP alpha) are quickly activated in hypoxia and are responsible for transcription and expression of PAI-1. Murine PAI-1 promoter constructs, including Egr, HIF-1 alpha, and/or C/EBP alpha binding sites, were transfected into RAW 264.7 murine macrophages. To identify the relative importance of each of these putative hypoxia-responsive elements, cells were exposed to normobaric hypoxia, and transcriptional activity was recorded. At 16 h of hypoxic exposure, murine PAW promoter deletion constructs that included Egr, HIF-1 alpha, and/or C/EBP alpha binding sites demonstrated increased transcriptional activity. Mutation of each of these three murine PAI-1 promoter sites (or a combination of them) resulted in a marked reduction in hypoxia sensitivity as detected by transcriptional analysis. Functional data obtained using P-32-labeled Egr, HIF-1 alpha response element (HRE), and C/EBP alpha oligonucleotides revealed induction of DNA binding activity in nuclear extracts from hypoxic RAW cells, with supershift analysis confirming activation of Egr-1, HIF-1 alpha, or C/EBP alpha. ChIP analysis confirmed the authenticity of these interactions as each of these transcription factors binds to chromatin under hypoxic conditions. Further, the induction of PAI-1 by Egr-I, HIF-1 alpha, or C/EBP alpha was replicated in primary peritoneal macrophages. These data suggest that although HIF-1 alpha appears to dominate the PAI-1 transcriptional response in hypoxia, Egr-1 and C/EBP alpha greatly augment this response and can do so independent of HIF-1 alpha or each other. These studies are relevant to ischemic up-regulation of the PAI-1 gene and consequent accrual of microvascular thrombus under ischemic conditions.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Pinsky, DJ (corresponding author), Univ Michigan Hlth Syst, 7220 MSRB III,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	dpinsky@umich.edu		Lawrence, Daniel/0000-0003-3126-1935; Hyman, Matthew/0000-0002-4050-6925	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059488] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59377, HL59488] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Al-Sarraj A, 2005, J CELL BIOCHEM, V94, P153, DOI 10.1002/jcb.20305; Banks MF, 2005, J APPL PHYSIOL, V98, P732, DOI 10.1152/japplphysiol.00821.2004; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Burgess-Beusse BL, 1998, MOL CELL BIOL, V18, P7269, DOI 10.1128/MCB.18.12.7269; Cao CZ, 2006, EMBO J, V25, P1860, DOI 10.1038/sj.emboj.7601082; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fujita T, 2004, J CLIN INVEST, V113, P1615, DOI 10.1172/JCI200419225; Gorlach A, 2003, THROMB HAEMOSTASIS, V89, P926; HAMER JD, 1981, BRIT J SURG, V68, P166, DOI 10.1002/bjs.1800680308; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ishiyama T, 2003, CANCER SCI, V94, P757, DOI 10.1111/j.1349-7006.2003.tb01515.x; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; Jung F, 2000, CIRC RES, V86, P319, DOI 10.1161/01.RES.86.3.319; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kietzmann T, 2003, THROMB HAEMOSTASIS, V89, P666; Kietzmann T, 2003, BLOOD, V101, P907, DOI 10.1182/blood-2002-06-1693; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Liu CT, 1998, CANCER GENE THER, V5, P3; Liu Q, 2004, BLOOD, V104, P3993, DOI 10.1182/blood-2004-03-1017; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MALONE PC, 1977, MED HYPOTHESES, V3, P189, DOI 10.1016/0306-9877(77)90005-6; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McCaffrey TA, 2000, J CLIN INVEST, V105, P653, DOI 10.1172/JCI8592; Okada K, 2000, J BIOL CHEM, V275, P21468, DOI 10.1074/jbc.M002682200; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; PINSKY DJ, 1995, THROMB HAEMOSTASIS, V74, P58; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; Samoylenko A, 2001, BLOOD, V97, P2657, DOI 10.1182/blood.V97.9.2657; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Thake CD, 2004, AVIAT SPACE ENVIR MD, V75, P811; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zagorska A, 2004, ACTA BIOCHIM POL, V51, P563, DOI 10.18388/abp.2004_3545; Zhang QZ, 2004, J CELL PHYSIOL, V199, P89, DOI 10.1002/jcp.10452; Zhang QZ, 2003, J INVEST DERMATOL, V121, P1005, DOI 10.1046/j.1523-1747.2003.12564.x	65	93	97	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					935	949		10.1096/fj.06-6285com	http://dx.doi.org/10.1096/fj.06-6285com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17197388	Green Submitted			2022-12-25	WOS:000244686400030
J	Matsuoka, H; Hirooka, K; Fujita, Y				Matsuoka, Hiroshi; Hirooka, Kazutake; Fujita, Yasutaro			Organization and function of the YsiA regulon of Bacillus subtilis involved in fatty acid degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MICROARRAY ANALYSIS; ESCHERICHIA-COLI; TRANSCRIPTION FACTOR; FADR; BIOSYNTHESIS; GENE; SEQUENCE; GENOME; METABOLISM; EXPRESSION	The organization and function of the Bacillus subtilis YsiA regulon involved in fatty acid degradation were investigated. Northern and primer extension analyses indicated that this regulon comprises five operons, i.e. lcfA-ysiA-B-etfB-A, ykuF-G, yhfL, yusM-L-K-J, and ywjF-acdA-rpoE. YusJ and AcdA, YsiB and YusL, and YusK presumably encode acyl-CoA dehydrogenases, 3-hydroxyl-CoA dehydrogenase/enoyl-CoA hydratase complexes, and acetyl-CoA C-acyltransferase, respectively, which are directly involved in the fatty acid,beta-oxidation cycle. In addition, LcfA and YhfL are likely to encode long chain acyl-CoA ligases. On gel retardation and footprinting analyses involving the purified YsiA protein, we identified cis-sequences for YsiA binding (YsiA boxes) in the promoter regions upstream of ysiA, ykuF, yusL, yhfL, and ywjF, the equilibrium dissociation constants (K-d) for YsiA binding being 20, 21, 37, 43, and 65 nm, respectively. YsiA binding was specifically inhibited by long chain acyl-CoAs with 14-20 carbon atoms, acyl-CoAs with 18 carbon atoms being more effective; out of long chain acyl-CoAs tested, monounsaturated oleoyl-CoA, and branched chain 12-metyltetradecanoyl-CoA were most effective. These in vitro findings were supported by the in vivo observation that the knock-out of acyl-CoA dehydrogenation through yusJ, et A, or etfB disruption resulted in YsiA inactivation, probably because of the accumulation of long chain acyl-CoAs in the cells. Furthermore, the disruption of yusL, yusK, yusJ, etfA, etfB, or ykuG affected the utilization of palmitic acid, a representative long chain fatty acid. Based on this work, ysiA, ysiB,.ykuF, ykuG, yhjL, yusM, yusL, yusK, yusJ, and ywjF can be renamed fadR, fadB, fadH,fadG, lcfB, fadM, fadN, fadA, fadE, and fadF.	Fukuyama Univ, Dept Biotechnol, Fac Life Sci & Biotechnol, Fukuyama, Hiroshima 7290292, Japan	Fukuyama University	Fujita, Y (corresponding author), Fukuyama Univ, Dept Biotechnol, Fac Life Sci & Biotechnol, 985 Sanzo, Fukuyama, Hiroshima 7290292, Japan.	yfujita@bt.fubt.fukuyama-u.ac.jp	Hirooka, Kazutake/K-9827-2017; Matsuoka, Hiroshi/AAI-8629-2020	Hirooka, Kazutake/0000-0001-5879-936X; Matsuoka, Hiroshi/0000-0001-9423-5473				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; Badger J, 2005, PROTEINS, V60, P787, DOI 10.1002/prot.20541; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bryan EM, 1996, J BACTERIOL, V178, P4778, DOI 10.1128/jb.178.16.4778-4786.1996; Campbell JW, 2001, J BACTERIOL, V183, P5982, DOI 10.1128/JB.183.20.5982-5990.2001; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; Choi KH, 2000, J BACTERIOL, V182, P365, DOI 10.1128/JB.182.2.365-370.2000; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Cronan JE, 1998, MOL MICROBIOL, V29, P937, DOI 10.1046/j.1365-2958.1998.00917.x; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; de Mendoza D., 2001, BACILLUS SUBTILIS IT, P43; De Mendoza Diego, 1993, P411; de Saro FJL, 1999, J BIOL CHEM, V274, P15953, DOI 10.1074/jbc.274.22.15953; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; DiRusso CC, 1998, MOL MICROBIOL, V27, P1, DOI 10.1046/j.1365-2958.1998.00645.x; FUJITA Y, 1981, J BACTERIOL, V145, P760, DOI 10.1128/JB.145.2.760-767.1981; HORINOUCHI S, 1982, J BACTERIOL, V150, P815, DOI 10.1128/JB.150.2.815-825.1982; Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42; Kobayashi K, 2001, J BACTERIOL, V183, P7365, DOI 10.1128/JB.183.24.7365-7370.2001; Koburger T, 2005, MOL GENET GENOMICS, V274, P1, DOI 10.1007/s00438-005-1119-8; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; NUNN WD, 1986, MICROBIOL REV, V50, P179, DOI 10.1128/MMBR.50.2.179-192.1986; Ogura M, 2001, NUCLEIC ACIDS RES, V29, P3804, DOI 10.1093/nar/29.18.3804; Rock CO, 2002, BIOCHEM BIOPH RES CO, V292, P1155, DOI 10.1006/bbrc.2001.2022; ROCK CO, 1996, BIOCHIM BIOPHYS ACTA, V1320, P1; Sambrook J, 2001, MOL CLONING LAB MANU; Schilling CH, 2000, J MOL MICROB BIOTECH, V2, P495; Schujman GE, 2003, DEV CELL, V4, P663, DOI 10.1016/S1534-5807(03)00123-0; SEUBERT W, 1960, BIOCHEM PREP, V7, P80; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; van Aalten DMF, 2000, EMBO J, V19, P5167, DOI 10.1093/emboj/19.19.5167; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Xu YB, 2001, J BIOL CHEM, V276, P17373, DOI 10.1074/jbc.M100195200; Yoshida K, 2000, MICROBIOL-UK, V146, P573, DOI 10.1099/00221287-146-3-573; Yoshida K, 2001, NUCLEIC ACIDS RES, V29, P683, DOI 10.1093/nar/29.3.683; Yoshida KI, 1997, J BACTERIOL, V179, P4591, DOI 10.1128/jb.179.14.4591-4598.1997; Yoshida KI, 2002, J BACTERIOL, V184, P983, DOI 10.1128/jb.184.4.983-991.2002	40	75	88	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5180	5194		10.1074/jbc.M606831200	http://dx.doi.org/10.1074/jbc.M606831200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189250	hybrid			2022-12-25	WOS:000244482300012
J	Qin, ZJ; Hu, DM; Han, SB; Reaney, SH; Monte, DA; Fink, AL				Qin, Zhijie; Hu, Dongmei; Han, Shubo; Reaney, Stephen H.; Di Monte, Donato A.; Fink, Anthony L.			Effect of 4-hydroxy-2-nonenal modification alpha-synuclein aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; FATTY-ACIDS; FIBRIL FORMATION; BINDING; MICE; ASSOCIATION; MUTATION; MODEL	Several observations have implicated oxidative stress and aggregation of the presynaptic protein alpha-synuclein in the pathogenesis of Parkinson disease. alpha-Synuclein has been shown to have affinity for unsaturated fatty acids and membranes enriched in polyunsaturated fatty acids, which are especially sensitive to oxidation under conditions of oxidative stress. One of the most important products of lipid oxidation is 4-hydroxy-2-nonenal (HNE), which has been implicated in the pathogenesis of Parkinson disease. Consequently, we investigated the effects of the interaction of HNE with a-synuclein. Incubation of HNE with alpha-synuclein at PH 7.4 and 37 degrees C resulted in covalent modification of the protein, with up to six HNE molecules incorporated as Michael addition products. Fourier transform infrared and CD spectra indicated that HNE modification of alpha-synuclein resulted in a major conformational change involving increased beta-sheet. HNE modification of alpha-synuclein led to inhibition of fibrillation in an HNE concentration-dependent manner. This inhibition of fibrillation was shown to be due to the formation of soluble oligomers based on size exclusion high pressure liquid chromatography and atomic force microscope data. Small angle x-ray scattering analysis indicated that the HNE-induced oligomers were compact and tightly packed. Treatment with guanidinium chloride demonstrated that the HNE-induced oligomers were very stable with an extremely slow rate of dissociation. Addition of 5 mu M HNE-modified oligomers to primary mesencephalic cultures caused marked neurotoxicity because the integrity of dopaminergic and GABAergic neurons was reduced by 95 and 85%, respectively. Our observations indicate that HNE modification of alpha-synuclein prevents fibrillation but may result in toxic oligomers, which could therefore contribute to the demise of neurons subjected to oxidative damage.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Fayetteville State Univ, Dept Nat Sci, Fayetteville, NC 28301 USA; Parkinsons Inst, Sunnyvale, CA 94089 USA	University of California System; University of California Santa Cruz; University of North Carolina; Fayetteville State University	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	enzyme@ucsc.edu	Han, Shubo/ABA-4350-2021	Han, Shubo/0000-0002-0216-5111; Di Monte, Donato/0000-0002-8296-836X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039985] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39985] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Cabin DE, 2002, J NEUROSCI, V22, P8797; Cole RN, 2001, J NEUROCHEM, V79, P1080, DOI 10.1046/j.1471-4159.2001.00655.x; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Dalfo E, 2005, J NEUROPATH EXP NEUR, V64, P816, DOI 10.1097/01.jnen.0000179050.54522.5a; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Dianzani Mario Umberto, 2003, Molecular Aspects of Medicine, V24, P263; DRISCOLL BF, 1991, J NEUROCHEM, V56, P1201, DOI 10.1111/j.1471-4159.1991.tb11411.x; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; FINK AL, 1999, INFRARED ANAL PEPTID, P132; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Fortin DL, 2004, J NEUROSCI, V24, P6715, DOI 10.1523/JNEUROSCI.1594-04.2004; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Gerson EA, 1999, PHYTOCHEM ANALYSIS, V10, P322, DOI 10.1002/(SICI)1099-1565(199911/12)10:6&lt;322::AID-PCA468&gt;3.0.CO;2-W; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lev N, 2001, ISRAEL MED ASSOC J, V3, P435; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lewy F.H., 2017, HDB NEUROLOGIE, V3, P920; Lotharius J, 2002, HUM MOL GENET, V11, P2395, DOI 10.1093/hmg/11.20.2395; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; Markesbery WR, 1999, ARCH NEUROL-CHICAGO, V56, P1449, DOI 10.1001/archneur.56.12.1449; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McCormack AL, 2005, J NEUROCHEM, V93, P1030, DOI 10.1111/j.1471-4159.2005.03088.x; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sajadi A, 2006, NEUROBIOL DIS, V22, P119, DOI 10.1016/j.nbd.2005.10.006; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Sharon R, 2003, J BIOL CHEM, V278, P49874, DOI 10.1074/jbc.M309127200; SHIMODA K, 1992, BRAIN RES, V586, P319, DOI 10.1016/0006-8993(92)91642-R; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Smith MP, 2007, NEUROSCIENCE, V144, P1057, DOI 10.1016/j.neuroscience.2006.10.004; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Trostchansky A, 2006, BIOCHEM J, V393, P343, DOI 10.1042/BJ20051277; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Wang DS, 2003, BIOCHEM BIOPH RES CO, V310, P236, DOI 10.1016/j.bbrc.2003.09.003; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Zarkovic Kamelija, 2003, Molecular Aspects of Medicine, V24, P293, DOI 10.1016/S0098-2997(03)00024-4; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com; Zhu M, 2003, J BIOL CHEM, V278, P16873, DOI 10.1074/jbc.M210136200; Zhu M, 2003, J BIOL CHEM, V278, P40186, DOI 10.1074/jbc.M305326200	57	146	159	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5862	5870		10.1074/jbc.M608126200	http://dx.doi.org/10.1074/jbc.M608126200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189262	hybrid			2022-12-25	WOS:000244482300082
J	Ghosh-Choudhury, N; Mandal, CC; Choudhury, GG				Ghosh-Choudhury, Nandini; Mandal, Chandi Charan; Choudhury, Goutam Ghosh			Statin-induced Ras activation integrates the phosphatidylinositol 3-kinase signal to Akt and MAPK for bone morphogenetic protein-2 expression in osteoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA REDUCTASE INHIBITORS; NF-KAPPA-B; BMP-2 GENE; TUMOR-SUPPRESSOR; RETINOBLASTOMA PROTEIN; MESANGIAL CELLS; DNA-SYNTHESIS; C-FOS; KINASE; TRANSCRIPTION	Lovastatin promotes osteoblast differentiation by increasing bone morphogenetic protein-2 (BMP-2) expression. We demonstrate that lovastatin stimulates tyrosine phosphorylation of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K), leading to an increase in its kinase activity in osteoblast cells. Inhibition of PI3K ameliorated expression of the osteogenic markers alkaline phosphatase, type I collagen, osteopontin, and BMP-2. Expression of dominant-negative PI3K and PTEN, an inhibitor of PI3K signaling, significantly attenuated lovastatin-induced transcription of BMP-2. Akt kinase was also activated in a PI3K-dependent manner. However, our data suggest involvement of an additional signaling pathway. Lovastatin-induced Erk1/2 activity contributed to BMP-2 transcription. Inhibition of PI3K abrogated Erk1/2 activity in response to lovastatin, indicating the presence of a signal relay between them. We provide, as a mechanism of this cross-talk, the first evidence that lovastatin stimulates rapid activation of Ras, which associates with and activates PI3K in the plasma membrane, which in turn regulates Akt and Erk1/2 to induce BMP-2 expression for osteoblast differentiation.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA; S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Geriatric Research Education & Clinical Center	Ghosh-Choudhury, N (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	choudhury@uthscsa.edu		Mandal, Chandi/0000-0002-2292-6635	NIAMS NIH HHS [R01 AR52425] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052425] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140-6736(00)02400-4; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Choudhury GG, 2004, J BIOL CHEM, V279, P27399, DOI 10.1074/jbc.M403530200; Choudhury GG, 1999, BIOCHEM BIOPH RES CO, V258, P490, DOI 10.1006/bbrc.1999.0599; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Choundhury GG, 1999, J BIOL CHEM, V274, P10897; Chung YS, 2000, J CLIN ENDOCR METAB, V85, P1137, DOI 10.1210/jcem.85.3.6476; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Edwards CJ, 2000, LANCET, V355, P2218, DOI 10.1016/S0140-6736(00)02408-9; Edwards CJ, 2001, CALCIFIED TISSUE INT, V69, P63, DOI 10.1007/s00223-001-2017-7; Feng JQ, 2003, J BIOL CHEM, V278, P29130, DOI 10.1074/jbc.M212296200; Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200; Ghosh-Choudhury N, 2000, BIOCHEM BIOPH RES CO, V272, P705, DOI 10.1006/bbrc.2000.2844; Ghosh-Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351; Ghosh-Choudhury N, 2000, BBA-MOL CELL RES, V1497, P186, DOI 10.1016/S0167-4889(00)00060-4; Ghosh-Choudhury N, 2006, J BIOL CHEM, V281, P20160, DOI 10.1074/jbc.M511071200; Ghosh-Choudhury NG, 2003, J BIOL CHEM, V278, P21998, DOI 10.1074/jbc.M302277200; GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331; GhoshChoudhury N, 1997, BIOCHEM BIOPH RES CO, V231, P196, DOI 10.1006/bbrc.1996.5962; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hatano Hiroshi, 2003, J Orthop Sci, V8, P842, DOI 10.1007/s00776-003-0724-9; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; KAVANAUGH WM, 1994, BIOCHEMISTRY-US, V33, P11046, DOI 10.1021/bi00202a026; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; Li XD, 2003, BONE, V33, P652, DOI 10.1016/S8756-3282(03)00239-4; Maeda N, 2005, J VIROL, V79, P4440, DOI 10.1128/JVI.79.7.4440-4450.2005; Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074; Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mahimainathan L, 2005, AM J PHYSIOL-RENAL, V289, pF72, DOI 10.1152/ajprenal.00277.2004; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; Meier CR, 2000, JAMA-J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Oxlund H, 2004, BONE, V34, P609, DOI 10.1016/j.bone.2003.12.014; Ozes ON, 1999, NATURE, V401, P82; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sato S, 2004, J BIOL CHEM, V279, P33759, DOI 10.1074/jbc.M402055200; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; Skaletz-Rorowski A, 2003, CARDIOVASC RES, V57, P253, DOI 10.1016/S0008-6363(02)00618-1; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697; Thompson JE, 2004, J CLIN ONCOL, V22, P4217, DOI 10.1200/jco.2004.01.103; Wang PS, 2000, JAMA-J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211	51	115	130	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4983	4993		10.1074/jbc.M606706200	http://dx.doi.org/10.1074/jbc.M606706200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17179158	hybrid			2022-12-25	WOS:000244482000081
J	Baniwal, SK; Chan, KY; Scharf, KD; Nover, L				Baniwal, Sanjeev K.; Chan, Kwan Yu; Scharf, Klaus-Dieter; Nover, Lutz			Role of heat stress transcription factor HsfA5 as specific repressor of HsfA4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR-DISTRIBUTION; ACTIVATOR FUNCTION; NUCLEAR IMPORT; TOMATO; GENES; ARABIDOPSIS; EXPRESSION; IDENTIFICATION; PROTEINS; SYSTEM	Unlike other eukaryotes, plants possess a complex family of heat stress transcription factors (Hsfs) with usually more than 20 members. Among them, Hsfs A4 and A5 form a group distinguished from other Hsfs by structural features of their oligomerization domains and by a number of conserved signature sequences. We show that A4 Hsfs are potent activators of heat stress gene expression, whereas A5 Hsfs act as specific repressors of HsfA4 activity. The oligomerization domain of HsfA5 alone is necessary and sufficient to exert this effect. Due to the high specificity of the oligomerization domains, other class A Hsfs are not affected. Pull-down assay and yeast two-hybrid interaction tests demonstrate that the tendency to form HsfA4/A5 heterooligomers is stronger than the formation of homooligomers. The specificity of interaction between Hsfs A4 and A5 was confirmed by bimolecular fluorescence complementation experiments. The major role of the representatives of the HsfA4/A5 group, which are not involved in the conventional heat stress response, may reside in cell type-specific functions connected with the control of cell death triggered by pathogen infection and/or reactive oxygen species.	Goethe Univ Frankfurt, Bioctr, Dept Mol Cell Biol, D-60438 Frankfurt, Germany	Goethe University Frankfurt	Nover, L (corresponding author), Goethe Univ Frankfurt, Bioctr, Dept Mol Cell Biol, Max Von Laue Str 9, D-60438 Frankfurt, Germany.	nover@cellbiology.uni-frankfurt.de						Almoguera C, 2002, J BIOL CHEM, V277, P43866, DOI 10.1074/jbc.M207330200; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Baniwal SK, 2004, J BIOSCIENCES, V29, P471, DOI 10.1007/BF02712120; Bharti K, 2000, PLANT J, V22, P355, DOI 10.1046/j.1365-313x.2000.00746.x; Bharti K, 2004, PLANT CELL, V16, P1521, DOI 10.1105/tpc.019927; Boscheinen O, 1997, MOL GEN GENET, V255, P322, DOI 10.1007/s004380050503; Busch W, 2005, PLANT J, V41, P1, DOI 10.1111/j.1365-313X.2004.02272.x; CZARNECKA E, 1985, P NATL ACAD SCI USA, V82, P3726, DOI 10.1073/pnas.82.11.3726; Czarnecka-Verner E, 2004, PLANT MOL BIOL, V56, P57, DOI 10.1007/s11103-004-2307-3; Davletova S, 2005, PLANT CELL, V17, P268, DOI 10.1105/tpc.104.026971; Doring P, 2000, PLANT CELL, V12, P265, DOI 10.1105/tpc.12.2.265; Heerklotz D, 2001, MOL CELL BIOL, V21, P1759, DOI 10.1128/MCB.21.5.1759-1768.2001; Kirschner M, 2000, PLANT J, V24, P397, DOI 10.1046/j.1365-313x.2000.00887.x; Kotak S, 2004, PLANT J, V39, P98, DOI 10.1111/j.1365-313X.2004.02111.x; Lohmann C, 2004, MOL GENET GENOMICS, V271, P11, DOI 10.1007/s00438-003-0954-8; Lyck R, 1997, PLANTA, V202, P117, DOI 10.1007/s004250050110; Miller G, 2006, ANN BOT-LONDON, V98, P279, DOI 10.1093/aob/mcl107; Mishra SK, 2002, GENE DEV, V16, P1555, DOI 10.1101/gad.228802; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nakai A, 1999, CELL STRESS CHAPERON, V4, P86, DOI 10.1379/1466-1268(1999)004<0086:NAITVH>2.3.CO;2; NOVER L, 1987, ENZYME MICROB TECH, V9, P130, DOI 10.1016/0141-0229(87)90066-4; Nover L, 2001, CELL STRESS CHAPERON, V6, P177, DOI 10.1379/1466-1268(2001)006<0177:AATHST>2.0.CO;2; PELHAM HRB, 1982, EMBO J, V1, P1473, DOI 10.1002/j.1460-2075.1982.tb01340.x; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Port M, 2004, PLANT PHYSIOL, V135, P1457, DOI 10.1104/pp.104.042820; Prandl R, 1998, MOL GEN GENET, V258, P269, DOI 10.1007/s004380050731; Prieto-Dapena P, 2006, PLANT PHYSIOL, V142, P1102, DOI 10.1104/pp.106.087817; Sambrook J., 2001, MOL CLONING LAB MANU; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; Scharf KD, 1998, MOL CELL BIOL, V18, P2240, DOI 10.1128/MCB.18.4.2240; Scharf KD, 2001, CELL STRESS CHAPERON, V6, P225, DOI 10.1379/1466-1268(2001)006<0225:TEFOAT>2.0.CO;2; Schramm F, 2006, PLANT MOL BIOL, V60, P759, DOI 10.1007/s11103-005-5750-x; Siddique M, 2003, CELL STRESS CHAPERON, V8, P381, DOI 10.1379/1466-1268(2003)008<0381:THSPHR>2.0.CO;2; TOPFER R, 1988, NUCLEIC ACIDS RES, V16, P8725, DOI 10.1093/nar/16.17.8725; TREUTER E, 1993, MOL GEN GENET, V240, P113, DOI 10.1007/BF00276890; Voellmy R, 2004, CELL STRESS CHAPERON, V9, P122, DOI 10.1379/CSC-14R.1; Walter M, 2004, PLANT J, V40, P428, DOI 10.1111/j.1365-313X.2004.02219.x; Yamanouchi U, 2002, P NATL ACAD SCI USA, V99, P7530, DOI 10.1073/pnas.112209199	39	104	116	6	34	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3605	3613		10.1074/jbc.M609545200	http://dx.doi.org/10.1074/jbc.M609545200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17150959	hybrid			2022-12-25	WOS:000244481900022
J	Munshi, UM; Kim, J; Nagashima, K; Hurley, JH; Freed, EO				Munshi, Utpal M.; Kim, Jaewon; Nagashima, Kunio; Hurley, James H.; Freed, Eric O.			An Alix fragment potently inhibits HIV-1 budding - Characterization of binding to retroviral YPXL late domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTIOUS-ANEMIA VIRUS; RECEPTOR DOWN-REGULATION; PROTEIN-SORTING PATHWAY; MULTIVESICULAR-BODY; SACCHAROMYCES-CEREVISIAE; PARTICLE-PRODUCTION; GAG PROTEIN; LIFE-CYCLE; ESCRT-I; UBIQUITIN	The retroviral structural protein, Gag, contains small peptide motifs known as late domains that promote efficient virus release from the infected cell. In addition to the well characterized PTAP late domain, the p6 region of HIV-1 Gag contains a binding site for the host cell protein Alix. To better understand the functional role of the Gag/Alix interaction, we overexpressed an Alix fragment composed of residues 364-716 (Alix 364-716) and examined the effect on release of wild type (WT) and Alix binding site mutant HIV-1. We observed that Alix 364-716 expression significantly inhibited WT virus release and Gag processing and that mutation of the Alix binding site largely relieved this inhibition. Furthermore, Alix 364-716 expression induced a severe defect on WT but not mutant particle morphology. Intriguingly, the impact of Alix 364-716 expression on HIV-1 release and Gag processing was markedly different from that induced by mutation of the Alix binding site in p6. The association of Alix 364-716 with HIV-1 and equine infectious anemia virus late domains was quantitatively evaluated by isothermal titration calorimetry and surface plasmon resonance techniques, and the effects of mutations in these viral sequences on Alix 364-716 binding was determined. This study identifies a novel Alix-derived dominant negative inhibitor of HIV-1 release and Gag processing and provides quantitative information on the interaction between Alix and viral late domains.	NCI Frederick, HIV Drug Resistance Program, Virus Cell Interact Sect, Frederick, MD 21702 USA; NIDDK, Mol Biol Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; NCI, SAIC Frederick, Res Technol Program, Image Anal Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Freed, EO (corresponding author), NCI Frederick, HIV Drug Resistance Program, Virus Cell Interact Sect, Bldg 535,Rm 108, Frederick, MD 21702 USA.	efreed@nih.gov			Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036125] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander L, 2000, J VIROL, V74, P4361, DOI 10.1128/JVI.74.9.4361-4376.2000; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Bieniasz PD, 2006, VIROLOGY, V344, P55, DOI 10.1016/j.virol.2005.09.044; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bouamr F, 2003, J VIROL, V77, P11882, DOI 10.1128/JVI.77.22.11882-11895.2003; Bowers K, 2005, BBA-MOL CELL RES, V1744, P438, DOI 10.1016/j.bbamcr.2005.04.004; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Chen CP, 2005, J BIOL CHEM, V280, P40474, DOI 10.1074/jbc.M509317200; Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899; Demirov DG, 2004, VIRUS RES, V106, P87, DOI 10.1016/j.virusres.2004.08.007; Demirov DG, 2002, J VIROL, V76, P105, DOI 10.1128/JVI.76.1.105-117.2002; FREED EO, 1994, J VIROL, V68, P5311, DOI 10.1128/JVI.68.8.5311-5320.1994; Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Goila-Gaur R, 2003, J VIROL, V77, P6507, DOI 10.1128/JVI.77.11.6507-6519.2003; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Hurley JH, 2006, ANNU REV BIOPH BIOM, V35, P277, DOI 10.1146/annurev.biophys.35.040405.102126; Joshi A, 2006, J VIROL, V80, P7939, DOI 10.1128/JVI.00355-06; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kikonyogo A, 2001, P NATL ACAD SCI USA, V98, P11199, DOI 10.1073/pnas.201268998; Kim JW, 2005, DEV CELL, V8, P937, DOI 10.1016/j.devcel.2005.04.001; Martin-Serrano J, 2005, J CELL BIOL, V168, P89, DOI 10.1083/jcb.200408155; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Ono A, 2000, J VIROL, V74, P2855, DOI 10.1128/JVI.74.6.2855-2866.2000; Patnaik A, 2002, J VIROL, V76, P2641, DOI 10.1128/JVI.76.6.2641-2647.2002; Pornillos O, 2002, NAT STRUCT BIOL, V9, P812, DOI 10.1038/nsb856; Schmidt MHH, 2004, MOL CELL BIOL, V24, P8981, DOI 10.1128/MCB.24.20.8981-8993.2004; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Shehu-Xhilaga M, 2004, J VIROL, V78, P724, DOI 10.1128/JVI.78.2.724-732.2004; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Trioulier Y, 2004, J BIOL CHEM, V279, P2046, DOI 10.1074/jbc.M309243200; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Vincent O, 2003, MOL CELL BIOL, V23, P1647, DOI 10.1128/MCB.23.5.1647-1655.2003; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Wang HT, 2004, J VIROL, V78, P1503, DOI 10.1128/JVI.78.3.1503-1512.2004; Yuan B, 1999, EMBO J, V18, P4700, DOI 10.1093/emboj/18.17.4700	51	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3847	3855		10.1074/jbc.M607489200	http://dx.doi.org/10.1074/jbc.M607489200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158451	hybrid			2022-12-25	WOS:000244481900048
J	Volkmer, T; Schneider, D; Bernat, G; Kirchhoff, H; Wenk, SO; Rogner, M				Volkmer, Thomas; Schneider, Dirk; Bernat, Gabor; Kirchhoff, Helmut; Wenk, Stephan-Olav; Roegner, Matthias			Ssr2998 of Synechocystis sp PCC 6803 is involved in regulation of cyanobacterial electron transport and associated with the cytochrome b(6)f complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN PCC-6803; SP PCC 6803; THYLAKOID MEMBRANES; PHOTOSYSTEM-I; STATE TRANSITIONS; PLASMA-MEMBRANE; REDOX STATE; PROTEINS; PHOTOSYNTHESIS; FLUORESCENCE	To analyze the function of a protein encoded by the open reading frame ssr2998 in Synechocystis sp. PCC 6803, the corresponding gene was disrupted, and the generated mutant strain was analyzed. Loss of the 7.2-kDa protein severely reduced the growth of Synechocystis, especially under high light conditions, and appeared to impair the function of the cytochrome b(6)f complex. This resulted in slower electron donation to cytochrome f and photosystem 1 and, concomitantly, over-reduction of the plastoquinone pool, which in turn had an impact on the photosystem I to photosystem 2 stoichiometry and state transition. Furthermore, a 7.2-kDa protein, encoded by the open reading frame ssr2998, was co-isolated with the cytochrome b(6)f complex from the cyanobacterium Synechocystis sp. PCC 6803. ssr2998 seems to be structurally and functionally associated with the cytochrome b(6)f complex from Synechocystis, and the protein could be involved in regulation of electron transfer processes in Synechocystis sp. PCC 6803.	Ruhr Univ Bochum, D-44780 Bochum, Germany; Univ Freiburg, Zentrum Biochem & Mol Zellforsch, D-79104 Freiburg, Germany; Inst Bot, D-48149 Munster, Germany	Ruhr University Bochum; University of Freiburg	Rogner, M (corresponding author), Ruhr Univ Bochum, Univ Str 150, D-44780 Bochum, Germany.	matthias.roegner@rub.de	Kirchhoff, Helmut/AAN-6695-2020; Bernat, Gabor/J-6333-2017; Kirchhoff, Helmut/A-6177-2008	Kirchhoff, Helmut/0000-0001-5874-3681; Bernat, Gabor/0000-0001-6147-9391; 				ALEXEYEV MF, 1995, BIOTECHNIQUES, V18, P52; Bald D, 1996, PHOTOSYNTH RES, V49, P103, DOI 10.1007/BF00117661; Berry S, 2002, BIOCHEMISTRY-US, V41, P3422, DOI 10.1021/bi011683d; Cooley JW, 2001, J BACTERIOL, V183, P4251, DOI 10.1128/JB.183.14.4251-4258.2001; Emlyn-Jones D, 1999, MOL MICROBIOL, V33, P1050, DOI 10.1046/j.1365-2958.1999.01547.x; FORK DC, 1983, PHOTOCHEM PHOTOBIOL, V37, P421, DOI 10.1111/j.1751-1097.1983.tb04495.x; Fulda S, 2000, EUR J BIOCHEM, V267, P5900, DOI 10.1046/j.1432-1327.2000.01642.x; Fulda S, 2006, PROTEOMICS, V6, P2733, DOI 10.1002/pmic.200500538; Hamel P, 2000, J BIOL CHEM, V275, P17072, DOI 10.1074/jbc.M001468200; Huang F, 2006, PROTEOMICS, V6, P910, DOI 10.1002/pmic.200500114; Huang F, 2004, MOL CELL PROTEOMICS, V3, P586, DOI 10.1074/mcp.M300137-MCP200; Huang F, 2002, MOL CELL PROTEOMICS, V1, P956, DOI 10.1074/mcp.M200043-MCP200; Kaneko T, 1996, DNA Res, V3, P109; Kashino Y, 2002, BIOCHEMISTRY-US, V41, P8004, DOI 10.1021/bi026012+; Kirchhoff H, 2000, BBA-BIOENERGETICS, V1459, P148, DOI 10.1016/S0005-2728(00)00143-2; KRUIP J, 1994, PHOTOSYNTH RES, V40, P279, DOI 10.1007/BF00034777; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; Mao HB, 2003, FEBS LETT, V553, P68, DOI 10.1016/S0014-5793(03)00973-6; Mao HB, 2002, FEBS LETT, V519, P82, DOI 10.1016/S0014-5793(02)02715-1; MEHLER AH, 1951, ARCH BIOCHEM BIOPHYS, V34, P339, DOI 10.1016/0003-9861(51)90012-4; Mullineaux CW, 1997, NATURE, V390, P421, DOI 10.1038/37157; Mullineaux CW, 2002, TRENDS PLANT SCI, V7, P237, DOI 10.1016/S1360-1385(02)02283-5; MURAKAMI A, 1993, PLANT CELL PHYSIOL, V34, P1175; MURATA N, 1969, BIOCHIM BIOPHYS ACTA, V172, P242, DOI 10.1016/0005-2728(69)90067-X; Nakamura Y, 1999, NUCLEIC ACIDS RES, V27, P66, DOI 10.1093/nar/27.1.66; Norling B, 1998, FEBS LETT, V436, P189, DOI 10.1016/S0014-5793(98)01123-5; OSIEWACZ HD, 1992, ARCH MICROBIOL, V157, P336, DOI 10.1007/BF00248678; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; ROGNER M, 1990, J BIOL CHEM, V265, P6189; Rogner M, 1996, TRENDS BIOCHEM SCI, V21, P44, DOI 10.1016/0968-0004(96)80862-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarcina M, 2001, J BIOL CHEM, V276, P46830, DOI 10.1074/jbc.M107111200; Sazuka T, 1999, ELECTROPHORESIS, V20, P2160, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2160::AID-ELPS2160>3.0.CO;2-#; Schluchter WM, 1996, PHOTOCHEM PHOTOBIOL, V64, P53, DOI 10.1111/j.1751-1097.1996.tb02421.x; Schneider D, 2004, J BIOL CHEM, V279, P39383, DOI 10.1074/jbc.M406288200; Schneider D, 2002, J BIOL CHEM, V277, P10949, DOI 10.1074/jbc.M104076200; Schneider D, 2001, J BIOL CHEM, V276, P16780, DOI 10.1074/jbc.M009503200; Srivastava R, 2006, ARCH MICROBIOL, V185, P238, DOI 10.1007/s00203-006-0086-8; Srivastava R, 2005, PROTEOMICS, V5, P4905, DOI 10.1002/pmic.200500111; Wang YC, 2000, ELECTROPHORESIS, V21, P1746, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1746::AID-ELPS1746>3.3.CO;2-F; Wenk SO, 2005, FEBS J, V272, P582, DOI 10.1111/j.1742-4658.2004.04501.x; WITTMERSHAUS BP, 1992, PHOTOSYNTH RES, V31, P75, DOI 10.1007/BF00028785	42	25	25	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3730	3737		10.1074/jbc.M604948200	http://dx.doi.org/10.1074/jbc.M604948200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17166849	hybrid			2022-12-25	WOS:000244481900036
J	Rayment, SJ; Ralevic, V; Barrett, DA; Cordell, R; Alexander, SPH				Rayment, Sarah J.; Ralevic, Vera; Barrett, David A.; Cordell, Rebecca; Alexander, Stephen P. H.			A novel mechanism of vasoregulation: ADP-induced relaxation of the porcine isolated coronary artery is mediated via adenosine release	FASEB JOURNAL			English	Article						RT-PCR; adenosine A(2A) receptor; purine release; adenine nucleotides	ADENINE-NUCLEOTIDES; CYCLIC-AMP; EXTRACELLULAR ATP; P2Y(1) RECEPTOR; A(2A) RECEPTORS; P2 RECEPTORS; GUINEA-PIG; INVOLVEMENT; NEUROTRANSMISSION; 5'-NUCLEOTIDASE	In this study, we have investigated the mechanism of ADP-induced relaxation of porcine coronary artery (PCA) rings. The P2Y receptor agonists ADP and ADP beta S produced concentration-dependent relaxation of endothelium-denuded PCA smooth muscle with pD(2) values of 5.3 and 4.9, respectively. RT-polymerase chain reaction (RT-PCR) and immunoblotting demonstrated mRNA and protein expression of P2Y(1) and A(2)A adenosine receptors in the PCA. The nonselective P2 antagonist PPADS or the P2Y(1)-selective antagonist MRS2179 failed to alter ADP- or ADP beta S-induced relaxations. Relaxations to ADP were, however, blocked by the A2A adenosine receptor-selective antagonists ZM241385 and SCH58261 (apparent pK(B) values of 9.2 and 8.9, respectively). We excluded roles for direct occupancy of A(2)A adenosine receptors by ADP or ADP beta S as well as metabolism to adenosine as mechanisms for ADP-evoked relaxations. However, ADP responses were significantly enhanced in the presence of the ENT1 nucleoside transporter inhibitors dipyridamole and NBTI and were significantly inhibited by adenosine deaminase, indicating a role for extracellular adenosine. Suprafusion of [H-3]-adenine-labeled PCA segments showed that ADP induced the release of a number of purines, including adenosine. These data suggest that ADP mediates relaxation of the PCA via a novel mechanism that involves adenine nucleotide-evoked adenosine release and the subsequent activation of A(2A) receptors.	Univ Nottingham, Sch Med, Sch Biomed Sci, Queens Med Ctr, Nottingham NG7 2UH, England; Univ Nottingham, Sch Pharm, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Alexander, SPH (corresponding author), Univ Nottingham, Sch Med, Sch Biomed Sci, Queens Med Ctr, Nottingham NG7 2UH, England.	steve.alexander@nottingham.ac.uk	Alexander, Steve P/B-8105-2009; Barrett, David A/C-9922-2011	Alexander, Steve P/0000-0003-4417-497X; Barrett, David A/0000-0001-6900-9474; Rayment, Sarah/0000-0002-5293-5815; Ralevic, Vera/0000-0002-5252-280X; Cordell, Rebecca Lynne/0000-0002-3775-0193				Abbracchio MP, 2003, TRENDS PHARMACOL SCI, V24, P52, DOI 10.1016/S0165-6147(02)00038-X; Alexander S. P. H., 1999, British Journal of Pharmacology, V128, p182P; Alexander SPH, 2006, BRIT J PHARMACOL, V147, pS1; Alexander SPH, 2001, EUR J PHARMACOL, V411, P205, DOI 10.1016/S0014-2999(00)00899-2; Anwar Z, 1999, BRIT J PHARMACOL, V128, P465, DOI 10.1038/sj.bjp.0702792; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Blaylock N A, 1991, J Neural Transm Suppl, V34, P99; Boarder MR, 1998, TRENDS PHARMACOL SCI, V19, P99, DOI 10.1016/S0165-6147(98)01170-5; Bodor ET, 2003, MOL PHARMACOL, V64, P1210, DOI 10.1124/mol.64.5.1210; Cadogan AK, 1997, J NEUROCHEM, V69, P1131; Camaioni E, 1998, J MED CHEM, V41, P183, DOI 10.1021/jm970433l; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; CORR L, 1994, J CARDIOVASC PHARM, V23, P709, DOI 10.1097/00005344-199405000-00004; CRACK BE, 1995, BRIT J PHARMACOL, V114, P475, DOI 10.1111/j.1476-5381.1995.tb13251.x; Cristalli G, 2001, MED RES REV, V21, P105, DOI 10.1002/1098-1128(200103)21:2<105::AID-MED1002>3.0.CO;2-U; Hasan AZMA, 2000, J CARDIOVASC PHARM, V35, P322, DOI 10.1097/00005344-200002000-00022; KEEF KD, 1992, J PHARMACOL EXP THER, V260, P592; King BF, 1998, J PHARMACOL EXP THER, V285, P1005; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; Kuo L, 2001, DRUG DEVELOP RES, V52, P350, DOI 10.1002/ddr.1134; Leon C, 1997, FEBS LETT, V403, P26, DOI 10.1016/S0014-5793(97)00022-7; Marala RB, 1998, J PHARMACOL EXP THER, V286, P1051; Marteau F, 2003, MOL PHARMACOL, V64, P104, DOI 10.1124/mol.64.1.104; Moro S, 1998, J MED CHEM, V41, P1456, DOI 10.1021/jm970684u; Ohkubo S, 1998, N-S ARCH PHARMACOL, V358, P153, DOI 10.1007/PL00005237; Ohkubo S, 2000, BRIT J PHARMACOL, V129, P291, DOI 10.1038/sj.bjp.0703053; Opgaard OS, 1997, BASIC RES CARDIOL, V92, P168; Picher M, 2003, J BIOL CHEM, V278, P13468, DOI 10.1074/jbc.M300569200; Qi AD, 2001, MOL PHARMACOL, V60, P1375, DOI 10.1124/mol.60.6.1375; Ralevic V, 1998, PHARMACOL REV, V50, P413; Schrier SM, 2002, BIOCHEM PHARMACOL, V63, P1119, DOI 10.1016/S0006-2952(01)00939-X; Schrier SM, 2001, BIOCHEM PHARMACOL, V61, P417, DOI 10.1016/S0006-2952(00)00573-6; Sevigny J, 1997, BBA-GEN SUBJECTS, V1334, P73, DOI 10.1016/S0304-4165(96)00079-7; SHINOZUKA K, 1994, BRIT J PHARMACOL, V113, P1203, DOI 10.1111/j.1476-5381.1994.tb17125.x; Simonsen U, 1997, BRIT J PHARMACOL, V120, P411, DOI 10.1038/sj.bjp.0700918; Sperlagh B, 2003, BRIT J PHARMACOL, V139, P623, DOI 10.1038/sj.bjp.0705285; Sprague RS, 1998, AM J PHYSIOL-HEART C, V275, pH1726, DOI 10.1152/ajpheart.1998.275.5.H1726; Ting N, 2000, N-S ARCH PHARMACOL, V361, P327, DOI 10.1007/s002109900198; TODOROV LD, 1994, J PHARMACOL EXP THER, V268, P985; von Kugelgen I, 2006, PHARMACOL THERAPEUT, V110, P415, DOI 10.1016/j.pharmthera.2005.08.014; VONKUGELGEN I, 1992, N-S ARCH PHARMACOL, V346, P187, DOI 10.1007/BF00165300; Waldo GL, 2004, MOL PHARMACOL, V65, P426, DOI 10.1124/mol.65.2.426; Westfall TD, 1996, BRIT J PHARMACOL, V117, P867, DOI 10.1111/j.1476-5381.1996.tb15273.x; Yegutkin G, 2000, BRIT J PHARMACOL, V129, P921, DOI 10.1038/sj.bjp.0703136; Zimmermann H, 2001, DRUG DEVELOP RES, V52, P44, DOI 10.1002/ddr.1097; Zocchi C, 1996, J PHARMACOL EXP THER, V276, P398	47	22	22	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					577	585		10.1096/fj.06-7050com	http://dx.doi.org/10.1096/fj.06-7050com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17167068				2022-12-25	WOS:000244686300030
J	Kitano, K; Yoshihara, N; Hakoshima, T				Kitano, Ken; Yoshihara, Nozomi; Hakoshima, Toshio			Crystal structure of the HRDC domain of human Werner syndrome protein, WRN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECQ; DOUBLE-STRAND BREAKS; DNA HELICASES; SYNDROME GENE; P53-MEDIATED APOPTOSIS; HOLLIDAY JUNCTIONS; MOLECULAR-BASIS; EXONUCLEASE; BINDING; BLOOMS	Werner syndrome is a human premature aging disorder characterized by chromosomal instability. The disease is caused by the functional loss of WRN, a member of the RecQ-helicase family that plays an important role in DNA metabolic pathways. WRN contains four structurally folded domains comprising an exonuclease, a helicase, a winged-helix, and a helicase-and-ribonuclease D/C-terminal (HRDC) domain. In contrast to the accumulated knowledge pertaining to the biochemical functions of the three N-terminal domains, the function of C-terminal HRDC remains unknown. In this study, the crystal structure of the human WRN HRDC domain has been determined. The domain forms a bundle of alpha-helices similar to those of Saccharomyces cerevisiae Sgs1 and Escherichia coli RecQ. Surprisingly, the extra ten residues at each of the N and C termini of the domain were found to participate in the domain architecture by forming an extended portion of the first helix alpha 1, and a novel looping motif that traverses straight along the domain surface, respectively. The motifs combine to increase the domain surface of WRN HRDC, which is larger than that of Sgs1 and E. coli. In WRN HRDC, neither of the proposed DNA-binding surfaces in Sgs1 or E. coli is conserved, and the domain was shown to lack DNA-binding ability in vitro. Moreover, the domain was shown to be thermostable and resistant to protease digestion, implying independent domain evolution in WRN. Coupled with the unique long linker region in WRN, the WRN HRDC may be adapted to play a distinct function in WRN that involves protein-protein interactions.	Nara Inst Sci & Technol, Struct Biol Lab, Ikoma, Nara 6300192, Japan	Nara Institute of Science & Technology	Kitano, K (corresponding author), Nara Inst Sci & Technol, Struct Biol Lab, 8916-5 Takayama, Ikoma, Nara 6300192, Japan.	kkitano@is.naist.jp; hakosima@bs.naist.jp						Agrelo R, 2006, P NATL ACAD SCI USA, V103, P8822, DOI 10.1073/pnas.0600645103; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Baynton K, 2003, J BIOL CHEM, V278, P36476, DOI 10.1074/jbc.M303885200; Bennett RJ, 2004, CRIT REV BIOCHEM MOL, V39, P79, DOI 10.1080/10409230490460756; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bernstein DA, 2005, STRUCTURE, V13, P1173, DOI 10.1016/j.str.2005.04.018; Bernstein DA, 2003, NUCLEIC ACIDS RES, V31, P2778, DOI 10.1093/nar/gkg376; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Bohr VA, 2005, MUTAT RES-FUND MOL M, V577, P252, DOI 10.1016/j.mrfmmm.2005.03.021; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hu JS, 2005, P NATL ACAD SCI USA, V102, P18379, DOI 10.1073/pnas.0509380102; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Jasiak AJ, 2006, MOL CELL, V23, P71, DOI 10.1016/j.molcel.2006.05.013; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Killoran MP, 2006, NUCLEIC ACIDS RES, V34, P4098, DOI 10.1093/nar/gkl538; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Lan L, 2005, J CELL SCI, V118, P4153, DOI 10.1242/jcs.02544; Lebel M, 2001, CELL MOL LIFE SCI, V58, P857, DOI 10.1007/s00018-001-8398-y; Lee JW, 2005, MECH AGEING DEV, V126, P79, DOI 10.1016/j.mad.2004.09.011; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Liu Z, 1999, STRUCTURE, V7, P1557, DOI 10.1016/S0969-2126(00)88346-X; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Matsumoto T, 1997, HUM GENET, V100, P123, DOI 10.1007/s004390050477; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Miyazaki Satoshi, 2002, Journal of Structural and Functional Genomics, V2, P37, DOI 10.1023/A:1014418700858; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Moser MJ, 1999, HUM MUTAT, V13, P271, DOI 10.1002/(SICI)1098-1004(1999)13:4<271::AID-HUMU2>3.0.CO;2-Q; Navarro CL, 2006, HUM MOL GENET, V15, pR151, DOI 10.1093/hmg/ddl214; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Oshima J, 2002, CANCER RES, V62, P547; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Perry JJP, 2006, NAT STRUCT MOL BIOL, V13, P414, DOI 10.1038/nsmb1088; Plank JL, 2006, P NATL ACAD SCI USA, V103, P11118, DOI 10.1073/pnas.0604873103; SALK D, 1982, HUM GENET, V62, P1, DOI 10.1007/BF00295598; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shen JC, 2001, MECH AGEING DEV, V122, P921, DOI 10.1016/S0047-6374(01)00248-2; Spillare EA, 2006, ONCOGENE, V25, P2119, DOI 10.1038/sj.onc.1209242; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; von Kobbe C, 2003, J BIOL CHEM, V278, P52997, DOI 10.1074/jbc.M308338200; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Wu L, 2005, EMBO J, V24, P2679, DOI 10.1038/sj.emboj.7600740; Yan H, 2005, J CELL BIOL, V171, P217, DOI 10.1083/jcb.200502077; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zhang XD, 2006, J BIOL CHEM, V281, P12655, DOI 10.1074/jbc.M513089200; Zuo YH, 2005, STRUCTURE, V13, P973, DOI 10.1016/j.str.2005.04.015	56	47	49	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2717	2728		10.1074/jbc.M610142200	http://dx.doi.org/10.1074/jbc.M610142200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17148451	hybrid			2022-12-25	WOS:000243593200064
J	Aboody, KS; Bush, RA; Garcia, E; Metz, MZ; Najbauer, J; Justus, KA; Phelps, DA; Remack, JS; Yoon, KJ; Gillespie, S; Kim, SU; Glackin, CA; Potter, PM; Danks, MK				Aboody, Karen S.; Bush, Rebecca A.; Garcia, Elizabeth; Metz, Marianne Z.; Najbauer, Joseph; Justus, Kristine A.; Phelps, Doris A.; Remack, Joanna S.; Yoon, Karina Jin; Gillespie, Shanna; Kim, Seung U.; Glackin, Carlotta A.; Potter, Philip M.; Danks, Mary K.			Development of a Tumor-Selective Approach to Treat Metastatic Cancer	PLOS ONE			English	Article							NEURAL STEM-CELLS; RABBIT LIVER CARBOXYLESTERASE; BONE-MARROW-TRANSPLANTATION; GENE-THERAPY; NEUROBLASTOMA; BRAIN; DELIVERY; GROWTH; CPT-11; ACTIVATION	Background. Patients diagnosed with metastatic cancer have almost uniformly poor prognoses. The treatments available for patients with disseminated disease are usually not curative and have side effects that limit the therapy that can be given. A treatment that is selectively toxic to tumors would maximize the beneficial effects of therapy and minimize side effects, potentially enabling effective treatment to be administered. Methods and Findings. We postulated that the tumor-tropic property of stem cells or progenitor cells could be exploited to selectively deliver a therapeutic gene to metastatic solid tumors, and that expression of an appropriate transgene at tumor loci might mediate cures of metastatic disease. To test this hypothesis, we injected HB1.F3.C1 cells transduced to express an enzyme that efficiently activates the anti-cancer prodrug CPT-11 intravenously into mice bearing disseminated neuroblastoma tumors. The HB1.F3.C1 cells migrated selectively to tumor sites regardless of the size or anatomical location of the tumors. Mice were then treated systemically with CPT-11, and the efficacy of treatment was monitored. Mice treated with the combination of HB1.F3.C1 cells expressing the CPT-11-activating enzyme and this prodrug produced tumor-free survival of 100% of the mice for >6 months (P < 0.001 compared to control groups). Conclusions. The novel and significant finding of this study is that it may be possible to exploit the tumor-tropic property of stem or progenitor cells to mediate effective, tumor-selective therapy for metastatic tumors, for which no tolerated curative treatments are currently available.	[Aboody, Karen S.; Garcia, Elizabeth; Metz, Marianne Z.; Najbauer, Joseph; Justus, Kristine A.; Gillespie, Shanna; Glackin, Carlotta A.] City Hope Natl Med Ctr, Div Hematol Hematopoiet Cell Transplantat, Duarte, CA 91010 USA; [Aboody, Karen S.; Garcia, Elizabeth; Metz, Marianne Z.; Najbauer, Joseph; Justus, Kristine A.; Gillespie, Shanna; Glackin, Carlotta A.] City Hope Natl Med Ctr, Div Neurosci, Duarte, CA 91010 USA; [Aboody, Karen S.; Garcia, Elizabeth; Metz, Marianne Z.; Najbauer, Joseph; Justus, Kristine A.; Gillespie, Shanna; Glackin, Carlotta A.] City Hope Natl Med Ctr, Dept Profess Educ, Duarte, CA 91010 USA; [Bush, Rebecca A.; Phelps, Doris A.; Remack, Joanna S.; Yoon, Karina Jin; Potter, Philip M.; Danks, Mary K.] St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; [Kim, Seung U.] Univ British Columbia Hosp, Dept Med, Vancouver, BC V6T 1W5, Canada; [Kim, Seung U.] Ajou Univ, Sch Med, Suwon 441749, South Korea	City of Hope; City of Hope; City of Hope; St Jude Children's Research Hospital; University of British Columbia; Ajou University	Aboody, KS (corresponding author), City Hope Natl Med Ctr, Div Hematol Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA.	kaboody@coh.org; mary.danks@stjude.org	Justus, Kristine/GRF-1361-2022; Bush, Rebecca/D-3458-2018; Potter, Philip/J-4515-2013	Bush, Rebecca/0000-0003-0388-5134; Potter, Philip/0000-0001-8922-8535	National Institutes of Health/National Cancer Institute [CA113446, CA79763, CA76202, CA21765]; Stop Cancer Foundation; Phi Beta Psi Sorority; Rosalinde and Arthur Gilbert Foundation; Neidorf Family Foundation; Marcus Foundation; American Lebanese Syrian Associated Charities (ALSAC); NATIONAL CANCER INSTITUTE [P30CA021765, R01CA113446, R01CA076202, R01CA079763] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Stop Cancer Foundation; Phi Beta Psi Sorority; Rosalinde and Arthur Gilbert Foundation; Neidorf Family Foundation; Marcus Foundation; American Lebanese Syrian Associated Charities (ALSAC)(American Lebanese Syrian Associated Charities (ALSAC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health/National Cancer Institute (CA113446, CA79763, CA76202, and CA21765); Stop Cancer Foundation, Phi Beta Psi Sorority, The Rosalinde and Arthur Gilbert Foundation, Neidorf Family Foundation, Marcus Foundation, and American Lebanese Syrian Associated Charities (ALSAC).	Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Aboody KS, 2006, NEURO-ONCOLOGY, V8, P119, DOI 10.1215/15228517-2005-012; Allers C, 2004, TRANSPLANTATION, V78, P503, DOI 10.1097/01.TP.0000128334.93343.B3; Beppu K, 2004, JNCI-J NATL CANCER I, V96, P46, DOI 10.1093/jnci/djh004; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brown AB, 2003, HUM GENE THER, V14, P1777, DOI 10.1089/104303403322611782; Conti Luciano, 2002, Methods Mol Biol, V198, P233; Danks MK, 1998, CANCER RES, V58, P20; Danks MK, 1999, CLIN CANCER RES, V5, P917; Ehtesham M, 2004, NEOPLASIA, V6, P287, DOI 10.1593/neo.03427; Ehtesham M, 2002, CANCER RES, V62, P7170; Ehtesham M, 2002, CANCER RES, V62, P5657; EVANS AE, 1994, MED PEDIATR ONCOL, V23, P323, DOI 10.1002/mpo.2950230402; Fraser SE, 1996, METHOD CELL BIOL, V51, P147, DOI 10.1016/S0091-679X(08)60627-5; Furman WL, 1999, J CLIN ONCOL, V17, P1815, DOI 10.1200/JCO.1999.17.6.1815; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Guemei AA, 2001, CANCER CHEMOTH PHARM, V47, P283, DOI 10.1007/s002800000258; Hung SC, 2005, CLIN CANCER RES, V11, P7749, DOI 10.1158/1078-0432.CCR-05-0876; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jeong SW, 2003, STROKE, V34, P2258, DOI 10.1161/01.STR.0000083698.20199.1F; Kabos P, 2003, EXPERT OPIN BIOL TH, V3, P759; Kim Seung U, 2002, Methods Mol Biol, V198, P55; Kim SK, 2005, CLIN CANCER RES, V11, P5965, DOI 10.1158/1078-0432.CCR-05-0371; Kim SU, 2004, NEUROPATHOLOGY, V24, P159, DOI 10.1111/j.1440-1789.2004.00552.x; Kucia M, 2005, STEM CELLS, V23, P879, DOI 10.1634/stemcells.2004-0342; Martinez-Serrano Alberto, 2001, Current Gene Therapy, V1, P279, DOI 10.2174/1566523013348562; MATTHAY KK, 1994, J CLIN ONCOL, V12, P2382, DOI 10.1200/JCO.1994.12.11.2382; McIntosh K, 2006, STEM CELLS, V24, P1246, DOI 10.1634/stemcells.2005-0235; McKenzie PP, 2003, CANCER RES, V63, P3840; Meng XL, 2003, J NEUROSCI RES, V74, P266, DOI 10.1002/jnr.10764; Morton CL, 2005, CANCER CHEMOTH PHARM, V56, P629, DOI 10.1007/s00280-005-1027-y; Morton CL, 2000, CANCER RES, V60, P4206; Muller FJ, 2006, NAT REV NEUROSCI, V7, P75, DOI 10.1038/nrn1829; Nakamizo A, 2005, CANCER RES, V65, P3307, DOI 10.1158/0008-5472.CAN-04-1874; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ourednik V, 2000, NOVART FDN SYMP, V231, P242, DOI 10.1002/0470870834.ch15; Potter PM, 1998, CANCER RES, V58, P3627; Potter PM, 1998, CANCER RES, V58, P2646; Ryu JK, 2003, J NEUROSCI RES, V72, P352, DOI 10.1002/jnr.10507; Schmidt NO, 2005, NEOPLASIA, V7, P623, DOI 10.1593/neo.04781; Studeny M, 2004, JNCI-J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299; Sun LX, 2004, J CLIN INVEST, V113, P1364, DOI 10.1172/JCI200420001; Thompson J, 2001, CANCER CHEMOTH PHARM, V47, P211, DOI 10.1007/s002800000235; Wagner LM, 2002, CANCER RES, V62, P5001; Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526; Zhou C, 2003, CELL BIOL INT, V27, P943, DOI 10.1016/j.cellbi.2003.08.001	46	110	111	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e23	10.1371/journal.pone.0000023	http://dx.doi.org/10.1371/journal.pone.0000023			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183650	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443600023
J	Calderon, IL; Arenas, FA; Perez, JM; Fuentes, DE; Araya, MA; Saavedra, CP; Tantalean, JC; Pichuantes, SE; Youderian, PA; Vasquez, CC				Calderon, Ivan L.; Arenas, Felipe A.; Perez, Jose Manuel; Fuentes, Derie E.; Araya, Manuel A.; Saavedra, Claudia P.; Tantalean, Juan C.; Pichuantes, Sergio E.; Youderian, Philip A.; Vasquez, Claudio C.			Catalases Are NAD(P)H-Dependent Tellurite Reductases	PLOS ONE			English	Article								Reactive oxygen species damage intracellular targets and are implicated in cancer, genetic disease, mutagenesis, and aging. Catalases are among the key enzymatic defenses against one of the most physiologically abundant reactive oxygen species, hydrogen peroxide. The well-studied, heme-dependent catalases accelerate the rate of the dismutation of peroxide to molecular oxygen and water with near kinetic perfection. Many catalases also bind the cofactors NADPH and NADH tenaciously, but, surprisingly, NAD(P)H is not required for their dismutase activity. Although NAD(P)H protects bovine catalase against oxidative damage by its peroxide substrate, the catalytic role of the nicotinamide cofactor in the function of this enzyme has remained a biochemical mystery to date. Anions formed by heavy metal oxides are among the most highly reactive, natural oxidizing agents. Here, we show that a natural isolate of Staphylococcus epidermidis resistant to tellurite detoxifies this anion thanks to a novel activity of its catalase, and that a subset of both bacterial and mammalian catalases carry out the NAD(P)H-dependent reduction of soluble tellurite ion (TeO32-) to the less toxic, insoluble metal, tellurium (Te degrees), in vitro. An Escherichia coli mutant defective in the KatG catalase/peroxidase is sensitive to tellurite, and expression of the S. epidermidis catalase gene in a heterologous E. coli host confers increased resistance to tellurite as well as to hydrogen peroxide in vivo, arguing that S. epidermidis catalase provides a physiological line of defense against both of these strong oxidizing agents. Kinetic studies reveal that bovine catalase reduces tellurite with a low Michaelis-Menten constant, a result suggesting that tellurite is among the natural substrates of this enzyme. The reduction of tellurite by bovine catalase occurs at the expense of producing the highly reactive superoxide radical.	[Calderon, Ivan L.; Arenas, Felipe A.; Perez, Jose Manuel; Fuentes, Derie E.; Araya, Manuel A.; Vasquez, Claudio C.] Univ Santiago Chile, Fac Quim & Biol, Mol Microbiol Lab, Santiago, Chile; [Saavedra, Claudia P.] Univ Andres Bello, Fac Ciencias Salud, Lab Microbiol Mol & Biotecnol, Santiago, Chile; [Tantalean, Juan C.] Univ San Luis Gonzaga Ica, Fac Ciencias, Lab Microbiol Ind & Biotecnol, Ica, Peru; [Pichuantes, Sergio E.] Chiron Corp, Blood Testing Div, Emeryville, CA 94608 USA; [Youderian, Philip A.] Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Universidad de Santiago de Chile; Universidad Andres Bello; Universidad Nacional San Luis Gonzaga; Novartis; Texas A&M University System; Texas A&M University College Station	Vasquez, CC (corresponding author), Univ Santiago Chile, Fac Quim & Biol, Mol Microbiol Lab, Santiago, Chile.	cvasquez@usach.cl	Pérez-Donoso, José M./G-3668-2013; Fuentes, Derie/GLS-8773-2022	Pérez-Donoso, José M./0000-0002-9506-1716; TANTALEAN, JUAN/0000-0002-9541-7102; Fuentes, Derie/0000-0002-8189-8515	Fondo de Ciencia y Tecnologia Chile [1030234, 1060022]; Direccion de Investigacion, Universidad de Santiago de Chile; National Institutes of Health [GM59336]; Comision Nacional de Ciencia y Tecnologia; Mejoramiento de la Calidad y Equidad de la Educacion Superior project of the government of Chile; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059336] Funding Source: NIH RePORTER	Fondo de Ciencia y Tecnologia Chile; Direccion de Investigacion, Universidad de Santiago de Chile; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Comision Nacional de Ciencia y Tecnologia; Mejoramiento de la Calidad y Equidad de la Educacion Superior project of the government of Chile; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from Fondo de Ciencia y Tecnologia Chile (#1030234 and #1060022) and from the Direccion de Investigacion, Universidad de Santiago de Chile to C. C. V. and by National Institutes of Health grant GM59336 to P. Y. Doctoral fellowships have been awarded to I. L. C. from the Comision Nacional de Ciencia y Tecnologia, and to D. E. F. and J. M. P. from the Mejoramiento de la Calidad y Equidad de la Educacion Superior project of the government of Chile.	AEBI H, 1960, B SOC CHIM BIOL, V42, P187; Avazeri C, 1997, MICROBIOL-SGM, V143, P1181, DOI 10.1099/00221287-143-4-1181; CHIONG M, 1988, J BACTERIOL, V170, P3269, DOI 10.1128/jb.170.7.3269-3273.1988; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; DU SH, 1983, ENVIRON EXP BOT, V23, P347, DOI 10.1016/0098-8472(83)90009-6; FITA I, 1985, P NATL ACAD SCI USA, V82, P1604, DOI 10.1073/pnas.82.6.1604; Fuentes DE, 2005, RES MICROBIOL, V156, P472, DOI 10.1016/j.resmic.2005.01.002; Gaetani GF, 2005, BIOCHEM J, V385, P763, DOI 10.1042/BJ20041495; Gill SR, 2005, J BACTERIOL, V187, P2426, DOI 10.1128/JB.187.7.2426-2438.2005; GREGORY EM, 1974, ANAL BIOCHEM, V58, P57, DOI 10.1016/0003-2697(74)90440-0; Grotti M, 2004, ANN CHIM-ROME, V94, P1, DOI 10.1002/adic.200490011; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HASSAN HM, 1978, J BIOL CHEM, V253, P6445; HEYM B, 1993, J BACTERIOL, V175, P4255, DOI 10.1128/JB.175.13.4255-4259.1993; KEILIN D, 1945, BIOCHEM J, V39, P293, DOI 10.1042/bj0390293; Kim HY, 2005, PLOS BIOL, V3, P2080, DOI 10.1371/journal.pbio.0030375; Kirkman HN, 1999, J BIOL CHEM, V274, P13908, DOI 10.1074/jbc.274.20.13908; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; KIRKMAN HN, 1987, J BIOL CHEM, V262, P660; Klotz MG, 2003, MOL BIOL EVOL, V20, P1098, DOI 10.1093/molbev/msg129; Klotz MG, 1997, MOL BIOL EVOL, V14, P951, DOI 10.1093/oxfordjournals.molbev.a025838; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDINOIS OM, 1995, FREE RADICAL RES, V22, P251, DOI 10.3109/10715769509147544; LEOW O, 1900, REPT US DEP AGR DIV, V65, P5; Lithgow JK, 2004, J BACTERIOL, V186, P1579, DOI 10.1128/JB.186.6.1579-1590.2004; Lohmeier-Vogel EM, 2004, APPL ENVIRON MICROB, V70, P7342, DOI 10.1128/AEM.70.12.7342-7347.2004; MAGOS L, 1978, BIOCHEM PHARMACOL, V27, P1373, DOI 10.1016/0006-2952(78)90122-3; Mao SZ, 2005, J AM CHEM SOC, V127, P11588, DOI 10.1021/ja052451v; MCCORD JM, 1969, J BIOL CHEM, V244, P6056; MOORE MD, 1992, J BACTERIOL, V174, P1505, DOI 10.1128/jb.174.5.1505-1514.1992; Moscoso H, 1998, RES MICROBIOL, V149, P389, DOI 10.1016/S0923-2508(98)80321-5; Nicholls P., 1963, ENZYMES, V8, P147; OGara JP, 1997, APPL ENVIRON MICROB, V63, P4713, DOI 10.1128/AEM.63.12.4713-4720.1997; OGATA M, 1983, PHYSIOL CHEM PHYS, V15, P89; OSHINO N, 1973, BIOCHEM J, V131, P555, DOI 10.1042/bj1310555; Peskin AV, 2000, CLIN CHIM ACTA, V293, P157, DOI 10.1016/S0009-8981(99)00246-6; Singh R, 2004, J BIOL CHEM, V279, P43098, DOI 10.1074/jbc.M406374200; Smith T, 1998, APPL ENVIRON MICROB, V64, P1328; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMMERS AO, 1977, J BACTERIOL, V129, P276, DOI 10.1128/JB.129.1.276-281.1977; Sumner JB, 1937, J BIOL CHEM, V121, P417; Tantalean JC, 2003, J BACTERIOL, V185, P5831, DOI 10.1128/JB.185.19.5831-5837.2003; Taylor DE, 1999, TRENDS MICROBIOL, V7, P111, DOI 10.1016/S0966-842X(99)01454-7; TAYLOR DE, 1988, J ULTRA MOL STRUCT R, V99, P18, DOI 10.1016/0889-1605(88)90029-8; Trutko SM, 1998, DOKL AKAD NAUK+, V358, P836; TUCKER FL, 1966, J BACTERIOL, V92, P1311, DOI 10.1128/JB.92.5.1311-1314.1966; Turner RJ, 1999, MICROBIOL-UK, V145, P2549, DOI 10.1099/00221287-145-9-2549; Turner RJ, 1995, MICROBIOL-UK, V141, P3133, DOI 10.1099/13500872-141-12-3133; VANITERSON W, 1964, J CELL BIOL, V20, P377, DOI 10.1083/jcb.20.3.377; VANITERSON W, 1964, J CELL BIOL, V20, P361, DOI 10.1083/jcb.20.3.361; Vasquez CC, 2001, CURR MICROBIOL, V43, P418, DOI 10.1007/s002840010331; WALTER EG, 1992, PLASMID, V27, P52, DOI 10.1016/0147-619X(92)90006-V; WOODBURY W, 1971, ANAL BIOCHEM, V44, P301, DOI 10.1016/0003-2697(71)90375-7; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; Zhang YQ, 2003, MOL MICROBIOL, V49, P1577, DOI 10.1046/j.1365-2958.2003.03671.x	55	69	69	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e70	10.1371/journal.pone.0000070	http://dx.doi.org/10.1371/journal.pone.0000070			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183702	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600070
J	Li, J; McClure, SM; King-Casas, B; Montague, PR				Li, Jian; McClure, Samuel M.; King-Casas, Brooks; Montague, P. Read			Policy Adjustment in a Dynamic Economic Game	PLOS ONE			English	Article							TEMPORAL DIFFERENCE MODELS; PREFRONTAL CORTEX; DECISION-MAKING; BRAIN-REGIONS; NEURAL BASIS; SYSTEMS; PREDICTION; RESPONSES; DOPAMINE; ACTIVATION	Making sequential decisions to harvest rewards is a notoriously difficult problem. One difficulty is that the real world is not stationary and the reward expected from a contemplated action may depend in complex ways on the history of an animal's choices. Previous functional neuroimaging work combined with principled models has detected brain responses that correlate with computations thought to guide simple learning and action choice. Those works generally employed instrumental conditioning tasks with fixed action-reward contingencies. For real-world learning problems, the history of reward-harvesting choices can change the likelihood of rewards collected by the same choices in the near-term future. We used functional MRI to probe brain and behavioral responses in a continuous decision-making task where reward contingency is a function of both a subject's immediate choice and his choice history. In these more complex tasks, we demonstrated that a simple actor-critic model can account for both the subjects' behavioral and brain responses, and identified a reward prediction error signal in ventral striatal structures active during these non-stationary decision tasks. However, a sudden introduction of new reward structures engages more complex control circuitry in the prefrontal cortex ( inferior frontal gyrus and anterior insula) and is not captured by a simple actor-critic model. Taken together, these results extend our knowledge of reward-learning signals into more complex, history-dependent choice tasks. They also highlight the important interplay between striatum and prefrontal cortex as decision-makers respond to the strategic demands imposed by non-stationary reward environments more reminiscent of real-world tasks.	[Li, Jian; McClure, Samuel M.; King-Casas, Brooks; Montague, P. Read] Baylor Coll Med, Dept Neurosci, Ctr Theoret Neurosci, Human Neuroimaging Lab, Houston, TX 77030 USA; [Montague, P. Read] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Montague, PR (corresponding author), Baylor Coll Med, Dept Neurosci, Ctr Theoret Neurosci, Human Neuroimaging Lab, Houston, TX 77030 USA.	read@bcm.tmc.edu			Kane Family Foundation [NS-045790]; NIDA [DA-11723]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011723] Funding Source: NIH RePORTER	Kane Family Foundation; NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was funded by the Kane Family Foundation (P. R. M.), NINDS grant NS-045790 (P. R. M.) and NIDA grant DA-11723 (P. R. M.).	Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Balleine BW, 1998, NEUROPHARMACOLOGY, V37, P407, DOI 10.1016/S0028-3908(98)00033-1; Berns GS, 1997, SCIENCE, V276, P1272, DOI 10.1126/science.276.5316.1272; Berns GS, 2001, J NEUROSCI, V21, P2793, DOI 10.1523/JNEUROSCI.21-08-02793.2001; Buchel C, 1998, NEURON, V20, P947, DOI 10.1016/S0896-6273(00)80476-6; Clayton EC, 2004, J NEUROSCI, V24, P9914, DOI 10.1523/JNEUROSCI.2446-04.2004; COASE RH, 1960, J LAW ECON, V3, P1, DOI 10.1086/466560; Cools R, 2004, J NEUROSCI, V24, P1129, DOI 10.1523/JNEUROSCI.4312-03.2004; Daw ND, 2006, NATURE, V441, P876, DOI 10.1038/nature04766; Daw ND, 2005, NAT NEUROSCI, V8, P1704, DOI 10.1038/nn1560; EAGLEMAN DM, 1998, J COGNITIVE NEUROSCI, V10, P623; Elliott R, 2000, J NEUROSCI, V20, P6159, DOI 10.1523/JNEUROSCI.20-16-06159.2000; Frank MJ, 2004, SCIENCE, V306, P1940, DOI 10.1126/science.1102941; Friston K. J., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402; Galvan A, 2005, J NEUROSCI, V25, P8650, DOI 10.1523/JNEUROSCI.2431-05.2005; Glascher J, 2005, NEURON, V47, P295, DOI 10.1016/j.neuron.2005.06.008; Gray JR, 2004, CURR DIR PSYCHOL SCI, V13, P46, DOI 10.1111/j.0963-7214.2004.00272.x; Greene JD, 2001, SCIENCE, V293, P2105, DOI 10.1126/science.1062872; Haruno M, 2004, J NEUROSCI, V24, P1660, DOI 10.1523/JNEUROSCI.3417-03.2004; Herrnstein R.J., 1982, QUANTITATIVE ANAL BE, VII, P433; HERRNSTEIN RJ, 1990, AM PSYCHOL, V45, P356; HERRNSTEIN RJ, 1991, J ECON PERSPECT, V5, P137, DOI 10.1257/jep.5.3.137; Kawagoe R, 2004, J NEUROPHYSIOL, V91, P1013, DOI 10.1152/jn.00721.2003; Knutson B, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0002.2001; Koechlin E, 1999, NATURE, V399, P148, DOI 10.1038/20178; McClure SM, 2003, NEURON, V38, P339, DOI 10.1016/S0896-6273(03)00154-5; McClure SM, 2004, SCIENCE, V306, P503, DOI 10.1126/science.1100907; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Montague PR, 2002, NEURON, V36, P265, DOI 10.1016/S0896-6273(02)00974-1; Montague PR, 2004, NATURE, V431, P760, DOI 10.1038/nature03015; Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996; O'Doherty J, 2003, J NEUROSCI, V23, P7931; O'Doherty J, 2004, SCIENCE, V304, P452, DOI 10.1126/science.1094285; O'Doherty JP, 2003, NEURON, V38, P329, DOI 10.1016/S0896-6273(03)00169-7; Pasupathy A, 2005, NATURE, V433, P873, DOI 10.1038/nature03287; Paulus MP, 2005, NEUROIMAGE, V25, P607, DOI 10.1016/j.neuroimage.2004.12.055; Price CJ, 1997, NEUROIMAGE, V5, P261, DOI 10.1006/nimg.1997.0269; Rescorla R., 1972, CLASSICAL CONDITION, DOI DOI 10.1101/GR.110528.110; Reynolds JNJ, 2001, NATURE, V413, P67, DOI 10.1038/35092560; Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976; Schmitz C, 2005, J NEUROPHYSIOL, V93, P1498, DOI 10.1152/jn.00230.2004; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Seymour B, 2004, NATURE, V429, P664, DOI 10.1038/nature02581; Stephens DW, 1987, FORAGING THEORY; Tanaka SC, 2004, NAT NEUROSCI, V7, P887, DOI 10.1038/nn1279; Tricomi EM, 2004, NEURON, V41, P281, DOI 10.1016/S0896-6273(03)00848-1; Wicker B, 2003, NEURON, V40, P655, DOI 10.1016/S0896-6273(03)00679-2; Yu AJ, 2002, NEURAL NETWORKS, V15, P719, DOI 10.1016/S0893-6080(02)00058-8; Zink CF, 2004, NEURON, V42, P509, DOI 10.1016/S0896-6273(04)00183-7	50	46	46	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e103	10.1371/journal.pone.0000103	http://dx.doi.org/10.1371/journal.pone.0000103			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183636	Green Published, gold			2022-12-25	WOS:000207443600102
J	Reddy, JV; Ganley, IG; Pfeffer, SR				Reddy, Jonathan V.; Ganley, Ian G.; Pfeffer, Suzanne R.			Clues to Neuro-Degeneration in Niemann-Pick Type C Disease from Global Gene Expression Profiling	PLOS ONE			English	Article								Background. Niemann-Pick Type C (NPC) disease is a neurodegenerative disease that is characterized by the accumulation of cholesterol and glycosphingolipids in the late endocytic pathway. The majority of NPC cases are due to mutations in the NPC1 gene. The precise function of this gene is not yet known. Methodology/Principal Findings. Using cDNA microarrays, we analyzed the genome-wide expression patterns of human fibroblasts homozygous for the I1061T NPC1 mutation that is characterized by a severe defect in the intracellular processing of low density lipoprotein-derived cholesterol. A distinct gene expression profile was identified in NPC fibroblasts from different individuals when compared with fibroblasts isolated from normal subjects. As expected, NPC1 mutant cells displayed an inappropriate homeostatic response to accumulated intracellular cholesterol. In addition, a number of striking parallels were observed between NPC disease and Alzheimer's disease. Conclusions/Significance. Many genes involved in the trafficking and processing of amyloid precursor protein and the microtubule binding protein, tau, were more highly expressed. Numerous genes important for membrane traffic and the cellular regulation of calcium, metals and other ions were upregulated. Finally, NPC fibroblasts exhibited a gene expression profile indicative of oxidative stress. These changes are likely contributors to the pathophysiology of Niemann-Pick Type C disease.	[Reddy, Jonathan V.; Ganley, Ian G.; Pfeffer, Suzanne R.] Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA	Stanford University	Pfeffer, SR (corresponding author), Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA.	pfeffer@stanford.edu		Ganley, Ian/0000-0003-1481-9407	Ara Parseghian Medical Research Foundation; NIH [DK37332]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037332, R37DK037332] Funding Source: NIH RePORTER	Ara Parseghian Medical Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Ara Parseghian Medical Research Foundation and the NIH (DK37332).	Abe-Dohmae S, 2004, J BIOL CHEM, V279, P604, DOI 10.1074/jbc.M309888200; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Appelt DM, 1997, BRAIN RES, V745, P21, DOI 10.1016/S0006-8993(96)01121-3; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; AUER IA, 1995, ACTA NEUROPATHOL, V90, P547; Blom TS, 2003, HUM MOL GENET, V12, P257, DOI 10.1093/hmg/ddg025; BRION JP, 1991, BRAIN RES, V539, P143, DOI 10.1016/0006-8993(91)90697-T; Burns M, 2003, J NEUROSCI, V23, P5645; Cam JA, 2005, J BIOL CHEM, V280, P15464, DOI 10.1074/jbc.M500613200; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Chang Y, 2003, J BIOL CHEM, V278, P51100, DOI 10.1074/jbc.M309561200; Chinopoulos C, 2006, FEBS J, V273, P433, DOI 10.1111/j.1742-4658.2005.05103.x; Choi HY, 2003, J BIOL CHEM, V278, P32569, DOI 10.1074/jbc.M304553200; CORREAS I, 1992, J BIOL CHEM, V267, P15721; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ekinci FJ, 1999, J BIOL CHEM, V274, P30322, DOI 10.1074/jbc.274.42.30322; Frolov A, 2003, J BIOL CHEM, V278, P25517, DOI 10.1074/jbc.M302588200; Ganley IG, 2006, J BIOL CHEM, V281, P17890, DOI 10.1074/jbc.M601679200; Grimm MOW, 2005, NAT CELL BIOL, V7, P1118, DOI 10.1038/ncb1313; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Hook V, 2005, BIOL CHEM, V386, P931, DOI 10.1515/BC.2005.108; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Jeyakumar Mylvaganam, 2005, Nat Rev Neurosci, V6, P713; Jin LW, 2004, AM J PATHOL, V164, P975, DOI 10.1016/S0002-9440(10)63185-9; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Klein William L, 2006, Alzheimers Dement, V2, P43, DOI 10.1016/j.jalz.2005.11.003; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Li W, 2004, BIOESSAYS, V26, P616, DOI 10.1002/bies.20042; LISCUM L, 1987, J BIOL CHEM, V262, P17002; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Martin V, 2001, CURR BIOL, V11, P601, DOI 10.1016/S0960-9822(01)00178-6; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Maxfield FR, 2005, NATURE, V438, P612, DOI 10.1038/nature04399; Millat G, 1999, AM J HUM GENET, V65, P1321, DOI 10.1086/302626; Muresan Z, 2005, J CELL BIOL, V171, P615, DOI 10.1083/jcb.200502043; Ohgami N, 2004, P NATL ACAD SCI USA, V101, P12473, DOI 10.1073/pnas.0405255101; Olkkonen VM, 2004, BIOCHEM CELL BIOL, V82, P87, DOI 10.1139/o03-088; Park WD, 2003, HUM MUTAT, V22, P313, DOI 10.1002/humu.10255; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Runz H, 2002, J NEUROSCI, V22, P1679, DOI 10.1523/JNEUROSCI.22-05-01679.2002; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Sherlock G, 2001, NUCLEIC ACIDS RES, V29, P152, DOI 10.1093/nar/29.1.152; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Strutt H, 2001, CURR BIOL, V11, P608, DOI 10.1016/S0960-9822(01)00179-8; Sturley SL, 2004, BBA-MOL CELL BIOL L, V1685, P83, DOI 10.1016/j.bbalip.2004.08.014; Tomizawa K, 2001, FEBS LETT, V492, P221, DOI 10.1016/S0014-5793(01)02256-6; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Twig G, 2005, AM J PHYSIOL-CELL PH, V288, pC169, DOI 10.1152/ajpcell.00308.2004; Ueda K, 1997, J NEUROCHEM, V68, P265; Vanier MT, 2003, CLIN GENET, V64, P269, DOI 10.1034/j.1399-0004.2003.00147.x; Yamazaki T, 2001, J BIOL CHEM, V276, P4454, DOI 10.1074/jbc.M009598200; Yang LS, 1999, J NEUROSCI RES, V55, P36, DOI 10.1002/(SICI)1097-4547(19990101)55:1<36::AID-JNR5>3.3.CO;2-5; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898	60	88	92	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e19	10.1371/journal.pone.0000019	http://dx.doi.org/10.1371/journal.pone.0000019			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183645	gold, Green Published, Green Submitted			2022-12-25	WOS:000207443600019
J	Rota, J; Wagner, DL				Rota, Jadranka; Wagner, David L.			Predator Mimicry: Metalmark Moths Mimic Their Jumping Spider Predators	PLOS ONE			English	Article							EVASIVE MIMICRY; ARANEAE; SALTICIDAE; HOMOPTERA	Cases of mimicry provide many of the nature's most convincing examples of natural selection. Here we report evidence for a case of predator mimicry in which metalmark moths in the genus Brenthia mimic jumping spiders, one of their predators. In controlled trials, Brenthia had higher survival rates than other similarly sized moths in the presence of jumping spiders and jumping spiders responded to Brenthia with territorial displays, indicating that Brenthia were sometimes mistaken for jumping spiders, and not recognized as prey. Our experimental results and a review of wing patterns of other insects indicate that jumping spider mimicry is more widespread than heretofore appreciated, and that jumping spiders are probably an important selective pressure shaping the evolution of diurnal insects that perch on vegetation.	[Rota, Jadranka; Wagner, David L.] Univ Connecticut, Dept Ecol & Evolutionary Biol, Storrs, CT 06269 USA	University of Connecticut	Rota, J (corresponding author), Univ Connecticut, Dept Ecol & Evolutionary Biol, Storrs, CT 06269 USA.	jadranka.rota@uconn.edu	Rota, Jadranka/C-6702-2011	Rota, Jadranka/0000-0003-0220-3920	Organization for Tropical Studies/Thompson Fellowship; University of Connecticut's Center for Conservation and Biodiversity Award; University of Connecticut Department of Ecology and Evolutionary Biology's/Connecticut State Natural History Museum's DeCoursey, Penner	Organization for Tropical Studies/Thompson Fellowship; University of Connecticut's Center for Conservation and Biodiversity Award; University of Connecticut Department of Ecology and Evolutionary Biology's/Connecticut State Natural History Museum's DeCoursey, Penner	Funding: This work was supported with the following awards to J. R.: Organization for Tropical Studies/Thompson Fellowship, University of Connecticut's Center for Conservation and Biodiversity Award, and three separate stipends from the University of Connecticut Department of Ecology and Evolutionary Biology's/Connecticut State Natural History Museum's DeCoursey, Penner, and Slater endowments.	Aiello Annette, 2004, Journal of the Lepidopterists' Society, V58, P55; Akino T, 1999, P ROY SOC B-BIOL SCI, V266, P1419, DOI 10.1098/rspb.1999.0796; Balgooyen TG, 1997, AM MIDL NAT, V137, P183, DOI 10.2307/2426768; Bates HW., 1862, T LINN SOC LOND, V23, P495, DOI [DOI 10.1111/J.1096-3642.1860.TB00146.X, 10.1111/j.1096-3642.1860.tb00146.x]; Clemens B., 1860, P ACAD NAT SCI PHILA, V12; Floren A, 2001, ECOTROPICA, V7, P33; GREENE E, 1987, SCIENCE, V236, P310, DOI 10.1126/science.236.4799.310; Harland DP, 1999, J ZOOL, V247, P357, DOI 10.1111/j.1469-7998.1999.tb00998.x; Jackson R.R., 1982, P213; Jackson RR, 1996, ANNU REV ENTOMOL, V41, P287, DOI 10.1146/annurev.en.41.010196.001443; LINDROTH C H, 1971, Entomologica Scandinavica, V2, P41; LLOYD JE, 1965, SCIENCE, V149, P653, DOI 10.1126/science.149.3684.653; MATHER MH, 1987, SCIENCE, V236, P308, DOI 10.1126/science.236.4799.308; MCIVER JD, 1993, ANNU REV ENTOMOL, V38, P351, DOI 10.1146/annurev.en.38.010193.002031; MULLER F., 1879, T ENTOMOL SOC LOND, V1879, pxx; Nelson XJ, 2005, J ARACHNOL, V33, P813, DOI 10.1636/S04-12.1; OBRIEN LB, 1967, PAN-PAC ENTOMOL, V43, P130; Owen D., 1980, CAMOUFLAGE MIMICRY; PERRONE M, 1981, CONDOR, V83, P383, DOI 10.2307/1367512; RETTENMEYER CW, 1970, ANNU REV ENTOMOL, V15, P43, DOI 10.1146/annurev.en.15.010170.000355; Ruxton GD, 2004, P ROY SOC B-BIOL SCI, V271, P2135, DOI 10.1098/rspb.2004.2816; Sokal RR, BIOMETRY PRINCIPLES; Stevens M, 2005, BIOL REV, V80, P573, DOI 10.1017/S1464793105006810; WELLS MS, 1988, ANIM BEHAV, V36, P321, DOI 10.1016/S0003-3472(88)80001-0; WHITMAN DW, 1988, ANN ENTOMOL SOC AM, V81, P532, DOI 10.1093/aesa/81.3.532; ZARET TM, 1977, EVOLUTION, V31, P421, DOI 10.1111/j.1558-5646.1977.tb01022.x; ZOLNEROWICH G, 1992, J NEW YORK ENTOMOL S, V100, P498	27	32	36	2	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e45	10.1371/journal.pone.0000045	http://dx.doi.org/10.1371/journal.pone.0000045			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183674	gold, Green Submitted, Green Published			2022-12-25	WOS:000207443600045
J	Goytain, A; Hines, RM; El-Husseini, A; Quamme, GA				Goytain, Angela; Hines, Rochelle M.; El-Husseini, Alaa; Quamme, Gary A.			NIPA1(SPG6), the basis for autosomal dominant form of hereditary spastic paraplegia, encodes a functional Mg2+ transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRADER-WILLI-SYNDROME; IDENTIFICATION; DELETION; FAMILY; GENES	Mutations in the NIPA1(SPG6) gene, named for "nonimprinted in Prader-Willi/Angelman" has been implicated in one form of autosomal dominant hereditary spastic paraplegia (HSP), a neurodegenerative disorder characterized by progressive lower limb spasticity and weakness. However, the function of NIPA1 is unknown. Here, we show that reduced magnesium concentration enhances expression of NIPA1 suggesting a role in cellular magnesium metabolism. Indeed NIPA1 mediates Mg2+ uptake that is electrogenic, voltage-dependent, and saturable with a Michaelis constant of 0.69 +/- 0.21 mm when expressed in Xenopus oocytes. Subcellular localization with immunofluorescence showed that endogenous NIPA1 protein associates with early endosomes and the cell surface in a variety of neuronal and epithelial cells. As expected of a magnesium-responsive gene, we find that altered magnesium concentration leads to a redistribution between the endosomal compartment and the plasma membrane; high magnesium results in diminished cell surface NIPA1 whereas low magnesium leads to accumulation in early endosomes and recruitment to the plasma membrane. The mouse NIPA1 mutants, T39R and G100R, corresponding to the respective human mutants showed a loss-of-function when expressed in oocytes and altered trafficking in transfected COS7 cells. We conclude that NIPA1 normally encodes a Mg2+ transporter and the loss-of function of NIPA1(SPG6) due to abnormal trafficking of the mutated protein provides the basis of the HSP phenotype.	Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Quamme, GA (corresponding author), Univ British Columbia, Dept Med, Koerner Pavil,2211 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	quamme@interchange.ubc.ca	Hines, Rochelle/AAE-3784-2020	Hines, Rochelle/0000-0002-0459-7911				Butler MG, 2004, PEDIATRICS, V113, P565, DOI 10.1542/peds.113.3.565; BUTLER MG, 1990, AM J MED GENET, V35, P319, DOI 10.1002/ajmg.1320350306; Chai JH, 2003, AM J HUM GENET, V73, P898, DOI 10.1086/378816; Chen SQ, 2005, HUM MUTAT, V25, P135, DOI 10.1002/humu.20126; DAI LJ, 1991, J CLIN INVEST, V88, P1255, DOI 10.1172/JCI115429; Dai LJ, 2001, PHYSIOL REV, V81, P51, DOI 10.1152/physrev.2001.81.1.51; FINK JK, 1995, NEUROLOGY, V45, P325, DOI 10.1212/WNL.45.2.325; FINK JK, 1995, AM J HUM GENET, V56, P188; Fink JK, 2003, ARCH NEUROL-CHICAGO, V60, P1045, DOI 10.1001/archneur.60.8.1045; Goytain A, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-48; Hedera P, 2005, NEURORADIOLOGY, V47, P730, DOI 10.1007/s00234-005-1415-3; Kaneko S, 2006, MOVEMENT DISORD, V21, P1531, DOI 10.1002/mds.21005; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Levinson JN, 2005, J BIOL CHEM, V280, P17312, DOI 10.1074/jbc.M413812200; Munhoz RP, 2006, MOVEMENT DISORD, V21, P279, DOI 10.1002/mds.20775; NICHOLLS RD, 1993, P NATL ACAD SCI USA, V90, P2050, DOI 10.1073/pnas.90.5.2050; Nicholls RD, 2001, ANNU REV GENOM HUM G, V2, P153, DOI 10.1146/annurev.genom.2.1.153; Quamme GA, 1997, KIDNEY INT, V52, P1180, DOI 10.1038/ki.1997.443; Rainier S, 2003, AM J HUM GENET, V73, P967, DOI 10.1086/378817; Reed JA, 2005, NEUROGENETICS, V6, P79, DOI 10.1007/s10048-004-0209-9; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHAFIK IM, 1989, AM J PHYSIOL, V257, pF974, DOI 10.1152/ajprenal.1989.257.6.F974; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876	23	96	105	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8060	8068		10.1074/jbc.M610314200	http://dx.doi.org/10.1074/jbc.M610314200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17166836	hybrid			2022-12-25	WOS:000245081000038
J	Kee, HJ; Kim, JR; Nam, KI; Park, HY; Shin, S; Kim, JC; Shimono, Y; Takahashi, M; Jeong, MH; Kim, N; Kim, KK; Kook, H				Kee, Hae Jin; Kim, Ju-Ryoung; Nam, Kwang-Il; Park, Hye Young; Shin, Sera; Kim, Jeong Chul; Shimono, Yohei; Takahashi, Masahide; Jeong, Myung Ho; Kim, Nacksung; Kim, Kyung Keun; Kook, Hyun			Enhancer of polycomb1, a novel homeodomain only protein-binding partner, induces skeletal muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; GENE-EXPRESSION; CARDIAC-HYPERTROPHY; CELL-LINE; MYOGENIN; EZH2; DROSOPHILA; GROWTH; PROLIFERATION; ANGIOGENESIS	Homeodomain only protein, Hop, is an unusual small protein that modulates target gene transcription without direct binding to DNA. Here we show that Hop interacts with Enhancer of Polycomb1 (Epc1), a homolog of a Drosophila polycomb group gene product that regulates transcription, to induce the skeletal muscle differentiation. Yeast two-hybrid assay with the human adult heart cDNA library revealed that Hop can associate with Epc1. The amino-terminal domain of Epc1 as well as full Epc1 physically interacted with Hop in mammalian cells and in yeast. Epc1 is highly expressed in the embryonic heart and adult skeletal muscles. Serum deprivation induced differentiation of H9c2, a myoblast cell line, into skeletal myocytes, and Epc1 was up-regulated. Differentiation of H9c2 was induced by Epc1 overexpression, although it was severely impaired in Epc1-in-knockdown cells. Co-transfection of Hop potentiated Epc1-induced transactivation of myogenin and myotube formation. Hop knock-out mice elicited a decrease in myosin heavy chain and myogenin expressions in skeletal muscle and showed delay in hamstring muscle healing after injury. Differentiation was impaired in skeletal myoblasts from Hop knock-out mice. These results suggest that Epc1 plays a role in the initiation of skeletal muscle differentiation, and its interaction with Hop is required for the full activity.	Chonnam Natl Univ, Sch Med, Dept Pharmacol, Kwangju 501746, South Korea; Chonnam Natl Univ, Sch Med, Med Res Ctr Gene Regulat, Kwangju 501746, South Korea; Chonnam Natl Univ, Sch Med, Res Inst Med Sci, Kwangju 501746, South Korea; Chonnam Natl Univ Hosp, Dept Surg, Kwangju 501746, South Korea; Chonnam Natl Univ, Sch Med, Brain Korea Project 21, Ctr Biomed Human Resources, Kwangju 501746, South Korea; Chonnam Natl Univ Hosp, Ctr Heart, Kwangju 501746, South Korea; Nagoya Univ, Sch Med, Dept Pathol, Nagoya, Aichi 4668550, Japan	Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University Hospital; Chonnam National University; Chonnam National University; Chonnam National University Hospital; Nagoya University	Kook, H (corresponding author), Chonnam Natl Univ, Sch Med, Dept Pharmacol, 5 Hak Dong, Kwangju 501746, South Korea.	kookhyun@chonnam.ac.kr	TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020; Kee, Hae Jin/ABC-9979-2021; Kook, Hyun/AAR-5405-2021; Nam, Kwang Il/C-4580-2019	Takahashi, Masahide/0000-0002-2803-2683; Kook, Hyun/0000-0002-0740-1806; Shimono, Yohei/0000-0002-6256-4704; Kee, Hae Jin/0000-0002-9774-4828; Nam, Kwang Il/0000-0001-5380-6815				Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Attwooll C, 2005, J BIOL CHEM, V280, P1199, DOI 10.1074/jbc.M412509200; Biederer CH, 2000, J BIOL CHEM, V275, P26245, DOI 10.1074/jbc.M001430200; Buckingham M, 2003, J ANAT, V202, P59, DOI 10.1046/j.1469-7580.2003.00139.x; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Davis FJ, 2005, AM J PHYSIOL-HEART C, V288, pH1477, DOI 10.1152/ajpheart.00789.2004; Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300; HAYES PH, 1984, P NATL ACAD SCI-BIOL, V81, P545, DOI 10.1073/pnas.81.2.545; HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Kashour T, 2003, J MOL CELL CARDIOL, V35, P937, DOI 10.1016/S0022-2828(03)00176-7; Kee HJ, 2006, CIRCULATION, V113, P51, DOI 10.1161/CIRCULATIONAHA.105.559724; Kee HJ, 2004, FEBS LETT, V569, P307, DOI 10.1016/j.febslet.2004.06.011; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; Koh JT, 2004, EXP CELL RES, V294, P172, DOI 10.1016/j.yexcr.2003.11.008; Kook H, 2003, J CLIN INVEST, V112, P863, DOI 10.1172/JCI200319137; L'Ecuyer T, 2001, MOL GENET METAB, V74, P370, DOI 10.1006/mgme.2001.3243; Li SJ, 2005, P NATL ACAD SCI USA, V102, P1082, DOI 10.1073/pnas.0409103102; Lindon C, 2001, DEV BIOL, V240, P574, DOI 10.1006/dbio.2001.0435; Menard C, 1999, J BIOL CHEM, V274, P29063, DOI 10.1074/jbc.274.41.29063; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Movassagh M, 2006, J PHARM PHARMACOL, V58, P73, DOI 10.1211/jpp.58.1.0009; Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0; Perry J, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-6; Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047; RAWLS A, 1995, DEV BIOL, V172, P37, DOI 10.1006/dbio.1995.0004; Saramaki OR, 2006, GENE CHROMOSOME CANC, V45, P639, DOI 10.1002/gcc.20327; SATO T, 1985, DEV BIOL, V110, P53, DOI 10.1016/0012-1606(85)90063-6; Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; Shirai M, 2002, J CLIN INVEST, V110, P177, DOI 10.1172/JCI200214839; Stankunas K, 1998, DEVELOPMENT, V125, P4055; Takahashi T, 2003, GENE THER, V10, P612, DOI 10.1038/sj.gt.3301900; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	35	54	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7700	7709		10.1074/jbc.M611198200	http://dx.doi.org/10.1074/jbc.M611198200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17192267	hybrid			2022-12-25	WOS:000245080900082
J	Uemoto, Y; Suzuki, SI; Terada, N; Ohno, N; Ohno, S; Yamanaka, S; Komada, M				Uemoto, Yoko; Suzuki, So-ichiro; Terada, Nobuo; Ohno, Nobuhiko; Ohno, Shinichi; Yamanaka, Shinya; Komada, Masayuki			Specific role of the truncated beta IV-spectrin Sigma 6 in sodium channel clustering at axon initial segments and nodes of Ranvier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN-G; PROTEIN; SITE; DOMAINS; BINDING; CELLS; CDNA	At axon initial segments and nodes of Ranvier in neurons, the spectrin membrane skeleton plays roles in physically stabilizing the plasma membrane integrity and in clustering voltage-gated sodium channels for proper conduction of the action potential. beta IV-Spectrin, an essential component of the membrane skeleton at these sites, has an N-terminal-truncated isoform, 16, which is expressed at much higher levels than the full-length isoform Sigma 1. To investigate the role of beta IV-spectrin Sigma 6, we generated Sigma 1-deficient mice with a normal level of Sigma 6 expression (Sigma 1(-/-) mice), and compared their phenotypes with those of previously generated mice lacking both Sigma 1 and Sigma 6 (Sigma 1 Sigma 6(-/-) mice). The gross neurological defects observed in Sigma 1 Sigma 6(-/-) mice, such as hindleg contraction, were apparently ameliorated in Sigma 1(-/-) mice. At cellular levels, Sigma 1 Sigma 6(-/-) and Sigma 1(-/-) neurons similarly exhibited waving and swelling of the plasma membrane at axon initial segments and nodes of Ranvier. By contrast, the levels of ankyrin G and voltage-gated sodium channels at these sites, which are significantly reduced in Sigma 1 Sigma 6(-/-) mice, were substantially recovered in Sigma 1(-/-) mice. We conclude that the truncated beta IV-spectrin isoform Sigma 6 plays a specific role in clustering voltage-gated sodium channels, whereas it is dispensable for membrane stabilization at axon initial segments and nodes of Ranvier.	Tokyo Inst Technol, Dept Biol Sci, Yokohama, Kanagawa 2268501, Japan; Univ Yamanashi, Dept Anat, Interdisciplinary Grad Sch Med & Engn, Yamanashi 4093898, Japan; Kyoto Univ, Ints Frontier Med Sci, Dept Stem Cell Biol, Kyoto 6068507, Japan	Tokyo Institute of Technology; University of Yamanashi; Kyoto University	Komada, M (corresponding author), 4259-B-16 Nagatsuta,Midori Ku, Yokohama, Kanagawa 2268501, Japan.	makomada@bio.titech.ac.jp						Ango F, 2004, CELL, V119, P257, DOI 10.1016/j.cell.2004.10.004; Arroyo EJ, 2000, HISTOCHEM CELL BIOL, V113, P1, DOI 10.1007/s004180050001; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bennett V, 1999, J NEUROCYTOL, V28, P303, DOI 10.1023/A:1007005528505; Berghs S, 2000, J CELL BIOL, V151, P985, DOI 10.1083/jcb.151.5.985; Caldwell JH, 2000, P NATL ACAD SCI USA, V97, P5616, DOI 10.1073/pnas.090034797; DELAUNAY J, 2006, IN PRESS BLOOD REV; HU RJ, 1995, J CELL BIOL, V128, P1069, DOI 10.1083/jcb.128.6.1069; Jenkins SM, 2002, P NATL ACAD SCI USA, V99, P2303, DOI 10.1073/pnas.042601799; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KENNEDY SP, 1994, J BIOL CHEM, V269, P11400; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Lacas-Gervais S, 2004, J CELL BIOL, V166, P983, DOI 10.1083/jcb.200408007; Parkinson NJ, 2001, NAT GENET, V29, P61, DOI 10.1038/ng710; Peles E, 2000, CURR OPIN NEUROBIOL, V10, P558, DOI 10.1016/S0959-4388(00)00122-7; Rasband MN, 2001, DEV BIOL, V236, P5, DOI 10.1006/dbio.2001.0326; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Tse WT, 2001, J BIOL CHEM, V276, P23974, DOI 10.1074/jbc.M009307200; Ursitti JA, 1996, J BIOL CHEM, V271, P6636, DOI 10.1074/jbc.271.12.6636; VIEL A, 1994, P NATL ACAD SCI USA, V91, P10839, DOI 10.1073/pnas.91.23.10839; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; Yang Y, 2004, J NEUROSCI, V24, P7230, DOI 10.1523/JNEUROSCI.2125-04.2004	28	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6548	6555		10.1074/jbc.M609223200	http://dx.doi.org/10.1074/jbc.M609223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17197442	hybrid			2022-12-25	WOS:000244867200063
J	Liang, FB; Liang, J; Wang, WQ; Sun, AP; Udho, E; Zhang, ZY				Liang, Fubo; Liang, Jiao; Wang, Wei-Qing; Sun, An-Peng; Udho, Eshwar; Zhang, Zhong-Yin			PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; COLORECTAL-CANCER; MOLECULAR TARGETS; CARCINOMA CELLS; KINASE-ACTIVITY; IN-VIVO; C-SRC; METASTASIS; EXPRESSION; MIGRATION	Phosphatase of regenerating liver 3 (PRL3) is overexpressed in a variety of tumors, and high levels of PRL3 expression are associated with tumorigenesis and metastasis. Consistent with an oncogenic role for PRL3, we show that ectopic PRL3 expression promotes cell proliferation and invasion. However, little is known about the molecular basis for PRL3 function. Obtaining this knowledge is vital for understanding PRL3-mediated disease processes and for the development of novel anticancer therapies targeted to PRL3. Here we report that up-regulation of PRL3 activates the Src kinase, which initiates a number of signal pathways culminating in the phosphorylation of ERK1/2, STAT3, and p130(Cas). The activation of these pathways likely contributes to the increased cell growth and motility of PRL3 cells. We provide evidence that PRL3 induces Src activation through down-regulation of Csk, a negative regulator of Src. Importantly, Src activation and Csk down-regulation are also observed in colon cancer cells expressing a higher level of PRL3. Thus, we have revealed a biochemical mechanism for the PRL3-mediated cell invasion and proliferation in which elevated PRL3 expression causes a reduction in Csk level, leading to Src activation.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Zhang, ZY (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	zyzhang@iupui.edu	SUN, JINPENG/F-9551-2013		NCI NIH HHS [CA69202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Arena S, 2005, CELL MOL LIFE SCI, V62, P2092, DOI 10.1007/s00018-005-5205-1; Avizienyte E, 2005, CURR OPIN CELL BIOL, V17, P542, DOI 10.1016/j.ceb.2005.08.007; Bardelli A, 2003, CLIN CANCER RES, V9, P5607; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Cam WR, 2001, CANCER, V92, P61, DOI 10.1002/1097-0142(20010701)92:1<61::AID-CNCR1292>3.0.CO;2-D; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; Critchley DR, 2004, BIOCHEM SOC T, V32, P831, DOI 10.1042/BST0320831; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Fiordalisi JJ, 2006, CANCER RES, V66, P3153, DOI 10.1158/0008-5472.CAN-05-3116; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kato H, 2004, CLIN CANCER RES, V10, P7318, DOI 10.1158/1078-0432.CCR-04-0485; Kubens BS, 1998, CANCER LETT, V131, P55, DOI 10.1016/S0304-3835(98)00201-8; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Masaki T, 1999, HEPATOLOGY, V29, P379, DOI 10.1002/hep.510290239; Matter WF, 2001, BIOCHEM BIOPH RES CO, V283, P1061, DOI 10.1006/bbrc.2001.4881; Miskad UA, 2004, PATHOBIOLOGY, V71, P176, DOI 10.1159/000078671; Nakagawa T, 2000, INT J CANCER, V88, P384, DOI 10.1002/1097-0215(20001101)88:3<384::AID-IJC10>3.3.CO;2-2; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Parker BS, 2004, CANCER RES, V64, P7857, DOI 10.1158/0008-5472.CAN-04-1976; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Polato F, 2005, CLIN CANCER RES, V11, P6835, DOI 10.1158/1078-0432.CCR-04-2357; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Rengifo-Cam W, 2004, ONCOGENE, V23, P289, DOI 10.1038/sj.onc.1207041; Rouleau C, 2006, MOL CANCER THER, V5, P219, DOI 10.1158/1535-7163.MCT-05-0289; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sager JA, 2004, CANCER BIOL THER, V3, P952, DOI 10.4161/cbt.3.10.1115; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schwering I, 2003, MOL MED, V9, P85, DOI 10.1007/BF03402041; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Stephens BJ, 2005, MOL CANCER THER, V4, P1653, DOI 10.1158/1535-7163.MCT-05-0248; Wu XP, 2004, AM J PATHOL, V164, P2039, DOI 10.1016/S0002-9440(10)63763-7; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zeng Q, 2003, CANCER RES, V63, P2716; Zeng Q, 1998, BIOCHEM BIOPH RES CO, V244, P421, DOI 10.1006/bbrc.1998.8291; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	45	135	143	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5413	5419		10.1074/jbc.M608940200	http://dx.doi.org/10.1074/jbc.M608940200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17192274	hybrid			2022-12-25	WOS:000244482300036
J	Nogami, K; Shima, M; Matsumoto, T; Nishiya, K; Tanaka, I; Yoshioka, A				Nogami, Keiji; Shima, Midori; Matsumoto, Tomoko; Nishiya, Katsumi; Tanaka, Ichiro; Yoshioka, Akira			Mechanisms of plasmin-catalyzed inactivation of factor VIII - A crucial role for proteolytic cleavage at Arg(336) responsible for plasmin-catalyzed factor VIII inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; VON-WILLEBRAND-FACTOR; INTRINSIC-FACTOR XASE; LIGHT-CHAIN; FACTOR-IXA; VONWILLEBRAND-FACTOR; HEAVY-CHAIN; A2 SUBUNIT; A1 SUBUNIT; FACTOR-V	Plasmin not only functions as a key enzyme in the fibrinolytic system but also directly inactivates factor VIII and other clotting factors such as factor V. However, the mechanisms of plasmin-catalyzed factor VIII inactivation are poorly understood. In this study, levels of factor VIII activity increased similar to 2-fold within 3 min in the presence of plasmin, and subsequently decreased to undetectable levels within 45 min. This time-dependent reaction was not affected by von Willebrand factor and phospholipid. The rate constant of plasmin-catalyzed factor VIIIa inactivation was similar to 12- and similar to 3.7-fold greater than those mediated by factor Xa and activated protein C, respectively. SDS-PAGE analysis showed that plasmin cleaved the heavy chain of factor VIII into two terminal products, Al37-336 and A2 subunits, by limited proteolysis at Lys(36), Arg(336), Arg(372), and Arg(740). The 80-kDa light chain was converted into a 67-kDa subunit by cleavage at Arg(1689) and Arg(1721), identical to the pattern induced by factor Xa. Plasmin-catatyzed cleavage at Arg(336) proceeded faster than that at Arg(372), in contrast to proteolysis by factor Xa. Furthermore, breakdown was faster than that in the presence of activated protein C, consistent with rapid inactivation of factor VIII. The cleavages at Arg(336) and Lys(36) occurred rapidly in the presence of A2 and A3-C1-C2 subunits, respectively. These results strongly indicated that cleavage at Arg(336) was a central mechanism of plasmin-catalyzed factor VIII inactivation. Furthermore, the cleavages at Arg(336) and Lys(36) appeared to be selectively regulated by the A2 and A3-C1-C2 domains, respectively, interacting with plasmin.	Nara Med Univ, Dept Pediat, Kashihara, Nara 6348522, Japan	Nara Medical University	Shima, M (corresponding author), Nara Med Univ, Dept Pediat, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.	mshima@naramed-u.ac.jp						Bick RL, 1999, HAEMOSTASIS, V29, P111; BLOOM AL, 2000, HAEMOSTASIS THROMBOS, P275; BLOOM AL, 1994, HAEMOSTASIS THROMBOS, P969; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILLAS G, 1971, COAGULATION, V4, P107; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; Fay PJ, 2004, BLOOD REV, V18, P1, DOI 10.1016/S0268-960X(03)00025-0; Fay PJ, 2001, J BIOL CHEM, V276, P12434, DOI 10.1074/jbc.M009539200; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1988, J CLIN INVEST, V82, P123, DOI 10.1172/JCI113559; GILES AR, 1990, THROMB HAEMOSTASIS, V63, P476; HOLMBERG L, 1983, THROMB RES, V31, P41, DOI 10.1016/0049-3848(83)90006-3; Jenkins PV, 2004, BIOCHEMISTRY-US, V43, P5094, DOI 10.1021/bi036289p; Kalafatis M, 2001, J BIOL CHEM, V276, P18614, DOI 10.1074/jbc.M007134200; KOEDAM JA, 1990, EUR J BIOCHEM, V189, P229, DOI 10.1111/j.1432-1033.1990.tb15481.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; Liu ML, 2000, BLOOD, V96, P979, DOI 10.1182/blood.V96.3.979.015k42a_979_987; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; MANN KG, 1990, BLOOD, V76, P1; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Nogami K, 2004, J BIOL CHEM, V279, P33104, DOI 10.1074/jbc.M405537200; Nogami K, 2003, J BIOL CHEM, V278, P1634, DOI 10.1074/jbc.M209811200; Nogami K, 2005, J BIOL CHEM, V280, P18476, DOI 10.1074/jbc.M412778200; Nogami K, 1999, J BIOL CHEM, V274, P31000, DOI 10.1074/jbc.274.43.31000; Nogami K, 2003, J BIOL CHEM, V278, P16502, DOI 10.1074/jbc.M213044200; Nogami K, 2002, BLOOD, V99, P3993, DOI 10.1182/blood.V99.11.3993; O'Brien LM, 2000, BLOOD, V95, P1714, DOI 10.1182/blood.V95.5.1714.005k40_1714_1720; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; OMAR MN, 1987, J BIOL CHEM, V262, P9750; Pryzdial ELG, 1999, J BIOL CHEM, V274, P8500, DOI 10.1074/jbc.274.13.8500; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; REGAN LM, 1994, J BIOL CHEM, V269, P9445; RICK ME, 1986, BLOOD, V67, P1649; Rosenblum MEK, 2002, J BIOL CHEM, V277, P11664, DOI 10.1074/jbc.M200037200; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; Samis JA, 2000, BLOOD, V95, P943, DOI 10.1182/blood.V95.3.943.003k34_943_951; SHIMA M, 1992, BRIT J HAEMATOL, V81, P533, DOI 10.1111/j.1365-2141.1992.tb02988.x; TAYLOR FB, 1992, BLOOD, V79, P1720; VANWERSCH JWJ, 1991, HAEMOSTASIS, V21, P117; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WEINSTEI.MJ, 1972, BIOCHIM BIOPHYS ACTA, V258, P577, DOI 10.1016/0005-2744(72)90250-1; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; WYSHOCK EG, 1995, THROMB RES, V80, P377, DOI 10.1016/0049-3848(95)00190-3	51	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5287	5295		10.1074/jbc.M607816200	http://dx.doi.org/10.1074/jbc.M607816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17189254	hybrid			2022-12-25	WOS:000244482300023
J	Murayama, K; Shirouzu, M; Kawasaki, Y; Kato-Murayama, M; Hanawa-Suetsugu, K; Sakamoto, A; Katsura, Y; Suenaga, A; Toyama, M; Terada, T; Taiji, M; Akiyama, T; Yokoyama, S				Murayama, Kazutaka; Shirouzu, Mikako; Kawasaki, Yoshihiro; Kato-Murayama, Miyuki; Hanawa-Suetsugu, Kyoko; Sakamoto, Ayako; Katsura, Yasuhiro; Suenaga, Atsushi; Toyama, Mitsutoshi; Terada, Takaho; Taiji, Makoto; Akiyama, Tetsu; Yokoyama, Shigeyuki			Crystal structure of the Rac activator, Asef, reveals its autoinhibitory mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; RHO-GTPASES; MOLECULAR-DYNAMICS; SH3 DOMAINS; COMPLEX; COLLYBISTIN; MIGRATION; SYSTEM; CDC42; APC	The Rac-specific guanine nucleotide exchange factor (GEF) Asef is activated by binding to the tumor suppressor adenomatous polyposis coli mutant, which is found in sporadic and familial colorectal tumors. This activated Asef is involved in the migration of colorectal tumor cells. The GEFs for Rho family GTPases contain the Dbl homology (DH) domain and the pleckstrin homology (PH) domain. When Asef is in the resting state, the GEF activity of the DH-PH module is intramolecularly inhibited by an unidentified mechanism. Asef has a Src homology 3 (SH3) domain in addition to the DH-PH module. In the present study, the three-dimensional structure of Asef was solved in its autoinhibited state. The crystal structure revealed that the SH3 domain binds intramolecularly to the DH domain, thus blocking the Rac-binding site. Furthermore, the RT-loop and the C-terminal region of the SH3 domain interact with the DH domain in a manner completely different from those for the canonical binding to a polyproline-peptide motif. These results demonstrate that the blocking of the Rac-binding site by the SH3 domain is essential for Asef autoinhibition. This may be a common mechanism in other proteins that possess an SH3 domain adjacent to a DH-PH module.	RIKEN Genom Sci Ctr, Yokohama Inst, Yokohama, Kanagawa, Japan; Tohoku Univ, Biomed Engn Res Org, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan	RIKEN; Tohoku University; University of Tokyo; University of Tokyo	Yokoyama, S (corresponding author), RIKEN Genom Sci Ctr, Yokohama Inst, 1-7-22 Suehiro Cho, Yokohama, Kanagawa, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Taiji, Makoto/N-1077-2014; Shirouzu, Mikako/A-6521-2016; Yokoyama, Shigeyuki/N-6911-2015	Taiji, Makoto/0000-0002-5317-0500; Yokoyama, Shigeyuki/0000-0003-3133-7338				BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Derewenda U, 2004, STRUCTURE, V12, P1955, DOI 10.1016/j.str.2004.09.003; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Harvey K, 2004, J NEUROSCI, V24, P5816, DOI 10.1523/JNEUROSCI.1184-04.2004; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kigawa Takanori, 2002, Journal of Structural and Functional Genomics, V2, P29, DOI 10.1023/A:1013203532303; Kristelly R, 2004, J BIOL CHEM, V279, P47352, DOI 10.1074/jbc.M406056200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Schiller MR, 2006, J BIOL CHEM, V281, P18774, DOI 10.1074/jbc.M512482200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; TAIJI M, 2004, P HOT CHIPS, V16; TAIJI M, 2003, P SUPERCOMPUTING; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Xiang S, 2006, J MOL BIOL, V359, P35, DOI 10.1016/j.jmb.2006.03.019; Zamanian JL, 2003, MOL BIOL CELL, V14, P1624, DOI 10.1091/mbc.E02-08-0494	28	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4238	4242		10.1074/jbc.C600234200	http://dx.doi.org/10.1074/jbc.C600234200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17190834	hybrid			2022-12-25	WOS:000244482000003
J	Shin, JH; Santangelo, TJ; Xie, YW; Reeve, JN; Kelman, Z				Shin, Jae-Ho; Santangelo, Thomas J.; Xie, Yunwei; Reeve, John N.; Kelman, Zvi			Archaeal minichromosome maintenance (MCM) helicase can unwind DNA bound by archaeal histones and transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; REPLICATION; PROTEINS; EUKARYAL	Protein-DNA complexes must be disassembled to facilitate DNA replication. Replication forks contain a helicase that unwinds the duplex DNA at the front of the fork. The minichromosome maintenance helicase from the archaeon Methanothermobacter thermautotrophicus required only ATP to unwind DNA bound into complexes by the M. thermautotrophicus archaeal histone HMtA2, transcription repressor TrpY, or into a transcription pre-initiation complex by M. thermautotrophicus TATA-box-binding protein, transcription factor B, and RNA polymerase. In contrast, the minichromosome maintenance helicase was unable to unwind DNA bound by this archaeal RNA polymerase in a stalled transcript-elongating complex.	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	Ohio State University	Kelman, Z (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.	kelman@umbi.umd.edu	Santangelo, Tom/L-8206-2019	Santangelo, Tom/0000-0003-4559-3244	NIGMS NIH HHS [GM073336-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM073336] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alilat M, 1999, J MOL BIOL, V291, P815, DOI 10.1006/jmbi.1999.2988; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Bailey KA, 1999, NUCLEIC ACIDS RES, V27, P532, DOI 10.1093/nar/27.2.532; Bartlett MS, 2004, J BIOL CHEM, V279, P5894, DOI 10.1074/jbc.M311429200; Boule JB, 2005, NATURE, V438, P57, DOI 10.1038/nature04091; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Chen YJ, 2005, J MOL BIOL, V346, P389, DOI 10.1016/j.jmb.2004.11.076; Darcy TJ, 1999, J BACTERIOL, V181, P4424, DOI 10.1128/JB.181.14.4424-4429.1999; Deshpande AM, 1996, SCIENCE, V272, P1030, DOI 10.1126/science.272.5264.1030; EGGLESTON AK, 1995, J BIOL CHEM, V270, P2024, DOI 10.1074/jbc.270.5.2024; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; Grabowski B, 2003, ANNU REV MICROBIOL, V57, P487, DOI 10.1146/annurev.micro.57.030502.090709; Holland L, 2002, EUR J BIOCHEM, V269, P5192, DOI 10.1046/j.1432-1033.2002.03224.x; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kaplan DL, 2002, MOL CELL, V10, P647, DOI 10.1016/S1097-2765(02)00642-1; Kelman LM, 2003, MOL MICROBIOL, V48, P605, DOI 10.1046/j.1365-2958.2003.03369.x; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kornberg A., 1992, DNA REPLICATION; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mirkin EV, 2005, MOL CELL BIOL, V25, P888, DOI 10.1128/MCB.25.3.888-895.2005; Pereira SL, 1997, P NATL ACAD SCI USA, V94, P12633, DOI 10.1073/pnas.94.23.12633; Reeve JN, 2003, MOL MICROBIOL, V48, P587, DOI 10.1046/j.1365-2958.2003.03439.x; Renfrow MB, 2004, J BIOL CHEM, V279, P2825, DOI 10.1074/jbc.M311433200; Santangelo TJ, 2006, J MOL BIOL, V355, P196, DOI 10.1016/j.jmb.2005.10.062; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; Stano NM, 2005, NATURE, V435, P370, DOI 10.1038/nature03615; Veaute X, 2005, EMBO J, V24, P180, DOI 10.1038/sj.emboj.7600485; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; Xie YM, 2004, J BACTERIOL, V186, P3492, DOI 10.1128/JB.186.11.3492-3498.2004; Xie YW, 2005, J BACTERIOL, V187, P6419, DOI 10.1128/JB.187.18.6419-6429.2005; YANCEYWRONA JE, 1992, NUCLEIC ACIDS RES, V20, P6713, DOI 10.1093/nar/20.24.6713; Yankulov K, 1999, MOL CELL BIOL, V19, P6154	36	17	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4908	4915		10.1074/jbc.M606847200	http://dx.doi.org/10.1074/jbc.M606847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158792	hybrid			2022-12-25	WOS:000244482000073
J	Thakur, KG; Joshi, AM; Gopal, B				Thakur, Krishan Gopal; Joshi, Anagha Madhusudan; Gopal, B.			Structural and biophysical studies on two promoter recognition domains of the extra-cytoplasmic function cr factor from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-SIGMA FACTOR; CRYSTAL-STRUCTURE; EXPRESSION; SEQUENCE	sigma factors are transcriptional regulatory proteins that bind to the RNA polymerase and dictate gene expression. The extracytoplasmic function (ECF) sigma factors govern the environment dependent regulation of transcription. ECF sigma factors have two domains sigma(2) and sigma(4) that recognize the -10 and -35 promoter elements. However, unlike the primary sigma factor sigma(4), the ECF sigma factors lack sigma(3), a region that helps in the recognition of the extended -10 element and sigma(1.1), a domain involved in the autoinhibition of sigma(A) in the absence of core RNA polymerase. Mycobacterium tuberculosis sigma(C) is an ECF sigma factor that is essential for the pathogenesis and virulence of M. tuberculosis in the mouse and guinea pig models of infection. However, unlike other ECF sigma factors, sigma c does not appear to have a regulatory anti- or factor located in the same operon. We also note that M. tuberculosis sigma c differs from the canonical ECF sigma factors as it has an N-terminal domain comprising of 126 amino acids that precedes the sigma(C)(2) and sigma(C)(4) domains. In an effort to understand the regulatory mechanism of this protein, the crystal structures of the sigma(C)(2) and sigma(C)(4) domains of sigma(C) were determined. These promoter recognition domains are structurally similar to the corresponding domains of sigma(A) despite the low sequence similarity. Fluorescence experiments using the intrinsic tryptophan residues of sigma(C)(2) as well as surface plasmon resonance measurements reveal that the sigma(C)(2) and sigma(C), domains interact with each other. Mutational analysis suggests that the Pribnow box-binding region of sigma(C)(2) is involved in this interdomain interaction. Interaction between the promoter recognition domains in M. tuberculosis sigma(C) are thus likely to regulate the activity of this protein even in the absence of an anti-sigma factor.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Gopal, B (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	bgopal@mbu.iisc.ernet.in	Thakur, Krishan/B-6480-2012; Gopal, Balasubramanian/ABG-3754-2021; Gopal, Balasubramanian/K-4566-2012	Joshi, Anagha/0000-0003-1184-3305; Thakur, Krishan/0000-0003-4500-2133	Wellcome Trust [078994] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arai M, 2004, NUCLEIC ACIDS RES, V32, pW390, DOI 10.1093/nar/gkh380; Beaucher J, 2002, MOL MICROBIOL, V45, P1527, DOI 10.1046/j.1365-2958.2002.03135.x; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Campbell EA, 2003, MOL CELL, V11, P1067, DOI 10.1016/S1097-2765(03)00148-5; Campbell EA, 2002, CELL, V108, P795, DOI 10.1016/S0092-8674(02)00662-1; Camus JC, 2002, MICROBIOL-SGM, V148, P2967, DOI 10.1099/00221287-148-10-2967; Costanzo A, 2006, J BACTERIOL, V188, P4627, DOI 10.1128/JB.01981-05; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002; Golovanov AP, 2004, J AM CHEM SOC, V126, P8933, DOI 10.1021/ja049297h; Hahn MY, 2005, J BACTERIOL, V187, P7062, DOI 10.1128/JB.187.20.7062-7071.2005; Helmann JD, 2002, ADV MICROB PHYSIOL, V46, P47; Karls RK, 2006, MICROBIOL-SGM, V152, P1591, DOI 10.1099/mic.0.28591-0; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Manganelli R, 2002, MOL MICROBIOL, V45, P365, DOI 10.1046/j.1365-2958.2002.03005.x; Manganelli R, 1999, MOL MICROBIOL, V31, P715, DOI 10.1046/j.1365-2958.1999.01212.x; Manganelli R, 2001, MOL MICROBIOL, V41, P423, DOI 10.1046/j.1365-2958.2001.02525.x; Manganelli R, 2004, J BACTERIOL, V186, P895, DOI 10.1128/JB.186.4.895-902.2004; Murakami KS, 2003, CURR OPIN STRUC BIOL, V13, P31, DOI 10.1016/S0959-440X(02)00005-2; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Prilusky J, 2005, BIOINFORMATICS, V21, P3435, DOI 10.1093/bioinformatics/bti537; Raman S, 2004, J BACTERIOL, V186, P6605, DOI 10.1128/JB.186.19.6605-6616.2004; Sambrook J, 2001, MOL CLONING LAB MANU; Shenoy AR, 2003, ANAL BIOCHEM, V319, P335, DOI 10.1016/S0003-2697(03)00286-0; Song TS, 2003, MOL MICROBIOL, V50, P949, DOI 10.1046/j.1365-2958.2003.03739.x; Sorenson MK, 2004, MOL CELL, V14, P127, DOI 10.1016/S1097-2765(04)00150-9; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Strong M, 2003, NUCLEIC ACIDS RES, V31, P7099, DOI 10.1093/nar/gkg924; Sun RG, 2004, MOL MICROBIOL, V52, P25, DOI 10.1111/j.1365-2958.2003.03958.x; Thakur KG, 2005, ACTA CRYSTALLOGR F, V61, P779, DOI 10.1107/S1744309105022669; Tomsic M, 2001, J BIOL CHEM, V276, P31891, DOI 10.1074/jbc.M105027200; von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005; Waagmeester A, 2005, TRENDS MICROBIOL, V13, P505, DOI 10.1016/j.tim.2005.08.009	33	24	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4711	4718		10.1074/jbc.M606283200	http://dx.doi.org/10.1074/jbc.M606283200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17145760	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000244482000052
J	Liang, MH; Chuang, DM				Liang, Min-Huei; Chuang, De-Maw			Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL REGULATION; NUCLEAR ACCUMULATION; NEGATIVE REGULATOR; CELL-SURVIVAL; LITHIUM; TYROSINE; PHOSPHORYLATION; INHIBITION; INSULIN; 3-BETA	Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase consisting of two isoforms, alpha and beta. The activities of GSK-3 are regulated negatively by serine phosphorylation but positively by tyrosine phosphorylation. GSK-3 inactivation has been proposed as a mechanism to promote neuronal survival. We used GSK-3 isoform-specific small interfering RNAs, dominant-negative mutants, or pharmacological inhibitors to search for functions of the two GSK-3 isoforms in regulating neuronal survival in cultured cortical neurons in response to glutamate insult or during neuronal maturation/aging. Surprisingly, RNA interference-induced depletion of either isoform was sufficient to block glutamate-induced excitotoxicity, and the resulting neuroprotection was associated with enhanced N-terminal serine phosphorylation in both GSK-3 isoforms. However, GSK-3 beta depletion was more effective than GSK-3 alpha depletion in suppressing spontaneous neuronal death in extended culture. This phenomenon is likely due to selective and robust inhibition of GSK-3 beta activation resulting from GSK-3 beta Ser(9) dephosphorylation during the course of spontaneous neuronal death. GSK-3 alpha silencing resulted in reduced tyrosine phosphorylation of GSK-3 beta, suggesting that tyrosine phosphorylation is also a critical autoregulatory event. Interestingly, GSK-3 inhibitors caused a rapid and long-lasting increase in GSK-3 alpha Ser(21) phosphorylation levels, followed by a delayed increase in GSK-3 beta Ser(9) phosphorylation and a decrease in GSK-3 alpha Tyr(279) and GSK-3 beta Tyr(216) phosphorylation, thus implying additional levels of GSK-3 autoregulation. Taken together, our results underscore important similarities and dissimilarities of GSK-3 alpha and GSK-3 beta in the roles of cell survival as well as their distinct modes of regulation. The development of GSK-3 isoform-specific inhibitors seems to be warranted for treating GSK-3-mediated pathology.	NIMH, Mol Neurobiol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Chuang, DM (corresponding author), NIMH, Mol Neurobiol Sect, Bldg 10,Room 4C-206,10 Ctr Dr,MSC 1363, Bethesda, MD 20892 USA.	chuang@mail.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002468, Z01MH002468, Z01MH002698] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Apostol BL, 2006, HUM MOL GENET, V15, P273, DOI 10.1093/hmg/ddi443; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bijur GN, 2003, NEUROREPORT, V14, P2415, DOI 10.1097/00001756-200312190-00025; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; Cole A, 2004, BIOCHEM J, V377, P249, DOI 10.1042/BJ20031259; Cruz JC, 2004, CURR OPIN NEUROBIOL, V14, P390, DOI 10.1016/j.conb.2004.05.002; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Franca-Koh J, 2002, J BIOL CHEM, V277, P43844, DOI 10.1074/jbc.M207265200; GOODE N, 1992, J BIOL CHEM, V267, P16878; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Hartigan JA, 2001, BIOCHEM BIOPH RES CO, V284, P485, DOI 10.1006/bbrc.2001.4986; Hashimoto R, 2002, J NEUROCHEM, V80, P589, DOI 10.1046/j.0022-3042.2001.00728.x; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hetman M, 2000, J NEUROSCI, V20, P2567; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; HOSHI M, 1995, J BIOCHEM-TOKYO, V118, P683, DOI 10.1093/oxfordjournals.jbchem.a124965; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Iitaka C, 2005, J BIOL CHEM, V280, P29397, DOI 10.1074/jbc.M503526200; Iwahana E, 2004, EUR J NEUROSCI, V19, P2281, DOI 10.1111/j.0953-816X.2004.03322.x; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Jope RS, 2002, MOL PSYCHIATR, V7, pS35, DOI 10.1038/sj.mp.4001017; Kim L, 1999, CELL, V99, P399, DOI 10.1016/S0092-8674(00)81526-3; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Liang MH, 2006, J BIOL CHEM, V281, P30479, DOI 10.1074/jbc.M607468200; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; Lucas FR, 1998, J CELL SCI, V111, P1351; Maggirwar SB, 1999, J NEUROCHEM, V73, P578, DOI 10.1046/j.1471-4159.1999.0730578.x; Manji HK, 1999, BIOL PSYCHIAT, V46, P929, DOI 10.1016/S0006-3223(99)00165-1; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; Muly EC, 2004, CEREB CORTEX, V14, P1398, DOI 10.1093/cercor/bhh101; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; O'Brien WT, 2004, J NEUROSCI, V24, P6791, DOI 10.1523/JNEUROSCI.4753-03.2004; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Rowe Michael K., 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404008385; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; Spittaels K, 2002, NEUROSCIENCE, V113, P797, DOI 10.1016/S0306-4522(02)00236-1; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Su Y, 2004, BIOCHEMISTRY-US, V43, P6899, DOI 10.1021/bi035627j; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Szatmari E, 2005, J BIOL CHEM, V280, P37526, DOI 10.1074/jbc.M502699200; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Terry-Lorenzo RT, 2005, MOL BIOL CELL, V16, P2349, DOI 10.1091/mbc.E04-12-1054; Wang Q, 2006, ONCOGENE, V25, P43, DOI 10.1038/sj.onc.1209004; WANG QM, 1994, BIOCHEMISTRY-US, V33, P143, DOI 10.1021/bi00167a018; WANG QM, 1994, J BIOL CHEM, V269, P14566; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yin L, 2006, SCIENCE, V311, P1002, DOI 10.1126/science.1121613; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200; Zmijewski JW, 2004, AGING CELL, V3, P309, DOI 10.1111/j.1474-9728.2004.00117.x	63	124	130	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3904	3917		10.1074/jbc.M605178200	http://dx.doi.org/10.1074/jbc.M605178200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148450	hybrid			2022-12-25	WOS:000244481900055
J	Lin, H; Chen, MC; Chiu, CY; Song, YM; Lin, SY				Lin, Ho; Chen, Mei-Chih; Chiu, Chih-Yuan; Song, Yuh-Min; Lin, Shih-Yi			Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; PREOPERATIVE DIAGNOSIS; ALZHEIMERS-DISEASE; INDUCED APOPTOSIS; P35; TRANSCRIPTION; EXPRESSION; PATHWAY; CANCER; P25	The biological behaviors of thyroid cancer are varied, and the pathological mechanisms remain unclear. Some reports indicated an apparent aggregation of amyloid accompanying medullary thyroid carcinoma (MTC). Amyloid aggregation in neurodegeneration leads to hyperactivation of Cdk5 and subsequent neuronal death. Based on the connection with amyloid, the role of Cdk5 in MTC is worthy of investigation. Initially, the expression of Cdk5 and its activator, p35, in MTC cell lines was identified. Cdk5 inhibition by specific inhibitors or short interfering RNA decreased the proliferation of MTC cell lines, which reveals the importance of Cdk5 in MTC cell growth. Although p35 cleavage has been considered as an important element in neurodegeneration, it seems that p35 cleavage was not a major cause in Cdk5 activity-dependent MTC cell proliferation because neither Cdk5 activity nor cell growth was affected by the inhibition of p35 cleavage. Clearance of amyloid by antibody neutralization indicated that MTC cell proliferation was supported by calcitonin-derived extracellular amyloid and subsequent Her2 and Cdk5 activation. Significantly, the STAT3 pathway was involved in Cdk5-dependent proliferation of MTC cells through Ser-727 phosphorylation. In addition, Cdk5 inhibition reduced nuclear distributions of both the Cdk5-p35 complex and phospho-STAT3 in MTC cells. Finally, Cdk5 inhibition retarded tumor formation in vivo accompanying the reduction of phospho-STAT3. Our findings suggest the first demonstration of a novel and specific role for Cdk5 kinase in supporting the proliferation of the medullary thyroid carcinoma cells and could shed light on a new field for diagnosis and therapy of thyroid cancer.	Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; Taichung Vet Gen Hosp, Biochem Sect, Dept Med Labs, Taichung 40705, Taiwan; Taichung Vet Gen Hosp, Div Endocrinol & Metab, Taichung 40705, Taiwan; Natl Yang Ming Univ, Dept Physiol, Taipei 11221, Taiwan	National Chung Hsing University; Taichung Veterans General Hospital; Taichung Veterans General Hospital; National Yang Ming Chiao Tung University	Lin, H (corresponding author), Natl Chung Hsing Univ, Dept Life Sci, 250 Kuo Kuang Rd, Taichung 40227, Taiwan.	hlin@dragon.nchu.edu.tw		Lin, Ho/0000-0001-7849-9137				Alevizaki M, 2001, EUR J ENDOCRINOL, V145, P585, DOI 10.1530/eje.0.1450585; Alvarez A, 2001, EXP CELL RES, V264, P266, DOI 10.1006/excr.2001.5152; Bojunga J, 2004, CLIN ENDOCRINOL, V61, P523, DOI 10.1111/j.1365-2265.2004.02131.x; Bugalho MJGB, 2000, EUR J ENDOCRINOL, V143, P335, DOI 10.1530/eje.0.1430335; Chen F, 2004, CANCER RES, V64, P5425, DOI 10.1158/0008-5472.CAN-04-0806; Chen F, 1999, EXP CELL RES, V249, P422, DOI 10.1006/excr.1999.4522; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Fu AKY, 2004, P NATL ACAD SCI USA, V101, P6728, DOI 10.1073/pnas.0307606100; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Halliday BE, 1998, DIAGN CYTOPATHOL, V18, P270, DOI 10.1002/(SICI)1097-0339(199804)18:4<270::AID-DC4>3.3.CO;2-2; HUANG SN, 1968, CANCER, V21, P302, DOI 10.1002/1097-0142(196802)21:2<302::AID-CNCR2820210220>3.0.CO;2-R; Khurana R, 2004, ENDOCRINOLOGY, V145, P5465, DOI 10.1210/en.2004-0780; Leboulleux S, 2004, CLIN ENDOCRINOL, V61, P299, DOI 10.1111/j.1365-2265.2004.02037.x; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li BS, 2003, J BIOL CHEM, V278, P35702, DOI 10.1074/jbc.M302004200; Li HB, 2004, BIOCHEM J, V381, P257, DOI 10.1042/BJ20040515; Lin H, 2004, J BIOL CHEM, V279, P29302, DOI 10.1074/jbc.M403664200; LIN H, 2007, IN PRESS CELL DEATH; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Menacho IP, 2005, CANCER RES, V65, P1729, DOI 10.1158/0008-5472.CAN-04-2363; MEYER JS, 1968, CANCER, V21, P406, DOI 10.1002/1097-0142(196803)21:3<406::AID-CNCR2820210310>3.0.CO;2-6; Musa FRM, 1998, J ANDROL, V19, P657; Musa FRM, 2000, J ANDROL, V21, P392; Nguyen KC, 2002, J ALZHEIMERS DIS, V4, P123, DOI 10.3233/JAD-2002-4207; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; O'Hare MJ, 2005, J NEUROSCI, V25, P8954, DOI 10.1523/JNEUROSCI.2899-05.2005; Park JI, 2003, MOL CELL BIOL, V23, P543, DOI 10.1128/MCB.23.2.543-554.2003; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Reches M, 2002, J BIOL CHEM, V277, P35475, DOI 10.1074/jbc.M206039200; Sandal T, 2002, J BIOL CHEM, V277, P20783, DOI 10.1074/jbc.M112248200; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; Strock CJ, 2006, CANCER RES, V66, P7509, DOI 10.1158/0008-5472.CAN-05-3048; Takano T, 1999, CANCER RES, V59, P4542; Tarricone C, 2001, MOL CELL, V8, P657, DOI 10.1016/S1097-2765(01)00343-4; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Ubeda M, 2004, ENDOCRINOLOGY, V145, P3023, DOI 10.1210/en.2003-1522; Xie HQ, 1997, J NEUROCHEM, V69, P1020; Yoo BC, 2001, NATURE, V411, P763, DOI 10.1038/35081146; Zabel M, 1997, HISTOL HISTOPATHOL, V12, P283	41	86	90	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2776	2784		10.1074/jbc.M607234200	http://dx.doi.org/10.1074/jbc.M607234200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145757	hybrid			2022-12-25	WOS:000243793900004
J	Nilsson, RH; Ryberg, M; Kristiansson, E; Abarenkov, K; Larsson, KH; Koljalg, U				Nilsson, R. Henrik; Ryberg, Martin; Kristiansson, Erik; Abarenkov, Kessy; Larsson, Karl-Henrik; Koljalg, Urmas			Taxonomic Reliability of DNA Sequences in Public Sequence Databases: A Fungal Perspective	PLOS ONE			English	Article							DIVERSITY; IDENTIFICATION; EXAMPLE	Background. DNA sequences are increasingly seen as one of the primary information sources for species identification in many organism groups. Such approaches, popularly known as barcoding, are underpinned by the assumption that the reference databases used for comparison are sufficiently complete and feature correctly and informatively annotated entries. Methodology/Principal Findings. The present study uses a large set of fungal DNA sequences from the inclusive International Nucleotide Sequence Database to show that the taxon sampling of fungi is far from complete, that about 20% of the entries may be incorrectly identified to species level, and that the majority of entries lack descriptive and up-to-date annotations. Conclusions. The problems with taxonomic reliability and insufficient annotations in public DNA repositories form a tangible obstacle to sequence-based species identification, and it is manifest that the greatest challenges to biological barcoding will be of taxonomical, rather than technical, nature.	[Nilsson, R. Henrik; Ryberg, Martin; Larsson, Karl-Henrik] Univ Gothenburg, Dept Plant & Environm Sci, Gothenburg, Sweden; [Kristiansson, Erik] Chalmers Univ Technol, Dept Math Stat, S-41296 Gothenburg, Sweden; [Abarenkov, Kessy; Koljalg, Urmas] Univ Tartu, Inst Bot & Ecol, EE-50090 Tartu, Estonia	University of Gothenburg; Chalmers University of Technology; University of Tartu	Nilsson, RH (corresponding author), Univ Gothenburg, Dept Plant & Environm Sci, Gothenburg, Sweden.	henrik.nilsson@botany.gu.se	Khor, Beesym/B-2832-2010; Nilsson, R. Henrik/A-6062-2009; Ryberg, Martin/AHA-1804-2022; Kõljalg, Urmas/H-6925-2015; 赵, 鹏/B-8401-2009; Kõljalg, Urmas/AAM-7828-2020; Abarenkov, Kessy/H-9611-2015	Nilsson, R. Henrik/0000-0002-8052-0107; Ryberg, Martin/0000-0002-6795-4349; Kõljalg, Urmas/0000-0002-5171-1668; Abarenkov, Kessy/0000-0001-5526-4845	Helge Ax:son Johnson; Wilhelm and Martina Lundgren; Lars Hierta	Helge Ax:son Johnson; Wilhelm and Martina Lundgren; Lars Hierta	This work was supported by the foundations of Helge Ax:son Johnson, Wilhelm and Martina Lundgren, and Lars Hierta.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Alvarez I, 2003, MOL PHYLOGENET EVOL, V29, P417, DOI 10.1016/S1055-7903(03)00208-2; Benson Dennis A, 2005, Nucleic Acids Res, V33, pD34; Blaxter M, 2005, PHILOS T R SOC B, V360, P1935, DOI 10.1098/rstb.2005.1725; Bridge PD, 2003, NEW PHYTOL, V160, P43, DOI 10.1046/j.1469-8137.2003.00861.x; Bruns TD, 2004, CAN J BOT, V82, P1122, DOI [10.1139/B04-021, 10.1139/b04-021]; Clapp JP, 2002, MYCORRHIZA, V12, P269, DOI 10.1007/s00572-002-0175-8; Cohan FM, 2002, ANNU REV MICROBIOL, V56, P457, DOI 10.1146/annurev.micro.56.012302.160634; Ebach MC, 2005, NATURE, V434, P697, DOI 10.1038/434697b; Hajibabaei M, 2005, PHILOS T R SOC B, V360, P1959, DOI 10.1098/rstb.2005.1727; Hawksworth DL, 2001, MYCOL RES, V105, P1422, DOI 10.1017/S0953756201004725; Hebert PDN, 2003, P ROY SOC B-BIOL SCI, V270, pS96, DOI 10.1098/rsbl.2003.0025; Hibbett DS, 2005, SYST BIOL, V54, P660, DOI 10.1080/10635150590947104; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; Horton TR, 2001, MOL ECOL, V10, P1855, DOI 10.1046/j.0962-1083.2001.01333.x; Izzo A, 2005, NEW PHYTOL, V166, P619, DOI 10.1111/j.1469-8137.2005.01354.x; Koljalg U, 2005, NEW PHYTOL, V166, P1063, DOI 10.1111/j.1469-8137.2005.01376.x; Meyer CP, 2005, PLOS BIOL, V3, P2229, DOI 10.1371/journal.pbio.0030422; Moritz C, 2004, PLOS BIOL, V2, P1529, DOI 10.1371/journal.pbio.0020354; Nilsson RH, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-178; Nilsson RH, 2004, BIOINFORMATICS, V20, P1447, DOI 10.1093/bioinformatics/bth119; Savolainen V, 2005, PHILOS T R SOC B, V360, P1805, DOI 10.1098/rstb.2005.1730; Schussler A, 2003, MYCORRHIZA, V13, P233, DOI 10.1007/s00572-003-0250-9; Steinke D, 2005, PHILOS T R SOC B, V360, P1975, DOI 10.1098/rstb.2005.1729; White T., 1990, PCR PROTOCOLS GUIDE, P315	25	439	461	5	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e59	10.1371/journal.pone.0000059	http://dx.doi.org/10.1371/journal.pone.0000059			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183689	gold, Green Submitted, Green Published			2022-12-25	WOS:000207443600059
J	Ralser, M; Heeren, G; Breitenbach, M; Lehrach, H; Krobitsch, S				Ralser, Markus; Heeren, Gino; Breitenbach, Michael; Lehrach, Hans; Krobitsch, Sylvia			Triose Phosphate Isomerase Deficiency Is Caused by Altered Dimerization-Not Catalytic Inactivity-of the Mutant Enzymes	PLOS ONE			English	Article								Triosephosphate isomerase (TPI) deficiency is an autosomal recessive disorder caused by various mutations in the gene encoding the key glycolytic enzyme TPI. A drastic decrease in TPI activity and an increased level of its substrate, dihydroxyacetone phosphate, have been measured in unpurified cell extracts of affected individuals. These observations allowed concluding that the different mutations in the TPI alleles result in catalytically inactive enzymes. However, despite a high occurrence of TPI null alleles within several human populations, the frequency of this disorder is exceptionally rare. In order to address this apparent discrepancy, we generated a yeast model allowing us to perform comparative in vivo analyses of the enzymatic and functional properties of the different enzyme variants. We discovered that the majority of these variants exhibit no reduced catalytic activity per se. Instead, we observed, the dimerization behavior of TPI is influenced by the particular mutations investigated, and by the use of a potential alternative translation initiation site in the TPI gene. Additionally, we demonstrated that the overexpression of the most frequent TPI variant, Glu104Asp, which displays altered dimerization features, results in diminished endogenous TPI levels in mammalian cells. Thus, our results reveal that enzyme deregulation attributable to aberrant dimerization of TPI, rather than direct catalytic inactivation of the enzyme, underlies the pathogenesis of TPI deficiency. Finally, we discovered that yeast cells expressing a TPI variant exhibiting reduced catalytic activity are more resistant against oxidative stress caused by the thiol-oxidizing reagent diamide. This observed advantage might serve to explain the high allelic frequency of TPI null alleles detected among human populations.	[Ralser, Markus; Lehrach, Hans; Krobitsch, Sylvia] Max Planck Inst Mol Genet, Berlin, Germany; [Heeren, Gino; Breitenbach, Michael] Salzburg Univ, Dept Cell Biol, A-5020 Salzburg, Austria	Max Planck Society; Salzburg University	Krobitsch, S (corresponding author), Max Planck Inst Mol Genet, Berlin, Germany.	krobitsc@molgen.mpg.de		Ralser, Markus/0000-0001-9535-7413	FWF [S9302-B05]; European Community [512020]; Max Planck Society	FWF(Austrian Science Fund (FWF)); European Community(European Commission); Max Planck Society(Max Planck SocietyFoundation CELLEX)	Funding: We are grateful to the FWF (Vienna, Austria; project S9302-B05 to M. B.), the European Community (for project MIMAGE, contr. no. 512020; to M. B.), and the Max Planck Society for providing financial support for this project.	Arya R, 1997, HUM MUTAT, V10, P290; Brachmann CB, 1998, YEAST, V14, P115; Buchanan BB, 2005, ANNU REV PLANT BIOL, V56, P187, DOI 10.1146/annurev.arplant.56.032604.144246; CHANG ML, 1993, AM J HUM GENET, V52, P1260; CIRIACY M, 1979, J BACTERIOL, V139, P152, DOI 10.1128/JB.139.1.152-160.1979; Colussi C, 2000, FASEB J, V14, P2266, DOI 10.1096/fj.00-0074com; Compagno C, 1996, BIOTECHNOL PROGR, V12, P591, DOI 10.1021/bp960043c; Concepcion GP, 2005, MED HYPOTHESES, V65, P865, DOI 10.1016/j.mehy.2005.06.006; Costa WMV, 2002, FREE RADICAL BIO MED, V33, P1507, DOI 10.1016/S0891-5849(02)01086-9; DAAR IO, 1986, P NATL ACAD SCI USA, V83, P7903, DOI 10.1073/pnas.83.20.7903; EBER SW, 1991, EUR J PEDIATR, V150, P761, DOI 10.1007/BF02026706; EBER SW, 1984, HUM GENET, V67, P336, DOI 10.1007/BF00291364; EBER SW, 1979, EUR J CLIN INVEST, V9, P195, DOI 10.1111/j.1365-2362.1979.tb00923.x; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Goehler H, 2004, MOL CELL, V15, P853, DOI 10.1016/j.molcel.2004.09.016; Gonzalez CI, 2001, GENE, V274, P15, DOI 10.1016/S0378-1119(01)00552-2; Grant CM, 1999, MOL CELL BIOL, V19, P2650; HAMMOND KB, 1991, NEW ENGL J MED, V325, P769, DOI 10.1056/NEJM199109123251104; Harju S, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-8; Heeren G, 2004, FEMS YEAST RES, V5, P157, DOI 10.1016/j.femsyr.2004.05.008; Henn IH, 2005, J NEUROCHEM, V92, P114, DOI 10.1111/j.1471-4159.2004.02854.x; Hollan S, 1997, P NATL ACAD SCI USA, V94, P10362, DOI 10.1073/pnas.94.19.10362; HOLLAN S, 1993, HUM GENET, V92, P486, DOI 10.1007/BF00216456; HOLLAN S, 1995, P NATL ACAD SCI USA, V92, P268, DOI 10.1073/pnas.92.1.268; Hollan Susan, 1998, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V192, P929; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Jung JH, 2002, J BIOL CHEM, V277, P48931, DOI 10.1074/jbc.M208806200; Kinoshita T, 2005, ACTA CRYSTALLOGR F, V61, P346, DOI 10.1107/S1744309105008341; Kochetov AV, 2005, MOL GENET GENOMICS, V273, P491, DOI 10.1007/s00438-005-1152-7; Kochetov AV, 2004, MOL GENET GENOMICS, V270, P442, DOI 10.1007/s00438-003-0941-0; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; KREMS B, 1995, CURR GENET, V27, P427, DOI 10.1007/BF00311211; Laun P, 2001, MOL MICROBIOL, V39, P1166, DOI 10.1046/j.1365-2958.2001.02317.x; Liu JS, 2000, ONCOGENE, V19, P2767, DOI 10.1038/sj.onc.1203599; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; MAITRA PK, 1971, J BIOL CHEM, V246, P475; Marianayagam NJ, 2004, TRENDS BIOCHEM SCI, V29, P618, DOI 10.1016/j.tibs.2004.09.006; MERKLE S, 1989, GENETICS, V123, P837; MOHRENWEISER HW, 1987, ANN HUM GENET, V51, P303, DOI 10.1111/j.1469-1809.1987.tb01065.x; MOHRENWEISER HW, 1981, P NATL ACAD SCI-BIOL, V78, P5046, DOI 10.1073/pnas.78.8.5046; MOHRENWEISER HW, 1982, PEDIATR RES, V16, P960, DOI 10.1203/00006450-198211000-00012; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NEEL JV, 1988, AM J HUM GENET, V42, P663; Olah J, 2005, BIOCHEM J, V392, P675, DOI 10.1042/BJ20050993; Olah J, 2002, BIOCHEM SOC T, V30, P30, DOI 10.1042/bst0300030; Orosz F, 2000, P NATL ACAD SCI USA, V97, P1026, DOI 10.1073/pnas.97.3.1026; Orosz F, 2001, BLOOD, V98, P3106, DOI 10.1182/blood.V98.10.3106; Orosz F, 1996, J THEOR BIOL, V182, P437, DOI 10.1006/jtbi.1996.0184; Overkamp KM, 2002, APPL ENVIRON MICROB, V68, P2814, DOI 10.1128/AEM.68.6.2814-2821.2002; Pedersen AG, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P226; PERRY BA, 1992, HUM GENET, V88, P634, DOI 10.1007/BF02265287; Ralser M, 2005, HUM MOL GENET, V14, P2893, DOI 10.1093/hmg/ddi321; Ralser M, 2005, BIOTECHNIQUES, V39, P165, DOI 10.2144/05392BM01; Ralser M, 2006, BIOCHEM BIOPH RES CO, V347, P747, DOI 10.1016/j.bbrc.2006.06.151; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; SAWYER TH, 1972, J BIOL CHEM, V247, P6499; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schneider A, 1996, BLOOD CELL MOL DIS, V22, P82, DOI 10.1006/bcmd.1996.0011; SCHNEIDER AS, 1965, NEW ENGL J MED, V272, P229, DOI 10.1056/NEJM196502042720503; Schneider AS, 2000, BEST PRACT RES CL HA, V13, P119, DOI 10.1053/beha.2000.0061; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; Serebriiskii IG, 2000, ANAL BIOCHEM, V285, P1, DOI 10.1006/abio.2000.4672; Shenton D, 2003, BIOCHEM J, V374, P513, DOI 10.1042/BJ20030414; Shi YH, 2005, J BIOL CHEM, V280, P41805, DOI 10.1074/jbc.M505181200; SNAPKA RM, 1974, COMP BIOCHEM PHYSIOL, V49, P733, DOI 10.1016/0305-0491(74)90259-4; Stamm S, 2006, NUCLEIC ACIDS RES, V34, pD46, DOI 10.1093/nar/gkj031; Thorpe GW, 2004, P NATL ACAD SCI USA, V101, P6564, DOI 10.1073/pnas.0305888101; Valentin C, 2000, BLOOD, V96, P1130; Watanabe M, 1996, AM J HUM GENET, V58, P308; Yamaji R, 2004, ARCH BIOCHEM BIOPHYS, V423, P332, DOI 10.1016/j.abb.2004.01.003	73	61	63	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e30	10.1371/journal.pone.0000030	http://dx.doi.org/10.1371/journal.pone.0000030			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183658	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600030
J	Li, B; Smith, CC; Laing, JM; Gober, MD; Liu, L; Aurelian, L				Li, B.; Smith, C. C.; Laing, J. M.; Gober, M. D.; Liu, L.; Aurelian, L.			Overload of the heat-shock protein H11/HspB8 triggers melanoma cell apoptosis through activation of transforming growth factor-beta-activated kinase 1	ONCOGENE			English	Article						H11/HspB8; heat shock protein; melanoma; apoptosis/growth arrest; TAK1; beta-catenin	CHAPERONE-LIKE ACTIVITY; PROSTATE-CANCER CELLS; TRANSCRIPTION FACTOR; DNA METHYLATION; BETA-CATENIN; RIBONUCLEOTIDE REDUCTASE; MALIGNANT-MELANOMA; EXPRESSION; KINASE; PATHWAY	Molecular therapeutics is a recognized promising approach for melanoma, but relevant target genes remain elusive. We report that overload of the recently cloned H11/HspB8 induces apoptosis in 55% of examined melanoma cultures. Apoptosis was determined by activation of caspases-9 and -3 and terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling (TUNEL), and was not seen in normal melanocytes. It was associated with H11/HspB8 complexation with transforming growth factor-beta-activated kinase (TAK) 1 and activation of TAK1 and p38 mitogen activated protein 3 kinases. TAK1 was not bound, nor activated by the H11/HspB8 mutant W51C, which has dominant antiapoptotic activity. beta-Catenin was phosphorylated by activated TAK1, inhibiting its nuclear accumulation and mictophthalmia-associated transcription factor and cyclin dependent kinase 2 expression. The dominant-negative TAK1 mutant K63W inhibited beta-catenin phosphorylation and caspase activation. The data indicate that H11/HspB8 overload causes melanoma growth arrest and apoptosis through TAK1 activation and suggest that H11/HspB8 is a promising molecular therapy target.	Univ Maryland, Virol Immunol Labs, Sch Med, Dept Pharmacol, Baltimore, MD 21201 USA; Univ Maryland, Dept Expt Therapeut, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Aurelian, L (corresponding author), Univ Maryland, Virol Immunol Labs, Sch Med, Dept Pharmacol, Room 4-023,655 W Baltimore St, Baltimore, MD 21201 USA.	laurelia@umaryland.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053512, R01AR042647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007263] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR053512, AR42647, R01 AR042647, R01 AR053512-01A2] Funding Source: Medline; NIEHS NIH HHS [T32 ES007263, ES07263] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aurelian L, 2005, CURR TOP MICROBIOL, V289, P79; Chabaud S, 2003, FEBS LETT, V545, P213, DOI 10.1016/S0014-5793(03)00547-7; Chae HD, 2004, ONCOGENE, V23, P4084, DOI 10.1038/sj.onc.1207482; Chowdary TK, 2004, BIOCHEM J, V381, P379, DOI 10.1042/BJ20031958; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Diao LR, 2005, EXP CELL RES, V308, P196, DOI 10.1016/j.yexcr.2005.04.016; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Fink D, 2001, MELANOMA RES, V11, P385, DOI 10.1097/00008390-200108000-00009; Furuta J, 2004, CANCER SCI, V95, P962, DOI 10.1111/j.1349-7006.2004.tb03184.x; Gallagher WM, 2005, CARCINOGENESIS, V26, P1856, DOI 10.1093/carcin/bgi152; Gober MD, 2005, FRONT BIOSCI-LANDMRK, V10, P2788, DOI 10.2741/1736; Gober MD, 2003, J BIOL CHEM, V278, P37600, DOI 10.1074/jbc.M303834200; Hase M, 2005, BIOCHEM J, V388, P475, DOI 10.1042/BJ20041314; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ivanov VN, 2001, ONCOGENE, V20, P2243, DOI 10.1038/sj.onc.1204314; Karpf AR, 2004, MOL PHARMACOL, V65, P18, DOI 10.1124/mol.65.1.18; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Margolin KA, 2004, CANCER-AM CANCER SOC, V101, P435, DOI 10.1002/cncr.20402; Park CS, 2004, J BIOL CHEM, V279, P19592, DOI 10.1074/jbc.M314208200; Perez-Stable C, 2006, CANCER LETT, V231, P49, DOI 10.1016/j.canlet.2005.01.018; Reu FJ, 2006, CANCER RES, V66, P2785, DOI 10.1158/0008-5472.CAN-05-2303; Saito H, 2003, PIGM CELL RES, V16, P261, DOI 10.1034/j.1600-0749.2003.00039.x; Sharma BK, 2006, DERMATOLOGY, V213, P192, DOI 10.1159/000095035; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Smith CC, 2000, J BIOL CHEM, V275, P25690, DOI 10.1074/jbc.M002140200; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sun XK, 2004, J BIOL CHEM, V279, P2394, DOI 10.1074/jbc.M311324200; Tsao H, 2005, DERMATOL CLIN, V23, P323, DOI 10.1016/j.det.2004.09.005; Van der Velden PA, 2003, INT J CANCER, V106, P472, DOI 10.1002/ijc.11262; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang TH, 2006, ONCOGENE, V25, P4857, DOI 10.1038/sj.onc.1209498; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Zendman AJW, 2002, INT J CANCER, V97, P195, DOI 10.1002/ijc.1584	37	25	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3521	3531		10.1038/sj.onc.1210145	http://dx.doi.org/10.1038/sj.onc.1210145			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17173073	Green Accepted			2022-12-25	WOS:000246799200008
J	Wu, SR; Haag, L; Hammar, L; Wu, B; Garoft, H; Xing, L; Murata, K; Cheng, RH				Wu, Shang-Rung; Haag, Lars; Hammar, Lena; Wu, Bomu; Garoft, Henrik; Xing, Li; Murata, Kazuyoshi; Cheng, R. Holland			The dynamic envelope of a fusion Class II virus - Prefusion stages of Semliki Forest virus revealed by electron cryomicroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; LOW PH; CRYOELECTRON MICROSCOPY; GLYCOPROTEIN SHELL; SPIKE PROTEIN; STEM REGION; LIFE-CYCLE; VISUALIZATION; ORGANIZATION; SEQUENCE	Semliki Forest virus is among the prototypes for Class II virus fusion and targets the endosomal membrane. Fusion protein E1 and its envelope companion E2 are both anchored in the viral membrane and form an external shell with protruding spikes. In acid environments, mimicking the early endosomal milieu, surface epitopes in the virus rearrange along with exposure of the fusion loop. To visualize this transformation into a fusogenic stage, we determined the structure of the virus at gradually lower pH values. The results show that while the fusion loop is available for external interaction and the shell and stalk domains of the spike begin to deteriorate, the E1 and E2 remain in close contact in the spike head. This unexpected observation points to E1 and E2 cooperation beyond the fusion loop exposure stage and implies a more prominent role for E2 in guiding membrane close encounter than has been earlier anticipated.	Karolinska Inst, Dept Biosci & Nutr, S-14157 Stockholm, Sweden; Univ Calif Davis, Davis, CA 95616 USA; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, Kyoto 1350064, Japan	Karolinska Institutet; University of California System; University of California Davis; National Institute of Advanced Industrial Science & Technology (AIST)	Wu, SR (corresponding author), Karolinska Inst, Dept Biosci & Nutr, S-14157 Stockholm, Sweden.	suw@biosci.ki.se	Cheng, Holland/A-8973-2008	Murata, Kazuyoshi/0000-0001-9446-3652				Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; Bhella D, 2004, J MOL BIOL, V340, P319, DOI 10.1016/j.jmb.2004.05.015; BRON R, 1993, EMBO J, V12, P693, DOI 10.1002/j.1460-2075.1993.tb05703.x; Chanel-Vos C, 2004, J VIROL, V78, P13543, DOI 10.1128/JVI.78.24.13543-13552.2004; Chanel-Vos C, 2006, J VIROL, V80, P6115, DOI 10.1128/JVI.00167-06; CHENG RH, 1995, CELL, V80, P621; FULLER SD, 1995, CELL, V81, P715, DOI 10.1016/0092-8674(95)90533-2; GAROFF H, 1980, NATURE, V288, P236, DOI 10.1038/288236a0; Gibbons DL, 2004, J VIROL, V78, P3514, DOI 10.1128/JVI.78.7.3514-3523.2004; Gibbons DL, 2004, NATURE, V427, P320, DOI 10.1038/nature02239; Haag L, 2002, EMBO J, V21, P4402, DOI 10.1093/emboj/cdf442; HAAG L, 2006, THESIS KAROLINSKA I; Hammar L, 2003, J BIOL CHEM, V278, P7189, DOI 10.1074/jbc.M206015200; HAMMAR L, 2004, CONFORMATIONAL PROTE, P78; JENG TW, 1989, J MOL BIOL, V205, P251, DOI 10.1016/0022-2836(89)90379-3; Kielian M, 2006, NAT REV MICROBIOL, V4, P67, DOI 10.1038/nrmicro1326; Kielian M, 2006, VIROLOGY, V344, P38, DOI 10.1016/j.virol.2005.09.036; Kielian M, 2000, Subcell Biochem, V34, P409; KIELIAN M, 1995, ADV VIRUS RES, V45, P113, DOI 10.1016/S0065-3527(08)60059-7; KLIMJACK MR, 1994, J VIROL, V68, P6940, DOI 10.1128/JVI.68.11.6940-6946.1994; Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8; LEVYMINTZ P, 1991, J VIROL, V65, P4292, DOI 10.1128/JVI.65.8.4292-4300.1991; Liao MF, 2006, J VIROL, V80, P11362, DOI 10.1128/JVI.01679-06; Liao MF, 2006, J VIROL, V80, P9599, DOI 10.1128/JVI.01054-06; Liao MF, 2005, J CELL BIOL, V171, P111, DOI 10.1083/jcb.200507075; Mancini EJ, 2000, MOL CELL, V5, P255, DOI 10.1016/S1097-2765(00)80421-9; Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Roussel A, 2006, STRUCTURE, V14, P75, DOI 10.1016/j.str.2005.09.014; Serpell LC, 2000, J MOL BIOL, V299, P225, DOI 10.1006/jmbi.2000.3650; WAHLBERG JM, 1992, J CELL BIOL, V116, P339, DOI 10.1083/jcb.116.2.339; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; WENGLER G, 1992, VIROLOGY, V191, P880, DOI 10.1016/0042-6822(92)90263-O; WHITE J, 1980, J CELL BIOL, V87, P264, DOI 10.1083/jcb.87.1.264	34	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6752	6762		10.1074/jbc.M609125200	http://dx.doi.org/10.1074/jbc.M609125200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17192272	hybrid			2022-12-25	WOS:000244867200085
J	Baidoobonso, SM; Guidi, BW; Myers, LC				Baidoobonso, Shamara M.; Guidi, Benjamin W.; Myers, Lawrence C.			Med19(Rox3) regulates intermodule interactions in the Saccharomyces cerevisiale mediator complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATOR GCN4P; YEAST MEDIATOR; GENE-EXPRESSION; SRB MEDIATOR; PROTEINS; HOLOENZYME; MODULE; ROX3; DOMAIN	The Saccharomyces cerevisiae Mediator is a 25-subunit complex that facilitates both transcriptional activation and repression. Structural and functional studies have divided Mediator subunits into four distinct modules. The Head, Middle, and Tail modules form the core functional Mediator complex, whereas a fourth, the Cyc-C module, is variably associated with the core. By purifying Mediator from a strain lacking the Medl9(Rox3) subunit, we have found that a complex missing only the Med19(Rox3) subunit can be isolated under mild conditions. Additionally, we have established that the entire Middle module is released when the Amed19(rox3) Mediator is purified under more stringent conditions. In contrast to most models of the modular structure of Mediator, we show that release of the Middle module in the Amed]9(rox3) Mediator leaves a stable complex made up solely of Head and Tail subunits. Both the intact and Head-Tail Delta medl 9(rox3) Mediator complexes have defects in enhanced basal transcription, enhanced TFIIH phosphorylation of the CTD, as well as binding of RNA Pol II and the CTD. The largely intact Delta med19(rox3) complex facilitates activated transcription at levels similar to the wild type Mediator. In the absence of the Middle module, however, the Amed19(rox3) Mediator is unable to facilitate activated transcription. Although the Middle module is unnecessary for holding the Head and Tail modules together, it is required for the complex to function as a conduit between activators and the core transcription machinery.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Myers, LC (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.	larry.myers@dartmouth.edu			NIGMS NIH HHS [GM62483, R01 GM062483] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062483] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becerra M, 2002, MOL MICROBIOL, V43, P545, DOI 10.1046/j.1365-2958.2002.02724.x; Beve J, 2005, J BIOL CHEM, V280, P41366, DOI 10.1074/jbc.M511181200; Bjorklund S, 2005, TRENDS BIOCHEM SCI, V30, P240, DOI 10.1016/j.tibs.2005.03.008; BROWN TA, 1995, J BACTERIOL, V177, P6836, DOI 10.1128/jb.177.23.6836-6843.1995; Chadick JZ, 2005, TRENDS BIOCHEM SCI, V30, P264, DOI 10.1016/j.tibs.2005.03.001; Conaway RC, 2005, TRENDS BIOCHEM SCI, V30, P250, DOI 10.1016/j.tibs.2005.03.002; Davis JA, 2002, MOL CELL, V10, P409, DOI 10.1016/S1097-2765(02)00598-1; Fishburn J, 2005, MOL CELL, V18, P369, DOI 10.1016/j.molcel.2005.03.029; Guglielmi B, 2004, NUCLEIC ACIDS RES, V32, P5379, DOI 10.1093/nar/gkh878; Guidi BW, 2004, J BIOL CHEM, V279, P29114, DOI 10.1074/jbc.M404426200; Gustafsson CM, 1997, J BIOL CHEM, V272, P48; Han SJ, 1999, MOL CELL BIOL, V19, P979; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; JIANG YW, 1995, GENETICS, V140, P47; Kang JS, 2001, J BIOL CHEM, V276, P42003, DOI 10.1074/jbc.M105961200; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kornberg RD, 2005, TRENDS BIOCHEM SCI, V30, P235, DOI 10.1016/j.tibs.2005.03.011; Lee YC, 1999, MOL CELL BIOL, V19, P2967; Lee YC, 1998, MOL CELL BIOL, V18, P5364, DOI 10.1128/MCB.18.9.5364; Linder T, 2006, BIOCHEM BIOPH RES CO, V349, P948, DOI 10.1016/j.bbrc.2006.08.099; Liu Y, 2004, MOL CELL BIOL, V24, P1721, DOI 10.1128/MCB.24.4.1721-1735.2004; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Qiu HF, 2005, MOL CELL BIOL, V25, P3461, DOI 10.1128/MCB.25.9.3461-3474.2005; Qiu HF, 2004, MOL CELL BIOL, V24, P4104, DOI 10.1128/MCB.24.10.4104-4117.2004; Rani PG, 2004, MOL CELL BIOL, V24, P1709, DOI 10.1128/MCB.24.4.1709-1720.2004; Reeves WM, 2005, MOL CELL BIOL, V25, P9092, DOI 10.1128/MCB.25.20.9092-9102.2005; ROSENBLUMVOS LS, 1991, MOL CELL BIOL, V11, P5639, DOI 10.1128/MCB.11.11.5639; Samuelsen CO, 2003, P NATL ACAD SCI USA, V100, P6422, DOI 10.1073/pnas.1030497100; Singh H, 2006, GENETICS, V172, P2169, DOI 10.1534/genetics.105.052738; Song WJ, 1996, MOL CELL BIOL, V16, P115; Tabtiang RK, 1998, MOL CELL BIOL, V18, P4707, DOI 10.1128/MCB.18.8.4707; Takagi Y, 2005, J BIOL CHEM, V280, P31200, DOI 10.1074/jbc.C500150200; Takagi Y, 2006, MOL CELL, V23, P355, DOI 10.1016/j.molcel.2006.06.007; Tong Amy Hin Yan, 2006, Methods Mol Biol, V313, P171; van de Peppel J, 2005, MOL CELL, V19, P511, DOI 10.1016/j.molcel.2005.06.033; Wang X, 2004, GENETICS, V168, P747, DOI 10.1534/genetics.104.029611; Zhang F, 2004, MOL CELL BIOL, V24, P6871, DOI 10.1128/mcb.24.15.6871-6886.2004	41	47	74	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5551	5559		10.1074/jbc.M609484200	http://dx.doi.org/10.1074/jbc.M609484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17192271	Green Published, hybrid			2022-12-25	WOS:000244482300051
J	Kishibe, M; Bando, Y; Terayama, R; Namikawa, K; Takahashi, H; Hashimoto, Y; Ishida-Yamamoto, A; Jiang, YP; Mitrovic, B; Perez, D; Iizuka, H; Yoshida, S				Kishibe, Mari; Bando, Yoshio; Terayama, Ryuji; Namikawa, Kazuhiko; Takahashi, Hidetoshi; Hashimoto, Yoshio; Ishida-Yamamoto, Akerni; Jiang, Ying-Ping; Mitrovic, Branka; Perez, Daniel; Iizuka, Hajime; Yoshida, Shigetaka			Kallikrein 8 is involved in skin desquamation in cooperation with other kallikreins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEUM CHYMOTRYPTIC ENZYME; HUMAN TISSUE KALLIKREINS; STRATUM-CORNEUM; SERINE-PROTEASE; HUMAN EPIDERMIS; NEUROPSIN; EXPRESSION; MICE; DIFFERENTIATION; RECOMBINANT	Kallikrein type serine proteases, KLK8/neuropsin, KLK6, and KLK7, have been implicated in the proliferation and differentiation of epidermal keratinocytes and in the pathogenesis of psoriasis. However, their mechanistic roles in these processes remain largely unknown. We applied 12-O-tetradecanoylphorbol-13-acetate on the wild type (WT) and the Klk8 gene-disrupted (Klk8(-/-)) mouse skin, inducing keratinocyte proliferation similar to the human psoriatic lesion. Klk8 mRNA as well as Klk6 and Klk7 mRNA were up-regulated after 12-O-tetradecanoylphorbol-13-acetate application in the WT mice. In contrast, Klk8(-/-) mice showed minimum increases of Klk6 and Klk7 transcripts, the proteins, and enzymatic activities. Relative to the WT, the Klk8(-/-) skin showed less proliferation and an increase in the number of cell layers in the stratum corneum. However, overexpression of Klk8 by adenovirus vector in knock-out keratinocytes did not result in an increase in Klk6 or Klk7 mRNA. The inefficient cleavage of adhesion molecules DSG1 and CDSN in Klk8(-/-) skin contributes to a delay in corneocyte shedding, resulting in the hyperkeratosis phenotype. We propose that in psoriatic lesion, KLK8 modulates hyperproliferation and prevents excessive hyperkeratosis by shedding the corneocytes.	Asahikawa Med Coll, Dept Struct Anat & Neurosci, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 0788510, Japan; Berlex Biosci, Dept Immunol, Richmond, CA 94804 USA	Asahikawa Medical College; Asahikawa Medical College	Yoshida, S (corresponding author), Asahikawa Med Coll, Dept Struct Anat & Neurosci, 2-1-1-1 Midrorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.	syoshida@asahikawa-med.ac.jp						Borgono CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474; Brattsand M, 2005, J INVEST DERMATOL, V124, P198, DOI 10.1111/j.0022-202X.2004.23547.x; Caubet C, 2004, J INVEST DERMATOL, V122, P1235, DOI 10.1111/j.0022-202X.2004.22512.x; Diamandis EP, 2002, CLIN CHEM, V48, P1198; EGELRUD T, 1993, ACTA DERM-VENEREOL, V73, P181; Ekholm E, 1999, ARCH DERMATOL RES, V291, P195, DOI 10.1007/s004030050393; EVANS BA, 1987, J BIOL CHEM, V262, P8027; Fluhr JW, 2004, J INVEST DERMATOL, V123, P140, DOI 10.1111/j.0022-202X.2004.22726.x; Gan L, 2000, GENE, V257, P119, DOI 10.1016/S0378-1119(00)00382-6; Hansson L, 2002, J INVEST DERMATOL, V118, P444, DOI 10.1046/j.0022-202x.2001.01684.x; Harvey TJ, 2000, J BIOL CHEM, V275, P37397, DOI 10.1074/jbc.M004525200; Hirata A, 2001, MOL CELL NEUROSCI, V17, P600, DOI 10.1006/mcne.2000.0945; Ishida-Yamamoto A, 2004, J INVEST DERMATOL, V122, P1137, DOI 10.1111/j.0022-202X.2004.22515.x; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; Kirihara T, 2003, BRIT J DERMATOL, V149, P700, DOI 10.1046/j.1365-2133.2003.05484.x; Kitayoshi H, 1999, ARCH DERMATOL RES, V291, P333, DOI 10.1007/s004030050418; Komatsu N, 2005, J INVEST DERMATOL, V125, P1182, DOI 10.1111/j.0022-202X.2005.23933.x; Kuwae K, 2002, J CLIN PATHOL-MOL PA, V55, P235, DOI 10.1136/mp.55.4.235; Matsui H, 2000, J BIOL CHEM, V275, P11050, DOI 10.1074/jbc.275.15.11050; Matsumoto-Miyai K, 2003, J NEUROSCI, V23, P7727; Momota Y, 1998, EUR J NEUROSCI, V10, P760, DOI 10.1046/j.1460-9568.1998.00068.x; Shimizu C, 1998, J BIOL CHEM, V273, P11189, DOI 10.1074/jbc.273.18.11189; Simon M, 2001, J BIOL CHEM, V276, P20292, DOI 10.1074/jbc.M100201200; Terayama R, 2005, NEUROSCI LETT, V382, P82, DOI 10.1016/j.neulet.2005.03.022; YOUSEF G, 2000, BIOCHEM BIOPH RES CO, V276, P25; Zeeuwen PLJM, 2004, EUR J CELL BIOL, V83, P761, DOI 10.1078/0171-9335-00388; Zhen YX, 1999, ARCH DERMATOL RES, V291, P555, DOI 10.1007/s004030050453	27	49	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5834	5841		10.1074/jbc.M607998200	http://dx.doi.org/10.1074/jbc.M607998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17182622	Green Submitted, hybrid			2022-12-25	WOS:000244482300079
J	Oka, T; Nemoto, T; Jigami, Y				Oka, Takuji; Nemoto, Tadashi; Jigami, Yoshifumi			Functional analysis of Arabidopsis thaliana RHM2/MUM4, a multidomain protein involved in UDP-D-glucose to UDP-L-rhamnose conversion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DTDP-L-RHAMNOSE; D-GLUCURONATE 4-EPIMERASE; GDP-L-FUCOSE; SACCHAROMYCES-CEREVISIAE; RHAMNOGALACTURONAN-II; NOVO SYNTHESIS; PLANT-CELL; SEED COAT; MUR1 GENE; BIOSYNTHESIS	UDP-L-rhamnose is required for the biosynthesis of cell wall rhamnogalacturonan-I, rhamnogalacturonan-II, and natural compounds in plants. It has been suggested that the RHM2/MUM4 gene is involved in conversion of UDP-D-glucose to UDP-L-rhamnose on the basis of its effect on rhamnogalacturonan-l-directed development in Arabidopsis thaliana. RHM2/MUM4-related genes, RHM1 and RHM3, can be found in the A. thaliana genome. Here we present direct evidence that all three RHM proteins have UDP-D-glucose 4,6-dehydratase, UDP-4-keto-6-deoxy-D-glucose 3,5-epimerase, and UDP-4-keto-Lrhamnose 4-keto-reductase activities in the cytoplasm when expressed in the yeast Saccharomyces cerevisiae. Functional domain analysis revealed that the N-terminal region of RHM2 (RHM2-N; amino acids 1-370) has the first activity and the C-terminal region of RHM2 (RHM2-C; amino acids 371-667) has the two following activities. This suggests that RHM2 converts UDP-D-glucose to UDP-L-rhamnose via an UDP-4-keto-6-deoxy-D-glucose intermediate. Site-directed mutagenesis of RHM2 revealed that mucilage defects in MUM4-1 and MUM4-2 mutant seeds of A. thaliana are caused by abolishment of RHM2 enzymatic activity in the mutant strains and furthermore, that the GXXGXX(G/A) and YXXXK motifs are important for enzymatic activity. Moreover, a kinetic analysis of purified His(6)-tagged RHM2-N protein revealed 5.9-fold higher affinity of RHM2 for UDP-D-glucose than for dTDP-D-glucose, the preferred substrate for dTDP-D-glucose 4,6-dehydratase from bacteria. RHM2-N activity is strongly inhibited by UDP-L-rhamnose, UDP-D-xylose, and UDP but not by other sugar nucleotides, suggesting that RHM2 maintains cytoplasmic levels of UDP-D-glucose and UDP-L-rhamnose via feedback inhibition by UDP-L-rhamnose and UDP-D-xylose.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Jigami, Y (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan.	jigami.yoshi@aist.go.jp	Nemoto, Tadashi/M-3256-2018	Nemoto, Tadashi/0000-0002-5405-267X; Oka, Takuji/0000-0002-5691-654X				Ahn JW, 2006, J BIOL CHEM, V281, P13708, DOI 10.1074/jbc.M512403200; Barber C, 2006, J BIOL CHEM, V281, P17276, DOI 10.1074/jbc.M512727200; Bindschedler LV, 2005, PLANT MOL BIOL, V57, P285, DOI 10.1007/s11103-004-7795-7; Bonin CP, 2000, PLANT J, V21, P445, DOI 10.1046/j.1365-313x.2000.00698.x; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; Brachmann CB, 1998, YEAST, V14, P115; Burget EG, 2003, PLANT CELL, V15, P523, DOI 10.1105/tpc.008425; Diet A, 2006, PLANT CELL, V18, P1630, DOI 10.1105/tpc.105.038653; Dong C, 2003, BIOCHEM SOC T, V31, P532, DOI 10.1042/BST0310532; Duax WL, 2000, VITAM HORM, V58, P121, DOI 10.1016/S0083-6729(00)58023-6; Egelund J, 2004, PLANT PHYSIOL, V136, P2609, DOI 10.1104/pp.104.042978; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Graninger M, 1999, J BIOL CHEM, V274, P25069, DOI 10.1074/jbc.274.35.25069; Harper AD, 2002, PLANT PHYSIOL, V130, P2188, DOI 10.1104/pp.009654; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Ikan R, 1999, NATURALLY OCCURRING; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; JONES EW, 1991, METHOD ENZYMOL, V194, P429; KAMSTEEG J, 1978, FEBS LETT, V91, P281, DOI 10.1016/0014-5793(78)81192-2; Kang YB, 2006, BIOTECHNOL BIOENG, V93, P21, DOI 10.1002/bit.20648; Kotake T, 2004, J BIOL CHEM, V279, P45728, DOI 10.1074/jbc.M408716200; Meyers BC, 2004, PLANT PHYSIOL, V135, P801, DOI 10.1104/pp.104.039495; Molhoj M, 2004, PLANT PHYSIOL, V135, P1221, DOI 10.1104/pp.104.043745; Nakamura Y, 2000, NUCLEIC ACIDS RES, V28, P292, DOI 10.1093/nar/28.1.292; Nakayama K, 2003, GLYCOBIOLOGY, V13, P673, DOI 10.1093/glycob/cwg099; Oka T, 2006, FEBS J, V273, P2645, DOI 10.1111/j.1742-4658.2006.05281.x; ONeill MA, 1996, J BIOL CHEM, V271, P22923, DOI 10.1074/jbc.271.37.22923; Pattathil S, 2005, PLANTA, V221, P538, DOI 10.1007/s00425-004-1471-7; Reiter WD, 2001, PLANT MOL BIOL, V47, P95, DOI 10.1023/A:1010671129803; Ridley BL, 2001, PHYTOCHEMISTRY, V57, P929, DOI 10.1016/S0031-9422(01)00113-3; ROSSMANN MG, 1978, MOL CELL BIOCHEM, V21, P161; Seifert GJ, 2004, CURR OPIN PLANT BIOL, V7, P277, DOI 10.1016/j.pbi.2004.03.004; Seki M, 1998, PLANT J, V15, P707, DOI 10.1046/j.1365-313x.1998.00237.x; Seki M, 2002, SCIENCE, V296, P141, DOI 10.1126/science.1071006; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Somoza JR, 2000, STRUCTURE, V8, P123, DOI 10.1016/S0969-2126(00)00088-5; Tenhaken R, 1996, PLANT PHYSIOL, V112, P1127, DOI 10.1104/pp.112.3.1127; Turner W, 2002, ARCH BIOCHEM BIOPHYS, V407, P209, DOI 10.1016/S0003-9861(02)00500-3; Usadel B, 2004, FEBS LETT, V569, P327, DOI 10.1016/j.febslet.2004.06.005; Usadel B, 2004, PLANT PHYSIOL, V134, P286, DOI 10.1104/pp.103.034314; Watt G, 2004, PLANT PHYSIOL, V134, P1337, DOI 10.1104/pp.103.037192; Western TL, 2004, PLANT PHYSIOL, V134, P296, DOI 10.1104/pp.103.035519	42	123	137	3	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5389	5403		10.1074/jbc.M610196200	http://dx.doi.org/10.1074/jbc.M610196200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17190829	hybrid			2022-12-25	WOS:000244482300034
J	Ahuatzi, D; Riera, A; Pelaez, R; Herrero, P; Moreno, F				Ahuatzi, Deifilia; Riera, Alberto; Pelaez, Rafael; Herrero, Pilar; Moreno, Fernando			Hxk2 regulates the phosphorylation state of Mig1 and therefore its nucleocytoplasmic distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNF1 PROTEIN-KINASE; CARBON CATABOLITE REPRESSION; SACCHAROMYCES-CEREVISIAE; YEAST SNF1; SUBCELLULAR-LOCALIZATION; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; GLUCOSE REPRESSION; PHOSPHATASE 1; HEXOKINASE 2	Mig1 and Hxk2 are two major mediators of glucose repression in Saccharomyces cerevisiae. However, the mechanism by which Hxk2 participates in the glucose repression signaling pathway is not completely understood. Recently, it has been demonstrated that Hxk2 interacts with Mig1 to generate a repressor complex located in the nucleus of S. cerevisiae. However, the mechanism by which Mig1 favors the presence of Hxk2 in the nucleus is not clear, and the function of Hxk2 at the nuclear repressor complex level is still unknown. Here, we report that serine 311 of Mig1 is a critical residue for interaction with Hxk2 and that this interaction is regulated by glucose. Our findings suggest that Snf1 interacts constitutively with the Hxk2 component of the repressor complex at high and low glucose conditions. Furthermore, we show that Snf1 binds to Mig1 under low glucose conditions and that binding is largely abolished after a shift to high glucose medium. We found that phosphorylation of serine 311 of Mig1 by Snf1 kinase is essential for Mig1 protein nuclear export and derepression of the SUC2 gene in glucose-limited cells. These results allow postulating that the Hxk2 operates by interacting both with Mig1 and Snf1 to inhibit the Mig1 phosphorylation at serine 311 during high glucose grown.	Univ Oviedo, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	University of Oviedo	Moreno, F (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Campus Cristo, E-33006 Oviedo, Spain.	fmoreno@uniovi.es	Peláez, Rafael/R-9458-2019	Peláez, Rafael/0000-0002-4047-6017				Ahuatzi D, 2004, J BIOL CHEM, V279, P14440, DOI 10.1074/jbc.M313431200; Alms GR, 1999, EMBO J, V18, P4157, DOI 10.1093/emboj/18.15.4157; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; Cereghino GP, 1996, EMBO J, V15, P363, DOI 10.1002/j.1460-2075.1996.tb00366.x; de la Cera T, 2002, J MOL BIOL, V319, P703, DOI 10.1016/S0022-2836(02)00377-7; DeVit MJ, 1999, CURR BIOL, V9, P1231, DOI 10.1016/S0960-9822(99)80503-X; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; Elbing K, 2006, J BIOL CHEM, V281, P26170, DOI 10.1074/jbc.M603811200; ENTIAN KD, 1980, MOL GEN GENET, V178, P633, DOI 10.1007/BF00337871; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; GASCON S, 1968, J BIOL CHEM, V243, P1573; GUELMAN R, 2002, BONE, V30, P23; Hedbacker K, 2004, MOL CELL BIOL, V24, P8255, DOI 10.1128/MCB.24.18.8255-8263.2004; Herrero P, 1998, FEBS LETT, V434, P71, DOI 10.1016/S0014-5793(98)00872-2; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Ludin K, 1998, P NATL ACAD SCI USA, V95, P6245, DOI 10.1073/pnas.95.11.6245; MA H, 1986, MOL CELL BIOL, V6, P4046, DOI 10.1128/MCB.6.11.4046; Mayordomo I, 2002, J BIOL CHEM, V277, P35650, DOI 10.1074/jbc.M204198200; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; Moreno F, 2005, BIOCHEM SOC T, V33, P265, DOI 10.1042/BST0330265; Moreno F, 2002, FEMS MICROBIOL REV, V26, P83, DOI 10.1111/j.1574-6976.2002.tb00600.x; Nath N, 2003, MOL CELL BIOL, V23, P3909, DOI 10.1128/MCB.23.11.3909-3917.2003; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; Ostling J, 1996, MOL CELL BIOL, V16, P753; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; Palomino A, 2005, BIOCHEM J, V388, P697, DOI 10.1042/BJ20050160; Portillo F, 2005, FEBS LETT, V579, P512, DOI 10.1016/j.febslet.2004.12.019; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; Rolland F, 2002, FEMS YEAST RES, V2, P183, DOI 10.1111/j.1567-1364.2002.tb00084.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; Smith FC, 1999, FEBS LETT, V453, P219, DOI 10.1016/S0014-5793(99)00725-5; Tettelin H, 1997, NATURE, V387, P81, DOI 10.1038/387s081; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; Tomas-Cobos L, 2002, BIOCHEM J, V368, P657, DOI 10.1042/BJ20020984; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; Vincent O, 2001, GENE DEV, V15, P1104, DOI 10.1101/gad.879301; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6	42	110	112	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4485	4493		10.1074/jbc.M606854200	http://dx.doi.org/10.1074/jbc.M606854200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17178716	hybrid			2022-12-25	WOS:000244482000030
J	Cho, S; Szeto, HH; Kim, E; Kim, H; Tolhurst, AT; Pinto, JT				Cho, Sunghee; Szeto, Hazel H.; Kim, Eunhee; Kim, Hyunjoo; Tolhurst, Aaron T.; Pinto, John T.			A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B SCAVENGER RECEPTOR; LOW-DENSITY LIPOPROTEINS; FATTY-ACID TRANSLOCASE; HUMAN SKELETAL-MUSCLE; OXIDIZED LDL; CEREBRAL-ISCHEMIA; PPAR-GAMMA; CEREBROSPINAL-FLUID; GLUTATHIONE ANALOG; OXIDATIVE STRESS	Oxidative stress is implicated in the pathogenesis of ischemia/reperfusion injury. Recently, we demonstrated that activation of CD36, a class B scavenger receptor, mediates free radical production and tissue injury in cerebral ischemia (1). Oxidized low density lipoproteins (oxLDL) are among the ligands that bind to CD36 and are elevated in acute cerebral infarction. SS31 is a cell-permeable antioxidant peptide that reduces intracellular free radicals and inhibits LDL oxidation/lipid peroxidation (2). The current study was designed to investigate whether treatment with SS31 normalizes ischemia-induced redox changes and attenuates CD36-mediated tissue injury. C57BL/6 mice were subjected to transient middle cerebral artery occlusion (MCAO). Redox status and infarct volume were measured in animals treated with either saline or SS31. Oxidative stress induced by ischemia/reperfusion profoundly depleted glutathione (GSH) concentrations in the ipsilateral cortex and striatum. Treating mice with SS31 immediately after reperfusion significantly attenuated ischemia-induced GSH depletion in the cortex and reduced infarct size. By contrast, the protective effect of SS31 was absent in CD36 knock-out mice, indicating that SS31 is acting through inhibition of CD36. Treating C57BL/6 mice with SS31 reduced CD36 expression in postischemic brain and mouse peritoneal macrophages (MPM). Further in vitro studies revealed that SS31 attenuated oxLDL-induced CD36 expression and foam cell formation in MPM. These in vivo and in vitro studies indicate that the down-regulation of CD36 by novel class antioxidant peptides may be a useful strategy to treat ischemic stroke victims.	Cornell Univ, Dept Neurosci, Weill Med Coll, Burke Med Res Inst, White Plains, NY 10605 USA; Cornell Univ, Weill Med Coll, Dept Neurol Sci, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Cho, S (corresponding author), Cornell Univ, Dept Neurosci, Weill Med Coll, Burke Med Res Inst, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	suc2002@med.cornell.edu			NHLBI NIH HHS [R01 HL082511] Funding Source: Medline; NIDA NIH HHS [P01 DA08924] Funding Source: Medline; NINDS NIH HHS [R21 NS048295] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS048295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA008924] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Bezaire V, 2006, AM J PHYSIOL-ENDOC M, V290, pE509, DOI 10.1152/ajpendo.00312.2005; Bonen A, 2004, P NUTR SOC, V63, P245, DOI 10.1079/PNS2004331; Campbell SE, 2004, J BIOL CHEM, V279, P36235, DOI 10.1074/jbc.M400566200; Castro M, 2001, J NEUROCHEM, V78, P815, DOI 10.1046/j.1471-4159.2001.00461.x; Chabowski A, 2006, MOL CELL BIOCHEM, V288, P201, DOI 10.1007/s11010-006-9140-8; Chabowski A, 2006, FEBS LETT, V580, P3617, DOI 10.1016/j.febslet.2006.05.045; CHO J, 2006, IN PRESS CORON ART D; Cho S, 2005, J NEUROSCI, V25, P2504, DOI 10.1523/JNEUROSCI.0035-05.2005; COOPER AJL, 1980, J NEUROCHEM, V35, P1242, DOI 10.1111/j.1471-4159.1980.tb07882.x; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Feng JW, 2000, J LIPID RES, V41, P688; Fuhrman B, 2002, ATHEROSCLEROSIS, V161, P307, DOI 10.1016/S0021-9150(01)00646-3; Gambert S, 2006, MOL CELL BIOCHEM, V283, P147, DOI 10.1007/s11010-006-2518-9; GOTOH O, 1994, ACTA NEUROCHIR, P318; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; Hirano K, 2003, TRENDS CARDIOVAS MED, V13, P136, DOI 10.1016/S1050-1738(03)00026-4; JNABI M, 2000, ARTERIOSCLER THROMB, V280, P1953; KUNZ A, 2006, IN PRESS J CEREB BLO; Lakritz J, 1997, ANAL BIOCHEM, V247, P63, DOI 10.1006/abio.1997.2032; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Maxeiner H, 1998, J EXP MED, V188, P2257, DOI 10.1084/jem.188.12.2257; McCullough LD, 2005, J BIOL CHEM, V280, P20493, DOI 10.1074/jbc.M409985200; Medeiros LA, 2004, J BIOL CHEM, V279, P10643, DOI 10.1074/jbc.M311735200; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Namba K, 2001, J NEUROSURG ANESTH, V13, P131, DOI 10.1097/00008506-200104000-00010; Nihashi T, 2001, ACTA NEUROCHIR, V143, P287, DOI 10.1007/s007010170109; Petri S, 2006, J NEUROCHEM, V98, P1141, DOI 10.1111/j.1471-4159.2006.04018.x; Pilitsis JG, 2003, BRAIN RES, V985, P198, DOI 10.1016/S0006-8993(03)03044-0; Pilitsis JG, 2002, J NEUROSURG, V97, P272, DOI 10.3171/jns.2002.97.2.0272; Pinto JT, 2005, J NEUROCHEM, V94, P1087, DOI 10.1111/j.1471-4159.2005.03255.x; Ricciarelli R, 2000, CIRCULATION, V102, P82, DOI 10.1161/01.CIR.102.1.82; Roepstorff C, 2004, P NUTR SOC, V63, P239, DOI 10.1079/PNS2004332; Schiller PW, 2000, EUR J MED CHEM, V35, P895, DOI 10.1016/S0223-5234(00)01171-5; Shie FS, 2004, AM J PATHOL, V164, P1173, DOI 10.1016/S0002-9440(10)63205-1; Song WH, 2005, CORONARY ARTERY DIS, V16, P407, DOI 10.1097/00019501-200509000-00011; Szeto HH, 2006, AAPS J, V8, pE277, DOI 10.1007/BF02854898; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Uno M, 2003, J NEUROL NEUROSUR PS, V74, P312, DOI 10.1136/jnnp.74.3.312; VANELLA A, 1993, NEUROCHEM RES, V18, P1337, DOI 10.1007/BF00975056; Venugopal SK, 2004, ATHEROSCLEROSIS, V175, P213, DOI 10.1016/j.atherosclerosis.2004.03.012; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; Winterbourn CC, 2004, BIOCHEM J, V381, P241, DOI 10.1042/BJ20040259; Wu CL, 2002, AM J PHYSIOL-HEART C, V283, pH783, DOI 10.1152/ajpheart.00193.2002; YAMAMOTO M, 1993, RES COMMUN CHEM PATH, V81, P221; Zhao KS, 2005, BIOCHEM PHARMACOL, V70, P1796, DOI 10.1016/j.bcp.2005.08.022; Zhao KS, 2004, J BIOL CHEM, V279, P34682, DOI 10.1074/jbc.M402999200	50	129	160	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4634	4642		10.1074/jbc.M609388200	http://dx.doi.org/10.1074/jbc.M609388200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17178711	hybrid			2022-12-25	WOS:000244482000044
J	Fries, B; Heukeshoven, J; Hauber, I; Gruttner, C; Stocking, C; Kehlenbach, RH; Hall, J; Chemnitz, J				Fries, Barbara; Heukeshoven, Jochen; Hauber, Ilona; Gruettner, Cordula; Stocking, Carol; Kehlenbach, Ralph H.; Hall, Joachim; Chemnitz, Jan			Analysis of nucleocytoplasmic trafficking of the HuR ligand APRIL and its influence on CD83 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; ACIDIC NUCLEAR-PROTEIN; T-CELL STIMULATION; DENDRITIC CELLS; MAMMALIAN-CELLS; B-LYMPHOCYTES; SOLUBLE FORM; RICH; PHOSPHORYLATION; SYSTEM	Dendritic cells (DC) are the most potent antigen-presenting cells of the immune system and are able to sensitize even naive T cells. Mature DC are characterized by expression of CD83, a surface molecule that is proposed to be involved in efficient T cell activation. It has been recently shown that CD83 mRNA is transported from the nucleus to the cytoplasm in a HuR- and CRM1-dependent manner. Therefore we here investigated the impact of two known protein ligands of HuR, pp32 and APRIL, on CD83 expression. Both pp32 (ANP32A) and APRIL (ANP32B) are shuttle proteins, and it has been reported earlier that these HuR ligands can act as adaptors that link HuR and the CRM1-specific nuclear export pathway. By employing RNA interference (RNAi) technology we demonstrate that pp32 is dispensable for CD83 expression, whereas APRIL contributes to the nuclear export and subsequent translation of CD83 mRNA. Furthermore, we have determined the nuclear import signal (NLS) as well as the nuclear export signal (NES) of human APRIL. Moreover, we analyzed the status of phosphorylation of endogenous APRIL and identified threonine 244 to be an as yet unrecognized phosphate acceptor. Finally, we were able to show that phosphorylation of this specific amino acid residue regulates the nuclear export of APRIL. In sum, we report here the signal sequences in APRIL that mediate its intracellular trafficking and provide evidence that this protein ligand of HuR is an important player in the post-transcriptional regulation of CD83 expression by affecting the nucleocytoplasmic translocation of CD83 mRNA.	Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	Heinrich Pette Institute; University of Gottingen	Chemnitz, J (corresponding author), Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	jan.chemnitz@hpi.uni-hamburg.de		Kehlenbach, Ralph/0000-0003-4920-9916				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Beyer WR, 2002, J VIROL, V76, P1488, DOI 10.1128/JVI.76.3.1488-1495.2002; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Erkmann JA, 2004, EXP CELL RES, V296, P12, DOI 10.1016/j.yexcr.2004.03.015; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Fujimoto Yoko, 2006, Journal of Medical and Dental Sciences, V53, P85; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Heger P, 1999, ONCOGENE, V18, P4080, DOI 10.1038/sj.onc.1202762; Hock BD, 2006, TISSUE ANTIGENS, V67, P57, DOI 10.1111/j.1399-0039.2005.00524.x; Hock BD, 2004, LEUKEMIA RES, V28, P237, DOI 10.1016/S0145-2126(03)00255-8; Hock BD, 2001, INT IMMUNOL, V13, P959, DOI 10.1093/intimm/13.7.959; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; ISHIDA R, 1982, CANCER RES, V42, P4000; Izaurralde E, 2004, NAT STRUCT MOL BIOL, V11, P210, DOI 10.1038/nsmb0304-210; Jang BC, 2003, J BIOL CHEM, V278, P2773, DOI 10.1074/jbc.C200620200; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Keene JD, 2003, NAT GENET, V33, P111, DOI 10.1038/ng0203-111; Kimura T, 2004, J CELL SCI, V117, P2259, DOI 10.1242/jcs.01076; KOZLOW EJ, 1993, BLOOD, V81, P454, DOI 10.1182/blood.V81.2.454.454; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; Lechmann M, 2002, TRENDS IMMUNOL, V23, P273, DOI 10.1016/S1471-4906(02)02214-7; Lechmann M, 2002, INT ARCH ALLERGY IMM, V129, P113, DOI 10.1159/000065883; Lechmann M, 2001, J EXP MED, V194, P1813, DOI 10.1084/jem.194.12.1813; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Liku ME, 2005, MOL BIOL CELL, V16, P5026, DOI 10.1091/mbc.E05-05-0412; Matilla A, 2005, CEREBELLUM, V4, P7, DOI 10.1080/14734220410019020; Matsubae M, 2000, FEBS LETT, V468, P171, DOI 10.1016/S0014-5793(00)01218-7; McKinsey TA, 2000, MOL IMMUNOL, V37, P783, DOI 10.1016/S0161-5890(00)00099-7; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Mencinger M, 1998, BBA-GENE STRUCT EXPR, V1395, P176, DOI 10.1016/S0167-4781(97)00165-6; O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; Prechtel AT, 2006, J BIOL CHEM, V281, P10912, DOI 10.1074/jbc.M510306200; Rodriguez MS, 2004, BIOL CELL, V96, P639, DOI 10.1016/j.biolcel.2004.04.014; Rohaly G, 2005, CELL, V122, P21, DOI 10.1016/j.cell.2005.04.032; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; Scholler N, 2002, J IMMUNOL, V168, P2599, DOI 10.4049/jimmunol.168.6.2599; Schutz S, 2006, J MOL BIOL, V358, P997, DOI 10.1016/j.jmb.2006.02.041; Senechal B, 2004, BLOOD, V103, P4207, DOI 10.1182/blood-2003-12-4350; Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1074/jbc.M412367200; Stauber RH, 1998, VIROLOGY, V251, P38, DOI 10.1006/viro.1998.9295; VALENT P, 1991, P NATL ACAD SCI USA, V88, P3339, DOI 10.1073/pnas.88.8.3339; ZHOU LJ, 1992, J IMMUNOL, V149, P735; ZHOU LJ, 1995, J IMMUNOL, V154, P3821	54	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4504	4515		10.1074/jbc.M608849200	http://dx.doi.org/10.1074/jbc.M608849200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17178712	hybrid			2022-12-25	WOS:000244482000032
J	Gardner, LA; Naren, AP; Bahouth, SW				Gardner, Lidia A.; Naren, Anjaparavanda P.; Bahouth, Suleiman W.			Assembly of an SAP97-AKAP79-cAMP-dependent protein kinase scaffold at the type 1 PSD-95/DLG/ZO1 motif of the human beta(1)-adrenergic receptor generates a receptosome involved in receptor recycling and networking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; COUPLED RECEPTOR; BETA-ARRESTIN; MEMBRANE; DOMAIN; PHOSPHORYLATION; ACTIVATION; INTERACTS; RESENSITIZATION; INTERNALIZATION	Appropriate trafficking of the beta(1)-adrenergic receptor (beta(1)-AR) after agonist-promoted internalization is crucial for the resensitization of its signaling pathway. Efficient recycling of the beta(1)-AR required the binding of the protein kinase A anchoring protein-79 (AKAP79) to the carboxyl terminus of the beta(1)-AR (Gardner, L. A., Tavalin, S. A., Goehring, A., Scott, J. D., and Bahouth, S. W. (2006) J. Biol. Chem. 281, 33537-33553). In this study we show that AKAP79 forms a complex with the type 1 PDZ-binding sequence (ESKV) at the extreme carboxyl terminus of the beta(1)-AR, which is mediated by the membrane-associated guanylate kinase (MAGUK) protein SAP97. Thus, the PDZ and its associated SAP97-AKAP79 complex are involved in targeting the cyclic AMP-dependent protein kinase (PKA) to the beta(1)-AR. The PDZ and its scaffold were required for efficient recycling of the beta(1)-AR and for PKA-mediated phosphorylation of the beta(1)-AR at Ser(312). Overexpression of the catalytic subunit of PKA or mutagenesis of Ser312 to the phosphoserine mimic aspartic acid both rescued the recycling of the trafficking-defective beta(1)-ARAPDZ mutant. Thus, trafficking signals transmitted from the PDZ-associated scaffold in the carboxyl terminus of the beta(1)-AR to Ser312 in the 3rd intracellular loop (3rd IC) were paramount in setting the trafficking itinerary of the beta(1)-AR. The data presented here show that a novel beta(1)-adrenergic receptosome is organized at the beta(1)-AR PDZ to generate a scaffold essential for trafficking and networking of the beta(1)-AR.	Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Bahouth, SW (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.	sbahouth@utmem.edu						Aguilar RC, 2005, P NATL ACAD SCI USA, V102, P2679, DOI 10.1073/pnas.0500213102; CAHILL L, 1994, NATURE, V371, P702, DOI 10.1038/371702a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carlson CR, 2006, J BIOL CHEM, V281, P21535, DOI 10.1074/jbc.M603223200; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Debiec J, 2004, NEUROSCIENCE, V129, P267, DOI 10.1016/j.neuroscience.2004.08.018; Delos Santos NM, 2006, J BIOL CHEM, V281, P12896, DOI 10.1074/jbc.M508500200; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Fink MA, 2001, CIRC RES, V88, P291, DOI 10.1161/01.RES.88.3.291; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Funke L, 2005, ANNU REV BIOCHEM, V74, P219, DOI 10.1146/annurev.biochem.74.082803.133339; Gage RM, 2005, J BIOL CHEM, V280, P3305, DOI 10.1074/jbc.M406934200; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Gardner LA, 2004, J BIOL CHEM, V279, P21135, DOI 10.1074/jbc.M313652200; Gardner LA, 2006, J BIOL CHEM, V281, P33537, DOI 10.1074/jbc.M601809200; Giles J, 2005, NATURE, V436, P448, DOI 10.1038/436448a; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall Randy A, 2004, Methods Mol Biol, V261, P167; He JQ, 2006, J BIOL CHEM, V281, P2820, DOI 10.1074/jbc.M509503200; He JQ, 2004, J BIOL CHEM, V279, P50190, DOI 10.1074/jbc.M404876200; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Hu LYA, 2003, J BIOL CHEM, V278, P26295, DOI 10.1074/jbc.M212352200; Huang YY, 1996, NEURON, V16, P611, DOI 10.1016/S0896-6273(00)80080-X; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Krueger KM, 1997, J BIOL CHEM, V272, P5; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lohse MJ, 2003, CIRC RES, V93, P896, DOI 10.1161/01.RES.0000102042.83024.CA; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Lynch MJ, 2005, J BIOL CHEM, V280, P33178, DOI 10.1074/jbc.M414316200; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nakagawa T, 2004, NEURON, V44, P453, DOI 10.1016/j.neuron.2004.10.012; Oliveria SF, 2003, J CELL BIOL, V160, P101, DOI 10.1083/jcb.200209127; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Przybyslawski J, 1999, J NEUROSCI, V19, P6623; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; Valenti G, 2005, ENDOCRINOLOGY, V146, P5063, DOI 10.1210/en.2005-0868; Vanhoose AM, 2003, J NEUROSCI, V23, P5827; Xiao RP, 2004, TRENDS PHARMACOL SCI, V25, P358, DOI 10.1016/j.tips.2004.05.007; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; YU SS, 1993, J BIOL CHEM, V268, P337; Zeitoun O, 2006, MOL PHARMACOL, V70, P838, DOI 10.1124/mol.106.025346	50	62	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					5085	5099		10.1074/jbc.M608871200	http://dx.doi.org/10.1074/jbc.M608871200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17170109	hybrid			2022-12-25	WOS:000244482000091
J	Hori, Y; Hashimoto, T; Wakutani, Y; Urakami, K; Nakashima, K; Condron, MM; Tsubuki, S; Saido, TC; Teplow, DB; Iwatsubo, T				Hori, Yukiko; Hashimoto, Tadafumi; Wakutani, Yosuke; Urakami, Katsuya; Nakashima, Kenji; Condron, Margaret M.; Tsubuki, Satoshi; Saido, Takaomi C.; Teplow, David B.; Iwatsubo, Takeshi			The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate A beta fibril formation without increasing protofibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; TRANSGENIC MICE; EARLY-ONSET; IN-VITRO; EXPERIMENTAL CONSTRAINTS; MISSENSE MUTATION; THIOFLAVINE-T; PEPTIDES; AGGREGATION; GENE	A subset of Alzheimer disease cases is caused by autosomal dominant mutations in genes encoding the amyloid beta-protein precursor or presenilins. Whereas some amyloid beta-protein precursor mutations alter its metabolism through effects on A beta production, the pathogenic effects of those that alter amino acid residues within the A beta sequence are not fully understood. Here we examined the biophysical effects of two recently described intra-A beta mutations linked to early-onset familial Alzheimer disease, the D7N Tottori-Japanese and H6R English mutations. Although these mutations do not affect A beta production, synthetic A beta(1-42) peptides carrying D7N or H6R substitutions show enhanced fibril formation. In vitro analysis using A beta(140)-based mutant peptides reveal that D7N or H6R mutations do not accelerate the nucleation phase but selectively promote the elongation phase of amyloid fibril formation. Notably, the levels of protofibrils generated from D7N or H6R A beta were markedly inhibited despite enhanced fibril formation. These N-terminal A beta mutations may accelerate amyloid fibril formation by a unique mechanism causing structural changes of A beta peptides, specifically promoting the elongation process of amyloid fibrils without increasing metastable intermediates.	Univ Tokyo, Dept Neuropathol & Neurosci, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Tottori Univ, Dept Neurol, Torrori 6838504, Japan; Tottori Univ, Dept Biol Regulat, Torrori 6838504, Japan; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA 90095 USA; RIKEN, Brain Sci Inst, Wako, Saitama 3510198, Japan	University of Tokyo; Tottori University; Tottori University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; RIKEN	Iwatsubo, T (corresponding author), Univ Tokyo, Dept Neuropathol & Neurosci, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	iwatsubo@mol.f.u-tokyo.ac.jp	Hashimoto, Tadafumi/A-7723-2013; Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903; Hashimoto, Tadafumi/0000-0001-5442-4800	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038328, R01NS044147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018921, P01AG027818] Funding Source: NIH RePORTER; NIA NIH HHS [AG027818, AG18921] Funding Source: Medline; NINDS NIH HHS [NS38328, NS44147] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Bitan G, 2003, J BIOL CHEM, V278, P34882, DOI 10.1074/jbc.M300825200; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Cheng IH, 2004, NAT MED, V10, P1190, DOI 10.1038/nm1123; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Davis J, 2004, J BIOL CHEM, V279, P20296, DOI 10.1074/jbc.M312946200; Fezoui Y, 2002, J BIOL CHEM, V277, P36948, DOI 10.1074/jbc.M204168200; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1994, J BIOL CHEM, V269, P17441; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Herzig MC, 2004, NAT NEUROSCI, V7, P954, DOI 10.1038/nn1302; HSAIO K, 1996, SCIENCE, V274, P99; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Janssen JC, 2003, NEUROLOGY, V60, P235, DOI 10.1212/01.WNL.0000042088.22694.E3; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Krishnan R, 2005, NATURE, V435, P765, DOI 10.1038/nature03679; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; Lord A, 2006, NEUROBIOL AGING, V27, P67, DOI 10.1016/j.neurobiolaging.2004.12.007; Luhrs T, 2005, P NATL ACAD SCI USA, V102, P17342, DOI 10.1073/pnas.0506723102; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Murakami K, 2002, BIOCHEM BIOPH RES CO, V294, P5, DOI 10.1016/S0006-291X(02)00430-8; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Naiki H, 1996, LAB INVEST, V74, P374; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; O'Nuallain B, 2004, J BIOL CHEM, V279, P17490, DOI 10.1074/jbc.M311300200; Osada Y, 2005, J BIOL CHEM, V280, P8596, DOI 10.1074/jbc.M413340200; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Petkova AT, 2006, BIOCHEMISTRY-US, V45, P498, DOI 10.1021/bi051952q; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/0304-3940(96)12970-0; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200; Wakutani Y, 2004, J NEUROL NEUROSUR PS, V75, P1039, DOI 10.1136/jnnp.2003.010611; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945	51	91	93	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4916	4923		10.1074/jbc.M608220200	http://dx.doi.org/10.1074/jbc.M608220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17170111	hybrid			2022-12-25	WOS:000244482000074
J	Que, XC; Engel, JC; Ferguson, D; Wunderlich, A; Tomavo, S; Reed, SL				Que, Xuchu; Engel, Juan C.; Ferguson, David; Wunderlich, Annette; Tomavo, Stanislas; Reed, Sharon L.			Cathepsin Cs are key for the intracellular survival of the protozoan parasite, Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-I; CONGENITAL TOXOPLASMOSIS; PLASMODIUM-FALCIPARUM; CYSTEINE PROTEASE; ENDOPEPTIDASE; INHIBITION; ACTIVATION; EXPRESSION; TOXOPAIN-1; INVASION	Cysteine proteases play key roles in apicomplexan invasion, organellar biogenesis, and intracellular survival. We have now characterized five genes encoding papain family cathepsins from Toxoplasma gondii, including three cathepsin Cs, one cathepsin B, and one cathepsin L. Unlike endopeptidases cathepsin B and L, T. gondii cathepsin Cs are exopeptidases and remove dipeptides from unblocked N-terminal substrates of proteins or peptides. TgCPCl was the most highly expressed cathepsin mRNA in tachyzoites (by real-time PCR), but three cathepsins, TgCPC1, TgCPC2, and TgCPB, were undetectable in in vivo bradyzoites. The specific cathepsin C inhibitor, Gly-Phe-dimethylketone, selectively inhibited the TgCPCs activity, reducing parasite intracellular growth and proliferation. The targeted disruption of TgCPC1 does not affect the invasion and growth of tachyzoites as TgCPC2 is then up-regulated and may substitute for TgCPCl. TgCPCl and TgCPC2 localize to constitutive secretory vesicles of tachyzoites, the dense granules. T. gondii cathepsin Cs are required for peptide degradation in the parasitophorous vacuole as the degradation of the marker protein, Escherichia coli beta-lactamase, secreted into the parasitophorous vacuole of transgenic tachyzoites was completely inhibited by the cathepsin C inhibitor. Cathepsin C inhibitors also limited the in vivo infection of T. gondii in the chick embryo model of toxoplasmosis. Thus, cathepsin Cs are critical to T. gondii growth and differentiation, and their unique specificities could be exploited to develop novel chemotherapeutic agents.	Univ Calif San Diego, Med Ctr, Div Infect Dis, Dept Pathol, San Diego, CA 92103 USA; Univ Calif San Diego, Med Ctr, Div Infect Dis, Dept Med, San Diego, CA 92103 USA; Univ Calif San Francisco, Vet Adm Med Ctr, Dept Pathol, San Francisco, CA 94121 USA; Univ Oxford, Nuffield Dept Pathol, Oxford OX3 9DU, England; Univ Sci & Tech Lille, UGSF, CNRS, UMR 8576, F-59655 Villeneuve Dascq, France	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Oxford; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Reed, SL (corresponding author), Univ Calif San Diego, Med Ctr, Div Infect Dis, Dept Pathol, 200 W Arbor Dr, San Diego, CA 92103 USA.	slreed@ucsd.edu		Ferguson, David/0000-0001-5045-819X; Que, Xuchu/0000-0002-6751-5493	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035707] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41093, AI35707] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bidere N, 2002, J BIOL CHEM, V277, P32339, DOI 10.1074/jbc.M205153200; Bohne W, 1998, MOL BIOCHEM PARASIT, V92, P291, DOI 10.1016/S0166-6851(97)00236-3; Carruthers VB, 2000, INFECT IMMUN, V68, P4005, DOI 10.1128/IAI.68.7.4005-4011.2000; Dahl SW, 2001, BIOCHEMISTRY-US, V40, P1671, DOI 10.1021/bi001693z; Donald RGK, 1998, MOL BIOCHEM PARASIT, V91, P295, DOI 10.1016/S0166-6851(97)00210-7; Dzierszinski F, 2001, J MOL BIOL, V309, P1017, DOI 10.1006/jmbi.2001.4730; Greenbaum DC, 2002, SCIENCE, V298, P2002, DOI 10.1126/science.1077426; Klemba M, 2004, J BIOL CHEM, V279, P43000, DOI 10.1074/jbc.M408123200; Korver GE, 2001, INT IMMUNOPHARMACOL, V1, P21, DOI 10.1016/S0162-3109(00)00267-8; Loftus B, 2005, NATURE, V433, P865, DOI 10.1038/nature03291; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; McLeod R, 2000, CURR CLIN TOPICS INF, V20, P189; Mercier C, 2002, MOL BIOL CELL, V13, P2397, DOI 10.1091/mbc.E02-01-0021; Nakaar V, 1999, J BIOL CHEM, V274, P5083, DOI 10.1074/jbc.274.8.5083; Que XC, 2004, INFECT IMMUN, V72, P2915, DOI 10.1128/IAI.72.5.2915-2921.2004; Que XC, 2002, J BIOL CHEM, V277, P25791, DOI 10.1074/jbc.M202659200; Sajid M, 2003, MOL BIOCHEM PARASIT, V131, P65, DOI 10.1016/S0166-6851(03)00194-4; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; Shaw MK, 2002, MICROBES INFECT, V4, P119, DOI 10.1016/S1286-4579(01)01520-9; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Thiele DL, 1997, J IMMUNOL, V158, P5200; Touz MC, 2003, J BIOL CHEM, V278, P6420, DOI 10.1074/jbc.M208354200; Tran TV, 2002, ARCH BIOCHEM BIOPHYS, V403, P160, DOI 10.1016/S0003-9861(02)00217-5; Turk D, 2001, EMBO J, V20, P6570, DOI 10.1093/emboj/20.23.6570	24	45	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4994	5003		10.1074/jbc.M606764200	http://dx.doi.org/10.1074/jbc.M606764200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17164247	hybrid			2022-12-25	WOS:000244482000082
J	Greenwald, J; Hoegy, F; Nader, M; Journet, L; Mislin, GLA; Graumann, PL; Schalk, IJ				Greenwald, Jason; Hoegy, Francoise; Nader, Mirella; Journet, Laure; Mislin, Gaeetan L. A.; Graumann, Peter L.; Schalk, Isabelle J.			Real time fluorescent resonance energy transfer visualization of ferric pyoverdine uptake in pseudomonas aeruginosa - A role for ferrous iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE RECEPTOR; FERRIPYOVERDINE RECEPTOR; ESCHERICHIA-COLI; SIDEROPHORE; FPVA; MECHANISM; TONB; TRANSPORT; IDENTIFICATION; OXIDOREDUCTASE	To acquire iron, Pseudomonas aeruginosa secretes a major fluorescent siderophore, pyoverdine (PvdI), that chelates iron and shuttles it into the cells via the specific outer membrane transporter, FpvAI. We took advantage of the fluorescence properties of PvdI and its metal chelates as well as the efficient FRET between donor tryptophans in FpvAI and PvdI to follow the fate of the siderophore during iron uptake. Our findings with PvdI-Ga and PvdI-Cr uptake indicate that iron reduction is required for the dissociation of PvdI-Fe, that a ligand exchange for iron occurs, and that this dissociation occurs in the periplasm. We also observed a delay between PvdI-Fe dissociation and the rebinding of PvdI to FpvAI, underlining the kinetic independence of metal release and siderophore recycling. Meanwhile, PvdI is not modified but recycled to the medium, still competent for iron chelation and transport. Finally, in vivo fluorescence microscopy revealed patches of PvdI, suggesting that uptake occurs via macromolecular assemblies on the cell surface.	Univ Strasbourg 1, ESBS, UMR 7175 LC1, Inst Gilbert Laustriat,CNRS, F-67413 Illkirch Graffenstaden, Strasbourg, France; Univ Freiburg, Inst Mikrobiol, D-79104 Freiburg, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Freiburg	Schalk, IJ (corresponding author), Univ Strasbourg 1, ESBS, UMR 7175 LC1, Inst Gilbert Laustriat,CNRS, Blvd Sebastien Brant,BP 10412, F-67413 Illkirch Graffenstaden, Strasbourg, France.	schalk@esbs.u-strasbg.fr		Graumann, Peter/0000-0002-8033-5171; Journet, Laure/0000-0002-5847-2962				ALBRECHTGARY AM, 1994, INORG CHEM, V33, P6391, DOI 10.1021/ic00104a059; ANKENBAUER R, 1986, J BACTERIOL, V167, P7, DOI 10.1128/jb.167.1.7-11.1986; Boukhalfa H, 2002, BIOMETALS, V15, P325, DOI 10.1023/A:1020218608266; Braun V, 2003, FRONT BIOSCI-LANDMRK, V8, pS1409, DOI 10.2741/1232; Buchanan SK, 1999, CURR OPIN STRUC BIOL, V9, P455, DOI 10.1016/S0959-440X(99)80064-5; Budzikiewicz H, 1997, Z NATURFORSCH C, V52, P713; Clement E, 2004, BIOCHEMISTRY-US, V43, P7954, DOI 10.1021/bi049768c; Cobessi D, 2005, J MOL BIOL, V352, P893, DOI 10.1016/j.jmb.2005.08.004; Cobessi D, 2005, J MOL BIOL, V347, P121, DOI 10.1016/j.jmb.2005.01.021; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; de Chial M, 2003, MICROBIOL-SGM, V149, P821, DOI 10.1099/mic.0.26136-0; DEAN CR, 1993, MOL MICROBIOL, V8, P1095, DOI 10.1111/j.1365-2958.1993.tb01654.x; DEMANGE P, 1990, BIOL MET, V3, P155; ECKER DJ, 1983, J BACTERIOL, V155, P616, DOI 10.1128/JB.155.2.616-622.1983; EMERY T, 1980, J NUCL MED, V21, P935; Ferguson AD, 1998, PROTEIN SCI, V7, P1636, DOI 10.1002/pro.5560070719; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Folschweiller N, 2002, BIOCHEMISTRY-US, V41, P14591, DOI 10.1021/bi0259711; Ghysels B, 2004, MICROBIOL-SGM, V150, P1671, DOI 10.1099/mic.0.27035-0; HALLE F, 1992, EUR J BIOCHEM, V209, P613, DOI 10.1111/j.1432-1033.1992.tb17327.x; HALLE F, 1992, EUR J BIOCHEM, V209, P621, DOI 10.1111/j.1432-1033.1992.tb17328.x; Koster W, 2001, RES MICROBIOL, V152, P291, DOI 10.1016/S0923-2508(01)01200-1; LANGMAN L, 1972, J BACTERIOL, V112, P1142, DOI 10.1128/JB.112.3.1142-1149.1972; LEONG J, 1976, J BACTERIOL, V126, P823, DOI 10.1128/JB.126.2.823-830.1976; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Mascarenhas J, 2002, EMBO J, V21, P3108, DOI 10.1093/emboj/cdf314; Matzanke BF, 2004, BIOCHEMISTRY-US, V43, P1386, DOI 10.1021/bi0357661; MATZANKE BF, 1997, IRON TRANPORT MICROB; Meyer JM, 2002, APPL ENVIRON MICROB, V68, P2745, DOI 10.1128/AEM.68.6.2745-2753.2002; Mielczarek E V, 1990, Biol Met, V3, P34, DOI 10.1007/BF01141175; Mies KA, 2006, BIOMETALS, V19, P115, DOI 10.1007/s10534-005-4342-1; Moeck GS, 1998, MOL MICROBIOL, V28, P675, DOI 10.1046/j.1365-2958.1998.00817.x; Poole K, 2003, FRONT BIOSCI-LANDMRK, V8, pD661, DOI 10.2741/1051; Poole K, 1996, MICROBIOL-UK, V142, P1449, DOI 10.1099/13500872-142-6-1449; POOLE K, 1993, J BACTERIOL, V175, P4597, DOI 10.1128/JB.175.15.4597-4604.1993; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; Ravel J, 2003, TRENDS MICROBIOL, V11, P195, DOI 10.1016/S0966-842X(03)00076-3; Royt P W, 1990, Biol Met, V3, P28, DOI 10.1007/BF01141174; SCHALK I, 2004, PSEUDOMONAS MOL BIOL, V4; Schalk IJ, 1999, BIOCHEMISTRY-US, V38, P9357, DOI 10.1021/bi990421x; Schalk IJ, 2004, MOL MICROBIOL, V54, P14, DOI 10.1111/j.1365-2958.2004.04241.x; Schalk IJ, 2002, BIOCHEMISTRY-US, V41, P1663, DOI 10.1021/bi0157767; Schalk IJ, 2001, MOL MICROBIOL, V39, P351, DOI 10.1046/j.1365-2958.2001.02207.x; Takase H, 2000, INFECT IMMUN, V68, P1834, DOI 10.1128/IAI.68.4.1834-1839.2000; Voulhoux R, 2006, J BACTERIOL, V188, P3317, DOI 10.1128/JB.188.9.3317-3323.2006; Yue WW, 2003, J MOL BIOL, V332, P353, DOI 10.1016/S0022-2836(03)00855-6	46	81	82	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2987	2995		10.1074/jbc.M609238200	http://dx.doi.org/10.1074/jbc.M609238200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148441	hybrid			2022-12-25	WOS:000243793900025
J	Wong, CH; Mruk, DD; Lee, WM; Cheng, CY				Wong, Ching-Hang; Mruk, Dolores D.; Lee, Will M.; Cheng, C. Yan			Targeted and reversible disruption of the blood-testis barrier by an FSH mutant-occludin peptide conjugate	FASEB JOURNAL			English	Article						spermatogenesis; light junction; adherens junction; ectoplasmic specialization; serfoli-germ cell interactions; male contraception	FOLLICLE-STIMULATING-HORMONE; GERM CELL-INTERACTIONS; IN-VIVO; JUNCTION DYNAMICS; TIGHT JUNCTIONS; SERTOLI-CELLS; CARBOHYDRATE RESIDUES; SIGNAL-TRANSDUCTION; RECEPTOR-BINDING; RAT TESTIS	The blood-testis barrier (BTB) is one of the tightest blood-tissue barriers in mammals. As such, it poses a challenge to deliver any drugs to the seminiferous epithelium of the testis, such as a nonhormonal male contraceptive. To circumvent this problem, a genetically engineered follicle-stimulating hormone (FSH) mutant protein was produced in Spodoptera furgiperda (Sf)-9 insect cells to serve as a testis-specific carrier. Subsequently, a 22-amino acid peptide corresponding to the second extracellular loop of occludin, which was known to disrupt BTB integrity in vivo, was inserted to the FSH mutant by polymerase chain reaction (PCR), as well as chemical cross-linking. This molecule was found to have negligible hormonal activity but was still capable of binding to FSH receptors, which are restricted to Sertoli cells in mammals. When this FSH mutant-occludin peptide conjugate was administered to adult rats at 40 mu g/adult rat (similar to 300 gm b.w.) via intraperitoneally (i.p.) injection, it induced transient and reversible disruption of the BTB, while at 150 mu g/rat, it induced partial germ cell loss from the testis, particularly elongating/elongate spermatids. Most importantly, this effect was limited to the BTB without compromising the TJ-barrier integrity or cell adhesion in epithelia of other organs, such as kidney, liver, and small intestine. In summary, the use of an FSH mutant-occludin peptide conjugate is a feasible nanodevice to transiently compromise the BTB.	Populat Council, Ctr Biomed Res, New York, NY 10021 USA; Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong, Peoples R China	Population Council; University of Hong Kong	Cheng, CY (corresponding author), Populat Council, Ctr Biomed Res, 1230 York Ave, New York, NY 10021 USA.	y-cheng@popcby.rockefeller.edu	Lee, Will M/D-2357-2009	Cheng, C Yan/0000-0003-3117-3791	NICHD NIH HHS [U01 HD045908-04, U01 HD045908, U54 HD029990, U01 HD045908-01, U01 HD045908-02, U01 HD045908-03, U54 HD029990-110007] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD029990] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD045908] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baccetti B, 1998, FASEB J, V12, P1045, DOI 10.1096/fasebj.12.11.1045; Balda MS, 2000, SEMIN CELL DEV BIOL, V11, P281, DOI 10.1006/scdb.2000.0177; Bart J, 2002, LANCET ONCOL, V3, P357, DOI 10.1016/S1470-2045(02)00776-3; BISHOP LA, 1995, ENDOCRINOLOGY, V136, P2635, DOI 10.1210/en.136.6.2635; BISHOP LA, 1994, MOL ENDOCRINOL, V8, P722, DOI 10.1210/me.8.6.722; Cheng CY, 2002, PHYSIOL REV, V82, P825, DOI 10.1152/physrev.00009.2002; Chung NPY, 2001, BIOL REPROD, V65, P1340, DOI 10.1095/biolreprod65.5.1340; COLOMA TAS, 1990, J BIOL CHEM, V265, P5037; Dias JA, 1998, BIOL REPROD, V58, P1331, DOI 10.1095/biolreprod58.6.1331; Dym M, 1970, Biology Reprod., V3, P308; FLACK MR, 1994, J BIOL CHEM, V269, P14015; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Ghabriel MN, 2004, J COMP PATHOL, V131, P52, DOI 10.1016/j.jcpa.2004.01.004; GRIMA J, 1992, MOL CELL ENDOCRINOL, V89, P127, DOI 10.1016/0303-7207(92)90219-V; GRISWOLD MD, 1995, J STEROID BIOCHEM, V53, P215, DOI 10.1016/0960-0760(95)00049-6; Griswold MD, 1998, SEMIN CELL DEV BIOL, V9, P411, DOI 10.1006/scdb.1998.0203; KEENE JL, 1989, J BIOL CHEM, V264, P4769; Kondoh M, 2005, MOL PHARMACOL, V67, P749, DOI 10.1124/mol.104.008375; Lee NPY, 2003, ENDOCRINOLOGY, V144, P3114, DOI 10.1210/en.2002-0167; LINDAUSHEPARD B, 1994, ENDOCRINOLOGY, V135, P1235, DOI 10.1210/en.135.3.1235; MEANS AR, 1980, ANNU REV PHYSIOL, V42, P59, DOI 10.1146/annurev.ph.42.030180.000423; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Moroi S, 1998, AM J PHYSIOL-CELL PH, V274, pC1708, DOI 10.1152/ajpcell.1998.274.6.C1708; Mruk DD, 2004, ENDOCR REV, V25, P747, DOI 10.1210/er.2003-0022; Rose MP, 2000, ENDOCR REV, V21, P5, DOI 10.1210/er.21.1.5; Sairam MR, 2001, ARCH MED RES, V32, P601, DOI 10.1016/S0188-4409(01)00328-9; SETCHELL BP, 1980, J ANDROL, V1, P3; SILVESTRINI B, 1990, CLIN CHEM, V36, P277; Siu MKY, 2005, J BIOL CHEM, V280, P25029, DOI 10.1074/jbc.M501049200; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; Ulloa-Aguirre A, 2003, BIOL REPROD, V69, P379, DOI 10.1095/biolreprod.103.016915; Ulloa-Aguirre A, 1999, ENDOCRINE, V11, P205, DOI 10.1385/ENDO:11:3:205; VALOVE FM, 1994, ENDOCRINOLOGY, V135, P2657, DOI 10.1210/en.135.6.2657; VanItallie CM, 1997, J CELL SCI, V110, P1113; WAHLSTROM T, 1983, J CLIN ENDOCR METAB, V57, P825, DOI 10.1210/jcem-57-4-825; Walker WH, 2005, REPRODUCTION, V130, P15, DOI 10.1530/rep.1.00358; Wong CH, 2005, CURR TOP DEV BIOL, V71, P263, DOI 10.1016/S0070-2153(05)71008-5; Wong CH, 2005, ENDOCRINOLOGY, V146, P1893, DOI 10.1210/en.2004-1464; Wong CH, 2004, J CELL SCI, V117, P783, DOI 10.1242/jcs.00900; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399	40	38	41	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2007	21	2					438	448		10.1096/fj.05-4144com	http://dx.doi.org/10.1096/fj.05-4144com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YD	17167075	Green Accepted			2022-12-25	WOS:000244686300017
J	Eger, KA; Sundrud, MS; Motsinger, AA; Tseng, M; Van Kaer, L; Unutmaz, D				Eger, Karla A.; Sundrud, Mark S.; Motsinger, Alison A.; Tseng, Michelle; Van Kaer, Luc; Unutmaz, Derya			Human Natural Killer T Cells Are Heterogeneous in Their Capacity to Reprogram Their Effector Functions	PLOS ONE			English	Article								Background. Natural killer T (NKT) cells are a subset of T cells that help potentiate and regulate immune responses. Although human NKT cell subsets with distinct effector functions have been identified, it is unclear whether the effector functions of these subsets are imprinted during development or can be selectively reprogrammed in the periphery. Results. We found that neonatal NKT cells are predominantly CD4+ and express higher levels of CCR7 and CD62L and lower levels of CD94 and CD161 than adult CD4+ or CD4- NKT cell subsets. Accordingly, neonatal NKT cells were more flexible than adult CD4+ NKT cells in their capacity to acquire Th1- or Th2-like functions upon either cytokine-mediated polarization or ectopic expression of the Th1 or Th2 transcription factors T-bet and GATA-3, respectively. Consistent with their more differentiated phenotype, CD4- NKT cells were predominantly resistant to functional reprogramming and displayed higher cytotoxic function. In contrast to conventional T cells, neither the expression of CXCR3 nor the cytotoxic capacity of neonatal NKT cells could be reprogrammed. Conclusions and Significance. Together, these results suggest that neonatal CD4+, adult CD4+, and adult CD4- NKT may represent unique states of maturation and that some functions of human NKT cells may be developmentally imprinted, while others are acquired similar to conventional T cell subsets during peripheral maturation and differentiation. Given the potent immuno-regulatory functions of NKT cells, these findings have important implications for the development of novel NKT cell-based therapeutics and vaccines.	[Eger, Karla A.; Sundrud, Mark S.; Tseng, Michelle; Van Kaer, Luc; Unutmaz, Derya] Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37212 USA; [Motsinger, Alison A.] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University	Unutmaz, D (corresponding author), NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.	Derya.Unutmaz@med.nyu.edu	Van Kaer, Luc/H-1033-2015; Motsinger-Reif, Alison/I-4167-2018	Van Kaer, Luc/0000-0001-5275-2309; Motsinger-Reif, Alison/0000-0003-1346-2493	National Institutes of Health [AI50953, NS44044, HL68744, GM62758, T32 HL069765, AI054206]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068744, T32HL069765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM062758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044044] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Funding: This work was supported by National Institutes of Health grants AI50953, NS44044, HL68744 to LVK, GM62758 to AAM, T32 HL069765 to KAE, and AI054206 to DU.	Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Baev DV, 2004, BLOOD, V104, P4150, DOI 10.1182/blood-2004-04-1629; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Berzins SP, 2005, EUR J IMMUNOL, V35, P1399, DOI 10.1002/eji.200425958; Bezbradica JS, 2005, J IMMUNOL, V174, P4696, DOI 10.4049/jimmunol.174.8.4696; Brigl M, 2004, ANNU REV IMMUNOL, V22, P817, DOI 10.1146/annurev.immunol.22.012703.104608; Couedel C, 1998, EUR J IMMUNOL, V28, P4391, DOI 10.1002/(SICI)1521-4141(199812)28:12<4391::AID-IMMU4391>3.0.CO;2-2; Crowe NY, 2005, J EXP MED, V202, P1279, DOI 10.1084/jem.20050953; D'Andrea A, 2000, EUR J IMMUNOL, V30, P1544, DOI 10.1002/1521-4141(200006)30:6<1544::AID-IMMU1544>3.0.CO;2-I; DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171; EMOTO M, 1995, INT IMMUNOL, V7, P1729, DOI 10.1093/intimm/7.11.1729; Fischer K, 2004, P NATL ACAD SCI USA, V101, P10685, DOI 10.1073/pnas.0403787101; Godfrey DI, 2004, NAT REV IMMUNOL, V4, P231, DOI 10.1038/nri1309; Gumperz JE, 2002, J EXP MED, V195, P625, DOI 10.1084/jem.20011786; HAHN S, 1995, IMMUNOL REV, V146, P57, DOI 10.1111/j.1600-065X.1995.tb00684.x; Hayakawa Y, 2001, J IMMUNOL, V166, P6012, DOI 10.4049/jimmunol.166.10.6012; Ho IC, 2002, CELL, V109, pS109, DOI 10.1016/S0092-8674(02)00705-5; Joyce S, 2001, CELL MOL LIFE SCI, V58, P442, DOI 10.1007/PL00000869; Kadowaki N, 2001, J EXP MED, V193, P1221, DOI 10.1084/jem.193.10.1221; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kim CH, 2002, BLOOD, V100, P11, DOI 10.1182/blood-2001-12-0196; Kinjo Y, 2005, NATURE, V434, P520, DOI 10.1038/nature03407; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; Laouar A, 2005, NAT IMMUNOL, V6, P698, DOI 10.1038/ni1212; Lee PT, 2002, J EXP MED, V195, P637, DOI 10.1084/jem.20011908; Loza MJ, 2002, EUR J IMMUNOL, V32, P3453, DOI 10.1002/1521-4141(200212)32:12<3453::AID-IMMU3453>3.0.CO;2-D; Matsuda JL, 2006, BLOOD, V107, P2797, DOI 10.1182/blood-2005-08-3103; Matsuda JL, 2003, P NATL ACAD SCI USA, V100, P8395, DOI 10.1073/pnas.1332805100; Matsumoto G, 2004, J IMMUNOL, V173, P4976, DOI 10.4049/jimmunol.173.8.4976; Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408; Messi M, 2003, NAT IMMUNOL, V4, P78, DOI 10.1038/ni872; Metelitsa LS, 2001, J IMMUNOL, V167, P3114, DOI 10.4049/jimmunol.167.6.3114; Miyamoto K, 2001, NATURE, V413, P531, DOI 10.1038/35097097; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Motsinger A, 2002, J EXP MED, V195, P869, DOI 10.1084/jem.20011712; Motsinger A, 2003, J VIROL, V77, P8153, DOI 10.1128/JVI.77.14.8153-8158.2003; Nuti S, 1998, EUR J IMMUNOL, V28, P3448, DOI 10.1002/(SICI)1521-4141(199811)28:11<3448::AID-IMMU3448>3.0.CO;2-5; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; OHTEKI T, 1994, J EXP MED, V180, P699, DOI 10.1084/jem.180.2.699; Ortaldo JR, 2004, J IMMUNOL, V172, P943, DOI 10.4049/jimmunol.172.2.943; Parekh VV, 2004, J IMMUNOL, V173, P3693, DOI 10.4049/jimmunol.173.6.3693; PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1; Porcelli S, 1996, HUM IMMUNOL, V48, P63, DOI 10.1016/0198-8859(96)00090-0; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sandberg JK, 2004, P NATL ACAD SCI USA, V101, P7058, DOI 10.1073/pnas.0305986101; Schmidt-Supprian M, 2004, P NATL ACAD SCI USA, V101, P4566, DOI 10.1073/pnas.0400885101; Schmieg J, 2003, J EXP MED, V198, P1631, DOI 10.1084/jem.20031192; Seino K, 2004, FRONT BIOSCI-LANDMRK, V9, P2577, DOI 10.2741/1418; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Sriram V, 2005, EUR J IMMUNOL, V35, P1692, DOI 10.1002/eji.200526157; Stanic AK, 2004, J IMMUNOL, V172, P4667, DOI 10.4049/jimmunol.172.8.4667; Stanic AK, 2004, J IMMUNOL, V172, P2265, DOI 10.4049/jimmunol.172.4.2265; Sundrud MS, 2003, J IMMUNOL, V171, P3542, DOI 10.4049/jimmunol.171.7.3542; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Takahashi T, 2002, J IMMUNOL, V168, P3140, DOI 10.4049/jimmunol.168.7.3140; Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.immunol.21.120601.141057; Taniguchi M, 2000, SEMIN IMMUNOL, V12, P543, DOI 10.1006/smim.2000.0270; Townsend MJ, 2004, IMMUNITY, V20, P477, DOI 10.1016/S1074-7613(04)00076-7; Unutmaz D, 1999, J EXP MED, V189, P1735, DOI 10.1084/jem.189.11.1735; van der Vliet HJJ, 2003, CANCER RES, V63, P4101; Van Kaer L, 2005, CURR BIOL, V15, pR429, DOI 10.1016/j.cub.2005.05.032; Wei DG, 2005, J EXP MED, V202, P239, DOI 10.1084/jem.20050413; Wu D, 2005, P NATL ACAD SCI USA, V102, P1351, DOI 10.1073/pnas.0408696102; Yu KOA, 2005, IMMUNOL LETT, V100, P42, DOI 10.1016/j.imlet.2005.06.010; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	70	35	37	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e50	10.1371/journal.pone.0000050	http://dx.doi.org/10.1371/journal.pone.0000050			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183680	Green Submitted, Green Published, gold			2022-12-25	WOS:000207443600050
J	Kapralov, MV; Filatov, DA				Kapralov, Maxim V.; Filatov, Dmitry A.			Molecular Adaptation during Adaptive Radiation in the Hawaiian Endemic Genus Schiedea	PLOS ONE			English	Article							EVOLUTION; SELECTION; RUBISCO; HYBRIDIZATION; SEQUENCES; SOFTWARE; MATK	Background. "Explosive'' adaptive radiations on islands remain one of the most puzzling evolutionary phenomena. The rate of phenotypic and ecological adaptations is extremely fast during such events, suggesting that many genes may be under fairly strong selection. However, no evidence for adaptation at the level of protein coding genes was found, so it has been suggested that selection may work mainly on regulatory elements. Here we report the first evidence that positive selection does operate at the level of protein coding genes during rapid adaptive radiations. We studied molecular adaptation in Hawaiian endemic plant genus Schiedea (Caryophyllaceae), which includes closely related species with a striking range of morphological and ecological forms, varying from rainforest vines to woody shrubs growing in desert-like conditions on cliffs. Given the remarkable difference in photosynthetic performance between Schiedea species from different habitats, we focused on the "photosynthetic'' Rubisco enzyme, the efficiency of which is known to be a limiting step in plant photosynthesis. Results. We demonstrate that the chloroplast rbcL gene, encoding the large subunit of Rubisco enzyme, evolved under strong positive selection in Schiedea. Adaptive amino acid changes occurred in functionally important regions of Rubisco that interact with Rubisco activase, a chaperone which promotes and maintains the catalytic activity of Rubisco. Interestingly, positive selection acting on the rbcL might have caused favorable cytotypes to spread across several Schiedea species. Significance. We report the first evidence for adaptive changes at the DNA and protein sequence level that may have been associated with the evolution of photosynthetic performance and colonization of new habitats during a recent adaptive radiation in an island plant genus. This illustrates how small changes at the molecular level may change ecological species performance and helps us to understand the molecular bases of extremely fast rate of adaptation during island adaptive radiations.	[Kapralov, Maxim V.; Filatov, Dmitry A.] Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England	University of Birmingham	Filatov, DA (corresponding author), Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England.	D.Filatov@bham.ac.uk		Filatov, Dmitry/0000-0001-8077-5452; Kapralov, Maxim/0000-0001-7966-0295	BBSRC; Biotechnology and Biological Sciences Research Council [BB/C512310/1] Funding Source: researchfish	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was funded by a grant from the BBSRC.	ARNOLD ML, 1997, NATURAL HYBRIDISATIO; Avise J.C., 2004, MOL MARKERS NATURAL; Barrier M, 2001, P NATL ACAD SCI USA, V98, P10208, DOI 10.1073/pnas.181257698; Cuenoud P, 2002, AM J BOT, V89, P132, DOI 10.3732/ajb.89.1.132; DEAN C, 1989, ANNU REV PLANT PHYS, V40, P415, DOI 10.1146/annurev.pp.40.060189.002215; Doiron S, 2002, MOL BIOL EVOL, V19, P1902, DOI 10.1093/oxfordjournals.molbev.a004014; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Filatov DA, 2002, MOL ECOL NOTES, V2, P621, DOI 10.1046/j.1471-8286.2002.00313.x; Filatov DA, 2004, HEREDITY, V92, P452, DOI 10.1038/sj.hdy.6800440; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hollocher H, 1996, PHILOS T R SOC B, V351, P735, DOI 10.1098/rstb.1996.0068; Kadereit G, 2003, INT J PLANT SCI, V164, P959, DOI 10.1086/378649; Kellogg EA, 1997, AM J BOT, V84, P413, DOI 10.2307/2446015; Kimura MA, 1985, NEUTRAL THEORY MOL E; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEWONTIN RC, 1966, EVOLUTION, V20, P315, DOI 10.1111/j.1558-5646.1966.tb03369.x; Machado CA, 2003, P ROY SOC B-BIOL SCI, V270, P1193, DOI 10.1098/rspb.2003.2333; Maddison WP, 1997, SYST BIOL, V46, P523, DOI 10.2307/2413694; Morjan CL, 2004, MOL ECOL, V13, P1341, DOI 10.1111/j.1365-294X.2004.02164.x; Nelson D., 2005, LEHNINGER PRINCIPLES; Neshich G, 2005, NUCLEIC ACIDS RES, V33, pD269, DOI 10.1093/nar/gki111; NEUHAUS H, 1987, CURR GENET, V11, P251, DOI 10.1007/BF00355398; OHTA T, 1992, ANNU REV ECOL SYST, V23, P263, DOI 10.1146/annurev.es.23.110192.001403; Parthiban V, 2006, NUCLEIC ACIDS RES, V34, pW239, DOI 10.1093/nar/gkl190; Portis AR, 2003, PHOTOSYNTH RES, V75, P11, DOI 10.1023/A:1022458108678; Remington DL, 2002, MOL BIOL EVOL, V19, P1563, DOI 10.1093/oxfordjournals.molbev.a004218; ROY II, 2000, PHOTOSYNTHESIS PHYSL, P53; Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434; Satagopan S, 2004, J BIOL CHEM, V279, P14240, DOI 10.1074/jbc.M313215200; Schluter D., 2000, ECOLOGY ADAPTIVE RAD; Seehausen O, 2004, TRENDS ECOL EVOL, V19, P198, DOI 10.1016/j.tree.2004.01.003; Shaw J, 2005, AM J BOT, V92, P142, DOI 10.3732/ajb.92.1.142; Slatkin M., 1976, P767; Spreitzer RJ, 2002, ANNU REV PLANT BIOL, V53, P449, DOI 10.1146/annurev.arplant.53.100301.135233; Stebbins G. L., 1959, Proceedings of the American Philosophical Society, V103, P231; Swanson WJ, 2003, MOL BIOL EVOL, V20, P18, DOI 10.1093/oxfordjournals.molbev.a004233; TABERLET P, 1991, PLANT MOL BIOL, V17, P1105, DOI 10.1007/BF00037152; Vogel J, 1997, J MOL BIOL, V270, P179, DOI 10.1006/jmbi.1997.1115; Wagner W.L., 2005, SYST BOT MONOGR, V72, P1; WILLIAM J, 1995, TRENDS ECOL EVOL, V10, P485, DOI 10.1016/S0169-5347(00)89195-8; Wong WSW, 2004, GENETICS, V168, P1041, DOI 10.1534/genetics.104.031153; Yang ZH, 2000, GENETICS, V155, P431; Yang ZH, 2005, MOL BIOL EVOL, V22, P1107, DOI 10.1093/molbev/msi097; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555	47	41	42	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e8	10.1371/journal.pone.0000008	http://dx.doi.org/10.1371/journal.pone.0000008			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183712	Green Published, Green Submitted, gold			2022-12-25	WOS:000207443600008
J	Rachman, H; Kim, N; Ulrichs, T; Baumann, S; Pradl, L; Eddine, AN; Bild, M; Rother, M; Kuban, RJ; Lee, JS; Hurwitz, R; Brinkmann, V; Kosmiadi, GA; Kaufmann, SHE				Rachman, Helmy; Kim, Nayoung; Ulrichs, Timo; Baumann, Sven; Pradl, Lydia; Eddine, Ali Nasser; Bild, Matthias; Rother, Marion; Kuban, Ralf-Juergen; Lee, Jong Seok; Hurwitz, Robert; Brinkmann, Volker; Kosmiadi, George A.; Kaufmann, Stefan H. E.			Critical Role of Methylglyoxal and AGE in Mycobacteria-Induced Macrophage Apoptosis and Activation	PLOS ONE			English	Article								Apoptosis and activation of macrophages play an important role in the host response to mycobacterial infection involving TNF-alpha as a critical autocrine mediator. The underlying mechanisms are still ill-defined. Here, we demonstrate elevated levels of methylglyoxal (MG), a small and reactive molecule that is usually a physiological product of various metabolic pathways, and advanced glycation end products (AGE) during mycobacterial infection of macrophages, leading to apoptosis and activation of macrophages. Moreover, we demonstrate abundant AGE in pulmonary lesions of tuberculosis (TB) patients. Global gene expression profiling of MG-treated macrophages revealed a diverse spectrum of functions induced by MG, including apoptosis and immune response. Our results not only provide first evidence for the involvement of MG and AGE in TB, but also form a basis for novel intervention strategies against infectious diseases in which MG and AGE play critical roles.	[Rachman, Helmy; Kim, Nayoung; Ulrichs, Timo; Baumann, Sven; Pradl, Lydia; Eddine, Ali Nasser; Bild, Matthias; Lee, Jong Seok; Kaufmann, Stefan H. E.] Max Planck Inst Infect Biol, Dept Immunol, Berlin, Germany; [Rother, Marion] Max Planck Inst Infect Biol, Dept Mol Biol, Berlin, Germany; [Kuban, Ralf-Juergen] Univ Med Berlin, Charite, Lab Funct Genom, Berlin, Germany; [Hurwitz, Robert; Brinkmann, Volker] Max Planck Inst Infect Biol, Core Facil, Berlin, Germany; [Kosmiadi, George A.] Cent TB Res Inst, Dept Immunol 2, Moscow, Russia	Max Planck Society; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society	Kaufmann, SHE (corresponding author), Max Planck Inst Infect Biol, Dept Immunol, Berlin, Germany.	kaufmann@mpiib-berlin.mpg.de	Brinkmann, Volker/A-6015-2009; Kaufmann, Stefan HE/I-5454-2014	Kaufmann, Stefan HE/0000-0001-9866-8268	German Ministry for Science and Technology	German Ministry for Science and Technology	Funding: This work received financial support to SHEK from the German Ministry for Science and Technology (Competence Networks "Pathogenomics" and "Structural Genomics of MTB").	Abe H, 2004, J BIOL CHEM, V279, P14201, DOI 10.1074/jbc.M310427200; Abordo EA, 1997, IMMUNOL LETT, V58, P139, DOI 10.1016/S0165-2478(97)00080-1; Akhand AA, 2001, FREE RADICAL BIO MED, V31, P20, DOI 10.1016/S0891-5849(01)00550-0; Chaplen FWR, 1998, P NATL ACAD SCI USA, V95, P5533, DOI 10.1073/pnas.95.10.5533; Chiu BC, 2002, MECH AGEING DEV, V123, P313, DOI 10.1016/S0047-6374(01)00372-4; Davidson SD, 2002, UROL RES, V30, P116, DOI 10.1007/s00240-002-0244-7; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Du J, 2000, J CELL BIOCHEM, V77, P333, DOI 10.1002/(SICI)1097-4644(20000501)77:2<333::AID-JCB15>3.0.CO;2-Q; Du J, 2001, FREE RADICAL BIO MED, V31, P469, DOI 10.1016/S0891-5849(01)00611-6; Fairbairn IP, 2004, BIOCHEM SOC T, V32, P496, DOI 10.1042/BST0320496; Heidland A, 2001, AM J KIDNEY DIS, V38, pS100, DOI 10.1053/ajkd.2001.27414; HEIJST JW, 2005, CANC LETT; Humeny A, 2002, J AGR FOOD CHEM, V50, P2153, DOI 10.1021/jf011349o; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kalapos MP, 1999, TOXICOL LETT, V110, P145, DOI 10.1016/S0378-4274(99)00160-5; Kalapos MP, 1999, BBA-GEN SUBJECTS, V1426, P1, DOI 10.1016/S0304-4165(98)00141-X; Kaneko H, 1999, LAB INVEST, V79, P379; Kang YB, 1996, LEUKEMIA RES, V20, P397, DOI 10.1016/0145-2126(95)00162-X; Kaufmann SHE, 2000, NAT MED, V6, P955, DOI 10.1038/79631; Kaufmann SHE, 2002, ANN RHEUM DIS, V61, P54; Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558; Klingler K, 1997, INFECT IMMUN, V65, P5272, DOI 10.1128/IAI.65.12.5272-5278.1997; Lal MA, 2002, KIDNEY INT, V61, P2006, DOI 10.1046/j.1523-1755.2002.00367.x; Lambrecht BN, 2006, IMMUNITY, V24, P366, DOI 10.1016/j.immuni.2006.03.008; Law K, 1996, AM J RESP CRIT CARE, V153, P799, DOI 10.1164/ajrccm.153.2.8564135; Mandl-Weber S, 2001, PERITON DIALYSIS INT, V21, P487; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; Mogga SJ, 2002, SCAND J IMMUNOL, V56, P383, DOI 10.1046/j.1365-3083.2002.01140.x; Okado A, 1996, BIOCHEM BIOPH RES CO, V225, P219, DOI 10.1006/bbrc.1996.1157; Oya T, 1999, J BIOL CHEM, V274, P18492, DOI 10.1074/jbc.274.26.18492; Rachman H, 2006, INFECT IMMUN, V74, P1233, DOI 10.1128/IAI.74.2.1233-1242.2006; Riendeau CJ, 2003, INFECT IMMUN, V71, P254, DOI 10.1128/IAI.71.1.254-259.2003; Rodriguez- Iturbe B, 2005, J PHARMACOL EXP THER, V315, P51, DOI 10.1124/jpet.105.088062; Schaible UE, 2003, NAT MED, V9, P1039, DOI 10.1038/nm906; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; Sly LM, 2003, J IMMUNOL, V170, P430, DOI 10.4049/jimmunol.170.1.430; THORNALLEY PJ, 1988, BIOCHEM J, V254, P751, DOI 10.1042/bj2540751; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Ulrichs T, 2005, J PATHOL, V205, P633, DOI 10.1002/path.1728; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Winau F, 2006, IMMUNITY, V24, P105, DOI 10.1016/j.immuni.2005.12.001; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; YIM HS, 1995, J BIOL CHEM, V270, P28228; Yim MB, 2001, ANN NY ACAD SCI, V928, P48, DOI 10.1111/j.1749-6632.2001.tb05634.x; Zhang Y, 2004, FRONT BIOSCI-LANDMRK, V9, P1136, DOI 10.2741/1291; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350	47	55	57	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e29	10.1371/journal.pone.0000029	http://dx.doi.org/10.1371/journal.pone.0000029			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183656	Green Published, gold, Green Submitted			2022-12-25	WOS:000207443600029
J	Van Bocxlaer, I; Roelants, K; Biju, SD; Nagaraju, J; Bossuyt, F				Van Bocxlaer, Ines; Roelants, Kim; Biju, S. D.; Nagaraju, J.; Bossuyt, Franky			Late Cretaceous Vicariance in Gondwanan Amphibians	PLOS ONE			English	Article							BIOGEOGRAPHY; DISPERSAL; RADIATION; DIVERSIFICATION; EVOLUTION; TIME; DNA	Overseas dispersals are often invoked when Southern Hemisphere terrestrial and freshwater organism phylogenies do not fit the sequence or timing of Gondwana fragmentation. We used dispersal-vicariance analyses and molecular timetrees to show that two species-rich frog groups, Microhylidae and Natatanura, display congruent patterns of spatial and temporal diversification among Gondwanan plates in the Late Cretaceous, long after the presumed major tectonic break-up events. Because amphibians are notoriously salt-intolerant, these analogies are best explained by simultaneous vicariance, rather than by oceanic dispersal. Hence our results imply Late Cretaceous connections between most adjacent Gondwanan landmasses, an essential concept for biogeographic and palaeomap reconstructions.	[Van Bocxlaer, Ines; Roelants, Kim; Biju, S. D.; Bossuyt, Franky] Vrije Univ Brussel, Dept Biol, Unit Ecol & Systemat, Brussels, Belgium; [Biju, S. D.] Univ Delhi, Sch Environm Studies, CEMDE, Delhi 110007, India; [Nagaraju, J.] Ctr DNA Fingerprinting & Diagnost, Mol Genet Lab, Hyderabad, Andhra Pradesh, India	Vrije Universiteit Brussel; University of Delhi; Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD)	Bossuyt, F (corresponding author), Vrije Univ Brussel, Dept Biol, Unit Ecol & Systemat, Brussels, Belgium.	fbossuyt@vub.ac.be	Van Bocxlaer, Ines/L-4852-2015	Roelants, Kim/0000-0001-5367-5958; Bossuyt, Franky/0000-0001-6804-9271	Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen); Fonds voor Wetenschappelijk Onderzoek-Vlaanderen;  [FWO 1.5.039.03N];  [FWO G. 0056.03];  [FWO G. 0307.04];  [VUB OZR834]	Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); Fonds voor Wetenschappelijk Onderzoek-Vlaanderen(FWO); ; ; ; 	Ines Van Bocxlaer is supported by the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen). Franky Bossuyt receives a postdoctoral fellowship from the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen. This work was supported by research grants FWO 1.5.039.03N, FWO G. 0056.03, FWO G. 0307.04 and VUB OZR834.	Azuma Y, 2000, CAN J EARTH SCI, V37, P1735, DOI 10.1139/e00-064; Bossuyt F, 2001, SCIENCE, V292, P93, DOI 10.1126/science.1058875; Bossuyt F, 2006, SYST BIOL, V55, P579, DOI 10.1080/10635150600812551; Briggs JC, 2003, J BIOGEOGR, V30, P381, DOI 10.1046/j.1365-2699.2003.00809.x; Chatterjee S, 1999, P INDIAN NATL SCI A, V65, P397; Cooper A, 2001, NATURE, V409, P704, DOI 10.1038/35055536; de Queiroz A, 2005, TRENDS ECOL EVOL, V20, P68, DOI 10.1016/j.tree.2004.11.006; Dubois Alain, 2006, Alytes (Paris), V24, P1; Duellman WE., 1994, BIOL AMPHIBIANS; Frost DR, 2006, B AM MUS NAT HIST, P8, DOI 10.1206/0003-0090(2006)297[0001:TATOL]2.0.CO;2; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Hay W.W., 1999, GEOL SOC AM SPEC PAP, V332, P1, DOI 10.1130/0-8137-2332-9.1; Hill RV, 2003, AM MUS NOVIT, P1, DOI 10.1206/0003-0082(2003)395<0001:ANSOPG>2.0.CO;2; Karanth KP, 2006, CURR SCI INDIA, V90, P789; Krause DW, 1997, NATURE, V390, P504, DOI 10.1038/37343; Linder HP, 2005, MOL PHYLOGENET EVOL, V35, P569, DOI 10.1016/j.ympev.2004.12.006; McCarthy D, 2005, J BIOGEOGR, V32, P2161, DOI 10.1111/j.1365-2699.2005.01355.x; Parker H. W., 1934, MONOGRAPH FROGS FAMI, P1; PATRIAT P, 1988, TECTONOPHYSICS, V155, P211, DOI 10.1016/0040-1951(88)90267-3; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Prasad V, 2005, SCIENCE, V310, P1177, DOI 10.1126/science.1118806; Rage JC, 2003, ACTA PALAEONTOL POL, V48, P661; Raxworthy CJ, 2002, NATURE, V415, P784, DOI 10.1038/415784a; Ronquist F, 1997, SYST BIOL, V46, P195, DOI 10.2307/2413643; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Sampson SD, 1998, SCIENCE, V280, P1048, DOI 10.1126/science.280.5366.1048; San Mauro D, 2005, AM NAT, V165, P590, DOI 10.1086/429523; Sanderson MJ, 2002, MOL BIOL EVOL, V19, P101, DOI 10.1093/oxfordjournals.molbev.a003974; Sanmartin I, 2004, SYST BIOL, V53, P216, DOI 10.1080/10635150490423430; Savage J.M., 1973, EVOLUTIONARY BIOL AN, P351; Sereno PC, 2004, P ROY SOC B-BIOL SCI, V271, P1325, DOI 10.1098/rspb.2004.2692; Smith A.G., 1994, ATLAS MESOZOIC CENOZ; Swofford D.L., 2002, PAUP PHYLOGENETIC AN; Thorne JL, 2002, SYST BIOL, V51, P689, DOI 10.1080/10635150290102456; Turner AH, 2004, P ROY SOC B-BIOL SCI, V271, P2003, DOI 10.1098/rspb.2004.2840; Upchurch P, 2002, GEOBIOS-LYON, V35, P277, DOI 10.1016/S0016-6995(02)00065-7; van der Meijden A, 2005, MOL PHYLOGENET EVOL, V37, P674, DOI 10.1016/j.ympev.2005.05.001; Vences M, 2003, P ROY SOC B-BIOL SCI, V270, P2435, DOI 10.1098/rspb.2003.2516; MAT METHODS AVAILABL	39	118	124	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e74	10.1371/journal.pone.0000074	http://dx.doi.org/10.1371/journal.pone.0000074			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183706	gold, Green Submitted, Green Published			2022-12-25	WOS:000207443600074
